<SEC-DOCUMENT>0001493152-24-024790.txt : 20240621
<SEC-HEADER>0001493152-24-024790.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621171402
ACCESSION NUMBER:		0001493152-24-024790
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		101
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tevogen Bio Holdings Inc.
		CENTRAL INDEX KEY:			0001860871
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981597194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280414
		FILM NUMBER:		241061365

	BUSINESS ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		646-807-8832

	MAIL ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Semper Paratus Acquisition Corp
		DATE OF NAME CHANGE:	20210505
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>forms-1.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:TVGN="http://tevogen.com/20240331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_TVGN_tevogen.com_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001860871 -->
<!-- Field: Set; Name: xdx; ID: xdx_07D_XDX_Z%2D%2D\2024 OPERATIONS\EDGAR\03 MARCH\TEVOGEN BIO HOLDINGS INC\03%2D23%2D2024\Form 10%2DK\Draft\Production\iXBRL\New folder\form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001860871</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0046" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0120" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ClassBOrdinaryShares" contextRef="AsOf2023-12-31" id="xdx2ixbrl0189" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ImpairmentOfAmountDueFromRelatedParty" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:NoncashInterestExpenses" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ExtensionAmountDepositedIntoTrustAccount" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:SaleOfClassBSharesToInvestor" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:SaleOfWarrants" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:NumberOfWarrantsIssuedPerUnit" contextRef="From2021-11-082021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember" id="xdx2ixbrl0743" decimals="INF" unitRef="Shares">0.5</ix:nonFraction>
  <ix:nonNumeric contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember" id="xdx2ixbrl0926" name="TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing">P5D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember" id="xdx2ixbrl0942" name="TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing">P5D</ix:nonNumeric>
  <ix:nonFraction name="TVGN:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" id="xdx2ixbrl1024" decimals="INF" unitRef="Integer">3</ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl1044" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl1046" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl1048" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1052" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl1059" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl1061" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1063" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1065" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_RelatedPartyMember" id="xdx2ixbrl1151" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:DeferredTransactionCosts" contextRef="AsOf2024-03-31" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-03-31" id="xdx2ixbrl1189" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_RelatedPartyMember" id="xdx2ixbrl1193" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2024-03-31" id="xdx2ixbrl1198" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1205" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1214" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1225" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1236" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:TransactionCosts" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1291" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1324" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1326" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1332" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1339" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1346" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1348" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1349" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1350" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1359" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1365" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1368" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1371" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1379" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1380" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1395" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1421" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1427" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1429" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1434" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1440" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1442" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1446" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1447" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1448" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1449" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1453" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1454" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1455" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1456" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1460" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1461" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1467" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1469" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1474" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1480" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl1482" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1499" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1505" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1514" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1543" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1546" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:CashAcquiredInConnectionWithReverseRecapitalization" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1553" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1556" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1559" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1561" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1580" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="xdx2ixbrl1583" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1619" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1627" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1661" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1663" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="xdx2ixbrl1667" decimals="INF" unitRef="Pure">75</ix:nonFraction>
  <ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="xdx2ixbrl1669" decimals="INF" unitRef="Pure">85</ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1774" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1776" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1786" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1788" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1790" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1792" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1798" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1800" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1802" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1804" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1832" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1945" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ConvertiblePromissoryNoteInterest" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1954" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="TVGN:ConvertiblePromissoryNoteChangeInFairValue" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1957" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1969" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1972" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl1975" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1992" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_custom_PublicWarrantsMember" id="xdx2ixbrl1995" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_custom_PrivateWarrantsMember" id="xdx2ixbrl1998" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_ConvertibleDebtSecuritiesMember" id="xdx2ixbrl2000" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_custom_EarnoutSharesMember" id="xdx2ixbrl2004" unitRef="Shares" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tvgn-20240331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:CommonClassaNotSubjectToRedemptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:CommonClassaNotSubjectToRedemptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ReverseRecapitalizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FeeReductionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-282023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FeeReductionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-28</xbrli:startDate>
        <xbrli:endDate>2023-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-302023-01-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-302023-01-30_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-302023-01-30_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-30_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-30_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-03_custom_FirstExtensionCharterAmendmentMember_custom_PublicSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FirstExtensionCharterAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_FirstExtensionCharterAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FirstExtensionCharterAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-14_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondExtensionCharterAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-142023-12-14_custom_SecondExtensionCharterAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondExtensionCharterAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-14</xbrli:startDate>
        <xbrli:endDate>2023-12-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondExtensionCharterAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-04</xbrli:startDate>
        <xbrli:endDate>2023-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_PrivatePlacementMember_custom_SsvkAssociatesLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-04</xbrli:startDate>
        <xbrli:endDate>2023-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-28_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesA1PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_CantorMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:CantorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-072023-06-07_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-07</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-222021-04-22_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-22</xbrli:startDate>
        <xbrli:endDate>2021-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-31_custom_FounderSharesMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-01_custom_FounderSharesMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-04</xbrli:startDate>
        <xbrli:endDate>2023-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_PrivatePlacementMember_custom_PurchaseAgreementMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-04</xbrli:startDate>
        <xbrli:endDate>2023-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_NonRedeemableOrdinaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:NonRedeemableOrdinaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-06_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsTransferredTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsTransferredThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicWarrantsTransferredOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicWarrantsTransferredTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-22_custom_PromissoryNoteWithRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-082021-11-08_custom_PromissoryNoteWithRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-08</xbrli:startDate>
        <xbrli:endDate>2021-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember_custom_DeSPACMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:DeSPACMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_us-gaap_InvestorMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember_custom_DeSPACMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:DeSPACMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SponsorMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:FirstPolarFundConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-03_custom_FirstPolarFundConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:FirstPolarFundConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20_custom_FirstPolarFundConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:FirstPolarFundConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20_custom_SecondPolarFundConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:SecondPolarFundConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_custom_SecondPolarFundConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:SecondPolarFundConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RelatedPartyLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:RelatedPartyLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WorkingCapitalLoansWarrantMember_custom_RelatedPartyLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:RelatedPartyLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember69274765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember69274781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AdministrativeSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AdministrativeSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AdministrativeSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-052021-11-05_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-05</xbrli:startDate>
        <xbrli:endDate>2021-11-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-03</xbrli:startDate>
        <xbrli:endDate>2023-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-312024-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-31</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember_custom_TevogenBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-272024-03-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-27</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-26_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesA1PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-262024-04-26_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-26</xbrli:startDate>
        <xbrli:endDate>2024-04-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MergerAgreementMember_custom_SponsorAdvisoryServiceFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TVGN:SponsorAdvisoryServiceFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-152024-04-16_custom_MergerAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-15</xbrli:startDate>
        <xbrli:endDate>2024-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TevogenBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_SemperParatusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-162024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-16</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwentyTwentyFourPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_IncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:IncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwentyTwentyFourPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-03-27_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-27_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-15</xbrli:startDate>
        <xbrli:endDate>2024-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_SponsorAdvisoryServicesFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SponsorAdvisoryServicesFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockMember69286687">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember69287000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>TVGN:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl1044" toRefs="Footnote001055"/>
  <ix:relationship fromRefs="xdx2ixbrl1046" toRefs="Footnote001055"/>
  <ix:relationship fromRefs="xdx2ixbrl1048" toRefs="Footnote001055"/>
  <ix:relationship fromRefs="Fact001846" toRefs="Footnote001853"/>
  <ix:relationship fromRefs="Fact001848" toRefs="Footnote001854"/>
  <ix:relationship fromRefs="Fact001850" toRefs="Footnote001855"/>
  <ix:relationship fromRefs="Fact001988" toRefs="Footnote002008"/>
  <ix:relationship fromRefs="Fact001989" toRefs="Footnote002008"/>
  <ix:relationship fromRefs="xdx2ixbrl2000" toRefs="Footnote002011"/>
  <ix:relationship fromRefs="Fact002001" toRefs="Footnote002011"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on June 21, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20240101__20240331_zLfZRqQCYIT8"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000011" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>UNDER</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>THE
SECURITIES ACT OF 1933</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20240101__20240331_zeOZ2XqitE22"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000012" name="dei:EntityRegistrantName">Tevogen
Bio Holdings Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20240101__20240331_zRRPsyh1UFv9"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2836</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20240101__20240331_zIAqsHlfHw7"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-1597194</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<br/>
    incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
    Standard Industrial<br/>
    Classification Code Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20240101__20240331_zlP5R20LoAFi"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000015" name="dei:EntityAddressAddressLine1">15
Independence Boulevard</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20240101__20240331_zkjK7WZNjb31"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite #410</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20240101__20240331_zQzm6gBwAZC3"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000017" name="dei:EntityAddressCityOrTown">Warren</ix:nonNumeric></span>,
<span id="xdx_90B_edei--EntityAddressStateOrProvince_c20240101__20240331_zob4sAItx4g"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20240101__20240331_zoT8f4K0qMwb"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000019" name="dei:EntityAddressPostalZipCode">07059</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_902_edei--CityAreaCode_c20240101__20240331_zf78jnBwzbji"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000020" name="dei:CityAreaCode">877</ix:nonNumeric></span>)
<span id="xdx_909_edei--LocalPhoneNumber_c20240101__20240331_zXBhE2KwSZy4"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000021" name="dei:LocalPhoneNumber">838-6436</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--ContactPersonnelName_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zameQkmwOwHf"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000022" name="dei:ContactPersonnelName">Ryan
Saadi</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zY5P4ByRirDh"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000023" name="dei:EntityAddressAddressLine1">Tevogen
Bio Holdings Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine2_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zzpnDMF6zkw6"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000024" name="dei:EntityAddressAddressLine2">15
Independence Boulevard</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine3_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zQGF8otXg9ca"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressAddressLine3">Suite #410</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zCvBt9bB5p1d"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000026" name="dei:EntityAddressCityOrTown">Warren</ix:nonNumeric></span>,
<span id="xdx_907_edei--EntityAddressStateOrProvince_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zVCQBLzgnJU7"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" format="ixt-sec:stateprovnameen" id="Fact000027" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zuDeryVWLp2a"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000028" name="dei:EntityAddressPostalZipCode">07059</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_908_edei--CityAreaCode_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zjNUkBPffRoj"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000029" name="dei:CityAreaCode">877</ix:nonNumeric></span>)
<span id="xdx_904_edei--LocalPhoneNumber_c20240101__20240331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zcPDmKnAxDk8"><ix:nonNumeric contextRef="From2024-01-012024-03-31_dei_BusinessContactMember" id="Fact000030" name="dei:LocalPhoneNumber">838-6436</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>William
I. Intner<br/>
J. Nicholas Hoover<br/>
Hogan Lovells US LLP<br/>
100 International Drive, Suite 2000</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baltimore,
Maryland 21202</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(410)
659-2700</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityFilerCategory_c20240101__20240331_zLv7gh7MpTod"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000031" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntitySmallBusiness_c20240101__20240331_zsclWbG3yLQ2"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleantrue" id="Fact000032" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20240101__20240331_zyQJWU0WGXo9"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleantrue" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span id="xdx_90F_edei--EntityExTransitionPeriod_c20240101__20240331_zIGHeyjGBPhb"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000034" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective
on such date as the Commission acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 429 under the Securities Act of 1933, as amended, the prospectus that forms a part of this Registration Statement on Form S-1
(this &#8220;Registration Statement&#8221;) is a combined prospectus relating to (i) the resale and, as applicable, issuance of the shares
of Common Stock and the resale of Warrants being newly registered under this Registration Statement as described in the prospectus that
forms a part of this Registration Statement and (ii) the issuance and sale of up to 24,500,000 shares of Common Stock issuable upon the
achievement of certain earnout triggering events, as described in the prospectus that forms a part of this Registration Statement, previously
registered under the registrant&#8217;s Registration Statement on Form S-4, as amended (File No. 333-274519) (the &#8220;Prior Registration
Statement&#8221;). This Registration Statement also constitutes a Post-Effective Amendment to the Prior Registration Statement. Such
Post-Effective Amendment shall become effective concurrently with the effectiveness of this Registration Statement in accordance with
Section 8(c) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Subject
to Completion, dated June 21, 2024.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>PRELIMINARY
PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tevogen
Bio Holdings Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>42,474,978
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>24,851,308
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock Offered by the Registered
Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>725,000
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Offered by the Registered Holders
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the issuance by us of up to (i) 17,974,978 shares of common stock, par value $0.001 per share (the &#8220;Common
Stock&#8221;), upon the exercise of outstanding warrants to purchase Common Stock (the &#8220;Warrants&#8221;) originally issued by Semper
Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;) (n/k/a Tevogen Bio Holdings Inc.) as part of Semper Paratus&#8217;s
(a) initial public offering and (b) concurrent private placement (the &#8220;Private Placement&#8221;) of units at a price
of $10.00 per unit, with each unit consisting of one Class A ordinary share of Semper Paratus and one-half of a warrant and (ii) 24,500,000
shares of Common Stock issuable upon the achievement of certain earnout triggering events, as described in this prospectus. This prospectus
also relates to the resale by the securityholders identified in this prospectus (each a &#8220;Registered Holder&#8221; and, collectively,
the &#8220;Registered Holders&#8221;) of up to (i) 24,851,308 shares of Common Stock (the &#8220;Total Resale Shares&#8221;)
and (ii) 725,000 of our outstanding Warrants, originally issued as part of units sold in the Private Placement (the &#8220;Private
Placement Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Total Resale Shares consist of (i) 8,988,889 shares of Common Stock and 500,000 shares of Common Stock underlying Private Placement Warrants
that were purchased by SSVK Associates, LLC (&#8220;SSVK&#8221;), which was Semper Paratus&#8217;s sponsor, from Semper Paratus Sponsor
LLC (the &#8220;Original Sponsor&#8221;), which was Semper Paratus&#8217;s original sponsor, for an aggregate purchase price of $1.00,
(ii) 174,000 shares of Common Stock issued pursuant to the Conversion Agreements (as defined elsewhere in this prospectus) at an effective
price of $10.00 per share, (iii) 1,651,000 shares of Common Stock issued pursuant to the Subscription Agreements (as defined elsewhere
in this prospectus) as consideration for extending loans in an aggregate amount of $1,651,000, (iv) 500,000 shares of Common Stock
issued pursuant to the Fee Reduction Agreement (as defined elsewhere in this prospectus) at an effective price of $10.00 per share, (v)
600,000 shares of Common Stock issued pursuant to the Letter of Engagement (as defined elsewhere in this prospectus) in consideration
for capital markets advisory services, (vi) 10,337,419 shares of Common Stock issued upon assumption and subsequent conversion of the
Tevogen Bio Convertible Notes (as defined elsewhere in this prospectus) that had an aggregate principal amount totaling approximately
$24.0 million and accrued interest totaling approximately $2.9 million at the time of the Business Combination (as defined elsewhere
in this prospectus), (vii) 500,000 shares of Common Stock issuable upon the conversion of shares of Series A Preferred Stock at a
conversion price of $4.00 per share, (viii) 600,000 shares of Common Stock issuable upon the conversion of shares of Series A-1
Preferred Stock at a conversion price of $10.00 per share, and (ix) 1,000,000 shares of Common Stock issued pursuant to the Loan
Agreement (as defined elsewhere in this prospectus) as a commitment fee in consideration for providing us with a credit
facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may receive up to an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise price of each of our
Warrants is $11.50 per warrant. However, the last reported sales price of our Common Stock on June 20, 2024 was $0.755.
The likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds that we may receive,
is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per
share, we do not expect holders to exercise their Warrants. Additionally, under certain circumstances, the Warrants may be exercised
on a cashless basis and we would not receive any proceeds from such exercise. We expect to use the net proceeds from the exercise of
such securities, if any, for general corporate and working capital purposes. We will have broad discretion over the use of any proceeds
from the exercise of such securities. Any proceeds from the exercise of such securities would increase our liquidity, but we are not
currently budgeting for any cash proceeds from the exercise of Warrants when planning for our operational funding needs. For further
information regarding our operational funding needs, see the section of this prospectus titled &#8220;<i>Risk Factors &#8211; Risks Related
to Our Financial Position and Need for Additional Capital &#8211; Our management has concluded that due to cash on hand, there is substantial
doubt about our ability to continue as a going concern</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the securities for resale including pursuant to certain of the Registered Holders&#8217; registration rights
under certain agreements between us and the Registered Holders and to facilitate the Company&#8217;s call right with respect to
the Series A Preferred Stock and the Series A-1 Preferred Stock. Our registration of the securities covered by this prospectus does not
mean that the Registered Holders will offer or sell any of the shares of Common Stock or Warrants. The Registered Holders may offer,
sell or distribute all or a portion of their shares of Common Stock or Warrants publicly or through private transactions at prevailing
market prices or at negotiated prices. We provide more information about how the Registered Holders may sell the shares of Common Stock
or Warrants in the section titled &#8220;<i>Plan of Distribution</i>.&#8221; Additionally, certain shares of our Common Stock held by
SSVK and the distributees of the Original Sponsor remain subject to contractual lock-ups. See the section of this prospectus titled &#8220;<i>Prospectus
Summary&#8212;Background</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of securities being offered in this prospectus could result in adverse effects on the market for our Common Stock, including increasing
volatility, limiting the availability of an active market, or resulting in a significant decline in the public trading price of our Common
Stock. Even if the prevailing trading price of our Common Stock is at or significantly below the price at which the units were issued
in Semper Paratus&#8217;s initial public offering, some of the Registered Holders may still be able to profit on sales due to the lower
price at which they purchased their shares compared to public investors, or because they acquired or may acquire their shares as compensation
for services rendered, in consideration of the extension of loans, or in other circumstances, and therefore may still have an incentive
to sell securities held by them and being offered in this prospectus. Public securityholders may not experience a similar rate of return
on the securities they purchase due to differences in the purchase prices and the current trading price. See &#8220;<i>Risk Factors &#8211;
Risks Related to Being a Public Company and Ownership of Securities &#8211; Sales of a substantial number of our securities in the public
market by the Registered Holders or by our other existing securityholders could cause the price of our Common Stock and Warrants to fall</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; for purposes of federal securities laws and
are subject to reduced public company reporting requirements. Accordingly, the information in this prospectus may not be comparable to
information provided by companies that are not emerging growth companies or smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and Warrants are listed on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221; respectively.
On June 20, 2024, the closing price of our Common Stock was $0.755 and the closing price for our Warrants was $0.021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock and Private Placement Warrants.
The Registered Holders will bear all commissions and discounts, if any, attributable to their sales of the shares of Common Stock or
Private Placement Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business and investment in our Common Stock and Warrants involve significant risks. These risks are described in the section titled &#8220;Risk
Factors&#8221; beginning on page 8 of this prospectus.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;, 2024.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS<sup></sup></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_001">ABOUT THIS PROSPECTUS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_002">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_003">PROSPECTUS SUMMARY</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_004">THE OFFERING</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_005">RISK FACTORS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">USE OF PROCEEDS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">DIVIDEND POLICY</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_002">BUSINESS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_003">MANAGEMENT</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">107</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_004">EXECUTIVE AND DIRECTOR COMPENSATION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">114</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_005">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">124</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_006">PRINCIPAL STOCKHOLDERS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">129</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_007">REGISTERED HOLDERS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">131</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_008">DESCRIPTION OF OUR SECURITIES</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">133</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_009">PLAN OF DISTRIBUTION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">143</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_010">LEGAL MATTERS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">146</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_011">EXPERTS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">147</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_012">WHERE YOU CAN FIND MORE INFORMATION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">148</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_013">INDEX TO FINANCIAL STATEMENTS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_001"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;)
using a &#8220;shelf&#8221; registration process. We will not receive any proceeds from the sale by the Registered Holders of the
securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock
issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants
pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part
that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add,
update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information
in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement
or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective
amendment, and any applicable prospectus supplement, together with the additional information described under the heading &#8220;<i>Where
You Can Find More Information</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the Registered Holders have authorized anyone to provide you with any information or to make any representations other than those
contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or
to which we have referred you. We and the Registered Holders take no responsibility for and can provide no assurance as to the reliability
of any other information that others may give you. We and the Registered Holders will not make an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any post-effective
amendment and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business,
financial condition, results of operations and prospects may have changed since those dates. This prospectus contains, and any post-effective
amendment or any prospectus supplement may contain, market data and industry statistics that are based on independent industry
publications and other publicly available information. We believe this information is reliable as of the applicable date of its publication;
however, we have not independently verified the accuracy or completeness of the information included in or assumptions relied on in these
third-party publications. In addition, the market and industry data and forecasts that may be included in this prospectus, any post-effective
amendment or any prospectus supplement may involve estimates, assumptions and other risks and uncertainties and are subject to change
based on various factors, including those discussed under the heading &#8220;<i>Risk Factors</i>&#8221; contained in this prospectus,
any post-effective amendment and the applicable prospectus supplement. Accordingly, investors should not place undue reliance on this
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to trademarks, trade names and service marks that we use in connection with the operation of our business. In addition,
our name, logos and website name and address are our trademarks or service marks. Solely for convenience, in some cases, the trademarks,
trade names and service marks referred to in this prospectus are listed without the applicable &#174;, &#8482; and SM symbols, but we
will assert, to the fullest extent under applicable law, our rights to these trademarks, trade names and service marks. Other trademarks,
trade names and service marks appearing in this prospectus are the property of their respective owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), we consummated the previously announced business combination pursuant to that certain
Agreement and Plan of Merger, dated June 28, 2023 (the &#8220;Merger Agreement&#8221;), by and among Semper Paratus Acquisition Corporation
(&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Semper Paratus (&#8220;Merger
Sub&#8221;), SSVK Associates, LLC (&#8220;SSVK&#8221;), in its capacity as purchaser representative, Tevogen Bio Inc (n/k/a Tevogen Bio
Inc.), a Delaware corporation (&#8220;Tevogen Bio&#8221;), and Dr. Saadi, in his capacity as seller representative, pursuant to which
Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of Semper Paratus
(the &#8220;Business Combination&#8221; and, collectively with the other transactions contemplated by the Merger Agreement, the &#8220;Transactions&#8221;).
On the Closing Date, and in connection with the closing of the Transactions (the &#8220;Closing&#8221;), we changed our name to Tevogen
Bio Holdings Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated, in this prospectus, when we refer to &#8220;Tevogen,&#8221; the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;
we mean the entity that remains following the Transactions. Additionally, unless otherwise stated, in this prospectus, when we refer
to &#8220;Tevogen Bio&#8221; or &#8220;Semper Paratus&#8221;, we are referring to each respective entity before the consummation of the
Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_002"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains statements that constitute &#8220;forward-looking statements&#8221; for purposes of the federal securities laws.
Forward-looking statements include, but are not limited to, statements that discuss future events, hopes, expectations, beliefs, intentions,
or strategies regarding the future, projections of results of operations or financial condition, changes in the markets in which we compete,
and trends in our business. In addition, any statements that refer to projections, forecasts, or other characterizations of future events
or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221;
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions or their opposites may identify forward-looking
statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this
prospectus may include, for example, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development of, potential benefits of, and patient access to our product candidates for the
                                            treatment of infectious diseases, cancer, and neurological disorders, including TVGN 489
                                            for the treatment of COVID-19 and Long COVID;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to develop additional product candidates, including through the use of our ExacTcell<sup>TM
                                            </sup>platform;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            anticipated benefits of ExacTcell;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding our future clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            manufacturing plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to generate revenue in the future;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to manage, grow, and diversify our business and execute our business initiatives
                                            and strategy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
                                            regarding the healthcare and biopharmaceutical industries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential liquidity and trading of our securities; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            future business, operations, and financial performance of our company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this prospectus are based on management&#8217;s current expectations, assumptions, and beliefs
concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will
be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond
our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. These risks and uncertainties include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effect of the Business Combination on our business relationships, operating results, and
                                            business generally;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            outcome of any legal proceedings that may be instituted against us related to the Business
                                            Combination;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the markets in which we compete, including with respect to its competitive landscape,
                                            technology evolution, or regulatory changes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in domestic and global general economic conditions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to execute our growth strategies or may experience difficulties in managing
                                            our growth and expanding operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to develop and maintain effective internal controls;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            related to the Business Combination and the failure to realize anticipated benefits of the
                                            Business Combination;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may fail to achieve our commercialization and development plans and identify and realize
                                            additional opportunities, which may be affected by, among other things, competition and our
                                            ability to grow and manage growth economically and hire and retain key employees;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may fail to keep pace with rapid technological developments to provide new and innovative
                                            products and services or make substantial investments in unsuccessful new products and services;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
                                            related to our ability to develop, license, or acquire new therapeutics;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            will need to raise additional capital, which may not be available on acceptable terms or
                                            at all, in order to execute our business plan;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk of regulatory lawsuits or proceedings relating to our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties
                                            inherent in the execution, cost, and completion of preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
                                            related to regulatory review and approval and commercial development;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
                                            associated with intellectual property protection;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            limited operating history;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
                                            related to the failure to satisfy continued listing requirements of The Nasdaq Stock Market
                                            LLC (&#8220;Nasdaq&#8221;), including maintaining a minimum closing bid price of $1.00
                                            per share pursuant to Nasdaq Listing Rule 5550(a)(2); and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those
                                            factors discussed under the heading &#8220;<i>Risk Factors</i>&#8221; below.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements should be considered in light of these factors and the factors described elsewhere in this prospectus, including in the sections
titled &#8220;<i>Risk Factors</i>&#8221; and &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations</i>.&#8221; You should read these factors and the other cautionary statements made in this prospectus as being applicable
to all related forward-looking statements wherever they appear in this prospectus. These risks are not exhaustive. New risks emerge from
time to time and it is not possible to predict or identify all such risks, nor can we assess the impact of all such risks on our business
or the extent to which any risk or combination of risks may cause actual results to differ materially from those contained in any forward-looking
statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based upon information currently available to us, and while we believe such information forms a reasonable basis for such statements,
such information may be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry
into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not
to unduly rely upon these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_003"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights, and is qualified in its entirety by, the more detailed information and financial statements included elsewhere in
this prospectus. This summary does not contain all of the information that may be important to you in making your investment decision.
You should read this entire prospectus carefully, especially the &#8220;Risk Factors&#8221; section beginning on page 8 and our consolidated
financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our Common Stock or
Warrants.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes (&#8220;CD8+ CTLs&#8221; or &#8220;CTLs&#8221;), to develop off-the-shelf, precision T cell therapies for the treatment
of infectious diseases, cancers, and neurological disorders, with the aim of addressing the significant unmet needs of large patient
populations. We believe that sustainability and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility
through advanced science, innovative business models and engagement across the development lifecycle and healthcare system. We believe
the full potential of T cell therapies remains largely untapped, and aspire to be the first biotechnology company offering commercially
attractive, economically viable, and cost-effective personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology platform, ExacTcell, represents a significant scientific breakthrough with
the potential to mainstream cell therapy with a new class of off the shelf &#8211; manufactured and stored for immediate use &#8211;
T cell therapies with diverse applications across virology, oncology, and neurology. ExacTcell is a set of processes and
methodologies to develop, enrich, and expand single human leukocyte antigen (&#8220;HLA&#8221;) restricted CTL therapies with proactively
selected, precisely defined targets. HLA molecules are proteins that play an important role in the immune system&#8217;s ability to recognize
&#8220;self&#8221; versus &#8220;foreign.&#8221; There are numerous HLA types that vary from person to person. CD8+ CTLs, also known
as killer T cells, are white blood cells that are part of the immune system and destroy infected, malignant, or otherwise damaged cells.
We are focused on using ExacTcell to develop allogeneic therapeutics, meaning therapeutics that are intended to be infused in patients
other than the original donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
therapies are based on carefully selected, naturally occurring CTLs that recognize targets of interest from the body&#8217;s native T
cell receptor pool, unlike genetically engineered T cell therapies. CD8+ CTLs in ExacTcell-based products target multiple and distinct
antigens, with the aim to circumvent the impact of mutations in viruses and cancer cells that can render existing treatments ineffective.
ExacTcell is designed to maximize the immunologic specificity of our products in order to eliminate malignant and virally infected cells
while allowing healthy cells to remain intact. We believe this high degree of specificity has the potential to significantly reduce the
chances of cross-reactivity or adverse impact on healthy cells. Our confidence in ExacTcell is reflected in our development pipeline,
which has been carefully tailored to address the unmet needs of large patient populations grappling with life-threatening viral diseases,
both viral and non-viral induced cancers, and neurological disorders such as multiple sclerosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised
and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease
(&#8220;Long COVID&#8221;). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production
plants. Elimination of infected cells is necessary to allow them to be replaced by healthy, uninfected counterparts. TVGN 489 consists
of CTLs active against multiple precise, well defined, and well characterized targets across the SARS-CoV-2 genome. The product progressed
from pre-discovery to the clinic in less than 18 months, and in January 2023, we completed the Phase 1 proof-of-concept clinical trial
of TVGN 489 for the treatment of ambulatory, high-risk adult COVID-19 patients. No dose-limiting toxicities or significant treatment-related
adverse events were observed in the treatment arm. Secondary endpoints showing a rapid reduction of viral load and that infusion of TVGN
489 did not prevent development of the patients&#8217; own T cell-related (cellular) or antibody-related (humoral) anti-COVID-19 immunity
were also met. None of the patients who participated in the trial reported progression of infection, reinfection, or the development
of Long COVID during the six-month follow-up period. These clinical observations were mirrored by laboratory evidence of the persistence
of TVGN 489 cells for at least six months after treatment. The results of the trial were submitted for peer-review and were published
in <i>Blood Advances</i> in June 2024. We believe these findings validate our initiative to develop off-the-shelf T cell therapies for
outpatient administration, targeting diseases that affect large patient populations &#8211; for the very first time. We plan to launch
a pivotal trial of TVGN 489 in COVID-19 patients with B cell malignancies, with studies of other highly vulnerable populations thereafter.
TVGN 489 is also in preclinical development for treatment and prevention of Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as Semper Paratus Acquisition Corporation on April 21, 2021. On February 14, 2024, we closed the Business Combination
with Tevogen Bio, as a result of which Tevogen Bio became a wholly owned subsidiary of ours, and we changed our name to Tevogen Bio Holdings
Inc. Although we are the legal acquirer of Tevogen Bio in the Business Combination, we are treated as the &#8220;acquired&#8221; entity
for financial reporting purposes and Tevogen Bio has been deemed to be the accounting acquirer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus assumed all obligations of Tevogen Bio under pre-existing
convertible promissory notes issued by Tevogen Bio (the &#8220;Tevogen Bio Convertible Notes&#8221;) with an aggregate principal amount
totaling approximately $24.0 million and aggregate accrued interest of approximately $2.8 million as of the consummation of the Business
Combination. The Tevogen Bio Convertible Notes converted pursuant to their terms immediately following the Closing into shares of Common
Stock, resulting in the issuance of 10,337,419 shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;),
on the Closing Date. The holders of the convertible notes included The Patel Family, LLP and HMP Partners, LLC (&#8220;HMP Partners&#8221;),
both of which are associated with Dr. Manmohan Patel, an existing investor in the Company and beneficial owner of more than 5% of
the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscription
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2023, we entered into a Subscription Agreement (the &#8220;First Subscription Agreement&#8221;) with Semper Paratus Sponsor
LLC (the &#8220;Original Sponsor&#8221;) and Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) pursuant to which Polar agreed
to make a cash contribution of $151,000 to the Original Sponsor (the &#8220;Initial Capital Contribution&#8221;) on or prior to May 3,
2023, which was in turn loaned to us to cover working capital expenses. In consideration for the Initial Capital Contribution, we issued
151,000 shares of Common Stock to Polar at the closing of the Business Combination, and we agreed to repay the cash contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, we entered into a second subscription agreement (the &#8220;Second Subscription Agreement&#8221; and together with the
First Subscription Agreement, the &#8220;Subscription Agreements&#8221;) with SSVK and Polar, pursuant to which Polar agreed to lend
to SSVK, which would in turn be lent to us, an aggregate of $1,500,000 (the &#8220;Additional Capital Commitment&#8221;) to cover working
capital expenses. In consideration for the Additional Capital Commitment, we issued 1,500,000 shares of Common Stock to Polar, and
we agreed to repay the
cash contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fee
Reduction Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) was entitled to an aggregate of $14,700,000 in deferred underwriting commissions,
to be deferred until consummation of the Business Combination. The deferred fee was to become payable to the underwriter from
the amounts held in the trust account created in connection with Semper Paratus&#8217; initial public offering solely in the event that
we completed a Business Combination. On June 28, 2023, we entered into a fee reduction agreement with Cantor (the &#8220;Fee Reduction
Agreement&#8221;) pursuant to which Cantor agreed to forfeit $9,700,000 of the deferred underwriting fees payable, resulting in a remainder
of $5,000,000 of deferred underwriting fees payable (the &#8220;Reduced Deferred Fee&#8221;) to Cantor that became payable in the form
of shares of Common Stock upon the closing of the Business Combination. We issued 500,000 shares of Common Stock to Cantor in payment
of the Reduced Deferred Fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase
shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024, we entered into an amended
and restated securities purchase agreement pursuant to which that amount was reduced to $2.0 million (as amended and restated, the &#8220;Purchase
Agreement&#8221;). The shares of Series A Preferred Stock are convertible into a total of 500,000 shares of Common Stock at the election
of the holder. The Series A Preferred Stock is subject to a call right providing us the right to call the stock if the volume weighted
average price of the Common Stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and in
each case there is an effective resale registration statement on file covering the underlying Common Stock. The investor in the
Series A Preferred Stock is an entity associated with Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the Common Stock.
This prospectus relates to the resale of up to 500,000 shares of Common Stock issuable upon the conversion of the Series A Preferred
Stock and the Series A-1 Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A-1 Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the investor agreed to purchase shares of our Series A-1 Preferred Stock for an aggregate purchase price of
$6.0 million. The shares of Series A-1 Preferred Stock will be convertible into a total of 600,000 shares of Common Stock at the election
of the holder. The Series A-1 Preferred Stock will be subject to a call right providing us the right to call the stock if the volume
weighted average price of the Common Stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share
and in each case there is an effective resale registration statement on file covering the underlying Common Stock. The investor
in the Series A-1 Preferred Stock is an entity associated with Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the Common
Stock. This prospectus relates to the resale of up to 600,000 shares of Common Stock issuable upon the conversion of the Series A-1 Preferred
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conversion
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into agreements (the &#8220;Conversion Agreements&#8221;) with SSVK and Mr. Ajjarapu pursuant to
which we issued an aggregate of 174,000 shares of Common Stock in relation to services that were to have been provided to us and
Tevogen Bio, at an effective price of $10.00 per share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2024, we entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with The Patel Family, LLP (the &#8220;Lender&#8221;)
providing for (i) an unsecured line of credit facility (the &#8220;Facility&#8221;), pursuant to which the Lender agreed to lend the
Company up to $36.0 million (the &#8220;Maximum Loan Amount&#8221;), and (ii) a contingent option for the Lender to purchase at least
$14.0 million of Common Stock in a future private placement (the &#8220;Optional PIPE&#8221;). Pursuant to the terms of the Agreement,
the Company issued to the Lender 1,000,000 shares of Common Stock as a commitment fee (the &#8220;Commitment Shares&#8221;), subject
to forfeiture by the Lender of the Commitment Shares or an equal number of shares of Common Stock in the event the Lender fails to (i)
make a deposit under the Facility when due or (ii) pay the purchase price for the Optional PIPE within 30 days after the Threshold
Price Notice Date (as defined in the Loan Agreement) in the event the Company has satisfied all applicable closing conditions. The
Lender is an entity associated with Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the Common Stock. This prospectus
relates to the resale of the Commitment Shares. The Loan Agreement is described in more detail under &#8220;<i>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Funding Requirements&#8212;Loan
Agreement</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Letter
of Engagement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2024, Semper Paratus and Tevogen Bio entered into a letter agreement (the &#8220;Letter of Engagement&#8221;) with Maxim Group
LLC and J.V.B. Financial Group, LLC (together with their affiliates, the &#8220;Placement Agents&#8221;) for capital markets advisory
services. In addition to certain cash compensation, Semper Paratus and Tevogen Bio agreed to issue 300,000 shares of Common Stock to
each Placement Agent in connection with the consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lock-Up
Agreements and Sale to SSVK</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2021, Semper Paratus entered into a letter agreement (the &#8220;Letter Agreement&#8221;) with the Original Sponsor and certain individuals party thereto (the &#8220;Insiders&#8221;), pursuant to which, among
others things, the Original Sponsor and each Insider agreed that the Class B ordinary shares of Semper Paratus then held by the Original
Sponsor would not be transferable or salable until the earlier of (A) one year after the completion of the Business Combination or (B)
the occurrence of certain events (the &#8220;Letter Agreement Lock-Up&#8221;) and that the private placement units then held by the Original
Sponsor would not be transferable or salable until 30 days after completion of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2023, the Original Sponsor, holding all of the issued and outstanding Class B ordinary shares of Semper Paratus elected to
convert its Class B ordinary shares into Class A ordinary shares on a one-for-one basis (the &#8220;Conversion&#8221;). As a result,
11,983,333 of the Company&#8217;s Class B ordinary shares were cancelled and 11,983,333 Class A ordinary shares were issued to the Original
Sponsor. The Original Sponsor agreed that all of the terms and conditions applicable to the founder shares (as defined elsewhere in
this prospectus) set forth in the Letter Agreement would continue to apply to the Class A ordinary shares that the founder shares
converted into, including the Letter Agreement Lock-Up.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, Semper Paratus, the Original Sponsor, and SSVK entered into a Sponsor Purchase Agreement (the &#8220;Sponsor Share Purchase
Agreement&#8221;), pursuant to which SSVK agreed to purchase from the Original Sponsor 7,988,889 Class A ordinary shares and 1,000,000
private placement units for an aggregate purchase price of $1.00. Additionally SSVK agreed to assume the responsibilities and obligations
of the Original Sponsor related to Semper Paratus. Consequently, the parties to the Letter Agreement were updated to include SSVK and
Semper Paratus&#8217; officers and directors as parties to the Letter Agreement. The transactions contemplated by the Sponsor Share Purchase
Agreement closed June 7, 2023, and the Original Sponsor transferred the Class A ordinary shares and the private placement units to SSVK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2024, Semper Paratus, the Original Sponsor, SSVK, and certain individuals party thereto entered into an Amendment to the
Letter Agreement, which, among others things, replaced the reference to &#8220;one year after completion of the initial business combination&#8221;
in the Letter Agreement Lock-Up with &#8220;six months after the completion of the initial business combination.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In addition,
on February 14, 2024, in connection with the consummation of the Business Combination, we entered into the Lock-Up Agreement (the
&#8220;Lock-Up Agreement&#8221;) with SSVK, our director Surendra Ajjarapu, and our Chief Executive Officer and Chairperson Ryan
Saadi (the &#8220;Locked-Up Parties&#8221;) with respect to our securities held by the Locked-Up Parties (the &#8220;Lock-Up
Securities&#8221;), pursuant to which each Locked-Up Party agreed subject to specified exceptions not to transfer any Lock-Up
Securities until the earlier of (A) six months after the Closing Date and (B) subsequent to the Business Combination, (x) if the
closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150
days after the Business Combination, or (y) the date on which we complete a liquidation, merger, share exchange, or other similar
transaction that results in all of our stockholders having the right to exchange their Common Stock for cash, securities, or other
property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Earnout Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Former
holders of Tevogen Bio common stock and SSVK are eligible to receive up to an aggregate of 24,500,000 shares of Common Stock
(&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Common Stock reaches specified
threshold levels during the three-year period commencing on the Closing Date. Following the Closing, former holders of Tevogen Bio
common stock may receive up to 20,000,000 Earnout Shares in tranches of 6,666,667, 6,666,667, and 6,666,666 shares of Common Stock
per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the Common Stock is greater
or equal to $15.00, $17.50, and $20.00, respectively, over any twenty trading days within any thirty consecutive day trading period
during the three-year period after the Closing. SSVK received the right to Earnout Shares with the same terms above, except
that each of SSVK&#8217;s three earnout tranches are for 1,500,000 shares of Common Stock, for an aggregate of 4,500,000
shares across the entire SSVK earnout.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock Repurchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, we entered into a Preferred Stock Repurchase Agreement (the &#8220;Repurchase Agreement&#8221;) with SSVK, pursuant
to which we repurchased and cancelled, with immediate effect, the outstanding shares of our Series B Preferred Stock in exchange for
(i)&#160;the reassignment to and reassumption by us of the liabilities assigned under the Assignment and Assumption Agreement (as defined
elsewhere in this prospectus) and (ii)&#160;the termination of the Assignment and Assumption Agreement, and SSVK released us from
certain claims relating to the Repurchase Agreement and the Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Bid Price Deficiency</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and our Warrants are listed on the Nasdaq Global Market. We are required to meet specified financial requirements in order
to maintain such listing, including a requirement that the closing bid price for our Common Stock remain above $1.00.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, we received a notification letter from Nasdaq&#8217;s Listing Qualifications Staff notifying us that the closing bid price
for our Common Stock had been below $1.00 for the previous 35 consecutive business days and that we therefore are not in compliance with
the minimum bid price requirement for continued inclusion on Nasdaq under Nasdaq Listing Rule 5450(a)(1). The notification has no immediate
effect on the listing of our Common Stock and our Warrants on Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq Listing Rules, we have a period of 180 calendar days, or until December 11, 2024, to regain compliance. To regain compliance,
the closing bid price of our Common Stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such
case, Nasdaq will provide us with written confirmation of compliance. If we do not regain compliance by December 11, 2024, we may be
eligible for an additional 180 calendar days, provided that we meet certain requirements. We intend to take all reasonable measures available
to us to achieve compliance to allow for continued listing on Nasdaq. However, there can be no assurance that we will be able to regain
compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to a variety of risks and uncertainties, including risks that could have a material adverse effect on our business, financial
condition, results of operations, and cash flows. The following summary of the principal factors that make an investment in our securities
speculative or risky should not be relied upon as an exhaustive summary of the material risks facing us. You should read the following
summary together with the more detailed description of risks under &#8220;Risk Factors&#8221; this prospectus and the other information
contained in this prospectus before investing in our securities. Capitalized terms not otherwise defined below have been defined elsewhere
in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Financial Position and Need for Additional Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history, no products approved for commercial sale, have never generated
                                            revenue from product sales, and have a history of significant losses.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is substantial doubt about the ability to continue as a going concern due to cash on hand.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will require substantial additional financing to pursue our business objectives.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Development, Regulatory Review, and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
                                            of cellular therapy product candidates is rigorous, complex, uncertain, and subject to change.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have limited experience designing and implementing preclinical and clinical trials, which
                                            are complex, expensive, time-consuming, difficult to design and implement, and involve uncertain
                                            outcomes.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to develop, receive regulatory approval for, and commercialize our product
                                            candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter substantial delays and disruptions in the development of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            FDA regulatory approval process is lengthy and time-consuming.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may never receive regenerative medicine advanced therapy designation for any product candidate,
                                            and this designation may not lead to a faster development or regulatory review or approval
                                            process.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business is highly dependent on our first product candidate, TVGN 489.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            from our clinical trials may change and are subject to audit, validation, and verification
                                            procedures.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
                                            results and results of earlier trials may not be predictive of future results.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            TVGN 489 proof-of-concept clinical trial results may be less reliable than results in larger
                                            clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in product candidate manufacturing or formulation may result in additional costs or delay.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
                                            is unproven and may not result in marketable products.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse
                                            or unacceptable side effects may be identified during development.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter difficulties enrolling patients in our clinical trials.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to suspend, repeat, or terminate our clinical trials if they are not conducted
                                            in accordance with regulatory requirements, the results are negative or inconclusive, or
                                            the trials are not well designed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not achieve our projected development goals in the time frames we announce and expect.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
                                            at government agencies could hinder or prevent product development and commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                            of product candidates in combination with other therapies presents additional regulatory
                                            risks.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Business Development and Commercialization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            commercial success depends upon attaining significant market acceptance of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulated
                                            biologics may be subject to biosimilar competition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            incidence and prevalence of target patient populations are based on estimates and third-party
                                            sources.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will face extensive ongoing regulatory requirements and regulatory review after regulatory
                                            approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to establish sales and marketing capabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                            to comply with or adapt to changes in data protection, privacy, and similar laws could materially
                                            and adversely harm our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
                                            systems may fail or suffer security breaches.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coverage
                                            and reimbursement may be limited or unavailable in certain market segments.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
                                            reform may negatively impact our ability to sell our product candidates profitably.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could violate healthcare fraud and abuse, false claims, and health information privacy and
                                            security laws.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail to comply with environmental, health and safety laws and regulations.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Manufacturing and Reliance on Third Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            manufacture of cell therapies is subject to a multitude of manufacturing risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            efforts to establish manufacturing capabilities will involve time and expense and may not
                                            be successful.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            loss of suppliers or their inability to supply us with adequate materials could harm our
                                            business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not obtain marketing approval for or successfully commercialize product candidates as
                                            a result of failures by third parties.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to establish collaborations on commercially reasonable terms.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to obtain and maintain sufficient patent protection for our product candidates
                                            or ExacTcell.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            patent protection could be reduced or eliminated for non-compliance with patent agency requirements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to protect our intellectual property rights throughout the world.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in patent law could diminish the value of patents in general.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may become involved in lawsuits to protect or enforce our intellectual property.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
                                            patents covering our product candidates could be found invalid or unenforceable if challenged
                                            in court.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
                                            parties may initiate legal proceedings alleging that we are infringing their intellectual
                                            property rights.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
                                            may claim an ownership interest in our intellectual property and our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to protect the confidentiality of our proprietary information.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to claims asserting that our agents have wrongfully used or disclosed alleged
                                            trade secrets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            trademarks and trade names may be inadequately protected.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
                                            property rights do not necessarily address all potential threats.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are highly dependent on our key personnel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may face substantial competition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to grow the size of our organization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
                                            liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be limited in our ability to use our net operating loss carryforwards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Being a Public Company and Ownership of Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            price of our Common Stock and Warrants may fluctuate significantly.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
                                            of a substantial number of our securities by existing securityholders could cause their price
                                            to fall.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not have the funds necessary to satisfy our future obligations under the terms of our
                                            outstanding preferred stock (the &#8220;Preferred Stock&#8221;).</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                            to regain compliance with Nasdaq&#8217;s $1.00 minimum closing bid price requirement or
                                            to otherwise meet Nasdaq continued listing requirements could result in delisting of
                                            our securities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            incur increased costs due to operating as a public company, and our management devotes substantial
                                            time to compliance initiatives and corporate governance practices.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may issue additional shares of our Common Stock or other equity securities without your approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have no current plans to pay regular cash dividends on our Common Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            management team has limited experience managing a public company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysts
                                            may not publish research about us or may change their recommendation regarding our Common
                                            Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could become subject to securities litigation or stockholder activism.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to take write-downs or write-offs, restructuring and impairment or other
                                            charges.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail to maintain proper and effective internal control over financial reporting.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            individuals have substantial control over us.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may redeem warrants at a time that is disadvantageous to warrant holders.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            warrant holder exercising warrants on a &#8220;cashless basis&#8221; will receive fewer shares
                                            of Common Stock from such exercise than through a cash exercise.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            public warrants may never be in the money and they may expire worthless.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio was incorporated June 1, 2020, as a Delaware corporation. Semper Paratus was incorporated on April 21, 2021 as a Cayman Islands exempted
company under the name Semper Paratus Acquisition Corporation. In connection with the closing of the Business Combination, Semper Paratus
became a Delaware corporation and we changed our name to Tevogen Bio Holdings Inc. Our Common Stock and Warrants are listed on Nasdaq
under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221; respectively. Our principal executive offices are located at 15 Independence
Boulevard, Suite #410, Warren, New Jersey 07059, and our telephone number is (877) 838-6436. Our website address is <i>www.tevogen.com</i>.
The information contained in, or accessible through, our website does not constitute a part of this prospectus. We have included our
website address in this prospectus solely as an inactive textual reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company and Smaller Reporting Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;).
As such, we are eligible for and intend to take advantage of certain exemptions from various reporting requirements applicable to other
public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including, but not
limited to, (a) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (b)
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and (c) exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies are required to comply with the standards. Semper Paratus previously elected to avail itself of the extended transition period
and we will take advantage of the benefits of the extended transition period emerging growth company status permits. During the extended
transition period, it may be difficult or impossible to compare our financial results with the financial results of another public company
that complies with public company effective dates for accounting standard updates because of the potential differences in accounting
standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2026 (the last day of the fiscal year
following the fifth anniversary of the consummation of Semper Paratus&#8217;s initial public offering (the &#8220;IPO&#8221;)),
(b) the last date of our fiscal year in which we have a total annual gross revenue of at least $1.235 billion, (c) the date on which
we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC with at least $700.0 million of outstanding securities
held by non-affiliates, and (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the
previous three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain
of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for
so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on
the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed
fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured
on the last business day of our second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_004"></span>THE
OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of Common Stock offered by us</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,474,978
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of Common Stock offered by the Registered Holders</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,851,308
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of Common Stock outstanding prior to the exercise of all Warrants, options referenced above</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">167,114,418
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (as of June 20, 2024).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                            offered by the Registered Holders</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">725,000
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                            outstanding</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,974,978
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants (as of June 21, 2024).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
                                            price per share pursuant to the Warrants</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
                                            of proceeds</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of shares by the Registered Holders. We will receive the proceeds from any exercise of
    the Warrants or options for cash, which we intend to use for general corporate and working capital purposes. We may receive up to
    an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise price of each of our Warrants is
    $11.50 per Warrant. However, the last reported sales price of our Common Stock on June 20, 2024 was $0.755. The
    likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds that we may receive,
    is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues to be less than $11.50
    per share, we do not expect holders to exercise their Warrants. Additionally, under certain circumstances, the Warrants may be exercised
    on a cashless basis and we will not receive any proceeds from such exercise, even if the Private Placement Warrants are in-the-money.
    See &#8220;<i>Use of Proceeds</i>&#8221; on page 49 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            factors</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should carefully read the &#8220;<i>Risk Factors</i>&#8221; beginning on page 8 and the other information included in this prospectus
    for a discussion of factors you should consider carefully before deciding to invest in our Common Stock or Warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            symbol for our Common Stock</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TVGN&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            symbol for our Warrants</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TVGNW&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_005"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our Common Stock or Warrants involves a high degree of risk. Before making an investment, you should carefully consider the following
risks and uncertainties, as well as general economic and business risks, and the other information contained in this prospectus. These
risk factors are not exhaustive, and investors are encouraged to perform their own investigation with respect to our business, financial
condition and prospects. Our business, financial condition, results of operations, or prospects could be materially and adversely affected
if any of these risks occurs, and as a result, the market price of our Common Stock and Warrants could decline and you could lose all
or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and no products approved for commercial sale and have never generated revenue from product sales. We
have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve
or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company with a limited operating history. Investment in immunotherapy product development
entails substantial upfront capital expenditures and significant risk that product candidates will fail to prove safe or effective, gain
regulatory approval or become commercially viable. Since our founding in 2020, we have incurred significant net losses. We have funded
our operations to date primarily with proceeds from offerings of convertible notes and preferred stock and have devoted substantially
all of our efforts and financial resources to organizing and staffing our company, conducting discovery, research, and development activities,
securing intellectual property rights related to our product candidates and ExacTcell platform, raising capital, and the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that it could be years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses
and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from year to year. We anticipate
that our expenses will increase substantially if, and as, we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            to advance the development of TVGN 489 and our preclinical product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leverage
                                            our ExacTcell platform to advance additional product candidates into preclinical and clinical
                                            development;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            regulatory approvals for any product candidates that successfully complete clinical trials
                                            and potential commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            and expand our current good manufacturing practice (&#8220;cGMP&#8221;) manufacturing capacity,
                                            including to provide drug supply for future clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            additional clinical, quality control, regulatory, scientific, and administrative personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
                                            our operational, financial, and management systems and increase personnel, including to support
                                            our clinical development, manufacturing, and commercialization efforts and our operations
                                            as a public company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                            expand, and protect our intellectual property portfolio;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            a marketing, sales, distribution, and medical affairs infrastructure to commercialize any
                                            products for which we may obtain marketing approval and commercialize, whether on our own
                                            or jointly with a partner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
                                            or in-license other technologies or engage in strategic partnerships; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
                                            additional legal, accounting, or other expenses in operating our business.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated revenue. To become and remain profitable, we, whether on our own or jointly with a collaborator, must develop
and commercialize products with significant market potential. Our ability to generate revenue from product sales and achieve profitability
depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory
approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for some time,
if ever. Our ability to generate future revenue from product sales depends heavily on our, or our potential future collaborators&#8217;,
success in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing
                                            preclinical studies and clinical trials of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
                                            and obtaining marketing approvals for any product candidates that we or our collaborators
                                            develop;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
                                            authorization of investigational new drug applications (&#8220;INDs&#8221;) for future product
                                            candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
                                            and developing new product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            cGMP supply of our product candidates for clinical trials and, if approved, commercial sales;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
                                            and commercializing products for which we obtain marketing approval by establishing a marketing,
                                            sales, distribution, and medical affairs infrastructure or, alternatively, collaborating
                                            with a commercialization partner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
                                            coverage and adequate reimbursement by hospitals and third-party payors, including governmental
                                            authorities, such as Medicare and Medicaid, private insurers, and managed care organizations,
                                            for product candidates, if approved, that we or our collaborators develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            market acceptance of product candidates, if approved, that we develop as viable treatment
                                            options;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
                                            any competing technological and market developments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
                                            favorable terms in any collaboration, licensing, or other arrangements into which we may
                                            enter and performing our obligations under such arrangements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining,
                                            protecting, and expanding our portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">defending
                                            against third-party interference or infringement claims, if any; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
                                            hiring, and retaining qualified personnel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough
to achieve profitability and may need to obtain additional funding to continue operations. If we do achieve profitability, we may not
be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease
the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business,
or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management has concluded that due to cash on hand, there is substantial doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our cash balance, as well as our history of operating losses and negative cash flows from operation combined with our anticipated
use of cash to, among other things, fund the preclinical and clinical development of our products, identify and develop new product candidates,
and seek approval for TVGN 489 and our other product candidates and any other product candidates we develop, our management has concluded
that under applicable accounting requirements and disclosure rules there is substantial doubt about our ability to continue as a going
concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
transactions entered into in connection with the Business Combination provided some capital and reduced our liabilities, $3.8 million
in expected proceeds from those transactions have not yet been received, and our future viability as an ongoing business is dependent
on our ability to generate cash from operating activities or to raise additional capital to finance our operations. Furthermore, the
disclosure regarding the ability to continue as a going concern could have an impact on our ability to raise additional funds through
the issuance of new debt or equity securities or otherwise and on our relationships with third party contractual parties, notwithstanding
our expectation that we will raise funds as and when required. If we are unable to continue as a going concern, we may have to liquidate
our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors
will lose all or a part of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are relying in part on forthcoming proceeds from the sale of our Series A-1 Preferred Stock to meet our liquidity needs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary sources of funds to meet our near-term liquidity and capital requirements include cash on hand, including the funding we have
received from the sale of our Series A Preferred Stock, and the funding we expect to receive from the Loan Agreement and the sale of
our Series A-1 Preferred Stock. On February 14, 2024, we entered into a securities purchase agreement with an investor pursuant to which
an investor agreed to purchase shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024,
we entered into an agreement pursuant to which that amount was reduced to $2.0 million and the investor agreed to purchase shares of
our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million. We have received only $2.2 million of the $6.0
million aggregate purchase price for the shares of Series A-1 Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying in part on the proceeds from the sale of our Series A-1 Preferred Stock to meet our liquidity needs. Even if we receive all
of such proceeds, we will still need additional capital to fully implement our business, operating, and development plans. At this time,
we have not secured any additional financing. There can be no assurance that additional capital will be available to us, or that, if
available, it will be on terms satisfactory to us. If we do not obtain additional capital on terms satisfactory to us, or at all, it
may cause us to delay, curtail, scale back or forgo some or all of our research and development or business operations, which could have
a material adverse effect on our business and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at
all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development,
commercialization efforts or other operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to spend substantial amounts of cash to continue the preclinical and clinical development of our current and future programs.
If we receive marketing approval for any product candidates, including TVGN 489, we will require significant additional amounts of cash
in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and
outcomes of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary
to successfully complete the development of and commercialize any product candidate we develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, timing, results, and costs of researching and developing TVGN 489 and our
                                            other product candidates, including product candidates developed with our ExacTcell platform,
                                            and of conducting preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of, and the costs involved in, obtaining marketing approval for TVGN 489 and any future
                                            product candidates we develop, if clinical trials are successful;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of manufacturing TVGN 489 and any future product candidates for preclinical studies
                                            and clinical trials and in preparation for marketing approval and commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of commercialization activities, including marketing, sales, and distribution costs,
                                            for TVGN 489 and any future product candidates we develop if any of these product candidates
                                            are approved for sale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to establish and maintain strategic collaborations, licensing, or other arrangements
                                            on favorable terms, if at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and
                                            enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing, receipt, and amount of sales of, or royalties on, our future products, if any; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            emergence of competing therapies and other developments in the markets we intend to address.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance
our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances,
and licensing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the terms of the Preferred Stock and our Loan Agreement may negatively impact our ability
to raise additional capital through equity or debt financings, due to the potential substantial dilution to our stockholders that could
occur as a result of the conversion of our convertible Preferred Stock or our issuance of shares under the Loan Agreement and due to
the other terms of our Preferred Stock and the Loan Agreement, or may negatively affect our ability to obtain favorable or acceptable
terms in connection with any such financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if we raise additional capital through marketing, sales, and distribution arrangements or other collaborations, strategic alliances,
or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, future revenue
streams, research programs, or technologies or grant licenses on terms that may not be favorable to us. If we raise additional capital
through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of Common Stock
or securities convertible or exchangeable into Common Stock, your ownership interest will be diluted. If we raise additional capital
through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our
ability to take specific actions, such as incurring additional debt, making capital expenditures, engaging in acquisition, merger, or
collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments,
declaring dividends, or other operating restrictions that could adversely impact our ability to conduct our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future debt financing or other financing of securities senior to our Common Stock will likely include financial and other covenants
that will restrict our flexibility. Any failure to comply with these covenants may cause an event of default and acceleration of the
obligation to pay the debt, which would have a material adverse effect on our business, prospects, financial condition, and results of
operations and we could lose our existing sources of funding and impair our ability to secure new sources of funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market
conditions. If we are unable to obtain additional financing on favorable terms when needed, we may be required to delay, limit, reduce,
or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Development, Regulatory Review, and Product Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory landscape that applies to cellular therapy product candidates is rigorous, complex, uncertain, and subject to change. Our
allogeneic T cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny,
delays in clinical development or delays in or our ability to achieve regulatory approval, if at all, and commercialization or payor
coverage and reimbursement of our product candidates, if approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our unique approach to T cell therapy. Because these programs, particularly our pipeline of allogeneic
T cell product candidates that are developed from donors, represent a novel approach to immunotherapy for the treatment of virus-infected
cells in order to produce T cell immunity, developing and commercializing our product candidates subjects us to a number of challenges,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            regulatory approval from FDA, which has relatively limited experience with regulating the
                                            development and commercialization of T cell immunotherapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            and deploying consistent and reliable processes for procuring blood from consenting third-party
                                            donors, isolating T cells from the blood of such donors, activating the isolated T cells
                                            against specific antigens, characterizing and storing the resulting activated T cells for
                                            future therapeutic use, selecting and delivering a sufficient supply and breadth of appropriate
                                            human leukocyte antigen-matched (&#8220;HLA-matched&#8221;) cells from among the available
                                            T cell lines, and finally infusing these activated T cells into patients to eliminate virus-infected
                                            cells in the patient and induce anti-disease benefit;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relying
                                            on healthcare provider site availability and accessibility to patients for receipt of T cell
                                            infusions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">utilizing
                                            these product candidates in combination with other therapies currently used to treat patients
                                            in our target population, which may increase the risk of adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">educating
                                            medical personnel regarding the potential side effect profile of each of our product candidates,
                                            particularly those that may be unique to our allogeneic T cell therapy product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">understanding
                                            and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately
                                            affect our ability to manufacture product in a reliable and consistent manner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            processes for the safe administration of these products, including long-term follow-up and
                                            registries, as applicable, for all patients who receive these product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            our product candidates to our specifications and in a timely manner to support our clinical
                                            trials and, if approved, commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sourcing
                                            clinical and, if approved by FDA, commercial supplies for the materials used to manufacture
                                            and process these product candidates that are free from viruses and other pathogens that
                                            may increase the risk of adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            a manufacturing process and distribution network that can provide a stable supply with a
                                            cost of goods that allows for an attractive return on investment;</span></td></tr></table>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            sales and marketing capabilities ahead of and after obtaining any regulatory approval to
                                            gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party
                                            payors and government authorities; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            therapies for types of diseases beyond those initially addressed by our current product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
developments in preclinical studies or clinical trials conducted by others in cellular therapy products may cause FDA and other regulatory
bodies to amend the requirements for approval of any product candidates we may develop or limit the use of products utilizing cellular
therapy technologies, either of which could harm our business. In addition, FDA&#8217;s clinical trial requirements and its criteria
for determining the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended
use and market of the potential products. The regulatory approval process for product candidates such as ours could be more expensive
and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we
are developing novel potential treatments for diseases in which in some cases there is relatively little clinical experience with new
endpoints and methodologies, there is heightened risk that FDA or other regulatory bodies may not consider the clinical trial endpoints
to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. Regulatory agencies
administering existing or future regulations or legislation may not allow production and marketing of products utilizing cellular therapy
technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation
could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that the manufacturing processes used in connection with our T cell immunotherapy product candidates will yield a sufficient
supply of satisfactory products that are safe, pure, and potent, scalable, or profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the
willingness of patients to participate in clinical trials, or if approved by FDA, of physicians to subscribe to the novel treatment mechanics.
FDA may ask for specific post-market requirements, such as establishment of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;),
and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of any
current or future product candidate. We cannot predict the likelihood, nature or extent of government regulation that may arise from
future legislation or administrative action. If we are slow or unable to adapt to changes in existing requirements or to the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we
may have obtained. In addition, the regulatory landscape applicable to artificial intelligence is immature and changes to existing regulations
or new regulations could impede our use of artificial intelligence, which could impair our ability to achieve our goals for our artificial
intelligence initiative and result in an adverse effect on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
an organization, we have limited experience designing and implementing preclinical and clinical trials, which is a complex, expensive,
and time-consuming process and involves uncertain outcomes, and we have never conducted pivotal clinical trials. We may fail to adequately
design a trial, which could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory
approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience designing and implementing preclinical and clinical trials, which is a complex, expensive, and time-consuming
process and involves uncertain outcomes. All of our product candidates are in preclinical or clinical development and their risk of failure
is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if
approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and
in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial
sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials
that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates
are subject to regulation as biological products, we will need to demonstrate that they are safe, pure, and potent for use in their target
indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for
its intended use. We cannot be certain of the timely completion or outcome of our preclinical studies and clinical trials and cannot
predict if FDA will accept our proposed clinical programs or if the outcome of our preclinical studies and clinical trials will ultimately
support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit
INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that such submission
will result in FDA allowing clinical trials to begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we may not successfully or cost-effectively design and implement preclinical and clinical trials that achieve our desired clinical endpoints
efficiently, or at all. A clinical trial that is not well designed may delay or prevent initiation or completion of the trial, can lead
to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on
the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product
successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or
more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could
lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. See &#8220;&#8212;
<i>Risks Related to Reliance on Manufacturing and Third Parties</i>.&#8221; If these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for
or commercialize TVGN 489 any future product candidates we develop, and our business could be materially harmed. We may require more
time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we
develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to successfully develop, receive regulatory approval for, and commercialize our product candidates, our business will be
harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our product candidates are still in preclinical and clinical development and, with the exception of TVGN 489, we are early in our
development efforts. FDA permitted our IND for TVGN 489 to proceed in May 2021,
and we began enrolling subjects in October 2021. Each of our programs and product candidates will require additional preclinical and/or
clinical development, regulatory approval, obtaining manufacturing supply, capacity, and expertise, building a commercial organization
or successfully outsourcing commercialization, substantial investment, and significant marketing efforts, before we generate any revenue
from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize
marketable products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenue from our product candidates, which could take years to develop, if it ever does, will depend heavily on the
successful development, regulatory approval, and eventual commercialization of our product candidates. The success of our product candidates
or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
                                            and successful completion of preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effective
                                            INDs submitted to FDA that allow commencement of our clinical trials for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficiency
                                            of our financial and other resources to complete the necessary preclinical studies and clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            development of, or making arrangements with third-party manufacturers for, our commercial
                                            manufacturing processes for our clinical trials and any of our product candidates that receive
                                            regulatory approval at an acceptable cost and on a timely basis;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            of timely marketing approvals from FDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
                                            commercial sales of products, if approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of the benefits and use of our products, if approved, by patients, the medical community,
                                            and third-party payors, for their approved indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of adverse events or other safety issues experienced with our product
                                            candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability, perceived advantages, cost, safety, and efficacy of alternative therapies for
                                            any product candidate, and any indications for such product candidate, that we develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to produce any product candidates we develop on a commercial scale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining patent, trademark and trade secret protection and regulatory exclusivity
                                            for our product candidates and otherwise protecting our rights in our intellectual property
                                            portfolio;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            compliance with regulatory requirements, including cGMP requirements;</span></td></tr></table>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining coverage and adequate reimbursement by third-party payors, including government
                                            payors, for our products, if approved by FDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            a continued acceptable safety, tolerability and efficacy profile of the products following
                                            approval; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            and growing an organization of scientists and functional experts who can develop and commercialize
                                            our products and technology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not succeed with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or
an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not
receive marketing approvals for any product candidate we develop, we may not be able to continue our operations. Even if regulatory approvals
are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product
candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of
any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays and disruptions in completing the development of our product candidates that could impair our ability
to successfully commercialize our product candidates and may harm our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience delays in completing planned clinical trials for a variety of reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extensive research and development required because our product candidates are based on new
                                            technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of financial resources to commence and complete the planned trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
                                            agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;)
                                            and clinical trial sites, the terms of which can be subject to extensive negotiation and
                                            may vary significantly among different CROs and trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            or independent institutional review boards (&#8220;IRBs&#8221;) may not authorize us or our
                                            investigators to commence a clinical trial or conduct a clinical trial at a prospective trial
                                            site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
                                            suitable patients to participate in a trial or sufficient patients to complete a trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
                                            patients complete a trial or return for post-treatment follow-up;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trial sites deviating from trial protocol or dropping out of a trial, which may require that
                                            we add new clinical trial sites or investigators;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            the necessary product for use in the clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trials of any product candidate may fail to show safety, purity, or potency, or may produce
                                            negative or inconclusive results, which may cause us to decide, or regulators to require
                                            us, to conduct additional nonclinical trials or clinical trials or which may cause us to
                                            decide to abandon product candidate development programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            of our product candidates could cause undesirable side effects that could result in significant
                                            negative consequences, including the inability to enter clinical development or receive regulatory
                                            approval; and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            from other clinical trial programs for similar indications and clinical trial patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinical trial may also be suspended or terminated by us, the IRB for the institutions in which such trials are being conducted, the
data and safety monitoring board (&#8220;DSMB&#8221;) for such trial, or by FDA due to a number of factors. Those factors could include
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by FDA, resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack
of adequate funding to continue the clinical trial. In addition, FDA may order the temporary or permanent discontinuation of our clinical
trials at any time if it believes that the clinical trials are not being conducted in accordance with applicable regulatory requirements
or that they present an unacceptable safety risk to the patients enrolled in our clinical trials, or that the applicable INDs do not
contain sufficient information to assess the risks to patients in the proposed trials. For example, in November 2020, FDA placed a clinical
hold on our IND for TVGN 489 for the treatment of patients with COVID-19 infection, requested certain information regarding the manufacture
of TVGN 489, and asked us to revise our sterility testing approach so that such testing is performed on the final drug product, as opposed
to testing before harvesting the cells for cryopreservation. In May 2021, FDA found that we sufficiently addressed all of these issues
and lifted the clinical hold, permitting us to initiate our Phase 1 trial, which we completed in January 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience regulatory delays or rejections as a result of many reasons. For example, we believe based on precedential industry examples,
including in areas with high unmet needs or strong early phase clinical trial results, that we may be able to commence pivotal trials
of TVGN 489 on the basis of the results of our completed Phase 1 trial. However, the clinical trial process usually includes three phases,
and our current plan to move TVGN 489 from its recently completed Phase 1 trial directly into pivotal trials may be rejected by FDA or
may be otherwise unfeasible. We may have to conduct additional Phase 1 testing or other Phase 2 trials, or may experience other delays,
prior to escalating TVGN 489 into a pivotal trial. At this stage, we cannot be certain whether we will be permitted to move from a Phase
1 trial directly to pivotal trials until FDA reviews and concurs with or rejects our proposed plans, and FDA may require us to conduct
further trials to generate additional safety and efficacy data. If regulatory inspectors conclude that we or our clinical trial sites
are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations
or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses
to be inadequate, or are dissatisfied with corrective actions, our clinical trials may be temporarily or permanently discontinued, we
or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve
our marketing applications or allow us to manufacture or market our products, we may face civil enforcement actions from FDA, and we
may be criminally prosecuted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects
for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our product development and approval process, and jeopardize our ability to commence
product sales and generate revenue. Significant clinical trial delays could also allow our competitors to bring products to market before
we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. In addition, many of the
factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of
regulatory approval of our product candidates or result in the development of our product candidates stopping early.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA regulatory approval process is lengthy and time-consuming and may lead to significant delays in the clinical development and regulatory
approval of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval from FDA is unpredictable but typically takes many years following the commencement of clinical trials
and depends upon numerous factors, including the substantial discretion of FDA. Any delay in obtaining FDA and/or other necessary regulatory
approvals in the United States for any investigational new drug and failure to receive such approvals would have an adverse effect on
the investigational new drug&#8217;s potential commercial success and on our business, prospects, financial condition, and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not obtained regulatory approval for any product candidate. We have not previously submitted a Biologics License Application (&#8220;BLA&#8221;)
to FDA. It is possible that none of our current or future product candidates will ever obtain regulatory approval from FDA. The novel
nature of our product candidates may create further challenges in obtaining regulatory approval. The regulatory approval pathway for
our product candidates may be uncertain, complex, expensive, and lengthy, and approval may not be obtained. In addition, factors outside
our control, such as government shutdowns, natural disasters, and public health emergencies, could disrupt business at FDA, which could
result in delays of reviews, approvals and communications with FDA related to our clinical trials and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may disagree with the design or implementation of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate to the satisfaction of FDA that a product candidate is safe,
                                            pure, and potent for its proposed indication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of clinical trials may not meet the level of statistical significance required by
                                            FDA for approval;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits
                                            outweigh its safety risks;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials of our product candidates may not be sufficient to support
                                            the submission of a BLA to FDA to obtain regulatory approval in the United States; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may find deficiencies with or fail to approve our manufacturing processes or facility or
                                            the manufacturing processes or facilities of third-party manufacturers with which we contract
                                            for clinical and commercial supplies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval
to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. Even if
we believe the data collected from current or future clinical trials of our product candidates are promising, such data may not be sufficient
to support approval by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approval, FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient
population, than we request; may grant approval contingent on the performance of costly post-approval clinical trials or other post-marketing
requirements; or may approve a product candidate with labeling that does not include the claims we believe are necessary or desirable
for the successful commercialization of such product candidates. Moreover, if we modify TVGN 489 and our other product candidates so
that they recognize and target new or more prevalent variants of COVID-19 and other viruses, we may have to either file a supplemental
BLA with FDA or receive FDA approval for a comparability protocol or obtain other regulatory approval. These requirements may be costly
and time-consuming and FDA ultimately may not approve of such changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also change its policies, promulgate additional regulations, revise existing regulations, or take other actions that may prevent
or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional
requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain
any marketing authorizations we may have obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may never receive regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation for TVGN 489 or any other product candidate,
and receiving this designation may not lead to a faster development or regulatory review or approval process, and will not increase the
likelihood that such product candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek RMAT designation from FDA for TVGN 489 for the treatment of COVID-19, or for our other product candidates. FDA may find that
TVGN 489 or our other product candidates do not meet the criteria for RMAT designation or may otherwise deny our requests for RMAT designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMAT
designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product
candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for
accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or
reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites post-approval, if appropriate.
RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the
submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence; through the collection
of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the
therapy. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), FDA is permitted to require that a post-approval confirmatory
study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated
approval. FDORA also requires sponsors to send updates to FDA on the status of such studies and FDA must promptly post this information
publicly. FDORA also gives FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited
basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to FDA, or if such post-approval studies
fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, FDA is empowered to take action, such as issuing fines, against
companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their
progress. In addition, for products being considered for accelerated approval, FDA generally requires, unless otherwise informed by the
agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval
be submitted to the agency for review during the pre-approval review period. There can be no assurance that FDA would allow any of the
product candidates we may develop to proceed on an accelerated approval pathway, and even if FDA did allow such pathway, there can be
no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted
on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify
clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval
does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMAT
designation does not change the standards for product approval, and there is no assurance that any such designation or eligibility will
result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation.
Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is highly dependent on our first product candidate, TVGN 489, and we must conduct clinical testing before we can obtain regulatory
approval and begin commercialization of any of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and personnel resources and are placing significant focus on the development of TVGN 489, we may forgo or delay
pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current
and future research and development programs and other future product candidates for specific indications may not yield any commercially
viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future
product candidate, we may relinquish valuable rights to those future product candidates through collaboration, licensing, or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim
and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit, validation, and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim
data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as
patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation,
and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously
published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the
final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects
and may cause the trading price of our Common Stock to fluctuate significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
results of earlier preclinical and clinical trials may not be predictive of future clinical trial results. Initial positive results in
any of our clinical trials may not be indicative of results obtained when the trial is completed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
can occur at any time during the clinical trial process. Preclinical studies and early-stage clinical trials are primarily designed to
test safety, to study pharmacokinetics and pharmacodynamics, and to understand the side effects of product candidates at various doses
and schedules, and the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the
results of larger, later-stage controlled clinical trials. For example, our current or future product candidates may demonstrate different
chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological
systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological
properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical
trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Product
candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical
trials. Our sole clinical trial to date was conducted on a small number of patients in a single academic clinical site for a limited
number of indications. We will have to conduct larger, well-controlled trials in our proposed indications at multiple sites to verify
the results obtained to date and to support any regulatory submissions for further clinical development of our product candidates. Our
assumptions related to our product candidates, such as with respect to lack of toxicity, are based on an early limited clinical trial
and may prove to be incorrect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even
after achieving promising results in earlier, smaller clinical trials, and any such setbacks in our clinical development could have a
material adverse effect on our business and operating results. Moreover, clinical data are often susceptible to varying interpretations
and analyses that may delay, limit, or prevent regulatory approval. We do not know whether any later stage clinical trials of TVGN 489
or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication
for use sufficient to receive regulatory approval or market our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the number of patients in our proof-of-concept clinical trial of TVGN 489 was small, the results from this trial may be less reliable
than results achieved in larger clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
trial design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as
proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes,
such as our proof-of-concept clinical trial of TVGN 489, can be disproportionately influenced by the impact the product had on a few
individuals, which limits the ability to generalize the results across a broader community, thus making the study results less reliable
than studies with a larger number of patients and making it difficult to predict final results from preliminary results. Our proof-of-concept
clinical trial only tested TVGN 489 in the most common HLA type, and while we intend to treat patients with the six most common HLA types
in our next clinical trial of TVGN 489, our results in our proof-of-concept clinical trial may not be predictive of results in other
HLA types. As a result, there may be less certainty that TVGN 489 would achieve a statistically significant effect in any future clinical
trials. If we conduct any future clinical trials of TVGN 489, we may not achieve a statistically significant result. Similarly, if we
conduct a clinical trial of any other product candidate we develop with a small sample size, the results of any such trial may be less
reliable than results achieved in larger clinical trials and may provide less certainty of achieving statistically significant effects
in any future clinical trials. Such results could negatively impact our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA notification, or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or
the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, and jeopardize
our ability to commence sales and generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
approach to the discovery and development of product candidates using our ExacTcell platform is unproven and may not result in marketable
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our business depends in part upon our ability to develop and commercialize cell therapies based on our proprietary ExacTcell
platform. We have only conducted one Phase 1 trial based on a product developed using ExacTcell. Our approach to the development of cell
therapies using ExacTcell is novel. We may not continue to have access to effective HLA-typing diagnostics and may have difficulties
in obtaining or manufacturing significant quantities and breadth of single HLA-restricted cell lines to use in clinical trials or sufficient
to cover desired patient populations. We cannot assure the product candidates we develop with ExacTcell will be found to be safe and
effective in treating any disease so as to achieve marketing approval. If we uncover any previously unknown risks related to ExacTcell,
or if we experience unanticipated problems or delays in developing our ExacTcell product candidates, we may be unable to achieve our
strategy of building a broad pipeline of cell therapy product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse
or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory
approval and commercialization, increase our costs, or necessitate the abandonment or limitation of the development of some of our product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive
preclinical studies and clinical trials that our product candidates are safe, pure, and effective for use in each target indication,
and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy
of the product candidate studied for the target indication. The use of our current or future product candidates could be associated with
side effects or adverse events, which could vary in severity from minor reactions to death and in frequency from infrequent to prevalent.
In addition, if one or more of our product candidates or our T cell platform technology proves to be unsafe it would also materially
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side
effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse
events were not caused by the drug or administration process or related procedures, FDA could order us to cease further development of,
or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious
adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete
the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our
product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from
any of these product candidates may be delayed or eliminated. In addition, these side effects may not be appropriately recognized or
managed by the treating medical staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our current and future product candidates have undergone and will undergo extensive safety testing and, where applicable, under such
conditions discussed with FDA, not all adverse effects of drugs can be predicted or anticipated. Immunotherapy and its method of action
of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials
or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates
have been approved by FDA and the approved product has been marketed, resulting in the exposure of additional patients. If our product
candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their
development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe,
or more acceptable from a risk-benefit perspective. So far, we have not demonstrated that TVGN 489 or any other product candidate is
safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates
fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue
and our business will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct
additional preclinical studies regarding the safety and efficacy of our product candidates that we have not planned or anticipated. Such
findings could further result in FDA failing to provide marketing authorization for our product candidates or limiting the scope of the
approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found
to cause side effects that prevented further development of the product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such
products, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may withdraw approvals of such product;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may require additional warnings on the labels such as a &#8220;black box&#8221; warning or
                                            a contraindication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to create a medication guide outlining the risks of such side effects for
                                            distribution to patients or other requirements subject to a REMS;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            could be sued and held liable for harm caused to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to achieve or maintain third-party payor coverage and adequate reimbursement;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                            restrictions may be imposed on the marketing of the particular product or the manufacturing
                                            processes for the product or any component thereof; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reputation and physician or patient acceptance of our products may suffer.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of FDA in a timely
manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to
enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We
may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends
on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patient eligibility criteria defined in the protocol;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            nature and size of the patient population required for analysis of the trial&#8217;s primary
                                            endpoints and the process for identifying patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number and location of participating clinical sites or patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            design of the trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
                                            and patients&#8217; perceptions as to the potential advantages and risks of the product candidate
                                            being studied in relation to other available therapies, including any new products that may
                                            be approved for the indications we are investigating;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of competing commercially available therapies and other competing drug candidates&#8217;
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain patient informed consents for participation in our clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that patients enrolled in clinical trials will drop out of the trials before completion;
                                            and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">factors
                                            outside of our control, including as a result of business interruptions resulting from natural
                                            disasters and public health emergencies, such as the coronavirus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons, including as a result of the
COVID-19 pandemic or similar occurrences. Conversely, a decrease in cases may reduce the number of eligible candidates for trials testing
COVID-19 therapeutics, such as TVGN 489. Additionally, as time passes, treating COVID-19 may become a less critical issue in the eyes
of the public, further limiting the potential patient population for COVID-19 therapeutics. Moreover, TVGN 489 may represent a departure
from more commonly used methods for COVID-19 treatment, and potential patients and their doctors may be inclined to use more conventional
therapies for the treatment of COVID-19 rather than enroll in any future clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the study until its conclusion. In addition, our clinical trials may compete with existing therapies
and other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition
may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead
opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee that our clinical trials will progress
as planned or as scheduled. Delays from difficulties in patient enrollment in a clinical trial may result in increased costs or affect
the timing, outcome, or completion of the trial, which could delay or prevent our receipt of regulatory approval of the applicable product
candidate or to abandon the trial altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to suspend, repeat, or terminate our clinical trials if they are not conducted in accordance with regulatory requirements,
the results are negative or inconclusive, or the trials are not well designed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted in accordance with FDA&#8217;s Good Clinical Practices (&#8220;GCP&#8221;) requirements. Clinical trials are
subject to oversight by FDA and IRBs or ethical committees at the study sites where the clinical trials are conducted. In addition, clinical
trials must be conducted with product candidates manufactured in accordance with applicable cGMP requirements. Clinical trials may be
suspended by FDA, us, a DSMB, or by an IRB with respect to a particular clinical trial site, for various reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the conduct of the clinical trials, including failure to conduct the clinical trial in
                                            accordance with regulatory requirements or study protocols;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the clinical trial operations or trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
                                            adverse side effects or the emergence of undue risks to study subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the trial design necessary to demonstrate efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            product candidate may not appear to offer benefits over current therapies; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            quality or stability of the product candidate may fall below acceptable standards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such suspension or delay may result in us failing to obtain regulatory approval for our product candidates, which would materially harm
our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may
be delayed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing, and other
product development goals, which we may refer to as milestones. These milestones may include the commencement or completion of preclinical
studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may announce the
expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual
timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, including
with respect to challenges related to enrollment, manufacturing, and our reliance on third parties to conduct, supervise or monitor some
or all aspects of our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at FDA and other government agencies, such as those that may be caused by funding shortages, could hinder their ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized
in a timely manner or at all, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
statutory, regulatory, and policy changes, FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees,
and other events that may otherwise affect FDA&#8217;s ability to perform routine functions. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of FDA and other government agencies on which our operations
may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid
and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at FDA and other agencies may also slow the time necessary for biological products, or biologics, or modifications to approved biologics
to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government
shutdown occurs, it could significantly impact the ability of FDA to timely review and process our regulatory submissions, which could
have a material adverse effect on our business. For example, over the last several years, the United States government has shut down
several times and certain regulatory agencies, such as FDA, have had to furlough critical FDA employees and stop critical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may develop future product candidates in combination with other therapies, which exposes us to additional regulatory risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may develop future product candidates in combination with one or more currently approved therapies. These combinations may, among other
things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other
combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those
clinical trials or obtain marketing approval for the combination therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with
other existing therapies, we would continue to be subject to the risk that FDA or a comparable foreign regulatory authorities could revoke
approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing, or supply issues could
arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also evaluate future product candidates in combination with one or more other therapies that have not yet been approved for marketing
by FDA or comparable foreign regulatory authorities. We will not be able to market and sell TVGN 489 or any product candidate we develop
in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing,
or supply issues arise with, the biologics we choose to evaluate in combination with any product candidate we develop, we may be unable
to obtain approval of or market any such product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Business Development and Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients,
healthcare payors and the medical community, including hospitals and outpatient clinics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not
gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts,
including hospitals and outpatient clinics. Market acceptance of any of our product candidates for which we receive approval depends
on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            efficacy and safety of the product candidates as demonstrated in clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            clinical indications and patient populations for which the product candidate is approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            by physicians and patients of the drug as a safe and effective treatment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            administrative and logistical burden of treating patients, including the availability and
                                            accessibility of healthcare provider sites for administering infusions to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            adoption of novel cellular therapies by physicians, hospitals, and third-party payors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential and perceived advantages of product candidates over alternative treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            safety of product candidates seen in a broader patient group, including its use outside the
                                            approved indications should physicians choose to prescribe for such uses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            restrictions on use together with other medications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
                                            product labeling or package insert requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of market introduction of our products as well as competitive products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development of manufacturing and distribution processes for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost of treatment in relation to alternative treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of coverage and adequate reimbursement from, and our ability to negotiate pricing
                                            with, third-party payors, providers, and government authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience and ease of administration; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of our sales and marketing efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect the product candidates we develop will be regulated biologics and therefore they may be subject to biosimilar competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) created an abbreviated pathway for the approval of for biological
product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. Under the BPCIA, an application
for a biosimilar product cannot be approved by FDA until 12 years after the reference product was approved under a BLA. The law is complex
and is still being interpreted and implemented by FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
Although it is uncertain when processes intended to implement BPCIA may be fully adopted by FDA, any of these processes could have a
material adverse effect on the future commercial prospects for our biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should
qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened, potentially creating
the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted
for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not
yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Additionally, the increased likelihood
of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to these risks, and uncertainties
regarding patent protection, if one of our product candidates are approved for marketing, it is not possible to predict the length of
market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current
forms of regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues
from product sales of that product and thus our financial results and condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the approval of a biologic product that is a biosimilar to one of our products could have a material adverse impact on our
business as it may be significantly less costly to bring to market and may be priced significantly lower than our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
incidence and prevalence of the target patient population for TVGN 489 are based on estimates and third-party sources. If the market
opportunity for TVGN 489 or our other product candidates is smaller than we estimate or if any approval that we obtain is based on a
narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
we make estimates regarding the incidence and prevalence of target patient populations based on various third-party sources and internally
generated analysis. These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity
for TVGN 489 will depend on, among other things, acceptance of TVGN 489 by the medical community, patient access, drug pricing and reimbursement,
and the number of eligible patients with COVID-19, which may decrease. The number of patients in the addressable markets may turn out
to be lower than expected, patients may not be otherwise amenable to treatment with TVGN 489, or new patients may become increasingly
difficult to identify or gain access to or may not have the requisite HLA-typing to receive the drug, all of which may significantly
harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our product candidates receive regulatory approval, we will still face extensive ongoing regulatory requirements and continued regulatory
review, which may result in significant additional expense, and our products may still face future development and regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for a product candidate, it would be subject to ongoing requirements by FDA governing the manufacture,
materials and facilities, qualification testing, quality control, further development, labeling, packaging, storage, distribution, post-approval
clinical data, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety
and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports,
establishment registration and product listing, as well as continued compliance by us and/or our contract manufacturing organizations
(&#8220;CMOs&#8221;) and CROs for any post-approval clinical trials that we conduct. The safety profile of any product will continue
to be closely monitored by FDA after approval. If FDA become aware of new safety information after approval of any of our product candidates,
they may require labeling changes or establishment of a REMS, impose significant restrictions on a product&#8217;s indicated uses or
marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of cell therapies and their facilities are subject to initial and continual review and periodic inspections by
FDA for compliance with cGMP, GCP, good laboratory practice (&#8220;GLP&#8221;), good tissue practice (&#8220;GTP&#8221;) and other regulations.
For certain commercial prescription biological products, manufacturers, and other parties involved in the supply chain must also meet
chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying FDA
of counterfeit, diverted, stolen, and intentionally adulterated products or other products that are otherwise unfit for distribution
in the United States. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated
severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on
that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension
of manufacturing. If we, our product candidates, or the manufacturing facilities for our product candidates fail to comply with applicable
regulatory requirements, a regulatory agency may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
                                            warning letters or untitled letters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandate
                                            modifications to promotional materials or require us to provide corrective information to
                                            healthcare practitioners, or require other restrictions on the labeling or marketing of such
                                            products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to enter into a consent decree, which can include imposition of various fines, reimbursements
                                            for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend,
                                            withdraw, or modify regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                            or modify any ongoing clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
                                            to approve pending applications or supplements to applications filed by us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                            or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
                                            or detain products, refuse to permit the import or export of products, or require us to initiate
                                            a product recall.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of the foregoing may inhibit our ability to successfully commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by FDA, the U.S. Federal
Trade Commission, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services, state attorneys
general, members of the U.S. Congress and the public. Violations, including actual or alleged promotion of our products for unapproved
or off-label uses, are subject to enforcement letters, inquiries and investigations, and potential civil and criminal sanctions by FDA.
Any actual or alleged failure to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective
information to healthcare practitioners, injunctions, or civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product
candidates, we may be unable to generate any revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are at an early stage of establishing an organization that will be responsible for the sale, marketing and distribution of cell therapy
products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to
market any products that may be approved by FDA, we must build our sales, marketing, managerial and other non-technical capabilities
or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate
training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of these products. We may be competing with many companies that currently have extensive and well-funded sales and marketing operations.
Without a sufficiently scaled, appropriately timed, and trained internal commercial organization or the support of a third party to perform
sales and marketing functions, we may be unable to compete successfully against these more established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes
in these laws could materially and adversely harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to federal and state data privacy and security laws and regulations and expectations relating to privacy continue to evolve.
Changes in these laws may limit our data access, use, and disclosure, and may require increased expenditures. In addition, data protection,
privacy and similar laws protect more than patient information and, although they vary by jurisdiction, these laws can extend to employee
information, business contact information, provider information, and other information relating to identifiable individuals. For example,
the California Consumer Privacy Act requires covered businesses to, among other things, provide disclosures to California
consumers regarding the collection, use and disclosure of such consumers&#8217; personal information and afford such consumers new rights
with respect to their personal information, including the right to opt out of certain sales of personal information. Comprehensive and
sensitive data laws in a number of states have gone into or will go into effect during the next few years. We believe that further increased
regulation in additional jurisdictions is likely in the area of data privacy. Any of the foregoing may have a material adverse effect
on our ability to provide services to patients and, in turn, our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
protection, privacy and similar laws protect more than patient information and, although they vary by jurisdiction, these laws can extend
to employee information, business contact information, provider information, and other information relating to identifiable individuals.
Failure to comply with these laws may result in, among other things, civil and criminal liability, negative publicity, damage to our
reputation, and liability under contractual provisions. In addition, compliance with such laws may require increased costs to us or may
dictate that wet not offer certain types of services in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those used by our contractors or consultants, may fail, or suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and the systems of our contractors and consultants are vulnerable to damage from cyber-attacks and unauthorized
access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations.
For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result
in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could
incur liability and the further development and commercialization of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult
for us to sell our product candidates, if approved, profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors
including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others.
Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance. Third-party
payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend
upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is a covered
benefit under its health plan, safe, effective, and medically necessary, appropriate for the specific patient, cost-effective, and neither
experimental nor investigational.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement of a product from a government or other third-party payor is a time consuming and costly process that could
require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we
obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for
use in their facility or third-party payors may require co-payments that patients find unacceptably high. Separate reimbursement for
the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing
the treatment or procedure in which our product is used. Further, at least annually, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)
revise the reimbursement systems used to reimburse health care providers, which may result in reduced Medicare payments. In some cases,
private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare
programs that reduce payments under these programs may negatively impact payments from private third-party payers and reduce the willingness
of physicians and providers to use our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage
for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
Because our product candidate may have a higher cost of goods than conventional therapies, and may require long-term follow-up evaluations,
the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant
uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and reimbursement for our product candidate. Moreover, payment methodologies
may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures
are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. We expect
to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare,
the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in
the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from
list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate
and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some
cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts
or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. Increased efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate
payment for our product candidate. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be
subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics
is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time
after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that
compare the cost-effectiveness of a particular product candidate to currently available therapies. Other European Union member states
allow companies to fix their own prices for medicines but monitor and control company profits. In addition, in some countries, cross-border
imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other
third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue.
Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status
is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates
may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory
changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been heightened governmental scrutiny in the United States of pharmaceutical and biologics pricing practices in light of the
rising cost of prescription drugs and biologics. This scrutiny has resulted in various Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates
or additional pricing pressures. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors, which may adversely affect our future profitability. Individual states in the United States have also
become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure
and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls
on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and
prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine
what drug products and which suppliers will be included in their prescription drug and other healthcare programs. The continuing efforts
of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs
of healthcare and/or impose price controls may adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the
federal False Claims Act, and federal and state transparency laws and regulations. These laws may impact, among other things, our proposed
sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government
and the states in which we conduct our business. These laws, described in further detail in &#8220;<i>Regulatory Environment &#8211;
Healthcare Regulation &#8211; Other Healthcare Laws and Compliance Requirements</i>,&#8221; include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly
                                            and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly,
                                            to induce, or in return for, the purchase or recommendation of an item or service reimbursable
                                            under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal civil False Claims Act, which prohibits, among other things, individuals or entities
                                            from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment
                                            of government funds, or knowingly making, using or causing to be made or used, a false record
                                            or statement material to an obligation to pay money to the government or knowingly concealing
                                            or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money
                                            to the federal government;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;),</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            which created new federal criminal statutes that prohibit executing a scheme to defraud any
                                            healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act, and
                                            its implementing regulations, which imposes specified requirements relating to the privacy,
                                            security, and transmission of individually identifiable health information;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            U.S. federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices,
                                            biologics, and medical supplies for which payment is available under Medicare, Medicaid or
                                            the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually
                                            to the CMS information related to direct or indirect payments and other transfers of value
                                            to physicians and teaching hospitals (and certain other practitioners), as well as ownership
                                            and investment interests held in the company by physicians and their immediate family members;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
                                            law equivalents of each of the above federal laws, such as anti-kickback and false claims
                                            laws that may apply to items or services reimbursed by any third-party payor, including governmental
                                            and private payors, laws that require manufacturers to comply with the pharmaceutical industry&#8217;s
                                            voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
                                            government, or otherwise restrict payments that may be made to healthcare providers and other
                                            potential referral sources, state laws that require drug manufacturers to report information
                                            related to payments and other transfers of value to physicians and other healthcare providers
                                            or marketing expenditures, and state laws governing the privacy and security of health information
                                            in specified circumstances, many of which differ from each other in significant ways and
                                            may not have the same scope or application, thus complicating compliance efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our collaborations with third parties, and our business generally, will comply with applicable United States and healthcare
laws and regulations will involve substantial costs. Governmental authorities could conclude that our business practices may not comply
with statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to violate any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs,
contractual damages, reputational harm, disgorgement or curtailment or restricting of our operations, any of which could substantially
disrupt our operations and diminish our profits and future earnings. If any of the physicians or other providers or entities with whom
we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs. The risk of our being found in violation of these laws is
increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions
are open to a variety of interpretations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers, physicians including clinical investigators, CROs and third-party payors are subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, transparency laws,
government price reporting and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial
partners, vendors, or other agents violate these laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
laws may impact, among other things, our clinical research programs as well as our proposed and future sales, marketing, and education
programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations
designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We
may also be subject to federal, state, and foreign laws governing the privacy and security of identifiable patient information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform.
Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare
providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. Because
of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that
some of our business activities, or our arrangements with physicians, could be subject to challenge under one or more of such laws. If
we or our employees, independent contractors, consultants, commercial partners, and vendors violate these laws, we may be subject to
investigations, enforcement actions and/or significant penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and
prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure
that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental
and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or
case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against
us, and we are not successful in defending themselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from
participation in federal healthcare programs, reputational harm, diminished profits and future earnings, additional reporting requirements
and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance
with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results
of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely
subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable
materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We cannot eliminate the
risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials,
we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs
associated with civil or criminal fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Manufacturing and Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
manufacture of cell therapies is subject to a multitude of manufacturing risks, any of which could substantially increase our costs and
limit supply of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing cell therapies is complex, highly regulated, subject to multiple risks, and requires significant expertise.
Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial
production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, shortages
of qualified personnel, and compliance with strictly enforced regulations. Cell therapy manufacturing facilities also require appropriate
commissioning and validation activities to demonstrate that they operate as designed. There are limited numbers of CMOs that operate
under cGMP regulations and that are capable of manufacturing cell therapies, and transferring manufacturing processes and know-how is
complex and may require utilization of new or different processes to meet the specific requirements of a given facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
therapy manufacturing is susceptible to product loss due to contamination, equipment failure, and vendor or operator error. The facilities
in which our product candidates will be made could also be adversely affected by pandemics, natural disasters, equipment failures, labor
shortages, power failures, supply chain problems, changes in laws and regulations, and numerous other factors. Even minor deviations
from normal manufacturing and distribution for any of our product candidates could result in reduced production yields, impact to product
quality, and other supply disruptions. Manufacturing cell therapies is susceptible to risks associated with the need to maintain aseptic
conditions throughout the manufacturing process. Contamination with pathogens or ingress of microbiological material may result in unusable
product and could also delay the manufacture of product candidates, resulting in delays in development. If contamination is discovered,
the facilities in which our product candidates are made may need to be closed for an extended period of time for investigation and remediation.
Because our cell therapy product candidates are manufactured from the cells of third-party donors, the manufacturing process is also
susceptible to insufficient quantity or inadequate quality of third-party donor material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
is also subject to FDA and comparable foreign regulation. For example, FDA will not approve a cellular product if the manufacturer is
not in compliance with cGMPs and GTPs, to the extent applicable. If we are unable to reliably produce products in accordance with specifications
acceptable to authorities, we may not obtain or maintain the approvals we need to commercialize our product candidates. Failure to comply
with manufacturing regulations may lead to regulatory enforcement actions against our third-party manufacturers or us that result in
fines and civil and criminal penalties, imprisonment, suspension, delay, or restriction of production, injunctions, delay or denial of
product approval, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications
warning the public about safety issues with the cell therapies, refusal to permit import or export, product seizure, detention, or recall,
lawsuits under the civil False Claims Act, or consent decrees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
efforts to establish manufacturing capabilities, either on our own or through a contract relationship, will involve significant time
and expense and may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing experience as an organization and with our contractors is limited. We relied on a Clinical Trial Services and Materials
Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our Phase 1 proof-of-concept trial. However, we will need
to establish manufacturing capabilities, either on our own or through a contract relationship, in order to meet our projected supply
needs for clinical and commercial materials to support our activities through regulatory approval and commercial manufacturing of our
product candidates, if approved. Our efforts to develop manufacturing capability are currently focused on acquiring existing manufacturing
facilities or constructing one or more new manufacturing facilities, including through collaboration with a potential facility development
partner. Securing a manufacturing facility will involve considerable time and expense, and may not be successful. In addition, we cannot
ensure that we can successfully manufacture our products in compliance with cGMP, GTP, and any other applicable laws, regulations, and
standards in sufficient quantities for clinical trials or for commercial sale. We have no prior experience in establishing a manufacturing
facility and we may encounter challenges given the complexity of manufacturing cell therapies. We must also compete for the small number
of individuals with expertise in cell therapy manufacturing. Even if we are able to establish manufacturing operations, given the complexities
of manufacturing cell therapy products, there is no assurance that we will be able to successfully produce sufficient amounts, or sufficient
quality, of TVGN 489 in order to move forward with our clinical development plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or
their inability to supply us with adequate materials could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence
on these suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited
control over pricing, availability, and quality and delivery schedules. We also face competition for supplies from other cell therapy
companies. Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable
terms or in a timely manner. Our negotiation leverage is limited, and we are likely to get lower priority than our competitors that are
larger than we are. In addition, the biotechnology market has recently experienced supply chain disruptions. We cannot be certain that
our suppliers will continue to provide us with the quantities of the raw materials that we require or satisfy our anticipated specifications
and quality requirements whether due to our size or otherwise. Any supply interruption in limited or sole sourced raw materials could
materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified.
We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance
failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including
limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the third parties we rely on to help conduct our preclinical studies and clinical trials do not successfully carry out their contractual
duties, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize
TVGN 489 and any future product candidates we develop, and our business could be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
outsource some of the conduct and management of our clinical trials to third parties. Agreements with clinical investigators and medical
institutions for clinical testing and with other third parties for data management services and clinical trial management services place
substantial responsibilities on these parties that, if unmet, could result in delays in, or termination of, our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on universities, medical institutions, clinical investigators, contract laboratories and other third parties to conduct or help
us conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While
we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their
actual performance. The third parties with whom we contract play a significant role in the conduct of these studies and trials and the
subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts
with such third parties, we have limited ability to control the amount or timing of resources that they devote to our current or future
product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical
trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its
investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory
responsibilities. If any of our clinical trial sites fail to comply with GCP, we may be unable to use the data gathered at those sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Some
of our agreements may also be terminated by these third parties under certain other circumstances. If the third parties conducting our
preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant
business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced,
or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and GCP,
or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly,
or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated, or repeated. As a result,
we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial
results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may depend on third-party collaborators for the development and commercialization of certain of our current and future product candidates.
If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may form or seek strategic alliances, joint ventures, or collaborations, or enter into licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we
develop. Potential future collaborations involving our product candidates may pose the following risks to us:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly enforce, maintain, or defend our intellectual property rights or may use our proprietary information in a way that
    gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information,
    exposing us to potential litigation or other intellectual property proceedings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between a collaborator and us that cause the delay or termination of the research, development, or commercialization of
    the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient
    resources to the marketing and distribution of such products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our product
    development or commercialization program under such collaboration could be delayed, diminished, or terminated; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
    agreements may restrict our right to independently pursue new product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41.75pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into collaboration agreements and strategic partnerships or license our intellectual property, products, or businesses, we may
not be able to realize the expected benefit of such transactions if we are unable to successfully integrate them with our existing operations,
which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction
or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above and any delays
in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development
and commercialization of our product candidates, which would harm our business prospects, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event a present or future collaborator terminates their agreement with us, we would be prevented from receiving the benefits of any
such agreement, which could have a materially adverse effect on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have to alter our development and commercialization plans if we seek to establish collaborations and are not able to establish them
on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advancement of our product candidates and development programs and the potential commercialization of our current and future product
candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide
to collaborate with third parties with respect to development and potential commercialization. Any of these relationships may require
us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing
stockholders, or disrupt our management and business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether
we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s
resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of
factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval
by FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs
and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence
of uncertainty with respect to our ownership of technology and market conditions generally. The collaborator may also consider alternative
product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could
be more attractive than the one with us for our product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators.
Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been
a significant number of business combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced
number of potential future collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have
to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program
or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which
may not be available to us on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain adequate patent protection for our product candidates or ExacTcell, our competitors could develop
and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our product candidates. We have sought, and intend to seek, to protect our proprietary position by filing patent applications
in the United States and abroad related to our product candidates and technology that are important to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial
value of our patent rights are highly uncertain. Our issued patents may not, and our pending and future patent applications may not result
in patents being issued that adequately protect our technology or product candidates or prevent others from commercializing similar or
alternative competitive technologies and product candidates. There is no assurance that all potentially relevant prior art relating to
our patents and patent applications is known to us or has been found. We may be unaware of prior art that could be used to invalidate
an issued patent or prevent a pending patent application from issuing as a patent. Because patent applications in the United States and
most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we
were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have
filed such patent applications, we may challenge their ownership, for example in a derivation proceeding before the U.S. Patent and Trademark
Office (the &#8220;USPTO&#8221;) to determine who has the right to the claimed subject matter in the applications. Similarly, if our
patent applications are challenged in a derivation proceeding, the USPTO may hold that a third party is entitled to certain patent ownership
rights instead of us. We may then be forced to seek a license from the third party that may not be available on commercially favorable
terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or
license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail
to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the
USPTO and various government patent agencies outside of the United States over the lifetime of our patents or applications and any patent
rights we own or may own in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural,
documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can
be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance
could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In
addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our patents in all countries
outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and,
further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as
that in the United States. These products may compete with our products and our patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition,
results of operations and prospects may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding
the prosecution of patent applications and the enforcement or defense of issued patents. After March 2013, under the Leahy-Smith America
Invents Act (the &#8220;America Invents Act&#8221;), the United States transitioned to a first inventor to file system in which, assuming
that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on
an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also included
a number of significant changes that affected the way patent applications are prosecuted and also may affect patent litigation. These
include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity
or ownership of a patent by USPTO administered post-grant proceedings, including post-grant review, <i>inter partes</i> review and derivation
proceedings. Additional changes in patent law could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events
has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material
adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property rights, or we may be required to defend against claims of infringement. Countering infringement
or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to
be negative, it could have a substantial adverse effect on the price of our Common Stock. Such litigation or proceedings could
substantially increase our operating losses and reduce the resources available for development activities or any future marketing, sales,
or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their
greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation
and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop
the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce
our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages
or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop
or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issued
patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect
our trade secrets in court.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we initiate legal proceedings against a third party to enforce any patent that is issued covering one of our product candidates, the
defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the
United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, or
non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type
double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or
the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding
of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third
parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.
Such mechanisms include re-examination, post grant review, <i>inter partes</i> review and equivalent proceedings in foreign jurisdictions.
Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover
our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain
that there is no invalidating prior art of which the patent examiner and we were unaware during prosecution. If a defendant were to prevail
on a legal assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection on one or more
of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents, including portions of our ExacTcell platform. However, trade secrets can be difficult to protect, and some courts
inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties.
We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods,
product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect
to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our product candidates and technology, including post grant review and <i>inter partes</i> review before
the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization
and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents
or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation
with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of
competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely
affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license
from such third party to continue developing, manufacturing, and marketing our product candidates and technology. However, we may not
be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could
require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing,
and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including
treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right.
A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of
our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or
trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Others
may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have
a significant adverse effect on our prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we
cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example,
a third party may claim an ownership interest in one or more of our patents or other proprietary or intellectual property rights. A third
party could bring legal actions against us to seek monetary damages or enjoin clinical testing, manufacturing, or marketing of the affected
product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause
a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential
liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or
product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure
you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a
product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other
intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially
true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably
disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter
into confidentiality agreements with our employees, consultants, collaborators, and others upon the commencement of their relationships
with us. These agreements require that all confidential information developed by the individual or made known to the individual by us
during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements
with employees and consultants also provide that any inventions conceived by the individual in the course of rendering services to us
shall be our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have
or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we have these agreements may
not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third
parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained,
may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees,
consultants, or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and
those third parties as to the rights in related inventions. We also seek to preserve the integrity and confidentiality of our trade secrets
by other means, including maintaining physical security of our premises and physical and electronic security of our information technology
systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets
would impair our competitive position and may materially harm our business, financial condition, and results of operations. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade
secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop
our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent
discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate
a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees
to attempt to independently reverse engineer or otherwise duplicate our cell therapy technologies to replicate our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets
of their current or former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical
companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents
and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates,
are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending
claims of misappropriation and similar claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
registered trademarks or trade names may be challenged, circumvented, or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential
partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name
or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered
or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks
and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or
protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective
and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may be able to make products that are similar to our product candidates but that are not
                                            covered by the claims of the patents that we own or may own in the future;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or any partners or collaborators, might not have been the first to make the inventions covered by the issued patents or pending patent
    applications that we own or may own in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or
    licensed intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that our pending patent applications or those that we may own in the future will not lead to issued patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
    patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others may have an adverse effect on our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering
    such intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel,
we may not be able to successfully implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of
our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221;
employees, and we do not have &#8220;key person&#8221; insurance on them. The loss of the services of our Chief Executive Officer Ryan
Saadi, Chief Scientific Officer Neal Flomenberg, or one or more of our other executive officers or key employees could impede the achievement
of our research, development, and commercialization objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting
and retaining qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also
be critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract
and retain personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies and academic
institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing
approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of
certain executives, key employees, consultants, or advisors, may impede the progress of our research, development and commercialization
objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully
than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries, and in particular the immunotherapy sector, are characterized by the rapid evolution of
technologies and understanding of disease etiology, intense competition, and strong pursuit and defense of intellectual property. We
may face substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical and existing or emerging
biotechnology companies, governmental agencies, academic institutions, public and private research institutions, technology companies
active in the artificial intelligence space, and others. Our commercial opportunities will be significantly impacted if our competitors
develop and commercialize products that are safer, more effective, have fewer side effects, are less expensive or obtain more significant
acceptance in the market than any product candidates that we develop. Additionally, our commercial opportunities will be significantly
impacted if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of diseases in our current
or future target population. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by
FDA. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market
before us and impair any ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the approved or commonly used drugs and therapies for certain of our target diseases are well established and are widely accepted
by physicians, patients, and third-party payors. Some of these drugs are branded and subject to patent protection, and other drugs and
nutritional supplements are available on a generic basis. Insurers and other third-party payors may encourage the use of generic products
or specific branded products. If any of our product candidates are approved, although we expect they may be priced at a discount to existing
cell therapies, we also expect they will be priced at a significant premium over any competitive generic products. Absent differentiated
and compelling clinical evidence, pricing premiums may impede the adoption of our products over currently approved or commonly used therapies,
which may adversely impact our business. In addition, many companies are developing new therapeutics, and we cannot predict what the
standard of care will become as our products continue in clinical development. We anticipate that we could face intense and increasing
competition as new therapies enter the market and advanced technologies become available from time to time. We expect that any treatments
which we develop and commercialize will need to compete on, among other things, efficacy, safety, convenience of administration and delivery,
and price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors or potential competitors, either alone or through collaborations, have significantly greater market presence, financial
resources and expertise in research and development, preclinical studies, conducting clinical trials, manufacturing, obtaining regulatory
approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Smaller or early-stage
companies may also prove to be significant competitors, including through collaborative arrangements or mergers with large and established
companies. These third parties compete with us in establishing clinical trial sites and patient enrollment for clinical trials, as well
as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also face substantial competition for our artificial intelligence initiatives and our computational approaches to drug discovery. Our
competitors may have significantly greater experience and expertise in using artificial intelligence, algorithmic tool development, predictive
analytics, and data science to expedite drug development, optimize laboratory processes and clinical trials, unravel complex biological
data, and improve patient outcomes than we do, and significantly greater financial and other resources with which to do so. Artificial
intelligence technologies are changing rapidly and we must adapt and develop these technologies in a timely and effective manner at an
acceptable cost in order to compete. There can be no assurance that we will be able to develop, acquire, or integrate artificial intelligence
technologies, tools, and processes successfully or as quickly or cost-effectively as our competitors, or that these technologies, tools,
and processes will meet our needs or achieve our goals. In addition, if the technologies, tools, or processes that we develop are incorrectly
designed, do not operate properly, or are otherwise deficient, or if we do not have the rights to use the data on which they rely, we
may not achieve our goals for this initiative, our performance and reputation could suffer or we could incur liability through the violation
of laws, privacy rights, or contracts. Even with the successful use of artificial intelligence, we may fail to allocate resources efficiently,
which could adversely impact our pipeline and ability to compete effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to attract and retain highly skilled personnel is critical to our operations and expansion. We also face competition for these
types of personnel from biotechnology and other companies and organizations, many of which have significantly larger operations and greater
financial, technical, human, and other resources than us. We may not be successful in attracting and retaining qualified personnel on
a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating
them into our operations, our business, prospects, financial condition, and results of operations will be materially adversely affected.
In such circumstances, we may be unable to conduct certain research and development programs, unable to adequately manage our clinical
trials and development of our product candidates, and unable to adequately address our management needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, these competitors may obtain regulatory approval of their products before we are able to, which could result
in our competitors obtaining a head start and establishing a frontrunner position before we are ready to commercialize and will limit
our ability to develop or commercialize our product candidates. Our ability to commercialize our proprietary cell products could also
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have a better safety profile,
are more convenient or are less expensive than our products. Our competitors also may be more successful than us in manufacturing and
marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover
the expenses of development and commercialization. If we are not able to compete effectively against our existing and potential competitors,
our business, financial condition, results of operations and growth prospects may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development plans and strategies develop, we expect to need additional managerial, operational, marketing, sales, financial and other
personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining, and motivating additional employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively, including the clinical and FDA review process for TVGN 489 and any future product candidates
    we develop, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to advance development of and, if approved, commercialize TVGN 489 and any future product
candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert
a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing
these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants
will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are
unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised
for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain marketing approval of any
current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize TVGN 489 and any future product
candidates we develop and, accordingly, may not achieve our research, development, and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater
risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our
trials, patients, healthcare providers or others using, administering, or selling our products. If we cannot successfully defend ourselves
against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for any product candidate we may develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire trial programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and significant negative media attention;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    time and costs to defend the related litigation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial subjects or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management and scientific resources from our business operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any product candidates that we may develop.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41.75pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we currently hold liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover
all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to
satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products
if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability
insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance
coverage, could decrease our cash and adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income,
if any, until such unused losses expire. Limitations imposed by the applicable jurisdictions on our ability to utilize net operating
loss carryforwards could cause income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause
such net operating loss carryforwards to expire unused, in each case reducing or eliminating the benefit of such net operating loss carryforwards.
Furthermore, we may not be able to generate sufficient taxable income to utilize our net operating loss carryforwards before they expire.
If any of these events occur, we may not derive some or all of the expected benefits from our net operating loss carryforwards. In addition,
we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside
of our control. As a result, even if we earn net taxable income, our ability to use our net operating loss and tax credit carryforwards
may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Being a Public Company and Ownership of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our Common Stock and Warrants may fluctuate significantly and you could lose all or part of your investment as a result.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Common Stock and Warrants has been and is likely to continue to be volatile. The stock market in general, and the
market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating
performance or prospects of particular companies. As a result of this volatility, you could lose all or part of your investment. Many
factors may have a material adverse effect on the market price of our securities, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment, delay. or results of our ongoing or future clinical trials, or changes in the development status of our
    product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate, not to initiate, or to terminate a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety concerns related to the use of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our product candidates and any adverse or perceived adverse development with respect to the applicable
    regulatory authority&#8217;s review of such filings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    actions, including failure to receive regulatory approval, with respect to our product candidates or our competitors&#8217; products
    or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to commercialize our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations, capital commitments,
    significant development milestones, or product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to obtain new commercial partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to obtain adequate manufacturing capacity or product supply for any approved product or inability to do so at acceptable
    cost;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to achieve expected product sales and profitability;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments applicable to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of expenses related to our product candidates or clinical development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    lawsuits, including without limitation patent or stockholder litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the incidence and development of COVID-19 on our business and product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes in our Board of Directors (the &#8220;Board&#8221;) or senior management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our cash position or operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates or recommendations by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation or financial results of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inconsistent
    trading volume levels of our shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    or expectation of additional financing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of Common Stock by us, our executive officers or directors, or our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    and market conditions in the U.S. equity markets generally and in the biotechnology sector;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, political and social conditions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control, or unrelated to our operating performance or prospects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or
disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations.
Broad market and industry factors may seriously affect the market price of our Common Stock and Warrants, regardless of actual operating
performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation
has often been brought against that company. Because of the potential volatility of our Common Stock and warrant price, we may become
the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s
attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including
those described in this &#8220;<i>Risk Factors</i>&#8221; section, could have a dramatic and material adverse impact on the market price
of our Common Stock following the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a substantial number of our securities in the public market by the Registered Holders or by our other existing securityholders could
cause the price of our Common Stock and Warrants to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders can sell, under this prospectus, up to 24,851,308 resale shares, representing approximately a 14.8% beneficial
ownership interest of our Common Stock as of June 20, 2024. Sales of a substantial number of our shares of Common Stock or Warrants
in the public market by the Registered Holders or by our other existing security holders, or the perception that those sales might occur,
could depress the market price of our Common Stock and Warrants and could impair our ability to raise capital through the sale of additional
equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our Common Stock and
Warrants. The sale of all the securities being offered in this prospectus could result in a significant decline in the public trading
price of our securities. Despite such a decline in the public trading price, which at $0.755 per share as of June 20,
2024 is significantly below the price for the Semper Paratus common shares upon closing of Semper Paratus&#8217;s initial public offering,
some of the Registered Holders may still experience a positive rate of return on the securities they purchased due to the differences
in the purchase prices described elsewhere in this prospectus. Other securityholders may not be able to experience positive rates of
return on securities they purchased due to the lower closing price at which our shares of Common Stock are trading as of June
20, 2024. In addition, the registration of these shares of Common Stock for resale creates the possibility of a significant
increase in the supply of our Common Stock in the market. The increased supply, coupled with the potential disparity in purchase prices,
may lead to heightened selling pressure, which could negatively affect the public trading price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
existing stockholders of Tevogen acquired such securities at a price below the current trading price of such securities, and may experience
a positive rate of return based on the current trading price or at lower trading prices. Future investors in Tevogen may not experience
a similar rate of return.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to consummation of the Business Combination, certain existing stockholders of Tevogen acquired shares of Common Stock or Warrants at
prices below, and in some cases considerably below, the current trading price of our Common Stock or for no cash consideration at all.
It is possible that these stockholders may experience a positive rate of return based on the current trading price or at lower trading
prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the relatively lower purchase prices that some of our stockholders paid to acquire some of their securities compared to the current trading
price of our shares of Common Stock and the fact that some of our stockholders received securities for services rendered, these
stockholders, including some of the Registered Holders, in some instances may earn a positive rate of return on their investment, which
may be a significant positive rate of return, depending on the market price of our shares of Common Stock at the time that such stockholders
choose to sell their shares of Common Stock. For example, based on the closing price of our Common Stock of $0.755 on June 20,
2024, SSVK could experience, with respect to 8,988,889 shares of Common Stock (not including 500,000 shares of Common Stock
subject to outstanding Warrants), potential profit of up to approximately $0.755 per share of Common Stock (although all but
1,000,000 of such shares are subject to a six-month lockup from the date of Closing), or approximately $6.8 million in the aggregate,
based on SSVK&#8217;s purchase from the Original Sponsor of such shares of Common Stock and Warrants prior to the Closing at an
aggregate purchase price of $1.00. Investors who purchased units in Semper Paratus&#8217; initial public offering (at a public offering
price of $10.00 per unit), who purchased shares on Nasdaq following Semper Paratus&#8217; initial public offering, or who purchased our
Common Stock on Nasdaq following consummation of the Business Combination may not experience a similar rate of return on the securities
they purchased due to differences in the purchase prices and the prevailing trading price. See the section of this prospectus titled
&#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; for additional information
on the potential profits the other registered holders may experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not have the funds necessary to satisfy our future obligations under the terms of our Preferred Stock and uncertainties with respect
to our obligations under the terms of our Preferred Stock could materially and adversely affect our ability to raise capital, our liquidity
position, our ability to operate our business and execute our business strategy, and the trading volatility and price of our securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainty
regarding our ability to satisfy our future obligations under the terms of our Preferred Stock could materially and adversely affect
our business. Our Series A Preferred Stock, which has an aggregate face value of $2.0 million, and our Series A-1 Preferred Stock, for
which we expect to receive aggregate gross proceeds of $6.0 million, carry an annual 5% cumulative dividend, increasing by 2% each year,
in the case of the Series A-1 Preferred Stock in no event to more than 15% per year. The Series A Preferred Stock and the Series A-1 Preferred Stock is callable if the volume weighted average price of the Common Stock
for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration
statement on file covering the underlying Common Stock. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have sufficient funds or be able to obtain financing from third parties to pay the dividends applicable to our Preferred Stock
or to redeem the Preferred Stock pursuant to our call rights, and the amount of dividend we may be required to pay on the Preferred Stock
is uncertain. These uncertainties could materially and adversely affect our ability to raise capital, our liquidity position, our ability
to operate our business and execute our business strategy, and the trading volatility and price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to regain compliance with Nasdaq&#8217;s
$1.00 minimum closing bid price requirement or otherwise to meet Nasdaq&#8217;s continued</i></b><b><i> listing requirements,
our Common Stock and our Warrants could be delisted.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock
and our Warrants are listed on Nasdaq. We are required to meet specified financial and other requirements in order to maintain such listing,
including a requirement that the closing bid price for our Common Stock remain above $1.00.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On June 14, 2024,
we received a notification letter from Nasdaq&#8217;s Listing Qualifications Staff notifying us that the closing bid price for our Common
Stock had been below $1.00 for the previous 35 consecutive business days and that we therefore are not in compliance with the minimum
bid price requirement for continued inclusion on Nasdaq under Nasdaq Listing Rule 5450(a)(1). The notification has no immediate effect
on the listing of our Common Stock and our Warrants on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Under the Nasdaq
Listing Rules, we have a period of 180 calendar days to regain compliance. To regain compliance, the closing bid price of our Common
Stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such case, Nasdaq will provide us with
written confirmation of compliance. If we do not regain compliance by December 11, 2024, we may be eligible for an additional 180 calendar
days, provided that we submit an online transfer application to transfer the listing of our Common Stock to the Nasdaq Capital Market,
submit an application fee, and meet the continued listing requirement for market value of publicly held shares and all other initial
listing standards for the Nasdaq Capital Market, except the bid price requirement. In addition, we will be required to provide written
notice of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. If
it appears to Nasdaq that we will not be able to cure the deficiency during the second compliance period, or if we determine not to submit
a transfer application or make the required representation, Nasdaq will provide written notice to us that our Common Stock will be subject
to delisting. In the event of such notification, we may appeal Nasdaq&#8217;s determination to delist its securities, but there can be
no assurance that Nasdaq would grant our request for continued listing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We intend to
take all reasonable measures available to us to achieve compliance to allow for continued listing on the Nasdaq Global Market. However,
there can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance
with other Nasdaq listing criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to regain compliance with the requirement to maintain a minimum closing bid price of $1.00 per share or to meet
other Nasdaq continued listing requirements, Nasdaq may take steps to delist our securities. Such a delisting would likely have a
negative effect on the price of our securities and would impair your ability to sell or purchase the securities when you wish to do so.
In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements
would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our
securities from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing
requirements. Additionally, if our securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on the
OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the
liquidity and price of our securities may be more limited than if our securities were quoted or listed on Nasdaq or another national
securities exchange. You may be unable to sell your securities unless a market can be established or sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives
and corporate governance practices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities
rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure
and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other
personnel in connection with our efforts to comply with the requirements of being, a public company, and our management and other personnel
devote a substantial amount of time towards maintaining compliance with these requirements. These requirements contribute significantly
to our legal and financial compliance costs. These rules and regulations are often subject to varying interpretations, in many cases
due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional shares of our Common Stock or other equity securities without your approval, which would dilute your ownership interests
and may depress the market price of your shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue additional shares of our Common Stock or other equity securities of equal or senior rank in the future in connection with,
among other things, raising additional capital, future acquisitions, repayment of outstanding indebtedness, or award issuances under
the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, without stockholder approval, in a number of circumstances. The additional
shares or other securities convertible into or exchangeable for our public shares may be offered at price that may not be the same as
the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less
than the price per share paid by the investors in this offering, and investors purchasing shares or other securities in the future could
have rights superior to existing shareholders. The price per share at which the additional shares or securities convertible or exchangeable
into public shares, will be sold in future transactions may be higher or lower than the price per share paid by investors in this offering.
If any of the above should occur, our stockholders, including investors who purchased public shares in this offering, will experience
additional dilution, and any such issuances may result in downward pressure on the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional shares of Common Stock or other equity securities of equal or senior rank could have the following effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">your
                                            proportionate ownership interest in Tevogen will decrease;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            relative voting strength of each previously outstanding share of Common Stock may be diminished;
                                            or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            market price of your shares of Common Stock may decline.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;, and certain exemptions from disclosure requirements
available to us could make our securities less attractive to investors and may make it more difficult to compare our performance to the
performance of other public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an &#8220;emerging growth company&#8221; as defined in Section 2(a)(19) of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), as modified by the JOBS Act. As such, we are eligible for and intend to take advantage of certain exemptions from various
reporting requirements applicable to other public companies that are not emerging growth companies for as long as we continue to be an
emerging growth company, including, but not limited to, (a) not being required to comply with the auditor attestation requirements of
Section 404 of the Sarbanes-Oxley Act, (b) reduced disclosure obligations regarding executive compensation in our periodic reports and
proxy statements and (c) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information
they may deem important. We cannot predict whether investors will find our securities less attractive because we rely on these exemptions.
If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities
may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our
securities may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest of : (i) the last day of the fiscal year (a) following the fifth anniversary
of the closing of Semper Paratus&#8217; initial public offering, or December 31, 2026, (b) in which we have total annual gross revenue
of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common
equity that is held by non-affiliates exceeds $700 million as of the last business day of its most recently completed second fiscal quarter;
and (ii) the date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period.
In addition, the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition period and, therefore,
we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
This may make comparison of our financial statements with the financial statements of other companies who comply with public company
adoption dates difficult or impossible because of the potential differences in accounting standards used. Investors may find our Common
Stock less attractive because it will rely on these exemptions, which may result in a less active trading market for our Common Stock
and its price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we qualify as a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may
take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial
statements. We will remain a smaller reporting company and may take advantage of certain scaled disclosures available to smaller reporting
companies for so long as the market value of our voting and non-voting common equity held by non-affiliates is less than $250.0 million,
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently
completed fiscal year and the market value of our common equity held by non-affiliates is less than $700.0 million, measured on the last
business day of our second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison
of its financial statements with other public companies difficult or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management team has limited experience managing a public company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of our management team have limited experience managing a publicly traded company, interacting with public company investors, and complying
with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our
transition to being a public company that is subject to significant regulatory oversight and reporting obligations under the federal
securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents require significant
attention from our senior management and could divert their attention away from the day-to-day management of our business, which could
harm our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendation
regarding our Common Stock or if our results of operations do not meet their expectations, including projections in those reports that
differ from our actual results, our share price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Common Stock may be influenced by research and reports that industry or securities analysts may
publish about us or our business. We do not have any control over these analysts. We have limited analyst coverage and we may continue
to have limited analyst coverage in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities or industry analysts fail to commence coverage of us, the trading price of our Common Stock may be negatively
impacted. In the event securities or industry analysts initiate coverage, and one or more of these analysts cease coverage of us or fail
to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause the price of our Common
Stock or trading volume to decline. Moreover, if one or more of the analysts who cover us publish negative reports, downgrade our stock,
or if our results of operations do not meet their expectations, the price of our Common Stock could decline. Securities research analysts
may establish and publish their own periodic projections for us. These projections may vary widely and may not accurately predict the
results we actually achieve. Our share price may decline if our actual results do not match the projections of these securities research
analysts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations could be negatively affected we become subject to any securities litigation or stockholder activism, which
could cause us to incur significant expense, hinder execution of business and growth strategy and impact its stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has
often been brought against that company. Stockholder activism, which could take many forms or arise in a variety of situations, has been
increasing recently. Volatility in the stock price of our Common Stock or other reasons may in the future cause it to become the target
of securities litigation or stockholder activism. Securities litigation and stockholder activism, including potential proxy contests,
could result in substantial costs and divert management&#8217;s and Board&#8217;s attention and resources from our business. Additionally,
such securities litigation and stockholder activism could give rise to perceived uncertainties as to our future, adversely affect its
relationships with service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to
incur significant legal fees and other expenses related to any securities litigation and activist stockholder matters. Further, its stock
price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities
litigation and stockholder activism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative
effect on its financial condition, results of operations and the share price of our securities, which could cause you to lose some or
all of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be forced to write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in
our reporting losses. In addition, unexpected risks may arise and previously known risks may materialize in a manner not consistent
with prior risk analysis. If any of these risks materialize, this could have a material adverse effect on our financial condition
and results of operations and could contribute to negative market perceptions about our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified material weaknesses in our internal control over financial reporting. If we are unable to develop and maintain proper
and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired,
investors may lose confidence in our financial reporting and the trading price of our Common Stock may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management concluded that we had material weaknesses in our internal controls over financial reporting related to our accounting
for complex financial instruments and internal controls over collectability over amounts due from related parties, not maintaining a
sufficient complement of personnel commensurate with its accounting and reporting requirements resulting in inadequate segregation of
duties over the preparation, review, and posting of manual journal entries to the general ledger, and resulting in not having a sufficient
risk assessment process to identify and analyze risks of misstatement due to error and/or fraud. A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material
misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we continue to evaluate steps to remediate these material weaknesses, the material weaknesses will not be considered remediated until
our plan has been fully implemented, the applicable controls are fully operational for a sufficient period of time, and we have concluded,
through testing, that the newly implemented and enhanced controls are operating effectively. At this time, we cannot predict the success
of such efforts or the outcome of future assessments of the remediation efforts. If the material weaknesses are not remediated, or if
we generally fail to establish and maintain effective internal controls appropriate for a public company, we may be unable to produce
timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which
could adversely impact our investors&#8217; confidence and our stock price. In addition, these remediation measures may be time consuming
and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent
or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial
statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic
reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our
stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the
future, will be sufficient to avoid potential future material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address these material weaknesses, we intend to hire additional accounting personnel with appropriate expertise in accounting and reporting
under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and SEC regulations in order to better align with segregation of duties and perform appropriate risk assessment procedures to evaluate risks
of material misstatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Our
independent registered public accounting firm is not required to provide an attestation report on the effectiveness of our internal control
over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material
weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Any failure to maintain internal
control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations
or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered
public accounting firm determines we have a material weakness in our internal control over financial reporting, investors may lose confidence
in the accuracy and completeness of our financial reports, the market price of our Common Stock could decline, and we could be
subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in
our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies,
could also restrict our future access to the capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near
future. This could cause the market price of our Common Stock to drop significantly, even if our business is doing well.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our Common Stock in the public market could occur at any time. In addition, we have a substantial
number of restricted stock units and we expect that tax obligations with respect to vesting and settlement of many of these restricted
stock units will be satisfied through sell-to-cover arrangements. These sales, or the perception in the market that the holders of a
large number of shares intend to sell shares, could reduce the market price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
certain of our stockholders are subject to certain restrictions regarding the transfer of our Common Stock, these shares may be sold
after the expiration or early termination of the respective applicable lock-ups under the Letter Agreement and the Lock-Up Agreement.
As restrictions on resale end and any registration statements we file for the resale of such shares are available for use, the market
price of our Common Stock could decline if the holders of currently restricted shares sell them or are perceived by the market as intending
to sell them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
directors, executive officers, and principal stockholders, and Dr. Ryan Saadi in particular, have substantial control over our company,
which could limit your ability to influence the outcome of key transactions, including a change of control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers, directors, and principal stockholders and their affiliates beneficially own approximately 90% of the outstanding
shares of Common Stock and our Chief Executive Officer, Dr. Ryan Saadi, beneficially owns approximately 71%, of the outstanding
shares of Common Stock. As a result, these stockholders exercise a significant level of control over all matters requiring stockholder
approval, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may
also have interests that differ from yours and may vote in a way with which you disagree. In addition, under the Nasdaq rules, a company
of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and
need not comply with certain requirements, including the requirement that a majority of the board of directors consist of independent
directors and the requirements that the company&#8217;s compensation and nominating and governance committees be composed entirely of
independent directors. We are not currently taking advantage of these exemptions. However, for so long as we qualify as a &#8220;controlled
company,&#8221; we maintain the option to rely on some or all of these exemptions. If we rely on these exemptions, we may not have a
majority of independent directors and our compensation and nominating and governance committees may not consist entirely of independent
directors. Accordingly, in the event we elect to rely on these exemptions in the future, our stockholders would not have the same protections
afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. This concentration
of ownership may have the effect of delaying, preventing or deterring a change of control, could deprive our stockholders of an opportunity
to receive a premium for their Common Stock as part of a sale, and might ultimately affect the market price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may redeem a warrant holder&#8217;s unexpired warrants prior to their exercise at a time that may be disadvantageous to such warrant
holder, thereby making its warrants worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the ability to redeem outstanding public warrants at any time after they become exercisable and prior to their expiration, at a
price of $0.01 per warrant, provided that the last reported sales price of Common Stock equals or exceeds $18.00 per share (as adjusted
for stock splits, stock capitalizations, reorganizations, recapitalizations and the like for certain issuances of public shares and equity-linked
securities for capital raising purposes in connection with the closing of its initial business combination) for any 20 trading days within
a 30 trading-day period ending on the third trading day prior to the date we send the notice of redemption to the warrant holders. We
may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable
state securities laws. Redemption of the outstanding warrants could force a warrant holder to: (i) exercise its warrants and pay the
exercise price at a time when it may be disadvantageous for such warrant holder to do so; (ii) sell its warrants at the then-current
market price when a warrant holder might otherwise wish to hold its warrants; or (iii) accept the nominal redemption price which, at
the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of a warrant holder&#8217;s
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their
warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
warrant holder may only be able to exercise its public warrants on a &#8220;cashless basis&#8221; under certain circumstances, and if
a warrant holder does so, such warrant holder will receive fewer shares of Common Stock from such exercise than if a warrant holder were
to exercise such warrants for cash.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant agreement provides that in the following circumstances holders of public warrants who seek to exercise their warrants
will not be permitted to do for cash and will, instead, be required to do so on a cashless basis in accordance with Section 3(a)(9) of
the Securities Act: (i) if the Common Stock issuable upon exercise of the warrants is not registered under the Securities Act in accordance
with the terms of the warrant agreement; (ii) if we have so elected and the Common Stock is at the time of any exercise of a warrant
not listed on a national securities exchange such that it satisfies the definition of &#8220;covered securities&#8221; under Section
18(b)(1) of the Securities Act; and (iii) if we have so elected and we call the public warrants for redemption. In addition, the private
placement warrants may be exercised on a cashless basis so long as they are held by the initial purchasers or their respective permitted
transferees. If you exercise your warrants on a cashless basis, you would pay the warrant exercise price by surrendering all
of the warrants for that number of Common Stock equal to the quotient obtained by dividing (x) the product of the number of Common Stock
underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; of the Common Stock (as defined in the next
sentence) over the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; is the average reported
closing price of the Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of the warrants. As a result, you would receive fewer shares of Common Stock from such exercise than if you were
to exercise such warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our warrants may never be in the money and they may expire worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for our outstanding warrants is $11.50 per share. Such warrants may never be in the money prior to their
expiration, and as such, the warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
amount of cash proceeds that we may receive is dependent upon the trading price of our Common Stock relative to the exercise price of
the Warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may receive up to an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise price of each of our
Warrants is $11.50 per warrant. However, the last reported sales price of our Common Stock on June 20, 2024 was $0.755.
The likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds that we may receive,
is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per
share, we do not expect holders to exercise their Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of shares of Common Stock or Warrants by the Registered Holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants,
including underwriters&#8217; commissions and discounts, brokerage fees, underwriting marketing costs, and all reasonable fees and
expenses of any legal counsel representing the Registered Holders, except that we will pay the reasonable fees and expenses of one
U.S. legal counsel and local counsel in any other applicable jurisdiction(s) for the Registered Holders party to the A&amp;R
Registration Rights Agreement (as defined below) in the event of a demanded underwritten offering of their securities. We
will bear all other costs, fees and expenses incurred in effecting the registration of the securities covered by this prospectus,
including, without limitation, all registration and filing fees, printing and delivery fees, Nasdaq listing fees and fees and
expenses of our counsel and our accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will receive the proceeds from any exercise of Warrants for cash. The exercise price of each of our Warrants is $11.50 per warrant. However,
the last reported sales price of our Common Stock on June 20, 2024 was $0.755. The likelihood that holders of Warrants
will exercise their Warrants, and therefore any amount of cash proceeds that we may receive, is dependent upon the trading price of our
Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per share, we do not expect holders to exercise
their Warrants. The Private Placement Warrants may be exercised on a cashless basis and we will not receive any proceeds from such exercise,
even if the Private Placement Warrants are in-the-money.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we inform you otherwise in a prospectus supplement, the Company intends to use the net proceeds from the exercise of Warrants for general
corporate and working capital purposes. Any proceeds from the exercise of Warrants would increase our liquidity, but we are not currently
budgeting for any cash proceeds from the exercise of Warrants when planning for our operational funding needs. The Company will have
broad discretion over the use of any such proceeds. There is no assurance that the holders of the Warrants will elect to exercise any
or all of such Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>DIVIDEND
POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our Common Stock to date and do not intend to pay cash dividends in the foreseeable future.
The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, and general
financial condition. The payment of any cash dividends will be within the discretion of our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><i>Defined terms included below generally
have the same meaning as terms defined and included elsewhere in this prospectus.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc. (&#8220;Tevogen Holdings&#8221;), formerly known as Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;),
is providing the following unaudited pro forma condensed combined financial information that presents the combination of the financial
information of Semper Paratus and Tevogen Bio Inc., formerly known as Tevogen Bio Inc (&#8220;Tevogen Bio&#8221;), adjusted to give effect
to the Business Combination (as defined below) and related transactions (collectively, the &#8220;Transaction Accounting Adjustments&#8221;).
Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;
in this section generally refer to Tevogen Holdings following the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to that certain Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Semper Paratus (&#8220;Merger
Sub&#8221;), SSVK Associates, LLC, Semper Paratus&#8217;s former sponsor (the &#8220;Sponsor&#8221;), in its capacity as purchaser representative,
Tevogen Bio, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and into Tevogen Bio, with Tevogen
Bio being the surviving company and a wholly owned subsidiary of Semper Paratus (the &#8220;Merger,&#8221; and together with the other
transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;). In connection with the closing of the Business
Combination (the &#8220;Closing&#8221;), we changed our name from &#8220;Semper Paratus Acquisition Corporation&#8221; to &#8220;Tevogen
Bio Holdings Inc.&#8221; As of the open of trading on February 15, 2024, our common stock and public warrants began trading on The Nasdaq
Stock Market LLC (&#8220;Nasdaq&#8221;) as &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221; respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the Merger, Tevogen Bio&#8217;s common stockholders received, in the aggregate, 120.0 million shares of our common
stock, valued at $10.00 per share, for an aggregate value equal to $1,200,000,000. Tevogen Bio&#8217;s former common stockholders will
also be entitled to receive, in the aggregate, an additional 20,000,000 shares of our common stock (the &#8220;Earnout Shares&#8221;)
in the event that the volume-weighted average price of our common stock, collectively, exceeds three separate market conditions as follows:
(a) $15.00 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date of the Merger Agreement until the 36-month
anniversary of the Closing Date, in which case the former holders of Tevogen Bio common stock will be entitled to receive an additional
6,666,667 shares of our common stock, (b) $17.50 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date
until the 36-month anniversary of the Closing Date, in which case those former holders will be entitled to receive an additional 6,666,667
shares of our common stock, and (c) $20.00 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date until
the 36-month anniversary of the Closing Date, in which case those former holders will be entitled to receive an additional 6,666,666
shares of our common stock (each separate issuance of shares in accordance with meeting the aforementioned three market conditions, an
&#8220;Earnout Share Payment&#8221;). In addition, for each Earnout Share Payment, we will also issue to the Sponsor an additional 1,500,000
shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Merger Agreement, each restricted stock unit (&#8220;RSU&#8221;) with respect to shares of the common stock of
Tevogen Bio (each &#8220;Tevogen Bio RSU&#8221;) that was then unvested was canceled and converted into an award under the Tevogen Bio
Holdings Inc. 2024 Omnibus Plan (the &#8220;2024 Plan&#8221;) with respect to a number of RSUs to be settled in our common stock (&#8220;Rollover
RSUs&#8221;) equal to the product, rounded up to the nearest whole number, of (i) the number of shares of the common stock of Tevogen
Bio subject to the Tevogen Bio RSU as of immediately prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), multiplied
by (ii) approximately 4.84 (the &#8220;Exchange Ratio&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, each Rollover RSU generally is subject to the same terms and conditions (including applicable vesting, expiration,
and forfeiture provisions) that applied to the corresponding Tevogen Bio RSU immediately prior to the Effective Time. Prior to the consummation
of the Business Combination, the vesting of all of the Tevogen Bio RSUs was subject to the satisfaction of both a service-based condition
and a liquidity event condition. The Tevogen Bio RSUs vest only to the extent both conditions have been satisfied. The liquidity condition
for all of the Tevogen Bio RSUs was satisfied by the consummation of the Business Combination. As a result, Rollover RSUs vested on the
Closing Date to the extent that their related service-based conditions had also been satisfied as of the Closing Date, resulting
in the vesting of Rollover RSUs for 7,146,688 shares of our common stock on the Closing Date in addition to the approximately 120,000,000
shares issued as consideration for the Merger. The Rollover RSUs have not yet been settled into shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement and a letter agreement with an investor pursuant to which the investor
agreed to purchase shares of our Series A Preferred Stock for an aggregate purchase price of $2.0 million. On March 27, 2024, we entered
into an Amended and Restated Securities Purchase Agreement with the investor pursuant to which we amended and restated the original agreement
and the investor agreed to purchase of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million, for which proceeds
of $2.2 million have been received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A Preferred Stock are convertible into a total of 500,000 shares of Common Stock at the election of the holder and the
Series A-1 Preferred Stock will be convertible into a total of 600,000 shares of Common Stock at the election of the holder. The Series
A Preferred Stock and the Series A-1 Preferred Stock are subject to a call right providing us the right to call the stock if the volume
weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and in
each case there is an effective resale registration statement on file covering the underlying common stock. The Series A Preferred
Stock is, and the Series A-1 Preferred Stock will be, non-voting, has or will have, as the case may be, no mandatory
redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the Series
A-1 Preferred Stock in no event to more than 15% per year. So long as each of the Series A Preferred Stock and Series A-1 Preferred
Stock is outstanding, we will not, without the written consent of the holders of 50.1% of the Series A Preferred Stock and the Series
A-1 Preferred Stock, amend, alter, or repeal any provision of our certificate of incorporation or bylaws in a manner adverse to such
series of Preferred Stock. The investor in the Series A Preferred Stock and the Series A-1 Preferred Stock is an entity associated with
Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus entered into an agreement as of February 14, 2024 with the
Sponsor, pursuant to which Semper Paratus assigned to the Sponsor and the Sponsor assumed certain liabilities and obligations,
including liabilities and obligations that became liabilities and obligations of the Company as a result of the Business Combination,
in the  amount of  $3.6 million, in consideration
for the issuance of preferred stock of the Company (the &#8220;Series B Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, we entered into the Repurchase Agreement with the Sponsor, pursuant to which we repurchased and cancelled, with immediate
effect, the outstanding shares of our Series B Preferred Stock in exchange for (i)&#160;the reassignment to and reassumption by us of
the liabilities assigned under the Assignment and Assumption Agreement (as defined elsewhere in this prospectus) and (ii)&#160;the termination
of the Assignment and Assumption Agreement, and the Sponsor released us from certain claims relating to the Repurchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into agreements (the &#8220;Conversion Agreements&#8221;) with SSVK and Mr. Ajjarapu pursuant to which
we issued an aggregate of 174,000 shares of Common Stock in relation to services that were to have been provided to us and Tevogen Bio,
at an effective price of $10.00 per share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus assumed all obligations of Tevogen Bio under certain convertible
promissory notes issued by Tevogen Bio (the &#8220;Tevogen Bio Convertible Notes&#8221;) pursuant to a written assumption agreement.
The Tevogen Bio Convertible Notes converted pursuant to their terms immediately following the Closing into shares of our common stock,
resulting in the issuance of 10,337,419 shares of our common stock on the Closing Date, in addition to the shares issued as consideration
for the Merger and shares issuable upon vesting and settlement of Rollover RSUs. Reflective of the conversion of the Tevogen Bio Convertible
Notes in connection with the consummation of the Business Combination, there are no liabilities associated with convertible promissory
notes shown on the following unaudited pro forma condensed combined balance sheet, and the non-cash charge related to the change in the
fair value of the convertible promissory notes has been eliminated from the following unaudited pro forma condensed combined statement
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in satisfaction of a condition to the Closing of the Business Combination, the Company issued an aggregate of 19,348,954 RSUs
under the 2024 Plan to Dr. Saadi (the &#8220;Special RSUs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Business Combination is accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, the Company,
which is the legal acquirer, is treated as the &#8220;acquired&#8221; company for financial reporting purposes and Tevogen Bio is treated
as the accounting acquirer. Tevogen Bio has been determined to be the accounting acquirer based on evaluation of the following facts
and circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
                                            Bio&#8217;s former stockholders hold approximately 90% of the voting interest of the
                                            Company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
                                            Bio&#8217;s senior management comprises the senior management of the Company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            directors nominated by Tevogen Bio represent the majority of our board of directors (six
                                            out of seven total directors were nominated by Tevogen Bio&#8217;s existing shareholders);
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
                                            Bio&#8217;s operations comprise the ongoing operations of the Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Business Combination is accounted for as the equivalent of a capital transaction in which Tevogen Bio has issued stock for the
net assets of Semper Paratus. The net assets of Semper Paratus are carried-over at historical cost, with no goodwill or other intangible
assets recorded. Operations prior to the Business Combination are of Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following unaudited pro forma condensed combined balance sheet as of December 31, 2023 combines the historical  balance sheet
of Semper Paratus as of December 31, 2023 with the historical balance sheet of Tevogen Bio as of December 31, 2023 giving further effect
to the Pro Forma Adjustments, as if the Business Combination had been consummated as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following unaudited pro forma condensed combined statements of operations for the year ended December 31, 2023 combine the historical
 statement of operations of Semper Paratus for the year ended December 31, 2023 and the historical statement of operations
of Tevogen Bio for the year ended December 31, 2023, giving effect to the Pro Forma Adjustments as if the Business Combination had been
consummated on January 1, 2023, the beginning of the fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The unaudited pro forma condensed
combined financial information does not include an unaudited pro forma condensed combined balance sheet as of March 31, 2024, as the
Business Combination was already reflected in our historical unaudited condensed consolidated balance sheets as of March 31, 2024. Further,
the unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2024, were not provided because
the historical operating results of Semper Paratus were not material and pro forma results would not be materially
different from reported results for the periods presented.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information has been derived from and should be read in conjunction with:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            accompanying notes to the unaudited pro forma condensed combined financial information;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            historical audited financial statements of Semper Paratus as of and for the year ended December
                                            31, 2023 and the related notes included elsewhere in this prospectus;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            historical audited financial statements of Tevogen Bio as of and for the year ended December
                                            31, 2023 and the related notes included elsewhere in this prospectus;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            section of this prospectus titled</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of
                                            Operations</i>&#8221;; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">factors
                                            detailed under the section titled &#8220;<i>Risk Factors</i>&#8221;.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information is for illustrative purposes only and is not necessarily indicative of what
the actual results of operations and financial position would have been had the transactions included in the Pro Forma Adjustments taken
place on the dates indicated, nor are they indicative of our future results of operations or financial position. The Pro Forma Adjustments
are based on currently available information and certain assumptions and estimates that we believe are reasonable under the circumstances.
In addition, a review is in process to align all accounting policies among the two entities. Therefore, the results below are not necessarily
indicative of figures post-transaction, and it is possible that the difference may be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Unaudited
Pro Forma Condensed Combined Balance Sheet</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>As
of December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Semper Paratus Acquisition Corp.<br/> (A)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Tevogen Bio<br/> (B)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction Accounting Adjustments</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Balance Sheet</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 35%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,052</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,322</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: center">3(a)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,383</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Due from Related Party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Prepaid Expenses and other assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">671</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,322</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and Equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">459</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,583</td>
    <td>)</td>
    <td style="text-align: center">3(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investments held in Trust Account</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,681</td>
    <td>)</td>
    <td style="text-align: center">3(c)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Total Assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,942</td>
    <td>)</td>
    <td style="text-align: center"/><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,601</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,418</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><p style="margin: 0">$</p></td><td style="text-align: right">(2,613</td>
    <td>)</td>
    <td style="text-align: center">3(d)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">901</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Convertible Promissory Notes, Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,712</td>
    <td>)</td>
    <td style="text-align: center">3(e)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,632</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Due to affiliate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,006</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(83,325</td>
    <td>)</td>
    <td style="text-align: center"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,160</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Derivative Warrant Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred Underwriting Commissions in Connection with the Initial Public Offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,700</td>
    <td>)</td>
    <td style="text-align: center">3(f)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,220</td>
    <td>)</td>
    <td style="text-align: center">3(e)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total Long Term Liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,920</td>
    <td>)</td>
    <td style="text-align: center"/><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total Liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,735</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99,934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,245</td>
    <td>)</td>
    <td style="text-align: center"/><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Class A common stock subject to  redemption</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,681</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,681</td>
    <td style="padding-bottom: 1.5pt">)</td>
    <td style="padding-bottom: 1.5pt; text-align: center">3(e)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shareholders&#8217; Equity (Deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Tevogen Bio Holdings Inc. Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Tevogen Bio Holdings Inc. Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Semper Paratus Acquisition Corp. Preferred shares, $0.0001 par value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Semper Paratus Acquisition Corp. Class A ordinary shares, $0.0001 par value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td>
    <td>&#160;</td>
    <td style="text-align: center">3(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Semper Paratus Acquisition Corp. Class B ordinary shares, $0.0001 par value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Tevogen Bio, Inc. Common Stock &#8211; Voting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td>
    <td>)</td>
    <td style="text-align: center">3(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Tevogen Bio, Inc. Common Stock &#8211; Non-voting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td>
    <td>)</td>
    <td style="text-align: center">3(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Additional Paid-In Capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,216</td>
    <td/>
    <td style="text-align: center">3(h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">307,383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accumulated Deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,379</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(99,658</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(190,184</td>
    <td>)</td>
    <td style="text-align: center">3(i)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(307,221</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Total Equity (Deficit)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,378</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94,429</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,984</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Total Liabilities, Ordinary Shares subject to  redemption and Shareholders&#8217; Equity (Deficit)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,942</td>
    <td>)</td>
    <td style="text-align: center"/><td style="text-align: center">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,601</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Unaudited
Pro Forma Condensed Combined STATEMENTS of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>For
the Year Ended December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Semper Paratus Acquisition Corp.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(A)</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Tevogen Bio<br/> (B)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction Accounting Adjustments</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Statement of Operations</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 35%; text-align: left">General and Administration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,563</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: center">4(a)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,276</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and Development</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,404</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total Operating Expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,563</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,680</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,274</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,843</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,563</td>
    <td>)</td>
    <td style="text-align: center"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,680</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense), net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain / (loss) on investments held in Trust Account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,734</td>
    <td>)</td>
    <td style="text-align: center">4(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment of amount due from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(250</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(250</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income (expense) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(256</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,206</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,462</td>
    <td>&#160;</td>
    <td style="text-align: center">4(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of promissory notes</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50,428</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,428</td>
    <td>&#160;</td>
    <td style="text-align: center">4(d)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,634</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,156</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(272</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(68</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,593</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,952</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="text-align: center">4(e)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(68</td><td style="vertical-align: middle; text-align: left"><p style="margin: 0">)</p></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">47,593</p></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,952</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net loss per share of Class A and Class B Common Stock (Semper Paratus Acquisition Corp); Common Stock (Tevogen Bio)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.08</td><td style="text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Weighted average shares outstanding, basic and diluted</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 12%">13,503,056</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 12%">24,752,000</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 12%">151,111,362</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 5%">4(f)</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 12%">164,614,418</td><td style="text-align: left; width: 1%">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Description of the Business Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, pursuant to the Merger Agreement, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving
company and a wholly owned subsidiary of Semper Paratus. In connection with the Closing, Semper Paratus changed its name to Tevogen Bio
Holdings Inc. As of the open of trading on February 15, 2024, the Company&#8217;s common stock and public warrants began trading on Nasdaq
as &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221; respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the Merger, Tevogen Bio&#8217;s common stockholders received, in the aggregate, 120.0 million shares of our common
stock, valued at $10.00 per share, for an aggregate value equal to $1,200,000,000. Tevogen Bio&#8217;s former common stockholders will
also be entitled to receive, in the aggregate, an additional 20,000,000 shares of the Company&#8217;s common stock in the event that
the volume-weighted average price of the Company&#8217;s common stock, collectively, exceeds three separate market conditions as follows:
(a) $15.00 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date of the Merger Agreement until the 36-month
anniversary of the Closing Date, in which case the former holders of Tevogen Bio common stock will be entitled to receive an additional
6,666,667 shares of the Company&#8217;s common stock, (b) $17.50 per share for 20 out of any 30 consecutive trading days beginning on
the Closing Date until the 36-month anniversary of the Closing Date, in which case those former holders will be entitled to receive an
additional 6,666,667 shares of the Company&#8217;s common stock, and (c) $20.00 per share for 20 out of any 30 consecutive trading days
beginning on the Closing Date until the 36-month anniversary of the Closing Date, in which case those former holders will be entitled
to receive an additional 6,666,666 shares of the Company&#8217;s common stock (each separate issuance of shares in accordance with meeting
the aforementioned three market conditions, an &#8220;Earnout Share Payment&#8221;). In addition, for each Earnout Share Payment, the
Company will also issue to the Sponsor an additional 1,500,000 shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Merger Agreement, each Tevogen Bio RSU that was then unvested was canceled and converted into a Rollover RSU for a number
of shares of the Company&#8217;s common stock equal to the product, rounded up to the nearest whole number, of (i) the number of shares
of the common stock of Tevogen Bio subject to the Tevogen Bio RSU as of immediately prior to the Effective Time, multiplied by (ii) the
Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, each Rollover RSU generally is subject to the same terms and conditions (including applicable vesting,
expiration, and forfeiture provisions) that applied to the corresponding Tevogen Bio RSU immediately prior to the Effective Time. The
vesting of all of the unvested Tevogen Bio RSUs as of the Closing was subject to the satisfaction of both a service-based condition and
a liquidity event condition. The Tevogen Bio RSUs would vest only to the extent both conditions have been satisfied. The liquidity condition
for all of the Tevogen Bio RSUs would be satisfied by, among other things, the closing of an acquisition of Tevogen Bio by a special
purpose acquisition company the shares of which are publicly traded on a U.S. national stock exchange or securities market, and therefore
was satisfied by the consummation of the Business Combination. As a result, Rollover RSUs vested on the Closing Date to the extent that
their related service-based conditions had also been satisfied as of the Closing Date, resulting in the vesting of Rollover RSUs for
7,146,688 shares of the Company&#8217;s common stock on the Closing Date in addition to the approximately 120,000,000 shares issued as
consideration for the Merger. The Rollover RSUs have not yet been settled into shares of Tevogen Holdings common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, Tevogen Holdings sold $2,000,000 of shares of Series A Preferred Stock. Tevogen
Holdings expects to issue Series A-1 Preferred Stock for an aggregate purchase price of $6,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A Preferred Stock are convertible into a total of 500,000 shares of Common Stock at the election of the holder and the
Series A-1 Preferred Stock will be convertible into a total of 600,000 shares of Common Stock at the election of the holder. The Series
A Preferred Stock and the Series A-1 Preferred Stock is subject to a call right providing us the right to call the stock if the volume
weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and in
each case there is an effective resale registration statement on file covering the underlying common stock. Each of the Series A Preferred
Stock and the Series A-1 Preferred Stock is non-voting, has no mandatory redemption, and carries an annual 5% cumulative dividend, increasing
by 2% each year, in the case of the Series A-1 Preferred Stock in no event to more than 15% per year. So long as each of the Series
A Preferred Stock and Series A-1 Preferred Stock is outstanding, we will not, without the written consent of the holders of 50.1% of
the Series A Preferred Stock and the Series A-1 Preferred Stock, amend, alter, or repeal any provision of our certificate of incorporation
or bylaws in a manner adverse to such series of Preferred Stock. The investor in the Series A Preferred Stock and the Series A-1 Preferred
Stock is an entity associated with Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus entered into an agreement as of February 14, 2024 with the
Sponsor, pursuant to which Semper Paratus assigned to the Sponsor and the Sponsor assumed certain liabilities and obligations,
including liabilities and obligations that became liabilities and obligations of the Company as a result of the Business Combination,
in the amount of $3.6 million, in consideration for the issuance of the Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, we entered into the Repurchase Agreement with the Sponsor, pursuant to which we repurchased and cancelled, with immediate
effect, the outstanding shares of our Series B Preferred Stock in exchange for (i)&#160;the reassignment to and reassumption by us of
the liabilities assigned under the Assignment and Assumption Agreement (as defined elsewhere in this prospectus) and (ii)&#160;the termination
of the Assignment and Assumption Agreement, and the Sponsor released us from certain claims relating to the Repurchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, Semper Paratus entered into agreements with the Sponsor and Mr. Ajjarapu pursuant to which (i) the Sponsor agreed
to convert $1.5 million in principal amount of loans that it made to Semper Paratus and (ii) Mr. Ajjarapu agreed to convert $240,000
in principal amount of loans that he made to the Sponsor, which funds had then been passed along to Semper Paratus, into shares of Semper
Paratus common stock at a conversion price of $10.00 per share of Semper Paratus common stock, following which the loans were terminated
and deemed to be of no further force or effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus assumed all obligations of Tevogen Bio under the Tevogen
Bio Convertible Notes pursuant to a written assumption agreement. The Tevogen Bio Convertible Notes converted pursuant to their terms
immediately following the Closing into shares of the Company&#8217;s common stock, resulting in the issuance of 10,337,419 shares of
the Company&#8217;s common stock on the Closing Date, in addition to the shares issued as consideration for the Merger and shares issuable
upon vesting and settlement of Rollover RSUs. In addition, in satisfaction of a condition to the Closing of the Business Combination,
Dr. Saadi was awarded 19,348,954 Special RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Business Combination, outstanding obligations of Semper Paratus to Polar Multi-Strategy Master Fund related to
a loan of $151,000 to Semper Paratus were partially settled for 151,000 shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the number of Earnout Shares and the price per share are subject to adjustment to reflect the effect of any stock split, reverse stock
split, stock dividend, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with
respect to the common stock (i.e., dilutive activities).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting for the Earnout Shares was first evaluated under Accounting Standards Codification 718, Compensation &#8211; <i>Stock
Compensation </i>(&#8220;ASC 718&#8221;) to determine if the arrangement represents a share-based payment arrangement. Because the
Earnout Shares are granted to all former Tevogen Bio stockholders (before the Merger) and the Sponsor and there are no service
conditions nor any requirement of the participants to provide goods or services, the Company determined that the Earnout Shares are
not within the scope of ASC 718. Next, the Company determined that the Earnout Shares represent a freestanding equity-linked
financial instrument to be evaluated under ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;), and ASC
815-40, <i>Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity </i>(&#8220;ASC 815-40&#8221;). Based upon the
analysis, the Company concluded that the Earnout Shares should not be classified as a liability under ASC 480.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40, an entity must first evaluate whether an equity-linked instrument is considered indexed to the reporting entity&#8217;s stock.
This analysis, which is performed under ASC 815-40-15, is a two-step test that includes evaluation of both exercise contingencies and
settlement provisions. The Earnout Share arrangement contains contingencies &#8211; the daily volume weighted average stock price
on the basis of a specific price per share. The contingency is based on an observable market or an observable index other than one based
on the Company&#8217;s stock. With respect to settlement provisions, the number of Earnout Shares is adjusted only for dilutive activities,
which are an input into the pricing of a fixed-for-fixed option on equity shares under ASC 815-40-15-7E(c). In absence of dilutive activities,
there will be either zero or 24,500,000 shares issuable under the Earnout Share arrangement (to the extent each triggering event is achieved)&#894;
therefore, the triggering events for issuance of shares is only an exercise contingency to be evaluated under step 1 of ASC 815-40-15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company next considered the equity classification conditions in ASC 815-40-25 and concluded that all of them were met. Therefore, the
Earnout Share arrangement is appropriately classified in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Merger is accounted for as a reverse recapitalization, the fair value of the Earnout Share arrangement as of the Closing Date is
accounted for as an equity transaction (as a deemed dividend) as of the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the first and second extension redemptions (together, the &#8220;Extension Redemptions&#8221;), Semper Paratus had 1,502,180 Class
A ordinary shares with redemption rights outstanding. There was no specified maximum redemptions threshold stipulated under the Merger
Agreement. The unaudited pro forma condensed combined statement of operations has been prepared assuming the Extension Redemptions occurred
at January 1, 2023 due to their materiality to the capitalization of the Company for purposes of determining pro forma weighted average
shares outstanding. The unaudited pro forma condensed combined financial information has been prepared using the assumptions below with
respect to the potential redemption into cash of Semper Paratus Class A ordinary shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, the ownership structure for the Company&#8217;s common stock is set forth in the table below as described in Note
3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Equity Holder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares Held</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Public Shareholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">69,723</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">0.0</td><td style="width: 1%; text-align: left"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sponsor and Original Sponsor</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,457,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Former Tevogen Bio Equityholders
                                 and Convertible Note Holders</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,686,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Maxim/Cohen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Polar Multi-Strategy Master Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cantor (Private Placement Shares)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cantor (Reduced Deferred Fees)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">164,614,418</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above does not include the issuance of up to (i) 17,250,000 shares of the Company&#8217;s common stock upon exercise of the public
warrants, (ii) 725,000 shares upon exercise of the private placement warrants, (iii) 7,146,688 shares associated with the vested Rollover
RSUs that had not yet been settled into shares; (iv) 3,753,432 shares upon the vesting of Rollover RSUs that remained unvested as of
the Closing, or (v) 24,500,000 Earnout Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock and warrants are listed on Nasdaq under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Basis of Pro Forma Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial statements were prepared in accordance with Article 11 of SEC Regulation S-X, as amended
by the final rule, SEC Release No. 33-10786 &#8220;Amendments to Financial Disclosures About Acquired and Disposed Businesses&#8221;.
The adjustments presented in the unaudited pro forma condensed combined financial statements (collectively, the &#8220;Pro Forma Adjustments&#8221;)
have been identified and presented to provide relevant information necessary for an understanding of the Company following the consummation
of the Business Combination and related transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined balance sheet as of December 31, 2023 was derived from the historical audited balance sheet of
Semper Paratus as of December 31, 2023 and the historical audited balance sheet of Tevogen Bio as of December 31, 2023 and giving further
effect to the Pro Forma Adjustments as if they occurred on December 31, 2023. The audited pro forma combined statements of operations
for the year ended December 31, 2023, combine the historical audited statement of operations of Semper Paratus for the year ended
December 31, 2023, and the historical audited statement of operations of Tevogen Bio for the year ended December 31, 2023,
giving effect to the Pro Forma Adjustments as if they had been consummated on January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
historical financial information has been adjusted to reflect the Pro Forma Adjustments giving effect to the Business Combination and
related transactions as described in more detail below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has made significant estimates and assumptions in its determination of the Pro Forma Adjustments. As the unaudited pro forma condensed
combined financial information has been prepared based on these estimates, final amounts recorded may differ materially
from the information presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pro Forma Adjustments reflecting the consummation of the Business Combination and certain other transactions as described in more
detail below are based on available information at the time they were made and certain assumptions and methodologies that the
Company believes are reasonable under the circumstances. The Company believes that its assumptions and methodologies provide a reasonable
basis for presenting all of the significant effects of the Pro Forma Adjustments based on information available to management
and that the Pro Forma Adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro
forma condensed combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies,
tax savings, or cost savings that may be associated with the Business Combination and related transactions as described in more detail
below. Semper Paratus and Tevogen Bio had no historical relationship prior to the Business Combination. Accordingly, no Pro Forma Adjustments were required to eliminate activities between the companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
outstanding as presented in the unaudited pro forma condensed combined financial statements include the 149.7 million shares of the Company&#8217;s
common stock issued to former Tevogen Bio equityholders and convertible note holders, the 0.1 million shares of Class A ordinary shares
outstanding after final redemptions, the 13.5 million Class A ordinary shares issued to the Sponsor and the Original Sponsor, the 0.6
million shares of the Company&#8217;s common stock issued to Maxim and Cohen, the 0.2 million shares of the Company&#8217;s common
stock issued to Polar Multi-Strategy Master Fund, and the 0.7 million shares previously held by or issued to Cantor Fitzgerald &amp;
Co (&#8220;Cantor&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined balance sheet as of December 31, 2023 has been prepared to illustrate the effect of the Pro Forma
Adjustments and has been prepared for informational purposes only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined balance sheet as of December 31, 2023 includes the Pro Forma Adjustments giving effect to the
Business Combination and related transactions noted in this filing. Semper Paratus and Tevogen Bio had no historical relationship prior
to the Business Combination. Accordingly, no Pro Forma Adjustments were required to eliminate activities between the companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pro
forma notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
                                            from the historical audited  balance sheet of Semper Paratus as of December 31,
                                            2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
                                            from the historical audited balance sheet of Tevogen Bio as of December 31, 2023.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pro
forma adjustments giving effect to the Business Combination and related transactions:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the combination of the following items: the release of $16.7 million of cash from
                                            the Trust Account to the cash account, the issuance of shares of Series A Preferred Stock
                                            in exchange for $2.0 million, the payment of certain transaction expenses of $0.6
                                            million, and the final redemptions of 1,432,457 Class A ordinary shares of Semper Paratus
                                            Acquisition Corp. See table below:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 82%; background-color: #CFF0FC"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Release
    of Trust Account</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; background-color: #CFF0FC"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; background-color: #CCEEFF; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,681</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of Series A Preferred Stock</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CFF0FC"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
    redemptions</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CFF0FC"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,796</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of transaction expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(563</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CFF0FC; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CFF0FC"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,322</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the reclassification of deferred transaction costs of $2.6 million to additional
                                            paid-in capital.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the release of $16.7 million of cash from the Trust Account to the cash account.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the recognition of transaction expenses incurred of $1.0 million during the first
                                            quarter of 2024, offset by the assignment and assumption of $3.6 million of liabilities
                                            to the Sponsor in exchange for 3,613 shares of Series B Preferred Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the conversion of the Tevogen Bio convertible notes with a fair value totaling $94.9
                                            million into 10.3 million Class A ordinary shares.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the extinguishment of $14.7 million of deferred underwriters&#8217; fees incurred
                                            during the Semper Paratus IPO that were payable upon completion of the Business Combination.
                                            The Company entered into a Fee Reduction Agreement with Cantor resulting in a fee reduction
                                            of $9.7 million with the remainder of $5.0 million to be paid in the form of 500,000 shares
                                            of the Company&#8217;s common stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the reclassification of common stock subject to redemption of 1.5 million Class A
                                            ordinary shares to permanent equity.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the reclassification of common stock subject to redemption of 1.5 million Class A
                                            ordinary shares to permanent equity, the conversion of the convertible notes with a fair
                                            value totaling $94.9 million, the $9.7 million reduction in the deferred underwriting commission
                                            and the associated issuance 500,000 shares of the Company&#8217;s common stock at a price
                                            of $10.00 per share, the redemption of 880,873 Class A ordinary shares as a result of the
                                            Final Redemption totaling $9.7 million, and the recognition of the fair value of the
                                            Earnout Shares as a deemed dividend in the amount of $206.0 million, and the issuance
                                            of shares of Series A Preferred Stock in exchange for $2.0 million. The value of the
                                            Earnout Shares was calculated using Monte Carlo simulation. The valuation was prepared as
                                            if the Business Combination occurred on December 31, 2023 and the principal assumptions of
                                            the evaluation are as follows: starting per share price $10.00; volatility 80.0%; risk free
                                            interest of 4.3%; zero dividends; and a period of three years.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the elimination of the accumulated deficit of Semper Paratus, the accounting acquiree,
                                            of $16.9 million, offset by the recognition of the fair value of the Earnout Shares as a
                                            deemed dividend in the amount of $206.0 million and additional transaction expenses of $1.6
                                            million.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations for the Year Ended December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semper
Paratus and Tevogen Bio had no historical relationship prior to the Business Combination. Accordingly, no Pro Forma Adjustments
were required to eliminate activities between the companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma basic and diluted earnings per share amounts presented in the unaudited pro forma condensed combined statements of operations
are based upon the number of shares of common stock outstanding at the closing of the Business Combination, assuming the Pro Forma Adjustments
occurred on January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pro
forma notes:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
                                            from the historical audited condensed statements of operations of Semper Paratus for the
                                            year ended December 31, 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
                                            from the historical audited statements of operations of Tevogen Bio for the year ended December
                                            31, 2023.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pro
forma adjustments giving effect to the Business Combination and related transactions:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the additional transaction expenses of $1.6 million associated with the Business
                                            Combination incurred during Q1 2024.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the removal of $2.7 million of unrealized gain on investments held in the Trust Account
                                            in 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the removal of interest expense associated with the Tevogen Bio promissory notes
                                            of $1.2 million in 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect the removal of change in fair value of the Tevogen Bio promissory notes of $50.4
                                            million in 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            a result of both Tevogen Bio and Semper Paratus being historically loss-making, any deferred
                                            tax assets created because of net operating losses would be offset by a full valuation allowance
                                            resulting in no income tax expense adjustments to be presented in the unaudited pro forma
                                            condensed combined statement of operations.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pro
forma weighted average shares outstanding:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            the Business Combination is being reflected as if it had occurred at January 1, 2023, the
                                            calculation of weighted average shares outstanding for basic and diluted net loss per share
                                            assumes that the shares issuable in connection with the Pro Forma Adjustments have been outstanding
                                            for the entirety of the periods presented. Weighted average common shares outstanding &#8212;
                                            basic and diluted for the year ended December 31, 2023 are calculated as follows:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Weighted average shares calculation &#8211; basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%">Class A ordinary shares weighted average shares outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">69,723</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Class A ordinary shares weighted average public shares outstanding (non-redeemable)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,940,903</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Class B ordinary shares weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,492,430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of LGST Class A ordinary shares in connection with assignment and assumption agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">925,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of LGST Class A ordinary shares in connection with the Closing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,686,362</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of LGST Class A ordinary shares to Cantor in connection with fee reduction agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Weighted average shares outstanding</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">164,614,418</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the weighted averages shares outstanding by each shareholder group. The table below excludes a combined 17,975,000
shares underlying outstanding public warrants and private placement warrants, the 24,500,000 Earnout Shares, the 7,146,688 shares associated
with the vested Rollover RSUs that had not yet been settled into shares, and the 3,753,432 shares underlying the unvested Rollover RSUs,
because including them would have had an anti-dilutive effect on net loss per share, causing net loss per share for the year ended December
31, 2023 to be $0.06.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Holders</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Actual Redemptions</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of <br/> Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Public shareholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">69,723</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">0.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sponsor and Original Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,457,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Former Tevogen Bio Equityholders and Convertible Note Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,686,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Maxim/Cohen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Polar Multi-Strategy Master Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cantor (Private Placement Shares)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cantor (Reduced Deferred Fees)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total Common Shares</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">164,614,418</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparative
Share Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth selected historical comparative share information for Semper Paratus and unaudited pro forma condensed combined
per share information for the Company after giving effect to the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma book value information reflects the Business Combination as if it had occurred on December 31, 2023. The weighted average shares
outstanding and net earnings per share information reflect the Business Combination as if it had occurred on January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
information is only a summary and should be read together with the historical financial statements of Semper Paratus and Tevogen Bio
and related notes. The unaudited pro forma condensed combined per share information of Semper Paratus and Tevogen Bio is derived from,
and should be read in conjunction with, the unaudited pro forma condensed combined financial statements and related notes included above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined earnings per share information below does not purport to represent the earnings per share which
would have occurred had Semper Paratus and Tevogen Bio been combined during the periods presented, nor the earnings per share for any
future date or period. Historically, Semper Paratus&#8217; statement of operations included a presentation of income (loss) per common
share subject to redemption in a manner similar to the two-class method of income (loss) per common share. The two-class method is not
required in the pro forma income (loss) per common share as the Class A shares are no longer subject to redemption. We have not
considered the effect of the warrants sold in the IPO and the private placement to purchase an aggregate of 17,975,000 Class A ordinary
shares in the calculation of diluted earnings per share, because they were contingently exercisable, and the contingencies had
not yet been met. As a result, diluted earnings per common share is the same as basic earnings per common share for the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Semper Paratus (Historical)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Tevogen Bio</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Pro Forma</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Historical)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Combined</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">As of and for the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    income (loss) per Class A and B Common Shares &#8211; basic and diluted</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">0.02</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">0.02</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2.44</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(0.08</p></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Weighted average shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">17,650,819</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">1,116,256</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">24,752,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">164,614,418</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Book value per share(1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3.82</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Book
                                            value per share = Total shareholders&#8217; equity (deficit)/shares outstanding.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our results of operations and our liquidity and capital resources should be read together with our
unaudited consolidated financial statements and the related notes and our audited consolidated financial statements and the related notes
appearing elsewhere in this prospectus. Certain of the information contained in this discussion and analysis or set forth elsewhere in
this prospectus, including information with respect to plans and strategies for Tevogen&#8217;s business, includes forward-looking statements
intended to be covered by the safe harbor provisions for forward-looking statements in Section 21E of the Exchange Act. Forward-looking statements should be considered in light of these factors and the
factors described elsewhere in this prospectus, including in the &#8220;Risk Factors&#8221; section, and in our various filings with
the SEC. It is important that you read these factors and the other cautionary
statements made in this prospectus as being applicable to all related forward-looking statements wherever they appear in this prospectus.
Please also see the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
in this section to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Tevogen,&#8221; &#8220;the Company&#8221; and similar
terms refer to Tevogen Bio Holdings Inc. and its subsidiaries collectively unless the context indicates otherwise.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ CTLs,
to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with
the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability and commercial success
in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative business models,
and engagement across the development lifecycle and healthcare system. We believe the full potential of T cell therapies remains largely
untapped, and aspire to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective
personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology platform, ExacTcell<sup>TM</sup>, represents a significant scientific breakthrough
with the potential to mainstream cell therapy with a new class of off the shelf &#8211; manufactured and stored for immediate
use &#8211; T cell therapies with diverse applications across virology, oncology, and neurology. ExacTcell is a set of
processes and methodologies to develop, enrich, and expand single HLA restricted CTL therapies with proactively selected, precisely defined
targets. HLA molecules are proteins that play an important role in the immune system&#8217;s ability to recognize &#8220;self&#8221;
versus &#8220;foreign.&#8221; There are numerous HLA types that vary from person to person. CD8+ CTLs, also known as killer T cells,
are white blood cells that are part of the immune system and destroy infected, malignant, or otherwise damaged cells. We are focused
on using ExacTcell to develop allogeneic therapeutics, meaning therapeutics that are intended to be infused in patients other than the
original donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
therapies are based on carefully selected, naturally occurring CTLs that recognize targets of interest from the body&#8217;s native T
cell receptor pool, unlike genetically engineered T cell therapies. CD8+ CTLs in ExacTcell-based products target multiple and distinct
antigens, with the aim to circumvent the impact of mutations in viruses and cancer cells that can render existing treatments ineffective.
ExacTcell is designed to maximize the immunologic specificity of our products in order to eliminate malignant and virally infected cells
while allowing healthy cells to remain intact. We believe this high degree of specificity has the potential to significantly reduce the
chances of cross-reactivity or adverse impact on healthy cells. Our confidence in ExacTcell is reflected in our development pipeline,
which has been carefully tailored to address the unmet needs of large patient populations grappling with life-threatening viral diseases,
both viral and non-viral induced cancers, and neurological disorders such as multiple sclerosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised
and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. Viruses, including COVID-19, hijack
cellular machinery to transform infected cells into virus production plants. Elimination of infected cells is necessary to allow them
to be replaced by healthy, uninfected counterparts. TVGN 489 consists of CTLs active against multiple precise, well defined, and well
characterized targets across the SARS-CoV-2 genome. The product progressed from pre-discovery to the clinic in less than 18 months, and
in January 2023, we completed the Phase 1 proof-of-concept clinical trial of TVGN 489 for the treatment of ambulatory, high-risk adult
COVID-19 patients. No dose-limiting toxicities or significant treatment-related adverse events were observed in the treatment arm. Secondary
endpoints showing a rapid reduction of viral load and that infusion of TVGN 489 did not prevent development of the patients&#8217; own
T cell-related (cellular) or antibody-related (humoral) anti-COVID-19 immunity were also met. None of the patients who participated in
the trial reported progression of infection, reinfection, or the development of Long COVID during the six-month follow-up period. These
clinical observations were mirrored by laboratory evidence of the persistence of TVGN 489 cells for at least six months after treatment.
The results of the trial were submitted for peer-review and were published in <i>Blood Advances</i> in June 2024. We believe these
findings validate our initiative to develop off-the-shelf T cell therapies for outpatient administration, targeting diseases that affect
large patient populations &#8211; for the very first time. We plan to launch a pivotal trial of TVGN 489 in COVID-19 patients with
B cell malignancies, with studies of other highly vulnerable populations thereafter. TVGN 489 is also in preclinical development for
treatment and prevention of Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, pursuant to the Merger Agreement, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving
company and a wholly owned subsidiary of Semper Paratus, and Semper Paratus was renamed Tevogen Bio Holdings Inc. See Note 4 to
our unaudited consolidated financial statements in this prospectus for additional information regarding the net assets acquired through
the Merger. The Merger was accounted for as a reverse recapitalization under GAAP because the Company was determined to be the accounting
acquirer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
commencing operations in June 2020, we have devoted substantially all our efforts and financial resources to establishing corporate governance,
recruiting essential staff, establishing research and development capability including securing laboratory space and equipment, conducting
scientific research, securing intellectual property rights to our inventions related to our product candidates and ExacTcell, carrying
out drug discovery including pre-clinical studies and our Phase 1 clinical trial of TVGN 489, raising capital, and pursuing the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue. Our net losses for the years ended December 31, 2023, and December 31, 2022, were $60.5 million
and $22.0 million, respectively, our net income for the three months ended March 31, 2024, was $11.3 million and our net loss for the
three months ended March 31, 2023, was $30.8 million. Net income for the three months ended March 31, 2024, was primarily attributable
to a $48.5 million decrease in fair value in the three months ended March 31, 2024 due to the decrease in the fair value of our Common
Stock prior to the Business Combination, partially offset by $7.5 million in transaction costs in connection with the Business Combination
and a $29.5 million loss from operations that primarily resulted from non-cash, stock-based compensation expense recognized when the
liquidity event condition contained in certain stock-based awards was satisfied upon the Closing. As of March 31, 2024, we had an accumulated
deficit of $88.4 million and cash of $1.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement with an investor, pursuant to which the investor purchased 500 shares
of our Series A Preferred Stock for an aggregate purchase price of $2.0 million. On March 27, 2024, we entered into an Amended and Restated
Securities Purchase Agreement with the investor pursuant to which we amended and restated the original agreement and the investor agreed
to purchase 600 shares of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million, of which $2.2 million
has been received as of June 21, 2024. The shares of Series A Preferred Stock are convertible into a total of 500,000 shares
of our Common Stock at the election of the holder, and the shares of Series A-1 Preferred Stock will be convertible into a total
of 600,000 shares of our Common Stock. The Series A Preferred Stock is and the Series A-1 Preferred Stock will be subject to a call right
providing us the right to call the stock if the volume weighted average price of the Common Stock for the 20 days prior to delivery
of the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the underlying
Common Stock. The Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have no mandatory
redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, and the dividend on the Series A-1
Preferred Stock is capped at 15% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in more detail in &#8220;<i>Liquidity and Capital Resources &#8211; Funding Requirements</i>&#8221; below, on June 6, 2024,
we entered into a Loan Agreement providing for (i) an unsecured line of credit facility, pursuant to which the lender agreed to lend
us up to $36.0 million, and (ii) a contingent option for the lender to purchase at least $14.0 million of our Common Stock in the Optional PIPE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on cash on hand, as well as our history of operating losses and negative cash flows from operation combined with our anticipated use
of cash, we have concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our unaudited
consolidated financial statements, and as a result, under the applicable accounting standards and disclosure rules, there is substantial
doubt about our ability to continue as a going concern. In making this determination, applicable accounting standards prohibited us from
considering the potential mitigating effect of plans that have not been fully implemented as of the date of our unaudited consolidated
financial statements, including without limitation plans to raise additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to generate product revenue unless and until we obtain marketing approval for and successfully commercialize TVGN 489 or
another product candidate, and we cannot assure you that we will ever generate significant revenue or profits. We expect to incur significant
expenses related to expanding our research and development capability, building our manufacturing infrastructure including through acquisitions,
and developing our commercialization organization, including reimbursement, marketing, managed market, and distribution functions, and
training and deploying a specialty medical science liaison team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue, and we do not expect to generate any revenue from the sale of products unless and until we obtain
marketing approval for and commercialize TVGN 489 or another product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for our research activities, including staffing, discovery efforts, preclinical
studies, and clinical development of TVGN 489, and preclinical studies of other product candidates, and include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisition
    of supplies and, equipment and, leasing lab spaces;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred to conduct the necessary pre-clinical studies required by the U.S. Food and Drug Administration to obtain the regulatory
    approval necessary to conduct our TVGN 489 clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries,
    benefits, and other related costs for personnel engaged in research and development functions&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of funding research performed by third parties, including pursuant to agreements with CROs,
    and investigative site costs to conduct our pre-clinical studies and clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    costs, including expenses incurred under agreements with CMOs, including manufacturing
    scale-up expenses, and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of outside consultants, including their fees, stock-based compensation, and related travel expenses&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of laboratory supplies and acquiring materials for pre-clinical studies and clinical trials&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility-related
    expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating
    costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are central to the biotechnology business model. Product candidates in later stages of clinical development
generally have higher development costs than those in earlier stages, primarily due to the increased study sizes, which also leads generally
to longer patient enrollment times in later-stage clinical trials. We expect our research and development expenses to increase significantly
over the next several years as we increase manufacturing, shipping, and storage of clinical batches required for clinical trials, personnel
costs, including stock-based compensation, conduct planned clinical trials for TVGN 489 and other clinical and pre-clinical activities
for other product candidates, and prepare regulatory filings for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of our current or future product candidates is highly uncertain. At this time, we cannot reasonably estimate or
know the nature, timing, and costs of the efforts that will be necessary to complete the development of any product candidates. The success
of TVGN 489 and our other product candidates will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to products other than TVGN 489, successfully completing pre-clinical studies&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    initiating future clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    enrolling patients in and completing clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applying
    for and receiving marketing approvals from applicable regulatory authorities&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining intellectual property protection and regulatory exclusivity for TVGN 489 and any other product candidates we are
    developing or may develop in the future and enforcing, defending, and protecting these rights&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    arrangements with third-party manufacturers, or establishing adequate commercial manufacturing capabilities&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    sales, marketing, and distribution capabilities and launching sales of our products, if and when approved, whether alone or in collaboration
    with others&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    adoption of TVGN 489 and any other product candidates, if and when approved, by patients and the medical community&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with potential therapeutic alternatives in our target disease areas; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    reimbursement by private and public payors including health technology appraisal entities in non-U.S. countries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables concerning the development, manufacturing, or commercialization activities of a product
candidate could result in a significant change in the costs and timing associated with the development of that product candidate. For
example, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently
contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of
these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed
safety or efficacy profile would not be competitive in the marketplace, we could be required to expend significant additional financial
resources and time on the completion of clinical development. Product commercialization will take several years, and we expect to spend
a significant amount in development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of personnel expenses, which include salaries, benefits, and stock-based long term incentive
compensation for employees. These expenses also encompass corporate facility costs such as rent, utilities, depreciation, and maintenance,
as well as costs not classified under research and development expenses. Legal fees pertaining to intellectual property and corporate
matters, as well as fees for accounting and consulting services, are also included in general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase in the future to support our continued research and development activities,
potential commercialization efforts, and increased costs of operating as a public company. These increases will likely include increased
costs related to the hiring of additional personnel and fees to outside consultants, lawyers, accountants, and recruitment firms, among
other expenses. Increased costs associated with being a public company will also include expenses related to services associated with
maintaining compliance with SEC and Nasdaq requirements, insurance, and investor relations costs. If any of our current
or future product candidates obtains marketing approval, we expect that we would incur significantly increased expenses associated with
sales and marketing efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense, Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense, net consists primarily of interest on our convertible promissory notes, partially offset by interest earned on bank deposits.
(See &#8220;&#8212;<i>Sources of Liquidity</i>&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Merger
Transaction Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
costs we incurred in relation to the Merger were initially capitalized as deferred transaction costs up through the Closing Date, at
which time such costs were charged to expense in our statements of operations less the amount of cash received in the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Convertible Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
accounting standards provide entities with an option to measure many financial instruments and certain other items at fair value. As
a result of us electing this option, we recorded all convertible promissory notes at fair value with changes in fair value reported in
our statements of operations at each balance sheet date through the settlement of the convertible promissory notes in connection with
the Closing, at which time the convertible promissory notes were converted into our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax Provision</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have generally incurred significant net losses. As of December 31, 2023, we had net operating loss carryforwards (&#8220;NOLs&#8221;)
for federal and state income tax purposes of $13.9 million and $16.4 million, respectively. We have provided a valuation allowance against
the full amount of our net deferred tax assets since, in the opinion of our management, based upon our historical and anticipated future
losses, it is more likely than not that the benefits will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
utilization of our NOLs may be subject to a substantial annual limitation in the event of certain cumulative changes in the ownership
interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;), respectively, as well as similar state provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three months ended March 31, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the three months ended March 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">20,811,582</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,347,173</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,705,142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">977,109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,516,724</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,324,282</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,516,724</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,324,282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(155,786</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(288,997</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,499,353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,973</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,468,678</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,142,865</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,264,842</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not track our internal research and development costs on a program-by-program basis. The following table summarizes our research and
development expenses for the three months ended March 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,381,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">678,782</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation from satisfaction of liquidity condition upon the Closing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,966,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other clinical and pre-clinical development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">435,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Facilities and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">244,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">232,492</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,811,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,347,173</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses for the three months ended March 31, 2024 were $20.8 million, compared to $1.3 million for the three months
ended March 31, 2023. The increase was primarily attributable to a non-cash stock-based compensation expense of $19.0 million recognized
when the liquidity event condition contained in certain stock-based awards (the &#8220;Liquidity Condition&#8221;) was satisfied upon
the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our general and administrative expenses for the three months ended March 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,543,787</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">289,921</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation from satisfaction of liquidity condition upon the Closing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,267,425</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">663,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,551</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Facilities and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">230,633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">217,637</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,705,142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">977,109</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for the three months ended March 31, 2024 were $8.7 million compared to $1.0 million for the three months
ended March 31, 2023. The increase was primarily attributable to a non-cash stock-based compensation expense of $6.3 million recognized
when the Liquidity Condition was satisfied upon
the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $0.2 million and $0.3 million in interest expense for the three months ended March 31, 2024 and 2023, respectively, which
was attributable primarily to the outstanding principal balance associated with our convertible promissory notes which converted into
Common Stock in connection with the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Merger
Transaction Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger
transaction costs in excess of cash received from the Merger of $7.5 million were recognized as period expenses for the three months
ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in Fair Value of Convertible Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized a non-cash gain of $48.5 million and a non-cash loss of $28.1 million for the change in fair value of the convertible promissory
notes for the three months ended March 31, 2024 and 2023, respectively. The change was primarily a result of the increase in the underlying
estimated fair value of the Common Stock during the three months ended March 31, 2023 compared to a decrease in the underlying
estimated fair value of the Common Stock from January 1, 2024 to the settlement of the convertible promissory notes upon the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the years ended December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,403,526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,774,298</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,439,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,949,766</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,843,025</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,724,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,843,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,724,064</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,206,352</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(932,419</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50,428,303</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,384,918</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,477,680</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(22,041,401</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023, and 2022, we tracked outsourced development and personnel costs and other external research and development
costs of our TVGN 489 program. The following table summarizes our research and development expenses for the years ended December 31,
2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">TVGN 489 external expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">671,078</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,263,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,480,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other clinical and pre-clinical development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,226,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,102,855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Facilities and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">913,413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">519,768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,403,526</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,774,298</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses for the year ended December 31, 2023 were $4.4 million, compared to $5.8 million for the year ended December
31, 2022. The decrease was primarily attributable to a $0.7 million decrease in costs related to TVGN 489 and a $1.9 million decrease
in other clinical and pre-clinical development expenses for other product candidates, partially offset by a $0.8 million increase in
personnel costs and a $0.4 million increase in facilities and other expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our general and administrative expenses for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel costs, including stock-based compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,095,468</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,801,243</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,616,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,276,924</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Facilities and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">727,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">871,599</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,439,499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,949,766</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for the year ended December 31, 2023 were $4.4 million compared to $7.9 million for the year ended December
31, 2022. The decrease was primarily attributable to a $4.7 million decrease in personnel costs since there was no stock-based compensation
expense for the year ended December 31, 2023 as all remaining unvested share-based awards include performance conditions that are not
probable of being achieved and a $0.1 million decrease in facilities and other expenses, partially offset by a $1.3 million increase
in legal and professional costs attributable to the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $1.2 million and $0.9 million in interest expense for the years ended December 31, 2023 and 2022, respectively, which was
attributable primarily to the outstanding principal balance associated with our convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in Fair Value of Convertible Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized a $50.4 million and $7.4 million non-cash charge for the change in fair value of the convertible promissory notes for the
years ended December 31, 2023 and 2022, respectively. The increase of $43.0 million was primarily caused by an increase in the underlying
estimated fair value of our Common Stock during 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had $1.3 million in cash and an accumulated deficit of $88.4 million compared to $1.1 million in cash and an accumulated
deficit of $99.7 million as of December 31, 2023. To date, we have not yet commercialized any products or generated any revenue from
product sales and have financed our operations primarily with proceeds from the sale of convertible promissory notes and research tax
credits. Since January 2021, we have raised aggregate gross proceeds of $24.0 million from the sale of convertible promissory notes,
$2.0 million from the sale of our Series A Preferred Stock, and $2.2 million from the sale of our Series A-1 Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows for the three months ended March 31, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for the three months ended March 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by (used in)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,163,825</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,177,135</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,429,328</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net change in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265,503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">189,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024, we used $2.2 million of net cash in operating activities. Cash used in operating activities reflected
our net income of $11.3 million offset by $13.9 million of non-cash charges related to the change in the fair value of the convertible
promissory notes, stock-based compensation expense, depreciation expense, reductions in the operating right of use (&#8220;ROU&#8221;)
assets, non-cash interest on the convertible promissory notes, offset by a $0.5 million net change in our operating assets and liabilities
attributable to the timing of our payments to our vendors for research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we used $2.2 million of net cash in operating activities. Cash used in operating activities reflected
our net loss of $30.8 million offset by $28.5 million of non-cash charges related to the change in the fair value of the convertible
promissory notes, depreciation expense, reductions in the operating ROU assets, and a $0.1 million net change in our operating assets
and liabilities attributable to the timing of our payments to our vendors for research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, the Company purchased $0.1 million of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024, we received $2.4 million of net cash from financing activities attributable to proceeds from the
issuance of $2.0 million Series A Preferred Stock, $0.2 million of non-refundable prepaid proceeds towards the anticipated issuance of
Series A-1 Preferred Stock and $0.2 million of cash in connection with the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we received $2.5 million of net cash from financing activities attributable to the proceeds from
the convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows for the years ended December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by (used in)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(8,171,118</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(8,655,855</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(479,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,872,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net change in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,431,868</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,634,897</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, we used $8.2 million of net cash in operating activities. Cash used in operating activities reflected
our net loss of $60.5 million offset by $52.0 million of non-cash charges related to the change in the fair value of the convertible
promissory notes, depreciation expense, reductions in the operating ROU assets, non-cash interest on the
convertible promissory notes, and a $0.3 million net change in our operating assets and liabilities attributable to the timing of our
payments to our vendors for research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, we used $8.7 million of net cash in operating activities. Cash used in operating activities reflected
our net loss of $22.0 million offset by $13.1 million of non-cash charges related to the change in the fair value of the convertible
promissory notes, depreciation expense, stock-based compensation, reductions in the operating ROU assets, and a $0.3 million net change
in our operating assets and liabilities attributable to the timing of our payments to our vendors for research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, we used $0.1 million and $0.5 million respectively, for the purchase of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, we received $4.0 million and $7.5 million respectively, of net cash from financing activities
attributable to the proceeds from the convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary sources of funds to meet our near-term liquidity and capital requirements include cash on hand, including the funding we have
received from the sale of our Series A Preferred Stock and our Series A-1 Preferred Stock, and the funding we expect to receive from
the Loan Agreement and the sale of our Series A-1 Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement with an investor pursuant to which an investor agreed to purchase
shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024, we entered into an agreement
pursuant to which that amount was reduced to $2.0 million and the investor agreed to purchase shares of our Series A-1 Preferred Stock
for an aggregate purchase price of $6.0 million. We have not yet received $3.8 million of the $6.0 million purchase price for
the Series A-1 Preferred Stock. Even if we receive such proceeds, we will still need additional capital to fully implement our business,
operating, and development plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Loan Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2024, we entered into the Loan Agreement, pursuant to which the Lender agreed to provide to the Company up to the
Maximum Loan Amount of $36.0 million under the Facility. The Lender is also the investor in our Series A and Series A-1
Preferred Stock. The Facility permits us to borrow up to $1.0 million monthly in a single monthly draw over a period of up to three years.
Draws will accrue interest at a fixed annual rate of the lower of (i) the daily secured overnight financing rate, measured on the date
we receive the draw (the &#8220;Deposit Date&#8221;), plus 2.00% and (ii) 7.00%, accruing quarterly beginning on the Deposit Date and
payable quarterly beginning on the three-month anniversary of the Deposit Date. Interest will be payable in shares of Common Stock with
an effective purchase price of $1.50 per share, and each draw will mature 48 months after the Deposit Date. Prepayment will be permitted
without penalty. The Company may repay or prepay any amount of outstanding principal balance under the Facility at the Company&#8217;s
election in cash or in shares of Common Stock with an effective purchase price of the greater of $1.50 per share and the 10-day trailing
volume weighted average price of the Common Stock (the &#8220;Trailing VWAP&#8221;) as of the trading day prior to payment, subject to
certain requirements related to resale registration. Pursuant to the Loan Agreement, we also agreed to provide the Lender an option
to purchase $14.0 million of shares of our Common Stock plus an additional amount up to the total then-remaining available and
undrawn portion of the Maximum Loan Amount (which amount would thereafter no longer be available under the Facility). The Optional PIPE
would be priced at a 30% discount to the Trailing VWAP on the date such price first reaches at least $10.00 per share (the &#8220;Threshold
Price Date&#8221;) and will be exercisable by the Lender by written notice within three business days after the Company has notified
the Lender of the Threshold Price Date (the date of such notice, the &#8220;Threshold Price Notice Date&#8221;). Pursuant to the terms
of the Agreement, we issued to the Lender the Commitment Shares,
subject to forfeiture by the Lender of the Commitment Shares or an equal number of shares of Common Stock in the event the Lender fails
to (i)&#160;make a deposit under the Facility when due or (ii)&#160;pay the purchase price for the Optional PIPE within 30 days after
the Threshold Price Notice Date in the event the Company has satisfied all applicable closing conditions. There is no assurance as
to the amount of proceeds we will ultimately receive under the Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of shares by the Registered Holders. We will receive the proceeds from any exercise of the
Warrants or options for cash, which we intend to use for general corporate and working capital purposes. We may receive up to an aggregate
of approximately $207 million from the cash exercise of the Warrants. The exercise price of each of our Warrants is $11.50 per Warrant.
However, the last reported sales price of our Common Stock on June 20, 2024 was $0.755. The likelihood that holders
of Warrants will exercise their Warrants, and therefore any amount of cash proceeds that we may receive, is dependent upon the trading
price of our Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per share, we do not expect holders
to exercise their Warrants. Additionally, under certain circumstances, the Warrants may be exercised on a cashless basis and we will
not receive any proceeds from such exercise, even if the Private Placement Warrants are in-the-money. Any proceeds from the exercise
of Warrants would increase our liquidity, but we are not currently budgeting for any cash proceeds from the exercise of Warrants when
planning for our operational funding needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct our planned clinical
trials of TVGN 489 and other product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve
product sales. In addition, our product candidates, if approved, may not achieve commercial success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our pre-clinical
studies and clinical trials. In addition, if we obtain marketing approval for TVGN 489 in any indication or for any other product candidate
we are developing or develop in the future, we expect to incur significant commercialization expenses related to product manufacturing,
sales, marketing, and distribution. Furthermore, we expect to continue to incur increased costs associated with operating as a public
company. Accordingly, we will need to obtain substantial additional funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress, costs, and results of our planned clinical trials of TVGN 489 and other planned and future clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, costs, and results of our pre-clinical testing and clinical trials of TVGN 489 for additional combinations, targets,
    and indications&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of and development requirements for additional indications for TVGN 489 or for any other product candidates&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to scale up our manufacturing processes and capabilities to support clinical trials of TVGN 489 and other product candidates
    we are developing and may develop in the future&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of TVGN 489 and other product candidates we are developing and may develop in the
    future&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in the regulatory environment and enforcement rules&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaboration, licensing, or other arrangements and the financial terms of such arrangements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product manufacturing, sales, marketing, and distribution, for
    TVGN 489 and other product candidates we are developing and may develop in the future for which we may receive marketing approval&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain acceptance of any approved products by patients, the medical community, and third-party payors&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount and timing of revenue, if any, received from commercial sales of TVGN 489 and any other product candidates we are developing
    or develop in the future for which we receive marketing approval&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in pharmaceutical pricing and reimbursement infrastructure&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of raw materials for use in production of our product candidates&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and
    proprietary rights, and defending any intellectual property-related claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had cash of $1.3 million. Based on our cash balance, as well as our history of operating losses and negative cash
flows from operation combined with our anticipated use of cash to, among other things, fund the preclinical and clinical development
of our products, identify and develop new product candidates, and seek approval for TVGN 489 and our other product candidates and any
other product candidates we may develop, management has concluded that we do not have sufficient cash to fund our operations for 12 months
from the date of our unaudited consolidated financial statements included in this prospectus without additional financing, and as a result,
there is substantial doubt about our ability to continue as a going concern. In making this determination, applicable accounting standards
prohibited us from considering the potential mitigating effect of plans that have not been fully implemented as of the date of our unaudited
consolidated financial statements, including raising additional capital. Our financial information has been prepared on a basis that
assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and
commitments in the normal course of business. This financial information and our unaudited consolidated financial statements do not include
any adjustments that may result from an unfavorable outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination
of public and private equity offerings and debt financings, strategic alliances, collaborations, and marketing, distribution, or licensing
arrangements. However, adequate additional financing may not be available to us on acceptable terms, or at all, and may be impacted by
the economic climate and market conditions. See the risk factor in &#8220;<i>Risk Factors</i>&#8221; above captioned <i>&#8220;We will
require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all.
A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development, commercialization
efforts or other operations.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contractual
Obligations and Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual obligations and commitments as of March 31, 2024, and as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 1 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 to 3 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contractual obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease commitments <sup>(1)</sup></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">463,608</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">219,162</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">244,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total contractual obligations</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">463,608</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">219,162</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">244,446</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 1 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 to 3 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contractual obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease commitments <sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">536,149</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">291,703</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">244,446</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,738,945</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,599,166</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,139,779</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total contractual obligations</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">27,275,094</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">14,890,869</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,384,225</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 1.45pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    obligations pursuant to our office and laboratory leases in Philadelphia, Pennsylvania and Warren, New Jersey.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    principal and accrued interest pursuant to our convertible promissory notes issued between January 2021 and October 2023. On February
    14, 2024, in connection with the consummation of the Business Combination, our convertible promissory notes were assumed by Semper
    Paratus and automatically converted immediately following consummation of the Business Combination in accordance with their terms
    into an aggregate of 10,337,419 shares of our Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant
terms, including fixed or minimum services to be used, fixed, minimum, or variable price provisions, and the approximate timing of the
actions under the contracts. Our contracts with CROs, CMOs, and other third parties for the manufacture of our product candidates and
to support pre-clinical research studies and clinical testing are generally cancelable by us upon prior notice and do not contain any
minimum purchase commitments. Payments due upon cancellation consisting only of payments for services provided or expenses incurred,
including noncancelable obligations of our service providers, up to the date of cancellation are not included in the table above as the
amount and timing of such payments are not known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared
in accordance with GAAP. The preparation of the financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On
an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, the fair value of our Common
Stock, the fair value of our convertible promissory notes, and stock-based compensation. We base our estimates on historical experience,
known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different assumptions or conditions, including those factors set out in the &#8220;<i>Risk
Factors</i>&#8221; section above. See also the section entitled &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#8221;
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in Note 3 to our financial statements contained in this prospectus,
we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our financial
statements or involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on
our financial condition or results of operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. As part of the process of preparing our financial statements, we are required to
estimate our accrued research and development expenses, including those related to clinical trials and product candidate manufacturing.
This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services
that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the services
when we have not yet been invoiced or otherwise notified of actual costs. Our service providers invoice us in arrears or require prepayments
for services performed, as well as on a pre-determined schedule or when contractual milestones are met. We make estimates of our accrued
expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically
confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research
and development expenses include fees paid to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors
    in connection with preclinical and clinical development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs
    in connection with clinical trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMOs
    in connection with the process development and scale-up activities and the production of preclinical and clinical trial materials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for clinical trials and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion
of specific tasks, using data such as participant enrollment, clinical site activations, or information provided to us by our vendors
regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing
may differ significantly from the period in which the services were performed. We determine accrual estimates through reports from and
discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services
completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.
Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services
are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing
of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that
are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued
research and development expenses. However, due to the nature of estimates, we cannot assure you that we will not make changes to our
estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under our compensation plans are accounted for in accordance with Accounting Standards Codification 718, Compensation &#8211; <i>Stock
Compensation</i>. Compensation cost is measured at the grant date fair value of the award and is recognized over the vesting period of
the award. We use the straight-line method to record compensation expense of awards with service-based vesting conditions. We account
for forfeitures of stock-based awards as they occur. We recognize share-based compensation expense for awards with performance conditions
when it is probable that the condition will be met, and the award will vest. Prior to the Merger, we estimated the fair value of our
common stock in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting
and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Estimating
the fair value of common stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Closing, we were required to estimate the fair value of shares of our common stock underlying our stock-based awards and in connection
with valuing our convertible promissory notes. Because our common stock was not publicly traded prior to February 15, 2024, the fair
value of our common stock prior to such date had been estimated on each grant date by our Board, with input from our management,
considering third-party valuations of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board considered various objective and subjective factors to estimate the estimated fair value of our common stock, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    estimated value of all classes of securities outstanding&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anticipated capital structure that will directly impact the value of the currently outstanding securities&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    results of operations and financial position&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    status of our research and development efforts&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    composition of, and changes to, our management team and Board&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of liquidity of our common stock as a private company&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    stage of development and business strategy and the material risks related to our business and industry&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">external
    market conditions affecting the life sciences and biotechnology industry sectors&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering, or a sale of the
    company, given the prevailing market conditions&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market value and volatility of comparable companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
recurring fair value measurements primarily consist of the convertible promissory notes prior to the Merger, for which we elected the
fair value option. As a result of our electing this option, we recorded our convertible promissory notes at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used the Probability Weighted Expected Return Method (&#8220;PWERM&#8221;) valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger for all the periods presented. The PWERM is a scenario-based methodology that estimates the fair
value based upon an analysis of future values for the company, assuming various outcomes. The value is based on the probability-weighted
present value of expected future investment returns considering each of the possible outcomes available. The future value under each
outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at
an indication of value. Significant assumptions used in determining the fair value of convertible promissory notes include volatility,
discount rate, and probability of a future liquidity event. In February 2024, concurrent with the Merger, we converted our outstanding
convertible promissory notes into 10,337,419 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 to our unaudited consolidated financial statements found in this prospectus for a description of recent accounting pronouncements
applicable to our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_002"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ CTLs,
to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, with
the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability and commercial success
in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative business models and
engagement across the development lifecycle and healthcare system. We believe the full potential of T cell therapies remains largely
untapped, and aspire to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective
personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology platform, ExacTcell<sup>TM</sup>, represents a significant scientific breakthrough
with the potential to mainstream cell therapy with a new class of off-the-shelf &#8211; manufactured and stored for immediate
use &#8211; T cell therapies with diverse applications across virology, oncology, and neurology. ExacTcell is a set of
processes and methodologies to develop, enrich, and expand single HLA restricted CTL therapies with proactively selected, precisely defined
targets. HLA molecules are proteins that play an important role in the immune system&#8217;s ability to recognize &#8220;self&#8221;
versus &#8220;foreign.&#8221; There are numerous HLA types that vary from person to person. CD8+ CTLs, also known as killer T cells,
are white blood cells that are part of the immune system and destroy infected, malignant, or otherwise damaged cells. We are focused
on using ExacTcell to develop allogeneic therapeutics, meaning therapeutics that are intended to be infused in patients other than the
original donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
therapies are based on carefully selected, naturally occurring CTLs that are designed to recognize targets of interest from the body&#8217;s
native T cell receptor pool, unlike genetically engineered T cell therapies. CD8+ CTLs in ExacTcell-based products target multiple and
distinct antigens, with the aim to circumvent the impact of mutations in viruses and cancer cells, which can render existing treatments
ineffective. ExacTcell is designed to maximize the immunologic specificity of our products in order to eliminate malignant and virally
infected cells while allowing healthy cells to remain intact. We believe this high degree of specificity has the potential to significantly
reduce the chances of cross-reactivity or adverse impact on healthy cells. Our confidence in ExacTcell is reflected in our development
pipeline, which has been carefully tailored to address the unmet needs of large patient populations grappling with life-threatening viral
diseases, both viral and non-viral induced cancers, and neurological disorders such as multiple sclerosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised
and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. Viruses, including COVID-19, hijack
cellular machinery to transform infected cells into virus production plants. Elimination of infected cells is necessary to allow them
to be replaced by healthy, uninfected counterparts. TVGN 489 consists of CTLs that are designed to be active against multiple precise,
well defined, and well characterized targets spread across the SARS-CoV-2 genome. The product progressed from pre-discovery to the clinic
in less than 18 months, and in January 2023, we completed the Phase 1 proof-of-concept clinical trial of TVGN 489 for the treatment of
ambulatory, high-risk adult COVID-19 patients. No dose-limiting toxicities or significant treatment-related adverse events were observed
in the treatment arm. Secondary endpoints showing a rapid reduction of viral load and that infusion of TVGN 489 did not prevent development
of the patients&#8217; own T cell-related (cellular) or antibody-related (humoral) anti-COVID-19 immunity were also met. None of the
patients reported progression of infection, reinfection, or the development of Long COVID during the six-month follow-up period. These
clinical observations were mirrored by laboratory evidence of the persistence of TVGN 489 cells for at least six months after treatment.
The results of the trial were submitted for peer-review and were published in <i>Blood Advances</i> in June 2024. We believe these
findings validate our initiative to develop off-the-shelf T cell therapies for outpatient administration, targeting diseases that affect
large patient populations &#8211; for the very first time. We plan to launch a pivotal trial of TVGN 489 in COVID-19 patients
with B cell malignancies, with studies of other highly vulnerable populations thereafter. TVGN 489 is also in preclinical development
for treatment and prevention of Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to February 14, 2024, Semper Paratus was a special purpose acquisition
company formed for the purpose of effecting a merger, stock purchase, reorganization or similar acquisition or business combination
with one or more businesses. On the Closing Date, Semper Paratus completed the previously
announced business combination pursuant to the Merger
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
contemplated by the Merger Agreement, on the Closing Date, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving
company and a wholly owned subsidiary of Semper Paratus. In connection with the closing of the Business Combination, we changed our name
from &#8220;Semper Paratus Acquisition Corporation&#8221; to &#8220;Tevogen Bio Holdings Inc.&#8221; As of the open of trading on February
15, 2024, our Common Stock and public warrants began trading on Nasdaq as &#8220;TVGN&#8221;
and &#8220;TVGNW,&#8221; respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our understanding of immunotherapy and our ExacTcell platform to discover, validate, and build a proprietary pipeline
of T cell therapies with diverse targets in infectious disease, cancer, and neurological disorders. The figure below details our pipeline
of product candidates and their targets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1 clinical trials are designed in part to generate proof of concept data and safety-related data on tolerability and side effects.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    pivotal trial is a trial designed to generate data sufficient to support the filing of an application for regulatory approval. A
    pivotal trial may not necessarily be denoted as a Phase 3 clinical trial, and instead may be a Phase 2 or Phase 2/3 clinical trial.
    We believe that Phase 2, Phase 2/3, or Phase 3 clinical trials may serve as pivotal trials for TVGN 489.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    completed Phase 1 clinical trial of TVGN 489 was specifically conducted in ambulatory, high-risk adult patients with acute cases
    of COVID-19.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>4</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    believe that the data from our completed Phase 1 clinical trial should be sufficient to serve as the basis for one or more later
    stage, potentially pivotal trials in acute COVID-19 patients with B-cell cancer immune suppression, other B cell immune suppressed
    acute COVID-19 patients without a B cell cancer indication, and for Long COVID prevention and treatment. We cannot be certain whether
    we will be permitted to move from a Phase 1 trial directly to a pivotal trial covering any specific target population until FDA reviews
    and concurs with or rejects our proposed plans, and FDA may require us to conduct further trials to generate additional safety and
    efficacy data prior to approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>5</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
    collected in the completed Phase 1 trial of TVGN 489 includes and in all future trials of TVGN 489 is expected to include information
    regarding the incidence of Long COVID in patients treated with TVGN 489 versus untreated patients or those treated with alternate
    approaches.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to have a positive impact on patients&#8217; health and treatment equity by developing and commercializing personalized cell
therapies to treat infectious disease, cancer, and neurological disease. Key elements of our strategy to advance toward this goal include
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advancing
    the clinical development of TVGN 489 for the treatment of COVID-19 and Long COVID</i></b>. We completed a Phase 1 proof-of-concept
    trial of TVGN 489 for the treatment of high-risk ambulatory adult COVID-19 patients in January 2023 and plan to launch a pivotal
    trial in COVID-19 patients with B cell malignancies. TVGN 489 is also in development for other highly vulnerable COVID-19 patients
    and sufferers of Long COVID. We will undertake a Long COVID genetic predisposition trial in the third quarter of 2024
    in part to generate information needed to expeditiously conduct a Long Covid treatment trial that we expect to be launched
    in approximately the second quarter of 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
    our ExacTcell platform to develop therapies for additional indications</i></b>. In addition to TVGN 489, we are leveraging our ExacTcell
    platform to advance product candidates in virology, oncology, and neurology. Preclinical investigation is underway with product candidates
    for the treatment of Epstein-Barr virus-associated lymphomas, multiple sclerosis, and several other viral and cancer targets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    manufacturing capabilities, including through acquisitions</i></b>. We will need to develop manufacturing capabilities for clinical
    and, if approved, commercial supply of our cell therapy products. Our efforts to develop manufacturing capability are currently focused
    on acquiring existing manufacturing facilities or constructing one or more new manufacturing facilities, including through collaboration
    with a potential facility development partner, and we have identified a potential clinical manufacturing facility for use.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forming
    strategic alliances and collaborating with partners to augment our capabilities</i></b>. We may pursue strategic alliances with other
    biopharmaceutical companies with well-established presences in the specialties we aim to target for our indications. This may include
    co-marketing, co-promotion, and co-development relationships, or a partnership with a diagnostics company to help improve availability
    of rapid HLA testing. We also intend to explore options to work with partners to augment the study and treatment of patients and
    the impact of our product candidates, including medical professionals, healthcare professional networks, pharmacy benefit managers,
    insurance companies, and artificial intelligence companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ExacTcell Platform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ExacTcell platform and our therapies harness one of nature&#8217;s own approaches to eradicating cancer and other diseases: the cytotoxic
or killer T cell. We believe that our patented ExacTcell precision allogeneic T cell development platform has the potential to be a broadly
applicable approach for developing convenient and reasonably priced cellular immunotherapies for the treatment of acute viral infections,
long-term consequences of viral infections such as Long COVID, viral- and non-viral-induced cancers, and certain neurological disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
focuses on the selection and expansion of naturally occurring, genetically unmodified CD8+ CTLs to target multiple, distinct, preselected
antigens present only on virus-infected or malignant cells and to kill those cells. We believe that by relying on CD8+ CTLs, ExacTcell
has the potential to produce an entirely new class of drugs that could present numerous benefits over existing platforms. In contrast
to other approaches, ExacTcell enables a single, specific HLA molecule to be targeted in a clinical product and the specific target peptides
to be known with certainty and precision. HLA molecules are proteins present on the cell surface that play an important role in the immune
system&#8217;s ability to recognize &#8220;self&#8221; versus &#8220;foreign.&#8221; Specifically, HLA molecules present foreign antigens
to T cells for eradication. There are numerous HLA types that vary from person to person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Killer
T cells are white blood cells that play a vital role in the immune system&#8217;s defense against diseases, including viruses and cancer.
Most CTLs, including those developed with ExacTcell, express T cell receptors (&#8220;TCRs&#8221;), which are surface proteins that provide
each T cell with its unique immune specificity to recognize and react against specific foreign antigenic peptides of infected or malignant
cells. These foreign antigenic peptides are presented in conjunction with an HLA molecule. The CTLs destroy their infected or malignant
cell targets by inducing them to undergo apoptosis, or programmed cell death, by releasing cytolytic granules that produce pores in the
target cell&#8217;s membrane. CTLs also possess a protein that spans the entirety of the cell membrane, known as Cluster Differentiation
8 (which makes them CD8+), that aids in the reaction. CD8+ T cells work in conjunction with HLA-class I molecules, and CD4+ T cells work
in conjunction with HLA-class II molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_004.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
available cell-based immunotherapy approaches include genetically unmodified T cells applied to the treatment of viruses early after
transplant and genetically modified chimeric antigen receptor (&#8220;CAR&#8221;) T cells used to treat a selected subset of malignancies.
We believe that to date, cellular therapy has not been harnessed to its full potential for clinical application. We believe that our
proprietary approach will allow T cell products to be generated with a much higher target-specific CD8+ content and better-defined target
specificity than existing commercially available approaches. Contrasted with our approach, the genetically unmodified T cells used after
hematopoietic stem cell transplantation for the treatment of viral infections have used large viral proteins, pools of peptides, or infected
cells to stimulate CTLs. These broader targets may stimulate both CD4+ and CD8+ T cell responses, resulting in more heterogeneous T cell
products with little information regarding the specific peptide targets recognized by the T cells. By stimulating with only carefully
defined smaller peptides that are selected to bind to a single HLA-class I molecule, our approach elicits a high degree of target-specific
CD8+ responses, which we believe may result in improved outcomes as compared to these other approaches. Knowing the specific peptide
targets also allows rapid identification of the impact of mutations on our CTL products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the targeted nature of the cells ExacTcell can produce, we also believe we may be able to avoid some of the unwanted corollary effects
observed in other T cell immunotherapies. For example, we believe products developed through ExacTcell could potentially avoid the high
incidence of adverse events, some life-threatening, such as cytokine release syndrome and neurotoxicity, that have been observed with
autologous and allogeneic CAR-T platforms. Autologous cell therapies are derived from a donor&#8217;s own cells, as contrasted with allogenic
therapies such as ours, where cells are from third party donors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to select candidate peptides for ExacTcell products, we rely on a combination of computer-facilitated prediction of the ability
of specific peptide candidates to bind to specific HLA molecules and published scientific research. Once candidates are selected, we
use tetramer staining to assess whether T cells recognize the target peptides and assess cytotoxicity against individual peptide-pulsed
and non-pulsed targets. This allows us to rapidly and proactively select multiple, precise, candidate T cell targets and then quickly
experimentally confirm them for use. Through our Tevogen.ai artificial intelligence initiative, we are exploring ways to deploy artificial
intelligence-powered target detection to further accelerate our product development pace, either internally or in collaboration with
leading entities in the field of artificial intelligence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
illustrated in the figure below, we begin the ExacTcell process by collecting cells from a healthy donor. T cells from the donor are
exposed to the preselected targeted peptides and through a repetitive process of selection and expansion. CD8+ CTLs specific for the
targeted, antigenic peptides become the major cellular component of the final product. The expansion of the antigen specific CTLs is
extensive enough to produce over 100, and up to hundreds, of doses from a single donor. Those doses can then be used to treat hundreds
of patients who share the same HLA type.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
stands in contrast with both autologous and allogeneic CAR-T platforms, which target antigens present on both healthy and diseased cells
and require genetic modification of the T cells. In autologous CAR-T approaches, the quantity and health of desired T cells in patient
blood samples used to manufacture the CAR-T product have been among the largest obstacles for T cell therapies to date. Much of this
is due to the chemotherapy treatments the patients have already received. Some existing CAR-T therapies may take weeks to manufacture,
may require patients to receive pre-infusion lymphodepleting (<i>i.e.</i>, immunosuppressing) chemotherapy as part of a lengthy preparation
process, and be hospitalized in many cases during the CAR-T cell infusion or afterwards due to the frequency of side effects from the
therapy such as cytokine release syndrome. These treatments may also require lifelong monitoring for the development and treatment of
infections due to eradication of normal parts of the immune system along with the cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, in November of 2023, FDA announced that it had &#8220;received reports of T-cell malignancies, including chimeric antigen receptor
positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.&#8221; These
secondary malignancies resulted in hospitalization and death in a small subset of patients. On January 19, 2024, FDA required a class-wide
black box warning be added to the label of these CAR T products regarding this risk. FDA also underscored that the benefits of CAR-T
therapies continue to outweigh their risks but recommended lifelong monitoring of this potential side effect. Currently approved autologous
CAR-T platforms utilize the patient&#8217;s own T cells to manufacture their products. These cells have previously been exposed to cancer
therapy and are genetically altered and subsequently expanded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast, CTLs generated using the ExacTcell platform come from a healthy donor with a normal immune system. ExacTcell CTLs are not genetically
altered in the manufacturing process and although they expand during manufacture, this is the expected response of a T-lymphocyte when
encountering its target antigen. The genetic modifications necessary to make CAR-T cells, which may be associated with the recent reports
of T-cell malignancies, are not utilized in the manufacture of our products made on the ExacTcell platform. Moreover, secondary malignancies
have not been described in the unmodified T cell products given to hundreds of post-transplant patients. Although our ExacTcell products
are not designed to be genetically modified, they are still in the early stages of testing, and only limited human and laboratory study
data are available regarding the risk profiles of our products. Allogeneic CAR-T approaches are in early-stage development, but concerns
exist regarding side effects similar to autologous CAR-T, and additionally, the development of graft versus host disease with allogeneic
CAR-T products, both of which we believe will be of lower risk with our platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hundreds
of doses per donor can be obtained using the ExacTcell approach, which is expected to facilitate off-the-shelf use and the ability to
administer doses within hours of diagnosis in the case of treatments against viruses where rapid therapeutic intervention is crucial.
Use of TVGN 489, for example, is expected to begin with a confirmatory COVID-19 test and rapid HLA typing for which results would be
available in six to eight hours, allowing selection of the proper product based on HLA type. After confirmation of HLA type, thawing
takes minutes, and cells are infused within ten minutes of thawing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convenience of &#8220;off-the-shelf&#8221; &#8211; manufactured and stored for immediate use &#8211; therapy has the potential to offer timely and
cost-efficient therapeutics by potentially eliminating the need for specialized medical facilities, unlike existing platforms. By producing
products in which the active CD8+ T cell components are present at high concentrations, we believe relatively small volumes will be required,
allowing our therapies to be easily and promptly delivered in the ambulatory setting as a very brief intravenous administration such
as in a physician&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working to further advance ExacTcell with a new, proprietary T cell receptor-engineered process, which we believe
may substantially increase the number of doses that can be produced from a single donor. Available technology can be used to allow us
to interrogate over a thousand individual T cells to determine which one kills peptide-pulsed targets fastest or kills the most in a
given timeframe. This highest performing T cell can then be isolated, and its T cell receptor sequenced, allowing us to make an artificial
TCR gene that can be introduced into CD8+ T cells collected from healthy donors. We believe this could allow at least a several-fold
increase in the number of desired CTLs as compared to our current approach. We expect efforts to produce second generation products based
on this process may begin shortly after and if initial regulatory approval of the first-generation product is obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
First Product Candidate</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19
therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention
of Long COVID. Treatment for these groups represents an area of unmet or incompletely met need which we believe TVGN 489 can significantly
address. We rapidly progressed TVGN 489 from pre-discovery to the clinic in only 18 months. TVGN 489 cells are derived from healthy donors
who recovered from a prior COVID-19 infection, and TVGN 489 is active against multiple, precise targets spread across the SARS-CoV-2
genome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we completed a Phase 1 proof-of-concept trial of TVGN 489 for the treatment of ambulatory high-risk adult COVID-19 patients.
No dose-limiting toxicities or significant TVGN 489-related adverse events were observed in this trial at any of the four dosing levels
tested. Secondary endpoints showing a rapid reduction of COVID-19 viral load and to show that infusion of TVGN 489 did not prevent development
of the patient&#8217;s own T cell-related (cellular) and antibody-related (humoral) anti-COVID-19 immunity were also met. In addition,
none of the patients in the treatment arm reported progression of infection, reinfection, or the development of Long COVID during the
six-month follow-up period. The TVGN 489 in the Phase 1 trial was formulated to match patients expressing HLA-A*02:01, the most common
HLA type in the population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe TVGN 489 has the potential to be less susceptible to viral mutation than monoclonal antibodies, less susceptible to drug resistance
than antivirals, and to rapidly be able to overcome any increased immune evasion of current and emerging SARS-CoV-2 variants. We also
believe ExacTcell can enable us to deliver products faster, at a greater scale, and at lower cost than future competing cell therapies,
if any. Despite selection of T cell targets in 2020, the HLA-A*02:01 TVGN 489 product has maintained a high degree of activity through
the full range of studied delta and subsequent omicron variants. In contrast, most monoclonal antibodies were withdrawn from the market
for lack of efficacy related to the emergence of new variants, providing what we believe to be evidence of decreased susceptibility of
TVGN 489 to viral mutation. In addition, knowing the precise peptide targets of our therapy helps allow rapid assessment regarding their
preservation or loss as soon as new variants are sequenced. We check emerging COVID-19 variants against TVGN 489 targets on an ongoing
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19
Background</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19,
caused by the SARS-CoV-2 virus, has killed millions and infected hundreds of millions since its emergence in late 2019. Groups currently
most at risk for poor outcomes due to COVID-19 are immunocompromised individuals unable to mount an adequate immune response, such as
those with immune system cancers, immunodeficiency disorders, transplant recipients, patients with immune-mediated disorders requiring
immunosuppressive therapy, or high doses of corticosteroids, the elderly and the unvaccinated. For example, recent data shows that the
majority of COVID-19 deaths occur in people over the age of 65. The risk of severe illness from COVID-19 for an individual tends to escalate
with an increase in their number of underlying medical conditions. In addition to the acute impacts of infection, a significant portion
of those who have been infected by COVID-19 in the past develop more chronic and potentially debilitating symptoms afterwards, a condition
termed Long COVID. Of US adults, 17.8% had experienced symptoms of Long COVID, and 5.3% were still experiencing symptoms of
Long COVID, according to the Centers for Disease Control and Prevention&#8217;s (&#8220;CDC&#8217;s&#8221;) household pulse survey
taken from April 2 through April 29, 2024. Despite the availability of vaccines and emergence of initial therapeutics, significant
gaps and shortcomings in treatment remain both for vulnerable patients experiencing an acute infection and for Long Covid sufferers for
whom there are no treatment options approved for the indication or its underlying causes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
other viruses that have RNA as their genetic material, SARS-CoV-2 is constantly evolving through random mutations. New mutations can
potentially increase or decrease infectiousness and virulence. In addition, mutations can increase the virus&#8217; ability to evade
adaptive immune responses from past SARS-CoV-2 infection or vaccination. New variants of the SARS-CoV-2 virus continue to emerge, and
many people continue to be adversely affected by COVID-19, particularly those at the highest risk and sufferers of Long COVID. Moreover,
a growing body of scientific data suggests new immune-evasive variants are more likely to arise in immunocompromised patients because
they are less able to eradicate the virus. The longer duration of infection within the host affords the virus more opportunity to mutate
so as to evade the immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of May 2023, about 103 million cumulative confirmed
COVID-19 cases were reported in the United States alone. While there has been a decrease in the number of confirmed and reported
cases, this is a multifactorial issue due in part to a decrease in testing by younger or healthier individuals, reliance on home tests,
the results of which are often not reported, expiration of federal funding for testing, and the CDC&#8217;s discontinuation of collection
of testing data. However, a large number of Americans remain highly vulnerable to COVID-19 infection, including immunocompromised and
elderly patients. For example, the rate of hospitalization in cancer patients with COVID-19 infection remains high, specifically for
those under active chemotherapy or immunosuppression. There is therefore a high unmet need to have an effective treatment available for
these populations. Classic herd immunity leading to eradication of COVID-19 is unlikely, much as is the case for influenza, respiratory
syncytial virus (RSV), and other endemic respiratory viruses. This contrasts with smallpox, for example, where both natural infection
and vaccination eliminated virus transmission. SARS-CoV-2 infection and vaccination produce a steadily waning natural and vaccine-induced
immunity, respectively, but do not eliminate transmission. Although the number of daily reported cases and deaths has declined, the emergence
of more transmissible variants has led to spikes in cases and mortality, and variants are expected to continue to evolve over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current COVID-19 landscape is also characterized by continued vaccine hesitancy among a significant portion of the population, unequal
access to vaccines and treatment, lack of response in some immunocompromised and other high-risk groups, and breakthrough cases among
the vaccinated due in part to increased immune evasion by current and emerging variants and the relatively short duration of protection
by booster shots. We expect these circumstances to continue, which could adversely impact long-term community-level protective immunity.
In addition, we believe that the expiration of the U.S. federal Public Health Emergency and U.S. government funding for COVID-19 testing,
and treatment could lead to higher pricing for diagnostics and therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
two anti-viral agents, Nirmatrelvir/Ritonavir (Paxlovid) and Remdesivir, have been FDA-approved for the treatment of COVID-19. While
Paxlovid is indicated for treatment in individuals at high risk for viral progression, neither drug has been specifically authorized
for use in immunocompromised patients, creating a need for the development of novel therapies in this area. Both drugs also present challenges
for subsets of patients. Paxlovid is associated with many drug-drug interactions, resulting in the need to temporarily stop ongoing medications
or seek alternative therapy and thereby making it difficult for some patients to take. This is especially true for patients on multiple
medications, which is often true of high-risk patients requiring anti-COVID-19 treatment. Paxlovid is also known to be associated with
COVID-19 rebound, which has been calculated as high as 21% in ambulatory patients, according to a study published in the Annals of Internal
Medicine in November 2023. Although the rate of rebound in high-risk subgroups is less well-documented, we anticipate it may be as high
or higher in this group. Paxlovid also must be started within five days of symptom development to be effective. Remdesivir must be given
within seven days and is only available in intravenous form, requiring three daily infusions in a treatment center. Remdesivir has also
been associated with liver enzyme abnormalities and gastrointestinal side effects. Monoclonal antibodies to the viral spike protein were
introduced early in the pandemic for treatment of COVID-19, but typically have been rendered ineffective over time as the virus continues
to evolve. No therapies have been approved to treat the underlying causes of the symptoms of Long COVID, and significant research is
ongoing to determine why some patients fully recover while others develop long-term complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Key
Advantages of TVGN 489</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the ongoing spread of COVID-19 and its effects and continued gaps in treatment, there is a clear need for alternatives to current therapeutic
options for COVID-19. We believe TVGN 489 has been shown to be less susceptible to viral mutations than monoclonal antibodies and thus
able to overcome the increased immune evasion of current and emerging COVID-19 variants. We also believe TVGN 489 has the potential to
be less susceptible to drug resistance than antivirals. As contrasted with existing therapies, TVGN 489 is designed to recognize multiple
specific target peptides from distinct COVID-19 proteins, versus one or two targets typically derived only from the spike protein. Whereas
other viral therapies buy time for natural immunity to emerge and definitively control the virus, TVGN 489 provides natural immunity
directly and immediately to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489&#8217;s targets have also persisted in studied COVID-19 variants. We have observed TVGN 489&#8217;s targets to be generally retained,
in nearly all cases at greater than a 95% level of retention, in the genome of all of the isolates of SARS-CoV-2 variants that we have
studied to date. This is in significant contrast with the target loss of anti-spike monoclonal antibody therapies, which led to the withdrawal
of emergency use authorizations (&#8220;EUAs&#8221;) that had been granted during the now-expired COVID-19 National Public Health Emergency.
For example, the EUA for AbCellera Biologics&#8217; and Eli Lilly&#8217;s bamlanivimab administered alone, which was granted in November
2020, was revoked in April 2021 due to a sustained increase in viral variants that were not sensitive to this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
variants have demonstrated how this virus is able to escape our immune system through mutation. However, we believe our proprietary approach
to manufacturing TVGN 489 may allow us to monitor the sequences of emerging variants and, if necessary, to proactively adjust or fine
tune our products to ensure that they continue to recognize and treat current and future variants of this and other viruses. For example,
with our approach, if a product contains T cells that recognize and target seven different peptides and one is lost through mutation,
that peptide can be dropped from future product batches. Similarly, if the mutation generates a new peptide target, that target can be
added to future batches. However, making these types of changes to TVGN 489 may require additional regulatory approvals, and there is
no guarantee that we will receive such approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 is also designed to be fast acting, as the cells are fully mature and crafted to be primed to act as soon as they find their way
to infected cells. All patients in the interventional arm of our Phase 1 clinical trial noted improved symptoms within two to three days,
which is shorter than the average noted by patients in the observational arm, and 83% of patients in the interventional arm had negative
nasal swab polymerase chain reaction tests within 14 days. The consistency of the resolution was suggestive of a treatment effect and
the observed period is in contrast to a range of up to 90 days in the general population. This observed consistency and rapidity of nasal
swab COVID-19 resolution was in a population where five individuals were on active immunosuppression for cancer and one for lupus at
the time of COVID-19 infection. Two patients on the trial went on to stem cell transplantation, an immunosuppressive procedure, within
a month of treatment. Neither experienced COVID-19 reactivation, which we believe further attests to the rapid acting nature of this
product. When immunocompromised patients get sick from COVID-19, their current treatment regimens for existing conditions are often stopped.
For oncology patients, this can be especially disruptive or even harmful. Given TVGN 489&#8217;s design and these results, we believe
TVGN 489 may allow immunocompromised patients to recover and be able to return to their pre-COVID-19 treatment regimen with minimal delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Production
of TVGN 489 and Mechanism of Action</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 cells are sourced from healthy donors who have recovered from a previous COVID-19 infection. These donor cells are subsequently expanded
by 600-fold or more by restimulating them toward specific peptide targets. This is accomplished by exposing them to antigen-presenting
cells and selectively isolating the T cells that recognize the specific targets. TVGN 489 is formulated to precisely target multiple
peptide targets spread across the SARS-CoV-2 genome, rather than focusing solely on the mutation-susceptible spike protein, which is
the primary target of most vaccines and monoclonal antibodies. Upon completion of the manufacturing process, the cells are frozen and
stored for future intravenous infusion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration
of TVGN 489 infuses the body with killer T cells that have been designed to attack COVID-19 infected cells. These highly purified, multi-target
CD8+ CTLs are intended to bind to and eliminate infected cells expressing the targeted peptides against which the CTLs were manufactured.
Peptides are presented in conjunction with the HLA molecule and the CTLs eradicate diseased cells expressing these viral or malignant
targets. To be clinically effective, a T cell therapy must be compatible with the patient&#8217;s specific HLA type. Therefore, a panel
of HLA-specific CTL products is necessary to broadly cover and treat the population. In our next clinical trial of TVGN 489, we expect
to treat patients with the six most common HLA types, which we believe would represent between 60% and 65% of the COVID-19 infected population.
We plan to continue expansion into additional HLA types until we are confident that between 90% and 95% of the population could be treated
based on our research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that once bound to infected cells, TVGN 489 cells then destroy the infected cells through formation of an immunological synapse
between the killer cell and target and the release of cytotoxic granules from TVGN 489 into the target. These both produce pores in the
target cell&#8217;s membrane and also trigger a process known as apoptosis, or programmed cell death, which is built into all our cells.
Then, once the infected cells die, new, healthy cells are able to grow in their place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_007.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Discovery
and Preclinical Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approach to identifying CTL targets starts with computer-based prediction and then tests candidate peptides functionally with T cells. We use a technique known as tetramer staining to assess whether T cells recognized these target peptides, assessed cytotoxicity against
individual peptide-pulsed and non-pulsed targets, and selected final peptides for use in TVGN 489 on that basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted multiple in-vitro studies of TVGN 489 in preparation for filing the IND with FDA and observed strong antiviral activity against SARS-CoV-2 in these laboratory studies. In preclinical studies, we observed that
TVGN 489 cells kill target cells that are exposed to SARS-CoV-2 peptides, but not cells that are not exposed to those peptides. This
is illustrated in the figure below, which shows the percentage of cells killed over a four-hour period when targets were pulsed with
the peptides and when they were not, with the x-axis showing the lysis rates based on the ratio of CTLs to target cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_008.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of appropriate COVID-19 peptide targets for additional HLA molecules remains ongoing, and we plan to continue this testing until we are
confident that between 90% and 95% of the COVID-19 infected population could be treated based on our research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Development for COVID-19 Patients</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
permitted our IND for TVGN 489 to proceed in May 2021, and we began enrolling patients in the Phase 1 proof-of-concept trial of TVGN
489 for the treatment of high-risk ambulatory adult COVID-19 patients in October 2021. Patients in the trial were newly diagnosed with
COVID-19 and were deemed to be at high risk for complications due to the presence of one or more underlying medical conditions defined
as high risk by the CDC, including among others cancer, hypertension, obesity, diabetes, cardiovascular disease, and old age. The trial,
which was conducted at Thomas Jefferson University Hospital in Philadelphia, was completed in January 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial included two arms, with 12 patients in the treatment, or interventional, arm and 18 patients in the observational arm. Assignment
to the interventional arm versus the observational arm was based on each patient&#8217;s HLA type. Patients expressing HLA-A*02:01, the
most common HLA type in the population, matched the CTLs and were enrolled in the interventional arm. Patients in the treatment arm had
been infected with either the delta variant or one of three omicron variants of COVID-19. Patients on the interventional arm had a higher
median number of comorbid conditions, a higher incidence of immune compromise, and a higher number of patients who were unvaccinated
or failed to respond to vaccination versus patients on the observational arm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
patient in the treatment arm received a single intravenous infusion of TVGN 489 within four days of diagnosis. Analysis of COVID-19 viral
load showed that the patients were early in their COVID-19 disease course. Patients were treated with TVGN 489 at one of four dose levels:
1 x 10<sup>5</sup>/kg; 3 x 10<sup>5</sup>/kg; 1 x 10<sup>6</sup>/kg; or 3 x 10<sup>6</sup>/kg. These dose levels were chosen based on
data regarding antiviral T cell therapy in hematopoietic transplant patients involving the administration of similar cell numbers. Three
patients were enrolled at each dosing level with the option to enroll three more if a significant side effect was observed. Each dose
level concluded with three patients rather than six and the treatment arm concluded with a total of 12 patients rather than 24, primarily
due to the absence of appreciable toxicities across all dose levels. The comparative arm, which was designed to end enrollment when treatment
arm enrollment was completed, concluded with 18 patients, appreciably less than what would have occurred if the treatment group required
additional enrollment. Observational arm patients received standard of care treatment, including monoclonal antibodies. Interventional
arm patients were monitored in the hospital for four days before being discharged and then were observed daily at home for ten additional
days and again at the one, two, three, and six-month anniversary of the initial infusion. Observational arm patients were monitored at
home over the same interval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoints of the trial, which were safety-related, were met. No dose-limiting toxicities or significant adverse events related
to TVGN 489, including acute infusion reactions, cytokine release syndrome, neurotoxicity, or instances of graft versus host disease,
were observed in any patient at any dose level of our Phase 1 trial of TVGN 489.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
endpoints showing a rapid reduction of COVID-19 viral load and showing that infusion of TVGN 489 did not prevent development of the patient&#8217;s
own T cell-related (cellular) and antibody-related (humoral) anti-COVID-19 immunity were also met. In other words, observations indicate
that TVGN 489 did not prevent the body from responding to the infection and generating its own CTLs and antibodies to COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
treatment arm patients reported returning to their baseline level of health without COVID-19 symptoms within 14 days of treatment. All
such patients also reported symptom improvement within two to three days of treatment, which corresponded with a decrease in the COVID-19
viral load on PCR testing in the majority of patients. None of the patients who participated in the trial reported progression of their
COVID-19 infection and none developed COVID-19 or Long COVID during the six-month follow-up period. These clinical observations were
mirrored by laboratory evidence of the persistence of infused TVGN 489 cells for at least six months after treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_009.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persistence
of infused therapeutic cells remains a significant issue in the T cell therapy space, leading to challenges in controlling viral infections,
preventing viral recurrence, and managing cancer relapse. The shorter the CTLs persist in the recipient, the less opportunity they have
to perform their intended therapeutic tasks. Genetic differences between donor and recipient in allogeneic cell products and new genes
introduced into autologous products can be recognized by the patient&#8217;s immune system, which can encourage elimination of the administered
cells. This is one of the reasons why lymphodepleting therapy is commonly administered prior to CAR-T treatments. Maximizing the percentage
of CTLs in the products is also useful as the CTLs may receive re-stimulation from the virus infecting the patient and have a better
ability to protect themselves against elimination by the patient&#8217;s immune system. Most studies of genetically unmodified CTLs have
suggested that they are eliminated within weeks, with three months, in highly immune-suppressed hematopoietic blood and marrow transplant
(&#8220;HSCT&#8221;) patients, being the longest that they typically are reported to persist. The highly immune-suppressed nature of
the HSCT patient group is thought to allow for longer than typical persistence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our Phase 1 clinical trial for TVGN 489, following infusion, peripheral blood of five patients was collected at various timepoints throughout
the six-month follow-up period. These samples were sent to Adaptive Biotechnologies (&#8220;Adaptive&#8221;) to evaluate the persistence
of infused TVGN 489 in the patients following treatment, and Adaptive conducted analyses by sequencing protein chains of TCRs in the
samples. As seen in the figure below, Adaptive&#8217;s data showed persistence of T cells present in the TVGN 489 product but absent
from the recipients prior to administration of TVGN 489. This subset of CTLs was found in all samples tested, including at the final
study assessment at six months. The TCRs used to recognize TVGN 489&#8217;s peptides were also shown to be largely distinct from person
to person, making it highly unlikely that the cells from later timepoints derive from anything other than the product in these five different
patients. Taken together, we believe this data shows the persistence of TVGN 489 cells six months after administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
489 COVID-19 Reactive CD8+ T Cells Detected Throughout the Six-Month Follow Up Period</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_010.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion
and persistence of allogeneic T cells has been associated with disease control in many settings. Whether the prolonged persistence of
the CTLs used in this study is of benefit in the treatment of COVID-19, Long COVID, or alternate future viral or oncologic targets for
these CTLs merits further examination. However, the evidence of their prolonged persistence provides us with encouragement for future
applications of the ExacTcell platform, particularly in oncology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe based on precedential industry examples, including in areas with high unmet needs or strong early phase clinical trial results,
that we may be able to commence pivotal trials of TVGN 489 on the basis of the results of our completed Phase 1 trial. A pivotal trial
is a trial designed to generate data sufficient to support the filing of an application for regulatory approval. Although the clinical
trial process usually includes three phases, a pivotal trial may not necessarily be denoted as a Phase 3 clinical trial, and instead
may be a Phase 2 or Phase 2/3 clinical trial. We hope to begin a pivotal trial of TVGN 489 for the treatment of COVID-19 in select
vulnerable populations with humoral immune suppression due to B cell malignancy or the treatment thereof. Patients with hematological
malignancies continue to experience higher rates of hospitalization and death as compared to the general population and those with solid
tumors. Increased mortality, hospitalization, and incidence of Long COVID are higher in patients with B cell malignancies due to inadequate
vaccination response and the immunosuppressive consequences of treatment received for B cell cancers. While the major acute outcomes
of patients with hematological malignancies and COVID-19 have improved with increasing experience, delays in cancer treatment due to
the infection are increasingly recognized as a long-term impact of COVID-19 in this population. Whereas treatment arm patients in our
Phase 1 proof-of-concept clinical trial all had a single HLA type, we expect to treat patients in this pivotal trial who have any of
the six most common HLA types, which we believe would represent between 60% and 65% of the population. The primary endpoint of this trial
is planned to be reduced risk of hospitalization, with secondary endpoints relating to pace of viral load reduction, duration of hospitalization,
intensive care unit admissions, hours on supplemental oxygen, mortality, COVID-19 recurrence, Long COVID diagnosis, and interruption
in cancer treatment associated with COVID-19. At this stage, however, we cannot be certain whether we will be permitted to move from
a Phase 1 trial directly to a pivotal trial until FDA reviews and concurs with or rejects our proposed plans, and FDA may require us
to conduct further trials to generate additional safety and efficacy data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
development of TVGN 489 continues, we may also seek FDA&#8217;s RMAT designation
for TVGN 489, which as explained in &#8220;Regulatory Environment &#8211; Expedited Development and Review Programs&#8221; below, is intended
to facilitate efficient development and expedited review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Target Patient Populations and Indications for TVGN 489</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
target patient populations for TVGN 489 that we are prioritizing include the treatment of COVID-19 in B cell immune suppressed acute
COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and Long COVID sufferers. As noted
above, these patients are among those with the greatest need for effective treatment. We believe that the safety and the clinical benefit
data from our completed Phase 1 clinical trial in ambulatory, high-risk adult patients should be sufficient to serve as the basis for
later-stage and potentially pivotal trials in these patient groups as well as for the prevention of Long COVID. However, whether such
trials may serve as pivotal trials, the phase of these trials, and the dose level to be selected in each trial remains subject to discussions
with and agreement by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to develop TVGN 489 for the treatment of acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant
patients. The suppression of these patients&#8217; immune systems may make them more susceptible to developing graft versus host disease.
Based on data analyzed from hundreds of bone marrow transplant patients receiving T cell therapies showing almost no incidence of graft
versus host disease, we believe it unlikely that patients on T cell suppressing drugs would develop graft versus host disease as a result
of treatment with TVGN 489. However, we believe the possibility nonetheless merits an additional safety study in this target population
prior to moving forward with later stage clinical development. In addition, higher doses may also be required for efficacy in these patients
as compared to other patients, as T cell suppressing drugs may reduce the impact of TVGN 489, requiring more cells to produce comparable
effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
studies have detected persistent viral spike and nucleocapsid proteins in some Long COVID patients, suggesting a persistent viral reservoir
in those patients. If that is correct, we believe that TVGN 489 may circumvent Long COVID by preventing such a reservoir from being established
or by minimizing its size. No treated patients in our Phase 1 proof-of-concept trial developed Long COVID. We expect considerable additional
information on Long COVID prevention to be obtained from our planned acute COVID-19 treatment trials in which patients treated with TVGN
489 are expected to be compared to patients receiving standard of care treatment. We believe that the comparative data with respect to
patients in these trial arms going on to develop Long COVID should provide sufficient information to obviate a separate Phase 1 Long
COVID prevention trial, and that the significant unmet need for treatment in vulnerable patients as well as the efficacy data in preventing
Long COVID generated in these studies will lend further support for a streamlined development pathway. However, we cannot be certain
whether FDA will require us to conduct a separate prevention trial until FDA reviews and concurs with or rejects our proposed plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work
is also beginning to identify Long COVID biomarkers in preparation for Long COVID treatment trials. We believe that certain individuals
may be genetically predisposed to Long COVID, in that the HLA types of Long COVID patients may be skewed toward some HLA types and away
from others. However, very limited Long COVID-related HLA typing information has been published to date. We therefore plan to launch
a non-therapeutic blood draw study in the third quarter of 2024 to assess whether the Long COVID population generally
reflects or is skewed towards or away from certain HLA types and to determine the optimal HLA types to target in a therapeutic trial
of TVGN 489 for the treatment of Long COVID. This will allow us to develop CTLs for the HLA types most commonly found in Long COVID.
Following the results of that study, we plan to begin a clinical trial in Long COVID treatment in approximately the second
quarter of 2025. Specific symptoms will also be explored for an association with the viral reservoir in advance of this trial.
Additional studies in vulnerable populations are expected to follow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Discovery Programs, Product Candidates and Indications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to TVGN 489, we have several product candidates under early-stage development in virology, neurology, and oncology using our
ExacTcell platform technology. We are developing Epstein-Barr virus (&#8220;EBV&#8221;) specific CTLs for potential use in multiple sclerosis
(&#8220;MS&#8221;) and EBV-associated lymphomas. Our TVGN 601 is being developed for MS, and our TVGN 930 is being developed for EBV-associated
lymphomas. EBV is a common virus that infects over 90% of the world&#8217;s adult population, according to the World Health Organization
(the &#8220;WHO&#8221;), and is mainly transmitted through saliva, but also through other body fluids such as blood and semen. EBV is
the leading cause of infectious mononucleosis, and infects B-cells, a type of immune cell. Recent studies have suggested a potential
link between infection with EBV and later onset of inflammation that causes MS, and EBV infection can lead to a variety of cancers and
cancer-like disorders, including lymphomas, nasopharyngeal cancers, Post-Transplant Lymphoproliferative Disorder, and others. Given the
widespread nature of EBV and the serious health problems it can cause, investigative work is underway to identify effective peptide targets
for this virus to further the development of TVGN 601 and TVGN 930. Investigative work is also underway to develop product candidates
targeted at human papilloma virus (&#8220;HPV&#8221;)-related diseases, including TVGN 920 in cervical cancer and TVGN 960 in oropharyngeal
cancer, which is a type of mouth and throat cancer. Cervical cancer and oropharyngeal cancer are both commonly caused by HPV. According
to the WHO, HPV is responsible for 99% of cervical cancers. Mouth and throat cancers are more diverse, but the WHO estimates that about
70% of oropharyngeal cancers are due to HPV. Although a vaccine for HPV exists, the National Cancer Institute estimates that as of 2022,
only 58.6% of adolescents between the ages of 13 and 15 had received the recommended doses, estimated vaccination among older
populations is lower, and the COVID pandemic has shown that significant portions of the population will avoid vaccination. We believe
that as with other viral infections, the availability of both a preventative strategy and a treatment strategy is important to reduce
incidence and impact of disease and is investigating peptide candidates for HPV to further the development of TVGN 920 and TVGN 960.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ExacTcell approach also presents a novel and highly specific technique to combating cancers with T cell therapy. Unlike
CAR-T or Bispecific T-cell Engager (BiTE) antibody approaches, which recruit a heterogeneous group of T cells to the tumor, our approach
would instead focus a highly purified population of CTLs on the tumor, which we believe may provide more potential to accomplish the
task of eradicating the cancer. Cancer cells may not always express an ideal T cell target on their own. However, it is possible to coat
a cancer cell with a well-recognized target peptide using monoclonal antibodies or liposomes. We believe this would allow our target
specific CTLs to then attack the cancer cells. We also believe that our approach has the potential to eventually bring the benefits of
cell therapies to first-line options in oncology, as well as to create products that may overcome current limitations of checkpoint inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
cells can lose their ability to fight viruses and tumors in prolonged infections and cancer in a state called T cell exhaustion that
is characterized by the presence of certain biomarkers. Expression of these markers, which include PD-1, PDL-1, and LAG-3, has been observed
to be low level to absent in TVGN 489 cells. Moreover, TVGN 489 cells are functionally tested after generation, and have been observed
to remain strongly cytolytic at very low ratios of CTLs to target cells, which shows that they are not displaying the functional limitations
associated with T cell exhaustion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
relied on a Clinical Trial Services and Materials Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our
Phase 1 proof-of-concept trial. However, we will need to develop manufacturing capabilities for clinical and, if approved, commercial
supply of our cell therapy products. Our efforts to develop manufacturing capability are currently focused on acquiring existing manufacturing
facilities or constructing one or more new manufacturing facilities, including through collaboration with a potential facility development
partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Commercialization Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, we plan to globally commercialize TVGN 489 and our other product candidates aimed at serving a large patient population suffering
from infectious diseases, cancer, and multiple sclerosis. Our commercial and market access team has been diligently working alongside
our research and development team and external experts to better understand market dynamics, identify segments with high unmet needs,
map the patient journey, understand the competition within each segment, and identify opportunities for our product candidates. The same
team continues to offer input in portfolio planning and target prioritization for our research pipeline. We are also proactive in identifying
potential collaboration and service partners, including distribution partners for our sophisticated, cryopreserved cell therapy products
like TVGN 489. As part of our company&#8217;s mission of patient centricity, we aim to collaborate with all stakeholders, including patients,
healthcare professionals, sales channel partners, public and private payers, and service providers. Essential commercial capabilities,
such as market analytics, pricing, and commercial operations functions, are continuously being developed as we progress toward the later-stage
development of TVGN 489.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Artificial
Intelligence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, we announced Tevogen.ai, a new early-stage initiative focused on harnessing the potential of artificial intelligence to
expedite drug development, optimize laboratory processes and clinical trials, unravel complex biological data, improve patient outcomes,
and pass on related savings to patients. We intend to assemble a team of research scientists, physicians, data scientists, and artificial
intelligence and machine learning engineers to help accomplish these goals by leveraging tools and techniques that might include large,
curated data sets, algorithmic models, pattern recognition, data analyses, automation, and artificial intelligence-powered software such
as chatbots. As an initial part of this initiative, we are specifically exploring ways to deploy artificial intelligence-powered target
detection to further accelerate our product development pace, either internally or in collaboration with leading entities in the field
of artificial intelligence. We also intend to explore the potential use of artificial intelligence to power tools that could anticipate
potential adverse reactions and efficacy concerns for and identify patients who would be most likely to respond to an investigational
therapy. The ability to search the human genome for specific peptide sequences might, for example, eliminate some peptide targets simplifying
the peptide screening/selection process. We have filed patents for algorithms to be trained against a curated dataset to predict immunologically
active HLA-peptide complexes and additionally to predict T-cell receptor engagement tied to specific HLA-peptide complexes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
History and Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as a Cayman Islands exempted company in April 2021, and Tevogen Bio was established in June 2020 as a Delaware corporation.
Our senior leadership team is composed of eminent scientists and accomplished biopharmaceutical leaders. The team brings together diverse
experience across the entire life sciences spectrum, including biotechnology, pharmaceuticals, hospitals, public and private insurance,
education, and health policy. Additionally, our team holds substantial expertise in drug development, global product launches, and commercialization
and ensuring patient access across a range of therapeutic areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology industry, and in particular the cell therapy sector, are characterized by the rapid evolution of technologies and understanding
of disease etiology, and strong pursuit and defense of intellectual property. We believe that our approach, strategy, scientific development
capabilities, know-how, access to global experts, and experience provide us with competitive advantages. However, we expect future competition
in some of the indications we are targeting and from existing or emerging pharmaceutical and biotechnology companies as well as possibly
from governmental agencies, academic institutions, and public and private research institutions, among others. Some of our competitors,
either alone or through collaborations, have greater financial resources and expertise in research and development, conducting clinical
trials, manufacturing, obtaining regulatory approvals, and marketing approved products than we do. Smaller or early-stage companies may
also prove to be competitors, particularly through collaborative arrangements with large and established companies. Entities in the biotechnology
industry also compete with us in recruiting and retaining qualified scientific, clinical, and management personnel and may compete with
us in establishing clinical trial sites and enrolling patients in clinical trials as well as in acquiring technologies complementary
to, or necessary for, our programs. As a result, our competitors may discover, develop, license, or commercialize products before or
more successfully than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 is being developed to fill the critical gaps that exist in COVID-19 therapeutics for the immunocompromised, the high-risk
elderly, and Long COVID. No treatments are specifically approved for immunocompromised patients as of June 21, 2024, and
clinical trial data of currently approved treatments in immunocompromised patients is limited. The National Institutes of Health&#8217;s
COVID-19 Treatment Guidelines Panel, a group of clinical experts that has developed guidance on COVID-19 care (the &#8220;NIH Panel Guidelines&#8221;),
currently recommends prompt treatment of COVID-19 in non-hospitalized immunocompromised patients with antiviral drugs, but acknowledges
the limitations of these drugs and related research in such patients. Two antivirals are currently FDA-approved for COVID-19 treatment:
Gilead Science&#8217;s Veklury<sup>&#174;</sup> (Remdesivir) for the treatment of mild-to-moderate COVID-19 in hospitalized or non-hospitalized
adults who are at high risk for progression to severe COVID-19, and Pfizer&#8217;s Paxlovid (Nirmatrelvir/Ritonavir tablets) for the
treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19. The NIH Panel Guidelines highlight
the limitation of the insights that clinical trials conducted for Remdesivir and for Nirmatrelvir/Ritonavir tablets in broader populations
can provide with respect to immunocompromised patients, as each trial enrolled only limited numbers of such patients. For example, a
retrospective study examining the use of Nirmatrelvir/Ritonavir tablets in vulnerable individuals with COVID-19 included only 13.2% highly
immunocompromised and 10.6% moderately immunocompromised patients with cancer, with cancer type and type immunosuppressive medications
not otherwise specified. Although the NIH Panel Guidelines acknowledge observation in retrospective studies of &#8220;some potential
benefits&#8221; of the use of Paxlovid for patients with &#8220;various immunocompromising conditions,&#8221; they also note that because
the pivotal trial of Nirmatrelvir/Ritonavir tablets did not enroll many immunocompromised participants, &#8220;efficacy ... was not established
for this population.&#8221; Based on our target product profile, therefore, we anticipate that these products may not be direct competitors
in our target patient population. Moreover, we believe that TVGN 489&#8217;s anticipated single outpatient infusion may be easier to
administer than Veklury&#8217;s multiple infusions over a number of days. Additionally, Paxlovid requires daily doses, has a significant
number of drug interaction issues, as discussed in &#8220;COVID-19 Background&#8221; and noted by the NIH Panel Guidelines, and has experienced
numerous patient reports of disease relapse or rebound, which in each case we do not anticipate for TVGN 489 based on its design and
our Phase 1 proof of concept trial results. We do expect that these products may present direct competition in high-risk elderly patients,
but we are initially targeting immunocompromised indications. There remains no documented effective treatments for Long COVID, with
a recent study showing no benefit from the use of Paxlovid (Nirmatrelvir/Ritonavir tablets) in patients with Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monoclonal
antibodies have also previously been considered promising as an effective therapeutic option for COVID-19, including in immunocompromised
patients, and several had been granted EUAs. However, these treatments have had their EUAs revoked by FDA due to lack of efficacy stemming
from viral mutations. For example, AstraZeneca&#8217;s Evusheld (tixagevimab co-packaged with cilgavimab), a monoclonal antibody pair
that previously had an EUA granted on December 8, 2021, for preventive use in immunocompromised patients, was undermined by viral mutations,
resulting in the revocation of its EUA in January 2023, only 13 months later. Evushield had previously been associated with a reduced
risk of mortality in ancestral strains of COVID-19, but the results of a trial reported in February 2024 showed that Evushield failed
to impact patient clinical status or increase viral clearance in hospitalized COVID-19 patients. This finding was thought to be due at
least in part to evasion of the therapy by newer COVID-19 variants, highlighting the difficulty of applying monoclonal antibody treatments
to COVID-19 therapy. There are nonetheless ongoing efforts to develop additional anti-COVID monoclonal antibodies for treatment and prevention
of Covid-19 infection. For example, in March 2024, Invivyd received an EUA of its product, VYD222, a broadly neutralizing
monoclonal antibody used for COVID-19 prevention in immunocompromised individuals. While this product has shown in vitro activity against
a currently circulating variant, JN.1, it may remain vulnerable to novel viral mutations. Antibodies, unlike T-cells, recognize intact
molecules. Consequently, even remote mutations, not directly where the antibodies bind, may alter how the target molecule folds and its
overall shape and therefore prevent antibody binding. T-cells, in contrast, recognize small peptide breakdown products of proteins and
are only affected if the mutation is directly within the target peptide. Although it is possible that the epitope targeted by VYD 222
and others like it will remain more durable, this remains to be seen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
broadly, known companies developing virus-specific T cell therapies include Atara Biotherapeutics (&#8220;Atara Bio&#8221;), whose Ebvallo
(tabelecleucel) has received approval in Europe for treating a rare hematologic cancer caused by EBV. AlloVir, Inc. (&#8220;AlloVir&#8221;) is another company developing
allogeneic T cell therapies for viral diseases. Neither Atara Bio nor AlloVir has an active development program for the treatment of
COVID-19. AlloVir conducted a Phase 1b trial of an allogeneic, partially HLA-matched product candidate in COVID-19 and reported results
of the trial in 2021 but has not continued clinical development. One patient in the trial experienced a recurrence of the disease and
died four weeks after treatment. Atara Bio announced in November 2023 that the Phase 2 trial of its T cell therapy, ATA 188, targeting
EBV-infected B cells and plasma cells in progressive forms of multiple sclerosis, failed to meet efficacy or biomarker endpoints. Patients
initially treated with placebo in this trial later received ATA 188, which we believe may have made it more challenging to discern a
difference between the study arms. ATA 188 targets only three latent EBV proteins, whereas our CTL peptide targets are selected from
all proteins expressed at the appropriate point in the viral life cycle, whether unique to that point in the viral life cycle or not.
This approach provides far more immunologic targets and thus more opportunities for viral control. In addition, ATA 188 is generated
against targets restricted by several HLA alleles, which is likely to reduce the functional dose of drug targeting any one HLA allele,
as contrasted with CTLs developed with ExacTcell, which are generated against a single HLA specificity and therefore allow a more precise
understanding and control of dosage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we may face competition as new therapies enter the market and advanced technologies become available from time to time.
We expect that any treatments which we develop and commercialize will need to compete on, among other things, efficacy, safety, convenience
of administration and delivery, and price. Commercialization of any treatments we develop will be affected by the level of competition
from original and biosimilars products and the availability of reimbursement from government and other third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize our proprietary cell products could be significantly and adversely affected if our competitors develop and commercialize
products that are more effective, have a better safety profile, are more convenient or are less expensive than our products. Our competitors
also may obtain relevant regulatory approvals for their products more rapidly than we may be able to obtain approval for ours, which
could result in our competitors obtaining a head start and establishing a frontrunner position before we are ready to commercialize.
If we are not able to compete effectively against our existing and potential competitors, our business, financial condition, results
of operations and growth prospects may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for our products and
methods, preserve the confidentiality of our trade secrets, operate without infringing, misappropriating, or otherwise violating the
valid, enforceable proprietary rights of others, and prevent others from infringing, misappropriating, or otherwise violating our proprietary
rights. We rely on a combination of patents, patent applications, and trade secrets to establish and protect our intellectual property
rights. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products without the right
to do so may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to build our intellectual property portfolio and seek to protect our proprietary position by, among other things, filing patent
applications. Our patent estate includes patents and patent applications with claims relating to our product candidates, methods of use,
and methods of preparing the product candidates. As of June 14, 2024, our U.S. intellectual property portfolio includes three
U.S. patents relating to TVGN 489 for the treatment of COVID-19, nine pending U.S. patent applications, including two patent applications
relating to the treatment of COVID-19, five relating to the treatment of other viruses or cancer, and two related to artificial intelligence-driven
T cell target identification and receptor engagement, as well as eleven ex-U.S. patent applications, including applications in Australia,
Canada, Europe, Japan, Qatar, and United Arab Emirates directed at viral specific T cells, methods of treating and preventing viral infections,
and methods for developing CD3+CD+ cells against multiple viral epitopes for the treatment of viral infections, which have anticipated
expiration dates through July 29, 2042.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our three issued utility patents, all of which will expire on December 9, 2040, are U.S. Patent No. 11,191,827 covering
methods of treating COVID-19 infection using COVID-19 peptide specific CTLs, U.S. Patent No. 11,207,401 covering COVID-19 peptide-specific
CTLs, and U.S. Patent No. 11,219,684 covering methods of manufacturing COVID-19 peptide specific CTLs. A pending utility patent application
in the United States directed at viral specific T cells and methods of treating and preventing viral infections has an anticipated expiration
of December 9, 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have applied for registered trademark protection for &#8220;Tevogen Bio&#8221; (and design) as well as &#8220;ExacTcell&#8221;
and &#8220;Tevogen AI&#8221; with the USPTO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine strategy for claim scope for our patent applications on a case-by-case basis, taking into account advice of counsel and our
business model and needs. We file patents containing claims for protection of useful applications of our proprietary technologies and
any product candidates, including new applications or uses we discover for existing technologies and product candidates, based on our
assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as our pending and
issued patent claims, to ensure maximum coverage and value are obtained for our processes and compositions, given existing patent office
rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to attract and retain highly qualified management and personnel. As of June 20, 2024, we had 17
full-time and no part-time employees. We value a work culture that encourages employees, contractors, and vendors to contribute
their unique and diverse perspectives, to harness optimism and creativity, and to be ready to learn and develop solutions towards a common
and greater purpose of developing accessible immunotherapies. Our work culture is centered around four &#8220;CORE&#8221; values: Curiosity,
Optimism, Respect, and Equality. We believe it is essential and necessary that these values are instilled and maintained in each of our
employees to foster a collaborative culture. At our current size, ensuring this culture is primarily achieved through the recruitment
process. Talent recruitment at our current stage is setting the foundation for further company growth. When attracting talent, we ensure
that every job description mentions our core values, and the importance of these values in achieving our mission. Beyond evaluating experience,
job applicants are also evaluated based on their values and passions. We believe it is necessary that each employee represents our four
core values. As our employee numbers increase, we plan to create more defined programs to further enhance our company culture and retention
of personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Facilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our corporate
headquarters are located in Warren, New Jersey, and consist of 6,708 square feet dedicated to corporate, operational, and pre-commercial
activities under a lease that expires February 14, 2026. We also have two research and development facilities located in Philadelphia:
our 3,620 square foot research and development center under a lease that expires June 30, 2025; and a shared facility with laboratory
space dedicated to us that is focused on preclinical and pharmacodynamic activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;),
and the Public Health Service Act (the &#8220;PHSA&#8221;), and other federal, state, and local statutes and regulations. Both the FDCA
and PHSA and their corresponding regulations govern, among other things, the research, development, clinical trials, testing, manufacturing,
quality control, safety, purity and potency (efficacy), labeling, packaging, storage, record keeping, distribution, reporting, marketing,
promotion, advertising, post-approval monitoring, and post-approval reporting involving biological products. Along with third-party contractors,
we will be required to navigate the various preclinical and clinical regulatory obligations and the commercial approval requirements
of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product
candidates. The processes for obtaining regulatory approvals in the United States, along with subsequent compliance with applicable laws
and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
policies may change and additional government regulations may be enacted that could prevent or delay further development or regulatory
approval of any product candidates, product or manufacturing changes, additional disease indications or label changes. We cannot predict
the likelihood, nature or extent of government regulation that might arise from future legislative or administrative action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Review
and Approval for Licensing Biologics in the United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, FDA regulates our current product candidates as biological products, or biologics, under the FDCA, the PHSA, and associated
implementing regulations. Biologics, like other drugs, are used for the diagnosis, cure, mitigation, treatment, or prevention of disease
in humans. In contrast to low molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics
are generally derived from living material (human, animal, or microorganism), are complex in structure, and thus are usually not fully
characterized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biologics
are also subject to other federal, state, and local statutes and regulations. The failure to comply with applicable statutory and regulatory
requirements at any time during the product development process, approval process, or after approval may subject a sponsor or applicant
to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by FDA,
FDA&#8217;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, issuance of warning or untitled
letters, product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions,
fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought
by FDA, the Department of Justice (&#8220;DOJ&#8221;), and other governmental entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
applicant seeking approval to market and distribute a biologic in the United States must typically undertake the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of non-clinical laboratory tests and studies performed in accordance with FDA&#8217;s GLP regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture,
    labeling and distribution of investigational drugs in compliance with FDA&#8217;s cGMP requirements;</span></td></tr>
  </table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to FDA of an IND, which must become effective before clinical trials may begin and must be updated annually and when significant
    changes are made;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an IRB for each clinical site before each clinical trial may be initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s GCP requirements to establish the safety,
    purity, and potency of the proposed biological product candidate for its intended purpose;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    completion of all pivotal clinical trials, preparation of and submission to FDA of a BLA requesting marketing approval, which includes providing sufficient evidence to establish the efficacy, safety, purity, and potency
    of the proposed biological product for its intended use, including from results of nonclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, when appropriate, as may be requested by FDA to assist with its review;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or certain components
    thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods, and
    controls are adequate to preserve the biological product&#8217;s identity, strength, quality, and purity and, if applicable, FDA&#8217;s GTP requirements for human cellular and tissue products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA inspections of selected clinical investigation sites to assure compliance with GCP requirements and the integrity
    of the clinical data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA sponsor GCP inspection, often conducted at the applicant&#8217;s headquarters facility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees (unless there is a waiver, exemption, or reduction) under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) for
    the relevant year;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
    review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the
    United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with post-approval requirements, including the potential requirements to implement a REMS,
    to report adverse events and biological product deviations, and to complete any post-approval studies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of any post-approval clinical studies required by FDA, such as confirmatory trials or pediatric studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing
the testing, approval, manufacturing, and marketing of biological products regulated by FDA. In addition to new legislation, FDA regulations,
guidance documents, and policies are often revised or interpreted by the agency in ways that may significantly affect the regulation
of biological products in the United States. It is impossible to predict whether further legislative changes will be enacted or whether
FDA regulations, guidance, policies, or interpretations will change, and the effects of any such changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
and Clinical Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
an applicant can begin testing the potential product candidate in human subjects, the applicant must first conduct preclinical studies.
Preclinical studies may include laboratory evaluations of product chemistry, toxicity, and formulation, as well as in vitro and animal
studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic
use. Preclinical studies are subject to federal regulations and requirements, including GLP regulations, which govern the conduct of
animal studies designed to test a product&#8217;s safety. None of our preclinical studies to date have been animal studies. The results
of an applicant&#8217;s preclinical studies are submitted to FDA as part of an IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from FDA to administer an investigational new drug product to humans. An IND is an exemption from
the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in a clinical trial. Such authorization must be
secured prior to interstate shipment and administration of a biological drug that is not subject of an approved BLA. In support of an
IND, applicants must submit a protocol for each clinical trial, which details, among other things, the objectives of the trial, the parameters
to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made
for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30 days after receipt by FDA, unless
FDA raises safety concerns or questions about the proposed clinical trial within the 30-day time period. In such a case, FDA may place
the IND on clinical hold and the IND sponsor must resolve any of FDA&#8217;s outstanding concerns or questions before the clinical trial
can begin. Submission of an IND therefore may or may not result in regulatory authorization to begin a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also place a clinical hold or partial clinical hold on a clinical trial following commencement of the trial under an IND. A clinical
hold is an order issued by FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial
clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, under a partial clinical
hold, FDA may instruct a sponsor not to enroll any new patients into a study, but permit the previously enrolled patients to continue
in the study. No more than 30 days after imposition of a clinical hold or partial clinical hold, FDA will provide the sponsor a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume
after FDA has notified the sponsor that the investigation may proceed. FDA will base that determination on information provided by the
sponsor addressing the deficiencies previously cited or otherwise satisfying FDA that the investigation can proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical trial. If a sponsor chooses to conduct a foreign clinical study under an IND, all FDA IND requirements must be met unless
waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with GCP regulations
in order to use the study as support for an IND or application for marketing approval, including review and approval by an IRB and informed
consent from subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
an independent IRB for all sites participating in a clinical trial must review and approve the plan for any clinical trial and its informed
consent form before the clinical trial begins at each site, and must monitor the trial until completed. Regulatory authorities, the IRB,
or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to
an unacceptable health risk or that the trial is unlikely to meet its stated objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a DSMB. DSMBs review unblinded study data at pre-specified times during the course of the study. If the
DSMB determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy, the DSMB
can make a recommendation to the sponsor to modify or stop the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
grounds for a sponsor&#8217;s decision to suspend or terminate a study may be made based on evolving business objectives or competitive
climate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of BLA approval, clinical trials are typically conducted in the following sequential phases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: The investigational product is initially introduced into a small group of healthy human
                                            subjects or patients with the target disease or condition. These trials are designed to test
                                            the safety, dosage tolerance, absorption, metabolism and distribution of the investigational
                                            product in humans and the side effects associated with increasing doses. These trials may
                                            also yield early evidence of effectiveness.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            2: The investigational product is administered to a slightly larger patient population with
                                            a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and
                                            dosing schedule and to identify possible adverse side effects and safety risks. Multiple
                                            Phase 2 clinical trials may be conducted to obtain information prior to beginning larger
                                            and more expensive Phase 3 clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            3: The investigational product is administered to an expanded patient population to further
                                            evaluate dosage, to provide statistically significant evidence of clinical efficacy and to
                                            further test for safety, generally at multiple geographically dispersed clinical trial sites.
                                            These clinical trials are intended to generate sufficient data to statistically demonstrate
                                            the efficacy and safety of the product, to establish the overall risk/benefit ratio of the
                                            investigational product, and to provide an adequate basis for product approval by FDA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
phases may overlap or be combined. In some cases, FDA may require, or companies may voluntarily pursue, additional clinical trials after
a product is approved to gain more information about the product, referred to as Phase 4 trials.
Such post-approval trials are conducted following initial approval, often to develop additional data and information relating to the
use of the product in new indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to FDA. In addition, IND safety reports must
be submitted to FDA for any of the following: serious and unexpected suspected adverse reactions in study subjects; findings from epidemiological
studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an
IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important
increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor&#8217;s planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, FDA or
the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution,
or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the
drug has been associated with unexpected serious harm to patients. FDA will typically inspect one or more clinical sites to assure compliance
with GCP and the integrity of the clinical data submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported
outcomes (&#8220;PROs&#8221;), the process typically is an iterative one. FDA has issued guidance on the framework it uses to evaluate
PRO instruments. Although the agency may offer advice on optimizing PRO instruments during the clinical development process, FDA usually
reserves final judgment until it reviews the BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and
physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things,
must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging
must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable
deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BLA
Submission and Review</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit
a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results
of nonclinical studies and clinical trials; detailed information on the product&#8217;s chemistry, manufacture, controls; and proposed
labeling. Under the PDUFA, a BLA submission is subject to an application user fee, unless a waiver, reduction, or exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
will initially review the BLA for completeness before accepting it for filing. Under FDA&#8217;s procedures, the agency has 60 days from
its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines
that the application does not meet this initial threshold standard, FDA may refuse to file the application and request additional information,
in which case the application must be resubmitted with the requested information and review of the application delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the BLA is accepted for filing, FDA reviews the BLA to determine, among other things, whether a product is safe, pure, and potent and
if the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued
identity, strength, quality, safety, purity, and potency. To ensure cGMP, GLP, GCP, GTP, and other regulatory compliance, an applicant
must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production and quality control.
In addition, FDA expects that all data be reliable and accurate, and requires sponsors to implement meaningful and effective strategies
to manage data integrity risks. Data integrity is an important component of the sponsor&#8217;s responsibility to ensure the safety,
efficacy and quality of its product or products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
cellular products, FDA will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable.
GTPs are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture
of human cells, tissue, and cellular and tissue-based products (&#8220;HCT/Ps&#8221;), which are human cells or tissue intended for implantation,
transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based
products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations
also specify how HCT/P establishments must register and list their HCT/Ps with FDA and how they must evaluate donors through screening
and testing, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies
in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance goals and policies implemented by FDA under the PDUFA generally provide for FDA action on an original BLA within 10 months
of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances.
Furthermore, the review process is often significantly extended by FDA&#8217;s requests for additional information or clarification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.
Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate, and provide
a recommendation as to whether the application should be approved and, if so, under what conditions. FDA is not bound by the recommendations
of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will
be produced, FDA may issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;).
An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A
CRL will describe all of the deficiencies that FDA has identified in the BLA, except that where FDA determines that the data supporting
the application are inadequate to support approval, FDA may issue the CRL without first conducting required inspections, testing submitted
product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to FDA&#8217;s satisfaction in a resubmission
of the BLA, FDA will issue an approval letter. In issuing the CRL, FDA may recommend actions that the applicant might take to place the
BLA in condition for approval, including requests for additional data, information, or clarification. FDA may delay or refuse approval
of a BLA if applicable regulatory criteria are not satisfied, and may require additional testing or information and/or require new clinical
trials. Even with submission of this additional information, FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the approval process, FDA will determine whether a REMS is necessary to help ensure the benefits outweigh the risks of the biologic.
A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued
access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to
assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If FDA concludes that
a REMS is needed, the BLA sponsor must submit a proposed REMS and FDA will not approve the BLA without a REMS that the agency has determined
is acceptable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings, or
precautions be included in the product labeling. FDA may also require that post-approval studies, including Phase
4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. FDA may prevent or limit further marketing
of a product based on the results of post-market studies or surveillance programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include
official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution.
The manufacturer then typically must submit samples of each lot of product to FDA, together with a release protocol showing a summary
of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. FDA may also
perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, an approved BLA only allows the sponsor to market the biologic as approved, without modification. If, for example, a sponsor
modifies an approved T cell product to target different peptides or in our case to target another HLA type, the sponsor would be required
to either file a supplemental BLA with FDA or receive FDA approval for a comparability protocol in order to implement this change into
the final product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after
the product reaches the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences,
product sampling and distribution, and advertising and promotion of the product. After approval, many types of changes to the approved
product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements
and FDA review and approval, depending on the nature of the post-approval change. There also are continuing user fee requirements, under
which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party
contractors are required to register their facilities with FDA and certain state agencies. These facilities are subject to routine and
periodic unannounced inspections by FDA and certain state agencies for compliance with cGMP, post-marketing safety reporting and data
integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product.
FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of its oversight.
Requirements with respect to data integrity include, among other things, controls ensuring complete and secure data; activities documented
at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records
for accuracy, completeness, and compliance with established standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon the sponsor and any third-party manufacturers that the sponsor may use. Accordingly, manufacturers must continue to
expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance,
and other aspects of regulatory compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-approval studies to assess new safety risks; or imposition of distribution
or other restrictions under a REMS. Other potential consequences include, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of a product, complete withdrawal of the product from the market, or product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning or untitled letters, or holds on post-approval clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal of FDA to permit the import or export of products; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permanent
    injunctions and consent decrees, including the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
strictly regulates the marketing, labeling, advertising, and promotion of prescription drug products placed on the market. A company
can make only those claims relating to safety and efficacy, purity and potency that are approved by FDA and in accordance with the provisions
of the approved labeling. FDA&#8217;s regulation includes, among other things, standards and regulations for direct-to-consumer advertising,
communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving
the Internet and social media. Promotional claims relating to a product&#8217;s safety or effectiveness are prohibited before the drug
is approved. After approval, a product generally may not be promoted for uses that are not approved by FDA, as reflected in the product&#8217;s
prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not
described in the drug&#8217;s labeling, known as off-label uses, because FDA does not regulate the practice of medicine. However, FDA
regulations impose rigorous restrictions on manufacturers&#8217; communications and prohibit the promotion of off-label uses. It may
be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication
regarding off-label information, such as distributing scientific or medical journal information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial
enforcement by FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services (&#8220;HHS&#8221;),
as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial
impact, including civil, administrative, and criminal fines, penalties, and agreements that materially restrict the manner in which a
company promotes or distributes products. The federal government has levied large civil, administrative, and criminal fines and penalties
against companies for alleged improper promotion, and has also requested that companies enter into Corporate
Integrity Agreements and Consent Decrees of Permanent Injunction under which specified promotional conduct is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;), which requires
manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification,
and licensing requirements. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the
distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution
and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful
from the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
offers a number of expedited development and review programs for qualifying product candidates. The fast-track program is intended to
expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for
fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential
to address unmet medical needs for the disease or condition. A product intended to treat a serious or life-threatening disease or condition
may also be eligible for breakthrough therapy designation to expedite its development and review. Any marketing application for a biologic
submitted to FDA for approval, including a product with a fast-track designation and/or breakthrough therapy designation, may be eligible
for other types of FDA programs intended to expedite FDA review and approval process, such as priority review and accelerated approval.
FDA also may grant accelerated approval to certain products studied for their safety and effectiveness in treating serious or life-threatening
diseases or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMAT designation, which we are currently planning to seek for some of our therapies, is intended to facilitate an efficient development
program for, and expedite review of, any drug that meets the following criteria: (1) the drug is a cell therapy, therapeutic tissue engineering
product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) the
drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical
evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough
therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development
plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be
eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical
benefit, or reliance upon data obtained from a meaningful number of sites (including through expansion to additional sites) so as to
remove any likelihood of site-specific or investigator-specific bias on the evidence of effectiveness. Once approved, when appropriate,
FDA can permit fulfillment of post-approval requirements for RMATs receiving accelerated approval through the submission of clinical
evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the
collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards
for approval but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Term Restoration and Marketing Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
approval, owners of relevant drug or biological product patents may apply for up to a five year term patent extension to restore a portion
of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial
marketing or use of a drug or biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration
Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is
calculated as one-half of the product&#8217;s testing phase, which is the time between the effective date of an IND and initial BLA submission,
and all of the approval phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be
shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension
may not exceed 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for
restoration and the patent holder must apply for restoration within 60 days of approval, even if the product cannot be commercially marketed
at that time. The USPTO, in consultation with FDA, reviews and approves the application for patent term restoration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
patents that might expire during the BLA application phase, the patent owner may request an interim patent extension. An interim patent
extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval
patent extension is reduced by one year. The director of the USPTO must determine that approval of the product candidate covered by the
patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for
which a BLA has not been submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and Marketing Exclusivities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BPCIA created an abbreviated approval
pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. A
biological product on which another biological product candidate&#8217;s BLA relies to establish biosimilarity is known as a reference
product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use,
route of administration, dosage form and strength, and no clinically meaningful differences between the biological product candidate
and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials
and at least one clinical trial, unless the Secretary of HHS waives a required element. A biosimilar product candidate may be deemed
interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same
clinical results as the reference product and, for products administered multiple times, the biological product candidate and the reference
biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative
to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics,
as well as the process by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval
pathway that are still being resolved by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for
a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biological product candidate
submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first
commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if
there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the
first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar&#8217;s application has been
approved if a patent lawsuit is ongoing within the 42 month period. At this time, it is unclear whether products deemed &#8220;interchangeable&#8221;
by FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Coverage,
Pricing, and Reimbursement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully commercialize any products for which we receive regulatory approval for commercial sale will depend, in part,
on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products, and significant
uncertainty exists as to the coverage and reimbursement status of any products for which may we obtain regulatory approval. In the United
States, third-party payors include federal and state health care programs, private managed care providers, health insurers and other
organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process
for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party
payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved
products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity, and
reviewing the cost-effectiveness of medical products, therapies, and services, in addition to questioning their safety and efficacy.
We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our
products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary
or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will
be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide
coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to
realize an appropriate return on our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has
increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Healthcare Laws and Compliance Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we currently do not have any commercialized products, our current and future business operations may be subject to additional healthcare
regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our
business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security,
price reporting and physician sunshine laws. Some of our pre-commercial activities are subject to some of these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute makes it illegal for any person or entity, including
a prescription drug manufacturer or a party acting on its behalf to knowingly and willfully, directly or indirectly, solicit, receive,
offer, or pay any remuneration in cash or in kind that is intended to induce or reward the referral of business, including the purchase,
order, or lease of any item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback
Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary
managers and beneficiaries on the other.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions
and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases
or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements
of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback
Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts
and circumstances. Several courts have found that the Anti-Kickback Statute may be
violated if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare program business. In
addition, liability may be established without actual knowledge of the statute or specific intent to violate it. Violations of this law
are punishable by up to ten years in prison, and can also result in criminal fines, civil money penalties and exclusion from participation
in federal healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment of government funds or knowingly making, using, or causing to be made or used, a false record
or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing,
or concealing an obligation to pay money to the federal government. Persons and entities can be held liable under these laws if they
are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding
information to customers or promoting a product off-label. Many pharmaceutical and other healthcare companies have been investigated
and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged
improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal
programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe
the company&#8217;s products; and inflating prices reported to private price publication services, which are used to set drug payment
rates under government healthcare programs. Penalties for federal civil False Claims Act violations may include up to three times the
actual damages sustained by the government, plus mandatory per claim civil penalties, and the potential for exclusion from participation in federal healthcare programs. In addition, although the federal False
Claims Act is a civil statute, False Claims Act violations may also implicate various federal criminal statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare fraud provisions of HIPAA prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud
any healthcare benefit program, including private third- party payors, knowingly and willfully embezzling or stealing from a healthcare
benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of
or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have analogous laws and regulations, such as: state anti-kickback and false claims laws that may apply to sales or marketing arrangements
and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; laws
that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to certain healthcare providers;
laws that require drug manufacturers to report information related to clinical trials or information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures; laws that restrict the ability of manufacturers to offer
co-pay support to patients for certain prescription drugs; and laws and local ordinances that require identification or licensing of
sales representatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations,
mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions,
as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption
of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security
standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive,
or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased
the civil and criminal penalties that may be imposed against covered entities and business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s
fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health
information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant
ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can
result in the imposition of significant civil and/or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Physician Payment Sunshine Act, implemented as the Open
Payments Program, requires manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions)
to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching
hospitals (and certain other practitioners as of 2022), as well as ownership and investment interests held in the company by physicians
and their immediate family members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we intend to commercialize products that could be reimbursed under a federal health care program and other governmental healthcare programs,
we intend to develop a comprehensive compliance program that establishes internal control to facilitate adherence to the rules and program
requirements to which we will or may become subject. Although the development and implementation of compliance programs designed to establish
internal control and facilitate compliance can mitigate the risk of investigation, prosecution, and penalties assessed for violations
of these laws, the risks cannot be entirely eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject
to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual
damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from
participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to
operate our business and our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Care Reform</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval
activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers
and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has
been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the Affordable Care Act (&#8220;ACA&#8221;)
substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.
pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for
drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain
Medicare Part D beneficiaries, and annual fees based on
pharmaceutical companies&#8217; share of sales to federal health care programs. The ACA made several changes to the Medicaid
Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid
rebate. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers
to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial challenges to certain aspects of the ACA, as well as efforts by Congress to modify, and by agencies to alter the implementation
of, certain aspects of the ACA. For example, Congress eliminated the tax penalty for failure to comply with the ACA&#8217;s individual
mandate to carry health insurance. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA to increase from 50
percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare
Part D to close the coverage gap in most Medicare drug plans, commonly referred to as the donut
hole (this existing coverage gap program will be sunset by the Inflation Reduction Act beginning in 2025 and replaced with a new manufacturer
discount program).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that the ACA, as currently enacted or as may be amended in the future, as well as other healthcare reform measures, including
those that may be adopted in the future, may result in more rigorous coverage criteria, and less favorable payment methodologies, or
other downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement
or restriction on coverage under Medicare or other federal health care programs may result in a similar reduction or restriction by private
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. For example, the Inflation Reduction Act introduces
several changes to the Medicare Part D benefit, including
a limit on annual out-of-pocket costs and a change in manufacturer liability under the program which could negatively affect the profitability
of our product candidates. The IRA sunsets the current Part D coverage gap discount program starting
in 2025 and replaces it with a new manufacturer discount program. Failure to pay a discount under this new program will be subject to
a civil monetary penalty. In addition, the IRA establishes a Medicare Part
B inflation rebate scheme effective January 2023 and a Medicare Part
D inflation rebate scheme effective October 2022, under which, generally speaking, manufacturers will owe rebates if the price of a Part
B or Part D drug increases faster than the pace of inflation. Failure to timely pay a Part
B or D inflation rebate is subject to a civil monetary penalty. The IRA also creates a drug price negotiation
program under which the prices for Medicare units of certain high Medicare spend drugs and biologicals without generic or biosimilar
competition will be capped by reference to, among other things, a specified non-federal average manufacturer price starting in 2026.
Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty.
Congress continues to examine various policy proposals that may result in pressure on the prices of prescription drugs with respect to
the government health benefit programs and otherwise. The IRA or other legislative changes could impact the market conditions for our
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, there has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their commercial
products, which has resulted in several Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the
state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Privacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to federal, state, national and international laws and regulations governing the privacy and security of health-related
and other personal data we collect and maintain (e.g., Section 5 of the Federal Trade Commission Act, the California
Privacy Rights Act, and the EU&#8217;s General Data Protection Regulation (the &#8220;GDPR&#8221;)). The GDPR, for example, imposes restrictions
on the processing (e.g., collection, use, or disclosure) of personal data in the EU and also imposes strict restrictions on the transfer
of personal data out of the EU to the United States. These laws and regulations are evolving and subject to interpretation and may impose
limitations on our activities or otherwise adversely affect our business. In addition, state laws govern the privacy and security of
health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect,
thus complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection
and privacy laws and regulations, or if we were to experience a data breach involving personal data, we could be subject to government
enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government actions could lead to
unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments
or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments
in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other
remedies that harm our business, including orders that we modify or cease existing business practices.</span></p>






<p style="margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_003"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors and Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of June 21, 2024, the name, age, and position of each our executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
    Officers</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ryan Saadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Chairperson and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti
    Desai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Neal Flomenberg</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Global R&amp;D Lead</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sadiq
    Khan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee
    Directors</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surendra
    Ajjarapu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Feike</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Keow Lin Goh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Curtis Patton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan
    Podlogar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victor
    Sordillo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Ryan Saadi</i></b>, 59, has served as our Chief Executive Officer and Chairperson since February 14, 2024, and served as Chief
Executive Officer and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the
Yale School of Public Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access,
and Strategic Pricing for CSL Behring, a biopharmaceutical company that manufactures plasma-derived and recombination therapeutic products,
from September 2018 to October 2019. Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen
from 2012 to September 2018 and Worldwide Vice President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson
&amp; Johnson&#8217;s Cordis business from 2008 to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes &amp; Pricing
for Genzyme and Global Head, Health Outcomes and Market Access for Sanofi-Aventis&#8217; oncology, bone and arthritis product portfolio.
From 2010 through 2019, Dr. Saadi has also served as a Voting Member of the CMS Medicare Evidence Development &amp; Coverage Advisory
Committee, which provides independent guidance and expert advice to CMS on clinical topics. We believe Dr. Saadi is qualified to serve
on our Board based on his extensive business leadership experience as well as his experience and track record as a problem solver in
the healthcare and life sciences industries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kirti
Desai</i></b>, 67, has served as our Chief Financial Officer since February 14, 2024, and served as Chief Financial Officer of
Tevogen Bio beginning in June 2020. Mr. Desai previously served as President of Star Accounting Services Inc., an accounting firm providing
accounting and tax services to businesses and individuals, from January 2005 to December 2021. Mr. Desai is a certified public accountant.
Mr. Desai also serves as the Treasurer of Shrimad Rajchandra Mission Dharampur (USA) Inc., a community outreach and development nonprofit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Neal Flomenberg</i></b>, 70, has served as our Chief Scientific Officer and Global R&amp;D Lead since February 14, 2024, and served
as Chief Scientific Officer and Global R&amp;D Lead of Tevogen Bio beginning in July 2022. Prior to joining Tevogen Bio, Dr. Flomenberg
served as professor and Chair of the Department of Medical Oncology at Sidney Kimmel Medical College of Thomas Jefferson University from
2008 to July 2022 and Deputy Director of Thomas Jefferson University&#8217;s Sidney Kimmel Cancer Center from 2015 to July 2022. Prior
to those positions, Dr. Flomenberg held a number of leadership roles in the academia, hospital, and research settings. Dr. Flomenberg&#8217;s
career has focused on blood cancers, particularly those requiring bone marrow or peripheral blood stem cell transplants, and he has authored
over 175 peer reviewed publications. At Jefferson, Dr. Flomenberg also maintained an active medical practice and was continually listed
in Philadelphia Magazine&#8217;s &#8220;Top Doctors in Philadelphia&#8221; for more than 15 years prior to joining Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sadiq
Khan</i></b>, 62, has served as our Chief Commercial Officer since February 14, 2024, and served as Chief Commercial Officer of
Tevogen Bio beginning in April 2022. Previously, Mr. Khan held several roles at the New Jersey Institute of Technology (&#8220;NJIT&#8221;),
a public research university, and its subsidiaries from 2014 to March 2022. Most recently, Mr. Khan served as Senior Director and then
Executive Director of Operations &amp; Business Planning at BioCentriq, a for-profit cell and gene therapy contract development and manufacturing
organization owned by New Jersey Innovation Institute (&#8220;NJII&#8221;), which was itself a non-profit subsidiary of NJIT, from September
2018 to March 2022. While at BioCentriq, Mr. Khan was part of the leadership team that prepared BioCentriq for its spin-off from NJII.
Mr. Khan held several roles at NJII from 2014 to February 2020, including Director of Business Development, Biopharma Innovation beginning
in 2018, where he worked to facilitate academic, government, and industry collaboration in the biopharmaceutical field. From 2008 to
March 2018, Mr. Khan also acted as Founder and Chief Strategist for Pharmique Health LLC, where he advised corporations on strategic
commercial planning and other matters. Previously, Mr. Khan co-founded Tegelix Therapeutics, a now-defunct pharmaceutical company, and
held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi-Aventis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Surendra
Ajjarapu</i></b>, 53, has served on our Board since February 14, 2024, and served as a director and Chief Executive Officer and
Chairman of Semper Paratus beginning in June 2023. In addition to his involvement with Semper Paratus, Mr. Ajjarapu has served as Chief
Executive Officer and Chairman of Integrated Wellness Acquisition Corp. (NYSE: WEL), a special purpose acquisition company, since February
2024, PowerUp Acquisition Corp. (Nasdaq: PWUP), a special purpose acquisition company, since August 2023, OceanTech Acquisitions I Corp.
(Nasdaq: OTEC), a special purpose acquisition company, from March 2023 to June 2024, and Kernel Group Holdings, Inc. (Nasdaq:
KRNL), a special purpose acquisition company, since December 2022. Mr. Ajjarapu currently serves Trxade Health, Inc. (Nasdaq: MEDS),
a health services information technology company, as Chairman of the Board, Chief Executive Officer and Secretary and has served in these
roles since its acquisition of Trxade Group, Inc., a Nevada corporation (&#8220;Trxade Nevada&#8221;) on January 8, 2014, and as the
Chairman of the Board, Chief Executive Officer and Secretary of Trxade Nevada since its inception in 2013. Mr. Ajjarapu is also currently
serving as a director of Ocean Biomedical Inc. (Nasdaq: OCEA) (f.k.a. Aesther Healthcare Acquisition Corp.), a biopharmaceutical company.
Mr. Ajjarapu has also served on the Board of Directors of Kano Energy, Inc which is involved in developing renewable natural gas sites
in the United States, since 2018 and as Chairman of the Board of Directors of Feeder Creek Group, Inc., a company involved in developing
renewable natural gas sites in Iowa, since 2018. Mr. Ajjarapu was also a Founder, CEO and Chairman of Sansur Renewable Energy, Inc.,
a company involved in developing wind power sites in the Midwestern United States, from 2009 to 2012. We believe Mr. Ajjarapu is qualified
to serve on our Board based on his extensive public company experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jeffrey
Feike</i></b>, 74, has served on our Board since February 14, 2024, and served on the board of directors of Tevogen Bio beginning
in August 2022. Mr. Feike served as the Hospital President of Covenant Health&#8217;s Fort Loudoun Medical Center from September 2004
to June 2022. Throughout his career, Mr. Feike has overseen the development of hospitals, outpatient clinics, and emergency medical services
(&#8220;EMS&#8221;) systems. Mr. Feike represents East Tennessee on the state EMS Board&#8217;s Clinical Issues Committee and serves
on the board of Regional Medical Communications Center for East Tennessee. We believe Mr. Feike is qualified to serve on our Board based
on his dedication to public health and healthcare industry experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Keow Lin Goh</i></b>, 52, has served on our Board since February 14, 2024, and served on the board of directors of Tevogen Bio
beginning in August 2022. Dr. Goh is a Partner at Tapestry Networks, a company that brings together leaders in different sectors in order
to facilitate economic, social, and organizational change. Dr. Goh has served as a Partner at Tapestry Networks since 2009 and focuses
on global healthcare policy with the goal of improving patient outcomes. Previously, Dr. Goh was a Senior Project Leader at Boston Consulting
Group from 2003 through 2009, where she worked with senior biotech and pharmaceutical executives in product development, research and
development restructuring, organizational and operational change initiatives, post-merger acquisition synergies, and regulatory issues.
We believe Dr. Goh is qualified to serve on our Board based on her experience in the healthcare sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Curtis Patton</i></b>, 89, has served on our Board since February 14, 2024, and served on the board of directors of Tevogen
Bio beginning in July 2020. Dr. Patton is Professor Emeritus at Yale School of Public Health, where he worked for 36 years. Dr. Patton
served in a variety of administrative capacities during his time at Yale, including as Division Head, Epidemiology of Microbial Diseases
and Acting Head of Global Health. While at Yale, Dr. Patton also served as the Director of International Medical Studies and was the
Chair of the Committee on International Health. We believe Mr. Patton is qualified to serve on our Board based on his work on and experience
with public health issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Susan
Podlogar</i></b>, 60, has served on our Board since February 14, 2024, and served on the board of directors of Tevogen Bio beginning
in August 2022. Ms. Podlogar is the Chief Human Resources Officer and Executive Vice President of MetLife, Inc (&#8220;MetLife&#8221;).
Ms. Podlogar joined MetLife in 2017 and oversees its global human resources strategies and practices. At MetLife, Ms. Podlogar has established
a &#8220;Workforce of the Future Development Fund&#8221; to prepare employees for future work needs and backed MetLife&#8217;s signing
of the Catalyst CEO Champions for Change Pledge, which is a commitment to advance diversity, inclusion, and gender equality in the workplace.
Ms. Podlogar also serves on the board of directors of MetLife Foundation, a philanthropic organization focused on advancing inclusive
economic mobility in underserved and underrepresented communities. Prior to her time at MetLife, Ms. Podlogar held a series of Human
Resources roles at Johnson &amp; Johnson from 2003 to June 2017, including Global Vice President of Human Resources and member of the
Human Resources Executive Committee. We believe Ms. Podlogar is qualified to serve on our Board based on her extensive human resources
and healthcare industry experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Victor
Sordillo</i></b>, 71, has served on our Board since February 14, 2024, and served on the board of directors of Tevogen Bio beginning
in July 2023. Mr. Sordillo has served as Managing Director of Risk Advisory Services at Verita CSG, Inc. (&#8220;Verita&#8221;), a provider
of holistic insurance and risk management solutions for commercial line clients, since March 2024. Before joining Verita, Mr. Sordillo
served as the Executive Vice President, Director of Risk Control Services of Sompo International, a global specialty provider of property
and casualty insurance and reinsurance from January 2017 to March 2024, and as Senior Vice President &#8211; Risk Solutions of QBE North
America (&#8220;QBE&#8221;) from May 2016 to April 2017. Prior to QBE, Mr. Sordillo served as the Global Technical Services Manager at
Chubb NA from January 2000 through May 2016. Mr. Sordillo is a registered professional civil and fire protection engineer and Certified
Safety Professional. Mr. Sordillo served as the mayor of Warren, New Jersey for more than 22 years. We believe Mr. Sordillo is qualified
to serve on our Board based on his extensive business and leadership experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have structured our corporate governance in a manner that we believe closely aligns our interests with those of our stockholders. We
have independent director representation on our audit, compensation, and nominating and corporate governance committees and our independent
directors will meet regularly in executive sessions without the presence of our corporate officers or non-independent directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Role
of Board in Risk Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has extensive involvement in the oversight of risk management related to our Company and its business and accomplishes this oversight
through the regular reporting to the Board by the audit committee. The audit committee represents the Board by periodically reviewing
our accounting, reporting, and financial practices, including the integrity of our financial statements, the surveillance of administrative
and financial controls, and our compliance with legal and regulatory requirements. Through its regular meetings with management, including
the finance, legal, internal audit, and information technology functions, the audit committee reviews and discusses all significant areas
of our business and summarizes for the Board all areas of risk and the appropriate mitigating factors. In addition, the Board receives
periodic detailed operating performance reviews from management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Composition
of the Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are managed under the direction of the Board. The Board is divided into three classes, designated as Class I, Class
II, and Class III. Each class consists, as nearly as may be possible, of one third of the total number of directors constituting the
whole Board. The term of the current Class I directors, Dr. Curtis Patton and Jeffrey Feike, expires at the first annual meeting of the
stockholders following the Business Combination; the term of the current Class II directors, Surendra Ajjarapu, Victor Sordillo, and
Dr. Keow Lin Goh, expires at the second annual meeting of the stockholders following the Business Combination; and the term of the current
Class III directors, Dr. Ryan Saadi and Susan Podlogar, expires at the third annual meeting of the stockholders following the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Director Independence</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock
is listed on Nasdaq. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors.
In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation
and nominating and corporate governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent
director&#8221; if in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. Audit committee members must also satisfy
the additional independence criteria set forth in Rule 10A-3 under the Exchange Act and the rules of Nasdaq. Compensation committee members
must also satisfy the additional independence criteria set forth in Rule 10C-1 under the Exchange Act and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In order to
be considered independent for purposes of Rule 10A-3 under the Exchange Act and under the rules of Nasdaq, a member of an audit committee
of a listed company may not, other than in the member&#8217;s capacity as a member of the committee, the board of directors, or any other
board committee: (a) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any
of its subsidiaries; or (b) be an affiliated person of the listed company or any of its subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">To be considered
independent for purposes of Rule 10C-1 under the Exchange Act and under the rules of Nasdaq, the board of directors must affirmatively
determine that the member of the compensation committee is independent, including a consideration of all factors specifically relevant
to determining whether the director has a relationship to the company which is material to that director&#8217;s ability to be independent
from management in connection with the duties of a compensation committee member, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the source of compensation of such director, including any consulting,
    advisory or other compensatory fee paid by the company to such director; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether such director is affiliated with the company, a subsidiary
    of the company or an affiliate of a subsidiary of the company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our Board has
undertaken a review of the independence of each director and considered whether each director has a material relationship with us that
could compromise the director&#8217;s ability to exercise independent judgment in carrying out the director&#8217;s responsibilities.
Each of our directors, other than Dr. Saadi and Mr. Ajjarapu, has been determined to qualify as &#8220;independent&#8221; under the listing
requirements and the rules of Nasdaq and the applicable rules under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Controlled
Company Status</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;controlled company&#8221; for purposes of the corporate governance rules of Nasdaq. Controlled companies under those rules
are companies of which more than 50% of the voting power for the election of directors is held by an individual, a group or another company.
Dr. Saadi owns more than 50% of our voting power. Accordingly, we are eligible for, but do not currently intend to rely on, certain exemptions
from the corporate governance requirements of Nasdaq. Specifically, as a &#8220;controlled company,&#8221; we are not required to have
(1) a majority of independent directors, (2) a nominating and corporate governance committee composed entirely of independent directors,
or (3) a compensation committee composed entirely of independent directors. In the event we elect to rely on some or all of these exemptions
in the future, stockholders would not have the same protections afforded to stockholders of companies that are subject to all of the
applicable corporate governance rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Committees</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standing committees of the Board consist of an audit committee, a compensation committee, and a nominating and corporate governance committee.
The Board may, from time to time, establish other committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers regularly report to the non-executive directors and the audit, the compensation, and the nominating and corporate
governance committees to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing
evaluation of management controls. We believe that the leadership structure of our Board provides appropriate risk oversight.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee consists of Victor Sordillo, who serves as the chairperson, Jeffrey Feike, and Susan Podlogar. Each of the members of
the audit committee satisfies the requirements for independence and financial literacy under the applicable rules and regulations of
the SEC and rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Feike qualifies as an audit committee financial expert through his decades of experience overseeing chief financial officers and the
preparation and analysis of financial statements as a hospital and hospital system chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of the audit committee include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent
    auditors or engage new independent auditors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our financial reporting processes and disclosure controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the adequacy and effectiveness of our internal control policies and procedures, including the effectiveness of our internal audit
    function;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with the independent auditors the annual audit plan, including the scope of audit activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and reviewing at least annually a report by our independent auditors describing the independent auditors&#8217; internal quality
    control procedures and any material issues raised by the most recent internal quality-control review;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating our independent auditor&#8217;s lead audit partner and the rotation of audit partners as required by law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought
    to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent
    auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our annual and quarterly financial statements and reports, including the disclosures contained in the section titled &#8220;<i>Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</i>,&#8221; and discussing the statements and reports with
    our independent auditors and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with our independent auditors and management significant issues that arise regarding accounting principles and financial statement
    presentation and matters concerning the scope, adequacy, and effectiveness of our financial controls and critical accounting policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with management and our auditors any earnings announcements and other public announcements regarding material developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for the receipt, retention and treatment of complaints we receive regarding accounting, internal accounting controls,
    auditing or other matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report that the SEC requires in our annual proxy statement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment
    and risk management is implemented; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating the audit committee charter annually and recommending any proposed changes to the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition and function of the audit committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable
SEC and Nasdaq rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board adopted a written charter for the audit committee, which is available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee consists of Susan Podlogar, who serves as the chairperson, and Dr. Keow Lin Goh. Each of the members of the compensation
committee meets the requirements for independence under the under the applicable rules and regulations of the SEC and rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of the committee include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving any corporate objectives that pertain to the determination of executive compensation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the compensation and other terms of employment of our executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving performance goals and objectives relevant to the compensation of our chief executive officer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    our chief executive officer&#8217;s performance in light of the foregoing goals and objectives and, either as a committee or together
    with the other independent directors, determining and approving our chief executive officer&#8217;s compensation level based on this
    evaluation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to the Board regarding non-chief executive officer compensation and the adoption or amendment of equity and cash
    incentive plans and approving amendments to such plans to the extent authorized by the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange
    Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    equity incentive plans, to the extent such authority is delegated by the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with management our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in periodic reports or proxy
    statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    an annual report on executive compensation that the SEC requires in our annual proxy statement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating the compensation committee charter annually and recommending any proposed changes to the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition and function of the compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable
SEC and Nasdaq rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board adopted a written charter for the compensation committee, which is available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee consists of Jeffrey Feike, who serves as the chairperson, and Dr. Keow Lin Goh. Each of
the members of the nominating and corporate governance committee meets the requirements for independence under the applicable rules and
regulations of the SEC and rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of this committee include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    reviewing, and making recommendations of candidates to serve on the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the performance of the Board, committees of the Board, and individual directors and determining whether continued service on the
    Board is appropriate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    nominations by stockholders of candidates for election to the Board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the current size, composition, and organization of the Board and its committees and making recommendations to the Board for approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the Board any changes to our corporate governance policies and principles;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    issues and developments related to corporate governance and identifying and bringing to the attention of the Board current and emerging
    corporate governance trends; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    periodically the nominating and corporate governance committee charter, structure and membership requirements and recommending any
    proposed changes to the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition and function of the nominating and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley
Act and all applicable SEC and Nasdaq rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board adopted a written charter for the nominating and corporate governance committee, which is available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of business conduct and ethics that applies to all of our directors, officers and employees, including those officers
responsible for financial reporting. A current copy of the code of business conduct and ethics is available under the Governance Documents
section of our website. We intend to disclose future amendments to the code or any waivers of its requirements on our website at https://ir.tevogen.com/governance/governance-documents/default.aspx.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Nominations for Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Business Combination, holders of Semper Paratus public shares did not have the right to recommend director candidates for nomination
to the Board. Following the Business Combination, our nominating and corporate governance committee is responsible for evaluating individuals
recommended for nomination by stockholders for election to the Board and recommending appropriate action for the Board in accordance
with our Corporate Governance Guidelines and applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_004"></span>EXECUTIVE
AND DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
and Director Compensation of Semper Paratus</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSVK,
the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Original Sponsor, our executive officers
and directors, and their respective affiliates were reimbursed for any out-of-pocket expenses incurred in connection with activities
on our behalf such as identifying potential target businesses and performing due diligence on business combinations. Our audit committee
reviewed on a quarterly basis all payments that were made by us to SSVK, the Original Sponsor, our executive officers or directors,
or our or their affiliates. Any such payments prior to the Business Combination were made using funds held outside the trust
account created in connection with the IPO (the &#8220;Trust Account&#8221;). Other than quarterly audit committee review of such
reimbursements, we did not have any additional controls in place governing our reimbursement payments to our directors and executive
officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and
consummating an initial business combination. Other than these payments and reimbursements, we paid no compensation of any kind, including
finder&#8217;s and consulting fees, to SSVK, the Original Sponsor, our executive officers and directors, or any of their respective
affiliates prior to completion of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
and Director Compensation of Tevogen </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables and accompanying narrative set forth information about the 2023 and 2022 compensation provided to our principal executive
officer and the two most highly compensated executive officers (other than our principal executive officer) who were serving as executive
officers as of December 31, 2023. These executive officers consist of Dr. Ryan Saadi, our Chief Executive Officer, Kirti Desai, our Chief
Financial Officer, and Dr. Neal Flomenberg, our Chief Scientific Officer and Global R&amp;D Lead, and are referred to in this section
as our &#8220;named executive officers&#8221; or &#8220;NEOs.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations, and determinations
regarding future compensation practices. Actual compensation practices in the future may differ materially from the forward-looking statements
included in this discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents summary information regarding the total compensation for services rendered in all capacities that was awarded
to, earned by, or paid to our named executive officers for the last two completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name and Principal Position</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards<sup>(1)</sup></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left"><i>Ryan Saadi, M.D., M.P.H. <br/>
    Chief Executive Officer</i></td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">501,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">501,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453,845</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Kirti Desai <br/>
Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Neal Flomenberg, M.D.<br/>
Chief Scientific Officer and Global R&amp;D Lead</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,576,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,926,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,775,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount in this column reflects the full grant-date fair value of restricted stock units (&#8220;RSUs&#8221;) during 2023 computed
    in accordance with Accounting Standards Codification 718, Compensation &#8211; <i>Stock Compensation</i>, excluding estimates of
    forfeitures related to service-based vesting conditions, and assuming satisfaction of the liquidity event condition contained in
    such awards (the &#8220;Liquidity Event Condition&#8221;). The amount reported reflects the accounting cost for the RSU awards and
    does not correspond to the actual value that may be recognized by Dr. Flomenberg in connection with the applicable award.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Base
Salary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
named executive officers receive base salaries to compensate them for services rendered to us. The base salary payable to each named
executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role,
and responsibilities. The annual base salaries for Dr. Saadi, Mr. Desai, and Dr. Flomenberg for 2023 were $501,000, $300,000, and $350,000,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of the Business Combination, from time to time, we granted equity awards under the Tevogen Bio Inc 2020 Equity Incentive
Plan (the &#8220;2020 Plan&#8221;) as incentives to attract, retain, and motivate our named executive officers. In July 2023, we granted
Dr. Flomenberg an equity award of 100,000 RSUs. The vesting of Dr. Flomenberg&#8217;s award requires the satisfaction of both a service-based
condition and the Liquidity Event Condition. The service-based condition was satisfied with respect to 50% of the RSUs upon grant and
is satisfied with respect to 25% of the RSUs on each of the first two anniversaries of the award. The Liquidity Event Condition was satisfied
upon the consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, we adopted the 2024 Plan and no longer grant awards pursuant to the 2020
Plan. Each RSU award granted under the 2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled
and converted into an award under the 2024 Plan with respect to the Common Stock. Such converted awards remain subject to the same terms
and conditions as set forth under the applicable award agreement prior to the consummation of the Business Combination. For a description
of the features of the 2024 Plan, see &#8220;&#8212;<i>Equity Incentive Plan</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding equity awards held by our named executive officers that were outstanding as of December
31, 2023. The awards listed in this table were granted under the 2020 Plan, which is summarized above under &#8220;&#8212;<i>Narrative
Disclosure to Summary Compensation Table&#8212;Equity Compensation</i>.&#8221; Our named executive officers did not hold any outstanding
stock options as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Market Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ryan Saadi, M.D., M.P.H</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kirti Desai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Neal Flomenberg, M.D.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">5,332,902</td><td style="padding-bottom: 0.05in; width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">34,177,000</td><td style="padding-bottom: 0.05in; width: 2%; text-align: left"><sup>(2)</sup></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    an award of 1,000,000 RSUs of Tevogen Bio granted on July 1, 2022 (the &#8220;Initial Flomenberg Award&#8221;), 75% of which vested
    upon the consummation of the Business Combination, and an award of 100,000 RSUs of Tevogen Bio granted on July 14, 2023 (the &#8220;Additional
    Flomenberg Award&#8221;), all of which remained unvested as of December 31, 2023, adjusted to reflect the Exchange
    Ratio and expressed in shares of Common Stock. The vesting of each award requires the satisfaction of both a service-based condition
    and the Liquidity Event Condition. The Liquidity Event Condition was satisfied with respect to both awards by the consummation of
    the Business Combination. The RSUs begin to vest to the extent both conditions have been satisfied on the first date upon which both
    conditions have been satisfied. The service-based condition was satisfied with respect to 75% of the RSUs of the Initial Flomenberg
    Award as of July 1, 2023, and will be satisfied with respect to the remaining 25% on July 1, 2024. The Additional Flomenberg Award
    will vest with respect to 25% of the RSUs on each anniversary of July 14, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    a fair market value per share of Tevogen Bio&#8217;s common stock of $34.77 based on Tevogen Bio&#8217;s most recent estimated fair
    value of its common stock as of December 31, 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the year ended December 31, 2023, we did not pay any fees to, or make any equity or non-equity awards to, or pay any other compensation
to the non-employee members of our Board for their services as directors, except that we granted Mr. Sordillo 19,000 RSUs
of Tevogen Bio on January 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Name</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Victor Sordillo</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,460</span></td><td style="padding-bottom: 0.05in; width: 6%; text-align: left">(1)(2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">253,460</td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All other non-employee directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2023, Mr. Sordillo held RSUs for a total of 96,962 shares of Common Stock, adjusted to reflect the Exchange Ratio.
    Except for these RSUs and RSUs for 193,924 shares of Common Stock held by Susan Podlogar, also as adjusted to reflect the Exchange
    Ratio, there were no outstanding stock awards or option awards held by our non-employee directors as of December 31, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    a grant date fair value per share of Tevogen Bio common stock of $13.34 on the date of the grant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in more detail below, certain notable features of the 2024 Plan include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granting
    of options and stock appreciation rights only at a per share exercise price at least equal to the fair market value of a share of
    our Common Stock on the grant date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granting
    of options with a ten-year maximum term;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">awards
    are subject to potential clawback, forfeiture, repayment or other similar action pursuant to any clawback policy adopted by us or
    an affiliate or applicable law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    liberal share recycling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    payment of dividends or dividend equivalent rights on options or stock appreciation rights, and no current payment of dividends or
    dividend equivalent rights on unvested performance-based awards; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    repricing of options or stock appreciation rights without prior stockholder approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of the Material Terms of the 2024 Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purpose
and Eligibility</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the 2024 Plan is (i) to provide eligible persons with an incentive to contribute to our success and to operate and manage
our business in a manner that will provide for our long-term growth and profitability and that will benefit our stockholders and other
important stakeholders, including our employees and customers, and (ii) to provide a means of recruiting, rewarding, and retaining key
personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
awards may be granted under the 2024 Plan to officers, directors, including non-employee directors, other employees, advisors, consultants
or other service providers of the Company or our subsidiaries or other affiliates, and to any other individuals who are approved by the
Committee (as defined below) as eligible to participate in the 2024 Plan. Only our employees or employees of our corporate subsidiaries
are eligible to receive incentive stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration,
Amendment and Termination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan generally is administered by a committee composed of not fewer than two directors designated by the Board, each of whom must
be a &#8220;non-employee director&#8221; and satisfy the composition requirements under the listing rules of Nasdaq (the &#8220;Committee&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
where the authority to act on such matters is specifically reserved to the Board under the 2024 Plan or applicable law, the Committee
has full power and authority to interpret and construe all provisions of the 2024 Plan, any award, and any award agreement, and take
all actions and to make all determinations required or provided for under the 2024 Plan, any award, and any award agreement, including
the authority to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designate
    grantees of awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the type or types of awards to be made to a grantee;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the number of shares of our Common Stock subject to an award or to which an award relates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    the terms and conditions of each award;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prescribe
    the form of each award agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to limitations in the 2024 Plan (including the prohibition on repricing of options or share appreciation rights without stockholder
    approval), amend, modify, or supplement the terms of any outstanding award; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    substitute awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board also is authorized to appoint one or more committees of the Board consisting of one or more directors who need not meet the independence
requirements above for certain limited purposes permitted by the 2024 Plan, and to the extent permitted by applicable law, the Committee
is authorized to delegate authority to our Chief Executive Officer and/or any other officers for certain limited purposes permitted
by the 2024 Plan. The Board will retain the authority under the 2024 Plan to exercise any or all of the powers and authorities related
to the administration and implementation of the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend, suspend, or terminate the 2024 Plan at any time; provided that with respect to awards that are granted under the 2024
Plan, no amendment, suspension or termination may materially impair the rights of the award holder without such holder&#8217;s consent.
No such action may amend the 2024 Plan without the approval of stockholders if the amendment is required to be submitted for stockholder
approval by the Board, the terms of the 2024 Plan, or applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under the 2024 Plan may be made in the form of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    options, which may be either incentive stock options or nonqualified stock options;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    appreciation rights (&#8220;SARs&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted
    stock units;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deferred
    stock units;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unrestricted
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    equivalent rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    awards, including performance shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    equity-based awards; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
incentive stock option is an option that meets the requirements of Section 422 of the Code, and a nonqualified stock option is an option
that does not meet those requirements. A SAR is a right to receive upon exercise, in the form of stock, cash or a combination of stock
and cash, the excess of the fair market value of one share of Common Stock on the exercise date over the exercise price of the SAR. Restricted
stock is an award of Common Stock subject to restrictions over restricted periods that subject the shares of Common Stock to a substantial
risk of forfeiture, as defined in Section 83 of the Code. A restricted stock unit or deferred stock unit is an award that represents
a conditional right to receive shares of Common Stock in the future and that may be made subject to the same types of restrictions and
risk of forfeiture as restricted stock. Unrestricted shares are shares of Common Stock free of restrictions other than those imposed
under federal or state securities law. Dividend equivalent rights are awards entitling the grantee to receive cash, shares of Common
Stock, other awards under the 2024 Plan or other property equal in value to dividends or other periodic payments paid or made with respect
to a specified number of shares of Common Stock. Performance awards are awards made subject to the achievement of one or more performance
goals over a performance period established by the Committee. Other equity-based awards are awards representing a right or other interest
that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to stock, other than
an option, SAR, restricted stock, restricted stock unit, unrestricted stock, dividend equivalent right, or a performance award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan provides that each award will be evidenced by an award agreement, which may specify terms and conditions of the award that
differ from the terms and conditions that would otherwise apply under the 2024 Plan in the absence of the different terms and conditions
in the award agreement. In the event of any inconsistency between the 2024 Plan and an award agreement, the provisions of the 2024 Plan
will control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under the 2024 Plan may be granted alone or in addition to, in tandem with, or in substitution or exchange for any other award under
the 2024 Plan, other awards under another compensatory plan of the Company or any of our affiliates (or any business entity that has
been a party to a transaction with us or any of our affiliates), or other rights to payment from us or any of our affiliates. Awards
granted in addition to or in tandem with other awards may be granted either at the same time or at different times.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may permit or require the deferral of any payment pursuant to any award into a deferred compensation arrangement, which may
include provisions for the payment or crediting of interest or dividend equivalent rights, in accordance with rules and procedures established
by the Committee. Awards under the 2024 Plan generally will be granted for no consideration other than past services by the grantee of
the award or, if provided for in the award agreement or in a separate agreement, the grantee&#8217;s promise to perform future services
to us or one of our subsidiaries or other affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forfeiture;
Clawback</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may reserve the right in an award agreement to cause a forfeiture of the gain realized by a grantee with respect to an award on account
of actions taken by, or failed to be taken by, such grantee in violation or breach of, or in conflict with, any employment agreement,
non-competition agreement, agreement prohibiting solicitation of our employees or clients or employees or clients of any affiliate, confidentiality
obligations with respect to us or any affiliate, or otherwise in competition with us or any affiliate, to the extent specified in such
award agreement. If the grantee is an employee and is terminated for &#8220;Cause&#8221; (as defined in the 2024 Plan), the Committee
may annul the grantee&#8217;s award as of the date of the grantee&#8217;s termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any award granted pursuant to the 2024 Plan will be subject to mandatory repayment by the grantee to us to the extent (i) set
forth in the 2024 Plan or in an award agreement, or (ii) the grantee is or becomes subject to any clawback policy or compensation recovery
policy or such other similar policy of us or an affiliate, or any applicable laws which impose mandatory recoupment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Subject to the 2024 Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to adjustment as described below,  the maximum number of shares of Common Stock reserved for issuance under the 2024 Plan is equal
to the sum of (a) 40,000,000 shares of Common Stock plus (b) an annual increase as of the first business day of each calendar year, for
a period of not more than ten (10) years and starting with the 2025 calendar year, in an amount equal to the lesser of (i) a number of
shares of Common Stock equal to 5.0% of the total number of shares of Common Stock outstanding as of the last day of the immediately
preceding calendar year, or (ii) such lesser number of shares of Common Stock as determined by the Committee. In addition, in connection with mergers, reorganizations, separations, and certain other transactions in which awards
previously granted under a compensatory plan of another business entity that is a party to such transaction are assumed or replaced with
substitute awards, the maximum number of shares of Common Stock reserved for issuance under the 2024 Plan will increase by the number
of shares of Common Stock subject to such assumed awards and substitute awards, including the 10,900,128 shares subject to the Rollover
RSU awards. The maximum number
of shares of Common Stock available for issuance pursuant to incentive stock options granted under the 2024 Plan is the same as the total
number of shares of Common Stock reserved for issuance under the 2024 Plan. Shares of Common Stock issued under the 2024 Plan may be
authorized and unissued shares of Common Stock, or treasury shares of Common Stock, or a combination of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
shares of Common Stock covered by an award, or portion of an award, granted under the 2024 Plan that are not purchased or forfeited or
canceled, or expire or otherwise terminate without the issuance of shares of Common Stock or are settled in cash in lieu of shares of
Common Stock, will again be available for issuance under the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Common Stock subject to an award granted under the 2024 Plan are counted against the maximum number of shares of Common Stock reserved
for issuance under the 2024 Plan as one share for every one share subject to such an award. In addition, at least the target number of
shares of Common Stock issuable under a performance award is counted against the maximum number of shares of Common Stock reserved for
issuance under the 2024 Plan as of the grant date, but such number is adjusted to equal the actual number of shares of Common Stock issued
upon settlement of the performance award to the extent different from such number initially counted against the share reserve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of Common Stock available for issuance under the 2024 Plan is not increased by the number of shares of Common Stock:
(i) tendered or withheld or subject to an award surrendered in connection with the purchase of shares of Common Stock upon exercise of
an option; (ii) that were not issued upon the net settlement or net exercise of a stock-settled SAR; (iii) deducted or delivered from
payment of an award in connection with our tax withholding obligations; or (iv) purchased by us with proceeds from option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant incentive stock options (under Section 422 of the Code) and options that do not qualify as
incentive stock options. An option granted under the 2024 Plan is exercisable only to the extent that it is vested. Each option becomes
vested and exercisable at such times and under such conditions as the Committee may approve consistent with the terms of the 2024 Plan.
No option may be exercisable more than ten years after the option grant date, or five years after the option grant date in the case of
an incentive stock option granted to a &#8220;ten percent stockholder&#8221; (as defined in the 2024 Plan); provided that, to the extent
deemed necessary or appropriate by the Committee to reflect differences in local law, tax policy, or custom with respect to any option
granted to a grantee who is a foreign national or is a natural person who is employed outside of the United States, such option may terminate,
and all rights to purchase shares of Common Stock thereunder may cease, upon the expiration of a period longer than ten (10)
years from the date of grant of such option as the Committee shall determine. The Committee may include in the option agreement provisions
specifying the period during which an option may be exercised following termination of the grantee&#8217;s service. The exercise price
of each option is determined by the Committee, provided that the per share exercise price will be equal to or greater than 100% of the
fair market value of a share of Common Stock on the grant date (other than as permitted for substitute awards). If we were to grant incentive
stock options to any ten percent stockholder, the per share exercise price would not be less than 110% of the fair market value of a
share of Common Stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
stock options and nonqualified stock options are generally non-transferable, except for transfers by will or the laws of descent and
distribution. The Committee may, in its discretion, determine that a nonqualified stock option may be transferred to family members by
gift or other transfers deemed not to be for value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share
Appreciation Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant SARs that provide the recipient with the right to receive, upon exercise of the SAR, cash,
Common Stock, or a combination of the two. The amount that the recipient receives upon exercise of the SAR generally equals the excess
of the fair market value of shares of Common Stock on the date of exercise over the fair market value of shares of Common Stock on the
grant date. SARs become exercisable in accordance with terms determined by the Committee. SARs may be granted in tandem with an option
grant or independently from an option grant. The term of a SAR cannot exceed ten (10) years from the date of grant. The per share exercise
price of a SAR is no less than the fair market value of one share of Common Stock on the grant date of such SAR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SARs
are nontransferable, except for transfers by will or the laws of descent and distribution. The Committee may determine that all or part
of a SAR may be transferred to certain family members of the grantee by gift or other transfers deemed not to be for value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Market Value</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as the Common Stock remains listed on Nasdaq, the fair market value of the Common Stock on an award&#8217;s grant date, or on
any other date for which fair market value is required to be established under the 2024 Plan, is the closing price of the Common Stock
as reported on Nasdaq on such date. If there is no such reported closing price on such date, the fair market value of the Common Stock
will be the closing price of the Common Stock as reported on such market on the next preceding date on which any sale of Common Stock
will have been reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Common Stock ceases to be listed on Nasdaq and is listed on another established national or regional stock exchange, or traded on
another established securities market, fair market value will similarly be determined by reference to the closing price of the Common
Stock on the applicable date as reported on such other stock exchange or established securities market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Common Stock ceases to be listed on Nasdaq or another established national or regional stock exchange, or traded on another established
securities market, the Committee will determine the fair market value of the Common Stock by the reasonable application of a reasonable
valuation method in a manner consistent with Section 409A of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>No
Repricing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
in connection with a corporate transaction involving us (including, without limitation, any stock dividend, distribution (whether in
the form of cash, shares of common stock, other securities or other property), stock split, extraordinary dividend, recapitalization,
change in control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of shares of common
stock or other securities or similar transaction), we may not, without obtaining stockholder approval, (a) amend the terms of outstanding
options or SARs to reduce the exercise price of such outstanding options or SARs, (b) cancel outstanding options or SARs in exchange
for, or in substitution of, options or SARs with an exercise price that is less than the exercise price of the original options or SARs,
or (c) cancel outstanding options or SARs with an exercise price above the current price of Common Stock in exchange for cash or other
securities, in each case, unless such action is (i) subject to and approved by our stockholders, or (ii) would not be deemed to be a
repricing under the rules of any stock exchange or securities market on which the Common Stock is listed or publicly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock, Restricted Stock Units, and Deferred Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant restricted stock, restricted stock units, and deferred stock units. Subject to the
provisions of the 2024 Plan, the Committee determines the terms and conditions of each award of restricted stock, restricted stock
units, and deferred stock units, including the restricted period for all or a portion of the award, the restrictions applicable to
the award, and the purchase price, if any, for the shares of Common Stock subject to the award. The restrictions, if any, may lapse
over a specified period of time or through the satisfaction of conditions, in installments or otherwise, as the Committee may
determine. A grantee of restricted stock has all of the rights of a stockholder as to those shares of Common Stock, including,
without limitation, the right to vote the shares of Common Stock and receive dividends or distributions on the shares of Common
Stock, except to the extent limited by the Committee. The Committee may provide in an award agreement evidencing a grant of
restricted stock that (a) cash dividend payments or distributions paid on restricted stock will be reinvested in shares of Common
Stock, which may or may not be subject to the same vesting conditions and restrictions as applicable to such shares of restricted
stock, or (b) any dividend payments or distributions declared or paid on shares of restricted stock will only be made or paid upon
satisfaction of the vesting conditions and restrictions applicable to such shares of restricted stock. Dividend payments or
distributions declared or paid on shares of restricted stock which vest or are earned based on the achievement of performance goals
do not vest unless such performance goals for such shares of restricted stock are achieved, and if such performance goals are not
achieved, the grantee of such shares of restricted stock promptly forfeits and, to the extent already paid or distributed, repay to
us such dividend payments or distributions. Grantees of restricted stock units and deferred stock units have no voting or dividend
rights or other rights associated with share ownership, although the Committee may award dividend equivalent rights on such
units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the restricted period, if any, when restricted stock, restricted stock units, and deferred stock units are non-transferable or forfeitable,
a grantee is prohibited from selling, transferring, assigning, pledging, exchanging, hypothecating, or otherwise encumbering or disposing
of the grantees&#8217; restricted stock, restricted stock units, and deferred stock units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unrestricted
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant unrestricted stock, free of any restrictions such as vesting requirements, in such amounts
and upon such terms as the Committee may determine. Unrestricted stock awards may be granted or sold in respect of past services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Equivalent Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant dividend equivalent rights. Dividend equivalent rights may be granted independently or in
connection with the grant of any equity-based award, except that no dividend equivalent right may be granted in connection with, or related
to an option or SAR. Dividend equivalent rights may be paid currently (with or without being subject to forfeiture or a repayment obligation)
or may be deemed to be reinvested in additional shares of Common Stock or awards which may thereafter accrue additional dividend equivalent
rights (with or without being subject to forfeiture or a repayment obligation) and may be payable in cash, shares of Common Stock, or
a combination of the two. Dividend equivalent rights granted as a component of another award may (a) provide that such dividend equivalent
right will be settled upon exercise, settlement, or payment of, or lase of restriction on, such other award and that such dividend equivalent
will expire or be forfeited or annulled under the same conditions as such award or (b) contain terms and conditions which are different
from the terms and conditions of such other award, provided that dividend equivalent rights credited pursuant to a dividend equivalent
right granted as a component of another award which vests or is earned based on the achievement of performance goals will not vest unless
such performance goals for such underlying award are achieved, and if such performance goals are not achieved, the grantee of such dividend
equivalent right will promptly forfeit and, to the extent already paid or distributed, repay to us payments or distributions made in
connection with such dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant performance awards. The Committee determines the applicable performance period, the performance
goals, and such other conditions that apply to the performance award. Any performance measures may be used to measure the performance
of the Company and its subsidiaries and other affiliates as a whole or any business unit of us, our subsidiaries, and/or our affiliates
or any combination thereof, as the Committee may deem appropriate, or any performance measures as compared to the performance of a group
of comparable companies, or published or special index that the Committee deems appropriate. Performance goals may relate to our financial
performance or the financial performance of our operating units, the grantee&#8217;s performance, or such other criteria determined by
the Committee. If the performance goals are met, performance awards will be paid in cash, shares of Common Stock, other awards, or a
combination thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Equity-Based Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant other types of stock-based awards under the 2024 Plan. The terms and conditions that apply
to other equity-based awards are determined by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forms
of Payment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for any option or the purchase price (if any) for restricted stock, vested restricted stock units, and/or vested deferred
stock units is generally payable (i) in cash or in cash equivalents acceptable to us, (ii) to the extent the award agreement provides,
by the tender (or attestation of ownership) of shares of Common Stock having a fair market value on the date of tender (or attestation)
equal to the exercise price or purchase price, (iii) to the extent permitted by law and to the extent permitted by the award agreement,
through a broker-assisted cashless exercise, or (iv) to the extent the award agreement provides and/or unless otherwise specified in
an award agreement, any other form permissible by applicable law, including net exercise or net settlement and service rendered to us
or our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Capitalization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may adjust the terms of outstanding awards under the 2024 Plan to preserve the proportionate interests of the holders in such
awards on account of any recapitalization, reclassification, share split, reverse share split, spin-off, combination of shares, exchange
of shares, share dividend or other distribution payable in capital shares, or other increase or decrease in such shares effected without
receipt of consideration by us. The adjustments will include proportionate adjustments to (i) the number and kind of shares subject to
outstanding awards and (ii) the per share exercise price of outstanding options or SARs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transaction
not Constituting a Change in Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are the surviving entity in any reorganization, merger, or consolidation of us with one or more other entities which does not constitute
a &#8220;change in control&#8221; (as defined in the 2024 Plan), any awards will be adjusted to pertain to and apply to the securities
to which a holder of the number of shares of Common Stock subject to such award would have been entitled immediately after such transaction,
with a corresponding proportionate adjustment to the per share price of options and SARs so that the aggregate price per share of each
option or SAR thereafter is the same as the aggregate price per share of each option or SAR subject to the option or SAR immediately
prior to such transaction. Further, in the event of any such transaction, performance awards (and the related performance measures if
deemed appropriate by the Committee) will be adjusted to apply to the securities that a holder of the number of Common Stock subject
to such performance awards would have been entitled to receive following such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effect
of a Change in Control in which Awards are not Assumed</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the applicable award agreement, in another agreement with the grantee, or as otherwise set forth in writing,
upon the occurrence of a change in control in which outstanding awards are not being assumed or continued, the following provisions will
apply to such awards, to the extent not assumed or continued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
                                            prior to the occurrence of such change in control, in each case with the exception of performance
                                            awards, all outstanding shares of restricted stock and all restricted stock units, deferred
                                            stock units, and dividend equivalent rights will be deemed to have vested, and all shares
                                            of Common Stock and/or cash subject to such awards will be delivered; and either or both
                                            of the following two actions will be taken:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 38.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            least fifteen (15) days prior to the scheduled consummation of such change in control, all
                                            options and SARs outstanding will become immediately exercisable and will remain exercisable
                                            for a period of fifteen (15) days. Any exercise of an option or SAR during this fifteen (15)
                                            day period will be conditioned on the consummation of the applicable change in control and
                                            will be effective only immediately before the consummation thereof, and upon consummation
                                            of such change in control, the 2024 Plan and all outstanding but unexercised options and
                                            SARs will terminate, with or without consideration as determined by the Committee in its
                                            sole discretion; and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Committee may elect, in its sole discretion, to cancel any outstanding awards of options,
                                            SARs, restricted stock, restricted stock units, deferred stock units, and/or dividend equivalent
                                            rights and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount
                                            in cash or capital stock having a value (as determined by the Committee acting in good faith),
                                            in the case of restricted stock, restricted stock units, deferred stock units, and dividend
                                            equivalent rights (for shares of Common Stock subject thereto), equal to the formula or fixed
                                            price per share paid to holders of shares of Common Stock pursuant to such change in control
                                            and, in the case of options or SARs, equal to the product of the number of shares of Common
                                            Stock such subject to such options or SARs multiplied by the amount, if any, which (i) the
                                            formula or fixed price per share paid to holders of shares of Common Stock pursuant to such
                                            change in control exceeds (ii) the option price or SAR price applicable to such options or
                                            SARs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 38.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            performance awards, if less than half of the performance period has lapsed, such awards will
                                            be treated as though the target performance thereunder has been achieved. If at least half
                                            of the performance period has lapsed, such performance awards will be earned, as of immediately
                                            prior to but contingent on the occurrence of such change in control, based on the greater
                                            of (i) deemed achievement of target performance or (ii) determination of actual performance
                                            as of a date reasonably proximate to the date of consummation of the change in control as
                                            determined by the Committee, in its sole discretion.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            Equity-Based Awards will be governed by the terms of the applicable award agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effect
of a Change in Control in which Awards are Assumed</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the applicable award agreement, in another agreement with the grantee, or as otherwise set forth in writing,
upon the occurrence of a change in control in which outstanding awards are being assumed or continued, the following provisions will
apply to such awards, to the extent not assumed or continued: The 2024 Plan and the options, SARs, restricted stock, restricted stock
units, deferred stock units, dividend equivalent rights, and other equity-based equity awards granted under the 2024 Plan will continue
in the manner and under the terms so provided in the event of any change in control to the extent that provision is made in writing in
connection with such change in control for the assumption or continuation of such awards, or for the substitution for such awards of
new options, SARs, restricted stock, restricted stock units, deferred stock units, dividend equivalent rights, and other equity-based
awards relating to the capital stock of a successor entity, or a parent or subsidiary thereof, with appropriate adjustment as to the
number of shares of Common Stock and exercise price of options and SARs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a &#8220;change in control&#8221; means:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction or series of related transactions whereby a person or group (with certain exceptions) becomes the beneficial owner of
    50% or more of the total voting power of our voting stock on a fully diluted basis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">individuals
    who, as of the Effective Date, constitute the Board (together with any new directors whose election was approved by at least a majority
    of the members of the Board then in office), cease to constitute a majority of the members of the Board then in office;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    merger or consolidation involving us, other than any such transaction in which the holders of our voting stock immediately prior
    to the transaction own directly or indirectly at least a majority of the voting power of the surviving entity immediately after the
    transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    sale of substantially all of our assets to another person or entity; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    consummation of a plan or proposal for the dissolution or liquidation of the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Equity Compensation Plan Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">As of December 31, 2023,
we did not have any securities authorized for issuance under equity compensation plans. In connection with the Business Combination,
our stockholders approved the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_005"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Person Transactions &#8212; Semper Paratus</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Founder
Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Original Sponsor paid $25,000 to cover certain offering costs of Semper Paratus in consideration for 8,625,000 Class B ordinary shares
(the &#8220;founder shares&#8221;) which were issued on April 22, 2021. In August 2021, Semper Paratus effectuated a dividend of approximately
0.3628 shares for each outstanding Class B ordinary share resulting in an aggregate of 11,754,150 Class B ordinary shares outstanding.
On October 1, 2021, Semper Paratus effectuated a dividend of approximately 0.0195 shares for each outstanding Class B ordinary share
resulting in an aggregate of 11,983,333 Class B Founder shares outstanding (up to 1,530,000 of which were subject to forfeiture if the
underwriters&#8217; over-allotment option was not exercised in full). The Original Sponsor had agreed to forfeit up to 1,530,000 founder
shares to the extent that the over-allotment option was not exercised in full by the underwriters. Since the underwriters&#8217; exercised
the over-allotment option in full, no founder shares were subject to forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
holding all of the founder shares </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
agreed </span>to the Letter Agreement Lock-Up. On February 13, 2024, Semper Paratus, the Original Sponsor, SSVK, and certain individuals
party thereto entered into an Amendment to the Letter Agreement, which, among others things, replaced the reference to &#8220;one year
after completion of the initial business combination&#8221; in the Letter Agreement Lock-Up with &#8220;six months after the completion
of the initial business combination.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2023, the Original Sponsor, holding all of the founder shares, elected to effect the Conversion of its founder shares
into Class A ordinary shares of Semper Paratus on a one-for-one basis. As a result, 11,983,333 of Semper
Paratus&#8217; Class B ordinary shares were cancelled and 11,983,333 Class A ordinary shares were issued to the Original Sponsor. The
Original Sponsor agreed that all of the terms and conditions applicable to the founder shares set forth in the Letter Agreement would
continue to apply to the Class A ordinary shares that the founder shares converted into, including the voting agreement, transfer restrictions
and waiver of any right, title, interest or claim of any kind to the Trust Account or any monies or other assets held therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, we entered into the Purchase Agreement with SSVK and the Original Sponsor, pursuant to which SSVK purchased
from the Original Sponsor (x) 7,988,889 Class A ordinary shares and (y) 1,000,000 private placement units, each consisting of one Class
A ordinary share and one-half of one redeemable warrant that was exercisable for one Class A ordinary share, free and clear of all liens
and encumbrances (other than those contained in the Letter Agreement), for an aggregate purchase price of $1.00 payable at the time of
the initial Business Combination. On June 7, 2023, we transferred 7,988,889 Class A ordinary shares to SSVK, pursuant to the Purchase
Agreement. We estimated the aggregate fair values of the 7,988,889 Class A non-redeemable ordinary shares, the 1,000,000 private placement
shares, and the 500,000 public warrants transferred to be $3,515,111, $440,000, and $20,000, respectively or $0.44 per share and $0.04
per warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscription
Agreement Loans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2023, we entered into the First Subscription Agreement with the Original Sponsor and Polar, pursuant to which Polar
agreed to make the Initial Capital Contribution of $151,000 to the Original Sponsor on or prior to May 3, 2023, which was
in turn loaned to us to cover working capital expenses. In consideration for the Initial Capital Contribution, we issued 151,000 shares
of Common Stock to Polar, and we agreed to repay the cash contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, we entered into the Second Subscription Agreement with SSVK and Polar, pursuant to which Polar agreed
to lend to SSVK, which would in turn be lent to us, the Additional Capital Commitment of $1,500,000 to cover working capital
expenses. In consideration for the Additional Capital Commitment, we issued 1,500,000 shares of Common Stock to Polar,
and we agreed to repay the cash contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Private
Placement Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the initial public offering, the Original Sponsor and Cantor purchased an aggregate of 1,450,000 private placement
units at a price of $10.00 per private placement unit in a private placement, generating gross proceeds of $14.5 million. 1,300,000 of
the private placement units were sold to the Original Sponsor and 150,000 private placement units were sold to Cantor. No underwriting
discounts or commissions were paid with respect to sale of the private placement units. The proceeds from the private placement units
were added to the proceeds from the initial public offering held in the Trust Account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination, each issued and outstanding private placement unit was cancelled and entitled
the holder thereof to one share of Common Stock and one-half of one public warrant, with a whole public warrant representing the right
to acquire one share of Common Stock at an exercise price of $11.50 per share on the terms and conditions set forth in the Semper Paratus
warrant agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Registration
Rights Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2021, Semper Paratus entered into a Registration and Shareholder Rights Agreement (the &#8220;registration rights agreement&#8221;),
pursuant to which the Original Sponsor, Cantor and their permitted transferees, if any, are entitled to certain registration rights with
respect to the private placement units, the securities issuable upon conversion of working capital loans (if any) and the Class A ordinary
shares issuable upon exercise of the foregoing and upon conversion of the founder shares. At the closing of the Business Combination,
we entered into the A&amp;R Registration Rights Agreement, which superseded the registration rights agreement. For additional information,
see &#8220;<i>&#8212;Certain Relationships and Related Person Transactions&#8212;Tevogen&#8212;Amended and Restated Registration
Rights Agreement</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Assignment
and Assumption Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus entered into an agreement as of February 14, 2024 with SSVK
(the &#8220;Assignment and Assumption Agreement&#8221;), pursuant to which Semper Paratus assigned to SSVK and SSVK
agreed to assume certain liabilities and obligations, including liabilities and obligations that would become liabilities and obligations
of the Company as a result of the Business Combination, in the aggregate initial amount of approximately $4.2 million, which amount was
later reduced to approximately $3.6 million, in consideration for the issuance of Series B Preferred Stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, we entered into the Repurchase Agreement with SSVK, pursuant to which we repurchased and cancelled, with immediate
effect, the outstanding shares of our Series B Preferred Stock in exchange for (i) the reassignment to and reassumption by us of the
liabilities assigned under the Assignment and Assumption Agreement (as defined elsewhere in this prospectus) and (ii) the termination
of the Assignment and Assumption Agreement, and SSVK released us from certain claims relating to the Repurchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conversion
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into the Conversion Agreements with SSVK and Mr. Ajjarapu pursuant to
which we issued an aggregate of 174,000 shares of Common Stock in relation to services that were to have been provided to us and Tevogen
Bio, at an effective price of $10.00 per share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Original Sponsor was
the beneficial owner of more than 5% of the Class A ordinary shares of Semper Paratus prior to the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">SSVK is the beneficial
owner of more than 5% of our Common Stock, and Suren Ajjarapu, managing member of SSVK, is a member of our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Person Transactions &#8212; Tevogen</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Family
Relationships</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judy
Akhtar, wife of our Chairman and Chief Executive Officer, Ryan Saadi, is party to a consulting agreement with Tevogen Bio pursuant to
which she received a compensatory grant of restricted stock units in January 2023 with an aggregate grant date fair value of $533,600
for advisory services provided to Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mehtaphoric
Consulting Inc. (&#8220;Mehtaphoric&#8221;), a company controlled by Puja Mehta, daughter of our Chief Financial Officer, Kirti Desai,
is party to a consulting agreement with Tevogen Bio pursuant to which Mehtaphoric received compensatory grants of restricted stock units
in 2021 and 2023 with an aggregate grant date fair value of $267,400 for information technology services provided to Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sordillo
Equity Grant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, Tevogen Bio granted Victor Sordillo, who is currently a member of the Board, restricted stock units for 19,000 shares of non-voting
common stock with a grant date fair value of $253,460 in anticipation of Mr. Sordillo&#8217;s joining the Tevogen Bio board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholder
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio was party to a Stockholder Agreement (the &#8220;Stockholder Agreement&#8221;) with certain of its stockholders, including Dr. Saadi,
Mr. Desai, former Chief Operating Officer and director Kevin McGrath, and director Jeffrey Feike. The Stockholder Agreement provided
for a drag-along right pursuant to which the stockholders party thereto agreed to vote their shares in favor of a merger or other transaction
in which Tevogen Bio sold capital stock representing at least 80% of the outstanding voting power of Tevogen Bio or substantially all
of the assets of Tevogen Bio, provided such transaction was approved by at least 50% of the holders of outstanding shares of Tevogen
Bio common stock and the Tevogen Bio board of directors. Additionally, the stockholders party to the Stockholder Agreement granted
Tevogen a right of first refusal with respect to any shares of Tevogen Bio common stock that the stockholders proposed to transfer
to a third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended
and Restated Registration Rights Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, we entered into an Amended and Restated Registration
Rights Agreement (the &#8220;A&amp;R Registration Rights Agreement&#8221;) with SSVK, the Original Sponsor, Dr. Saadi, Mr. Desai,
Dr. Flomenberg, the Sponsor Holders (as defined therein), and Cantor. Pursuant to the A&amp;R Registration Rights Agreement, we agreed
to use commercially reasonable efforts to file a registration statement registering the resale of certain shares of Common Stock and
warrants (the &#8220;Registrable Securities&#8221;). In addition, at any time (after the expiration of any lock-up period) and from time
to time after the shelf registration statement has been declared effective, the Special Holders holding at least a majority in interest
of Registrable Securities may request to sell all or any portion of their Registrable Securities in an underwritten offering that is
registered pursuant to the shelf registration statement (each, an &#8220;Underwritten Shelf Takedown&#8221;); provided that such Underwritten
Shelf Takedown meets certain requirements and that we shall not be obligated to effect more than one Underwritten Shelf Takedown during
any twelve-month period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lock-Up
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, we entered into the Lock-Up Agreement with the Locked-Up
Parties, pursuant to which each Locked-Up Party agreed subject to specified exceptions not to transfer any Lock-Up Securities
until the earlier of (A) six months after the Closing Date and (B) subsequent to the Business Combination, (x) if the closing price of
the Common Stock equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations
and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Business Combination, or
(y) the date on which we complete a liquidation, merger, share exchange, or other similar transaction that results in all of our
stockholders having the right to exchange their Common Stock for cash, securities, or other property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sponsor
Advisory Services Fee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In June 2023, pursuant to
the Merger Agreement, Tevogen Bio agreed that at the Effective Time, it would pay $2.0 million to SSVK for advisory services (the
&#8220;Sponsor Advisory Services Fee&#8221;). Thereafter, in connection with the closing of the Business Combination and the Conversion
Agreements, the Sponsor Advisory Services Fee was reduced to $500,000. This amount was further reduced to $250,000 by reducing a
repayment obligation of SSVK. That repayment obligation arose from a transaction in December 2023 when Semper Paratus transferred
$250,000 to an affiliate of Mr. Ajjarapu.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A and Series A-1 Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement with an investor pursuant to which the investor agreed to
purchase shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024, we entered into an agreement pursuant to which that amount was reduced to $2.0 million and the
investor agreed to purchase shares of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A Preferred Stock are convertible into a total of 500,000 shares of Common Stock at the election of the holder and the
Series A-1 Preferred Stock will be convertible into a total of 600,000 shares of Common Stock at the election of the holder. The Series
A Preferred Stock is and the Series A-1 Preferred Stock will be subject to a call right providing us the right to call the stock if the
volume weighted average price of the Common Stock for the 20 days prior to delivery of the call notice is greater than $5.00 per
share and in each case there is an effective resale registration statement on file covering the underlying Common Stock. The Series
A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no mandatory redemption,
and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the Series A-1 Preferred Stock
in no event to more than 15% per year. We also agreed that so long as each of the Series A Preferred Stock and the Series A-1 Preferred
Stock is outstanding, we will not, without the written consent of the holders of 50.1% of the Series A Preferred Stock and the Series
A-1 Preferred Stock, amend, alter, or repeal any provision of our certificate of incorporation or bylaws in a manner adverse to such
series of Preferred Stock. The investor in the Series A Preferred Stock and the Series A-1 Preferred Stock is an existing stockholder
and an affiliate of Dr. Manmohan Patel, a beneficial owner of more than 5% of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Loan Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On June 6, 2024, we
entered into the Loan Agreement with the Lender providing for (i) the Facility, pursuant to which the Lender agreed to lend the
Company up to the Maximum Loan Amount of $36.0 million, and (ii) a contingent option for the Lender to purchase at least $14.0
million of Common Stock and/or pre-funded warrants in a future private placement. The Lender is an existing stockholder and an
affiliate of Dr. Patel, a beneficial owner of at least 5% of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Person Transaction Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 14, 2024, the Board adopted a written related-person transactions policy that conforms with the requirements for issuers having
securities listed on Nasdaq. Under the policy, the audit committee serves as the approval authority for related person transactions.
Any transaction that we intend to undertake with a related person will be submitted to either our Chief Financial Officer, who serves
as the compliance officer under the policy, the audit committee, or the full Board for review. If the compliance officer, the audit committee,
or the Board becomes aware of a transaction with a related person that has not been previously approved or previously ratified under
the policy that required such approval, the transaction will be submitted promptly to the approval authority for review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_006"></span>PRINCIPAL
STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of Common Stock as of June 20, 2024, by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person known by us to be the beneficial owner of more than 5% of the outstanding shares of
                                            Common Stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our named executive officers and directors; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of our executive officers and directors as a group.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if they possess sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities
that the individual or entity has the right to acquire, such as through the exercise of warrants or the vesting of RSUs, within 60 days
of June 20, 2024. Shares subject to warrants that are currently exercisable or exercisable within 60 days of June 20, 2024,
or subject to RSUs that vest within 60 days of June 20, 2024, are considered outstanding and beneficially owned by
the person holding such warrants or RSUs for the purpose of computing the percentage ownership of that person but are not treated as
outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community
property laws where applicable, based on the information provided to us, we believe that the persons and entities named in the table
below have sole voting and investment power with respect to all shares shown as beneficially owned by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial ownership of the Common Stock is based on 167,114,418 shares issued and outstanding as of June 20, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name and Address of Beneficial Owner</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of<br/> Tevogen<br/> Common<br/> Stock</td><td style="text-align: center; padding-bottom: 0.05in; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-style: italic">5% Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">SSVK Associates, LLC</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">9,488,889</td><td style="padding-bottom: 0.05in; width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manmohan Patel, MD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,374,489</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tevogen Directors and Named Executive Officers<sup>(3)</sup></i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Ryan Saadi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,443,976</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kirti Desai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,699,186</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Neal Flomenberg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,969,297</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surendra Ajjarapu<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,662,889</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jeffrey Feike</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">581,771</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Keow Lin Goh</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193,923</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Curtis Patton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">969,618</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Susan Podlogar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193,923</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Victor Sordillo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,298</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All Tevogen directors and executive officers as a group (10 individuals)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,734,500</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84.2</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> by SSVK include 500,000 shares underlying currently exercisable warrants. Shares held by Mr. Ajjarapu also include 174,000 shares held by
    a trust. Mr. Ajjarapu is the managing member of SSVK and may be deemed to have beneficial ownership of the ordinary shares held directly
    by SSVK and the trust. Mr. Ajjarapu disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary
    interest he may have therein, directly or indirectly. The business address of SSVK, the trust, and Mr. Ajjarapu is c/o SSVK Associates,
    LLC, 767 Third Avenue, 38th Floor, New York, NY 10017.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    646,412 RSUs that have vested but remain subject to settlement and 1,100,000 shares issuable upon conversion of Preferred
    Stock that is held by The Patel Family, LLP or that The Patel Family, LLP has the right to acquire within 60 days of June 20,
    2024. Dr. Patel may be deemed to beneficially own the shares of stock issuable upon conversion of the Preferred Stock as well
    as 7,972,487 and 1,655,590 shares of Common Stock held by HMP Partners and The Patel Family, LLP, respectively. The business
    address of HMP Partners, The Patel Family, LLP, and Dr. Patel is 5 Jennie Court, Cedar Grove, New Jersey 07009. Dr. Patel is the managing member of HMP Partners and the spouse of the managing member of The Patel Family, LLP.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise provided, the address of each of these individuals is c/o Tevogen Bio Holdings Inc., 15 Independence Boulevard,
    Suite 410, Warren, New Jersey 07059.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    193,923 shares of Common Stock underlying RSUs held by Dr. Saadi&#8217;s wife that have vested but remain subject to settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    3,636,071 shares of Common Stock underlying RSUs that have vested but remain subject to settlement and 1,333,226 shares
    issuable upon the vesting of RSUs within 60 days of June 20, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(6)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents shares of Common Stock underlying RSUs that
    have vested but remain subject to settlement.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes 42,622 shares of Common Stock underlying
    RSUs that have vested but remain subject to settlement and 7,676 shares issuable upon the vesting of RSUs within 60 days of
    June 20, 2024.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes 4,066,541 shares of Common Stock underlying
    RSUs that have vested but remain subject to settlement, 1,340,902 shares issuable upon the vesting of RSUs within 60 days
    of June 20, 2024, and 500,000 shares underlying currently exercisable warrants.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_007"></span>REGISTERED
HOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders listed in the table below may from time to time offer and sell any or all of the shares of our Common Stock and Warrants
set forth below pursuant to this prospectus. When we refer to the &#8220;Registered Holders&#8221; in this prospectus, we refer to the
persons listed in the table below, and the pledgees, donees, transferees, assignees, successors, and other permitted transferees that
hold any of the Registered Holders&#8217; interest in the shares of Common Stock and Warrants after the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information provided by or on behalf of the Registered Holders concerning the Common Stock and Warrants
that may be offered from time to time by each Registered Holder pursuant to this prospectus. The Registered Holders identified below
may have sold, transferred, or otherwise disposed of all or a portion of their securities after the date on which they provided us with
information regarding their securities. Any changed or new information given to us by the Registered Holders, including regarding the
identity of, and the securities held by, each Registered Holder, will be set forth in a prospectus supplement or amendments to the registration
statement of which this prospectus is a part, if and when necessary. A Registered Holder may sell all, some or none of such securities
in this offering. See &#8220;<i>Plan of Distribution</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
ownership is based on 167,114,418 shares of Common Stock outstanding as of June 20, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described below or elsewhere in this prospectus, none of the Registered Holders has any material relationship with us or any
of our predecessors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Beneficially<br/>
                                            Owned Prior to this<br/> Offering</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Securities <br/> to be <br/> Sold
    in <br/> this Offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Securities <br/> Beneficially
    <br/> Owned After this <br/> Offering (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Registered Holder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of <br/> Common <br/> Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of <br/> Common <br/> Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of <br/> Common <br/> Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Ian Adelson (2)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">412,464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">396,314</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ajjarapu Sandhya Revocable Trust (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ASJC Global LLC - Series 18 (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">476,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basil Ben Baldanza (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">157,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cantor Fitzgerald &amp; Co. (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">725,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corbin ERISA Opportunity Fund, Ltd. (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,155,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">868,507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,145,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">858,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corbin Opportunity Fund, L.P. (8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FourWorld Event Opportunities, L.P. (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,080</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">FourWorld Global Opportunities Fund, Ltd. (10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322,454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Game Boy Partners LLC (11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gregory Gooding (12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">HBP Investors LLC (13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,709,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,709,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">HMP Partners, LLC (14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,972,487</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,972,487</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">J.V.B. Financial Group, LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pouria Paul Jebely (15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Philippe J. Kurzweil (16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Michael Magruder (17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marblegate Special Opportunities Master Fund, L.P. (18)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Maxim Partners LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Millennium Trust Co LLC Custodian FBO Hooman Yazhari Traditional IRA (19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Harold A Neu (20)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Parizad June Olver (21)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Richard Peretz (22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Polar Multi-Strategy Master Fund (23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,702,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">717,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,034,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jeffrey Rogers (24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sabona Investments Limited SA (25)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Schwaikert (26)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Semper Paratus Sponsor LLC (27)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SSVK Associates, LLC (28)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,488,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,488,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bradley John Stewart (29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,954</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The HGC Fund LP (30)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">810,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">586,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798,467</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">The Patel Family, LLP (31)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,755,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,755,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
                                            that the Registered Holders sell all of their shares of Common Stock and Warrants offered
                                            pursuant to this prospectus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares beneficially owned prior to this offering include&#160;16,150 shares underlying warrants.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sandhya
                                            and Suren Ajjarapu may be deemed to beneficially own these shares. Mr. Ajjarapu is the spouse
                                            of Sandjya Ajjarapu, Trustee of the trust, and is the managing member of SSVK and may be
                                            deemed to have beneficial ownership of the shares of Common Stock held directly by the trust
                                            and the shares of Common Stock and Warrants held directly by SSVK. Mr. Ajjarapu disclaims
                                            any beneficial ownership of the reported shares other than to the extent of any pecuniary
                                            interest he may have therein, directly or indirectly.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares beneficially owned prior to this offering
                                                                                                                                                                    include 32,757 shares underlying warrants.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 5,758 shares underlying warrants.
                                            Former Chief Executive Officer of Semper Paratus from April 2021 to June 2023.</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(6)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 75,000 shares underlying warrants. Cantor Fitzgerald &amp; Co. (&#8220;CF&amp;CO&#8221;) is the record owner of the securities. Cantor Fitzgerald Securities
(&#8220;CFS&#8221;) controls the managing general partner of CF&amp;CO. Cantor Fitzgerald, L.P. (&#8220;CFLP&#8221;) indirectly controls
each of CFS and CF&amp;CO. CFLP is controlled by CF Group Management, Inc. (&#8220;CFGM&#8221;), which is its managing general partner.
Mr. Howard Lutnick is the Chairman and Chief Executive Officer of CFGM and also the trustee of CFGM&#8217;s sole stockholder and therefore
controls CFGM. As such, each of CFS, CFLP, CFGM and Mr. Lutnick may be deemed to have beneficial ownership of the securities directly
held by CF&amp;CO. Each such entity or person disclaims any beneficial ownership of the reported shares other than to the extent of any
pecuniary interest they may have therein, directly or indirectly.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(7)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;868,507 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(8)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;305,151 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(9)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;48,919 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(10)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;244,495 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(11)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;2,884 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(12)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;853 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(13)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Himanshu
                                            Patel, President of HBP Investors LLC, may be deemed to beneficially own these shares. Dr.
                                            Patel also beneficially owns 484,810 shares of Common Stock underlying RSUs held directly
                                            by Dr. Patel that have vested but remain subject to settlement.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(14)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Manmohan Patel, who is a <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficial
                                                                     owner of more than 5% of the Common Stock, is the managing member of HMP Partners. Dr. Patel also may be deemed to beneficially own
                                                                     shares of Common Stock directly or beneficially owned by The Patel Family, LLP and beneficially owns 646,412 shares of Common Stock
                                                                     underlying RSUs held directly by Dr. Patel that have vested but remain subject to settlement.</span></td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(15)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;2,303 shares underlying warrants.
                                            Former director of Semper Paratus from April 2021 to June 2023.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(16)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 2,303 shares underlying warrants.
                                            Former Chief Financial Officer of Semper Paratus from April 2021 to April 2022.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(17)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 2,015 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(18)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 11,382 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(19)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 691 shares underlying warrants. Hooman Yazhari may be deemed to beneficially own these shares and also directly owns 10,000 shares of Common Stock.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(20)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 16,150 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(21)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 2,303 shares underlying warrants.
                                            Former director of Semper Paratus from November 2021 to June 2023.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(22)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 3,455 shares underlying warrants.
                                            Former Executive Chairman of Semper Paratus from April 2021 to June 2023.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(23)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 717,307 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(24)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 921 shares underlying warrants. Former
                                            President of Semper Paratus from November 2021 to April 2022 and Chief Financial Officer
                                            and President from April 2022 to June 2023</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(25)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 2,884 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(26)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 576 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(27)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering consist of 7 shares underlying warrants. Former
                                            sponsor of Semper Paratus.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(28)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 500,000 shares underlying warrants. The shares
                                            and Warrants held by SSVK, including any shares of Common Stock issued upon exercise of such
                                            Warrants, are subject to a contractual lock-up as described above under &#8220;<i>Prospectus
                                            Summary&#8212;Background&#8212;Lock-Up Agreement</i>.&#8221; Mr. Ajjarapu is the managing
                                            member of SSVK and may be deemed to have beneficial ownership of the shares of Common Stock
                                            and Warrants held directly by SSVK and the shares of Common Stock held directly by the trust.
                                            Mr. Ajjarapu disclaims any beneficial ownership of the reported shares other than to the
                                            extent of any pecuniary interest he may have therein, directly or indirectly.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(29)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;691 shares underlying warrants. Former
                                            director of Semper Paratus from November 2021 to June 2023.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(30)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include&#160;586,928 shares underlying warrants.</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                               <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">(31)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 1,100,000 shares issuable upon conversion
                                            of Preferred Stock. Dr. Patel is the spouse of the managing member of The Patel Family, LLP. Dr. Patel also may be deemed to beneficially own shares of Common Stock directly or beneficially owned by HMP Partners
and beneficially owns 646,412 shares of Common Stock underlying RSUs held directly by Dr. Patel that have vested but remain subject to
settlement.</td></tr>
                                                               </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_008"></span>DESCRIPTION
OF OUR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following sets forth a summary of the material terms of our securities registered under Section 12 of the Securities Act, including certain provisions of the law of the State of Delaware and the Company&#8217;s
Certificate of Incorporation (the &#8220;Charter&#8221;), Bylaws (the &#8220;Bylaws&#8221;), and certain warrant-related documents. This
summary is qualified by reference to the full text of the Charter, Bylaws, and warrant-related documents described herein, which are
exhibits to the report to which this exhibit is attached. We urge you to read each of the Charter, the Bylaws, and the warrant-related
documents described herein in their entirety for a complete description of the rights and preferences of our securities. The summary
below is also qualified by reference to the provisions of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;),
as applicable.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter authorizes the issuance of a total of 820,000,000 shares of capital stock, each with par value $0.0001 per share, consisting
of (a) 800,000,000 shares of Common Stock and (b) 20,000,000 shares of preferred stock. As of June 20, 2024, there were 167,114,418
shares of Common Stock outstanding held by 51 stockholders of record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Power</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law or as otherwise provided in any preferred stock designation, the holders of Common Stock will possess all
voting power for the election of directors and all other matters submitted to a vote of stockholders. Generally, each holder of Common
Stock is entitled to one vote per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law, holders of Common Stock, as such, will not be entitled to vote on any amendment to the Charter (including
any preferred stock designation) that relates solely to the rights, powers, preferences (or the qualifications, limitations or restrictions
thereof) or other terms of one or more outstanding series of preferred stock of the Company if the holders of such affected series of
preferred stock are entitled to vote on such amendment pursuant to the Charter (including any preferred stock designation) or pursuant
to the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the rights and preferences of any holders of any outstanding class or series of preferred stock of the
Company, holders of Common Stock will be entitled to receive dividends when, as and if declared by the Board, payable either in
cash, in property, or in shares of capital stock. All shares of Common Stock shall be of equal rank and shall be identical
with respect to rights to such dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation,
Dissolution, and Winding Up</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our voluntary or involuntary liquidation, dissolution, or winding up and after payment in full of our debts and other liabilities and
to any holders of preferred stock of the Company having liquidation preferences, if any, the holders of the shares of the Common Stock
shall be entitled to receive all the remaining assets of the Company available for distribution to our shareholders, ratably in proportion
to the number of shares of the Common Stock then issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preemptive
or Other Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the preferential rights of any other class or series of stock, all shares of Common Stock will have equal dividend,
distribution, liquidation, and other rights, and will have no preference or appraisal rights, except for any appraisal rights provided
by the DGCL. Furthermore, subject to applicable law, holders of Common Stock will have no preemptive rights and there are no conversion,
sinking fund, or redemption rights, or rights to subscribe for any of our securities. The rights, powers, preferences, and privileges
of holders of Common Stock will be subject to those of the holders of any shares of preferred stock that the Board may authorize and
issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Election
of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is divided into three classes, each of which generally serves for a term of three years with only one class of directors being
elected in each year. Directors are generally elected by a plurality of votes cast at a meeting of the shareholders at which a quorum
is present, and there is no cumulative voting with respect to the election of directors, with the result that the holders of more than
50% of the shares voted for the election of directors can elect all of the directors and that the director nominees receiving the highest
number of votes will be elected at such a meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that shares of preferred stock may be issued from time to time in one or more classes or series. The Board is authorized
to establish the voting rights, if any, designations, preferences, and relative, participating, optional, or other special rights of
the shares of such series, and the qualifications, limitations or restrictions thereof, applicable to the shares of each series of preferred
stock. The Board may, without shareholder approval, issue preferred stock with voting and other rights that could adversely affect the
voting power and other rights of the holders of Common Stock and could have anti-takeover effects. The ability of the Board to issue
preferred stock without shareholder approval could have the effect of delaying, deferring, or preventing a change of control of the Company
or the removal of existing management. We currently have 500 shares of Series A Preferred Stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Voting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">The
Series A Preferred Stock does not have any voting rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Holders
of Series A Preferred Stock are entitled to receive dividends accruing daily on a cumulative basis at a fixed rate of 5% per annum per
share on the Series A Original Issue Price (as defined in the Certificate of Designation of Series A Preferred Stock of the Company),
automatically increasing by 2% every year that the Series A Preferred Stock remains outstanding (the &#8220;Series A Accruing Dividends&#8221;).
The Series A Accruing Dividends become payable when and if declared by the Board. The Series A Preferred Stock will also participate
on an as-converted basis in any regular or special dividends paid to holders of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Liquidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">The
Series A Preferred Stock ranks senior to the Common Stock in liquidation priority. In the event of a liquidation of the Company, or certain
deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price plus all
Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the Series A
converted into shares of Common Stock immediately before the liquidation or deemed liquidation event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Redemption</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Holders
of Series A Preferred Stock are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a
deemed liquidation event. The Company is entitled to redeem that Series A Preferred Stock at a price equal to the Series A Original Issue
Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the volume-weighted average price of the Common Stock exceeds
$5.00 per share for the twenty days immediately prior to our call election.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Conversion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Holders
of Series A Preferred Stock have the option to convert the Series A Preferred Stock into shares of Common Stock at a ratio equal to the
Series A Original Issue Price divided by the Series A Conversion Price, which is initially $4.00 per share and is subject to standard
antidilution adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on the Common Stock to date and do not intend to pay cash dividends in the foreseeable future. The payment
of cash dividends in the future will be dependent upon our revenue and earnings, if any, capital requirements, and general financial
condition. The payment of any cash dividends is within the discretion of the Board. Our ability to declare dividends may also be limited
by restrictive covenants pursuant to any debt financing agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b>Restrictions
on Transfer and Alienability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Certain
shares of our Common Stock and certain outstanding warrants to purchase our Common Stock are subject to contractual lock-ups as described
under &#8220;<i>Prospectus Summary&#8212;Background</i>&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Anti-Takeover Provisions of Delaware Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Classified
Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that the Board is divided into three classes of directors, with the classes to be as nearly equal in number as possible,
and with each director serving a three-year term. As a result, approximately one-third of the Board is elected each year. The classification
of directors will have the effect of making it more difficult for shareholders to change the composition of the Board. Amending the classified
Board provisions requires approval by two-thirds (2/3) of the then-outstanding voting power.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
but Unissued Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized but unissued shares of Common Stock and preferred stock are available for future issuance without shareholder approval, subject
to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance
transactions, acquisitions, and employee benefit plans. The existence of authorized but unissued and unreserved, Common Stock and preferred
stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer,
merger, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shareholder
Action; Special Meetings of Shareholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that, subject to the rights of the holders of any series of preferred stock, any action required or permitted to be
taken by the shareholders must be effected at a duly called annual or special meeting of the shareholders and may not be effected by
any consent by such shareholders. As a result, a holder controlling a majority of our capital stock cannot amend the Bylaws or remove
directors without holding a meeting of shareholders called in accordance with the Bylaws. This restriction does not apply to actions
taken by the holders of any series of preferred stock to the extent expressly provided in the applicable preferred stock designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the Charter provides that, subject to any special rights of the holders of preferred stock, special meetings of the shareholders may
only be called by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance
Notice Requirements for Shareholder Proposals and Director Nominations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that shareholders seeking to bring business before our annual meeting of shareholders, or to nominate candidates for election
as directors at our annual meeting of shareholders, must provide timely notice. To be timely, a shareholder&#8217;s notice must be received
by the Secretary at our principal executive offices not later than the close of business on the 90<sup>th</sup> day nor earlier than
the close of business on the 120<sup>th</sup> day before the anniversary date of the immediately preceding annual meeting of shareholders.
However, in the event that the annual meeting is more than 30 days before or more than 60 days after such anniversary date (or if there
has been no prior annual meeting), notice by the shareholder to be timely must be so delivered not earlier than the close of business
on the 120<sup>th</sup> day before the meeting and not later than the later of (x) the close of business on the 90<sup>th</sup> day before
the meeting or (y) the close of business on the 10<sup>th</sup> day following the day on which public announcement of the date of the
annual meeting is first made by us. The Bylaws also specify certain requirements as to the form and content of a shareholders&#8217;
notice. These provisions may preclude our shareholders from bringing matters before our annual meeting of shareholders or from making
nominations for directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
of Charter or Bylaws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws may be amended or repealed by the Board or by the affirmative vote of the holders of a majority of the voting power of all of
the shares of our capital stock entitled to vote in the election of directors, voting as one class. The affirmative vote of the holders
of at least two-thirds (2/3) of the voting power of the then-outstanding shares of our capital stock entitled to vote generally in the
election of directors, voting together as a single class, is required to amend certain provisions of the Charter related to the classified
Board and limitation of liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Vacancies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
vacancy on the Board may be filled by a majority vote of the directors then in office, although less than a quorum, or by a sole remaining
director, subject to any special rights of the holders of preferred stock. Any director chosen to fill a vacancy will hold office until
the expiration of the term of the class for which he or she was elected and until the director&#8217;s successor is duly elected and
qualified or until their earlier resignation, removal from office, death, or incapacity. Except as otherwise provided by law, in the
event of a vacancy on the Board, the remaining directors may exercise the powers of the full Board until the vacancy is filled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Charter, during any period when the holders of one or more series of preferred stock have the separate right to elect additional
directors, the then-otherwise total authorized number of directors will automatically be increased by such number of directors that the
holders of any series of preferred stock have a right to elect. Whenever the holders of one or more series of preferred stock having
a separate right to elect additional directors cease to have such right, the terms of office of all preferred stock directors elected
by the holders of such series of preferred stock, and the total authorized number of directors, will be automatically reduced accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive
Forum Selection</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that (A) (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any current or former director, officer, other employee, or shareholder of the Company to the Company
or our shareholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Charter, or the Bylaws (as
either may be amended or restated) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or
(iv) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest
extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject
matter jurisdiction thereof, the federal district court of the State of Delaware; and (B) the federal district courts of the United States
shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Under
the Charter, these provisions may be waived by us at our discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive forum provision in the Charter does not apply to suits brought to enforce any duty or liability created by the Exchange Act
or any other claim for which the federal courts have exclusive jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that these provisions benefit the Company by providing increased consistency in the application of Delaware law in the types
of lawsuits to which it applies, a court may determine that these provisions are unenforceable, and to the extent they are enforceable,
the provisions may have the effect of discouraging lawsuits against our directors and officers, although our stockholders will not be
deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
203 of the Delaware General Corporation Law</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the DGCL until the election to opt-out of Section 203 of the DGCL in the Charter becomes
effective 12 months from the date the Charter first became effective under the DGCL. In general, Section 203 prohibits a Delaware corporation
that is listed on a national securities exchange or held of record by more than 2,000 shareholders from engaging in a &#8220;business
combination&#8221; with an &#8220;interested shareholder&#8221; for a three-year period following the time that such shareholder becomes
an interested shareholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes,
among other things, certain mergers, asset or stock sales, or other transactions resulting in a financial benefit to the interested shareholder.
An &#8220;interested shareholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years
prior to the determination of interested shareholder status, 15% or more of the corporation&#8217;s outstanding voting stock. Under Section
203, a business combination between a corporation and an interested shareholder is prohibited unless it satisfies one of the following
conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    the shareholder became interested, the board of directors approved either the business combination or the transaction which resulted
    in the shareholder becoming an interested shareholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
    of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans,
    in some instances; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    or after the time the shareholder became interested, the business combination was approved by the board of directors of the corporation
    and authorized at an annual or special meeting of the shareholders by the affirmative vote of at least two thirds (2/3) of the outstanding
    voting stock which is not owned by the interested shareholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, Section 203 of the DGCL would make it more difficult for a person who would be an &#8220;interested shareholder&#8221;
to effect various business combinations with a corporation for a three-year period. This provision may encourage companies interested
in acquiring us to negotiate in advance with the Board because the shareholder approval requirement would be avoided if the Board approves
either the business combination or the transaction which results in the shareholder becoming an interested shareholder. Section 203 of
the DGCL also may have the effect of preventing changes in the Board and may make it more difficult to accomplish transactions which
shareholders may otherwise deem to be in their best interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that a director or officer shall not be personally liable to us or our shareholders for monetary damages for breach
of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the
DGCL as the same exists or may hereafter be amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
and Advancement of Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that our directors and officers are indemnified and advanced expenses by us to the fullest extent authorized or permitted
by the DGCL as it now exists or may in the future be amended. In addition, the Bylaws provide that our directors are not personally liable
to us or our shareholders for monetary damages for breaches of their fiduciary duty as directors to the fullest extent permitted by the
DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws also permit us to purchase and maintain insurance on behalf of any officer, director, employee, or agent of the Company for any
liability arising out of such person&#8217;s status as such, regardless of whether the DGCL would permit indemnification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage shareholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action,
if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
We believe that these provisions, the insurance, and the indemnity agreements are necessary to attract and retain talented and experienced
directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">As
of June 20, 2024, there were 17,974,978 warrants to purchase Common Stock outstanding held by 27 holders of record.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
whole warrant entitles the registered holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment
as discussed below, at any time. Warrant holders may, until such time as there is an effective registration statement and during
any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant
to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or
another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless
exercise, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the
quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference
between the exercise price of the warrants and the &#8220;fair market value&#8221; (as defined below) by (y) the fair market value. The
&#8220;fair market value&#8221; for this purpose means the average reported last sale price of the shares of Common Stock for the 10
trading days ending on the third trading day prior to the date on which the notice of exercise is sent to the warrant agent. The warrants
will expire five years after the completion of the Business Combination on February 14, 2029, at 5:00 p.m., New York City time,
or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption
of warrants when the price per share of Common Stock equals or exceeds $18.00.</i> Once the warrants become exercisable, we may redeem
the outstanding warrants except as described herein with respect to the private placement warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.01 per warrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    a minimum of 30 days&#8217; prior written notice of redemption to each warrant holder; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number
    of shares issuable upon exercise or the exercise price of a warrant as described under &#8220;&#8212;<i>Anti-Dilution</i><i>
    Adjustments</i>&#8221; below) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the
    date on which we send the notice of redemption to the warrant holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the
Common Stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Common Stock
is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we may exercise our redemption
right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the
call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption
of the warrants, each warrant holder will be entitled to their warrant prior to the scheduled redemption date. However, the price of
the Common Stock may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon
exercise or the exercise price of a warrant as described under &#8220;&#8212;<i>Anti-dilution</i><i> Adjustments</i>&#8221; below)
as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the warrants for redemption as described above, our management has the option to require all holders that wish to exercise warrants
to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their warrants on a &#8220;cashless
basis,&#8221; our management would consider, among other factors, our cash position, the number of warrants that are outstanding and
the dilutive effect on our shareholders of issuing the maximum number of Common Stock issuable upon the exercise of our warrants. In
such event, each holder would pay the exercise price by surrendering the warrants for that number shares of Common Stock equal to the
lesser of (A) the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied
by the excess of the fair market value of our shares of Common Stock over the exercise price of the warrants by (y) the fair market value
and (B) 0.361 per warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption
of warrants when the price per share of Common Stock equals or exceeds $10.00.</i> Once the warrants become exercisable, we may redeem
the outstanding warrants except as described herein with respect to the private placement warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption; provided that holders will be able
    to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the
    table below, based on the redemption date and the &#8220;fair market value&#8221; of our Class A ordinary shares, except as otherwise
    described below; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the closing price of the Common Stock equals or exceeds $10.00 per public share (as adjusted for adjustments to the
    number of shares issuable upon exercise or the exercise price of a warrant as described under &#8220;&#8212;<i>Anti-dilution</i><i>
    Adjustments</i>&#8221; below) on the trading day prior to the date on which we send the notice of redemption to the warrant holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants
on a cashless basis. The numbers in the table below represent the number of shares of Common Stock that a warrant holder will receive
upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the &#8220;fair market
value&#8221; of the Common Stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants
are not redeemed for $0.10 per warrant), determined for these purposes based on volume weighted average price of the Common Stock for
the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants,
and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the
table below. We will provide our warrant holders with the final fair market value no later than one business day after the 10-trading
day period described above ends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="34" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
    Market Value of Common Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8804;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8805;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(period
    to expiration of warrants)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$10.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$11.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$12.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$13.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$14.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$15.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$16.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$17.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$18.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.261</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.281</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.311</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.324</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.337</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.348</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.358</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.257</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.277</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.294</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.310</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.324</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.337</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.348</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.358</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.272</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.291</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.307</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.322</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.335</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.347</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.357</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.246</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.268</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.287</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.304</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.320</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.333</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.346</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.357</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.241</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.263</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.283</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.301</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.317</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.332</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.344</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.235</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.258</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.279</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.298</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.315</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.330</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.343</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.228</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.274</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.294</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.312</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.328</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.342</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.355</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.221</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.246</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.290</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.309</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.325</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.340</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.354</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.213</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.239</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.263</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.285</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.305</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.323</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.339</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.353</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.205</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.232</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.257</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.280</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.301</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.320</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.337</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.352</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.196</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.224</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.274</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.316</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.335</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.351</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.185</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.214</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.242</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.268</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.291</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.313</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.332</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.350</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.173</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.204</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.260</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.285</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.308</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.329</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.348</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.161</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.193</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.223</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.279</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.304</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.326</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.347</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.146</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.211</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.242</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.271</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.298</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.322</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.345</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.130</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.164</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.197</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.230</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.262</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.291</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.317</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.342</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.111</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.146</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.181</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.216</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.282</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.312</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.339</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.090</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.125</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.162</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.199</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.237</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.272</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.305</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.336</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.099</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.137</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.178</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.219</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.259</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.296</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.331</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.150</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.197</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.243</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.286</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.326</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.042</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.115</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.281</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.323</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between
two values in the table or the redemption date is between two redemption dates in the table, the number of shares of Common Stock to
be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the
higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.
For example, if the volume weighted average price of the Common Stock for the 10 trading days ending on the third trading day prior to
the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and at such time there are 57
months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants
for 0.277 shares of Common Stock for each whole warrant. For an example where the exact fair market value and redemption date are not
as set forth in the table above, if the volume weighted average price of the Common Stock for the 10 trading days ending on the third
trading day prior to the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such
time there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise
their warrants for 0.298 shares of Common Stock for each whole warrant. In no event will the warrants be exercisable on a cashless basis
in connection with this redemption feature for more than 0.361 shares of Common Stock per warrant (subject to adjustment). Finally, as
reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis
in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
redemption feature differs from the typical warrant redemption features established by many other blank check companies, which typically
only provide for a redemption of warrants for cash when the trading price for their shares exceeds $18.00 per share for a specified period
of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the shares of Common
Stock are trading at or above $10.00 per public share, which may be at a time when the trading price of Common Stock is below the exercise
price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without
the warrants having to reach the $18.00 per share threshold described above under &#8220;&#8212;<i>Redemption</i><i> of warrants
when the price per share of Common Stock equals or exceeds $18.00</i>&#8221; above. Holders choosing to exercise their warrants in connection
with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing
model with a fixed volatility input as of the date of this prospectus. This redemption right provides us with an additional mechanism
by which to redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no
longer be outstanding and would have been exercised or redeemed. We will be required to pay the applicable redemption price to warrant
holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we
determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best
interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
stated above, we can redeem the warrants when the shares of Common Stock are trading at a price starting at $10.00, which is below the
exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant
holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem
the warrants when the shares of Common Stock are trading at a price below the exercise price of the warrants, this could result in the
warrant holders receiving fewer shares of Common Stock than they would have received if they had chosen to wait to exercise their warrants
for shares of Common Stock if and when such shares of Common Stock were trading at a price higher than the exercise price of $11.50.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Common Stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional
interest in a share, we will round down to the nearest whole number of the number of shares of Common Stock to be issued to the holder.
If, at the time of redemption, the warrants are exercisable for a security other than the shares of Common Stock pursuant to the warrant
agreement, the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than
the shares of Common Stock, the company (or surviving company) will use its commercially reasonable efforts to register under the Securities
Act the security issuable upon the exercise of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s
affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder
may specify) of the Common Stock issued and outstanding immediately after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-dilution
Adjustments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is increased by a capitalization or share dividend payable in shares of Common Stock,
or by a split-up of shares or other similar event, then, on the effective date of such capitalization or share dividend, split-up or
similar event, the number of shares of Common Stock issuable on exercise of each warrant will be increased in proportion to such increase
in the outstanding shares of Common Stock. A rights offering made to all or substantially all holders of ordinary shares entitling holders
to purchase shares of Common Stock at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed
a share dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold
in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable
for shares of Common Stock) and (ii) one minus the quotient of (x) the price per shares of Common Stock paid in such rights offering
and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable
for shares of Common Stock, in determining the price payable for shares of Common Stock, there will be taken into account any consideration
received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market
value&#8221; means the volume weighted average price of shares of Common Stock as reported during the 10 trading day period ending on
the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market,
regular way, without the right to receive such rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities
or other assets to all or substantially all of the holders of shares of Common Stock, other than (a) as described above or (b) any cash
dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on
the shares of Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution does not exceed
$0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in
an adjustment to the exercise price or to the number of shares of Common Stock issuable on exercise of each warrant) but only with respect
to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, then the warrant exercise
price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value
of any securities or other assets paid on each share of Common Stock in respect of such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse share sub-division, or reclassification
of the shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse share sub-division,
reclassification, or similar event, the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion
to such decrease in outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise
price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator
of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment
and (y) the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if (x) we issued additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with
the Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective
issue price to be determined in good faith by the Board and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the Business Combination as of the Closing (net of redemptions), and (z)
the volume weighted average trading price of our Common Stock during the 20 trading day period starting on the trading day prior to the
Closing (such price, the &#8220;Market Value&#8221;) was below $9.20 per share, the exercise price of the warrants would be adjusted
(to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption
trigger price described above under &#8220;&#8212;<i>Redemption</i><i> of warrants when the price per shares of Common Stock equals
or exceeds $18.00</i>&#8221; would be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly
Issued Price, and the $10.00 per share redemption trigger price described above under <i>&#8220;&#8212;Redemption</i><i> of warrants
when the price per shares of Common Stock equals or exceeds $10.00</i>&#8221; would be adjusted (to the nearest cent) to be equal to
the higher of the Market Value and the Newly Issued Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely
affects the par value of such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation
or entity (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification
or reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity
of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders
of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in
the warrants and in lieu of the shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights
represented thereby, the kind and amount of shares of Common Stock or other securities or property (including cash) receivable upon such
reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder
of the warrants would have received if such holder had exercised their warrants immediately prior to such event. However, if such holders
were entitled to exercise a right of election as to the kind or amount of securities, cash, or other assets receivable upon such consolidation
or merger, then the kind and amount of securities, cash, or other assets for which each warrant will become exercisable will be deemed
to be the weighted average of the kind and amount received per share by such holders in such consolidation or merger that affirmatively
make such election, and if a tender, exchange, or redemption offer has been made to and accepted by such holders under circumstances
in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning
of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together
with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group
of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) more than
50% of the issued and outstanding shares of Common Stock, the holder of a warrant will be entitled to receive the highest amount of cash,
securities, or other property to which such holder would actually have been entitled as a shareholder if such warrant holder had exercised
the warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the shares of Common Stock held
by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustment (from and after the consummation of
such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in the Semper Paratus warrant agreement.
If less than 70% of the consideration receivable by the holders of shares of Common Stock in such a transaction is payable in the form
of shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter
market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly
exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced
as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose
of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction occurs during
the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of
the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Private
Placement Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below, the private placement warrants have terms and provisions that are identical to those of the public warrants described
above. The private placement warrants (including the shares of Common Stock issuable upon exercise of the private placement warrants)
are not redeemable by us so long as they are held by SSVK, the Original Sponsor, Cantor, or their permitted transferees. SSVK,
the Original Sponsor, Cantor, or their permitted transferees have the option to exercise the private placement warrants on a cashless
basis. If the private placement warrants are held by holders other than SSVK, the Original Sponsor, Cantor, and their permitted
transferees, the private placement warrants would be redeemable by us and exercisable by the holders on the same basis as the public
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering
their warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of
shares of Common Stock underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (as defined below)
over the exercise price of the warrants by (y) the Sponsor fair market value. For these purposes, the &#8220;fair market value&#8221;
shall mean the average reported closing price of the shares of Common Stock for the 10 trading days ending on the third trading day prior
to the date on which the notice of warrant exercise is sent to the warrant agent. We have agreed that these warrants will be exercisable
on a cashless basis so long as they are held by SSVK, Original Sponsor, Cantor, or their permitted transferees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing
of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and public warrants are currently listed on Nasdaq, under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221;
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>






<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_009"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants, including
underwriter&#8217;s commissions and discounts, brokerage fees, underwriting marketing costs, and all reasonable fees and expenses of
any legal counsel representing the Registered Holders, except that we will pay reasonable fees and expenses of one U.S. legal counsel
and local counsel in any other applicable jurisdiction(s) for the Registered Holders party to the A&amp;R Registration Rights
Agreement in the event of a demanded underwritten offering of their securities. We will bear all other costs, fees, and expenses
incurred in effecting the registration of the shares of Common Stock and Warrants covered by this prospectus, including, without limitation,
all registration and filing fees, printing and delivery fees, Nasdaq listing fees, and fees and expenses of our counsel and our accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Common Stock and Warrants beneficially owned by the Registered Holders covered by this prospectus may be offered and sold from
time to time by the Registered Holders. The term &#8220;Registered Holders&#8221; includes donees, pledgees, transferees, or other successors
in interest selling securities received after the date of this prospectus from a Registered Holder as a gift, pledge, partnership distribution,
or other transfer. The Registered Holders will act independently of us in making decisions with respect to the timing, manner, and size
of each sale. Such sales may be made on one or more exchanges, including any exchange, market or trading facility on which the Common
Stock or Warrants are traded, including Nasdaq, or in the over-the-counter market or otherwise, at prices and under terms then prevailing
or at prices related to the then-current market price or in negotiated transactions. The Registered Holders may sell their shares of
Common Stock and Warrants by one or more of, or a combination of, the following methods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
                                            by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant
                                            to this prospectus;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
                                            brokerage transactions and transactions in which the broker solicits purchasers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
                                            trades in which the broker-dealer so engaged will attempt to sell the shares as agent but
                                            may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            over-the-counter distribution in accordance with the rules of Nasdaq;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            trading plans entered into by a Registered Holder pursuant to Rule 10b5-1 under the Exchange
                                            Act, that are in place at the time of an offering pursuant to this prospectus and any applicable
                                            prospectus supplement hereto that provide for periodic sales of their securities on the basis
                                            of parameters described in such trading plans;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            or through underwriters or broker-dealers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at
                                            negotiated prices, at prices prevailing at the time of sale, or at prices related to such
                                            prevailing market prices, including sales made directly on a national securities exchange
                                            or sales made through a market maker other than on an exchange or other similar offerings
                                            through sales agents;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            privately negotiated transactions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            options transactions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            a combination of any of the above methods of sale; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other method permitted pursuant to applicable law.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Registered Holder that is an entity may elect to make an in-kind distribution of Common Stock to its members, partners, stockholders,
or other equityholders pursuant to the registration statement of which this prospectus forms a part by delivering a prospectus. To the
extent that such members, partners, stockholders, or other equityholders are not affiliates of ours, such members, partners, stockholders,
or other equityholders would thereby receive freely tradable shares of Common Stock pursuant to a distribution pursuant to the registration
statement of which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In
connection with distributions of the shares or otherwise, the Registered Holders may enter into hedging transactions with broker-dealers
or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short
sales of shares of Common Stock in the course of hedging the positions they assume with Registered Holders. The Registered Holders may
also sell shares of Common Stock short and redeliver the shares to close out such short positions. The Registered Holders may also enter
into option or other transactions with broker-dealers or other financial institutions that require the delivery to such broker-dealer
or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Registered Holders may also pledge shares
to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect
sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Registered Holder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives,
the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by any Registered Holder or borrowed from any Registered Holder or others to settle
those sales or to close out any related open borrowings of stock, and may use securities received from any Registered Holder in settlement
of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter
and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any Registered Holder may
otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using
this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities
or in connection with a concurrent offering of other securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
effecting sales, broker-dealers or agents engaged by the Registered Holders may arrange for other broker-dealers to participate. Broker-dealers
or agents may receive commissions, discounts, or concessions from the Registered Holders in amounts to be negotiated immediately prior
to the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
offering the securities covered by this prospectus, the Registered Holders and any broker-dealers who execute sales for the Registered
Holders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits
realized by the Registered Holders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through
registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have advised the Registered Holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of securities
in the market and to the activities of the Registered Holders and their affiliates. In addition, we will make copies of this prospectus
available to the Registered Holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Registered
Holders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities,
including liabilities arising under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number
of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price
paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed
or reallowed or paid to any dealer, and the proposed selling price to the public.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Warrants may exercise its Warrants in accordance with the Warrant Agreement on or before the expiration date by surrendering,
at the office of the warrant agent, Continental Stock Transfer &amp; Trust Company, the certificate evidencing such Warrant, an election
to purchase, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes
due in connection with the exercise of the Warrant, subject to any applicable provisions relating to cashless exercises in accordance
with the Warrant Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the A&amp;R Registration Rights Agreement, we have agreed to indemnify the Registered Holders party thereto against certain liabilities
that they may incur in connection with the sale of the securities registered hereunder, including liabilities under the Securities Act,
and to contribute to payments that the Registered Holders may be required to make with respect thereto. In addition, we and the Registered
Holders party to the A&amp;R Registration Rights Agreement have agreed to indemnify any underwriter against certain liabilities
related to the selling of the securities, including liabilities arising under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to maintain the effectiveness of the registration statement of which this prospectus is a part until (i) solely with
respect to the shares of Common Stock issued pursuant to the Fee Reduction Agreement, for a period of at least two years from the
date of the effectiveness, (ii) with respect to the shares of Common Stock issuable upon exercise of the Warrants, until the
expiration of the Warrants in accordance with the provisions of the Warrant Agreement, and (iii) with respect to the
Registrable Securities under the A&amp;R Registration Rights Agreement, the earlier of such time that (A) a registration
statement with respect to the sale of such Registrable Securities has become effective under the Securities Act and such Registrable
Securities have been sold, transferred, disposed of or exchanged in accordance with the plan of distribution set forth in such
registration statement, (B) such Registrable Securities shall have ceased to be issuable or outstanding, (C) such Registrable
Securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities
transaction, (D) such Registrable Securities shall have been otherwise transferred, new certificates for them not bearing a legend
restricting further transfer shall have been delivered by Company and subsequent public distribution of them shall not require
registration under the Securities Act and (E) the first date on which such Common Stock is able to be sold without any volume
restrictions under Rule 144 of the Securities Act .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_010"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of Common Stock and Warrants offered hereby will be passed upon for us by Hogan Lovells US LLP, Baltimore, Maryland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_011"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of and for the years ended December 31, 2023 and 2022, included in this prospectus have been audited by Marcum
LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph relating
to substantial doubt about our ability to continue as a going concern as described in Note 1 to the financial statements), appearing
elsewhere in this prospectus, and are included in reliance upon such report given on the authority of such firm as experts in accounting
and auditing. Marcum LLP was dismissed as auditors on April 29, 2024 and, accordingly, have not performed any audit or review procedures
with respect to any financial statements appearing in this prospectus for the periods after the date of their dismissal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Tevogen Bio Inc. as of December 31, 2023 and 2022, and for the years then ended, have been included herein
and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing
elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December
31, 2023, financial statements contains an explanatory paragraph that states that Tevogen Bio Inc&#8217;s losses and negative cash flows
from operations since inception raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The financial
statements do not include any adjustments that might result from the outcome of that uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_012"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of Common Stock and
Warrants offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information
set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the shares
of Common Stock and Warrants offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto.
Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the
registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text
of such contract or other document filed as an exhibit to the registration statement. We file periodic reports, proxy statements, and
other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements
and other information about registrants, like us, that file electronically with the SEC. The address of that site is <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_013"></span>INDEX
TO FINANCIAL STATEMENTS<sup></sup></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Semper
Paratus Acquisition Corporation Financial Statements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 91%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID # 688)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_002">Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_003">Statements of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_004">Statements of Changes in Shareholders&#8217; Deficit</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_005">Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_006">Notes to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-8</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tevogen
Bio Holdings Inc. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unaudited
    Consolidated Financial Statements</i></b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#dda_001">Balance Sheets, March 31, 2024 and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#dda_002">Statements of Operations, Three months ended March 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-25</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#dda_003">Statements of Changes in Stockholders&#8217; Deficit, Three months ended March 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-26</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#dda_004">Statements of Cash Flows, Three months ended March 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-27</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#dda_005">Notes to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-28</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 91%; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audited
    Financial Statements</i></b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_002">Balance Sheets, December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_003">Statements of Operations, Years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_004">Statements of Changes in Stockholders&#8217; Deficit, Years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_005">Statements of Cash Flows, Years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_006">Notes to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-43</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 156; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEMPER
PARATUS ACQUISITION CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID # 688)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="#s_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="#s_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="#s_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Changes in Shareholders&#8217; Deficit</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="#s_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><a href="#s_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8    &#8211; F-23</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">To the Shareholders and Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Tevogen Bio Holdings Inc. (f/k/a Semper Paratus Acquisition
Corporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have audited the accompanying balance sheets of
Semper Paratus Acquisition Corporation (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related statements of operations,
stockholders&#8217; deficit and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States
of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Explanatory Paragraph &#8211; Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. As described in Note 1 to the financial statements, the
Company is a Special Purpose Acquisition Corporation that was formed for the purpose of completing a merger, capital stock exchange, asset
acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Company entered
into a definitive merger agreement with a business combination target on June 28, 2023; which was completed on February 14, 2024. As described
in Note 1, the Company needs to raise additional funds to sustain its operations. These conditions raise substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcum LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum <span style="font-variant: small-caps">llp</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2021<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, CA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 26,
2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB
ID # 688</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_002"></span>SEMPER
PARATUS ACQUISITION CORPORATION<br/>
BALANCE
SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_zmjKYIjrpyCa" summary="xdx: Statement - Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zSnxZwN4Bag6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zCKP2lUbdy4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zOxa3GSR6bm1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zR8nrtxfZJGe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Cash_i02I_pp0p0_maACzqLs_zkIkGnrxGx3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000042" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,835</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherReceivablesNetCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzqLs_zEvowcmx8Or6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000045" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">344,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0046">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzqLs_zPZ84rjDZ5j5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,501</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">145,170</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzqLs_maAzN8a_zajOvyfyYRWg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">355,836</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">274,356</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzN8a_zjMhvqo5cbpc" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Property and equipment, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0_maAzN8a_zcDExJIKR0c7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Right-of-use assets - operating leases</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTransactionCosts_i01I_pp0p0_maAzN8a_ziUFMwMp4BC7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Deferred transaction costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherAssetsNoncurrent_i01I_pp0p0_maAzN8a_zuKq1zEvbmed" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsHeldInTrustNoncurrent_i01I_pp0p0_maAzN8a_zIOjrOyLUPsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and marketable securities held in Trust Account</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,681,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2022-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">356,864,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_iTI_pp0p0_mtAzN8a_zDR3qCJ0L6of" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,037,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">357,138,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0_maLCz5EQ_zjkgp62Z2Oe5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,142,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">210,454</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCz5EQ_zjfel6y2Wldj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCz5EQ_zzCMvgOG4BEb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCz5EQ_z97G4cWJ5jo2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_pp0p0_maLCz5EQ_zs3cFNoktGm5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pp0p0_maLCz5EQ_zEtgXB20wUFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note payable, net of discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,631,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_maLCz5EQ_zF7jQwgmNfFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Due to affiliate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCz5EQ_maLzlxu_zbMgedgbbaPc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,004,130</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,454</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_i01I_pp0p0_maLzlxu_z1w5itFfBP2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" contextRef="AsOf2022-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleLongTermNotesPayable_i01I_pp0p0_maLz1lF_maLzlxu_zVObvzvyd2uj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0_maLz1lF_maLzlxu_znBBtbl8YZde" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_pp0p0_maLz1lF_maLzlxu_z0hY2PVwdQR4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredOfferingCostsNoncurrent_i01I_pp0p0_maLzlxu_z4nTateU1uc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred underwriting fee payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,700,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,700,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Liabilities_i01TI_pp0p0_mtLzlxu_maLASEzzKl_zKjoIL4MA00j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,733,130</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,057,704</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzzKl_zDqwJatwa923" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--TemporaryEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">REDEEMABLE ORDINARY SHARES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i02I_pp0p0_maLASEzzKl_zQiLTUAqn7o2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Class A ordinary shares subject to possible redemption, $<span id="xdx_90B_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKfrZd8si6Aj" title="Temporary equity, par value (in dollar per share)"><span id="xdx_90E_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zYETLMHipUN9" title="Temporary equity, par value (in dollar per share)"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
    par value, <span id="xdx_903_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zSKwYQJ2dyd1" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,502,180</ix:nonFraction></span>
    and <span id="xdx_900_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zljp0Rk4OK2e" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,500,000</ix:nonFraction></span> shares at redemption value of $<span id="xdx_900_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_pp2d_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zUBiDkDkbC02" title="Temporary equity, redemption price (In Dollar per share)"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000137" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">11.10</ix:nonFraction></span>
    and $<span id="xdx_902_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_pp2d_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zNL2XR7yZHp9" title="Temporary equity, redemption price (In Dollar per share)"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000139" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">10.34</ix:nonFraction></span>
    per share as of December 31, 2023 and 2022, respectively</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,681,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">356,864,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_i01B_zNrqaTE1A5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">SHAREHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEzCcl_zqnmlRiULUJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zdlpotj67yBb" title="Preferred stock, par value (in dollar per share)"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zC7HI7CZxTr6" title="Preferred stock, par value (in dollar per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zJxNGJ7F7Jyf" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zfvsYdTzhJ1i" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_dn_c20231231_zOdIRTrLEvW" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20231231_zyJnuFpTO5we" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_zUuOQbBOTRw7" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20221231_zjgIu9SOBRy7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000155" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000157" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000159" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000161" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued or outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzCcl_zApiqMj1otW" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock, $0.0001 par value; 800,000,000 shares authorized; 164,614,418 and 119,999,989 shares issued and outstanding at March 31,
2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ClassAOrdinaryShares_i02I_pp0p0_maSEzCcl_z9bVa1rZ8RT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Class A ordinary shares; $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z8os8fRF0ab3" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_znE1N4HCxM" title="Ordinary shares, par value (In Dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkXx5IoY5tR6" title="Ordinary shares, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbDf8WTKgbV5" title="Ordinary shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zwTOcPThyqce" title="Ordinary shares, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzLdvOe28Mre" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,433,333</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_znM0brsY7PJc" title="Ordinary shares, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCAK11zSAoyd" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding (excluding <span id="xdx_900_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zTxdXdAMFev3" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,502,180</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zY2CDSv1NgHd" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,500,000</ix:nonFraction></span> shares subject to possible redemption) as of December 31, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ClassAOrdinaryShares" contextRef="AsOf2023-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ClassAOrdinaryShares" contextRef="AsOf2022-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">145</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ClassBOrdinaryShares_i02I_pp0p0_maSEzCcl_zi163GWATl17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Class B ordinary shares; $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zILQyLmfeuk2" title="Ordinary shares, par value (in dollar per share)"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z8Jny3Zrckc9" title="Ordinary shares, par value (in dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
    par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zI8YF4XWUZVj" title="Ordinary shares, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zr8O6WXQ4yif" title="Ordinary shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized; <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z0lCXpT6EXAg" title="Ordinary shares, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z3SEPvGBk9Uj" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zwGSl20qyx7c" title="Ordinary shares, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zKxiuYDp4hMc" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ClassBOrdinaryShares" contextRef="AsOf2022-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzCcl_zBMEFiULskv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">17,378,637</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">14,784,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzCcl_zEUarqnRMbW7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Additional paid-in capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzCcl_maLASEzzKl_zPnoF4GaAWya" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; deficit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">17,377,294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">14,783,348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzzKl_zMIJbEvPvBoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS&#8217; DEFICIT</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,037,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">357,138,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_003"></span>SEMPER
PARATUS ACQUISITION CORPORATION<br/>
STATEMENTS
OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zdlhfH8Piinc" summary="xdx: Statement - Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zG3SHhqRPWW4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_ztKhIqQt8cxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">For the</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">For the</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_maCAEzC6g_zOrUK1mPmMN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,273,970</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">953,083</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_maCAEzC6g_zhwY4f17mtS2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostsAndExpenses_iNT_pp0p0_di_mtCAEzC6g_msNILz1G2_zWUalsvmv41a" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,273,970</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-012022-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">953,083</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--UnrealizedGainLossOnInvestments_i01_pp0p0_maNIEz8KX_zQQ5zah8AJgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized gain on investments held in Trust Account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2023-01-012023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,734,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,948,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueAdjustmentOfWarrants_i01N_pp0p0_di_msNIEz8KX_zJCjUk6FPhpe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">413,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TransactionCosts_i01N_pp0p0_di_msNIEz8KX_zFMWHOurRryc" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_i01N_pp0p0_di_msNIEz8KX_zmVVZ78b2yJd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ImpairmentOfAmountDueFromRelatedParty_i01NI_pp0p0_di_msNIEz8KX_zJZK5do2wrTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of amount due from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ImpairmentOfAmountDueFromRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_i01N_pp0p0_di_msNIEz8KX_zDx3OTDaviIb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,031</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_mtNIEz8KX_maNILz1G2_zinsaawf4Fk6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,206,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,361,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILz1G2_zLUl9tuvAdb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">67,325</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,408,361</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares outstanding of Class A Ordinary shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJEKx1l4Afkc" title="Weighted average number of shares outstanding ordinary shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zssB81XFizU4" title="Weighted average number of shares outstanding ordinary shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,333,742</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOIP9UIxsoUj" title="Weighted average number of shares outstanding ordinary shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsDRTn5Taf3d" title="Weighted average number of shares outstanding ordinary shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,500,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net income (loss) per share, Class A (redeemable)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjwoWiTSikS8" title="Net loss income per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEfNF57zn3Je" title="Net loss income per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zFdhkTTdWOn5" title="Net loss income per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zralWcyOXKYk" title="Net loss income per share class A  - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares outstanding of Class A Ordinary shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zgr090AoxLia" title="Weighted average number of shares outstanding class A non redeemable - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z9MSqaVVNqf" title="Weighted average number of shares outstanding class A non redeemable - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,317,077</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zfhRl0xsuL3k" title="Weighted average number of shares outstanding class A non redeemable - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z81lUeajlQt8" title="Weighted average number of shares outstanding class A non redeemable - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net income (loss) per share, Class A (non-redeemable)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWYZgGH8cCsl" title="Net loss income per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_ztCaLP1I9ONb" title="Net loss income per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000282" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_" id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zcPz8BLTjWr9" title="Net loss income per share - basic"><b><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zjGGbDaXhEFj" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_" title="Net loss income per share - diluted"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000286" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></b></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares outstanding of Class B Ordinary shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zNgmtTEefvGc" title="Weighted average number of shares outstanding ordinary shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zEV1d9G62Dbl" title="Weighted average number of shares outstanding ordinary shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000288" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,116,256</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zUW5Oc7jf8L3" title="Weighted average number of shares outstanding ordinary shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zfyai8KJgsYe" title="Weighted average number of shares outstanding ordinary shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000294" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted income (loss) per share, Class B</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zkcSF3fF9qj8" title="Net loss income per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zMB0Dicw7dWb" title="Net loss income per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000296" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000298" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpoEV7VXybq7" title="Net loss income per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zzVRw2g6Fddk" title="Net loss income per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_004"></span>SEMPER
PARATUS ACQUISITION CORPORATION<br/>
STATEMENTS
OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEAR ENDED DECEMBER 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_z6iDMLhdf5T6" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassAMember_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zXlbl8K9qkVd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassBMember_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zmbIKizazdrc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zIcsfGNCS7fj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in Capital</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zrqaG8CKF67g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_z4qxm0KOqit" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder&#8217;s Deficit</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Non-redeemable)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in Capital</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder&#8217;s Deficit</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_438_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zQUDTK8BcHtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 37%; font-weight: bold">Balance, December 31, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOEfQG8RMdl" title="Balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWVYN58Srrm4" title="Balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,784,691</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,783,348</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zYw9gHyS2Qdh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of Class B shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2i046tOLTS6" title="Conversion of Class B shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP7fuMfLZkj4" title="Conversion of Class B shares, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,198</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zI1rMCrHxwl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds allocated to Class A shares issuable from the note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccretionOfCarryingValueToRedemptionValue_zO7SOXdPFOOl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">275,306</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,526,621</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2023-01-012023-12-31" id="Fact000334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,801,927</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_ztjhMGtIEqvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zDOVXiG3ovfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoH4KEAm40u3" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,433,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,343</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIZE76yipjtd" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,378,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,377,294</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEAR ENDED DECEMBER 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Additional<br/>
Paid-in Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/>
Shareholder&#8217;s Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_433_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zPn5jRFIVNo7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 37%; font-weight: bold">Balance, December 31, 2021</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsZ7vcHGdy9f" title="Balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000358" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zawpwDiwFf2g" title="Balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,229,052</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,227,709</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zjjzYUTdfeGg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">Balance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBsVKL41fs52" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJoHOYkMdwpb" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,229,052</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,227,709</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
<tr id="xdx_405_ecustom--AccretionOfCarryingValueToRedemptionValue_znjw5zDf70ul" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,964,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000376" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,964,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zCB5GIUyualk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,408,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,408,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zuh1RQOZGJy1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWj0SmXle3xa" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLb62pstPL59" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,784,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,783,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_439_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zWwM8cTzT5G8" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7eKcSqRscK3" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000400" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkLvd34LzFU3" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000397" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,784,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,783,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_005"></span>SEMPER
PARATUS ACQUISITION CORPORATION<br/>
STATEMENTS
OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zjmjssLh2cof" summary="xdx: Statement - Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zfgOh3xLP5Ie" style="font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zqqHOTCjUC9b" style="font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzLn6_ziR8SWMWgLJi" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net (loss) income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000407" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">67,325</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,408,361</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net (loss) income to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--UnrealizedGainLossOnInvestments_i02N_pp0p0_di_msNCPBUzLn6_zFMxske4PJM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized gain on investments held in Trust Account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2023-01-012023-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,734,426</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000414" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,948,194</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--NoncashInterestExpenses_i02_pp0p0_maNCPBUzLn6_zSgNoorBoH9j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="TVGN:NoncashInterestExpenses" contextRef="From2023-01-012023-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,031</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ImpairmentOfAmountDueFromRelatedParty_i02_pp0p0_maNCPBUzLn6_zUk8i0iZJK2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment of amount due from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ImpairmentOfAmountDueFromRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000419" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzLn6_zLWfsA0Sam7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000422" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">413,250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzLn6_znWVxIBZYX6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">142,669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">446,609</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInDueFromRelatedPartiesCurrent_i03N_di_msNCPBUzLn6_zXIx4JfjCuvf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" contextRef="From2023-01-012023-12-31" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInDueToAffiliatesCurrent_i03_pp0p0_maNCPBUzLn6_zaO0hWtoJAEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due to affiliate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToAffiliatesCurrent" contextRef="From2023-01-012023-12-31" id="Fact000434" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToAffiliatesCurrent" contextRef="From2022-01-012022-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_pp0p0_maNCPBUzLn6_zNtGKyptpy6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000437" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">931,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">171,079</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_maCCERCz6q2_mtNCPBUzLn6_ziga6vuFH6G7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000440" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,376,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">215,395</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ExtensionAmountDepositedIntoTrustAccount_i01N_di_msNCPBUzooL_zetqL2X3HZVh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Extension amount deposited into Trust Account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ExtensionAmountDepositedIntoTrustAccount" contextRef="From2023-01-012023-12-31" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_i01_pp0p0_maNCPBUzooL_zvsAtH1WubJg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash withdrawn from Trust Account in connection with redemption</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" contextRef="From2023-01-012023-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">342,984,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzooL_maCCERCz6q2_zBh7qePgmCw" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000452" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">342,916,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUzpSf_zHkvnxQ6LU85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,323,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsForRepurchaseOfCommonStock_i01N_pp0p0_di_msNCPBUzpSf_zwx0b0erQDqa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Redemption of ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">342,984,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUzpSf_maCCERCz6q2_znGFZp0kVH41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">341,660,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCCERCz6q2_zF4PLtGU1LQh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Change in Cash</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">120,351</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">215,395</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash &#8211; Beginning</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">344,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Cash &#8211; Ending</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,835</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,186</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of noncash activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_i01_zznUjZKlkxze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in value of Class A ordinary shares subject to redemption amount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" contextRef="From2023-01-012023-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,801,927</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" contextRef="From2022-01-012022-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,964,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SaleOfClassBSharesToInvestor_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Sale of Class B shares to Investor</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:SaleOfClassBSharesToInvestor" contextRef="From2023-01-012023-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,955,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SaleOfWarrants_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Sale of warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:SaleOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p id="xdx_04E_c20230101__20231231_z2ILORLRXEw1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000488" name="us-gaap:NatureOfOperations"><p id="xdx_808_eus-gaap--NatureOfOperations_zDJFUh9gK4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_006"></span>Note
1 &#8212; <span id="xdx_82B_zbRh0MYh8YDi">Description of Organization, Business Operations and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semper
Paratus Acquisition Corporation (the &#8220;Company&#8221;) was incorporated as a Cayman Islands exempted company on April 21, 2021.
The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with <span id="xdx_907_ecustom--ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_dc_uInteger_c20230101__20231231_zMWGIEMfvKxj" title="Condition for future business combination number of businesses minimum"><ix:nonFraction name="TVGN:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" contextRef="From2023-01-012023-12-31" id="Fact000490" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></span> or more businesses (the &#8220;Business Combination&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company
is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and
emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023, relates to the Company&#8217;s
formation and Initial Public Offering (&#8220;IPO&#8221;), which is described below, and the search for a prospective initial Business
Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at
the earliest. The Company will generate non-operating income in the form of interest income earned on investments from the proceeds derived
from the IPO. The registration statement for the Company&#8217;s IPO was declared effective on November 3, 2021. On November 8, 2021,
the Company consummated the IPO of <span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_pid_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLHmTymUPMXd" title="Units Issued During Period, Shares, New Issues"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2021-11-082021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000492" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span> units (&#8220;Units&#8221;) with respect to the ordinary shares included in the Units being
offered (the &#8220;Public Shares&#8221;) at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNGHyHlxNe89" title="Purchase price, per unit"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit generating gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjIs6le75hF" title="Proceeds from Issuance Initial Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-11-082021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000,000</ix:nonFraction></span>, which is discussed in Note 3.
The company has selected December 31 as its fiscal year end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the IPO, the Company consummated the sale of <span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq6Kw3dFp78a" title="Units Issued During Period, Shares, New Issues"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember" id="Fact000498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,360,000</ix:nonFraction></span> private placement units (&#8220;Private Placement Units&#8221;)
at a price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbYk6jXFSDU4" title="Purchase price, per unit"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-11-08_us-gaap_PrivatePlacementMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Private Placement Unit in a private placement to the Company&#8217;s sponsor, Semper Paratus Sponsor LLC (the
&#8220;Original Sponsor&#8221;) and underwriter Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) generating gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaiAenvmmHFe" title="Proceeds from Issuance Initial Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,600,000</ix:nonFraction></span>
which is described in Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the IPO, the Company consummated the closing of the sale of <span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBqlRFJutaP6" title="Units issued during period, shares new"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2021-11-082021-11-08_us-gaap_OverAllotmentOptionMember" id="Fact000504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500,000</ix:nonFraction></span> additional Units upon receiving notice of the
underwriter&#8217;s election to fully exercise its overallotment option (&#8220;Overallotment Units&#8221;), generating additional gross
proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zyVOD8AzgT2c" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-11-082021-11-08_us-gaap_OverAllotmentOptionMember" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000,000</ix:nonFraction></span> and incurring additional offering costs of $<span id="xdx_90A_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zcZlqCYYSBH" title="Deferred offering costs noncurrent"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrent" contextRef="AsOf2021-11-08_us-gaap_OverAllotmentOptionMember" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,700,000</ix:nonFraction></span> in underwriting fees all of which are deferred until completion
of the Company&#8217;s Business Combination. Simultaneously with the exercise of the overallotment, the Company consummated the Private
Placement of an additional <span id="xdx_900_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zDYXZViuAVrl" title="Common equity securities"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember_custom_SponsorMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></span> Private Placement Units to the Original Sponsor, generating gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zSlgdCB6G0e7" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember_custom_SponsorMember" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs for the IPO amounted to $<span id="xdx_90D_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zM0kMRZ02hRe"><ix:nonFraction name="TVGN:TransactionCosts" contextRef="From2021-11-082021-11-08_us-gaap_IPOMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,266,594</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
consisting of $<span id="xdx_90E_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6hPQ2q0R0Ue"><ix:nonFraction name="TVGN:SaleOfStockUnderwritingFees" contextRef="From2021-11-082021-11-08_us-gaap_IPOMember" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of paid underwriting fees, $<span id="xdx_90E_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCkiu10bqmKi"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrent" contextRef="AsOf2021-11-08_us-gaap_IPOMember" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,700,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of deferred underwriting fees payable (which
are held in the Trust Account (defined below)) and $<span id="xdx_90A_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zoUEDVkE0YGh" title="Other offering costs"><ix:nonFraction name="TVGN:SaleOfStockOtherOfferingCosts" contextRef="AsOf2021-11-08_us-gaap_IPOMember" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,594</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of other costs. On June 28, 2023, the Company
and Cantor entered into a fee reduction agreement (the &#8220;Fee Reduction Agreement&#8221;), pursuant to which Cantor agreed to forfeit
$<span id="xdx_90F_ecustom--DeferredOfferingCostsNoncurrentForfeited_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zn4kU3FxyPk9" title="Deferred underwriting fees"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrentForfeited" contextRef="AsOf2023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,700,000</ix:nonFraction></span> of the deferred underwriting fees payable, resulting in a remainder of $<span id="xdx_909_ecustom--DeferredOfferingCostsNoncurrent_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zEO3SgCutDUk" title="Deferred offering costs non current"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrent" contextRef="AsOf2023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> of deferred underwriting fees payable (the
&#8220;Reduced Deferred Fee&#8221;) by the Company to Cantor upon the closing of the Transaction (as defined below) with Tevogen Bio
Inc (&#8220;Tevogen Bio&#8221;), such fee payable to Cantor in the form of <span id="xdx_903_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230628__20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zzt6gdXHo7od" title="Common equity securities"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-282023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember" id="Fact000523" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of the common equity securities of the entity
surviving the Transaction. The Fee Reduction Agreement only applies to the consummation of the Transaction with Tevogen Bio and no other
potential Business Combinations that may be contemplated or consummated by the Company. In the event that the Company were not to complete
the Transaction with Tevogen Bio, the Original Deferred fee would become due and payable by the Company to Cantor as originally set forth
in the Underwriting Agreement, upon the consummation of a Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the IPO, $<span id="xdx_908_ecustom--PaymentsForInvestmentOfCashInTrustAccount_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3KspCMAjPDj" title="Payments for investment of cash in trust account"><ix:nonFraction name="TVGN:PaymentsForInvestmentOfCashInTrustAccount" contextRef="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,900,000</ix:nonFraction></span> ($<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMPFV6fwpes3" title="Purchase price, per unit"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember" id="Fact000527" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.20</ix:nonFraction></span> per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement
Units was placed in a trust account (&#8220;Trust Account&#8221;) and will be invested in U.S. government securities, within the meaning
set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity
of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting
the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until
the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale
of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating
a Business Combination. As of December 31, 2023, there is no assurance that the Company will be able to complete a Business Combination successfully. The Company
must complete one or more initial Business Combinations having an aggregate fair market value of at least <span id="xdx_909_ecustom--ConditionForFutureBusinessCombinationUseOfProceedsPercentage_iI_dp_uPure_c20231231_z45et9GfPFY7" title="Condition for future business combination use of proceeds percentage"><ix:nonFraction name="TVGN:ConditionForFutureBusinessCombinationUseOfProceedsPercentage" contextRef="AsOf2023-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the assets held in the
Trust Account excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of
the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction
company owns or acquires <span id="xdx_90C_ecustom--ConditionForFutureBusinessCombinationThresholdPercentageOwnership_iI_pid_dp_c20231231_z76yREbwvLV6" title="Condition for future business combination threshold ownership (as a percent)"><ix:nonFraction name="TVGN:ConditionForFutureBusinessCombinationThresholdPercentageOwnership" contextRef="AsOf2023-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest
in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will provide the holders of the outstanding Public Shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem
all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting
called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder
approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to
redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZaHgeiI0YXh" title="Purchase price, per unit"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_us-gaap_IPOMember" id="Fact000533" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.20</ix:nonFraction></span> per Public
Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to
the Company&#8217;s warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s
liquidation, if there is a shareholder vote or tender offer in connection with the Company&#8217;s Business Combination and in connection
with certain amendments to the Company&#8217;s amended and restated memorandum and articles of association (the &#8220;Memorandum and
Articles of Association&#8221;). In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 480-10-S99, redemption provisions
not solely within the control of a company require Class A ordinary shares subject to redemption to be classified outside of permanent
equity. Given that the Public Shares were issued with other freestanding instruments (i.e., public warrants), the initial carrying value
of ordinary shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The ordinary shares
are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either
(i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that
the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting
period. The Company has elected to recognize the changes immediately. While redemptions cannot cause the Company&#8217;s net tangible
assets to fall below $<span id="xdx_901_ecustom--ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_iI_c20231231_zqwayskvZtv6" title="Net tangible assets"><ix:nonFraction name="TVGN:ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" contextRef="AsOf2023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,001</ix:nonFraction></span>, the Public Shares are redeemable and are classified as such on the balance sheet until such date that
a redemption event takes place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemptions
of the Company&#8217;s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to
an agreement relating to the Company&#8217;s Business Combination. If the Company seeks shareholder approval of the Business Combination,
the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination,
or such other vote as required by law or stock exchange rule. If a shareholder vote is not required by applicable law or stock exchange
listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant
to its Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender
offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required
by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other
reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant
to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed
to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business
Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective
of whether they vote for or against the proposed transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2023, shareholders (the &#8220;Initial Shareholders&#8221;) holding all of the issued and outstanding Class B ordinary shares
(the &#8220;Founder Shares&#8221;) of the Company elected to convert their Class B ordinary shares into Class A ordinary shares of the
Company on a <span id="xdx_907_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_zeBYVwN7gdDk" title="Conversion ratio"><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="From2023-01-302023-01-30" id="Fact000537" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span>-for-one basis (the &#8220;Conversion&#8221;). As a result, <span id="xdx_90D_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z2ZYNNSqJV0e" title="Shares cancelled"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-01-302023-01-30_us-gaap_CommonClassBMember" id="Fact000539" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></span> of the Company&#8217;s Class B ordinary shares
were cancelled and <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqQyyjgoU3Cc" title="Shares issued upon conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-01-302023-01-30_us-gaap_CommonClassAMember" id="Fact000541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></span> Class A ordinary shares were issued to such converting Class B shareholders. The Initial Shareholders agreed
that all of the terms and conditions applicable to the Founder Shares set forth in the Letter Agreement, dated November 3, 2021, by and
among the Company, its officers, its directors and the Initial Shareholders (the &#8220;Letter Agreement&#8221;), shall continue to apply
to the Class A ordinary shares that the Founder Shares converted into, including the voting agreement, transfer restrictions and waiver
of any right, title, interest or claim of any kind to the Trust Account (as defined in the Letter Agreement) or any monies or other assets
held therein. Following the Conversion, on January 30, 2023, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zP1gjbscAhqh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-01-30_us-gaap_CommonClassAMember" id="Fact000543" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,933,333</ix:nonFraction></span> Class A ordinary shares issued and outstanding
and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgySFaZSCsnl" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zwX2xLaD0Bne" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-01-30_us-gaap_CommonClassBMember" id="Fact000545" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-01-30_us-gaap_CommonClassBMember" id="Fact000547" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> Class B ordinary shares issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 3, 2023, the Company&#8217;s shareholders approved an amendment (the &#8220;First Extension Charter Amendment&#8221;) to the
Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial
Business Combination from February 8, 2023 to December 15, 2023. Under Cayman Islands law, the First Extension Charter Amendment took
effect upon approval by the shareholders. In connection with the meeting, shareholders holding approximately <span id="xdx_904_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_z33fQd6UXHD2" title="Minimum period to file charter amendment"><ix:nonFraction name="TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" contextRef="AsOf2023-02-03_custom_FirstExtensionCharterAmendmentMember_custom_PublicSharesMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32,116,947</ix:nonFraction></span> Public Shares
exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember_zqFSwarHdFjd" title="Cash withdrawn from Trust Account in connection with redemption"><ix:nonFraction name="TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" contextRef="From2023-02-022023-02-03_custom_FirstExtensionCharterAmendmentMember" id="Fact000551" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">333</ix:nonFraction></span>
million (approximately $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrnaTqrsici1" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-02-03_custom_FirstExtensionCharterAmendmentMember_custom_PublicSharesMember" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.38</ix:nonFraction></span> per Public Share) was removed from the Trust Account to pay such holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 14, 2023, the Company&#8217;s shareholders approved an amendment (the &#8220;Second Extension Charter Amendment&#8221;) to the
Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial
Business Combination to September 15, 2024. Under Cayman Islands law, the Second Extension Charter Amendment took effect upon approval
by the shareholders. In connection with the meeting, shareholders holding approximately <span id="xdx_90A_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zXYa3o808VCk" title="Minimum period to file charter amendment"><ix:nonFraction name="TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" contextRef="AsOf2023-12-14_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">880,873</ix:nonFraction></span> Public Shares exercised their right to
redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<span id="xdx_90F_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn4n6_c20231214__20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember_zt1tLSiARXGi" title="Cash withdrawn from trust account in connection with redemption"><ix:nonFraction name="TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" contextRef="From2023-12-142023-12-14_custom_SecondExtensionCharterAmendmentMember" id="Fact000557" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">9.71</ix:nonFraction></span> million (approximately
$<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrf2ccm725nh" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-14_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.03</ix:nonFraction></span> per Public Share) was removed from the Trust Account to pay such holders. Approximately $<span id="xdx_907_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pn5n6_c20231231_zQKEGPZSGhh3" title="ash and marketable securities held in Trust Account"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2023-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.7</ix:nonFraction></span> million remained in the Trust Account
as of December 31, 2023 and the Company had <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zLJ4vIkIdKbh" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember" id="Fact000563" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,502,180</ix:nonFraction></span> public shares outstanding as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with SSVK Associates, LLC (the &#8220;Sponsor&#8221;)
and the Original Sponsor, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zH5jDdhu5VY7" title="Stock issued during period, Shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember" id="Fact000565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,988,889</ix:nonFraction></span> Class A ordinary shares
and (y) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zlLyy02ze1qi" title="Stock issued during period, Shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_PrivatePlacementMember_custom_SsvkAssociatesLlcMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that
is exercisable for one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter
Agreement, dated November 3, 2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement,
dated November 3, 2021, by and between the Company and Cantor, as representative of the several underwriters (the &#8220;Underwriting
Agreement&#8221;)), for an aggregate purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zVaC2L3t6W2e" title="Purchase price, per unit"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> (the &#8220;Purchase Price&#8221;) payable at the time of the initial Business
Combination (see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder
or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section 13 of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more
than an aggregate of <span id="xdx_907_ecustom--RedemptionLimitPercentageWithoutPriorConsent_dp_uPure_c20230101__20231231_ztHl250zlGz5" title="Redemption limit percentage without prior consent"><ix:nonFraction name="TVGN:RedemptionLimitPercentageWithoutPriorConsent" contextRef="From2023-01-012023-12-31" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% or more of the ordinary shares sold in the IPO, without the prior consent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Shareholders have agreed not to propose an amendment to the Memorandum and Articles of Association that would affect the substance
or timing of the Company&#8217;s obligation to redeem <span id="xdx_905_ecustom--PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_dp_uPure_c20230101__20231231_z7I1R0qtqSv7" title="Obligation to redeem public shares if entity does not complete a business combination (as a percent)"><ix:nonFraction name="TVGN:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="From2023-01-012023-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of its Public Shares if the Company does not complete a Business Combination,
unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such
amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company is unable to complete a Business Combination by September 15, 2024 (&#8220;Combination Period&#8221;), the Company will (i)
cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days
thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account including interest earned on the funds held in the Trust Account and not previously released to us to pay the Company&#8217;s
franchise and income taxes (less up to $<span id="xdx_909_ecustom--MaximumAllowedDissolutionExpenses_c20230101__20231231_zVAJkI5epihf" title="Maximum allowed dissolution expenses"><ix:nonFraction name="TVGN:MaximumAllowedDissolutionExpenses" contextRef="From2023-01-012023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> of interest to pay dissolution expenses), divided by the number of then outstanding Public
Shares, which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive
further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the Company&#8217;s remaining shareholders and the Company&#8217;s board of directors, dissolve and liquidate,
subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. On December 18, 2023, the Company deposited $<span id="xdx_902_eus-gaap--AssetsHeldInTrust_iI_c20231218_zVShfNGa696i" title="Extension amount deposited into Trust Account"><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="AsOf2023-12-18" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,500</ix:nonFraction></span> into the Trust Account in order to extend the date by which
the Company has to complete the initial business combination by three months from December 14, 2023, to March 15, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete
a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the
IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails
to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to its deferred
underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within
the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be
available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of
the residual assets remaining available for distribution (including Trust Account assets) will be only $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNODw1vph2m4" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_us-gaap_IPOMember" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.20</ix:nonFraction></span> per share held in the Trust
Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the
extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the
Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not
apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any
monies held in the Trust Account or to any claims under the Company&#8217;s indemnity of the underwriters of the IPO against certain
liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the
event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent
of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify
the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&#8217;s independent
registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements
waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i> Business Combination</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On June 28, 2023, the Company entered into an Agreement
and Plan of Merger by and among the Company, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company
(&#8220;Merger Sub&#8221;), the Sponsor, in its capacity as purchaser representative, Tevogen Bio, and Ryan Saadi, in his capacity as
seller representative (as may be amended and/or restated from time to time, the &#8220;Merger Agreement&#8221;), pursuant to which, among
other things, the parties will affect the merger of Merger Sub with and into Tevogen Bio, with Tevogen Bio continuing as the surviving
entity (the &#8220;Merger&#8221;), as a result of which all of the issued and outstanding capital stock of Tevogen Bio shall be exchanged
for shares of Class A common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230628__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zDptEao3aUA7" title="Ordinary shares, par value (in dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-28_us-gaap_CommonClassAMember" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;Class A Common Stock&#8221;), of the Company (the &#8220;Share
Exchange&#8221;) subject to the conditions set forth in the Merger Agreement, with Tevogen Bio surviving the Share Exchange as a wholly
owned subsidiary of the Company (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the &#8220;Transaction&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On September 14, 2023, the Company filed a registration
statement on Form S-4 with the SEC relating to the Transaction with Tevogen, and on February 14, 2024, the Company consummated the Transaction. See Note 10 for more information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action,
various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further,
the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements
and the specific impact on the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as
of the date of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had $<span id="xdx_906_eus-gaap--Cash_iI_c20231231_zODOpYi3K2e6" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,835</ix:nonFraction></span> in its operating bank accounts, $<span id="xdx_906_eus-gaap--AssetsHeldInTrustNoncurrent_iI_c20231231_z9lqJZcCJUD4" title="Assets held in trust noncurrent"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2023-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,681,497</ix:nonFraction></span> in cash held in the
Trust Account to be used for a Business Combination or to repurchase or redeem its ordinary shares in connection therewith and working
capital deficit of $<span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_c20231231_zSxmpiZut0Td" title="Working capital deficit"><ix:nonFraction name="TVGN:WorkingCapitalDeficit" contextRef="AsOf2023-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,648,294</ix:nonFraction></span>. As of December 31, 2023, approximately $<span id="xdx_903_eus-gaap--InvestmentIncomeInterest_c20230101__20231231_zlzvEPktqM16" title="Investment income interest"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-012023-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,734,000</ix:nonFraction></span> of the amount on deposit in the Trust Account represented
interest income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company management believes that cash on hand following
consummation of the Transaction as well as $<span id="xdx_904_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7QPqAiWlDL"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction>
</span>to the Company from a Series A Preferred Stock financing in February 2024 and $<span id="xdx_905_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zt1yebqOBlpe"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></span> in connection with the Series A-1
Preferred Stock financing thereafter (see Note 10) is not sufficient to sustain planned operations for 12 months from the issuance
date of these financial statements. As a result, the Company has concluded that substantial doubt exists about its ability to continue
as a going concern for one year from the date that these financial statements are issued. The accompanying financial statements have
been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course
of business. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Management is currently evaluating different strategies to obtain the additional
funding for future operations for subsequent years. These strategies may include but are not limited to private placements of equity and/or
debt, licensing and/or marketing arrangements, and public offerings of equity and/or debt securities. The Company may not be able to obtain
financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable
terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000593" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zNRCBCcrYlWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8212; <span id="xdx_82A_z09laoPAkQZ3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000595" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDufdfSqr987">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000597" name="TVGN:EmergingGrowthCompanyPolicyPolicyTextBlock"><p id="xdx_840_ecustom--EmergingGrowthCompanyPolicyPolicyTextBlock_zPTHX6hDDIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z51bx9GmNCf6">Emerging
Growth Company</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for
public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company
nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000599" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zzoVedJkZirl">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000601" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zpjGtuKXUP3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjW2yciTNI63">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_z8n1KGVCSxn" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zjnpuZTVh3Wb" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000603" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000605" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000607" name="TVGN:AssetsHeldInTrustAccountPolicyPolicyTextBlock"><p id="xdx_844_ecustom--AssetsHeldInTrustAccountPolicyPolicyTextBlock_ztBsSHZlY6w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zoaPRIdCAmoa">Investments
Held in Trust Account</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, substantially all of the assets held in the Trust Account were held in a demand deposit cash account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">At December
31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company&#8217;s investments
held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at
the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included
in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values
of investments held in Trust Account are determined using available market information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000609" name="TVGN:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock"><p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_zCwy56mbqjbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zCXACvIfWnUi">Offering
Costs associated with the Initial Public Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs, including additional underwriting fees associated with the underwriters&#8217; exercise of the over-allotment option, consist
principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable
to the underwriters&#8217; exercise of the over-allotment option in full, amounted to $<span id="xdx_909_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDpn1E4hnJBc" title="Offering costs"><ix:nonFraction name="TVGN:TransactionCosts" contextRef="From2021-11-082021-11-08_us-gaap_IPOMember" id="Fact000611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,266,594</ix:nonFraction></span> consisting of $<span id="xdx_909_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNa6Aky0zUCa" title="Underwriting fees"><ix:nonFraction name="TVGN:SaleOfStockUnderwritingFees" contextRef="From2021-11-082021-11-08_us-gaap_IPOMember" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span> of paid underwriting
fees, $<span id="xdx_90B_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyD2joOQN139" title="Deferred underwriting fee payable"><ix:nonFraction name="TVGN:DeferredOfferingCostsNoncurrent" contextRef="AsOf2021-11-08_us-gaap_IPOMember" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,700,000</ix:nonFraction></span> of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $<span id="xdx_907_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTd94FcM7BSj" title="Other offering costs"><ix:nonFraction name="TVGN:SaleOfStockOtherOfferingCosts" contextRef="AsOf2021-11-08_us-gaap_IPOMember" id="Fact000617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,594</ix:nonFraction></span> of other costs
and was charged to shareholders&#8217; equity upon the completion of the IPO. On June 28, 2023, the Company and Cantor entered into the Fee Reduction
Agreement, pursuant to which Cantor agreed to the Reduced Deferred Fee in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRzNADdXwd9i" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-282023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of the common equity securities of
the entity surviving the Transaction. See Note 1 for more information on the Fee Reduction Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000621" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zcm94hOGvmZ9">Concentration
of Credit Risk</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000625" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_znPUUrddfrUi">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the (&#8220;FASB&#8221;) ASC 820,
&#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000627" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8Ot8VIhkg52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Related
Party Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for amounts due from related parties at historical cost and evaluates the collectability of these receivables for determination
on if impairment should be recognized. In the same manner, the Company evaluated the $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_z3uF8gdQDCwh" title="Impairment of due from related party"><ix:nonFraction name="TVGN:ImpairmentOfAmountDueFromRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> loan to Srirama Associates, LLC and determined
that the amount was uncollectable and therefore recognized an impairment loss, see Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000631" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zkpWCEwQfXz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zLIWqLIv8yUi">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes.&#8221; Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. There were <span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20231231_zVaiAAGIGva9" title="Unrecognized tax benefits"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zF5N2A4rIB24" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact000633" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" id="Fact000635" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized tax benefits as of December 31, 2023 and 2022.
The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. <span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20231231_zrUaDPZSdxM3" title="Unrecognized tax benefits accrued for interest and penalties"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20221231_zurXvR5vPrF5" title="Unrecognized tax benefits accrued for interest and penalties"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="AsOf2023-12-31" id="Fact000637" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="AsOf2022-12-31" id="Fact000639" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> amounts were accrued for the payment of
interest and penalties for the year ended December 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the
Company. Consequently, income taxes are not reflected in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000641" name="TVGN:TemporaryEquityPolicyPolicyTextBlock"><p id="xdx_844_ecustom--TemporaryEquityPolicyPolicyTextBlock_zD0efC8N3eda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zgtCoOZ7zQ9k">Class
A Ordinary Shares Subject to Possible Redemption</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing
Liabilities from Equity.&#8221; Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument
and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#8217;s control) is classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders&#8217;
equity. The Company&#8217;s Public Shares feature certain redemption rights that are considered to be outside of the Company&#8217;s
control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023 and 2022, <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp8ry42IgPWa" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,502,180</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJYI75T357lb" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,500,000</ix:nonFraction></span>, respectively,
Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders&#8217; deficit
section of the Company&#8217;s balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary
share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable
ordinary share are affected by charges against additional paid in capital and accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000647" name="us-gaap:TemporaryEquityTableTextBlock"><p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zMZGt80hTdmi" style="display: none">Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" title="Class A ordinary share subject to possible redemption" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2021-12-31" id="Fact000649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,900,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Class A ordinary share subject to possible redemption" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Class A ordinary share subject to possible redemption" style="text-align: right"><p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" title="Accretion of carrying value to redemption value" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,964,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="Class A ordinary share subject to possible redemption" style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" title="Class A ordinary share subject to possible redemption" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,864,000</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" title="Accretion of carrying value to redemption value" style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2023-01-012023-12-31" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,801,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Redemption of ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" title="Redemption of ordinary shares" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="TVGN:TemporaryEquityRedemptionAmount" contextRef="From2023-01-012023-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">342,984,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class A ordinary share subject to possible redemption, December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" title="Class A ordinary share subject to possible redemption" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,681,497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z1HYxxQQhzOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000661" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zK1LsoVBPXid">Net
Income (Loss) per Ordinary Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#8220;Founder Shares&#8221;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-08_us-gaap_WarrantMember" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,975,000</ix:nonFraction></span> ordinary shares at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-08_us-gaap_WarrantMember" id="Fact000665" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">11.50</ix:nonFraction></span> per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,975,000</ix:nonFraction></ix:nonFraction></span></span> Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000671" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000672" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000674" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">44,186</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000676" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,005</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000678" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,172,916</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000680" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,355</ix:nonFraction></span></td><td style="text-align: left">&#160;</td>
    <td/>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000682" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,102,090</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000686" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,333,742</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,317,077</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,116,256</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">34,500,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000700" format="ixt:numdotdecimal" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,450,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000703" format="ixt:numdotdecimal" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000705" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,983,333</ix:nonFraction></ix:nonFraction></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000713" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td>
    <td/>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000731" name="TVGN:WarrantLiabilitiesPolicyPolicyTextBlock"><p id="xdx_842_ecustom--WarrantLiabilitiesPolicyPolicyTextBlock_z7WEXKlufkK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zVTXpxyIBmS5">Accounting
for Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment
considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own ordinary shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments
are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and Private Placement Warrants
qualify for liability accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000733" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zE8ozL4HOjF7">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#8217;s financial statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000735" name="TVGN:InitialPublicOfferingTextBlock"><p id="xdx_80B_ecustom--InitialPublicOfferingTextBlock_zGP5ttt1Hp11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8212; <span id="xdx_823_zMij8QymoKDa">Initial Public Offering and Over-Allotment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the IPO, the Company sold <span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssue_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of units in initial public offering, gross (in shares ) | shares"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssue" contextRef="From2021-11-082021-11-08_us-gaap_IPOMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,500,000</ix:nonFraction></span> units at a price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp2d" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-11-08_us-gaap_IPOMember" id="Fact000739" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit. Each Unit consists of <span id="xdx_90A_ecustom--NumberOfSharesIssuedPerUnit_dc_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ5lLQYbWgT" title="Number of shares in a unit"><ix:nonFraction name="TVGN:NumberOfSharesIssuedPerUnit" contextRef="From2021-11-082021-11-08_us-gaap_IPOMember" id="Fact000741" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">one</ix:nonFraction></span> ordinary share (such ordinary
shares included in the Units being offered, the &#8220;Public Shares&#8221;), and <span id="xdx_904_ecustom--NumberOfWarrantsIssuedPerUnit_dxL_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAFYDg8NfD6h" title="Number of warrants in a unit::XDX::0.5"><span style="-sec-ix-hidden: xdx2ixbrl0743">one</span></span>-half of one redeemable warrant (each, a &#8220;Public
Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaJHoG2KGFM4" title="Number of shares issuable per warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember" id="Fact000745" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">one</ix:nonFraction></span> ordinary share at a price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVwZvvcFOcrg" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share, subject
to adjustment (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000749" name="TVGN:PrivatePlacementTextBlock"><p id="xdx_805_ecustom--PrivatePlacementTextBlock_zYmNEZKmm2sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8212; <span id="xdx_82E_zp3DtiskTul3">Private Placement Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, simultaneously with the consummation of the IPO and the underwriters&#8217; exercise of their over-allotment option,
the Company consummated the issuance and sale (&#8220;Private Placement&#8221;) of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZcC7XRRaCX3" title="Number of warrants to purchase shares issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></span> units (the &#8220;Private Placement Units&#8221;)
in a private placement transaction at a price of $<span id="xdx_901_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp2d" title="Price of warrants"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact000753" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">10.00</ix:nonFraction></span> per Placement Unit, generating gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0d_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCGPjvAzbm6h" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,500,000</ix:nonFraction></span>. The Private Placement
Units were purchased by Cantor (<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CantorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Number of warrants to purchase shares issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_CantorMember_us-gaap_PrivatePlacementMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> Units) and the Sponsor (<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIT4Fhke8l7h" title="Number of warrants to purchase shares issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,300,000</ix:nonFraction></span> Units). Each Private Placement Unit consisted of one Placement
Share and one-half of a redeemable warrant (&#8220;Placement Warrant&#8221;). Each whole Placement Warrant will be exercisable to purchase
one Class A ordinary share at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zzT20lahBfK7" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact000761" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">11.50</ix:nonFraction></span> per share. A portion of the proceeds from the Private Placement Units was added to the
proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination
Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to
the requirements of applicable law), and the Private Placement Units and all underlying securities will be worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify">On
June 7, 2023, the Original Sponsor transferred <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230607__20230607__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOngJOFWwf9j" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-06-072023-06-07_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Private Placement Units to the Sponsor in connection with the Purchase Agreement
(see Note 6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000765" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z8Gca90BJdx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8212; <span id="xdx_824_z3tPgZy1PhK9">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Founder
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Sponsor paid $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z37xhhFLck0j" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-222021-04-22_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> to cover certain offering costs of the Company in consideration for <span id="xdx_908_eus-gaap--CommonStockDividendsShares_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLqmjGsoo5l" title="Share dividend"><ix:nonFraction name="us-gaap:CommonStockDividendsShares" contextRef="From2021-04-222021-04-22_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></span> Founder Shares which were issued on
April 22, 2021. In August 2021, the Company effectuated a dividend of approximately <span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionRatio_iI_pp4d_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z3fkeWJiaBo8" title="Stock dividend ratio"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="AsOf2021-08-31_custom_FounderSharesMember_us-gaap_CommonClassBMember" id="Fact000771" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">0.3628</ix:nonFraction></span> shares for each outstanding Class B ordinary
share resulting in an aggregate of <span id="xdx_901_ecustom--AggregateNumberOfSharesOwned_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Aggregate number of shares owned"><ix:nonFraction name="TVGN:AggregateNumberOfSharesOwned" contextRef="AsOf2021-08-31_custom_FounderSharesMember_us-gaap_CommonClassBMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,754,150</ix:nonFraction></span> Class B ordinary shares outstanding. On October 1, 2021, the Company effectuated a dividend
of approximately <span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionRatio_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pp4d" title="Stock dividend ratio"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="AsOf2021-10-01_custom_FounderSharesMember_us-gaap_CommonClassBMember" id="Fact000775" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">0.0195</ix:nonFraction></span> shares for each outstanding Class B ordinary share resulting in an aggregate of <span id="xdx_90B_ecustom--AggregateNumberOfSharesOwned_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z8thw2vx3Xzf" title="Aggregate number of shares owned"><ix:nonFraction name="TVGN:AggregateNumberOfSharesOwned" contextRef="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></span> Class B Founder shares
outstanding (up to <span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbbYrYEYOVZ8" title="Shares subject to forfeiture"><ix:nonFraction name="TVGN:NumberOfSharesSubjectToForfeiture" contextRef="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,530,000</ix:nonFraction></span> of which are subject to forfeiture if the underwriters&#8217; over-allotment option is not exercised in
full). The Founder Shares will automatically convert into Class A ordinary shares at the time of the Company&#8217;s initial Business
Combination and are subject to certain transfer restrictions. The initial shareholders had agreed to forfeit up to <span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_za45SZyhmTw5" title="Shares subject to forfeiture"><ix:nonFraction name="TVGN:NumberOfSharesSubjectToForfeiture" contextRef="AsOf2023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,530,000</ix:nonFraction></span> Founder
Shares to the extent that the over-allotment option is not exercised in full by the underwriters. Since the underwriters&#8217; exercised
the over-allotment option in full, no Founder Shares are subject to forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial shareholders will agree, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the
earliest of (A) <span id="xdx_90A_ecustom--RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zTgzZxac35I7" title="Restrictions on transfer period of time after business combination completion"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" format="ixt-sec:durwordsen" id="Fact000783" name="TVGN:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">one year</ix:nonNumeric></span> after the completion of our initial business combination and (B) subsequent to our initial business combination,
(x) if the closing price of our Class A ordinary shares equals or exceeds $<span id="xdx_90C_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_pp2d_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zaSUTpiQeMA5" title="Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)"><ix:nonFraction name="TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" id="Fact000785" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">12.00</ix:nonFraction></span> per share (as adjusted for share subdivisions, share
capitalizations, reorganizations, recapitalizations and the like) for any <span id="xdx_90B_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLT4KgYAvK21" title="Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" format="ixt-sec:durday" id="Fact000787" name="TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">20</ix:nonNumeric></span> trading days within any <span id="xdx_901_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znQYiGVJBmgg" title="Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" format="ixt-sec:durday" id="Fact000789" name="TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">30</ix:nonNumeric></span>-trading day period commencing
at least <span id="xdx_905_ecustom--ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqLhRrOgfY3k" title="Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember" format="ixt-sec:durday" id="Fact000791" name="TVGN:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">150</ix:nonNumeric></span> days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange
or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash,
securities or other property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 30, 2023, the initial shareholders holding
all of the Founder Shares elected to convert their Founder Shares into Class A ordinary shares of the Company on a <span id="xdx_90B_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_z6kgaFsCsbi4" title="Conversion ratio"><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="From2023-01-302023-01-30" id="Fact000793" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span>-for-one basis (the
&#8220;Conversion&#8221;). As a result, <span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Shares cancelled"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-01-302023-01-30_us-gaap_CommonClassBMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></span> of the Company&#8217;s Class B ordinary shares were cancelled and <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjOqRKSqb3bl" title="Shares issued upon conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-01-302023-01-30_us-gaap_CommonClassAMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></span> Class
A ordinary shares were issued to such converting Initial Shareholders. The Initial Shareholders agreed that all of the terms and conditions
applicable to the Founder Shares set forth in the Letter Agreement shall continue to apply to the Class A ordinary shares that the Founder
Shares converted into, including the voting agreement, transfer restrictions and waiver of any right, title, interest or claim of any
kind to the Trust Account or any monies or other assets held therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 4, 2023, the Company entered into the Purchase
Agreement, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zqWw1dV3wJTh" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,988,889</ix:nonFraction></span> Class A ordinary shares and (y) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_z0BuF9bT2ri8" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_PrivatePlacementMember_custom_PurchaseAgreementMember_custom_SponsorMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>
Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for
one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Underwriting Agreement), for
an aggregate purchase price of $<span id="xdx_909_ecustom--AggregatePurchasePrice_iI_pp2d_c20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zWdV0O8ECMT" title="Aggregate purchase price"><ix:nonFraction name="TVGN:AggregatePurchasePrice" contextRef="AsOf2023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember" id="Fact000803" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">1.00</ix:nonFraction></span> payable at the time of the initial Business Combination. On June 7, 2023, the Original Sponsor transferred
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zg81rbK0W3c6" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,988,889</ix:nonFraction></span> Class A ordinary shares to the Sponsor, pursuant to the Purchase Agreement (see Note 6). The Company estimated the aggregate
fair values of the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableOrdinaryMember_zm8IjkwCuH2i" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_NonRedeemableOrdinaryMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,988,889</ix:nonFraction></span> Class A non-redeemable ordinary shares, the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230606__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2W0MKjKtkB8" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-062023-06-06_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Private Placement shares, and the <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zamAYC1vlNR6" title="Class of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> public warrants
transferred to be $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zv9xZ9pyUphf" title="Proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,515,111</ix:nonFraction></span>, $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredTwoMember_zeZWU5vFe9Ma" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">440,000</ix:nonFraction></span>, and $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredThreeMember_zwGWLnWeh8If" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredThreeMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>, respectively or $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredOneMember_z8FSFlPAmFBj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredOneMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.44</ix:nonFraction></span> per share and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredTwoMember_zpoAKPyTTn49" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.04</ix:nonFraction></span> per warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000823" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z2fvY4XooUQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The fair value of the Class A non-redeemable shares
was based on the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span id="xdx_8B6_zR8Qc92B1zJ5">Schedule
of Fair Value Non Redeemable Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230503__20230504_zjRvdjmAJfIf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 4, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_zvPeAx7Xrov7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Discount for lack of marketability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="From2023-05-032023-05-04" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.80</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--StockPriceOfMeasurement_pid_z3xkbBKhZqze" style="vertical-align: bottom; background-color: White">
    <td>Stock price as of measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockPriceOfMeasurement" contextRef="From2023-05-032023-05-04" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10.77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProbabilityOfTransactionPercentage_pid_dp_uPure_zhofbGhptox2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of transaction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ProbabilityOfTransactionPercentage" contextRef="From2023-05-032023-05-04" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.40</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zRyKqWehGf5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Party Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2021, the Sponsor agreed to loan the Company an aggregate of up to $<span id="xdx_90A_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_c20210422__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Maximum borrowing capacity of related party promissory note"><ix:nonFraction name="TVGN:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" contextRef="AsOf2021-04-22_custom_PromissoryNoteWithRelatedPartyMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> to cover expenses related to the IPO pursuant to
a promissory note (the &#8220;Note&#8221;). This loan was non-interest bearing and payable on the earlier of December 31, 2021 or the
completion of the IPO. The note payable of $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20211108__20211108__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Amount of notes payable repaid"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-11-082021-11-08_custom_PromissoryNoteWithRelatedPartyMember" id="Fact000833" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,158</ix:nonFraction></span> was repaid on November 8, 2021. As of December 31, 2022, the Company had <span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_do_c20221231_zjdeSA05noib" title="Borrowings amount"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-12-31" id="Fact000835" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> borrowings
under the Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2023, the Company advanced the Sponsor $<span id="xdx_901_ecustom--WorkingCapital_iI_c20231002_zZpXIhQn8Xvf" title="Working capital"><ix:nonFraction name="TVGN:WorkingCapital" contextRef="AsOf2023-10-02" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span>
for working capital purposes. The advances are non-interest bearing and are due on demand. This related party transaction is included on the accompanying balance sheet as a due from related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of December 31, 2023, the remainder of the Second SPAC Loan of $<span id="xdx_901_eus-gaap--PaymentsForAdvanceToAffiliate_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zehGaV6BMI8h" title="Loan from affiliate"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2023-01-012023-12-31_custom_SponsorMember" id="Fact000839" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">577,500</ix:nonFraction></span> is due from the Sponsor. This related
party transaction is included on the accompanying balance sheet as a due from related party. As of December 31, 2023, the Company determined that $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zF9dggB2C5u9" title="Impairment of due from related party"><ix:nonFraction name="TVGN:ImpairmentOfAmountDueFromRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> of the $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z1OlrjQ6gNef" title="Loan from affiliate"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2023-01-012023-12-31_custom_SponsorMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">577,500</ix:nonFraction></span> was deemed to be uncollectible, therefore
the Company recorded impairment totaling $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zXicAIVb55D7" title="Impairment of due from related party"><ix:nonFraction name="TVGN:ImpairmentOfAmountDueFromRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> on the amount due from related party in the other income section of the statement of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2023, the Company and the Original Sponsor entered into a Subscription Agreement with Polar Multi-Strategy Master Fund (the &#8220;Investor&#8221;)
where the Investor agreed to make a cash contribution of $<span id="xdx_902_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zrzfpG4AdEFa" title="Initial capital contribution"><ix:nonFraction name="TVGN:InitialCapitalContribution" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember" id="Fact000847" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,000</ix:nonFraction></span> to the Original Sponsor (the &#8220;Initial Capital Contribution&#8221;)
on or prior to May 3, 2023. The Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover
working capital expenses (the &#8220;First SPAC Loan&#8221;). In consideration for the Initial Capital Contribution, the Company will
issue <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLiyrpFxH8tk" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember" id="Fact000849" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">151,000</ix:nonFraction></span> Class A ordinary shares, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zUh01rxjvlU2" title="Ordinary shares, par value (in dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, of the Company to the Investor at the closing of the initial business
combination (the &#8220;De-SPAC Closing&#8221;). The First SPAC Loan shall not accrue interest and shall be repaid by the Company upon
the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares
of the Company at a rate of one Class A ordinary share for each $<span id="xdx_90D_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zJn5mGhF4Lg3" title="Initial capital contribution"><ix:nonFraction name="TVGN:InitialCapitalContributionPerShare" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember_custom_DeSPACMember" id="Fact000853" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">10.00</ix:nonFraction></span> of Initial Capital Contribution. If the Company liquidates without
consummating the initial business combination, any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the
Company&#8217;s Trust Account, will be paid to the Investor within five days of the liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, the Sponsor and the Company entered into a second subscription agreement (the &#8220;Second Subscription
Agreement&#8221;) with the Investor where the Investor agreed to lend to the Sponsor, which would in turn be lent to the Company, an
aggregate of $<span id="xdx_908_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__dei--LegalEntityAxis__custom--SponsorMember_zppqeb1abZF4" title="Maximum borrowing capacity of related party promissory note"><ix:nonFraction name="TVGN:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" contextRef="AsOf2023-06-20_us-gaap_InvestorMember_custom_SponsorMember" id="Fact000855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span>
(the &#8220;Additional Capital Commitment&#8221;) to cover working capital expenses (the &#8220;Second SPAC Loan&#8221;). One half
of the Additional Capital Commitment was made by the Investor to the Sponsor in cash on or prior to June 21, 2023, and the remaining
$<span id="xdx_906_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_znxv21J0Pl6h" title="Remaining borrowing capacity amount"><ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" contextRef="AsOf2023-06-20_us-gaap_InvestorMember" id="Fact000857" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span>
would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#8217;s request and the first filing of the S-4 for
the Company&#8217;s business combination. In consideration for the Second SPAC Loan, the Company will issue one Class A ordinary
share for each dollar of the Additional Capital Commitment funded by the Investor at the De-SPAC Closing. The Second SPAC Loan shall
not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to
receive such payments in (a) cash or (b) Class A ordinary shares at a rate of one Class A ordinary share for each $<span id="xdx_904_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zVE2avjo7wna" title="Initial capital contribution"><ix:nonFraction name="TVGN:InitialCapitalContributionPerShare" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember_custom_DeSPACMember" id="Fact000859" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">10.00</ix:nonFraction></span>
of Additional Capital Contribution. If the Company liquidates without consummating the initial business combination, any amounts
remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account, will be paid to the
Investor within five days of the liquidation. Collectively, the First SPAC Loan and the Second SPAC Loan are referred to as the SPAC
Loans. As of December 31, 2023, the Company had $<span id="xdx_901_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--SponsorMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zTOfKsdZSv0d" title="Debt instrument, fee amount"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2023-12-31_custom_SponsorMember_us-gaap_InvestorMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></span>
borrowings under the  SPAC Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company accounted for the Class A common stock
they could be converted (&#8220;equity instrument&#8221;) to as equity-classified instruments based on an assessment of the specific
terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the equity instrument is freestanding
financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the equity instrument
meets all the requirements for equity classification under ASC 815, including whether the equity instrument is indexed to the Company&#8217;s
own common stock, among other conditions for the equity classification. This assessment, which requires the use of professional judgment,
was conducted at the time of equity instrument issuance. The SPAC Loans and the equity instrument meet the scope exception of ASC 815-10-15-74(a).
The Company applied the guidance in ASC 470-20-25-2 &#8220;<i>Debt With Conversion and Other Options</i>&#8221;, requiring that the loan
proceeds be allocated to the SPAC Loans based on their relative fair values. At May 3, 2023 the Company allocated $<span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zH5tFmPsSaLe"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember" id="Fact000862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,861</ix:nonFraction>
</span>of the proceeds to the First SPAC Loan and $<span id="xdx_901_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503_znpJNBOUam8b"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-05-032023-05-03" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,139</ix:nonFraction>
</span>for the equity instrument. The Company estimated the aggregate fair value of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zQ5uzwnhioCh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,000</ix:nonFraction>
</span>shares to be issued to be $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zcUJF80uBLxf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,440</ix:nonFraction>
</span>or $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_znJXZYBHVUVg"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-03_custom_FirstPolarFundConvertibleNoteMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.44</ix:nonFraction>
</span>per share. At June 20, 2023 the Company allocated $<span id="xdx_90C_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zqkCQLrLAbp5"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-06-202023-06-20_custom_FirstPolarFundConvertibleNoteMember" id="Fact000867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,833</ix:nonFraction>
</span>of the proceeds to the Second SPAC Loan and $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620_zA16ZwwVF4P3"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-06-202023-06-20" id="Fact000868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,167</ix:nonFraction>
</span>for the equity instruments. The Company estimated the aggregate fair value of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zGk94zI4YmL8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-202023-06-20_custom_SecondPolarFundConvertibleNoteMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction>
</span>shares to be issued to be $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zVKj7ZCPgeu6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-06-202023-06-20_custom_SecondPolarFundConvertibleNoteMember" id="Fact000870" format="ixt:numdotdecimal" decimals="0" unitRef="USD">330,000</ix:nonFraction>
</span>or $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zBiMxfWHbnw8"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-20_custom_SecondPolarFundConvertibleNoteMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.44</ix:nonFraction>
</span>per share. At December 31, 2023 the carrying values of the SPAC Loans and the discounts were $<span id="xdx_909_eus-gaap--OtherNotesPayableCurrent_iI_c20231231_zbRrvzroSfhh"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,631,725</ix:nonFraction>
</span>and $<span id="xdx_902_ecustom--ConvertibleNotesPayableDiscounts_iI_c20231231_zp5qO5A6B4m"><ix:nonFraction name="TVGN:ConvertibleNotesPayableDiscounts" contextRef="AsOf2023-12-31" id="Fact000873" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,306</ix:nonFraction></span>, respectively. The Company recorded amortization of the discounts on the SPAC Loans of
$<span id="xdx_906_ecustom--NoncashInterestExpenses_c20230101__20231231_zbT0QTObPMne" title="Non cash interest expenses"><ix:nonFraction name="TVGN:NoncashInterestExpenses" contextRef="From2023-01-012023-12-31" id="Fact000875" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,031</ix:nonFraction></span>, which is disclosed in the statement of cash flows as non-cash interest expense. As of
December 31, 2023, the unamortized discount on the SPAC Loans was $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231_zcC6nyEXuTt1"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,274</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the remainder of the Second SPAC Loan of $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zvujXd3eujaf" title="Loan from affiliate"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2023-01-012023-12-31_custom_SponsorMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">577,500</ix:nonFraction></span> is due from the Sponsor. This amount is included on the accompanying
balance sheet as a due from related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Working
Capital Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor,
or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working
Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the
proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside
the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the
Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements
exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without
interest, or, at the lender&#8217;s discretion, up to $<span id="xdx_90C_ecustom--MaximumLoansConvertibleIntoWarrants_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_zqF4920S6Gxl" title="Loan conversion agreement warrant"><ix:nonFraction name="TVGN:MaximumLoansConvertibleIntoWarrants" contextRef="AsOf2023-12-31_custom_RelatedPartyLoansMember" id="Fact000880" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million of such Working Capital Loans may be convertible into private placement-equivalent
units at a price of $<span id="xdx_904_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WorkingCapitalLoansWarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_z4W4b2kmRjc4" title="Price of warrant"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightPriceOfWarrantsOrRights" contextRef="AsOf2023-12-31_custom_WorkingCapitalLoansWarrantMember_custom_RelatedPartyLoansMember" id="Fact000882" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit. As of December 31, 2023 and 2022, the Company had <span id="xdx_90B_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zbhE3rm7aWq5" title="Working capital loan"><span id="xdx_903_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20221231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zVIH4BX8WiRh" title="Working capital loan"><ix:nonFraction name="TVGN:WorkingCapitalLoan" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember69274765" id="Fact000884" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="TVGN:WorkingCapitalLoan" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember69274781" id="Fact000886" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> borrowings under the Working Capital Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administrative
Support Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
on the date of the final prospectus, the Company will agree to pay the Sponsor a total of $<span id="xdx_902_ecustom--RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zngBZMp1EOv3" title="Expenses per month"><ix:nonFraction name="TVGN:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" contextRef="From2023-01-012023-12-31_custom_AdministrativeSupportAgreementMember" id="Fact000888" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> per month for office space and administrative
and support services. Upon completion of the Initial Business Combination or the Company&#8217;s liquidation, the Company will cease
paying these monthly fees. At December 31, 2023 and 2022, $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zTeRuZsi8pS3" title="Amount accrued"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_AdministrativeSupportAgreementMember" id="Fact000890" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--OtherLiabilities_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zrcFWHNGvSWh" title="Amount accrued"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_AdministrativeSupportAgreementMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></span>, respectively, have been accrued under this arrangement
and included in due to affiliate on the accompanying balance sheets.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000894" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zndJCv4P9LIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8212; <span id="xdx_825_zYPPAmLATiS5">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registration
Rights</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Founder Shares, Private Placement Units (including the underlying securities), and securities that may be issued upon conversion
of Working Capital Loans, if any, will be entitled to registration rights pursuant to a registration rights agreement signed upon consummation
of the IPO. These holders will be entitled to certain demand and &#8220;piggyback&#8221; registration rights. However, the registration
rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective
until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underwriting
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted the underwriters a <span id="xdx_90F_ecustom--UnderwritingOptionPeriod_dtD_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zKq3usiUpiPb" title="Underwriting option period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_OverAllotmentOptionMember" format="ixt-sec:durday" id="Fact000896" name="TVGN:UnderwritingOptionPeriod">45</ix:nonNumeric></span>-day option from the final prospectus relating to the IPO to purchase up to <span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjEWU0ZKlgy7" title="Sale of units, net of underwriting discounts (in shares)"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_OverAllotmentOptionMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500,000</ix:nonFraction></span> additional
Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On November 5, 2021, the underwriters
elected to fully exercise the over-allotment option purchasing <span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211105__20211105__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0D1xMmG4LCe" title="Sale of units, net of underwriting discounts (in shares)"><ix:nonFraction name="TVGN:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="From2021-11-052021-11-05_us-gaap_OverAllotmentOptionMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500,000</ix:nonFraction> </span>Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters were paid a cash underwriting discount of $<span id="xdx_903_ecustom--UnderwritingCashDiscountPerUnit_pp2d_c20230101__20231231_zAMMEaSn8KUb" title="Underwriting cash discount per unit"><ix:nonFraction name="TVGN:UnderwritingCashDiscountPerUnit" contextRef="From2023-01-012023-12-31" id="Fact000902" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.20</ix:nonFraction></span> per unit, or $<span id="xdx_901_ecustom--PaymentOfUnderwriterDiscount_pp0p0_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zv3FDpkejT3d" title="Payment of underwriter discount"><ix:nonFraction name="TVGN:PaymentOfUnderwriterDiscount" contextRef="From2023-01-012023-12-31_us-gaap_IPOMember" id="Fact000904" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></span> in the aggregate at the closing of the IPO. The
underwriters have agreed to defer the cash underwriting discount of $<span id="xdx_903_ecustom--UnderwritingCashDiscountPerUnit_pp2d_c20230101__20231231_z3qhrRkyXa4d" title="Underwriting cash discount per unit"><ix:nonFraction name="TVGN:UnderwritingCashDiscountPerUnit" contextRef="From2023-01-012023-12-31" id="Fact000906" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.20</ix:nonFraction></span> per share related to the over-allotment to be paid at Business
Combination ($<span id="xdx_909_ecustom--AggregateUnderwriterCashDiscount_c20230101__20231231_z80p0EzYGGpl" title="Aggregate underwriter cash discount"><ix:nonFraction name="TVGN:AggregateUnderwriterCashDiscount" contextRef="From2023-01-012023-12-31" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,000</ix:nonFraction></span> in the aggregate). In addition, the underwriters are entitled to a deferred underwriting commissions of $<span id="xdx_90E_ecustom--DeferredFeePerUnit_iI_pp2d_c20231231_z8IhYd0PEnqd" title="Deferred underwriting commission fee (per unit)"><ix:nonFraction name="TVGN:DeferredFeePerUnit" contextRef="AsOf2023-12-31" id="Fact000910" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.40</ix:nonFraction></span> per
unit, or $<span id="xdx_90F_ecustom--DeferredUnderwritingFeePayable_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXmGoyaNlnMj" title="Deferred underwriting fee payable"><ix:nonFraction name="TVGN:DeferredUnderwritingFeePayable" contextRef="From2023-01-012023-12-31_us-gaap_IPOMember" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,800,000</ix:nonFraction></span> from the closing of the IPO. The total deferred fee is $<span id="xdx_90D_ecustom--AggregateDeferredUnderwritingFeePayable_c20230101__20231231_zjExYO1ZECU6" title="Aggregate deferred underwriting fee payable"><ix:nonFraction name="TVGN:AggregateDeferredUnderwritingFeePayable" contextRef="From2023-01-012023-12-31" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,700,000</ix:nonFraction></span> consisting of the $<span id="xdx_90F_ecustom--DeferredUnderwritingFeePayable_c20230101__20231231_zGMVX4ykE115" title="Deferred underwriting fee payable"><ix:nonFraction name="TVGN:DeferredUnderwritingFeePayable" contextRef="From2023-01-012023-12-31" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,800,000</ix:nonFraction></span> deferred portion
and the $<span id="xdx_902_ecustom--UnderwriterCashDiscount_c20230101__20231231_zNPRC1kHaj6c" title="Underwriter cash discount"><ix:nonFraction name="TVGN:UnderwriterCashDiscount" contextRef="From2023-01-012023-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,000</ix:nonFraction></span> cash discount agreed to be deferred until Business Combination. The deferred fee will become payable to the underwriters
from the amounts held in the Trust Account solely if the Company completes a Business Combination, subject to the terms of the underwriting
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in Note 5, on May 3, 2023, the Company entered into a subscription agreement (&#8220;Subscription Agreement&#8221;) with the Investor
and the Original Sponsor. Pursuant to the May 4, 2023 Purchase Agreement, the Sponsor assumed the obligations of the Original Sponsor
under the Subscription Agreement. Subject to, and in accordance with the terms and conditions of the Subscription Agreement, the parties
agreed that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investor would make a cash contribution of $<span id="xdx_90C_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmSM6yYtItk8" title="Initial capital contribution"><ix:nonFraction name="TVGN:InitialCapitalContribution" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,000</ix:nonFraction></span> to the Original Sponsor (the &#8220;Initial Capital Contribution&#8221;) on or
    prior to May 3, 2023, or on such date as the parties may agree in writing.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover working capital expenses (the
    &#8220;First SPAC Loan&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    consideration for the Initial Capital Contribution, the Company will issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z4RpHdiUDdq1" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,000</ix:nonFraction></span> Class A ordinary shares, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zwjIHYyyuwVi" title="Ordinary shares, par value (in dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per
    share, of the Company to the Investor at the De-SPAC Closing, which shares shall be subject to no transfer restrictions or any other
    lock-up provisions, earn outs, or other contingencies and shall be registered as part of any registration statement to be filed in
    connection with the De-SPAC Closing or, if no such registration statement is filed in connection with the De-SPAC Closing, pursuant
    to the first registration statement to be filed by the Company or the surviving entity following the De-SPAC Closing.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    SPAC Loan shall not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Sponsor will pay to the Investor
    all repayments of the SPAC Loan the Sponsor has received within <span id="xdx_906_ecustom--MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_dxL_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z30n1seYNRR2" title="Minimum period for receiving spac loan from de-spac closing::XDX::P5D"><span style="-sec-ix-hidden: xdx2ixbrl0926">five</span></span> business days of the De-SPAC Closing. The Investor may elect
    at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares at a rate of <span id="xdx_901_ecustom--NumberOfSharesIssuableForEach10InitialCapitalContribution_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zqyTVL6zYLD3" title="Number of shares issuable for each $10 initial capital contribution">one</span> Class A ordinary share
    for each $<span id="xdx_909_ecustom--AmountOfInitialCapitalConsideredToIssueOneShare_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zFYoqro2Dr5b" title="Amount of initial capital considered to issue one share"><ix:nonFraction name="TVGN:AmountOfInitialCapitalConsideredToIssueOneShare" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10.00</ix:nonFraction></span> of the Initial Capital Contribution. If the Company liquidates without consummating the initial business combination,
    any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account, will be paid
    to the Investor within <span id="xdx_906_ecustom--MinimumPeriodForPaymentInCaseOfLiquidation_dc_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zAOm15oQBdVf" title="Minimum period for payment in case of liquidation"><ix:nonNumeric contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember" format="ixt-sec:durwordsen" id="Fact000932" name="TVGN:MinimumPeriodForPaymentInCaseOfLiquidation">five days</ix:nonNumeric></span> of the liquidation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the De-SPAC Closing, the Sponsor will pay the Investor an amount equal to the reasonable attorney fees incurred by the Investor in
    connection with the Subscription Agreement not to exceed $<span id="xdx_90C_ecustom--MaximumReasonableAttorneyFees_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zKDgwTu0Kmpb" title="Maximum reasonable attorney fees"><ix:nonFraction name="TVGN:MaximumReasonableAttorneyFees" contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, the Company entered into a second subscription agreement (the &#8220;Second Subscription Agreement&#8221;) with the Investor
and the Sponsor. Subject to, and in accordance with the terms and conditions of the Second Subscription Agreement, the parties agreed
that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investor would make a cash contribution of up to $<span id="xdx_900_ecustom--InitialCapitalContribution_pp0p0_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_ziuucL2LkLZ5" title="Initial capital contribution"><ix:nonFraction name="TVGN:InitialCapitalContribution" contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">750,000</ix:nonFraction></span> to the Sponsor (the &#8220;Additional Capital Contribution&#8221;) on or
    prior to June 21, 2023, and the remaining $<span id="xdx_90E_ecustom--InitialCapitalContribution_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zAHmT1WTqsqa" title="Initial capital contribution"><ix:nonFraction name="TVGN:InitialCapitalContribution" contextRef="From2023-01-012023-12-31_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember" id="Fact000938" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">750,000</ix:nonFraction></span> would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#8217;s
    request and the first filing of the S-4 for the De-SPAC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Additional Capital Contribution would in turn be loaned by the Sponsor to the Company in cash on the later of the Sponsor&#8217;s
    request and the first filing of the S-4 for the SPAC&#8217;s business combination (the &#8220;Second SPAC Loan&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    consideration for the Additional Capital Commitment, SPAC will issue a further <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zkvSdiWuJlI1" title="Number of shares issued">one</span> Class A ordinary share for each dollar of the
    Additional Capital Commitment funded to the Investor at the close of the business combination (&#8220;Subscription Shares&#8221;).
    The Subscription Shares shall be subject to no transfer restrictions or any other lock-up provisions, earn outs, or other contingencies.
    The Subscription Shares (i) shall be registered as part of any registration statement issuing shares before or in connection with
    the De- SPAC Closing or (ii) if no such registration statement is filed in connection with the de-SPAC Closing, shall promptly be
    registered pursuant to the first registration statement filed by the SPAC or the surviving entity following the De-SPAC Closing,
    which shall be filed no later than 30 days after the De-SPAC Closing and declared effective no later than 90 days after the De-SPAC
    Closing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Second SPAC Loan shall not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Sponsor will pay to the
    Investor all repayments of the Second SPAC Loan the Sponsor has received within <span id="xdx_906_ecustom--MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_dxL_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zgBkLbKUZo3b" title="Minimum period for receiving spac loan from de-spac closing::XDX::P5D"><span style="-sec-ix-hidden: xdx2ixbrl0942">five</span></span> business days of the De-SPAC Closing. The Investor
    may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares at a rate of <span id="xdx_902_ecustom--NumberOfSharesIssuableForEach10InitialCapitalContribution_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zj2uNiqyPKY8" title="Number of shares issuable for each $10 initial capital contribution">one</span> Class A ordinary
    share for each $<span id="xdx_901_ecustom--AmountOfInitialCapitalConsideredToIssueOneShare_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zLdYsqU579O8" title="Amount of initial capital considered to issue one share"><ix:nonFraction name="TVGN:AmountOfInitialCapitalConsideredToIssueOneShare" contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10.00</ix:nonFraction></span> of the Additional Capital Contribution. If the Company liquidates without consummating the initial business
    combination, any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account,
    will be paid to the Investor within five days of the liquidation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the De-SPAC Closing, the Sponsor will pay the Investor an amount equal to the reasonable attorney fees incurred by the Investor in
    connection with the Second Subscription Agreement not to exceed $<span id="xdx_90D_ecustom--MaximumReasonableAttorneyFees_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zQiqrVEYjNX2" title="Maximum reasonable attorney fees"><ix:nonFraction name="TVGN:MaximumReasonableAttorneyFees" contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with the Sponsor and the Original Sponsor,
pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_zdO0ljFVGdu6" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,988,889</ix:nonFraction> </span>Class A ordinary shares and (y) <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_z1Q4DOn6S8g2" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_PrivatePlacementMember_custom_SsvkAssociatesLlcMember" id="Fact000952" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> Private
Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for one Class
A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter Agreement, dated November 3,
2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement, dated November 3, 2021,
by and between the Company and Cantor, as representative of the several underwriters (the &#8220;Underwriting Agreement&#8221;), for
an aggregate purchase price of $<span id="xdx_906_ecustom--AggregatePurchasePrice_iI_c20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_zXUAMPheSpI" title="Purchase price"><ix:nonFraction name="TVGN:AggregatePurchasePrice" contextRef="AsOf2023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> (the &#8220;Purchase Price&#8221;) payable at the time of the initial business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the payment of the Purchase Price, the Sponsor also assumed the following obligations: (i) responsibility for all of Company&#8217;s
public company reporting obligations; (ii) the obligations of the Original Sponsor under the May 3, 2023 Subscription Agreement, (iii)
responsibility for the Company&#8217;s D&amp;O insurance premium to extend the Company&#8217;s existing D&amp;O insurance policy and
maintain D&amp;O coverage through the closing of the initial business combination and obtain appropriate tail coverage; (iv) responsibility
for the Company&#8217;s outstanding legal fees owed by the Company; and (v) all other obligations of the Original Sponsor related to
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Sponsor had the right to replace the Company&#8217;s current directors and officers with directors and
officers as the Sponsor may select in its sole discretion. The obligations of the Original Sponsor to consummate the transactions contemplated
by the Purchase Agreement were subject to the satisfaction or written waiver by the Original Sponsor of the following conditions: (a)
the approval of the board of directors the SPAC; (b) the approval of the members of the Original Sponsor; (c) the consent or waiver of
the underwriters under the Underwriting Agreement; (d) the filing of its quarterly report on Form 10-Q by the SPAC for the quarter ended
March 31, 2023. On June 7, 2023, the parties to the Purchase Agreement closed the transactions contemplated thereby. In connection with
the closing, the Sponsor replaced the Company&#8217;s directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement contains customary representations and warranties of the parties, including, among others, with respect to corporate
organization, corporate authority, and compliance with applicable laws. The representations and warranties of each party set forth in
the Purchase Agreement were made solely for the benefit of the other parties to the Purchase Agreement, and investors are not third-party
beneficiaries of the Purchase Agreement. In addition, such representations and warranties (a) are subject to materiality and other qualifications
contained in the Purchase Agreement, which may differ from what may be viewed as material by investors, (b) were made only as of the
date of the Purchase Agreement or such other date as is specified in the Purchase Agreement and (c) may have been included in the Purchase
Agreement for the purpose of allocating risk between the parties rather than establishing matters as facts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000956" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zleahcFRElM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8212; <span id="xdx_829_zxRgFLkxaid1">Shareholders&#8217; Deficit</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
A Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z3SFuwRzr81f" title="Ordinary shares, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zchjqu3Qokf3" title="Ordinary shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> Class A ordinary shares with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zImyFic4gI33" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxQiWvMyIGQl" title="Ordinary shares, par value (In Dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000962" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. As of December 31, 2023 and
2022, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcMPHebQv53h" title="Ordinary shares, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z6e2WPRTJ7Oh" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,433,333</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z39e0fKBc1he" title="Ordinary shares, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBC1BOAGBxoc" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,450,000</ix:nonFraction></ix:nonFraction></span></span> Class A ordinary shares issued and outstanding (excluding <span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfPNNf5ZvKT9" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,502,180</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2oissxe3H04" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,500,000</ix:nonFraction></span> Class A
ordinary shares subject to possible redemption), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
B Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4wWYQu9dw32" title="Ordinary shares, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zsIkoeyUHNQg" title="Ordinary shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> Class B ordinary shares with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zYmYGRMYhN0h" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z49zdW0LprNc" title="Ordinary shares, par value (In Dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. Holders of Class B ordinary
shares are entitled to <span id="xdx_903_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zA50ZpBPWOZ1" title="Ordinary shares, vote per share"><span id="xdx_90D_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z5P97QEnPJi6" title="Ordinary shares, vote per share"><ix:nonFraction name="TVGN:CommonStockNumberOfVotesPerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000986" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer"><ix:nonFraction name="TVGN:CommonStockNumberOfVotesPerShare" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000988" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></ix:nonFraction></span></span> vote for each share of Class B ordinary shares. As of December 31, 2023 and 2022, there were <span title="Ordinary shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAcwgpj0sVZc" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span></span> and <span title="Ordinary shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zvD0066NA6Zk" title="Ordinary shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,983,333</ix:nonFraction></span></span>
Class B ordinary shares outstanding, respectively, none of which are subject to forfeiture since the underwriters&#8217; over-allotment
option was exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to our initial Business Combination, only holders of our Class B ordinary shares will have the right to vote on the appointment of directors.
Holders of our Class A ordinary shares will not be entitled to vote on the election of directors during such time. In addition, prior
to the completion of an initial Business Combination, holders of a majority of our Class B ordinary shares may remove a member of the
board of directors for any reason. These provisions of our Memorandum and Articles of Association may only be amended by a special resolution
passed by not less than 90% of our ordinary share shareholders who attend and vote at our general meeting. With respect to any other
matter submitted to a vote of our shareholders, including any vote in connection with our initial Business Combination, except as required
by law, holders of our Class B ordinary shares and holders of our Class A ordinary shares will vote together as a single class, with
each share entitling the holder to one vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination on a
one-for-one basis, subject to adjustment. In the case that additional Class A ordinary shares, or equity-linked securities, are issued
or deemed issued in excess of the amounts offered in the IPO and related to the closing of the initial Business Combination, the ratio
at which Class B ordinary shares shall convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the
outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the
number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted
basis, <span id="xdx_905_ecustom--ConvertibleStocksConversionRatio_pp2d_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zmV42KXKTiPc" title="Ratio to be applied to the stock in the conversion"><ix:nonFraction name="TVGN:ConvertibleStocksConversionRatio" contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember" id="Fact000994" format="ixt:numdotdecimal" decimals="2" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of the sum of the total number of all ordinary shares outstanding upon the completion of the IPO plus all Class A ordinary
shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares
or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent
warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preference
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zazauzFLiK9a" title="Preference shares , shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zJDNnakKyA9b" title="Preference shares , shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> preference shares with such designations, voting and other rights and preferences as may be
determined from time to time by the Company&#8217;s board of directors. As of December 31, 2023 and 2022, there were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_ztPeBlPZ5ec5" title="Preference shares, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zq17rCvt7rs7" title="Preference shares, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_ztfqe4EbgzA6" title="Preference shares, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_z9Zk2qATZUm2" title="Preference shares, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001000" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001002" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact001004" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact001006" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> preferred shares
issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Public Warrants will become exercisable on the later of (i) <span id="xdx_90A_ecustom--WarrantExercisePeriodConditionOne_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztzdgo41Df2" title="Minimum threshold written notice period for redemption of public warrants"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durday" id="Fact001008" name="TVGN:WarrantExercisePeriodConditionOne">30</ix:nonNumeric></span> days after the completion of a Business Combination and (ii) <span id="xdx_901_ecustom--WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_dc_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zQOsYxkSzvij" title="Public warrants exercisable term from the closing of the initial public offering"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durwordsen" id="Fact001010" name="TVGN:WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering">one year</ix:nonNumeric></span>
from the closing of the IPO. No warrants will be exercisable for cash unless the Company has an effective and current registration statement
covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such Class A ordinary
shares. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon exercise of the
Public Warrants is not effective within a specified period following the consummation of a Business Combination, warrant holders may,
until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain
an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the
Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not
be able to exercise their warrants on a cashless basis. The Public Warrants will expire <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zkzZ5UAsOTCh" title="Public warrants expiration term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durwordsen" id="Fact001012" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> after the completion of a Business
Combination or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the warrants become exercisable, the Company may redeem the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $<span id="xdx_90C_ecustom--ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zekJbq7X1MQl" title="Redemption price per public warrant (in dollars per share)"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" id="Fact001014" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.01</ix:nonFraction></span> per warrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than <span id="xdx_906_ecustom--RedemptionPeriod_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrBwEljK2dUf" title="Redemption period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durday" id="Fact001016" name="TVGN:RedemptionPeriod">30</ix:nonNumeric></span> days&#8217; prior written notice of redemption;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $<span id="xdx_907_ecustom--WarrantRedemptionConditionMinimumSharePrice_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9vhPKWd3Ubk" title="Warrant redemption condition minimum share price"><ix:nonFraction name="TVGN:WarrantRedemptionConditionMinimumSharePrice" contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" id="Fact001018" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">18.00</ix:nonFraction></span> per share (as adjusted for share
    subdivisions, share dividends, reorganizations and recapitalizations), for any <span id="xdx_906_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zOEzySEWuLMd" title="Threshold trading days for redemption of public warrants"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durday" id="Fact001020" name="TVGN:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">20</ix:nonNumeric></span> trading days within a <span id="xdx_90B_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z63PpM15jw8l" title="Threshold consecutive trading days for redemption of public warrants"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durday" id="Fact001022" name="TVGN:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">30</ix:nonNumeric> </span>trading day period commencing
    at any time after the warrants become exercisable and ending on the <span id="xdx_909_ecustom--ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_dcxL_uInteger_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zocKlIJZEHTc" title="Threshold number of business days before sending notice of redemption to warrant holders::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1024">third</span></span> business day prior to the notice of redemption to warrant
    holders; and if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying
    the warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the
Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Warrants are identical to the Public Warrants underlying the Units being sold in the IPO, except that the Private Warrants and
the Class A ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until
after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable
for cash or on a cashless basis, at the holder&#8217;s option, and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees,
the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of Class A ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including
in the event of a share dividend, extra Class A Ordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of Class A ordinary shares at a price below their respective exercise prices. Additionally,
in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination
within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any
of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of
the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection
with the closing of a Business Combination at an issue price or effective issue price of less than $<span id="xdx_907_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrnWI2UP5Qyl" title="Share price trigger used to measure dilution of warrant"><ix:nonFraction name="TVGN:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="AsOf2023-12-31_custom_PublicWarrantsMember" id="Fact001026" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">9.20</ix:nonFraction></span> per Class A ordinary share (with
such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors, and in the case of
any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by them prior
to such issuance), (y) the aggregate gross proceeds from such issuances represent more than <span id="xdx_909_ecustom--PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztRCScGKUfjj" title="Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant"><ix:nonFraction name="TVGN:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span>% of the total equity proceeds, and interest
thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Class A ordinary shares during the <span id="xdx_905_ecustom--TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwsPSdo8y9sc" title="Trading period after business combination used to measure dilution of warrant"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" format="ixt-sec:durday" id="Fact001030" name="TVGN:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">20</ix:nonNumeric></span> trading day period starting
on the trading day prior to the day on which the Company consummates Business Combination (such price, the &#8220;Market Value&#8221;)
is below $<span id="xdx_90E_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdONLKLPoV82" title="Share price trigger used to measure dilution of warrant"><ix:nonFraction name="TVGN:SharePriceTriggerUsedToMeasureDilutionOfWarrants" contextRef="AsOf2023-12-31_custom_PublicWarrantsMember" id="Fact001032" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">9.20</ix:nonFraction></span> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <span id="xdx_90E_ecustom--ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_pid_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrrgKbUSjwrd" title="Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">115</ix:nonFraction></span>% of the greater
of (i) the Market Value or (ii) the price at which the Company issues the additional Class A ordinary shares or equity-linked securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001036" name="TVGN:WarrantLiabilitiesDisclosureTextBlock"><p id="xdx_80A_ecustom--WarrantLiabilitiesDisclosureTextBlock_zlcP5brLQtCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8212; <span id="xdx_82C_zeu0TEWjRXgf">Warrant Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_z2XLa9qsk8r4" title="Number of warrants to purchase shares issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_PrivatePlacementWarrantsMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></span> Private Placement Warrants in accordance with the guidance contained in ASC 815-40 due to the fact the
Private Placement Warrants will be exercisable for cash or on a cashless basis, at the holder&#8217;s option, and be non-redeemable so
long as they are held by the initial purchasers or their permitted transferee. Such guidance provides that, based on these features,
the private placement warrants do not meet the criteria for equity treatment thereunder, and each such warrant must be recorded as a
liability. Accordingly, the Company will classify each private placement warrant as a liability at its fair value. This liability is
subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value,
with the change in fair value recognized in the Company&#8217;s statement of operations. The Company has determined the Public Warrants
do not contain such features, and accordingly will be accounted for as equity and are not subject to subsequent remeasurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001040" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zscPJiCAlwRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8212; <span id="xdx_822_zpLtguBL6Bdf">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions
    for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities
    and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the assets held in the Trust Account were held in a demand deposit account. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001042" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmjRVkh3pYg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at December 31, 2023 and 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine
such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUJd3DIqYfuc" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2023:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/>
Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Active<br/>
 Markets <br/>
(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Observable<br/>
 Inputs<br/>
 (Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unobservable<br/>
 Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zL6j0eZA5kQd" title="U.S. Treasury Securities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zzQOWVq1njL9" title="U.S. Treasury Securities" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zJHJYSgOXqh5" title="U.S. Treasury Securities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzF2KHIA6d1h" title="Warrant Liability- Private Placement Warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8zohv8G7zn4" title="Warrant Liability- Private Placement Warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zu6DplRasUnk" title="Warrant Liability- Private Placement Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001054" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F05_zRz5qzPWqC91" style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/><td id="xdx_F10_zr00BowB9Rdj" style="text-align: justify"><ix:footnote id="Footnote001055" xml:lang="en-US">As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.</ix:footnote></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2022:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted<br/>
 Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Active<br/>
 Markets</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlSzSgdzh8Qj" title="U.S. Treasury Securities" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact001057" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">356,864,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQbFfgPIFlQa" title="U.S. Treasury Securities" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1059">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTtiidvpzIVb" title="U.S. Treasury Securities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7MNmEfSplwb" title="Warrant Liability- Private Placement Warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgz3GX8Bzzn1" title="Warrant Liability- Private Placement Warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCeQqJgFIhE8" title="Warrant Liability- Private Placement Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001067" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zsi8CYImWPEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model to value the warrants at each reporting period, with changes in fair value recognized
in the statement of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in a Monte
Carlo pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield.
The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining
life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity
similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining
contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned warrant liabilities are not subject to qualified hedge accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001069" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zW6iO4IeZbtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zXnCn4NfJng1" style="display: none">Schedule
of Quantitative Information    in Fair Value Measurements</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At <br/>
December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At <br/>
December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Share Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDNiR2mPr5Tf" title="Measurement Input" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact001071" format="ixt:numdotdecimal" decimals="2" unitRef="Pure">11.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHJCNf8UNgHk" title="Measurement Input" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact001073" format="ixt:numdotdecimal" decimals="2" unitRef="Pure">10.33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise Price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zToyf7clZ7g2" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember" id="Fact001075" format="ixt:numdotdecimal" decimals="2" unitRef="Pure">11.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z6w3yUrmoJ9d" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember" id="Fact001077" format="ixt:numdotdecimal" decimals="2" unitRef="Pure">11.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zHVt8y7rXMvd" title="Measurement Input" style="text-align: right"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001079" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.21</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z52dsppE8ln7" title="Measurement Input" style="text-align: right"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001081" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Industry Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBJriKpznZxe" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001083" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">6.50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0Jh1aYzxPrb" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001085" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">4.40</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk Free Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8GUjclHjgli" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001087" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">3.77</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5935i02fu9d" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001089" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">3.91</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgMQm2a5w1M9" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001091" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7p3iyXq8RK3" title="Measurement Input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001093" format="ixt:numdotdecimal" decimals="4" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z7L6IdXctr51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001095" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zwUj1SXx7tRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8212; <span id="xdx_82C_z5LIHdAv0NUc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date these financial statements
were available to be issued. Based on this review, other than as described below, the Company did not identify any subsequent events
that would have required adjustment or disclosure in these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 31, 2024, in connection with an extraordinary
meeting of shareholders called to approve the proposals relating to the entry into and consummation of the Business Combination, shareholders
holding <span id="xdx_90F_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zESopOj6QJL9" title="Minimum period to file charter amendment"><ix:nonFraction name="TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" contextRef="AsOf2024-01-31_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,432,457</ix:nonFraction></span> of the Company&#8217;s Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of
the funds in the Company&#8217;s trust account. As a result, approximately $<span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn5n6_c20240131__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzcFQlaXULFc" title="Cash withdrawn from Trust Account in connection with redemption"><ix:nonFraction name="TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" contextRef="From2024-01-312024-01-31_us-gaap_SubsequentEventMember" id="Fact001099" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.0</ix:nonFraction></span> million (approximately $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3ofPKqs9OJc" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-01-31_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.14</ix:nonFraction></span> per Public Share) were
removed from the Trust Account to pay such holders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 14, 2024, pursuant to the Merger Agreement
by and among the Company, Merger Sub, the Sponsor, Tevogen Bio, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub
merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company. Prior to
the effective time of the Merger (the &#8220;Effective Time&#8221;), pursuant to the Merger Agreement, the Company changed its jurisdiction
of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated
under the laws of the State of Delaware (the &#8220;Domestication&#8221;). In connection with the Domestication, the Company changed its
name to &#8220;Tevogen Bio Holdings Inc.&#8221; Also in connection with the Domestication, the Company&#8217;s governing documents were
amended and restated as set forth in the Company&#8217;s definitive proxy statement filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on&#160;<span style="text-decoration: underline">January 10, 2024</span>&#160;(the &#8220;Definitive Proxy Statement&#8221;). At the Effective Time, in
accordance with the terms and subject to the conditions of the Merger Agreement, each share of the common stock of Tevogen Bio issued
and outstanding immediately prior to the Effective Time was converted into the right to receive the number of shares of duly authorized,
validly issued, fully paid, and nonassessable shares of the common stock of the Company, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zl1vUIz346fc" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> (the &#8220;Common Stock&#8221;),
equal to the quotient obtained by dividing (x) the quotient obtained by dividing (i) $<span id="xdx_90B_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_c20240214__20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--TevogenBioMember_zk7sxtZpvkDa" title="Merger agreement share issuable"><ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" contextRef="From2024-02-142024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember_custom_TevogenBioMember" id="Fact001105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000,000</ix:nonFraction></span> by (ii) ten dollars ($<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zpEEP9ZGg5K5" title="Merger agreement share issuable, per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>) by (y)
the aggregate number of shares of the common stock of Tevogen Bio that were issued and outstanding immediately prior to the Effective
Time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, the Company entered into a securities purchase agreement with an investor pursuant to which the investor agreed
to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0BQ6cP3Jxn3" title="Aggregate purchase price amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember" id="Fact001109" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span>
million. On March 27, 2024, the Company entered into an agreement pursuant to which that amount was reduced to $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zMjDSNJx8fye" title="Shares purchase amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-03-272024-03-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember" id="Fact001111" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span>
million and the investor agreed to purchase shares of the Company&#8217;s Series A-1 Preferred Stock for an aggregate purchase price
of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zuAiSl9zOlm3" title="Aggregate purchase price amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-03-272024-03-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember" id="Fact001113" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span>
million. As of April 26, 2024, the Company has received $<span id="xdx_90A_eus-gaap--Cash_iI_pn5n6_c20240426__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdvhVzlHnwkg" title="Received"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-04-26_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001115" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million of the $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zwoBPcWviCz5" title="Aggregate purchase price amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-04-262024-04-26_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember" id="Fact001117" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million aggregate purchase price for the shares of
Series A-1 Preferred Stock. The shares of Series A Preferred Stock are convertible into a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQAix7ayD9Kd" title="Conversion of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock and the shares of the Series A-1 Preferred Stock will be convertible into a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z7CySHCzWF2a" title="Conversion of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock, in each case at the election of the holder. Each of the Series A Preferred Stock is and
the Series A-1 Preferred Stock will be subject to a call right providing the Company the right to call the stock if the volume
weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCt9ozyeW1G8" title="Share price, per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001123" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span>
per share and there is an effective resale registration statement on file covering the underlying common stock. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zr4CuyIiL8Lh" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember" id="Fact001125" name="us-gaap:PreferredStockVotingRights">The
Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no
mandatory redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the
Series A-1 Preferred Stock in no event to more than 15% per year.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, the Company entered into an agreement with the Sponsor,
pursuant to which the Company assigned to the Sponsor and the Sponsor agreed to assume certain liabilities and obligations in the aggregate
initial amount of approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9aSiJHU6C9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember" id="Fact001126" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which amount was later reduced to approximately
$<span id="xdx_902_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn5n6_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGBYMFN8WOCf"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="AsOf2024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember" id="Fact001127" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (the &#8220;Series B Preferred Stock&#8221;).
<span id="xdx_902_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhzB2z5Zgcbj"><ix:nonNumeric contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember" id="Fact001128" name="us-gaap:PreferredStockVotingRights">The
Series B Preferred Stock is non-voting, non-convertible, callable by the Company at any time, and pays a 3.5% quarterly dividend beginning
35 days after issuance. Any dividend will be paid by the Company on behalf of the Sponsor to the creditors to which the assumed liabilities
and obligations are owed, pro rata in accordance with those liabilities and obligations unless otherwise agreed by the Company and the
Sponsor. The dividend rate will increase by 0.25% each month that the Series B Preferred Stock remains outstanding after the first 30
days after its issuance, but in no event will increase to more than 7.5% per quarter.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Merger Agreement, Tevogen Bio agreed
that at the Effective Time, it would pay $<span id="xdx_900_eus-gaap--SponsorFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_ztou06C0annd"><ix:nonFraction name="us-gaap:SponsorFees" contextRef="From2023-01-012023-12-31_custom_MergerAgreementMember" id="Fact001129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction>
</span>to the Sponsor for advisory services (the &#8220;Sponsor Advisory Services Fee&#8221;). Thereafter, in connection with the closing
of the Business Combination, the Sponsor Advisory Services Fee was reduced to $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SponsorAdvisoryServiceFeeMember_z8XGWrI0odn6"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2023-01-012023-12-31_custom_MergerAgreementMember_custom_SponsorAdvisoryServiceFeeMember" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>.
On April 16, 2024, the Sponsor agreed to further reduce the Sponsor Advisory Services Fee by informing Tevogen Bio that $<span id="xdx_90D_eus-gaap--SponsorFees_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQnU0u6Np1rd"><ix:nonFraction name="us-gaap:SponsorFees" contextRef="From2024-04-152024-04-16_custom_MergerAgreementMember_us-gaap_SubsequentEventMember" id="Fact001131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction>
</span>of the $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlPTlKsgfGlj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-152024-04-16_custom_MergerAgreementMember_us-gaap_SubsequentEventMember" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">577,500</ix:nonFraction>
</span>that was due from the Sponsor as of December 31, 2023 would be applied to offset a portion of the $<span id="xdx_90D_ecustom--OffsetValue_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z9wT2SNHvZRl" title="Offset value"><ix:nonFraction name="TVGN:OffsetValue" contextRef="AsOf2023-12-31_custom_MergerAgreementMember" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> Sponsor Advisory Services
Fee. Therefore, the total amount due to the Sponsor under the Sponsor Advisory Services Fee is $<span id="xdx_90F_ecustom--ServicesFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zuxRHWoHWbCe" title="Service fees"><ix:nonFraction name="TVGN:ServicesFees" contextRef="From2023-01-012023-12-31_custom_MergerAgreementMember" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</span></p>

</ix:nonNumeric><p id="xdx_816_zgLijVS0YIuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="dda_001"></span>Tevogen
Bio Holdings Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zUcuKf50iMM9" summary="xdx: Statement - Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240331_zIyMAPBJokyf" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__srt--RestatementAxis__custom--ReverseRecapitalizationMember_zPOA3A0mb0m4" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zofslguFqKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_z272RBBK9qXc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Cash_i02I_pp0p0_maACzW0w_zR7sS56CK7ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-left: 10pt">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-03-31" id="Fact001144" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,317,900</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001145" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzW0w_zfB6IhyhfKk1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-03-31" id="Fact001147" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">923,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001148" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">670,582</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherReceivablesNetCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzW0w_ztHRWPW4Jpm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Due from related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-03-31_us-gaap_RelatedPartyMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,819</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzW0w_maAzDKc_zvQrZzpO4NW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-03-31" id="Fact001153" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,399,921</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001154" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,722,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzDKc_zCSGk31wgbfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-03-31" id="Fact001156" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">418,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001157" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">458,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0_maAzDKc_zVruAy5pHvo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact001159" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">412,111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001160" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">469,862</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTransactionCosts_i01I_pp0p0_maAzDKc_zyedYTGVohRc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTransactionCosts" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001163" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,582,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAssetsNoncurrent_i01I_pp0p0_maAzDKc_zJWa8F5cygFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-03-31" id="Fact001165" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,276</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_pp0p0_mtAzDKc_zJ0J6Onq7rod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-03-31" id="Fact001168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,363,407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001169" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,505,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zepiSmgECgX6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Liabilities and stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrentAbstract_i01B_zmPqPNqbwvu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzkNn_zAlSey88WAD3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-03-31" id="Fact001177" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,211,899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001178" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,418,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzkNn_zzbrK8x1hBHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact001180" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,564,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001181" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,096,450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzkNn_zNkxwnIdlOvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact001183" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,583</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001184" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">252,714</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NotesPayableCurrent_i02I_pp0p0_maLCzkNn_z6JVZv81nmeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-03-31" id="Fact001186" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,651,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pp0p0_maLCzkNn_zXmWcQpwVLT5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001190" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,712,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzkNn_za45SljlOn2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Due to related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-03-31_us-gaap_RelatedPartyMember" id="Fact001192" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_maLz1lF_mtLCzkNn_z3bY0SBGyvJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact001195" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,938,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001196" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,479,542</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ConvertibleLongTermNotesPayable_i01I_pp0p0_maLz1lF_zkmZqLUY5RA1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001199" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,220,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0_maLz1lF_zxYjDnH7wPMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact001201" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">166,788</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001202" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_pp0p0_maLz1lF_z8THnwYlUwq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-03-31" id="Fact001204" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Liabilities_i01TI_pp0p0_mtLz1lF_maLASEzmHk_zxXSs7OvGPve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-03-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,166,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001208" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,934,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_i01B_zxWPLu8C8vPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zp8ng4gYuQwh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Series A Preferred Stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUvtUDeR9w47" title="Preferred stock, par value (in dollar per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value; <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZZPJQyiPo5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></span> shares authorized; <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG2TmnSjG2d8" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5iKzGrFQpej" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwZGUAQNOcJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Series B Preferred Stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7rSMzUWKyU2" title="Preferred stock, par value (in dollar per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zngzpB1Pndh8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></span> shares authorized; <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWn3soEZbYzb" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCcQ9kssvuoa" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001224" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1225">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_maSEzcHo_zygRNiyB88va" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001235" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1236">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzcHo_zjc6theIGMgh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240331_zZCL6wTZQMQi" title="Common shares, par value (in dollar per share)"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zS1mNQG0qbA" title="Common shares, par value (in dollar per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20240331_zc5tyYOfZaga" title="Common shares, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_znOdm9XfeBU8" title="Common shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240331_z8VqS4d1Nqub" title="Common shares, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zJKr3rR0LNSh" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20231231_zD6B05gy5Mbd" title="Common shares, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zXQ20pKmqjx9" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at March 31, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-03-31" id="Fact001238" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001239" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzcHo_zCXFTCQR5d14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-03-31" id="Fact001257" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,160,773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001258" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzcHo_z0CfzcTEmVac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact001260" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">88,392,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001261" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzcHo_maLASEzmHk_zr4O95FVyyvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact001263" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,802,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001264" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzmHk_zq3el0IPFTz4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-03-31" id="Fact001266" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,363,407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001267" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,505,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the unaudited consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 179; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="dda_002"></span>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_zYLAnZ3ZSlId" summary="xdx: Statement - Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20240331_zikVSbQlUKk6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20230331_zzhYebTWgpY6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_zRoazW6fQqvk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_maCAEz9ye_zZAJIg9HgZbh" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-03-31" id="Fact001272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,811,582</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,347,173</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_maCAEz9ye_zC7VuDpyOqtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,705,142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31" id="Fact001276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostsAndExpenses_i01T_mtCAEz9ye_msOILzaNu_zwxwYew3YXja" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2024-01-01to2024-03-31" id="Fact001278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,516,724</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-01-012023-03-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,324,282</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtOILzaNu_maNILzP5I_zAepDt3RJDI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact001281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,516,724</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact001282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,324,282</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--InterestExpense_iN_di_msNILzP5I_zOdurx69MOg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-03-31" id="Fact001284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,786</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-03-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,997</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--TransactionCosts_iN_di_msNILzP5I_zm00TWKUAxcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:TransactionCosts" contextRef="From2024-01-01to2024-03-31" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499,353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_msNILzP5I_zqbR9U2GMr68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-03-31" id="Fact001290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,973</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_iN_di_msNILzP5I_zNK4mLfRhl9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2024-01-01to2024-03-31" id="Fact001293" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,468,678</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2023-01-012023-03-31" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,142,865</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtNILzP5I_zfGrY15UISk2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact001296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,264,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact001297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zSKZQ1HQqxK" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Net income (loss) attributable to common stockholders, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,506,866</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-03-31" id="Fact001300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_zWDZXIAkwkQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Net loss attributable to common stockholders, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact001302" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,049,420</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-03-31" id="Fact001303" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zDOYWS7ww7ol" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Net income (loss) per share attributable to common stockholders, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_z21Ga335iL7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share attributable to common stockholders, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zqs3avI9FrH9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,333,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zxkPmbx8N1Lj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average common stock outstanding, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-03-31" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,387,651</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the unaudited consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="dda_003"></span>Tevogen
Bio Holdings Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_zQYv6ZVRQrif" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_srt--RestatementAxis_custom--ReverseRecapitalizationMember_zXAvy406SVz6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_srt--RestatementAxis_custom--ReverseRecapitalizationMember_zenPMPIEIqhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_srt--RestatementAxis_custom--ReverseRecapitalizationMember_zlTpp3BVwih6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_srt--RestatementAxis_custom--ReverseRecapitalizationMember_zOjj6Yhkvlgj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_srt--RestatementAxis_custom--ReverseRecapitalizationMember_zvvj7WMkAxeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_srt--RestatementAxis_custom--ReverseRecapitalizationMember_zP8rhqlGKiXf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A <br/> Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B <br/> Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zuaAIpTEdH69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYjgz2Dt358l" title="Balance, shares" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1317">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxmK1cVJTx4d" title="Balance, shares" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGADYcI2entb" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001321" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zWDZRA5BZS71" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Issuance of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMK2onwSKTbh" title="Issuance of Series A preferred stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="Fact001330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_zkUQAjnGe1O2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_zh89yfVvc5Mj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Issuance of Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzLHjjsWsP22" title="Issuance of Series B preferred stock, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8212;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1350">&#8212;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zWwykfiVvPT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Conversion of convertible promissory notes into common stock in connection with merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeBa1f44TATg" title="Conversion of convertible promissory notes into common stock in connection with merger, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,337,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,621,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,622,627</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zBrN8d7eOr93" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Merger, net of redemptions and transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFXh32oJpUZ8" title="Merger, net of redemptions and transaction costs, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zC8LDjB4tvti" title="Merger, net of redemptions and transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,778,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001367" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,885,459</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001369" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,883,981</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zzzlJGvUPXo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Issuance of restricted common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1375">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znjLPAk2vLkl" title="Issuance of restricted common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001378" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1380">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zG3wYkkq3SSg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Issuance of common stock for Sponsor advisory service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of common stock for Sponsor advisory service fee, shares" id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfy4t72z83xi" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z02a6LBXpwYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1394">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,333,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1397">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,333,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zUlmzisDgMI6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1402">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1403">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,264,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,264,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zz7Gv3CZX5pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Balance at March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEFbVLG2yAXe" title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="Fact001414" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember" id="Fact001407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfvwnh0p4Cf1" title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="Fact001416" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember" id="Fact001408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBtPG3zBHcg1" title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact001418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,160,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,392,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_ReverseRecapitalizationMember" id="Fact001412" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,802,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zp1la3L222E4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at January 1, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDNlFGGSegi3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1427">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zL6QKrHkBLJ6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1421">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDApEeFhKmA2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,180,057</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_ReverseRecapitalizationMember" id="Fact001425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,951,217</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20230331_eus-gaap--StockholdersEquity_iS_z5XBBOO8iNy1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztIOl8NVTvnl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXwAWLeRBmlh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTykupcJsoh6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,180,057</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_ReverseRecapitalizationMember" id="Fact001438" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,951,217</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_zyOiNAPkd2e1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1447">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1448">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1449">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001450" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zhaxGPYnDvrk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Income (loss)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1453">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1454">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1455">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1456">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001457" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_432_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zK6y39AglLdi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkzkaK2JWwgl" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfCbqgL66wl8" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1469">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwmZfVD5IaG8" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001464" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,936,201</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ReverseRecapitalizationMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,707,361</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zkSBe9pItI6e" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBFpTdyhhDGe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFU7VwrA2H8" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1482">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlhLPfx5QLek" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember" id="Fact001475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember" id="Fact001476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember" id="Fact001477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,936,201</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ReverseRecapitalizationMember" id="Fact001478" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,707,361</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the unaudited consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="dda_004"></span>Tevogen
Bio Holdings Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zDqXPFJfc8C6" summary="xdx: Statement - Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240331__srt--RestatementAxis__custom--ReverseRecapitalizationMember_zyQQDmUOHmG3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331__srt--RestatementAxis__custom--ReverseRecapitalizationMember_zwnZtE3la1Y8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zk3ynKX9ADg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzexg_znWi8ZM8owog" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001489" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,264,842</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001490" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zPEL7aZP6XQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Adjustments to reconcile net income (loss) to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Depreciation_i02_maNCPBUzexg_zdJSlOLFeZS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,735</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_maNCPBUzexg_zAvmxAzduDT9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,333,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1499">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaidInKindInterest_i02_maNCPBUzexg_zTyPfeKtV2m8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashMergerRelatedCosts_i02_pp0p0_maNCPBUzexg_zX5UAGo4JIY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001504" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,099,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_i02_pp0p0_maNCPBUzexg_z6GTA9Oanyek" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001507" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001508" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,142,865</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--LossOnPreferredStockIssuance_i02_pp0p0_maNCPBUzexg_zrAsfRdiSFDi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Loss on Series A Preferred Stock issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001510" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">799,990</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzexg_zZYs2Jl986Dh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001513" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,973</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1514">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pp0p0_maNCPBUzexg_zK0wyZZkhfUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Amortization of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001516" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001517" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zXWBWbuJ6Ek1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzexg_zvZlQW1v1zQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 30pt">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001522" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001523" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">70,552</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_pp0p0_di_msNCPBUzexg_zi9UK6zxLBS4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001525" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,446</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001526" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,344</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_pp0p0_maNCPBUzexg_zd5PZdeKB2Gl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 30pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,697,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_pp0p0_maNCPBUzexg_zKdwNiTZm0Le" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001531" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">800,742</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001532" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">480,404</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherOperatingLiabilities_i03_pp0p0_maNCPBUzexg_zEb2g3fDQAle" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001534" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">60,201</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001535" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">53,174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzexg_maCCERCzoM3_zvABfTPV9ucg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001537" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,163,825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001538" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,177,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zHiZugT7wRd8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUz0gn_zwn1M2KacPz2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1543">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUz0gn_maCCERCzoM3_zSJvZZTmqZ56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1546">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001547" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z7h03DTv4Q6f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashAcquiredInConnectionWithReverseRecapitalization_i01_maNCPBUz8Qo_zLwIlnFKoVv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Cash acquired in connection with the reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:CashAcquiredInConnectionWithReverseRecapitalization" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1553">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_maNCPBUz8Qo_z4PXJ66AcQp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1556">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_i01_maNCPBUz8Qo_zlaD4p6nDdfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1559">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_i01_maNCPBUz8Qo_z8DueHVCifI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Proceeds from issuance of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1561">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUz8Qo_maCCERCzoM3_zuTDppzJJMpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001564" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,429,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001565" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCCERCzoM3_zjlfGwCc5Huf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001567" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember" id="Fact001568" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,865</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0_zOVtvIiXaROi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cash &#8211; beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001570" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31_custom_ReverseRecapitalizationMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,484,265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0_zwNCRQDA10C4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Cash &#8211; end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31_custom_ReverseRecapitalizationMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,317,900</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31_custom_ReverseRecapitalizationMember" id="Fact001574" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,674,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z6fy1FRPObIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplementary disclosure of noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_i01_z0vqX3D3Mv34" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; text-align: left; padding-left: 20pt">Conversion of convertible promissory notes into common stock in connection with Merger</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="TVGN:ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,622,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_i01_zP7EkL78vDUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: justify">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember" id="Fact001582" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,113,309</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1583">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the unaudited consolidated financial statements.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_040_c20240101__20240331_zPnWR8YiwiHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="dda_005"></span>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001585" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zkerNkuEYq8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82A_zvWj43xTF1V7">NATURE OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc. (f/k/a Semper Paratus Acquisition Corporation), a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage
specialty immunotherapy company harnessing the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies
for the treatment of infectious diseases, cancers, and neurological disorders. The Company&#8217;s precision T cell technology platform,
ExacTcell, is a set of processes and methodologies to develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies
with proactively selected, precisely defined targets. The Company has completed a Phase 1 proof-of-concept trial for the first clinical
product of ExacTcell, TVGN 489, for the treatment of ambulatory, high-risk adult COVID-19 patients, and has other product candidates
in its pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to the agreement and plan of merger dated June 28, 2023 (the &#8220;Merger
Agreement&#8221;), by and among Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;) SSVK Associates, LLC, (the &#8220;Sponsor&#8221;) Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;), and Dr. Ryan Saadi in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company (the &#8220;Merger,&#8221;
and together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;), and Semper Paratus
was renamed Tevogen Bio Holdings Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination (the &#8220;Closing&#8221;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately <span id="xdx_905_ecustom--ExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhl9FPe3OPhl" title="Exchange ratio"><ix:nonFraction name="TVGN:ExchangeRatio" contextRef="AsOf2024-02-14_us-gaap_CommonStockMember" id="Fact001587" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.85</ix:nonFraction></span> shares of Company common
stock for each share of Tevogen Bio common stock (the &#8220;Exchange Ratio&#8221;). See Note 4 for more information on the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240101__20240331__srt--TitleOfIndividualAxis__custom--TevogenBioMember_zEA80jFaGSh5" title="Equity holders percentage"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2024-01-012024-03-31_custom_TevogenBioMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span>% of the outstanding shares
of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240101__20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zQjT8fq4JfXk" title="Equity holders percentage"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2024-01-012024-03-31_custom_SemperParatusMember" id="Fact001591" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.1</ix:nonFraction></span>% of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001593" name="TVGN:DevelopmentStageRisksAndLiquidityTextBlock"><p id="xdx_80C_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zbgRuV5EqCd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_82E_zwIsFmav7HG">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generally incurred losses and negative cash flows from operations since inception and had an accumulated deficit of
$<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zMy2obJYRxfa" title="Amount of accumulated undistributed earnings"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact001595" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,392,895</ix:nonFraction></span>
as of March 31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant
sales from its product candidates currently in development. Management believes that cash of $<span id="xdx_90A_eus-gaap--Cash_iI_c20240331_znGHeD1saMK9" title="Management cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-03-31" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,317,900</ix:nonFraction></span>
as of March 31, 2024, and $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zQzirfvaXBK1" title="Sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-03-31_custom_SeriesAOnePreferredStockMember" id="Fact001599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>
received for the sale of Series A-1 Preferred Stock subsequent to March 31, 2024, is not sufficient to sustain planned operations
for 12 months from the issuance date of these unaudited consolidated financial statements. As a result, the Company has concluded
that substantial doubt exists about its ability to continue as a going concern for one year from the date that the unaudited
consolidated financial statements are issued. The accompanying unaudited consolidated financial statements have been prepared on a
going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of
recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this
uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years. These strategies
may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings
of equity and/or debt securities. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely
affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and clinical trials, and pursuing the Business Combination. The Company is subject to those
risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be
no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary
regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of
rapid technological change and is largely dependent on the services of its employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001601" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweFcfJCPe72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_821_z7Yxg4Jk1c6b">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies included in the Company&#8217;s annual financial statements that can be found in Exhibit 99.1
of the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on April 29, 2024 (the
&#8220;Form 8-K&#8221;), have not materially changed, except as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001603" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zGbPuBzg5CKl">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001605" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z2UVV4YCU6v4">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001607" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zsweBwNQyFF3">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001609" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zJZFeTaEcaDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zPtwxjycLoh9">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001611" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_ztdxsUcE1y6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public
offering (the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i>
(&#8220;ASC 815&#8221;), and considering ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;). The
assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to
ASC 480 and meet all of the conditions for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own shares of common stock, among other conditions. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of
issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are
recognized as a non-cash loss on the consolidated statements of operations. Under these standards, the Company&#8217;s private
placement warrants sold at the time of the IPO do not meet the criteria for equity classification and must be recorded as
liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification and must be recorded as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001613" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOp0Gnh2gwmd">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s
convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001615" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zLAFUKdBZV45" style="display: none">Schedule
of Fair Value Measurement</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" title="Fair value beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,932,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Initial fair value at issuance" id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" title="Accrued interest expense" style="text-align: right"><ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001623" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" title="Derecognition upon conversion of convertible promissory notes" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001625" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,622,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" title="Fair value ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" title="Fair value beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,297,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" title="Initial fair value at issuance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" title="Initial fair value at issuance" style="text-align: right"><ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" contextRef="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" title="Initial fair value at issuance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,142,865</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" title="Fair value ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact001637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,229,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-01to2024-03-31" id="Fact001639" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>%),
discount rate (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="From2024-01-012024-03-31_srt_MinimumMember" id="Fact001641" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%
- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="From2024-01-012024-03-31_srt_MaximumMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span>%),
and probability of a future liquidity event (<span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event"><ix:nonFraction name="TVGN:PercentageOfProbabilityOfLiquidityEvent" contextRef="AsOf2024-03-31_srt_MinimumMember" id="Fact001645" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>%
- <span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event"><ix:nonFraction name="TVGN:PercentageOfProbabilityOfLiquidityEvent" contextRef="AsOf2024-03-31_srt_MaximumMember" id="Fact001647" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95</ix:nonFraction></span>%).</span> The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the three months ended March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants the fair value of which increased by $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31_srt_MaximumMember" id="Fact001649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,973</ix:nonFraction></span>
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001651" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zTyrtDvrDzJk">Schedule
of Fair Values Of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at February 15, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" title="Balance, beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-02-15" id="Fact001653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" title="Change in fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-162024-03-31" id="Fact001655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" title="Balance, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-03-31" id="Fact001657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,973</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001659" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" title="Derivative warrant liabilities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" title="Derivative warrant liabilities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" title="Derivative warrant liabilities" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001665" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,973</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between <span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1667">75%</span></span> to <span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1669">85%</span></span>, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from <span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years"><ix:nonNumeric contextRef="AsOf2024-03-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001671" name="TVGN:RangeInYears">0.5</ix:nonNumeric></span> to <span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years"><ix:nonNumeric contextRef="AsOf2024-03-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001673" name="TVGN:RangeInYears">10.0</ix:nonNumeric></span> years, and a risk-free interest rate between <span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001675" format="ixt:numunitdecimalin" decimals="INF" unitRef="Pure">4.3</ix:nonFraction>%</span> and <span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001677" format="ixt:numunitdecimalin" decimals="INF" unitRef="Pure">5.3</ix:nonFraction>%</span>. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001681" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuKunqOFiF5k">Net
Income (Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001683" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zaS2rj0QNrb1">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, Debt &#8211; <i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001685" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_ztQqt7jA75tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_82B_zB9TrLOIyD8d">BUSINESS COMBINATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors,
including: (i) former Tevogen Bio equityholders and holders of convertible promissory notes owned approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zrf7MrCxxDz9" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-03-31_custom_TevogenBioMember" id="Fact001687" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.0</ix:nonFraction></span>% of the Company
following the Merger; (ii) Former Tevogen Bio directors constituted the majority (six of seven) of the directors of the Company following
the Merger; and (iii) former Tevogen Bio management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire the net assets of Semper Paratus. As a
result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date fair value in the consolidated financial
statements and the reported operating results prior to the Merger are those of Tevogen Bio. Immediately after the Merger, there were
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331_zWmMoVzxq46g" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-01to2024-03-31" id="Fact001689" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></span> shares of the Company&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001691" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_z0UveVE1Z4Rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zoftPmTp3y0f" style="display: none">SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zc4CykHVrO3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 14, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_zV26RK6wEI0g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2024-02-14" id="Fact001693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z9ExmMKMHUbh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="AsOf2024-02-14" id="Fact001695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,819</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_z0ckBmta55U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2024-02-14" id="Fact001697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,501</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zRRY1Onz2Gog" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2024-02-14" id="Fact001699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,175</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zmkHDZ64vAS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="AsOf2024-02-14" id="Fact001701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,126</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_msBCRIAzgn3_zQHvgagApXC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" contextRef="AsOf2024-02-14" id="Fact001703" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_iNI_di_msBCRIAzgn3_zPIFDH3dmFli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" contextRef="AsOf2024-02-14" id="Fact001705" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maTNLAPz196_zg7P9MDwAob7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2024-02-14" id="Fact001707" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,654,653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--PlusMergerTransactionCostsLimitedToCashAcquired_iI_maTNLAPz196_z5xGmUJppzPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="TVGN:PlusMergerTransactionCostsLimitedToCashAcquired" contextRef="AsOf2024-02-14" id="Fact001709" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">229,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TotalNetLiabilitiesAcquiredPlusTransactionCosts_iTI_mtTNLAPz196_zvfeqz28WXeh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="TVGN:TotalNetLiabilitiesAcquiredPlusTransactionCosts" contextRef="AsOf2024-02-14" id="Fact001711" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,883,981</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z1QziPvFDykb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
transaction costs of $<span id="xdx_900_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_zIOzuNWVhvIl" title="Transaction costs"><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="AsOf2024-02-14" id="Fact001713" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,728,681</ix:nonFraction></span>
were incurred in relation to the Merger up through the Closing Date, of which $<span id="xdx_900_ecustom--TransactionCosts_c20240214__20240214_zJWnZosVmtHi" title="Transaction costs"><ix:nonFraction name="TVGN:TransactionCosts" contextRef="From2024-02-142024-02-14" id="Fact001715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were
charged directly to equity to the extent of the cash received from the Merger with the balance of $<span id="xdx_90D_ecustom--TransactionCost_c20240101__20240331_zE1kFlO5byR4" title="Charged expense"><ix:nonFraction name="TVGN:TransactionCost" contextRef="From2024-01-01to2024-03-31" id="Fact001717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499,353</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">charged
to Merger transaction costs for the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_z1u7azhHCoNa" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_EarnoutSharesMember" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500,000</ix:nonFraction></span>
shares of common stock (&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Company&#8217;s
common stock reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5,
Earnout Shares, for further details of the earnout arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor. The issuance date fair value of the Series B
Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. See Note 9 for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: sp_001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001721" name="TVGN:EarnoutSharesDisclosureTextBlock"><p id="xdx_802_ecustom--EarnoutSharesDisclosureTextBlock_zezZHVWR3rTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_821_ze9t1JFAlNOg">EARNOUT SHARES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, former holders of Tevogen Bio common stock may receive up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zF6pEB5Y4MC6" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember" id="Fact001723" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout
Shares in tranches of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zSyvwVMMBLbc" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember" id="Fact001725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zIs0VCfutmub" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember" id="Fact001727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zk6lHxtoD50h" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember" id="Fact001729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,666</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the
Company&#8217;s common stock is greater or equal to
$<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHKG1bgeCYN3" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember" id="Fact001731" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
$<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOvg7oReEA0a" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember" id="Fact001733" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPDwtSTZV8bd" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember" id="Fact001735" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, <span id="xdx_902_ecustom--EarnoutSharesTradingDaysDescription_c20240101__20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zNkPNJJTyhq9" title="Earnout shares trading days description"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember" id="Fact001737" name="TVGN:EarnoutSharesTradingDaysDescription">over
any twenty trading days within any thirty consecutive day trading period during the three-year period after the
Closing.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#8217;s three earnout tranches
are for <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zKessTEbQwKa" title="Earnout shares"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zwIsXdW0uRpf" title="Earnout shares"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zLLVCklvlkle" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact001741" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact001743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> shares of common stock, for an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zUewsBnPcgGe" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember" id="Fact001745" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500,000</ix:nonFraction></span> shares across the entire Sponsor earnout.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Earnout Shares are a form of dividend for holders of Tevogen Bio common stock, and the Earnout Shares earnable by the Sponsor are treated
as contingent consideration in a reverse recapitalization. In accordance with ASC 815, the Earnout Shares were considered to be indexed
to the Company&#8217;s common stock and are classified within permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001747" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zkfxlxCibSS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_821_zlKXu5pkRWzc">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001749" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zllsvmfRvbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z1XStT9irsL4" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240331_zCNwgiFUWVxh" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231__srt--RestatementAxis__custom--ReverseRecapitalizationMember_z9vhWj64T8g6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December, 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedProfessionalServiceFeesCurrent_iI_maALCzC3I_zLX4Kx1CaUm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="TVGN:AccruedProfessionalServiceFeesCurrent" contextRef="AsOf2024-03-31" id="Fact001751" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337,588</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="TVGN:AccruedProfessionalServiceFeesCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,301</ix:nonFraction></td><td style="width: 1%; text-align: left"/></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_z1JlnIguFiji" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact001754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zBj95Ne7Kmxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact001757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,564,834</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember" id="Fact001758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zA14P3pBJgah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001760" name="us-gaap:MortgageNotesPayableDisclosureTextBlock"><p id="xdx_80A_eus-gaap--MortgageNotesPayableDisclosureTextBlock_z6fM0BTC6wjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_82F_zaNShb19JN88">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) for which the proceeds were to be used for working capital purposes by Semper Paratus with
an outstanding balance of $<span id="xdx_90D_ecustom--WorkingCapital_iI_c20240331_z2rd1NgbhOi5"><ix:nonFraction name="TVGN:WorkingCapital" contextRef="AsOf2024-03-31" id="Fact001761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
the Closing Date and remain outstanding at March 31, 2024. The notes payable do not accrue interest. The outstanding balance of the notes was required to be repaid in full within five business days of the Merger, and
the Company is therefore in default of its obligations at March 31, 2024. The notes&#8217; default provisions require the Sponsor to transfer
a certain number of its own shares to Polar on a monthly basis until the default is cured, subject to an aggregate cap, but do not require
the Company to transfer any shares or pay any amounts to Polar. Polar waived the Sponsor&#8217;s requirement to transfer shares with respect
to the initial month of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001763" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1Qm76faae74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_82F_zQsBKeqcG9T6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Each restricted stock unit (&#8220;RSU&#8221;)
award granted under the 2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into
an award under the 2024 Plan with respect to the common stock of the Company. Such converted awards remain subject to the same terms
and conditions as set forth under the applicable award agreement prior to the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2024 Plan, the Company is authorized to grant awards up to an aggregate <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember_zotpVhPc43Tl" title="Granted awards shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember" id="Fact001765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span>
shares of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, restricted stock, restricted
stock units, and other equity-based awards. As of March 31, 2024, awards for <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zYPiJh01P4Zc" title="Granted awards shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-03-31_custom_IncentivePlanMember" id="Fact001767" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,651,046</ix:nonFraction></span>
shares remained available to be granted under the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#8220;Performance-Based RSUs&#8221;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 187; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z9bIoNHLNVW4"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs
under the 2024 Plan to the Company&#8217;s Chief Executive Officer, Dr. Ryan Saadi (the &#8220;Special RSU Award&#8221;). Such RSUs
immediately converted into shares of restricted common stock (&#8220;Restricted Stock&#8221;), the restrictions on which lapse in
four equal annual installments beginning on February 14, 2031 (&#8220;Vesting Period&#8221;). Pursuant to the terms of the Special
RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged,
hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock in the
event he departs the Company. The fair value per share for the Special RSU Award was determined to be $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeb7T8TzId62"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact001769" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, equivalent to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date fair value of $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zmWTaIEjNy61"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact001770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,263,783</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In accordance with ASC 718, <i>Compensation &#8211; Stock Compensation</i> (&#8220;ASC 718&#8221;), the Company will recognize
compensation expense on a straight-line basis from the Closing Date until the completion of the Vesting Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001772" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zdpajvJt0qTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zhJqhOvAGR6l" style="display: none">SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Nonvested as of January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z83uWATEILW1" title="Nonvested Shares, Beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zu0LhFu4Aasj" title="Nonvested weighted average grant-date fair value, Beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></td><td style="border-right: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaujT7apMUpl" title="Nonvested Shares, Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zsyxDlVNXEGl" title="Nonvested weighted average grant-date fair value, Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z9yU478s4eg8" title="Nonvested Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember" id="Fact001782" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zbAsZYkbhM2f" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember" id="Fact001784" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1wIbOm1tbYh" title="Nonvested Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYg3gbr3SUyg" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zyx6Tm6CnHce" title="Nonvested Shares, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zoIvjh7wYkxd" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zFAIDCc7Y2K" title="Nonvested Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,148,506</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zB1hX4HVoBPf" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="Fact001796" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z1p6P8RsdBzk" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zPUaRSuSVK6l" title="Nonvested weighted average grant-date fair value, Forfeited" style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zGGyRtxUb7B4" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z7ISujfViPa9" title="Nonvested weighted average grant-date fair value, Forfeited" style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOi2SXcJII9f" title="Nonvested Shares, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-03-31_custom_ServiceBasedRestrictedStockMember" id="Fact001806" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zS1RixakFqQ3" title="Nonvested weighted average grant-date fair value, Ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-03-31_custom_ServiceBasedRestrictedStockMember" id="Fact001808" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zN0k23fzW3vj" title="Nonvested Shares, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-03-31_custom_PerformanceBasedRSUsMember" id="Fact001810" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,751,622</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlPecO79tg4" title="Nonvested weighted average grant-date fair value, Ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-03-31_custom_PerformanceBasedRSUsMember" id="Fact001812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AC_zH39E8Sq4aRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYIPCDMfcVok" title="Compensation cost recognized"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,233,487</ix:nonFraction></span> was recognized
for the Performance-Based RSUs, which will be issued and outstanding after March 31, 2024. There was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyBQiB0pbdsd" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,164,020</ix:nonFraction></span> of unrecognized compensation cost related to Restricted Stock as
of March 31, 2024 which will be expensed over a weighted average period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyVejtu9QN68" title="Weighted average period"><ix:nonNumeric contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember" format="ixt-sec:duryear" id="Fact001818" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.9</ix:nonNumeric></span> years. There was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znWueLWMrKP2" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-03-31_custom_PerformanceBasedRSUsMember" id="Fact001820" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,104,643</ix:nonFraction></span> of unrecognized compensation
cost related to Performance-Based RSUs as of March 31, 2024 which will be expensed over a weighted average period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zLJSwvfiUEO7" title="Weighted average period"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember" format="ixt-sec:duryear" id="Fact001822" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.2</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001824" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zC9fXNTzWGk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zXFl7uLL0Hs7" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20240331_zoqt4oqEtHwc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDfPraaNw6Qe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,735,896</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKiaDPHxJTql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,597,353</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z2AeX3C1J044" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-03-31" id="Fact001830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,333,249</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zJW6Jpols79i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensation_dxL_c20230101__20230331_zSFgaGmTfXI7" title="Compensation cost recognized::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1832">No</span></span>
stock-based compensation expense was recognized during the three months ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001834" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztGFWxBTy8kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_826_zBea3ZTkddpg">STOCKHOLDERS&#8217; DEFICIT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>Common Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of February 15, 2024, the Company&#8217;s
common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW&#8221;,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of March 31, 2024, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240331_zFhYlpmWMJke" title="Common shares, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zcJLFKJFOmM5" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact001836" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact001838" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested or are not subject
to repurchase are considered issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001840" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zY5jL67Rs2Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Below is a reconciliation of shares of common stock issued and outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zZo8Qih3N086">SCHEDULE
OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock legally issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20240331_zsMZdC6rjITa" title="Common shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zjYfmLv5o8Ea" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact001842" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact001844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: Shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares issuable to Polar <span>(a)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesToBeIssuedOnSharesIssuable_iI_c20240331_fKGEp_zMeI2mD6dNV4" title="Shares issuable to Polar" style="text-align: right"><ix:nonFraction name="TVGN:SharesToBeIssuedOnSharesIssuable" contextRef="AsOf2024-03-31" id="Fact001846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issuable to Polar" style="text-align: right"><p id="xdx_983_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20240331_fKGIp_zXBFTzzS3Bq7" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing" style="margin: 0"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2024-03-31" id="Fact001848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,148,506</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Issuance of restricted common stock subject to forfeiture
    <span>(c)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20240331_fKGMp_z5jRYgf928xj" title="Issuance of restricted common stock subject to forfeiture" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" contextRef="AsOf2024-03-31" id="Fact001850" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued and outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20240331_zU2AIRwtMn07" title="Total shares issued and outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" contextRef="AsOf2024-03-31" id="Fact001852" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">153,913,970</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0E_zSFUsb3mIPXf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zVLlsyBIhf2g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001853" xml:lang="en-US">Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td id="xdx_F0A_z3CtrESEccf7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(b)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p id="xdx_F18_zIQMiBkzr678" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:footnote id="Footnote001854" xml:lang="en-US">As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.</ix:footnote></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zHMvLEAIjjn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zdgGRYz4aBu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001855" xml:lang="en-US">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A2_zNrP1QjuNk07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s
common stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio,
as discussed in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 188; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Preferred Stock</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331_zYPXBdzcNdI9" title="Preferred shares, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact001857" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331_zESzwfjnzTsa" title="Preferred shares, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">I<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n
March 2024, the Company authorized and issued <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1TQsskKFFYe" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001861" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></span> and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1sAf5wyTPj" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares,
respectively, of Series A Preferred Stock (the &#8220;Series A&#8221;) to an investor at a price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUYzddNAGNmk"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001864" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (the &#8220;Series A Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCJnWajq7eXj" title="Proceeds from issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001866" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span> The Company recorded an expense of $<span id="xdx_904_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zn3WtQPCy6hh" title="Loss on preferred stock issuance"><ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">799,990</ix:nonFraction></span> in its consolidated statements of operations related to issuance of the Series A equal
to the fair value of the Series A when issued of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW0vScNOJjhf" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5,600</ix:nonFraction></span> per share less the purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zWezmWpjHre"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001871" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuaTZfQiWyF5" title="Dividend rate, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-03-262024-03-27_us-gaap_SeriesAPreferredStockMember" id="Fact001873" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
per annum per share on <span id="xdx_90B_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWbqiruCDfd" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-03-262024-03-27_us-gaap_SeriesAPreferredStockMember" id="Fact001875" name="us-gaap:PreferredStockDividendPaymentRateVariable">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the
&#8220;Series A Accruing Dividends&#8221;)</ix:nonNumeric></span>. These dividends become payable when and if declared by the Company. The Series A
Preferred Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series B Preferred Stock (the &#8220;Series B&#8221;) in liquidation priority. In the
event of a liquidation of the Company, or certain deemed liquidation events, the Series A is redeemable for a price
equal to the greater of the Series A Original Issue Price plus all Series A Accruing Dividends that are unpaid through the
redemption date, or such amount that would have been payable had the Series A converted into shares of
common stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence
of a deemed liquidation event. The Company is entitled to redeem that Series A at a price equal to the Series A Original
Issue Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds
$<span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCWwsmAWOVz6" title="Redemption per share"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2024-03-27_us-gaap_SeriesAPreferredStockMember" id="Fact001877" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span> per share for <span id="xdx_905_eus-gaap--PreferredStockRedemptionTerms_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7UH72EETIwl" title="Redemption term"><ix:nonNumeric contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001879" name="us-gaap:PreferredStockRedemptionTerms">the twenty days immediately prior to the Company&#8217;s call election</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal
to the Series A Original Issue Price divided by the Series A Conversion Price, which is initially $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTbEsICcDl5l" title="Conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-03-27_us-gaap_SeriesAPreferredStockMember" id="Fact001881" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share and is subject to standard
antidilution adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A-1 Preferred Stock </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Series A investor covering the
issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zXZHxPobwsVf" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember" id="Fact001883" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span> shares of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zvjrGPPmFNRd" title="Stock issuance, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember" id="Fact001885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span>. <span id="xdx_901_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zJ5kIXmKRtdc" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember" id="Fact001887" name="us-gaap:PreferredStockDividendPaymentRateVariable">The terms of the Series A-1 Preferred
Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum and the Series
A-1 Issuance Price is defined as $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfdbaJOfPvO9"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_custom_SeriesAOnePreferredStockMember" id="Fact001888" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,000</ix:nonFraction></span> per share.</ix:nonNumeric></span> As of March 31, 2024, the investor had paid a non-refundable deposit of $<span id="xdx_90A_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zFh4aSmduqa2" title="Non refundable amount"><ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember" id="Fact001890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>
towards the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the
Sponsor assuming liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. On March 15,
2024, <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8YcxbKTk1M9" title="Conversion of certain liabilities into Series B preferred stock, shares"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities" contextRef="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember" id="Fact001892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613</ix:nonFraction></span>
shares of Series B were issued in return for the assumption of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWozjgcIKip6" title="Conversion of certain liabilities into Series B preferred stock"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities" contextRef="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></span>
of liabilities. As these liabilities were unpaid and the Company was not legally released by the creditors, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
liabilities were not extinguished and</span> remain on the Company&#8217;s balance sheets at March 31, 2024. The issuance date fair
value of the Series B was determined to be $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zC4nA0EymVBi" title="Conversion of certain liabilities into Series B preferred stock"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities" contextRef="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember" id="Fact001896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></span>
and was recorded within Merger transaction costs in the consolidated statements of operations. The Series B is classified as
permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series B are entitled to receive cumulative dividends at the Series B Dividend Rate, which accrue quarterly on the basis of a
360-day year and accrue whether or not declared by the Company provided that to the extent the Assumed Liabilities are outstanding,
any dividend(s) will be paid by the Company on behalf of the Sponsor to the creditors first. <span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z46y9HrWiFE9" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001898" name="us-gaap:PreferredStockDividendPaymentRateVariable">The
Series B Dividend Rate is initially 3.25% per quarter, increases by 0.25% on each 30-day anniversary of the Initial Dividend Date
(Defined below), and capped at 7.5% per quarter.</ix:nonNumeric></span> The &#8220;Initial Dividend Date&#8221; is defined as 35 days after the
initial issuance date of the Series B. Subsequent dividends are due and payable on the quarterly anniversary of the initial issuance
date, or if that date is not a business day, due and payable on the next succeeding business day. Series B dividends payable are
calculated as the Dividend Rate multiplied by the Series B Issue Price of $<span id="xdx_90F_eus-gaap--DividendsPayableAmountPerShare_iI_c20240331_zqMcpNZytuxa" title="Dividends payable per share"><ix:nonFraction name="us-gaap:DividendsPayableAmountPerShare" contextRef="AsOf2024-03-31" id="Fact001900" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span>
per share. Series B dividends are payable whether or not declared by the Company, and are recorded within accounts payable of the
consolidated balance sheets as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Preferred Stock ranks senior to common stock and junior to Series A in liquidation priority. In the event of
a liquidation of the Company, the Series B is redeemable for a price equal to the aggregate amount of the liabilities
assumed by the Sponsor following the Closing, which was $<span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyQiao17idza" title="Redemption per share"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 189; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B are not entitled to redeem their shares outside of the liquidation of the Company. The Company is
entitled to redeem the Series B at a price equal to the Series B Issue Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B Preferred Stock do not contain any conversion rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zfYPWcrbQ0pe" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-30_custom_SemperParatusMember" id="Fact001904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,975,000</ix:nonFraction></span> warrants initially issued by Semper Paratus in November 2021, comprising <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zlwWEOh4MHud" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001906" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,250,000</ix:nonFraction></span> public warrants sold in the
IPO and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMSTg0CyeeL9" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember" id="Fact001908" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></span> warrants issued in a concurrent private placement, were assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z8zqCNTi4dk1" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001910" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span>
per share, became exercisable on <span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zH1p7LRjbER7" title="Exercisable date"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001912" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March
15, 2024</ix:nonNumeric></span>, and will expire at 5:00 p.m., New York City time, on February 14, 2029, or earlier upon redemption or liquidation.
Warrant holders may, until such time as there is an effective registration statement and during any period when the Company has
failed to maintain an effective registration statement covering the shares of the Company&#8217;s common stock issuable upon
exercise of the warrants, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities
Act of 1933, as amended, or another exception. <span id="xdx_90D_ecustom--WarrantsDescription_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zSMe7Blb9Hpf" title="Warrants description"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001914" name="TVGN:WarrantsDescription">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days
within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption
to the holders of public warrants.</ix:nonNumeric></span> As of March 31, 2024, there are <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zNO0OzvNYTYg" title="Number of warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-03-31_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001916" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,250,000</ix:nonFraction></span>
public warrants outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Private
Placement Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the Sponsor or its permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders on a cashless
basis. As of March 31, 2024, there are <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfnAt6a825Vj" title="Number of warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-03-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember" id="Fact001918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></span> private placement warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for additional information on the Company&#8217;s
warrant accounting policy.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001920" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdq2OcXxCE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_829_zqHcsCJYp0Qc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><i>Transactions with Sponsor</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Pursuant to the Merger Agreement, the
Company incurred $<span id="xdx_90D_eus-gaap--SponsorFees_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zGSzqMPEi0e7"><ix:nonFraction name="us-gaap:SponsorFees" contextRef="From2024-01-012024-03-31_custom_SponsorAdvisoryServicesFeeMember" id="Fact001921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction>
</span>in fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory Service Fee&#8221;). In connection with the Merger and
thereafter, the Company and Sponsor agreed that $<span id="xdx_904_eus-gaap--SponsorFees_c20240101__20240331_zDcK1SOKuNva" title="Sponsor advisory services fee"><ix:nonFraction name="us-gaap:SponsorFees" contextRef="From2024-01-01to2024-03-31" id="Fact001923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> of the Sponsor Advisory Service Fee is payable in cash, $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember_zEqpHQEHwr8a" title="Due to Sponsor"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-03-31_custom_SponsorMember" id="Fact001925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> would be offset
against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zB1MkZ813bog"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-03-31_custom_SponsorAdvisoryServicesFeeMember" id="Fact001926" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction>
</span>shares of the Company&#8217;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented <span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember__us-gaap--DebtInstrumentAxis__custom--PolarNotesMember_z53BiEN4NwJ9">on
the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated balance sheets under the line item
&#8220;Due to related party&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the Sponsor owes the Company $<span id="xdx_908_ecustom--WorkingCapitalExpenses_c20240101__20240331_z5jjTLp86GZ9" title="Working capital expenses"><ix:nonFraction name="TVGN:WorkingCapitalExpenses" contextRef="From2024-01-01to2024-03-31" id="Fact001929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,819</ix:nonFraction></span> to cover working capital expenses which is presented on the consolidated balance
sheets under the line item &#8220;Due from related party&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 9 for additional information on the Series B issued to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 190; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.<br/>
NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84Gt1zrAZfg" title="Isssued shares to related party"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefExecutiveOfficerMember" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> Performance-Based RSUs to the wife of the Company&#8217;s chair and chief executive officer for
advisory services provided to the Company, and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZuYGnbdjli4" title="Isssued shares to related party"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefFinancialOfficerMember" id="Fact001933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> Performance-Based RSUs to Mehtaphoric Consulting Inc, a company controlled by
the daughter of the Company&#8217;s chief financial officer, for information technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20240331_zb5osuQACug2" title="Compensation cost recognized"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2024-01-01to2024-03-31" id="Fact001935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,396</ix:nonFraction></span> has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001937" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zKJHQFDWeYV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE 11. <span id="xdx_823_z0unTaUMmM02">NET INCOME (LOSS) PER SHARE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001939" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUEM9njRKv4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the computation of
basic and diluted income (loss) per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zvAOzgDMPIJa" style="display: none">SCHEDULE
OF NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240101__20240331_zBIw8xRlZL0l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230101__20230331_z7sjC8XY7KTh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILATz5q6_z2PwMSipxGSd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact001941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,264,842</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact001942" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iN_di_msNILATz5q6_zmkQDyPhYEve" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Less: Undistributed earnings allocated to participating securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">756,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz5q6_zSf2SWBkWWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,506,866</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-03-31" id="Fact001948" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_maNILATzP0S_z2Ff6mKtEnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact001950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,264,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact001951" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ConvertiblePromissoryNoteInterest_iT_mtNILATzP0S_zROaggmn9VJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ConvertiblePromissoryNoteInterest" contextRef="From2024-01-01to2024-03-31" id="Fact001953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,786</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ConvertiblePromissoryNoteChangeInFairValue_iT_mtNILATzP0S_zBXxLczt6Ci9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ConvertiblePromissoryNoteChangeInFairValue" contextRef="From2024-01-01to2024-03-31" id="Fact001956" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1957">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATzP0S_zO8LeU0GiuFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact001959" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,049,420</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-03-31" id="Fact001960" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,756,144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zUtr9hiU9Yf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,333,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31" id="Fact001963" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zSoaT7mNY0Na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) per share attributable to common stockholders, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001965" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" id="Fact001966" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_zk7Qs7Ur6R39" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2024-01-01to2024-03-31" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,333,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1969">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zV9daeYBB5P" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Effect of potentially dilutive convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="From2024-01-01to2024-03-31" id="Fact001971" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,053,849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_iT_zxSCH2gN79V3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2024-01-01to2024-03-31" id="Fact001974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,053,849</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zLkpyy5nDPWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-03-31" id="Fact001977" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,387,651</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31" id="Fact001978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zTLtB4KeNMN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss per share attributable to common stockholders - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact001980" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact001981" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_zmXT4wuhRAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt; text-align: left">Net loss per share attributable to common stockholders -
    diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact001983" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact001984" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A7_zVZkqKtyZ87g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of March 31, 2024 and 2023, the
Company&#8217;s potentially dilutive securities included Series A Preferred Stock, outstanding public warrants and convertible
promissory notes on an as-converted basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Series A and Restricted Stock are
participating securities as Series A is entitled to participate in dividends and in earnings (but not losses) of the Company on an
as-converted basis as common shares and the Restricted Stock holder is entitled to participate in any dividends declared on common
stock. Accordingly, undistributed earnings are allocated to common shares and participating securities based on the weighted-average
shares of each class outstanding during the period. See Note 8 and Note 9 for additional rights and privileges of Restricted Stock
and Series A, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Restricted Stock are excluded from
the weighted average common stock outstanding pending the achievement of underlying service conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company excluded the
following potential shares from the computation of diluted net loss per share because including them would have had an anti-dilutive
effect:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001986" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1svLnbgkff9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zX9yJpSE6KId" style="display: none">SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240101__20240331_zjzz6uQ0sK1j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230101__20230331_zp4V5Ik7QbQe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z1yhHirk81E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding restricted stock units <span id="xdx_F4B_zVGWFtbf7tW2">(a)</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001988" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,751,622</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001989" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,355,527</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zbB4ALKPBuLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember69286687" id="Fact001991" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zRl78jxQ6Duh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Public warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_custom_PublicWarrantsMember" id="Fact001994" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1995">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivateWarrantsMember_zg3ia8cpuoPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Private warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_custom_PrivateWarrantsMember" id="Fact001997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1998">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zgoXgyIZ6op5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible promissory notes <span id="xdx_F49_zZoNJbq20IK3">(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact002001" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,946,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zStoCMObkkt" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Earnout Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_custom_EarnoutSharesMember" id="Fact002003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2004">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zUZkOPaurhna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-03-31" id="Fact002006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,575,576</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31" id="Fact002007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,301,863</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F07_zDLLC4XmVDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zXrMPp7PXma3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002008" xml:lang="en-US">As
    of March 31, 2024, there were an additional <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8" title="Stock option vested" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember69287000" id="Fact002010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,148,506</ix:nonFraction></span>
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_z9Nlj73FiGLd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zjwOKjJ29YB8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002011" xml:lang="en-US">The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zHpNNTXLUHT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact002013" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zU884nHpm3Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span>SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">Note
10 &#8212; <span id="xdx_82D_zxi6St8bGCMe">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and transactions
for potential recognition or disclosure from the balance sheet date through May 28, 2024, the issuance date of these the financial statements
and has not identified any additional items requiring disclosure that have not previously been mentioned elsewhere.</p>

</ix:nonNumeric><p id="xdx_813_zVpBciauKCbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 191; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#sj_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#sj_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets, December 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#sj_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations, Years ended December 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#sj_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Changes in Stockholders&#8217; Deficit, Years ended December 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#sj_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows, Years ended December 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#sj_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-43</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 192; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_001"></span><b>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Inc:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Opinion
on the Financial Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Tevogen Bio Inc (the Company) as of December 31, 2023 and 2022, the related statements
of operations, changes in stockholders&#8217; deficit, and cash flows for the years then ended, and the related notes (collectively,
the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity
with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company has incurred losses and negative cash flows from operations since inception that raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note
2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
for Opinion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
KPMG LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
26,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 193; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_002"></span><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BALANCE
SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,052,397</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,484,265</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">670,582</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">352,977</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,722,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,837,242</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">621,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">684,919</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,582,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">271,141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">594,883</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,505,503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,738,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,418,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">865,910</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,096,450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">816,369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278,207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,712,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,479,542</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,960,486</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,220,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">234,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">432,726</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99,934,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,690,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and Contingencies (Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock &#8211; voting, $0.0025 par value; 36,000,000 shares authorized; 23,800,000 shares issued and outstanding at December 31, 2023 and 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock &#8211; non-voting, $0.0025 par value; 4,000,000 shares authorized; 952,000 shares issued and outstanding at December 31, 2023 and 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,380</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,166,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,166,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(99,657,737</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39,180,057</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94,428,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,951,217</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,505,503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,738,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 194; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_003"></span><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS
OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,403,526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,774,298</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,439,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,949,766</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,843,025</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,724,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,843,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,724,064</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,206,352</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(932,419</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50,428,303</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,384,918</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,477,680</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(22,041,401</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.44</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.87</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,752,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,253,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 195; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_004"></span>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS
OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock &#8211; voting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock &#8211; non-voting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Additional</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">paid-in</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">24,600,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">61,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">952,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">586,228</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(17,138,656</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(16,488,548</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Forfeiture of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(800,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,578,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,578,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,041,401</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,041,401</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,166,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,180,057</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33,951,217</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,477,680</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,477,680</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,800,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">952,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,380</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,166,960</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(99,657,737</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(94,428,897</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 196; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_005"></span>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS
OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(60,477,680</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(22,041,401</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,441</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,578,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,206,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">933,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,428,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,384,918</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,382</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(317,605</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(299,014</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,742</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(252,235</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,114,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354,913</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(603,832</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">568,695</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(223,361</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(114,368</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,171,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,655,855</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(479,042</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(479,042</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Payments of deferred transaction costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,872,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net decrease in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,431,868</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,634,897</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Cash &#8211; beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,484,265</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,119,162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash &#8211; end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,052,397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplementary disclosure of noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">133,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">de-SPAC transaction fees included in accounts payable, accrued expenses, and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,455,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 197; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_006"></span><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. BACKGROUND</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tevogen Bio Inc, a Delaware corporation (the &#8220;Company&#8221;),
is a clinical-stage specialty immunotherapy company harnessing the power of CD8+ cytotoxic T lymphocytes (&#8220;CD8+ CTLs&#8221;) to
develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The Company&#8217;s
precision T cell technology platform, ExacTcell, is a set of processes and methodologies to develop, enrich, and expand single human leukocyte
antigen-restricted CTL therapies with proactively selected, precisely defined targets. The Company has completed a Phase 1 proof-of-concept
trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of ambulatory, high-risk adult COVID-19 patients, and has
other product candidates in its pipeline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2024, pursuant to the Agreement
and Plan of Merger dated June 28, 2023 (the &#8220;Merger Agreement&#8221;) by and among Semper Paratus Acquisition Corporation
(&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK
Associates, LLC (&#8220;SSVK&#8221;), the Company, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged
with and into the Company, with the Company being the surviving entity and a wholly owned subsidiary of Semper Paratus
(together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc. (&#8220;Tevogen Holdings&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. DEVELOPMENT-STAGE RISKS AND LIQUIDITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred losses and negative cash flows from operations since inception, including an accumulated deficit of $99,657,737
as of December 31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant
sales from its product candidates currently in development. Management believes that cash of $1,052,397 as of December 31, 2023 as well
as $2,000,000 to Tevogen Holdings from a Series A Preferred Stock financing in February 2024 and $1,200,000 in connection with the Series A-1 Preferred Stock financing
thereafter (see Note 12) is not sufficient to sustain planned operations for 12 months from the issuance date of these financial
statements. As a result, the Company has concluded that substantial doubt exists about its ability to continue as a going concern for
one year from the date that the financial statements are issued. The accompanying financial statements have been prepared on a going-concern
basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements
do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification
of liabilities that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years. These strategies
may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings
of equity and/or debt securities. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely
affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and clinical trials, and pursuing the Business Combination. The Company is subject to those
risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be
no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary
regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of
rapid technological change and is largely dependent on the services of its employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 198; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Any reference in these
notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards
Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of expenses. Actual results
could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in
the financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock, the fair value of the convertible promissory
notes, the estimated useful lives of property and equipment and accrued research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations
of Credit Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that
    market participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable. The Company believes that the carrying
value of accounts payable approximates their fair values due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 199; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements primarily consist of the convertible promissory notes, for which the Company has elected
the fair value option to reduce accounting complexity. Such fair value measurements are Level 3 inputs. The following table provides
a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory notes, which are described in more detail in
Note 8:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">23,479,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">933,082</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,384,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,206,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,428,303</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">94,932,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes. Significant assumptions and ranges used in determining the fair value of convertible promissory notes include volatility (80%),
discount rate (35% - 36%), and probability of a future liquidity event (85% - 95%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were no cash equivalents as of December 31, 2023 and 2022 as all amounts consisted of bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment, net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center">5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">3-4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center">5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center">7</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of
an asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based
on this assessment, management has determined that there was no impairment during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted an accounting policy which provides that leases with an initial term of 12 months or less and without a purchase option
that the Company is reasonably certain of exercising will not be included within the lease ROU assets and lease liabilities on its balance
sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 200; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
The Company estimates the fair value of the Company&#8217;s common stock on the date of grant in accordance with the guidance outlined
in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of Privately-Held-Company
Equity Securities Issued as Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(ASC 740)
which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been
recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the
basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for
the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision
for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and,
to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the
deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for
recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax
planning strategies. At December 31, 2023 and 2022, the Company has concluded that a full valuation allowance is necessary for its net
deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. The
Company computes diluted net loss per share by dividing the net loss by the sum of the weighted-average number of common stock outstanding
during the period, plus the potential dilutive effects, if any, of unvested shares of common stock and the convertible promissory notes
on an as-converted basis. Given the Company&#8217;s net loss, the impact of the unvested shares of common stock and the convertible promissory
notes are anti-dilutive, and basic and diluted net loss per share for the years ended December 31, 2023 and 2022 are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the Company&#8217;s potentially dilutive securities were outstanding restricted stock units and the convertible
promissory notes on an as-converted basis. The Company excluded the following potential shares from the computation of diluted net loss
per share because including them would have had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding restricted stock units</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,248,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,041,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes <sup>(a)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">183,845</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">538,037</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,432,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,579,037</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            number of shares was determined based on the conversion upon maturity provisions in the convertible
                                            promissory note agreements, dividing the conversion amount (principal plus accrued interest)
                                            by three times the estimated fair value of the Company&#8217;s common stock derived from
                                            the Company&#8217;s most recently completed convertible promissory notes valuation as of
                                            the balance sheet date.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 201; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Standards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, Debt - <i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. This amended guidance is effective for the Company
for annual and interim periods beginning after December 15, 2023. Early adoption is permitted. The Company is currently evaluating the
potential impact of the standard on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. PROPERTY AND EQUIPMENT, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,341</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,341</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,217</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture and fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,743</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,743</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,769</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(263,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(99,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">621,951</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2023 and 2022 was $163,300 and $90,441, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. ACCRUED EXPENSES AND OTHER LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">445,288</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,481</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">883,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">816,369</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using an incremental
borrowing rate of 11.1%, which was determined using a synthetic credit rating model. Lease expense for the year ended December 31, 2023
was $1,050,452, which consisted of $882,626 and $167,826 recognized as a component of research and development expense and general and
administrative expense, respectively. This amount included $770,092 of expense under short-term leases. Lease expense for the year ended
December 31, 2022 was $629,208, which consisted of $481,971 and $147,237 recognized as a component of research and development expense
and general and administrative expense, respectively. This amount included $423,264 of expense under short-term leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining lease term for the Company&#8217;s operating leases as of December 31, 2023 was 1.88 years. The weighted average
discount rate for the Company&#8217;s operating leases for the year ended December 31, 2023 was 11.1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Years Ending December 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">291,703</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,471</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,975</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536,149</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48,577</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">487,572</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash payments related to leases for the years ended December 31, 2023 and 2022 were $1,058,754 and $600,366, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 202; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. CONVERTIBLE PROMISSORY NOTES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into the following convertible promissory notes at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Original Issuance Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rate</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued Interest as of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value as of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value as of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%">Note 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center">1/22/2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center">7/22/2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">6.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,768,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">65,063,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">25,140,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Note 2</td><td>&#160;</td>
    <td style="text-align: center">10/18/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">10/18/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,649,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,023,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Note 3</td><td>&#160;</td>
    <td style="text-align: center">3/14/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/14/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,616</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,358,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,510,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Note 4</td><td>&#160;</td>
    <td style="text-align: center">12/23/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/23/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,057,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,624,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Note 5</td><td>&#160;</td>
    <td style="text-align: center">2/3/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/3/2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,040,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">N/A</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Note 6</td><td>&#160;</td>
    <td style="text-align: center">9/25/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">9/25/2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,895</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,354,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">N/A</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Note 7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">10/8/2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">350,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">10/8/2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">411,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">N/A</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">94,932,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,297,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
interest expense incurred on the convertible promissory notes (collectively referred to as the &#8220;Notes&#8221;) during the years
ended December 31, 2023 and 2022 totaled $1,206,697 and $933,082, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the fair value measurement option to account for the Notes. Under this method, changes in fair value are reported in
the statements of operations. There were no changes in instrument-specific credit risk for the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, the Notes and accrued interest were automatically
converted into an aggregate of 10,337,419 shares of common stock of Tevogen Holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. STOCK-BASED COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Company adopted the 2020 Equity Incentive Plan (&#8220;Incentive Plan&#8221;), under which the Company is authorized to grant
awards up to an aggregate 4,000,000 shares of non-voting common stock. The Incentive Plan provides for the grant of options, stock appreciation
rights, restricted stock, restricted stock units, and other equity-based awards. As of December 31, 2023, awards for 959,667 shares remained
available to be granted under the Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;) that are subject to either
service-based vesting conditions or service-based and performance-based vesting conditions. Compensation expense for service-based RSAs
and RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation expense for service-based and performance-based
RSAs and RSUs (referred to as &#8220;Performance-Based&#8221; RSAs and RSUs) are recognized when the performance condition, which is
based on a liquidity event condition being satisfied, is deemed probable of achievement. All awards issued for periods presented were
non-voting common stock. Performance-Based RSAs forfeited during the year ended December 31, 2022 were voting common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 203; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU
activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,041,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">13.80</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,041,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,248,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14.38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSA
activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Service-Based RSAs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Performance-Based RSAs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Nonvested as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">463,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">800,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(463,334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.63</td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(800,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the performance condition was not probable of achievement and therefore no compensation cost has been recognized.
There was $32,338,156 of unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2023 which was subsequently
recognized as stock-based compensation expense in the Company&#8217;s Statement of Operations in February 2024 upon the consummation
of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
$4,578,732 of the stock-based compensation expense in 2022 was categorized to general and administrative expense in the accompanying
statements of operations. No stock-based compensation expense was recognized in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s net losses for 2023 and 2022, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Federal benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.9</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.5</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 204; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
deferred tax assets as of December 31, 2023 and 2022 consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,755,008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,828,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,958</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">718,425</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">577,269</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Capitalized research and development expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,589,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,430,195</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">192,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,549,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,319,074</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,426,952</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,175,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122,798</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,833</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Right of use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,833</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,833</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company has federal net operating loss (NOL) carryforwards of $13,882,569 that can be carried forward indefinitely.
Additionally, the Company has state NOL carryforwards of $16,351,869 which begin to expire in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company has federal and state tax credit carryforwards of $145,515 and $217,646, respectively, which begin
to expire in 2040 and 2028, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research and developmental (&#8220;R&amp;D&#8221;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;D expenditures
that are paid or incurred in connection with their trade or business. Specifically, costs for U.S. based R&amp;D activities must be amortized
over five years and costs for foreign R&amp;D activities must be amortized over 15 years&#8212;both using a midyear convention. During
the years ended December 31, 2023 and 2022, the Company capitalized $5,104,720 and $7,567,169, respectively, of R&amp;D expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s deferred tax assets. Given the
Company&#8217;s history of net losses since inception, management has determined that it is more likely than not that the Company will
not realize the benefits of its deferred tax assets. As a result, a full valuation allowance has been established at December 31, 2023
and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
382 of the Internal Revenue Code of 1986, as amended, contains rules that limit the ability of a company that undergoes an ownership
change to utilize its NOLs and tax credits existing as of the date of such ownership change. Under the rules, such an ownership change
is generally any change in ownership of more than 50% of a company&#8217;s stock within a rolling three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Valuation allowance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,175,241</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,618,774</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increases recorded to income tax provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,251,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,556,467</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,426,952</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,175,241</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than 50%
likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain tax positions
as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 205; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO INC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been
recognized in the Company&#8217;s statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the United States and various state and local jurisdictions. The federal and state tax returns are
generally subject to examination for the years ended December 31, 2020 through December 31, 2023. There are currently no pending tax
examinations. To the extent the Company has tax attribute carryforwards, the tax year in which the attribute was generated may still
be adjusted upon examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued 40,000 Performance-Based RSUs to the wife of the Company&#8217;s chairman and chief executive officer
for advisory services provided to the Company, and 20,000 Performance-Based RSUs to Mehtaphoric Consulting Inc., a company controlled
by the daughter of the Company&#8217;s chief financial officer, for information technology services provided to the Company. As of December
31, 2023, the performance condition was not probable of achievement and therefore no compensation cost has been recognized. There was
$533,600 and $266,800, respectively, of unrecognized compensation cost related to these Performance-Based RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 26, 2024, the issuance date of these the financial statements, and has not identified any requiring disclosure except
as described in Note 1 and Note 8 and as noted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In February 2024, Tevogen
Holdings sold $2,000,000 of shares of Series A Preferred Stock. In March 2024, Tevogen Holdings entered into an agreement to sell
$6,000,000 of Series A-1 Preferred Stock, for which proceeds of $1,200,000 have been received. The shares of Series A
Preferred Stock are convertible into a total of 500,000 shares of Tevogen Holdings common stock and the shares of Series A-1
Preferred Stock will be convertible into a total of 600,000 shares of Tevogen Holdings common stock, in each case at the election of
the holder. Each of the Series A Preferred Stock and the Series A-1 Preferred Stock is subject to a call right providing Tevogen
Holdings the right to call the stock if the volume weighted average price of the common stock for the 20 days prior to delivery of
the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the
underlying common stock. Each of the Series A Preferred Stock and the Series A-1 Preferred Stock is non-voting, has no mandatory
redemption, and carries an annual 5% cumulative dividend, increasing by 2% each year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2024, in connection with the
consummation of the Business Combination, the obligation to pay $1,700,000 of transaction costs included in accounts payable and
accrued expenses and other liabilities as of December 31, 2023 was assumed by a third party in consideration for the issuance of
Series B Preferred Stock of Tevogen Holdings. The Series B Preferred Stock is non-voting, non-convertible, callable by Tevogen
Holdings at any time, and pays a 3.25% quarterly dividend beginning 35 days after issuance. The dividend rate will increase by 0.25%
each month that the Series B Preferred Stock remains outstanding after the first 30 days after its issuance, but in no event will
increase to more than 7.5% per quarter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 206; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Other Expenses of Issuance and Distribution.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other
than underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants, including
underwriters&#8217; commissions and discounts, brokerage fees, underwriter marketing costs, and all reasonable fees and expenses of any
legal counsel representing the Registered Holders, except that we will pay the reasonable fees and expenses of one U.S. legal counsel
and local counsel in any other applicable jurisdiction(s) for the Registered Holders party to the A&amp;R Registration Rights
Agreement in the event of a demanded underwritten offering of their securities. We will bear all other costs, fees and expenses
incurred in effecting the registration of the securities covered by this prospectus, including, without limitation, all registration
and filing fees, printing and delivery fees, and fees and expenses of our counsel and our accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    and Exchange Commission registration fee</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,344.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    printing and miscellaneous expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,800.69</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">336,145.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Indemnification of Directors and Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, the Company is subject to the provisions of the DGCL.
Section 145(a) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than
an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person
acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its
equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably
believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had
reasonable cause to believe that such person&#8217;s conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(b) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason
of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise
against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or
settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not
opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court
of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of
liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
which the Delaware Court of Chancery or such other court shall deem proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 207; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(c) of the DGCL provides that to the extent that a present or former director or officer of a corporation has been successful on the
merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a) and (b), or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred
by such person in connection therewith, and the corporation may indemnify any other person who is not a present or former director or
officer of the corporation against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person to the
extent he or she has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a)
and (b), or in defense of any claim, issue or matter therein. For indemnification with respect to any act or omission occurring after
December 31, 2020, references to &#8220;officer&#8221; for purposes of Section 145(c) shall mean only a person who at the time of such
act or omission is deemed to have consented to service by the delivery of process to the registered agent of the corporation pursuant
to section 3114(b) of title 10 (for purposes of this sentence only, treating residents of the State of Delaware as if they were nonresidents
to apply section 3114(b) of title 10 to this sentence).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(d) of the DGCL provides that any indemnification under Section 145(a) and (b) (unless ordered by a court) shall be made by the
corporation only as authorized in the specific case upon a determination that indemnification of the present or former director,
officer, employee or agent is proper in the circumstances because such person has met the applicable standard of conduct set forth
in Section 145(a) and (b). Such determination shall be made, with respect to a person who is a director or officer of the
corporation at the time of such determination, (1) by a majority vote of the directors who were not parties to such action, suit or
proceeding, even though less than a quorum; or (2) by a committee of such directors designated by majority vote of such directors,
even though less than a quorum; or (3) if there are no such directors, or if such directors so direct, by independent legal counsel
in a written opinion; or (4) by the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(e) of the DGCL provides that expenses (including attorneys&#8217; fees) incurred by an officer or director of the corporation in
defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of
the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to
repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized
in Section 145. Such expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents
of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation,
partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the board of directors
deems appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(f) of the DGCL provides that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall
not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity
and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under
a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to the certificate of
incorporation or the bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or
investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect
at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(g) of the DGCL provides that a corporation shall have the power to purchase and maintain insurance on behalf of any person who is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted
against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or
not the corporation would have the power to indemnify such person against such liability under Section 145.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(j) of the DGCL states that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall,
unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or
agent and shall inure to the benefit of the heirs, executors and administrators of such a person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 208; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
174 of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends
or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful
actions were approved or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the
books containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
director receives notice of the unlawful acts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certificate
of Incorporation. </i>The Charter provides that the Company to fullest extent permitted by the DGCL as it presently exists or
may hereafter be amended, may indemnify and advance expenses to any person made or threatened to any person threatened to be made a party
to an action, suit, or proceeding, whether criminal, civil, administrative, or investigative, by reason of the fact that such person,
or such person&#8217;s testator or intestate, is or was a director or officer of the Company or any predecessor of the Company,
or serves or served at any other enterprise as a director, employee, or agent at the request of the Company or any predecessor
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter also provides that to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, a director
or officer of the Company shall not be personally liable to the Company or to its stockholders for monetary damages for
any breach of fiduciary duty as a director or officer. No amendment to, modification of, or repeal of the Charter shall apply to or have
any effect on the liability or alleged liability of any director or officer of the Company for or with respect to any acts or
omissions of such director or officer occurring prior to such amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bylaws.
</i>The Bylaws provide that the Company shall indemnify and advance expenses to any person who was or is a party or is threatened
to be made a party to any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the Company) by reason of the fact that they are or were a director or officer of
the Company, or are or were serving at the request of the Company as a director, officer, employee, or agent of another
corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines
and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably
withheld) actually and reasonably incurred by them in connection with such action, suit, or proceeding if such person acted in good faith
and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that the Company shall indemnify and advance expenses to any person who was or is a party or is threatened to be
made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in
its favor by reason of the fact that they are or were a director, officer, employee or agent of the Company, or is or was serving
at the request of the Company as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust,
or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by them in connection with the
defense or settlement of such action or suit, if such person acted in good faith and in a manner such person reasonably believed to be
in or not opposed to the best interests of the Company, except that no indemnification shall be made in respect of any claim,
issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that
the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Delaware Court of Chancery or such other court shall deem proper; provided that no person shall be indemnified
hereunder for any expenses or amounts paid in settlement with respect to any action to recover short-swing profits under Section 16(b)
of the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification
Agreements</i>. The Company has entered into indemnification agreements with each of its directors and executive officers, which
generally provide indemnity to the fullest extent permitted by applicable law against liabilities and expenses incurred in connection
with the defense or disposition of certain actions, suits or proceedings in which such person may be involved or to which such person
was, is or is threatened to be made, a party by reason of the service of such person as a director or an officer of the Company
or in certain other representative or fiduciary capacities on behalf thereof and which establish processes and procedures for indemnification
claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liability
Insurance</i>. The Company also maintains standard policies of insurance that provide coverage (a) to its directors and officers
against losses arising from claims made by reason of breach of duty or other wrongful act and (b) to the Company with respect
to indemnification payments that the Company may make to such directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 209; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Recent Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following
sets forth information as to all of the registrant&#8217;s securities sold in the last three years that were not registered under the
Securities Act. Capitalized terms used and not defined in this Item 15 have the meanings assigned to them in the prospectus that forms
a part of this registration statement. Unless stated otherwise, each of the following issuances was made pursuant to the exemption from
registration contained in Section 4(a)(2) of the Securities Act as transactions not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On November
8, 2021, simultaneously with the closing of the IPO, Semper Paratus consummated the sale to the Original Sponsor and Cantor of an
aggregate of 1,450,000 private placement units at a price of $10.00 per private placement unit in a private placement, generating
gross proceeds of $14.5 million. No underwriting discounts or commissions were paid with respect to sale of the private placement
units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On May 3,
2023 and June 20, 2023, Semper Paratus entered into the Subscription Agreements. Pursuant to the Subscription Agreements, we issued
an aggregate of 1,651,000 shares of Common Stock to Polar in consideration for Polar making capital contributions to SSVK, which were in turn to be lent to us, in the amount of $1,651,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On June 28, 2023,
Semper Paratus and Cantor entered into the Fee Reduction Agreement, pursuant to which Cantor agreed to forfeit a portion of the deferred underwriting commission owed to Cantor as underwriter of the IPO,
resulting in a remainder of $5.0 million of deferred underwriting fees payable to Cantor upon the closing of the Business Combination
in the form of 500,000 shares of Common Stock. We issued the 500,000 shares of Common Stock to Cantor
in payment of the Reduced Deferred Fee in connection with the closing of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February
14, 2024, pursuant to the Conversion Agreements, we issued an aggregate of 174,000 shares of Common Stock to an entity affiliated
with Suren Ajjarapu in relation to services that were to have been provided to us and Tevogen Bio, at an effective price of $10.00
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, in connection with the consummation of the Business Combination, the Company and Tevogen Bio entered into an Assignment and Assumption
Agreement, pursuant to which the Company assumed all obligations of Tevogen Bio under convertible promissory notes that were outstanding as of the Closing Date (the &#8220;Assumed Notes&#8221;). The Assumed Notes were automatically
converted immediately following Closing, at which time they had an aggregate principal amount totaling approximately $24.0 million and
accrued interest totaling approximately $2.9 million, in accordance with their terms into an aggregate of 10,337,419 shares of Common
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, the Company issued an aggregate of 19,348,954 RSUs under the 2024 Plan to Dr. Saadi. The Special RSUs were immediately vested into shares of restricted common stock (&#8220;Restricted Stock&#8221;)
that vest in four equal annual installments beginning on February 14, 2031. Pursuant to the terms of the Special RSU Award, Dr. Saadi
will be entitled to vote the Restricted Stock, but it may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered,
subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock in the event he departs the Company for any reason,
unless termination of his service triggers accelerated vesting pursuant to the terms of the Special RSU Award or the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, the Company issued 300,000 shares of Common Stock to each Placement Agent pursuant to the Letter
of Engagement, in consideration for capital markets advisory services provided by the Placement Agents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In connection
with the consummation of the Business Combination, Semper Paratus entered into an agreement as of February 14, 2024 with SSVK, pursuant
to which, as amended, we issued 3,613 shares of Series B Preferred Stock to SSVK in consideration of the assumption by SSVK of certain liabilities
and obligations in the amount of approximately $3.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, we entered into the Purchase Agreement, pursuant to which an investor
agreed to purchase shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024, we entered
into an amended and restated securities purchase agreement pursuant to which that amount was reduced to $2.0 million and the investor
agreed to purchase shares of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million. Pursuant to the Purchase Agreement, we issued shares of Series A Preferred Stock convertible into
a total of 500,000 shares of Common Stock at a conversion price of $4.00 per share and agreed to sell shares of Series A-1 Preferred
Stock convertible into a total of 600,000 shares of Common Stock at a conversion price of $10.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On June 6, 2024,
we entered into the Loan Agreement. Pursuant to the Loan Agreement, we issued the Commitment Shares to The Patel Family, LLP as a commitment
fee in consideration of the extension of credit. The Commitment Shares were <span style="background-color: white">issued in a pursuant
the exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 210; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Exhibits and Financial Statements Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; white-space: nowrap; width: 0.85in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    </b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated June 28, 2023, by and among the Company, Semper Merger Sub, Inc., SSVK Associates, LLC, Tevogen Bio Inc, and Ryan Saadi, in his capacity as seller representative (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on June 29, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224010806/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on March 21, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224012650/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Series A-1 Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form
    8-K filed with the SEC on April 2, 2024 (File No. 001-41002))</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224010806/ex3-2.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Series B Preferred Stock of the Company (incorporated by reference to Exhibit 3.2 to the Current Report on Form
    8-K filed with the SEC on March 21, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921135566/tm2132195d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agreement, dated November 3, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on November 8, 2021 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921124178/tm2126753d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1 (Registration Statement No. 333-260113) filed with the SEC on October 7, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Hogan Lovells US LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service Agreement, dated as of April 15, 2022, between Tevogen Bio Inc and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.15 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of June 9, 2022, between Tevogen Bio Inc and Wanamaker Office Lease, LP (incorporated by reference to Exhibit 10.16 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of February 14, 2022, between Tevogen Bio Inc and Mitsui Sumitomo Insurance Company of America (incorporated by reference to Exhibit 10.17 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465923057818/tm2315115d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated May 3, 2023, by and among Semper Paratus Acquisition Corporation, Semper Paratus Sponsor LLC and Polar Multi-Strategy Master Fund (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 9, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465923057818/tm2315115d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement, dated May 4, 2023, by and among SSVK Associates, LLC, Semper Paratus Acquisition Corporation and Semper Paratus Sponsor LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 9, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223029606/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated June 20, 2023, by and among Semper Paratus Acquisition Corporation, Semper Paratus Sponsor LLC and Polar Multi-Strategy Master Fund (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed with the SEC on August 21, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223029606/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Reduction Agreement, dated June 28, 2023, by and among Semper Paratus Acquisition Corporation and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q filed with the SEC on August 21, 2023 (File No. 001-41002))</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 211; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">10.8</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921135566/tm2132195d1_ex10-1.htm" style="-sec-extract: exhibit">Letter Agreement, dated November 3, 2021, by and among the Company, its officers, its directors and Semper Paratus Sponsor LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on November 8, 2021 (File No. 001-41002))</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Letter Agreement, dated February 13, 2024, by and among the Company, its officers, its directors, SVKK Associates, LLC, and Semper Paratus Sponsor LLC (incorporated by reference to Exhibit 10.5 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Registration Rights Agreement, dated February 14, 2024, by and among the Company, SSVK Associates, LLC, Semper Paratus Sponsor LLC, Cantor Fitzgerald &amp; Co., and the other signatories thereto (incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-Up Agreement, dated February 14, 2024, between the Company, SSVK Associates, LLC, Ryan Saadi, and the other signatories thereto (incorporated by reference to Exhibit 10.7 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Competition and Non-Solicitation Agreement, effective as of February 14, 2024, by and between the Company and Ryan Saadi (incorporated by reference to Exhibit 10.8 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224023230/ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Unit Agreement (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-8 (Registration No. 333-280075) filed with the SEC on June 10, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Unit Agreement, dated as of February 14, 2024, by and between the Company and Ryan Saadi (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex10-10.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.10 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated February 14, 2024, by and among the Company and The Patel Family, LLP (incorporated by reference to Exhibit 10.15 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224012650/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Securities Purchase Agreement, dated as of March 27, 2024, by and between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 2, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224023483/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement, dated as of June 6, 2023, by and between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 11, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">10.20</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224024727/ex10-1.htm" style="-sec-extract: exhibit">Preferred Stock Repurchase Agreement, dated as of June 15, 2023, by and between Tevogen Bio Holdings Inc. and SSVK Associates, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 21, 2024 (File No. 001-41002))</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Marcum LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of KPMG LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Hogan Lovells US LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#as_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page of the initial filing of this Registration Statement)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex107-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
    and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a
    copy of any omitted schedule or exhibit to the SEC upon request.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    management contract or compensatory plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statement Schedules.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 212; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. Undertakings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee
Tables&#8221; table in the effective registration statement&#894; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant
to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or
other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of
the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that
is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to
Rule 424&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant&#894; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 213; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-1 to be signed
on its behalf by the undersigned, thereunto duly authorized in the City of Warren, State of New Jersey on the 21st day of June,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
    BIO HOLDINGS INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Saadi</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan Saadi and Kirti Desai,
and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for
him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective
amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement
and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents
and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents,
or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
held on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and <br/>
    Chairperson of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Saadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kirti Desai</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti
    Desai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and <br/>
    Principal Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Surendra Ajjarapu</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surendra
    Ajjarapu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jeffrey Feike</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Feike</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Keow Lin Goh</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Keow Lin Goh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Curtis Patton</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Curtis Patton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Susan Podlogar</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan
    Podlogar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Victor Sordillo</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victor
    Sordillo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 214; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="HL_color" STYLE="height: 95px; width: 95px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hogan
    Lovells US LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
    International Drive</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    2000</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baltimore,
    MD 21202</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
    +1 410 659 2700</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F
    +1 410 659 2701</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.hoganlovells.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
21, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15
Independence Boulevard, Suite #410</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warren,
New Jersey 07059</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the addressee referred to above:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are acting as counsel to Tevogen Bio Holdings Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with its
registration statement on Form S-1, as amended (the &ldquo;<B>Registration Statement</B>&rdquo;), filed with the Securities and Exchange
Commission under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), relating to (A) the issuance by the Company of
up to an aggregate of 42,474,978 shares of common stock, par value $0.0001 per share, of the Company (&ldquo;<B>Common Stock</B>&rdquo;),
comprising (i) 17,974,978 shares of Common Stock (the &ldquo;<B>Warrant Shares</B>&rdquo;) underlying warrants to purchase shares
of Common Stock (the &ldquo;<B>Warrants</B>&rdquo;) and (ii) 24,500,000 shares of Common Stock issuable upon the achievement of certain
earnout triggering events (the &ldquo;<B>Earnout Shares</B>&rdquo;), and (B) the resale, from time to time, by the selling stockholders
named in the prospectus contained in the Registration Statement and any supplement thereto (the &ldquo;<B>Prospectus</B>&rdquo;) or their
permitted transferees of (i) up to an aggregate of 24,851,308 shares of Common Stock (the &ldquo;<B>Resale Shares</B>&rdquo;), including
(1) 500,000 Warrant Shares issuable upon exercise of Warrants (the &ldquo;<B>Resale Warrants</B>&rdquo;), (2) 500,000 shares of Common
Stock issuable upon conversion (the &ldquo;<B>Series A Conversion Shares</B>&rdquo;) of shares of the Company&rsquo;s Series A Preferred
Stock, par value $0.0001 per share (the &ldquo;<B>Series A Preferred Shares</B>&rdquo;), (3) 600,000 shares of Common Stock issuable
upon conversion (the &ldquo;<B>Series A-1 Conversion Shares</B>&rdquo; and, together with the Series A Conversion Shares, the &ldquo;<B>Conversion
Shares</B>&rdquo;) of the Company&rsquo;s Series A-1 Preferred Stock, par value $0.0001 per share (the &ldquo;<B>Series A-1 Preferred
Shares</B>&rdquo;), and (4) 23,251,308 shares of Common Stock held by certain of the selling stockholders identified in the Prospectus;
and (ii) the Resale Warrants. This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item
601(b)(5) of Regulation S-K, 17 C.F.R. &sect; 229.601(b)(5), in connection with the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this opinion letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate
basis on which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness
of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity
of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of fact, we have relied on the representations and statements of fact made in the
documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and all statements
herein are made, in the context of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hogan
Lovells US LLP is a limited liability partnership registered in the state of Delaware. &ldquo;Hogan Lovells&rdquo; is an international
legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: &nbsp;Alicante&nbsp; Amsterdam&nbsp; Baltimore&nbsp;
Berlin &nbsp;Beijing&nbsp; Birmingham &nbsp;Boston &nbsp;Brussels&nbsp; Colorado Springs &nbsp;Denver&nbsp; Dubai &nbsp;Dusseldorf&nbsp; Frankfurt&nbsp; Hamburg&nbsp; Hanoi&nbsp; Ho Chi Minh City&nbsp; Hong Kong&nbsp;
Houston&nbsp; Johannesburg&nbsp; London &nbsp;Los Angeles&nbsp; Luxembourg&nbsp; Madrid&nbsp; Mexico City &nbsp;Miami&nbsp; Milan &nbsp;Minneapolis &nbsp;Monterrey &nbsp;Munich&nbsp; New York&nbsp; Northern Virginia
&nbsp;Paris&nbsp; Philadelphia&nbsp; Riyadh&nbsp; Rome&nbsp; San Francisco &nbsp;S&atilde;o Paulo&nbsp; Shanghai &nbsp;Silicon Valley&nbsp; Singapore&nbsp; Sydney&nbsp; Tokyo&nbsp; Warsaw&nbsp; Washington, D.C.&nbsp;
Associated Offices:&nbsp; Budapest &nbsp;Jakarta&nbsp; Shanghai FTZ.&nbsp; Business Service Centers: &nbsp;Johannesburg &nbsp;Louisville. For more information see www.hoganlovells.com</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 33%">Tevogen Bio Holdings Inc.</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="text-align: right; width: 33%">June
                                            21, 2024</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter is based as to matters of law solely on the Delaware General Corporation Law, as amended. We express no opinion herein
as to any other statutes, rules or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon, subject to and limited by the foregoing, we are of the opinion that, as of the date hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Resale Shares have been duly authorized and (other than the Conversion Shares and the Warrant Shares) are validly issued, fully paid,
    and nonassessable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Conversion Shares have been duly authorized and, following the issuance of the Conversion Shares upon conversion of the Series
    A Preferred Shares and the Series A-1 Preferred Shares in accordance with the Certificate of Designation of Series A Preferred Stock
    or the Certificate of Designation of Series A-1 Preferred Stock, as applicable, and the Certificate of Incorporation
    of the Company, will be validly issued, fully paid, and nonassessable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Earnout Shares have been duly authorized and, following the issuance of the Earnout Shares in accordance with the terms of the Agreement and Plan of Merger, dated June 28, 2023, by and among the Company, Semper Merger Sub, Inc., SSVK Associates,
LLC, Tevogen Bio Inc, and Ryan Saadi, in his capacity as seller representative, will be validly issued, fully paid, and nonassessable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Warrant Shares have been duly authorized and, following (i) the exercise of the applicable Warrants in accordance with their terms,
    (ii) the receipt by the Company of the exercise price for the Warrant Shares as specified in the applicable Warrants, and (iii) the
    issuance of the Warrant Shares thereunder, the Warrant Shares will be validly issued, fully paid, and nonassessable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Resale Warrants constitute valid and binding agreements of the Company, enforceable against the Company in accordance with their
    terms.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter has been prepared for use in connection with the Registration Statement. We assume no obligation to advise of any changes
in the foregoing subsequent to the effective date of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to this firm under
the caption &ldquo;Legal Matters&rdquo; in the Prospectus. In giving this consent, we do not thereby admit that we are an &ldquo;expert&rdquo;
within the meaning of the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Hogan Lovells US LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOGAN
LOVELLS US LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM&rsquo;S CONSENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Registration Statement of Tevogen Bio Holdings Inc. (f/k/a Semper Paratus Acquisition Corporation) on
Form S-1 of our report dated April 26, 2024, which includes an explanatory paragraph as to the company&rsquo;s ability to continue as
a going concern, with respect to our audits of the financial statements of Tevogen Bio Holdings Inc. (f/k/a Semper Paratus Acquisition
Corporation) as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022, which appear in the Prospectus, which is part of this Registration Statement. We were dismissed as auditors
on April 29, 2024 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements appearing
in such Prospectus for the periods after the date of our dismissal. We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo;
in the Prospectus, which is part of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, CA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
21, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of our report dated April 26, 2024, with respect to the financial statements of Tevogen Bio Inc, included herein,
and to the reference to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
KPMG LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
21, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ex107-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Form
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tevogen
Bio Holdings Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered and Carry Forward Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Security<BR> Type</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Security Class<BR> Title</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee Calculation or Carry Forward Rule</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount<BR> Registered<SUP>(1)</SUP></B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Maximum Offering Price Per Unit</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum Aggregate Offering Price</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee Rate</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of Registration<BR> Fee</B></FONT></P></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 11%; text-align: center">Fees to Be <BR>Paid</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center">Equity</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">Common Stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">24,851,308</TD><TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.7725</TD><TD STYLE="width: 1%; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">19,197,635.43</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">0.0001476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">2,833.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">Fees to Be <BR>Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Warrants to purchase shares of Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">725,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Fees to Be <BR>Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,974,978</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">206,712,247.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,510.73</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">Fees <BR>Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Total Offering Amounts</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">225,909,882.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33,344.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Total Fees Previously Paid</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Total Fee Offsets</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Net Fee Due</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33,344.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
                                            the registrant is also registering an indeterminate number of additional shares of the common
                                            stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), of the registrant that
                                            may become issuable as a result of any stock dividend, stock split, recapitalization, or
                                            other similar transaction.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            the sum of (i) 8,988,889 shares of Common Stock issued in connection with the Business Combination
                                            (as defined in the prospectus that forms a part of this registration statement), (ii) 174,000
                                            shares of Common Stock issued pursuant to the Conversion Agreements (as defined in the prospectus),
                                            (iii) 1,651,000 shares of Common Stock issued pursuant to the Subscription Agreements (as
                                            defined in the prospectus), (iv) 500,000 shares of Common Stock issued pursuant to the Fee
                                            Reduction Agreement (as defined in the prospectus), (v) 600,000 shares of Common Stock issued
                                            pursuant to the Letter of Engagement (as defined in the prospectus), (vi) 500,000 shares
                                            of Common Stock issuable upon the exercise of the Private Placement Warrants (as defined
                                            in the prospectus), (vii) 10,337,419 shares of Common Stock issued upon assumption and conversion
                                            of the Tevogen Bio Convertible Notes (as defined in the prospectus), (viii) 500,000 shares
                                            of Common Stock issuable upon the conversion of shares of the Series A Preferred Stock, par
                                            value $0.0001 per share, of the registrant, (ix) 600,000 shares of Common Stock issuable
                                            upon the conversion of shares of the Series A-1 Preferred Stock, par value $0.0001 per share,
                                            of the registrant, and (x) 1,000,000 shares of Common Stock issued pursuant to the Loan Agreement
                                            (as defined in the prospectus).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
                                            solely for the purpose of calculating the amount of the registration fee pursuant to Rule
                                            457(c) under the Securities Act based on the average of the high and low prices for a share
                                            of the Common Stock as reported on The Nasdaq Stock Market LLC on June 20, 2024 (such date
                                            being within five business days prior to the date that this registration statement was filed
                                            with the U.S. Securities and Exchange Commission).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            accordance with Rule 457(g), the entire registration fee for the Private Placement Warrants
                                            is allocated to the shares of Common Stock underlying the Private Placement Warrants, and
                                            no separate fee is payable for the Private Placement Warrants.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
                                            the shares of Common Stock that may be issued upon exercise of outstanding Warrants, with
                                            each such Warrant exercisable for one share of Common Stock, subject to adjustment, for an
                                            exercise price of $11.50 per share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
3: Combined Prospectuses</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security Type</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security Class Title</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of Securities</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Previously Registered<SUP>(1)</SUP></B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum Aggregate Offering Price of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Previously Registered</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form Type</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File Number</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial<BR> Effective Date</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 13%; text-align: center">Equity</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">Common Stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">24,500,000</TD><TD STYLE="width: 1%; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">269,745,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">Form S-4</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">333-274519</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">1/4/2024</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            registration fee is payable in connection with 24,500,000 shares of Common Stock issuable
                                            upon the achievement of certain earnout triggering events, as described in the prospectus
                                            that forms a part of this registration statement, previously registered under the registrant&rsquo;s
                                            registration statement on Form S-4, as amended (File No. 333-274519), which was declared
                                            effective on January 4, 2024 (the &ldquo;Prior Registration Statement&rdquo;), because such
                                            securities are being transferred from the Prior Registration Statement pursuant to Rule 429(b)
                                            under the Securities Act. See &ldquo;Statement Pursuant to Rule 429&rdquo; in this registration
                                            statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !? %\# 2(  A$! Q$!_\0
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3BNJHHKGK5Y55%/9:+^F4E8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ 3T# 2(  A$! Q$!_\0
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MW=I?R^'O&&A:=X@TAKZQD,EG>BQU.WN;=+NV9G\FY1%FC625%<)+(K?RW_\
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M =N69+72+F\(7)W!+1V.UMJME=W<_P#!7W_E'5^T;_UZ_#'_ -71\.:_.O\
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M%_&*UTC3B)$6VT%_'VN7?AX1";#O;RZ'<:?/;,P)D@DC<,P<,=;P1=Q'R<D
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MC+#SHUY_T_\ [#'C71M>^"&D^%[:\MCK7@^^UFTU#3Q(HO%M-2U:[UBQOV@
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MHZ)>Z5X?\+^%=%FU"W+1JLD)UN+6--:2*25!<:9/$=DD4@/R9XPUS3OV=/\
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M6LT#/^#BC_CR_9$_Z^OCO_Z)^#U?LM^R+^PS\!OV+?#^L:7\(]'U.YUWQ/\
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '( G8# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z8_X*_?\
M!;__ (*$?L<_\%#/CA^SG\"?%WPBTKX7>!-%^$-]X=L?%/P@M?%6MQ3^,?A5
MX4\5ZW]LUV3Q-ILEXLNN:M?36JM:QK;6LD-J"RPF5_S2_P"(EK_@K/G(\??
M+C/_ #;_ &78_P#8Y9SZ?TKS[_@X?_Y2_?M/_P#8L?L\?^J)\ _Y'OZ=:_%L
M8 SC'\\>_P#GW/>OW')<BR6MDV55JV59?6K5LNPM6I4J8>$JDZDJ;<IRESJ\
MI/5NVKZ'\]9_Q)GV'SS-\/0S?'4J-#,L71I4J=9QA3IPK*,(0BJ32C%.R5W9
M=S]Y?^(EK_@K..?^$_\ @'Z\?L_V(P._/_"9=^_6E/\ P<N?\%9N_C_X!#..
MOP LCGC(Z>,NXY!/&!]*_"G1O$6C^#]5L?%?B+PCIWC_ $+PV\^LZMX'U;5=
M4T+3/%EG86=Q,^B:AK.B_P#$WTRTNG$;2W>FG[2@C5(R%9F']!?[1'[*W[!6
MB_%S]N_X32?"F[_9R\!_LX?L\?L$>/\ 1OB]X0U7QY\:?B'I_B3]J/XR?LBR
M^(I--\%>(M=T71;W4'TCXJ>*_A-I,=[<OIO]C^)?^$BO_P"S+W3%GAK'X+AK
M+IPA7R#!RC4IU*OM*6#I3C&%*MAJ%5N+Q$:DI1EBJ34:<)RG'F4/>3165X_B
MS-X5'AN(:\)4ZU*A[.OB:L9SJ5L-B<33Y7'"S@HSAA:D>:=2"A*SE:/-)<.?
M^#EO_@K+S_Q<#X \>G[/]G_\V6#CH<\ ]:=_Q$M?\%9L<_$#X!8/0C]G^RQG
MU_Y'(CVYQ]>]>9^-_P#@D!/\,O@=\7/BGX^_:4\*:1XG\%?%']L/P#\//"L/
MATOIGQ'L/V+OC5_PI;QM#+<RZA_;>E>._B+JEIJ^M?#[0K73;W1;*QLK'_A+
MM9TQ-;L9F[VX_P""-O@W5/BI^UE\+O 7[2?CKQ'_ ,,O7_BKP+/XVUSX(1>%
M?!WB+XP>"/ ?C3XF^)O!,UW=>*+B[GTRP\*>'-'MTU'PS;ZO>S:IK%]>K:C0
M=-%]-AR\$\KE]0RUQ@G*4XY=6<'%2I1<E-J,7'FK1BK.3<XSBHWIR1K[3CQ-
M1>/Q\9-QCR/,,,JG,XUFH.*4I1E:C*3YDE&$J3<[58,O_P#$2U_P5GZ_\)_\
M >.O_&/]E].?^*SZ9X'O[4?\1+7_  5G!Q_PGWP"R>W_  S_ &7;O_R.?UQ^
M-<7H?_!(_P "ZW!\,;>3]I_Q#H>M^-M7_9N\.:_)XD^#<^B>!]'\1_M??!3Q
MI\1?@#I'AGQU>ZTFD>+;F]\?>%+'X;>.8('BN=!3Q/IFLV,-[)!=6R?G'^U=
M^SCJ'[*'Q,\-_!CQ3K=Y?_%&R^#7P=\<?&GPQ>Z0FE-\)_BE\4_!.G?$+4_A
M$D\=U=+KTW@GP[XA\,0:MK9^RM)KUWJVF_98O[-#R]&&P?"6,K.AA\KRV=7E
MJ3Y'@*L/=I."G+FFU'EBYP3ES)-U(17O22.7%YCQK@J'UG$YGCZ=%2HQ<UCJ
M-2TZ\9RI1Y:<7)RDH5))*+:C"<F[1;/U0_XB6O\ @K-_T/\ \ O_ !'VT/\
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M%+BCB65VLYS%J*YFU7FU&+=N9M4':+>EVU&_4_<7_B):_P""LW_0_P#P"_\
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MZ _XB6O^"L__ $/WP"S_ -F_V0Q[$?\ "9'KD8&<^O>@_P#!RU_P5G')\?\
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M6;./^$_^ 60"<?\ "@+'('KC_A,R<9XR,<C&>#2_\1+?_!6<C_D?O@'UZ?\
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M!K%\T=HUKJOB"[T@0,NG">7S_P  _P#)&_VF<]O#/P7!SCO\?_ )STQTX/0
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M0G*G24:U.+JJ498=^WHN%>2I3<Y)5%%RG^]YH17O>0?#35/^"HWAKXH_ ?\
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MJ.C:_;W/AWQ3/=V%M%JSP:;XG\,V=[IEO!?6^F0ZYH=O>1:?]ILXY!^@%O\
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MLTT_^$^ALU9[3[,J/A]PW&49+#XR\6I+_A1Q+U336CCKJEIU/\^V^_X-5_\
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M_AOH?_)B_P"(><-?] ^,_P##EBO_ )$_SY/^(5#_ (*2?]%<_8=_\.=\=_\
MZ&JC_B%0_P""DG_17/V'?_#G?'?_ .AJK_0;P/0?D*,#T'Y"C_7GB'_G[@?_
M  WT/_DP_P"(><-?] ^,_P##EBO_ )$_SY/^(5#_ (*2?]%<_8=_\.=\=_\
MZ&JC_B%0_P""DG_17/V'?_#G?'?_ .AJK_0;P/0?D*,#T'Y"C_7GB'_G[@?_
M  WT/_DP_P"(><-?] ^,_P##EBO_ )$_SY/^(5#_ (*2?]%<_8=_\.=\=_\
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MN?L._A\3_CP#_P"LUC^9H_XA4?\ @I+_ -%;_8<_\.?\=_\ Z&K_ #@^V?\
M0!NM;TBT34I;K6-,M4TE8'U1[F^LX$TQ;B-)8'U%I9D%BLZ.K0O=&)95960D
M,";4E_91W%M:27UG%=W,DL4%K+/ ES<216S7<B0V[2"::1+9'N72-&=( TS*
M(E+C-<<\1_SX-JU_^1;1:M92;7OI6Y91E?;E:>BU-?\ 4#A?_GUBGJE_R,\1
M=-RE!1M;=SBXI:MR3BKR3B?Y^G_$*C_P4E_Z*W^PY_X<_P"/'_T--+_Q"H?\
M%)/^BN?L._\ ASOCQ_\ 0U5_H!2:QI44%Y/+JVEQP:=>)8:A/)>VD<5E>/\
M9=EG=RO,$M+MC=6X6VN&29S<V^U")HR]S[99M=_8Q=V@N_+:7[)YT!N?*4JK
M2FW+B8(K$*S&/:K, 2":?^O'$6OOX-6NW?+:*T5G=^^[))IMZ)76NJNO]0.%
MWM2Q;],SQ#U;:2VU;<9))7;<9*S<6H_Y^/\ Q"H?\%)/^BN?L._^'.^._P#]
M#53?^(5#_@I+C_DK?[#N<]/^%G_'C^?_  S5^G3CZ5_H,E0.K8_#_"G;5P1Z
M<D\9]:7^O7$*M:M@=>V7T/E]O75].I?_ !#SAG3]QC-G_P S'%=M?LZM'^?I
MIW_!MM^WG\$6UK6/&WQ8_8[DM/B-X.\8_ #PZN@?$#XX:E.OCKX]Z!<_##P3
M<ZI'<_L\6"VGAVT\0:]97/B+4(7NKNPTJ.YN;+3=1N$CM9*3_P#!JA_P4D)S
M_P +;_8?&<_>^*'QY'<GM^S4?7.<]^@Z5_;?^UQJFF:'X'^&>L:UJ6GZ1I&E
M_M)?LZWVIZMJEY:Z?INGV5O\6/#<D]W?WU[+#:VEM @+R33RHB  E@<5II^V
M+^RI(H*_M'?!=P5!!'Q"\,MD,,@_\?XQG\3C'''.^'XLXLQ#G4PM&&(^"%26
M'R?V\(\J:II^RA447RW=G)-K7E.?%<'\%X54J6,K_5)/VDZ4<3G:PU2HI22G
M)*O7HSG%2BE=1:3NKWNE_#U_Q"H?\%)<?\E;_8<_\.A\>,_G_P ,TY_SQ2_\
M0I__  4C_P"BN?L/?^'/^//_ -#77]PZ_M?_ +*_'_&1?P:.>/\ DH/AD]>F
M/^)AUX.#^E/_ .&NOV6N/^,B/@[R>,?$#PR<@C_K^]>>.U="XFXVO_N-1?\
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M&)%WDABC!,C0'[5W[,Y.1\?OA$>.G_"=>'<#IS_Q_P#'U]Z7^LW&K_Y@)_\
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M&!^OC#0CU(7K]L]>/QH7$O&K_P"8"?G_ ,8_6_\ E(/ACP_7_,PPWSXDH?\
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MHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>W..H_/_\
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M_#_BG1?#NK^'].LQXWUF^^*EE)JU[=Z('TKPI\/_  +X;L=3U)?#MA/']G?
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M32;ZQU33;ZVAOM/U'3KN"]L;^QN8UFM[RSN[9Y8+FVGB99(9X'DAE1E:-V#
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M>)/#FJ:/IAUNY^'\36]SK&E7GT[^SY\/_CV?B7I7B[XQ_$GXM^*=*\+?LZ_
MK1-!768M'^&WA/QG\2=5/Q-'Q?\ &'C+X2^&=4UFWM/B%+IL?PU36=,U#6M4
M\,>&M4M%N? =CI-QJ?B?[>]?V^_A)_92ZM<^#_BW;6^J:;X5U;P/:R^!;Q]3
M^(-AXM^*NF?!NPF\):=#*UQ=F#QOK6B17<=PMM(FA:QI?B%%?3KN.4Z5O^W3
M\)C<VEK>:#\0-(.G>'/CSXL^(EUJ7ATP:5\*O#W[-?C.3P'\6=1\<:JLTEI;
M)I?B,V[>'XM.>]E\5Z'<CQ!H:76F6US-%OB7G>(P]:$LKH0=:G6E6Q5&CAE6
ME&NJ/M*G,HR2E)8?ZO[6'+:4JF&7+B]9\V!I\.X/%4)T\^Q=6-&I0C1P6(Q>
M,EAJ<L.Z_LJ*A>-HKZRL5["HZC<8TL9[V!:4/CSX%_ 7X]^$_C];^)],T37]
M(U'3/'?[?L5S?_$[P'X/?X5_#CPG\;OC_P",_BC\//$?@?7/ VI^!/B-\4[G
MX@W,7@?5_$'@KQ'XM\4:5I^G:OK]VVK?#SQ%X6T#2[ST_P"(^C_M@G7/C[<Z
M->?&.[^*ITRWT_X)ZKX%G\,:=^SD_P -3;^%)]9EM?!7B'Q8IM_C'+=KXU6T
ME\6:I<:Y;WDFA6FA^+;/0O-N4]C\/?M[_!_Q+::6=-T;QO'K&J>+/"GA2+1]
M2TF/2_L+^-_!>L^/?#E_JNMWTT'A[2XK_0_#VNV,EI=ZE'J%GXMTVX\'W4$.
MMRVUM<:&L_MR_"'1]+U+5;K3O%J/'\1]4^%F@Z1-ID-GKGB'Q-H4>I2:VT>E
M7D\-]H>G6*:5<RQ:AXBATZ+4K6?3[O36N+?4+=SK.KG53%MU<EHU*_LJ&#5*
MI1=2<?J^)A+E3<I2Y*DZ<J5:C[.%.=%SA*M%1=26-*CPW2R^$*'$N(HX;VV)
MQ_MZ.(C2A)8K"3A*:4*5.'M:5.M&O0K\]2M'$N%2.'J2E&G'XI\:_ ?]H;QG
MH'P^<6OQ$^)\.BGQ!::9J/CKP_<>$/&/AKPZW[5G[+7CG1O"FMOXW^)7COQ=
MXJ&C>$? _C+4M/\ %WB?Q#=Z]K.DZ&?[4:749+3[;]2?M">"OVDM?^,7BV3X
M97_CGPYX*UWPK^PWX=A\3>"[_P )Z;J=C:V7[7_B^^_:632KW6;>[U"UN(O@
M#J=O_;D[VDK1Z-=K+X3:'Q5#'/"NM?MP:-XKO_A%:?!/1O$NLZ-XQ^*/P=\,
M^+/%^M>"-5C\-:)H_P 4O!VH^.(-%N)[JZTN]TKQ&WA]=&N'OI;2ZT[3+O4[
M+3+M6OM0MX:]@\;?M<_#OP!\1KKP!KVB^.E@TCQY\$_AGXC\=6OANYF\"Z!X
MR_:)U_2O"'P>T6[UE'WW-SXG\9>(?#GAB\^PP3KX=OO$WARZUUK+3]9M;DYU
ML5FSEAYRR["QDL-F;HTK4VZ-.56C&M5G3;C"%:E.$'0A*BI5)/F>&G*JHU-,
M)@L@Y<92I9OCIQGB\C5:NIU4J]6C2K?5Z-+$1C4KU:.(A*I3QE15W"G%.FL;
M3C2E.E\)I\*?VZ-%\)Z]INE?$7]HG4-2\1>$OCOX7^VZKXW\!ZMK7AN#P5^U
M7X?T+]FJ_P##E]?::]O9^)[K]F5_$5_K/BNX@U+7OB)]NFUWXOWOB?QQIOAR
MXTB[J/PM_;C\,:GXS_X0[QU\>O$VF+K?Q_\ "WAFU\4>/?".I[OAOX<TCP=X
MG^"-YIMY>1:?='Q=KGB>X\;:%8^+]=OF\4ZM:&ST+QMKO]@66FR6OT+=_M^>
M$+_5+;PYX(^'WB_Q/XHMOBQ\!? /BC1;J72M*/A_PS\?_$/BK0?"7C<ZB;N7
M3+R-KKP7XCAN-#BO!?Z??VUM!JK6$=U'.+6G?MZ?"K2+OPUX:\6ZGJ&K>)->
MUC4(;VX\,>%=8AT_0](O/BSJOPJ\+SZCI]WYVJ3376N6<-K<KI\=RZV:S^(6
MCATG]XFSEGKC*^481M2=:M26&PTJDX0DZCE5A"ES4Z2IJ-.+4\,JE)Q=-UJC
ME(QA3X9A)/\ UAS%1:C0H5I8_&0I4JDZ5.ERT*E6LHUJ\YQE6J1<,8Z5:55U
MOJ])QB>!^(_"G[87Q?\ &6MW45[^TK\(OAMJ%A\9M2T.STSQEX,\'^)O[5T[
MX-? NV^$D-RFG:GXHO=+TN^^*EE\0?$>FZ4)])U&[U6PO-,^(%J/!7B#Q)X.
M\3]7\)=)_;,U7]HSPWXH^+?BGXB>%-,2_P# <DWAJU\%VOB'X3^)_A/>?LI:
M!_PG7@_5[K0/B?IW@CP#XNT[]J\>+_$Y\97GPYUKXRK=Z5X;\$>'O$FH_ /Q
M/=:9I?9>)O\ @H?X,L_A_?\ C'P=\+_B/KE[+#X*U?P9HOB#2H_"2_$+P]XA
M^.?A;X':_J7A:^O)94ED\.ZSXIL;^""Z2 ZM8W^A7UJXT[54O(OJ3X=?'+P[
M\1OB!X_^'NGZ'K^D:[\-;BWTSQ$-<CM+,1ZL=*\.:O=VUC:?:3?WVG06_BC3
MH[/Q);6TOAW6+F+4X-+U&XETR[6/'%5LTIX:K[7)<%A\/&E6H<WLJ,JN&A-8
M>%6HIRYJ\FY5</&4ZJDY5)2A"6'J0JI;8'#Y+7Q=!4.(\SQ>*J8G#XAQ>)Q%
M.EBZD'BZU"C*E!0PZA&.&Q4Z=&BZ2A1BJE2&+HU:+?YV?\%U\_\ #M'XT<YS
MXG^$'\.W _X6AX5Y().!T_(XS7\*%KW^L7_H;5_=C_P79_Y1H_&?W\3?"#KV
M_P"+H>%O\_B>*_A.M>_UB_\ 0VK^@_ 33AC-5_U/):[_ /,NP:WZ[7;W;=V?
MS+])16XRR3_LG5_ZM<P?31;Z+HM#H8.W_;#_ -&M6O!]^+_?7_T161!V_P"V
M'_HUJUX/OQ?[Z_\ HBOW"'Q?)G\\8GX7_761J1]9/J?_ $2:UH/_ &DW_H"5
MDQ]9/J?_ $2:UH/_ &DW_H"5MT^_]#S5N_\ %3_4VX/O+_UT_P#: K:M?NP_
M]<3_ #CK%@^\O_73_P!H"MJU^[#_ -<3_..D:1^)^O\ [<C3@_U?_;*/_P!!
M:M6'_7)_O+_Z#+65!_J_^V4?_H+5JP_ZY/\ >7_T&6@U^U#U_0U[?[R_6;_T
M,5>AZ1?0?SBJC;_>7ZS?^ABKT/2+Z#^<5*7\3_MQFE39^K_])@:$70_[[?SD
MK07[H^D7_HQJSXNA_P!]OYR5H+]T?2+_ -&-1#XE\O\ VT:V?^.G_P"E5S13
MJO\ O+_Z.%6H^J_]='_]'553JO\ O+_Z.%6H^J_]='_]'5;Z^L?SD7T7_<+_
M --%M?O-]8__ $-:NV_^LD_S_#'5)?O-]8__ $-:NV_^LD_S_#'6;Z_XX?DC
M6&\?\$O_ $J1<3_6G_=7_P!GJ?\ CC_W_P#V5J@3_6G_ '5_]GJ?^./_ '__
M &5J7\_^)?E$U_R_0LTL75O]\_R:DI8NK?[Y_DU$]Z?_ %\7_I,P6S^7ZC^[
M?[K?^A&OTH_X)._\GD>#O^Q;\9?^HCK]?FOW;_=;_P!"-?I1_P $G?\ D\CP
M=_V+?C+_ -1'7Z^#\4_^3?\ %'_8#0_]6V7'Z/X0?\G+X0_[&.(_]5&;']7*
M=#]?Z"GTQ.A^O]!3Z_AU;(_T.CM]_P"84444R@K)M3_Q,]5!:[*JMF%23/V9
M ;<L?L@#G!;CSL(G[P#EB16M63:Y_M;5>;@C;8X$G_'N/W!XM_F/)ZRX5?FZ
MYZT :U%%% !1110 5\K?L*?\F1?L<?\ 9JW[/7_JH_"%?5-?*W["G_)D7[''
M_9JW[/7_ *J/PA0!]4T444 %%%% &5JK;1IWSW:9U6R7_13C=EG^2X^=,VC?
M\MP=_ 'R-6K63JV<:;@W _XFUCG[/W&Y\B?YE_T?_GK][L-IK5YR,X/!R>AS
MQT'H>_T% "T444 %%%% 'S/H/_)X_P 5_P#LV?\ 9^_]6E^TS11H/_)X_P 5
M_P#LV?\ 9^_]6E^TS10!J_ __D;?VF_^S@Y/_5)?!2OH.OGSX'_\C;^TW_V<
M')_ZI+X*5]!U,?A7]=6-[OY?D@HHHJA!1110 4444 %%%% !111D#J<4 %%-
M+@ ^HXQG&3Z \].I].]<C?\ Q!\#:7XRT#X=ZEXQ\+:?X]\4Z7J^M^&O!5[K
M^F6WBWQ!HV@>2-=U;1/#DUPNJZKIFC-=6JZK?V5M-;:>]S MU)$TL89I2E\,
M92M&4VHQE)J$%S3FU%-J$(^]*3]V,?>DTM2)U*=-)U*D(*4X4XN<HP4JE27)
M3A%R:O.I/W(05Y3E[L4WH=A140E!#$ _+['&,XSG&/?&?UXJLFIZ?)J%UI,=
M[:2:I96=CJ%YIJ7,#ZA:6.J3:A;Z9>75DLAN;>UU&?2=4@L+B:)(KR;3;^*W
M>22RNEBE---K5)7;2;LKI7?NZ*[2N[+5:ZJ].459-I.3Y4FTFWJ[).5V[1D[
M*[LF[63Y;U%,#@C)!'&<'.>I'0@$=._]#2[NGH03UZ=,9X]^?3^1==-;[6UO
M?^M5NNJ'?I_7IZ^5QU(0.2?3].?\:6DQSGZ#\B<_SH_X?[MOQ0;_ ->IRGC3
MPIIOC;POK/A;5+G5K*PUBU:TGO="U.YT;6+(YW)=Z;J=HRSV=W ZK)#*N]=P
MVR1O&60_-NE_L1?L[:-<> Y-)\):CIMO\/H]'?2=-L/$FL6FDZI?^'_$FH^+
M]&U?Q'IEM<1VNN:MI_B76M<U:VN;A%1+C6;]!#]FEBAB^O2,Y'0'\\_YQ^M9
M]_:0WUK=Z?<B0VU];S6<_DSS6\_D743P2>3/"T<T#B-FVSPRI+$P#QLCA6KH
MI8S%X:+A0Q5?#TIRDZD:52<5+VD%1G)QBO?DZ+<+-ZQ]U.+]^/!B\NP&+FJN
M)P.%Q56$8QA*O2A.24*KKTX*<[\D?K%JETFE-\TE-7A+\][;_@G5\-+;X71>
M!6\1>([CQ!/J7PPDU;QK>:AJ,]S%X=^'/QETKXSW/AGPII\EV+?P?I_B'Q!I
M\\MZVD/%+#?W*7R,4L[6VB](T+X4?LH>!?"6C^)P^E7_ (7\6>%I/A7-K'B#
M6;[Q$OCNQ_; ^+&AWUROB<7'G7>KZK\;/BIXFTSS-6O[>&.ZO-<D@C-EIBNE
MK\H_";X"_MUZ;\6?!+_$?QKJ>J?"V7QAHVB^.O-^)27 L/ 7[.AUBZ^&_B?1
M=/C6\U&\UW]I+Q5KFAZYX^TN>XBNM%\.^ O[ UO49X]<>P?R_P +_L7?'=M)
MTJP\;^"_$E[X]\;?#'_@E:?B!\2]-^*^GVHTCQ!^S#\<_@OJ7[1OAVYU"U\6
M6?B&'QFWA/P0OCCPSXM\*://8ZXND:M:VGB/1O%$]A:^(OI*ZE*-2EB^)XUX
M*G'$I822G"I.I5H4ZU&34J34J%-.M"$6XQA1M1I\U9U8_%X-4Z=2E7P/!=3#
M575E@W/'0]E4A"C0Q-;#UX?NZ\>3$U91H3J5%&<JF(<L1/DP\:$_T3E_8O\
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M_P#ME'_Z"U:L/^N3_>7_ -!EH-?M0]?T->W^\OUF_P#0Q5Z'I%]!_.*J-O\
M>7ZS?^ABKT/2+Z#^<5*7\3_MQFE39^K_ /28&A%T/^^W\Y*T%^Z/I%_Z,:L^
M+H?]]OYR5H+]T?2+_P!&-1#XE\O_ &T:V?\ CI_^E5S13JO^\O\ Z.%6H^J_
M]='_ /1U54ZK_O+_ .CA5J/JO_71_P#T=5OKZQ_.1?1?]PO_ $T6U^\WUC_]
M#6KMO_K)/\_PQU27[S?6/_T-:NV_^LD_S_#'6;Z_XX?DC6&\?\$O_2I%Q/\
M6G_=7_V>I_XX_P#?_P#96J!/]:?]U?\ V>I_XX_]_P#]E:E_/_B7Y1-?\OT+
M-+%U;_?/\FI*6+JW^^?Y-1/>G_U\7_I,P6S^7ZC^[?[K?^A&OTH_X)._\GD>
M#O\ L6_&7_J(Z_7YK]V_W6_]"-?I1_P2=_Y/(\'?]BWXR_\ 41U^O@_%/_DW
M_%'_ & T/_5MEQ^C^$'_ "<OA#_L8XC_ -5&;']7*=#]?Z"GTQ.A^O\ 04^O
MX=6R/]#H[??^84444R@K*M0PU35#MN0"MEAI"?L[8AP?LPQ@%<GSL$Y?'2M6
MLJUC*ZIJL@AN$\Q;/$TA)MY=L&,0+Y:X\LX$N))-S?W",4 :M%%% !1110 5
M\K?L*?\ )D7[''_9JW[/7_JH_"%?5-?*W["G_)D7[''_ &:M^SU_ZJ/PA0!]
M4T444 %%%% &3JJLPT[:+DXU:R8_9NRJ7)-QP?\ 1A_RVZ<;>16MC_/Y?X"L
MK58S(-.Q#<3;-5LY#]G8KY04OF:?$<FZWCS^]4[ <C]XN.=6@ HHHH ****
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M7Z4?\$G?^3R/!W_8M^,O_41U^OS7[M_NM_Z$:_2C_@D[_P GD>#O^Q;\9?\
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M[/W_ *M+]IFBC0?^3Q_BO_V;/^S]_P"K2_:9HH U?@?_ ,C;^TW_ -G!R?\
MJDO@I7T'7SY\#_\ D;?VF_\ LX.3_P!4E\%*^@CD XY.#@>_:IC\*_KJQO=_
M+\D+141=P3A<@8&?SW')(&!CT'Y&G%CMR!SG!&.G'/&1GGI@G/&,YHYH]WIO
MI+\VDG\F^^UVE\G;OI_F[?-+JM]!]%0B1R<%#]W/<9.<8&>O<]CC!('2GEB,
MXQZC/?IP.>>O7IV]Z.:/=_=)>76*O\M^@KVWTMH]M/7WM/F_4?141=_X5/?
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M55"EB:%6LZ-2NH4JM.J_90J4J$IN5*=6"2JU(0LZG->2?*H^\?F9_P %V?\
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M?X5Z'6+'/H%F_P#C/I5?\1WXS_Z%?#?_ (;L?_\ -YA_Q+/P0KO^V^+-7?\
MW_*]UM_S+]>BWOH?Q"1?\$D_^"CJ.J-^R]JP<[Y G_"VOV?=Y552-F5?^%M%
MV5"R@GHI9=Q.16I#_P $F/\ @HV@4?\ #+^L<(5 /Q5^ .1E@>WQ:XQC&.A
M'3G/]J[^*_#!U2"4:GIQC6PN4,Y,XE1FN("(A'L ,;X+,YC9@54!E!^;0_X2
M_P *=]8L<]_EE_\ C-'_ !'?C/\ Z%?#;_[IV/\ _F_^M!_\2T\$;K.^*]E>
M^.RK>]WM@'V2Z.U]#^*:/_@D_P#\%%E7!_9BU@$!1Q\4_@(1P,8X^*_KSG.,
M<9)YK0A_X)3?\%$%92_[,>L<-G(^*7P&..#C _X6LP.,\9R1DG)X _M)'C#P
MIGC6+'/;Y9?T_<TO_"8>%>G]LV6>.-LW8<?\L>PZ>@I_\1WXS_Z%?#?_ (;L
M?_\ -Z*7T:^";W_MKBG??Z]E>_;_ ' _C&C_ ."5O_!0P<_\,RZP.7//Q0^
MN1GGC'Q5Q\W0\'!Y'.35R/\ X)8_\%"%QG]FC6.#@?\ %S_@1C:=G'/Q3/
MY. >N<D<_P!EO_"7^%L?\A>RSUZ38SGK_J/3VZ]Z%\7^%<KC6+$MN4'"R]R!
M@?N>N>F2/>I_XCMQDW?^R^&M5;_D78_;_P .%BW]&W@I[YUQ1_X6Y9NK?]2_
MLNB[G\8'AC_@FW^W/XLTM]8\-?L^:EJNFQ:SXCT&2[C^)'P8@1=7\)^(=4\*
M>(K(1WWQ)LYG_LSQ#HVJ:<US'$;2\-JUU87%W936]S+UD?\ P2Z_;_#<_LV:
MNJA0.?B;\#,GD'JOQ1(R.<;0.!@DYP?ZF/V:O$&@:=\,K^VU#4;>WG_X6_\
MM$7 B=6+>1>?'_XEW=K)\D;+MGM9X9UQ_#(,@,& ]]_X2_PG_P!!BT_[YE_^
M,TO^([\8)MK+>&5>_P#S X[RTUS"_36_F5_Q+9P7=-9QQ4[-/7&9;VE_U+NO
M._P/X]D_X)?_ +?B[0?V;M7.,$M_PLSX&YR&+#=GXGG.#C Y''([593_ ()A
M_M\ALG]F_5L#<?\ DIGP/P2S9SS\3C\P)." /?&23_8#_P )?X3_ .@Q:<=/
MEEX^G[FC_A+_  G_ -!BU]/NR].N/]3Z\T_^(\<8_P#0NX9_\(<;_P#/ /\
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M&YCDX55_K=M_%OA18( ^K62N(8PRH)2JD( 54^420#P,DG ZGK4O_"7>$O\
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M--4&(A\MD<H[&4D0?\MD)VH0"/+(&63K6K65:X_M75/^/7.VR_U8(NO]2?\
MCY)0!E_YY8=P%P/E)((!JT444 %%%% !7RK^PH /V(?V-P  !^RK^ST  ,
M?"/P@  !P !T%?55?*W["G_)D7[''_9JW[/7_JH_"% 'U31110 4444 96J]
M-.XA/_$ULO\ 7.4Q\S\Q8^],.L:'AN<UJUE:KTT[_CV_Y"UEC[2"?XG_ -1A
M'Q<X_P!43M .<NM:N><?4_EC_&@ HHHH **** /F?0?^3QOBM_V;/^S]_P"K
M2_:8_P !11H/_)X_Q7_[-G_9^_\ 5I?M,T4 :OP/_P"1M_:;_P"S@Y/_ %27
MP4KZ#KY\^!__ "-O[3?_ &<')_ZI+X*5]!U,?A7]=6-[OY?D@HHHJA!1110
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M_P!O'_LE?O/\WI'\T?S1+XG\OU.SL^B_[[_^CEKIK+^#_<C_ /0Q7,V?1?\
M??\ ]'+7367\'^Y'_P"ABI-X[?\ ;OZ(Z2VZI]5_G/6_;?<;_KG'_)ZP+;JG
MU7^<];]M]QO^N<?\GI]_ZZHU7PP]:?\ Z53-F+JOU/\ -:V;;H/]W_V=JQHN
MJ_4_S6MFVZ#_ '?_ &=JA[_]O0_)FU+[?I_[?,MI_JI/K+_-JMGHO^ZW_H-5
M$_U4GUE_FU6ST7_=;_T&KA_%I^J_].T32I]KT?\ Z9JG]>O_  30_P"3(?@1
M_P!@KQ5_ZG_B>ON^OA#_ ()H?\F0_ C_ +!7BK_U/_$]?=]?YT9C_P C3,_^
MQEFG_JUS$_U%R7_D495_V*<I_P#55EH4445RGJ!5+4B1IU^1Y0Q979S.-T((
M@?'G+LD#1?\ /0%'RF1L;.*NU2U+_D'7_,:_Z%=?-,,PK^XDYE'>,=7'=<B@
M"2S_ ./6WY0X@BR8QMC/R+_JP%4!/[N%  XP,8JS5>TYM;<_*<PQG*<(<J#E
M!_=/5?;%6* "BBB@ KYP^+?_ "6[]E+_ +'OXF_^J2\>U]'U\X?%O_DMW[*7
M_8]_$W_U27CV@#Z/HHHH **** "LBU)_M35@#;$A;+ C3;.,P''VEP@+@GF+
MYW*Q\?+T.O63:8_M75N8"<6.1&,3C-OUN#WR /*ZX0=>U &M1110 4444 %?
M*W["G_)D7[''_9JW[/7_ *J/PA7U37RM^PI_R9%^QQ_V:M^SU_ZJ/PA0!]4T
M444 %%%% &3JQP--YMAG5[$?Z2@?/S.<091]MSQ^Y<;2ISAUZUJCTYXXYSZ#
MN>OU]<UE:L0!IN6MU_XFUB!]H4')W/A8<YQ<'I$W4'.,=1K<\<=N?8^G^?2@
M HHHH **** /F?0?^3Q_BO\ ]FS_ +/W_JTOVF:*-!_Y/'^*_P#V;/\ L_?^
MK2_:9HH U?@?_P C;^TW_P!G!R?^J2^"E?0=?/GP/_Y&W]IO_LX.3_U27P4K
MZ#J8_"OZZL;W?R_)!1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/!.M_!#PFGQ)N8/AOX>\&>*O&G[0O@;X#_$GX>>%O#MSXL^)F@:M:7<G@?\
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M#QD$\._'3'[T'H>3TR>/3M7460^0'C.T<YY^\,=/3''OCU(I7C_-'_P*G_\
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M*-!_Y/'^*_\ V;/^S]_ZM+]IFB@#5^!__(V_M-_]G!R?^J2^"E?0=?/GP/\
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M2:U\/_"GP-^%-MX,OOA5?>#I?#.L>"].\6:*++Q9=:IK=_[<'\78XTOPMC&
M/[8U3IG/_0 YYYZ<'/<THD\8?] WPSR.O]LZKDC!P/\ D >AQZX^E*>/Q]7V
M?M,;B'[&3J4[5>7DJ2JSK2G'EI03G[2;:FXOE5J<(TZ2=&HJ.3Y90554L#A(
MJO3A2JVI-JI3C1C05-\]:=J;I0ASP@X^TFG5J3JXB2Q-/P9OV2/@Q<WG@34-
M47XM:_=?#KPS-X9\*R>*_P!I#]HSQ:L"&XU6YL_$VMP^)?BGJL/BWXDZ%/K&
MH2^%/BSXN37/B=X-+0CPIXMTA;"P6VY^V_88_9CM/#U]H1\"^(;HZII$VF:A
MXGU/XN?&76/B->W,GB.U\7?\)9=?%;5O'E[\2[CXEV^OV%A>V/Q8F\4O\3=/
MCL;'3[#Q9;:;8VUI%],[_%XP?[,\,<#:/^)SJIP#QC_D \ ]".E)YOB_E?[-
M\,D=,?VSJI SZ#^P, 'O4K&8U**6,Q24;<J5>45&TI32BHPA:U2<YVUBY2<I
M0FW94\KRV3E-X'!2E/FYI2PT)-N5.%&3E*4ZC;=*G3IN3:GR0C"-6FHW?A.E
M_L@_L^:1X9UWPE8^!K_^RO%O@?5/A]XMEOO'WQ&U37O%OA_Q#XBU7Q7XBNO%
M/BO5/%=UXH\1^,/$?B36M5USQ%\1=9UB\^(6O:G?376K^*+U\;?IH1*H55&
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M%>3=HJ[;NWT]%<P9?&)S_P 2[PSSC_F-:IV.?^@!2^=XR_Z!WAG_ ,'6J_\
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MF>ZB!_X6M^T]SON+2T;;Y0@(/EY\TS*0%2-Y"@#H?@?_ ,C;^TW_ -G!R?\
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M?6[/K*,)TZ5*G.I*M*%*G"56:BI5)0A",JDU%**E4E%SDHI)2E*R2:"DXS^
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M,YM_V/9_^J[!G\4_237_ !F&2/\ ZIW_ -ZV/_S.@@[?]L/_ $:U:\'WXO\
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M?P%+_B//"/\ T+.(O_"; _\ S67_ ,2V<<W3_M7A?1W_ -[Q_P#\QG\:=O\
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M-6K2Q"F\/1K1C@JU2&.J4\+/Z:_MGQ=_T,%A_P"$]%_\MJ/[8\7_ /0?L?\
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M.;=;&>V^!OCB8S/;QZDRWHDB:2%89)($1G69FE\M8V]RKP?XE?\ )9_V7/\
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M?_Q_V'_7[:?^E$=?+O[%?_)F7['W_9J7[-__ *I;P10!],?VQXO_ .@_9?\
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M$^IV2KMU&R"J;20JIDDW CM%Z#\<_7//ZU'\Q."68=<-G(]2,D^@&/KWJ0#
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MG_PNX[K%RB_DW\M@HHHKY\_:@I\?^MB_ZZQ?^C%IE/C_ -;%_P!=8O\ T8M
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MKJM[-WU4N'"3?W7(YR,L#AL$Y/"L,]0<G&!DD!BY8W7^!B2!G"^A)Z\9SGT
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MR,<@XQCO@Y_'D]<9KM_^$'\&?]"KX>_\$]A_\8H_X0?P9_T*OA[_ ,$]A_\
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M )?_ %Z\V_9H\+^&]4^&>HW>I>']%OKH?&']HFV^T76F64LWV>S^/_Q+L[2
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MMO\ A!_!G_0J^'O_  3V'_QBC_A!_!G_ $*OA[_P3V'_ ,8H XG:_P#SS?\
M+_Z]4(89!?7S^2P!6SPX))DVVX!#)D[-@X4[5WD*V&R*]%_X0?P9_P!"KX>_
M\$]A_P#&*S;?P3X0;4-11O"7AP1J+38PT^RD+[H?F#6YB*0;3T(5#+G>=W6@
M#F]LG>-_R_\ KT;7_P">;_E_]>NV_P"$'\&?]"KX>_\ !/8?_&*/^$'\&?\
M0J^'O_!/8?\ QB@#B=K_ //-_P O_KT;7_YYO^7_ ->NV_X0?P9_T*OA[_P3
MV'_QBC_A!_!G_0J^'O\ P3V'_P 8H Y33U?[?8Y1P/MMJ22. !/&237RY^Q4
M&;]C']CYE5F4_LH_LW$,HR"#\%O!&"#GD5]H)X*\'QNDB>%O#Z/&ZNCKI%B&
M5T8,K*1!P58 @]B*^8?V*/#7A_6_V-?V1M8UC0](U35=3_9@^ %[J6I7^G6E
MS?7UY<?";PG)<75U<2PM)//-*QDEED8N[L[,2QR0#V;:_P#SS?\ +_Z]&U_^
M>;_E_P#7KMO^$'\&?]"KX>_\$]A_\8H_X0?P9_T*OA[_ ,$]A_\ &* .)VO_
M ,\W_+_Z]&U_^>;_ )?_ %Z[;_A!_!G_ $*OA[_P3V'_ ,8H_P"$'\&?]"KX
M>_\ !/8?_&* /.[Z-V^Q?N"^-1M&^9BFPJS'S!AE\PK_ ,\CN#Y^XV.+H23^
MX_Y9_,\9X'H.2Q[UTVH^"O"""Q,?A/PX=VI6B/NTZQ@Q&S,&(Q$@F('2W;<L
MG=&*@5H_\(/X-_Z%3P[CC_F#V&<\Y_Y8=.G]>@H XG:__/-_R_\ KT;7_P">
M;_E_]>NV_P"$'\&?]"KX>_\ !/8?_&*/^$'\&?\ 0J^'O_!/8?\ QB@#B=K_
M //-_P O_KT;7_YYO_WS_P#7KMO^$'\&?]"KX>_\$]A_\8H_X0?P9_T*OA[_
M ,$]A_\ &* /G+X?*R_M;?%/<I4_\,R?L^9!'3/Q@_:M(_,<CU'(XHJ_X1TO
M3-)_;!^*]OI>GV6G0']F?]GW,5E;0VT9V_%;]IZ1<I"B*<27$[CC[TLAZL:*
M .D^!_\ R-O[3?\ V<')_P"J2^"E?0=?/GP/_P"1M_:;_P"S@Y/_ %27P4KZ
M#/ )]*E.T;]DW]W,_P!!O?[OR0A('N?0<FDW*>_Z&O"_'GQQL_ GCCPSX$NO
MA[\2-<U/QE*]MX8U+P[9^#I]&U>YM;9;W5K>&?5O&FCWUL^BV3&[U%[[3[2$
MQ*XL);Z53%6%!^U1\)G\->"O%=[>:YH^D>,=.^)>K2MJNCM;W/@_1_@[I&KZ
MG\2=7\;6\5Q</HUAX5GTE="U&:V.HLVO:IH]A DT=Z+B+S99QET*M6C/'8:%
M6@VJ\*E1TY4G%4W+G=2C&"Y55IRDU4FHQG&4I*#YULL+B9PA.%"I*-36G*,5
M/G3YK<JC4<G?DFDG%-N+BES*S^DMPP#V/?\ /_"@')(]*^8M8_:>T/PQX&U?
MXA^+?AC\9?"?AC34\+36<^M>%=#&H:_'XNU[3= TI-)TC3O%>H:G;WB7.JV5
MQ?:1KUKH>LVEI)(7T][JWN+2/N;?XZ_#RXL_'^J+JERFB?#OPQX=\8Z[KK6@
M;3)_#OBC0;GQ'H^H:/+#++/?QSZ7:O*RFWA<22P1HLA<E9AG663ER1Q^$<_8
M1Q+A*JX36'E&K.-=QJTJ4E2E&A6DJC48N-.3T22FWA,5%<TL/54?:.C=14E[
M6,H1=.\)S3FI5()Q3;3FEJ[N/LIX!/I3=P]^N.A_S_6OE]?VIO"DO@WQ1XQA
M\"_%&9? RQWOC'P^NB^&(_$7A[PY/X:7Q?;>*[Z&X\7PZ3+H%WX=EBU&V-AK
M%YJTHD-H-*^W13VT.DO[4'PSE\:^'?!]NGB>XA\0:MX1\,Q^+5T6.+PGIGC#
MQWX.?Q_X/\(:M<W5];ZU;Z[KOA4V>IPFWT*\TJS?5=+L-4U2PU&\6U$_V]E#
M=-+,L&W4=+D7M6G/VU>>'I\MZ&JG6ISI7?*H5(N-65'W92IX'&>];#5O=YN;
MW4^7DA&K*]JEOX<HU$E=RB[P4[-+Z0HI 1DC(Z]/3CIC\"?SI<_X?E_^JO8.
M1/;5;!112,<8[Y.,>O!_+\>/QQ0_ZZ##(YZX SGU'7BOEK]H[Q%K6DZG\*]+
MT[Q-J_AO3M?U_P 20ZP^C^*_#O@B>\@T_P ,37MI&_B'Q197NG01P70^T?9
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M5=7.V+E;$;HV!G/[@_ZU>JX_Y9YZKDT :]%%% !1110 5\K?L*?\F1?L<?\
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M_N]?\GM^$E- X'L!_0_TJ))NUE?22^])+]0Z_P!;GYV_\%1,_P##)U_P<?\
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M$KJ]UA':S3?_ #&]5?7RVMH<7]NY1K_PH4.MK.OU_P"Y>SZ=M5?J=U^Q(/\
MB9_$(_N/^/7P^,L2+HY?4N(TR,PY!,SE3\_E#<.!7Z#5\N_L]?!C6/A!/KB^
M(-7T74=5\110N;?2%NF@L[/2W*0&&YO;>RN9S.]Y*UVILHHXF2V$<DAWL?J*
MOW/A' XK+N'\!A,;1E0Q-*-9U*,G!RASUZLXJ7LY3@FXR3<5.5KV;N? YUB*
M.*S/%5\/-5*4W34*D5)*?+2A&37,HR:YDTFXQO;9=2BBBOI#R@HHHH ^=/V6
MO^25ZE_V6?\ :1_]:'^*%?1=?.G[+7_)*]2_[+/^TC_ZT/\ %"OHN@ HHHH
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M-^O_  T'+^0^"?P4_P#K5]!U\??#N*Y;QK^TJT.IZM9@_M#W0V6.HSVL94?
MCX!%5*("N SR/P!^\EE8DE^/5?(O_P#H/^)/_!W<_P#Q-);*WG^;&]W\OR1[
M917B?D7_ /T'_$G_ (.[G_XFCR+_ /Z#_B3_ ,'=S_\ $TQ'ME%>)^1?_P#0
M?\2?^#NY_P#B:/(OO^A@\2?^#NY_^)I:]OQ_X 'ME%>)^1?_ /0?\2?^#NY_
M^)H\B_\ ^@_XD_\ !W<__$T]>WX_\ #VRBO$_(O_ /H/^)/_  =W/_Q-/C@O
M3(BMK_B4JSA2!K=ST/\ P$4 >TTUAG'3@Y&?7M^F?QQ7BODWQZ:_XDZG_F-W
M/3./[OM1Y-]_T,'B3G_J-W/_ ,32:NK/3ST=K:WVW6Z_X9@>GZ%X;T7PQI\V
MF:%81:?8SZMK^O301O/-YFK^)]<U'Q)K]ZTES+-,9-2UK5=0OI09/+C>Y:*!
M(K=(H8UU70-(UY=._M:QBO?['U>SUW3/,:5/LNK6 D%I>IY4D>Z2 32A4D+P
MMO8/&PP!Y>8KY1_R'O$K'(Z:W<_D.!T _'/;%((KT_\ ,?\ $H^NM7 QSC&,
M9ZX'3H<].N+PU+D</90=))15/V=+V:2=U%1=+ELF^91V3O[KNVVW+63E/FOK
M/FG?56;<K[M::N]O):>T[#QG'''3/ Z=NW8=!VQ2"/F0@+^\(W' R=H*@GCY
MB   3G  '0"O%_*OLX_M_P 2'KTUNYYQU&=N.,8]B>?9!%>GIX@\2]<?\AJY
M!_+:.W./0'/0TW2C972NGHVJ;5[.-[.%D[/ETM[KY;\ONDZ/OIYR_&TNVR:W
MUM?4]J X'&"00<@9SSC/!Z\_4=2>Z+'@(.!LZ    8P !C _#MQT KQ<Q7H)
MSK_B7W(UNY/)Y'4#L/I^- BOB/\ D/\ B4'_ +#5SW]3@CCG/TQR:;IQ;ORQ
M:Z>[3TU3T?L]-4GZJ^DDF'W_ 'OM_BUMM\^S:/;?7Z\?D**\3\B__P"@_P")
M/_!W<_\ Q-/$%Z(I'.O^)"RRVR+_ ,3NZP!(MT7R,#.3''SU 4@=2:N[_E_%
M#/:0<_Y[]Z*\3\B__P"@_P")/_!W<_\ Q/\ GM1Y%_\ ]!_Q)_X.[G_XFGKV
M_'_@ >V45XGY%_\ ]!_Q)_X.[G_XFCR+_P#Z#_B3_P '=S_\31KV_'_@ >V4
M5XGY%_\ ]!_Q)_X.[G_XFCR+_P#Z#_B3_P '=S_\31KV_'_@ >V45XGY%_\
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M_P#GWUM[U'9>7-O_ %J3[2'\U+K_ ,OJ/2W>NM=3VSS/;]?_ *U(6]B"/?\
MF,5XGLN_^AA\2_\ @\N>O?'KQ^N1ZFEV7@P?[?\ $QP<<ZU=' [EN#QZ=R/3
MBBT--:?77GI?BG+[@]K#;GHKIK7H+\?;>:^\]89A_;5JN8@3IMV<,N;AL7%L
M,H__ #R&3YB]W*'M6Q7@I6];485'B'Q!S97#;#K%T9L^?;@LK[2!&/E#+O\
MF8HP4A<B]Y%__P!!_P 2?^#NY_\ B:M/32UNC3337RNON9:::3333ZQ:DOE*
M,I1?JI/7K<]LHKQ/R+__ *#_ (D_\'=S_P#$T>1?_P#0?\2?^#NY_P#B:>O;
M\?\ @#/;**\3\B__ .@_XD_\'=S_ /$T^*"],D8;7_$A4R(I']MW/(+ ?W>G
M//M3 YW]EK_DE>I?]EG_ &D?_6A_BA7T77Q'^SS]LF^'>J%-7UFU6+XR?M&V
MR166I36L.RT_:!^)5NDAC0%3<3B,SW<Q^>YNY9[F3]Y*V?</(O\ _H/^)/\
MP=W/_P 31K_3_P" ![917B?D7_\ T'_$G_@[N?\ XFCR+_\ Z#_B3_P=W/\
M\32U[?C_ , #VRJ6I<:??G,:D65T=TPS$N().91WC&27'==U>0>1?_\ 0?\
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M@ >7#$N/DR2F OPW_P"1S_:4_P"SA[O_ -41\ *]9/M_G_\ 57DWPW_Y'/\
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M2J&Q(%+,5# A23C'.0M(R1Q/+(\<6?*C9F,<>X@MY:$E4+$9)4#)Y//-8O\
MPD.B?]!.T_[^#_"C_A(=$_Z"=I_W\'^%.R[+YZ_F_EZ:$V75)_+Y=^S:VV;5
MNIT!N[UB"][>.5W8+7,S8+#:VT,YVAERK 'YE)4\$[F&:X)BS<3G[/C[/F:0
MF# 4 0DM^Z "+CRPOW5YX%87_"0Z)_T$[3_OX/\ "C_A(=$_Z"=I_P!_!_A1
M9=E_EZ:Z::?U<.6*V25MK7TWV]Y]VNNFG16Z 7=\':07UV'955G%Q,'=4W;
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MS16-_P )#HG_ $$[3_OX/\*/^$AT3_H)VG_?P?X4 ;--9=W?T]NF?3ZUD?\
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MC/&TCG!)SBO[KAX5^#8'R^"/A6J^@\#>#P?3MH@_#CBG_P#"+_!WC_BB_A@
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M3-3N8K'4;']EK]G6TO;*Y;R[FTNK?X->"HKBVN(R,Q3P2(\<L;?-&ZE6PP(
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MK]5/:B@#NO@BB/XM_::WHCX_:#DQN56QGX)?!/ID'T'X #L*^@/(@_YXQ?\
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MY!$:9!]>E2T4 ?./[+D<;_"S42\:.1\9OVD5!9%8@#]H?XH8&2"<#H!V& .
M!7T3Y$'_ #QB_P"_:?X5\\_LM?\ )*]2_P"RS_M(_P#K0_Q0KZ+H B\B#_GC
M%_W[3_"CR(/^>,7_ '[3_"I:* (O(@_YXQ?]^T_PJGJ,<,>GWTFT0[+.Z?SH
MHD:6+; [>9$NZ/=(F-R#S(\L -Z?>&C5/46*Z??,))8BMG=,)8!NFC(@<B2%
M=\6Z5,;HQYL>7 &]/O  +6*%[:W8HDA:&(EY(D5WR@.YQE\,W5AN;DGYCUJ?
MR(/^>,7_ '[3_"F6AW6MNVYWS#$=\@Q(V4'S.-SX<]6&]N<_,>M6* (O(@_Y
MXQ?]^T_PH\B#_GC%_P!^T_PJ6B@"+R(/^>,7_?M/\*^<OBU'&OQL_935415;
MQW\3@RJH 8?\*1\>\,  &'L<BOI*OG#XM_\ );OV4O\ L>_B;_ZI+Q[0!]%>
M1!_SQB_[]I_A1Y$'_/&+_OVG^%2T4 1>1!_SQB_[]I_A1Y$'_/&+_OVG^%2T
M4 1>1!_SQB_[]I_A65:K"VJ:I%N,GE+9'R'A00P;X"W[EO,<MYOWY!Y4.&_O
MYW5M5DVKEM5U5//N'"+9$0R+BWAW0DYMV\YPWF8W2CR8</W?[U &CY$'_/&+
M_OVG^%'D0?\ /&+_ +]I_A4M% $7D0?\\8O^_:?X4>1!_P \8O\ OVG^%2T4
M 1B&$$$11@@@@B-001R""!D$'H:^5_V%XHW_ &)/V.7>-'=OV5OV>BS.JLS'
M_A4?A#EF8$D^Y)-?5E?*W["G_)D7[''_ &:M^SU_ZJ/PA0!]2>1!_P \8O\
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M,$7,O^M/R+S)R?G_ +W)YSR:L57M!_HMO]_F&(_O?]8?D7F3@?.?XN!SFK%
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M (>J#_YWE%%%DNG]?B^BZ@'_  FOQ_\ ^B$^%?\ P]4'_P [RC_A-?C_ /\
M1"?"O_AZH/\ YWE%%, _X37X_P#_ $0GPK_X>J#_ .=Y1_PFOQ__ .B$^%?_
M  ]4'_SO*** #_A-?C__ -$)\*_^'J@_^=Y1_P )K\?_ /HA/A7_ ,/5!_\
M.\HHH /^$U^/_P#T0GPK_P"'J@_^=Y1_PFOQ_P#^B$^%?_#U0?\ SO*** #_
M (37X_\ _1"?"O\ X>J#_P"=Y1_PFOQ__P"B$^%?_#U0?_.\HHH /^$U^/\
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M%% !_P )K\?_ /HA/A7_ ,/5!_\ .\H_X37X_P#_ $0GPK_X>J#_ .=Y110
M?\)K\?\ _HA/A7_P]4'_ ,[RO,/&5M^T3XH\?_!OQ=#\%O!MM:_#7Q%XOUK4
M;>7XU(;B^A\0?#SQ+X1M(+&-/AL\<DJ:AK5K<7#7%S9I!90W$D?VN<Q6K%%
M'I__  FOQ_\ ^B$^%?\ P]4'_P [RC_A-?C_ /\ 1"?"O_AZH/\ YWE%% !_
MPFOQ_P#^B$^%?_#U0?\ SO*/^$U^/_\ T0GPK_X>J#_YWE%% !_PFOQ__P"B
M$^%?_#U0?_.\JK'XK^/D5U<70^!WAMGNQ$&C?XV6IAC\E-@\D#X=!U+@;GRS
M@D9&W&*** +7_":_'_\ Z(3X5_\ #U0?_.\H_P"$U^/_ /T0GPK_ .'J@_\
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:COP^EA*+F[N+VZ;4HY+2SBL(+C4"BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %) 5X# 2(  A$! Q$!_\0
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M3C)_'7_!,7XR_&S]I3]N+X:_L1?&+]MBZ^)WPD_X)T^(OC5XU^$7COP?XO\
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MYMY C.!D=C]I4MM"RECQ@1L".#D$$$AARW08&WD\@_S=^)]3^/?[-7P,\/\
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M2FH*LY.$(>UGR./+S)V_IZ$I/0RD@]A*X/!S\H).-I!'/)Q[4TS_ ";QYI0
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M2:QNH=42PDN+ZUE4+);*\T(D_-[4O^"?WQ7N_C3<>-O%'BOP'\:/"OQ"U_\
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M[XD\:7EOX@\#_$WPA86ROI>M7VA^*--TX7NDZP]JKVB?:;2:2YB2$_$^C?\
M!.C]H.^\16/C+QW\0/ <NO-^T7^P;\9-6>Z\<_%SXHZC+H'[)WC'4O$7C73Y
M/&?Q*>_\17^L>+(;T2Z';12V7AS2]1GF"V&GP.4DC#X/(JM*A4Q.+GAW'#86
M=>FJ\9UI8A/&2Q,(1J8.4(0:CA8TY0E)4N:3M4C.ZTQ&)SVG4JT\/A:=93Q6
M)C1JNARTJ6'O@HX:<N3%QE4=Y8N4TX1E5BHJ].4%?]$[S]MS]ERR^(F@_"2?
MXM:4GQ%\0>(/"WA32O"\&A>+[F<^+_&^BP^(_#/A34=0M?#DFCZ%XKU/P_>Q
M:_)X=UN_T[6M-T<RZKJEG8V,%S/%SY_;^_9'OM$^+NN^'/B_HOC=_@;H-[XG
M\?Z1X+TW7/$/B:VT;3=5N/#]QJV@Z/;Z4MQXJT6'Q+;GP_<>)/#SZEX8TO56
M6#6=:TV$-*GY52_#_P"*%C^W'XF\*>(_@O\ 'WQ7\/?%O[;&I?$'0_"^G^"_
MC%I/P<\*V7B7X;W&DV_[4DWQ)L? NH_LSZE%X-O)[W7[CP=KWQ-T#QSJ&O6]
MN/\ A%=6\6OI-K<?2W[._P#P3N^(/PLTO7?"'C+4?AWK<>B_LL?&+]F'X9?&
M"Q\>?''Q#XZTSPQ\5-:\#ZC-9CX9^,=<O_AO\/O#NI#P'X?U7Q1I?@:.W%SK
MWA?0?[(^S6$U]"W3B,LR##TZ<IXO$5:]2E@IN$*N$Y:LIK#5L5.4J="7LU1C
M*IA723]M3J\N)HRK4Z<H+&AC\\KU*L5A*-*G"KBZ;DZ.*4Z7)&M]6<54Q')5
MC6:HU/:0;A.,Y4*D*,GS/[%\,?MY_LP>)K?X7O;?$.YT_5_C#X7\,>,?"GA6
M_P#!_C;_ (2:RT/QCJ<F@^';WQ?8:=X=U"+P3!J^O6U_I&D:AXENM-TC7;K3
MM0FT/4M2LK*:\'V*$;'EYR I)4XQC;M,>,E=B-P5P4P0 .*_)*T_8V_:977?
MV5O$NA^*/A%\*?'7P6\#?#3X;?$7XL_#OQ'\3AXC^('PZ^'NJ(=1^'/B/P9<
MP6O@[XE>#_$&D6J7&AQ>-DDO_AUXAUS7]0\-7=N9[D7WZZ0Q[!G. 2S[>ZA@
MN ?7 7D]2V37CYCA\OA*G]0JRJ4ZD<5&K2E-U)TK5YQI)5(0HPG&K0E3G":3
MJIJI[90J-7];+ZN.J1J+'4HPE!T/9U(P4(U5+#PE5?)*I5G&=.M[6G--JG_#
M]BY03D,2(9S)MD,9)3."4(^4%,Y*$)@$KMSSV-.0;6?[G+9R!C=PV"<]2/ND
M@Y]>.:G  &!TYZ<=3FEKCC"*MHM&W:VS=M5VVMH[6NMK(]"S[O\ 6W9]_P#A
MFM0HHHJQA1110 4444 )@G.>G(_,#G^=1M&K<X.1C'.#P01@G) '/'Y5+10U
M=6#^OPMYD#P@EB,88$8QGG& 3R,X Z]?R&&K"R$E6Z]CR.>N,GN,9)()QQCB
MK-%+E6OG:]TGM:W1=ENW\A6M=+2_]:;V^5BN8VP!D'G.0%!!]>?QSW.<8X!I
MK1L S%N@] >!Z#!QGCM_#D\ 5:I",@CUJ7"-K*,7MNM[?/3RM:SMV!KU?E>W
MRV/F#]K/X_7G[,WP/\4?%O3O"<'CN_T+6/!.BV7AFYUH>&[;5+SQIXX\.^#+
M1)M;73]6.G1V]QK\=P\YTR["Q1,?*<96OCE_^"E&K:7\>Q\&O$/PI\&>3X9^
M*G@;X!_$EO#'Q6N=:^(EC\3_ !AX8\+^)M1\1_#[X93>!-.U/QC\$_!C^.?"
MNBZ]\0=7U#PCJ\M\_B._L_"+Z-X5U.^K]"_C+\%O _QX\#:A\.?B+:ZA?^%=
M3U+PUK%Y::7J5SI%W)?>$?$VB^+=$D6_LVCN8TM]9T.QEFA1PEU );>8&.0J
M?-+W]DGX8/\ &&^^-FBZI\4/!?BG7_$.D^+O&6A^ _BIXT\(_#[Q_P"+-%T>
MQ\-V?B3QSX TK5H_#7B'6I?#ND:'H&HW]S9K+JNC^']"M-1-RNFVY3T,)4RR
MGAIPQ>$G.O?%RC4A[5ZN.&6&C:E6CI[N)]_D?LYN,JG/&24/)Q5'-I8E3PN*
MI4\-SX.]*=.G*].+Q#Q:7-&,E.=\.HOVC3@I*$8R3YO@/Q1_P43^-VO?LS_M
M@?%/P?\ #?X/_#KX@?LY:3XBN+OX9^//B'XIU'XP?#U]!UB_L[MOBW\)KWX;
M>'5TV[U70;.U\8^ K[0?$_B#P)X\TG4;)M(\736K/>58_:5_;5^.GA7X)_MD
MV=U\/-'\':I^S5^QKH/QE^(GQ$^&WQ7N;;Q)I/CWQ]X"\4^(=-T'X3VGB'X5
MZU;WG]F7?AF]?_A+O$=A!!90^5(=!U&Z86A^R+3]@[X -%\73XDL/&_Q!O/C
M=\/I/A/XYUGXC?$/Q3XSUN3X:&YNKR#P1HNIZM?M<Z+H-E?7DU_90VC"XM;H
M1M%/LB1*EU?]A3X%>(_AY\9?AKXFC\>^)M%_:!^#O@WX&?%S5->\>Z_J'BKQ
M;X%\"Z%KWAO0S<^)'N$U"#Q =)\1ZK!J?B&U*:EJC2Q3W3M-%&X]*GBL@C.'
M-@)RI1Q6'K/]S4=7V,EEGUFC"4L<I3A3]EF2HJM&-6I*O&55ZP]GQ3PN?24G
M'&1C)T*U.-J]/V:J<^8.A5</J;2JN,\![1PDZ,53G"&BE*>39?M$?&#X@?$+
MX_\ ACX1?"+P%>^!_@3?^(OA]<^,_B!\3=2\.ZCXF^,>F> M*\;V>D:;X/T'
MP1XDDLO EO-K>D:)K/BC5=9L-2626ZO]"T/5[6S99/@W0O\ @JE\2?"_P8^
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M3=&M_BWX;M[+6?&27^@R:5>3:/!%>WUO MQ%(\NBJDMI=S_LMK'[-?@#Q+\
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MHH **** "BBB@ HHHH **** "BBB@ II4GN.F.G4<]\CU^GM3J*32>_E^'R
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MG@OQ3X!_9R\'Z;XCM=3M[C5]3U76+3^TK;4[.>319S:V.ERM9ZK&EW:Q306
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MJ8^G3E4GBJJJU,LK8'%5N90P=2E1PTH-8V#A][^&8BEC#M!"%8QM.>PB?=Z
M%<]3R>1DMD]7UZ5BZ8J1Q0%?NF!6!)Y)VA?7;RH7DE1GID#(V-Z\\XP,\@@X
MY[$ GH>GI7Y!?OIZV_K[C[2]]?Z_R_'U' @]"#]/IG^1!^AHIJYYR0>G(^@S
M^N?PQ3J=UW0!1110 57N7$<,TCL$1(V=G895$5<LS<$A4 +DCC ]:L52O KQ
M2HZ%T:/;(AP5EC<[9(CD@8=24;<0,, S*"6I/2W:ZO;>UTW;?6R=M'=I*SO9
MIWL[6O9VNKJ]G:ZNKJ]KJZNKJZ3;7QI\:/VN/#WPIT]]52+1=2T^W\SS7U#7
MXM),T,0)END=F9+6T6,22K+=(Q:&-R(P<9]0_9]_:&^&O[27@#0_B1\,/$6F
M^(O#VM81)M/O[+4A9WD21&\TVXNK"YNK2:>W2>&>.2WGEM[BTGM[R%C'.N/Y
MQ_VJ/V</VP](^.?C70M<\':S\7_A7XDOK&#X17/A35]"@T*SM\+87NE^-(-4
MU'3[KPZUQ>3SQZKKGBJ]TS1=LTC6NJ36]JK/]I_\$G-+TCX*_ Z^T[3/$J^.
MY-5\7ZCK&HOH5CK&G>#-)U"YM8(+2R\-ZQXDTW1[KQ+X>O+-+;4(_$VEZ0NF
MWPFDCM4,UL]HOZ3Q1DO!N6<-Y57R[-L-5SW&<F)ITL/C:.)GC<.J2GCEB,-"
M=2IA_P"S>>+KJ<<'55>?(X2HT^>7XMP#F_B/B^),XI\5TY_V6ZN)C"G+*X8#
M"Y,XXBN\)A\+F'+&KBZE6A"@I\LL7AI^W5JM*LI17[RM($*@J O'4A1G[Q(!
MQRN"WYD'D&GJZ-\P((.>>!GD?]]8/&03R/4BOA6Q^-6K_$+Q!%XQT2:72?"F
MG66JZ-X4#V>M6%UX@NKNY@BUOQ6^GZ]I>G"32"NFPV'A+4 MS;:MIMW>Z]IY
M%I?V%Q+Z-+\>++PMILU[XOU/0K>QTZ,S7]]?W\>GW:0H/F'V6)WN+VYD)*VU
MOI]E<W]Y.T<%K9W$T@2OS*,E+#NO)QI4WS.$JDE&,HQ:3J<TE!<O.I02Y9IV
M4ES*2/V65:G&<::<IU++FBHW<).[46DWS-QM*Z:MS6W3;^I>02>!DOG/&.
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M[/ZU1;24:L*:K4*E&O&,(XBA7I5HP@I<JV:***\BY]*%5[D@0R DKE&Y4@,
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MK5E5J5.;\K='_;AM_$6L?M$6_B^Y\#:'I?@SQ]/9ZO9:#XJU+5Y=$\4Z1?\
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M6<?,K%_F=R6./,D8[F^E;K1H+VV*.JM&R!'4(K!E5<X.2<#<JGG!(P,@BO\
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M'BF+PW9:BNJ6EP=771[B2ZATS5+:ULH[MO$>GRV]SJ=C;17RV]A<00WT<?\
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MB3P#=>);WP5K.N6S7-_X4O?%_A^[\*^)[G1+M)D>SGUOPY?76C7DJ[RMC.1
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M1110 44'@$XS@=/7VINX<9X.W<?8=\_J/PH =13=Z]R!C_Z_\\<?_7J,S+N
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MS7ZG^'[S]G?2O VK?!?P1\6+&PT_XFZ;XZL?"&MV'BJ&^TC3KOQQ9WT<6G>
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M    , #T'%  '0 ?3Z8_D*6M5LB0HHHI@%%%% !1110 4444 %%%% !1110
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MS]?<9(/J06/)-2TF,?X=NI.?QSS]!2UB=@4444 %%%% !1110 4444 %%%%
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MA;Q!X(\;:)IGB?PAXITNZT+Q'X>UJSBO=+UC2KV.2*\L;^UF#1W-O/$X1XI
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MKOC[2O#&EZ9JUMH5S_5,W_!%_P#X)D2H4D_8^^#[*WRLI\-V)5T(8%2IMR,
M$C:<@@88L*A_X<N_\$QMS?\ &'_PD(*VRG?H-M(K"SP+)7CEB=76RSFR5D*V
M>6^SB('C)\0Y;"4/J^*S^E3II)T)RI25U.$N>$Z-6G%N48U(-3C[JJ7M>$9.
MX\'YTZ4X8G!\,XJI4]HG5C&K!RO1JTZ?M95</*4H0<X2A3I^S<907-.SE?\
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M=+?+MZ ( !T^O<\YSGGWY^M+110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #, >H# 2(  A$! Q$!_\0
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M#;3)RSIX6^&ND7*E-,M84=H=1\1O&=<UZ0RS37$5O(L-?38;YB2V#G/S'CU
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MSHRS$,XP3N /55'W5S@Y( P.N 6X/"X-([LAF&U-QPPYSEB""<<X)&""3C/
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MNUY_BKGY'%J-Y*VFLGTVM=V\GZ&X\H49W[QN! 9LCOCTR1R>^.>ZBJ#W*KG
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M"Y(R>5^;:21SRP.0><$Y%?E-\2M:626<E\C]X5VG'/S<8./O9X].^:_AK/\
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M(G59_+02!@B8 /QP_9#_ &Q[J.R_M3XU_'#0[R2Z_83_ &8/BUX?TKQKXO\
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M$4,70H8K#5H5\-BJ-+$8>M!IPK4*]*G7HU8-.SC5HUJ52+6EIHDHHI#T/?\
M7_"I-A<CIGGTI&/!]P0/R)_D#3<XZ@ A?KTSQG/3C./UK%U/Q#I.C0QS:OJ%
MCI<,\RV\<^HZA8V$,ER^/+MXY;RXACDDE_ACC9W.>@)X=F](IMZ*R3DVWM:,
M4V[]K-[]A+WG&$5)SJ74().4YM1<FHQBI2=HIMV3M;T3X+PW_P E6^)(Z_\
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MN".X:QOXTTV6..\LVD-M<HDLBI-%(@8[:M']M;]EK'_)9O"ISQ_J]:_II)H
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MF;YFE"G1HX[ZNL+FL:6&FZTL.E&U2%7FII0>K1^+MI>%2/F8EN.3G@#DJ/\
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M:N;C4Y+"[>XCOM2$]U:J\A-O:R108"QJJ@'[79'J/S%&1ZC\Q7YX_P#"LO\
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M<^(O#UA;2B[UC38'+;88I-0M#)(3E0J1B42EF8@*JQ,\F=H#9Q7[/_\ !/\
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M8E> >3T+=\\9Z>F1GTJ!G  ,C DJ0%Z YQG\SC).._X.>8*$ ;C##[O+;57
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M7;6W?N!=<J(V+ #D@[L$8"$Y!&.6.!@''&,4P*Q .Y>0#]P=Q]:9N*[6=SR
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M (.#_&+6I_M[]E?0?MH/RC0_BO>M:D8R"YU/P5!,1CD^6C'@\'DUB:G_ ,'
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M7@CC^Y6+KT8VYZM*%]N:K3UM_P!O';'"XNI%2AA*]GT5*>GE90=KI77DS^*
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MCW(M\\6VVWN^^MNMWOW_ #. XM1M++QE2H..F=B9Q[$Y-*>/T'YG%23J!(F
M!NCW-@8RW[L@]NF3V]>W6,D=,'T/'';K[8/?T-;">Q$V0,]2,XR<'(4@D<<^
MV<\@>O'Z$_L-W*?$+Q-:_"36]4?3K.WDFUD:A\CW$'AR(>9JUO9I*P3SXIBD
M=J6RL(N@^PB/ _/@\XSCJ>_;GD'TZ8X].QKT[X,>*+_P7\4/".N:;<26TPU
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M!N_8,F,\9Z#./7@\9-5SP#S@DCJ0.>!W^G^%2W!_>1#(R(^1ST/EDX[\=,]
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MESU'_M_X$?1YX/\ !/)**PF&P^;<7XO#T_[;XHQ%",L15K3A"5;"Y7[7VE3
M9;3JJ484X5%5Q"@ZN)J3<XPBD6=N#D%3MP?8#GZ_US7C/Q]^/GP<_9F^&'BC
MXQ_'3QYH'PX^'OA*S^TZOXC\0W7E0&:197M=,TVS0->:SK-^8Y$T_1]+AN=0
MO74B&!E5V7VK!YZGMUQP< GIU&"1_P#7KX'_ ."A7_!._P" O_!1[X-'X1?&
M^QUFSN=$N[GQ!\-OB%X7OC9^*OAGXT?3[G3[;Q/HD5P9=(U3;!<O;ZAH^MV5
M]I>J63RVEU;E7#+^88>-%UZ,,3.I2PSG%5IT*<:E6%/6[IPG*$&U:-E)VU?E
M;]ZQ<L7#"8B6!IT:N,C1G+#4\14E2H3KI7A&K.FI3C!R;4G%7ML^_N?P+_:E
M_9Z_:-TXWWP5^,'@#XC20:%H7B/5=*\*^)]'UG6O#NG^(K6WO-,7Q'I6FWEW
M<:+>,LZ6]S9W866UO4ELY<30NJ_.>I?MUW]Y\4_VA/"O@3X#^+?&?PP_97@U
MRV^-WQID\7^&/#FBZ5XK\/\ P^OOB%J/A+PEX6U&WN=>\97ME86]CI>IWME)
M8VNG:GJENDGFQ1NYY+]@'_@E!^R=_P $YG\4ZS^SYX;\8:?XR^(GA?PSX>^)
M.O\ B/QYXK\3VGB6Y\/^7<R:I8:'KNKZC8>'#J&KM=:@+?2TB2&.X%J@2"-(
MTS=7_8<^.^@_&#]I2_\ A5\>?!>C?LX_M<?\)MXA^,/PH\8_"N^\2>-M(^(?
MC'X877P[O-<^&WC_ $GQAX?L]&T6^E&D>(-7TK7?#^N7DUS83VMEJ-G!=L%Z
M7# .MB8TYU70C&D\-+$ITJDOW\%6YXX=22G[!5'3C?EN_>;:2?G*><RPN#E6
MHX>&+E4Q"QM+!S^L4HKZK)X3V53%.DU%XQTXXE^]*-./N-QE)KQO2_\ @LOX
M+MOA[JGB_P"(OP!\?_#GQ+??";X(?''X4>#[[Q;X0UVR^)_PR^/_ ,3]*^#_
M (1\2W'CC3EAT'X<V/A3Q[JUM%\4;GQG%;6?@CP\1XDN;R]T]N/=/AS_ ,%2
MOV?M<^#_ (V^+7Q:O]'^"EMX!_:#L_V:]6M]4\>^"O%OAOQ/X[U/5/AW86.K
M?"OXA:5J.F^&/B;X-M;7XJ>$]1\5>(_#TGV7P6MIXNM?$*VDOA/4_+^(]$_X
M(O?%W7_A1J7A7XY_M-^$O&/Q!\._ +X(?LX?!C4? /P>N_"/PQT7X<? CXUZ
M5\=]/TKXO^!=;\<>)=1^*>G_ !'\2Z#I'A_XC:7+K^EZ==>%;:>V\/VNBZI=
M2ZDWV/\  G_@F7X*\/\ P>^,'PW_ &C_ /A"OBQ<_'+]J%/VL?$6B?#[P4_P
MR^%GPZ\;VNM?"[Q%9^$_@[X7N-8\1^(O#G@N[U[X1Z%X@\7V6J>)-2N?&FIZ
M_P"+X-?FO-,UV>S%UZ>6)3<'.\ZU-1]E*K)NG[>;ER.M;1T5&5ZBC%5.>+5G
M$Y<)/B*3A&O&C%>PKMNO2IT[57AZ7L75^J2<;+%+$Q2PTE+V"H2DW*4XKZ+_
M &J/VK(OV>OV7?%/[5W@?P1!^T'\-/ /@#Q)\9O&=SX#^('A;3+6/X)^$/AQ
MXJ^)?B'XC>%-<OEU#1O&T/\ 9?AVTMM"T?1KI7UZ37;2[M-1CM+::0Z.G_M4
MZ#X4_9QT_P#:6_:4TJT_9O\ #%S::5?7>EZ[XCMO']Q:6/BF_P!/LO!$5K<>
M"],GN-<U_P 6MJVEP:;X7T32M0UIM8O8='MX+VZ"!M;]J#]G6V^/O[(?[1G[
M*_AF\TWX;67QS_9M^+_[/FB:M9Z%#<Z'X MOB7\,?$OP\TO4K;POI]SI,%QI
M/AA==CO$T+3[K35N(;;[%!<VJR>;%YK^T_\ LC^)_CE^S#\/O@IX-^(NG>!_
M'_PC\8_LY?%#X?\ CW6_"*>*_"S_ ! _9I\;>"_B!X4_X2KP<-4TR\U+PIKN
MN>"[6UUW3-.US3=3&FW<RV&JVUPB3CEI+#.,(3;ISEBXN=1<_.L-*C*:BXIR
MHJU1*%XQ;2;NFDK^M6^N056IA_WSA@YJEAYQIJ$\7&<$G[1\M=N4'.5I32=H
MV<9.36K#_P % _V3M0\3>$_ FF_%_2;CQ_X^\+Z=XH\%>$+_ ,/^-- U+58/
M$-OKTWA31M4GU[PSI]AX4\4^*SX<UE- \(^++G1?%&K#3[J73=&NHH@S<%^Q
M5^WWI'[9&H7%CI?PRU?P$UI\)/ /Q6>35->T[6E>'QUXF\8^'(M$46-O"1<:
M;+X0FNIKTDQ7$=]%&D8>)R?E)O\ @EU\9]8_:@TW]I#Q=\9?A+XID\8^)_A!
M\3OCIX1O?A;XZM]/N/C!\'=$USPYX?\ &GP1*?%1K+P9:-I.HZ<UKIOCNP\?
MS:-JFF3ZCI5[;MJ]ZK_27["_[ FH?L;ZC=WUQ\2D^(!O/@_\/?A24C\,_P#"
M/^6_@;Q5XU\2S:VQ?5=1#+J@\8"UCL@@:V-@96GE\\!.B4<!&E-TZDZE;V5.
M24KZ57%^T@DHPCRJ6D7*\OM*24K+S:-?/:N.IJMA(4,#&M7IR<*D+SHJ47AZ
MLDZE2?/*',JBI\L(3;IVGR^UE^F-%%%<)]"%%%% !1110 4444 %)G_/Y_X4
MM-(R<^W3UX(Y[]_Y^M ?\#\_\CP?]IKXY:-^S3\!OB]\?_$>C:EXCT'X0> ]
M<\>:KH&C2VT.JZM9Z!:FZFL=/FO,6L5U..(FG_=AP-W!X^=+#_@IE^QD^NP>
M"M4^-&D:+\0UT*RU;5O K:#XOU/4M$U2[\!V'Q)D\&7.K:9X<NO#5YXW@\*7
M\>HP>%;+5Y]>U.W1YM.TZX"R(GN'[7GP(N?VG/V9_CC^SY:>(E\(7'QB^&WB
M/P#%XIETPZS'H$FO6[6JZI+I0N[%M06VR'-JEU 9>GFJ.:_.+0?^"3>MZ-XE
MT_7O^%V6TL=C^V%\./VJ'M&\"M&9K7X?_L[1? 8^#EE7Q&0E[JDL9\3Q:VT9
MCMHV_LQK*1E^T5T8>. G2J/%SK0J1J2Y(4VUSPM"TI2=*JDDU)V24[.R:2U\
M?,*V<0Q%*.7X:A6P\J*=6K6?-[.KS5%:-*-6C.=U[-^]+E5FVF]#U']FW_@K
MK^S3\9_A?\*/B1\1_$.D? R[^.?B34M/^%?@G79_%'B+7-2\-/XV/@/PEXG\
M5WMAX+LM+\$6WBSQ ]KI-I=ZY<Q>&CKEU%H=EXEU#4A)$/0?CM_P5/\ V,O@
M+H'Q;\0>(?B'KWB@_ _QAX2\"_$;3O 7P\\>^)O[#\5>+_B#:_#.#2E\06_A
MV+PAJ5UH/B>YFA\5VNE^(;V^T(:;>65S:MK$NGZ7>_#&L?\ !%WQ?)HO[,>@
MZ;\:/ ?B31?A1\"O ?[./QH\,_$;X<>+K[PI\5_ASX)^-%]\9K74/#EEX/\
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M3PSX@^%/Q*LO%.FZ/INBR+JVEZIK6A^+_"?B>4W&EW46AWND1ZK=!O ?"?\
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ME^G.*6D!SGV)%%K_ 'Z_UY]>X"$=3EC[<$<GT/''Z?G2XX Y'3].W]#ZT'_
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(:6ZI=/1G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $> E@# 2(  A$! Q$!_\0
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M6W[@VT8Q@_7/KT/'2K2MNSG .< 9]@>^/6@!]%%(QP">,@$X^@)H &. 3QD
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M> ",Y'2OC#3/COXMM;PRZM#IFJV+L/,M(K<6$L*AL[K6YA\TET!.!>0WGF8
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M:5BK?*I.",98$D@X R!R>U<SXF\1Z;X5T?4=<UBXAM-/TZW\R>X<2_*&(@C
M\B&>9GDN9(8(UCC=WDE"JA-73A.K.%*G&4ZE2<*=.$4Y2G.<HPA",4FY2E.<
M8Q23;<DDFVD<V+Q>&P.&Q.-QN)P^$P>#H5L5B\7BJU/#X;#87#TZE6OB*]>J
MXTZ-&C2HUJM:K4E&G2I4JE2I*,*<VNF+!CE@!P!R#C@D]2!Z]/;\HF8*1@)C
M&<GCG)Z8],5^<7Q._;X\-?#:^^TR>$KC4=!,N5?_ (2.TL]<G10V[RM.>PNK
M0LSH/*BFU=%*G]]+$[+'7K'AK]L'X<^.O#6F^(O <-_XEM-8M?M5H98SHT-N
MZ,T%Q:7OVN*2[6\L;V*XL;Z."REBBN;>98KFXA"3O]%F_!W$V183"8_,\GQ6
M%P6.FJ6%Q51T)4I5?9^U=*LJ5:I/"UN12E&CB(0J3BN9+ENU^7<#>.GA-XDY
MCG64\%<;95GV8\/JI/,L'AJ6/HUE0IU_JKQ6#6-PF%AF.#>):I4\=@9UL'63
M4Z-:47%R^P7GVY5FV[AD@<Y!R"><8X&.AZ9J/S(^PR>PV]3VKXKU'X\>-;F<
M-8QZ-I5OU:W6R;4#*H))$\][(YP1\I^SQ6^X*. 36%XF_:V.BK'IO]BZ3;:Z
M(4GN);J_N)K Q3"587AM8XEN5=UAD:5;G4-ELLR;6G9UB'!E>1YIG6-IY?EF
M%EB,554I*-^2$813O.=1W48IJ\G9VBI2UM9^SQIXH<&>'O#N8<5\79E4RK(\
MMJ8:C5Q/U/$XRO7Q.-G5AA<-A,%@HU<3B*U5T:KLE"$8QUJ)O3[P$B#[X /;
M ZCIWP>O'_ZZ7SHQA@<$'@@=_P"ON*_%/Q?_ ,%#_$?@'Q''+=W&D^,-(_>2
M7.AVRZ9I,LMMO>*2?3M72(R64UM(OV:UCU5C9WCO%#<N6>WNX_T[^&/Q8\._
M$WPQX?\ %GAJ_&H:'XFTC3];T:[">3]HLM2MHKNUD:"54FB?RI0)4>-'CD#1
MD?*"?9XGX'XAX2I8+$9QA80PN8/DPN*HU/:T9UHQ<ZE&<N6#A4C%.23B^:-I
M+1Z?*^$/C_X<>-L<XAP3CLQ^O9%&A6S'*\ZRYY9F$,%B:U2AA\PP]..+QU'$
MX2M*,+3IXA5*,INCBJ5'$0E3/=EG+C.5;/&6..G;'/3)YSW]JE0JP)(4<XXQ
M@\ ]_K7/17(.W+9RP)&/H",Y/IZ<C ]ZNQS(Q' #;A@ =<8.,]1[\' YKY _
M:S85BH(4*03GK[ 8X'MG\?SE1MP.< YQUZ\ ]_K6<DQ7@*N"PZ$\9P.F/QZU
M81MW)VY##&#UQ@XSU[XH N44Q&W YP#G'7KP#W^M/H 1C@$@9/&![DX'OC)Y
MP"<= 3@'R3Q7\9O /@^^OM.UG4K]=4T]K=;FQL="UJ_G1KFU2Z@V/;V)MI%D
MM9$F#BX$6QL;]P(KU6>0HGRX^;<,YZ'!(QP1SC!_3FO@OX]VQB\<:DP4E+_0
M/#&JNS8.ZXL[[6M%E" 9.(K>WTYL8&9)7;C9\X!]?>'_ !AI_BC1M/\ $&G"
MY2PU2.2:V2^@^RWBQQ7$UJPN+9F=X)?,MY,Q.2Z# ;YL@=/%<HP7:58DD D8
M.?3C/(]<\Y' KXY^%/B6.T\&6=I-,EO!INH:Q \LS1Q0Q)<:A<:LS222 1QJ
M3J*F,L^'5O,;R^0OIK?&CP-I,)#ZW'JEU'D+::(/[2E? Q@3PO\ 8(U#$KOE
MNU4\D%NA:3;26[:2]69U:M.C'GJU*=.%[7G*SOOM9Z'T TK*-QP,=P22#G'3
MC/4CK_*H#/&Q)9MQ[DCH!^/'^-?(^L?M":I=*8]!T"UL 00MUJEP^H7&#T)M
M;7[+:HX.<!Y[M.<D$5EV?[0][IEE./%VF1ZA;((O]-T0)8:@&>9$C@>SFF6R
MN))G9$B\B:SE9FCC,;[G<]%+"8BM5IT:5*=2K5J0I4Z<+.<ZE22A"$$W%.4I
M248IRBFVKR2NUXV*XCRG!4L5B<9B5A,'@L-7QF*Q^(2IX+#X7#4JE;$5ZM9R
M7+2H4:52K5DU%1IP<FUH?8[7" D *0,=1ZC//%'VJ #YL ^F!CVZD'I7P]JO
M[3NH3W*'1/#EM96"#%P/$=P);^=_NJ8O[,O6L;.)&*%7$^I33Q3Y=;%T5'\>
M\1_M*?$K2+MM1&JZ5Y?#1Z.VDVKZ3Y+*66,;2FK D2!UF?5I+K.W=)+&S0/]
MO@/#'B['Q3^JX/!N</:4H8S'48U)I:RA*%!5O8U%%.7-5DJ$%9U:L(\SC_,O
M$OTW?H^<.5_JU/B/..(ZD,<\'B:_#/#>9X[+\-%2C"6+>.QDLJCB,.JC=)/!
MX2O5G6BZ5&GB9.#J?J,EXG"K@CG!SSDY/0 CCIUZ GV%B.6.3 X+'/;/3/?Z
M"OS9^%7[9V@ZYJ;>%?B9?Z)X<\63:O'8Z#=6L=RGA[5UO#Y<-F+\W&K6^EZI
M%.T=@WV_48M.OC<VOV*9+K[3:Q?=&E^(([G #DY)R64HQ920<J0"K J1@C<.
MF <U\SG?#^;<.XSZEFV#K8>K+F="OR.6!QE.";E5P6+=H8NBK2@ZU%.FZL)T
MU)N#9^_>'WB1P;XHY!2XCX,SFAF>!DE#%8>4:F%S7)L9'E5;+>(<JQ$:>.R/
M,Z$Y1I3P&/I0Q$I3IU(*6'K4JLO1 0""-N1G X&<@CMSWS_G-2*[%@"% .>0
M3V!/?Z5D6MTLQ7&"V#@^N 5Q[8&>!GH/7-7A(2P4A<'.<'/0$YY[<5XI]R7J
M*A1L;5&-I+<Y_P!YOI@=.M39&,Y&/7M0 4UFP"1@GCC/J0.WUJ-V))7 VY7G
MO_"W3H0>E1,0H) 7(Q[8R0.?3K0 XX9B3MR<<=>@ [\]L_C^-1%\,0%3C&,\
M'D ]A[UF:CJ>GZ9$;K4[RTTZWZFXOKF"TAPH&=DMP\09MJN2B[F4*&Q@[AY)
MX@^-_@C25D%C=7'B"[XVQ:5"1;C)(#2:C<B.T5/ER3!)<OALB$*0U-)MI+=N
MR]685L30PZ3K5:=)-V7/*S;]+/3S/:6N0IP2%(P002<9'7MG()'7O[5&9D8D
MY#.?4 #@ >^  ,U\;ZQ\??%5Z632-/TS0XN\CF75;L 8()>=;2R&<9;=ILC
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MU(S52$YPE%W3Y5MMN]O+S/V02=>$3!ZGG(XR3VZ 9Q_^O%2J^Y@"$YSD@Y/
M)[CVKG([TL%&X '.3U'4]N.N/7KFKD5S&P4':>N3CGC)Z?3%9'2;@(!!7;D9
MP.!G(([?7/X?C4BNQ8 A0#GD$]@3W^E9D4@RA 7'S8).#SOZ\=,\5:60L0#M
MP<YP<] 3W^E %ZBH4;&U1C:2W.?]YOI@=.M34 %%%% !1102!U('UH C9R"
MN#G.>?3'IGUJI++' A=VC2-4D>221Q&B)$F^1Y)&PJ(B!G=W(55!).< RK@
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MXCN+/Q#(8MEU/J4=O>PW[E$,D\.G%#I\$$KYEMX+6SB*HZ/E[AI9Y?E[X_\
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MPU<>'=.:=8S=K?ZA/&K(C&.*6UM;0RJ58LJS27AB SF13E28\-^+OA/]J/\
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M5W>3<R,$8["&:*>0#*Q>6[ I&<?AG$_@_@^&H5>(<FQ-?&Y;@7[3%99CL/\
M6L1A:#7*\="OA:,98JE@]<1C?:TJ<Z.%4ZM!591=,_2N&O%7%\0\N0YMA:&'
MS'%4W'"YCA*ZPN'QF(B^98&M0Q%5JC7QNE' ^RJU(U<3:E6<(RC-\S^TM^SG
MI'QBT[1O&'AV\U#P3\;OAZTFI_#OXH>"FATSQWI(2.26ZTA-21/,UO0=0_UE
MWX4U9I=$U"0W%O);Q7.I-=+\/6W[:_[0/PB2/2OV@M'TC5= MW6*/XX>#O"=
MW<^&[N-=T?F_$'P[HS+J?@C4=BPI<SV=G<:%-,Q^S2VUOY!;]?;*:ZO8A<I,
MD=NZ[XV@$,I9!GYUE=65U8Y*E=IQU!!%?"OQO\#R>%?%-QJUMEO#_BB:2ZMY
M(_)6"VU.Z8O?Z3<NL2+$);B5[FRA#H;FRNFMXQ(;66,_C?$SQ.'P\,YRFKBL
M$O<IXE4I\E+$*FG;%.DG*-3%1NU4ES2=24HRGJH(_H[P^XEP%3#PX)XXRC+N
M+LEPRKU<DACJE;"YUP]*56>*S#"<-<14/;8W+J$I.MF4>'L7#,>&L7C98VKB
M<HPM6M];?Y<V_A?]F[]OSXP?M(?M'_'SXIZO=3?!K7O#'P?^%/PJ^&7B#0="
MC7P;X;\.0ZK)\1!+JUGX@U76- \0^-=1\92:(UBFGZ?!/::@E]=W]S?:;IVG
M?GYJ7PCUGX!>.;'QI\0?A#?_ !/\ 2^(+W1/AC8:W-9:WX8\9S76KB+P]?:]
MIFBC7I;":S\+37/B:W\,:AHJW6JZKI]U:Z;IWV339[W3O(?VEO!NJ_L^_M,_
M$.*:\O\ PKH/C[5+KQGX0\3Z0T6FS7/@_6?%%CXGU/1M)U:%7;2+BTU"VN_"
MM\]I+#/Y]C;1W@CL=5L1)]0?LX_\%$/&'P(^-UCXNU^PU;QYX B\.:GI5@NH
M6,"^,-)U;6IK,:9XA\/6>H:C:Z==1Z1IMK=PWEPL]I!<6&J:A/I.H+<&WLYO
MZ:\$> .#I^'6=>.^?\983%YGP)+$XG,?#.AB<)@8\0TLAS%8BME_$N&KYC@,
MTSRCQ?@\9AWP]@\=ECPM'-,&HT<NS+%U)1?YS]*7QC^D=D7C!PK]#GP<\.,_
MXD\%O'_P^R#(N$?$ZIA.((Y_X9SXHX*E1Q&=>">=<,\+OA_A#BG@#&Y=GF6\
M9YK#B2AQ3FV69EQ,\[S'@_#YCDN>R]T_8O\ VII],_;=T.'4?!ND>!-"\67]
MW\)-;TKPM;3:=I^JPZ]ILNJZ*T_AK^RM/VSZ%XITC0H1++;>=]BOKEQ)M-P#
M^_\ XCOM'U&^6XT:Q>SA\DK.3"+5)Y]YW.EJQW1!%(#N0JRE]R*H4U^2.@_'
MG0O^"A?[4_[.MQX8\ 2R>(O@EXNO/BC\2?BEJ&@-I5YI7PRTC298_#7@?5+^
M>**?5+CQ9XW6S;1M.DGO'M]-T_Q#J=D6M;;5G/Z\^(/#ITXF\LP389_>H6+F
MQD< IECRUM(WR1,260[?,)!Y\O(O$GAWCWQ+SKBS"95+@'"9]BL-6R+A?!4:
M&"R>=2AEV$P.,P^/IX:GA:$L=C,QP6)Q=>A'"4J,JDE%U9*G3E+Y'Q+\'N(O
M!KPB\(?#3B+,>(>,^-N#> \?E/'^=\;8^MFW%^"HPXVSW,.$9T<7BL9FV.GE
M^%X2S..$RRIFN=8_/\%EN&I8+'1I4J. PN%RM'8QW0?C(1A@GU=6!SSW3'3G
M)],'UC2+H$H/,QE<9P. <<\]N2>V..3W\BT\[7)QDL.G0=F//\7//X=<XSZ3
MI+%C$>.$!'7GE#S^77\:_:ZW\2>^_P"?JOT:]=4?B.40E3P-+FT<I3JQM?X:
MDE*+Z:NR>CTTMK9GX=_MU?\ !O\ >'/V]/VL/B-^U!J'[5EY\*Y?B3IWPVT^
M[\'1_!"T\;1:,? 'PT\(?#K[0GB"3XD>&Y]1CU"+PJNIF,Z1 ;9KA[1'G6-)
M7]/_ ."'/_!'3QC^P'9ZA^T#\>O'^KK^T/\ %/P/:>'M?^"O@;Q;<O\ ";X<
M:'<7%GK$&C>-7TN=-)^+OQ+T6[BEA_M]_M?@;P;->ZQ8^!#XAFE3Q[??N-I$
MC83@8\L8&3S]W@^_/'K^->D6 !\H8' ?CT^?_"O4GG^;5,M>4SQ;E@W"G2<)
M4J*E[*D[PIQE3IT[1O9NZE=QBURVL_)I<&\.4,[7$%' 2AF:J5\0ZWUO&.,L
M5B'>==P=?EO\24=O?E=M.SZM&54))7Y/XB0.@#9)/ Y)R3QU)XS7X[_\%0+:
MXUOP]J(OM2$%AX7\,KJMAI\TLEK807$IOSJ.JS[I(XEF$%HL$M^Q1H;2(6[R
M'R3C]@4&8\XY<;N.HR #@]CQD'KFOC7]L7X2:1\2_ \<6I6<=P7NGTF[D\I
M\VG:QI^II-9R;DD2XM)KE(RUI<B>V82S Q[&*U[GA[Q)@N%.+<KSG'X>IB,-
MA95N94*2K8BDZM-4E6ITW**GR=8J<).]HR3:/ROZ2_AEG_BYX1Y[P7PYF]#)
M\PQ&.R3,I5,56QN&PN887*<QAC:N48C$813Y*>-JPPU2+J4:RC6P="3I5(2J
M0/Y$_P!B30)OAU^TE\,6\'Z^QTSQWH_CF;Q5H]OKEW>6%]HMQX?U^YM?M_V.
MX:&YGDNK:/4+.&\>Y@BO[:QNRJW=I:RK^T_P5_X)I>%=?^,1^)%SXS\7ZEH>
MGZ_)\19]-\17>EZII?A_Q)J,L9M[S2?^)39ZG<:JUQY__".6^JZG?:;H?E3W
MWV:=K"T\OYLUGPC^SA^P%:_\)3'X)DT_3;AF6^U#2'FU+7S8BX@1ET]+UKBZ
MN+=WM[:8Z-82:?;J\>]5CMUE@D_6+X&_M >&M8\!V/CKX=S?\)EX$\=Z)I=]
M;W.E&.#48EM&NTLKR.*Z94^TV4MUJ&GZGI%S<6DL.H0S0).\MDP?]%\:.+>-
M88;&\1<-8#B7*,JS[AZ.64*OLL%@YYU[#ZUBXRAA_K685<)B:\<5*AA)5Y49
M2PLJTK7E+E_$OHV\+>%N8SI\/<19WPAQIQ/P/Q7C*N+J498G,J?#.)]GE6!K
MX=9C+ X+*LT?]I82&(SB65T\7E$,=[-5Z4\;@7B*-'XN:O\ "[P7<VWANVM+
MF#4[:06NG7-S(]Y;7%S%"9!87<T\K)&]RL;?OH;2*WBEX0QC]V*;Z[IU_H$E
MTJK:Z%:VL;ZY.P,:W!(41:.DBQC,++(L^LR1Q2-#:RPZ;;R_:KVZ^S?/_P 4
MM'UCQ'JNI>,Y-'OYK71/[0U.RM]9DM[!YI%@D=I)5M9K^&V\J 21M+%>W,GE
MR&,0VSRI-'\^_LR_MJ:3\=O%WBW]GCQC\*V\)_9M&U.YT'6=/U275_#GB[PY
M8W]OI&MK<I.UOJ>C:F+J_B\O?+>I>9GDEFL[B-1<?S/X%<#^+&)X6X@XWX]P
M56KDM+B*5=9=+'8-YIEV1TL4XUH-1K-JIBZ,XT_90;MRJ:ES-)?U-XY^*GA!
M#C;+?"7PZXEPN$\1L=P4ZV'Q,LJQU3*/[8S3#XBADN(G.=%8-JACJ%>4*&(L
MG*E3Q,E*G"?M-_PY_P %!M!O_P!I#1?@A/H46H>&_%ESJ>D>&_'^BJT6FVOB
M#2[*>^BTF_66YN1<VVHVT$UO:7MKY"VEQ'%;RRW$<\-O;?HC<:]HED;9;[5M
M.L9+PQ"UCNKVWM7N'GPL,,*W,L)DEED;;&D8=G(98U+E%/Q/\*?V"?A#\(/%
M\'BGPM#JTITY)X/"]IK^MZAKZ^$--U"262[L/"[:EYKZ1#>)</#<2>9/<RVZ
MPVJSK:?:;>[_ #<_;8_:3\8:]XM\;? J+[=\/-1\'Q6\-I=WEI/%JWBU];M9
M%L[WP58-9SS:L%E86T,I 6XE>5X"/*VI_46 X2X/\2.*,12X3^L<,9/A,HP7
MUF-=.6)Q6,2EAZM:CA:N*4(*$K/&2C6_?5)<U5+<_CO.O$/Q:\!N ^%</Q=A
M*7BMQ5Q!Q/FM&KG=?&TLMP>4Y%0>#KU<7FF)P.'A*4Y+$UWE^%P^7N,:. KJ
MDY2<*<_Z.O WBOP_X4UY=9UQ@EH=+U&SL]0:-Y(-,U&;R%6XND2*=XUEMHKN
MT6ZV;+)Y2[G:S$?&_P 7-?\ $'Q%^(\<FA:K&FFP7%]'<W=M=%[.33;FTFLT
MMGNHV^Q"U9+B2X*M/DW$,0,2R*P'%_L-ZO\ %#6/@!X M/C'%J%QXWM-!AM=
M6EU<L^KSVZ32_P!C3ZV929DUF31#IQU6"=%FAO/-CFCBE$L,?"_M2?M/^$O@
MAK4?@:2U23Q=XJMYH/".EV5G=7=S=O#I,=[.ZI8V<\=D\?VB!6N;I[82_:$A
M1IB!$/P'$^ F \3_ !'R[ 8_.<74P_!V98G,)4L'6IK)\=5R>O3HX+'SDX1Q
M%6,*U-8O#8:%>G0J4ZM"51N4I./]*\4_2>S'P/\ !O%\3Y7P9BLTS/B[#Y=D
MF"P$\&O[5R^OQ%@L9CL1@\9>&(A@FL%A,QP^+Q=/"XC%472HJA2]I7Y:?WEH
M9ABTFRA2\ANO*@6,3QS+,LA15&Y71F4C."03E2P#!3R?9=&N2! I8#$2@=".
M%'7TP03CL,_A_,_^RQ^UA\6H/VL-.^'^NV*67@KXBZ/J4\VE3M>M>V&NZ9I-
MYJ\%]/9SW4=M9W,B:=<V7G16;3S6LGDS^;L22#^C[PQ??;+.TF"_ZY3DG"\L
M&)("Y! !Z\'(P>F:^X\1N"L1P%Q#')*V*HXZC/"0QF$Q5%*$:M%XG$X.M"<%
M*:IU:.,P6*H3BI2BU"-2+<9IM^ 'B._%/@JGQ;7R6OP_F$J]/!9ID]?%TL?'
M"XKZKAL?#V..HQIQKTJN$Q-*?)4I4L5AYRE0Q=*G7BXGB/[?G[&EE_P4 _9=
M\0?LTZA\1I?A7!KWB_P+XN'C.#PI!XWDM)/!.L-JT>G_ /".S:_X969-3RUL
MUV=5B-KN,@AN>8S_ #XZ)_P:R>)K#]H'X;Z,?VFVU;]G"#2H?%_Q4^).E^"=
M+\!?%.U\0:?XA*:=\/?A9X>'BGQI;)K^IZ79_P!K2?$GQ"(=$\$[[6]M-!\:
M:K;_ /".R?UMZ,Q41@ 8W-^?S#\L"O3]*)*QY &-XP/]Y?ZY_"OF<#GV9Y;0
MGAL%B/88>:G^[5*C-IU(SC-J=2E.:O[23M%Q5W?XDI+](S;@W(,]QN'S'-<)
M+$XR@\(U6CB*]%RC@ZDZE*$HTIQ@T[TXRYHR;5.U^64HF[X*\.67@_PEX6\(
M:=?^(=4T_P )^']"\,6.J>,/$VN>,_%VIV?A[2;+2+34O%/C+Q->:IXE\6>)
M+^"RCNM?\4>(-0U#7?$&K37FKZM=W>HWEQ/)YU\:/C)X'^'.@ZG!K\]W>W4N
MEW;MIVE1VDMQ:17%G,D-UJ!N[VS@M(9Y&C$222M<R@JPMO)\Z:#UR ,8I=N-
MP4E.=N6,8 &[*[03CYMPQU) &:_FA_X*R^/OC1\*/C7%I,VB:OH?P/\ B>LU
MY+\5%L[O5-/L]2L]$\+1/H9_LF6W32[A=5EU:W,.NB&=K6UM8[+:@BNYOI_#
M?A;*^,>)891F^/\ J5#ZOB<;RQKO"U<;.$Z*J8:C75W"352>(G92:IT:DHPE
M+1_DGTDO$+COPO\ #>.=>&^0X'-\ZKYKALIG6S2A4Q66</Y?+ X[%RS;%T*4
MZ$ZL93P-/*:$9UZ6'>,Q^$6(<:#K3C]D?#S7OA!\4K;5Y?#4UK?O:O/8ZSI5
MU"EI>6<UQ%PES:QR,IAU"%Y[B*[LYYX+E698IDG26*'Y L/^"9GPZTKX@/KD
M&LZ]JG@P>+;SQSIG@36+JTNM$TOQ)J>KSZU=WEYJ*V2:UKNGPW]R]SINDZQ?
M3PV;-Y=W-J=L_P!FKXF_X)V>"_B+I7QP\<_$ZS'B*'X=>+=!M=.^WZZEY8+X
MMU>34+*_M=8T+3+R-R^F6L,5RLVHP26UK%'<16=H;Y[N?R/TP_;0_:D\2?L]
M6GP>T7PIX4G\5:W\5/$6J:5,D%\-*EL=-\/6NF7FISQ:E+#<6T-TT=^([:U:
MVDN;YU:WM;K39,7-?<XK)\UR/CO'<%\ \25Z6#S^G3CB7*O#VF'H5:#K8G!X
MFK!5)PQ^&I8>:K5*-6,OJE>FE*G.3J4ORO"<1Y?G7A'DOB?XK\$X+,\YX8E5
MEE\,+EU6A'.,9[6E#*\3DN6YAB:-%9=F>:8A0]EF"Q66<^'JYCA*-11IXDR_
MVA?V%O"OQ>\3Z/X]TKQ+XG\$>,[/04\+:]K/A66P,_B?P[;I.;"QU1-6L]0@
M^U:;-,HL[UH92+4S6TEJSO!<VOR-\7?^">WB+P9^SZ_@SX)^&==^(/BS7/BA
MX>\4^)I-2U;0(]=U:*P\/^(+"?4I[G4[CP]IB6=E+<VRP6D):2":_GPTD4NU
M/J3X/?MO^%OB7XDTCPSI,<EMJK1A-0TBZN%-U;QQVTTD=TVG22":RMQ]DECC
MF6W7SC"PR\RR%OT6M+@7-M%."/WJ;A@;<^AP.>>/<^G7/F\2X[CW@7$9?PMF
MV:SQ>!P&&P6.P&7JM[;!5\'S8JMAJ=>K3=/&8BG3G5E."K8N:YY*<EI)/[3Z
M-_'?A_Q/G&6^//!'!-/*.*<KS^O''4^)<)B*>-PV<4LOPT,3*NL/CGA/8XK+
M,PP%>6)P+ITI2J8NN^6K5;I_R/WO[,'QYT_XFZ-\%+WX7:S;_$OQ%IEMK>G^
M$X[C1-0D_P"$?N[N\LE\0:AJ6C:KJ.AZ7HUM/I]ZM]J6K:G806!@C^V-"+NS
MDE_<O4_V4/BW-^R&WP3\4_&W4]=^(5MINIIHOB:.W,VF^%([SP_=:/8>!]'U
MEDMO$FHZ'HYNY$TSQ%J\PU"V>WM#I&GZ9HMAI]E:_H5!HNCV^LW_ (BM]+TZ
M#7M5T_3M*U/6XK.W75M0TG1YK^XTO2[O40GVJ?3M/N=5U&YM+*61K:"XO;J>
M*&.>:21M&:))4*LH/! ST!;].3US[UXN+\0<VK8S+,;A*.%PE?*\32QU&I+#
M*K&KBZ<)J//"M*I4IT(JM7H5*="O3]I3KU)*5.JXSC_6?CCXIXKQVX/H<#\3
MY%@,+D&)R^C#/:-&%%8[&YKSTJF)KX+,(NOB\OPM'%8'+,7AJ<,35>)KX6C4
MQCQ&%E7P57^7;1/V:OVB[#38_AA=_"G3M#UJ."]TZX\:74VSPQ':[IUAF_M?
M1M/M;&XTJ+2KZXM[6#0UGU/^T5CL['3+;P_]L2/]'?V(_AMXA^"J:M\/)M'F
MFL-+OH;W5-?OKZ2.[O\ Q!=Z78P--HNFLLPF\"WVG:;I_P#PCE]]KM]0B>*Z
MTW6-/%U8WGV7]1+KPEIES*))+>,MR2=J8)8G.[J>O/7O@ $C.?<:5H^F,@VQ
MM,JETBCQN"\CS&3<!%$"I02R>6C2'9OSN9?:XD\3.)..<-2R*M@,)'"XJ5)R
MPF!CBJ];$XS#J'L*]>MC:U:K]5PS=1T<)&U&DZD7SN<$Y_R/P5X:^&_@Q1XB
MXLQU>C7K1P&(IT.(N)\7E^48#ABGC:R>+Q%*&$GA<OK8O,<-1EEM6OC9XFM5
M525:E0PE94W1_GC_ &WH/'?A3]KVSCU[Q9XKT3X9W%@OBOPS?KK%WI&F7U]K
M%\=4UMFN/M$-CK%]"9_^$5LQJ]GJ6EK90ZEI_P!C:_6)6^1_C7K/BG3+22'1
MOB!J4VLZ[J2Z7:WNE^8NH:@+:]@BMX;%9A:VC1W4\=K:/IL6K/*)[257O+>T
MFA,7]$WQST7X&?%V?3?!/Q*T^(Z@MU<VN@:FNH76DW]O)J$4ECJ.FVWB31+N
MRU+3K/6H-VFZAH]Q<_V7K"211SQ3R!%'Q#\3OV,?@Y\/]3\/:CX:^$MSXNU/
MQ[-K/A;16UKQ'XPU?P_IGBVST2^UGPU_:5E#K#Z]JL'B:\TJX\/7[1ZM]FT_
M3;O4]3N/LEI#=.W[+DWBI'A[*\IRGBC*N(<ISJ664,+B</'+<LE0S.C@:<H?
MVAA,PQ688=TXRHTZ>(Q%X<N#A1G.#J.FHR_FG)OHV8/QMXQQF;^$N?\ AGQ=
MP^\^S;&9;F<\^G@O[+JYGB\SSK'87B+#U,GKXNM4P52OC*\L;BJO/FU"E#,*
M#]FH1/N?_@FO>>)X_@-\/I_$3/'>:NNNZ[#9R06\,EC8:YK^J:G:V[2VEGI]
MO?>>;B34HK^WTW3[6XAU",65G%8QVHKAO^"DW_!$S1O^"E_QW\#_ !XU3]I.
M]^#EQX/^"?AGX.-X:@^$5CX_34+3P]X]^)_CO_A(#K-[\0_"'V0W)^)4VFG3
M?L,\5O\ V*EQ-?1+J:"'[#_9G674O"_A[5M0\.W?A75#:&RU7PW>VGV%]%U3
M2))M'U*PM;;+A=,M[RPF326C9HIM,%G,FT2;$_0?1&PL8"@#;".I[@C(SZ9Q
M]/?-?RQG&?8ROQ5GF?X=+ XO'9OF.)E1A*E7AA?K$E%T(U(<V'K>[&G4J5J;
ME"O4JS<XW33_ -#\K\/\NR'@[(?#O-(0S+"<+Y7DV2UW"K6I4Z^(R7!4\-5K
MX:6'KJ,<%B*[E7P*3DXX944VKN,?YY_^"//_  0J\5_L2_'S7OVG_C;\6-:/
MB_PIKGQ+\!?![X<_#G6K[PWHGB+X9RZOJ_AC2/'GQTFT74[NSU[_ (3C0[+3
M/&FA?!"+5-8\->#KV7P_J_B_4==\8Z3'HWA#^D;QOX6\2^*;?38?#?Q0\6_#
M*2SENWNKSPCHOPXUNZU-;E(A!%<K\1?!/C>TMDLI(C-!_9=K8RS2RR"\DNH5
MBB37LV(#)@8&U<]^<<XZ#&<_A5S69]1M]'U:;1H+*?6(--NY-'AU"62WL)]6
M6TE?38;V>%'EBM)+X6\=R\222+"S[$=L*?.QF8XS-<=]9Q52-7$552HQE4C3
MA"+;C"+ER4XP<5*?/)RA+12O>*L>QDN58'A;+8X3*:$H8?"K%8F4)PGCZ]>I
M.G5K5Y*%64I5:U1TE&A2M+FM1PZC-S3?YP?&+P!XJ@\8W.GZE^T5\5-;N/[-
MTI3?7>D? O3+V:1I1<@-_P (]\']+5'"JNGJB(C2VY D\R7#5\_:O\)]0"22
MS_&'XI31/\DK7>H> F5A*7:,*Q^'L<=O(5#!98!$Y\O#'AVK\</&'_!03X[7
MOA'Q7J7B3P_I>F:U:>)/$^FZGX4OM<N;?QI#JVDZU)I-Q9^(K-[$:AIGB&;4
M8Y6U.ULK&=[<F8:=:6TD<*Q_5_QJ^.?QQTO]DGX6?%7PEIT*ZM=ZKX%G\=RZ
MK9WNI/H&C>)]/,(UW4+33[C3]2G6TN9H;2]M(Y#+'JNLVE_=6P_LZ[MF_;,S
M\*\;E.)X4P53B/+ZCXCQJRV<X87!P^I5IX!9A1LW1FJL<125:E0FU9XB-.$E
M^\2?\><,?2TXKXHRSQ3S+_B'7]D5."LKAG.2X6MB.&L;2SS XC'X3+J-3-,7
M3X<K1R:6&68X'&9C&G/$>RH4,VP=!U<RP+B_IN7X.SW=U);6GQC^*%M<I$Z.
MC:AX(N9T&1ME*7_@60J5WA?,$9BE1D10%*FM:U^#?BO3F4Q_'?Q[;'RB85OO
M#GPAU ONE+SS2+)\.8IICF18XV!C:+)*.^X%/RF^!O[2_P 7?B+^U)X'\.1Z
MSI'BSP^UIXBO]?UG16OF73-,AMIUMY+]3&Z)'/<16UI+#=6/VV+4+S1HI;RU
M+LJ?1O[7W[1OQH^#WQMT3P]8-X>\.^!/$7PS&N:'XBUN*_B%]K&FS7L6I>'H
MKV&:6PCOK">6?4-0^TV5R][I>H6VV[TFR^U">ZWAG4P_&6$X37$>!GA:^1?V
MVL54P&"P\X6J*G5PBI1P=%5<13DIUZDY6E&CRS@IOW%>&^E3XAS\&<R\0:OA
MQE,>),#Q+3X<CP_3H9#/+E3J1Q&(IX[Z[5R)2I5I4Z5+ SP6$A.I5S:M&C2K
MJ52-1??VD^$/C%"7GT'XW^#]7C-T'CA\3_!RPU!8K968FU$W@SQUX1N))%&R
M*60K$0T>#]G)PO<23?'6R$S#0?@WXH19E\DP>+_'7@:>XLP=T]U-;WG@SQ]#
M:7'E_,MN=4OA&5\R:\:+#G\W?^"=GQQ^)'Q<UOXHW/BJ*V'AW3O$FE:9I&JV
M1NS8:E<0V5RFH211SP+ DMNDFGK>O9RBQ6"YL'$8:1I#2\=?\%%;FRU?XIZ=
M:?#_ ,3X\ >,M7\)7^H2I"38:EHLEW)>)#]AU%I5CL?L$ML;EX-/CGGB?[)<
M3VZ)?R>?0\,\US'C#B#A; X[)L52R&EA9U\PK4J=*,ECHQEAZ36'47[\57<J
MB?M(>SBM)345Z6>_2K_U>\,>"O$#B7PRHYGFO%U6MA:W#F183)JD,)B<OFZ.
M,QM'/*.+R:GB\+5J^P66*,98[%1G6G+"Q67XUK]%M0\7^,[0L-<^!GCNX1$4
MSW?@GQ%\.?&%D)%,7F+!!?\ B[PCXANHP&;R=GAP:A<!5$>FEV6,^9_$R[\
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MO(I(5<;NC^(=5L;R&#7;>PUG32BHWC3PY)!#9VTHVKCQ)X:FN[F_T<;9$?\
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MZM@UG+("4CO;=UN;.1RN"BK/!'%(_007,ZGY7<5VB<JP.<,2 0">-H&1Q_\
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MKXEO)=3UN_"RN\BP(RKI^AVTHD='M=&M;)9H2(;V2\$<3Q_I_P"'+$6=O;1
M[?*4%44 C 3@9&,?=(Z9&1Q@"L.RL1\N(QUZ>O3KSD8[+R3SQQ7H.E6>TI\@
M/R\YX^BD\C:,<-[#D9%?0YKF^9YYCJV8YOCL1F&,K64L1B:DJE3DBK0I17-[
M*G2I*T:5*C2HTX02CRMI-=G#O#>1<)Y50R3AW*L%D^5X=RG3PF"I2A!U*D:2
MJUJTZDZM:O7K2I\]2M6JSG*4GK;?M]&7<(SDCYF[?[QST]^E>G:6-JQ=3]_M
MSRP[ =\9KA=)@=?*V@8P#[9P5QG'3G .3T&3\W'I&G1D"+)(/S=!NZD''0]^
MA'4#/? \X]LZBTY5^Q.W&>.RXQGOQ^?6N:\7>#-#\5Z==V.L6=K>6LRDS07<
M,<\,H3+J)(9PUO*$?YH_,3=&X+(Z%LCK(8^%Y/WU[>R<GTQ^'?\ "S)$LD3Q
ML0RMG>'52&4C:496!4JPX(*D$9!!&150G5IRA4HU*E*M3EST:E*<J=2G5MRQ
ME&<6I:/ET4HNZNIQ:4HQ.$*D*E.K3IUJ56'LZU*M"%2G5I-WE3G"I^[<9)N+
MYTX-2:G&4'-/^=3X]?M0_ [X+_$'XE^"].N--;Q1H6L:[;QZ18W\$MQ96]CK
M-YH<EU;Z?9N)H;%M6MKBUMO)@"VRPBVA_=VH"_*GP\^*_P ._P!OC_A.?@O\
M0+35Y]7^&MY!KWA7Q+:M<Z'XA\-R:A&^C2W6CZM"?*ODM;F>R^SQW]A=6=_\
M\>KVNH)IUJ!]N?MM_P#!+/6?'_QUUOX_? CQ7H'@?7OB%!#8_$_P]XFT-]7\
M.7TJ.YN?%7AZWLK:8_VS>O+/=ZMHM\+*SUC6+B34I/$6F7%S<^=\R_L]?LP:
M%^RY\3O%EEJ?C,>,OB+J[VUOXFU^2+3M"TRTLH[F34M-TO3]'MWU2]TR]EB>
MSGU:RU#5;[RH[1-D>G2RS ?U/A<TX)QW!&&P7 ]*K_KW1R^AC,$\OP=2KGF5
M9IE\\*ZU?%XMT(87 Y?7Q-3'JK4Q^85J6<4L0LNEAZG+&G7_ ,P\TX*X]\-O
M%7BGC[QEXNQS\,LTSS,LKSA<0YM+,.#<QRG.,7F>-RO)LDX9H8_,\XS>>'H5
M<E61X? \/Y)F^3YADE;,:F*H4X82,IOAM^QY\./V0F\?_'/QAXMU?6([#2!=
MZYXW\7O;H=%\,64J$V:-80000"YO+B#^T=0=,.D=LH@@1)S/]F_#C]JKX2>/
M_$ND^"O"OBC2M9U+4-';5[**RD2.=K"%H!+.UI/*]XUNK7,47VH1I$LSI$^P
MDE>R\32>!OBCX7\3_"GQC!8ZMHOBW0-0T76=-6Z\ZWU#3+^ VUS&MPAMY[:[
MM_.,\$T(%U93>3>6=U%/$CK\]? []@WX<_!7XE7?Q0T7Q#XP\2:Y<Z,OA^UO
M/%VL6>KW&DZ'YME<2Z?I[6&AZ.";Z?3K*:_O=1.HWT_D "YB#N3^=9AC<MQ&
M#XF_XB-0X@GX@^SPBR;$.$OJD,)&FHT*+^JPAAZ5.FO:75.E3A*,Y\T5R.W[
M7P_AL?FV/\.L[\!^*N$\/X)T*V;2XFRG*Z>78[^U\36Q-2GB85L;FCKY[0Q5
M.$<OPOU6<\)6R_\ L^A0JX*IB*CKQ^^\]3V'?C],$\=/?)(YQ02/7L.F"<$@
M<#ODD#TR0.](!@  X&?3. 3T ]NG/;DU\Z?M"?&SPK\&=$L=6\6ZOI>D:/)'
MJ%S?76IR7"VZ1P"VM[2.2.WC?[2]Y=WCV=C8%9I=1U"2WB@M)FA8+\+D&28K
MB'-\%E&#7[[&5)Q4G9^SA2@ZM2;3:34:<9O5Q3<;76I^K>(G&^"\.N#<]XQQ
M^"Q>8T<FPU*K2R[ 1C+%YCB\3BJ& P.!PRDI)UL1F&+PE"W)-JG5G4A3JRIN
MF_>I-3TY)6M3?VOVC<$6#SHQ(TAQA!$"97))"@!0&8A0V:_,?]N3]K#5_P!G
M_P 3^&-(TK1;[4;CQL;&PTJ9[NYTS2;,K#JLE]J<E]%IE_#/-;-"EC:V9,<9
MU#4;?^TKG2[&07X\#^.G[=OA1M/DN-%:>YTRWTJ?4X[CP^\-Y<2Z?!(TL$6F
M6]H^;6YN'M7_ 'R7<GV6*7SI8%*&&O2?A9JO@+]N[X!Z?9?$"QN-;?2M9EM;
M'5HBUIKFDZO:65M?Z;JUGJ+17< \2Z=I6IVEGJ]U-;M9S:Q;71NM,(\H#]QH
M<%R\)\;EG&&<5J>9Y/5C5RK,X1PL)X[+:69.DJ.94\)3KS6+PU&OAJ<*U)U:
M$YQG5Y)*?LV_XUP/B9B?I?Y#GWAG7X/K<(YE1QV"S[(6\WGB\JXGCP]+,)8_
MAC,<7/+<OQ.3YBZ6:87'5*]'!YM@Z2PJHUU3I2Q%6C^5_P"T#\4?C%<7>G:Z
MWB2#3)6\3Z4R6?GV&IPW=A)YD.E0:IJ,5J+>TT=85M=1FNH[C3KVUM5EUE+=
M;[3HKFOZ-/V>KNY^(/PU\":CXGM([K6+GPYX6UZYDU*WMKJ]M]>GT&VDN=1+
MQQ^5!J9DN;U99[98Y83<RPPR10/-#+\-V'_!.CPCH5G=:OHUM=^+/'FE"]OO
M">M_$>YEUS1["^+SW4-C/X?TU-)T"73[UY'CNY[C2[V\BO[J37;9AJ4<6?T?
M_9Z\"Z]X)\/V&B:WK.H^(;BT01IJ.K1HVKK:>1&([/5-1CEE_MR^LI1/!+K<
MI\^_5(VG:YDC:]N?F/%OQ!R+C7"931R6-9+*<9B9O$SPT, ZM/$X2G0Y:&'C
MBL74IT/<O*->5.JYRE!TN1*H_P"I/HO?1_S?P6RC/\PS?,\JP.(S=9?E]+AC
M"XRMF6;Q^J8K'8NIG.:9G#!87+94L-AL9+*L%1A4K59T,0Y*4(QC3?TMX5\/
M)92@Q@;B%&_:RX XX#<\*!CT QP!@>^:3&1LW9!58^@SG:6(Z#CW_I7!Z3:G
M^Z!P!DGGD#GTST_$'UX]0TFWQU<@X7. ".K<#OGV(S^=?A9_4AUUDN0TF3DJ
M!MQ['CU_BST_2MZ10\)4@D,J@CY@<$@'!4A@<="""IP1R*S;*/8PPQ/"'E<
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M9S@<1BL12C6ITJ=5PJ6O:SG4C"G[=-/_ &*4XXF*WM&<&=-"S6:^7<SB>!6
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M#%B&!K0_LCC[B_ES^>*FNH+$5_9_P_;8A4ET5'ZWB'32^3;7DT^MW."=9X'
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MAQ3MNY'.2  PQCK\OOSU./PJRJELG)&#@<>P.>?K2,-IP23P#G'N<]..,=Z
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MC#< 8&0.<9R .V>#CH 1@<OBMMK!BH."!U[#DD<<GGH/3N0!6C'&.-N5&\<
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M]$UBZ^(K^&M&C\+)\,].U#P_=>!M#\7>'?!UGJMWXZ\>G5-#T"6<1: SV]K
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M?1:;927?F:?*LQEA]NIC)N.<D$#MQZCD@@D8)XZ9YZ@8 /@KPY^T#\?)M,\
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MVL^/;75;+6;;5M*O-,T%[77+K@[#]H[XR^);[5?'V@Z9I5O\,_&7@+X2Z_\
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MKTEQ?7?P'C\,VNF>%AX6;6-8?Q9IW[1GPOU32UM+=KM(?$=G;-I4NI0Z[:Z
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M&)M%&L#2EL[&TT;1=.TGJ?CS\.[GXN_ _P",GPILKK3K&^^)?PL^('@&PO\
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M#_\ R0?VKA_^?./_ /#9FG_S$?H!YD?_ #T3_OI?\:/,C_YZ)_WTO^-?G_\
M\+J_;\_Z,$\!?^)I^&?_ )R-(?C7^WV!D_L"^ 0!U)_;4\, #\3\$:/JTO\
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ME_[Z'^-<S_:47_/3_P B+_A1_:47_/3_ ,B+_A1[/S_#_@A[>/\ +4_\ ?\
MD=-O3^\O_?0_QJIJ$KI87SP$&=+.Y>$*HE8RI [1@1@/YAW 83:V[[NTYP<3
M^THO^>G_ )$7_"C^THO^>G_D1?Z#/Y<TU"S3O>S3LUH[-.SUV=K/R;)G5C.,
MH?O8\\91YE!IQYHRCS)VT<>;F3Z.*?0_EKU#XU_\%GK#]CWX)?$:V^(?QHUK
MQQ\;-,T_QYX9L;;X7_LII\>#-X8_8"^-GQ?^)GASQ-X>TS]E/7OA5X/^&.L?
M'OPOX"M_A-X"U;P*/V@=7L;+Q!X#\2?$W1_$/CSPSHOAGWC6_P!K+]KRY^(?
M[6=[IGQJ\>2^ _#OQ!_97T?PL/!OP=\+WVL?"K]F;XE:+^QSJ?QT_:A^&?P6
MU+]C/Q3XRUV[\+Z5\1/BGKND:S\0OVB_CYHO@][S6K;QU^SUJ.E_"R[OA_0S
M_:,.6/FN2Y4G]YC)7H2P7<>PRQ8@ +G:J@+_ &C%A<S2-M;?EIVY88ZA2HQP
M/E !R"1AGE+^C/'4W:^789?O)S_<QE35I.34'LK1NN65KOD3DM6CP5DU>FWR
M9[F512HPI..(JNK[\=)55+V=.2E43ES*]H\S5.4=U_.Q\</VJ_VOO!FI^-)_
MA1\=?VA_BG\)O!/B#]DW4O"FI6WP*^%_A[]H']I#PCXP^'G[1<_Q*\'_  >O
M?^&$_%OPJU7XJ>*_'FB_##5=)\+^)_A3\.=!\7>'O#DVB>!_B/\ "R;Q++XF
MU=?BE^U=^VW96?Q<EN?BE\>/AEK7A&T_;<UG]EO0? '[*'@SXA+^TO\ &WP%
M^V-^T+X ^"7[+WC^6]^!WQ%%AX1T7X1>#?@%8Z%IO@F?X5_%/XIZ#\3O%'CY
M?CIJ<?AF[U[1_P"B;^THSC]])T(_URG@E2<GENJ\\_,#M;<H4!5U&)%8"3AE
MP<2 'IC(V@<XX .55<*BJJ1JB6+IP4%_9].4H\J=1O62BX7YDKQ7,XRYI<O,
MXU)+[,&E+)\4Y2:SG%PA*I4J<D9596YZ=:G&,9UJ]><84G4A4IPC*,54HP=F
MG-/\3_@Y^T/^W&/VOOA_\-/B/+XOUCX.?%K]M/\ :PL_#FLVWP@\.66D^ O@
M]\"_"/[1OA&?X(>,?$ND>![-[#PU-XC\-_LY_%SX0?$_4M17QC\1+_Q+\2?"
M][XVUWPSX?L]$E_=?>G]Y?\ OH?XURHU&(<>=(<[1\T@P0&WXP%"@;LE1@",
M92,)%A*D_M*+_GI_Y$7_  KGQ52.(E3E'#T,+R4U!QH1:4[<MIRO;WK1:W=^
M:3O=L]+ 8=X"-:%3'XS,/:U75A/$VG.A&TU[&$H4J5X*4Y33E%RN[-M)-]-O
M3^\O_?0_QHWI_>7_ +Z'^-<S_:47_/3_ ,B+_A1_:47_ #T_\B+_ (5S>S\_
MP_X)W^WC_+4_\ ?^1TV]/[R_]]#_ !HWI_>7_OH?XUS/]I1?\]/_ "(O^%']
MI1?\]/\ R(O^%'L_/\/^"'MX_P M3_P!_P"1TV]/[R_]]#_&C>G]Y?\ OH?X
MUS/]I1?\]/\ R(O^%']I1?\ /3_R(O\ A1[/S_#_ ((>WC_+4_\  '_D=-O3
M^\O_ 'T/\:-Z?WE_[Z'^-<S_ &E%_P ]/_(B_P"%']I1?\]/_(B_X4>S\_P_
MX(>WC_+4_P# '_D=-O3^\O\ WT/\:-Z?WE_[Z'^-<S_:47_/3_R(O^%']I1?
M\]/_ "(O^%'L_/\ #_@A[>/\M3_P!_Y'3;T_O+_WT/\ &H;AU\B4AESL;'1N
MW4KD9 ZD;ER,_,OWAS_]I1?\]/\ R(O^%(=1A((,G!&/]8O^%'L_/\!.M"ST
MJ+1Z\DM-'KHF]-]$WIHF?@!\2/VJ?VSO#?QD_:@\ P_$#XOZA\.]/^/?PIM=
M1^/?PL^#7@SQ7X*_9*_9H\0?%GQ!X1\:6NA>!?&'[)^E>+6_:(\-:/9^&(?$
M>M^,_%?[:OPDU'P#<ZE^T7I^E_#_ ,,Z8WP];H/$'[7_ .U3IG[0>C)\,=4_
M:*^*'[*&A?#"S_9[G^*?C']G?P#;Q^.?VB_&GP(\7_'/PA^TGJVK>&_A?\/_
M !+I-WI_B=O@I\$(=!T/X7>'/@+>:[\2?&VH:_H>B:AX;T3S/W>_M&+Y?W\F
M478K&0$X8;22"I4G@')4JIY7;DY:M[ N2LK@]0WG!F!#,P^9@Q8Y8_>R-Q:0
MCS7ED?O^MTH\E\NHS:HSI-V;4Y3]FE6<>6/+4C[**BHWA:4VTY2;7B3R[%R]
MKRYSBJ7-B*==2ITU"=*E&-1/"PE)5.>C555SJ.4/;<\81A4I12B?@2?^"@'[
M2OB%/V)?&'PVMOBSXY^'?PW^#_P'\>?\%!]:T/X":9>Z-XK\1_&/Q#X-^%7C
M/P]XB-[X:\/^,O!NK?!#2['XU_'_ %S1/@;X;&I76IZ5\/\ 0M4T^T\ ZA/H
M/B+QCX1_MR_MQ>'_ !W\2;SXR_$7XAZU\*O#W[1_P&@U3Q-)\%?">L:/\,OA
MPW[6'[0?PX^+_@#7;WPU^RK\)+SP[)XB^#>F?"'6-.T2WN_C[XGT'POHNI_$
MB3X\^'I?%^E^%Y?Z7?[0BZB:3(W88S,S#)!X,FXD A2%)*$(%9&!?<X:C&.L
M\A(QAC,,@ AL*% &. I!4@KD8.XD[4<;0A2E#^R<-)M656=_:IN56;DW>U27
M[UQBY)*$(4XQ7NZQ+*<?*K&;S[&<T949>S4*2I2Y*=&FHRBDDX5HTG.K%MMU
MJU2HY<R@H_C?^Q9^U9\6=<\7?\%!/B#^T7\6_'WB[P3\$_B/^TAKWPU^$<7A
M#PQ:WVC?L^_#+XN_%8>$-=\+^!/#W[(WPI\;W]QJ?PGT/P-;^#-3U']IK]H>
MY^*5MK4FLW6@> -8-M'JGRGX(_:W_P""IR>$_AUX/\:^$OBHO[0^@?M.^"OB
MSX^\":I\"_A_IEI\6?V4/&_[&?QG_:-U_P#9M\-:QIGAM?#VCZMI?QI^"/Q;
M_9C^%OQ%.K^%_'9U_2?@'XK^+>O1ZAXV\7^"[W^CK[="4""638JX51*%"@*J
M J0%:(JH'EM&4,;#?'M?YZ/MT&T(7;:,_+YP5&)SNWQQE48-GYAMVY <!7^:
MLHXFG"=6?U"A+F]ER1G=JFJ5)TVHQC92=23E5DY.+51IQMRQ;VJ8+$N%"E'-
M\72E1==5)TX<U2M[>NZR4JM2,^3V#5*G0FHU72HTW!>[5JH_FN^$/[9'[<GB
MWXE_#6XE^*7QMUOQ!XA'_!/._P#A]\ ]2_9F\&:%\.?C1X%^/'[0/CSPI^US
MX[^).N6/[-EG\3_AS-\%?V;;*#XHV6I:;\3?AYH/@?7_  _HJ^+/#'C,:O>>
M!-?^M_VB/VN?VLO"G[97CK2?A]X;^)!_9?\ "'AN7]F>]U&T^$7A[6_"%K^T
MMXP_9Y\:_M$>'/C;9^+9=,U3XA:Z= \27G[/G[/&E^%K&PE^#L.O?$+XEW'C
M+4M:\7:%#IG@/]F_M\) #2NW3=OF+!^0Q\R-CY+[F&?FCRH_=H4B"QJGVV ,
M7\^8N4V$^> 2I(+ ,,,N['(5E"G<\821Y'>98FE4K>VE@*%O9SIQI3<E&+G*
M$E./*F_<=.*2DYIZI^[9)4\LQ$,']6_M7%RG[6%2>+5.FZ]2$8582I56THVG
M&HVYT849)KF2<G<_G]^'WQ$_X*B_;OV=8CXV^+WCK7KC]@OXC_M4>,?"'B70
M_P!F&QTWXB?&&WN/!X^'/PM\;:YX9_8R^'4UGI.IWFNOI"_"7X>ZE\'?B;I<
M&I7%YJWQGU9]&DNV\PN/VB_V_P#Q'X?\,:)\#?CU^TY\9+3QG=_L:V'BCXC>
M*/V;?@+\$?&?@#XT?$F7XW?\+\^ O@74O'?['L/P[T+0=%\/^'?A_>:\OQ,^
M"?Q3\8?!34+W3]+\:_$R6;QQ:Z?IG])XOH%7;O=EWF3:TJ, Q?S"0N,#Y^5
MP(^L>PA2''4(6/S22$E"C$RC)4DG!;&<#)P 0.3G.:U>-I\_.\JPDU[S<5%*
M.LZLXW3:DW!U5RVL[4X+F>RPCD^)49>SSS,$W.$W)RM).+HRDHOEBUSNE)R:
M>GMZJCRI0:_G(^%_[9?[8#Z[\*_$_CWXU?&;5?&EKIO[ VH^,?V>%_9+\,Z?
M\,_&7PQ\?_#3P'JO[=?Q6\:7%A\"[?XQ_#/Q3\%[2[^*OC>R>V^->@>'K/XA
M^!M(^'5E\*]53Q+HW@K4>#UK]MK_ (*.I\(;W1O'FI_&KX$_%+Q3\?OA-\6M
M(\6>+OA)\,/A_;>#OV:?VA_V??CAXJL/@5'X@TW]EC]LS0;73_@=^T%\+A\.
MM1\<>(/@/XO^+VNZ-J?P^L/&=[HMSXP?QHG].AU"'!'FOC(.///&&## )VKR
M,@@!E."K JA47484R0[@G=R)R,;CDD*K!<D\ERID)ZOCBG''TE-3_LC"2M.$
MK.,8Q7)S:<FTHR<[RYG)OE4+\MR'DV+Y/9OB#,5>,XWLZDGS\B3]I5G4<>50
M2BH<D;RE.2E)G\W6L_MU?MGW'P&^.=IK7C?XF_"GX_6'C+_@FCJ_A.R\0_ ;
MP[\+O$?@+X2?&#X:_L;1_M4ZU>:=JWP"_:;\,>%H(/B)\0OB[)XKG\2>#/V@
M?$WP6GGUG2[;2+V#P,NF6?\ 0S\$=5O]9^#_ ,+-8UGQ))XPUC5OA[X+U#5/
M%EQ=:=>3^)=3O/#FGSW^NR7NE?#SX1:7>R:I=227;W>F_";X76ET9A<0?#OP
M7#*GAW3^K&HQ JPFE^7<5!E4A2RLK$ K]XY)#')!)4$*SJSQJ<73>>O4R9(/
M4G<=Q(YQDD]^3R:YL74AB>6-+"4L):<JLU3LN=24$E>RY8PY+QC%MWE)--69
MZ. PU?!:8C'UL=>DH+VD'[1-5*E3G]U.G)M3C2;D^;DIQ<;-M/I]Z?WE_P"^
MA_C1O3^\O_?0_P :YG^THO\ GI_Y$7_"C^THO^>G_D1?\*Y/9^?X?\$]/V\?
MY:G_ ( _\CIMZ?WE_P"^A_C1O3^\O_?0_P :YG^THO\ GI_Y$7_"C^THO^>G
M_D1?\*/9^?X?\$/;Q_EJ?^ /_(Z;>G]Y?^^A_C1O3^\O_?0_QKF?[2B_YZ?^
M1%_PH_M*+_GI_P"1%_PH]GY_A_P0]O'^6I_X _\ (Z;>G]Y?^^A_C1O3^\O_
M 'T/\:YG^THO^>G_ )$7_"C^THO^>G_D1?\ "CV?G^'_  0]O'^6I_X _P#(
MZ;>G]Y?^^A_C4<LF$)0[F!3 7YCC>N3M&2<#)].,$@5SO]I1?\]/_(B_X4'4
MHO\ GIZ8^=>#D$'@"A4]=_P!5J;:4E-1;2;<)62ZMV3=EULF^R/P_P#C-^TI
M^U3X?\1?MG75K\6/CIX3^)_P\^+7AOP9\,_V=_"W[-/@_P 5?#[PI^R)J?CC
MX :%XQ_;&\&^(;KX%^-O''QG^(OA'X4^+OBK\6-,*?%Z^^&%KXUT*?X3:W\!
MM>UCP#K^GZUYIIW[4W[</AWQ]X;U[PAX]^,?Q]_9?^%?Q0_:*\4:KXS\6?L]
M>#?#'Q)_:I_9<\"?#7]CG_A+=<FMO"'P(^&-O!XT^"WQ"^,_[3_B#X*R?!WP
M%X _X:.B_9\TKX=1:1XUN]=_X2S7/Z"FU*)A_K6!!#*1+@J1TVALH#UYV[BI
MVDE3@M.HQ%MQD<DG/^N0 $<JW&#N7 PQ)/'S%@6SWT\3&%O]AHU%9J\M$N:%
M.GY3O'DE.+N^65232DXQMXN(RW$56W#-\702E&<'1O&=HUZF)=^:,HR4YRI0
MG3=-1G3P\(2TJ54_YS/"W[3G_!3$_"K3O!?B'5OB-<?%B;]BWPQ^WK>?%"X^
M GP^@6'P9+_P3XGT#7OV>[;1;7X7:;X*N?B[:_\ !1&SM/'<G@B3PW;>/8/A
MGX@?PU&T/A^.W@MN4\6_M<_\%#?"'P?@^)WP^^)WCWXS:/X?_8L^)7BKQPFE
M?"[X=_$O6#\6?'?CSXE_#KX??$'PAK.C?L7_ ++[ZMXH^ 'C.S^$>J^)_A?>
M?!G2?#0^$6H?$K4?$.E_%76-#T+QCJ']+HOX!D;VP6+G,W\?4-D'<&7 P^=Y
M/S.S.2Q=_:$><F>0X8L,SYVG 7CC. ,C!)ZDG)QBXXZ$)0Y\MP]6,9JI*'++
MEJ))QE"4KJ4%)6MR6Y&KQBU*47RO)<1*,W#/,QC4]DJ5.L^2]%Q;E&<*3I*G
M)PG*4O?7ON24Y?NZ;C^#UE^TE^V#>?M8?!CP1XK^*OC+P9\,M4_:%_;E\/ZS
MI-QX*\ ^$-/\<^&?A=^T=\%_!_P$\ OJ^I?L@?&+5_$<%QX"\2^,[;1M.TOQ
MG^S[K?CW3!JGBJ^^/D5UH5K=CYJM?VF_^"GFJ?LX^.;?7OB/\=O!WQE^%'_!
M.K6/VK]"^(_@_P#9S^"9E^,?CKQA+X1\7?"?0=8T3Q7^SIXQ\'6GB72K?Q!X
M^^"WQ)^$_@WPYX4\83ZE\&8?&=C;^'(/&UI--_3K_:$(4*)7P%5 %F"@*. N
MU=L9 !(^93@8"X  IHOX3P99!ERY;S$W;CD$CCY"<@;HPCJ I1E9=U3]<ARI
M4\LPT%&-",6XQM%T7=S<6[3=9:5>:,KQLE[R4C6648BHX-YQCE%5*\YJG-Q=
M2-;X*;?+HJ&]%IIJ3M*\?=*GP_T#5_"O@_PUX?\ $'C?Q1\1]:TG2;:SU/QY
MXXL_!&G>+O%5U&C&75O$-E\-_!GP[\!VVISLP$\/A7P/X8TE-BBWTJW^8-VX
M92<!E)] 037,C4H54*). , ;U  SD  < #H !@  # H&I1 \/GKQO7N/85PR
MAS.Z>]]+:*[;LO)7T\D>[":I1C"7M)-1@N9Q<F^6$87;2M>7+S-+2[=M+'3%
ME!P64'T) - 92<!E)] 036%'J<1 &Y,C/)8<<DC/('3U(_I5V&Y60KM(+<G(
MY'0CD9SR.G/H>E9.+B[/U5K[=]4O5]NYI&K";LI)2U?(VE.RZ\C?-R^?+;S-
M&BHE=BP!Q@GT(/W2P/)/48/T-2TC0**** "BBB@"&;@ GIM89[9.W'YUY+\6
M_'T?PS^&_P 1OB-+8-J\/P_\!^,_',VD0SBUEU1?"'AK4?$+:6EVT<R6LNH#
M3C:I<M%(L!D+F)\$5ZO=,1&,8Y9<Y&>XQW%?*?[6\@7]F;]H\!@,_ 'XU$Y(
MY_XMIXH(;KTR21GUZ5OAJ<:N(I1EM[2BFK)\RG6A2<'?HU-RTU;2TM<X,QJR
MH83$UHNTJ>%Q4XZVM*G0G5C)/>Z=-+R3;WL?QD7'_!S7^W]>3SSVOPQ_9"LK
M2>62:TM9OAQ\8;V>UM9'+VUK->_\-!6(O)K>)EBENULK1;F1#<);6ZR"&*@?
M^#EO_@H"V,_#K]D/_P -O\8OZ_M!5_/9;\6\'_7&+_T!:G"N>D;_ 'MGW3]_
M^Y_O=>/8^E?UNN!^$%MP]@'\L1+\\2_SUMZG^?C\4?$%2FX\59FM=;K!RVYD
MKN66]5&6KM>TM[.W]!?_ !$L_P#!0'_HG7[(?_AM_C#_ /1 T?\ $2S_ ,%
M?^B=?LA_^&W^,/\ ]$#7\^A5P0"C@E@H!&"6.<*!GEC@X'7@^E-SGH"< DX!
MXP,G/'&!R?0<G&1D_P!2.$-O]7\OOLERU[MM.227UB[;C&4DEJXQDTK1DTUX
MI>(;NUQ5F325VU3P;25TKM_V=9*[2NVE=I7NTG_0;_Q$L_\ !0'_ *)U^R'_
M .&W^,/_ -$#1_Q$L_\ !0'_ *)U^R'_ .&W^,/_ -$#7\^@#,2%5F(&6"J6
M(&0 2!DX)( .,9(%-W#@\X/(.#R,XR/Q!'J2,#-'^I'"#VR#+GI?:MM=J_\
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MTKNV6NRNTKNRNTKW:3_H-_XB6?\ @H#_ -$Z_9#_ /#;_&'_ .B!H_XB6?\
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MU/\  _H._P"(EG_@H#_T3K]D/_PV_P 8?_H@:/\ B)9_X* _]$Z_9#_\-O\
M&'_Z(&OY\LG)&ULC@C XZ]>>.AHW#W[]CGCM@<D^PY['!XI?ZD\'IV_L#+KO
M1+][=M]+?61KQ1\1&[+BG,VWLE2P;;UMHEEK;NVDK)W;25VTG_0;_P 1+/\
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MLDFF[)IN?^(I^(=K_P"M>8VNU?DP5KI<S5_[.M=1]YJ]U'5I+4_H,_XB6?\
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M_P 1+/\ P4!_Z)U^R'_X;?XP_P#T0-'_ !$L_P#!0'_HG7[(?_AM_C#_ /1
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MO_L!S'_U!K'^5?;_ /'O!_UQB_#Y%Y_#K7WO^Q?\(_A7\8+#XAGQ[X4?7?\
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M=ZWXITJ:820:UX7U_7?'7@EKG5B\NG^(O$_BK0;2.>_US4+2V?:,<RJ-5/\
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M<P6NG'#TKP3^UI>:+HGC;1/#G[0MQH6MZAI7P<\/:_I<7Q$>'4[Z;Q)=^&]
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M?%SX3Z5\*]7@GT*QL]&\-^%M3/AWQAXGL_"'B+PGX'UC6=>\%Z9K'PZEN)-
M;4-&N]1TJVEUHR3+J4GA?2O$#Z19^*KWQ!KFL?(=%.&0Y13J8>M' TE6PU6-
M:E5YJEU4@FHMQ<G"7*G[J:?)IR\O*FIGQ-G-2A6P\\;5E1Q%)T*T')M2I2;<
MH1OK",VTYJ#2FTG).[1^B6J_MS:-H$;:%\.OA!X;N_#WC'X5_L]^ _CC<^,-
M5\8G5OBRGPC_ &+/&W[)-]I$<5CXFN+3X?VMCIOQH^+KZ3K_ (0GM+O798?!
M.OZEI\%G:Z[X9UKG_"W[>GBGP7K/A;5?#GPO\!V,/PN\9?L]>+O@[IT^K^,[
MZV\#Q_L^^"]>^'5IH.IWDFK_ -K>,](\?>#O$_B2'Q7+<ZAHNL:+XAUR76?
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MGR=FKQRK-8.SW7-' J5G?57L^I\$%G;;N9FV*R*'8NJJSO(RKDG8IED>3:N
M7=W(WNY*U][?\.M/^"C7_1EWQ\_\(YO_ )+H_P"'6G_!1K_HR[X^?^$<W_R7
M1'-LFBFHYIE:3;E99A@K<TG>3UQ;UD]6#X8XE;N^'\^;LHWEE.:2=HJT5K@=
M$EHCX)HK[V_X=:?\%&O^C+OCY_X1S?\ R71_PZT_X*-?]&7?'S_PCF_^2ZK^
MV,H_Z&N6?^'#!?\ S4'^K'$O_1/9[_X9\S_^8#X)H!92K(2KHRNC*2K*R$,I
M5A@JP(!# Y!P1R*^]O\ AUI_P4:_Z,N^/G_A'-_\ET?\.M/^"C7_ $9=\?/_
M  CF_P#DNE_;&3O1YKE;3T:>88%IKJFOK6J:NFNJ;74%PSQ*FFN'\]333364
M9HFFFFFFL#=--)IK5-)K5(^!SDE>",9ZG/4D]22<_CQ],"G5][?\.M/^"C7_
M $9=\?/_  CF_P#DNC_AUI_P4:_Z,N^/G_A'-_\ )=*.;Y/%66:Y8M]LQP5K
M7T2C];M%17NI1LK;ZB7#'$JO_P 8_GNK;URC-).[=Y-R>!;;;U;?Y'P0>G/;
MGIGH<\CN/7V[BD#X69%9ECN##Y\:,Z+.;=VDMC,B,J3&VF=YK82J_DS-YJ;7
M 9/OC_AUI_P4:_Z,N^/G_A'-_P#)='_#K3_@HU_T9=\?/_".;_Y+I2S7)9VY
MLTRJ5K-<V.P$TFFFFE+$M*2:NI;II-6:351X:XF@^:'#^>QE9QYEE&:J7+)6
ME%2C@X.TDVFK-/KHVG\$ 8SSG./;H !P.!@  !0%50JJJJH 6OO;_AUI_P %
M&O\ HR[X^?\ A'-_\ET?\.M/^"C7_1EWQ\_\(YO_ )+J_P"V,H_Z&N6?^'#!
M?_-0O]6.)?\ HGL\_P##/F?_ ,P'P03CG@X.0#G!(Z9P1QWZC'7M2^:Q6-=V
M5@EDFMT$D@2WGF8M+/;QE_*AGF8[YI8T$DCJ'9B[.S?>W_#K3_@HU_T9=\?/
M_".;_P"2Z/\ AUI_P4:_Z,N^/G_A'-_\EU$LUR6;BYYGE,^6[BIX[ 2Y9-./
M,F\4VGRMJVUBH\-\3PYN3(,^BY)1DXY3FJ;BFI)7CA([27,G9M2L^EG\#LWW
M%/\  -J\L2%)9BJAB5 +R2NQ7:S/-,6R&"AU?>W_  ZT_P""C7_1EWQ\_P#"
M.;_Y+H_X=:?\%&O^C+OCY_X1S?\ R75+.,G226:Y6DE9*./P$4EVLL5K\_R$
M^&N)Y.\\@SZ;[RRC,Y2^<G@+O76[U/@FD(S^8/\ GZ]*^]_^'6G_  4:_P"C
M+OCY_P"$<W_R71_PZT_X*-?]&7?'S_PCF_\ DNG_ &QE'_0URS_PX8+_ .:A
M?ZL<2?\ 1/9Y_P"&?,__ )@/@D.R"95.Q+A$2Y"Y5;B.&430)<*,"<03A9[<
MN"UO./-A*/\ -39)3*?FP<F(@ ,0/(A>V@"Y8X\BV<V\!QN2 F(MM>7?]\?\
M.M/^"C7_ $9=\?/_  CF_P#DNC_AUI_P4:_Z,N^/G_A'-_\ )=3_ &MDN[S'
M)K_S+%Y>I76S<OK7,Y)[2;;5EK9(I\-\4.,8O(N()1@FH1EE6;-0B]XP7U1*
M,7UBDTW=N]VG\$T5][?\.M/^"C7_ $9=\?/_  CF_P#DNC_AUI_P4:_Z,N^/
MG_A'-_\ )=5_;&4?]#7+/_#A@O\ YJ)_U8XE_P"B>SW_ ,,^9_\ S ?!-%?>
MW_#K3_@HU_T9=\?/_".;_P"2Z/\ AUI_P4:_Z,N^/G_A'-_\ET?VQE'_ $-<
ML_\ #A@O_FH/]6.)?^B>SW_PSYG_ /,!\$TA&1].?_K<<\^U?>__  ZT_P""
MC7_1EWQ\_P#".;_Y+H_X=:?\%&O^C+OCY_X1S?\ R71_;&4?]#7+/_#A@O\
MYJ#_ %8XD>G^KV>?^&?,_P#Y@/@A6=%E1#^[N/(-Q$?]3.ULS26KSQ8"3/:R
MDRV[2JY@=F\O =PR,VY]S9+-C&69B !M RS,Q55 "Y)P  , 8'WQ_P .M/\
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MCF_^2Z/^'6G_  4:_P"C+OCY_P"$<W_R71_;&4?]#7+/_#A@O_FH/]6.)?\
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MJ'D1?W:/(B_NT?79]W]S_P P^HO^6/WO_,\O_P"$=/\ SS_]"_QH_P"$=/\
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MCI_YY_\ H7^-'_".G_GG_P"A?XUZAY$7]VCR(O[M'UV?=_<_\P^HO^6/WO\
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3]"-<[;D[NWR.I*RL/HHHI#/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #8 E@# 2(  A$! Q$!_\0
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MM_$7@W7_ !1X_P##NL>+=-U?2)=-USX?>(=3T/4XKJZO[?4O$!N[G6)VOKD
M^7OB+^T]_P %2_ G[0GPF_9WF\&_L(R^*?CXOQ2U7X7W8F^/<VC1Z%\,-)N?
M$VJQ^,M877[2YTG5KC0XHHK,:7H>JVD^IR%)6L+1#(OZG6'B/XG^&O@(_B_X
MH6/@D?%SPY\,M4\2>,],\$R:Y+\/G\9Z)X?O-2OK/P]+K;CQ#)X8EO[7R[1M
M0E&IFR<-)*LX#U\)?M,)(_\ P5._X)G2)%*T47@_]KXRNL;O'")/A+=+&)9
MI5"Y#+'O*ER"%R017Z%_&4$_!_XL*H+,WPS\>A54$L2?"FK !0,EF)X"J"2>
M@ZT ?BWH'_!0W]O'0/V4?!?[>7Q ^&_[*?BO]G&^NK1_&GA+X?7'Q7\)?&/1
MM!O/B%+\,1J]A-XHU_Q7X0NKB'Q,L&S2T_M6ZGAO;-9191G4;W3/N_P+^V->
M2?M#?M[^"OB=-X3\-_!7]D/PE\!_'.D^+]-TCQ1<>)G\._$KX5:K\1/&%WXM
M2#5->CUG^R&L FAVGA?PQIM_]E#6DL&LWQCGD_/+_@GO_P $^OA[^T'^QO\
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M !IJE[I<&HKX.ET2P\4^-(KOQ/XCT33'A6X /U[HKD/ &OW7BKP3X4\37O\
MPC7VOQ!X=T/6[D^#/%3^.?!S2ZMI5GJ#2>$_&DFC^'W\6>&Y?M'FZ)XC;0=&
M.M:<]OJ7]EV/VD6\?7T %%%% !1132P )R#@$XR.<=J %(!&#TX_0Y'ZU^>O
MQ%^-OA3X*_M7:)\,_AY^RE#XH^)WQCT*#6-=^)/A'3_"?A/7M=7[7=K))KFM
M2:"+SQ!H>A0:7+>^)->UWQ':0Z2?(MK>TU*\DAB/Z#>8?[A_,?XU@>)/$WA_
MPAHFH>)/%>O:-X9\.Z6@GU77?$.K66BZ+I<$DJ0QS:AJFHS6]C9Q-/+# KW$
M\2M-+'$A:62-' /Y@_VIO@'J/@3]IKXH3?%._L/AGX%\976N?&&37/#'AK7/
MBM!?6'BK5=4OAX4\."+1O!TEWXDOM?35]$L[+7;KPEH>E7$UO-)JKI-IAO?'
MOBWX-_92^)G[/OP6\7M??M3:_H7PW^*'QI^&=MI6B:3\'?!7B;5]5\2'PM\6
M]3'B'5=9\2^.=&\.:-]K\0W5IIFH:5HGCB\(EO;>^M-,33=,>;]C?VOO%_P9
M_;!^'OB7PQ\-_&G@N:Q^"UC+\0/B3\?M276&\#?"GP<UC=7-]HNG:E8Q6K>.
M]<\=)HR*GAG2GNO#T%GX=O-8U36-.\5Z/X-L-1_+W4OV1/VS+OP-X!T'3?AY
M#\1?AEJ.[XB>$?$7PLOO"FH^'=8O_B+X9\+R/XF::\O-!\0WJW.C^']!T^PE
M\76=E%I5O;R+!>+8:G)+/VX/&2P3E7P\L10Q\91^JXS#UU#V,)1JTL33E2E3
MG&;K4ZBC&I&4)P<;:JS7TG#_ !%6X:=3,LGJ9IEG%-#$4*F3<0Y;FOU26786
MIAL?@<VPTL%/+\7"M6QV$QW+A\?3KT:^!E"I!4*\*T:N%^,M;U6Z\6^)7\1W
M.@:1X2TVQ\&^#_AK\/? FG:C?:SHW@'X<?#WP]I'AOP?H3:U.MO?>)M0CL=!
ML[G6]<_T#^U-7FO=>BCTV34I]*M/W:_X)/\ PJ\.:1IGQ"^--AKT&I07.EZ3
M\.X[@WUM&MO>V]POB?QC.EHZ1S6.E2SR>%M*TV>\E#Z@^CZG?VZ+9S6UW>_G
MQ9?L3>*OA]XH\ 7'[5'Q(\*?L]^'OB[=ZWX5\#:3K][:^)))_&VCIIVK:3I/
MC>\\+ZW::/X2\/\ BK1[B_TV;Q+:^-;B_P!/O[2PTN2TTF\UK3Y$_2?QG/\
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MG^'OB_3K'XGWOPUM_%?A37_#4%WJ,_A[Q_K.CRZ'J<6N6T]W(UOIU[WGA_\
MX)=Z+_PF_P 9=%\7?%OQ';^$? 'QM\*_!7PUKOACP[\.[74Y;GQ?\//#GQ-;
MQ[XWM_B5\2_ ^EVGAGPAX=\:>'+;7-"\#W_B;Q5JM^VHSZ%HZVEHD5UK/*,V
MK5E#V#E6J5*U6K%XF,I^VE.JZM6JKI<\\1#$1527Q.,YKV:34.;#^-_@_D.2
MT*. S?%Y5D.2Y3D^#RRCA^%\YP^!A@5A,II9?DF3PC"'UJOEF7XG+Y5,NH-Q
MPN$A"K0Q&/IRIUL9^/BJJ9*Y7(.<,P'S$%N-V,$@9&,$ *1M  FCGFA2:.&X
MGAANAMN8(9Y8K>Z4@#;<P1NL-PN  $F1UX&!P,?K;\*OV9/@/I7PU^&][K,>
MJ>(?CEIW_!3CP=^RC?\ BB]TS1_&?P@U[^R-=TA]2TJX\'W/BFPTKQ/\(=>\
M-2W'B.._N].D\8:[XEGM/"=U/;>")KF\?YY^-OP!^&/PS\&S^._&7BWQJ/'G
MQC^(?[14'P=\$_"WX<^#A\/M-TSX5?&#4/AXT7C*74_&FD:GX?M=;U>"?_A'
M]!\!Z-XA&@Z5:+8.TS2!;CEGE6+A159JC[-13<O;J$8*47RP<TG:;</9N"3]
M[EBY.$E(]_+?%SAC-\]ED&&>?2Q53,<1E. <LFQ,ZF;XG#8W#0K8O 8>G5;>
M24\LQ,<^J9WCL;EU.AE]'$*KEE.O"G1Q'PGA<8XP   ,* -[2<;<8)=F<L,,
MS,Q).:LM>WDEI'827U[)80E/+T^6]NI+!#&Q=,6+S-:;E=BX)A+!L-G(&/V^
M^"G[!OPW\(_&O]FCQI>Q^*O$?AO4_P!HV[^!_P 2/@S^T%X9^"UWK*:KJ7P$
M\>?$_0[W5_#7PR^)?Q:TG2H8XO#WE:EX*^(AT+Q=I^I_V=>W.B+!LN[KY>\0
M_L\>%/B!\ _A9J_A:TC\/?$KPC^P0?C]9Z+HGAS2(_\ A:\FA_M >*/"_CN?
MQ7J%HEMJ>J^*=/\ ">J:5/HUUMU#6+^QTLVA;[%I<$:="R/'^RG65.*JJ-U1
M4W[2K3E3HSO3FN2,^:-5V@XJ4G3FN53<8OP\+X\\$9AG6#R["U\RJX3$3A[?
M/*V%IT<)EV-K5\7@Y4\91J5\5BX*.(IY5SYIAL5BLMC@L^R[-'F*P5+&SI?F
MMY,6PQ>5$8BP<Q-&CQ%U0QB3RG5H_,",5#[=_?.0")58K!-:*<6<Y1KBR'_'
ME,\22)#)-:?\>TDD"RR&WDDB:2W>1I8&CE8O7WC#^R%X1N?V\]#_ &-(/B#J
ME]I;^*=!\$^*?'EG8Z?+=Z?XHB\ CQ%XYL=)T^*Z-C/'H?BAKWP]:&XN2?+L
MII+D&5#"FG\(?V/_ (=^.?A)\.OB_P"+_B3XXT#0_$GP<_;!^+WBNU\,>$O#
MFOZEHVG_ +*^O?#^Q6R\/V.JZ[HMGK%[XJTSQCJ%P8-4U;288+_3[&V6_@MY
MI;FWYX99C)S=.$87IUZ]"3=9PA"M1GAJ5:,G=J-O;>])IWC1D]59KZG'^*_!
MV P.69ABLZS+V.:Y1P]Q!E4(Y-G%?$XG <4PS+%<.U*.$C%5:>,S'^RL3*A@
MZE.ECJ5:6%52%&IBL/-_G[!++:NDEK--;2QH42>WEDAN41E=&5;F-EN%#QNT
M;XE'F1[4?<J1A62_OF=I0KM(Q>0E4!>0L7,C;5&9&<EW?[SN2[EG^:OTU?\
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MO"3):Q8]$!P5(.,E1QT(S_@34Y.#C#'H#A2<9( SCZY^@- 'QSX=_8-_9O\
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M\@CP2&(.>5&0H R2W(PO;/0$@'&13@V>Q'U&/7_"@#XB/_!/_P"!;_"GX@?
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MI\*/B/\ #;X@?$^?XA^)K?X&^ KKX?\ PI\+> +/X::7IFK>$=5U#Q'?>)O
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MPSJ7C#P(^H:CI]IJ<K>%-9TOR]6A75+?RK^22Z/>7O[:W[0-]XS\'?$>76O
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M>*?#?@"'2_#4EG-<:_IR:UX:6#Q9J*ZII3:)9ZK:WFF6?B$Z;XACTO@_A_\
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M'A:P^'OA:W\,?&CX(_$KQW_P4)B^'%_?W/\ P4#^._QHU*7QE\"?@3\']1^
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MM@G3G&-J]>KCJ=%0<8JG"I4HU:D8-\L5[-2J3;>DMR+XM_L?:%^VW^P_\6/
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M ()UZWXE@\&C5'CUO5_!NMV_@#]IK2_#<.OSZ'\/['Q)X3M)O"OA7P5X:O\
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MGZO)I6L>#[.X\2_\)+=VOAF\LY+7Q9?VEG8>(%N;'^UKJQOHK9]0MM.:/V/
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MX1Z+;V?AC7?'FO3ZCJEO9:=)=75Y/XZT'1[2.6+2-,\.-X5B'A60 ]AMK_\
M8XN]?T/57L/V?+'Q5X3\<Q_!#P??ZYHGP_T/Q)I/C[P$DND:?\-/!-QK=E9:
MJ=7\-6FK36/A_0?##R+;Z?J,L.B0_8[MED(M*_8JTT:!X)BTC]EG33I?Q'73
M_"O@Y++X/VK:?\7?[-TJ467A[PZB)]C^)/\ 9*:$?LNG6D/BHZ>FD$Q&T2R(
M\Q_X8HLK70KKP?HWQ+U&W\*ZGX<\=?#?44U+PM'JWBB7X4?$M?AG+XJT;2O%
M \363Z'\1/MOP\>31_B/I^EK;V]MKEJVJ^"]?UKPGX4U[3]O7OV3(-0L? ]C
MH_Q N?#R>$?&7Q7\57>HZ=X7-OJE]'\7OCA8_'3Q#86%YH7BGP\(&_MO3K:S
MOM*\80_$#X<^+9K73_$'C/X<Z[J^E:0UFV[VTM\O3?0#ZQ\5^+/#/@;0-5\6
M>,_$NA>$?"VB1"YUGQ)XHUO3/#OA_28))X[=+C4]:UNZL=-L(9;N>&W22[NH
M4\^>*'(=@M9MEX^\%:OJUOH&D^,_"VJ:]=>'T\66FB:;XDT2_P!:NO"D[Z>D
M'BBVTJUO9;^?PY/)JFE)!KD5N^ES-JFFE+LI>VS2><>+?A]XM\<>$O!\6N^*
M?#^F?$'P9X^TSXBZ/KMAX7N]4\'MK&CZEK1TFQU/PI>Z[I.IZKI9\+ZO+87+
MV_B/0;]M;@A\2:?<67V>+3'QO@=\!]%^!MOJT6E:Y<:[)K7A_P"'7A^ZN[W2
M['3)]GP^T._TF*6-K.23_1=1N=5OM1M=(0QV7A^.X.G6 EC,MQ*TG=+=/RTV
MZK;[_(3=DW^!]!F1F!'S#..25.,$'M[#CKS^8@>4J<,'8 @=1U(SGMT&1R>M
M5'N"RD H 0!M# GDCVR..N.G;GFJS/P-Y51GJ7(R<'C)(^OX5JDELDO1)$>T
M\OQ_X!;><@G[_P V_;@KQZ'KVR.]9.K1VM_IFHV.I1Q3Z??V5S8WT%V(9+:>
MSO(GMKF"X25'A>":&5XI4GCD@>-V29&B9Q4C3PX8;QG!&<Y_+)K.NC'<V\UG
M.D4MO<PO%/$_SB6*5622,C/(9,J<'C)/:KBTI1;DXI2BW)*[BE*+YDM;M6NE
M9ZI=+DQE*,HRC4G3<9PDJE.<H5*;C.G)5*<XRC*%2GR\].<91E&I"$E*+C=?
MDMI/[+7[$DGPHUGQ39_'34?^$+N=+T#X+:U\1HM2\*^'WL+OPQHG[*<?A?0O
M$6JZ=X+TAHS!_P ,O^ -9M-)U>&STC5KOXG>-YK2$-XZT%K7LM<3]CSQ%X9^
M#]OJ_P 7-0T+3/V<? .IZ?IPO-.\,>)KF?X<:9\2M-^%L?BC69]2\)>/X?"6
MJZEXV^!TNE^%_&'@Z\\'?$CP]'I_B2WTB;PQ=6NJV?A[ZJTW]ECX :-\)_$?
MP1M?AM;K\*_%NHV.I>)/"%YXG\;:RFLWFEV?ANQTV>ZUK6/%%[XD7['9>#O"
MUC!%'K,=O'8Z):V:QBWDN4N(-:_9<_9]\0V7B33M7^'IN+#Q5=V%_K\">,?'
MU@=0O-+^(?Q.^*EA-%<Z=XKMKVP\GQU\8_B7K;PZ9=65I<P>*Y="O+6?P[IF
MBZ1IOVW^L&$J5I/$9IQ54A3S'$UL-4<\GIUZ.%KX:AA5*:<92CBZE*KCJ4FI
M5*-J>'E#EE5K-?T)5\5,HS#&UZN<<=>,V.AA<\S"ODF(E#@NCB,-E>:Y;A<I
MS'$8C#K"U*=/.,5E6-XDP6(P476P%&E5R;ZE4I?6L?#"?'?PA^"_[)7PI\-:
M#X^TOXM>.=(\*^ ?B5J_AK2_$'C75?#LVF>(_$'P(O/%'C_5KW3Y]+T:Y@N]
M'OO#GA37]66^TR321X@TO1+G4;.TL]5OU6>UXF^&W[%.N^,_%_B34?CGIECK
MP^,'BN2[33D\#Q77A3QWXR\;>&/'GB>"VNH?!,^JPVU]J'P>UC1]<\87ES>0
M-H#^.M!UKQ/(MI+%I7V>WP ^"A\!1?#(^ K"?P)!X[TGXFP>';G5/$=W##XW
MT3Q7IWC;3M9BOKS69]6@2+Q%I=M=3:3#?IHEW9O?:->:=/H6JZGIEW@VW[,G
MP-T_49]6TKP-+H^IW/BR?QM+?Z3XT^(VCW(UV^GUBYU&WMY=*\8626GA35IM
M>UR;6_AU8K:_#S6Y=5NI-6\+W1D01M<2TJF*Q6+K9OQ5]:J.<:53FRBLOJL:
M]&K25?FHU:BJ5O\ :*M2/O<DZD8QER2KTZF$/%?+ZN89MG&.XW\9*6=XN5?
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MQF9$,LEC<RV%S=1VNH)#^_\ LD[)*\(D:(/Y$_E^6UWOQHUCXAZ[\6?&U_\
M$K3]0T/Q7JFJ1:GJWA^YOGOAI-O/:07.DV,4RR-%/I^G:3/:Q:=(N8H[>4%?
M+<MG@-RYQN7/3&1G/IUKX_%JA'$588>EB:-.$YQC#%J,<3RQG.,9U(1A#V7/
M&"E&FXIPO*$G*5.4G^L9+_:T\DRG$YY4RJMFF,P&&QF*J9#&L\F;Q=&EB(0R
M^M5Q6.^MX>FJLJ5+'T\76H9A3H1QU!QI8E0INHHHKF/1"BBB@ HHHH ****
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M^*O#-UIWQ1\1^"/LWQ?_ &,OB[J]]HW@+4(O@WX.\=P0WW[(<&B0^!M3\0^
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MGPF^ ^MWMYXLUW3?"/Q6_:6\%>*M)^.,?HNA?LP?LB0?!7X2_%OXF?#/P?\
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M/P/X?NOAWXBUK4O#7CSX:7?[,/A;PIX>?_A=_DW[*W[/W@5+S]K73OC'X%^
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MCQS\,-*T+X3C5?A]+8^)_'&M1:)_PF'C'X$?"C5-=>R@?05\!Z#>_#B[T/Q
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M+(X#VJ>?Y1#/*DGAGPO_ &V;/P;X\AUSP?XUMM;T32KS3[CQOX1T/6=_]MZ
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MM-#TK[:U_P#X*[:KXR^)UWXK\<>#_B_XG\"7'C:_\;6_@";]HGQ18MH^IO\
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M\)R?':'Q%J'P>\87-]\+1J_Q6\7:C;^$)=7\1>,7F^Z[_P#X*J>%[7PQ'8>
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MZV)WFPI&7Z#^,'^(=,=#_(5 TI8 !F&#G)8$]".F1Z]ZKM,%'RE6  YR2,Y
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MPX?AXDX_ 4X8;PA\.\+6JT*W%V+P>*QV6OB&U"K'#5)97EJJX#.\;GM#A_\
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M:AHFMS7][H-Y?ZSHOQ.^ _AOP'H#&_LX;7X4_M)?M +!#;3WZV[_ %S\+_\
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MXG1YM$U#Z'\8_M!?\$CO%$VI:+I7P5UWP3I7B+X9?&GPUX/\6Z!^S=X?&I_
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M+XV0^&+;Q//<>:VI_P#"NQJ6NQ0WME 5&C:C9W<L-TMJMU<5%[[W\_ET]?\
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MX.3R,]#V!SU(-(25E:[?FW=OU9!?7\5G!+<7$JPQ0QR2//+A8X8XT+RR2$#
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M]6M/$VEMHEK>S0Z?X&30=3TNYUGPU::S+]JE_I,_9H^!?P,^%_P\\ Z_X/\
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MZ\.^%+7PMI$L>L^)8?$FJZ==Z;9S0RM:3S7-JD_^HKXO^&GP>\<>*- ^(GQ
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M.J$_V/>2V<=U>7OUI:WAX^;''M@'.!CD 8ZCV.3FO+H;EXBA#-G:%P2>!P<
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M+[L#!^7/]/;M^%0ZA>6^K:;J6DZ@KO9:O8WNFWT1&PRV>H6TEK<IU+#=%+(
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MQ8W%WXN^ GBFP.XR:?'JM_H3R%6-P^B21ZW;0PR.&!6>]@N].:90WE1AUR6
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MK5Q:F6XU?X=_"3QOJNNVMI!87X^,ND:?)H]DSSZGJ&5=_$_]IU=>TBPT_P"
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MP[XW_M&*VL;/0=!OXE@U&U;0E2[U>'Q3"DFG2ZJVGQVUAK^DVVIP7_'^(_\
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M'IT)3DIMI+1117K'C!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(9!\R*3SSM! SGL 2?3DGDY/ HHH:3W2=NX%0Z7;@Y6(9SG)&!^C9Q_O*/<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #S E@# 2(  A$! Q$!_\0
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M^R)\0/!7A[5;NRT=M8MM3\+Z]\5/&MSJ#1ZW/=WMUK$^FZO?ZOI>E:+;Z?\
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M<LZ17NL:%K_A[0?#.L3:=!)AKV+0M2\)V;ZF8$/V(:_I[S;$ND:ODS_@KO\
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M=W.N?%J:271_'/CGP[:MXANO!=T8Y/M7@WP/8VUM>KJWQ CC5_[<U=+>^M?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEPKA\Q=/+9\^98:$LPK86EB<P^HJE'&SC@*>(BU0GB</RSC4<X>Y)*.A>?\
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MISA.$YPG&<I****DW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<,-J>+)_!EGY8>3S;AD^PS?T2?LO?L@_!?\ 91\.2:-\,] >77M2M(8O%'Q
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ME1JT/8X24<-3<:.,I557H<\J\53JXC$U*^*:A.HTNS_M&T"_NI&EV@8"8)
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MX+$87#XO&X; U<#_ &7FN,>&J5,;17LZ^(RNE-PP?UCV$IJ>)<7*/^Z_[/\
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M<L=>'AV7Q1]AM_%6F^&;_1C8)>2:0'@LM8TV[N//Q];"3<,MKK#UYX^CBG'
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M/U?,L=]3Q& AAZ#_ *IH[I')8L,8Z#IGC&"0">AS[G Z595PV0,\8SD>N?\
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M=FZW%RT$Z^'HO$6JSPF.(3K%?W<TTDL44C0\1\)-$U7PQHOCJ2]^'=AX'O\
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MH .E<_XHTM=;T'7=&:X^R?VQH>J:3]J"-*UO_:-C=6?GK$N&D,7G^8$5E+E
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MQ-3$.&6\/XJG7A7=1\DLUQV%I8+"U5.<I_NJ6$Q&(C2JNU.,X\E*DFY3_/\
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MQ3SG*\J=:HZE>GEF!XDXSIY73E*2YJUL/4E&51S4H1:G)5)5)(_37(]_R/\
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M[:71 MKN,%AS!)(5.U90DFY1^[^M_"7X<W@8VFAG09%:9X_^$;U'4-$M(&F
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MXM_0:\J\8L8O'/A.?C:G@[Q['DGI)-KGPVVMMQ@XCCF&>H+  %6;'F9Q65#
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MN)Q3HT8T<1ELO;5I0C4GCJ4:<JG/&4OJGS$'\0IP((R#D'O6;'.6QEPWS$8
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MG.-25/%X3%4ZF'K4_:4Z<XTY4U"G*E2E25)TJ;A_,]\8O^"'WP8\2>,;?7_
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M2;77L--GM+K2=0D71GEN-/\ L<V^75M1FCL]/MICI\=I='[8\R?U#?\ !/\
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M *".O'!].G'X8X %<_H.E?9XT( ! !VD<* 1R1C...<$D'H<$UW4>X#:00%
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MY[B,/&E3G3J+"X*@L/AW4HQ<:<IP3;ER\TI*+LN:5W=V:****_3S\^"BBB@
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M2HTI*495$YQ</:144[KGBE^C'P$MC%X'GNR(@=4\2:]=KY>,>5:7?]AP[B
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M4JT,+B7]6KRE15"^(P5>GBL!B)PHWITJM?!5:]"$I1H5Z,92B_B>,O#7P_\
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M'XAM-3T']H6RU)_&TVNZCXGT?7_AIK7C":ZT^62S\$VWA;4[?O?AOX!_:?\
M!/[-?[34GA#0OB1I'QD\;?&K6/&O@%_B!J/P3OOB]K'@[4M*^$VCZCK5Q=^'
MKR[^#$/Q(D\*:%XKM?#":Y(FAQ^*;'1)/%2/#)=SW )PM]J+O;9[;;_?^?8_
M4"6:.&-Y9&"I&I=V+* JCEF9F8(J(,L[LRHBAF9@H)&5I'B+0M?#MHFKZ9JR
M106-U(^F:C8Z@B6^J6<.HZ9.[65Q<!(=2TZXM]0T^5]L=]8SPWEJTUO(LA_+
M>+1_VYK[XM> ;.*Z^.=O\%!X8\/6#P>.H/V:]:U;4])N#\0+/XAZ=\=SX2\0
MZ'=V_CRZA_X0M_!WB3X<2:UI^EZ.FASZC8:QXFN?B%;R>@?\$\O@G\3_ (-:
M3XMM?B5X+N?!\^H_"?\ 8W\.V45QJ&@ZA]HU?X9?LN?#_P  ^.-/#Z%JFIQJ
M_AOQ=I.I:#++(ZVMY)9M=:3/?Z<\5VX#@DK\T7Y)Z_\ #_Y,_2*BBB@@****
M "BBB@ HKYO_ &C/B+XF^'4'P9E\,7-E;R>-OVBOA#\-]>%Y9Q7AF\*^,=7N
M++7(+02L!9WL]O$JP7T2M-!Y;^5ASO3\\_$W[??QN^+'PDT0?"WX<:=\(O&_
MCZ^_8[UWPKXA?XH>'O$=W#\-/VEOCMKOP=:]MW\0?!3Q3X:T?Q=_PD_@^;PU
M%%K/@WQ?IVE^&?&,'Q %IJFM^&[CX>WP4HMJZM:]M6EK\VC]G**_*CPY_P %
M+/[>T76;[3?@EJ4,=_XS\#>!OAAK?BSQR?"GA?Q%J?C+Q]XG^'\,WQ5\37WP
M^M[3X77FFR>%I=;U6#PII?Q7TY5U"TT*ROI/$L=UHEMFWO\ P42\?>%]:^*5
MMXA^%'PXU@6'Q=^#WPP^%6E^$OBOJNK27=Q\4/V=K'X]_;?&FN>&_ /C3[=H
M!T&#47T+QEX%\,:S:ZQK6J:=X-M-#NK'2+OXB:P%NC54E%QM)[)RBF];:+FU
MMUVM9GZTT5^5*_MU^,?B3\:/V?? 7@[PO'\,]"UKXN?"K0/B1!XF\5>%+SXA
M:LGQ'_9)\1_M!S>!1\.;CP]?W]CX:T$:]X+M]0^)>B>);*YG\7^&]3\/6-HV
MASW5YJ'I/Q5_;VM_AEK?Q]MF^'&EZOH/P+U?PWX'FN+CXGZ3H?C;Q-\1?%=O
M\*+O2XH/AK)X>U#7K+X800?%[03J7Q)LKG7M1B.EZY)I_@/4[2+3KK40APE%
M\K5GH[.W7;J?H;17X]:U^V3\9O%/C#PM=:0UW\*=+UJ3]E6PU+P+=Z?H'B!(
M[WQ?^WYK/[/GQ#U+2M=\3^"-$\3WNA>// &BFWT2YU71?#6K:9HVH66IV_A[
MPKXQ2]DM/V%H$TUO;7S3^^VWS"BBB@04444 %%%8&K>*_"^@/<QZ[XDT#19+
M/1KWQ'>1ZMK&G:<]IX>TV:"WU'7KE;RYA:#1K">ZMH+W5)0EC:S7,$4\\;S1
MJP!OT5Y-?_';X,:;-/!>_%GX;6LEM-K=M=+-XU\/YM;CPUXR\/?#OQ%;7.R_
M8076@>/O%GACP9K=K,T<^D^)]?T?0M02WU/4+:VD]5:500NY=QX"D\DDX&/7
MHPXST. 2,4 -:,ERPP.F#DYP,9'3Y1D=FP<9QFH/LTN[=YHR#D' +8R2%W%=
MV 3ZY')ZDYY*W^)WPYN-%TSQ$OCSP:-"UKQ=-X T?6&\2Z1%I>J^.H/%%]X*
M?P9IM]/=107_ (J'B_3-0\+#0+9I-5D\0V5UI$=H]]"\ M^-_'W@GX;>&=5\
M:?$#Q;X:\$>$-#2!M9\4>+-:T_P_H.E_:[RWTZR6]U74Y[:S@DO=1N[73[.*
M299;N_N;:SMUDN9XHGF45*W,KVVO?[]&M5LKWLK)+0EQ3>M[^3<7\^7EOMUN
M=*T,CCYI 1QE<L <'(R1Z'D<=?Q-2QQ^7T"@!<8&>.2?0<8QZ>^<9ID5S')$
MDP>-HI%21)4D5XWCD57C='4E71U965U)4@Y!*\EXF0D@.A8$*5#KE25#[2,\
M,5(8#J5(8#'-$8\JMS3:[2FY+Y)I)>J5_/H"2OS)6=DFU&S:6MFTKM:[7Y?*
M^I+17.ZSXL\.^'KKP]9Z[KFD:/<>+-=B\,>&H=2U&VLY=?\ $<VFZGK,6A:.
MD[Q_VAJTFDZ+J^I)I]L9+I['3+ZY6(PVLK+N^=%DKYB[@ 2,\@'H2.N#Z],\
M516_?[F2T5Y_KWQ4^'/A;6T\-^)/'7A'0-?DB\-W":-K&OZ;IVJ/;>,O%D'@
M/PA<)8W5Q'<M#XF\;75KX2T201[-2\0S+I5F9KQEA/?Y&<9&?3//7'\P1]>*
M %HHHH **** "BBB@ HHHH *JO\ =E_WD_\ 1IJU59P<R(.I*G)Z#YV?\?0X
MH ^??VD(H)/@;\;_ +5&LUN?@[\2_.BD >-T3P9KLG,;$*?F5<GK]T$XK^1^
M]U"\%I:WCP3I:WT]S:V]Y)"ZVEU<64=N]]:VUPZ>3+-9QW=H\\4,CO;+<VWF
MA1+'N_L3^)?ABV\<>#/&O@B\NVL;;QEX1\2>%9KR,,TEE#XAT74-(FO%C"OO
M^S1WGGA-CAS&RE2-PK^-3XM> O'?P:\7WO@?XCZ%J&@>)-":XMUM[^"86E_:
M2RQQS:WX7U%E^R:OX=UF>SCN;34]-FE@N(T@BN3'<P-!#_87T7,PPOU7BK)W
MB<-#'U,QRC,882M5E3Q&)R]8'%X3$U\!!.U:="JE0Q":Y*:<547OTY+_ !L_
M:J<$9IFF<^#_ !8\KQM7A_ 9'Q9P_6SC"X9U<-@\[QN?Y1G.!P688E4IK"PQ
M.#IXVMA?:U*"KXFA6H4*BKTZD)_DW\0/'^I_'CXRQ>&+[QO8^"O YUZZT+1;
M[7;R[M/#.B:?IS79N-<U1+".26[OM3-E(D ,;R37%Q8Z=%/!#N:+T7X0S7Z7
M5AH4OBLV6@3W1@FU*^MM4U73[:S1),:C#IL:MJG[V)5ECM8!;2&25(;EX566
M:/YNN_ TNF?%'5_">LZ_H?A6"QN-=U >(/$\][;:.=.M-+U/7K#]Y86%_>3W
MFN1VT6D:/;VUG,;S7;JUL',,KR-'Z[\/?$$$45J[G8 JDHQY5G4C#8XW;R-V
MW)#'@DCG^D5B*\,RQ;EBYTJE.C&BJ*IPE'#<]>I*DXJ<E&LEAYTZ;HUE&ERI
MSC[R@S\ XDRK*\#P/D&!R3*<!7R:C@\'5PBIPBZ>*I?4\+*FZD:=*%1UZZG'
M$5\4I_6ZM?$5I3J^T24?HF7PWKM["+B.VMV66-2RI=?,I8!B'%RMJV5SMPKG
M!Y+$<!OBR37_ !'J^K^(_%5S!)JFKW+75TMM]GMX=VR*%+>V@MK9+&PM;>WA
M2"SM;>*6W@B1(MCQKLKJ-(\1V$.I6.D^)I]0\/6W]HV-OK<TND376J:-823Q
M?;KL:--+97-Q=6MDS7,5FSVS7+&!?,\N3=7EWBKQ78M+<K;S2/:B6X6T:XCB
MMKJ6W663[/)-;PRW$<%S)!Y331)/*D,[/&K[%!KV)9C&K)15-2Q$<+5MBXTJ
MD4Z=65.G7A&JI.C3JUI4J525*"<X0ITZM-I12?X;EU+B"IS1EA\+A\/''JC'
M#QC_ +5&4(JK&<L-5J3J.C&"]DJ\DHR:E3E9NYQ7Q5NO#%_XCUV]\(Z!)X8\
M-3W+G1M!N]3N]9N[&R6&*-!=ZE>R2SW5Y<.KW5T^[[.DTOEVBQP!(U\<^']_
M-I7Q.\-ZW:Z3H6M-X>N[C6&T[Q+I,&M:'*UO8W$%O-?Z7=XM+O[)>7-M<V0N
M5E@BU**QN98+Q(&M)^W^(7B#PA/H_A:'PVGB!_$+:=J \83ZH]D]A<:S-JLR
M:9:^&;.PM%NQ9PZ4ELTTM]=W=Q=WMPZI;VBHL-=]\*?AAXK^*'C^'0?!7A"T
MMO&'Q#UDC3O".AFX.G>'[!A/=QV-M>ZW>ZA<6FD:/8QS7NK:CJFK3I:VENT^
MH7L[PM+)XN!IX;$4Y/%JI1RO+Z&(JX_$YAB(T8QPV!J<E;ZS7Q-2G6J1K4J<
M\5&M%R>)PU/VK2]I3O\ T!ET<QP5+GPZI8G/,VJT*&4X#*<+6K2J8_-?8TZ.
M'PF#HT)-SI5\7#!1PM*A5BL=5I8.C6E4E&;_ $*_X)7::=0_:[\/7[XD/A_P
M)X^U4.56-@USI?\ 84DI5%2-Y"^M1H$1(Q$)'V[D.X_U9^')G8Q*&/W%/(Z\
MX/<<=/KR<8-?D=^PC^PQ<?LQZCK7CKQ?XJL/%/Q"\1:$OAI+308;H>'?#.CR
MZA8ZIJ5M!?WRV]WK>JWM[IMA#->G3M*MK**UN+>WAO#>RW"_K?X:B=6C&S)"
M@9!'(#'IZCD=,\#C/2OX6\>N+,FXOX]>+R#&QS'*\MR3+,HHXVG"M"CB:N&E
MCJV(J4'6ITY5:*J8A4J=>,7"M&C&<6TT?ZT_1+\/.(?#?PFCEG%665,FSK..
M)<YX@K9=B)498O#X/%T<KPF7?7(X>=>E1Q-7#8*K7J8=8G$5*"J1I5W0KQJX
M6C[GH<A)CW'+!OE^4<?? SZ\C)_$UZ79LQ 7@Y"9X&,9<GCMP#^/Z>9:&A!C
M/OGN>AD)'OW_ $]:]+LCT//1.Q[^8/TSGFOQ<_ILWH<<XZ;4Q]/FQ4U0PC&1
MUPJ#/TW5-0 5$84.,@G'3)SCZ5+10!^</[3?B77-/_:(\(>'_'/COX^?##X$
M_P#"H;[Q#X6U_P"!&B^,+R?Q-\=;;QG':77A[Q3J'@;P7XSU6\N=)\%G2]3\
M&^ ]9M4\->-;G4O$1O=&\33:.EOI_P \_$3]IO\ :\UBQ^*&C:"_A7X7:E^S
MA\8?A#X"^,7C*Q^!OBSXC6GB-?''Q]O;0ZWX9\*1>-)=2A^&VF?LZW7PX^*O
MQ!AB;4/$5YIOB[6/#/A[Q+X1U"WM/&NF?M'@9S@9.,G')QD#)[XR<9Z9K"T7
MPKX8\-S:[<^'?#NA:#<^*->N/%/B:XT;2;#3)_$7B:[L=/TNZ\1:[-9002:O
MKEQIFDZ5ILVK:@UQ?R:?IFG63W!M;*VBB"HR2WBGI_P[^[\=?(_'#XJ_M/\
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M +$OQQ^.-WK7[/OP6\>66K7OA8_LA?"[Q'J&K:G\.?B+JOCBW^(4/@7P5?\
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MX8TNVUW1?&'AK1=.O+AFU2*Q\/KIKPVFF6.G0+]^T$?CY]_/YA1110 4444
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M%!<>%+*Z6T74PUO5_D[+6*O^O;\+]--7P!\ OCQX3_9H^!'P[AB?1O''A/\
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MO^/-)#>$+C3H[R32=4\%^%?$?BC3M?@FDT:]T[1-1B@OGU*!M/KZK^'WQ"\
M>-D\)GPQKT5]/XV^&FE?%_PW826.I6&H7_PYUF73X=/\326VH6ELMG;O<ZI8
MVDUK=O!?VEU.8KFUA,4YB_%,9D6=9?0^M8[*LPPN&_?_ .T5L+45!K#4*.)Q
M$U5A*M"5*EA\1AZ[KQE/#2HUJ=2EB:T7>/\ 2V XTX1S3%O 9=Q+DN,QRCAI
M2P5''T_KD7C,7B<!A:4L-6IX:O'$UL=@\3@XX*5)8^&)HRHULOP\Y4E7]AT>
MW*"(KQRH("GOD=2<9P3CT/W@:] M$8#!W ,J@$@9. Y..W!P/I^!KYF\'_M
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MC_L\?MU>/'_:1T'6M>\3ZYX4\>_![XA^$_!7A6_\;>']8\'ZO;:W\.?!NF>
M_#&I:EJ7Q/TBST3QQX7\86>MS:UXMTCX%>'V\17+:_?ZY\2=>TKQ!I.D:)Z5
MX7^!O[4OA#XV^&-9T6V\36?P\N_VJOVA_B-XST:R^)6E:+X!O_AW\2?B-_;F
MC>+/$%CX=\9Z9XGUGQ7;^'K0+H7@S6_"7Q'\(ZA%K-]8ZIIWPWUZT7Q5<@<J
M2=YIM;>G;9:[GW%XN_94_9U\?2W,_C'X0^"O$<U[XF\1>+[Z35-,^T27VO\
MB^QT#3/%=U>R"9'N[7Q/I_A7PS9^(=(N&ET76H= TA=2TZY.GVIB["+X+?"R
MVO%OH/ NA17D?Q,E^,B7$=JZ,/BC-X=?PF_C<!9 HUP^&Y)-&\X 1"R8H(0P
M##U)1U/'.,8]A_GH3]:=01>325VK=.F[Z/3K?YON?.5[^R/^S=J.D:5H=[\'
M?!<^EZ'H?@;PWHML]A.K:1H/PUA\66W@72M-N8[J.[L[7PY9^//&NG6:P3QM
M)I?BG7=*NVN-.U*ZMI/2/ ?PD^''PP%VOP^\(:-X36_TKP?H=ZND0/ +G1_
M'ARU\(>"].D#2./LWASPQ96NBZ:BX\JRA1&+L-Y]%HH&VW:[;MM?].WR"BBB
M@044SS%]3_WRW^%'F+ZG_OEO\* 'T4SS%]3_ -\M_A1YB^I_[Y;_  H ?13/
M,7U/_?+?X4>8OJ?^^6_PH ?13/,7U/\ WRW^%'F+ZG_OEO\ "@"!TQ\I/.%(
M;;TP>G7V]>]9=W;;]W\6  %" 9) .[/.><_+@GDGL:VF9&&"3@XZ*PZ'/I4#
MA3QD[<Y4LP3MZM@YR3@=2/84 <!?Z<'#G;R#QG!P3VSGC!ZD9XY]JX?4=&#!
MLQ@L2/F&.Q!QC!Y]3UYYR1S[-<01LK %1GS.HR6(SC'O_//%8-QI\1YVYXR0
M1QW SD#O[]\\ 9H \"N_#P;(\L'<I^503G)Y[G*]CW.?:L5O#N#@H2<<97 S
MTZY..G)_PY]ZGTE3@C .2#A3QQG!QQ[9&1GIQ6:=&C['(]2K#G\A]>G?\ ?)
M>ME?[]P^;]+NS]5L[=+[=#R&U\/%61O+VD$D-@$##<'/3('ZU\L:Q^QCXCU?
MPU\:/AOHOQPOO#_PB^,MS\1=<F\#2_#3P_K>I^&O$_Q*E^WZQ/;>-I/$&FZC
MJ?A2RU^6\UW3_#7]G:7K(GFM].N_&ESI-O=6>H?H9%HZ#!)P,-_"V.&QZ9YZ
MCVK9M=-C0J&"D87D*<C/KQDG&<8S@]>:]7*\ZS+)IU*F75Z=*52K@:\E5PF#
MQD%B<LQD<PR[%4Z>-PV)A1Q>!QD?;X3%T52Q%"<ZJA4Y*LXGSG$7">1<54J%
M'.\)7Q$</2S+#TI87,LTRNK]5SG+ZF5YM@JM?*L=@:V(P&98&HJ.,P.(E6PE
M=T,)5G25;"8>I'\X?'/[!>L_%2T\3ZKXY^-B>(?B+XT\7>$-?\4:KJGPCTJ7
MX5:KX=\"^$O&GA3PKX'G^#=KXVLEETK19/'FO^+;&_O_ ![J%ZGC:2S\02)/
M+IVG16OMOPR_86^#?@#XA^ /BRUOJ7BOXG>!/AIX?^'[>-O$PLKK6_%&M:!I
M.FZ#'\4O$5_'"FHW7Q!NM!T]M N=0-^]B='O;JV>SDNV^VG[.M[2), 'OCE'
M/09'8=_TX]ZUXD10N< ;6!(!7)R,#'4#&>.^*]2MQKQ16P#RO^UZV'R]T<5A
MOJ>!HX7+J'U/&87"X*O@5# 4,+; O"8/#4*>#3^KT:=/]U%2G.<OG,'X2^'>
M"S2&=PX8PN)S:%;+L7''YGB<QS?$+'Y3B\;C\#F?/F>-Q*>:4\9F&*KU,PE%
MUZ\YTU6IN%"C3AX_X;^$2:)\:?B?\8O[?-R_Q%\!_"'P1_PCKZ.(%T4_"K5/
MBUJ2ZI'JPU%WOUU__A:1MY-/_LZR&F?V$KQ7=X-1\NP^*?$/_!->;6_#FH>&
M;+XWOI>GZ7\8-4^+GPVN8?ANECXAT*X\2ZQ\5=7\5:!\0?&GA7QUX4\=_$JS
MO9OB[XB31+RU\4^![C0EM-.,D>K+-K<>L?J&-N<L3Q@C )Y!).< ^W7\.]2^
M8OJ?^^6_PKCR[B7.LIK2KX#%JA5E0R[#N3PV%J?NLJAB*> 48U*7+&=&EB\5
M1=11]I6HXFM"M*;G[:GW9]X<<&\3818'.LH>+PT<1GF*5../S'#MUN(\1@L7
MG$I3H8CGE'%8S+<NQ<*<KPPN)P.%JX7V2I.A7^!?AI^PGI_PU\??"_QKI_Q$
M,]M\,]9\ :K:>'H?"#6EI>P> OV1]=_94MM-AO;CQ7J=U8V]U:ZROC2.:X&J
M7-G]C3PTTEY'*VMI]^TSS%]3_P!\M_A1YB^I_P"^6_PKES3.<QSJK0KYEB%B
M*N&H/"T9*C1H\E!UZF)<.6A3IQE^^K5)\TE*7O<O-RJ*7L<.<+9%PGA,1@>'
M\"L!A<5B5C*U)8C%8A2Q"PU'"*:EBJU:<$L/AZ--4X2C37(I**DVV^BF>8OJ
M?^^6_P */,7U/_?+?X5YA] /HIGF+ZG_ +Y;_"CS%]3_ -\M_A0 ^BF>8OJ?
M^^6_PH\Q?4_]\M_A0 ^BF>8OJ?\ OEO\*/,7U/\ WRW^% #Z*9YB^I_[Y;_"
MCS%]3_WRW^% #Z*9YB^I_P"^6_PH\Q?4_P#?+?X4 /HIGF+ZG_OEO\*/,7U/
M_?+?X4 /HIGF+ZG_ +Y;_"CS%]3_ -\M_A0 ^BF>8OJ?^^6_PH\Q?4_]\M_A
M0 ^BF>8OJ?\ OEO\*/,7U/\ WRW^% #Z*9YB^I_[Y;_"CS%]3_WRW^% #Z*9
MYB^I_P"^6_PH\Q?4_P#?+?X4 /HIGF+ZG_OEO\*/,7U/_?+?X4 /HIGF+ZG_
M +Y;_"CS%]3_ -\M_A0 ^BF>8OJ?^^6_PH\Q?4_]\M_A0 ^BF>8OJ?\ OEO\
M*/,7U/\ WRW^% #Z*9YB^I_[Y;_"CS%]3_WRW^% #Z*9YB^I_P"^6_PH\Q?4
M_P#?+?X4 /HIGF+ZG_OEO\*/,7U/_?+?X4 /HIGF+ZG_ +Y;_"CS%]3_ -\M
M_A0 ^D(!Z@'MR.WI3?,7U/\ WRW^%'F+ZG_OEO\ "@!VU?[H_(>_^)_,T;5_
MNC\AW))_4D_4GUIOF+ZG_OEO\*/,7U/_ 'RW^% #MJ^@_(48'H.W8=CD?D>1
M[\TWS%]3_P!\M_A1YB^I_P"^6_PH <%48PJC P, <#T'M054XRH.#D9 X/J/
M?WIOF+ZG_OEO\*/,7U/_ 'RW^% #Z*9YB^I_[Y;_  H\Q?4_]\M_A0 ^BF>8
MOJ?^^6_PH\Q?4_\ ?+?X4 /HIGF+ZG_OEO\ "B@#-\Q_[QH\Q_[QHHH /,?^
M\:/,?^\:** #S'_O&CS'_O&BB@ \Q_[QH\Q_[QHHH /,?^\:/,?^\:** &R,
MRA2#@L"2>,GH>_N3T]:K.S%E!)(*Y(]P6Q_(444 5R 2V1GYF_\ 0C54 8'
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..T44 'F/_ 'C1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #[ 9@# 2(  A$! Q$!_\0
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MD_Z(G\6_^_GPA_\ GG4 >OT5Y!_PL3Q)_P!$3^+?_?SX0_\ SSJ/^%B>)/\
MHB?Q;_[^?"'_ .>=0!Z_17D'_"Q/$G_1$_BW_P!_/A#_ //.H_X6)XD_Z(G\
M6_\ OY\(?_GG4 >OT5Y!_P +$\2?]$3^+?\ W\^$/_SSJ/\ A8GB3_HB?Q;_
M ._GPA_^>=0!Z_17D'_"Q/$G_1$_BW_W\^$/_P \ZC_A8GB3_HB?Q;_[^?"'
M_P">=0!Z_17D'_"Q/$G_ $1/XM_]_/A#_P#/.H_X6)XD_P"B)_%O_OY\(?\
MYYU 'K]%>0?\+$\2?]$3^+?_ '\^$/\ \\ZC_A8GB3_HB?Q;_P"_GPA_^>=0
M!Z_17D'_  L3Q)_T1/XM_P#?SX0__/.H_P"%B>)/^B)_%O\ [^?"'_YYU 'K
M]%>0?\+$\2?]$3^+?_?SX0__ #SJ/^%B>)/^B)_%O_OY\(?_ )YU 'K]%>0?
M\+$\2?\ 1$_BW_W\^$/_ ,\ZC_A8GB3_ *(G\6_^_GPA_P#GG4 >OT5Y!_PL
M3Q)_T1/XM_\ ?SX0_P#SSJ/^%B>)/^B)_%O_ +^?"'_YYU 'K]%>0?\ "Q/$
MG_1$_BW_ -_/A#_\\ZC_ (6)XD_Z(G\6_P#OY\(?_GG4 >OT5Y!_PL3Q)_T1
M/XM_]_/A#_\ /.H_X6)XD_Z(G\6_^_GPA_\ GG4 >OT5Y!_PL3Q)_P!$3^+?
M_?SX0_\ SSJU? _C=/&$6OQ#PYK7AZ\\,ZP-&U/2O$SZ&^HC43H^B:\#_P 4
M_P"(?%*!/)UR%@3+(2Y95'R!Y0#TJBBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "O(?AY_R.?QT_[*5X=_]4U\):]>KR'X>?\
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M0+?Y[3X8_MC_  >T7Q"VT8 TEOBEX!V^*@. H)7DCKM :@#]O:*_%@?MK_\
M!3WX.AHOVDO^"7VJ?$_1X1LN_&_[$GQK\'_%1SC!)7X6_$ >#?%I)'.=V,#(
MQS70^&O^"W__  3_ !JL?A7XU>//B/\ LB^,)P0?"O[7_P '/B5\ )7)!R?[
M>\>>'(O"@)&,@>*B,<C&<T ?L-17DWPQ^-'PC^,NB6_B;X3?%'P!\3] NK;[
M5:ZM\/O&&A^,M.:/( =7\/33J1D\!B'/(VJ2#7K- !1110!6"X"A>!SQG.?S
MY&.3[U#Y<."0H'3)()[\=:R+R[@M()=1N[B*WM+9?M%S/.,*B@ $GN!N PV!
MC YX.?AGP+^VWX#\7?M2?%O]GM]2\%V>F?#_ .&?PO\ 'FE^,W\::01XHU#Q
MYKGQ"T6?14A5EDC;PV_@5!*SLX<Z[$2C%%6L95\+AE?F46W%-I:\SN[/F;U5
MGK9+97NT=F7Y1FV:X7-,7@\MG-9+3=:<DI.*CS0A)J2BTG><+03YFKR2Y(2D
MOO%XU"%5C!V 9#-M"AB"!DXSN'/? X^D$(2!) 8_+8Y*IO+\@EF^8DX W9YR
M<-MSZ?EY_P %;/BE\1OA1^QMXN\8_"?QSJ7P[\52^-_A)X=M_&>C1Z-)J&B6
M7C7XH>$?#&K3HOB & _N=9E!&-P)4_+C%?$WPV_:<\8_LD?MD>(_A/\ $O\
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MJ'CU2/5URLBF,X#!W&<J&=@Q391UR5$\88\D;./J-PZ ?_JR<5CB<!A<6O\
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MB:Z.IZSXC\0>+?$H7<^N>(=<U^6Z\1:[KI0'+2R9*Y50&.T_D-XS^$\/@O\
MX+I?L?\ CH_M)?$GXQ'XB^ OVR;T_"?Q=XNTC7_#'P)QX+\ _P#$F\#Z#H8\
MSPX&Q@JXRN206&)&_HLK^8N?4_V1;S_@X _9TL/@9\$?^%>_&[3/"'[8_P#P
MT?\ $-/A#_PA1^*^I?\ "#^'QH;?\)RR(/'Q1S(0QW$+ALC<44 _ITHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N,\3^&/#OC/PYK'A7Q3HNG>
M)/#.NZ7J.C^(= U2TCU'3=9TUHS&^EZJLBR*5*.PVN'!)DV@MC/9T4 ?STZM
MX?\ BO\ \$6?$5]XK\#Z3XS^,?\ P2H\4ZRUUXZ^'>G)KGB_XD_L+2ZIYC#Q
MAX'T9HWDUS]G97,DWB_PT@:7P2H:ZMQ-#YGF?NC\//B%X%^+O@?PS\3/AKXJ
MT/Q_X"\<:+I_B/PEXK\,:M'JGAO7M(F;]UJ^BZM#E)87!X*.N3&4.)/."=C/
M;PWMM-;W$,%Q;W%L;6[M+G&&!!!1\JPP0S#H.<,IR!C\,/B1^S=\9O\ @F1X
MT\6_M(?L#>%]5^(_[*/BG6=1\;_M,_L!Z5=;)-#U2,I+K7QH_8_1DV^&O$[@
M ^.?A4 GA+QD 9HA;RH/( /WCHKYW_9U_:-^$?[57PB\,_&SX&>*K7QE\/\
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MQX$_;+LO@]\3M)^*6B>.-2^*NF'P3X!4ZKK/@:+PY%)\/PCJ2BR2M.69E,X
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M-\+_ !W#^"/ .=7\#RZ#XBE\22JD@93+XMCC+(\>+9BLAH _H>HHHH ****
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M?XY_91_9\^%VFZ_\+M2\+V7Q4\)_MP_'S]K/XF6>FKK?ARX\/_#/1!\9(_\
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MDDQ0&WMK< _4O]AC]I3]HT_M(_M0?L.?M@>+O ?Q+^*W[/.B_#'XF>$OC1X
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M.?QT_P"RE>'?_5-?"6@#UZBBB@ HHHH **** "BBB@ HHHH **** /(OCO\
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M^+(_#8#IU_Y%LD#WY^M $7_#R#]@;_H\+X!?^')\*?\ R31_P\@_8&_Z/"^
M7_AR?"G_ ,DUI_\ #NW]@K_HS#]F/_PQ_P -?_F?H_X=V_L%?]&8?LQ_^&/^
M&O\ \S] &9_P\@_8&_Z/"^ 7_AR?"G_R37,:_P#MY?\ !.#Q3'9Q>*?VF_V8
MO$D.FW8N[,:_XT\':H+'4USM,<<K&)& )R0JE\ L'PN.T_X=V_L%?]&6?LN_
M^&2^&O\ \S=?"/[<_P#P2S^ /Q!\%? RQ^!?[%_[.XU7P]^UE\"/&OCQ]+^'
M'PU\,%/A?H&NRGQ[O!BC778TC,6SPUYCB0!\*/*:24 ^X_\ AXW^P-_T>%\
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MPI_\DTO_  \<_8,_Z/!^ ?\ X<KPG_\ 'ZN?\.[?V"O^C+/V7?\ PR7PU_\
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M@#]C'XP?#+Q9X=T=?'WPX\5ZQ)X=UW7]#BC\/_$O_A&-=\>>*/#.MI'\&?\
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8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R G8# 2(  A$! Q$!_\0
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M]!U33M;T;5+6&^TS5](O;;4M,U&RN$$D%Y87]G+-:7EK,A#PW%O+)%(A#([
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M:=6M&.!I8#"YAB<6_84*]>?U?"552H4:M:LZ-*#F_P!)\CU'Y^O2EK\Q[_\
MX*-3:CX@_:S\)_"[]G3XA_$_Q1^S/\/?V:?B%HWABSUK3/"OB/XIV'[1VAZ9
MXCM=.AT?Q1IMG<>!M4\$:/J7VS7;+7C>7LPL-2M4L[.^@@M+C] K[X@^$="T
MJTU/Q=X@\/\ @HSRZ'975GXI\1Z!I<VF:WXBA672O#][/+J;6']LWDI>WLK2
MVN[C^T9HI#ISW<6V1IQF39G@/8K%X65*5=4Y4J4:E&M7<:N%H8RE*6'P]7$5
MX0J8?$4IPG.E&$I.=*,Y5:56G"\NXER3-?K#P&/A6IX5U56KSIU\/A8RH8S$
M8"M&.+Q='"X:I.GBL+6A.%.O*<8>SK3A"A7HU*G;9'3//I17AW_"U_%O_#2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,-F,_S/[]:*_@*_XBT/VW?^C<?V5O\ P%^+G_SQZ/\ B+0_;=_Z-Q_96_\
M 7XN?_/'H_U XG_Z!,-_X7X8/^(K\$_]##%_^&S&?YG]^M%?P%?\1:'[;O\
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MOX"O^(M#]MW_ *-Q_96_\!?BY_\ /'H_XBT/VW?^C<?V5O\ P%^+G_SQZ/\
M4#B?_H$PW_A?A@_XBOP3_P!##%_^&S&?YG]^M%?P%?\ $6A^V[_T;C^RM_X"
M_%S_ .>/1_Q%H?MN_P#1N/[*W_@+\7/_ )X]'^H'$_\ T"8;_P +\,'_ !%?
M@G_H88O_ ,-F,_S/[]:*_@*_XBT/VW?^C<?V5O\ P%^+G_SQZ/\ B+0_;=_Z
M-Q_96_\  7XN?_/'H_U XG_Z!,-_X7X8/^(K\$_]##%_^&S&?YG]^M%?P%?\
M1:/[;O?]G']E;_P%^+?_ ,\>KMU_P=C_ +;=O!IDR_LY_LKL;^PENW!M?BUA
M&CU74]/"+CXCYVE+!).<G<[#.  $^ >)DTOJF&UNE_M^&Z*[_ :\5N"FFUF&
M+LK7_P"$S&:7=EU[G]]%%?P%?\1:'[;O_1N/[*W_ ("_%S_YX]'_ !%H?MN_
M]&X_LK?^ OQ<_P#GCT_]0.)_^@3#?^%^&%_Q%?@G_H88O_PV8S_,_OUHK^ K
M_B+0_;=_Z-Q_96_\!?BY_P#/'H_XBT/VW?\ HW']E;_P%^+G_P \>C_4#B?_
M *!,-_X7X8/^(K\$_P#0PQ?_ (;,9_F?WZT5_ 5_Q%H?MN_]&X_LK?\ @+\7
M/_GCT?\ $6A^V[_T;C^RM_X"_%S_ .>/1_J!Q/\ ] F&_P#"_#!_Q%?@G_H8
M8O\ \-F,_P S^_6BOX"O^(M#]MW_ *-Q_96_\!?BY_\ /'H_XBT/VW?^C<?V
M5O\ P%^+G_SQZ/\ 4#B?_H$PW_A?A@_XBOP3_P!##%_^&S&?YG]^M%?P%?\
M$6A^V[_T;C^RM_X"_%S_ .>/1_Q%H?MN_P#1N/[*W_@+\7/_ )X]'^H'$_\
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M_H(P_P#X%5_^9@^LR_Z!,9_X+H?_ #:?2-%?-W_"+_M??]%R_9N_\14^)_\
M]&31_P (O^U]_P!%R_9N_P#$5/B?_P#1DT>RC_T$8?\ \"J__,P?69?] F,_
M\%T/_FT^D:*^;O\ A%_VOO\ HN7[-W_B*GQ/_P#HR:/^$7_:^_Z+E^S=_P"(
MJ?$__P"C)H]E'_H(P_\ X%5_^9@^LR_Z!,9_X+H?_-I](T5\W?\ "+_M??\
M1<OV;O\ Q%3XG_\ T9-'_"+_ +7W_1<OV;O_ !%3XG__ $9-'LH_]!&'_P#
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M[Y&1GG('^>O-+7I__"D/C9C'_"F/B[@=!_PK+QQ@?^4*C_A2'QM_Z(Q\7?\
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M^&R\<?\ RBH_X4A\;?\ HC'Q=_\ #9>./_E%1]8H?]!%'_P?2_\ EP?4L?\
M] F,_P#";$?_ "D\PK_3F_X-W/\ E#W^R7_UV^/7Z?M)?&&O\VC_ (4A\;?^
MB,?%W_PV7CC_ .45?Z5/_!OGHNL^'O\ @D=^RMHOB'1]6T#6K"X^.J7^CZYI
MM[I&K6+S_M%?%N[@6]TW48+:]M6GM+BWNH5G@C,MM<07$8:&:-V_.?$VK3J9
M)@5"K3FUFM-M0J0FTOJF+U:C4DTKVU:2O;6]C]=\&L/B:7$>8RK4*])/):JC
M*K2JTTW]>P+LG.$4W;6R=[=#])/VG_\ DAOC;_>\,?\ J8^'J]\KP/\ :?\
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M86/@KXA M%(T;$?\)!\+NK*0<<G^E>N5X_XY_P"1]\'?]B7\0_\ T_\ PNH
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MA8:SI4LL46I:9=>5>6,DB)<PQ,Z@_D#\7OV2?VXK[XU_$FZ^!'Q(LO ?P/\
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M@N=7T:\_M?Q)XFODFU_4O::++L%WW?WEG[?J/_/_ 'O_ (&3_P#Q5'V_4?\
MG_O?_ R?_P"*JM119=@N^[^\L_;]1_Y_[W_P,G_^*H^WZC_S_P![_P"!D_\
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M_P# R?\ ^*H^WZC_ ,_][_X&3_\ Q55J*++L%WW?WEG[?J/_ #_WO_@9/_\
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M_P# ;PG_ /,O1_8FI?\ 0W^(O_ ;PG_\R]=%10!SO]B:E_T-_B+_ ,!O"?\
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M/@KX?6UCJ'C77=:@N+^.#18/#6DZC#KVJ6NJSV=_!X<M]4\2?96T+1M7U"Q
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M:1K&FW*@M;WVG7EQ:S $QRL!0!E_\(C<_P#/]!_X#R?_ !VC_A$;G_G^@_\
M >3_ ..UW=% '"?\(C<_\_T'_@/)_P#':/\ A$;G_G^@_P# >3_X[7=T4 <)
M_P (C<_\_P!!_P" \G_QVC_A$;G_ )_H/_ >3_X[7=T4 <)_PB-S_P _T'_@
M/)_\=H_X1&Y_Y_H/_ >3_P".UW=% '"?\(C<_P#/]!_X#R?_ !VN9T#PM/)J
MWCI%O8@8O%EDK$P/@G_A ? W(Q+P,@]<\8/!) ]AKD/#7_(:^(/_ &-]E_Z@
M/@B@"G_PB-S_ ,_T'_@/)_\ ':/^$1N?^?Z#_P !Y/\ X[7=T4 <)_PB-S_S
M_0?^ \G_ ,=H_P"$1N?^?Z#_ ,!Y/_CM=W10!PG_  B-S_S_ $'_ (#R?_':
M/^$1N?\ G^@_\!Y/_CM=W10!PG_"(W/_ #_0?^ \G_QVC_A$;G_G^@_\!Y/_
M ([7=T4 <)_PB-S_ ,_T'_@/)_\ ':/^$1N?^?Z#_P !Y/\ X[7=T4 <)_PB
M-S_S_0?^ \G_ ,=H_P"$1N?^?Z#_ ,!Y/_CM=W10!PG_  B-S_S_ $'_ (#R
M?_':/^$1N?\ G^@_\!Y/_CM=W10!PG_"(W/_ #_0?^ \G_QVC_A$;G_G^@_\
M!Y/_ ([7=T4 <)_PB-S_ ,_T'_@/)_\ ':=X&M38Q^)[5I!*8O%FHY=5*AM]
MCI<HPI+$8#A3R>02.*[FN2\+?\?'B[_L;;W_ -->CT >8?M/_P#)#?&W^]X7
M_P#4Q\/5[Y7@?[3_ /R0WQM_O>%__4Q\/5^;7_!<#XD?#[X??L[_  .D\6^.
M?AKX.\0-^U7\)/$OAB'Q=^U$/V0OB%JNA>#3K5_\61\"?C5<?'?]FS0_"7Q/
M;X5WOBG0+35?&OQC\)>"H])\3ZCIEZOBCQ+K'A+P+XLV?^[T_P#K]6_]-T3F
MC_OE;_L&PW_I[$G[0UP/AK_D<_B1_P!A#PS_ .HQ8UX5X,@^)_Q&_8Y^#;^#
MO&>E:9\2O%'P@^"6K/X\TSQ#XVO-)AO;O0_".J^(O$>BZU\2=$\5>/?$L$EJ
M=1O]&@^)NFW>N^+"]I8_$2=)-3UV:NQ^$GAKQEI<.J:-XL\:W^H>+-'TCP%I
MOB;6+!-*NH=8UNV\'Z>E_J!NM5T WEVTDN(OMLMOI[WPA%]-IUG<W4\*XG2?
M05%<]_8VI_\ 0VZ[_P" GAC_ .9VC^QM3_Z&W7?_  $\,?\ S.T =#17/?V-
MJ?\ T-NN_P#@)X8_^9VC^QM3_P"AMUW_ ,!/#'_S.T =#17/?V-J?_0VZ[_X
M">&/_F=H_L;4_P#H;==_\!/#'_S.T =#17/?V-J?_0VZ[_X">&/_ )G:/[&U
M/_H;==_\!/#'_P SM '0T5SW]C:G_P!#;KO_ (">&/\ YG:/[&U/_H;==_\
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M]_8VI_\ 0VZ[_P" GAC_ .9VC^QM3_Z&W7?_  $\,?\ S.T =#17/?V-J?\
MT-NN_P#@)X8_^9VC^QM3_P"AMUW_ ,!/#'_S.T =#7SW^R__ ,DDC_[*5\>/
M_5\?$NO:;?2]0AGBEE\2:Q=QHVY[:>V\/I#,,$;)&M=$MKA5R0V89XFR!\VW
M(/BW[+__ "22/_LI7QX_]7Q\2ZUC_!K_ /7S#?\ N8Y*G^^87_KSB_\ W5/H
M2BBBLCK"N'U#_DI/A/\ [$?XA?\ I^^&-=Q7#ZA_R4GPG_V(_P 0O_3]\,:
M/E+7OV,UU'Q+^TU;CXB7VK_ ;]KBY\1>(?CK^S[K?AK19X/$_B#Q-^SSIO[.
M/B31/"_Q+A>WUGP/\/O&7A3PQX-\3^)-#70M>\2+\0]$O-<T3QKHWAKQ)XA\
M&ZA\M^#_ /@EOK^H_ GX.>%/BI\>O$%U\8+7X"_$CPK^T1XSL-(TCQ-9?$/X
M^_&SXR_#W]JKXA?%S0(]0L?#NCVUC8?M,^"IM3L_!.O>#]5^'WBCX0:E<?"C
M5O ^F:&;-M.X#QSJO[66O_M@^/8/@3KEUI_BK0?^"HW@+X>ZO?\ BGP_X_\
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M_P"H#X(H Z^BBB@ HHHH **** "OYJ?@)_P7SUG6-#\ ZE^TI\#].\#:K<?
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MK?\ INB<T?\ ?*W_ &#8;_T]B3]'?V?WU:3X#_!-]?LO[-UU_A'\-WUK3O\
MA8&H?%G[!JS>#=&.I67_  M35M7\0ZI\2_LMX9H/^%@:EK^N:AXR\O\ X2.\
MU?4KG4I+V?>\-?\ (Y_$C_L(>&?_ %&+&N;_ &=X? 5O^S_\#+?X5:7'HGPO
M@^#OPRA^&^BQ>(AXOBTCP%%X*T1/!^EQ^+!J_B >*([#P\NG6B>(AKVMC6UB
M&I#5]2^T_;)ND\-?\CG\2/\ L(>&?_48L:Q.D[ZBBB@ HHHH **** "BBB@
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M!$7_ ,71]NLO^?RU_P# B+_XNO(,#T'Y"C ]!^0H ]?^W67_ #^6O_@1%_\
M%UR7AN\M%UGX@%KJV ;Q=9%29X@&'_"!>".1E^1]*XW ]!^0KG=$ _M3QMP/
M^1JLNP_Z$'P+0!] _;K+_G\M?_ B+_XNC[=9?\_EK_X$1?\ Q=>08'H/R%&!
MZ#\A0!Z_]NLO^?RU_P# B+_XNC[=9?\ /Y:_^!$7_P 77D&!Z#\A1@>@_(4
M>O\ VZR_Y_+7_P "(O\ XNC[=9?\_EK_ .!$7_Q=>08'H/R%&!Z#\A0!Z_\
M;K+_ )_+7_P(B_\ BZ/MUE_S^6O_ ($1?_%UY$L9=E1$+NS!555W,S,<*JJ
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M71E=&\6WN&1@RG&F:0#AE)!P00<'@@@\@BN%P/0?D*Z7X<?\>'B'_L;-4_\
M2;3Z .'_ &G_ /DAOC;_ 'O"_P#ZF/AZOS!_X+@_%;X/:'\%?@]\%OB+\2_V
M4O!'B+XB_&;X9?$70?"O[8NM>%?!OPJ^*O@KX6?&SX,>$/B-X-LOB7XI^&?Q
MD?X6>(1+\;/!NHZA\1_"WPR\2>+_  7\/8/'?B+2;[P5#IU[X]\,?I]^T_\
M\D-\;?[WA?\ ]3'P]7Q]_P %5/VC8_V=/@?X(U/3OBM\)OA5XM\;?$VU\+Z/
M?_$'7_V?O#_C'6-%LO"GBGQ5XCT[X07?[4WB_P !?L^IXK230-$G\2S_ !7\
M8>'O#T?PY'C"U\.7MU\5;[X;:+JVS_W>G_U^K?\ INB<T?\ ?*W_ &#8;_T]
MB3ZM\ ^&?'$'[,?P6\,^ _B/X"O_ !5H_@#X$VW_  LCP-X?\+:;\-/%VC>'
MX_!4OC#4_ _AO0M&U+PEHO@_Q[X4L-<M_"&G^&M,ATK1-+US3$\.3Z3#9V-_
M9Z'PHT7Q_:Q:G8>-_%\=_P".=.T3X>V/C76=)L=)?3]=\56O@K3(M<UFU4Z#
MHT4<.HWPDN$BM=$T2T12#;:1I\;?9DZ[X'>*-9\;_!3X/^-/$<OA*?Q#XN^%
MOP_\4:]-X!M]?M/ LVLZ_P"$](U75)?!5KXKM;'Q3;>$I+Z[G?PY;^);*SU^
M'1S9QZQ:V^HK<PIJ>&O^1S^)'_80\,_^HQ8UB=)N_P!E:U_T-%[_ ."W1O\
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M_P"0J/[*UK_H:+W_ ,%NC?\ R%70T4 <]_96M?\ 0T7O_@MT;_Y"H_LK6O\
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M]:U?GXK^!-=_9*U3XG?&PZ_XA\-OJ'BS6OBKX$^$GC7X$ZA!XDC@OTTCX?\
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M(W/_ #^P?]^I/_BJ .2HKK?^$1N?^?V#_OU)_P#%4?\ "(W/_/[!_P!^I/\
MXJ@#DJ*ZW_A$;G_G]@_[]2?_ !5'_"(W/_/[!_WZD_\ BJ .2HKK?^$1N?\
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M'_Y.H_L_Q'_T,=O_ .".'_Y.H Z*BN=_L_Q'_P!#';_^".'_ .3J/[/\1_\
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MBWX\M=*^$&EI8_#E8M6LS-X;FE\/^'9-* .8_::_X*.^"OV9OB;\9OA9X@\
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M]FWX)0>!M!\2IJGAKPS)X%@N=*T>VN-=\4RZZ =Q^S!^VO\ LX?MB6WB6Z^
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M$'@#P^-*N;GP0]]J;^#;B>Q\B6;PJVI:@WAZ1VTAKZ[-F9Y.W\-?\CG\2/\
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MTOB_X2_"WQ7)K7P_\.>T4 7/[1U+_H(WW_@5-_\ %4?VCJ7_ $$;[_P*F_\
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MV[M)--OM&L8;>YOO,D6TM+/[+:MNBM;BY@$<K?05<#X:_P"1S^)'_80\,_\
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M7KA<O3^[^WF?B+^D_P#1[7_-WN"WZ8W,7^/^KR_(_;;[)XH_Z#FC?^$Y=_\
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M,<PIX+B'$Y_0QM3#5LJR6A3Q-.&59-F.'>&J5,-5IPE.O&LZM*JG2C!0E/\
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MB_\ DRO=Z* /"/M&J_\ 0I^*_P#P5Q?_ "91]HU7_H4_%?\ X*XO_DRO=Z*
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MUL9?,,;F:?1=10HKQ^0&=98^#_9?_P"221_]E*^/'_J^/B76L?X-?_KYA_\
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M.WB'PW=^*/BU\4?!7Q2C^)^@:+^PQ_PCW@+PS^T5^S^OAWX,>&?AK8^*S?\
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M*_$-]XC@@^#GCCXC>-KKP,NE&V\,:Y_P@%WX0TZP^ZJ "BBB@ HHHH ****
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M 6;QH/C1;_&GQ5X"U#]GWP0/ASXH\0>%O$5;?A;_ (*2?\% /B5=:/XBM_\
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M[/?[;NJ7;#^WXX[:3P)JOP#MOA[9($G/B"Q\3W'B6YETN\TM-*O_ )0_9_\
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MK_HJ?[/O_A@OB-_]$G1_87[57_14_P!GW_PP7Q&_^B3H]DO^?]#_ ,#J?_*
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M_#!?$;_Z).C^POVJO^BI_L^_^&"^(W_T2='LE_S_ *'_ ('4_P#E ?6G_P!
MN,_\%4?_ )L/H'!]3^G^%&#ZG]/\*^?O["_:J_Z*G^S[_P"&"^(W_P!$G1_8
M7[57_14_V??_  P7Q&_^B3H]DO\ G_0_\#J?_* ^M/\ Z!<9_P""J/\ \V'T
M#@^I_3_"C!]3^G^%?/W]A?M5?]%3_9]_\,%\1O\ Z).C^POVJO\ HJ?[/O\
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M*^??["_:J_Z*G^S[_P"&"^(W_P!$G1_87[57_14_V??_  P7Q&_^B3H]DO\
MG_0_\#J?_* ^M/\ Z!<9_P""J/\ \V'O#V-E)>6^HR6=K)J%G;W=I:7SV\3W
MEK:W\EI+?6UO<LAG@M[R6PL9+N&)UCN)+*T>97:VA*6J^??["_:J_P"BI_L^
M_P#A@OB-_P#1)T?V%^U5_P!%3_9]_P##!?$;_P"B3H]DO^?]#_P.I_\ * ^M
M/_H%QG_@JC_\V'T%28/J?T_PKY^_L+]JK_HJ?[/O_A@OB-_]$G1_87[57_14
M_P!GW_PP7Q&_^B3H]DO^?]#_ ,#J?_* ^M/_ *!<9_X*H_\ S8?0.#ZG]/\
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MVB^.-0TOQ)XF\!1"_P#$/]DPGPCXOT?2K^XN+_ZCF_9D_9;N?AN/@W<?LT_
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M+A5IU+KF]R<9J+C*/-_9M_Q$&_\ !,O_ *+!\1?_  R7Q/\ _E'1_P 1!O\
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MA&K)2E&+DKMVDX?W;_\ $0=_P3+_ .BP?$3_ ,,C\3O_ )14?\1!O_!,L_\
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M$E)4*,74K14_:4HV]I2BY04_[B_^(@__ ()E_P#18/B+_P"&0^)W_P HJ/\
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MQU_(]_P=%D_\*R_8V&>!\1/C1@>G_%+_  YK]!\-/^2OR-]JU?\ '+\;_P
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M-7[*_P +/$?P<\'>./#7C#2/ NJ:MH'PW\7>#O$37?CCX273:]K$7B[3M/\
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M>V^M1:'=^#+*Y\%W-M"RW4VO7.^6"31Y)9A]-Z[_ ,%%OA;XC_: ^'GQYN-
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M-PIQI7^J.K[##2S&O1G&G6S*5*5#!RIXO#0K34H0E4P^&E5KN>$J0]:\>_\
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M2I#'U,35J2>7X95*$\7"I2KO!RU6$4L/6KX:"I4VJ5"O6A1C3E/VD6O]QO\
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M$R:=/&49R^KTZN+IX-8;$4L-+$8S%NK3JSJRG@Y3PG)(^3=3_P"">W[1MM\
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MP_"/X@>#?#6K_;+>*]FUG0SK^C:&/%UE9VEU8W$YT&YG7RM0T^66>*&[AE;
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MHVVB";_ALW]HEKZ6XD\4^!9]&G\+Q^#IOAW=? +]GBZ^"=QHL/BB[\;Q33_
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M:9^SIXG\-_$WQYXO\3>.OV;M6_9:^.=GJ_C']J;2+_XF:E;_  Y^*TGQ F^
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MTG*A4E3IU,-&-&<9N5+#UE#F=*E^8OAWX\?%GPQ\6?$'QQT[Q9'>?%'Q=?\
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M\3OA?XYM/V7->^&_Q(_X*#?MM^-]*USP=X_UO^P_AQ\)?'?P ^%]Q\(/BO\
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MU?$R]G3]C*K4^#**0>_O_G_/3WI:^C/B0HHHH :_W&_W6_D:_P!.G_@GX?\
MC"_]C\?]6O? '_U5?A8_R.:_S%9/N-]#7^G=_P $_P!"/V+/V/3_ 'OV7?V?
MSR..?A1X4&2>.A<<C. .YQ7X_P",7_(JR==\?B[?^$4#^@_H]IO/.(;?]"O
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MQOR>O_%,1<_C]M_I7^E4?"V ?W()/I^/&#@<9.#G//'>F_\ "+'_ )X']/\
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M1_PBQ_YX']/_ (JC_B,>:?\ 0MRJW7W\<O\ W(/_ (E\R3_H;YS_ . Y?_\
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M7_!1C_HS?XY?^$O'_P#)5?Z5?_"+#_GB?S'^%'_"+#_GB?S'^%'_ !&+,_\
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MXSO_ , R_P#^4G^:K_PZS_X*+_\ 1FOQP_\ "73MT_Y>^U'_  ZS_P""B_\
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M.S_*>!X63J0<<F\V@^F< 'D],U_H8?L=?#SQ/\-/V6_V9_AUXVTPZ+XS\!?
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G.O?H***BILO7]#:GNO\ MS_VXGB_C/?=C/MZ4445D=*V7HOR1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %G 5X# 2(  A$! Q$!_\0
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MX;,_95_Z. ^%/_A8:;_\70!]-45\R_\ #9G[*O\ T<!\*?\ PL--_P#BZ/\
MALS]E7_HX#X4_P#A8:;_ /%T ?35%?,O_#9G[*O_ $<!\*?_  L--_\ BZ/^
M&S/V5?\ HX#X4_\ A8:;_P#%T ?35%?,O_#9G[*O_1P'PI_\+#3?_BZ/^&S/
MV5?^C@/A3_X6&F__ != 'TU17S+_ ,-F?LJ_]' ?"G_PL--_^+H_X;,_95_Z
M. ^%/_A8:;_\70!]-45\R_\ #9G[*O\ T<!\*?\ PL--_P#BZ/\ ALS]E7_H
MX#X4_P#A8:;_ /%T ?35%?,O_#9G[*O_ $<!\*?_  L--_\ BZ/^&S/V5?\
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MM*="I)1>K3W@YQ3E'YIO/^3P]"_[-G\:?^K4\%5].5\QWG_)X>A?]FS^-/\
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MVM&L+:WMX(X(((M+N$@@@MXXXH8(52^$:Q0QA8XECP@1<*-J\7,:C_S\V?\
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M>BU]2U\M?MK_ /)K?QA_[ &G_P#J1Z+0!]1)U?\ WS_):?3$ZO\ [Y_DM/H
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MU6F^CJ593]:DNR&O]TX&3D#'U(';->:_$OP'I_Q'\':GX<U%OL\TD:7.D:B
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MFM_&'_L :?\ ^I'HM?4M?+7[:_\ R:W\8?\ L :?_P"I'HM 'U$G5_\ ?/\
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M8\ U-PHY. !U)_F37RM^U=XOU:U\$:9\,?!\P_X3OXT:[#X T#RBQFL--NV
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M!((#*2"I(8$ \$$$'/0BG!E/ (/T(/3@_D>OIWI77==/QV^_IWZ7.\^9+O\
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MB3\*_AYK6H66A?#[XC_$_P 5>&_%.L>#O"6H:'?SZSK>H>%>Y\4?\%,OV;?
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ME3JRPV=48T<GS3ECAJ57&5\JQ^)2I8&I(^J(Y(WP%?<1\W.,G(8!C@ <KD]
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M+]WM+N8PW&B:HF?M.CZ[;MYFFZA \?[Q#'.!',8V5FM9KB-75G!'YR_L^_\
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MHNG_ !;L[[[1\4?"/BK2/BM*?$&D?$O2M:?]PS&F[<Q?*+D,7;@,""5(.02
M02,,1QFE$:?,07.\JYW.[ G:%!PY( PHX  R-Q&XEC;FKKX;I./JY1:U5]7R
M[=M_,E1=I*3OS-?]NI34UR]M8J^][M;-)2#)Y]0/ZG^M+114I62796+V_'\=
M0Z5^!VK?M*_"SP5X<_:Z^!G[9/Q4_;E\%_M+_$7]H#XQ:UX/\,_"72_VKH_'
MNJ?#G1OB9K$/[($G[",OP-\.7GA'7_#=Q\'-$^$Y\4>'?AT^KZ?XR^*,OQ&\
M/_M2Z)K>J:G\0="F_?$]#_3K^%?F1^V;^W/XF_9'^(W@O0M \-?"_P".,?BC
MP9)K:_LU^#?'/CD_MT>)Y[76[ZSN_$GP*^"?A+X;_$?2_BSX7GM88],V^+M3
M^"WAG0M:L-2GU3XH&.>/3;,:NFKM7BXW6C5^J=G9]OR&G:VVDHR_\!OH_P"Z
M[^\NMEJNOV+^S1<_%^^_9W^!=[^T':167Q[O?@U\,+OXUVEO#I%O#;?%BX\&
M:/+\0K9(?#\DN@0M!XL?5HY8-"EET6"17BTF:73EM7.5^U3XC^(7@O\ 9Q^.
M'C;X5>(O#WA+QYX-^%?CKQCX>U[Q1X4;QIHNGW?A7PYJ&O.9/#D7B+PO]KO9
M[>PFM]-N;K4[G3-.OWM]1U31/$%A:SZ)J-C]G?\ :!\+_M"^%-;U[1?"?Q,^
M'/B7PEKUOX3^(OPO^,?@R[\"_$GX=>+;CPOX<\:6_A[Q+I37>K:%?RR^%/%W
MAK5[77_!?B/Q7X0U2VU)!IGB.^N;:_AM/<;W3[/4K.YL=0M+:^L[RUN;.[LK
MR&.YM+NTNXFAN;6[M9E>WN;:YA=X9X)TDBEA>2*16CD=23T<W:S<N9QCI:[3
MY4M;*VB6NG4S@N5P2;:4.6[U3MHF]KO=MZ:W/G?XF?M#Z+\([/X8?\)%IFLZ
MU/\ $BWBL--GT2;04BM-88>'8XK_ ,2_;M0T]?#O@R2;7XEU?Q_.G_"(>%KN
M32M&U>ZM]<\5^#M,UGR']IGXS?&;X1_$#Q#<>%]=\+ZGX1L?V'OVO_C)X<\
MOX*GEUN[^*_P.U+X&MX<U77/%9\27$^L:#-;?$"\TRU\):%X8\-O#+=ZC=:M
MKOB*>70;?1?NAK"R>,PO:0-$;9K(HT4;1FS=55[1D92IMG5562W*F%U4!E(
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M  93?_*:C?JW_/K8_P#@RF_^4U:5%,#-WZM_SZV/_@RF_P#E-1OU;_GUL?\
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MOG:ZMI2??*N7Q2U3UZ;?)]4135H):]=_70****DL*^6OVU_^36_C#_V -/\
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MOVU7$QI83#3J2_*+_@D#^UIX[\;_ +/OQ/\ $'QT^(7QA^,UAI'[37Q&\*^
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M;6M /@I-)M7Z^ZO)MJTGO[JL[[>J*CUZ65][723O%?WGTWVV?3])?V4-)N=
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M5\/\K6]_6^B>G70S_P"Q=/\ ^?9>_P#RVN<<G/ \W &3T'%']BZ?_P ^R_\
M?ZY_^.UK45QFAD_V+I__ #[+_P!_KG_X[1_8NG_\^R_]_KG_ ..UK44 9/\
M8NG_ //LO_?ZY_\ CM']BZ?_ ,^R_P#?ZY_^.UK44 9/]BZ?_P ^R_\ ?ZY_
M^.T?V+I__/LO_?ZY_P#CM:U% &3_ &+I_P#S[+_W^N?_ ([1_8NG_P#/LO\
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M]M?_ )-;^,/_ & -/_\ 4CT6OJ6OEK]M?_DUOXP_]@#3_P#U(]%H ^HDZO\
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M'[;\:?VLM7^%.D2R!_&GC[PWX0U"6 L9+#P1\/;:WU'Q?=QJ9,!(-2TZVDD
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M%U 'V?17QA_PS%\>/^DBO[6?_ANOV"?_ *"ZO*_CG^SS^VGH'P8^*^M_ /\
M;L_:-\;_ !QTGX>>+M0^#_@_QIX%_8,L/"'B?XEVFAWLW@O0?%%['^R7X7DM
M- U;Q EA8ZK<Q^(]#D@LIYIEU.T*>8 #](Z*^(M+_9G_ &AI],TZ;5/^"AO[
M5EIJDMA9R:G:VOP[_8*:UMM2:WC-_!;$_L:W1\B*[,T<(:ZN6$:J&N9V!E>]
M_P ,Q?'C_I(K^UG_ .&Z_8)_^@NH ^SZ*^,/^&8OCQ_TD5_:S_\ #=?L$_\
MT%U>5:9^SW^VG-\</'.A:K^W;^T;:_ 6P^%/PKU3P!XRMO G[!C>,=:^,&J^
M+?C!9_%_PQK%FW[)4Z1>&/#/@W0_@KJ_AJX3PSI;W&L>,/%\+Z_KR6,>F>&@
M#])**^,/^&8OCQ_TD5_:S_\ #=?L$_\ T%U'_#,7QX_Z2*_M9_\ ANOV"?\
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M8M)OO2)$$B,A (88P<@'N <<X)'/MV/2ORS^+'P7^(6E?$KQ;<:?X%\0^/\
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DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>tvgn-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeNCbP9z5Z8eekhvWBybWm63y8pDHk05S8TtRx24dgO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:TVGN="http://tevogen.com/20240331" elementFormDefault="qualified" targetNamespace="http://tevogen.com/20240331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://tevogen.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" id="DescriptionOfOrganizationBusinessOperationsAndLiquidity">
          <link:definition>00000007 - Disclosure - Description of Organization, Business Operations and Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" id="InitialPublicOfferingAndOver-allotment">
          <link:definition>00000009 - Disclosure - Initial Public Offering and Over-Allotment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PrivatePlacementWarrants" id="PrivatePlacementWarrants">
          <link:definition>00000010 - Disclosure - Private Placement Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000011 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ShareholdersDeficit" id="ShareholdersDeficit">
          <link:definition>00000013 - Disclosure - Shareholders&#8217; Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/WarrantLiabilities" id="WarrantLiabilities">
          <link:definition>00000014 - Disclosure - Warrant Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>00000015 - Disclosure - Fair Value Measurements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000016 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NatureOfBusiness" id="NatureOfBusiness">
          <link:definition>00000017 - Disclosure - NATURE OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" id="Development-stageRisksAndLiquidity">
          <link:definition>00000018 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" id="SummaryOfSignificantAccountingPoliciesDisclosure">
          <link:definition>00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombination" id="BusinessCombination">
          <link:definition>00000020 - Disclosure - BUSINESS COMBINATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/EarnoutShares" id="EarnoutShares">
          <link:definition>00000021 - Disclosure - EARNOUT SHARES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
          <link:definition>00000022 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NotesPayable" id="NotesPayable">
          <link:definition>00000023 - Disclosure - NOTES PAYABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>00000024 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficit" id="StockholdersDeficit">
          <link:definition>00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" id="RelatedPartyTransactionsDisclosure">
          <link:definition>00000026 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetIncomeLossPerShare" id="NetIncomeLossPerShare">
          <link:definition>00000027 - Disclosure - NET INCOME (LOSS) PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEventsDisclosure" id="SubsequentEventsDisclosure">
          <link:definition>00000028 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" id="SummaryOfSignificantAccountingPoliciesPoliciesDisclosure">
          <link:definition>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000031 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>00000032 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>00000033 - Disclosure - Fair Value Measurements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" id="SummaryOfSignificantAccountingPoliciesTablesDisclosure">
          <link:definition>00000034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombinationTables" id="BusinessCombinationTables">
          <link:definition>00000035 - Disclosure - BUSINESS COMBINATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
          <link:definition>00000036 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficitTables" id="StockholdersDeficitTables">
          <link:definition>00000038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetIncomeLossPerShareTables" id="NetIncomeLossPerShareTables">
          <link:definition>00000039 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" id="DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative">
          <link:definition>00000040 - Disclosure - Description of Organization, Business Operations and Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" id="ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails">
          <link:definition>00000041 - Disclosure - Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" id="ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails">
          <link:definition>00000042 - Disclosure - Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" id="InitialPublicOfferingAndOver-allotmentDetailsNarrative">
          <link:definition>00000044 - Disclosure - Initial Public Offering and Over-Allotment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" id="PrivatePlacementWarrantsDetailsNarrative">
          <link:definition>00000045 - Disclosure - Private Placement Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" id="ScheduleOfFairValueNonRedeemableSharesDetails">
          <link:definition>00000046 - Disclosure - Schedule of Fair Value Non Redeemable Shares (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000047 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000048 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" id="ShareholdersDeficitDetailsNarrative">
          <link:definition>00000049 - Disclosure - Shareholders&#8217; Deficit (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" id="WarrantLiabilitiesDetailsNarrative">
          <link:definition>00000050 - Disclosure - Warrant Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>00000051 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" id="ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails">
          <link:definition>00000052 - Disclosure - Schedule of Quantitative Information in Fair Value Measurements (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000053 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
          <link:definition>00000054 - Disclosure - NATURE OF BUSINESS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" id="Development-stageRisksAndLiquidityDetailsNarrative">
          <link:definition>00000055 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" id="ScheduleOfFairValueMeasurementDetails">
          <link:definition>00000056 - Disclosure - Schedule of Fair Value Measurement (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" id="ScheduleOfFairValuesOfWarrantsDetails">
          <link:definition>00000057 - Disclosure - Schedule of Fair Values Of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" id="SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure">
          <link:definition>00000058 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" id="ScheduleOfNetLiabilitiesAcquiredInMergerDetails">
          <link:definition>00000059 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" id="BusinessCombinationDetailsNarrative">
          <link:definition>00000060 - Disclosure - BUSINESS COMBINATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" id="EarnoutSharesDetailsNarrative">
          <link:definition>00000061 - Disclosure - EARNOUT SHARES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
          <link:definition>00000062 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
          <link:definition>00000063 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" id="ScheduleOfRestrictedStockAndRsuActivityDetails">
          <link:definition>00000064 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>00000065 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>00000066 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" id="ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails">
          <link:definition>00000067 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" id="StockholdersDeficitDetailsNarrative">
          <link:definition>00000068 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" id="RelatedPartyTransactionsDetailsNarrativeDisclosure">
          <link:definition>00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" id="ScheduleOfNetLossPerShareDetails">
          <link:definition>00000070 - Disclosure - SCHEDULE OF NET LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" id="ScheduleOfAnti-dilutiveNetLossPerShareDetails">
          <link:definition>00000071 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" id="ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical">
          <link:definition>00000072 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="TVGN_ReverseRecapitalizationMember" name="ReverseRecapitalizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonClassaNotSubjectToRedemptionMember" name="CommonClassaNotSubjectToRedemptionMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorMember" name="SponsorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FeeReductionAgreementMember" name="FeeReductionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FirstExtensionCharterAmendmentMember" name="FirstExtensionCharterAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicSharesMember" name="PublicSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SecondExtensionCharterAmendmentMember" name="SecondExtensionCharterAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SsvkAssociatesLlcMember" name="SsvkAssociatesLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicWarrantsMember" name="PublicWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CantorMember" name="CantorMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FounderSharesMember" name="FounderSharesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NonRedeemableOrdinaryMember" name="NonRedeemableOrdinaryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicWarrantsTransferredTwoMember" name="PublicWarrantsTransferredTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicWarrantsTransferredThreeMember" name="PublicWarrantsTransferredThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicWarrantsTransferredOneMember" name="PublicWarrantsTransferredOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PromissoryNoteWithRelatedPartyMember" name="PromissoryNoteWithRelatedPartyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SubscriptionAgreementMember" name="SubscriptionAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeSPACMember" name="DeSPACMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SecondSubscriptionAgreementMember" name="SecondSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FirstPolarFundConvertibleNoteMember" name="FirstPolarFundConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SecondPolarFundConvertibleNoteMember" name="SecondPolarFundConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RelatedPartyLoansMember" name="RelatedPartyLoansMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WorkingCapitalLoansWarrantMember" name="WorkingCapitalLoansWarrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AdministrativeSupportAgreementMember" name="AdministrativeSupportAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TevogenBioMember" name="TevogenBioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorAdvisoryServiceFeeMember" name="SponsorAdvisoryServiceFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SemperParatusMember" name="SemperParatusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesMember" name="EarnoutSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TevogenBioCommonStockMember" name="TevogenBioCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorsMember" name="SponsorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TwentyTwentyFourPlanMember" name="TwentyTwentyFourPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IncentivePlanMember" name="IncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PerformanceBasedRSUsMember" name="PerformanceBasedRSUsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ServiceBasedRestrictedStockMember" name="ServiceBasedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorAdvisoryServicesFeeMember" name="SponsorAdvisoryServicesFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PolarNotesMember" name="PolarNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivateWarrantsMember" name="PrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTransactionCosts" name="DeferredTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredOfferingCostsNoncurrent" name="DeferredOfferingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassAOrdinaryShares" name="ClassAOrdinaryShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassBOrdinaryShares" name="ClassBOrdinaryShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TransactionCosts" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" name="ChangeInFairValueOfConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ImpairmentOfAmountDueFromRelatedParty" name="ImpairmentOfAmountDueFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AccretionOfCarryingValueToRedemptionValue" name="AccretionOfCarryingValueToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" name="StockIssuedDuringPeriodValueNewIssuesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" name="StockIssuedDuringPeriodSharesNewIssuesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NoncashInterestExpenses" name="NoncashInterestExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ExtensionAmountDepositedIntoTrustAccount" name="ExtensionAmountDepositedIntoTrustAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" name="ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" name="ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SaleOfClassBSharesToInvestor" name="SaleOfClassBSharesToInvestor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SaleOfWarrants" name="SaleOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LossOnPreferredStockIssuance" name="LossOnPreferredStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" name="CashAcquiredInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" name="NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" name="ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" name="IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract" name="DisclosureInitialPublicOfferingAndOverallotmentAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_InitialPublicOfferingTextBlock" name="InitialPublicOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosurePrivatePlacementWarrantsAbstract" name="DisclosurePrivatePlacementWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivatePlacementTextBlock" name="PrivatePlacementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureWarrantLiabilitiesAbstract" name="DisclosureWarrantLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantLiabilitiesDisclosureTextBlock" name="WarrantLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" name="DisclosureDevelopmentstageRisksAndLiquidityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" name="DevelopmentStageRisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureEarnoutSharesAbstract" name="DisclosureEarnoutSharesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesDisclosureTextBlock" name="EarnoutSharesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock" name="EmergingGrowthCompanyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock" name="AssetsHeldInTrustAccountPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" name="OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TemporaryEquityPolicyPolicyTextBlock" name="TemporaryEquityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock" name="WarrantLiabilitiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" name="ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_UnitsIssuedDuringPeriodSharesNewIssues" name="UnitsIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SaleOfStockUnderwritingFees" name="SaleOfStockUnderwritingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SaleOfStockOtherOfferingCosts" name="SaleOfStockOtherOfferingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredOfferingCostsNoncurrentForfeited" name="DeferredOfferingCostsNoncurrentForfeited" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PaymentsForInvestmentOfCashInTrustAccount" name="PaymentsForInvestmentOfCashInTrustAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" name="ConditionForFutureBusinessCombinationUseOfProceedsPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" name="ConditionForFutureBusinessCombinationThresholdPercentageOwnership" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" name="ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" name="ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RedemptionLimitPercentageWithoutPriorConsent" name="RedemptionLimitPercentageWithoutPriorConsent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" name="PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MaximumAllowedDissolutionExpenses" name="MaximumAllowedDissolutionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TemporaryEquityRedemptionAmount" name="TemporaryEquityRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_UnitsIssuedDuringPeriodSharesNewIssue" name="UnitsIssuedDuringPeriodSharesNewIssue" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NumberOfSharesIssuedPerUnit" name="NumberOfSharesIssuedPerUnit" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NumberOfWarrantsIssuedPerUnit" name="NumberOfWarrantsIssuedPerUnit" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" name="ClassOfWarrantOrRightPriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockPriceOfMeasurement" name="StockPriceOfMeasurement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ProbabilityOfTransactionPercentage" name="ProbabilityOfTransactionPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AggregateNumberOfSharesOwned" name="AggregateNumberOfSharesOwned" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NumberOfSharesSubjectToForfeiture" name="NumberOfSharesSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" name="RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" name="ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AggregatePurchasePrice" name="AggregatePurchasePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" name="MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_InitialCapitalContribution" name="InitialCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_InitialCapitalContributionPerShare" name="InitialCapitalContributionPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConvertibleNotesPayableDiscounts" name="ConvertibleNotesPayableDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MaximumLoansConvertibleIntoWarrants" name="MaximumLoansConvertibleIntoWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WorkingCapitalLoan" name="WorkingCapitalLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_UnderwritingOptionPeriod" name="UnderwritingOptionPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_UnderwritingCashDiscountPerUnit" name="UnderwritingCashDiscountPerUnit" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PaymentOfUnderwriterDiscount" name="PaymentOfUnderwriterDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AggregateUnderwriterCashDiscount" name="AggregateUnderwriterCashDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredFeePerUnit" name="DeferredFeePerUnit" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredUnderwritingFeePayable" name="DeferredUnderwritingFeePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AggregateDeferredUnderwritingFeePayable" name="AggregateDeferredUnderwritingFeePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_UnderwriterCashDiscount" name="UnderwriterCashDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" name="MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" name="NumberOfSharesIssuableForEach10InitialCapitalContribution" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" name="AmountOfInitialCapitalConsideredToIssueOneShare" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" name="MinimumPeriodForPaymentInCaseOfLiquidation" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MaximumReasonableAttorneyFees" name="MaximumReasonableAttorneyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonStockNumberOfVotesPerShare" name="CommonStockNumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConvertibleStocksConversionRatio" name="ConvertibleStocksConversionRatio" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantExercisePeriodConditionOne" name="WarrantExercisePeriodConditionOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" name="WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RedemptionPeriod" name="RedemptionPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantRedemptionConditionMinimumSharePrice" name="WarrantRedemptionConditionMinimumSharePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" name="ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" name="SharePriceTriggerUsedToMeasureDilutionOfWarrants" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" name="PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" name="TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" name="ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_OffsetValue" name="OffsetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ServicesFees" name="ServicesFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ExchangeRatio" name="ExchangeRatio" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PercentageOfProbabilityOfLiquidityEvent" name="PercentageOfProbabilityOfLiquidityEvent" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RangeInYears" name="RangeInYears" nillable="true" xbrli:periodType="instant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" name="PlusMergerTransactionCostsLimitedToCashAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" name="TotalNetLiabilitiesAcquiredPlusTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TransactionCost" name="TransactionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesTradingDaysDescription" name="EarnoutSharesTradingDaysDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AccruedProfessionalServiceFeesCurrent" name="AccruedProfessionalServiceFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SharesToBeIssuedOnSharesIssuable" name="SharesToBeIssuedOnSharesIssuable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" name="VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" name="SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" name="CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" name="StockIssuedDuringPeriodSharesConversionOfLiabilities" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" name="StockIssuedDuringPeriodValueConversionOfLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsDescription" name="WarrantsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WorkingCapitalExpenses" name="WorkingCapitalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConvertiblePromissoryNoteInterest" name="ConvertiblePromissoryNoteInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ConvertiblePromissoryNoteChangeInFairValue" name="ConvertiblePromissoryNoteChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" name="WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SaleOfStockTransactionCostsAllocatedToWarrants" name="SaleOfStockTransactionCostsAllocatedToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IncreaseDecreaseInDueFromSponsor" name="IncreaseDecreaseInDueFromSponsor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SriramaAssociatesLLCMember" name="SriramaAssociatesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CharterAmendmentMember" name="CharterAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>tvgn-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20240331.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfCashFlows" xlink:href="tvgn-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:href="tvgn-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" xlink:href="tvgn-20240331.xsd#InitialPublicOfferingAndOver-allotment" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PrivatePlacementWarrants" xlink:href="tvgn-20240331.xsd#PrivatePlacementWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ShareholdersDeficit" xlink:href="tvgn-20240331.xsd#ShareholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/WarrantLiabilities" xlink:href="tvgn-20240331.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/FairValueMeasurements" xlink:href="tvgn-20240331.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20240331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20240331.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20240331.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20240331.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20240331.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20240331.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NotesPayable" xlink:href="tvgn-20240331.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20240331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20240331.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetIncomeLossPerShare" xlink:href="tvgn-20240331.xsd#NetIncomeLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDisclosure" xlink:href="tvgn-20240331.xsd#SubsequentEventsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsTables" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/FairValueMeasurementsTables" xlink:href="tvgn-20240331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20240331.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20240331.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20240331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20240331.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetIncomeLossPerShareTables" xlink:href="tvgn-20240331.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:href="tvgn-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:href="tvgn-20240331.xsd#InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" xlink:href="tvgn-20240331.xsd#PrivatePlacementWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValueNonRedeemableSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="tvgn-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" xlink:href="tvgn-20240331.xsd#ShareholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="tvgn-20240331.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20240331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20240331.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20240331.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20240331.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20240331.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NotesPayableDetailsNarrative" xlink:href="tvgn-20240331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20240331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20240331.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20240331.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredTransactionCosts" xlink:label="loc_TVGNDeferredTransactionCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_TVGNDeferredTransactionCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaapAssetsHeldInTrustNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsHeldInTrustNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassAOrdinaryShares" xlink:label="loc_TVGNClassAOrdinaryShares" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_TVGNClassAOrdinaryShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassBOrdinaryShares" xlink:label="loc_TVGNClassBOrdinaryShares" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_TVGNClassBOrdinaryShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_TVGNTransactionCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpenses" xlink:label="loc_TVGNNoncashInterestExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNNoncashInterestExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToAffiliatesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToAffiliatesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:label="loc_TVGNExtensionAmountDepositedIntoTrustAccount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TVGNExtensionAmountDepositedIntoTrustAccount" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:title="00000007 - Disclosure - Description of Organization, Business Operations and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" xlink:title="00000009 - Disclosure - Initial Public Offering and Over-Allotment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PrivatePlacementWarrants" xlink:title="00000010 - Disclosure - Private Placement Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ShareholdersDeficit" xlink:title="00000013 - Disclosure - Shareholders&#8217; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/WarrantLiabilities" xlink:title="00000014 - Disclosure - Warrant Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/FairValueMeasurements" xlink:title="00000015 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="00000017 - Disclosure - NATURE OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="00000018 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="00000020 - Disclosure - BUSINESS COMBINATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="00000021 - Disclosure - EARNOUT SHARES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="00000022 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NotesPayable" xlink:title="00000023 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="00000024 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" xlink:title="00000026 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetIncomeLossPerShare" xlink:title="00000027 - Disclosure - NET INCOME (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDisclosure" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsTables" xlink:title="00000032 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/FairValueMeasurementsTables" xlink:title="00000033 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:title="00000034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="00000035 - Disclosure - BUSINESS COMBINATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="00000036 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetIncomeLossPerShareTables" xlink:title="00000039 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:title="00000040 - Disclosure - Description of Organization, Business Operations and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:title="00000041 - Disclosure - Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:title="00000042 - Disclosure - Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:title="00000044 - Disclosure - Initial Public Offering and Over-Allotment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" xlink:title="00000045 - Disclosure - Private Placement Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" xlink:title="00000046 - Disclosure - Schedule of Fair Value Non Redeemable Shares (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" xlink:title="00000049 - Disclosure - Shareholders&#8217; Deficit (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000050 - Disclosure - Warrant Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000051 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:title="00000052 - Disclosure - Schedule of Quantitative Information in Fair Value Measurements (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000053 - Disclosure - Subsequent Events (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000054 - Disclosure - NATURE OF BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="00000055 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="00000056 - Disclosure - Schedule of Fair Value Measurement (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="00000057 - Disclosure - Schedule of Fair Values Of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:title="00000058 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:label="loc_TVGNTotalNetLiabilitiesAcquiredPlusTransactionCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNTotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" xlink:label="loc_TVGNPlusMergerTransactionCostsLimitedToCashAcquired" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNTotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:to="loc_TVGNPlusMergerTransactionCostsLimitedToCashAcquired" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS COMBINATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="00000061 - Disclosure - EARNOUT SHARES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccruedProfessionalServiceFeesCurrent" xlink:label="loc_TVGNAccruedProfessionalServiceFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_TVGNAccruedProfessionalServiceFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NotesPayableDetailsNarrative" xlink:title="00000063 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000066 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000068 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:title="00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertiblePromissoryNoteInterest" xlink:label="loc_TVGNConvertiblePromissoryNoteInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNConvertiblePromissoryNoteInterest" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertiblePromissoryNoteChangeInFairValue" xlink:label="loc_TVGNConvertiblePromissoryNoteChangeInFairValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNConvertiblePromissoryNoteChangeInFairValue" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="00000072 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>tvgn-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20240331.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfCashFlows" xlink:href="tvgn-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:href="tvgn-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" xlink:href="tvgn-20240331.xsd#InitialPublicOfferingAndOver-allotment" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PrivatePlacementWarrants" xlink:href="tvgn-20240331.xsd#PrivatePlacementWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ShareholdersDeficit" xlink:href="tvgn-20240331.xsd#ShareholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/WarrantLiabilities" xlink:href="tvgn-20240331.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/FairValueMeasurements" xlink:href="tvgn-20240331.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20240331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20240331.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20240331.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20240331.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20240331.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20240331.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NotesPayable" xlink:href="tvgn-20240331.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20240331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20240331.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetIncomeLossPerShare" xlink:href="tvgn-20240331.xsd#NetIncomeLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDisclosure" xlink:href="tvgn-20240331.xsd#SubsequentEventsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsTables" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/FairValueMeasurementsTables" xlink:href="tvgn-20240331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20240331.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20240331.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20240331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20240331.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetIncomeLossPerShareTables" xlink:href="tvgn-20240331.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:href="tvgn-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:href="tvgn-20240331.xsd#InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" xlink:href="tvgn-20240331.xsd#PrivatePlacementWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValueNonRedeemableSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="tvgn-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" xlink:href="tvgn-20240331.xsd#ShareholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="tvgn-20240331.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20240331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20240331.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20240331.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20240331.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20240331.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NotesPayableDetailsNarrative" xlink:href="tvgn-20240331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20240331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20240331.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20240331.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapAssetsCurrentAbstract_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapCash_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAssetsCurrent_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredTransactionCosts" xlink:label="loc_TVGNDeferredTransactionCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_TVGNDeferredTransactionCosts_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapOtherAssetsNoncurrent_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaapAssetsHeldInTrustNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapAssetsHeldInTrustNoncurrent_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccountsPayableCurrent_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapNotesPayableCurrent_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrent_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_130" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent_130" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapLiabilities_130" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapCommitmentsAndContingencies_130" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapTemporaryEquityAbstract_130" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityAbstract_130" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_130" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapStockholdersEquityAbstract_130" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapPreferredStockValue_130" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapCommonStockValue_130" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassAOrdinaryShares" xlink:label="loc_TVGNClassAOrdinaryShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_TVGNClassAOrdinaryShares_130" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassBOrdinaryShares" xlink:label="loc_TVGNClassBOrdinaryShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_TVGNClassBOrdinaryShares_130" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapAdditionalPaidInCapital_130" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapStockholdersEquity_130" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_130" xlink:type="arc" order="39" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaapTemporaryEquityRedemptionPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityRedemptionPricePerShare_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_100" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:label="loc_TVGNCommonClassaNotSubjectToRedemptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNCommonClassaNotSubjectToRedemptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_TVGNTransactionCosts_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapInterestExpense_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapNonoperatingIncomeExpense_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_110" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_TVGNAccretionOfCarryingValueToRedemptionValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAccretionOfCarryingValueToRedemptionValue_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_150" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpenses" xlink:label="loc_TVGNNoncashInterestExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_TVGNNoncashInterestExpenses_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToAffiliatesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInDueToAffiliatesCurrent_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:label="loc_TVGNExtensionAmountDepositedIntoTrustAccount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_TVGNExtensionAmountDepositedIntoTrustAccount_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapProceedsFromNotesPayable_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" xlink:label="loc_TVGNChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfClassBSharesToInvestor" xlink:label="loc_TVGNSaleOfClassBSharesToInvestor_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNSaleOfClassBSharesToInvestor_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfWarrants" xlink:label="loc_TVGNSaleOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNSaleOfWarrants_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapDepreciation_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapPaidInKindInterest_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaapNoncashMergerRelatedCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapNoncashMergerRelatedCosts_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNLossOnPreferredStockIssuance_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" xlink:label="loc_TVGNConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" xlink:label="loc_TVGNIssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_TVGNIssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_50" xlink:type="arc" order="45" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:title="00000007 - Disclosure - Description of Organization, Business Operations and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" xlink:title="00000009 - Disclosure - Initial Public Offering and Over-Allotment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PrivatePlacementWarrants" xlink:title="00000010 - Disclosure - Private Placement Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ShareholdersDeficit" xlink:title="00000013 - Disclosure - Shareholders&#8217; Deficit" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/WarrantLiabilities" xlink:title="00000014 - Disclosure - Warrant Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/FairValueMeasurements" xlink:title="00000015 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="00000017 - Disclosure - NATURE OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="00000018 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="00000020 - Disclosure - BUSINESS COMBINATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="00000021 - Disclosure - EARNOUT SHARES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="00000022 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NotesPayable" xlink:title="00000023 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="00000024 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" xlink:title="00000026 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetIncomeLossPerShare" xlink:title="00000027 - Disclosure - NET INCOME (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDisclosure" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsTables" xlink:title="00000032 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/FairValueMeasurementsTables" xlink:title="00000033 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:title="00000034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="00000035 - Disclosure - BUSINESS COMBINATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="00000036 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetIncomeLossPerShareTables" xlink:title="00000039 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:title="00000040 - Disclosure - Description of Organization, Business Operations and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TVGNSponsorMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FeeReductionAgreementMember" xlink:label="loc_TVGNFeeReductionAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNFeeReductionAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FirstExtensionCharterAmendmentMember" xlink:label="loc_TVGNFirstExtensionCharterAmendmentMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNFirstExtensionCharterAmendmentMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondExtensionCharterAmendmentMember" xlink:label="loc_TVGNSecondExtensionCharterAmendmentMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecondExtensionCharterAmendmentMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="loc_TVGNPurchaseAgreementMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNPurchaseAgreementMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_TVGNSecuritiesPurchaseAgreementMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecuritiesPurchaseAgreementMember_310" xlink:type="arc" order="313" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="loc_TVGNPrivatePlacementWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPrivatePlacementWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicSharesMember" xlink:label="loc_TVGNPublicSharesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNPublicSharesMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesA1PreferredStockMember" xlink:label="loc_TVGNSeriesA1PreferredStockMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesA1PreferredStockMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="loc_TVGNSsvkAssociatesLlcMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_TVGNSsvkAssociatesLlcMember_260" xlink:type="arc" order="264" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_TVGNConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNTransactionCosts_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockUnderwritingFees" xlink:label="loc_TVGNSaleOfStockUnderwritingFees_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNSaleOfStockUnderwritingFees_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockOtherOfferingCosts" xlink:label="loc_TVGNSaleOfStockOtherOfferingCosts_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNSaleOfStockOtherOfferingCosts_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrentForfeited" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrentForfeited_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrentForfeited_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="loc_TVGNPaymentsForInvestmentOfCashInTrustAccount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNPaymentsForInvestmentOfCashInTrustAccount_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:label="loc_TVGNConditionForFutureBusinessCombinationUseOfProceedsPercentage_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationUseOfProceedsPercentage_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:label="loc_TVGNConditionForFutureBusinessCombinationThresholdPercentageOwnership_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationThresholdPercentageOwnership_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:label="loc_TVGNConditionForFutureBusinessCombinationThresholdNetTangibleAssets_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationThresholdNetTangibleAssets_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_340" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_340" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:label="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_340" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_340" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaapAssetsHeldInTrustNoncurrent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsHeldInTrustNoncurrent_340" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RedemptionLimitPercentageWithoutPriorConsent" xlink:label="loc_TVGNRedemptionLimitPercentageWithoutPriorConsent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNRedemptionLimitPercentageWithoutPriorConsent_340" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_TVGNPercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNPercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_340" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumAllowedDissolutionExpenses" xlink:label="loc_TVGNMaximumAllowedDissolutionExpenses_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNMaximumAllowedDissolutionExpenses_340" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaapAssetsHeldInTrust_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsHeldInTrust_340" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_340" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_340" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalDeficit" xlink:label="loc_TVGNWorkingCapitalDeficit_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNWorkingCapitalDeficit_340" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest_340" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:title="00000041 - Disclosure - Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:title="00000042 - Disclosure - Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:label="loc_TVGNCommonClassaNotSubjectToRedemptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNCommonClassaNotSubjectToRedemptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FeeReductionAgreementMember" xlink:label="loc_TVGNFeeReductionAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNFeeReductionAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNTransactionCosts_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockUnderwritingFees" xlink:label="loc_TVGNSaleOfStockUnderwritingFees_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNSaleOfStockUnderwritingFees_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockOtherOfferingCosts" xlink:label="loc_TVGNSaleOfStockOtherOfferingCosts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNSaleOfStockOtherOfferingCosts_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:title="00000044 - Disclosure - Initial Public Offering and Over-Allotment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssue" xlink:label="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesIssuedPerUnit" xlink:label="loc_TVGNNumberOfSharesIssuedPerUnit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNNumberOfSharesIssuedPerUnit_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_TVGNNumberOfWarrantsIssuedPerUnit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNNumberOfWarrantsIssuedPerUnit_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" xlink:title="00000045 - Disclosure - Private Placement Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="loc_TVGNPrivatePlacementWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPrivatePlacementWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CantorMember" xlink:label="loc_TVGNCantorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNCantorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" xlink:title="00000046 - Disclosure - Schedule of Fair Value Non Redeemable Shares (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FounderSharesMember" xlink:label="loc_TVGNFounderSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNFounderSharesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_TVGNPromissoryNoteWithRelatedPartyMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNPromissoryNoteWithRelatedPartyMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RelatedPartyLoansMember" xlink:label="loc_TVGNRelatedPartyLoansMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNRelatedPartyLoansMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapRelatedPartyMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AdministrativeSupportAgreementMember" xlink:label="loc_TVGNAdministrativeSupportAgreementMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNAdministrativeSupportAgreementMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="loc_TVGNSsvkAssociatesLlcMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSsvkAssociatesLlcMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonRedeemableOrdinaryMember" xlink:label="loc_TVGNNonRedeemableOrdinaryMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNNonRedeemableOrdinaryMember_140" xlink:type="arc" order="144" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredOneMember" xlink:label="loc_TVGNPublicWarrantsTransferredOneMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNPublicWarrantsTransferredOneMember_200" xlink:type="arc" order="204" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredTwoMember" xlink:label="loc_TVGNPublicWarrantsTransferredTwoMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNPublicWarrantsTransferredTwoMember_210" xlink:type="arc" order="214" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeSPACMember" xlink:label="loc_TVGNDeSPACMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TVGNDeSPACMember_300" xlink:type="arc" order="303" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="loc_TVGNPurchaseAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNPurchaseAgreementMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SubscriptionAgreementMember" xlink:label="loc_TVGNSubscriptionAgreementMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSubscriptionAgreementMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondSubscriptionAgreementMember" xlink:label="loc_TVGNSecondSubscriptionAgreementMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecondSubscriptionAgreementMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorMember_100" xlink:type="arc" order="104" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredTwoMember" xlink:label="loc_TVGNPublicWarrantsTransferredTwoMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsTransferredTwoMember_180" xlink:type="arc" order="184" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredThreeMember" xlink:label="loc_TVGNPublicWarrantsTransferredThreeMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsTransferredThreeMember_190" xlink:type="arc" order="194" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalLoansWarrantMember" xlink:label="loc_TVGNWorkingCapitalLoansWarrantMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNWorkingCapitalLoansWarrantMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TVGNSponsorMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FirstPolarFundConvertibleNoteMember" xlink:label="loc_TVGNFirstPolarFundConvertibleNoteMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_TVGNFirstPolarFundConvertibleNoteMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondPolarFundConvertibleNoteMember" xlink:label="loc_TVGNSecondPolarFundConvertibleNoteMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_TVGNSecondPolarFundConvertibleNoteMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_510" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaapCommonStockDividendsShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockDividendsShares_510" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaapPreferredStockConvertibleConversionRatio_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionRatio_510" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateNumberOfSharesOwned" xlink:label="loc_TVGNAggregateNumberOfSharesOwned_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNAggregateNumberOfSharesOwned_510" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesSubjectToForfeiture" xlink:label="loc_TVGNNumberOfSharesSubjectToForfeiture_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNNumberOfSharesSubjectToForfeiture_510" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_TVGNRestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNRestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_510" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_510" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_510" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_510" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_TVGNThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_510" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1_510" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_510" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_510" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_510" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregatePurchasePrice" xlink:label="loc_TVGNAggregatePurchasePrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNAggregatePurchasePrice_510" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_510" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_510" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_510" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_TVGNMaximumBorrowingCapacityOfRelatedPartyPromissoryNote_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNMaximumBorrowingCapacityOfRelatedPartyPromissoryNote_510" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_510" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings_510" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapital" xlink:label="loc_TVGNWorkingCapital_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNWorkingCapital_510" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaapPaymentsForAdvanceToAffiliate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForAdvanceToAffiliate_510" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty_510" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContribution" xlink:label="loc_TVGNInitialCapitalContribution_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNInitialCapitalContribution_510" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_510" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContributionPerShare" xlink:label="loc_TVGNInitialCapitalContributionPerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNInitialCapitalContributionPerShare_510" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount_510" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_510" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity_510" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice_510" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherNotesPayableCurrent_510" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertibleNotesPayableDiscounts" xlink:label="loc_TVGNConvertibleNotesPayableDiscounts_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNConvertibleNotesPayableDiscounts_510" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpenses" xlink:label="loc_TVGNNoncashInterestExpenses_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNNoncashInterestExpenses_510" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_510" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_TVGNMaximumLoansConvertibleIntoWarrants_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNMaximumLoansConvertibleIntoWarrants_510" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights_510" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalLoan" xlink:label="loc_TVGNWorkingCapitalLoan_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNWorkingCapitalLoan_510" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_TVGNRelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNRelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_510" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities_510" xlink:type="arc" order="39" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SubscriptionAgreementMember" xlink:label="loc_TVGNSubscriptionAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSubscriptionAgreementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondSubscriptionAgreementMember" xlink:label="loc_TVGNSecondSubscriptionAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecondSubscriptionAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="loc_TVGNPurchaseAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNPurchaseAgreementMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNSponsorMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TVGNSponsorMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="loc_TVGNSsvkAssociatesLlcMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_TVGNSsvkAssociatesLlcMember_150" xlink:type="arc" order="154" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwritingOptionPeriod" xlink:label="loc_TVGNUnderwritingOptionPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnderwritingOptionPeriod_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwritingCashDiscountPerUnit" xlink:label="loc_TVGNUnderwritingCashDiscountPerUnit_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnderwritingCashDiscountPerUnit_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PaymentOfUnderwriterDiscount" xlink:label="loc_TVGNPaymentOfUnderwriterDiscount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNPaymentOfUnderwriterDiscount_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateUnderwriterCashDiscount" xlink:label="loc_TVGNAggregateUnderwriterCashDiscount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAggregateUnderwriterCashDiscount_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredFeePerUnit" xlink:label="loc_TVGNDeferredFeePerUnit_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNDeferredFeePerUnit_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredUnderwritingFeePayable" xlink:label="loc_TVGNDeferredUnderwritingFeePayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNDeferredUnderwritingFeePayable_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateDeferredUnderwritingFeePayable" xlink:label="loc_TVGNAggregateDeferredUnderwritingFeePayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAggregateDeferredUnderwritingFeePayable_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwriterCashDiscount" xlink:label="loc_TVGNUnderwriterCashDiscount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnderwriterCashDiscount_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContribution" xlink:label="loc_TVGNInitialCapitalContribution_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNInitialCapitalContribution_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" xlink:label="loc_TVGNMinimumPeriodForReceivingSpacLoanFromDeSpacClosing_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMinimumPeriodForReceivingSpacLoanFromDeSpacClosing_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" xlink:label="loc_TVGNNumberOfSharesIssuableForEach10InitialCapitalContribution_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNNumberOfSharesIssuableForEach10InitialCapitalContribution_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" xlink:label="loc_TVGNAmountOfInitialCapitalConsideredToIssueOneShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAmountOfInitialCapitalConsideredToIssueOneShare_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" xlink:label="loc_TVGNMinimumPeriodForPaymentInCaseOfLiquidation_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMinimumPeriodForPaymentInCaseOfLiquidation_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumReasonableAttorneyFees" xlink:label="loc_TVGNMaximumReasonableAttorneyFees_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMaximumReasonableAttorneyFees_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregatePurchasePrice" xlink:label="loc_TVGNAggregatePurchasePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAggregatePurchasePrice_190" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" xlink:title="00000049 - Disclosure - Shareholders&#8217; Deficit (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonStockNumberOfVotesPerShare" xlink:label="loc_TVGNCommonStockNumberOfVotesPerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNCommonStockNumberOfVotesPerShare_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertibleStocksConversionRatio" xlink:label="loc_TVGNConvertibleStocksConversionRatio_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNConvertibleStocksConversionRatio_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantExercisePeriodConditionOne" xlink:label="loc_TVGNWarrantExercisePeriodConditionOne_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantExercisePeriodConditionOne_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" xlink:label="loc_TVGNWarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_TVGNClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RedemptionPeriod" xlink:label="loc_TVGNRedemptionPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNRedemptionPeriod_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_TVGNWarrantRedemptionConditionMinimumSharePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantRedemptionConditionMinimumSharePrice_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_TVGNThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="loc_TVGNSharePriceTriggerUsedToMeasureDilutionOfWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNSharePriceTriggerUsedToMeasureDilutionOfWarrants_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_TVGNPercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNPercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_TVGNTradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNTradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" xlink:label="loc_TVGNClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_100" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000050 - Disclosure - Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="loc_TVGNPrivatePlacementWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPrivatePlacementWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000051 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_160" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:title="00000052 - Disclosure - Schedule of Quantitative Information in Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_130" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000053 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesA1PreferredStockMember" xlink:label="loc_TVGNSeriesA1PreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesA1PreferredStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MergerAgreementMember" xlink:label="loc_TVGNMergerAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNMergerAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_TVGNSecuritiesPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecuritiesPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_TVGNTevogenBioMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorAdvisoryServiceFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServiceFeeMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_TVGNSponsorAdvisoryServiceFeeMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:label="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCash_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSponsorFees_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_OffsetValue" xlink:label="loc_TVGNOffsetValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNOffsetValue_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ServicesFees" xlink:label="loc_TVGNServicesFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNServicesFees_170" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000054 - Disclosure - NATURE OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSemperParatusMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExchangeRatio" xlink:label="loc_TVGNExchangeRatio_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNExchangeRatio_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="00000055 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="00000056 - Disclosure - Schedule of Fair Value Measurement (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="00000057 - Disclosure - Schedule of Fair Values Of Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:title="00000058 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageOfProbabilityOfLiquidityEvent" xlink:label="loc_TVGNPercentageOfProbabilityOfLiquidityEvent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNPercentageOfProbabilityOfLiquidityEvent_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RangeInYears" xlink:label="loc_TVGNRangeInYears_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNRangeInYears_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNTransactionCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCost" xlink:label="loc_TVGNTransactionCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNTransactionCost_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="00000061 - Disclosure - EARNOUT SHARES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="loc_TVGNTevogenBioCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorsMember" xlink:label="loc_TVGNSponsorsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesTradingDaysDescription" xlink:label="loc_TVGNEarnoutSharesTradingDaysDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNEarnoutSharesTradingDaysDescription_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccruedProfessionalServiceFeesCurrent" xlink:label="loc_TVGNAccruedProfessionalServiceFeesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAccruedProfessionalServiceFeesCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NotesPayableDetailsNarrative" xlink:title="00000063 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000066 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TwentyTwentyFourPlanMember" xlink:label="loc_TVGNTwentyTwentyFourPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNTwentyTwentyFourPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IncentivePlanMember" xlink:label="loc_TVGNIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000068 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSemperParatusMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNLossOnPreferredStockIssuance_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="loc_us-gaapPreferredStockDividendPaymentRateVariable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentRateVariable_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaapPreferredStockRedemptionTerms_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionTerms_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_190" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsDescription" xlink:label="loc_TVGNWarrantsDescription_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsDescription_190" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_190" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:title="00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServicesFeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSponsorAdvisoryServicesFeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNSponsorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PolarNotesMember" xlink:label="loc_TVGNPolarNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_TVGNPolarNotesMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSponsorFees_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalExpenses" xlink:label="loc_TVGNWorkingCapitalExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNWorkingCapitalExpenses_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF NET LOSS PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNPublicWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivateWarrantsMember" xlink:label="loc_TVGNPrivateWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNPrivateWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="00000072 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>tvgn-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="TVGN_ReverseRecapitalizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ReverseRecapitalizationMember" xlink:to="TVGN_ReverseRecapitalizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ReverseRecapitalizationMember_lbl" xml:lang="en-US">Reverse Recapitalization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:label="TVGN_CommonClassaNotSubjectToRedemptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:to="TVGN_CommonClassaNotSubjectToRedemptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CommonClassaNotSubjectToRedemptionMember_lbl" xml:lang="en-US">Common Class A Not Subject To Redemption [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="TVGN_SponsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorMember" xlink:to="TVGN_SponsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FeeReductionAgreementMember" xlink:label="TVGN_FeeReductionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FeeReductionAgreementMember" xlink:to="TVGN_FeeReductionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FeeReductionAgreementMember_lbl" xml:lang="en-US">Fee Reduction Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="TVGN_PrivatePlacementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivatePlacementWarrantsMember" xlink:to="TVGN_PrivatePlacementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FirstExtensionCharterAmendmentMember" xlink:label="TVGN_FirstExtensionCharterAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FirstExtensionCharterAmendmentMember" xlink:to="TVGN_FirstExtensionCharterAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FirstExtensionCharterAmendmentMember_lbl" xml:lang="en-US">First Extension Charter Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicSharesMember" xlink:label="TVGN_PublicSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicSharesMember" xlink:to="TVGN_PublicSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicSharesMember_lbl" xml:lang="en-US">Public Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondExtensionCharterAmendmentMember" xlink:label="TVGN_SecondExtensionCharterAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecondExtensionCharterAmendmentMember" xlink:to="TVGN_SecondExtensionCharterAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SecondExtensionCharterAmendmentMember_lbl" xml:lang="en-US">Second Extension Charter Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="TVGN_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PurchaseAgreementMember" xlink:to="TVGN_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="TVGN_SsvkAssociatesLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SsvkAssociatesLlcMember" xlink:to="TVGN_SsvkAssociatesLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SsvkAssociatesLlcMember_lbl" xml:lang="en-US">SSVK Associates, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecuritiesPurchaseAgreementMember" xlink:label="TVGN_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecuritiesPurchaseAgreementMember" xlink:to="TVGN_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesA1PreferredStockMember" xlink:label="TVGN_SeriesA1PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesA1PreferredStockMember" xlink:to="TVGN_SeriesA1PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SeriesA1PreferredStockMember_lbl" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="TVGN_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsMember" xlink:to="TVGN_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CantorMember" xlink:label="TVGN_CantorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CantorMember" xlink:to="TVGN_CantorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CantorMember_lbl" xml:lang="en-US">Cantor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FounderSharesMember" xlink:label="TVGN_FounderSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FounderSharesMember" xlink:to="TVGN_FounderSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FounderSharesMember_lbl" xml:lang="en-US">Founder Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonRedeemableOrdinaryMember" xlink:label="TVGN_NonRedeemableOrdinaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonRedeemableOrdinaryMember" xlink:to="TVGN_NonRedeemableOrdinaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NonRedeemableOrdinaryMember_lbl" xml:lang="en-US">Non Redeemable Ordinary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredTwoMember" xlink:label="TVGN_PublicWarrantsTransferredTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsTransferredTwoMember" xlink:to="TVGN_PublicWarrantsTransferredTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicWarrantsTransferredTwoMember_lbl" xml:lang="en-US">Public Warrants Transferred Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredThreeMember" xlink:label="TVGN_PublicWarrantsTransferredThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsTransferredThreeMember" xlink:to="TVGN_PublicWarrantsTransferredThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicWarrantsTransferredThreeMember_lbl" xml:lang="en-US">Public Warrants Transferred Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredOneMember" xlink:label="TVGN_PublicWarrantsTransferredOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsTransferredOneMember" xlink:to="TVGN_PublicWarrantsTransferredOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicWarrantsTransferredOneMember_lbl" xml:lang="en-US">Public Warrants Transferred One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PromissoryNoteWithRelatedPartyMember" xlink:label="TVGN_PromissoryNoteWithRelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PromissoryNoteWithRelatedPartyMember" xlink:to="TVGN_PromissoryNoteWithRelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PromissoryNoteWithRelatedPartyMember_lbl" xml:lang="en-US">Promissory Note with Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SubscriptionAgreementMember" xlink:label="TVGN_SubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SubscriptionAgreementMember" xlink:to="TVGN_SubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SubscriptionAgreementMember_lbl" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeSPACMember" xlink:label="TVGN_DeSPACMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeSPACMember" xlink:to="TVGN_DeSPACMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeSPACMember_lbl" xml:lang="en-US">De S P A C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondSubscriptionAgreementMember" xlink:label="TVGN_SecondSubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecondSubscriptionAgreementMember" xlink:to="TVGN_SecondSubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SecondSubscriptionAgreementMember_lbl" xml:lang="en-US">Second Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FirstPolarFundConvertibleNoteMember" xlink:label="TVGN_FirstPolarFundConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FirstPolarFundConvertibleNoteMember" xlink:to="TVGN_FirstPolarFundConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FirstPolarFundConvertibleNoteMember_lbl" xml:lang="en-US">First Polar Fund Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondPolarFundConvertibleNoteMember" xlink:label="TVGN_SecondPolarFundConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecondPolarFundConvertibleNoteMember" xlink:to="TVGN_SecondPolarFundConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SecondPolarFundConvertibleNoteMember_lbl" xml:lang="en-US">Second Polar Fund Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RelatedPartyLoansMember" xlink:label="TVGN_RelatedPartyLoansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RelatedPartyLoansMember" xlink:to="TVGN_RelatedPartyLoansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RelatedPartyLoansMember_lbl" xml:lang="en-US">Related Party Loans [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalLoansWarrantMember" xlink:label="TVGN_WorkingCapitalLoansWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalLoansWarrantMember" xlink:to="TVGN_WorkingCapitalLoansWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WorkingCapitalLoansWarrantMember_lbl" xml:lang="en-US">Working capital loans warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AdministrativeSupportAgreementMember" xlink:label="TVGN_AdministrativeSupportAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AdministrativeSupportAgreementMember" xlink:to="TVGN_AdministrativeSupportAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AdministrativeSupportAgreementMember_lbl" xml:lang="en-US">Administrative Support Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MergerAgreementMember" xlink:label="TVGN_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerAgreementMember" xlink:to="TVGN_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="TVGN_TevogenBioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioMember" xlink:to="TVGN_TevogenBioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TevogenBioMember_lbl" xml:lang="en-US">Tevogen Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="TVGN_SeriesAOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorAdvisoryServiceFeeMember" xlink:label="TVGN_SponsorAdvisoryServiceFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServiceFeeMember" xlink:to="TVGN_SponsorAdvisoryServiceFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorAdvisoryServiceFeeMember_lbl" xml:lang="en-US">Sponsor Advisory Service Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SemperParatusMember" xlink:label="TVGN_SemperParatusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SemperParatusMember" xlink:to="TVGN_SemperParatusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SemperParatusMember_lbl" xml:lang="en-US">Semper Paratus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="TVGN_EarnoutSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesMember" xlink:to="TVGN_EarnoutSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesMember_lbl" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="TVGN_TevogenBioCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioCommonStockMember" xlink:to="TVGN_TevogenBioCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TevogenBioCommonStockMember_lbl" xml:lang="en-US">Tevogen Bio Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorsMember" xlink:label="TVGN_SponsorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorsMember" xlink:to="TVGN_SponsorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorsMember_lbl" xml:lang="en-US">Sponsors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TwentyTwentyFourPlanMember" xlink:label="TVGN_TwentyTwentyFourPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TwentyTwentyFourPlanMember" xlink:to="TVGN_TwentyTwentyFourPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TwentyTwentyFourPlanMember_lbl" xml:lang="en-US">Twenty Twenty Four Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IncentivePlanMember" xlink:label="TVGN_IncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncentivePlanMember" xlink:to="TVGN_IncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_IncentivePlanMember_lbl" xml:lang="en-US">Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="TVGN_PerformanceBasedRSUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PerformanceBasedRSUsMember" xlink:to="TVGN_PerformanceBasedRSUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PerformanceBasedRSUsMember_lbl" xml:lang="en-US">Performance Based R S Us [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="TVGN_ServiceBasedRestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServiceBasedRestrictedStockMember" xlink:to="TVGN_ServiceBasedRestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ServiceBasedRestrictedStockMember_lbl" xml:lang="en-US">Service Based Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServicesFeeMember" xlink:to="TVGN_SponsorAdvisoryServicesFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember_lbl" xml:lang="en-US">Sponsor Advisory Services Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivateWarrantsMember" xlink:label="TVGN_PrivateWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivateWarrantsMember" xlink:to="TVGN_PrivateWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PrivateWarrantsMember_lbl" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredTransactionCosts" xlink:label="TVGN_DeferredTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTransactionCosts" xlink:to="TVGN_DeferredTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTransactionCosts_lbl" xml:lang="en-US">Deferred transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xml:lang="en-US">Cash and marketable securities held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="TVGN_DeferredOfferingCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredOfferingCostsNoncurrent" xlink:to="TVGN_DeferredOfferingCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US">Deferred underwriting fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">REDEEMABLE ORDINARY SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Class A ordinary shares subject to possible redemption, $0.0001 par value, 1,502,180 and 34,500,000 shares at redemption value of $11.10 and $10.34 per share as of December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 800,000,000 shares authorized; 164,614,418 and 119,999,989 shares issued and outstanding at March 31, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassAOrdinaryShares" xlink:label="TVGN_ClassAOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassAOrdinaryShares" xlink:to="TVGN_ClassAOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassAOrdinaryShares_lbl" xml:lang="en-US">Class A ordinary shares; $0.0001 par value; 200,000,000 shares authorized; 13,433,333 and 1,450,000 shares issued and outstanding (excluding 1,502,180 and 34,500,000 shares subject to possible redemption) as of December 31, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassBOrdinaryShares" xlink:label="TVGN_ClassBOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassBOrdinaryShares" xlink:to="TVGN_ClassBOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassBOrdinaryShares_lbl" xml:lang="en-US">Class B ordinary shares; $0.0001 par value; 20,000,000 shares authorized; 0 and 11,983,333 shares issued and outstanding as of December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary equity, par value (in dollar per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US">Temporary equity, redemption price (In Dollar per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollar per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in dollar per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized gain on investments held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="TVGN_TransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransactionCosts" xlink:to="TVGN_TransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_TransactionCosts_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="TVGN_ImpairmentOfAmountDueFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:to="TVGN_ImpairmentOfAmountDueFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_ImpairmentOfAmountDueFromRelatedParty_lbl" xml:lang="en-US">Impairment of amount due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common stock outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per share attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss) attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Proceeds allocated to Class A shares issuable from the note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccretionOfCarryingValueToRedemptionValue" xlink:label="TVGN_AccretionOfCarryingValueToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AccretionOfCarryingValueToRedemptionValue" xlink:to="TVGN_AccretionOfCarryingValueToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AccretionOfCarryingValueToRedemptionValue_lbl" xml:lang="en-US">Accretion of carrying value to redemption value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Series A preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Issuance of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Issuance of Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Merger, net of redemptions and transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Merger, net of redemptions and transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for Sponsor advisory service fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for Sponsor advisory service fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xml:lang="en-US">Unrealized gain on investments held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpenses" xlink:label="TVGN_NoncashInterestExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NoncashInterestExpenses" xlink:to="TVGN_NoncashInterestExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NoncashInterestExpenses_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:to="TVGN_ImpairmentOfAmountDueFromRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ImpairmentOfAmountDueFromRelatedParty_2_lbl" xml:lang="en-US">Impairment of amount due from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent_lbl" xml:lang="en-US">Due to affiliate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:label="TVGN_ExtensionAmountDepositedIntoTrustAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:to="TVGN_ExtensionAmountDepositedIntoTrustAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_ExtensionAmountDepositedIntoTrustAccount_lbl" xml:lang="en-US">Extension amount deposited into Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:to="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_lbl" xml:lang="en-US">Cash withdrawn from Trust Account in connection with redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Redemption of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash &#8211; beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash &#8211; end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplementary disclosure of noncash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" xlink:label="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" xlink:to="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_lbl" xml:lang="en-US">Change in value of Class A ordinary shares subject to redemption amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfClassBSharesToInvestor" xlink:label="TVGN_SaleOfClassBSharesToInvestor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfClassBSharesToInvestor" xlink:to="TVGN_SaleOfClassBSharesToInvestor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SaleOfClassBSharesToInvestor_lbl" xml:lang="en-US">Sale of Class B shares to Investor</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfWarrants" xlink:label="TVGN_SaleOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfWarrants" xlink:to="TVGN_SaleOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SaleOfWarrants_lbl" xml:lang="en-US">Sale of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_2_lbl" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="TVGN_LossOnPreferredStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LossOnPreferredStockIssuance_lbl" xml:lang="en-US">Loss on Series A Preferred Stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_lbl" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" xlink:label="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" xlink:to="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" xlink:label="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" xlink:to="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_lbl" xml:lang="en-US">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Description of Organization, Business Operations and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract" xlink:label="TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract" xlink:to="TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract_lbl" xml:lang="en-US">Initial Public Offering And Over-allotment</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialPublicOfferingTextBlock" xlink:label="TVGN_InitialPublicOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialPublicOfferingTextBlock" xlink:to="TVGN_InitialPublicOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US">Initial Public Offering and Over-Allotment</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosurePrivatePlacementWarrantsAbstract" xlink:label="TVGN_DisclosurePrivatePlacementWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosurePrivatePlacementWarrantsAbstract" xlink:to="TVGN_DisclosurePrivatePlacementWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosurePrivatePlacementWarrantsAbstract_lbl" xml:lang="en-US">Private Placement Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementTextBlock" xlink:label="TVGN_PrivatePlacementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivatePlacementTextBlock" xlink:to="TVGN_PrivatePlacementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_PrivatePlacementTextBlock_lbl" xml:lang="en-US">Private Placement Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="TVGN_DisclosureWarrantLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureWarrantLiabilitiesAbstract" xlink:to="TVGN_DisclosureWarrantLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureWarrantLiabilitiesAbstract_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantLiabilitiesDisclosureTextBlock" xlink:label="TVGN_WarrantLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantLiabilitiesDisclosureTextBlock" xlink:to="TVGN_WarrantLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_WarrantLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract_lbl" xml:lang="en-US">Development-stage Risks And Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xml:lang="en-US">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="TVGN_DisclosureEarnoutSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureEarnoutSharesAbstract" xlink:to="TVGN_DisclosureEarnoutSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureEarnoutSharesAbstract_lbl" xml:lang="en-US">Earnout Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesDisclosureTextBlock" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesDisclosureTextBlock" xlink:to="TVGN_EarnoutSharesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock_lbl" xml:lang="en-US">EARNOUT SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:to="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET INCOME (LOSS) PER SHARE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_2_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:to="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:to="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xml:lang="en-US">Investments Held in Trust Account</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:label="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:to="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs associated with the Initial Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TemporaryEquityPolicyPolicyTextBlock" xlink:label="TVGN_TemporaryEquityPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TemporaryEquityPolicyPolicyTextBlock" xlink:to="TVGN_TemporaryEquityPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TemporaryEquityPolicyPolicyTextBlock_lbl" xml:lang="en-US">Class A Ordinary Shares Subject to Possible Redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Income (Loss) per Ordinary Share</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:label="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:to="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting for Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_2_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Non Redeemable Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Quantitative Information in Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Values Of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2_lbl" xml:lang="en-US">SCHEDULE OF NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US">Condition for future business combination number of businesses minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="TVGN_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredOfferingCostsNoncurrent" xlink:to="TVGN_DeferredOfferingCostsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_DeferredOfferingCostsNoncurrent_2_lbl" xml:lang="en-US">Deferred offering costs non current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransactionCosts" xlink:to="TVGN_TransactionCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TransactionCosts_2_lbl" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockUnderwritingFees" xlink:label="TVGN_SaleOfStockUnderwritingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfStockUnderwritingFees" xlink:to="TVGN_SaleOfStockUnderwritingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US">Sale of stock underwriting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockOtherOfferingCosts" xlink:label="TVGN_SaleOfStockOtherOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfStockOtherOfferingCosts" xlink:to="TVGN_SaleOfStockOtherOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US">Other offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrentForfeited" xlink:label="TVGN_DeferredOfferingCostsNoncurrentForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredOfferingCostsNoncurrentForfeited" xlink:to="TVGN_DeferredOfferingCostsNoncurrentForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredOfferingCostsNoncurrentForfeited_lbl" xml:lang="en-US">Deferred underwriting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="TVGN_PaymentsForInvestmentOfCashInTrustAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PaymentsForInvestmentOfCashInTrustAccount" xlink:to="TVGN_PaymentsForInvestmentOfCashInTrustAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US">Payments for investment of cash in trust account</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:label="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:to="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_lbl" xml:lang="en-US">Condition for future business combination use of proceeds percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:label="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:to="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_lbl" xml:lang="en-US">Condition for future business combination threshold ownership (as a percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:label="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:to="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_lbl" xml:lang="en-US">Net tangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Conversion ratio</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_2_lbl" xml:lang="en-US">Shares cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Shares issued upon conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:label="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:to="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_lbl" xml:lang="en-US">Minimum period to file charter amendment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:to="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_2_lbl" xml:lang="en-US">Cash withdrawn from trust account in connection with redemption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_2_lbl" xml:lang="en-US">Assets held in trust noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, Shares new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RedemptionLimitPercentageWithoutPriorConsent" xlink:label="TVGN_RedemptionLimitPercentageWithoutPriorConsent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RedemptionLimitPercentageWithoutPriorConsent" xlink:to="TVGN_RedemptionLimitPercentageWithoutPriorConsent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RedemptionLimitPercentageWithoutPriorConsent_lbl" xml:lang="en-US">Redemption limit percentage without prior consent</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:to="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumAllowedDissolutionExpenses" xlink:label="TVGN_MaximumAllowedDissolutionExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumAllowedDissolutionExpenses" xlink:to="TVGN_MaximumAllowedDissolutionExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MaximumAllowedDissolutionExpenses_lbl" xml:lang="en-US">Maximum allowed dissolution expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrust" xlink:to="us-gaap_AssetsHeldInTrust_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xml:lang="en-US">Extension amount deposited into Trust Account</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Ordinary shares, par value (in dollar per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalDeficit" xlink:label="TVGN_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalDeficit" xlink:to="TVGN_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment income interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xml:lang="en-US">Class A ordinary share subject to possible redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US">Accretion of carrying value to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TemporaryEquityRedemptionAmount" xlink:label="TVGN_TemporaryEquityRedemptionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TemporaryEquityRedemptionAmount" xlink:to="TVGN_TemporaryEquityRedemptionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TemporaryEquityRedemptionAmount_lbl" xml:lang="en-US">Redemption of ordinary shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3_lbl" xml:lang="en-US">Class A ordinary share subject to possible redemption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Allocation of net (loss) income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net income (loss) per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Dilution net income (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransactionCosts" xlink:to="TVGN_TransactionCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_TransactionCosts_3_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfStockUnderwritingFees" xlink:to="TVGN_SaleOfStockUnderwritingFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_SaleOfStockUnderwritingFees_2_lbl" xml:lang="en-US">Underwriting fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal depository insurance coverage amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:to="TVGN_ImpairmentOfAmountDueFromRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_ImpairmentOfAmountDueFromRelatedParty_3_lbl" xml:lang="en-US">Impairment of due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized tax benefits accrued for interest and penalties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued to purchase ordinary shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Number of shares excluded from computation of diluted earnings per ordinary share</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssue" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnitsIssuedDuringPeriodSharesNewIssue" xlink:to="TVGN_UnitsIssuedDuringPeriodSharesNewIssue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssue_lbl" xml:lang="en-US">Sale of units in initial public offering, gross (in shares ) | shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesIssuedPerUnit" xlink:label="TVGN_NumberOfSharesIssuedPerUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfSharesIssuedPerUnit" xlink:to="TVGN_NumberOfSharesIssuedPerUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US">Number of shares in a unit</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfWarrantsIssuedPerUnit" xlink:label="TVGN_NumberOfWarrantsIssuedPerUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfWarrantsIssuedPerUnit" xlink:to="TVGN_NumberOfWarrantsIssuedPerUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US">Number of warrants in a unit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of shares issuable per warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Number of warrants to purchase shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US">Price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount for lack of marketability</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockPriceOfMeasurement" xlink:label="TVGN_StockPriceOfMeasurement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockPriceOfMeasurement" xlink:to="TVGN_StockPriceOfMeasurement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockPriceOfMeasurement_lbl" xml:lang="en-US">Stock price as of measurement date</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProbabilityOfTransactionPercentage" xlink:label="TVGN_ProbabilityOfTransactionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProbabilityOfTransactionPercentage" xlink:to="TVGN_ProbabilityOfTransactionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ProbabilityOfTransactionPercentage_lbl" xml:lang="en-US">Probability of transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Share dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US">Stock dividend ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateNumberOfSharesOwned" xlink:label="TVGN_AggregateNumberOfSharesOwned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregateNumberOfSharesOwned" xlink:to="TVGN_AggregateNumberOfSharesOwned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AggregateNumberOfSharesOwned_lbl" xml:lang="en-US">Aggregate number of shares owned</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesSubjectToForfeiture" xlink:label="TVGN_NumberOfSharesSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfSharesSubjectToForfeiture" xlink:to="TVGN_NumberOfSharesSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US">Shares subject to forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:to="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US">Restrictions on transfer period of time after business combination completion</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:to="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregatePurchasePrice" xlink:label="TVGN_AggregatePurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregatePurchasePrice" xlink:to="TVGN_AggregatePurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Class of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:to="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US">Maximum borrowing capacity of related party promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Amount of notes payable repaid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Borrowings amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapital" xlink:label="TVGN_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapital" xlink:to="TVGN_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Loan from affiliate</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContribution" xlink:label="TVGN_InitialCapitalContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialCapitalContribution" xlink:to="TVGN_InitialCapitalContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_InitialCapitalContribution_lbl" xml:lang="en-US">Initial capital contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContributionPerShare" xlink:label="TVGN_InitialCapitalContributionPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialCapitalContributionPerShare" xlink:to="TVGN_InitialCapitalContributionPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_InitialCapitalContributionPerShare_lbl" xml:lang="en-US">Initial capital contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US">Remaining borrowing capacity amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt instrument, fee amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from Other Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Other Notes Payable, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertibleNotesPayableDiscounts" xlink:label="TVGN_ConvertibleNotesPayableDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertibleNotesPayableDiscounts" xlink:to="TVGN_ConvertibleNotesPayableDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConvertibleNotesPayableDiscounts_lbl" xml:lang="en-US">[custom:ConvertibleNotesPayableDiscounts-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NoncashInterestExpenses" xlink:to="TVGN_NoncashInterestExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_NoncashInterestExpenses_2_lbl" xml:lang="en-US">Non cash interest expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumLoansConvertibleIntoWarrants" xlink:label="TVGN_MaximumLoansConvertibleIntoWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumLoansConvertibleIntoWarrants" xlink:to="TVGN_MaximumLoansConvertibleIntoWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US">Loan conversion agreement warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights_2_lbl" xml:lang="en-US">Price of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalLoan" xlink:label="TVGN_WorkingCapitalLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalLoan" xlink:to="TVGN_WorkingCapitalLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WorkingCapitalLoan_lbl" xml:lang="en-US">Working capital loan</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US">Expenses per month</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Amount accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwritingOptionPeriod" xlink:label="TVGN_UnderwritingOptionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnderwritingOptionPeriod" xlink:to="TVGN_UnderwritingOptionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_UnderwritingOptionPeriod_lbl" xml:lang="en-US">Underwriting option period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="TVGN_UnitsIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Sale of units, net of underwriting discounts (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwritingCashDiscountPerUnit" xlink:label="TVGN_UnderwritingCashDiscountPerUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnderwritingCashDiscountPerUnit" xlink:to="TVGN_UnderwritingCashDiscountPerUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_UnderwritingCashDiscountPerUnit_lbl" xml:lang="en-US">Underwriting cash discount per unit</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PaymentOfUnderwriterDiscount" xlink:label="TVGN_PaymentOfUnderwriterDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PaymentOfUnderwriterDiscount" xlink:to="TVGN_PaymentOfUnderwriterDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PaymentOfUnderwriterDiscount_lbl" xml:lang="en-US">Payment of underwriter discount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateUnderwriterCashDiscount" xlink:label="TVGN_AggregateUnderwriterCashDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregateUnderwriterCashDiscount" xlink:to="TVGN_AggregateUnderwriterCashDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AggregateUnderwriterCashDiscount_lbl" xml:lang="en-US">Aggregate underwriter cash discount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredFeePerUnit" xlink:label="TVGN_DeferredFeePerUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredFeePerUnit" xlink:to="TVGN_DeferredFeePerUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredFeePerUnit_lbl" xml:lang="en-US">Deferred underwriting commission fee (per unit)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredUnderwritingFeePayable" xlink:label="TVGN_DeferredUnderwritingFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredUnderwritingFeePayable" xlink:to="TVGN_DeferredUnderwritingFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_DeferredUnderwritingFeePayable_lbl" xml:lang="en-US">Deferred underwriting fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateDeferredUnderwritingFeePayable" xlink:label="TVGN_AggregateDeferredUnderwritingFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregateDeferredUnderwritingFeePayable" xlink:to="TVGN_AggregateDeferredUnderwritingFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AggregateDeferredUnderwritingFeePayable_lbl" xml:lang="en-US">Aggregate deferred underwriting fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwriterCashDiscount" xlink:label="TVGN_UnderwriterCashDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnderwriterCashDiscount" xlink:to="TVGN_UnderwriterCashDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_UnderwriterCashDiscount_lbl" xml:lang="en-US">Underwriter cash discount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" xlink:label="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" xlink:to="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_lbl" xml:lang="en-US">Minimum period for receiving spac loan from de-spac closing</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" xlink:label="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" xlink:to="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution_lbl" xml:lang="en-US">Number of shares issuable for each $10 initial capital contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" xlink:label="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" xlink:to="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare_lbl" xml:lang="en-US">Amount of initial capital considered to issue one share</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" xlink:label="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" xlink:to="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation_lbl" xml:lang="en-US">Minimum period for payment in case of liquidation</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumReasonableAttorneyFees" xlink:label="TVGN_MaximumReasonableAttorneyFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumReasonableAttorneyFees" xlink:to="TVGN_MaximumReasonableAttorneyFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MaximumReasonableAttorneyFees_lbl" xml:lang="en-US">Maximum reasonable attorney fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregatePurchasePrice" xlink:to="TVGN_AggregatePurchasePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AggregatePurchasePrice_2_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Ordinary shares, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xml:lang="en-US">Ordinary shares, par value (In Dollar per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_3_lbl" xml:lang="en-US">Ordinary shares, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xml:lang="en-US">Class A ordinary shares subject to possible redemption, outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonStockNumberOfVotesPerShare" xlink:label="TVGN_CommonStockNumberOfVotesPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockNumberOfVotesPerShare" xlink:to="TVGN_CommonStockNumberOfVotesPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US">Ordinary shares, vote per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertibleStocksConversionRatio" xlink:label="TVGN_ConvertibleStocksConversionRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertibleStocksConversionRatio" xlink:to="TVGN_ConvertibleStocksConversionRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConvertibleStocksConversionRatio_lbl" xml:lang="en-US">Ratio to be applied to the stock in the conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preference shares , shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preference shares, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preference shares, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantExercisePeriodConditionOne" xlink:label="TVGN_WarrantExercisePeriodConditionOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantExercisePeriodConditionOne" xlink:to="TVGN_WarrantExercisePeriodConditionOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantExercisePeriodConditionOne_lbl" xml:lang="en-US">Minimum threshold written notice period for redemption of public warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" xlink:label="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" xlink:to="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_lbl" xml:lang="en-US">Public warrants exercisable term from the closing of the initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Public warrants expiration term</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US">Redemption price per public warrant (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RedemptionPeriod" xlink:label="TVGN_RedemptionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RedemptionPeriod" xlink:to="TVGN_RedemptionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RedemptionPeriod_lbl" xml:lang="en-US">Redemption period</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantRedemptionConditionMinimumSharePrice" xlink:label="TVGN_WarrantRedemptionConditionMinimumSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantRedemptionConditionMinimumSharePrice" xlink:to="TVGN_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US">Warrant redemption condition minimum share price</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US">Threshold trading days for redemption of public warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US">Threshold consecutive trading days for redemption of public warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:to="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xml:lang="en-US">Threshold number of business days before sending notice of redemption to warrant holders</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:to="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US">Share price trigger used to measure dilution of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:to="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:to="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US">Trading period after business combination used to measure dilution of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" xlink:label="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" xlink:to="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_lbl" xml:lang="en-US">Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">U.S. Treasury Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant Liability- Private Placement Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Measurement Input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Share price, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xml:lang="en-US">Merger agreement share issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Aggregate purchase price amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Shares purchase amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="us-gaap_SponsorFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SponsorFees" xlink:to="us-gaap_SponsorFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SponsorFees_lbl" xml:lang="en-US">Sponsor Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_OffsetValue" xlink:label="TVGN_OffsetValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OffsetValue" xlink:to="TVGN_OffsetValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_OffsetValue_lbl" xml:lang="en-US">Offset value</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ServicesFees" xlink:label="TVGN_ServicesFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServicesFees" xlink:to="TVGN_ServicesFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ServicesFees_lbl" xml:lang="en-US">Service fees</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExchangeRatio" xlink:label="TVGN_ExchangeRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ExchangeRatio" xlink:to="TVGN_ExchangeRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ExchangeRatio_lbl" xml:lang="en-US">Exchange ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Equity holders percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Amount of accumulated undistributed earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Management cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Sale of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_lbl" xml:lang="en-US">Derecognition upon conversion of convertible promissory notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Fair value ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Balance, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xml:lang="en-US">Balance, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_2_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageOfProbabilityOfLiquidityEvent" xlink:label="TVGN_PercentageOfProbabilityOfLiquidityEvent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PercentageOfProbabilityOfLiquidityEvent" xlink:to="TVGN_PercentageOfProbabilityOfLiquidityEvent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PercentageOfProbabilityOfLiquidityEvent_lbl" xml:lang="en-US">Percentage of probability of liquidity event</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xml:lang="en-US">Risk-free interest rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RangeInYears" xlink:label="TVGN_RangeInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RangeInYears" xlink:to="TVGN_RangeInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RangeInYears_lbl" xml:lang="en-US">Range in years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Due from Sponsor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total net liabilities acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" xlink:label="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" xlink:to="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired_lbl" xml:lang="en-US">Plus: Merger transaction costs limited to cash acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:label="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:to="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts_lbl" xml:lang="en-US">Total net liabilities acquired plus transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCost" xlink:label="TVGN_TransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransactionCost" xlink:to="TVGN_TransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TransactionCost_lbl" xml:lang="en-US">Charged expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Earnout shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesTradingDaysDescription" xlink:label="TVGN_EarnoutSharesTradingDaysDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesTradingDaysDescription" xlink:to="TVGN_EarnoutSharesTradingDaysDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesTradingDaysDescription_lbl" xml:lang="en-US">Earnout shares trading days description</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccruedProfessionalServiceFeesCurrent" xlink:label="TVGN_AccruedProfessionalServiceFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AccruedProfessionalServiceFeesCurrent" xlink:to="TVGN_AccruedProfessionalServiceFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AccruedProfessionalServiceFeesCurrent_lbl" xml:lang="en-US">Professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapital" xlink:to="TVGN_WorkingCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_WorkingCapital_2_lbl" xml:lang="en-US">[custom:WorkingCapital-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Nonvested Shares, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Nonvested Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Nonvested Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Nonvested Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Nonvested Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Nonvested Shares, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted awards shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Compensation cost recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharesToBeIssuedOnSharesIssuable" xlink:label="TVGN_SharesToBeIssuedOnSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesToBeIssuedOnSharesIssuable" xlink:to="TVGN_SharesToBeIssuedOnSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SharesToBeIssuedOnSharesIssuable_lbl" xml:lang="en-US">Shares issuable to Polar</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_lbl" xml:lang="en-US">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:to="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_lbl" xml:lang="en-US">Issuance of restricted common stock subject to forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:to="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_lbl" xml:lang="en-US">Total shares issued and outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred shares, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_lbl" xml:lang="en-US">Proceeds from issuance of preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_LossOnPreferredStockIssuance_2_lbl" xml:lang="en-US">Loss on preferred stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_3_lbl" xml:lang="en-US">Price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="us-gaap_PreferredStockDividendPaymentRateVariable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPaymentRateVariable" xlink:to="us-gaap_PreferredStockDividendPaymentRateVariable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendPaymentRateVariable_lbl" xml:lang="en-US">Dividend variable rate, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionTerms" xlink:to="us-gaap_PreferredStockRedemptionTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xml:lang="en-US">Redemption term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_2_lbl" xml:lang="en-US">Non refundable amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_lbl" xml:lang="en-US">Conversion of certain liabilities into Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_lbl" xml:lang="en-US">Conversion of certain liabilities into Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends payable per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Exercisable date</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsDescription" xlink:label="TVGN_WarrantsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsDescription" xlink:to="TVGN_WarrantsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantsDescription_lbl" xml:lang="en-US">Warrants description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PolarNotesMember" xlink:label="TVGN_PolarNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PolarNotesMember" xlink:to="TVGN_PolarNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PolarNotesMember_lbl" xml:lang="en-US">Polar Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SponsorFees" xlink:to="us-gaap_SponsorFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SponsorFees_2_lbl" xml:lang="en-US">Sponsor advisory services fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilities_2_lbl" xml:lang="en-US">Due to Sponsor</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Isssued shares to related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalExpenses" xlink:label="TVGN_WorkingCapitalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalExpenses" xlink:to="TVGN_WorkingCapitalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WorkingCapitalExpenses_lbl" xml:lang="en-US">Working capital expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Compensation cost recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US">Less: Undistributed earnings allocated to participating securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3_lbl" xml:lang="en-US">Net income (loss) attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertiblePromissoryNoteInterest" xlink:label="TVGN_ConvertiblePromissoryNoteInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertiblePromissoryNoteInterest" xlink:to="TVGN_ConvertiblePromissoryNoteInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="TVGN_ConvertiblePromissoryNoteInterest_lbl" xml:lang="en-US">Less: Convertible promissory note interest</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertiblePromissoryNoteChangeInFairValue" xlink:label="TVGN_ConvertiblePromissoryNoteChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertiblePromissoryNoteChangeInFairValue" xlink:to="TVGN_ConvertiblePromissoryNoteChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="TVGN_ConvertiblePromissoryNoteChangeInFairValue_lbl" xml:lang="en-US">Less: Convertible promissory note change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US">Weighted average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Effect of potentially dilutive convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Total potentially dilutive securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_3_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Stock option vested</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:to="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_doc" xml:lang="en-US">Warrants, each exercisable for one share of Common Stock for $11.50 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonStock0.0001ParValuePerShareMember" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStock0.0001ParValuePerShareMember" xlink:to="TVGN_CommonStock0.0001ParValuePerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember_doc" xml:lang="en-US">Common Stock, $0.0001 par value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredOfferingCostsNoncurrent" xlink:to="TVGN_DeferredOfferingCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredOfferingCostsNoncurrent_doc" xml:lang="en-US">The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorMember" xlink:to="TVGN_SponsorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorMember_doc" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassAOrdinaryShares" xlink:to="TVGN_ClassAOrdinaryShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassAOrdinaryShares_doc" xml:lang="en-US">Class A ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassBOrdinaryShares" xlink:to="TVGN_ClassBOrdinaryShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassBOrdinaryShares_doc" xml:lang="en-US">Class B ordinary shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockTransactionCostsAllocatedToWarrants" xlink:label="TVGN_SaleOfStockTransactionCostsAllocatedToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfStockTransactionCostsAllocatedToWarrants" xlink:to="TVGN_SaleOfStockTransactionCostsAllocatedToWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SaleOfStockTransactionCostsAllocatedToWarrants_doc" xml:lang="en-US">Sale of stock transaction costs allocated to warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:to="TVGN_CommonClassaNotSubjectToRedemptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonClassaNotSubjectToRedemptionMember_doc" xml:lang="en-US">This member represents of classification of common stock representing ownership interest in a corporation that is not subject to redemption.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AccretionOfCarryingValueToRedemptionValue" xlink:to="TVGN_AccretionOfCarryingValueToRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AccretionOfCarryingValueToRedemptionValue_doc" xml:lang="en-US">Accretion of carrying value to redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:to="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_doc" xml:lang="en-US">The cash inflow from cash withdrawn from Trust Account in connection with redemption.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfClassBSharesToInvestor" xlink:to="TVGN_SaleOfClassBSharesToInvestor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SaleOfClassBSharesToInvestor_doc" xml:lang="en-US">Sale of class B shares to investor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfWarrants" xlink:to="TVGN_SaleOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SaleOfWarrants_doc" xml:lang="en-US">Sale of warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IncreaseDecreaseInDueFromSponsor" xlink:label="TVGN_IncreaseDecreaseInDueFromSponsor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncreaseDecreaseInDueFromSponsor" xlink:to="TVGN_IncreaseDecreaseInDueFromSponsor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_IncreaseDecreaseInDueFromSponsor_doc" xml:lang="en-US">Increase decrease in due from sponsor</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:to="TVGN_ExtensionAmountDepositedIntoTrustAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ExtensionAmountDepositedIntoTrustAccount_doc" xml:lang="en-US">Extension amount deposited into trust account</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" xlink:to="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount_doc" xml:lang="en-US">Change in value of class ordinary shares subject to redemption amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_doc" xml:lang="en-US">Condition for future business combination number of businesses minimum.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="TVGN_UnitsIssuedDuringPeriodSharesNewIssues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssues_doc" xml:lang="en-US">Number of new units issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransactionCosts" xlink:to="TVGN_TransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TransactionCosts_doc" xml:lang="en-US">Transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfStockUnderwritingFees" xlink:to="TVGN_SaleOfStockUnderwritingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SaleOfStockUnderwritingFees_doc" xml:lang="en-US">Sale of stock underwriting fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SaleOfStockOtherOfferingCosts" xlink:to="TVGN_SaleOfStockOtherOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SaleOfStockOtherOfferingCosts_doc" xml:lang="en-US">Sale of stock other offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PaymentsForInvestmentOfCashInTrustAccount" xlink:to="TVGN_PaymentsForInvestmentOfCashInTrustAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PaymentsForInvestmentOfCashInTrustAccount_doc" xml:lang="en-US">Payments for investment of cash in trust account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivatePlacementWarrantsMember" xlink:to="TVGN_PrivatePlacementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PrivatePlacementWarrantsMember_doc" xml:lang="en-US">Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:to="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_doc" xml:lang="en-US">Condition for future business combination use of proceeds percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:to="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_doc" xml:lang="en-US">Condition for future business combination threshold percentage ownership.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:to="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_doc" xml:lang="en-US">Condition for future business combination threshold net tangible assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:to="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_doc" xml:lang="en-US">Shareholders exercised their right to redeem shares number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicSharesMember" xlink:to="TVGN_PublicSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicSharesMember_doc" xml:lang="en-US">Public Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FirstExtensionCharterAmendmentMember" xlink:to="TVGN_FirstExtensionCharterAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FirstExtensionCharterAmendmentMember_doc" xml:lang="en-US">First Extension Charter Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecondExtensionCharterAmendmentMember" xlink:to="TVGN_SecondExtensionCharterAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SecondExtensionCharterAmendmentMember_doc" xml:lang="en-US">Second Extension Charter Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PurchaseAgreementMember" xlink:to="TVGN_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SsvkAssociatesLlcMember" xlink:to="TVGN_SsvkAssociatesLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SsvkAssociatesLlcMember_doc" xml:lang="en-US">SSVK Associates, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RedemptionLimitPercentageWithoutPriorConsent" xlink:to="TVGN_RedemptionLimitPercentageWithoutPriorConsent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RedemptionLimitPercentageWithoutPriorConsent_doc" xml:lang="en-US">Redemption limit percentage without prior consent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:to="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_doc" xml:lang="en-US">Percentage obligation to redeem public shares if entity does not complete business combination.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumAllowedDissolutionExpenses" xlink:to="TVGN_MaximumAllowedDissolutionExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MaximumAllowedDissolutionExpenses_doc" xml:lang="en-US">Maximum allowed dissolution expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalDeficit" xlink:to="TVGN_WorkingCapitalDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WorkingCapitalDeficit_doc" xml:lang="en-US">Working capital deficit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:to="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock_doc" xml:lang="en-US">Emerging Growth Company Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:to="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock_doc" xml:lang="en-US">Assets Held In Trust Account Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:to="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_doc" xml:lang="en-US">Offering Costs Associated With Initial Public Offering [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TemporaryEquityPolicyPolicyTextBlock" xlink:to="TVGN_TemporaryEquityPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TemporaryEquityPolicyPolicyTextBlock_doc" xml:lang="en-US">Temporary Equity Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TemporaryEquityRedemptionAmount" xlink:to="TVGN_TemporaryEquityRedemptionAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TemporaryEquityRedemptionAmount_doc" xml:lang="en-US">Temporary equity redemption amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:to="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantLiabilitiesPolicyPolicyTextBlock_doc" xml:lang="en-US">Warrant Liabilities Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialPublicOfferingTextBlock" xlink:to="TVGN_InitialPublicOfferingTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_InitialPublicOfferingTextBlock_doc" xml:lang="en-US">The entire disclosure on information about initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnitsIssuedDuringPeriodSharesNewIssue" xlink:to="TVGN_UnitsIssuedDuringPeriodSharesNewIssue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_UnitsIssuedDuringPeriodSharesNewIssue_doc" xml:lang="en-US">Number of new units issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfWarrantsIssuedPerUnit" xlink:to="TVGN_NumberOfWarrantsIssuedPerUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NumberOfWarrantsIssuedPerUnit_doc" xml:lang="en-US">Represents the number of warrants in a unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsMember" xlink:to="TVGN_PublicWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicWarrantsMember_doc" xml:lang="en-US">Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivatePlacementTextBlock" xlink:to="TVGN_PrivatePlacementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PrivatePlacementTextBlock_doc" xml:lang="en-US">Private Placement [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights_doc" xml:lang="en-US">Represents the price per share or per unit of warrants or rights outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CantorMember" xlink:to="TVGN_CantorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CantorMember_doc" xml:lang="en-US">This member stands for cantor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FounderSharesMember" xlink:to="TVGN_FounderSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FounderSharesMember_doc" xml:lang="en-US">This member stands for founder shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnderwritingOptionPeriod" xlink:to="TVGN_UnderwritingOptionPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_UnderwritingOptionPeriod_doc" xml:lang="en-US">It represents the underwriting option period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnderwritingCashDiscountPerUnit" xlink:to="TVGN_UnderwritingCashDiscountPerUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_UnderwritingCashDiscountPerUnit_doc" xml:lang="en-US">Represents the cash underwriting discount per unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PaymentOfUnderwriterDiscount" xlink:to="TVGN_PaymentOfUnderwriterDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PaymentOfUnderwriterDiscount_doc" xml:lang="en-US">Represents the payment of underwriting discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregateUnderwriterCashDiscount" xlink:to="TVGN_AggregateUnderwriterCashDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AggregateUnderwriterCashDiscount_doc" xml:lang="en-US">The carrying value of the cash underwriting discount in the aggregate if the underwriter's option to purchase additional units is exercised in full.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredFeePerUnit" xlink:to="TVGN_DeferredFeePerUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredFeePerUnit_doc" xml:lang="en-US">Represents the deferred fee per unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregateNumberOfSharesOwned" xlink:to="TVGN_AggregateNumberOfSharesOwned_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AggregateNumberOfSharesOwned_doc" xml:lang="en-US">The number of shares owned by the founders after the impact of the stock dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredUnderwritingFeePayable" xlink:to="TVGN_DeferredUnderwritingFeePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredUnderwritingFeePayable_doc" xml:lang="en-US">Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_UnderwriterCashDiscount" xlink:to="TVGN_UnderwriterCashDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_UnderwriterCashDiscount_doc" xml:lang="en-US">Represents the cash underwriting discount per unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialCapitalContribution" xlink:to="TVGN_InitialCapitalContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_InitialCapitalContribution_doc" xml:lang="en-US">Amount of initial cash contribution received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SubscriptionAgreementMember" xlink:to="TVGN_SubscriptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SubscriptionAgreementMember_doc" xml:lang="en-US">Represents the information pertaining to Subscription agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" xlink:to="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution_doc" xml:lang="en-US">Represents number of shares issuable for each $10 initial capital contribution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfSharesSubjectToForfeiture" xlink:to="TVGN_NumberOfSharesSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NumberOfSharesSubjectToForfeiture_doc" xml:lang="en-US">The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" xlink:to="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AmountOfInitialCapitalConsideredToIssueOneShare_doc" xml:lang="en-US">Represents amount of initial capital considered to issue one share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:to="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_doc" xml:lang="en-US">The period of time after completion of a business combination during which the shares or warrant may not be transferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" xlink:to="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MinimumPeriodForPaymentInCaseOfLiquidation_doc" xml:lang="en-US">Represents minimum period for payment in case of liquidation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumReasonableAttorneyFees" xlink:to="TVGN_MaximumReasonableAttorneyFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MaximumReasonableAttorneyFees_doc" xml:lang="en-US">Represents maximum reasonable attorney fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecondSubscriptionAgreementMember" xlink:to="TVGN_SecondSubscriptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SecondSubscriptionAgreementMember_doc" xml:lang="en-US">Second Subscription Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_doc" xml:lang="en-US">The contractual monthly amount to be paid for support services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AdministrativeSupportAgreementMember" xlink:to="TVGN_AdministrativeSupportAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AdministrativeSupportAgreementMember_doc" xml:lang="en-US">This member stands for Administrative Support Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalLoan" xlink:to="TVGN_WorkingCapitalLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WorkingCapitalLoan_doc" xml:lang="en-US">Working capital loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalLoansWarrantMember" xlink:to="TVGN_WorkingCapitalLoansWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WorkingCapitalLoansWarrantMember_doc" xml:lang="en-US">It represents the working capital loans warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RelatedPartyLoansMember" xlink:to="TVGN_RelatedPartyLoansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RelatedPartyLoansMember_doc" xml:lang="en-US">This member stands for related party loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumLoansConvertibleIntoWarrants" xlink:to="TVGN_MaximumLoansConvertibleIntoWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MaximumLoansConvertibleIntoWarrants_doc" xml:lang="en-US">The maximum amount which a potential loan could have repaid through issuance of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FirstPolarFundConvertibleNoteMember" xlink:to="TVGN_FirstPolarFundConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FirstPolarFundConvertibleNoteMember_doc" xml:lang="en-US">First Polar Fund Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecondPolarFundConvertibleNoteMember" xlink:to="TVGN_SecondPolarFundConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SecondPolarFundConvertibleNoteMember_doc" xml:lang="en-US">Second Polar Fund Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertibleNotesPayableDiscounts" xlink:to="TVGN_ConvertibleNotesPayableDiscounts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConvertibleNotesPayableDiscounts_doc" xml:lang="en-US">Convertible notes payable discounts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialCapitalContributionPerShare" xlink:to="TVGN_InitialCapitalContributionPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_InitialCapitalContributionPerShare_doc" xml:lang="en-US">Initial capital contribution per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeSPACMember" xlink:to="TVGN_DeSPACMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeSPACMember_doc" xml:lang="en-US">DeSPAC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:to="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_doc" xml:lang="en-US">Amount of maximum borrowing capacity of related party promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PromissoryNoteWithRelatedPartyMember" xlink:to="TVGN_PromissoryNoteWithRelatedPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PromissoryNoteWithRelatedPartyMember_doc" xml:lang="en-US">This member stands for promissory note with related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregatePurchasePrice" xlink:to="TVGN_AggregatePurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AggregatePurchasePrice_doc" xml:lang="en-US">Aggregate purchase price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:to="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_doc" xml:lang="en-US">The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_doc" xml:lang="en-US">When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_doc" xml:lang="en-US">Transfer assign or sell any shares or warrants after completion of initial business combination threshold consecutive trading days</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_doc" xml:lang="en-US">The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockNumberOfVotesPerShare" xlink:to="TVGN_CommonStockNumberOfVotesPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStockNumberOfVotesPerShare_doc" xml:lang="en-US">Represents the number of votes that each common share is entitled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertibleStocksConversionRatio" xlink:to="TVGN_ConvertibleStocksConversionRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConvertibleStocksConversionRatio_doc" xml:lang="en-US">The ratio to be applied to the stock in a conversion of convertible stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantExercisePeriodConditionOne" xlink:to="TVGN_WarrantExercisePeriodConditionOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantExercisePeriodConditionOne_doc" xml:lang="en-US">The period of time after completion of a business combination before a warrant may be exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_doc" xml:lang="en-US">Represents the redemption price per share or per unit of warrants or rights outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RedemptionPeriod" xlink:to="TVGN_RedemptionPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RedemptionPeriod_doc" xml:lang="en-US">The Period of redemption for written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantRedemptionConditionMinimumSharePrice" xlink:to="TVGN_WarrantRedemptionConditionMinimumSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantRedemptionConditionMinimumSharePrice_doc" xml:lang="en-US">The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_doc" xml:lang="en-US">Threshold number of specified trading days for stock price trigger considered for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_doc" xml:lang="en-US">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:to="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_doc" xml:lang="en-US">Represents the threshold number of business days before sending notice of redemption to warrant holders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:to="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants_doc" xml:lang="en-US">The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:to="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_doc" xml:lang="en-US">The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:to="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_doc" xml:lang="en-US">The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" xlink:to="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_doc" xml:lang="en-US">Percentage of adjustment of exercise price of warrants based on market value and newly issued price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantLiabilitiesDisclosureTextBlock" xlink:to="TVGN_WarrantLiabilitiesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantLiabilitiesDisclosureTextBlock_doc" xml:lang="en-US">Warrant Liabilities Disclosure [TextBlock}</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SecuritiesPurchaseAgreementMember" xlink:to="TVGN_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NumberOfSharesIssuedPerUnit" xlink:to="TVGN_NumberOfSharesIssuedPerUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NumberOfSharesIssuedPerUnit_doc" xml:lang="en-US">Represents the number of shares in a unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" xlink:to="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_doc" xml:lang="en-US">Represents minimum period for receiving spac loan from de-spac closing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" xlink:to="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_doc" xml:lang="en-US">The period of warrants exercisable term from the closing of the business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AggregateDeferredUnderwritingFeePayable" xlink:to="TVGN_AggregateDeferredUnderwritingFeePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AggregateDeferredUnderwritingFeePayable_doc" xml:lang="en-US">Aggregate deferred underwriting fee payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SeriesAOnePreferredStockMember_doc" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredOfferingCostsNoncurrentForfeited" xlink:to="TVGN_DeferredOfferingCostsNoncurrentForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredOfferingCostsNoncurrentForfeited_doc" xml:lang="en-US">Deferred offering costs non current forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FeeReductionAgreementMember" xlink:to="TVGN_FeeReductionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FeeReductionAgreementMember_doc" xml:lang="en-US">Fee Reduction Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonRedeemableOrdinaryMember" xlink:to="TVGN_NonRedeemableOrdinaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NonRedeemableOrdinaryMember_doc" xml:lang="en-US">Non Redeemable Ordinary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsTransferredTwoMember" xlink:to="TVGN_PublicWarrantsTransferredTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicWarrantsTransferredTwoMember_doc" xml:lang="en-US">Public Warrants Transferred Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsTransferredThreeMember" xlink:to="TVGN_PublicWarrantsTransferredThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicWarrantsTransferredThreeMember_doc" xml:lang="en-US">Public Warrants Transferred Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsTransferredOneMember" xlink:to="TVGN_PublicWarrantsTransferredOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicWarrantsTransferredOneMember_doc" xml:lang="en-US">Public Warrants Transferred One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockPriceOfMeasurement" xlink:to="TVGN_StockPriceOfMeasurement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockPriceOfMeasurement_doc" xml:lang="en-US">Stock price of measurement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProbabilityOfTransactionPercentage" xlink:to="TVGN_ProbabilityOfTransactionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ProbabilityOfTransactionPercentage_doc" xml:lang="en-US">Probability of transaction percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerAgreementMember" xlink:to="TVGN_MergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MergerAgreementMember_doc" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioMember" xlink:to="TVGN_TevogenBioMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TevogenBioMember_doc" xml:lang="en-US">Tevogen Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpense" xlink:label="TVGN_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NoncashInterestExpense" xlink:to="TVGN_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NoncashInterestExpense_doc" xml:lang="en-US">Non cash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NoncashInterestExpenses" xlink:to="TVGN_NoncashInterestExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NoncashInterestExpenses_doc" xml:lang="en-US">Non cash interest expenses.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SriramaAssociatesLLCMember" xlink:label="TVGN_SriramaAssociatesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SriramaAssociatesLLCMember" xlink:to="TVGN_SriramaAssociatesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SriramaAssociatesLLCMember_doc" xml:lang="en-US">Srirama Associates LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CharterAmendmentMember" xlink:label="TVGN_CharterAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CharterAmendmentMember" xlink:to="TVGN_CharterAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CharterAmendmentMember_doc" xml:lang="en-US">Charter Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:to="TVGN_ImpairmentOfAmountDueFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ImpairmentOfAmountDueFromRelatedParty_doc" xml:lang="en-US">Impairment of amount due from related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapital" xlink:to="TVGN_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesA1PreferredStockMember" xlink:to="TVGN_SeriesA1PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SeriesA1PreferredStockMember_doc" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServiceFeeMember" xlink:to="TVGN_SponsorAdvisoryServiceFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorAdvisoryServiceFeeMember_doc" xml:lang="en-US">Sponsor Advisory Service Fee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OffsetValue" xlink:to="TVGN_OffsetValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_OffsetValue_doc" xml:lang="en-US">Offset value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServicesFees" xlink:to="TVGN_ServicesFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ServicesFees_doc" xml:lang="en-US">Services fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTransactionCosts" xlink:to="TVGN_DeferredTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTransactionCosts_doc" xml:lang="en-US">Deferred transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_doc" xml:lang="en-US">Change in fair value of convertible promissory notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_doc" xml:lang="en-US">Stock issued during period value new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xml:lang="en-US">Stock issued during period shares new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LossOnPreferredStockIssuance_doc" xml:lang="en-US">Loss on preferred stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_doc" xml:lang="en-US">Cash acquired in connection with reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_doc" xml:lang="en-US">Non refundable prepaid proceeds towards anticipated preferred stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" xlink:to="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger_doc" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" xlink:to="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts_doc" xml:lang="en-US">Issuance of common stock for net liabilities upon reverse recapitalization net of transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ExchangeRatio" xlink:to="TVGN_ExchangeRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ExchangeRatio_doc" xml:lang="en-US">Exchange ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_doc" xml:lang="en-US">Development Stage Risks And Liquidity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PercentageOfProbabilityOfLiquidityEvent" xlink:to="TVGN_PercentageOfProbabilityOfLiquidityEvent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PercentageOfProbabilityOfLiquidityEvent_doc" xml:lang="en-US">Percentage of probability of liquidity event.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RangeInYears" xlink:to="TVGN_RangeInYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RangeInYears_doc" xml:lang="en-US">Range in years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities derivative warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" xlink:to="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PlusMergerTransactionCostsLimitedToCashAcquired_doc" xml:lang="en-US">Plus merger transaction costs limited to cash acquired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:to="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts_doc" xml:lang="en-US">Total net liabilities acquired plus transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TransactionCost" xlink:to="TVGN_TransactionCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TransactionCost_doc" xml:lang="en-US">Transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesDisclosureTextBlock" xlink:to="TVGN_EarnoutSharesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock_doc" xml:lang="en-US">Earnout Shares Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesTradingDaysDescription" xlink:to="TVGN_EarnoutSharesTradingDaysDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EarnoutSharesTradingDaysDescription_doc" xml:lang="en-US">Earnout shares trading days description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AccruedProfessionalServiceFeesCurrent" xlink:to="TVGN_AccruedProfessionalServiceFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AccruedProfessionalServiceFeesCurrent_doc" xml:lang="en-US">Accrued professional service fees current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesToBeIssuedOnSharesIssuable" xlink:to="TVGN_SharesToBeIssuedOnSharesIssuable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SharesToBeIssuedOnSharesIssuable_doc" xml:lang="en-US">Shares to be issued on shares issuable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:to="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_doc" xml:lang="en-US">Shares subject to future vesting issuance of restricted common stock subject to forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:to="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_doc" xml:lang="en-US">Common stock shares issued  and Outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_doc" xml:lang="en-US">Stock issued during period shares conversion of liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_doc" xml:lang="en-US">Stock issued during period value conversion of liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsDescription" xlink:to="TVGN_WarrantsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsDescription_doc" xml:lang="en-US">Warrants description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WorkingCapitalExpenses" xlink:to="TVGN_WorkingCapitalExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WorkingCapitalExpenses_doc" xml:lang="en-US">Working capital expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertiblePromissoryNoteInterest" xlink:to="TVGN_ConvertiblePromissoryNoteInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConvertiblePromissoryNoteInterest_doc" xml:lang="en-US">Convertible promissory note interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertiblePromissoryNoteChangeInFairValue" xlink:to="TVGN_ConvertiblePromissoryNoteChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ConvertiblePromissoryNoteChangeInFairValue_doc" xml:lang="en-US">Convertible promissory note interest change in fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ReverseRecapitalizationMember" xlink:to="TVGN_ReverseRecapitalizationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ReverseRecapitalizationMember_doc" xml:lang="en-US">Reverse Recapitalization [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SeriesAOnePreferredStockMember_3_lbl" xml:lang="en-US">Series A One Preferred Stock [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_4_lbl" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_3_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Due from Related Parties, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:to="TVGN_ExtensionAmountDepositedIntoTrustAccount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ExtensionAmountDepositedIntoTrustAccount_3_lbl" xml:lang="en-US">ExtensionAmountDepositedIntoTrustAccount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_2_lbl" xml:lang="en-US">Paid-in-Kind Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivatePlacementTextBlock" xlink:to="TVGN_PrivatePlacementTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PrivatePlacementTextBlock_3_lbl" xml:lang="en-US">PrivatePlacementTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantLiabilitiesDisclosureTextBlock" xlink:to="TVGN_WarrantLiabilitiesDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantLiabilitiesDisclosureTextBlock_3_lbl" xml:lang="en-US">WarrantLiabilitiesDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_2_lbl" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_InitialCapitalContributionPerShare" xlink:to="TVGN_InitialCapitalContributionPerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_InitialCapitalContributionPerShare_3_lbl" xml:lang="en-US">Initial capital contribution per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredUnderwritingFeePayable" xlink:to="TVGN_DeferredUnderwritingFeePayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredUnderwritingFeePayable_3_lbl" xml:lang="en-US">Deferred Underwriting Fee Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_3_lbl" xml:lang="en-US">FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:to="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts_3_lbl" xml:lang="en-US">TotalNetLiabilitiesAcquiredPlusTransactionCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2_lbl" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_2_lbl" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertiblePromissoryNoteInterest" xlink:to="TVGN_ConvertiblePromissoryNoteInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConvertiblePromissoryNoteInterest_3_lbl" xml:lang="en-US">ConvertiblePromissoryNoteInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ConvertiblePromissoryNoteChangeInFairValue" xlink:to="TVGN_ConvertiblePromissoryNoteChangeInFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ConvertiblePromissoryNoteChangeInFairValue_3_lbl" xml:lang="en-US">ConvertiblePromissoryNoteChangeInFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>tvgn-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20240331.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfCashFlows" xlink:href="tvgn-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:href="tvgn-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" xlink:href="tvgn-20240331.xsd#InitialPublicOfferingAndOver-allotment" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PrivatePlacementWarrants" xlink:href="tvgn-20240331.xsd#PrivatePlacementWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ShareholdersDeficit" xlink:href="tvgn-20240331.xsd#ShareholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/WarrantLiabilities" xlink:href="tvgn-20240331.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/FairValueMeasurements" xlink:href="tvgn-20240331.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20240331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20240331.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20240331.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20240331.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20240331.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20240331.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NotesPayable" xlink:href="tvgn-20240331.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20240331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20240331.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetIncomeLossPerShare" xlink:href="tvgn-20240331.xsd#NetIncomeLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDisclosure" xlink:href="tvgn-20240331.xsd#SubsequentEventsDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsTables" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/FairValueMeasurementsTables" xlink:href="tvgn-20240331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20240331.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20240331.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20240331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20240331.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetIncomeLossPerShareTables" xlink:href="tvgn-20240331.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:href="tvgn-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:href="tvgn-20240331.xsd#InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" xlink:href="tvgn-20240331.xsd#PrivatePlacementWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValueNonRedeemableSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="tvgn-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" xlink:href="tvgn-20240331.xsd#ShareholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="tvgn-20240331.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20240331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20240331.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20240331.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:href="tvgn-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20240331.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20240331.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NotesPayableDetailsNarrative" xlink:href="tvgn-20240331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20240331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20240331.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:href="tvgn-20240331.xsd#RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20240331.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20240331.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredTransactionCosts" xlink:label="loc_TVGNDeferredTransactionCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_TVGNDeferredTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaapAssetsHeldInTrustNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsHeldInTrustNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassAOrdinaryShares" xlink:label="loc_TVGNClassAOrdinaryShares" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_TVGNClassAOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassBOrdinaryShares" xlink:label="loc_TVGNClassBOrdinaryShares" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_TVGNClassBOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaapTemporaryEquityRedemptionPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:label="loc_TVGNCommonClassaNotSubjectToRedemptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNCommonClassaNotSubjectToRedemptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_TVGNTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_TVGNReverseRecapitalizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_TVGNAccretionOfCarryingValueToRedemptionValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAccretionOfCarryingValueToRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpenses" xlink:label="loc_TVGNNoncashInterestExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNNoncashInterestExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToAffiliatesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToAffiliatesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExtensionAmountDepositedIntoTrustAccount" xlink:label="loc_TVGNExtensionAmountDepositedIntoTrustAccount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_TVGNExtensionAmountDepositedIntoTrustAccount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" xlink:label="loc_TVGNChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfClassBSharesToInvestor" xlink:label="loc_TVGNSaleOfClassBSharesToInvestor" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNSaleOfClassBSharesToInvestor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfWarrants" xlink:label="loc_TVGNSaleOfWarrants" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNSaleOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaapNoncashMergerRelatedCosts" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapNoncashMergerRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" xlink:label="loc_TVGNConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" xlink:label="loc_TVGNIssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNIssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity" xlink:title="00000007 - Disclosure - Description of Organization, Business Operations and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/InitialPublicOfferingAndOver-allotment" xlink:title="00000009 - Disclosure - Initial Public Offering and Over-Allotment">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract" xlink:label="loc_TVGNDisclosureInitialPublicOfferingAndOverallotmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialPublicOfferingTextBlock" xlink:label="loc_TVGNInitialPublicOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureInitialPublicOfferingAndOverallotmentAbstract" xlink:to="loc_TVGNInitialPublicOfferingTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PrivatePlacementWarrants" xlink:title="00000010 - Disclosure - Private Placement Warrants">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosurePrivatePlacementWarrantsAbstract" xlink:label="loc_TVGNDisclosurePrivatePlacementWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementTextBlock" xlink:label="loc_TVGNPrivatePlacementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosurePrivatePlacementWarrantsAbstract" xlink:to="loc_TVGNPrivatePlacementTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ShareholdersDeficit" xlink:title="00000013 - Disclosure - Shareholders&#8217; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/WarrantLiabilities" xlink:title="00000014 - Disclosure - Warrant Liabilities">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_TVGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantLiabilitiesDisclosureTextBlock" xlink:label="loc_TVGNWarrantLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_TVGNWarrantLiabilitiesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/FairValueMeasurements" xlink:title="00000015 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="00000017 - Disclosure - NATURE OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="00000018 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="loc_TVGNDevelopmentStageRisksAndLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="loc_TVGNDevelopmentStageRisksAndLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="00000020 - Disclosure - BUSINESS COMBINATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="00000021 - Disclosure - EARNOUT SHARES">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="loc_TVGNDisclosureEarnoutSharesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesDisclosureTextBlock" xlink:label="loc_TVGNEarnoutSharesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureEarnoutSharesAbstract" xlink:to="loc_TVGNEarnoutSharesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="00000022 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NotesPayable" xlink:title="00000023 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:label="loc_us-gaapMortgageNotesPayableDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapMortgageNotesPayableDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="00000024 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDisclosure" xlink:title="00000026 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetIncomeLossPerShare" xlink:title="00000027 - Disclosure - NET INCOME (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDisclosure" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="loc_TVGNEmergingGrowthCompanyPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNEmergingGrowthCompanyPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_TVGNAssetsHeldInTrustAccountPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNAssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:label="loc_TVGNOfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNOfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TemporaryEquityPolicyPolicyTextBlock" xlink:label="loc_TVGNTemporaryEquityPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNTemporaryEquityPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:label="loc_TVGNWarrantLiabilitiesPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNWarrantLiabilitiesPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure" xlink:title="00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaapTemporaryEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTemporaryEquityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsTables" xlink:title="00000032 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/FairValueMeasurementsTables" xlink:title="00000033 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure" xlink:title="00000034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="00000035 - Disclosure - BUSINESS COMBINATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="00000036 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetIncomeLossPerShareTables" xlink:title="00000039 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative" xlink:title="00000040 - Disclosure - Description of Organization, Business Operations and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FeeReductionAgreementMember" xlink:label="loc_TVGNFeeReductionAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNFeeReductionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FirstExtensionCharterAmendmentMember" xlink:label="loc_TVGNFirstExtensionCharterAmendmentMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNFirstExtensionCharterAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondExtensionCharterAmendmentMember" xlink:label="loc_TVGNSecondExtensionCharterAmendmentMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecondExtensionCharterAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="loc_TVGNPurchaseAgreementMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_TVGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="loc_TVGNPrivatePlacementWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicSharesMember" xlink:label="loc_TVGNPublicSharesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNPublicSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesA1PreferredStockMember" xlink:label="loc_TVGNSeriesA1PreferredStockMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesA1PreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="loc_TVGNSsvkAssociatesLlcMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_TVGNSsvkAssociatesLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_TVGNConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockUnderwritingFees" xlink:label="loc_TVGNSaleOfStockUnderwritingFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNSaleOfStockUnderwritingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockOtherOfferingCosts" xlink:label="loc_TVGNSaleOfStockOtherOfferingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNSaleOfStockOtherOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrentForfeited" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrentForfeited" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrentForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="loc_TVGNPaymentsForInvestmentOfCashInTrustAccount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNPaymentsForInvestmentOfCashInTrustAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:label="loc_TVGNConditionForFutureBusinessCombinationUseOfProceedsPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:label="loc_TVGNConditionForFutureBusinessCombinationThresholdPercentageOwnership" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:label="loc_TVGNConditionForFutureBusinessCombinationThresholdNetTangibleAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:label="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaapAssetsHeldInTrustNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsHeldInTrustNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RedemptionLimitPercentageWithoutPriorConsent" xlink:label="loc_TVGNRedemptionLimitPercentageWithoutPriorConsent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNRedemptionLimitPercentageWithoutPriorConsent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_TVGNPercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNPercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumAllowedDissolutionExpenses" xlink:label="loc_TVGNMaximumAllowedDissolutionExpenses" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNMaximumAllowedDissolutionExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaapAssetsHeldInTrust" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsHeldInTrust" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalDeficit" xlink:label="loc_TVGNWorkingCapitalDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNWorkingCapitalDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails" xlink:title="00000041 - Disclosure - Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TemporaryEquityRedemptionAmount" xlink:label="loc_TVGNTemporaryEquityRedemptionAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNTemporaryEquityRedemptionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" xlink:title="00000042 - Disclosure - Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonClassaNotSubjectToRedemptionMember" xlink:label="loc_TVGNCommonClassaNotSubjectToRedemptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNCommonClassaNotSubjectToRedemptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FeeReductionAgreementMember" xlink:label="loc_TVGNFeeReductionAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNFeeReductionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockUnderwritingFees" xlink:label="loc_TVGNSaleOfStockUnderwritingFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNSaleOfStockUnderwritingFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredOfferingCostsNoncurrent" xlink:label="loc_TVGNDeferredOfferingCostsNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNDeferredOfferingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SaleOfStockOtherOfferingCosts" xlink:label="loc_TVGNSaleOfStockOtherOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNSaleOfStockOtherOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative" xlink:title="00000044 - Disclosure - Initial Public Offering and Over-Allotment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract" xlink:label="loc_TVGNDisclosureInitialPublicOfferingAndOverallotmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureInitialPublicOfferingAndOverallotmentAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssue" xlink:label="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesIssuedPerUnit" xlink:label="loc_TVGNNumberOfSharesIssuedPerUnit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNNumberOfSharesIssuedPerUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_TVGNNumberOfWarrantsIssuedPerUnit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TVGNNumberOfWarrantsIssuedPerUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative" xlink:title="00000045 - Disclosure - Private Placement Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosurePrivatePlacementWarrantsAbstract" xlink:label="loc_TVGNDisclosurePrivatePlacementWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosurePrivatePlacementWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="loc_TVGNPrivatePlacementWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CantorMember" xlink:label="loc_TVGNCantorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNCantorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails" xlink:title="00000046 - Disclosure - Schedule of Fair Value Non Redeemable Shares (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockPriceOfMeasurement" xlink:label="loc_TVGNStockPriceOfMeasurement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_TVGNStockPriceOfMeasurement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProbabilityOfTransactionPercentage" xlink:label="loc_TVGNProbabilityOfTransactionPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_TVGNProbabilityOfTransactionPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FounderSharesMember" xlink:label="loc_TVGNFounderSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNFounderSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_TVGNPromissoryNoteWithRelatedPartyMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNPromissoryNoteWithRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RelatedPartyLoansMember" xlink:label="loc_TVGNRelatedPartyLoansMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNRelatedPartyLoansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AdministrativeSupportAgreementMember" xlink:label="loc_TVGNAdministrativeSupportAgreementMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNAdministrativeSupportAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="loc_TVGNSsvkAssociatesLlcMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSsvkAssociatesLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonRedeemableOrdinaryMember" xlink:label="loc_TVGNNonRedeemableOrdinaryMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNNonRedeemableOrdinaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredOneMember" xlink:label="loc_TVGNPublicWarrantsTransferredOneMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNPublicWarrantsTransferredOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredTwoMember" xlink:label="loc_TVGNPublicWarrantsTransferredTwoMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNPublicWarrantsTransferredTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeSPACMember" xlink:label="loc_TVGNDeSPACMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TVGNDeSPACMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="loc_TVGNPurchaseAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SubscriptionAgreementMember" xlink:label="loc_TVGNSubscriptionAgreementMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondSubscriptionAgreementMember" xlink:label="loc_TVGNSecondSubscriptionAgreementMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecondSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredTwoMember" xlink:label="loc_TVGNPublicWarrantsTransferredTwoMember_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsTransferredTwoMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsTransferredThreeMember" xlink:label="loc_TVGNPublicWarrantsTransferredThreeMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsTransferredThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalLoansWarrantMember" xlink:label="loc_TVGNWorkingCapitalLoansWarrantMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNWorkingCapitalLoansWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_3" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TVGNSponsorMember_3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FirstPolarFundConvertibleNoteMember" xlink:label="loc_TVGNFirstPolarFundConvertibleNoteMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_TVGNFirstPolarFundConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondPolarFundConvertibleNoteMember" xlink:label="loc_TVGNSecondPolarFundConvertibleNoteMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_TVGNSecondPolarFundConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaapCommonStockDividendsShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockDividendsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaapPreferredStockConvertibleConversionRatio" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionRatio" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateNumberOfSharesOwned" xlink:label="loc_TVGNAggregateNumberOfSharesOwned" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNAggregateNumberOfSharesOwned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesSubjectToForfeiture" xlink:label="loc_TVGNNumberOfSharesSubjectToForfeiture" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNNumberOfSharesSubjectToForfeiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_TVGNRestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNRestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_TVGNThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregatePurchasePrice" xlink:label="loc_TVGNAggregatePurchasePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNAggregatePurchasePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_TVGNMaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNMaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapital" xlink:label="loc_TVGNWorkingCapital" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaapPaymentsForAdvanceToAffiliate" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForAdvanceToAffiliate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ImpairmentOfAmountDueFromRelatedParty" xlink:label="loc_TVGNImpairmentOfAmountDueFromRelatedParty" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNImpairmentOfAmountDueFromRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContribution" xlink:label="loc_TVGNInitialCapitalContribution" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNInitialCapitalContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContributionPerShare" xlink:label="loc_TVGNInitialCapitalContributionPerShare" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNInitialCapitalContributionPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertibleNotesPayableDiscounts" xlink:label="loc_TVGNConvertibleNotesPayableDiscounts" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNConvertibleNotesPayableDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NoncashInterestExpenses" xlink:label="loc_TVGNNoncashInterestExpenses" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNNoncashInterestExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_TVGNMaximumLoansConvertibleIntoWarrants" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNMaximumLoansConvertibleIntoWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalLoan" xlink:label="loc_TVGNWorkingCapitalLoan" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNWorkingCapitalLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_TVGNRelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNRelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SubscriptionAgreementMember" xlink:label="loc_TVGNSubscriptionAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecondSubscriptionAgreementMember" xlink:label="loc_TVGNSecondSubscriptionAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecondSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PurchaseAgreementMember" xlink:label="loc_TVGNPurchaseAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TVGNSponsorMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SsvkAssociatesLlcMember" xlink:label="loc_TVGNSsvkAssociatesLlcMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_TVGNSsvkAssociatesLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwritingOptionPeriod" xlink:label="loc_TVGNUnderwritingOptionPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnderwritingOptionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnitsIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwritingCashDiscountPerUnit" xlink:label="loc_TVGNUnderwritingCashDiscountPerUnit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnderwritingCashDiscountPerUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PaymentOfUnderwriterDiscount" xlink:label="loc_TVGNPaymentOfUnderwriterDiscount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNPaymentOfUnderwriterDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateUnderwriterCashDiscount" xlink:label="loc_TVGNAggregateUnderwriterCashDiscount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAggregateUnderwriterCashDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredFeePerUnit" xlink:label="loc_TVGNDeferredFeePerUnit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNDeferredFeePerUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DeferredUnderwritingFeePayable" xlink:label="loc_TVGNDeferredUnderwritingFeePayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNDeferredUnderwritingFeePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregateDeferredUnderwritingFeePayable" xlink:label="loc_TVGNAggregateDeferredUnderwritingFeePayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAggregateDeferredUnderwritingFeePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_UnderwriterCashDiscount" xlink:label="loc_TVGNUnderwriterCashDiscount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNUnderwriterCashDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_InitialCapitalContribution" xlink:label="loc_TVGNInitialCapitalContribution" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNInitialCapitalContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing" xlink:label="loc_TVGNMinimumPeriodForReceivingSpacLoanFromDeSpacClosing" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMinimumPeriodForReceivingSpacLoanFromDeSpacClosing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution" xlink:label="loc_TVGNNumberOfSharesIssuableForEach10InitialCapitalContribution" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNNumberOfSharesIssuableForEach10InitialCapitalContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AmountOfInitialCapitalConsideredToIssueOneShare" xlink:label="loc_TVGNAmountOfInitialCapitalConsideredToIssueOneShare" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAmountOfInitialCapitalConsideredToIssueOneShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MinimumPeriodForPaymentInCaseOfLiquidation" xlink:label="loc_TVGNMinimumPeriodForPaymentInCaseOfLiquidation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMinimumPeriodForPaymentInCaseOfLiquidation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MaximumReasonableAttorneyFees" xlink:label="loc_TVGNMaximumReasonableAttorneyFees" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMaximumReasonableAttorneyFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AggregatePurchasePrice" xlink:label="loc_TVGNAggregatePurchasePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAggregatePurchasePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ShareholdersDeficitDetailsNarrative" xlink:title="00000049 - Disclosure - Shareholders&#8217; Deficit (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonStockNumberOfVotesPerShare" xlink:label="loc_TVGNCommonStockNumberOfVotesPerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNCommonStockNumberOfVotesPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertibleStocksConversionRatio" xlink:label="loc_TVGNConvertibleStocksConversionRatio" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNConvertibleStocksConversionRatio" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantExercisePeriodConditionOne" xlink:label="loc_TVGNWarrantExercisePeriodConditionOne" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantExercisePeriodConditionOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" xlink:label="loc_TVGNWarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_TVGNClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RedemptionPeriod" xlink:label="loc_TVGNRedemptionPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNRedemptionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_TVGNWarrantRedemptionConditionMinimumSharePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantRedemptionConditionMinimumSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_TVGNThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="loc_TVGNSharePriceTriggerUsedToMeasureDilutionOfWarrants" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNSharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_TVGNPercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNPercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_TVGNTradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNTradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" xlink:label="loc_TVGNClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000050 - Disclosure - Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_TVGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivatePlacementWarrantsMember" xlink:label="loc_TVGNPrivatePlacementWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000051 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails" xlink:title="00000052 - Disclosure - Schedule of Quantitative Information in Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000053 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesA1PreferredStockMember" xlink:label="loc_TVGNSeriesA1PreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesA1PreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_MergerAgreementMember" xlink:label="loc_TVGNMergerAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_TVGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorAdvisoryServiceFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServiceFeeMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_TVGNSponsorAdvisoryServiceFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:label="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNShareholdersExercisedTheirRightToRedeemSharesNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:label="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSponsorFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_OffsetValue" xlink:label="loc_TVGNOffsetValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNOffsetValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ServicesFees" xlink:label="loc_TVGNServicesFees" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_TVGNServicesFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000054 - Disclosure - NATURE OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSemperParatusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ExchangeRatio" xlink:label="loc_TVGNExchangeRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNExchangeRatio" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="00000055 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="00000056 - Disclosure - Schedule of Fair Value Measurement (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="00000057 - Disclosure - Schedule of Fair Values Of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure" xlink:title="00000058 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PercentageOfProbabilityOfLiquidityEvent" xlink:label="loc_TVGNPercentageOfProbabilityOfLiquidityEvent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNPercentageOfProbabilityOfLiquidityEvent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_RangeInYears" xlink:label="loc_TVGNRangeInYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNRangeInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PlusMergerTransactionCostsLimitedToCashAcquired" xlink:label="loc_TVGNPlusMergerTransactionCostsLimitedToCashAcquired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNPlusMergerTransactionCostsLimitedToCashAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:label="loc_TVGNTotalNetLiabilitiesAcquiredPlusTransactionCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNTotalNetLiabilitiesAcquiredPlusTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCosts" xlink:label="loc_TVGNTransactionCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TransactionCost" xlink:label="loc_TVGNTransactionCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="00000061 - Disclosure - EARNOUT SHARES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="loc_TVGNDisclosureEarnoutSharesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureEarnoutSharesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="loc_TVGNTevogenBioCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorsMember" xlink:label="loc_TVGNSponsorsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesTradingDaysDescription" xlink:label="loc_TVGNEarnoutSharesTradingDaysDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNEarnoutSharesTradingDaysDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="00000062 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ReverseRecapitalizationMember" xlink:label="loc_TVGNReverseRecapitalizationMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_TVGNReverseRecapitalizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_AccruedProfessionalServiceFeesCurrent" xlink:label="loc_TVGNAccruedProfessionalServiceFeesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNAccruedProfessionalServiceFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NotesPayableDetailsNarrative" xlink:title="00000063 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapital" xlink:label="loc_TVGNWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_TVGNWorkingCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000066 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_TwentyTwentyFourPlanMember" xlink:label="loc_TVGNTwentyTwentyFourPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNTwentyTwentyFourPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_IncentivePlanMember" xlink:label="loc_TVGNIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharesToBeIssuedOnSharesIssuable" xlink:label="loc_TVGNSharesToBeIssuedOnSharesIssuable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNSharesToBeIssuedOnSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:label="loc_TVGNSharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNSharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:label="loc_TVGNCommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNCommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000068 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSemperParatusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="loc_us-gaapPreferredStockDividendPaymentRateVariable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentRateVariable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaapPreferredStockRedemptionTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WarrantsDescription" xlink:label="loc_TVGNWarrantsDescription" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure" xlink:title="00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServicesFeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSponsorAdvisoryServicesFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PolarNotesMember" xlink:label="loc_TVGNPolarNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_TVGNPolarNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSponsorFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_WorkingCapitalExpenses" xlink:label="loc_TVGNWorkingCapitalExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNWorkingCapitalExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLossPerShareDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertiblePromissoryNoteInterest" xlink:label="loc_TVGNConvertiblePromissoryNoteInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_TVGNConvertiblePromissoryNoteInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_ConvertiblePromissoryNoteChangeInFairValue" xlink:label="loc_TVGNConvertiblePromissoryNoteChangeInFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_TVGNConvertiblePromissoryNoteChangeInFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_PrivateWarrantsMember" xlink:label="loc_TVGNPrivateWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNPrivateWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20240331.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="00000072 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394779504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tevogen
Bio Holdings Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001860871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1597194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15
Independence Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite #410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-6436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Tevogen
Bio Holdings Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">15
Independence Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite #410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-6436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Ryan
Saadi<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395610256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,317,900<span></span>
</td>
<td class="nump">$ 8,835<span></span>
</td>
<td class="nump">$ 129,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">923,202<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
<td class="nump">145,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,399,921<span></span>
</td>
<td class="nump">355,836<span></span>
</td>
<td class="nump">274,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">418,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">412,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTransactionCosts', window );">Deferred transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">133,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash and marketable securities held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,681,497<span></span>
</td>
<td class="nump">356,864,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,363,407<span></span>
</td>
<td class="nump">17,037,333<span></span>
</td>
<td class="nump">357,138,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,405<span></span>
</td>
<td class="nump">210,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,211,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,564,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">260,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,631,725<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,938,316<span></span>
</td>
<td class="nump">3,004,130<span></span>
</td>
<td class="nump">350,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Derivative warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">7,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">166,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">60,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,166,077<span></span>
</td>
<td class="nump">17,733,130<span></span>
</td>
<td class="nump">15,057,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>REDEEMABLE ORDINARY SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption, $0.0001 par value, 1,502,180 and 34,500,000 shares at redemption value of $11.10 and $10.34 per share as of December 31, 2023 and 2022, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,681,497<span></span>
</td>
<td class="nump">356,864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000 shares authorized; 164,614,418 and 119,999,989 shares issued and outstanding at March 31, 2024 and December 31, 2023</a></td>
<td class="nump">16,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassAOrdinaryShares', window );">Class A ordinary shares; $0.0001 par value; 200,000,000 shares authorized; 13,433,333 and 1,450,000 shares issued and outstanding (excluding 1,502,180 and 34,500,000 shares subject to possible redemption) as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassBOrdinaryShares', window );">Class B ordinary shares; $0.0001 par value; 20,000,000 shares authorized; 0 and 11,983,333 shares issued and outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(88,392,895)<span></span>
</td>
<td class="num">(17,378,637)<span></span>
</td>
<td class="num">(14,784,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">76,160,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(5,802,670)<span></span>
</td>
<td class="num">(17,377,294)<span></span>
</td>
<td class="num">(14,783,348)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">3,363,407<span></span>
</td>
<td class="nump">17,037,333<span></span>
</td>
<td class="nump">357,138,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">2,799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember', window );">Reverse Recapitalization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTransactionCosts', window );">Deferred transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,582,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,505,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,418,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,096,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,479,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,934,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000 shares authorized; 164,614,418 and 119,999,989 shares issued and outstanding at March 31, 2024 and December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,657,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(5,802,670)<span></span>
</td>
<td class="num">(94,428,897)<span></span>
</td>
<td class="num">(33,951,217)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,505,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember', window );">Reverse Recapitalization [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember', window );">Reverse Recapitalization [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party</a></td>
<td class="nump">158,819<span></span>
</td>
<td class="nump">344,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Reverse Recapitalization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassAOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class A ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassAOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassBOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class B ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassBOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=TVGN_ReverseRecapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693397390080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">1,502,180<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary equity, redemption price (In Dollar per share)</a></td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">13,433,333<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">13,433,333<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693386855632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 8,705,142<span></span>
</td>
<td class="nump">$ 977,109<span></span>
</td>
<td class="nump">$ 2,273,970<span></span>
</td>
<td class="nump">$ 953,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,811,582<span></span>
</td>
<td class="nump">1,347,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="num">(29,516,724)<span></span>
</td>
<td class="num">(2,324,282)<span></span>
</td>
<td class="num">(2,273,970)<span></span>
</td>
<td class="num">(953,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734,426<span></span>
</td>
<td class="nump">4,948,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="num">(31,973)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,750)<span></span>
</td>
<td class="nump">413,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCosts', window );">Merger transaction costs</a></td>
<td class="num">(7,499,353)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">48,468,678<span></span>
</td>
<td class="num">(28,142,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ImpairmentOfAmountDueFromRelatedParty', window );">Impairment of amount due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(155,786)<span></span>
</td>
<td class="num">(288,997)<span></span>
</td>
<td class="num">(256,031)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,206,645<span></span>
</td>
<td class="nump">5,361,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 11,264,842<span></span>
</td>
<td class="num">$ (30,756,144)<span></span>
</td>
<td class="num">(67,325)<span></span>
</td>
<td class="nump">4,408,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">137,333,802<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="nump">142,387,651<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 29,516,724<span></span>
</td>
<td class="nump">$ 2,324,282<span></span>
</td>
<td class="nump">$ 2,273,970<span></span>
</td>
<td class="nump">$ 953,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,516,724)<span></span>
</td>
<td class="num">(2,324,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders, basic</a></td>
<td class="nump">10,506,866<span></span>
</td>
<td class="num">(30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (37,049,420)<span></span>
</td>
<td class="num">$ (30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,742<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,742<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,134)<span></span>
</td>
<td class="nump">$ 3,172,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_CommonClassaNotSubjectToRedemptionMember', window );">Common Class A Not Subject To Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,317,077<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,317,077<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,186)<span></span>
</td>
<td class="nump">$ 133,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116,256<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116,256<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,005)<span></span>
</td>
<td class="nump">$ 1,102,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInFairValueOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ImpairmentOfAmountDueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of amount due from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ImpairmentOfAmountDueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_CommonClassaNotSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_CommonClassaNotSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693393992832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Common Class A [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Common Class B [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Reverse Recapitalization [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Reverse Recapitalization [Member]</div>
</th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Reverse Recapitalization [Member]</div>
</th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Reverse Recapitalization [Member]</div></th>
<th class="th">
<div>Series A Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series A Preferred Stock [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Reverse Recapitalization [Member]</div>
</th>
<th class="th">
<div>Series B Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series B Preferred Stock [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Reverse Recapitalization [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,229,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,227,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,450,000<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AccretionOfCarryingValueToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,964,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,964,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,216,840<span></span>
</td>
<td class="num">(14,784,691)<span></span>
</td>
<td class="num">$ (39,180,057)<span></span>
</td>
<td class="num">(14,783,348)<span></span>
</td>
<td class="num">$ (33,951,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,450,000<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,756,144)<span></span>
</td>
<td class="num">(30,756,144)<span></span>
</td>
<td class="num">(30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,936,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,707,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
<td class="num">(14,784,691)<span></span>
</td>
<td class="num">(39,180,057)<span></span>
</td>
<td class="num">(14,783,348)<span></span>
</td>
<td class="num">(33,951,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,450,000<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger</a></td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="num">$ (1,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger, shares</a></td>
<td class="nump">11,983,333<span></span>
</td>
<td class="num">(11,983,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Proceeds allocated to Class A shares issuable from the note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AccretionOfCarryingValueToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,526,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,801,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
<td class="num">$ (17,378,637)<span></span>
</td>
<td class="num">(99,657,737)<span></span>
</td>
<td class="num">(17,377,294)<span></span>
</td>
<td class="num">(94,428,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">13,433,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,621,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,622,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,264,842<span></span>
</td>
<td class="nump">$ 11,264,842<span></span>
</td>
<td class="nump">11,264,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Issuance of Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Merger, net of redemptions and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,885,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,883,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Merger, net of redemptions and transaction costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,778,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for Sponsor advisory service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for Sponsor advisory service fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,333,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,333,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,160,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88,392,895)<span></span>
</td>
<td class="num">$ (5,802,670)<span></span>
</td>
<td class="num">$ (5,802,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AccretionOfCarryingValueToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of carrying value to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AccretionOfCarryingValueToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395804912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 11,264,842<span></span>
</td>
<td class="num">$ (30,756,144)<span></span>
</td>
<td class="num">$ (67,325)<span></span>
</td>
<td class="nump">$ 4,408,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,734,426)<span></span>
</td>
<td class="num">(4,948,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NoncashInterestExpenses', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,031<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ImpairmentOfAmountDueFromRelatedParty', window );">Impairment of amount due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">31,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,750<span></span>
</td>
<td class="num">(413,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,669<span></span>
</td>
<td class="nump">446,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent', window );">Due to affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,950<span></span>
</td>
<td class="nump">171,079<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,376,351)<span></span>
</td>
<td class="num">(215,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ExtensionAmountDepositedIntoTrustAccount', window );">Extension amount deposited into Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from Trust Account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,984,430<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,916,930<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Redemption of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342,984,430)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(341,660,930)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,351)<span></span>
</td>
<td class="num">(215,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of period</a></td>
<td class="nump">8,835<span></span>
</td>
<td class="nump">129,186<span></span>
</td>
<td class="nump">129,186<span></span>
</td>
<td class="nump">344,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,835<span></span>
</td>
<td class="nump">129,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount', window );">Change in value of Class A ordinary shares subject to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,801,927<span></span>
</td>
<td class="nump">4,964,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SaleOfClassBSharesToInvestor', window );">Sale of Class B shares to Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955,111<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SaleOfWarrants', window );">Sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">26,333,249<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">28,142,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember', window );">Reverse Recapitalization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">11,264,842<span></span>
</td>
<td class="num">(30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">31,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(250,119)<span></span>
</td>
<td class="nump">70,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,163,825)<span></span>
</td>
<td class="num">(2,177,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,429,328<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">265,503<span></span>
</td>
<td class="nump">189,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of period</a></td>
<td class="nump">1,052,397<span></span>
</td>
<td class="nump">5,484,265<span></span>
</td>
<td class="nump">5,484,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of period</a></td>
<td class="nump">1,317,900<span></span>
</td>
<td class="nump">5,674,130<span></span>
</td>
<td class="nump">$ 1,052,397<span></span>
</td>
<td class="nump">$ 5,484,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">40,552<span></span>
</td>
<td class="nump">39,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">26,333,249<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">159,305<span></span>
</td>
<td class="nump">289,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Merger transaction costs</a></td>
<td class="nump">7,099,353<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">28,142,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on Series A Preferred Stock issuance</a></td>
<td class="nump">799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">57,751<span></span>
</td>
<td class="nump">51,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(68,446)<span></span>
</td>
<td class="nump">21,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,697,346<span></span>
</td>
<td class="nump">497,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(800,742)<span></span>
</td>
<td class="num">(480,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(60,201)<span></span>
</td>
<td class="num">(53,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_CashAcquiredInConnectionWithReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">229,328<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series A Preferred Stock</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance', window );">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger', window );">Conversion of convertible promissory notes into common stock in connection with Merger</a></td>
<td class="nump">46,622,627<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts', window );">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</a></td>
<td class="num">$ (3,113,309)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CashAcquiredInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in connection with reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CashAcquiredInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInFairValueOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in value of class ordinary shares subject to redemption amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible promissory notes into common stock in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ExtensionAmountDepositedIntoTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extension amount deposited into trust account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ExtensionAmountDepositedIntoTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ImpairmentOfAmountDueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of amount due from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ImpairmentOfAmountDueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for net liabilities upon reverse recapitalization net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NoncashInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NoncashInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable prepaid proceeds towards anticipated preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from cash withdrawn from Trust Account in connection with redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SaleOfClassBSharesToInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of class B shares to investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SaleOfClassBSharesToInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SaleOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SaleOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in current obligations (due within one year or one operating cycle) owed to an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=TVGN_ReverseRecapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693519397072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization, Business Operations and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Organization, Business Operations and Liquidity</a></td>
<td class="text"><p id="xdx_808_eus-gaap--NatureOfOperations_zDJFUh9gK4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_006"></span>Note
1 &#8212; <span id="xdx_82B_zbRh0MYh8YDi">Description of Organization, Business Operations and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semper
Paratus Acquisition Corporation (the &#8220;Company&#8221;) was incorporated as a Cayman Islands exempted company on April 21, 2021.
The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with <span id="xdx_907_ecustom--ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_dc_uInteger_c20230101__20231231_zMWGIEMfvKxj" title="Condition for future business combination number of businesses minimum">one</span> or more businesses (the &#8220;Business Combination&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company
is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and
emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023, relates to the Company&#8217;s
formation and Initial Public Offering (&#8220;IPO&#8221;), which is described below, and the search for a prospective initial Business
Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at
the earliest. The Company will generate non-operating income in the form of interest income earned on investments from the proceeds derived
from the IPO. The registration statement for the Company&#8217;s IPO was declared effective on November 3, 2021. On November 8, 2021,
the Company consummated the IPO of <span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_pid_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLHmTymUPMXd" title="Units Issued During Period, Shares, New Issues">30,000,000</span> units (&#8220;Units&#8221;) with respect to the ordinary shares included in the Units being
offered (the &#8220;Public Shares&#8221;) at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNGHyHlxNe89" title="Purchase price, per unit">10.00</span> per Unit generating gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjIs6le75hF" title="Proceeds from Issuance Initial Public Offering">300,000,000</span>, which is discussed in Note 3.
The company has selected December 31 as its fiscal year end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the IPO, the Company consummated the sale of <span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq6Kw3dFp78a" title="Units Issued During Period, Shares, New Issues">1,360,000</span> private placement units (&#8220;Private Placement Units&#8221;)
at a price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbYk6jXFSDU4" title="Purchase price, per unit">10.00</span> per Private Placement Unit in a private placement to the Company&#8217;s sponsor, Semper Paratus Sponsor LLC (the
&#8220;Original Sponsor&#8221;) and underwriter Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) generating gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaiAenvmmHFe" title="Proceeds from Issuance Initial Public Offering">13,600,000</span>
which is described in Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the IPO, the Company consummated the closing of the sale of <span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBqlRFJutaP6" title="Units issued during period, shares new">4,500,000</span> additional Units upon receiving notice of the
underwriter&#8217;s election to fully exercise its overallotment option (&#8220;Overallotment Units&#8221;), generating additional gross
proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zyVOD8AzgT2c" title="Proceeds from issuance initial public offering">45,000,000</span> and incurring additional offering costs of $<span id="xdx_90A_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zcZlqCYYSBH" title="Deferred offering costs noncurrent">2,700,000</span> in underwriting fees all of which are deferred until completion
of the Company&#8217;s Business Combination. Simultaneously with the exercise of the overallotment, the Company consummated the Private
Placement of an additional <span id="xdx_900_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zDYXZViuAVrl" title="Common equity securities">90,000</span> Private Placement Units to the Original Sponsor, generating gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zSlgdCB6G0e7" title="Proceeds from issuance initial public offering">900,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs for the IPO amounted to $<span id="xdx_90D_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zM0kMRZ02hRe">21,266,594</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
consisting of $<span id="xdx_90E_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6hPQ2q0R0Ue">6,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of paid underwriting fees, $<span id="xdx_90E_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCkiu10bqmKi">14,700,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of deferred underwriting fees payable (which
are held in the Trust Account (defined below)) and $<span id="xdx_90A_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zoUEDVkE0YGh" title="Other offering costs">566,594
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of other costs. On June 28, 2023, the Company
and Cantor entered into a fee reduction agreement (the &#8220;Fee Reduction Agreement&#8221;), pursuant to which Cantor agreed to forfeit
$<span id="xdx_90F_ecustom--DeferredOfferingCostsNoncurrentForfeited_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zn4kU3FxyPk9" title="Deferred underwriting fees">9,700,000</span> of the deferred underwriting fees payable, resulting in a remainder of $<span id="xdx_909_ecustom--DeferredOfferingCostsNoncurrent_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zEO3SgCutDUk" title="Deferred offering costs non current">5,000,000</span> of deferred underwriting fees payable (the
&#8220;Reduced Deferred Fee&#8221;) by the Company to Cantor upon the closing of the Transaction (as defined below) with Tevogen Bio
Inc (&#8220;Tevogen Bio&#8221;), such fee payable to Cantor in the form of <span id="xdx_903_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230628__20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zzt6gdXHo7od" title="Common equity securities">500,000</span> shares of the common equity securities of the entity
surviving the Transaction. The Fee Reduction Agreement only applies to the consummation of the Transaction with Tevogen Bio and no other
potential Business Combinations that may be contemplated or consummated by the Company. In the event that the Company were not to complete
the Transaction with Tevogen Bio, the Original Deferred fee would become due and payable by the Company to Cantor as originally set forth
in the Underwriting Agreement, upon the consummation of a Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the IPO, $<span id="xdx_908_ecustom--PaymentsForInvestmentOfCashInTrustAccount_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3KspCMAjPDj" title="Payments for investment of cash in trust account">351,900,000</span> ($<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMPFV6fwpes3" title="Purchase price, per unit">10.20</span> per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement
Units was placed in a trust account (&#8220;Trust Account&#8221;) and will be invested in U.S. government securities, within the meaning
set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity
of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting
the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until
the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale
of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating
a Business Combination. As of December 31, 2023, there is no assurance that the Company will be able to complete a Business Combination successfully. The Company
must complete one or more initial Business Combinations having an aggregate fair market value of at least <span id="xdx_909_ecustom--ConditionForFutureBusinessCombinationUseOfProceedsPercentage_iI_dp_uPure_c20231231_z45et9GfPFY7" title="Condition for future business combination use of proceeds percentage">80</span>% of the assets held in the
Trust Account excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of
the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction
company owns or acquires <span id="xdx_90C_ecustom--ConditionForFutureBusinessCombinationThresholdPercentageOwnership_iI_pid_dp_c20231231_z76yREbwvLV6" title="Condition for future business combination threshold ownership (as a percent)">50</span>% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest
in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will provide the holders of the outstanding Public Shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem
all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting
called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder
approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to
redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZaHgeiI0YXh" title="Purchase price, per unit">10.20</span> per Public
Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to
the Company&#8217;s warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s
liquidation, if there is a shareholder vote or tender offer in connection with the Company&#8217;s Business Combination and in connection
with certain amendments to the Company&#8217;s amended and restated memorandum and articles of association (the &#8220;Memorandum and
Articles of Association&#8221;). In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 480-10-S99, redemption provisions
not solely within the control of a company require Class A ordinary shares subject to redemption to be classified outside of permanent
equity. Given that the Public Shares were issued with other freestanding instruments (i.e., public warrants), the initial carrying value
of ordinary shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The ordinary shares
are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either
(i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that
the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting
period. The Company has elected to recognize the changes immediately. While redemptions cannot cause the Company&#8217;s net tangible
assets to fall below $<span id="xdx_901_ecustom--ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_iI_c20231231_zqwayskvZtv6" title="Net tangible assets">5,000,001</span>, the Public Shares are redeemable and are classified as such on the balance sheet until such date that
a redemption event takes place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemptions
of the Company&#8217;s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to
an agreement relating to the Company&#8217;s Business Combination. If the Company seeks shareholder approval of the Business Combination,
the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination,
or such other vote as required by law or stock exchange rule. If a shareholder vote is not required by applicable law or stock exchange
listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant
to its Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender
offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required
by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other
reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant
to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed
to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business
Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective
of whether they vote for or against the proposed transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2023, shareholders (the &#8220;Initial Shareholders&#8221;) holding all of the issued and outstanding Class B ordinary shares
(the &#8220;Founder Shares&#8221;) of the Company elected to convert their Class B ordinary shares into Class A ordinary shares of the
Company on a <span id="xdx_907_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_zeBYVwN7gdDk" title="Conversion ratio">one</span>-for-one basis (the &#8220;Conversion&#8221;). As a result, <span id="xdx_90D_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z2ZYNNSqJV0e" title="Shares cancelled">11,983,333</span> of the Company&#8217;s Class B ordinary shares
were cancelled and <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqQyyjgoU3Cc" title="Shares issued upon conversion">11,983,333</span> Class A ordinary shares were issued to such converting Class B shareholders. The Initial Shareholders agreed
that all of the terms and conditions applicable to the Founder Shares set forth in the Letter Agreement, dated November 3, 2021, by and
among the Company, its officers, its directors and the Initial Shareholders (the &#8220;Letter Agreement&#8221;), shall continue to apply
to the Class A ordinary shares that the Founder Shares converted into, including the voting agreement, transfer restrictions and waiver
of any right, title, interest or claim of any kind to the Trust Account (as defined in the Letter Agreement) or any monies or other assets
held therein. Following the Conversion, on January 30, 2023, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zP1gjbscAhqh" title="Common stock, shares outstanding">47,933,333</span> Class A ordinary shares issued and outstanding
and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgySFaZSCsnl" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zwX2xLaD0Bne" title="Common stock, shares outstanding">no</span></span> Class B ordinary shares issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 3, 2023, the Company&#8217;s shareholders approved an amendment (the &#8220;First Extension Charter Amendment&#8221;) to the
Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial
Business Combination from February 8, 2023 to December 15, 2023. Under Cayman Islands law, the First Extension Charter Amendment took
effect upon approval by the shareholders. In connection with the meeting, shareholders holding approximately <span id="xdx_904_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_z33fQd6UXHD2" title="Minimum period to file charter amendment">32,116,947</span> Public Shares
exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember_zqFSwarHdFjd" title="Cash withdrawn from Trust Account in connection with redemption">333</span>
million (approximately $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrnaTqrsici1" title="Price per share">10.38</span> per Public Share) was removed from the Trust Account to pay such holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 14, 2023, the Company&#8217;s shareholders approved an amendment (the &#8220;Second Extension Charter Amendment&#8221;) to the
Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial
Business Combination to September 15, 2024. Under Cayman Islands law, the Second Extension Charter Amendment took effect upon approval
by the shareholders. In connection with the meeting, shareholders holding approximately <span id="xdx_90A_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zXYa3o808VCk" title="Minimum period to file charter amendment">880,873</span> Public Shares exercised their right to
redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<span id="xdx_90F_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn4n6_c20231214__20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember_zt1tLSiARXGi" title="Cash withdrawn from trust account in connection with redemption">9.71</span> million (approximately
$<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrf2ccm725nh" title="Price per share">11.03</span> per Public Share) was removed from the Trust Account to pay such holders. Approximately $<span id="xdx_907_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pn5n6_c20231231_zQKEGPZSGhh3" title="ash and marketable securities held in Trust Account">16.7</span> million remained in the Trust Account
as of December 31, 2023 and the Company had <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zLJ4vIkIdKbh" title="Common stock shares outstanding">1,502,180</span> public shares outstanding as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with SSVK Associates, LLC (the &#8220;Sponsor&#8221;)
and the Original Sponsor, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zH5jDdhu5VY7" title="Stock issued during period, Shares new issues">7,988,889</span> Class A ordinary shares
and (y) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zlLyy02ze1qi" title="Stock issued during period, Shares new issues">1,000,000</span> Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that
is exercisable for one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter
Agreement, dated November 3, 2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement,
dated November 3, 2021, by and between the Company and Cantor, as representative of the several underwriters (the &#8220;Underwriting
Agreement&#8221;)), for an aggregate purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zVaC2L3t6W2e" title="Purchase price, per unit">1.00</span> (the &#8220;Purchase Price&#8221;) payable at the time of the initial Business
Combination (see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder
or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section 13 of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more
than an aggregate of <span id="xdx_907_ecustom--RedemptionLimitPercentageWithoutPriorConsent_dp_uPure_c20230101__20231231_ztHl250zlGz5" title="Redemption limit percentage without prior consent">15</span>% or more of the ordinary shares sold in the IPO, without the prior consent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Shareholders have agreed not to propose an amendment to the Memorandum and Articles of Association that would affect the substance
or timing of the Company&#8217;s obligation to redeem <span id="xdx_905_ecustom--PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_dp_uPure_c20230101__20231231_z7I1R0qtqSv7" title="Obligation to redeem public shares if entity does not complete a business combination (as a percent)">100</span>% of its Public Shares if the Company does not complete a Business Combination,
unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such
amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company is unable to complete a Business Combination by September 15, 2024 (&#8220;Combination Period&#8221;), the Company will (i)
cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days
thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account including interest earned on the funds held in the Trust Account and not previously released to us to pay the Company&#8217;s
franchise and income taxes (less up to $<span id="xdx_909_ecustom--MaximumAllowedDissolutionExpenses_c20230101__20231231_zVAJkI5epihf" title="Maximum allowed dissolution expenses">100,000</span> of interest to pay dissolution expenses), divided by the number of then outstanding Public
Shares, which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive
further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the Company&#8217;s remaining shareholders and the Company&#8217;s board of directors, dissolve and liquidate,
subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. On December 18, 2023, the Company deposited $<span id="xdx_902_eus-gaap--AssetsHeldInTrust_iI_c20231218_zVShfNGa696i" title="Extension amount deposited into Trust Account">67,500</span> into the Trust Account in order to extend the date by which
the Company has to complete the initial business combination by three months from December 14, 2023, to March 15, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete
a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the
IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails
to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to its deferred
underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within
the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be
available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of
the residual assets remaining available for distribution (including Trust Account assets) will be only $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNODw1vph2m4" title="Shares issued, price per share">10.20</span> per share held in the Trust
Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the
extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the
Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not
apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any
monies held in the Trust Account or to any claims under the Company&#8217;s indemnity of the underwriters of the IPO against certain
liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the
event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent
of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify
the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&#8217;s independent
registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements
waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i> Business Combination</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On June 28, 2023, the Company entered into an Agreement
and Plan of Merger by and among the Company, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company
(&#8220;Merger Sub&#8221;), the Sponsor, in its capacity as purchaser representative, Tevogen Bio, and Ryan Saadi, in his capacity as
seller representative (as may be amended and/or restated from time to time, the &#8220;Merger Agreement&#8221;), pursuant to which, among
other things, the parties will affect the merger of Merger Sub with and into Tevogen Bio, with Tevogen Bio continuing as the surviving
entity (the &#8220;Merger&#8221;), as a result of which all of the issued and outstanding capital stock of Tevogen Bio shall be exchanged
for shares of Class A common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230628__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zDptEao3aUA7" title="Ordinary shares, par value (in dollar per share)">0.0001</span> per share (the &#8220;Class A Common Stock&#8221;), of the Company (the &#8220;Share
Exchange&#8221;) subject to the conditions set forth in the Merger Agreement, with Tevogen Bio surviving the Share Exchange as a wholly
owned subsidiary of the Company (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the &#8220;Transaction&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On September 14, 2023, the Company filed a registration
statement on Form S-4 with the SEC relating to the Transaction with Tevogen, and on February 14, 2024, the Company consummated the Transaction. See Note 10 for more information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action,
various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further,
the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements
and the specific impact on the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as
of the date of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had $<span id="xdx_906_eus-gaap--Cash_iI_c20231231_zODOpYi3K2e6" title="Cash">8,835</span> in its operating bank accounts, $<span id="xdx_906_eus-gaap--AssetsHeldInTrustNoncurrent_iI_c20231231_z9lqJZcCJUD4" title="Assets held in trust noncurrent">16,681,497</span> in cash held in the
Trust Account to be used for a Business Combination or to repurchase or redeem its ordinary shares in connection therewith and working
capital deficit of $<span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_c20231231_zSxmpiZut0Td" title="Working capital deficit">2,648,294</span>. As of December 31, 2023, approximately $<span id="xdx_903_eus-gaap--InvestmentIncomeInterest_c20230101__20231231_zlzvEPktqM16" title="Investment income interest">2,734,000</span> of the amount on deposit in the Trust Account represented
interest income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company management believes that cash on hand following
consummation of the Transaction as well as $<span id="xdx_904_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7QPqAiWlDL">2,000,000
</span>to the Company from a Series A Preferred Stock financing in February 2024 and $<span id="xdx_905_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zt1yebqOBlpe">1,200,000</span> in connection with the Series A-1
Preferred Stock financing thereafter (see Note 10) is not sufficient to sustain planned operations for 12 months from the issuance
date of these financial statements. As a result, the Company has concluded that substantial doubt exists about its ability to continue
as a going concern for one year from the date that these financial statements are issued. The accompanying financial statements have
been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course
of business. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Management is currently evaluating different strategies to obtain the additional
funding for future operations for subsequent years. These strategies may include but are not limited to private placements of equity and/or
debt, licensing and/or marketing arrangements, and public offerings of equity and/or debt securities. The Company may not be able to obtain
financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable
terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693392389840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweFcfJCPe72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_821_z7Yxg4Jk1c6b">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies included in the Company&#8217;s annual financial statements that can be found in Exhibit 99.1
of the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on April 29, 2024 (the
&#8220;Form 8-K&#8221;), have not materially changed, except as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zGbPuBzg5CKl">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z2UVV4YCU6v4">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zsweBwNQyFF3">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zJZFeTaEcaDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zPtwxjycLoh9">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_ztdxsUcE1y6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public
offering (the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i>
(&#8220;ASC 815&#8221;), and considering ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;). The
assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to
ASC 480 and meet all of the conditions for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own shares of common stock, among other conditions. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of
issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are
recognized as a non-cash loss on the consolidated statements of operations. Under these standards, the Company&#8217;s private
placement warrants sold at the time of the IPO do not meet the criteria for equity classification and must be recorded as
liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification and must be recorded as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOp0Gnh2gwmd">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s
convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zLAFUKdBZV45" style="display: none">Schedule
of Fair Value Measurement</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance">94,932,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance">289,135</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance">28,142,865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance">70,229,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility">80</span>%),
discount rate (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate">35</span>%
- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate">36</span>%),
and probability of a future liquidity event (<span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event">85</span>%
- <span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event">95</span>%).</span> The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the three months ended March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants the fair value of which increased by $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants">31,973</span>
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zTyrtDvrDzJk">Schedule
of Fair Values Of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at February 15, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">31,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">60,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities">60,973</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between <span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1667">75%</span></span> to <span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1669">85%</span></span>, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from <span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years">0.5</span> to <span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years">10.0</span> years, and a risk-free interest rate between <span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage">4.3%</span> and <span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage">5.3%</span>. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock">2,000,000</span> upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuKunqOFiF5k">Net
Income (Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zaS2rj0QNrb1">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, Debt &#8211; <i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zNRCBCcrYlWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8212; <span id="xdx_82A_z09laoPAkQZ3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDufdfSqr987">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--EmergingGrowthCompanyPolicyPolicyTextBlock_zPTHX6hDDIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z51bx9GmNCf6">Emerging
Growth Company</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for
public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company
nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zzoVedJkZirl">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zpjGtuKXUP3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjW2yciTNI63">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_z8n1KGVCSxn" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zjnpuZTVh3Wb" title="Cash equivalents">no</span></span>t have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--AssetsHeldInTrustAccountPolicyPolicyTextBlock_ztBsSHZlY6w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zoaPRIdCAmoa">Investments
Held in Trust Account</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, substantially all of the assets held in the Trust Account were held in a demand deposit cash account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">At December
31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company&#8217;s investments
held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at
the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included
in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values
of investments held in Trust Account are determined using available market information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_zCwy56mbqjbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zCXACvIfWnUi">Offering
Costs associated with the Initial Public Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs, including additional underwriting fees associated with the underwriters&#8217; exercise of the over-allotment option, consist
principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable
to the underwriters&#8217; exercise of the over-allotment option in full, amounted to $<span id="xdx_909_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDpn1E4hnJBc" title="Offering costs">21,266,594</span> consisting of $<span id="xdx_909_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNa6Aky0zUCa" title="Underwriting fees">6,000,000</span> of paid underwriting
fees, $<span id="xdx_90B_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyD2joOQN139" title="Deferred underwriting fee payable">14,700,000</span> of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $<span id="xdx_907_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTd94FcM7BSj" title="Other offering costs">566,594</span> of other costs
and was charged to shareholders&#8217; equity upon the completion of the IPO. On June 28, 2023, the Company and Cantor entered into the Fee Reduction
Agreement, pursuant to which Cantor agreed to the Reduced Deferred Fee in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRzNADdXwd9i" title="Number of shares issued">500,000</span> shares of the common equity securities of
the entity surviving the Transaction. See Note 1 for more information on the Fee Reduction Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zcm94hOGvmZ9">Concentration
of Credit Risk</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount">250,000</span>. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_znPUUrddfrUi">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the (&#8220;FASB&#8221;) ASC 820,
&#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8Ot8VIhkg52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Related
Party Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for amounts due from related parties at historical cost and evaluates the collectability of these receivables for determination
on if impairment should be recognized. In the same manner, the Company evaluated the $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_z3uF8gdQDCwh" title="Impairment of due from related party">250,000</span> loan to Srirama Associates, LLC and determined
that the amount was uncollectable and therefore recognized an impairment loss, see Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zkpWCEwQfXz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zLIWqLIv8yUi">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes.&#8221; Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. There were <span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20231231_zVaiAAGIGva9" title="Unrecognized tax benefits"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zF5N2A4rIB24" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits as of December 31, 2023 and 2022.
The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. <span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20231231_zrUaDPZSdxM3" title="Unrecognized tax benefits accrued for interest and penalties"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20221231_zurXvR5vPrF5" title="Unrecognized tax benefits accrued for interest and penalties">No</span></span> amounts were accrued for the payment of
interest and penalties for the year ended December 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the
Company. Consequently, income taxes are not reflected in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--TemporaryEquityPolicyPolicyTextBlock_zD0efC8N3eda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zgtCoOZ7zQ9k">Class
A Ordinary Shares Subject to Possible Redemption</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing
Liabilities from Equity.&#8221; Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument
and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#8217;s control) is classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders&#8217;
equity. The Company&#8217;s Public Shares feature certain redemption rights that are considered to be outside of the Company&#8217;s
control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023 and 2022, <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp8ry42IgPWa" title="Temporary equity, shares outstanding">1,502,180</span> and <span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJYI75T357lb" title="Temporary equity, shares outstanding">34,500,000</span>, respectively,
Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders&#8217; deficit
section of the Company&#8217;s balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary
share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable
ordinary share are affected by charges against additional paid in capital and accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zMZGt80hTdmi" style="display: none">Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption">351,900,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value">4,964,000</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption">356,864,000</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value">2,801,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Redemption of ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares">(342,984,430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class A ordinary share subject to possible redemption, December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption">16,681,497</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z1HYxxQQhzOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zK1LsoVBPXid">Net
Income (Loss) per Ordinary Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#8220;Founder Shares&#8221;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)">17,975,000</span> ordinary shares at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants">11.50</span> per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share">17,975,000</span></span> Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(19,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(44,186</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(4,005</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income">3,172,916</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income">133,355</span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income">1,102,090</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted">5,333,742</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted">12,317,077</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted">1,116,256</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted">34,500,000</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted">1,450,000</span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted">11,983,333</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share">0.09</span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_ecustom--WarrantLiabilitiesPolicyPolicyTextBlock_z7WEXKlufkK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zVTXpxyIBmS5">Accounting
for Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment
considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own ordinary shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments
are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and Private Placement Warrants
qualify for liability accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zE8ozL4HOjF7">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#8217;s financial statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391855008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Initial Public Offering and Over-Allotment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract', window );"><strong>Initial Public Offering And Over-allotment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialPublicOfferingTextBlock', window );">Initial Public Offering and Over-Allotment</a></td>
<td class="text"><p id="xdx_80B_ecustom--InitialPublicOfferingTextBlock_zGP5ttt1Hp11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8212; <span id="xdx_823_zMij8QymoKDa">Initial Public Offering and Over-Allotment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the IPO, the Company sold <span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssue_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of units in initial public offering, gross (in shares ) | shares">34,500,000</span> units at a price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp2d" title="Shares issued, price per share">10.00</span> per Unit. Each Unit consists of <span id="xdx_90A_ecustom--NumberOfSharesIssuedPerUnit_dc_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ5lLQYbWgT" title="Number of shares in a unit">one</span> ordinary share (such ordinary
shares included in the Units being offered, the &#8220;Public Shares&#8221;), and <span id="xdx_904_ecustom--NumberOfWarrantsIssuedPerUnit_dxL_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAFYDg8NfD6h" title="Number of warrants in a unit::XDX::0.5"><span style="-sec-ix-hidden: xdx2ixbrl0743">one</span></span>-half of one redeemable warrant (each, a &#8220;Public
Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaJHoG2KGFM4" title="Number of shares issuable per warrant">one</span> ordinary share at a price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVwZvvcFOcrg" title="Exercise price of warrants">11.50</span> per share, subject
to adjustment (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502599648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosurePrivatePlacementWarrantsAbstract', window );"><strong>Private Placement Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PrivatePlacementTextBlock', window );">Private Placement Warrants</a></td>
<td class="text"><p id="xdx_805_ecustom--PrivatePlacementTextBlock_zYmNEZKmm2sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8212; <span id="xdx_82E_zp3DtiskTul3">Private Placement Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, simultaneously with the consummation of the IPO and the underwriters&#8217; exercise of their over-allotment option,
the Company consummated the issuance and sale (&#8220;Private Placement&#8221;) of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZcC7XRRaCX3" title="Number of warrants to purchase shares issued">1,450,000</span> units (the &#8220;Private Placement Units&#8221;)
in a private placement transaction at a price of $<span id="xdx_901_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp2d" title="Price of warrants">10.00</span> per Placement Unit, generating gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0d_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCGPjvAzbm6h" title="Aggregate purchase price">14,500,000</span>. The Private Placement
Units were purchased by Cantor (<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CantorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Number of warrants to purchase shares issued">150,000</span> Units) and the Sponsor (<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIT4Fhke8l7h" title="Number of warrants to purchase shares issued">1,300,000</span> Units). Each Private Placement Unit consisted of one Placement
Share and one-half of a redeemable warrant (&#8220;Placement Warrant&#8221;). Each whole Placement Warrant will be exercisable to purchase
one Class A ordinary share at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zzT20lahBfK7" title="Exercise price of warrant">11.50</span> per share. A portion of the proceeds from the Private Placement Units was added to the
proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination
Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to
the requirements of applicable law), and the Private Placement Units and all underlying securities will be worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify">On
June 7, 2023, the Original Sponsor transferred <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230607__20230607__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOngJOFWwf9j" title="Sale of stock, number of shares issued in transaction">1,000,000</span> Private Placement Units to the Sponsor in connection with the Purchase Agreement
(see Note 6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosurePrivatePlacementWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosurePrivatePlacementWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private Placement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395045136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdq2OcXxCE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_829_zqHcsCJYp0Qc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><i>Transactions with Sponsor</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Pursuant to the Merger Agreement, the
Company incurred $<span id="xdx_90D_eus-gaap--SponsorFees_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zGSzqMPEi0e7">2,000,000
</span>in fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory Service Fee&#8221;). In connection with the Merger and
thereafter, the Company and Sponsor agreed that $<span id="xdx_904_eus-gaap--SponsorFees_c20240101__20240331_zDcK1SOKuNva" title="Sponsor advisory services fee">250,000</span> of the Sponsor Advisory Service Fee is payable in cash, $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember_zEqpHQEHwr8a" title="Due to Sponsor">250,000</span> would be offset
against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zB1MkZ813bog">150,000
</span>shares of the Company&#8217;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented <span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember__us-gaap--DebtInstrumentAxis__custom--PolarNotesMember_z53BiEN4NwJ9">on
the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated balance sheets under the line item
&#8220;Due to related party&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the Sponsor owes the Company $<span id="xdx_908_ecustom--WorkingCapitalExpenses_c20240101__20240331_z5jjTLp86GZ9" title="Working capital expenses">158,819</span> to cover working capital expenses which is presented on the consolidated balance
sheets under the line item &#8220;Due from related party&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 9 for additional information on the Series B issued to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.<br/>
NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84Gt1zrAZfg" title="Isssued shares to related party">40,000</span> Performance-Based RSUs to the wife of the Company&#8217;s chair and chief executive officer for
advisory services provided to the Company, and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZuYGnbdjli4" title="Isssued shares to related party">20,000</span> Performance-Based RSUs to Mehtaphoric Consulting Inc, a company controlled by
the daughter of the Company&#8217;s chief financial officer, for information technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20240331_zb5osuQACug2" title="Compensation cost recognized">800,396</span> has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z8Gca90BJdx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8212; <span id="xdx_824_z3tPgZy1PhK9">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Founder
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Sponsor paid $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z37xhhFLck0j" title="Aggregate purchase price">25,000</span> to cover certain offering costs of the Company in consideration for <span id="xdx_908_eus-gaap--CommonStockDividendsShares_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLqmjGsoo5l" title="Share dividend">8,625,000</span> Founder Shares which were issued on
April 22, 2021. In August 2021, the Company effectuated a dividend of approximately <span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionRatio_iI_pp4d_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z3fkeWJiaBo8" title="Stock dividend ratio">0.3628</span> shares for each outstanding Class B ordinary
share resulting in an aggregate of <span id="xdx_901_ecustom--AggregateNumberOfSharesOwned_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Aggregate number of shares owned">11,754,150</span> Class B ordinary shares outstanding. On October 1, 2021, the Company effectuated a dividend
of approximately <span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionRatio_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pp4d" title="Stock dividend ratio">0.0195</span> shares for each outstanding Class B ordinary share resulting in an aggregate of <span id="xdx_90B_ecustom--AggregateNumberOfSharesOwned_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z8thw2vx3Xzf" title="Aggregate number of shares owned">11,983,333</span> Class B Founder shares
outstanding (up to <span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbbYrYEYOVZ8" title="Shares subject to forfeiture">1,530,000</span> of which are subject to forfeiture if the underwriters&#8217; over-allotment option is not exercised in
full). The Founder Shares will automatically convert into Class A ordinary shares at the time of the Company&#8217;s initial Business
Combination and are subject to certain transfer restrictions. The initial shareholders had agreed to forfeit up to <span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_za45SZyhmTw5" title="Shares subject to forfeiture">1,530,000</span> Founder
Shares to the extent that the over-allotment option is not exercised in full by the underwriters. Since the underwriters&#8217; exercised
the over-allotment option in full, no Founder Shares are subject to forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial shareholders will agree, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the
earliest of (A) <span id="xdx_90A_ecustom--RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zTgzZxac35I7" title="Restrictions on transfer period of time after business combination completion">one year</span> after the completion of our initial business combination and (B) subsequent to our initial business combination,
(x) if the closing price of our Class A ordinary shares equals or exceeds $<span id="xdx_90C_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_pp2d_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zaSUTpiQeMA5" title="Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)">12.00</span> per share (as adjusted for share subdivisions, share
capitalizations, reorganizations, recapitalizations and the like) for any <span id="xdx_90B_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLT4KgYAvK21" title="Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination">20</span> trading days within any <span id="xdx_901_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znQYiGVJBmgg" title="Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination">30</span>-trading day period commencing
at least <span id="xdx_905_ecustom--ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqLhRrOgfY3k" title="Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences">150</span> days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange
or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash,
securities or other property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 30, 2023, the initial shareholders holding
all of the Founder Shares elected to convert their Founder Shares into Class A ordinary shares of the Company on a <span id="xdx_90B_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_z6kgaFsCsbi4" title="Conversion ratio">one</span>-for-one basis (the
&#8220;Conversion&#8221;). As a result, <span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Shares cancelled">11,983,333</span> of the Company&#8217;s Class B ordinary shares were cancelled and <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjOqRKSqb3bl" title="Shares issued upon conversion">11,983,333</span> Class
A ordinary shares were issued to such converting Initial Shareholders. The Initial Shareholders agreed that all of the terms and conditions
applicable to the Founder Shares set forth in the Letter Agreement shall continue to apply to the Class A ordinary shares that the Founder
Shares converted into, including the voting agreement, transfer restrictions and waiver of any right, title, interest or claim of any
kind to the Trust Account or any monies or other assets held therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 4, 2023, the Company entered into the Purchase
Agreement, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zqWw1dV3wJTh" title="Number of shares issued">7,988,889</span> Class A ordinary shares and (y) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_z0BuF9bT2ri8" title="Number of shares issued">1,000,000</span>
Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for
one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Underwriting Agreement), for
an aggregate purchase price of $<span id="xdx_909_ecustom--AggregatePurchasePrice_iI_pp2d_c20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zWdV0O8ECMT" title="Aggregate purchase price">1.00</span> payable at the time of the initial Business Combination. On June 7, 2023, the Original Sponsor transferred
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zg81rbK0W3c6" title="Number of shares issued">7,988,889</span> Class A ordinary shares to the Sponsor, pursuant to the Purchase Agreement (see Note 6). The Company estimated the aggregate
fair values of the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableOrdinaryMember_zm8IjkwCuH2i" title="Number of shares issued">7,988,889</span> Class A non-redeemable ordinary shares, the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230606__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2W0MKjKtkB8" title="Number of shares issued">1,000,000</span> Private Placement shares, and the <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zamAYC1vlNR6" title="Class of warrants">500,000</span> public warrants
transferred to be $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zv9xZ9pyUphf" title="Proceeds">3,515,111</span>, $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredTwoMember_zeZWU5vFe9Ma" title="Number of shares issued">440,000</span>, and $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredThreeMember_zwGWLnWeh8If" title="Number of shares issued">20,000</span>, respectively or $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredOneMember_z8FSFlPAmFBj" title="Exercise price">0.44</span> per share and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredTwoMember_zpoAKPyTTn49" title="Exercise price">0.04</span> per warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z2fvY4XooUQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The fair value of the Class A non-redeemable shares
was based on the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span id="xdx_8B6_zR8Qc92B1zJ5">Schedule
of Fair Value Non Redeemable Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230503__20230504_zjRvdjmAJfIf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 4, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_zvPeAx7Xrov7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Discount for lack of marketability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">6.80</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--StockPriceOfMeasurement_pid_z3xkbBKhZqze" style="vertical-align: bottom; background-color: White">
    <td>Stock price as of measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10.77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProbabilityOfTransactionPercentage_pid_dp_uPure_zhofbGhptox2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of transaction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.40</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zRyKqWehGf5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Party Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2021, the Sponsor agreed to loan the Company an aggregate of up to $<span id="xdx_90A_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_c20210422__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Maximum borrowing capacity of related party promissory note">300,000</span> to cover expenses related to the IPO pursuant to
a promissory note (the &#8220;Note&#8221;). This loan was non-interest bearing and payable on the earlier of December 31, 2021 or the
completion of the IPO. The note payable of $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20211108__20211108__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Amount of notes payable repaid">121,158</span> was repaid on November 8, 2021. As of December 31, 2022, the Company had <span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_do_c20221231_zjdeSA05noib" title="Borrowings amount">no</span> borrowings
under the Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2023, the Company advanced the Sponsor $<span id="xdx_901_ecustom--WorkingCapital_iI_c20231002_zZpXIhQn8Xvf" title="Working capital">17,000</span>
for working capital purposes. The advances are non-interest bearing and are due on demand. This related party transaction is included on the accompanying balance sheet as a due from related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of December 31, 2023, the remainder of the Second SPAC Loan of $<span id="xdx_901_eus-gaap--PaymentsForAdvanceToAffiliate_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zehGaV6BMI8h" title="Loan from affiliate">577,500</span> is due from the Sponsor. This related
party transaction is included on the accompanying balance sheet as a due from related party. As of December 31, 2023, the Company determined that $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zF9dggB2C5u9" title="Impairment of due from related party">250,000</span> of the $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z1OlrjQ6gNef" title="Loan from affiliate">577,500</span> was deemed to be uncollectible, therefore
the Company recorded impairment totaling $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zXicAIVb55D7" title="Impairment of due from related party">250,000</span> on the amount due from related party in the other income section of the statement of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2023, the Company and the Original Sponsor entered into a Subscription Agreement with Polar Multi-Strategy Master Fund (the &#8220;Investor&#8221;)
where the Investor agreed to make a cash contribution of $<span id="xdx_902_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zrzfpG4AdEFa" title="Initial capital contribution">151,000</span> to the Original Sponsor (the &#8220;Initial Capital Contribution&#8221;)
on or prior to May 3, 2023. The Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover
working capital expenses (the &#8220;First SPAC Loan&#8221;). In consideration for the Initial Capital Contribution, the Company will
issue <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLiyrpFxH8tk" title="Number of shares issued">151,000</span> Class A ordinary shares, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zUh01rxjvlU2" title="Ordinary shares, par value (in dollar per share)">0.0001</span> per share, of the Company to the Investor at the closing of the initial business
combination (the &#8220;De-SPAC Closing&#8221;). The First SPAC Loan shall not accrue interest and shall be repaid by the Company upon
the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares
of the Company at a rate of one Class A ordinary share for each $<span id="xdx_90D_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zJn5mGhF4Lg3" title="Initial capital contribution">10.00</span> of Initial Capital Contribution. If the Company liquidates without
consummating the initial business combination, any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the
Company&#8217;s Trust Account, will be paid to the Investor within five days of the liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, the Sponsor and the Company entered into a second subscription agreement (the &#8220;Second Subscription
Agreement&#8221;) with the Investor where the Investor agreed to lend to the Sponsor, which would in turn be lent to the Company, an
aggregate of $<span id="xdx_908_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__dei--LegalEntityAxis__custom--SponsorMember_zppqeb1abZF4" title="Maximum borrowing capacity of related party promissory note">1,500,000</span>
(the &#8220;Additional Capital Commitment&#8221;) to cover working capital expenses (the &#8220;Second SPAC Loan&#8221;). One half
of the Additional Capital Commitment was made by the Investor to the Sponsor in cash on or prior to June 21, 2023, and the remaining
$<span id="xdx_906_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_znxv21J0Pl6h" title="Remaining borrowing capacity amount">750,000</span>
would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#8217;s request and the first filing of the S-4 for
the Company&#8217;s business combination. In consideration for the Second SPAC Loan, the Company will issue one Class A ordinary
share for each dollar of the Additional Capital Commitment funded by the Investor at the De-SPAC Closing. The Second SPAC Loan shall
not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to
receive such payments in (a) cash or (b) Class A ordinary shares at a rate of one Class A ordinary share for each $<span id="xdx_904_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zVE2avjo7wna" title="Initial capital contribution">10.00</span>
of Additional Capital Contribution. If the Company liquidates without consummating the initial business combination, any amounts
remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account, will be paid to the
Investor within five days of the liquidation. Collectively, the First SPAC Loan and the Second SPAC Loan are referred to as the SPAC
Loans. As of December 31, 2023, the Company had $<span id="xdx_901_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--SponsorMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zTOfKsdZSv0d" title="Debt instrument, fee amount">1,651,000</span>
borrowings under the  SPAC Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company accounted for the Class A common stock
they could be converted (&#8220;equity instrument&#8221;) to as equity-classified instruments based on an assessment of the specific
terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the equity instrument is freestanding
financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the equity instrument
meets all the requirements for equity classification under ASC 815, including whether the equity instrument is indexed to the Company&#8217;s
own common stock, among other conditions for the equity classification. This assessment, which requires the use of professional judgment,
was conducted at the time of equity instrument issuance. The SPAC Loans and the equity instrument meet the scope exception of ASC 815-10-15-74(a).
The Company applied the guidance in ASC 470-20-25-2 &#8220;<i>Debt With Conversion and Other Options</i>&#8221;, requiring that the loan
proceeds be allocated to the SPAC Loans based on their relative fair values. At May 3, 2023 the Company allocated $<span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zH5tFmPsSaLe">104,861
</span>of the proceeds to the First SPAC Loan and $<span id="xdx_901_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503_znpJNBOUam8b">46,139
</span>for the equity instrument. The Company estimated the aggregate fair value of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zQ5uzwnhioCh">151,000
</span>shares to be issued to be $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zcUJF80uBLxf">66,440
</span>or $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_znJXZYBHVUVg">0.44
</span>per share. At June 20, 2023 the Company allocated $<span id="xdx_90C_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zqkCQLrLAbp5">520,833
</span>of the proceeds to the Second SPAC Loan and $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620_zA16ZwwVF4P3">229,167
</span>for the equity instruments. The Company estimated the aggregate fair value of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zGk94zI4YmL8">750,000
</span>shares to be issued to be $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zVKj7ZCPgeu6">330,000
</span>or $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zBiMxfWHbnw8">0.44
</span>per share. At December 31, 2023 the carrying values of the SPAC Loans and the discounts were $<span id="xdx_909_eus-gaap--OtherNotesPayableCurrent_iI_c20231231_zbRrvzroSfhh">1,631,725
</span>and $<span id="xdx_902_ecustom--ConvertibleNotesPayableDiscounts_iI_c20231231_zp5qO5A6B4m">275,306</span>, respectively. The Company recorded amortization of the discounts on the SPAC Loans of
$<span id="xdx_906_ecustom--NoncashInterestExpenses_c20230101__20231231_zbT0QTObPMne" title="Non cash interest expenses">256,031</span>, which is disclosed in the statement of cash flows as non-cash interest expense. As of
December 31, 2023, the unamortized discount on the SPAC Loans was $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231_zcC6nyEXuTt1">19,274</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the remainder of the Second SPAC Loan of $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zvujXd3eujaf" title="Loan from affiliate">577,500</span> is due from the Sponsor. This amount is included on the accompanying
balance sheet as a due from related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Working
Capital Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor,
or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working
Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the
proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside
the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the
Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements
exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without
interest, or, at the lender&#8217;s discretion, up to $<span id="xdx_90C_ecustom--MaximumLoansConvertibleIntoWarrants_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_zqF4920S6Gxl" title="Loan conversion agreement warrant">1.5</span> million of such Working Capital Loans may be convertible into private placement-equivalent
units at a price of $<span id="xdx_904_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WorkingCapitalLoansWarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_z4W4b2kmRjc4" title="Price of warrant">10.00</span> per unit. As of December 31, 2023 and 2022, the Company had <span id="xdx_90B_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zbhE3rm7aWq5" title="Working capital loan"><span id="xdx_903_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20221231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zVIH4BX8WiRh" title="Working capital loan">no</span></span> borrowings under the Working Capital Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administrative
Support Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
on the date of the final prospectus, the Company will agree to pay the Sponsor a total of $<span id="xdx_902_ecustom--RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zngBZMp1EOv3" title="Expenses per month">10,000</span> per month for office space and administrative
and support services. Upon completion of the Initial Business Combination or the Company&#8217;s liquidation, the Company will cease
paying these monthly fees. At December 31, 2023 and 2022, $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zTeRuZsi8pS3" title="Amount accrued">230,000</span> and $<span id="xdx_905_eus-gaap--OtherLiabilities_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zrcFWHNGvSWh" title="Amount accrued">120,000</span>, respectively, have been accrued under this arrangement
and included in due to affiliate on the accompanying balance sheets.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693393243344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zndJCv4P9LIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8212; <span id="xdx_825_zYPPAmLATiS5">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registration
Rights</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Founder Shares, Private Placement Units (including the underlying securities), and securities that may be issued upon conversion
of Working Capital Loans, if any, will be entitled to registration rights pursuant to a registration rights agreement signed upon consummation
of the IPO. These holders will be entitled to certain demand and &#8220;piggyback&#8221; registration rights. However, the registration
rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective
until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underwriting
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted the underwriters a <span id="xdx_90F_ecustom--UnderwritingOptionPeriod_dtD_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zKq3usiUpiPb" title="Underwriting option period">45</span>-day option from the final prospectus relating to the IPO to purchase up to <span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjEWU0ZKlgy7" title="Sale of units, net of underwriting discounts (in shares)">4,500,000</span> additional
Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On November 5, 2021, the underwriters
elected to fully exercise the over-allotment option purchasing <span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211105__20211105__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0D1xMmG4LCe" title="Sale of units, net of underwriting discounts (in shares)">4,500,000 </span>Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters were paid a cash underwriting discount of $<span id="xdx_903_ecustom--UnderwritingCashDiscountPerUnit_pp2d_c20230101__20231231_zAMMEaSn8KUb" title="Underwriting cash discount per unit">0.20</span> per unit, or $<span id="xdx_901_ecustom--PaymentOfUnderwriterDiscount_pp0p0_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zv3FDpkejT3d" title="Payment of underwriter discount">6,000,000</span> in the aggregate at the closing of the IPO. The
underwriters have agreed to defer the cash underwriting discount of $<span id="xdx_903_ecustom--UnderwritingCashDiscountPerUnit_pp2d_c20230101__20231231_z3qhrRkyXa4d" title="Underwriting cash discount per unit">0.20</span> per share related to the over-allotment to be paid at Business
Combination ($<span id="xdx_909_ecustom--AggregateUnderwriterCashDiscount_c20230101__20231231_z80p0EzYGGpl" title="Aggregate underwriter cash discount">900,000</span> in the aggregate). In addition, the underwriters are entitled to a deferred underwriting commissions of $<span id="xdx_90E_ecustom--DeferredFeePerUnit_iI_pp2d_c20231231_z8IhYd0PEnqd" title="Deferred underwriting commission fee (per unit)">0.40</span> per
unit, or $<span id="xdx_90F_ecustom--DeferredUnderwritingFeePayable_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXmGoyaNlnMj" title="Deferred underwriting fee payable">13,800,000</span> from the closing of the IPO. The total deferred fee is $<span id="xdx_90D_ecustom--AggregateDeferredUnderwritingFeePayable_c20230101__20231231_zjExYO1ZECU6" title="Aggregate deferred underwriting fee payable">14,700,000</span> consisting of the $<span id="xdx_90F_ecustom--DeferredUnderwritingFeePayable_c20230101__20231231_zGMVX4ykE115" title="Deferred underwriting fee payable">13,800,000</span> deferred portion
and the $<span id="xdx_902_ecustom--UnderwriterCashDiscount_c20230101__20231231_zNPRC1kHaj6c" title="Underwriter cash discount">900,000</span> cash discount agreed to be deferred until Business Combination. The deferred fee will become payable to the underwriters
from the amounts held in the Trust Account solely if the Company completes a Business Combination, subject to the terms of the underwriting
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in Note 5, on May 3, 2023, the Company entered into a subscription agreement (&#8220;Subscription Agreement&#8221;) with the Investor
and the Original Sponsor. Pursuant to the May 4, 2023 Purchase Agreement, the Sponsor assumed the obligations of the Original Sponsor
under the Subscription Agreement. Subject to, and in accordance with the terms and conditions of the Subscription Agreement, the parties
agreed that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investor would make a cash contribution of $<span id="xdx_90C_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmSM6yYtItk8" title="Initial capital contribution">151,000</span> to the Original Sponsor (the &#8220;Initial Capital Contribution&#8221;) on or
    prior to May 3, 2023, or on such date as the parties may agree in writing.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover working capital expenses (the
    &#8220;First SPAC Loan&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    consideration for the Initial Capital Contribution, the Company will issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z4RpHdiUDdq1" title="Number of shares issued">151,000</span> Class A ordinary shares, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zwjIHYyyuwVi" title="Ordinary shares, par value (in dollar per share)">0.0001</span> per
    share, of the Company to the Investor at the De-SPAC Closing, which shares shall be subject to no transfer restrictions or any other
    lock-up provisions, earn outs, or other contingencies and shall be registered as part of any registration statement to be filed in
    connection with the De-SPAC Closing or, if no such registration statement is filed in connection with the De-SPAC Closing, pursuant
    to the first registration statement to be filed by the Company or the surviving entity following the De-SPAC Closing.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    SPAC Loan shall not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Sponsor will pay to the Investor
    all repayments of the SPAC Loan the Sponsor has received within <span id="xdx_906_ecustom--MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_dxL_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z30n1seYNRR2" title="Minimum period for receiving spac loan from de-spac closing::XDX::P5D"><span style="-sec-ix-hidden: xdx2ixbrl0926">five</span></span> business days of the De-SPAC Closing. The Investor may elect
    at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares at a rate of <span id="xdx_901_ecustom--NumberOfSharesIssuableForEach10InitialCapitalContribution_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zqyTVL6zYLD3" title="Number of shares issuable for each $10 initial capital contribution">one</span> Class A ordinary share
    for each $<span id="xdx_909_ecustom--AmountOfInitialCapitalConsideredToIssueOneShare_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zFYoqro2Dr5b" title="Amount of initial capital considered to issue one share">10.00</span> of the Initial Capital Contribution. If the Company liquidates without consummating the initial business combination,
    any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account, will be paid
    to the Investor within <span id="xdx_906_ecustom--MinimumPeriodForPaymentInCaseOfLiquidation_dc_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zAOm15oQBdVf" title="Minimum period for payment in case of liquidation">five days</span> of the liquidation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the De-SPAC Closing, the Sponsor will pay the Investor an amount equal to the reasonable attorney fees incurred by the Investor in
    connection with the Subscription Agreement not to exceed $<span id="xdx_90C_ecustom--MaximumReasonableAttorneyFees_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zKDgwTu0Kmpb" title="Maximum reasonable attorney fees">5,000</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, the Company entered into a second subscription agreement (the &#8220;Second Subscription Agreement&#8221;) with the Investor
and the Sponsor. Subject to, and in accordance with the terms and conditions of the Second Subscription Agreement, the parties agreed
that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investor would make a cash contribution of up to $<span id="xdx_900_ecustom--InitialCapitalContribution_pp0p0_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_ziuucL2LkLZ5" title="Initial capital contribution">750,000</span> to the Sponsor (the &#8220;Additional Capital Contribution&#8221;) on or
    prior to June 21, 2023, and the remaining $<span id="xdx_90E_ecustom--InitialCapitalContribution_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zAHmT1WTqsqa" title="Initial capital contribution">750,000</span> would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#8217;s
    request and the first filing of the S-4 for the De-SPAC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Additional Capital Contribution would in turn be loaned by the Sponsor to the Company in cash on the later of the Sponsor&#8217;s
    request and the first filing of the S-4 for the SPAC&#8217;s business combination (the &#8220;Second SPAC Loan&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    consideration for the Additional Capital Commitment, SPAC will issue a further <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zkvSdiWuJlI1" title="Number of shares issued">one</span> Class A ordinary share for each dollar of the
    Additional Capital Commitment funded to the Investor at the close of the business combination (&#8220;Subscription Shares&#8221;).
    The Subscription Shares shall be subject to no transfer restrictions or any other lock-up provisions, earn outs, or other contingencies.
    The Subscription Shares (i) shall be registered as part of any registration statement issuing shares before or in connection with
    the De- SPAC Closing or (ii) if no such registration statement is filed in connection with the de-SPAC Closing, shall promptly be
    registered pursuant to the first registration statement filed by the SPAC or the surviving entity following the De-SPAC Closing,
    which shall be filed no later than 30 days after the De-SPAC Closing and declared effective no later than 90 days after the De-SPAC
    Closing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Second SPAC Loan shall not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Sponsor will pay to the
    Investor all repayments of the Second SPAC Loan the Sponsor has received within <span id="xdx_906_ecustom--MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_dxL_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zgBkLbKUZo3b" title="Minimum period for receiving spac loan from de-spac closing::XDX::P5D"><span style="-sec-ix-hidden: xdx2ixbrl0942">five</span></span> business days of the De-SPAC Closing. The Investor
    may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares at a rate of <span id="xdx_902_ecustom--NumberOfSharesIssuableForEach10InitialCapitalContribution_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zj2uNiqyPKY8" title="Number of shares issuable for each $10 initial capital contribution">one</span> Class A ordinary
    share for each $<span id="xdx_901_ecustom--AmountOfInitialCapitalConsideredToIssueOneShare_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zLdYsqU579O8" title="Amount of initial capital considered to issue one share">10.00</span> of the Additional Capital Contribution. If the Company liquidates without consummating the initial business
    combination, any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account,
    will be paid to the Investor within five days of the liquidation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the De-SPAC Closing, the Sponsor will pay the Investor an amount equal to the reasonable attorney fees incurred by the Investor in
    connection with the Second Subscription Agreement not to exceed $<span id="xdx_90D_ecustom--MaximumReasonableAttorneyFees_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zQiqrVEYjNX2" title="Maximum reasonable attorney fees">5,000</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with the Sponsor and the Original Sponsor,
pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_zdO0ljFVGdu6" title="Number of shares issued">7,988,889 </span>Class A ordinary shares and (y) <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_z1Q4DOn6S8g2" title="Number of shares issued">1,000,000</span> Private
Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for one Class
A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter Agreement, dated November 3,
2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement, dated November 3, 2021,
by and between the Company and Cantor, as representative of the several underwriters (the &#8220;Underwriting Agreement&#8221;), for
an aggregate purchase price of $<span id="xdx_906_ecustom--AggregatePurchasePrice_iI_c20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_zXUAMPheSpI" title="Purchase price">1.00</span> (the &#8220;Purchase Price&#8221;) payable at the time of the initial business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the payment of the Purchase Price, the Sponsor also assumed the following obligations: (i) responsibility for all of Company&#8217;s
public company reporting obligations; (ii) the obligations of the Original Sponsor under the May 3, 2023 Subscription Agreement, (iii)
responsibility for the Company&#8217;s D&amp;O insurance premium to extend the Company&#8217;s existing D&amp;O insurance policy and
maintain D&amp;O coverage through the closing of the initial business combination and obtain appropriate tail coverage; (iv) responsibility
for the Company&#8217;s outstanding legal fees owed by the Company; and (v) all other obligations of the Original Sponsor related to
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Sponsor had the right to replace the Company&#8217;s current directors and officers with directors and
officers as the Sponsor may select in its sole discretion. The obligations of the Original Sponsor to consummate the transactions contemplated
by the Purchase Agreement were subject to the satisfaction or written waiver by the Original Sponsor of the following conditions: (a)
the approval of the board of directors the SPAC; (b) the approval of the members of the Original Sponsor; (c) the consent or waiver of
the underwriters under the Underwriting Agreement; (d) the filing of its quarterly report on Form 10-Q by the SPAC for the quarter ended
March 31, 2023. On June 7, 2023, the parties to the Purchase Agreement closed the transactions contemplated thereby. In connection with
the closing, the Sponsor replaced the Company&#8217;s directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement contains customary representations and warranties of the parties, including, among others, with respect to corporate
organization, corporate authority, and compliance with applicable laws. The representations and warranties of each party set forth in
the Purchase Agreement were made solely for the benefit of the other parties to the Purchase Agreement, and investors are not third-party
beneficiaries of the Purchase Agreement. In addition, such representations and warranties (a) are subject to materiality and other qualifications
contained in the Purchase Agreement, which may differ from what may be viewed as material by investors, (b) were made only as of the
date of the Purchase Agreement or such other date as is specified in the Purchase Agreement and (c) may have been included in the Purchase
Agreement for the purpose of allocating risk between the parties rather than establishing matters as facts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693518885632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Deficit</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztGFWxBTy8kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_826_zBea3ZTkddpg">STOCKHOLDERS&#8217; DEFICIT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>Common Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of February 15, 2024, the Company&#8217;s
common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW&#8221;,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of March 31, 2024, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240331_zFhYlpmWMJke" title="Common shares, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zcJLFKJFOmM5" title="Common shares, shares outstanding">164,614,418</span></span>
shares of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested or are not subject
to repurchase are considered issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zY5jL67Rs2Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Below is a reconciliation of shares of common stock issued and outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zZo8Qih3N086">SCHEDULE
OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock legally issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20240331_zsMZdC6rjITa" title="Common shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zjYfmLv5o8Ea" title="Common shares, shares outstanding">164,614,418</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: Shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares issuable to Polar <span>(a)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesToBeIssuedOnSharesIssuable_iI_c20240331_fKGEp_zMeI2mD6dNV4" style="text-align: right" title="Shares issuable to Polar">1,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Shares issuable to Polar"><p id="xdx_983_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20240331_fKGIp_zXBFTzzS3Bq7" style="margin: 0" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing">7,148,506</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Issuance of restricted common stock subject to forfeiture
    <span>(c)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20240331_fKGMp_z5jRYgf928xj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture">(19,348,954</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued and outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20240331_zU2AIRwtMn07" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding">153,913,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0E_zSFUsb3mIPXf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zVLlsyBIhf2g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td id="xdx_F0A_z3CtrESEccf7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(b)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p id="xdx_F18_zIQMiBkzr678" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zHMvLEAIjjn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zdgGRYz4aBu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A2_zNrP1QjuNk07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s
common stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio,
as discussed in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Preferred Stock</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331_zYPXBdzcNdI9" title="Preferred shares, shares authorized">20,000,000</span> shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331_zESzwfjnzTsa" title="Preferred shares, par value">0.0001</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">I<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n
March 2024, the Company authorized and issued <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1TQsskKFFYe" title="Preferred stock, shares authorized">2,000</span> and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1sAf5wyTPj" title="Preferred stock, shares issued">500</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares,
respectively, of Series A Preferred Stock (the &#8220;Series A&#8221;) to an investor at a price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUYzddNAGNmk">4,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (the &#8220;Series A Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCJnWajq7eXj" title="Proceeds from issuance of preferred stock">2.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span> The Company recorded an expense of $<span id="xdx_904_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zn3WtQPCy6hh" title="Loss on preferred stock issuance">799,990</span> in its consolidated statements of operations related to issuance of the Series A equal
to the fair value of the Series A when issued of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW0vScNOJjhf" title="Price per share">5,600</span> per share less the purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zWezmWpjHre">4,000</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuaTZfQiWyF5" title="Dividend rate, percentage">5</span>%
per annum per share on <span id="xdx_90B_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWbqiruCDfd" title="Dividend variable rate, description">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the
&#8220;Series A Accruing Dividends&#8221;)</span>. These dividends become payable when and if declared by the Company. The Series A
Preferred Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series B Preferred Stock (the &#8220;Series B&#8221;) in liquidation priority. In the
event of a liquidation of the Company, or certain deemed liquidation events, the Series A is redeemable for a price
equal to the greater of the Series A Original Issue Price plus all Series A Accruing Dividends that are unpaid through the
redemption date, or such amount that would have been payable had the Series A converted into shares of
common stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence
of a deemed liquidation event. The Company is entitled to redeem that Series A at a price equal to the Series A Original
Issue Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds
$<span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCWwsmAWOVz6" title="Redemption per share">5.00</span> per share for <span id="xdx_905_eus-gaap--PreferredStockRedemptionTerms_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7UH72EETIwl" title="Redemption term">the twenty days immediately prior to the Company&#8217;s call election</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal
to the Series A Original Issue Price divided by the Series A Conversion Price, which is initially $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTbEsICcDl5l" title="Conversion price">4.00</span> per share and is subject to standard
antidilution adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A-1 Preferred Stock </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Series A investor covering the
issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zXZHxPobwsVf" title="Stock issuance">600</span> shares of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zvjrGPPmFNRd" title="Stock issuance, value">6,000,000</span>. <span id="xdx_901_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zJ5kIXmKRtdc" title="Dividend variable rate, description">The terms of the Series A-1 Preferred
Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum and the Series
A-1 Issuance Price is defined as $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfdbaJOfPvO9">10,000</span> per share.</span> As of March 31, 2024, the investor had paid a non-refundable deposit of $<span id="xdx_90A_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zFh4aSmduqa2" title="Non refundable amount">200,000</span>
towards the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the
Sponsor assuming liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. On March 15,
2024, <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8YcxbKTk1M9" title="Conversion of certain liabilities into Series B preferred stock, shares">3,613</span>
shares of Series B were issued in return for the assumption of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWozjgcIKip6" title="Conversion of certain liabilities into Series B preferred stock">3,613,000</span>
of liabilities. As these liabilities were unpaid and the Company was not legally released by the creditors, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
liabilities were not extinguished and</span> remain on the Company&#8217;s balance sheets at March 31, 2024. The issuance date fair
value of the Series B was determined to be $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zC4nA0EymVBi" title="Conversion of certain liabilities into Series B preferred stock">3,613,000</span>
and was recorded within Merger transaction costs in the consolidated statements of operations. The Series B is classified as
permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series B are entitled to receive cumulative dividends at the Series B Dividend Rate, which accrue quarterly on the basis of a
360-day year and accrue whether or not declared by the Company provided that to the extent the Assumed Liabilities are outstanding,
any dividend(s) will be paid by the Company on behalf of the Sponsor to the creditors first. <span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z46y9HrWiFE9" title="Dividend variable rate, description">The
Series B Dividend Rate is initially 3.25% per quarter, increases by 0.25% on each 30-day anniversary of the Initial Dividend Date
(Defined below), and capped at 7.5% per quarter.</span> The &#8220;Initial Dividend Date&#8221; is defined as 35 days after the
initial issuance date of the Series B. Subsequent dividends are due and payable on the quarterly anniversary of the initial issuance
date, or if that date is not a business day, due and payable on the next succeeding business day. Series B dividends payable are
calculated as the Dividend Rate multiplied by the Series B Issue Price of $<span id="xdx_90F_eus-gaap--DividendsPayableAmountPerShare_iI_c20240331_zqMcpNZytuxa" title="Dividends payable per share">1,000</span>
per share. Series B dividends are payable whether or not declared by the Company, and are recorded within accounts payable of the
consolidated balance sheets as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Preferred Stock ranks senior to common stock and junior to Series A in liquidation priority. In the event of
a liquidation of the Company, the Series B is redeemable for a price equal to the aggregate amount of the liabilities
assumed by the Sponsor following the Closing, which was $<span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyQiao17idza" title="Redemption per share">1,000</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B are not entitled to redeem their shares outside of the liquidation of the Company. The Company is
entitled to redeem the Series B at a price equal to the Series B Issue Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B Preferred Stock do not contain any conversion rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zfYPWcrbQ0pe" title="Number of warrants issued">17,975,000</span> warrants initially issued by Semper Paratus in November 2021, comprising <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zlwWEOh4MHud" title="Number of warrants issued">17,250,000</span> public warrants sold in the
IPO and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMSTg0CyeeL9" title="Number of warrants issued">725,000</span> warrants issued in a concurrent private placement, were assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z8zqCNTi4dk1" title="Exercise price">11.50</span>
per share, became exercisable on <span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zH1p7LRjbER7" title="Exercisable date">March
15, 2024</span>, and will expire at 5:00 p.m., New York City time, on February 14, 2029, or earlier upon redemption or liquidation.
Warrant holders may, until such time as there is an effective registration statement and during any period when the Company has
failed to maintain an effective registration statement covering the shares of the Company&#8217;s common stock issuable upon
exercise of the warrants, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities
Act of 1933, as amended, or another exception. <span id="xdx_90D_ecustom--WarrantsDescription_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zSMe7Blb9Hpf" title="Warrants description">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days
within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption
to the holders of public warrants.</span> As of March 31, 2024, there are <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zNO0OzvNYTYg" title="Number of warrants outstanding">17,250,000</span>
public warrants outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Private
Placement Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the Sponsor or its permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders on a cashless
basis. As of March 31, 2024, there are <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfnAt6a825Vj" title="Number of warrants outstanding">725,000</span> private placement warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for additional information on the Company&#8217;s
warrant accounting policy.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zleahcFRElM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8212; <span id="xdx_829_zxRgFLkxaid1">Shareholders&#8217; Deficit</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
A Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z3SFuwRzr81f" title="Ordinary shares, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zchjqu3Qokf3" title="Ordinary shares, shares authorized">200,000,000</span></span> Class A ordinary shares with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zImyFic4gI33" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxQiWvMyIGQl" title="Ordinary shares, par value (In Dollar per share)">0.0001</span></span> per share. As of December 31, 2023 and
2022, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcMPHebQv53h" title="Ordinary shares, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z6e2WPRTJ7Oh" title="Ordinary shares, shares outstanding">13,433,333</span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z39e0fKBc1he" title="Ordinary shares, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBC1BOAGBxoc" title="Ordinary shares, shares outstanding">1,450,000</span></span> Class A ordinary shares issued and outstanding (excluding <span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfPNNf5ZvKT9" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)">1,502,180</span> and <span id="xdx_905_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2oissxe3H04" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)">34,500,000</span> Class A
ordinary shares subject to possible redemption), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
B Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4wWYQu9dw32" title="Ordinary shares, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zsIkoeyUHNQg" title="Ordinary shares, shares authorized">20,000,000</span></span> Class B ordinary shares with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zYmYGRMYhN0h" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z49zdW0LprNc" title="Ordinary shares, par value (In Dollar per share)">0.0001</span></span> per share. Holders of Class B ordinary
shares are entitled to <span id="xdx_903_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zA50ZpBPWOZ1" title="Ordinary shares, vote per share"><span id="xdx_90D_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z5P97QEnPJi6" title="Ordinary shares, vote per share">one</span></span> vote for each share of Class B ordinary shares. As of December 31, 2023 and 2022, there were <span title="Ordinary shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAcwgpj0sVZc" title="Ordinary shares, shares outstanding">0</span></span> and <span title="Ordinary shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zvD0066NA6Zk" title="Ordinary shares, shares outstanding">11,983,333</span></span>
Class B ordinary shares outstanding, respectively, none of which are subject to forfeiture since the underwriters&#8217; over-allotment
option was exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to our initial Business Combination, only holders of our Class B ordinary shares will have the right to vote on the appointment of directors.
Holders of our Class A ordinary shares will not be entitled to vote on the election of directors during such time. In addition, prior
to the completion of an initial Business Combination, holders of a majority of our Class B ordinary shares may remove a member of the
board of directors for any reason. These provisions of our Memorandum and Articles of Association may only be amended by a special resolution
passed by not less than 90% of our ordinary share shareholders who attend and vote at our general meeting. With respect to any other
matter submitted to a vote of our shareholders, including any vote in connection with our initial Business Combination, except as required
by law, holders of our Class B ordinary shares and holders of our Class A ordinary shares will vote together as a single class, with
each share entitling the holder to one vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination on a
one-for-one basis, subject to adjustment. In the case that additional Class A ordinary shares, or equity-linked securities, are issued
or deemed issued in excess of the amounts offered in the IPO and related to the closing of the initial Business Combination, the ratio
at which Class B ordinary shares shall convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the
outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the
number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted
basis, <span id="xdx_905_ecustom--ConvertibleStocksConversionRatio_pp2d_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zmV42KXKTiPc" title="Ratio to be applied to the stock in the conversion">25</span>% of the sum of the total number of all ordinary shares outstanding upon the completion of the IPO plus all Class A ordinary
shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares
or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent
warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preference
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zazauzFLiK9a" title="Preference shares , shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zJDNnakKyA9b" title="Preference shares , shares authorized">1,000,000</span></span> preference shares with such designations, voting and other rights and preferences as may be
determined from time to time by the Company&#8217;s board of directors. As of December 31, 2023 and 2022, there were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_ztPeBlPZ5ec5" title="Preference shares, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zq17rCvt7rs7" title="Preference shares, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_ztfqe4EbgzA6" title="Preference shares, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_z9Zk2qATZUm2" title="Preference shares, shares outstanding">no</span></span></span></span> preferred shares
issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Public Warrants will become exercisable on the later of (i) <span id="xdx_90A_ecustom--WarrantExercisePeriodConditionOne_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztzdgo41Df2" title="Minimum threshold written notice period for redemption of public warrants">30</span> days after the completion of a Business Combination and (ii) <span id="xdx_901_ecustom--WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_dc_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zQOsYxkSzvij" title="Public warrants exercisable term from the closing of the initial public offering">one year</span>
from the closing of the IPO. No warrants will be exercisable for cash unless the Company has an effective and current registration statement
covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such Class A ordinary
shares. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon exercise of the
Public Warrants is not effective within a specified period following the consummation of a Business Combination, warrant holders may,
until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain
an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the
Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not
be able to exercise their warrants on a cashless basis. The Public Warrants will expire <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zkzZ5UAsOTCh" title="Public warrants expiration term">five years</span> after the completion of a Business
Combination or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the warrants become exercisable, the Company may redeem the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $<span id="xdx_90C_ecustom--ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zekJbq7X1MQl" title="Redemption price per public warrant (in dollars per share)">0.01</span> per warrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than <span id="xdx_906_ecustom--RedemptionPeriod_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrBwEljK2dUf" title="Redemption period">30</span> days&#8217; prior written notice of redemption;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $<span id="xdx_907_ecustom--WarrantRedemptionConditionMinimumSharePrice_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9vhPKWd3Ubk" title="Warrant redemption condition minimum share price">18.00</span> per share (as adjusted for share
    subdivisions, share dividends, reorganizations and recapitalizations), for any <span id="xdx_906_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zOEzySEWuLMd" title="Threshold trading days for redemption of public warrants">20</span> trading days within a <span id="xdx_90B_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z63PpM15jw8l" title="Threshold consecutive trading days for redemption of public warrants">30 </span>trading day period commencing
    at any time after the warrants become exercisable and ending on the <span id="xdx_909_ecustom--ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_dcxL_uInteger_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zocKlIJZEHTc" title="Threshold number of business days before sending notice of redemption to warrant holders::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1024">third</span></span> business day prior to the notice of redemption to warrant
    holders; and if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying
    the warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the
Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Warrants are identical to the Public Warrants underlying the Units being sold in the IPO, except that the Private Warrants and
the Class A ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until
after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable
for cash or on a cashless basis, at the holder&#8217;s option, and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees,
the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of Class A ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including
in the event of a share dividend, extra Class A Ordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of Class A ordinary shares at a price below their respective exercise prices. Additionally,
in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination
within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any
of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of
the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection
with the closing of a Business Combination at an issue price or effective issue price of less than $<span id="xdx_907_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrnWI2UP5Qyl" title="Share price trigger used to measure dilution of warrant">9.20</span> per Class A ordinary share (with
such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors, and in the case of
any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by them prior
to such issuance), (y) the aggregate gross proceeds from such issuances represent more than <span id="xdx_909_ecustom--PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztRCScGKUfjj" title="Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant">60</span>% of the total equity proceeds, and interest
thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Class A ordinary shares during the <span id="xdx_905_ecustom--TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwsPSdo8y9sc" title="Trading period after business combination used to measure dilution of warrant">20</span> trading day period starting
on the trading day prior to the day on which the Company consummates Business Combination (such price, the &#8220;Market Value&#8221;)
is below $<span id="xdx_90E_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdONLKLPoV82" title="Share price trigger used to measure dilution of warrant">9.20</span> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <span id="xdx_90E_ecustom--ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_pid_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrrgKbUSjwrd" title="Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)">115</span>% of the greater
of (i) the Market Value or (ii) the price at which the Company issues the additional Class A ordinary shares or equity-linked securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693522524976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantLiabilitiesDisclosureTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p id="xdx_80A_ecustom--WarrantLiabilitiesDisclosureTextBlock_zlcP5brLQtCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8212; <span id="xdx_82C_zeu0TEWjRXgf">Warrant Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_z2XLa9qsk8r4" title="Number of warrants to purchase shares issued">725,000</span> Private Placement Warrants in accordance with the guidance contained in ASC 815-40 due to the fact the
Private Placement Warrants will be exercisable for cash or on a cashless basis, at the holder&#8217;s option, and be non-redeemable so
long as they are held by the initial purchasers or their permitted transferee. Such guidance provides that, based on these features,
the private placement warrants do not meet the criteria for equity treatment thereunder, and each such warrant must be recorded as a
liability. Accordingly, the Company will classify each private placement warrant as a liability at its fair value. This liability is
subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value,
with the change in fair value recognized in the Company&#8217;s statement of operations. The Company has determined the Public Warrants
do not contain such features, and accordingly will be accounted for as equity and are not subject to subsequent remeasurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities Disclosure [TextBlock}</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502938592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zscPJiCAlwRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8212; <span id="xdx_822_zpLtguBL6Bdf">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions
    for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities
    and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the assets held in the Trust Account were held in a demand deposit account. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmjRVkh3pYg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at December 31, 2023 and 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine
such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUJd3DIqYfuc" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2023:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/>
Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Active<br/>
 Markets <br/>
(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Observable<br/>
 Inputs<br/>
 (Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unobservable<br/>
 Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zL6j0eZA5kQd" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zzQOWVq1njL9" style="width: 12%; text-align: right" title="U.S. Treasury Securities">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zJHJYSgOXqh5" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzF2KHIA6d1h" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8zohv8G7zn4" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zu6DplRasUnk" style="text-align: right" title="Warrant Liability- Private Placement Warrants">29,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F05_zRz5qzPWqC91" style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td id="xdx_F10_zr00BowB9Rdj" style="text-align: justify">As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2022:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted<br/>
 Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Active<br/>
 Markets</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlSzSgdzh8Qj" style="width: 12%; text-align: right" title="U.S. Treasury Securities">356,864,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQbFfgPIFlQa" style="width: 12%; text-align: right" title="U.S. Treasury Securities">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1059">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTtiidvpzIVb" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7MNmEfSplwb" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgz3GX8Bzzn1" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCeQqJgFIhE8" style="text-align: right" title="Warrant Liability- Private Placement Warrants">7,250</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zsi8CYImWPEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model to value the warrants at each reporting period, with changes in fair value recognized
in the statement of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in a Monte
Carlo pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield.
The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining
life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity
similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining
contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned warrant liabilities are not subject to qualified hedge accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zW6iO4IeZbtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zXnCn4NfJng1" style="display: none">Schedule
of Quantitative Information    in Fair Value Measurements</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At <br/>
December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At <br/>
December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Share Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDNiR2mPr5Tf" style="width: 20%; text-align: right" title="Measurement Input">11.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHJCNf8UNgHk" style="width: 20%; text-align: right" title="Measurement Input">10.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise Price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zToyf7clZ7g2" style="text-align: right" title="Measurement Input">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z6w3yUrmoJ9d" style="text-align: right" title="Measurement Input">11.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zHVt8y7rXMvd" style="text-align: right" title="Measurement Input">5.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z52dsppE8ln7" style="text-align: right" title="Measurement Input">5.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Industry Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBJriKpznZxe" style="text-align: right" title="Measurement Input">6.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0Jh1aYzxPrb" style="text-align: right" title="Measurement Input">4.40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk Free Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8GUjclHjgli" style="text-align: right" title="Measurement Input">3.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5935i02fu9d" style="text-align: right" title="Measurement Input">3.91</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgMQm2a5w1M9" style="text-align: right" title="Measurement Input">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7p3iyXq8RK3" style="text-align: right" title="Measurement Input">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A9_z7L6IdXctr51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693518881424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zU884nHpm3Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span>SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">Note
10 &#8212; <span id="xdx_82D_zxi6St8bGCMe">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and transactions
for potential recognition or disclosure from the balance sheet date through May 28, 2024, the issuance date of these the financial statements
and has not identified any additional items requiring disclosure that have not previously been mentioned elsewhere.</p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zwUj1SXx7tRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8212; <span id="xdx_82C_z5LIHdAv0NUc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date these financial statements
were available to be issued. Based on this review, other than as described below, the Company did not identify any subsequent events
that would have required adjustment or disclosure in these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 31, 2024, in connection with an extraordinary
meeting of shareholders called to approve the proposals relating to the entry into and consummation of the Business Combination, shareholders
holding <span id="xdx_90F_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zESopOj6QJL9" title="Minimum period to file charter amendment">1,432,457</span> of the Company&#8217;s Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of
the funds in the Company&#8217;s trust account. As a result, approximately $<span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn5n6_c20240131__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzcFQlaXULFc" title="Cash withdrawn from Trust Account in connection with redemption">16.0</span> million (approximately $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3ofPKqs9OJc" title="Price per share">11.14</span> per Public Share) were
removed from the Trust Account to pay such holders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 14, 2024, pursuant to the Merger Agreement
by and among the Company, Merger Sub, the Sponsor, Tevogen Bio, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub
merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company. Prior to
the effective time of the Merger (the &#8220;Effective Time&#8221;), pursuant to the Merger Agreement, the Company changed its jurisdiction
of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated
under the laws of the State of Delaware (the &#8220;Domestication&#8221;). In connection with the Domestication, the Company changed its
name to &#8220;Tevogen Bio Holdings Inc.&#8221; Also in connection with the Domestication, the Company&#8217;s governing documents were
amended and restated as set forth in the Company&#8217;s definitive proxy statement filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on&#160;<span style="text-decoration: underline">January 10, 2024</span>&#160;(the &#8220;Definitive Proxy Statement&#8221;). At the Effective Time, in
accordance with the terms and subject to the conditions of the Merger Agreement, each share of the common stock of Tevogen Bio issued
and outstanding immediately prior to the Effective Time was converted into the right to receive the number of shares of duly authorized,
validly issued, fully paid, and nonassessable shares of the common stock of the Company, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zl1vUIz346fc" title="Common stock, par value">0.0001</span> (the &#8220;Common Stock&#8221;),
equal to the quotient obtained by dividing (x) the quotient obtained by dividing (i) $<span id="xdx_90B_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_c20240214__20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--TevogenBioMember_zk7sxtZpvkDa" title="Merger agreement share issuable">1,200,000,000</span> by (ii) ten dollars ($<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zpEEP9ZGg5K5" title="Merger agreement share issuable, per share">10.00</span>) by (y)
the aggregate number of shares of the common stock of Tevogen Bio that were issued and outstanding immediately prior to the Effective
Time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, the Company entered into a securities purchase agreement with an investor pursuant to which the investor agreed
to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0BQ6cP3Jxn3" title="Aggregate purchase price amount">8.0</span>
million. On March 27, 2024, the Company entered into an agreement pursuant to which that amount was reduced to $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zMjDSNJx8fye" title="Shares purchase amount">2.0</span>
million and the investor agreed to purchase shares of the Company&#8217;s Series A-1 Preferred Stock for an aggregate purchase price
of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zuAiSl9zOlm3" title="Aggregate purchase price amount">6.0</span>
million. As of April 26, 2024, the Company has received $<span id="xdx_90A_eus-gaap--Cash_iI_pn5n6_c20240426__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdvhVzlHnwkg" title="Received">1.2</span> million of the $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zwoBPcWviCz5" title="Aggregate purchase price amount">6.0</span> million aggregate purchase price for the shares of
Series A-1 Preferred Stock. The shares of Series A Preferred Stock are convertible into a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQAix7ayD9Kd" title="Conversion of shares">500,000</span>
shares of the Company&#8217;s common stock and the shares of the Series A-1 Preferred Stock will be convertible into a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z7CySHCzWF2a" title="Conversion of shares">600,000</span>
shares of the Company&#8217;s common stock, in each case at the election of the holder. Each of the Series A Preferred Stock is and
the Series A-1 Preferred Stock will be subject to a call right providing the Company the right to call the stock if the volume
weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCt9ozyeW1G8" title="Share price, per share">5.00</span>
per share and there is an effective resale registration statement on file covering the underlying common stock. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zr4CuyIiL8Lh" title="Preferred stock voting rights">The
Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no
mandatory redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the
Series A-1 Preferred Stock in no event to more than 15% per year.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, the Company entered into an agreement with the Sponsor,
pursuant to which the Company assigned to the Sponsor and the Sponsor agreed to assume certain liabilities and obligations in the aggregate
initial amount of approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9aSiJHU6C9">4.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which amount was later reduced to approximately
$<span id="xdx_902_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn5n6_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGBYMFN8WOCf">3.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (the &#8220;Series B Preferred Stock&#8221;).
<span id="xdx_902_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhzB2z5Zgcbj">The
Series B Preferred Stock is non-voting, non-convertible, callable by the Company at any time, and pays a 3.5% quarterly dividend beginning
35 days after issuance. Any dividend will be paid by the Company on behalf of the Sponsor to the creditors to which the assumed liabilities
and obligations are owed, pro rata in accordance with those liabilities and obligations unless otherwise agreed by the Company and the
Sponsor. The dividend rate will increase by 0.25% each month that the Series B Preferred Stock remains outstanding after the first 30
days after its issuance, but in no event will increase to more than 7.5% per quarter.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Merger Agreement, Tevogen Bio agreed
that at the Effective Time, it would pay $<span id="xdx_900_eus-gaap--SponsorFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_ztou06C0annd">2,000,000
</span>to the Sponsor for advisory services (the &#8220;Sponsor Advisory Services Fee&#8221;). Thereafter, in connection with the closing
of the Business Combination, the Sponsor Advisory Services Fee was reduced to $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SponsorAdvisoryServiceFeeMember_z8XGWrI0odn6">500,000</span>.
On April 16, 2024, the Sponsor agreed to further reduce the Sponsor Advisory Services Fee by informing Tevogen Bio that $<span id="xdx_90D_eus-gaap--SponsorFees_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQnU0u6Np1rd">250,000
</span>of the $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlPTlKsgfGlj">577,500
</span>that was due from the Sponsor as of December 31, 2023 would be applied to offset a portion of the $<span id="xdx_90D_ecustom--OffsetValue_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z9wT2SNHvZRl" title="Offset value">500,000</span> Sponsor Advisory Services
Fee. Therefore, the total amount due to the Sponsor under the Sponsor Advisory Services Fee is $<span id="xdx_90F_ecustom--ServicesFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zuxRHWoHWbCe" title="Service fees">250,000</span>.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394637504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">NATURE OF BUSINESS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zkerNkuEYq8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82A_zvWj43xTF1V7">NATURE OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc. (f/k/a Semper Paratus Acquisition Corporation), a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage
specialty immunotherapy company harnessing the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies
for the treatment of infectious diseases, cancers, and neurological disorders. The Company&#8217;s precision T cell technology platform,
ExacTcell, is a set of processes and methodologies to develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies
with proactively selected, precisely defined targets. The Company has completed a Phase 1 proof-of-concept trial for the first clinical
product of ExacTcell, TVGN 489, for the treatment of ambulatory, high-risk adult COVID-19 patients, and has other product candidates
in its pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to the agreement and plan of merger dated June 28, 2023 (the &#8220;Merger
Agreement&#8221;), by and among Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;) SSVK Associates, LLC, (the &#8220;Sponsor&#8221;) Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;), and Dr. Ryan Saadi in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company (the &#8220;Merger,&#8221;
and together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;), and Semper Paratus
was renamed Tevogen Bio Holdings Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination (the &#8220;Closing&#8221;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately <span id="xdx_905_ecustom--ExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhl9FPe3OPhl" title="Exchange ratio">4.85</span> shares of Company common
stock for each share of Tevogen Bio common stock (the &#8220;Exchange Ratio&#8221;). See Note 4 for more information on the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240101__20240331__srt--TitleOfIndividualAxis__custom--TevogenBioMember_zEA80jFaGSh5" title="Equity holders percentage">90.9</span>% of the outstanding shares
of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240101__20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zQjT8fq4JfXk" title="Equity holders percentage">9.1</span>% of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394818192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT-STAGE RISKS AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract', window );"><strong>Development-stage Risks And Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DevelopmentStageRisksAndLiquidityTextBlock', window );">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</a></td>
<td class="text"><p id="xdx_80C_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zbgRuV5EqCd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_82E_zwIsFmav7HG">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generally incurred losses and negative cash flows from operations since inception and had an accumulated deficit of
$<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zMy2obJYRxfa" title="Amount of accumulated undistributed earnings">88,392,895</span>
as of March 31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant
sales from its product candidates currently in development. Management believes that cash of $<span id="xdx_90A_eus-gaap--Cash_iI_c20240331_znGHeD1saMK9" title="Management cash">1,317,900</span>
as of March 31, 2024, and $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zQzirfvaXBK1" title="Sale of preferred stock">2,000,000</span>
received for the sale of Series A-1 Preferred Stock subsequent to March 31, 2024, is not sufficient to sustain planned operations
for 12 months from the issuance date of these unaudited consolidated financial statements. As a result, the Company has concluded
that substantial doubt exists about its ability to continue as a going concern for one year from the date that the unaudited
consolidated financial statements are issued. The accompanying unaudited consolidated financial statements have been prepared on a
going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of
recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this
uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years. These strategies
may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings
of equity and/or debt securities. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely
affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and clinical trials, and pursuing the Business Combination. The Company is subject to those
risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be
no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary
regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of
rapid technological change and is largely dependent on the services of its employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DevelopmentStageRisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Stage Risks And Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DevelopmentStageRisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502961744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweFcfJCPe72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_821_z7Yxg4Jk1c6b">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies included in the Company&#8217;s annual financial statements that can be found in Exhibit 99.1
of the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on April 29, 2024 (the
&#8220;Form 8-K&#8221;), have not materially changed, except as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zGbPuBzg5CKl">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z2UVV4YCU6v4">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zsweBwNQyFF3">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zJZFeTaEcaDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zPtwxjycLoh9">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_ztdxsUcE1y6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public
offering (the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i>
(&#8220;ASC 815&#8221;), and considering ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;). The
assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to
ASC 480 and meet all of the conditions for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own shares of common stock, among other conditions. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of
issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are
recognized as a non-cash loss on the consolidated statements of operations. Under these standards, the Company&#8217;s private
placement warrants sold at the time of the IPO do not meet the criteria for equity classification and must be recorded as
liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification and must be recorded as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOp0Gnh2gwmd">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s
convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zLAFUKdBZV45" style="display: none">Schedule
of Fair Value Measurement</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance">94,932,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance">289,135</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance">28,142,865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance">70,229,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility">80</span>%),
discount rate (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate">35</span>%
- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate">36</span>%),
and probability of a future liquidity event (<span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event">85</span>%
- <span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event">95</span>%).</span> The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the three months ended March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants the fair value of which increased by $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants">31,973</span>
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zTyrtDvrDzJk">Schedule
of Fair Values Of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at February 15, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">31,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">60,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities">60,973</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between <span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1667">75%</span></span> to <span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1669">85%</span></span>, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from <span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years">0.5</span> to <span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years">10.0</span> years, and a risk-free interest rate between <span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage">4.3%</span> and <span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage">5.3%</span>. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock">2,000,000</span> upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuKunqOFiF5k">Net
Income (Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zaS2rj0QNrb1">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, Debt &#8211; <i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zNRCBCcrYlWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8212; <span id="xdx_82A_z09laoPAkQZ3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDufdfSqr987">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--EmergingGrowthCompanyPolicyPolicyTextBlock_zPTHX6hDDIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z51bx9GmNCf6">Emerging
Growth Company</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for
public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company
nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zzoVedJkZirl">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zpjGtuKXUP3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjW2yciTNI63">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_z8n1KGVCSxn" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zjnpuZTVh3Wb" title="Cash equivalents">no</span></span>t have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--AssetsHeldInTrustAccountPolicyPolicyTextBlock_ztBsSHZlY6w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zoaPRIdCAmoa">Investments
Held in Trust Account</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, substantially all of the assets held in the Trust Account were held in a demand deposit cash account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">At December
31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company&#8217;s investments
held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at
the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included
in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values
of investments held in Trust Account are determined using available market information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_zCwy56mbqjbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zCXACvIfWnUi">Offering
Costs associated with the Initial Public Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs, including additional underwriting fees associated with the underwriters&#8217; exercise of the over-allotment option, consist
principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable
to the underwriters&#8217; exercise of the over-allotment option in full, amounted to $<span id="xdx_909_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDpn1E4hnJBc" title="Offering costs">21,266,594</span> consisting of $<span id="xdx_909_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNa6Aky0zUCa" title="Underwriting fees">6,000,000</span> of paid underwriting
fees, $<span id="xdx_90B_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyD2joOQN139" title="Deferred underwriting fee payable">14,700,000</span> of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $<span id="xdx_907_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTd94FcM7BSj" title="Other offering costs">566,594</span> of other costs
and was charged to shareholders&#8217; equity upon the completion of the IPO. On June 28, 2023, the Company and Cantor entered into the Fee Reduction
Agreement, pursuant to which Cantor agreed to the Reduced Deferred Fee in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRzNADdXwd9i" title="Number of shares issued">500,000</span> shares of the common equity securities of
the entity surviving the Transaction. See Note 1 for more information on the Fee Reduction Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zcm94hOGvmZ9">Concentration
of Credit Risk</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount">250,000</span>. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_znPUUrddfrUi">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the (&#8220;FASB&#8221;) ASC 820,
&#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8Ot8VIhkg52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Related
Party Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for amounts due from related parties at historical cost and evaluates the collectability of these receivables for determination
on if impairment should be recognized. In the same manner, the Company evaluated the $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_z3uF8gdQDCwh" title="Impairment of due from related party">250,000</span> loan to Srirama Associates, LLC and determined
that the amount was uncollectable and therefore recognized an impairment loss, see Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zkpWCEwQfXz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zLIWqLIv8yUi">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes.&#8221; Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. There were <span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20231231_zVaiAAGIGva9" title="Unrecognized tax benefits"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zF5N2A4rIB24" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits as of December 31, 2023 and 2022.
The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. <span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20231231_zrUaDPZSdxM3" title="Unrecognized tax benefits accrued for interest and penalties"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20221231_zurXvR5vPrF5" title="Unrecognized tax benefits accrued for interest and penalties">No</span></span> amounts were accrued for the payment of
interest and penalties for the year ended December 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the
Company. Consequently, income taxes are not reflected in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--TemporaryEquityPolicyPolicyTextBlock_zD0efC8N3eda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zgtCoOZ7zQ9k">Class
A Ordinary Shares Subject to Possible Redemption</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing
Liabilities from Equity.&#8221; Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument
and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#8217;s control) is classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders&#8217;
equity. The Company&#8217;s Public Shares feature certain redemption rights that are considered to be outside of the Company&#8217;s
control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023 and 2022, <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp8ry42IgPWa" title="Temporary equity, shares outstanding">1,502,180</span> and <span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJYI75T357lb" title="Temporary equity, shares outstanding">34,500,000</span>, respectively,
Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders&#8217; deficit
section of the Company&#8217;s balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary
share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable
ordinary share are affected by charges against additional paid in capital and accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zMZGt80hTdmi" style="display: none">Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption">351,900,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value">4,964,000</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption">356,864,000</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value">2,801,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Redemption of ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares">(342,984,430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class A ordinary share subject to possible redemption, December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption">16,681,497</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z1HYxxQQhzOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zK1LsoVBPXid">Net
Income (Loss) per Ordinary Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#8220;Founder Shares&#8221;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)">17,975,000</span> ordinary shares at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants">11.50</span> per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share">17,975,000</span></span> Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(19,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(44,186</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(4,005</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income">3,172,916</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income">133,355</span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income">1,102,090</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted">5,333,742</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted">12,317,077</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted">1,116,256</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted">34,500,000</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted">1,450,000</span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted">11,983,333</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share">0.09</span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_ecustom--WarrantLiabilitiesPolicyPolicyTextBlock_z7WEXKlufkK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zVTXpxyIBmS5">Accounting
for Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment
considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own ordinary shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments
are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and Private Placement Warrants
qualify for liability accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zE8ozL4HOjF7">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#8217;s financial statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395333056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_ztQqt7jA75tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_82B_zB9TrLOIyD8d">BUSINESS COMBINATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors,
including: (i) former Tevogen Bio equityholders and holders of convertible promissory notes owned approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zrf7MrCxxDz9" title="Ownership percentage">91.0</span>% of the Company
following the Merger; (ii) Former Tevogen Bio directors constituted the majority (six of seven) of the directors of the Company following
the Merger; and (iii) former Tevogen Bio management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire the net assets of Semper Paratus. As a
result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date fair value in the consolidated financial
statements and the reported operating results prior to the Merger are those of Tevogen Bio. Immediately after the Merger, there were
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331_zWmMoVzxq46g" title="Common stock, shares outstanding">164,614,418</span> shares of the Company&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_z0UveVE1Z4Rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zoftPmTp3y0f" style="display: none">SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zc4CykHVrO3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 14, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_zV26RK6wEI0g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">229,328</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z9ExmMKMHUbh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,819</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_z0ckBmta55U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,501</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zRRY1Onz2Gog" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,175</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zmkHDZ64vAS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,269,126</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_msBCRIAzgn3_zQHvgagApXC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,651,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_iNI_di_msBCRIAzgn3_zPIFDH3dmFli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maTNLAPz196_zg7P9MDwAob7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,654,653</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--PlusMergerTransactionCostsLimitedToCashAcquired_iI_maTNLAPz196_z5xGmUJppzPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229,328</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TotalNetLiabilitiesAcquiredPlusTransactionCosts_iTI_mtTNLAPz196_zvfeqz28WXeh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,883,981</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AE_z1QziPvFDykb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
transaction costs of $<span id="xdx_900_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_zIOzuNWVhvIl" title="Transaction costs">7,728,681</span>
were incurred in relation to the Merger up through the Closing Date, of which $<span id="xdx_900_ecustom--TransactionCosts_c20240214__20240214_zJWnZosVmtHi" title="Transaction costs">229,328 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were
charged directly to equity to the extent of the cash received from the Merger with the balance of $<span id="xdx_90D_ecustom--TransactionCost_c20240101__20240331_zE1kFlO5byR4" title="Charged expense">7,499,353</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">charged
to Merger transaction costs for the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_z1u7azhHCoNa" title="Earnout shares">24,500,000</span>
shares of common stock (&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Company&#8217;s
common stock reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5,
Earnout Shares, for further details of the earnout arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor. The issuance date fair value of the Series B
Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. See Note 9 for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391849056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNOUT SHARES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureEarnoutSharesAbstract', window );"><strong>Earnout Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EarnoutSharesDisclosureTextBlock', window );">EARNOUT SHARES</a></td>
<td class="text"><p id="xdx_802_ecustom--EarnoutSharesDisclosureTextBlock_zezZHVWR3rTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_821_ze9t1JFAlNOg">EARNOUT SHARES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, former holders of Tevogen Bio common stock may receive up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zF6pEB5Y4MC6" title="Earnout shares">20,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout
Shares in tranches of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zSyvwVMMBLbc" title="Earnout shares">6,666,667</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zIs0VCfutmub" title="Earnout shares">6,666,667</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zk6lHxtoD50h" title="Earnout shares">6,666,666 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the
Company&#8217;s common stock is greater or equal to
$<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHKG1bgeCYN3" title="Shares issued, price per share">15.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
$<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOvg7oReEA0a" title="Shares issued, price per share">17.50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPDwtSTZV8bd" title="Shares issued, price per share">20.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, <span id="xdx_902_ecustom--EarnoutSharesTradingDaysDescription_c20240101__20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zNkPNJJTyhq9" title="Earnout shares trading days description">over
any twenty trading days within any thirty consecutive day trading period during the three-year period after the
Closing.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#8217;s three earnout tranches
are for <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zKessTEbQwKa" title="Earnout shares"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zwIsXdW0uRpf" title="Earnout shares"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zLLVCklvlkle" title="Earnout shares">1,500,000</span></span></span> shares of common stock, for an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zUewsBnPcgGe" title="Earnout shares">4,500,000</span> shares across the entire Sponsor earnout.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Earnout Shares are a form of dividend for holders of Tevogen Bio common stock, and the Earnout Shares earnable by the Sponsor are treated
as contingent consideration in a reverse recapitalization. In accordance with ASC 815, the Earnout Shares were considered to be indexed
to the Company&#8217;s common stock and are classified within permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureEarnoutSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureEarnoutSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EarnoutSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout Shares Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EarnoutSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693393932288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zkfxlxCibSS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_821_zlKXu5pkRWzc">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zllsvmfRvbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z1XStT9irsL4" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240331_zCNwgiFUWVxh" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231__srt--RestatementAxis__custom--ReverseRecapitalizationMember_z9vhWj64T8g6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December, 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedProfessionalServiceFeesCurrent_iI_maALCzC3I_zLX4Kx1CaUm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,337,588</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">976,301</td><td style="width: 1%; text-align: left"></td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_z1JlnIguFiji" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">227,246</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zBj95Ne7Kmxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,564,834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zA14P3pBJgah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502894016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageNotesPayableDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--MortgageNotesPayableDisclosureTextBlock_z6fM0BTC6wjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_82F_zaNShb19JN88">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) for which the proceeds were to be used for working capital purposes by Semper Paratus with
an outstanding balance of $<span id="xdx_90D_ecustom--WorkingCapital_iI_c20240331_z2rd1NgbhOi5">1,651,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
the Closing Date and remain outstanding at March 31, 2024. The notes payable do not accrue interest. The outstanding balance of the notes was required to be repaid in full within five business days of the Merger, and
the Company is therefore in default of its obligations at March 31, 2024. The notes&#8217; default provisions require the Sponsor to transfer
a certain number of its own shares to Polar on a monthly basis until the default is cured, subject to an aggregate cap, but do not require
the Company to transfer any shares or pay any amounts to Polar. Polar waived the Sponsor&#8217;s requirement to transfer shares with respect
to the initial month of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for mortgage notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693390665456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1Qm76faae74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_82F_zQsBKeqcG9T6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Each restricted stock unit (&#8220;RSU&#8221;)
award granted under the 2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into
an award under the 2024 Plan with respect to the common stock of the Company. Such converted awards remain subject to the same terms
and conditions as set forth under the applicable award agreement prior to the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2024 Plan, the Company is authorized to grant awards up to an aggregate <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember_zotpVhPc43Tl" title="Granted awards shares">40,000,000</span>
shares of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, restricted stock, restricted
stock units, and other equity-based awards. As of March 31, 2024, awards for <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zYPiJh01P4Zc" title="Granted awards shares">20,651,046</span>
shares remained available to be granted under the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#8220;Performance-Based RSUs&#8221;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z9bIoNHLNVW4">19,348,954 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs
under the 2024 Plan to the Company&#8217;s Chief Executive Officer, Dr. Ryan Saadi (the &#8220;Special RSU Award&#8221;). Such RSUs
immediately converted into shares of restricted common stock (&#8220;Restricted Stock&#8221;), the restrictions on which lapse in
four equal annual installments beginning on February 14, 2031 (&#8220;Vesting Period&#8221;). Pursuant to the terms of the Special
RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged,
hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock in the
event he departs the Company. The fair value per share for the Special RSU Award was determined to be $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeb7T8TzId62">4.51 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, equivalent to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date fair value of $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zmWTaIEjNy61">87,263,783</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In accordance with ASC 718, <i>Compensation &#8211; Stock Compensation</i> (&#8220;ASC 718&#8221;), the Company will recognize
compensation expense on a straight-line basis from the Closing Date until the completion of the Vesting Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zdpajvJt0qTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zhJqhOvAGR6l" style="display: none">SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Nonvested as of January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z83uWATEILW1" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zu0LhFu4Aasj" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></td><td style="border-right: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaujT7apMUpl" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning">10,900,128</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zsyxDlVNXEGl" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning">2.97</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z9yU478s4eg8" style="text-align: right" title="Nonvested Shares, Granted">19,348,954</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zbAsZYkbhM2f" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted">4.51</td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1wIbOm1tbYh" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYg3gbr3SUyg" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zyx6Tm6CnHce" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zoIvjh7wYkxd" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zFAIDCc7Y2K" style="text-align: right" title="Nonvested Shares, Vested">(7,148,506</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zB1hX4HVoBPf" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested">2.85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z1p6P8RsdBzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zPUaRSuSVK6l" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zGGyRtxUb7B4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z7ISujfViPa9" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOi2SXcJII9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending">19,348,954</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zS1RixakFqQ3" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending">4.51</td><td style="border-right: Black 1.5pt solid; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zN0k23fzW3vj" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending">3,751,622</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlPecO79tg4" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending">3.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AC_zH39E8Sq4aRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYIPCDMfcVok" title="Compensation cost recognized">25,233,487</span> was recognized
for the Performance-Based RSUs, which will be issued and outstanding after March 31, 2024. There was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyBQiB0pbdsd" title="Unrecognized compensation cost">86,164,020</span> of unrecognized compensation cost related to Restricted Stock as
of March 31, 2024 which will be expensed over a weighted average period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyVejtu9QN68" title="Weighted average period">9.9</span> years. There was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znWueLWMrKP2" title="Unrecognized compensation cost">7,104,643</span> of unrecognized compensation
cost related to Performance-Based RSUs as of March 31, 2024 which will be expensed over a weighted average period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zLJSwvfiUEO7" title="Weighted average period">1.2</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zC9fXNTzWGk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zXFl7uLL0Hs7" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20240331_zoqt4oqEtHwc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDfPraaNw6Qe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,735,896</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKiaDPHxJTql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,597,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z2AeX3C1J044" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,333,249</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zJW6Jpols79i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensation_dxL_c20230101__20230331_zSFgaGmTfXI7" title="Compensation cost recognized::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1832">No</span></span>
stock-based compensation expense was recognized during the three months ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391896064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztGFWxBTy8kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_826_zBea3ZTkddpg">STOCKHOLDERS&#8217; DEFICIT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>Common Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of February 15, 2024, the Company&#8217;s
common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW&#8221;,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of March 31, 2024, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240331_zFhYlpmWMJke" title="Common shares, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zcJLFKJFOmM5" title="Common shares, shares outstanding">164,614,418</span></span>
shares of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested or are not subject
to repurchase are considered issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zY5jL67Rs2Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Below is a reconciliation of shares of common stock issued and outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zZo8Qih3N086">SCHEDULE
OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock legally issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20240331_zsMZdC6rjITa" title="Common shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zjYfmLv5o8Ea" title="Common shares, shares outstanding">164,614,418</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: Shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares issuable to Polar <span>(a)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesToBeIssuedOnSharesIssuable_iI_c20240331_fKGEp_zMeI2mD6dNV4" style="text-align: right" title="Shares issuable to Polar">1,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Shares issuable to Polar"><p id="xdx_983_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20240331_fKGIp_zXBFTzzS3Bq7" style="margin: 0" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing">7,148,506</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Issuance of restricted common stock subject to forfeiture
    <span>(c)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20240331_fKGMp_z5jRYgf928xj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture">(19,348,954</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued and outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20240331_zU2AIRwtMn07" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding">153,913,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0E_zSFUsb3mIPXf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zVLlsyBIhf2g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td id="xdx_F0A_z3CtrESEccf7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(b)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p id="xdx_F18_zIQMiBkzr678" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zHMvLEAIjjn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zdgGRYz4aBu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A2_zNrP1QjuNk07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s
common stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio,
as discussed in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Preferred Stock</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331_zYPXBdzcNdI9" title="Preferred shares, shares authorized">20,000,000</span> shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331_zESzwfjnzTsa" title="Preferred shares, par value">0.0001</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">I<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n
March 2024, the Company authorized and issued <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1TQsskKFFYe" title="Preferred stock, shares authorized">2,000</span> and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1sAf5wyTPj" title="Preferred stock, shares issued">500</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares,
respectively, of Series A Preferred Stock (the &#8220;Series A&#8221;) to an investor at a price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUYzddNAGNmk">4,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share (the &#8220;Series A Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCJnWajq7eXj" title="Proceeds from issuance of preferred stock">2.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span> The Company recorded an expense of $<span id="xdx_904_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zn3WtQPCy6hh" title="Loss on preferred stock issuance">799,990</span> in its consolidated statements of operations related to issuance of the Series A equal
to the fair value of the Series A when issued of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW0vScNOJjhf" title="Price per share">5,600</span> per share less the purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zWezmWpjHre">4,000</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuaTZfQiWyF5" title="Dividend rate, percentage">5</span>%
per annum per share on <span id="xdx_90B_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWbqiruCDfd" title="Dividend variable rate, description">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the
&#8220;Series A Accruing Dividends&#8221;)</span>. These dividends become payable when and if declared by the Company. The Series A
Preferred Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series B Preferred Stock (the &#8220;Series B&#8221;) in liquidation priority. In the
event of a liquidation of the Company, or certain deemed liquidation events, the Series A is redeemable for a price
equal to the greater of the Series A Original Issue Price plus all Series A Accruing Dividends that are unpaid through the
redemption date, or such amount that would have been payable had the Series A converted into shares of
common stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence
of a deemed liquidation event. The Company is entitled to redeem that Series A at a price equal to the Series A Original
Issue Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds
$<span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCWwsmAWOVz6" title="Redemption per share">5.00</span> per share for <span id="xdx_905_eus-gaap--PreferredStockRedemptionTerms_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7UH72EETIwl" title="Redemption term">the twenty days immediately prior to the Company&#8217;s call election</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal
to the Series A Original Issue Price divided by the Series A Conversion Price, which is initially $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTbEsICcDl5l" title="Conversion price">4.00</span> per share and is subject to standard
antidilution adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A-1 Preferred Stock </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Series A investor covering the
issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zXZHxPobwsVf" title="Stock issuance">600</span> shares of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zvjrGPPmFNRd" title="Stock issuance, value">6,000,000</span>. <span id="xdx_901_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zJ5kIXmKRtdc" title="Dividend variable rate, description">The terms of the Series A-1 Preferred
Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum and the Series
A-1 Issuance Price is defined as $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfdbaJOfPvO9">10,000</span> per share.</span> As of March 31, 2024, the investor had paid a non-refundable deposit of $<span id="xdx_90A_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zFh4aSmduqa2" title="Non refundable amount">200,000</span>
towards the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the
Sponsor assuming liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. On March 15,
2024, <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8YcxbKTk1M9" title="Conversion of certain liabilities into Series B preferred stock, shares">3,613</span>
shares of Series B were issued in return for the assumption of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWozjgcIKip6" title="Conversion of certain liabilities into Series B preferred stock">3,613,000</span>
of liabilities. As these liabilities were unpaid and the Company was not legally released by the creditors, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
liabilities were not extinguished and</span> remain on the Company&#8217;s balance sheets at March 31, 2024. The issuance date fair
value of the Series B was determined to be $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zC4nA0EymVBi" title="Conversion of certain liabilities into Series B preferred stock">3,613,000</span>
and was recorded within Merger transaction costs in the consolidated statements of operations. The Series B is classified as
permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series B are entitled to receive cumulative dividends at the Series B Dividend Rate, which accrue quarterly on the basis of a
360-day year and accrue whether or not declared by the Company provided that to the extent the Assumed Liabilities are outstanding,
any dividend(s) will be paid by the Company on behalf of the Sponsor to the creditors first. <span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z46y9HrWiFE9" title="Dividend variable rate, description">The
Series B Dividend Rate is initially 3.25% per quarter, increases by 0.25% on each 30-day anniversary of the Initial Dividend Date
(Defined below), and capped at 7.5% per quarter.</span> The &#8220;Initial Dividend Date&#8221; is defined as 35 days after the
initial issuance date of the Series B. Subsequent dividends are due and payable on the quarterly anniversary of the initial issuance
date, or if that date is not a business day, due and payable on the next succeeding business day. Series B dividends payable are
calculated as the Dividend Rate multiplied by the Series B Issue Price of $<span id="xdx_90F_eus-gaap--DividendsPayableAmountPerShare_iI_c20240331_zqMcpNZytuxa" title="Dividends payable per share">1,000</span>
per share. Series B dividends are payable whether or not declared by the Company, and are recorded within accounts payable of the
consolidated balance sheets as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Preferred Stock ranks senior to common stock and junior to Series A in liquidation priority. In the event of
a liquidation of the Company, the Series B is redeemable for a price equal to the aggregate amount of the liabilities
assumed by the Sponsor following the Closing, which was $<span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyQiao17idza" title="Redemption per share">1,000</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B are not entitled to redeem their shares outside of the liquidation of the Company. The Company is
entitled to redeem the Series B at a price equal to the Series B Issue Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B Preferred Stock do not contain any conversion rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zfYPWcrbQ0pe" title="Number of warrants issued">17,975,000</span> warrants initially issued by Semper Paratus in November 2021, comprising <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zlwWEOh4MHud" title="Number of warrants issued">17,250,000</span> public warrants sold in the
IPO and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMSTg0CyeeL9" title="Number of warrants issued">725,000</span> warrants issued in a concurrent private placement, were assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z8zqCNTi4dk1" title="Exercise price">11.50</span>
per share, became exercisable on <span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zH1p7LRjbER7" title="Exercisable date">March
15, 2024</span>, and will expire at 5:00 p.m., New York City time, on February 14, 2029, or earlier upon redemption or liquidation.
Warrant holders may, until such time as there is an effective registration statement and during any period when the Company has
failed to maintain an effective registration statement covering the shares of the Company&#8217;s common stock issuable upon
exercise of the warrants, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities
Act of 1933, as amended, or another exception. <span id="xdx_90D_ecustom--WarrantsDescription_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zSMe7Blb9Hpf" title="Warrants description">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days
within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption
to the holders of public warrants.</span> As of March 31, 2024, there are <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zNO0OzvNYTYg" title="Number of warrants outstanding">17,250,000</span>
public warrants outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Private
Placement Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the Sponsor or its permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders on a cashless
basis. As of March 31, 2024, there are <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfnAt6a825Vj" title="Number of warrants outstanding">725,000</span> private placement warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 3 for additional information on the Company&#8217;s
warrant accounting policy.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zleahcFRElM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8212; <span id="xdx_829_zxRgFLkxaid1">Shareholders&#8217; Deficit</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
A Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z3SFuwRzr81f" title="Ordinary shares, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zchjqu3Qokf3" title="Ordinary shares, shares authorized">200,000,000</span></span> Class A ordinary shares with a par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zImyFic4gI33" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxQiWvMyIGQl" title="Ordinary shares, par value (In Dollar per share)">0.0001</span></span> per share. As of December 31, 2023 and
2022, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcMPHebQv53h" title="Ordinary shares, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z6e2WPRTJ7Oh" title="Ordinary shares, shares outstanding">13,433,333</span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z39e0fKBc1he" title="Ordinary shares, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBC1BOAGBxoc" title="Ordinary shares, shares outstanding">1,450,000</span></span> Class A ordinary shares issued and outstanding (excluding <span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfPNNf5ZvKT9" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)">1,502,180</span> and <span id="xdx_905_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2oissxe3H04" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)">34,500,000</span> Class A
ordinary shares subject to possible redemption), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class
B Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4wWYQu9dw32" title="Ordinary shares, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zsIkoeyUHNQg" title="Ordinary shares, shares authorized">20,000,000</span></span> Class B ordinary shares with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zYmYGRMYhN0h" title="Ordinary shares, par value (In Dollar per share)"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z49zdW0LprNc" title="Ordinary shares, par value (In Dollar per share)">0.0001</span></span> per share. Holders of Class B ordinary
shares are entitled to <span id="xdx_903_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zA50ZpBPWOZ1" title="Ordinary shares, vote per share"><span id="xdx_90D_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z5P97QEnPJi6" title="Ordinary shares, vote per share">one</span></span> vote for each share of Class B ordinary shares. As of December 31, 2023 and 2022, there were <span title="Ordinary shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAcwgpj0sVZc" title="Ordinary shares, shares outstanding">0</span></span> and <span title="Ordinary shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zvD0066NA6Zk" title="Ordinary shares, shares outstanding">11,983,333</span></span>
Class B ordinary shares outstanding, respectively, none of which are subject to forfeiture since the underwriters&#8217; over-allotment
option was exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to our initial Business Combination, only holders of our Class B ordinary shares will have the right to vote on the appointment of directors.
Holders of our Class A ordinary shares will not be entitled to vote on the election of directors during such time. In addition, prior
to the completion of an initial Business Combination, holders of a majority of our Class B ordinary shares may remove a member of the
board of directors for any reason. These provisions of our Memorandum and Articles of Association may only be amended by a special resolution
passed by not less than 90% of our ordinary share shareholders who attend and vote at our general meeting. With respect to any other
matter submitted to a vote of our shareholders, including any vote in connection with our initial Business Combination, except as required
by law, holders of our Class B ordinary shares and holders of our Class A ordinary shares will vote together as a single class, with
each share entitling the holder to one vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination on a
one-for-one basis, subject to adjustment. In the case that additional Class A ordinary shares, or equity-linked securities, are issued
or deemed issued in excess of the amounts offered in the IPO and related to the closing of the initial Business Combination, the ratio
at which Class B ordinary shares shall convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the
outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the
number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted
basis, <span id="xdx_905_ecustom--ConvertibleStocksConversionRatio_pp2d_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zmV42KXKTiPc" title="Ratio to be applied to the stock in the conversion">25</span>% of the sum of the total number of all ordinary shares outstanding upon the completion of the IPO plus all Class A ordinary
shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares
or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent
warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preference
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zazauzFLiK9a" title="Preference shares , shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zJDNnakKyA9b" title="Preference shares , shares authorized">1,000,000</span></span> preference shares with such designations, voting and other rights and preferences as may be
determined from time to time by the Company&#8217;s board of directors. As of December 31, 2023 and 2022, there were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_ztPeBlPZ5ec5" title="Preference shares, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zq17rCvt7rs7" title="Preference shares, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_ztfqe4EbgzA6" title="Preference shares, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_z9Zk2qATZUm2" title="Preference shares, shares outstanding">no</span></span></span></span> preferred shares
issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Public Warrants will become exercisable on the later of (i) <span id="xdx_90A_ecustom--WarrantExercisePeriodConditionOne_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztzdgo41Df2" title="Minimum threshold written notice period for redemption of public warrants">30</span> days after the completion of a Business Combination and (ii) <span id="xdx_901_ecustom--WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_dc_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zQOsYxkSzvij" title="Public warrants exercisable term from the closing of the initial public offering">one year</span>
from the closing of the IPO. No warrants will be exercisable for cash unless the Company has an effective and current registration statement
covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such Class A ordinary
shares. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon exercise of the
Public Warrants is not effective within a specified period following the consummation of a Business Combination, warrant holders may,
until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain
an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the
Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not
be able to exercise their warrants on a cashless basis. The Public Warrants will expire <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zkzZ5UAsOTCh" title="Public warrants expiration term">five years</span> after the completion of a Business
Combination or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the warrants become exercisable, the Company may redeem the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $<span id="xdx_90C_ecustom--ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zekJbq7X1MQl" title="Redemption price per public warrant (in dollars per share)">0.01</span> per warrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than <span id="xdx_906_ecustom--RedemptionPeriod_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrBwEljK2dUf" title="Redemption period">30</span> days&#8217; prior written notice of redemption;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $<span id="xdx_907_ecustom--WarrantRedemptionConditionMinimumSharePrice_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9vhPKWd3Ubk" title="Warrant redemption condition minimum share price">18.00</span> per share (as adjusted for share
    subdivisions, share dividends, reorganizations and recapitalizations), for any <span id="xdx_906_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zOEzySEWuLMd" title="Threshold trading days for redemption of public warrants">20</span> trading days within a <span id="xdx_90B_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z63PpM15jw8l" title="Threshold consecutive trading days for redemption of public warrants">30 </span>trading day period commencing
    at any time after the warrants become exercisable and ending on the <span id="xdx_909_ecustom--ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_dcxL_uInteger_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zocKlIJZEHTc" title="Threshold number of business days before sending notice of redemption to warrant holders::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1024">third</span></span> business day prior to the notice of redemption to warrant
    holders; and if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying
    the warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the
Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Warrants are identical to the Public Warrants underlying the Units being sold in the IPO, except that the Private Warrants and
the Class A ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until
after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable
for cash or on a cashless basis, at the holder&#8217;s option, and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees,
the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of Class A ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including
in the event of a share dividend, extra Class A Ordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of Class A ordinary shares at a price below their respective exercise prices. Additionally,
in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination
within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any
of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of
the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection
with the closing of a Business Combination at an issue price or effective issue price of less than $<span id="xdx_907_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrnWI2UP5Qyl" title="Share price trigger used to measure dilution of warrant">9.20</span> per Class A ordinary share (with
such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors, and in the case of
any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by them prior
to such issuance), (y) the aggregate gross proceeds from such issuances represent more than <span id="xdx_909_ecustom--PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztRCScGKUfjj" title="Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant">60</span>% of the total equity proceeds, and interest
thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Class A ordinary shares during the <span id="xdx_905_ecustom--TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwsPSdo8y9sc" title="Trading period after business combination used to measure dilution of warrant">20</span> trading day period starting
on the trading day prior to the day on which the Company consummates Business Combination (such price, the &#8220;Market Value&#8221;)
is below $<span id="xdx_90E_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdONLKLPoV82" title="Share price trigger used to measure dilution of warrant">9.20</span> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <span id="xdx_90E_ecustom--ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_pid_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrrgKbUSjwrd" title="Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)">115</span>% of the greater
of (i) the Market Value or (ii) the price at which the Company issues the additional Class A ordinary shares or equity-linked securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391845200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdq2OcXxCE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_829_zqHcsCJYp0Qc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><i>Transactions with Sponsor</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Pursuant to the Merger Agreement, the
Company incurred $<span id="xdx_90D_eus-gaap--SponsorFees_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zGSzqMPEi0e7">2,000,000
</span>in fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory Service Fee&#8221;). In connection with the Merger and
thereafter, the Company and Sponsor agreed that $<span id="xdx_904_eus-gaap--SponsorFees_c20240101__20240331_zDcK1SOKuNva" title="Sponsor advisory services fee">250,000</span> of the Sponsor Advisory Service Fee is payable in cash, $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember_zEqpHQEHwr8a" title="Due to Sponsor">250,000</span> would be offset
against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with issuance of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zB1MkZ813bog">150,000
</span>shares of the Company&#8217;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented <span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember__us-gaap--DebtInstrumentAxis__custom--PolarNotesMember_z53BiEN4NwJ9">on
the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated balance sheets under the line item
&#8220;Due to related party&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the Sponsor owes the Company $<span id="xdx_908_ecustom--WorkingCapitalExpenses_c20240101__20240331_z5jjTLp86GZ9" title="Working capital expenses">158,819</span> to cover working capital expenses which is presented on the consolidated balance
sheets under the line item &#8220;Due from related party&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 9 for additional information on the Series B issued to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.<br/>
NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84Gt1zrAZfg" title="Isssued shares to related party">40,000</span> Performance-Based RSUs to the wife of the Company&#8217;s chair and chief executive officer for
advisory services provided to the Company, and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZuYGnbdjli4" title="Isssued shares to related party">20,000</span> Performance-Based RSUs to Mehtaphoric Consulting Inc, a company controlled by
the daughter of the Company&#8217;s chief financial officer, for information technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20240331_zb5osuQACug2" title="Compensation cost recognized">800,396</span> has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z8Gca90BJdx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8212; <span id="xdx_824_z3tPgZy1PhK9">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Founder
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Sponsor paid $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z37xhhFLck0j" title="Aggregate purchase price">25,000</span> to cover certain offering costs of the Company in consideration for <span id="xdx_908_eus-gaap--CommonStockDividendsShares_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLqmjGsoo5l" title="Share dividend">8,625,000</span> Founder Shares which were issued on
April 22, 2021. In August 2021, the Company effectuated a dividend of approximately <span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionRatio_iI_pp4d_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z3fkeWJiaBo8" title="Stock dividend ratio">0.3628</span> shares for each outstanding Class B ordinary
share resulting in an aggregate of <span id="xdx_901_ecustom--AggregateNumberOfSharesOwned_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Aggregate number of shares owned">11,754,150</span> Class B ordinary shares outstanding. On October 1, 2021, the Company effectuated a dividend
of approximately <span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionRatio_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pp4d" title="Stock dividend ratio">0.0195</span> shares for each outstanding Class B ordinary share resulting in an aggregate of <span id="xdx_90B_ecustom--AggregateNumberOfSharesOwned_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z8thw2vx3Xzf" title="Aggregate number of shares owned">11,983,333</span> Class B Founder shares
outstanding (up to <span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbbYrYEYOVZ8" title="Shares subject to forfeiture">1,530,000</span> of which are subject to forfeiture if the underwriters&#8217; over-allotment option is not exercised in
full). The Founder Shares will automatically convert into Class A ordinary shares at the time of the Company&#8217;s initial Business
Combination and are subject to certain transfer restrictions. The initial shareholders had agreed to forfeit up to <span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_za45SZyhmTw5" title="Shares subject to forfeiture">1,530,000</span> Founder
Shares to the extent that the over-allotment option is not exercised in full by the underwriters. Since the underwriters&#8217; exercised
the over-allotment option in full, no Founder Shares are subject to forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial shareholders will agree, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the
earliest of (A) <span id="xdx_90A_ecustom--RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zTgzZxac35I7" title="Restrictions on transfer period of time after business combination completion">one year</span> after the completion of our initial business combination and (B) subsequent to our initial business combination,
(x) if the closing price of our Class A ordinary shares equals or exceeds $<span id="xdx_90C_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_pp2d_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zaSUTpiQeMA5" title="Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)">12.00</span> per share (as adjusted for share subdivisions, share
capitalizations, reorganizations, recapitalizations and the like) for any <span id="xdx_90B_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLT4KgYAvK21" title="Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination">20</span> trading days within any <span id="xdx_901_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znQYiGVJBmgg" title="Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination">30</span>-trading day period commencing
at least <span id="xdx_905_ecustom--ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqLhRrOgfY3k" title="Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences">150</span> days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange
or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash,
securities or other property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 30, 2023, the initial shareholders holding
all of the Founder Shares elected to convert their Founder Shares into Class A ordinary shares of the Company on a <span id="xdx_90B_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_z6kgaFsCsbi4" title="Conversion ratio">one</span>-for-one basis (the
&#8220;Conversion&#8221;). As a result, <span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Shares cancelled">11,983,333</span> of the Company&#8217;s Class B ordinary shares were cancelled and <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjOqRKSqb3bl" title="Shares issued upon conversion">11,983,333</span> Class
A ordinary shares were issued to such converting Initial Shareholders. The Initial Shareholders agreed that all of the terms and conditions
applicable to the Founder Shares set forth in the Letter Agreement shall continue to apply to the Class A ordinary shares that the Founder
Shares converted into, including the voting agreement, transfer restrictions and waiver of any right, title, interest or claim of any
kind to the Trust Account or any monies or other assets held therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 4, 2023, the Company entered into the Purchase
Agreement, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zqWw1dV3wJTh" title="Number of shares issued">7,988,889</span> Class A ordinary shares and (y) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_z0BuF9bT2ri8" title="Number of shares issued">1,000,000</span>
Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for
one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Underwriting Agreement), for
an aggregate purchase price of $<span id="xdx_909_ecustom--AggregatePurchasePrice_iI_pp2d_c20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zWdV0O8ECMT" title="Aggregate purchase price">1.00</span> payable at the time of the initial Business Combination. On June 7, 2023, the Original Sponsor transferred
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zg81rbK0W3c6" title="Number of shares issued">7,988,889</span> Class A ordinary shares to the Sponsor, pursuant to the Purchase Agreement (see Note 6). The Company estimated the aggregate
fair values of the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableOrdinaryMember_zm8IjkwCuH2i" title="Number of shares issued">7,988,889</span> Class A non-redeemable ordinary shares, the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230606__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2W0MKjKtkB8" title="Number of shares issued">1,000,000</span> Private Placement shares, and the <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zamAYC1vlNR6" title="Class of warrants">500,000</span> public warrants
transferred to be $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zv9xZ9pyUphf" title="Proceeds">3,515,111</span>, $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredTwoMember_zeZWU5vFe9Ma" title="Number of shares issued">440,000</span>, and $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredThreeMember_zwGWLnWeh8If" title="Number of shares issued">20,000</span>, respectively or $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredOneMember_z8FSFlPAmFBj" title="Exercise price">0.44</span> per share and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredTwoMember_zpoAKPyTTn49" title="Exercise price">0.04</span> per warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z2fvY4XooUQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The fair value of the Class A non-redeemable shares
was based on the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span id="xdx_8B6_zR8Qc92B1zJ5">Schedule
of Fair Value Non Redeemable Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230503__20230504_zjRvdjmAJfIf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 4, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_zvPeAx7Xrov7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Discount for lack of marketability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">6.80</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--StockPriceOfMeasurement_pid_z3xkbBKhZqze" style="vertical-align: bottom; background-color: White">
    <td>Stock price as of measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10.77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProbabilityOfTransactionPercentage_pid_dp_uPure_zhofbGhptox2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of transaction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.40</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zRyKqWehGf5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Party Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2021, the Sponsor agreed to loan the Company an aggregate of up to $<span id="xdx_90A_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_c20210422__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Maximum borrowing capacity of related party promissory note">300,000</span> to cover expenses related to the IPO pursuant to
a promissory note (the &#8220;Note&#8221;). This loan was non-interest bearing and payable on the earlier of December 31, 2021 or the
completion of the IPO. The note payable of $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20211108__20211108__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Amount of notes payable repaid">121,158</span> was repaid on November 8, 2021. As of December 31, 2022, the Company had <span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_do_c20221231_zjdeSA05noib" title="Borrowings amount">no</span> borrowings
under the Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2023, the Company advanced the Sponsor $<span id="xdx_901_ecustom--WorkingCapital_iI_c20231002_zZpXIhQn8Xvf" title="Working capital">17,000</span>
for working capital purposes. The advances are non-interest bearing and are due on demand. This related party transaction is included on the accompanying balance sheet as a due from related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of December 31, 2023, the remainder of the Second SPAC Loan of $<span id="xdx_901_eus-gaap--PaymentsForAdvanceToAffiliate_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zehGaV6BMI8h" title="Loan from affiliate">577,500</span> is due from the Sponsor. This related
party transaction is included on the accompanying balance sheet as a due from related party. As of December 31, 2023, the Company determined that $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zF9dggB2C5u9" title="Impairment of due from related party">250,000</span> of the $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z1OlrjQ6gNef" title="Loan from affiliate">577,500</span> was deemed to be uncollectible, therefore
the Company recorded impairment totaling $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zXicAIVb55D7" title="Impairment of due from related party">250,000</span> on the amount due from related party in the other income section of the statement of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2023, the Company and the Original Sponsor entered into a Subscription Agreement with Polar Multi-Strategy Master Fund (the &#8220;Investor&#8221;)
where the Investor agreed to make a cash contribution of $<span id="xdx_902_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zrzfpG4AdEFa" title="Initial capital contribution">151,000</span> to the Original Sponsor (the &#8220;Initial Capital Contribution&#8221;)
on or prior to May 3, 2023. The Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover
working capital expenses (the &#8220;First SPAC Loan&#8221;). In consideration for the Initial Capital Contribution, the Company will
issue <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLiyrpFxH8tk" title="Number of shares issued">151,000</span> Class A ordinary shares, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zUh01rxjvlU2" title="Ordinary shares, par value (in dollar per share)">0.0001</span> per share, of the Company to the Investor at the closing of the initial business
combination (the &#8220;De-SPAC Closing&#8221;). The First SPAC Loan shall not accrue interest and shall be repaid by the Company upon
the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares
of the Company at a rate of one Class A ordinary share for each $<span id="xdx_90D_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zJn5mGhF4Lg3" title="Initial capital contribution">10.00</span> of Initial Capital Contribution. If the Company liquidates without
consummating the initial business combination, any amounts remaining in the Sponsor or Company&#8217;s cash accounts, not including the
Company&#8217;s Trust Account, will be paid to the Investor within five days of the liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, the Sponsor and the Company entered into a second subscription agreement (the &#8220;Second Subscription
Agreement&#8221;) with the Investor where the Investor agreed to lend to the Sponsor, which would in turn be lent to the Company, an
aggregate of $<span id="xdx_908_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__dei--LegalEntityAxis__custom--SponsorMember_zppqeb1abZF4" title="Maximum borrowing capacity of related party promissory note">1,500,000</span>
(the &#8220;Additional Capital Commitment&#8221;) to cover working capital expenses (the &#8220;Second SPAC Loan&#8221;). One half
of the Additional Capital Commitment was made by the Investor to the Sponsor in cash on or prior to June 21, 2023, and the remaining
$<span id="xdx_906_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_znxv21J0Pl6h" title="Remaining borrowing capacity amount">750,000</span>
would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#8217;s request and the first filing of the S-4 for
the Company&#8217;s business combination. In consideration for the Second SPAC Loan, the Company will issue one Class A ordinary
share for each dollar of the Additional Capital Commitment funded by the Investor at the De-SPAC Closing. The Second SPAC Loan shall
not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to
receive such payments in (a) cash or (b) Class A ordinary shares at a rate of one Class A ordinary share for each $<span id="xdx_904_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zVE2avjo7wna" title="Initial capital contribution">10.00</span>
of Additional Capital Contribution. If the Company liquidates without consummating the initial business combination, any amounts
remaining in the Sponsor or Company&#8217;s cash accounts, not including the Company&#8217;s Trust Account, will be paid to the
Investor within five days of the liquidation. Collectively, the First SPAC Loan and the Second SPAC Loan are referred to as the SPAC
Loans. As of December 31, 2023, the Company had $<span id="xdx_901_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--SponsorMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zTOfKsdZSv0d" title="Debt instrument, fee amount">1,651,000</span>
borrowings under the  SPAC Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company accounted for the Class A common stock
they could be converted (&#8220;equity instrument&#8221;) to as equity-classified instruments based on an assessment of the specific
terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the equity instrument is freestanding
financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the equity instrument
meets all the requirements for equity classification under ASC 815, including whether the equity instrument is indexed to the Company&#8217;s
own common stock, among other conditions for the equity classification. This assessment, which requires the use of professional judgment,
was conducted at the time of equity instrument issuance. The SPAC Loans and the equity instrument meet the scope exception of ASC 815-10-15-74(a).
The Company applied the guidance in ASC 470-20-25-2 &#8220;<i>Debt With Conversion and Other Options</i>&#8221;, requiring that the loan
proceeds be allocated to the SPAC Loans based on their relative fair values. At May 3, 2023 the Company allocated $<span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zH5tFmPsSaLe">104,861
</span>of the proceeds to the First SPAC Loan and $<span id="xdx_901_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503_znpJNBOUam8b">46,139
</span>for the equity instrument. The Company estimated the aggregate fair value of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zQ5uzwnhioCh">151,000
</span>shares to be issued to be $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zcUJF80uBLxf">66,440
</span>or $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_znJXZYBHVUVg">0.44
</span>per share. At June 20, 2023 the Company allocated $<span id="xdx_90C_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zqkCQLrLAbp5">520,833
</span>of the proceeds to the Second SPAC Loan and $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620_zA16ZwwVF4P3">229,167
</span>for the equity instruments. The Company estimated the aggregate fair value of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zGk94zI4YmL8">750,000
</span>shares to be issued to be $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zVKj7ZCPgeu6">330,000
</span>or $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zBiMxfWHbnw8">0.44
</span>per share. At December 31, 2023 the carrying values of the SPAC Loans and the discounts were $<span id="xdx_909_eus-gaap--OtherNotesPayableCurrent_iI_c20231231_zbRrvzroSfhh">1,631,725
</span>and $<span id="xdx_902_ecustom--ConvertibleNotesPayableDiscounts_iI_c20231231_zp5qO5A6B4m">275,306</span>, respectively. The Company recorded amortization of the discounts on the SPAC Loans of
$<span id="xdx_906_ecustom--NoncashInterestExpenses_c20230101__20231231_zbT0QTObPMne" title="Non cash interest expenses">256,031</span>, which is disclosed in the statement of cash flows as non-cash interest expense. As of
December 31, 2023, the unamortized discount on the SPAC Loans was $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231_zcC6nyEXuTt1">19,274</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the remainder of the Second SPAC Loan of $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zvujXd3eujaf" title="Loan from affiliate">577,500</span> is due from the Sponsor. This amount is included on the accompanying
balance sheet as a due from related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Working
Capital Loans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor,
or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working
Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the
proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside
the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the
Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements
exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without
interest, or, at the lender&#8217;s discretion, up to $<span id="xdx_90C_ecustom--MaximumLoansConvertibleIntoWarrants_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_zqF4920S6Gxl" title="Loan conversion agreement warrant">1.5</span> million of such Working Capital Loans may be convertible into private placement-equivalent
units at a price of $<span id="xdx_904_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WorkingCapitalLoansWarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_z4W4b2kmRjc4" title="Price of warrant">10.00</span> per unit. As of December 31, 2023 and 2022, the Company had <span id="xdx_90B_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zbhE3rm7aWq5" title="Working capital loan"><span id="xdx_903_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20221231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zVIH4BX8WiRh" title="Working capital loan">no</span></span> borrowings under the Working Capital Loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administrative
Support Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
on the date of the final prospectus, the Company will agree to pay the Sponsor a total of $<span id="xdx_902_ecustom--RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zngBZMp1EOv3" title="Expenses per month">10,000</span> per month for office space and administrative
and support services. Upon completion of the Initial Business Combination or the Company&#8217;s liquidation, the Company will cease
paying these monthly fees. At December 31, 2023 and 2022, $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zTeRuZsi8pS3" title="Amount accrued">230,000</span> and $<span id="xdx_905_eus-gaap--OtherLiabilities_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zrcFWHNGvSWh" title="Amount accrued">120,000</span>, respectively, have been accrued under this arrangement
and included in due to affiliate on the accompanying balance sheets.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391849808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zKJHQFDWeYV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE 11. <span id="xdx_823_z0unTaUMmM02">NET INCOME (LOSS) PER SHARE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUEM9njRKv4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the computation of
basic and diluted income (loss) per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zvAOzgDMPIJa" style="display: none">SCHEDULE
OF NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240101__20240331_zBIw8xRlZL0l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230101__20230331_z7sjC8XY7KTh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILATz5q6_z2PwMSipxGSd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,264,842</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(30,756,144</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iN_di_msNILATz5q6_zmkQDyPhYEve" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Less: Undistributed earnings allocated to participating securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(756,606</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz5q6_zSf2SWBkWWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,506,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_maNILATzP0S_z2Ff6mKtEnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,264,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(30,756,144</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ConvertiblePromissoryNoteInterest_iT_mtNILATzP0S_zROaggmn9VJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ConvertiblePromissoryNoteChangeInFairValue_iT_mtNILATzP0S_zBXxLczt6Ci9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,468,678</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1957">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATzP0S_zO8LeU0GiuFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(37,049,420</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zUtr9hiU9Yf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,333,802</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,999,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zSoaT7mNY0Na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) per share attributable to common stockholders, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_zk7Qs7Ur6R39" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">137,333,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1969">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zV9daeYBB5P" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Effect of potentially dilutive convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,053,849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_iT_zxSCH2gN79V3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,053,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zLkpyy5nDPWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">142,387,651</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,999,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zTLtB4KeNMN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss per share attributable to common stockholders - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_zmXT4wuhRAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt; text-align: left">Net loss per share attributable to common stockholders -
    diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


<p id="xdx_8A7_zVZkqKtyZ87g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of March 31, 2024 and 2023, the
Company&#8217;s potentially dilutive securities included Series A Preferred Stock, outstanding public warrants and convertible
promissory notes on an as-converted basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Series A and Restricted Stock are
participating securities as Series A is entitled to participate in dividends and in earnings (but not losses) of the Company on an
as-converted basis as common shares and the Restricted Stock holder is entitled to participate in any dividends declared on common
stock. Accordingly, undistributed earnings are allocated to common shares and participating securities based on the weighted-average
shares of each class outstanding during the period. See Note 8 and Note 9 for additional rights and privileges of Restricted Stock
and Series A, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Restricted Stock are excluded from
the weighted average common stock outstanding pending the achievement of underlying service conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company excluded the
following potential shares from the computation of diluted net loss per share because including them would have had an anti-dilutive
effect:</p>

<p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1svLnbgkff9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zX9yJpSE6KId" style="display: none">SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240101__20240331_zjzz6uQ0sK1j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230101__20230331_zp4V5Ik7QbQe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z1yhHirk81E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding restricted stock units <span id="xdx_F4B_zVGWFtbf7tW2">(a)</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,751,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">10,355,527</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zbB4ALKPBuLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">19,348,954</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zRl78jxQ6Duh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Public warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1995">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivateWarrantsMember_zg3ia8cpuoPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Private warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">725,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1998">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zgoXgyIZ6op5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible promissory notes <span id="xdx_F49_zZoNJbq20IK3">(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,946,336</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zStoCMObkkt" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Earnout Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2004">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zUZkOPaurhna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">65,575,576</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,301,863</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F07_zDLLC4XmVDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zXrMPp7PXma3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of March 31, 2024, there were an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8" title="Stock option vested">7,148,506</span>
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_z9Nlj73FiGLd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zjwOKjJ29YB8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</span></td></tr>
  </table>
<p id="xdx_8AC_zHpNNTXLUHT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.5pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693390132320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zU884nHpm3Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span>SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">Note
10 &#8212; <span id="xdx_82D_zxi6St8bGCMe">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and transactions
for potential recognition or disclosure from the balance sheet date through May 28, 2024, the issuance date of these the financial statements
and has not identified any additional items requiring disclosure that have not previously been mentioned elsewhere.</p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zwUj1SXx7tRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8212; <span id="xdx_82C_z5LIHdAv0NUc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date these financial statements
were available to be issued. Based on this review, other than as described below, the Company did not identify any subsequent events
that would have required adjustment or disclosure in these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 31, 2024, in connection with an extraordinary
meeting of shareholders called to approve the proposals relating to the entry into and consummation of the Business Combination, shareholders
holding <span id="xdx_90F_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zESopOj6QJL9" title="Minimum period to file charter amendment">1,432,457</span> of the Company&#8217;s Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of
the funds in the Company&#8217;s trust account. As a result, approximately $<span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn5n6_c20240131__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzcFQlaXULFc" title="Cash withdrawn from Trust Account in connection with redemption">16.0</span> million (approximately $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3ofPKqs9OJc" title="Price per share">11.14</span> per Public Share) were
removed from the Trust Account to pay such holders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 14, 2024, pursuant to the Merger Agreement
by and among the Company, Merger Sub, the Sponsor, Tevogen Bio, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub
merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company. Prior to
the effective time of the Merger (the &#8220;Effective Time&#8221;), pursuant to the Merger Agreement, the Company changed its jurisdiction
of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated
under the laws of the State of Delaware (the &#8220;Domestication&#8221;). In connection with the Domestication, the Company changed its
name to &#8220;Tevogen Bio Holdings Inc.&#8221; Also in connection with the Domestication, the Company&#8217;s governing documents were
amended and restated as set forth in the Company&#8217;s definitive proxy statement filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on&#160;<span style="text-decoration: underline">January 10, 2024</span>&#160;(the &#8220;Definitive Proxy Statement&#8221;). At the Effective Time, in
accordance with the terms and subject to the conditions of the Merger Agreement, each share of the common stock of Tevogen Bio issued
and outstanding immediately prior to the Effective Time was converted into the right to receive the number of shares of duly authorized,
validly issued, fully paid, and nonassessable shares of the common stock of the Company, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zl1vUIz346fc" title="Common stock, par value">0.0001</span> (the &#8220;Common Stock&#8221;),
equal to the quotient obtained by dividing (x) the quotient obtained by dividing (i) $<span id="xdx_90B_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_c20240214__20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--TevogenBioMember_zk7sxtZpvkDa" title="Merger agreement share issuable">1,200,000,000</span> by (ii) ten dollars ($<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zpEEP9ZGg5K5" title="Merger agreement share issuable, per share">10.00</span>) by (y)
the aggregate number of shares of the common stock of Tevogen Bio that were issued and outstanding immediately prior to the Effective
Time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, the Company entered into a securities purchase agreement with an investor pursuant to which the investor agreed
to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0BQ6cP3Jxn3" title="Aggregate purchase price amount">8.0</span>
million. On March 27, 2024, the Company entered into an agreement pursuant to which that amount was reduced to $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zMjDSNJx8fye" title="Shares purchase amount">2.0</span>
million and the investor agreed to purchase shares of the Company&#8217;s Series A-1 Preferred Stock for an aggregate purchase price
of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zuAiSl9zOlm3" title="Aggregate purchase price amount">6.0</span>
million. As of April 26, 2024, the Company has received $<span id="xdx_90A_eus-gaap--Cash_iI_pn5n6_c20240426__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdvhVzlHnwkg" title="Received">1.2</span> million of the $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zwoBPcWviCz5" title="Aggregate purchase price amount">6.0</span> million aggregate purchase price for the shares of
Series A-1 Preferred Stock. The shares of Series A Preferred Stock are convertible into a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQAix7ayD9Kd" title="Conversion of shares">500,000</span>
shares of the Company&#8217;s common stock and the shares of the Series A-1 Preferred Stock will be convertible into a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z7CySHCzWF2a" title="Conversion of shares">600,000</span>
shares of the Company&#8217;s common stock, in each case at the election of the holder. Each of the Series A Preferred Stock is and
the Series A-1 Preferred Stock will be subject to a call right providing the Company the right to call the stock if the volume
weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCt9ozyeW1G8" title="Share price, per share">5.00</span>
per share and there is an effective resale registration statement on file covering the underlying common stock. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zr4CuyIiL8Lh" title="Preferred stock voting rights">The
Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no
mandatory redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the
Series A-1 Preferred Stock in no event to more than 15% per year.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, the Company entered into an agreement with the Sponsor,
pursuant to which the Company assigned to the Sponsor and the Sponsor agreed to assume certain liabilities and obligations in the aggregate
initial amount of approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9aSiJHU6C9">4.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which amount was later reduced to approximately
$<span id="xdx_902_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn5n6_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGBYMFN8WOCf">3.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (the &#8220;Series B Preferred Stock&#8221;).
<span id="xdx_902_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhzB2z5Zgcbj">The
Series B Preferred Stock is non-voting, non-convertible, callable by the Company at any time, and pays a 3.5% quarterly dividend beginning
35 days after issuance. Any dividend will be paid by the Company on behalf of the Sponsor to the creditors to which the assumed liabilities
and obligations are owed, pro rata in accordance with those liabilities and obligations unless otherwise agreed by the Company and the
Sponsor. The dividend rate will increase by 0.25% each month that the Series B Preferred Stock remains outstanding after the first 30
days after its issuance, but in no event will increase to more than 7.5% per quarter.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Merger Agreement, Tevogen Bio agreed
that at the Effective Time, it would pay $<span id="xdx_900_eus-gaap--SponsorFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_ztou06C0annd">2,000,000
</span>to the Sponsor for advisory services (the &#8220;Sponsor Advisory Services Fee&#8221;). Thereafter, in connection with the closing
of the Business Combination, the Sponsor Advisory Services Fee was reduced to $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SponsorAdvisoryServiceFeeMember_z8XGWrI0odn6">500,000</span>.
On April 16, 2024, the Sponsor agreed to further reduce the Sponsor Advisory Services Fee by informing Tevogen Bio that $<span id="xdx_90D_eus-gaap--SponsorFees_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQnU0u6Np1rd">250,000
</span>of the $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlPTlKsgfGlj">577,500
</span>that was due from the Sponsor as of December 31, 2023 would be applied to offset a portion of the $<span id="xdx_90D_ecustom--OffsetValue_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z9wT2SNHvZRl" title="Offset value">500,000</span> Sponsor Advisory Services
Fee. Therefore, the total amount due to the Sponsor under the Sponsor Advisory Services Fee is $<span id="xdx_90F_ecustom--ServicesFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zuxRHWoHWbCe" title="Service fees">250,000</span>.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693492965568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zGbPuBzg5CKl">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDufdfSqr987">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_ecustom--EmergingGrowthCompanyPolicyPolicyTextBlock_zPTHX6hDDIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z51bx9GmNCf6">Emerging
Growth Company</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for
public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company
nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z2UVV4YCU6v4">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zzoVedJkZirl">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zpjGtuKXUP3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zjW2yciTNI63">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did <span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_z8n1KGVCSxn" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zjnpuZTVh3Wb" title="Cash equivalents">no</span></span>t have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock', window );">Investments Held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--AssetsHeldInTrustAccountPolicyPolicyTextBlock_ztBsSHZlY6w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zoaPRIdCAmoa">Investments
Held in Trust Account</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, substantially all of the assets held in the Trust Account were held in a demand deposit cash account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">At December
31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company&#8217;s investments
held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at
the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included
in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values
of investments held in Trust Account are determined using available market information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock', window );">Offering Costs associated with the Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_zCwy56mbqjbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zCXACvIfWnUi">Offering
Costs associated with the Initial Public Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs, including additional underwriting fees associated with the underwriters&#8217; exercise of the over-allotment option, consist
principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable
to the underwriters&#8217; exercise of the over-allotment option in full, amounted to $<span id="xdx_909_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDpn1E4hnJBc" title="Offering costs">21,266,594</span> consisting of $<span id="xdx_909_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNa6Aky0zUCa" title="Underwriting fees">6,000,000</span> of paid underwriting
fees, $<span id="xdx_90B_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyD2joOQN139" title="Deferred underwriting fee payable">14,700,000</span> of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $<span id="xdx_907_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTd94FcM7BSj" title="Other offering costs">566,594</span> of other costs
and was charged to shareholders&#8217; equity upon the completion of the IPO. On June 28, 2023, the Company and Cantor entered into the Fee Reduction
Agreement, pursuant to which Cantor agreed to the Reduced Deferred Fee in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRzNADdXwd9i" title="Number of shares issued">500,000</span> shares of the common equity securities of
the entity surviving the Transaction. See Note 1 for more information on the Fee Reduction Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zsweBwNQyFF3">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zcm94hOGvmZ9">Concentration
of Credit Risk</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount">250,000</span>. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOp0Gnh2gwmd">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s
convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zLAFUKdBZV45" style="display: none">Schedule
of Fair Value Measurement</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance">94,932,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance">289,135</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance">28,142,865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance">70,229,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility">80</span>%),
discount rate (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate">35</span>%
- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate">36</span>%),
and probability of a future liquidity event (<span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event">85</span>%
- <span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event">95</span>%).</span> The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the three months ended March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants the fair value of which increased by $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants">31,973</span>
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zTyrtDvrDzJk">Schedule
of Fair Values Of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at February 15, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">31,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">60,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities">60,973</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between <span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1667">75%</span></span> to <span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1669">85%</span></span>, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from <span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years">0.5</span> to <span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years">10.0</span> years, and a risk-free interest rate between <span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage">4.3%</span> and <span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage">5.3%</span>. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock">2,000,000</span> upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_znPUUrddfrUi">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the (&#8220;FASB&#8221;) ASC 820,
&#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Related Party Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8Ot8VIhkg52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Related
Party Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for amounts due from related parties at historical cost and evaluates the collectability of these receivables for determination
on if impairment should be recognized. In the same manner, the Company evaluated the $<span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_z3uF8gdQDCwh" title="Impairment of due from related party">250,000</span> loan to Srirama Associates, LLC and determined
that the amount was uncollectable and therefore recognized an impairment loss, see Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zkpWCEwQfXz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zLIWqLIv8yUi">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes.&#8221; Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. There were <span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20231231_zVaiAAGIGva9" title="Unrecognized tax benefits"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zF5N2A4rIB24" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits as of December 31, 2023 and 2022.
The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. <span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20231231_zrUaDPZSdxM3" title="Unrecognized tax benefits accrued for interest and penalties"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20221231_zurXvR5vPrF5" title="Unrecognized tax benefits accrued for interest and penalties">No</span></span> amounts were accrued for the payment of
interest and penalties for the year ended December 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the
Company. Consequently, income taxes are not reflected in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TemporaryEquityPolicyPolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_ecustom--TemporaryEquityPolicyPolicyTextBlock_zD0efC8N3eda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zgtCoOZ7zQ9k">Class
A Ordinary Shares Subject to Possible Redemption</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing
Liabilities from Equity.&#8221; Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument
and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#8217;s control) is classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders&#8217;
equity. The Company&#8217;s Public Shares feature certain redemption rights that are considered to be outside of the Company&#8217;s
control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023 and 2022, <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp8ry42IgPWa" title="Temporary equity, shares outstanding">1,502,180</span> and <span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJYI75T357lb" title="Temporary equity, shares outstanding">34,500,000</span>, respectively,
Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders&#8217; deficit
section of the Company&#8217;s balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary
share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable
ordinary share are affected by charges against additional paid in capital and accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zMZGt80hTdmi" style="display: none">Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption">351,900,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value">4,964,000</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption">356,864,000</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value">2,801,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Redemption of ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares">(342,984,430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class A ordinary share subject to possible redemption, December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption">16,681,497</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z1HYxxQQhzOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Ordinary Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuKunqOFiF5k">Net
Income (Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zK1LsoVBPXid">Net
Income (Loss) per Ordinary Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#8220;Founder Shares&#8221;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)">17,975,000</span> ordinary shares at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants">11.50</span> per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share">17,975,000</span></span> Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(19,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(44,186</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(4,005</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income">3,172,916</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income">133,355</span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income">1,102,090</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted">5,333,742</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted">12,317,077</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted">1,116,256</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted">34,500,000</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted">1,450,000</span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted">11,983,333</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share">0.09</span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantLiabilitiesPolicyPolicyTextBlock', window );">Accounting for Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_ecustom--WarrantLiabilitiesPolicyPolicyTextBlock_z7WEXKlufkK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zVTXpxyIBmS5">Accounting
for Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment
considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own ordinary shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments
are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and Private Placement Warrants
qualify for liability accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zaS2rj0QNrb1">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, Debt &#8211; <i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zE8ozL4HOjF7">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#8217;s financial statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Held In Trust Account Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Associated With Initial Public Offering [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693390104640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zGbPuBzg5CKl">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDufdfSqr987">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z2UVV4YCU6v4">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zzoVedJkZirl">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zsweBwNQyFF3">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zcm94hOGvmZ9">Concentration
of Credit Risk</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount">250,000</span>. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zJZFeTaEcaDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zPtwxjycLoh9">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_ztdxsUcE1y6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public
offering (the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i>
(&#8220;ASC 815&#8221;), and considering ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;). The
assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to
ASC 480 and meet all of the conditions for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own shares of common stock, among other conditions. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of
issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are
recognized as a non-cash loss on the consolidated statements of operations. Under these standards, the Company&#8217;s private
placement warrants sold at the time of the IPO do not meet the criteria for equity classification and must be recorded as
liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification and must be recorded as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zOp0Gnh2gwmd">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s
convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zLAFUKdBZV45" style="display: none">Schedule
of Fair Value Measurement</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance">94,932,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance">289,135</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance">28,142,865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance">70,229,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility">80</span>%),
discount rate (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate">35</span>%
- <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate">36</span>%),
and probability of a future liquidity event (<span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event">85</span>%
- <span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event">95</span>%).</span> The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the three months ended March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants the fair value of which increased by $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants">31,973</span>
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zTyrtDvrDzJk">Schedule
of Fair Values Of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at February 15, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">31,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">60,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities">60,973</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between <span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1667">75%</span></span> to <span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1669">85%</span></span>, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from <span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years">0.5</span> to <span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years">10.0</span> years, and a risk-free interest rate between <span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage">4.3%</span> and <span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage">5.3%</span>. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock">2,000,000</span> upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_znPUUrddfrUi">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the (&#8220;FASB&#8221;) ASC 820,
&#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuKunqOFiF5k">Net
Income (Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zK1LsoVBPXid">Net
Income (Loss) per Ordinary Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#8220;Founder Shares&#8221;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)">17,975,000</span> ordinary shares at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants">11.50</span> per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share">17,975,000</span></span> Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(19,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(44,186</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(4,005</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income">3,172,916</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income">133,355</span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income">1,102,090</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted">5,333,742</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted">12,317,077</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted">1,116,256</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted">34,500,000</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted">1,450,000</span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted">11,983,333</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share">0.09</span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DECEMBER
31, 2023</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zaS2rj0QNrb1">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, Debt &#8211; <i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zE8ozL4HOjF7">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#8217;s financial statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395540384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zMZGt80hTdmi" style="display: none">Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption">351,900,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal; text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: normal; font-weight: normal; text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value">4,964,000</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Class A ordinary share subject to possible redemption, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"><p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption">356,864,000</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value">2,801,927</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Redemption of ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares">(342,984,430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Class A ordinary share subject to possible redemption, December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption">16,681,497</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUEM9njRKv4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the computation of
basic and diluted income (loss) per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zvAOzgDMPIJa" style="display: none">SCHEDULE
OF NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240101__20240331_zBIw8xRlZL0l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230101__20230331_z7sjC8XY7KTh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILATz5q6_z2PwMSipxGSd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,264,842</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(30,756,144</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iN_di_msNILATz5q6_zmkQDyPhYEve" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Less: Undistributed earnings allocated to participating securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(756,606</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz5q6_zSf2SWBkWWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,506,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_maNILATzP0S_z2Ff6mKtEnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,264,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(30,756,144</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ConvertiblePromissoryNoteInterest_iT_mtNILATzP0S_zROaggmn9VJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ConvertiblePromissoryNoteChangeInFairValue_iT_mtNILATzP0S_zBXxLczt6Ci9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,468,678</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1957">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATzP0S_zO8LeU0GiuFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(37,049,420</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zUtr9hiU9Yf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,333,802</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,999,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zSoaT7mNY0Na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) per share attributable to common stockholders, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_zk7Qs7Ur6R39" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">137,333,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1969">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zV9daeYBB5P" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Effect of potentially dilutive convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,053,849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_iT_zxSCH2gN79V3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,053,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zLkpyy5nDPWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">142,387,651</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,999,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zTLtB4KeNMN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss per share attributable to common stockholders - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_zmXT4wuhRAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt; text-align: left">Net loss per share attributable to common stockholders -
    diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(19,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(44,186</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(4,005</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income">3,172,916</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income">133,355</span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income">1,102,090</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted">5,333,742</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted">12,317,077</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted">1,116,256</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted">34,500,000</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted">1,450,000</span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted">11,983,333</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share">0.09</span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693526405600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Fair Value Non Redeemable Shares</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z2fvY4XooUQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The fair value of the Class A non-redeemable shares
was based on the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span id="xdx_8B6_zR8Qc92B1zJ5">Schedule
of Fair Value Non Redeemable Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230503__20230504_zjRvdjmAJfIf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">May 4, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_zvPeAx7Xrov7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Discount for lack of marketability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">6.80</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--StockPriceOfMeasurement_pid_z3xkbBKhZqze" style="vertical-align: bottom; background-color: White">
    <td>Stock price as of measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10.77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProbabilityOfTransactionPercentage_pid_dp_uPure_zhofbGhptox2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of transaction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.40</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693522526016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities">60,973</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmjRVkh3pYg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at December 31, 2023 and 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine
such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUJd3DIqYfuc" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2023:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/>
Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Active<br/>
 Markets <br/>
(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Observable<br/>
 Inputs<br/>
 (Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unobservable<br/>
 Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zL6j0eZA5kQd" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zzQOWVq1njL9" style="width: 12%; text-align: right" title="U.S. Treasury Securities">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zJHJYSgOXqh5" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzF2KHIA6d1h" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8zohv8G7zn4" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zu6DplRasUnk" style="text-align: right" title="Warrant Liability- Private Placement Warrants">29,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F05_zRz5qzPWqC91" style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td id="xdx_F10_zr00BowB9Rdj" style="text-align: justify">As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2022:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted<br/>
 Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Active<br/>
 Markets</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlSzSgdzh8Qj" style="width: 12%; text-align: right" title="U.S. Treasury Securities">356,864,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQbFfgPIFlQa" style="width: 12%; text-align: right" title="U.S. Treasury Securities">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1059">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTtiidvpzIVb" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7MNmEfSplwb" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgz3GX8Bzzn1" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCeQqJgFIhE8" style="text-align: right" title="Warrant Liability- Private Placement Warrants">7,250</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Quantitative Information in Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zW6iO4IeZbtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zXnCn4NfJng1" style="display: none">Schedule
of Quantitative Information    in Fair Value Measurements</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At <br/>
December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At <br/>
December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Share Price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDNiR2mPr5Tf" style="width: 20%; text-align: right" title="Measurement Input">11.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHJCNf8UNgHk" style="width: 20%; text-align: right" title="Measurement Input">10.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise Price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zToyf7clZ7g2" style="text-align: right" title="Measurement Input">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z6w3yUrmoJ9d" style="text-align: right" title="Measurement Input">11.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zHVt8y7rXMvd" style="text-align: right" title="Measurement Input">5.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z52dsppE8ln7" style="text-align: right" title="Measurement Input">5.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Industry Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBJriKpznZxe" style="text-align: right" title="Measurement Input">6.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0Jh1aYzxPrb" style="text-align: right" title="Measurement Input">4.40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk Free Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8GUjclHjgli" style="text-align: right" title="Measurement Input">3.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5935i02fu9d" style="text-align: right" title="Measurement Input">3.91</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgMQm2a5w1M9" style="text-align: right" title="Measurement Input">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7p3iyXq8RK3" style="text-align: right" title="Measurement Input">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391996416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value Measurement</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zLAFUKdBZV45" style="display: none">Schedule
of Fair Value Measurement</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance">94,932,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance">39,297,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance">289,135</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance">28,142,865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance">70,229,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Values Of Warrants</a></td>
<td class="text"><p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zTyrtDvrDzJk">Schedule
of Fair Values Of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; font-weight: bold">Balance at February 15, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">31,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">60,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zSBy0zjFPzxa" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted Prices in Active Markets <br/>
(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant Other Observable Inputs <br/>
(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
Other Unobservable Inputs <br/>
(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 38%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">3</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1661">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities">60,973</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmjRVkh3pYg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring
basis at December 31, 2023 and 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine
such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUJd3DIqYfuc" style="display: none">Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2023:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted <br/>
Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Active<br/>
 Markets <br/>
(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Observable<br/>
 Inputs<br/>
 (Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unobservable<br/>
 Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zL6j0eZA5kQd" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zzQOWVq1njL9" style="width: 12%; text-align: right" title="U.S. Treasury Securities">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zJHJYSgOXqh5" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzF2KHIA6d1h" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1050">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8zohv8G7zn4" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zu6DplRasUnk" style="text-align: right" title="Warrant Liability- Private Placement Warrants">29,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F05_zRz5qzPWqC91" style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td id="xdx_F10_zr00BowB9Rdj" style="text-align: justify">As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">December 31, 2022:</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted<br/>
 Prices in</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant<br/>
 Other</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Active<br/>
 Markets</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable<br/>
 Inputs</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">U.S. Treasury Securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlSzSgdzh8Qj" style="width: 12%; text-align: right" title="U.S. Treasury Securities">356,864,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQbFfgPIFlQa" style="width: 12%; text-align: right" title="U.S. Treasury Securities">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1059">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTtiidvpzIVb" style="width: 12%; text-align: right" title="U.S. Treasury Securities"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant Liability- Private Placement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7MNmEfSplwb" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgz3GX8Bzzn1" style="text-align: right" title="Warrant Liability- Private Placement Warrants"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCeQqJgFIhE8" style="text-align: right" title="Warrant Liability- Private Placement Warrants">7,250</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693505274000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_z0UveVE1Z4Rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zoftPmTp3y0f" style="display: none">SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zc4CykHVrO3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February 14, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_zV26RK6wEI0g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">229,328</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z9ExmMKMHUbh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,819</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_z0ckBmta55U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,501</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zRRY1Onz2Gog" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,175</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zmkHDZ64vAS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,269,126</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_msBCRIAzgn3_zQHvgagApXC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,651,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_iNI_di_msBCRIAzgn3_zPIFDH3dmFli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maTNLAPz196_zg7P9MDwAob7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,654,653</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--PlusMergerTransactionCostsLimitedToCashAcquired_iI_maTNLAPz196_z5xGmUJppzPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229,328</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TotalNetLiabilitiesAcquiredPlusTransactionCosts_iTI_mtTNLAPz196_zvfeqz28WXeh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,883,981</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394037120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zllsvmfRvbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z1XStT9irsL4" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240331_zCNwgiFUWVxh" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231__srt--RestatementAxis__custom--ReverseRecapitalizationMember_z9vhWj64T8g6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December, 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedProfessionalServiceFeesCurrent_iI_maALCzC3I_zLX4Kx1CaUm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,337,588</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">976,301</td><td style="width: 1%; text-align: left"></td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_z1JlnIguFiji" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">227,246</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zBj95Ne7Kmxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,564,834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502748880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zdpajvJt0qTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zhJqhOvAGR6l" style="display: none">SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Nonvested as of January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z83uWATEILW1" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zu0LhFu4Aasj" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></td><td style="border-right: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaujT7apMUpl" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning">10,900,128</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zsyxDlVNXEGl" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning">2.97</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z9yU478s4eg8" style="text-align: right" title="Nonvested Shares, Granted">19,348,954</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zbAsZYkbhM2f" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted">4.51</td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1wIbOm1tbYh" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYg3gbr3SUyg" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zyx6Tm6CnHce" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zoIvjh7wYkxd" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zFAIDCc7Y2K" style="text-align: right" title="Nonvested Shares, Vested">(7,148,506</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zB1hX4HVoBPf" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested">2.85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z1p6P8RsdBzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zPUaRSuSVK6l" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zGGyRtxUb7B4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z7ISujfViPa9" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOi2SXcJII9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending">19,348,954</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zS1RixakFqQ3" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending">4.51</td><td style="border-right: Black 1.5pt solid; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zN0k23fzW3vj" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending">3,751,622</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlPecO79tg4" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending">3.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zC9fXNTzWGk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zXFl7uLL0Hs7" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20240331_zoqt4oqEtHwc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDfPraaNw6Qe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,735,896</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKiaDPHxJTql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,597,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z2AeX3C1J044" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,333,249</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391980864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zY5jL67Rs2Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Below is a reconciliation of shares of common stock issued and outstanding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zZo8Qih3N086">SCHEDULE
OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock legally issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20240331_zsMZdC6rjITa" title="Common shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zjYfmLv5o8Ea" title="Common shares, shares outstanding">164,614,418</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: Shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares issuable to Polar <span>(a)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesToBeIssuedOnSharesIssuable_iI_c20240331_fKGEp_zMeI2mD6dNV4" style="text-align: right" title="Shares issuable to Polar">1,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Shares issuable to Polar"><p id="xdx_983_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20240331_fKGIp_zXBFTzzS3Bq7" style="margin: 0" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing">7,148,506</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Issuance of restricted common stock subject to forfeiture
    <span>(c)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20240331_fKGMp_z5jRYgf928xj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture">(19,348,954</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued and outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20240331_zU2AIRwtMn07" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding">153,913,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0E_zSFUsb3mIPXf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zVLlsyBIhf2g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td id="xdx_F0A_z3CtrESEccf7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(b)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p id="xdx_F18_zIQMiBkzr678" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zHMvLEAIjjn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zdgGRYz4aBu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502560816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUEM9njRKv4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the computation of
basic and diluted income (loss) per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zvAOzgDMPIJa" style="display: none">SCHEDULE
OF NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240101__20240331_zBIw8xRlZL0l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230101__20230331_z7sjC8XY7KTh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILATz5q6_z2PwMSipxGSd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,264,842</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(30,756,144</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iN_di_msNILATz5q6_zmkQDyPhYEve" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Less: Undistributed earnings allocated to participating securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(756,606</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz5q6_zSf2SWBkWWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,506,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_maNILATzP0S_z2Ff6mKtEnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,264,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(30,756,144</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Cumulative undeclared Series A dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ConvertiblePromissoryNoteInterest_iT_mtNILATzP0S_zROaggmn9VJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ConvertiblePromissoryNoteChangeInFairValue_iT_mtNILATzP0S_zBXxLczt6Ci9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: Convertible promissory note change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,468,678</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1957">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATzP0S_zO8LeU0GiuFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(37,049,420</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(30,756,144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zUtr9hiU9Yf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,333,802</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,999,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zSoaT7mNY0Na" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net income (loss) per share attributable to common stockholders, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_zk7Qs7Ur6R39" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">137,333,802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1969">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zV9daeYBB5P" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Effect of potentially dilutive convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,053,849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_iT_zxSCH2gN79V3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,053,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zLkpyy5nDPWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Weighted average common stock outstanding, diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">142,387,651</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,999,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zTLtB4KeNMN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss per share attributable to common stockholders - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_zmXT4wuhRAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt; text-align: left">Net loss per share attributable to common stockholders -
    diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zyUK767o3DFd" style="display: none">Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Redeemable)</b></p>
 Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A (Non &#8211; Redeemable) Ordinary Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Class B Ordinary Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Basic and diluted net (loss) income per share:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 6%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allocation of net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right">(19,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income">(44,186</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income">(4,005</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income">3,172,916</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income">133,355</span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income">1,102,090</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted">5,333,742</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted">12,317,077</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted">1,116,256</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted">34,500,000</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted">1,450,000</span></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted">11,983,333</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted net (loss) income per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share">0.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share">0.09</span></span></td><td style="text-align: left">&#160;</td>
    <td></td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share">0.09</span></span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1svLnbgkff9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zX9yJpSE6KId" style="display: none">SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240101__20240331_zjzz6uQ0sK1j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230101__20230331_zp4V5Ik7QbQe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z1yhHirk81E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding restricted stock units <span id="xdx_F4B_zVGWFtbf7tW2">(a)</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,751,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">10,355,527</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zbB4ALKPBuLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">19,348,954</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zRl78jxQ6Duh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Public warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1995">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivateWarrantsMember_zg3ia8cpuoPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Private warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">725,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1998">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zgoXgyIZ6op5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible promissory notes <span id="xdx_F49_zZoNJbq20IK3">(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,946,336</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zStoCMObkkt" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Earnout Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2004">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zUZkOPaurhna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">65,575,576</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,301,863</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F07_zDLLC4XmVDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zXrMPp7PXma3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of March 31, 2024, there were an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8" title="Stock option vested">7,148,506</span>
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_z9Nlj73FiGLd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zjwOKjJ29YB8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</span></td></tr>
  </table>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693381490384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization, Business Operations and Liquidity (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 05, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum', window );">Condition for future business combination number of businesses minimum | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred offering costs non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 229,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,499,353<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage', window );">Condition for future business combination use of proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership', window );">Condition for future business combination threshold ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets', window );">Net tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from trust account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,984,430<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Assets held in trust noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,681,497<span></span>
</td>
<td class="nump">356,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, Shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RedemptionLimitPercentageWithoutPriorConsent', window );">Redemption limit percentage without prior consent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MaximumAllowedDissolutionExpenses', window );">Maximum allowed dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Extension amount deposited into Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,317,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,835<span></span>
</td>
<td class="nump">$ 129,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,648,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Investment income interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from trust account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Shares cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,433,333<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,433,333<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares', window );">Minimum period to file charter amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,432,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_FirstExtensionCharterAmendmentMember', window );">First Extension Charter Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from trust account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_FirstExtensionCharterAmendmentMember', window );">First Extension Charter Amendment [Member] | Public Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares', window );">Minimum period to file charter amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,116,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SecondExtensionCharterAmendmentMember', window );">Second Extension Charter Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from trust account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SecondExtensionCharterAmendmentMember', window );">Second Extension Charter Amendment [Member] | Public Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,502,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares', window );">Minimum period to file charter amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 880,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A One Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TVGN_SponsorMember', window );">Sponsor [Member] | Purchase Agreement [Member] | Common Class A [Member] | SSVK Associates, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, Shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,988,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred offering costs non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,266,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SaleOfStockUnderwritingFees', window );">Sale of stock underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PaymentsForInvestmentOfCashInTrustAccount', window );">Payments for investment of cash in trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Fee Reduction Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Common equity securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred offering costs non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrentForfeited', window );">Deferred underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, Shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Common equity securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Common equity securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Sponsor [Member] | Purchase Agreement [Member] | SSVK Associates, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, Shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Common equity securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred offering costs non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Shares cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,778,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Common equity securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Condition for future business combination number of businesses minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Condition for future business combination threshold net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Condition for future business combination threshold percentage ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Condition for future business combination use of proceeds percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredOfferingCostsNoncurrentForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs non current forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredOfferingCostsNoncurrentForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MaximumAllowedDissolutionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum allowed dissolution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MaximumAllowedDissolutionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PaymentsForInvestmentOfCashInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for investment of cash in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PaymentsForInvestmentOfCashInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage obligation to redeem public shares if entity does not complete business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from cash withdrawn from Trust Account in connection with redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RedemptionLimitPercentageWithoutPriorConsent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption limit percentage without prior consent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RedemptionLimitPercentageWithoutPriorConsent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock other offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders exercised their right to redeem shares number of shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_FirstExtensionCharterAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_FirstExtensionCharterAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_PublicSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_PublicSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SecondExtensionCharterAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SecondExtensionCharterAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=TVGN_SsvkAssociatesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=TVGN_SsvkAssociatesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_FeeReductionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_FeeReductionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693502961616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary share subject to possible redemption</a></td>
<td class="nump">$ 356,864,000<span></span>
</td>
<td class="nump">$ 351,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">2,801,927<span></span>
</td>
<td class="nump">4,964,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TemporaryEquityRedemptionAmount', window );">Redemption of ordinary shares</a></td>
<td class="num">(342,984,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary share subject to possible redemption</a></td>
<td class="nump">$ 16,681,497<span></span>
</td>
<td class="nump">$ 356,864,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TemporaryEquityRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity redemption amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TemporaryEquityRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395886144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="nump">$ 10,506,866<span></span>
</td>
<td class="num">$ (30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">137,333,802<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="nump">142,387,651<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilution net income (loss) per share</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,134)<span></span>
</td>
<td class="nump">$ 3,172,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,742<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,742<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilution net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_CommonClassaNotSubjectToRedemptionMember', window );">Common Class A Not Subject To Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,186)<span></span>
</td>
<td class="nump">$ 133,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,317,077<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,317,077<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilution net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,005)<span></span>
</td>
<td class="nump">$ 1,102,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116,256<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116,256<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilution net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_CommonClassaNotSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_CommonClassaNotSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693386329888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCosts', window );">Offering costs</a></td>
<td class="nump">$ 229,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,499,353<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal depository insurance coverage amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ImpairmentOfAmountDueFromRelatedParty', window );">Impairment of due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits accrued for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from computation of diluted earnings per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,575,576<span></span>
</td>
<td class="nump">13,301,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from computation of diluted earnings per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,975,000<span></span>
</td>
<td class="nump">17,975,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,502,180<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,266,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Fee Reduction Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ImpairmentOfAmountDueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of amount due from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ImpairmentOfAmountDueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock other offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_FeeReductionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_FeeReductionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693397500768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Initial Public Offering and Over-Allotment (Details Narrative) - IPO [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssue', window );">Sale of units in initial public offering, gross (in shares ) | shares</a></td>
<td class="nump">34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NumberOfSharesIssuedPerUnit', window );">Number of shares in a unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants in a unit</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares issuable per warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_UnitsIssuedDuringPeriodSharesNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395855872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Private Placement Warrants (Details Narrative) - Private Placement Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 07, 2023</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember', window );">Private Placement [Member] | Cantor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember', window );">Private Placement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_CantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_CantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394756624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Non Redeemable Shares (Details)<br></strong></div></th>
<th class="th">
<div>May 04, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for lack of marketability</a></td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockPriceOfMeasurement', window );">Stock price as of measurement date</a></td>
<td class="nump">10.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProbabilityOfTransactionPercentage', window );">Probability of transaction</a></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ProbabilityOfTransactionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probability of transaction percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ProbabilityOfTransactionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockPriceOfMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock price of measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockPriceOfMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693382814016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 06, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 22, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 02, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowings amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ImpairmentOfAmountDueFromRelatedParty', window );">Impairment of due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from Other Equity</a></td>
<td class="nump">$ 229,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Other Notes Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,631,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConvertibleNotesPayableDiscounts', window );">[custom:ConvertibleNotesPayableDiscounts-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NoncashInterestExpenses', window );">Non cash interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,031<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=TVGN_FirstPolarFundConvertibleNoteMember', window );">First Polar Fund Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from Other Equity</a></td>
<td class="nump">520,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=TVGN_SecondPolarFundConvertibleNoteMember', window );">Second Polar Fund Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Remaining borrowing capacity amount</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument, fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialCapitalContribution', window );">Initial capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SecondSubscriptionAgreementMember', window );">Second Subscription Agreement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialCapitalContribution', window );">Initial capital contribution</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=TVGN_DeSPACMember', window );">De S P A C [Member] | Subscription Agreement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialCapitalContributionPerShare', window );">Initial capital contribution | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=TVGN_DeSPACMember', window );">De S P A C [Member] | Second Subscription Agreement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialCapitalContributionPerShare', window );">Initial capital contribution | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Shares cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Subscription Agreement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Loan from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Purchase Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,988,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Purchase Agreement [Member] | Sponsor [Member] | Public Warrants Transferred Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Purchase Agreement [Member] | Sponsor [Member] | Public Warrants Transferred Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Private Placement [Member] | Purchase Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Common Class A [Member] | Purchase Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">7,988,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AggregatePurchasePrice', window );">Aggregate purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,515,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Non Redeemable Ordinary [Member] | Purchase Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,988,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Public Warrants Transferred One [Member] | Purchase Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember', window );">SSVK Associates, LLC [Member] | Public Warrants Transferred Two [Member] | Purchase Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_FounderSharesMember', window );">Founder Shares [Member] | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Stock dividend ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0195<span></span>
</td>
<td class="nump">0.3628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AggregateNumberOfSharesOwned', window );">Aggregate number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,754,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_FounderSharesMember', window );">Founder Shares [Member] | Sponsor [Member] | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Share dividend | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AggregateNumberOfSharesOwned', window );">Aggregate number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger', window );">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_FounderSharesMember', window );">Founder Shares [Member] | Sponsor [Member] | Common Class B [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NumberOfSharesSubjectToForfeiture', window );">Shares subject to forfeiture | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_PromissoryNoteWithRelatedPartyMember', window );">Promissory Note with Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Amount of notes payable repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_RelatedPartyLoansMember', window );">Related Party Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MaximumLoansConvertibleIntoWarrants', window );">Loan conversion agreement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_RelatedPartyLoansMember', window );">Related Party Loans [Member] | Working capital loans warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_AdministrativeSupportAgreementMember', window );">Administrative Support Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth', window );">Expenses per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Amount accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AggregateNumberOfSharesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders after the impact of the stock dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AggregateNumberOfSharesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConvertibleNotesPayableDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes payable discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConvertibleNotesPayableDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ImpairmentOfAmountDueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of amount due from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ImpairmentOfAmountDueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_InitialCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of initial cash contribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_InitialCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_InitialCapitalContributionPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial capital contribution per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_InitialCapitalContributionPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MaximumLoansConvertibleIntoWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount which a potential loan could have repaid through issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MaximumLoansConvertibleIntoWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NoncashInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NoncashInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NumberOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NumberOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contractual monthly amount to be paid for support services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer assign or sell any shares or warrants after completion of initial business combination threshold consecutive trading days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WorkingCapitalLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WorkingCapitalLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=TVGN_FirstPolarFundConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=TVGN_FirstPolarFundConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=TVGN_SecondPolarFundConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=TVGN_SecondPolarFundConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SecondSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SecondSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=TVGN_DeSPACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=TVGN_DeSPACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SsvkAssociatesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsTransferredTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsTransferredTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsTransferredThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsTransferredThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_NonRedeemableOrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_NonRedeemableOrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_PublicWarrantsTransferredOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_PublicWarrantsTransferredOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_PublicWarrantsTransferredTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_PublicWarrantsTransferredTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=TVGN_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=TVGN_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=TVGN_PromissoryNoteWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=TVGN_PromissoryNoteWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=TVGN_RelatedPartyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=TVGN_RelatedPartyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_WorkingCapitalLoansWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_WorkingCapitalLoansWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=TVGN_AdministrativeSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=TVGN_AdministrativeSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693386993792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>May 04, 2023</div></th>
<th class="th"><div>May 03, 2023</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnderwritingCashDiscountPerUnit', window );">Underwriting cash discount per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AggregateUnderwriterCashDiscount', window );">Aggregate underwriter cash discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredFeePerUnit', window );">Deferred underwriting commission fee (per unit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AggregateDeferredUnderwritingFeePayable', window );">Aggregate deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnderwriterCashDiscount', window );">Underwriter cash discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Class A [Member] | Sponsor [Member] | SSVK Associates, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,988,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AggregatePurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialCapitalContribution', window );">Initial capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MinimumPeriodForPaymentInCaseOfLiquidation', window );">Minimum period for payment in case of liquidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Subscription Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing', window );">Minimum period for receiving spac loan from de-spac closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AmountOfInitialCapitalConsideredToIssueOneShare', window );">Amount of initial capital considered to issue one share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MaximumReasonableAttorneyFees', window );">Maximum reasonable attorney fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Subscription Agreement [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Second Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_InitialCapitalContribution', window );">Initial capital contribution</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Second Subscription Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing', window );">Minimum period for receiving spac loan from de-spac closing</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AmountOfInitialCapitalConsideredToIssueOneShare', window );">Amount of initial capital considered to issue one share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MaximumReasonableAttorneyFees', window );">Maximum reasonable attorney fees</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnderwritingOptionPeriod', window );">Underwriting option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of units, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PaymentOfUnderwriterDiscount', window );">Payment of underwriter discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of units, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of units, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Purchase Agreement [Member] | Sponsor [Member] | SSVK Associates, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AggregateDeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate deferred underwriting fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AggregateDeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AggregateUnderwriterCashDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value of the cash underwriting discount in the aggregate if the underwriter's option to purchase additional units is exercised in full.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AggregateUnderwriterCashDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AmountOfInitialCapitalConsideredToIssueOneShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of initial capital considered to issue one share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AmountOfInitialCapitalConsideredToIssueOneShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredFeePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred fee per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredFeePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_InitialCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of initial cash contribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_InitialCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MaximumReasonableAttorneyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents maximum reasonable attorney fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MaximumReasonableAttorneyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MinimumPeriodForPaymentInCaseOfLiquidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents minimum period for payment in case of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MinimumPeriodForPaymentInCaseOfLiquidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents minimum period for receiving spac loan from de-spac closing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PaymentOfUnderwriterDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment of underwriting discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PaymentOfUnderwriterDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_UnderwriterCashDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash underwriting discount per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_UnderwriterCashDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_UnderwritingCashDiscountPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash underwriting discount per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_UnderwritingCashDiscountPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_UnderwritingOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the underwriting option period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_UnderwritingOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=TVGN_SsvkAssociatesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=TVGN_SsvkAssociatesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SecondSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SecondSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693378785904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Deficit (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Integer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 28, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Integer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (In Dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">119,999,989<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">119,999,989<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares , shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantExercisePeriodConditionOne', window );">Minimum threshold written notice period for redemption of public warrants</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering', window );">Public warrants exercisable term from the closing of the initial public offering</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of public warrants</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders | Integer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants', window );">Share price trigger used to measure dilution of warrant | $ / shares</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices', window );">Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)</a></td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (In Dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">13,433,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">13,433,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,933,333<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A ordinary shares subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">1,502,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (In Dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,983,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_CommonStockNumberOfVotesPerShare', window );">Ordinary shares, vote per share | Integer</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConvertibleStocksConversionRatio', window );">Ratio to be applied to the stock in the conversion</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjustment of exercise price of warrants based on market value and newly issued price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConvertibleStocksConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio to be applied to the stock in a conversion of convertible stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConvertibleStocksConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Period of redemption for written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold number of business days before sending notice of redemption to warrant holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantExercisePeriodConditionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination before a warrant may be exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantExercisePeriodConditionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of warrants exercisable term from the closing of the business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395336432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Liabilities (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="nump">725,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693398992368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 60,973<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant Liability- Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">356,864,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant Liability- Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant Liability- Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 60,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693492735968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Quantitative Information in Fair Value Measurements (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">11.13<span></span>
</td>
<td class="nump">10.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Measurement Input</a></td>
<td class="text">5 years 2 months 15 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">4.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">3.77<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693386043520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 16, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from Trust Account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,984,430<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,317,900<span></span>
</td>
<td class="nump">$ 8,835<span></span>
</td>
<td class="nump">$ 129,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_OffsetValue', window );">Offset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ServicesFees', window );">Service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_MergerAgreementMember', window );">Merger Agreement [Member] | Sponsor Advisory Service Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from Trust Account in connection with redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Merger Agreement [Member] | Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Merger agreement share issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares', window );">Minimum period to file charter amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,432,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Aggregate purchase price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no
mandatory redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the
Series A-1 Preferred Stock in no event to more than 15% per year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember', window );">Series A One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember', window );">Series A One Preferred Stock [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Aggregate purchase price amount</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesA1PreferredStockMember', window );">Series A One Preferred Stock [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Received</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Series B Preferred Stock is non-voting, non-convertible, callable by the Company at any time, and pays a 3.5% quarterly dividend beginning
35 days after issuance. Any dividend will be paid by the Company on behalf of the Sponsor to the creditors to which the assumed liabilities
and obligations are owed, pro rata in accordance with those liabilities and obligations unless otherwise agreed by the Company and the
Sponsor. The dividend rate will increase by 0.25% each month that the Series B Preferred Stock remains outstanding after the first 30
days after its issuance, but in no event will increase to more than 7.5% per quarter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_OffsetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offset value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_OffsetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from cash withdrawn from Trust Account in connection with redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ServicesFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Services fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ServicesFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders exercised their right to redeem shares number of shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SponsorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SponsorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=TVGN_SponsorAdvisoryServiceFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=TVGN_SponsorAdvisoryServiceFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395340160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioMember', window );">Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity holders percentage</a></td>
<td class="nump">90.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity holders percentage</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_SemperParatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_SemperParatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693399034352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Amount of accumulated undistributed earnings</a></td>
<td class="nump">$ 88,392,895<span></span>
</td>
<td class="nump">$ 17,378,637<span></span>
</td>
<td class="nump">$ 14,784,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Management cash</a></td>
<td class="nump">1,317,900<span></span>
</td>
<td class="nump">$ 8,835<span></span>
</td>
<td class="nump">$ 129,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember', window );">Series A One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sale of preferred stock</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693397468400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value Measurement (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value beginning balance</a></td>
<td class="nump">$ 94,932,000<span></span>
</td>
<td class="nump">$ 39,297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value at issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest', window );">Initial fair value at issuance</a></td>
<td class="nump">159,305<span></span>
</td>
<td class="nump">289,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Initial fair value at issuance</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">28,142,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable', window );">Derecognition upon conversion of convertible promissory notes</a></td>
<td class="num">(46,622,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 70,229,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693397311328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Values Of Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance, beginning</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="nump">31,973<span></span>
</td>
<td class="nump">$ 31,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21,750<span></span>
</td>
<td class="num">$ (413,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance, ending</a></td>
<td class="nump">$ 60,973<span></span>
</td>
<td class="nump">$ 60,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693379612896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 04, 2023</div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,973<span></span>
</td>
<td class="nump">$ 31,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21,750<span></span>
</td>
<td class="num">$ (413,250)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sale of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PercentageOfProbabilityOfLiquidityEvent', window );">Percentage of probability of liquidity event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RangeInYears', window );">Range in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Risk-free interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Risk-free interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.03<span></span>
</td>
<td class="nump">4.03<span></span>
</td>
<td class="nump">4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PercentageOfProbabilityOfLiquidityEvent', window );">Percentage of probability of liquidity event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RangeInYears', window );">Range in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Risk-free interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Risk-free interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.03<span></span>
</td>
<td class="nump">5.03<span></span>
</td>
<td class="nump">5.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PercentageOfProbabilityOfLiquidityEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of probability of liquidity event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PercentageOfProbabilityOfLiquidityEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RangeInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range in years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RangeInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693392786032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 14, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 229,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Due from Sponsor</a></td>
<td class="nump">158,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(96,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(1,269,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable', window );">Notes payable</a></td>
<td class="num">(1,651,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities', window );">Derivative warrant liabilities</a></td>
<td class="num">(29,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities acquired</a></td>
<td class="num">(2,654,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PlusMergerTransactionCostsLimitedToCashAcquired', window );">Plus: Merger transaction costs limited to cash acquired</a></td>
<td class="num">(229,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts', window );">Total net liabilities acquired plus transaction costs</a></td>
<td class="num">$ (2,883,981)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities derivative warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PlusMergerTransactionCostsLimitedToCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plus merger transaction costs limited to cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PlusMergerTransactionCostsLimitedToCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total net liabilities acquired plus transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693393741072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 7,728,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 229,328<span></span>
</td>
<td class="nump">$ 7,499,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TransactionCost', window );">Charged expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,499,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember', window );">Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693390823040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNOUT SHARES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">24,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">17.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EarnoutSharesTradingDaysDescription', window );">Earnout shares trading days description</a></td>
<td class="text">over
any twenty trading days within any thirty consecutive day trading period during the three-year period after the
Closing.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorsMember', window );">Sponsors [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorsMember', window );">Sponsors [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorsMember', window );">Sponsors [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorsMember', window );">Sponsors [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EarnoutSharesTradingDaysDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout shares trading days description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EarnoutSharesTradingDaysDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_SponsorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_SponsorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693397311328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AccruedProfessionalServiceFeesCurrent', window );">Professional services</a></td>
<td class="nump">$ 1,337,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">227,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,564,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember', window );">Reverse Recapitalization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_AccruedProfessionalServiceFeesCurrent', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 976,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,096,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_AccruedProfessionalServiceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued professional service fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_AccruedProfessionalServiceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=TVGN_ReverseRecapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=TVGN_ReverseRecapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391741664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WorkingCapital', window );">[custom:WorkingCapital-0]</a></td>
<td class="nump">$ 1,651,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693386291952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service Based Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested Shares, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Nonvested Shares, Granted</a></td>
<td class="nump">19,348,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Granted | $ / shares</a></td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Nonvested Shares, Vested</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Nonvested Shares, Vested</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested Shares, Ending</a></td>
<td class="nump">19,348,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending | $ / shares</a></td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance Based R S Us [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">10,900,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Beginning | $ / shares</a></td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Nonvested Shares, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Nonvested Shares, Vested</a></td>
<td class="nump">7,148,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Vested | $ / shares</a></td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Nonvested Shares, Vested</a></td>
<td class="num">(7,148,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested Shares, Ending</a></td>
<td class="nump">3,751,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending | $ / shares</a></td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394335808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 26,333,249<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">19,735,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 6,597,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395221120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost recognized</a></td>
<td class="nump">$ 26,333,249<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance Based R S Us [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted awards shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost recognized</a></td>
<td class="nump">$ 25,233,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 7,104,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 86,164,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average period</a></td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_TwentyTwentyFourPlanMember', window );">Twenty Twenty Four Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted awards shares</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_TwentyTwentyFourPlanMember', window );">Twenty Twenty Four Plan [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross</a></td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 87,263,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted awards shares</a></td>
<td class="nump">20,651,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TVGN_TwentyTwentyFourPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TVGN_TwentyTwentyFourPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TVGN_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TVGN_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693395347872">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SharesToBeIssuedOnSharesIssuable', window );">Shares issuable to Polar</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,148,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture', window );">Issuance of restricted common stock subject to forfeiture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(19,348,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture', window );">Total shares issued and outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">153,913,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued  and Outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares subject to future vesting issuance of restricted common stock subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SharesToBeIssuedOnSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares to be issued on shares issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SharesToBeIssuedOnSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693379608736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantsDescription', window );">Warrants description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days
within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption
to the holders of public warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on preferred stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the
&#8220;Series A Accruing Dividends&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Redemption term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the twenty days immediately prior to the Company&#8217;s call election<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember', window );">Series A One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">The terms of the Series A-1 Preferred
Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum and the Series
A-1 Issuance Price is defined as $10,000 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A preferred stock, shares</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A preferred stock</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance', window );">Non refundable amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Series B Dividend Rate is initially 3.25% per quarter, increases by 0.25% on each 30-day anniversary of the Initial Dividend Date
(Defined below), and capped at 7.5% per quarter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities', window );">Conversion of certain liabilities into Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities', window );">Conversion of certain liabilities into Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable prepaid proceeds towards anticipated preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentRateVariable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis of dividend, such as adjustable rate. Excludes percentage rate dividend payments or fixed dollar amounts per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentRateVariable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_SemperParatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_SemperParatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693394014000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor advisory services fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WorkingCapitalExpenses', window );">Working capital expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance Based R S Us [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Isssued shares to related party</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance Based R S Us [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Isssued shares to related party</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=TVGN_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Due to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember', window );">Sponsor Advisory Services Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor advisory services fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Isssued shares to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WorkingCapitalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WorkingCapitalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SponsorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SponsorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693387599152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET LOSS PER SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 11,264,842<span></span>
</td>
<td class="num">$ (30,756,144)<span></span>
</td>
<td class="num">$ (67,325)<span></span>
</td>
<td class="nump">$ 4,408,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Undistributed earnings allocated to participating securities</a></td>
<td class="num">(756,606)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="nump">10,506,866<span></span>
</td>
<td class="num">(30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConvertiblePromissoryNoteInterest', window );">Less: Convertible promissory note interest</a></td>
<td class="nump">155,786<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ConvertiblePromissoryNoteChangeInFairValue', window );">Less: Convertible promissory note change in fair value</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (37,049,420)<span></span>
</td>
<td class="num">$ (30,756,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">137,333,802<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">137,333,802<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of potentially dilutive convertible promissory notes</a></td>
<td class="nump">5,053,849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Total potentially dilutive securities</a></td>
<td class="nump">5,053,849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="nump">142,387,651<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConvertiblePromissoryNoteChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note interest change in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConvertiblePromissoryNoteChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ConvertiblePromissoryNoteInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ConvertiblePromissoryNoteInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693392048288">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65,575,576<span></span>
</td>
<td class="nump">13,301,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,751,622<span></span>
</td>
<td class="nump">10,355,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">725,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,946,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of March 31, 2024, there were an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8" title="Stock option vested">7,148,506</span>
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140693391942128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Stock option vested</a></td>
<td class="nump">7,148,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<"5Z_76>+L>9^LUOZ!1]O4O0ZU>_G9]5JM@Z\]EH7<2'51%D1Q'7:?$&43Q
M)"#,DGT(9T_D:).=6K(G^V<G9O8SQ=6&,+(AC#1X=!=ARZ*0\PJE9:DX>FNC
M8P7 [ #U0'Y;+M*1?'^B1FHIBT=Y<O'K+S@,WMG(\0F6> (SB*,;XBB$?C%,
MRXF-K54NWN2J9ZG'"TQQ% ?!^=GC-A'==$)0;B9*+& DQB+<)#,>G6T>G8&/
M_KF0BS0;(_E#3;>E+%$Z'Z.\FLABW0UL]5I!AEN/$A.J.F&K6MUDA >X5:UN
M(LPXC@)[M?BF6ARLUI>\2J=JDMGNT+::\.XCTCB.2>LIA]UTE'-!PU9E+' 1
MHWQ'&X6;RH0];:36PJ+ZV;2-_&.9+=3J5 W07%:V.H6=AV!8!''<JA)8INOH
M\P1FT!-MZ(E >IH%_31_.%V6<MW4:DZO*4NK;/X-3:5:/*VM'UF8(ABW&Q\L
MWI4I3V &4V+#E "92N2#5"-BC*HBG9?I2IZ,\M(^-D L^Y,BVS1_ ,YN^CR!
M&?3%&_IBD+Y//=-BW)W**"51:Y(8@H6X\N$)S. #!UIA!;T+7S,K*6']75;I
M_52B4JII-ZLRM99,Y'2,LCGZ4BBUARY'HWPYMTY9<#&NNF*-9C1$& K,XJ@U
M7UM2JME:A"P(=BQ >$M]XCV6H-V]99W=*)N&E 6MAQQ:$JKUD4:4TG9U+) \
MPE3L7(*PUH9X/W$XS=+[;-JTKU4A8J\2T2M:X@O-I%"K1 S+Q/4 *-$B_=D,
ME7KDI*-1L91:@%DY!7&=.:7=_H0984%;<5H2$APPSG;T):TY,2PZVT18Z]P5
MAERMS:*C8^"RG+N()S23&2U;,:Q;+UN]84N.;PT\*U]=[8EYR 1E;;[ )W#F
MRQ.:R9=6QAB6QI],E==+4E<;DS!00K[-D5=Q[ O-Y$C+8PSKXYN\DO!0Z^I@
M''(<='PJ7) S+<>0PEAK80R+X6$^?U2N*JLGXD61S[*RS(N?:%ZS967)EQY>
M YET4QR1SOS[\A)-;K30Q;#2398253DJY+39/%NDRGU:.?&I98>X*Z )#3K=
M,+&DPRS8*=F(EK,$EK/FKD'/7$*ZVE'$2FKAMMZW)%2U8IBVZV5+R'>OMT1+
M40)+T406V6-:[T*CI[10WJ^_<B"@\T9?5Y>2N-NNEF1J4.QJU:U=35#6.0]T
M&,YAH!\"!&QP'D.\$BU>"2Q>'5=:8A&981@)T1X</J5MX@O-Y$CK6@+KV@/&
M65?EAD$<M?4(7*XS2\?0N$1K7 )KW,TNU'(^EL53O5>@>M6#E)!&@3&=)R2+
M6&918%EK]DEI\J"U*X&UZVJUZ>L@7<4:JX$41.U= DM"'$646I892TH>\"@*
M=BTT6FH26&H./UU??_QR?77SY0Y=WB1H^.GFR\>;OU[=##]>W:'7M1)%H?6<
M#09V;M\#T&Q3>.+KL4P^M48E MQTN;U*KJZN+S_\[0I]NDT^WES>_A/=_7YY
M>W5GY=#G3NO0*UKB"\TD4@M: @O:X30M2W2)\F*<S5.U^I>35)6#RN7]?^2H
MJL7N(B_+1B.HJ4G.%O7>^ "]"MZHD8YK!8P>T^E2#A >\( ,L @:;TZ9^AH,
M5*)GR+3:0EAE0OD#>H7Q&[S*\PH';RA#:D%=Y4%I6:=(Y$C.[M4/GT^$F\3U
MV>Y (98+V<013*U"'*Z^<]-;!+9] ]62LF<#E6HU3@.P\]]5^>C[))^J1:+\
M]1=!</2N#GO(1IEU#YEZW4/VBI;X0C.9U/J?POK_<_&\Y#:<6MGS*O@/0;/.
MOQZ 3,ZT:Z!]KF$V4^.WK FSS /OD%@->V/H+ZM)7F1_RO$[A$,V"#$;,"R:
M<8QQ/(AC]:^(GY,K(U+O]35;?,NJK-2'6@FI">0Z+4:336!)DZ(S.UA;D5@&
M+@O;!_-PU9T[]U%"+[9B+WJ"+^Q3^SM;FY&>-J,#1NF TM74BP>,&VEW--AK
M^6,T738?^Q8'>+WY#5P)VC_=8UF J7,>U19/1UG[$,J6BO$=BX&V5A2V5JM6
M_K!G*T.-'*R'HQJ)JZ;N&8TO7IOAFCDWP@%H]JG5$GF#8[&CH;2[H[TG&,O9
M<K5O"*W675]U*@2-B8AY>[:R),41C41(VW+$FI1%@H4QWE$Q;=<H;-<NQ^.L
M'J3*L]414Z?9'(W21:8\G+5^79,5A;CV;6UO#Q?K/!D?XZR!:@-(80.X\K2E
MHW+KGC^<<A&0,.H$REE2UETA(C%K=P5;4M45*&6[^KBV910^.N@X]V8V<*UU
M]QC ?OYO2;CC_-\&"9__4^V@*.R@[F115_02M<0D^M=U,S/^VUI'K[;$*UKB
M"\T,N]3NAGEU-\RKN_&*EOA",YG4[H:]V-TPRP%$I-1XW)Y@X**<B?&$9A*C
M+0R#+<QZR'YP&K(PIG-'\^HT?*&9?&JGP:C7(>M5?'M%2WRAF4QN!9WW1IWW
M#MFN/*4AIMV@!+@H9V*.<3;"M'IFL'J^E8^J<TET*]?:,OLS;?81P2'K]6S$
M*UKB"\WD4XMV%H)#=H\K+<RG_AYZ14M\H9GL:37/>HYS=MQK@;,Y4V8)/PHX
MH9W-9E_%FFQHU<]@U7_851FO9S*L*_"52>*"M)DZQFD+TUZ!P5YAW]LW,(PS
M.993BXB0.(K;[!Q#^7.M_#D<9>1XG0=&<R6)=V.,&!<A;U_+\E6JR9'6]!S6
M](??Z8&!G>GJ&@<6QJ*]HY[X*M6D2RM]#BM]MXL],)@S1=TS!Z)F)-'>O$E\
M%6MRI-4[[PE@ZIFIX>S.K%ABYR.,66><'4.(<RW$.2S$^RZIP-F=2>EJ>LX#
M]4][(\M7L28K6Y='^5ZJL>^N"_<JO+VB);[03 JU\.8]N^5[7/& (9SIZ^ZX
M4X8%C42[<QU#5',MJCDLJ@^_X@$#._-ED]UQR'AGWCZ&[.9:=G-8=CL&GL)H
MSB1U!3?A:B)OGS;X*M7D2 MN#@ONWBL><'YG5@Y LYY!^GHL\UJ]5N)AS_55
MQ\AP&,Z5Q=!R@2"(,.D&H?HJUZ1)B_%PGYNL>UZ+@+&<.>KJ;\%9%'/65N"^
MRC4YT@H\]'O) (9SILD2]\,(L<0S^RK7I$F+\-#K+0(8S9DEBR:G3/"V0/!5
MJLF1UN0AK,G=;Q' @,XT^8HP\?58)H]:Q8?[O .FCSJO$C[LQI_$<4P9ZX[#
M8\CS<.N-,O"^N.-15NA5J7M%2WRAF4QJ.1_V[)'_/\:)PG5R;D^+D["IF&/X
MB%#[B!#V$7L&IL$HSM1T_<-I'(<\BCJQ:[X*-NG1%B*$+81;>!L,YLQ2=^>>
M$QP*UNE"Q_ +D?8+T3[W@QWCO**NS-\1W69+&3-&A.@<A=F24AISK)[&'ND5
M:;D?[2/W7QC=!I?AVD&BK@VP;QSZ*M:D3KN "'8!O<?WZ+_HH$ ZN%QG.KU&
MY?A",SG7EB+R&I43>;447M$27V@FD]IX1"^.RH$1G-GSY31\/99)G'8:T0NC
M=O2P=PO&@\MUIMOK 8,O-)-S[6 BKPXF\NI@O*(EOM!,)K=>GPD[F'V&O5>_
M< B:?=@?PU%$VE%$L*.X7;\>YW/]>AQX''LU%5[1$E]H)HG:=T3Q7F>M0(1>
MY-5L>$5+?*&9[W/5CD3 CJ1^4=-#D<_Z7]4D+"_%Y$+@]NOT+.DH8[SCYN$'
M<[^9*[0_$=C+Z;SP:D&\HB6^T$P*M4\1/?%">[[?:PVS_=)QPKNG"D.X.&=R
MCF$HA#84 CZCL$_K2L(=%)P-%^;<"[WZ#5]H)M':;PCVTJE?>/4;7M$27V@F
M>]ITB)[7*.T_]7MU$8>@6=6;K\<R^=,&0NQW-:!W&?'J'+RB);[03 JU<Q"P
M<]A[&?%J'PY!LW= K_;A;.LOU=1_5^@Z+;YE\Q)-Y8."#][4?KE8_:F>U9<J
M7S1_O.8^KZI\UGR<R%3YV3J!^OU#GE?/7^J_A[/Y@TD7_P-02P,$%     @
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MG/X#01OD/.;T# MVLN,"<[==#?2X!#T>!)H*<6@'/&X N81JLJB!G)0@)X-
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M&/-\9RB_D"S--E=>F)0LSDY#( %P;:">[QB3;Q=ZOZ;<GUO_"U!+ P04
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M?TY>+';:H5'!6R:;[/"_]'+:=MB3ED]9GFQ/C;F";;P[?HU^/W7$FP::WM!
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M^CJ R@H!LLJ#\1+6E%NE-9L^T:4')9%GY(.26M\$9>1,JF33)[[(/-T<2EM
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MUPIXA2?UFI]SA979JLE7)[OEZJ?.*]%Y\,IY^XIW_@'* 908*#Q3AF-FVMD
M(<J,H 783X=-*6ZY#=UFY[/+!D:FI\/7H^'KV=E9'&J3H8M<S$24XILB4]F6
M]]$>+O*J+)PC^:*M5% C%'>9X9SB'*H"P$E4E,9:0U"W!7M9ZTSH'?!*J3C
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M+<#WBP)QQ7V@#9H?>+[['U!+ P04    " "IB=58_PHY. P<  !&50  &
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MO,[3)$ZT^?F@A/MPUT%LSS[EL_M;SA[(BSPK%T:>9W,];]E_]O+^7O^% PX
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MRN[U/)+Z*=8K((8!F%/P!^:=/%4F,0CL-5(^ PS16",ED60$.Q*MRE0U3TJ
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MC9U59+^57LXP7I%AY%H24RNUP,$QV^P! Q4KVR)J1%3"L=DW1#;5D$HR+8-
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MT='FWN[ M]OP8%7I?L&;*LS]N?N8"H1'TP)\/U/*A@?:H/E)]_@_4$L#!!0
M   ( *F)U5CGY#*[E!$  ,@S   9    >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;*U;66_;2!)^YZ]H>#(#!V!D'3YS ;*M3(1U;".2,P^+?6B1+:DG%*EA
MDW8\OWZ_JNZF2%WC701(;(ED5]?YU='T^Z<L_V[F2A7BQR))S8>#>5$LWQX=
MF6BN%M*TLJ5*<6>:Y0M9X&L^.S++7,F8%RV2HVZ[?7JTD#H]^/B>K]WG']]G
M99'H5-WGPI2+A<R?+U62/7TXZ!SX"U_U;%[0A:./[Y=RID:J>%C>Y_AV5%&)
M]4*E1F>IR-7TPT&_\_;JF)[G![YI]61JGP5),LFR[_1E&'\X:!-#*E%1010D
M?CVJ*Y4D1 AL_.5H'E1;TL+Z9T_]$\L.62;2J*LL^4/'Q?S#P?F!B-54EDGQ
M-7OZK)P\)T0ORA+#/\63?;;;/1!1:8ILX1:#@X5.[6_YP^FAMN"\O6-!URWH
MOG1!SRWHL:"6,Q;K6A;RX_L\>Q(Y/0UJ](%UPZLAC4[)BJ,BQUV-=<7'T5SF
M:IXEL<K-;[^<=SMG[\2UFNI(%^^/"FQ CQU%CMBE)=;=0:PGOF1I,3=BD,8J
MWK+^:O_Z3G</@2-(5HG7]>)==O=2_"+SENAU0M%M=X^W,;1_^;6*JN6]/>ST
M*FWWF%YO![W!7Z4NGL6_^Q-3Y/#@_VS3L25QO)T$1?5;LY21^G" L#4J?U0'
M'W_[I7/:?K=-OI]$K"'M<27M\3[J_ZMO[26VG=7;N_$@N&B)T?CNZE^?[VZN
M!U]'U4Z#3\.KX5A<98L%\&)49-%WT3<BFXI/:I*7P"S1.;&>$8IBKNC)I4R?
M'0$31':EX94RC<63S'.9%D9,U$RF B:,=3H3>&:,Y;?2Q/(OMQ$<[SLP^.;F
M2I3PY9PW,,^+">)5T [=]KOQM]]O^6/G'9.O7?[#70\#R+I4C'7)<\OQ#^+1
MO'+K!O-B+F/1.3T.3SO'X7'G7#!0"VV$!.A&61KI1$M&4! R9"$FV9!5&U.J
MF'D"\)L"'R#G6S&Z^CRX?K@9!'>?Q-?!U=WMU?!FV!\/[VX%KHP^][\.1O3I
MZN[+%UQCJXCA:/0PN!;]VVMQ]S >C?%A>/M[4,D0D S!."MDLHN?!.I.DN<=
M?-7%#>Z3TH!12Z?(8"FWZFW@+M)7.4D4W;W/$IF+0_E:=,*3=CMLM]O!-V4*
M;'*O<LZ1::3>7")/Q.+KZ,&(:9XMA($"S51&7HV)1ES'%-E0,'[3Y7*)'VR8
M)#/$Y>'DM3@+.\?GV.DTN%%FQ:<I)W_"QL31M"S*7(E',$$J#X;$+7B@;?!H
MD>N(N&NHI[X\RZ=*$XG@,'HM#CL780\[7IP<B]=-'>_2Y4DOO.C@_UD[(+WL
M5)KU:DF;FRC72YN49[E2R/&%D-;A#+(IL4Z*^*+RF0(<CQ1B)2N4."-VA8RM
MQL":3FU9@F^M@/2UT]VAHB?ZL<-*Q5P6% G!HS7FTUQ98VRSE%PN$QUYZ4R)
MO20B/3:(=^-LK4%DPZ*3DC<1:5; S["#]U.CBB+!"IV"H#55P*:J"7^^7W@8
M[SIO!2,)B$%)D"1"EJ@%<#OB+9RA!;[ %$[,KRL'L2@T([C"MV69DQNQBY $
M(T"*QIY0ENB3K-B=;ZA',AX^Q&HI\X(TJ0('+2]D7C@M;>S1$O>YSO+ \6#=
M(11C]9C-H+Q+G;$VZ]ZXPH/'C.*!W37-TC?N:ST,6N)AS4 -VEM1W24G0D8%
MA(UK&VY)"&L@"<_!OT560F.Q*E2.\@PD)L_>HSP\$*G!CV@NTYD27^ER&,"S
M8FU0X!GV$ZO63DN,!]_N?A_<!I?#.T$)#5 Y$L/;JY:@7#<*QG=B_'D@'F[[
M#]?#,7 5*#RZNQE>]^G+I^%M'Z#<OP'VXL*7P>UX!*VKJ<KSRBG&*Y-R7BB+
M>9;KOW$?EF%80)P1%-)_T6[A9P>FS[4R07^#VE"D#LLW<U&--!G.04Z7Z0)N
MG;:;.2XDC=G=Q.9NAT3>Y4G_D$N5KXE]6$1S-)![(CK$$O' X/E*'/.^2Y4'
MO.]66N(NUS--'CUD1=S3<K]!R%X_RS-C0#>+E(J-)=UMM5&<)PG%KCB[N @O
M+B!A>(K][*[7^E''*L7SGZW+!74IB1O$G6;0@!3.'>$A?I6,HKPDCX^E1O03
M:J$[6)2))*U1(P-++N4SHQ@+/M4_0"R7!4M_PH&\5\H0**EA1EZR!7%T&J%-
M-(H<O/LK(04*J&<E<XNV'/*>?JZH@32-6"9U!^OJ[GNY*@55UKQAJ+9!-*XS
M#TS[#EQ6*<!$5 !;*]/<DY<O\9[+:C\$85+;<DE8A431$D,&E<!"(W0I&\\U
MH0+>FXM(Y07$!R@@%\:-IYF("9O:T@1 ]#!;CY'5^FV@_BIA) >8R*TP3>YW
MW&M,L40=Q,EACZJMX<CYRG0I-5QOGF?E;,[B$D<+F]7!NV+!;&ZTB,=KG[(R
MB8':Y(*4 +T'$HXW>$2VA;\4/B=6,-NLL?4"^D)U"A@ /2A"U9*V4W>^4ZTM
M\<UFA8:WQ!E^489F+@F57.[(J<$W+23-2E!:Z%/">GP2B6:,$A_$G\XK>>#N
M4*VWT&XW(3'H:Q9%)?P3U4O CK5;M'%M,?QE*R<PR(KE%?@UG&C#:X)-K\$6
M^[R&L8@2'<J?RG%0C&5I*+05\]L?_?L7)5'U@U$T>"5.D&?X^>()PCW#Z9Y-
MPR$X(+T8&T3)U:O9T!5[F]EG4O8&-H$U/>,(^^A:;#;<=0UK2,<YF<GJ.-BE
MXT9D6E#G.J'Q<(WI!A[#VCI%G<4@C"Q&>O+9^$UG ^/NJG1\MJT]A&Y5[L,0
MV;*/:CUV^9G*1\G%HX);8DOP=5^"%J%^ORKMGW0Q7U>22[E1!A'(6PA!=*UU
MH4QX6M44Y,Q4+YEU+*O+$UAY*/;(\3@-K7MQR ZT+%8IJ)84:]D3-"(4921G
M@1;G5ZH"('):+ECP%4E6:=5S68/! +&:<FV'JNV5Z%@ANDX8MW SVPQ3H%N:
M.I^LM%85I_O,LFJDJIILY815?JNJ^2PUT+ZFN2IZOY1S""=\=T>"PH+L@MY_
MHA-K6F[])HF>,= 8<>@R8Y\>!B\WJV>K),F[+TA[]Q*>7UHJM3*[!0=T#5OG
MQ/;VH>BA/>_9GZPR8JW.";=R#+ _")I+;>;.)5=K]E50ESLKJ.WNT(CQRXHT
MU>95V%F4$XAKI*W<UERTRI9:A-9![[3]!C!EBR#BUJU!MTF 2"!/0L4J0L.\
MBGAO<Y20%@FL\UI;0@-L=7S<8@>6LU94H8\ (2_9H7EM"[<)D)Q@>6U#2#!1
M<YE,J[!S[N'V1GV'ABX#4DYU;FS2";9KJ8E*O5;7Q9135UA5BX:8:/-]2F:2
M&GFK-82?)L"C.9SC9V@IKK:ZQE;!X;6+O@F-LE"%DZI7X7S6:N[=$AUVF+7Z
M<7=5^(_UY)^EOU5#O+W%HO#%8K"_6&RXX<XRL)G!Y0S8,",;N$JLJC8J-PFD
M<QV?8YR=IUD"#3I\7@&1=?@G"VX6H']^%[I9FUW^A-KL\N?79NNU5K"=<HV#
M_:7693W[M]9KDYU>&6<L%C((]Q+$2[1:ZA7TAY](T^PC:%BU<Q9>G)VP.?&Q
M>V*SU5G77KHO@?Q14*TG7I9\;37E=E8!)JD\TJ@!:LUTI],Z:5N@#_P4O3%9
M6"#$:]I:IZU?4AR2-@W!J"L3Q:O.><OV\-:L'"7==C6)IZ(QH$Q+&B.@J=V@
M53J+X2A^:,_5YESGL6@\5J\S8^Z?4Q<B=3 UKH-B[]-^0.O=U9>"-8]=TT"K
M;A7XQB-!W7TB(YOV*\,, )G!TMY'?>[O.S*,P^O5T=I.FT723G)XUF0BR6C2
MQL(]<WS-54)8$M2QA.H-L+>DL5=!12-TF!JXL%*@<JA=*K*ST3JPK24E MA#
MC<?)82:J<K8*O"H5\LQ#FGFBC DX#>\Y#P'7Q+EW]VIRV7O!Y'+]',CK&NF=
M )<<99E!PX"*;4=N_\\Y%E@+SG@TT>F^$WL.SA#? /> >@MX+.5.-Z%_T51O
M8ZR'XNJXUPM[O1Z0_]AY(YV%=,/.>5OTCOVQR$M2PE;<OQY<#;Y<#KX&_AC5
M27#Y_TFP+D"6*@&..^'%N16CFC%G9>Y+%'%9 A/A-F3:"38E:X=8B]JE%J&T
M@ID#'&>>.9<^V)FKII'AE]AZS"P^<&)>+C/4[PLW)HHUBE"JIEK!YVU[]+?O
MX0*FGG3JFU0];GT'$9?<=?%\IM +Q76(=_+00IJ')$#L,E&>!@],]RFIIA^)
M&/V3ZYQ_TI8%_T5&^4,LU&)2C:V"24;'#0WN.2)36B$-#5#A")QL4!X;[DS<
M;E] $8$8NZZMGP/U$ML2H5;.(G>N29NS:2=4(MGVEH;RPK@3"7"8)27#]%(:
M!S6D=T(60LE47+1_];LV9;,_O5*>YNC6@'ZI[5;84,!86H9^2.78;*$4(092
M-36 ;M)M1]5@DY J6! )FJY-/)3BKK.ZY:&^*=?621G;XY!G^QSRW7JO^<_^
M[]*"I+H3U1#UW%!$(I_"ET8%";WUT1W.S;P6Z!6Y/^(S0BI6D!4B6A8RYP%W
M"5;;-@Q\Q6JW(O50V!,QVZ/L#=KF%-L/>;C1WL6K2Y,42;XXW*=)3DT!6'H#
M3WY#K'%V"NL'LS+^LS2,#56/$-%8Q8Y@5^EH!TL\?E7\]L@;J.,['5550YK0
M#DGX="58#4C=<8M.V="F&K;8MH&^3MW,P39?]W=LSUPETCDA<^D..U^@!]O/
M\$ LH.$PUTR[;(-?,,Z+S.%[6JM#L'98IBY4U6Y\(K"IGS_L]&$:M9"T3Y+&
M!';&75G+QM):V/(SJ_%60^-TZ3554;[:"M+2X]\N :O3=3YBKI7Y)%22[$]*
M7"6'WHI5=QBR5^*?>5,-WP/GE]T3UV[PY/GEZ;=39=\TV]I!V&NKXM59#BFG
M*NQ83I?,$G^>0>5BK\U1S<.4*5F"/AEQ1RS2P[67;];I-6=I:YW'&D]O@]]^
MN3@]NW@'C07 ;SHO2^T9OJ8#C+QX5STABZ!Q@HB:HU/=)%L%S:S1^XEETHK-
M*4UY8IO2\,4&F5IF?)P"SRB$D4FM.;-=X'9/V])2"=M3H8OJM5T[-)P&=842
M<IIMNN3,O6IZ0J@^E3,_):X73*LINTLU[-<^=NU9DC9S>J#J-HLM#H7[:(Q-
M9KL!-[#T38&#W>J5*IK;TKLIDQ7(5:6\GZ_:!.+ZK]4^6Z?.Z\SP*S#)L\].
M#ZEF[^1*#)+5@'6S!=O<,8V#?99K8H0=%3I%.9MOD*S7D[X[L^&"+?0LM:&8
MD_M8RA W">2T<*^KK56*.S"_EN3\P6>B4<A Z59H*N'0J54Y+G&#K^W\3AJ1
M'9"'D7V)ST8'Z'.LTZ=UI6J.D#F'I,"9*'YEI-:"[NEQ&TENZ0X_:-B<NW'2
MUH87.7V'#>JD#6"+((ZK/HL8VW<3^W<+@[WJV]]KUV%XXE)9K<6FQPVJ9C?G
MEEOCW@;-VEB(4?3EJ2Y+-QRX0G@W"JCR/56WSK4BG4?E@I)Z1-1\)1SHYMR5
M"DLN(/ULG"(0*JSXJII/_P [6$EP%LFE+F2B_W8.GJLLG\FT^K[@%Y?XH)]&
M(8D;([;$Y^R)WHH(F^FJ'H651.36OEHP^_15&R[R^-OYQ>J-F;7IW'JDD6*0
MK*U>F)6Z0["WV-*?XC=5A0TV^P);PRB5B]=JA#+U;\TYJ% [4,+/Y-SZJG"^
MMR,Y?P;G2?OAK++>-RUIU,91Y&B,<ZB1SJ:IDFUT*YMJ]T=!($Q'1NSPEN)Z
M:6=5NQJ%I3"25]ESG0Z]NE4@KW /:5\)W3;,I-ZR<(ROQL_!A@"KL\$:,\SG
M2OGT*+G&S*-G(UC4CR7EU"?4! R.U&,$J_Y?KUL.Q9QY0=>QK^D0%IDY5%#S
M:VX2 &'+S'!@UOK1H)*OUDQL=Q3V]]25FZZB 0_H5*RS-VY,:Z77*W'10@ES
MRH4,?^QT3L2VE]B/:G\LP:%,?T-"DV=8PO[=1'6U^C.5/O]UQM'J<?LW+E]D
M/J/7G!(UQ=)VZ^SDP(Z&_)<B6_*?7DRR DTH?YPK"5^E!W!_FJ&'=5]H@^J/
M=S[^%U!+ P04    " "IB=58:@&VVU0"   O!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6REE-UNXC 0A>]YBE$J]:HB(= 6M1")G[1%@E"5;'MM
MDH%83>RL;4K[]K6=D&4EBE;:F\1CS_E\QLEXL.?B76:("CZ+G,FADRE5WKFN
M3#(LB&SS$IE>V7!1$*5#L75E*9"D5E3DKN]Y-VY!*'."@9U[%L& [U1.&3X+
MD+NB(.)KC#G?#YV.<YAXH=M,F0DW&)1DBRM4O\IGH2.WH:2T0"8I9R!P,W1&
MG;MQS^3;A%>*>WDT!E/)FO-W$\S2H>,90YACH@R!Z-<'3C#/#4C;^%TSG69+
M(SP>'^@/MG9=RYI(G/#\C:8J&SI]!U+<D%VN7OC^">MZK@TOX;FT3]A7N;[G
M0+*3BA>U6#LH**O>Y+,^AR-!_R>!7PM\Z[O:R+J<$D6"@>![$"9;T\S EFK5
MVAQEYJ.LE-"K5.M4\$:$($S!G)(US:FB* >NTF"S["8U9%Q!_!\@'1\6G*E,
M0LA23/\&N-I18\L_V!K[9XE33-K0[5R![_G=,[QN4V;7\KK_5V8%Z9V&F/ZX
MDR5)<.CH!I H/M )+B\Z-][]&8N]QF+O'/U?+9Z%G+88<86M/EQ>]/V.?P\G
M-H(XP]:$%R5A7[I1$KYC2H)N>5 9PJU_?>5Y'L3AZ_(QC%KCV1*>EO/I+'I<
MP2R:M"%:QN&J%2_A81:-HLEL-(=5/(K#11C%*YB&DW Q#E]:AP\*IX[+/?J)
M"Q1;VZH2K)?J?VYFF]M@5#7!G_3J*ED0L:5,0HX;+?7:M]<.B*H]JT#QTK;$
MFBO=8':8Z1L-A4G0ZQNNCZP.S ;-'1E\ U!+ P04    " "IB=58!S; 1 H(
M  "W%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RU6%MSV[82?N>O
MP*@]G7A&H6Z^)([M&=E66LW$EUI..IU.'R 2$G%,$C( 6E9^?;\%2(JR)>><
MA[Z(%+'WW6]WR9.ET@\F$<*RYRS-S6DKL79QW.F8*!$9-Z%:B!PG,Z4S;O%7
MSSMFH06/'5.6=OK=[F$GXS)OG9VX9[?Z[$05-I6YN-7,%%G&]>I<I&IYVNJU
MJ@=W<IY8>M Y.UGPN9@(^W5QJ_&O4TN)929R(U7.M)B=MH:]X_-]HG<$WZ18
MFL8](T^F2CW0GW%\VNJ202(5D24)')<G<2'2E 3!C,=29JM628S-^TKZ9^<[
M?)ER(RY4^H>,;7+:^M!BL9CQ(K5W:OF;*/TY('F12HW[94M/.]AOL:@P5F4E
M,RS(9.ZO_+F,0X/A0W<'0[]DZ#N[O2)GY26W_.Q$JR731 UI=.-<==PP3N:4
ME(G5.)7@LV>?N=3L&T\+P:X$-X46B+@U)QT+X432B4I!YUY0?X>@7I]=J=PF
MAHWR6,2; CJPJC:M7YEVWG]3XJ6(0C;HM5F_VQ^\(6]0NSIP\@8_=O52FBA5
MY*UA?PVGQFI4Q]_;G/8B][>+),0<FP6/Q&D+D#!"/XG6V2\_]0Z[G]XP>+\V
M>/\MZ?]/;MX4M-W,:V5%\)']\M.'?J__B>U0QNX3$<SH[,F=J1FSB6 7*EOP
M?.68CSX9-I,YSR/)4\:-$6#C><Q2R:<RE58BRL : =&@=G. G637S,)8"7PY
MX3Q3!:FU";=-30!WD<9!PI\$9$4"4(Z9S%FD\KP$^%+:Q+$8GM:&EN8HS19<
M[N1 _G,S$[KB:EH.%IY#0"QTNO*4W+$'4V&70N1P23^@?2ZXMC*2L);\]]9G
MZU"R&"Z&;/S: D\D\[ECV0RV)%E;0]INAB<P0CP@:HIZ@\SD=^%."^.$J"GE
MG$\1%IDO"LAZ5]H,FSB.+;HWXCG3*@-%+-#R8S+9J$)'PNPYW21<YJ^$%_E:
M?%")E[D5.O?E4&0+\A4.3#$56 (0;(N82S!;:!F)'1[OA52-;*92C!(*5R-4
MB12:ZRA9,6D"6.;,C5((DK/5KJ*D=AXSI('<>1TD(F]Z5SUWXF59$Z3'F] H
M-W &#47'P1?Q)-*@=\Q^+P"[.'!N^MIR8ZF,"("$2I44>QFMP81G#6DA&[Y@
M<UPH4D?>I*9H,%Y10=LRD5'2+&(3$&]M^B:SBJ)"^QHUQ6R&5%%1S+1X+$0>
MK5R GE1:9(*BL-#J"::[%%)V9.YW!JISY4&4SQ6=(.[2A&50^L?LYE4!*5A$
M9H')4;%>&?R0C9YYMD@1/-2>/^M7B9%YE!:PX-$%F;T99(-"3KG>'N* /-N4
M\C\DAC15*ES_XEJP7-E2?>7PX)A]W8*9NAB!.2??&-<VUHVL!I(3OAM#!$R8
M4N5A>W)113; B!79%)&NQFR[6<6)2%V=TZ-[C5V$#:.(VC-;"GA6'7-L01D%
M#'U#&4GN.JK0SXX:K=9AR V@W"5K71Z^,VP;+#N06X>W;+ Q-=QFYR2S,"<*
M37TU< 5')*\<=I)QTW<WZ'U(KW4*Q/;V4J:#'GO;R_0U9U5A8>=WWX-B@4Z(
MOBD"4P!Z:YDAFV##C@M4 &0.UWY^:?AYU7"O,:&A]JYRCIV3<Z]36?4:-I'S
M7 *\J)#FO:]&I-1!8PW!S>+T=AT'7\,)\JF=.2LV(>7.PG>]/6#SYWJ-V'(7
M_,&U)N658ZOW[%;+)YKXMRFV$E?F)9%A@UI"=>U_;'>[W8!4#1WL=Y0M@5,+
M6^?((\3Y9&J#-ZK:NJHNZS5P55T6L>OP2!]1[2CO5R'O_S#D/PBVS\B[LN/M
M57?]^FZP]\.$N&P,#@[;'P[W*6S_2D:.VOV#KH/WBY*G:4.O < "UZFB+END
M'B>9BN'!QK1<5AI0W8(#'1HA1CM#42^$EBIN^^$380[,?7]M8!+P5@@M<!:4
MZ306'E1-$^^MVFDV?FVHMLR8O5YG2T,VYV:-7.JH9%.9@WH2C7,,*=+FFJ!S
M._!N5ZW7^TQ]JMF^M4B='8B%>%Y@$\2]24#UWF\_&*G<.C/::X)4SD2;:6D>
MWF, 4X.'=?"):<J:JT])XQ<W*XD2#X/[1D>JG/=]:JV@6C&QRF"#1R$Y.QK#
M"!T1$,%!(O$NJMWP:["7D\BBDWG1M;U8>K%44O,ERU\$NDS)+F_DB]5LL]:_
M"ZW> X(+G#I7\9Z,-YJ*>.XR2<NV7XO(/,(&=N1RY)>P?FTJVVWJ1AY>DK@M
MBQ+LDSH%^6,!.*54'%X;*FX=$;P N#?. L&D&O,JZOQMC4$C_G3>KE:Y1I)Y
M[C<!EV95ZB-L4<2@8_3MYM?1=7 ^OF&_W7RY'%__.F'CZXN07=_<CR;!_0W[
M/+X>7E^,AU_8Y'YX/[H:7=]/V.7H8G1U/KH+ZIE)P.<(KL,:2AI6OD00=:)J
M_3'%]+\('MGT")?1#,& T3<752]%4'9M"VZG-,0(,N";^F=S==!BSJEXU_!L
MP#MKOLF^.?Z/-Z;Q[TUMXX8VQ'/'BW(PM+1130@_U$R!XY]9KQ?V!G3MAH-!
M,'H6.I)FX_B@6UV#>U0">[<27..%ZR#L]_#3ZP;C"H'?UK [)+[_L/UP'Y?@
M#C!BGPE&=U0Y@_#H"(>#\&,/AY=55?WIH-(-N\197K9]I.@T/B9E0L_=)S/#
M7)[\=Z7Z:?U5;N@_1JW)_2>]*Z[G$@TO%3.P=L.C@Q8P[SZ3^3]6+=RGJ:FR
M5F7N-A$<;U5$@/.9PC@M_Y""^EOEV3]02P,$%     @ J8G56)3:+;5'"
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M0+CXD2W>!+OF[U1S&X*M^'*E)&8QVH#UA<7K97-#!W1?.B__"U!+ P04
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MBS*S6$'2@T7'OH")2FQ='$/P&*V3+WH$E!(=F69&"3B":GNHE Z8+YH((+T
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MM*%=B4<[&.JL2*R A,&I( JTJQP ZGG2/,?BBJ6CYYC#R'FAP7+HXMK%[W#
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M#DZ4/H]H:V((2+A/ =V!G:DH= Q:A)]FJJP*'<G=QT42+]QZ$+<$C$"2DAD
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MQ<9QB0[:<28F>0;KB3;WKLB7<$1N K0Z 7'7#0!Y*6(%\!W=4*$?( 5!K^F
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MV?+?V/K5B]*P.SR,#OM]^'<$9P607U!6-:@!W]^.UP"^'IQ$_9,CPFMB8\<
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MUGY%S+"7M DIEUIL155OD+D.7*VTUVKBXZ"-P'[>5!O3M/Y-^SJND0NSOHL
MI\ $P[5?O:?D[AB[CO_BT._:Q[1CC@TO;$@7JMP5A7%UX"HGC$E8N>,U851F
M5XD RG>B3GN=H#98A#9JW_ZKY6&#P5F>O>K_1>#_?;WNI?K<AM>5;_*ZCI5A
MB;,A$B($8+U@B(4." QIT@#.4D6*I:*E;=]UY+_TLY,;+RLV\&O?@I+DJH=-
M]1=;@?!&3K$U19(%]LZ9L:/1W\'@_5UV.R/9ZW:Z<M@9_%V.\#_RW>Q6?GS%
MX1*"ZTD&011X^2^0AN[):Q"UZ0(Y$GHQ#+,J5$G4W%AF$&@G=EM*V["F8VC;
M#/-*"(ZHZ[:Q#KY% GL'J,!GJ/NU>C(8'X.M1C05@67GRO<+H@'ZJ17(6;#?
M D757<>9NFB-00!H*=?? P HQ:BSCI),KE8%NCX3)#@@$.&^19[.R3E5KHR"
M2=O:,5SG;&+AR3M/T@JA>2N!D2RP5K02&9RYLY0;],XJZCN1WVZGO-R@?"17
M:67K1:Y4S1"#S1&VZ1')!"NFSQ'1/*AHNX72H'DAF]1! PH+TF<Q@=!#;VE7
M3S(QKNXKL#?@)+KLH['E3"$>;IK>RLN\0]_N=P^Q #@KJ6C8Z[WG-U0@/*O#
M5&2^-;TVWMF=5K,R7X%P#X^Z^_TNM\_72HG"EA+]X6\L*=:''_=&<G_8W7L7
MHHK9T%D0-4^"7!6A:-RBUB\2P45 JLO\@7N*&.*\2*S!?O<H<O5Q6=?'=V\(
MU/XQ@CE98J[CAEERNXRDW^W\Z'MV1K9-(_V5F1X0'-%G,O??@_?PLSJA\VR;
MLGKCF$I[L_JU 91P.*@>-+GW$RG*3:18/W*;46]O6E(X@Q'&4F.E0;3.IKQY
M\J3NE3E-HA7G3SR_@V8%PV]$/*R?3\_];$A'G@,D*,KB<Y$_DG*P*0JM/L9H
M8/?L2FPYX,K8A<=U%1G0G=KIS5ZWOSO;V^WY29)_0DH!-"X@UJD*>>K:#U/\
MJ%H9#(YP:;_;ZS>@_>?5Z10RMK*>6.(86S]IR%',%K!\E7ZF>5*B[EQ3J< R
M,M./6"FB[FRCNQ5PV#@#)/"#U&<!]46[/ Q"C47L']-;/U>U4.CU QXAIL#%
MQ-B>72UZV-U)%<+)5I2F"0HYS^U!\%8)6,%]MMJ VN,T[N1:/Q+0RP%<N&?[
MSNUD8/?Q':3H"'1;R!K"QI=!./[?+BM8B:3J#D*0KTIT-$Y J J.(1)E=UQ6
ML$UN;BPWX;6X<"#*]ZYP08G$RO:WBP5Z982%"[\6'AO6.9! XA.($1[R>*.&
M1XU+5Z%"MM3;T-S0J=M1<=*+ U^67(]8[%>>MG0WV^B:'38C*NER'EB@80B>
M)J/S>90+S)3@WAGNWA#51F*+5>P7F!41M]0<D6L1$ ^O+61"/*PW+Q2O[D?B
M@J5>JF>>*:&M16+J(:CUU*359K-=SK@<;BG@I,ZJ)T"0T-?;<199_M+73K.Q
MLXKLM]++&<8K,HQ<2V)JI18X.&:;/6"@8F5;1(V(2C@V^X;(IAI22:9E$ B-
M-T\"^6FRM\[]\&PE#A]:!3.M/ @&@_X_AX'H_7?/ O$MJ! ;<W2BQKX#B3BU
MT&O /<I-],#5%#$(;6/"X/=J;COFE-/6AZ DSW0]N9';<5K4MF6.K3*>Z!5A
MI06D  )WL]8TX=8VP)@^VX')[?-+ 6RPNGV::4)J /1)(>U&)Z1 S>"V9^'%
MT3<F?(;KS#/SC\8J8S>1%\&UI:V]8#=+TX(X*>)JB5(:.Y^@G] _S=_*&V\F
M:SZX=BB'&4@Y"H. ?]@U<M!&EBBQKY"QZ5'@$K$)8ELCU)XLF!UVO X5(<$4
M\E[H!Y:/[Q\7.U-F01U@?$'!^(-*2=6:632C8FB -6C1)!#[VUE69]#\# 7.
M9Z.[MU6OH+B)K2X,I<B10. (N!L_!49SH;H&A#VW3YL3]&&0+OA[(;5)B<(W
M!69:-K26XU*L#RD.L'<Z0R[;S Z1<8T/ULR%/0L_:IY'E5SWM8*X9TF:SK-'
M#+0U>,"&T@]("GMW_X?=3?;NIJ RU',C)VVKB@4,$MLOH'XX1FF@CW:VHE!<
MA0C/W_AL+?'(6[J/:_5455+9&GP.8D]%C\+G;ZY.\IGFNLA*\FP5"S2E/RS%
M.M"79CT[E,A%JV0H&DWEZA:8M*"IHHJ,L>#N+5FU -GVXRQ!&TE:\U&!>JB)
M>50/\@5--O%FV(/*D:T4>A-LN]F!G>Z\I?C66F'[>'YV?G%Z_E7X5M&5G6T"
MLV!*JJCG8 7+\'D.U]&ZYGC&[:BWQK@ULO0GX.=LF&$3)0*/2&QDM-;M5_A5
M8(ZLF-?^SFH4Y/W%/FA83L2T?5@_;"_\6 \/%Z;ZGB8D?+P2M8&"$DO!&*$
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M:'7A4G?8%?B#T\#O=KNT-$/%GYF]&4@92C'Q8VY.B'MMN)*DL?=S=Q(2*)W
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MHC&@3$L:(Z"IW:!5.HOA*'YHS]7F7.>Q:#Q6KS-C[I]3%R)U,#6N@V+OTWY
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M\L>YDO!5>@#WIQEZ6/>%-JC^>.?C?P%02P,$%     @ J8G56%.GE2TQ"@
M3AD  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK5EI;^,X$OVN7T%D
M>@?=@.)8DJ_T$<!QTC,9= [$WAXL%ON!EFF;$TG4D%+<^??[BJ1DN]OQ[ (#
M)-%%%NMX]:K(?-PH_6360E3L6YX5YM/)NJK*]V=G)EV+G)N.*D6!+TNE<U[A
M4:_.3*D%7]A)>786=[N#LYS+XN3BHWWWH"\^JKK*9"$>-#-UGG/]<BDRM?ET
M$ITT+Q[E:EW1B[.+CR5?B:FH_ED^:#R=M5(6,A>%D:I@6BP_G8RC]Y,>C;<#
MODJQ,3OWC"R9*_5$#S>+3R==4DAD(JU( L?E64Q$EI$@J/&GEWG2+DD3=^\;
MZ9^M[;!ESHV8J.QWN:C6GTY&)VPAEKS.JD>U^55X>_HD+U69L7_9QHU-,#BM
M3:5R/QD:Y+)P5_[-^V%GPJC[RH383XC_UPF)GY!80YUFUJPK7O&+CUIMF*;1
MD$8WUC=V-JR1!45Q6FE\E9A773Q>?QG/KJ_8P_AQ]B\V>QS?3<>3V<W]W?3C
M607Y-.HL];(NG:SX%5D)NU5%M3;LNEB(Q8'YD^/SH_B(@#,8UEH7-]9=QD<E
MWG+=84D4LK@;]PXI='SZE4C;Z<D1=9+6V8F5E[SF;)'Q2BS8 ]?5"YMI7AAN
MT6S8O\=S4VD\_>>0WYW8WF&QE.CO3<E3\>D$F6R$?A8G%S__% VZ'P[9_#<)
MV_- K_5 [YCT_Q-NQV7=W<^N@ZC;8:\+W??Q1E9K-BUQJS1[J+6I>5&Q2K%J
M+=BMT"NAV7BEA0!+52&]#28J+WGQPF21UEHC=&]8'':[7?H-XKZ]LN8:N6N@
MBH DIK10)A<VY'.>\2(5S&:J834 KNVZ9!63E<B#GW\:Q7'WPU4M2"?ML5(2
M5NRGZ$.'C4V@E@RP3M<MKJVFK5UJ(XQ]T:C^!GJ-PE%TSJ9"!'>J$NR<@?X9
M7RPD.89G,,_5 R)6_%AY0DM(NF32F!IZ>#?Y93IL=OWU_I?KN^#RYI[]>O_E
MZN;NERF[N9MTV+12Z=/I);AU894 Y3O)-T7P&R]J% N;4.&>FGZ9GG>INXS@
MZ>1\< C%1[%Q&,5D>]!GY,PH_L".9.-G90,43-<<L]E]C5OOWY)+BX*^4S <
M^+MN)QG$(Q9%X;#?"P$%O.E&YWUZ<SY*PB1)6!3V$P^5]FX&E,D"@4 8#"VW
M5AF6)K1F&>,$QQ U=OX'ZAX%(9.Y)*W%MU245MN0%<K!F$Q8"ATR;HQ<(90H
MUX*DP+^ #=PM=6,;\[;5124SBW7!=8:05S3T[?@=@"#8"UZR*.[8D+#$8IS=
M%ZR)(XS8B>5!.^@JBU7 H8A3XGL5;$UW$$/./ M='595%A@QR6 <&\,V2"45
MC/OH13=PH@[!6K#K_NTM3+CE+ZP7'D BDE]0JMOEZ .H(ET#SL$..90[]+%9
M2Z3C;A+:L%F#2C^7+;7*[9A[+5>2DJX9_/;;.S:$9DC2T3F0X>F%1>3U[8=#
M0_K^FH3]J!]&4<1Z^PG4[?1Z!,0>X8PM.9SZS#,P3.,N[\U"%:>P&=;Q>2:\
M3X,--[9'6C2DL%09VCY$$\XIZ\J\9U.TE8LZ$T1+GTG\5RO^#A,>M_)< (,=
MEP=7TJ0(;V6I*./I$ZF$1O))5'PN,XF4''1&7?:/P/()*[4$?7(;Z%QP4VL;
M"4;T2AS7[0R'P8-6\V8V6;C-:=;K]""L2?K )?T7A0$ 0S"&^(S%L54N"E\)
M9H;A>U#!(U_A\XJ4P()U2</>("U\""$+[ OWTB+W::7F@'-\"'5\\4P%8K&W
M-.P:6D%C:S?Z$9&3A*8G<2+@";3KE"@^JE.!/%JPZ<-X8DVD]V]8?S@,^SOE
MZOOG:3TWJ9:65+90W_J(HI<<5+U8'$;V7B;QO06VA=:5Y0>5@6ENT7S+4Q Y
M_+EZ08H:"&"?P0+L+:W@2^0-2 *=L?9E\5VP66,=JT/S:2=J.7\"<%C*S9KX
MI=)R7KM*M[3%,?+%._(9@[\1X:E+3!?\5H-$XCV::X'A[3Y('!S4:Z-@=JWF
MK=6[]C3Q.AB QDCGIST;CYJ=B>+[JAUZJMJH.B,U657K@LT%C6T;(6\-BD@1
M[('[#54M#^QAT_)8-T7AP'OO]:Z NK5I,+MGGV_NQG>3F_$7-IVA;;N]OIM-
MV=7UY/KV\OHQ:)!M^:H%6&JI G816>SR5JKR'&XU1!'4=+W@#=DV%TTIP:2W
MWLWBSYJ(01;HM.L]UU*\4(?L]].49,NEM)%LANX0(26],<(8&T>?<J84*>:D
M 2"0&PL-7I:93"W_\;I:*RTK3GM6MJK1%%(SB B,IQ/6 \W1!+H?1?V.M7UG
M"6HDI>L)U@*+.1?\8 U:*%09 1Q &%7<)9*Q2*7M[[9V[%8NOWH(1A6VZ-(.
MV%9QEQX<[4;#IP?GD=I'E0IRV^]2\7=4A0&.N8T-II_0^#QUG:(K^]X?(77?
M64TF_;4#B >_;=M5CR#;\@T_H'G>%'N8@06X7S%EI5(62M<!-D [J!]%"&MM
M0]0DEC?/->"UL6E3:K7$,-=H_U$O5G:"K:VT7FU;'^Z\7\G<SCED&CD_%0X<
M+;.;EH1^G-+&%(6V%-N&D1;PKCV-NJ?X.^R]Y>\ZP5[*$7A]-?H!K\/N:8R?
M_FG<,!A*T[QBOQ-#36S>V5,>TNW>>O;>M:K@BUXX&D1!;Q!&R7G@23<8#$(T
M+@%U*T$?9#M*DB".S\-H, P\U02):YC=(# .F&(8]X-XV ^3[@!5;!!V$Q#W
M>1@/>WZC]/<4S-^5?J)\FO 2*9QYQV,WT^R@"*'4D!(P%7-I)_:ZCU29BL!)
M(2_\"9;E<\XN:X/-"]@,KI]CJA.XMZ73EG.62R2BY^)=4@_P/073<5E\UP4W
ML,=K0)<(A"*R $+1B> IYZ!Y%$.&[LQN(M0\DRON>O'PQW9GB;PDV--$HE@/
M]RW#'O14P[(==K/?HR,1RTQ42)=C7FA&NZ*E18FUZ;U?B^U'1=4-)0=(O!2U
ML-T:S'2-S<W8U1+:7PO+Z/M,T7& W4@CPB/+;)HJ0_I(*@O92[.V\]):8 #>
M$','/RP/7SC7BF=;>M<@@,-.8 L%!U%PTDPU2C4^H3@0S7!6*MWD=FOWK@K6
M(_L>L(<,1[WIP('F=5^D+ [XL_5([9WZJNS RNZP:TM(+=/B*E8*XYR)KH["
M'%.#6%]13RZ9;576_-D!>"X$/"9H,CRYL'B'_AO4WDKLM%\F$-^D\;TG"+OT
MNVN[6.;TF_U%](6TU+8%05W:3"_LB?BVA!Z&-JV,V&#O3TVC00FA_LS7 >K=
MA&[3=X&]DA9N7K/%B#I]WWW!OO$"YDHZ0*0&(YC6)>&!SG">D?=V95B=4FKZ
MG=QBATB6MFE'C*T;:O-=WK7G$'8_ZV/:]L!X28YQ_:'?>S:'''X3>NC<\&SG
MR#JGHS<ZR:>*""RYT^OV;?O/@K$](S_;#G?_:;CE&ML. Z<M,17[P/X)T^[T
MWCU4JK0'X'-552JWMVO!X6 :@.]+I:KF@19H_X5R\5]02P,$%     @ J8G5
M6*UQ16/0!@  T1$  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULQ5A=
M;^)&%'WWKQC1JDHD!XQM#&232&R6:B/M)E&2;1^J/@SV -;:'CHS3I9_WW/'
MQIA V&[[4"D!;,\]]]S/N>.+%ZF^ZJ40AGW+LT)?=I;&K,Y[/1TO1<YU5ZY$
M@2=SJ7)N<*D6/;U2@B=6*,]ZON=%O9RG1>?JPMZ[5U<7LC196HA[Q729YURM
MWXM,OEQV^IW-C8=TL31THW=UL>(+\2C,E]6]PE6O04G27!0ZE0538G[9F?3/
MWX>TWB[X+14ONO6;D24S*;_2Q4URV?&(D,A$; B!X^M97(LL(R#0^*O&[#0J
M2;#]>X/^J[4=MLRX%M<R^SU-S/*R,^JP1,QYF9D'^?)1U/8,""^6F;:?[*5:
M&W@=%I?:R+P6!H,\+:IO_JWV0TM@]): 7POXEG>ER++\P V_NE#RA2E:#33Z
M84VUTB"7%A241Z/P-(6<N;J=/K&;V^N[SU-V\NGN\?&4W4\?V./'R</THF>@
M@);UXAKL?07FOP$6L,^R,$O-ID4BDEWY'H@U[/P-N_?^4<#/7'59T'>9[_GA
M$;R@L3:P>,$;>%.NBK18:'8O%'M<<B78'Y.9-@K)\><A>RNX\# <%<RY7O%8
M7'90$5JH9]&Y^N6G?N2].T(V;,B&Q]!_-#1'P0Y3O;U[FK)^O\N.J&)/2\'F
M,D/UPG/,\%DFF!9&XZ8R2V;P.);YJC3<EIF<.ZB2-&:\2%B29J41"4L++!'L
M))-:G[(5G*_)^>?L\?KC],.73U/G[E=+@I1O=3M/2R7$3E(QI$2\I)QP*"<H
M,0+GMLR%XD:J<^<6?6Q7V\^PT/6CT!V%/BY. L\=#B*W'X;LU/DDM#YGUV5>
M9IS: RNA),[ +6&/0J5"LPFL>$X3422:G?3=8.BQ4_;+3R._[[^KY;\428HD
M2F?66+%),@ZGQ9QN&<E67)DT3E=0 S=J$9<J-81_0FPB+VJA[AO!305OO0\T
M/,OA;+2'^.M29HE0F@SUW($7N:,HVC/T?_'+M2R>!<PFTBLE\U1KJ=:LD$:
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M<VH$^$AP)!]((K7;B9$ A\8#""/C4YE0@ 6[I7X]LIKMSS%-#8PG24K# GJ
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M8;L5J(U)G*UAM75#\4EM[!)5<JWMD(5OT5\^[A"\F92%YL@20'()*M5A1[#
MI%)"F5/,JP:YP;C2/P.AQF71YJ&(P=H[BI=Z3X PW1@-$&STAN[R!FKLE-@B
M9"AJNS5-3>E"4X":F#>^IN*#TP!4L DG:[%0/$Z)@ FMW=N8^C-=4T5GXS=W
MW<9/V,@/)V]^^7;0]XLB1^60YQI%_G?MM"\T0S+!P=KDUJVMBTA!KH #M=0>
MM4[.(K!2W,A=A=B_]2C[ AQRKZHU44@_$@ <X%BS#&X+6RD?=!XQREKZYSR<
MJHJDQA02B:646]]&8Q8:HKX%TK? Z%Y@;A_T6]/&)15OGU8<">WM?C8VB9$5
M$U)S1A\(O\?"\#@A3YOSQ%7I[:$B/WXDD_79&R^6J&IGN&W8O&8B$<2."<R@
MP8P#"3 'YFN&>!#HDC@ALM$3C1BG-?7,#3/%_>Z!HD!;98M]CJX"JV.GBK1_
M=Q_C0!HKD#&!HQ_NV=U-&V1BYY;J)N/( F*<CL?C"6@#+S/#<?S#*IZ"-9(#
MK-%/ <Q3Q+V1O.!E9QI@#KM NK(%=L>BVFP0&1H9>J6P7>D\^M<MLV218+%3
MQHS'.)L!Y+BZ0G6JA>(N-PLV__*H>BGH=*9<0MF28-GI6CN=,TI?B%<@R@Q_
M3)AIQK^G32A>-K^G%!'JR<^>K)L^S#F*>WZ=/-FUU65)?=-8\^O&4HT-N;W#
M3EZBIC8DR)">G RM)$T>0T@DJ&4T:8M\0"&5,B.4BU@Z/K)50_<[]MP@X:4X
M_1&O2%5=,K>B.VZHS19$QSG>:#U!&0R2_2B41!YV2KIA"U4V(H8U.>(8=AL;
MNS0EM+)QDC)B@K/7H E2FCX#JF=*\?M[X?.H-(\AV.]7R6$,MIHDZFEI8C/O
MB3WDN;UGJ'++QS@$*LJ5"Q).E5K.=?E0K79>ZJ6,,UH3W@Z:"1, <H5^6],4
MLX@#Q+U& !0ZU0MQDF9)A?2RR]'<9O,6B$%RN8T6==Z;/UKQY(68IB];\3U*
M;K)Z_3BG'3LG/> _V47 [Z.9KI$X,&30F!.'/!#QQ B$[44W\(Q'C32">"UW
MU&ZF*1#S%0B!.^6N RN*8*D-L6XR/<6P2GMYL&U?$%)Q97K;VTI;2TR6CXZF
MAJE6LEQT/:O)9)-H% 7>%"RFN3U<Q.P6_;0FC]-*_<YN%6H+P1?HDY(R+7.T
MS8)G[P:$%E5U#!ZU*0GE/$%O=<ND3SQIH)@T#J3\)M?%@-IT#$13Z)R$<9J=
M-I5>T>>$^+K0(ZZG.7:*OG/!G#J@,QD>-1]>*Q;:^2"FXZ2?%?3$-C-#,:_#
M'D/LV[3'%V=I0Q@-!#"!?7-FZC?\MF^03XU;^\,8Z*9]A0#B4%99V_B2EO6S
MT^;^[&QX^O3YH1?^4>_+$L^K],$-@RZ59_S(U#WMONE=\:>LT</V^$'PG71+
M"G:I%A =IV>G ^'B1[9X$^R:OU/-;0BVXLN5DIC%: /6%Q:OE\T-'=!]Z;S\
M+U!+ P04    " "IB=58FY0"*2 <  !O70  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6R]/-ERVT:V[_T579[,E%0%T5RUV(ZK*$I.E+$E75-.'F[=
MAR;8%!&# (U%2[Y^SM+=:) @9"F>^Y"8(M&G3Y]]:[R[3[.O^5+K0CZLXB3_
M^=6R*-9O7K_.PZ5>J;R3KG4"ORS2;*4*^#.[?9VO,ZWFM&@5O^YWNX>O5RI*
M7KU_1]]=9^_?I6411XF^SF1>KE8J>SS5<7K_\ZO>*_O%Y^AV6> 7K]^_6ZM;
M/=7%E_5U!G^]=E#FT4HG>90F,M.+GU^->V\FO2-<0$_\'NG[W/LL\2BS-/V*
M?US,?W[518QTK,,"02CXYTY/=!PC),#CFP'ZRNV)"_W/%OH'.CP<9J9R/4GC
M/Z)YL?SYU?$K.=<+5<;%Y_3^5VT.-$)X81KG]']YS\^.3E[)L,R+=&46 P:K
M*.%_U8,AA+?@N+MC0=\LZ'_O@H%9,*"#,F9TK#-5J/?OLO1>9O@T0,,/1!M:
M#:>)$F3CM,C@UPC6%>^GS#Z9+N0TNDVB112JI)#C,$S+I(B26WF=QE$8Z5SN
MV4_[[UX7L#4">!V:;4YYF_Z.;0;R4YH4RUR>)W,];U@_:5_?Z[< > UG=@?O
MVX.?]ELA?E)91PYZ@>QW^\,FA-J7G^G0+1^TH#-P?!@0O,$.>$T$_]_Q+"\R
M$/3_:R(XPQLVPT/M?Y.O5:A_?@7JG>OL3K]Z_Z]_] Z[;YL.^X. U8X^=$<?
MMD%_?ZKR*$<!O$;82:%0OYM.W JF&4F"+39@RYNE%@H(OEJKY!%)7B:JG$>%
MGLLP37*@_USA'XLH44D8J5CFL%*#]2H(T6*IY8172Y5IN6;@L")*$ ):UZAX
M!%4NEO)+9]J1O^A$9RJ.'U&S]!H?]3F>1;#-.D8E^]<_COO][MM?QN-K^MA[
MNR\!'D N=!:M/)RBA*TX6<-D+M=EEI>HO$5*&&8E L1?,GU;QO0@T0)_G)Y/
M.G(,^(/5U)E.0HVXPR^YEDE:P$* HM9K$$4UB[6\+8$F]%0N5]KL0FOQ V(K
M50Z(ELG< /(/."T #97-<R#;G&P,(B/L8<?3B3LKXMNX\LL:F5)1:#S]XA:9
M0WUPM&F$<)K"/V[]A_'TU +HB O&.5U'"=(3 *Y4 GX,>1[03R\6&.!M7,X!
M0!Q+-?\3;#I]']#2*"<D83\%= =VQB+389EE^&VBBC+3@=R[7T;ATCX/XA:!
MS8YBLMJ 5E:J&,!I +5"$@5$1)6#:UX3TP%_5<@(L \+.LN32.\+WA*E.]&A
MSG-T$BB'2BY4E%F19^DSY*\ K=,\PE\"("C(/1T1%H!K98$,5;Z4"P@A<H*)
MB^&Y* 4F.5WJ_#TUS9=I&<_E#/0 HANCF'^6"4</I)EUG+VUB.(GQWX4DM[1
MVUR<13EXY-SJVSA1\:,Q797D3=)D'CF=_&P.#8]<,260'?#7C;Y+;W4B3Z,4
M<(@U\DN>/RRC602/GYQT>K0>/O2M/F/8(H\/_DV$<?; DK5.1\\D$0O3PK$1
MY$9$@"/JX)VVO+-@8"\@F7Y80YB%I#50'[7*I(95P 5P?7HU \6WWA.XG+%L
M@#U9E"BS#CW#UHYL\CK_/8/>S-:G3+6JK,:Z,LFWSG8K:[N-A?N2D#!."S),
M@-1X!<<-E6BTXM]MHRU/IF@(0);,$^</X5(EM^1Z5A'+X1X^9S8#D^[LF6SQ
MRR/GET>M?OD<#G.+M/@%%@)UC,=K\LRM@)X;B[P F$55U%$EN;"?(Z2BU/90
MM_QD:-UXCL$_[$7,G9HDH]?M[\WV]WK.P_P&)A4D*BOD59G)TS*'%7F.$I 5
MY3H'OU/@H_TN!*P^;WZ[.IT*^-$R*)!L7_6#!AN=[T +.;_(TA6H)%O0;V64
M 88@//A ;,0V@60)M"_3=U%>,X>>/.?6"PK\(D;YO@.I]3;:8R>1H[=+(0J@
M/Y?JCJW'$FRH\B423PHR&V&$2K1RB@:$#&.%>.K%0H=L93(Y3PT@^%,)>"(G
M0<\KD Q.XTH((S1;'B?UL.$^J? N,N#3SR)%1Z A1=;0:=99>A?-M?&6+;(2
MXF^8AR(&Z1HX7A960/1#H3%#D4"6A)V@-<GD^#;P-6<A^R1XWS4^4""QDH/=
M8C$K"S*W>8E>VN"#FWDH@<1'&9 BI1".W8;5AB4(/*T!5)$MU3(TK@1U]U&L
M]&(@:,AUOP1GIAQM:6\(0&!UQ0Z.2Z*"-H<PD +/PD:9!)]#/##*8EW.X%M<
MO26J@1^ !ZBZNYD5$+?4' _7(" .7\4_0P2EMS<43ZY'XH)?6JE'B!N_FJ59
ME%?!D4'7!A/-'HJ]$/!C"=)O*&"ESJ@G8!#1S[O/+)*T[6>KV3ER'!G$THNV
M[/8I&4:N12%$"D@$""A3<$.8'LQTJ,K<11-KR"! V2"8M6R&V ,-:Y,:PLX8
M[;5XK$/GL0Y;/=87QN#<!L)-KJH50K-W ;#"!RLO$@&_(H.?G0ILQ1P8(@1>
MLH$L]BT<B9,+[3<C>V,SR,X:@[).,PK[5DAH,K'PO#91;1RI6123N64MFD-,
M&Z<YAFSP)""'O"&M;%Q$?S?M@P3"J#')-01[8$XA)W%!94BA.(L".S1V,>Y8
M'8^XF[D+16TD?6 D, I#W=/WUIR0P-+Y\:R"%-.M@P35V#@3L3V365Y #1\Y
MV9]K<%$KBA0X6';Y4<<OH0EX5AGC:/CI<=F9@8JS-DVDK 13K#L5ETZC0'=7
MY&33\*OQ),F=S@K2/O!<&!"FD*)Q[@X6# /W5.#23V %=!;L #R%XZ$[QX :
MV)-1/&LW,3^>;OX8,"('6$!EIP:,-Y6(BG6\I3WA'/5\4<8@3G<<+0/:0%Q0
M!-P*2;3F;)LD --:C6%Q#JD'^;BYF.L[':?TE"=L33'DC]!R#!Y9S5V6^[U*
MS34?+(H8UN>-/L#3^O^FIM/?SU9TW@7U8RN_%]7I.Y H?T4S6"'NCEP_'H2Z
M60A.4^9>G?G/<GZ+#X#J4,CA@* G!=W*R]F?)M R82#HU"J%0V"-!!8*OPH&
M7BA=(>YW*HJI;&5$*<TP<\6XB@HYNXV3AQL\W6RJ+LA& WUB4'!4;@5N'G9[
M%,X=$J]\X7?A(?./RCVAK12 -D6 $@L9X*#I@3#*PG*%7C*T,:E^P/AX_KV\
M<6%:Q0<J(<TIQ :Q1<I1T@G\P[*#Q38P1#$D-X8PP1H VCXY!_.! 6-"@3VQ
MPZ3]J @16L=; ;I*\O%\7] 2"1RY2."H-1*88($)F4\?SD$@P>@A/DTA02NH
MYV:O+P"&.(HF9&OYJV5=3H7$? G*?T#<B, 1F)JB#2"!+1%$?D#V%980T2Z1
MG&0:G!#W48!Q,::N%+BO2S"Q9,O9I5%]3E>(<*9D,9E'F#.TL>G8L>FXE4T7
M'NJ_ZIB$\B8K<]> :F)7*\CGLNL%P#RD12/2<ER(S2+9($!;AMJ,83'6DH")
M1G>-!5X:6/A5'=X]**S[64$$LB*+KJG,RLPR@36H6^$*=,+LW?]A>Y-?NT&+
M5T*L4:7NM=S2N3=/,,7N#3"FHFH V%TN@T+:087&&ORM[S;*>2G#GJF8VA3<
M P=#Z44\JJ!X"'(;/+U68!K9B5+!C\(\\-HJ2HPW!&M.[@P-%Q45V5IISR[6
MXRE?$Y>-DJ&H-$J!WAQ<%Y=)80U@DR5\BI7*ONJ"O)=WV&9PAJ"UTF>]596Z
MJC/SJ(K&*M0I>/\^W+W@E_/%RM4RWGY7"G8\__WJE_-+<7IQ)7^]^GAV<?G+
M5%Y<3CKR\NKF?"INKN2'B\OQY>1B_%%.;\8WYY_.+V^F\NQ\<O[I]/RSE>!!
MF[$Y<<;FI-787*'+09PG:8X!#P3,X#"1%*X<<Y%$J"+RFE-ONZ+)"K7N]5PK
M] )@%C?Q[-.X#R+$I8$12.+FG",26$05N'N4/I1\K9NW<$^!7S)Z7P5ZQL2D
MD*<<@,E)2;JPZ$ QC^EF"5-I)\,$*V)]J^+ *Q0$3:B@"E,5A(X 'BF#L(IR
MPY@0-.7UB^NK3G7NK>-RY*&*(HMF):F<, M??"XR"F6,)Z"PG''Y2?9[0?_P
M,!B=#.5AT.UV\3_9&P9'YN/(_#@R?[?(>Z];S79TVZ.@%$QA4E3YRP0"/_ 8
MGZ/\:^,,1RNX'<&+OP=9$F^3JB\&QBXOLI+M"P6SKD84/U9AOA=E -G\3"&L
M[4,!,N^3X3Z-K5%TC#7/)'"NJ2 #;YPG96\+/3<-'OBES&KU $0;@G/>%)[5
M#YCL4RZXM2J.( /,M^NL6%_%=!5R:3C#7.#WQKD 1*[@LKBS9,]T'&G,D2,N
M^/'RU(1G/E'H["AT&%C3:1M':_XN6W\L5[^/DX9_%64H]&ED3,#-ZH#RHFB%
MI2U,'Y%5F@M$'YA7$!EQR'2!'*,X89)F$ &P@H2HT9 I,2,1 ]#;T=/ZZ,U:
M]5KU\0.ZW-]MM%#UC"\J*C:J92O49O[A5H*W^D3AF@D))CI#!1"[LGX,QE26
M19QE>N$-=V2PIM&1'ZJOHZIOIKC( 2H8F@SXOFK!ASJZ,_UDE7#4*;"VKR(V
MUEAIQHQ0.70>Y1[DNP7#VW?5..LM./,$05'S.U %8%M:YC8(L6UKVH=2'0<4
MQ0CS(S@-U@-P7T6=$S'3Q;W6-@ #U" PQ*THDN+=5Q4I*?NNZSH(8QS]!51$
MTK!(%3I<)M&WTF;P*_4 LO475_E,P3R=(<\HAHJ2=0G!,G(%@JRM)\MDZUGK
MZ:AFC^K'%8B._ /S.ILSHK/;/E:MS%H/9KV#Y@%%S8L4/-T]>>#JL64$"@.I
M(^:$-,A21A!XY]*2TD,7S]2 OZU1L. 5^A8RU[^X.D'E!5/=L)N+&$N ^1OQ
M$?\5/?DEX9$:,*O?RA3=+<F+:390[Y$/SA,20 RP3B$V!%D!/-D ^7]KX/;E
ME4-4&$)SO %<3"0])'MFJ\"8\%S6,<#]<N!AK+* ^G5HR!T"03,&VWB_%=M@
MJV-4>^R&9PG %40S#L*;O,7'^616GNQ#%:M04;&+AH6!-,O2&1I,0&CVZ#/8
MR!>HA;)D' ![TBU" D;,<]R6+ B@6L142TI2'\Y&(8]7V6+ZAE<QM6%RA>E]
MLCW^Q'!%3:W90*%V 5)(7PJ"DP:[T=GA],"RI>"/_V)[N00M2#.6KY5S6UMY
M:>Y[.>?@UNK1'=64\?F;>@SCH@-79$2#3:F?2T2?AHE=URQ],-56@ (Z[66$
MML2'X+U2$P^D89^%)P4]2G3\8I4K 52S;#N,BT\),YGV=%M#^FT-U <G3ZY:
M9GO;FTV/M6V20\A1AMIO2%)O'ET.-R1L%_@>J$O"HA:%F4G@K4W-NH(N:@=#
M'6)#,3"ZQ7RL#"DG^6[L0,D,?CJ \]QC1]H6:&YO,TB)"EUC3W-36;11#] -
MEW#HF-H<7BCBQ0?BU(@I2-9O*BEQZ,\,>4$L=#(,3@9]#(?$@1B;!DU5P>"&
MC.R-3H)!=R0F3462O>%Q,#P\#@Z/CN6^.--&?8@IY9IB,#Q!;O*55FG8&QX&
MA_T^_'<$L#S,/U'#:% A?K#[7 /X>7 2]$^.Z%PV9:Y5C6B2@9;W Y.?[3Y^
M__@DZ UV'+]_'/2&_>#X<+037T3HJ!OT^R<4=_H5X#(W @VDF-EXYIXN*N"P
MC9W9RS0H*5A]#>GMW(M%^(LT3F^-P32EG)T=1T=[\3V:6.M^UCNX.-Z&U.!6
M/]+$;FY'#NK;/W=K5U*3=RFV,SAZE,==.1C)P:$\'LF3$9(RTX+JF4D5<5;!
M"H<68/DRBU6M8,XC$1NRA4=#IG7D%Y!>"I0FD-I1V<)W4"HT'?TMJ[)]>C9F
M<"2LL[*;_0EW/#D:[%#A7%XMY!\&HB]9'_0L8V$?.65@P6J63]ZE59<.NX0(
MRN6V):-B;%Z?3)_A?$E3]W-'"N("$&---Q,1A%GY%3&CVP-;F)I9(YYSU5MD
MK@)7(^V5FK@X:"NPG]?5)J];_[I]'5>'^^@=[I-W)C\;3.1GYREYQ)5=Q_]P
MZ'?M8MHQQX:?3$CGJ]P5A7%5X II)9W$'TK@9_RHS#PE/"S?H&%&,<6=C*#6
M6(0VZL#\5\G#%H.3-'G2_PO/_[M1A+;1@RVO*[_+Z[K>E3>]41,)X2.P.0MA
M:MUT!PE@J2S&.LS*#.QVY+_UHY4;)RLF\&M>0@UQVQNNJ;_8B80S<HJM*9+,
MLW?6C!V-_@D&[Y^RVQG)7K?3E</.X)]RA/_KN\KC=Q3F;WX]EU\NQU_.+F[.
MS^3DZG)Z]?'B;(Q_--;L&RM/?Z]RL:M(PM9GRV-]GX&Q&>>W4L71@B9_ZU4E
MNTDU@]IT942.IQ-YW.\&PO[8&%'Q]F=N^"(/#("M +P*XVWJD.G:M/I6IZ>6
M4P2BJGU6P3N@M!6^MS;8>_VJF-5O+69]-J7V:X4C/#=5(:6YAM4*[+G]DI=
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M";;2C)UH28;!FL%X96-$',EI%+.&3(X($2'B5),#8"28(ULB-IHG\>>F=4A
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MH.\AFH%N]Z.P+<?WJW"U&_A(4:U@4>JUC50XLBCU1C-GT6B6UIJQ6JO,:E6
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MS6>5D?V:T+W;7GV3@>%BQ;A"&5V"J'O4A_22U7>.ZD:+PGXJ6 BM16XOUY1
MZIH-\'PIH*;5-^: YF/3\!]02P,$%     @ J8G56**[0W2C @  R04  !D
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M#P_"0PB)."YAT8M=/>]#0[HML(=GO 6(D0C7.5&&SUMHA)B.6PO;-GK>#X+
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M,JF0V\RJ^V['\ZS@3OA^?^"V@AWP_;[;:OMNO]O9&:\)J.>YOC\P?J"N6G^
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M4!H!>K\01$9Q8QR4_UD8_@-02P,$%     @ J8G56+EWOZ). P  [P8  !D
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M+)(_C<O'+3W'<\[X>"Y'?;YU]YR/Y[(1GU4\O1)E7ZKM>G@#![W>0/\<>-+
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MU6)4DY2FIF1;&9GJ*R/?N](%+8J@FHEJ%JK9T^,2RT"=?3CH@"ZJ>:CFHUJ
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M@&HAJ@E4BU M1C5):6H&#ML,'+[T68L%6I= -1/5+%2S4<U!-1?5/%3S42U
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M-9A(W+2.=US%&YR)UP_0/6<JE^@#RR#;)W"U^"8#P2X#X^ BXQVD-RCTWZ'
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MKREHB0%*\QI:IZ YTCPFZD/=!E!:"*5%*%I74FWUP#97#][TN+69V5MBT.J
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M+W=O<FMS:&5E=',O<VAE970T-2YX;6RUF%UOTS 4AO^*%1 ""9J/?C+:2-"
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M#?LQ-.N8KG,[@W3CNR73Q+WGAR4_=FC<!E[?:$TOAFO X?E,_P!02P,$%
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MX)> 7$RS2%:>Z1!+'/0XVR*NK16;'N1RY6B58$)U84TE5[M$X60P596:K%-
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MW[+U.]EF%9"M%#E9E:)00MJ8&X3PC-D/HLB/[<Q!RQQT,C])*!G?$'C%@J-
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MV3UK=>:SX8')'2_P0&"+IM[- #%DTXF;B19EW?W60F,OK8=[_'H!:3;@^ZW
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M>IVAUEWDEXGY@^)I=H'WP)7B25:,@(0@3 -=O^!<[1Y,!^65[N0_4$L#!!0
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M)WA"F+I GI]2*EYVU #9HF7O7U!+ P04    " "IB=58!,G^:9 $  !Z#0
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M 5&<W/*(BAIS+YN1'NS:H.R\M;QCZ>?(PT;P#\9;MR*AVVCZ-Y * G(+(C_
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M[)T :W0@8%@%#'<#Q@<"1E7 J.TFC:N <=N 214P:;L/YU7 >=N BRK@HFW
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M<V7GV5 [SX;:>5": Z6Y4)H'I?E0&H72&(JFZUG9>;;9SOM'6L/FG)U5#S4
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M*(VA:+H&E1<X-'HSKUA2P@SL+$.H'5C1MJND\7XM"'7YVJ3TH2DIE,90-%V
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MJ)P6.!,@-XP1\3[$G%=]I^7L%^9TG2FSX(9!2=88HUJ4,Z%G;L.24H:%I+P
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MX&G$$<P!>,"0.+;OP;WW4;1Y3T7;_U*.?P-02P,$%     @ JHG56)>*NQS
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M(Y#VBT%.-ARFVT$@G9>#Y'H#(%T$TJ6%G J=*;EKCK<I5O>\D#_:[_W!QC6
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M)/U, 01B8A9RGW-[YU$P]Q 3LY!+78X#T3193^-@TFQAM+60DVAB%G*I]WT
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MOGG^ E!+ 0(4 Q0    ( *F)U5@'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ J8G56$3PC<;N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ J8G56)E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "IB=58@*;<S+L$   E%0  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ J8G56!FMZ?(@#0  /&D  !@              ("!_@P  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *F)U5ABBBWY! 0  *L3
M   8              " @50:  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "IB=585EEJ9 \)   E1   &               @(&.'@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ J8G56!S4P2*(
M#0  $9\  !@              ("!TR<  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( *F)U5BJJ1-(S0P  %YA   8              "
M@9$U  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "IB=58
MI94_)<(3  #L.0  &               @(&40@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ J8G56/\*.3@,'   1E4  !@
M     ("!C%8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M *F)U5@#>1?90P(  &4%   8              " @<YR  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "IB=58B0\OU/4"  !R!@  &0
M            @(%'=0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( *F)U5@IU/J=, H  $X9   9              " @7-X  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ J8G56)W79C4]"@
MWAT  !D              ("!VH(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "IB=58Y^0RNY01  #(,P  &0              @(%.
MC0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *F)U5AJ
M ;;;5 (  "\%   9              " @1F?  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ J8G56 <VP$0*"   MQ0  !D
M     ("!I*$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *F)U5A?M2  <P4  &@+   9              "
M@63;  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ J8G5
M6&R$)Q7D P  N @  !D              ("!#N$  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "IB=58\H)M6K4"  #U!0  &0
M        @($IY0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( *F)U5A:=!AVRP,  $T(   9              " @17H  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ J8G56/X#5QOI!P  $Q(
M !D              ("!%^P  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "IB=58#"F5+),1  #(,P  &0              @($W]
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *F)U5A3IY4M
M,0H  $X9   9              " @0$& 0!X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ J8G56*UQ16/0!@  T1$  !D
M ("!:1 ! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "I
MB=58.U@ITT@(  #U%   &0              @(%P%P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *F)U5B;E (I(!P  &]=   9
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M970S,RYX;6Q02P$"% ,4    " "IB=58_98@($D%  !E$   &0
M    @('270$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M *F)U5BY=[^B3@,  .\&   9              " @5)C 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ J8G56.TD+BVW @  VP4  !D
M             ("!UV8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "IB=58PYQ?Q=8#  #&"   &0              @('%:0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *F)U5BCM7\\0P0
M %D)   9              " @=)M 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ J8G56#W)4U65!@  7!(  !D              ("!
M3'(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "IB=58
M/*H;4L =  !K'@( &0              @($8>0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( *F)U5@IG5P=!P,  'P(   9
M      " @0^7 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ J8G56*?(&]N#!0  S20  !D              ("!39H! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "IB=589P43FN '  !?20
M&0              @($'H $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( *F)U5ADRC;,. ,  '$+   9              " @1ZH 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ J8G56 C::&'0
M P  C18  !D              ("!C:L! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "IB=58N@R6F5P"  !*!0  &0
M@(&4KP$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( *F)
MU5CMPUY@O!\   %6 @ 9              " @2>R 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ J8G56*.2S%_>"@  ?H<  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( *F)U5A D?61/P\  %?$   9
M  " @8/R 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MJ8G56#O8!K7' @  )@D  !D              ("!^0$" 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " "IB=58"AI=5/D"  "'"   &0
M            @('W! ( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( *F)U5CE.*P.1@,  . )   9              " @2<( @!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ J8G56)!AE2,2 P
M0 P  !D              ("!I L" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " "IB=58M=I!]6T'  !#3@  &0              @('M
M#@( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( *F)U5B=
MTOB05 ,  !L)   9              " @9$6 @!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ J8G56+W5]*M= P  :@T  !D
M     ("!'!H" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *F)U5@6SH33*P,  -D+   9              "
M@?\K @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ J8G5
M6&>D-O<7!0  P!P  !D              ("!82\" 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " "IB=58!,G^:9 $  !Z#0  &0
M        @(&O- ( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( *F)U5C!,4%U1 X  /ND   9              " @78Y @!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ J8G56+*-.K4*!   *Q0
M !D              ("!\4<" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    " "IB=58M9>WYP,%  !:&0  &0              @($R3 (
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( *F)U5AME[H#
ME00  *08   9              " @6Q1 @!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ JHG56+'-?,V- @  J 4  !D
M ("!.%8" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " "J
MB=58K?QFKDD#  "R%   #0              @ '\6 ( >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( *J)U5B7BKL<P    !,"   +              "  7!<
M @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *J)U5C\SVPY(P8  ,DO   /
M          "  5E= @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "JB=58
MK&U05SP"  "O*@  &@              @ &I8P( >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "JB=580&L7N@ "  #&*0  $P
M        @ $=9@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     4 !0 .<5
(  !.: (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>318</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Organization, Business Operations and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity</Role>
      <ShortName>Description of Organization, Business Operations and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Initial Public Offering and Over-Allotment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/InitialPublicOfferingAndOver-allotment</Role>
      <ShortName>Initial Public Offering and Over-Allotment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Private Placement Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PrivatePlacementWarrants</Role>
      <ShortName>Private Placement Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Shareholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ShareholdersDeficit</Role>
      <ShortName>Shareholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/WarrantLiabilities</Role>
      <ShortName>Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NatureOfBusiness</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Development-stageRisksAndLiquidity</Role>
      <ShortName>DEVELOPMENT-STAGE RISKS AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombination</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - EARNOUT SHARES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/EarnoutShares</Role>
      <ShortName>EARNOUT SHARES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tevogen.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - STOCKHOLDERS??? DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficit</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactionsDisclosure</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - NET INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetIncomeLossPerShare</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEventsDisclosure</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/RelatedPartyTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - BUSINESS COMBINATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombinationTables</Role>
      <ShortName>BUSINESS COMBINATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/BusinessCombination</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/Stock-basedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - STOCKHOLDERS??? DEFICIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficitTables</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/StockholdersDeficit</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Description of Organization, Business Operations and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative</Role>
      <ShortName>Description of Organization, Business Operations and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails</Role>
      <ShortName>Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails</Role>
      <ShortName>Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Initial Public Offering and Over-Allotment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative</Role>
      <ShortName>Initial Public Offering and Over-Allotment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/InitialPublicOfferingAndOver-allotment</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Private Placement Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative</Role>
      <ShortName>Private Placement Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/PrivatePlacementWarrants</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Fair Value Non Redeemable Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails</Role>
      <ShortName>Schedule of Fair Value Non Redeemable Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Shareholders??? Deficit (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ShareholdersDeficitDetailsNarrative</Role>
      <ShortName>Shareholders??? Deficit (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/ShareholdersDeficit</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Warrant Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>Warrant Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/WarrantLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Quantitative Information in Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails</Role>
      <ShortName>Schedule of Quantitative Information in Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - NATURE OF BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>NATURE OF BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/NatureOfBusiness</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative</Role>
      <ShortName>DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Development-stageRisksAndLiquidity</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Schedule of Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails</Role>
      <ShortName>Schedule of Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of Fair Values Of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails</Role>
      <ShortName>Schedule of Fair Values Of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails</Role>
      <ShortName>SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - BUSINESS COMBINATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombinationDetailsNarrative</Role>
      <ShortName>BUSINESS COMBINATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/BusinessCombinationTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - EARNOUT SHARES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/EarnoutSharesDetailsNarrative</Role>
      <ShortName>EARNOUT SHARES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/EarnoutShares</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tevogen.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/NotesPayable</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/StockholdersDeficitTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/RelatedPartyTransactionsDisclosure</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing, TVGN:NumberOfWarrantsIssuedPerUnit, TVGN:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders, us-gaap:AlternativeInvestmentMeasurementInput -  forms-1.htm 67, 68, 69, 70, 169, 170</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="forms-1.htm">forms-1.htm</File>
    <File>tvgn-20240331.xsd</File>
    <File>tvgn-20240331_cal.xml</File>
    <File>tvgn-20240331_def.xml</File>
    <File>tvgn-20240331_lab.xml</File>
    <File>tvgn-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>forms-1_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="872">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "forms-1.htm": {
   "nsprefix": "TVGN",
   "nsuri": "http://tevogen.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "forms-1.htm"
     ]
    },
    "schema": {
     "local": [
      "tvgn-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tvgn-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tvgn-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tvgn-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tvgn-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 231,
   "keyCustom": 119,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 39,
   "memberCustom": 42,
   "hidden": {
    "total": 171,
    "http://fasb.org/us-gaap/2024": 141,
    "http://tevogen.com/20240331": 28,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 318,
   "entityCount": 1,
   "segmentCount": 94,
   "elementCount": 593,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 872,
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://tevogen.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://tevogen.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://tevogen.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonClassAMember",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://tevogen.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)",
     "shortName": "Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://tevogen.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity",
     "longName": "00000007 - Disclosure - Description of Organization, Business Operations and Liquidity",
     "shortName": "Description of Organization, Business Operations and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://tevogen.com/role/InitialPublicOfferingAndOver-allotment",
     "longName": "00000009 - Disclosure - Initial Public Offering and Over-Allotment",
     "shortName": "Initial Public Offering and Over-Allotment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://tevogen.com/role/PrivatePlacementWarrants",
     "longName": "00000010 - Disclosure - Private Placement Warrants",
     "shortName": "Private Placement Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:PrivatePlacementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:PrivatePlacementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://tevogen.com/role/RelatedPartyTransactions",
     "longName": "00000011 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://tevogen.com/role/CommitmentsAndContingencies",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://tevogen.com/role/ShareholdersDeficit",
     "longName": "00000013 - Disclosure - Shareholders\u2019 Deficit",
     "shortName": "Shareholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://tevogen.com/role/WarrantLiabilities",
     "longName": "00000014 - Disclosure - Warrant Liabilities",
     "shortName": "Warrant Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:WarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:WarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://tevogen.com/role/FairValueMeasurements",
     "longName": "00000015 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://tevogen.com/role/SubsequentEvents",
     "longName": "00000016 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://tevogen.com/role/NatureOfBusiness",
     "longName": "00000017 - Disclosure - NATURE OF BUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://tevogen.com/role/Development-stageRisksAndLiquidity",
     "longName": "00000018 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
     "shortName": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure",
     "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://tevogen.com/role/BusinessCombination",
     "longName": "00000020 - Disclosure - BUSINESS COMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://tevogen.com/role/EarnoutShares",
     "longName": "00000021 - Disclosure - EARNOUT SHARES",
     "shortName": "EARNOUT SHARES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "TVGN:EarnoutSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "TVGN:EarnoutSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://tevogen.com/role/AccruedExpensesAndOtherLiabilities",
     "longName": "00000022 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://tevogen.com/role/NotesPayable",
     "longName": "00000023 - Disclosure - NOTES PAYABLE",
     "shortName": "NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://tevogen.com/role/Stock-basedCompensation",
     "longName": "00000024 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://tevogen.com/role/StockholdersDeficit",
     "longName": "00000025 - Disclosure - STOCKHOLDERS\u2019 DEFICIT",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://tevogen.com/role/RelatedPartyTransactionsDisclosure",
     "longName": "00000026 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://tevogen.com/role/NetIncomeLossPerShare",
     "longName": "00000027 - Disclosure - NET INCOME (LOSS) PER SHARE",
     "shortName": "NET INCOME (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://tevogen.com/role/SubsequentEventsDisclosure",
     "longName": "00000028 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:EmergingGrowthCompanyPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure",
     "longName": "00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000031 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "TVGN:TemporaryEquityPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "TVGN:TemporaryEquityPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://tevogen.com/role/RelatedPartyTransactionsTables",
     "longName": "00000032 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://tevogen.com/role/FairValueMeasurementsTables",
     "longName": "00000033 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure",
     "longName": "00000034 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://tevogen.com/role/BusinessCombinationTables",
     "longName": "00000035 - Disclosure - BUSINESS COMBINATION (Tables)",
     "shortName": "BUSINESS COMBINATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables",
     "longName": "00000036 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://tevogen.com/role/Stock-basedCompensationTables",
     "longName": "00000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://tevogen.com/role/StockholdersDeficitTables",
     "longName": "00000038 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Tables)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://tevogen.com/role/NetIncomeLossPerShareTables",
     "longName": "00000039 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)",
     "shortName": "NET INCOME (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
     "longName": "00000040 - Disclosure - Description of Organization, Business Operations and Liquidity (Details Narrative)",
     "shortName": "Description of Organization, Business Operations and Liquidity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails",
     "longName": "00000041 - Disclosure - Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)",
     "shortName": "Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "TVGN:TemporaryEquityPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
     "longName": "00000042 - Disclosure - Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)",
     "shortName": "Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
     "longName": "00000044 - Disclosure - Initial Public Offering and Over-Allotment (Details Narrative)",
     "shortName": "Initial Public Offering and Over-Allotment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2021-11-082021-11-08_us-gaap_IPOMember",
      "name": "TVGN:UnitsIssuedDuringPeriodSharesNewIssue",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:InitialPublicOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-11-082021-11-08_us-gaap_IPOMember",
      "name": "TVGN:UnitsIssuedDuringPeriodSharesNewIssue",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:InitialPublicOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
     "longName": "00000045 - Disclosure - Private Placement Warrants (Details Narrative)",
     "shortName": "Private Placement Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_PrivatePlacementWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:PrivatePlacementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails",
     "longName": "00000046 - Disclosure - Schedule of Fair Value Non Redeemable Shares (Details)",
     "shortName": "Schedule of Fair Value Non Redeemable Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2023-05-032023-05-04",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-05-032023-05-04",
      "name": "TVGN:StockPriceOfMeasurement",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000047 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-01-302023-01-30",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000048 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:UnderwritingCashDiscountPerUnit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:UnderwritingCashDiscountPerUnit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
     "longName": "00000049 - Disclosure - Shareholders\u2019 Deficit (Details Narrative)",
     "shortName": "Shareholders\u2019 Deficit (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative",
     "longName": "00000050 - Disclosure - Warrant Liabilities (Details Narrative)",
     "shortName": "Warrant Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_PrivatePlacementWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "00000051 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails",
     "longName": "00000052 - Disclosure - Schedule of Quantitative Information in Fair Value Measurements (Details)",
     "shortName": "Schedule of Quantitative Information in Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000053 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_MergerAgreementMember",
      "name": "us-gaap:SponsorFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
     "longName": "00000054 - Disclosure - NATURE OF BUSINESS (Details Narrative)",
     "shortName": "NATURE OF BUSINESS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_TevogenBioMember",
      "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_TevogenBioMember",
      "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
     "longName": "00000055 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)",
     "shortName": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
     "longName": "00000056 - Disclosure - Schedule of Fair Value Measurement (Details)",
     "shortName": "Schedule of Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
     "longName": "00000057 - Disclosure - Schedule of Fair Values Of Warrants (Details)",
     "shortName": "Schedule of Fair Values Of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-15",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure",
     "longName": "00000058 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails",
     "longName": "00000059 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)",
     "shortName": "SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
     "longName": "00000060 - Disclosure - BUSINESS COMBINATION (Details Narrative)",
     "shortName": "BUSINESS COMBINATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
     "longName": "00000061 - Disclosure - EARNOUT SHARES (Details Narrative)",
     "shortName": "EARNOUT SHARES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31_custom_EarnoutSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:EarnoutSharesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
     "longName": "00000062 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "TVGN:AccruedProfessionalServiceFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "TVGN:AccruedProfessionalServiceFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://tevogen.com/role/NotesPayableDetailsNarrative",
     "longName": "00000063 - Disclosure - NOTES PAYABLE (Details Narrative)",
     "shortName": "NOTES PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "TVGN:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:MortgageNotesPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
     "longName": "00000064 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "00000065 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "00000066 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
     "longName": "00000067 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "TVGN:SharesToBeIssuedOnSharesIssuable",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
     "longName": "00000068 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-11-30_custom_SemperParatusMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
     "longName": "00000069 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SponsorFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "TVGN:WorkingCapitalExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
     "longName": "00000070 - Disclosure - SCHEDULE OF NET LOSS PER SHARE (Details)",
     "shortName": "SCHEDULE OF NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
     "longName": "00000071 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
     "longName": "00000072 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember69287000",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember69287000",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/AccruedExpensesAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r65",
      "r779"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r669"
     ]
    },
    "TVGN_AccretionOfCarryingValueToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AccretionOfCarryingValueToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of carrying value to redemption value",
        "documentation": "Accretion of carrying value to redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "TVGN_AccruedProfessionalServiceFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AccruedProfessionalServiceFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Accrued professional service fees current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r669",
      "r819"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r723",
      "r724",
      "r725",
      "r726",
      "r784",
      "r820"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds allocated to Class A shares issuable from the note payable",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r328"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_AdministrativeSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AdministrativeSupportAgreementMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative Support Services [Member]",
        "documentation": "This member stands for Administrative Support Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_AggregateDeferredUnderwritingFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AggregateDeferredUnderwritingFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate deferred underwriting fee payable",
        "documentation": "Aggregate deferred underwriting fee payable."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_AggregateNumberOfSharesOwned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AggregateNumberOfSharesOwned",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate number of shares owned",
        "documentation": "The number of shares owned by the founders after the impact of the stock dividend."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_AggregatePurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AggregatePurchasePrice",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate purchase price",
        "label": "Purchase price",
        "documentation": "Aggregate purchase price per share."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_AggregateUnderwriterCashDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AggregateUnderwriterCashDiscount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate underwriter cash discount",
        "documentation": "The carrying value of the cash underwriting discount in the aggregate if the underwriter's option to purchase additional units is exercised in full."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate percentage",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r788",
      "r789",
      "r790"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_AmountOfInitialCapitalConsideredToIssueOneShare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AmountOfInitialCapitalConsideredToIssueOneShare",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of initial capital considered to issue one share",
        "documentation": "Represents amount of initial capital considered to issue one share."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares excluded from computation of diluted earnings per ordinary share",
        "verboseLabel": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r107",
      "r123",
      "r140",
      "r189",
      "r193",
      "r204",
      "r205",
      "r242",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r386",
      "r388",
      "r424",
      "r493",
      "r571",
      "r638",
      "r639",
      "r669",
      "r682",
      "r747",
      "r748",
      "r803"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r127",
      "r140",
      "r242",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r386",
      "r388",
      "r424",
      "r669",
      "r747",
      "r748",
      "r803"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrust": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsHeldInTrust",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension amount deposited into Trust Account",
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "TVGN_AssetsHeldInTrustAccountPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Held in Trust Account",
        "documentation": "Assets Held In Trust Account Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsHeldInTrustNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and marketable securities held in Trust Account",
        "verboseLabel": "Assets held in trust noncurrent",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r381",
      "r652",
      "r653"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r381",
      "r652",
      "r653"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r10"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS COMBINATION",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r382"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from Sponsor",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Derivative warrant liabilities",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities derivative warrant liabilities.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities note payable.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger agreement share issuable",
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF BUSINESS",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "TVGN_CantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "CantorMember",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cantor",
        "documentation": "This member stands for cantor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Received",
        "terseLabel": "Management cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r497",
      "r546",
      "r566",
      "r669",
      "r682",
      "r714"
     ]
    },
    "TVGN_CashAcquiredInConnectionWithReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "CashAcquiredInConnectionWithReverseRecapitalization",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "Cash acquired in connection with reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash \u2013 beginning of period",
        "periodEndLabel": "Cash \u2013 end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r84",
      "r138"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r84"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r815"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal depository insurance coverage amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary disclosure of noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ChangeInFairValueOfConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ChangeInFairValueOfConvertiblePromissoryNotes",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of convertible promissory notes",
        "label": "Change in fair value of convertible promissory notes",
        "documentation": "Change in fair value of convertible promissory notes."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in value of Class A ordinary shares subject to redemption amount",
        "documentation": "Change in value of class ordinary shares subject to redemption amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ClassAOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassAOrdinaryShares",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A ordinary shares; $0.0001 par value; 200,000,000 shares authorized; 13,433,333 and 1,450,000 shares issued and outstanding (excluding 1,502,180 and 34,500,000 shares subject to possible redemption) as of December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Class A ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ClassBOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassBOrdinaryShares",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B ordinary shares; $0.0001 par value; 20,000,000 shares authorized; 0 and 11,983,333 shares issued and outstanding as of December 31, 2023 and 2022, respectively",
        "documentation": "Class B ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r125",
      "r126",
      "r140",
      "r168",
      "r169",
      "r179",
      "r183",
      "r191",
      "r192",
      "r242",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r299",
      "r300",
      "r304",
      "r307",
      "r314",
      "r424",
      "r527",
      "r528",
      "r529",
      "r530",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r558",
      "r580",
      "r602",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r703",
      "r720",
      "r727"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r191",
      "r299",
      "r300",
      "r302",
      "r304",
      "r307",
      "r312",
      "r314",
      "r527",
      "r528",
      "r529",
      "r530",
      "r648",
      "r703",
      "r720"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "TVGN_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)",
        "documentation": "Percentage of adjustment of exercise price of warrants based on market value and newly issued price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrant",
        "terseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issuable per warrant",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants issued to purchase ordinary shares (in shares)",
        "verboseLabel": "Number of warrants to purchase shares issued",
        "terseLabel": "Class of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ClassOfWarrantOrRightPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price of warrants",
        "verboseLabel": "Price of warrant",
        "documentation": "Represents the price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold consecutive trading days for redemption of public warrants",
        "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold trading days for redemption of public warrants",
        "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price per public warrant (in dollars per share)",
        "documentation": "Represents the redemption price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r103",
      "r496",
      "r557"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r265",
      "r266",
      "r625",
      "r741",
      "r746"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "TVGN_CommonClassaNotSubjectToRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "CommonClassaNotSubjectToRedemptionMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A Not Subject To Redemption [Member]",
        "documentation": "This member represents of classification of common stock representing ownership interest in a corporation that is not subject to redemption."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share dividend",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r723",
      "r724",
      "r726",
      "r784",
      "r817",
      "r820"
     ]
    },
    "TVGN_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, vote per share",
        "documentation": "Represents the number of votes that each common share is entitled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, par value (in dollar per share)",
        "verboseLabel": "Ordinary shares, par value (in dollar per share)",
        "terseLabel": "Ordinary shares, par value (In Dollar per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares authorized",
        "verboseLabel": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r558"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares issued",
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares issued and outstanding",
        "documentation": "Common stock shares issued  and Outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares outstanding",
        "verboseLabel": "Common stock shares outstanding",
        "terseLabel": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r558",
      "r577",
      "r820",
      "r821"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized; 164,614,418 and 119,999,989 shares issued and outstanding at March 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r499",
      "r669"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "verboseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r112"
     ]
    },
    "TVGN_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condition for future business combination number of businesses minimum",
        "documentation": "Condition for future business combination number of businesses minimum."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConditionForFutureBusinessCombinationThresholdNetTangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net tangible assets",
        "documentation": "Condition for future business combination threshold net tangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConditionForFutureBusinessCombinationThresholdPercentageOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConditionForFutureBusinessCombinationThresholdPercentageOwnership",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condition for future business combination threshold ownership (as a percent)",
        "documentation": "Condition for future business combination threshold percentage ownership."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConditionForFutureBusinessCombinationUseOfProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConditionForFutureBusinessCombinationUseOfProceedsPercentage",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condition for future business combination use of proceeds percentage",
        "documentation": "Condition for future business combination use of proceeds percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with Merger",
        "documentation": "Conversion of convertible promissory notes into common stock in connection with merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon conversion",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible promissory notes",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "TVGN_ConvertibleNotesPayableDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConvertibleNotesPayableDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ConvertibleNotesPayableDiscounts-0]",
        "documentation": "Convertible notes payable discounts."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConvertiblePromissoryNoteChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConvertiblePromissoryNoteChangeInFairValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Less: Convertible promissory note change in fair value",
        "documentation": "Convertible promissory note interest change in fair value.",
        "label": "ConvertiblePromissoryNoteChangeInFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConvertiblePromissoryNoteInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConvertiblePromissoryNoteInterest",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Less: Convertible promissory note interest",
        "documentation": "Convertible promissory note interest.",
        "label": "ConvertiblePromissoryNoteInterest"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ConvertibleStocksConversionRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ConvertibleStocksConversionRatio",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ratio to be applied to the stock in the conversion",
        "documentation": "The ratio to be applied to the stock in a conversion of convertible stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r284",
      "r302",
      "r450",
      "r471",
      "r492",
      "r629",
      "r631"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeSPACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DeSPACMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "De S P A C [Member]",
        "documentation": "DeSPAC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r60",
      "r61",
      "r100",
      "r102",
      "r146",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r667",
      "r721",
      "r742",
      "r743",
      "r744",
      "r797",
      "r798"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity holders percentage",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, fee amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r146",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r667",
      "r721",
      "r742",
      "r743",
      "r744",
      "r797",
      "r798"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price amount",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r57"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining borrowing capacity amount",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r271"
     ]
    },
    "TVGN_DeferredFeePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DeferredFeePerUnit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriting commission fee (per unit)",
        "documentation": "Represents the deferred fee per unit."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredOfferingCostsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DeferredOfferingCostsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriting fee payable",
        "verboseLabel": "Deferred offering costs non current",
        "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredOfferingCostsNoncurrentForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DeferredOfferingCostsNoncurrentForfeited",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriting fees",
        "documentation": "Deferred offering costs non current forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DeferredTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred transaction costs",
        "documentation": "Deferred transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredUnderwritingFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DeferredUnderwritingFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred underwriting fee payable",
        "documentation": "Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.",
        "label": "Deferred Underwriting Fee Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r30"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative warrant liabilities",
        "periodStartLabel": "Balance, beginning",
        "periodEndLabel": "Balance, ending",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r51",
      "r52",
      "r53",
      "r54",
      "r145",
      "r162"
     ]
    },
    "TVGN_DevelopmentStageRisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DevelopmentStageRisksAndLiquidityTextBlock",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
        "documentation": "Development Stage Risks And Liquidity [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DisclosureDevelopmentstageRisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Development-stage Risks And Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureEarnoutSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DisclosureEarnoutSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureInitialPublicOfferingAndOverallotmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DisclosureInitialPublicOfferingAndOverallotmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering And Over-allotment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r330",
      "r357",
      "r358",
      "r360",
      "r655"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Non Redeemable Shares",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "TVGN_DisclosurePrivatePlacementWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DisclosurePrivatePlacementWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureWarrantLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "DisclosureWarrantLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends payable per share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r696",
      "r697"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) per share attributable to common stockholders, basic",
        "verboseLabel": "Basic net income (loss) per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r168",
      "r179",
      "r182",
      "r183",
      "r188",
      "r379",
      "r384",
      "r400",
      "r401",
      "r490",
      "r508",
      "r633"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, diluted",
        "verboseLabel": "Dilution net income (loss) per share",
        "terseLabel": "Net loss per share attributable to common stockholders - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r159",
      "r168",
      "r179",
      "r182",
      "r183",
      "r188",
      "r379",
      "r384",
      "r400",
      "r401",
      "r490",
      "r508",
      "r633"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) per Ordinary Share",
        "verboseLabel": "Net Income (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r185"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetIncomeLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET INCOME (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r184",
      "r186",
      "r187"
     ]
    },
    "TVGN_EarnoutSharesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "EarnoutSharesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/EarnoutShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNOUT SHARES",
        "documentation": "Earnout Shares Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_EarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "EarnoutSharesMember",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_EarnoutSharesTradingDaysDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "EarnoutSharesTradingDaysDescription",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout shares trading days description",
        "documentation": "Earnout shares trading days description."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_EmergingGrowthCompanyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "EmergingGrowthCompanyPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Emerging Growth Company Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost recognized",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r117",
      "r132",
      "r133",
      "r134",
      "r147",
      "r148",
      "r149",
      "r151",
      "r157",
      "r160",
      "r162",
      "r190",
      "r243",
      "r246",
      "r260",
      "r316",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r384",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r399",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r434",
      "r436",
      "r443",
      "r506",
      "r513",
      "r514",
      "r515",
      "r535",
      "r602"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r375",
      "r704",
      "r705",
      "r706",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "TVGN_ExchangeRatio": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ExchangeRatio",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange ratio",
        "documentation": "Exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ExtensionAmountDepositedIntoTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ExtensionAmountDepositedIntoTrustAccount",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Extension amount deposited into Trust Account",
        "documentation": "Extension amount deposited into trust account",
        "label": "ExtensionAmountDepositedIntoTrustAccount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrants",
        "label": "Change in fair value of warrants",
        "verboseLabel": "Change in fair value",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r416",
      "r657"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r416",
      "r657"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r660"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r660"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Quantitative Information in Fair Value Measurements",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r660"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r415",
      "r416",
      "r418",
      "r458",
      "r459",
      "r460",
      "r644",
      "r645",
      "r649",
      "r650",
      "r651",
      "r657",
      "r660"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r657",
      "r789",
      "r794"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://tevogen.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r489",
      "r657",
      "r661"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r318",
      "r323",
      "r404",
      "r416",
      "r458",
      "r649",
      "r650",
      "r651",
      "r657"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r318",
      "r323",
      "r404",
      "r405",
      "r416",
      "r459",
      "r644",
      "r645",
      "r649",
      "r650",
      "r651",
      "r657"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r404",
      "r405",
      "r406",
      "r407",
      "r416",
      "r460",
      "r644",
      "r645",
      "r649",
      "r650",
      "r651",
      "r657",
      "r660"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Values Of Warrants",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Measurement",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r412",
      "r417"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r657",
      "r789",
      "r794"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "verboseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial fair value at issuance",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.",
        "label": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition upon conversion of convertible promissory notes",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial fair value at issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r417"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial fair value at issuance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r793"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value beginning balance",
        "periodEndLabel": "Fair value ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r417"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r415",
      "r416",
      "r418",
      "r458",
      "r459",
      "r460",
      "r644",
      "r645",
      "r649",
      "r650",
      "r651",
      "r657",
      "r660"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "TVGN_FeeReductionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "FeeReductionAgreementMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Reduction Agreement [Member]",
        "documentation": "Fee Reduction Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use asset",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r440",
      "r668"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r297",
      "r312",
      "r396",
      "r423",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r507",
      "r642",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r670",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r736",
      "r737",
      "r738",
      "r739",
      "r785",
      "r788",
      "r789",
      "r790",
      "r792",
      "r794"
     ]
    },
    "TVGN_FirstExtensionCharterAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "FirstExtensionCharterAmendmentMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Extension Charter Amendment [Member]",
        "documentation": "First Extension Charter Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FirstPolarFundConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "FirstPolarFundConvertibleNoteMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Polar Fund Convertible Note [Member]",
        "documentation": "First Polar Fund Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares [Member]",
        "documentation": "This member stands for founder shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r582"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ImpairmentOfAmountDueFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ImpairmentOfAmountDueFromRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of amount due from related party",
        "label": "Impairment of amount due from related party",
        "verboseLabel": "Impairment of due from related party",
        "documentation": "Impairment of amount due from related party."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "IncentivePlanMember",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r263",
      "r264",
      "r409",
      "r412",
      "r417",
      "r510",
      "r512",
      "r587",
      "r628",
      "r659",
      "r816"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r409",
      "r412",
      "r417",
      "r510",
      "r512",
      "r587",
      "r628",
      "r659",
      "r816"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r526"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due from related party",
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToAffiliatesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to affiliate",
        "documentation": "The increase (decrease) in current obligations (due within one year or one operating cycle) owed to an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of potentially dilutive convertible promissory notes",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r183"
     ]
    },
    "TVGN_InitialCapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "InitialCapitalContribution",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial capital contribution",
        "documentation": "Amount of initial cash contribution received."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_InitialCapitalContributionPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "InitialCapitalContributionPerShare",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial capital contribution",
        "documentation": "Initial capital contribution per share.",
        "label": "Initial capital contribution per share"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_InitialPublicOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "InitialPublicOfferingTextBlock",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering and Over-Allotment",
        "documentation": "The entire disclosure on information about initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r193",
      "r195",
      "r196",
      "r205",
      "r432",
      "r638",
      "r639"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment income interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r194",
      "r205",
      "r638",
      "r718"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Treasury Securities",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r792"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800"
     ]
    },
    "TVGN_IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs",
        "documentation": "Issuance of common stock for net liabilities upon reverse recapitalization net of transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r60",
      "r61",
      "r62",
      "r64",
      "r65",
      "r66",
      "r67",
      "r140",
      "r242",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r387",
      "r388",
      "r389",
      "r424",
      "r556",
      "r634",
      "r682",
      "r747",
      "r803",
      "r804"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r104",
      "r502",
      "r669",
      "r722",
      "r740",
      "r795"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r121",
      "r140",
      "r242",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r387",
      "r388",
      "r389",
      "r424",
      "r669",
      "r747",
      "r803",
      "r804"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_LossOnPreferredStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "LossOnPreferredStockIssuance",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on Series A Preferred Stock issuance",
        "verboseLabel": "Loss on preferred stock issuance",
        "documentation": "Loss on preferred stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MaximumAllowedDissolutionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MaximumAllowedDissolutionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum allowed dissolution expenses",
        "documentation": "Maximum allowed dissolution expenses."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum borrowing capacity of related party promissory note",
        "documentation": "Amount of maximum borrowing capacity of related party promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MaximumLoansConvertibleIntoWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MaximumLoansConvertibleIntoWarrants",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan conversion agreement warrant",
        "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r325",
      "r362",
      "r407",
      "r487",
      "r509",
      "r511",
      "r523",
      "r548",
      "r549",
      "r610",
      "r612",
      "r615",
      "r616",
      "r617",
      "r626",
      "r627",
      "r641",
      "r648",
      "r654",
      "r660",
      "r661",
      "r665",
      "r666",
      "r671",
      "r749",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "TVGN_MaximumReasonableAttorneyFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MaximumReasonableAttorneyFees",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum reasonable attorney fees",
        "documentation": "Represents maximum reasonable attorney fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r660"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r660"
     ]
    },
    "TVGN_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement [Member]",
        "documentation": "Merger Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r325",
      "r362",
      "r407",
      "r487",
      "r509",
      "r511",
      "r523",
      "r548",
      "r549",
      "r610",
      "r612",
      "r615",
      "r616",
      "r617",
      "r626",
      "r627",
      "r641",
      "r648",
      "r654",
      "r660",
      "r661",
      "r665",
      "r671",
      "r749",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "TVGN_MinimumPeriodForPaymentInCaseOfLiquidation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MinimumPeriodForPaymentInCaseOfLiquidation",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum period for payment in case of liquidation",
        "documentation": "Represents minimum period for payment in case of liquidation."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MinimumPeriodForReceivingSpacLoanFromDeSpacClosing": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "MinimumPeriodForReceivingSpacLoanFromDeSpacClosing",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum period for receiving spac loan from de-spac closing",
        "documentation": "Represents minimum period for receiving spac loan from de-spac closing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MortgageNotesPayableDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageNotesPayableDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE",
        "documentation": "The entire disclosure for mortgage notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization, Business Operations and Liquidity",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net Income (loss)",
        "verboseLabel": "Net income (loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r86",
      "r105",
      "r119",
      "r129",
      "r130",
      "r134",
      "r140",
      "r150",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r161",
      "r162",
      "r176",
      "r242",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r379",
      "r384",
      "r401",
      "r424",
      "r505",
      "r579",
      "r600",
      "r601",
      "r680",
      "r747"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) attributable to common stockholders, basic",
        "verboseLabel": "Allocation of net (loss) income",
        "totalLabel": "Net income (loss) attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r152",
      "r153",
      "r155",
      "r156",
      "r165",
      "r166",
      "r178",
      "r183",
      "r384"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to common stockholders, diluted",
        "totalLabel": "Net loss attributable to common stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r167",
      "r170",
      "r171",
      "r172",
      "r173",
      "r178",
      "r183"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "verboseLabel": "Recently Issued Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_NonRedeemableOrdinaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NonRedeemableOrdinaryMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Redeemable Ordinary [Member]",
        "documentation": "Non Redeemable Ordinary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_NoncashInterestExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NoncashInterestExpenses",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "verboseLabel": "Non cash interest expenses",
        "documentation": "Non cash interest expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashMergerRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger transaction costs",
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance",
        "verboseLabel": "Non refundable amount",
        "documentation": "Non refundable prepaid proceeds towards anticipated preferred stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "TVGN_NumberOfSharesIssuableForEach10InitialCapitalContribution": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NumberOfSharesIssuableForEach10InitialCapitalContribution",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issuable for each $10 initial capital contribution",
        "documentation": "Represents number of shares issuable for each $10 initial capital contribution."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_NumberOfSharesIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NumberOfSharesIssuedPerUnit",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares in a unit",
        "documentation": "Represents the number of shares in a unit."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_NumberOfSharesSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NumberOfSharesSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares subject to forfeiture",
        "documentation": "The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_NumberOfWarrantsIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "NumberOfWarrantsIssuedPerUnit",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants in a unit",
        "documentation": "Represents the number of warrants in a unit."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs associated with the Initial Public Offering",
        "documentation": "Offering Costs Associated With Initial Public Offering [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_OffsetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "OffsetValue",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset value",
        "documentation": "Offset value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r635",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount accrued",
        "verboseLabel": "Due to Sponsor",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r494",
      "r552",
      "r553",
      "r682",
      "r814",
      "r818"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related party",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r669"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Notes Payable, Current",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related party",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PaymentOfUnderwriterDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PaymentOfUnderwriterDiscount",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of underwriter discount",
        "documentation": "Represents the payment of underwriting discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan from affiliate",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "TVGN_PaymentsForInvestmentOfCashInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PaymentsForInvestmentOfCashInTrustAccount",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for investment of cash in trust account",
        "documentation": "Payments for investment of cash in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of ordinary shares",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "TVGN_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation to redeem public shares if entity does not complete a business combination (as a percent)",
        "documentation": "Percentage obligation to redeem public shares if entity does not complete business combination."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant",
        "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PercentageOfProbabilityOfLiquidityEvent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PercentageOfProbabilityOfLiquidityEvent",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of probability of liquidity event",
        "documentation": "Percentage of probability of liquidity event."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PerformanceBasedRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PerformanceBasedRSUsMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based R S Us [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "TVGN_PlusMergerTransactionCostsLimitedToCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PlusMergerTransactionCostsLimitedToCashAcquired",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus: Merger transaction costs limited to cash acquired",
        "documentation": "Plus merger transaction costs limited to cash acquired."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PolarNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PolarNotesMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Polar Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock dividend ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_PreferredStockDividendPaymentRateVariable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendPaymentRateVariable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend variable rate, description",
        "documentation": "Description of basis of dividend, such as adjustable rate. Excludes percentage rate dividend payments or fixed dollar amounts per share."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r36",
      "r69"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r611",
      "r613",
      "r614",
      "r618"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r676",
      "r677",
      "r678",
      "r679",
      "r817",
      "r820"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollar per share)",
        "verboseLabel": "Preferred shares, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r299"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption per share",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r39"
     ]
    },
    "us-gaap_PreferredStockRedemptionTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionTerms",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption term",
        "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preference shares , shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r558"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "verboseLabel": "Preference shares, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r299"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Preference shares, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r558",
      "r577",
      "r820",
      "r821"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r498",
      "r669"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r69"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PrivatePlacementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PrivatePlacementTextBlock",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Private Placement Warrants",
        "documentation": "Private Placement [Text Block]",
        "label": "PrivatePlacementTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants [Member]",
        "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ProbabilityOfTransactionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ProbabilityOfTransactionPercentage",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probability of transaction",
        "documentation": "Probability of transaction percentage."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash withdrawn from Trust Account in connection with redemption",
        "verboseLabel": "Cash withdrawn from trust account in connection with redemption",
        "documentation": "The cash inflow from cash withdrawn from Trust Account in connection with redemption."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible promissory notes",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series A Preferred Stock",
        "verboseLabel": "Sale of preferred stock",
        "terseLabel": "Proceeds from issuance of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "TVGN_PromissoryNoteWithRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PromissoryNoteWithRelatedPartyMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note with Related Party [Member]",
        "documentation": "This member stands for promissory note with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r441",
      "r491",
      "r504",
      "r669"
     ]
    },
    "TVGN_PublicSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PublicSharesMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Shares [Member]",
        "documentation": "Public Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PublicWarrantsTransferredOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PublicWarrantsTransferredOneMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Transferred One [Member]",
        "documentation": "Public Warrants Transferred One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PublicWarrantsTransferredThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PublicWarrantsTransferredThreeMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Transferred Three [Member]",
        "documentation": "Public Warrants Transferred Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PublicWarrantsTransferredTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PublicWarrantsTransferredTwoMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Transferred Two [Member]",
        "documentation": "Public Warrants Transferred Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r317",
      "r325",
      "r353",
      "r354",
      "r355",
      "r362",
      "r407",
      "r461",
      "r470",
      "r487",
      "r509",
      "r511",
      "r523",
      "r548",
      "r549",
      "r610",
      "r612",
      "r615",
      "r616",
      "r617",
      "r626",
      "r627",
      "r641",
      "r648",
      "r654",
      "r660",
      "r661",
      "r665",
      "r666",
      "r671",
      "r674",
      "r745",
      "r749",
      "r789",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "TVGN_RangeInYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "RangeInYears",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range in years",
        "documentation": "Range in years."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r317",
      "r325",
      "r353",
      "r354",
      "r355",
      "r362",
      "r407",
      "r461",
      "r470",
      "r487",
      "r509",
      "r511",
      "r523",
      "r548",
      "r549",
      "r610",
      "r612",
      "r615",
      "r616",
      "r617",
      "r626",
      "r627",
      "r641",
      "r648",
      "r654",
      "r660",
      "r661",
      "r665",
      "r666",
      "r671",
      "r674",
      "r745",
      "r749",
      "r789",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "TVGN_RedemptionLimitPercentageWithoutPriorConsent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "RedemptionLimitPercentageWithoutPriorConsent",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption limit percentage without prior consent",
        "documentation": "Redemption limit percentage without prior consent."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_RedemptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "RedemptionPeriod",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption period",
        "documentation": "The Period of redemption for written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r324",
      "r447",
      "r448",
      "r495",
      "r503",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r576",
      "r578",
      "r609"
     ]
    },
    "TVGN_RelatedPartyLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "RelatedPartyLoansMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Loans [Member]",
        "documentation": "This member stands for related party loans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r447",
      "r448",
      "r449",
      "r450",
      "r495",
      "r503",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r576",
      "r578",
      "r609"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r802"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses per month",
        "documentation": "The contractual monthly amount to be paid for support services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r583",
      "r584",
      "r587"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r324",
      "r447",
      "r448",
      "r495",
      "r503",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r576",
      "r578",
      "r609",
      "r802"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactions",
      "http://tevogen.com/role/RelatedPartyTransactionsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r448",
      "r451",
      "r532",
      "r533",
      "r534",
      "r585",
      "r586",
      "r587",
      "r606",
      "r608"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of notes payable repaid",
        "verboseLabel": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "auth_ref": [
      "r143",
      "r144",
      "r284",
      "r302",
      "r450",
      "r471",
      "r492",
      "r630",
      "r631"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r628",
      "r638",
      "r811"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r188",
      "r244",
      "r245",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r398",
      "r399",
      "r400",
      "r401",
      "r433",
      "r435",
      "r442",
      "r443",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r734"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "auth_ref": [
      "r118",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r188",
      "r244",
      "r245",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r398",
      "r399",
      "r400",
      "r401",
      "r433",
      "r435",
      "r442",
      "r443",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r734"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on transfer period of time after business combination completion",
        "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Amount of accumulated undistributed earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r95",
      "r501",
      "r517",
      "r522",
      "r531",
      "r559",
      "r669"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r147",
      "r148",
      "r149",
      "r151",
      "r157",
      "r160",
      "r162",
      "r243",
      "r246",
      "r260",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r384",
      "r390",
      "r392",
      "r393",
      "r395",
      "r399",
      "r434",
      "r436",
      "r513",
      "r515",
      "r535",
      "r820"
     ]
    },
    "TVGN_ReverseRecapitalizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ReverseRecapitalizationMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization [Member]",
        "documentation": "Reverse Recapitalization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SaleOfClassBSharesToInvestor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SaleOfClassBSharesToInvestor",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Class B shares to Investor",
        "documentation": "Sale of class B shares to investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SaleOfStockOtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SaleOfStockOtherOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering costs",
        "documentation": "Sale of stock other offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SaleOfStockUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SaleOfStockUnderwritingFees",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock underwriting fees",
        "verboseLabel": "Underwriting fees",
        "documentation": "Sale of stock underwriting fees."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SaleOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SaleOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of warrants",
        "documentation": "Sale of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetIncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetIncomeLossPerShareTables",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share",
        "verboseLabel": "SCHEDULE OF NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r375",
      "r704",
      "r705",
      "r706",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/FairValueMeasurementsTables",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTablesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r583",
      "r584",
      "r587"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r36",
      "r37",
      "r38",
      "r40",
      "r91",
      "r93",
      "r94",
      "r95",
      "r124",
      "r125",
      "r126",
      "r191",
      "r299",
      "r300",
      "r302",
      "r304",
      "r307",
      "r312",
      "r314",
      "r527",
      "r528",
      "r529",
      "r530",
      "r648",
      "r703",
      "r720"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "TVGN_SecondExtensionCharterAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SecondExtensionCharterAmendmentMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Extension Charter Amendment [Member]",
        "documentation": "Second Extension Charter Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SecondPolarFundConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SecondPolarFundConvertibleNoteMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Polar Fund Convertible Note [Member]",
        "documentation": "Second Polar Fund Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SecondSubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SecondSubscriptionAgreementMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Subscription Agreement [Member]",
        "documentation": "Second Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r636",
      "r637",
      "r640"
     ]
    },
    "TVGN_SemperParatusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SemperParatusMember",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Semper Paratus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SeriesA1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SeriesA1PreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A One Preferred Stock [Member]",
        "documentation": "Series A One Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A One Preferred Stock [Member]",
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r751"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r751"
     ]
    },
    "TVGN_ServiceBasedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ServiceBasedRestrictedStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Based Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ServicesFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ServicesFees",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service fees",
        "documentation": "Services fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "verboseLabel": "Total",
        "terseLabel": "Compensation cost recognized",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout shares",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount for lack of marketability",
        "verboseLabel": "Discount rate",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Granted",
        "verboseLabel": "Granted awards shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Granted",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SharePriceTriggerUsedToMeasureDilutionOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SharePriceTriggerUsedToMeasureDilutionOfWarrants",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price trigger used to measure dilution of warrant",
        "documentation": "The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested Shares, Beginning",
        "periodEndLabel": "Nonvested Shares, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Forfeited",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Forfeited",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested weighted average grant-date fair value, Beginning",
        "periodEndLabel": "Nonvested weighted average grant-date fair value, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Vested",
        "negatedLabel": "Nonvested Shares, Vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Vested",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum period to file charter amendment",
        "documentation": "Shareholders exercised their right to redeem shares number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "verboseLabel": "Share price, per share",
        "terseLabel": "Price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock subject to forfeiture",
        "documentation": "Shares subject to future vesting issuance of restricted common stock subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative warrant liabilities",
        "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "TVGN_SharesToBeIssuedOnSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SharesToBeIssuedOnSharesIssuable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable to Polar",
        "documentation": "Shares to be issued on shares issuable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings amount",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r100",
      "r669",
      "r813"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r742",
      "r743",
      "r744"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r742",
      "r743",
      "r744"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "TVGN_SponsorAdvisoryServiceFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SponsorAdvisoryServiceFeeMember",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Advisory Service Fee [Member]",
        "documentation": "Sponsor Advisory Service Fee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SponsorAdvisoryServicesFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SponsorAdvisoryServicesFeeMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Advisory Services Fee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SponsorFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SponsorFees",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Fees",
        "verboseLabel": "Sponsor advisory services fee",
        "documentation": "Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "TVGN_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SponsorMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]",
        "documentation": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SponsorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SponsorsMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SsvkAssociatesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SsvkAssociatesLlcMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SSVK Associates, LLC [Member]",
        "documentation": "SSVK Associates, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r125",
      "r126",
      "r140",
      "r168",
      "r169",
      "r179",
      "r183",
      "r191",
      "r192",
      "r242",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r299",
      "r300",
      "r304",
      "r307",
      "r314",
      "r424",
      "r527",
      "r528",
      "r529",
      "r530",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r558",
      "r580",
      "r602",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r703",
      "r720",
      "r727"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r73",
      "r74",
      "r117",
      "r132",
      "r133",
      "r134",
      "r147",
      "r148",
      "r149",
      "r151",
      "r157",
      "r160",
      "r162",
      "r190",
      "r243",
      "r246",
      "r260",
      "r316",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r384",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r399",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r434",
      "r436",
      "r443",
      "r506",
      "r513",
      "r514",
      "r515",
      "r535",
      "r602"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r190",
      "r436",
      "r488",
      "r525",
      "r547",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r581",
      "r582",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r602",
      "r675"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r190",
      "r208",
      "r436",
      "r488",
      "r525",
      "r547",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r581",
      "r582",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r602",
      "r675"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with merger, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r36",
      "r70",
      "r73",
      "r95",
      "r291"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesConversionOfLiabilities",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of certain liabilities into Series B preferred stock, shares",
        "documentation": "Stock issued during period shares conversion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r36",
      "r69",
      "r70",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Sponsor advisory service fee, shares",
        "verboseLabel": "Isssued shares to related party",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series A preferred stock, shares",
        "verboseLabel": "Stock issued during period, Shares new issues",
        "terseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r95",
      "r527",
      "r602",
      "r620"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesNewIssuesOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOne",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B preferred stock, shares",
        "documentation": "Stock issued during period shares new issues one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock, shares",
        "verboseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with merger",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r73",
      "r74",
      "r95"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "StockIssuedDuringPeriodValueConversionOfLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of certain liabilities into Series B preferred stock",
        "documentation": "Stock issued during period value conversion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Sponsor advisory service fee",
        "verboseLabel": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series A preferred stock",
        "verboseLabel": "Aggregate purchase price",
        "terseLabel": "Shares purchase amount",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r95",
      "r535",
      "r602",
      "r620",
      "r681"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueNewIssuesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "StockIssuedDuringPeriodValueNewIssuesOne",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B preferred stock",
        "documentation": "Stock issued during period value new issues one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r95"
     ]
    },
    "TVGN_StockPriceOfMeasurement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "StockPriceOfMeasurement",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueNonRedeemableSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price as of measurement date",
        "documentation": "Stock price of measurement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger, net of redemptions and transaction costs, shares",
        "verboseLabel": "Shares cancelled",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger, net of redemptions and transaction costs",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r89",
      "r560",
      "r577",
      "r603",
      "r604",
      "r669",
      "r682",
      "r722",
      "r740",
      "r795",
      "r820"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Deficit",
        "verboseLabel": "STOCKHOLDERS\u2019 DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r139",
      "r298",
      "r300",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r397",
      "r605",
      "r607",
      "r624"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "TVGN_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Member]",
        "documentation": "Represents the information pertaining to Subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r453"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r453"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r453"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r453"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r453"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://tevogen.com/role/SubsequentEvents",
      "http://tevogen.com/role/SubsequentEventsDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "verboseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/PrivatePlacementWarrantsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REDEEMABLE ORDINARY SHARES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accretion of carrying value to redemption value",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A ordinary shares subject to possible redemption, $0.0001 par value, 1,502,180 and 34,500,000 shares at redemption value of $11.10 and $10.34 per share as of December 31, 2023 and 2022, respectively",
        "periodStartLabel": "Class A ordinary share subject to possible redemption",
        "periodEndLabel": "Class A ordinary share subject to possible redemption",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r361",
      "r500"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, par value (in dollar per share)",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32"
     ]
    },
    "TVGN_TemporaryEquityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TemporaryEquityPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Ordinary Shares Subject to Possible Redemption",
        "documentation": "Temporary Equity Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TemporaryEquityRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TemporaryEquityRedemptionAmount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfOrdinaryShareSubjectToPossibleRedemptionReflectedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of ordinary shares",
        "documentation": "Temporary equity redemption amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, redemption price (In Dollar per share)",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares outstanding",
        "verboseLabel": "Class A ordinary shares subject to possible redemption, outstanding (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32"
     ]
    },
    "TVGN_TevogenBioCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TevogenBioCommonStockMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tevogen Bio Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TevogenBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TevogenBioMember",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tevogen Bio [Member]",
        "documentation": "Tevogen Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold number of business days before sending notice of redemption to warrant holders",
        "documentation": "Represents the threshold number of business days before sending notice of redemption to warrant holders."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences",
        "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r801"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "auth_ref": []
    },
    "TVGN_TotalNetLiabilitiesAcquiredPlusTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TotalNetLiabilitiesAcquiredPlusTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities acquired plus transaction costs",
        "documentation": "Total net liabilities acquired plus transaction costs.",
        "label": "TotalNetLiabilitiesAcquiredPlusTransactionCosts"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading period after business combination used to measure dilution of warrant",
        "documentation": "The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TransactionCost",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Charged expense",
        "documentation": "Transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Merger transaction costs",
        "label": "Transaction costs",
        "verboseLabel": "Offering costs",
        "documentation": "Transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)",
        "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination",
        "documentation": "Transfer assign or sell any shares or warrants after completion of initial business combination threshold consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination",
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r297",
      "r312",
      "r396",
      "r423",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r507",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r670",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r736",
      "r737",
      "r738",
      "r739",
      "r785",
      "r788",
      "r789",
      "r790",
      "r792",
      "r794"
     ]
    },
    "TVGN_TwentyTwentyFourPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "TwentyTwentyFourPlanMember",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Four Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r649",
      "r651",
      "r657",
      "r812"
     ]
    },
    "TVGN_UnderwriterCashDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "UnderwriterCashDiscount",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter cash discount",
        "documentation": "Represents the cash underwriting discount per unit."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_UnderwritingCashDiscountPerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "UnderwritingCashDiscountPerUnit",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting cash discount per unit",
        "documentation": "Represents the cash underwriting discount per unit."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_UnderwritingOptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "UnderwritingOptionPeriod",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting option period",
        "documentation": "It represents the underwriting option period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Undistributed earnings allocated to participating securities",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r180",
      "r181"
     ]
    },
    "TVGN_UnitsIssuedDuringPeriodSharesNewIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssue",
     "presentation": [
      "http://tevogen.com/role/InitialPublicOfferingAndOver-allotmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of units in initial public offering, gross (in shares ) | shares",
        "documentation": "Number of new units issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_UnitsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common equity securities",
        "verboseLabel": "Sale of units, net of underwriting discounts (in shares)",
        "documentation": "Number of new units issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on investments held in Trust Account",
        "negatedLabel": "Unrealized gain on investments held in Trust Account",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r368",
      "r656"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits accrued for interest and penalties",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r656"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPoliciesDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r110",
      "r111",
      "r113",
      "r114"
     ]
    },
    "TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "TVGN_WarrantExercisePeriodConditionOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WarrantExercisePeriodConditionOne",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum threshold written notice period for redemption of public warrants",
        "documentation": "The period of time after completion of a business combination before a warrant may be exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WarrantLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WarrantLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/WarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liabilities",
        "documentation": "Warrant Liabilities Disclosure [TextBlock}",
        "label": "WarrantLiabilitiesDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WarrantLiabilitiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WarrantLiabilitiesPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting for Warrants",
        "documentation": "Warrant Liabilities Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r676",
      "r677",
      "r678",
      "r679"
     ]
    },
    "TVGN_WarrantRedemptionConditionMinimumSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WarrantRedemptionConditionMinimumSharePrice",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant redemption condition minimum share price",
        "documentation": "The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability- Private Placement Warrants",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "TVGN_WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering",
     "presentation": [
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public warrants exercisable term from the closing of the initial public offering",
        "documentation": "The period of warrants exercisable term from the closing of the business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfQuantitativeInformationInFairValueMeasurementsDetails",
      "http://tevogen.com/role/ShareholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public warrants expiration term",
        "verboseLabel": "Measurement Input",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "TVGN_WarrantsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WarrantsDescription",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants description",
        "documentation": "Warrants description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total potentially dilutive securities",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock outstanding, diluted",
        "verboseLabel": "Weighted average shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r183"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average common stock outstanding, basic",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails",
      "http://tevogen.com/role/ScheduleOfNetLossPerShareDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock outstanding, basic",
        "verboseLabel": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r183"
     ]
    },
    "TVGN_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/NotesPayableDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "verboseLabel": "[custom:WorkingCapital-0]",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DescriptionOfOrganizationBusinessOperationsAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital deficit",
        "documentation": "Working capital deficit."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WorkingCapitalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WorkingCapitalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrativeDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital expenses",
        "documentation": "Working capital expenses."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WorkingCapitalLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WorkingCapitalLoan",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital loan",
        "documentation": "Working capital loan."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WorkingCapitalLoansWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20240331",
     "localname": "WorkingCapitalLoansWarrantMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital loans warrant [Member]",
        "documentation": "It represents the working capital loans warrant."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001493152-24-024790-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-024790-xbrl.zip
M4$L#!!0    ( *J)U5A]=CE*JPL  /1\   +    97@Q,#<M,2YH=&WM76UO
MXKH2_K[2_@=?M&=%I4!Y+7UAD?K"GNU5MT4M>X_.1Y,8\-F0L$[2EO/K[XR3
M0'@)X"Z4T*92U0*)_8QGYIEQ; _U;^WO-XV/'^K?FN=7\)?@3[U]W;YI-NJ'
M_E_X]##XN'YQ=_4W>6C_?=/\DNG:EGM*BH6A2]I\P!QRRY[(O3V@EN:_H9$'
M)G@W S?"K2W5^\Z(RY[='#5YSSHE.K-<)L[(@(H>MW*N/3PET,3XC8[MNO9
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MK.2U &Q2Z><#8'E7NN(D-M4??K0:V2+D(OA/JO*WI?*6L(>V QG(=_K,!]Z
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M ;=PUZKE#3H &?!1P^"X]PWRWLGB.S:IR[4K-2@.+G1I9$@%>:2FQ\@G?ZV
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M BN"VH6!,;TON.&EH:G2N:J,_@I*-AM76%FP\;K.L"HT:(;C%B+T%\$XUUQ
M[W4;>A>]5VVWV-"TBC5"Q$0">\P%D<0JO8<<_26:Y"D04^.B*LN)W!^J#U6V
M7'"[=\/(@.6R8"C=;!!(%.)PG91II'#';8K!F)S1DB07&RDB;HV+U)F.N222
M<B+ U.R8KZ2GV?B$'U+:\QEEV185+KLE#Y>(.W(WO?(&IV89SIX1;8#)"'G[
MLDK-(<&I3'25; 8KK4J@A3ER;!R=ML+ZQ6HXAW<,=DPSB+C)N#'H&X,N>5(:
M:47A0PY_KW+H FD#H51I1XS8HT,&*7E@()4%Y,4M-<Z,W%=V0+FB>.!8W;E6
ME$4%9N59>ISX9Q-2 457S0:"-05B^XCV2![ZY2I"Z1B7T++'%6!=DP=P1)1X
MB3!E\3R=/IK%R *63ETJ,<>RQFWR8"UEQ,&%,Q&Y.@P>T:$U9[I\*B/[JC2<
M[$ITX@MIQW2:C1NB:9'!<ZL/6'?$ 3 9$<*C)#>MD1#Y$>Z)HC[QI%7YPHC_
M,PF;*UR*QS)APDE-QR<+Y(]"XJM+K]K47ITLC,].( 3PPO/@BC,1]?'E(&$#
M-'!?N%T%%0>PS-VJ;_HP)\:"YQW.R$-_]F<=507'LRHO(=7XO*VR5N$+_&O7
MM\6ME^ECWT3@F0ZZY[\A=*,$CQ!I.)[, Y@&\_EJ[/OX"O^F==$JGS>K\;1^
M/CC=\<BF#MK%2Z>ZQLNOQYZ?3P;PB7Q-1>B[0_[:_3G?V"*L&N$37CJ.F K\
MR6<<3[9+_Z[ZJ.&^??P-4$L#!!0    ( *J)U5B_O*Y<AP(  -P,   *
M97@R,RTR+FAT;>U77V^;,!!_CY3O<(NT/H4FS;8^ (V4%-IFHRU*T:8^.F#
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M"LUJ:RRAM[*@ I9,8FFD8V BY4V&5DNL"R;&PP$166]%T1RI(J668./(L4@
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M"TJ+7>V/-9:(];ZSJ5NW%ASV!C>U#C,DA+ EA!!I+OB+OJ+2LD >T]&#9WO
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M_*(Z2_.<"UAR_P!O-24-K+"= 'IPW*\.++"(F8PU$)7P;,_P#CC8XS8/CHB
MQ;=+?52$=>*&>9#"4@'U/4D)]B=^!\IB*U</]A?H3ODQXQ:1/$N >@8("N?!
MPOP/LE6Q]_@^'!-F3ZI !_4O-B(#+;_P55EIBX<,N !<HDMA05+=C[*.#;<J
M-JL?6PNS;<SXNK!D_='J.%("K+7=0L@5Q,1-Z@5V=Y80HBR$A!#E@ WN@]$6
MEQN/?,.:1=M5Q5W8*XR@Y,7 2Q;]1_NZE69P#U ^"6''T>$_?3H.16AY6;K_
M%,C7+"9F..:.<C^_I2^RG;,JQLH</#AZI3H.^QTE=F0C)S[(*95QIE4\ZOSU
MR>8+,@6LD(0]A[M-UM]X>!SRK"4S6,[N6@-Z%YN;W)51=01%#U)='>PLCJ_R
M'SX30CH3V7N^2?UJXNE3!3K',WO@9:"2H\^ @&1>\@I47_L]5+&__?Z%4K!O
MU7/_R# \_><FE4X?B%<_&* :KPG#0>)@S-Z>Y< Y0<WJE.9E$=), 7?MI1"R
MGG!PBB>O^ZZ)W]G]-0PH5,ULS(LHGK729AIC .^/1B0^Y?1I,/M)=<-?X6^W
ME%%^0LB]- R]HDV*@RXL^8&V!*3DTGO(B'MJQ[*O"T0FIIVVJEB8^V@Q#KJ%
MZ<9<FXHX^K9F7L:[4U;"Y]+AAIWCD*7OB'];'CP>(+9MDZ8)# 1]C: P/(IB
MS:UIYO&3MHIQ?-_P8U>#!++$Q:E[@Z("Q57&LY41A8'X-5$+*@W/=L+=)M7.
M4DC)^'JO+JE)W!FV6@D#GDS:#[M&VO45R&4BNM.CZ;G)*#&Z?HK:06JUE3J2
M8$N-<=*_E.D-/'SQHQ$:SH8E+Z]-+80'N3?X:.F.'\US(_MH,[ZH[3)MGC@J
M7IE2)B]^\;Q[C1F58G["!=> .SE;X#J^,IWBU*OY8VC0%*_\Q%$4.V@0D^^A
MJ>C9Y2!;HF3J\:"B7__RT<=I056>7E'AML<W5OX-%9_N@ X"Q (8_)<)3P\0
M0BH&<4*(OXTF_]QO2WQ- <;&\[</0C"__?HW%<S'V8P>&KLZ(H7$AL,F9IFP
M=N(=-:VMG!9[EC(T)8Y4!P<I,M4 .,/?240F(R9%.Q$@_D34V'&=AP0'$:'#
M8;7V97RO'*@2RA)W'HAE%.Z='*2\"HZK4#%'EY1/_J*V@)I\A_\(RI(3U@F5
MDNK!*X9> 'AT6C=1"=#OG(PC8_9,HRYS3+I@MVGU.Q"0E@@VP6[H.><AVV9Z
M+3<\GA4.A5MIW>M6RGE:$F8E73?TG1/;XOF8X^:K;$IPTVYWR<]&\I2>B/$\
M%J$MWXK-NFRZ>.<'G]ITR[D5^(E7Q(WB53J=W/H-GCRP<<EM+,L@+.;5?"R)
M"''>WQ*JX>PR$_V]4%/!V7C.Y ;FWUAZ!?D;2_7$%$!-B:DU/1(DJF:XT &]
M(PNB" 8\;0HV@7J&V19^$?='9$_:ZP$T_E]FOZRY>2"A1$ G<KGN0#AGE@)3
ML]"OX%_@1-QKVPZL4# [!YXT1H2#^F12^4P^@CU:M'O,=3G<FN)EM;,QT1P*
M[:\.F?1\JM$U,P^$KKKY'643Q7CG4&J ,6/P\SVN$K#"IC(V4EOD6%*IS4)(
MSZ XRGW< LY\MR)#9M;8,8H:RBZ&*$W?=PW>M'W*>*>\_NYM#MFV+N.'=>AM
M^XI0O3V]5#N1SC=)R3&&:6WU!A>;GVC'JM^9>5$U4J+]TVFLPL%Y_WU$786S
M<8!9R'+I4I?72=8>D_&2!P,&]:&7;[B_7BWE1!9\52M##C5SW4.[/.Y_*_2.
M#72XD3+I5+4%"G)I/9#!ZW  7+#MZO9((41\>\_!6RR!C&%DD:'!^V[D/[.'
M MPO:-NV];G_# 7GBO#LIY$=ZPL(/$FE30U09L 6>WE[4*=SR4?AZ325M97]
M@G&\ M_N^<1DF+_%B$"!?YESZBD]8J*'$83]:W7/W_Z][)(.$^@!7;Y^N6FN
M.\>N*]&XD-GX&(*Q06' NAL"E#F9K(A.$9[E5A6C:?$11YD![P9Y7H*E>;<!
M(\>WX_2DAUM)H"X!FNQ\OSI@BKW TL.QQQ?H@UT@$2!+6+CD&*F'G\[$)S*D
M9('4"ZGDKZ+U3>/U#\.)4558AH-TB86MT^V2L^^Z$[171$4=(CM&W;\M5T6;
M44-+V:,E\JXQY0-E-<%]E1DZ::\-:_:<BDZM\9%2V5YSUK2"=Q$.M1]-";V(
MME&QG!NAC&65.!=Z#[V@F1CE7 +!+Q=&KR830=(RG;<'ZXT#ILTZUY?S:_@_
MA.8K!;R!0FX5X>O6<T3_8*," 94@R[<O&WL$8G%L+XK5#@#.,YUK7O.V6Y((
MXPP*Q$'W)+F3P[O ;BR+!G66^"SWR+A1NO8LF29^7(.S3L!J8"E*L8*D\HN7
MD/<Z3TR?*F;ZW0J/HVR>RF<D!&"^@R)X1^]6EM&@).#8F4=;LF&5<*2Z24U[
M\3R#.9@B2I=> Z5@1&)J1'H0$D:X R@#N.+%=.<IMZ'U/N(!Y#VR0)%SLRHL
M(2Z(,'^K]:.27RLWG]!5_H4AU_'S.NPSX(Q&>^S,&2T?.SJOC4R>&YPF>+A6
MF+Z8C@A2"[*?[C;1;@E7J#@^NX\YMVIFT9TEW^!"T&+0RQSS8BN:ZQE:MMJX
M>E31F$_A,N[?WO8CZ$/D0!]2( T2OM1?JRQ]HJC<7)OT;UH!.:UBLHF,2V_3
M('%H[8UC**EBOED;>]6&??2#PN%F$(]P8H"U>]A[T=12GJ]329A\Q9YSQ2D,
M5B$TYC*<15B*Y.F'DFKE,]!0O@;G16M</"?A F! UW\(5>3+Q9:\S-4$:5^9
M?];)FJ+D11:[?F!YIJ%J"]9NHB;%V?4:]6G2^&454Z+UX+_Z"&(SJZ )%T)Z
ME;=>1(/"<V?'P&D^ABTV^$<,?0VRMKU5XS%[65W23MI:NR_0H9[]D^!JZNQ_
MRXUB:_')K3S_/J/_VEB9J#PT*J3(]PTVY<3GYL]_.8?CTGTM(D]4.5]\ G_<
M8&'TO413Z;K>A<),KYN/LZZN',A=V."?J_O-"<IPOB9X_U=DL]^0]UI$\5>\
M$'*_KYP>L[ )Y>RG\N7R!=C?@U10M5\2D#B7(@4)7O0/F6D9Z(U7FG&:5K_F
M,I[A?-N::5)7)>"+?S7%"2$G7H'%@H#U)O;L9[:IAPHA4Y<RFKRO0.&\) QI
M)6CE(+@)OY^?;;5@V!+XS2:>00^1GX$@($+AP,,XT">," Z(MEO@_GW&DL0P
M'+P.T^8K'@QX$?_C5N8H3^VV&M_$-8P;U$Y[W;.8(,^7P="I2Y:<!*]QOA9'
MF06]![L^$3,H.XT*'Z[7/\V<7>1PW,CHW5OX-E64%:!L<I]H#'\("F-9#<ZA
MH1:P))E.ID@K1XG$FPF C-?= 2N5FY?(\8GF'CK?D&:58ZQD@HK5+N-*\TR"
M9V6+7'!?]MFL+WGO/&_BWFE"[73[W]095?@702TH'4-D1SG7BVD1K^^^J!PN
M"S3!YF7-F+]RP;W#?'^7DOM"ZM^/FGZ7IKP(?=^\%*BE<"H%LP(=??_3N(K^
M0[_S\EO&DF&<&U:0M2._B3JFQQ</TA$.T1?!!87476OD?M@DB;GK#L\<]4>N
M Z )73+@A-&OE3!.P[!6EAR]=VQU%\"-K4^F*1M?)*XT^&1;Z;-Q?/7<)B\O
M@:G?^9 \W;%.;[\^;<H1*T6F%*!.RJB?PCVP4ANRLD#J]*B9L1%+RNP-N@X0
M1%:3X1A/!GMK4E;V(T7)_GN!+H[MSW-)?#&Z[O75GG$M@I]=1&7#0/'531TC
M[\*9:J<NIQM.Y]WRVV=BMLI,W6]4W2W0M+<O+_/PO_!B]&5IZ7#=_>>SXEE?
M6L6'69O&H:Z;RX$>G64.J+7768'B+Z7=OI<@N]W2F%/ISTOSLC04!N1D+<,$
MAWU^CX! SN@"RT6U'01#$@*H%D(&I,;_IWT<!)4-2F1-",G$U&J.P'Z:W>Q!
M6S6P84N7>5 @CFL$]+'S.[WQ%#\=;AZ[*:5!M(5CDMQV -2]]P6'G#3OHS6G
MD9I=I#WH#EW<@P:X))+0G;/I;[&MNJ<DE&JH^>"OZYEGFDFO<YWR8, QDP[]
MN[2ZE2Y:,GZOE>R<_V$V(BV7BP0"F)C)./K& RMU;[X/GJZYI,M\&+OD U*)
MJ#Q3#H^UT-U%Q##TQ0?I9*:N#L_0GF]"G/X:DMM4&[IK_@.Y-@?1N3Y_6>M3
M[RLY]?22!S5GG[>7C\QT]MH2Z]UJQ$>I%EF7S5QB9D\](RQI[.Z[^S*\Z_.M
MBY/9JP6!FK>)2<4/RHY?#73#*XJ:^_>/D$=+?*;3RDQ'B$N'=GR?^]D=A:/A
M_UL[(P!<(Y[_^=,_LV_2[]$W:*)XP3!\VFUBQ\<[H\R_URS?6&QZQ6VV_BV$
M#.7K@O;@(N;GX/O57+E(52I?]QH"N, 30J@E&SX>8.$^^3WX.G7+GQ GCQ-
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M3;M[WZ(_"\;PH+<,7-DG +4;KAUWYU;<XC2]%3W('0 ,.&%P=C>6 /:;8S6
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MVK'/J6F/K[0=_%%T?&0%\[H8B#U%,.F< ?!QY7Y]P3G-(9^,:^ 4;RC.6#>
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MR#S1BU9GZCN^9GA^K:5AOP?1*/,VZ+P#C">1"F8Q84F-08G#* FM1TMK6'$
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MN%2EI89R&:R:&M"RLK_8&&HX_K*$XM%4KYV9::]O&1H:+-^C6466%_/VJI]
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M&E;4M )#+PY>35M_\M-*I7[:*&;+9P/U5!.&3WR<D4RDLQ6#V&[S %^->&#
M3\T,W/X</ E^Q1SEQH='X5-0!YK,?"?8\/T<DUHF!>+O*\WZ5#1F.W'@&/]#
MR/8L+[5O^B:J'^X+0G1X94]0 %7RPQ;)D1DQI"#2FZV^<YH'@W/\&'UTJOC#
M8T:G1GLF%H2I^#8K89858ZH]6SUAGR4CPT:<8PXP&?T7N,^T2D%)=&A,5YYP
M'6/Q#9--^UI<P3%D&@_\>L!)N="7\XH'&YS7KBDJM'XX?>4UP\'/(=U5*=0:
M7_O0_5;>81'B[4*G<MMLB[.YQS*"@]%622Q'1:EWB5JO(Q-3:]W"2CL':E3T
M3N%/I1L8S%;=L4_1TNW__52<'O20HU\%+-D.A>%VSE32U&S:[PH1:/@#KB/C
M,Z=3J!3!2'2;UD*4%]YQ0'/.2MJR]R%3UF[)]EV]I4+(^HX#NGO">+ #+0<X
M5H!NI1F5F)BW:P@M6/F%6Z1VH]9/L[&@V5/\HIY3!4LJ-:'4?\3ZI1B^),8W
MU#"=VZ%\4EHV/1TWPX,E("=*6R0; 24C2<"9A0%2 NGO-(FI0TXH*:.CF+[;
M>%&.K1^6^83>Y?S7W*V93.)V#C+(+[B( N!,!SGV!3/B#;[Q33X5@!/)MK[/
M0-?P\V>B*#J<^^(20&38LR(9<>78TL@T&BJFR9C])\"F$1+55\L]5490!S@^
MP,MP6C3RSV_Y-8GCXXO?_/:?JYR+.%U7-Q1 LS*[&#>NZRCX.3?RAK6?4P7F
M36:3PFZ'L*QTFP#W](NEMC1U\X9;^0O>4A:BV"A%)^5"U>Y;5VZ]MY+2B+Q!
MGHM\U)^"NHU_^^KW7%\!H]LQV=_Z5;'N8&A1NE)73N[/"&"E [4,&\;.PTNP
M,T?65LD+P3R88C0;A?WQ'>Q';C9C#@Y_SCLD#^[G!CWFP0X&, %N*L:H=I6R
M< M+5R<&]'\'AY UPX;$R0:.,?)3\^ZB-R><[EY6"<.N2MM\7'DQ/.#/@WTW
M07#-?._9R9G]6J 0J$,9N!40^]7F1M8T&YP"3<5QD5PF#Z:QJ XHXCK)D$7F
M:S$"YDB0Z#$PJ8ST;H]GG>'6H!&^=ZC8?5Z1EEU2F<D&P6RCR/KVEKV,X?L<
M5V_?:.W8IG":Y]W987,&]M$(7/[/X:H;M9(^-H?.@96 (KA'FGT"\PTK>$,3
M/N+<3ME5LR2$/LMM,A+Q:SD.!#$3>SJP(F@?*OE'-17+$5[IQ&X_9F08@-WG
MW2]&=P2^$"(_M9_]AK9G6LMK)RQI!>WS/"?T5]8%6\]V#N5M3$SRQ*+'U(.=
M_!)TO!W\7-J'70YR'6DQ.?LB=5L5<VZ=T+NZEQ'02;H:>0-SV"7K+<&Z,57J
M1+F%Q]M7KUO&.NV;TZ=4F#F%RKHFWXI*.Q7=' T_\^^C+<]KW@I[&5<:G_PF
M)%>OY[ESAL;WE8:ZD-L%)9\TZ;NZ3CD6E;T/L7N(?$&.&\8R+(E"G!W<O[([
MW(;G*YF^M*IXFDV,WG!*#0\F,9U5WRY0[JF- MRKVIFX,P ^BDI^>+<_P+<5
ML?]W'^'88E/4':94?^=(7K;@8(V4TWW]'T[\R>$XX.C.QVQ]S(";69PB(,B,
MH765TWBP$3>*-?//S1".R/"1)U;>I@W<+'0H0_'/-X AX4O0JVDWQ^;!%/(#
M]$F:>AQ&;OA7XU#\H_D7EME^WIQ])V/>;4M.?8@XT_2X'99_,"0TYW=N]0[K
M;2,G=*;^&B,?3%Y%'C>OPJYAQY/'?;/JI3XU9=:_S6FI7ZNW1J<?"!O%?#'=
MDV5[T\I\)!$"-]?<0M&GDTR[]B8]'LPWY);-3D;>D% 8=Z2I#E^37;)!J_Q(
M< 4;P"](28P4H KNKF5?Y9P$TIG#;2->;YC>K+M,WX<@Q!=]+?)0<+4[5(,2
MAK UZC&8@]-$H37DCQX7Q@/.;@88P_S#BM^5>;2<?69Z_$0FC3^6<Y*VVZ[7
MM#+(]W(QQI3Y_IZNY(;UB?.+-K]WPB]XORGYA/[1>B1L,O54)-DPQ)P?-KGR
M31)&(GHU8\FHOF:/HWLDW-Z-]$*3_TZH=$A^*=&5PTV^OMQ_T=+:I<K/<CRG
M><[T\_+).P_?/ W9U(C5.4;<O681DCQK$7YP3N^KHZRY5L'DP*%=RV>/V]JE
M]XLE*E4-5U-\>UD8,UGZ.!*-_0QV8B>^X3>D>+") @1+'=.)V+S%?7T]'Q3<
MS8,]+@?W&"]1E[[G(^)>LB_Y;O2BR#(!/)B"42 /ABK%SFKQ;2(?("?3NXGS
M4L5@X974)' /]/[V4UP"<>(ED7$1,>++2@%$F7#6M6_HW:=+&=7443^L*-J7
MZ=X^?CP&!0F]I;A;LV0C/#7HP;A6;[;5NT"+$4^CW_!]'I::[F!O8,#1:5([
MEKDGGB.22>PD?P][<H<'2\(S)S '(9^JY4M9^4U\CW_ 9W2<6]1,O&ZN#]\\
MC-T!]QK3=_YVZ$XW29<N.;>(;6MD-/GD44]\1ZOM>:9E)F JHE0Z<?VK?ZXF
M753YD]]7I\:0C"7G:]Y)$S?ENFA,G8;5DS=;5)HOF/C*8([N#P_0TGW7MG_R
M0<B@J9[952Q>FW/VY=91#P_VZCU;B >C?@66>+!O@V;_33]J6OO^-/*0*?\+
M3FP0V,2$<[@?H'=;( P[&HKM,* 2-OF[L-0>41[L(WZJFP?;5X)M-4=.5V':
MB4!HBSX/MJIE^X^]SIN"$W?A'VVWAC?;7.E KJSS\6!QFPC.L__-XSK[,2B@
M(,2Y#Y( )(T_ILFY%.W,353L;S(DN/MGOOZ.M@1^*<S7,<ST&MQ(P6R=T3,K
MPH?3A3W./MM[X1X=23':VJT=QMLOA>R:UF>:,TG[-/O+[U=;(0&;E]5.43;5
M*D:(6S]])"'%PO2W!$6"U1WZW73FRMS"D>0Z-B@(^=@'?WGX2Z4,(,615Q#'
MYRX2&W!? #SSA\]^3R]RL,1C>]:-<-<_+/AB']^[]:FB?6\ MD,%P;!#;:KB
M7R\BYXLYD5,,:-'^'V;OWAW>%-P!"^-/>W)W3==P,R]O;%J@^Z,$"2:D8VA#
M1'Z-)1F<?9)8_N"M.?9C2URO;>)X0($=FYT 1+5;6W%14J-/"[$+,G9#UG91
MIMW:BD4?>3 C%!![#MQCSH.9A+)DH63.95)XL)=EN'_N)GX+XON&.9L,-][8
M@YTC[^/!R#_AH/0T=ADR18_NM*-6X<G0IS-4H;I%DM/ 0Q>A]3_!]GIPX[&,
M*70$#S;MG_^/O815Z0^KB+_RMX;'K4T]PDXM\O-@@JO(C1/_!XQ,.-.+G1@F
M $H9N8QJ6L2#8J"2+=9"H",ET2),H70#Y %01_:X "*.A9<\-/1JX!KVQY?C
M+QL;,VE'4[@9&741ME:R=27#H6Z:8@EWN M_9W6J*8P4S#4C\F!N11Y!'0?,
M]=ZI*INZ^:R*O7GRA!WT9U]@>&TB+IZC+>0K)='Y1=*8!VM+56!7>[QU"NZM
M&2%:D5?HT (<L!,%S4CJ34S[]VX#SD6 $9J60P<ERR6FBFPD6^5+_U47V*VZ
M>,^#O<4SZ<2MYS)JA8X^@:\15B6-B">^WA4RLVZI\4Z=6/FJ2S^"]PK9J0&*
M8N>&]\W=?2?K'@0*EZ@M\F#X+Y3+6X67K3!_,I<XZ9W8Z\<=J#,/_ ;ED3</
MMK,8LMSFP>1.XG=HTX2PI,=S%%"R6!'9WXQ@[L%Q1)YN/6$PE"6S":V$##"P
MZR,![$4F.:7I)&.N3>XPDY*LY5*#$@#<+=X-:35;7_^=?FQ>[8R?S\DS3ZQ4
M;UZ6N=4IW7VDXE&BY387O""H HC3ZG(K_>5V#_7;RXDSU99BFFPO!_N%%L^"
MTDQKO&^Q?Z:;4&.15Z?@>&X)#^8]IW?ZS7:-+J/! O]-K^(;?3]0HU\4JK1H
M$::.PX-><L(IND.N/@CO/6GUQQ2,PD5U0Q5$QD;]U-QL=M]2W]75=.*MXY!*
MH:YCG.3OVL$[?3'^X8=LZ$\/TS8*16@5H[W:B(GZ?^4.M$SQH'^5#7V-!TOV
MIZ\5_"M4/UJ!1K;0A#<.<.7!9,G$<VS-J9F/+!KQFS#;UWSYR+/9!M=$67OV
M8;_8M6>):A<]*E_T*Z1]W945/Y*KEI)THF%ETL4 ?_(!7IFQM+"-0>Z4,Q@P
MDKT^4KD**O=Q;.C(79X_>@I0QC>SINZ%483\6X[4N7?+[S-PRO!2Z9VL?^=T
MTK.FSVS;M?J__C#PZQB4M[OHXFJ:<V?60M='SN4LZW=.\RO;E-7&!NL1_ZJR
M6]J[^M*5!AUG/C5Q<R5Z-#N4'4OZ,Q6T/OTL[)'43,]-J[Y]&Q2QX4C]!\(!
M$<*@ 033%4/(YU!!VFYM" _6Z\Z-1S*F.']7$P^F8_2#!SLC71ETOL;*PKW2
M^T*ME<*E:-O%H(H)JY,WY<TO19L4/M^1^#6U4F!,(L/1Y^J1$T<',EFV/]W=
MS*-]1<<^/^G<45'](5/[@,F-X9 CIQ<.9OD=^"'WJT_3]SS?A4^'[>A:) ,S
M#G"Z$KLAUNL_9!<8->.>89O.^N4W7:O%@UW408'15_)*L1_)^\-^%NZ0=H_0
M>5=8'F*MLFRMN+$)03#R;PC&OIX"97@P'((KJ$G\F__3P,2I>8A;XO7ID.@_
MYXA](9+5E2XBGM93[A?<6NRE$/?2(+/N<:=/) _F\\,W0O7S@;Z%E,%W[@%Q
MYCD_1Q?.'DUN)M>YUE*^=XZ]:%P>0;V]\TT:KVQ1;A'8D_! =5]%EV'9YVT'
ML[!SI/T!2Q.#56/+(ZHFOA%+C4>R J?3AQK*"6M\L>,#;X+Z-3H,W?W4:@.[
MS!5N_[Q:\=,-MP'P8'^SA\T6>RR!,DNI/!A7T('R-YI;XC:@!2V&]H-B6!)N
MB@?;.[@91I]!39]R$*K$M7.41YVWWPVQD5PK!)N#]]267PI?R/RV$=T<'JV7
M":'(2EP8MTO#%S(_,LZ!F*^5B*F98FQK':4>WRHV5(N31KMP4R=K@)2))0D.
MC#$[C=AGI.-O3TAM,9P61^XU$ XM,PME&[BH%<<'&A@37#V I(NQBU7SFB6+
M-V_4C)E2Y6N?I$$ 4@9-_VPH!!1!+(0D>1QXR9R,4*R?'X@.S5F?UG-F4=@>
M_EG7XB>P<7>[:DO]-DT?%X)]J.I*5G&Y?V9& R:[^(<[QX7Q,VV,0O'J$:PL
MK-DET*VY_.H@+(-?M A?ISY?>O@!L2:B-0*B=?191L_5$Q^13/ DOH,N$_P5
MP!RC?3Z7>T%-XHK1+H<,A"*+@5/QS\)\$A5!J8WEI 5XV>-%6SGBL0ZEWJI<
M.YL1ZZ?!NB/M#B6%1XJ/E _GZW9:*'N:%"P2H@HYAO_&Y![8[K^3?QH=2=[:
M]'[\2J<ZYRP>*AGYOTL&CJ62 0@SO@VC?NJ!PQ!&$Q',Q]B=J5 */8FAI@T7
M(6F7AV-B-NTAN59%]*E"T@\;"2U'DCK@>W,>(.?8PWGZSF=I-T\3V2DF/-AM
M;B":![NWM*R+',3!AS92I0>9"G#PAE<Q8PX*XQ9(GX>J$*(#"A *&FS)I+ZM
MM($RWK:?!B7W#"2N]>D?YDA<:>>IA;QF578RHI8T_^X.HD:[%:(<*#AQCSC!
MT7T%B%KB?$L(_\(.QAV<E\$=*KGDHSA7"+D_"W& 63O(T$)POZEBEQ]:4@EP
M/.?SZQ;\W'$$#Y:-M0?\D Q_(D?DX86Z!6842TJX6R;MR#D:EI3[9>^-Q&5O
MB#86XQYO,X!G\^D<+?P7=!)7G7BPRV2.+@\FA]R4"F#'!HTTLGSU<@[ 1P0F
M?K?ZA$JB "N.SC5?C='7JNJC0M_3C04E'D<\D<C?_O$;HC9B_JNU&6GIH5DJ
MGI$;&<%7C(2</&EX/'/S2Q<!O*2X]:OJ(- >P''=&&N!SZBGASA6\7<7>##C
M8L;@%HUNT1MVNA)LQV]M''95L^\?R\V1VX-M=P2_*((!4VU&P<F14^WY!'G^
M!5)),7P$S_+7(9&(#Z>.W,?)1H9-)J_R8%8L31YLR%H+N[(-R3&;PR['(6:'
M(5F^>K*-!Z.90U>_![![2:#@W^R2AQ>#MJ%_#I< [<-.?@*BVG'K45P#2X"R
MAFH) $%P2NM?", -(1?YL\ 7M"HW)/,IIFJ@?C*XI=AKXQ0YC$@.DY2*-IR+
MZ5O/B]1<XY80?0_T0)Q%H=KVP#=R.4BRX6[V;7[ZM] ^W%IV2D82GWT_%U6Q
MN<2!\6!.:.3<L\M/5F@68M'8:8U-,\;ZUE%[':J>0 I@!\D!"!IQ/D(H]C(5
MJF&TRG,#$Z8 _2:^!)E@Q =$60/R=,MGE15$WQ13^0*OR'8JJSZ".OK\^)/9
M]?85O_KZ.K?P7Y]'HJN@)<4X("<*<L'C_TK44&#+:TT.LVS9.F O<ILF*@[Z
M-*$K**XA<)3CSGVQ-#2RU"5U1%A:S9E.Z4BQM&I8_M7HM _E-WR[?NBM]]6A
M^A/6#PL2;1JA<:S!K_'%)&1L\3TSCM/(M@DH"IE?<WX7R9AW_97L+2-J:>*&
M9-SWK*D:AU;<".01/ EO0JA5VW)^Z5[3\;,(/ T%[((AX=.3MZFG1TT4 J8;
MYH*HV'_Q/WRC'$H'.A-);P6QU:@-6N8_B\K%&% JB!5A:*3+49,'25;\1&[+
M.FEFP1*2IQIL SDD-9)SG(Q<T9TV;.#!>GXAH6"@.!\&MYXL6@_A<!+7!;(&
M8)P$BG-^F@=;\0VTH8;]"T+/\6!:_R;=(9N*5?]1]5R=(U4.8<[A.%V%--K2
M_.G')M+=\O4=$+M)N/1:ZLM@OBC^<MCK3D"D8\/HK&?</ BS&D'Q_8^A.^7%
M0A;2)GZ9U5IRDP?S0_U@6>K7X.@1;5_( 2%E9!IWYY][OS641H)#X)6=\B$W
MHN>6 V],$-<R4[#3.XO)\7/ARZS=";=(,.V@!1EMJW=/XJG@CW70E]&"9_CC
M.2(I@YY&4)QO)/.IPA,1<KLNM1^Z#Z&,G\&^2.Z)$\J4O^5C)IA(F8>*/Q[Y
M-_5:8<,N@GW8:D;<08PV^OBQ-UT%A.0P!3M'$1_GA8 :F:O'>^N+=IZTPXTX
MLZ(1*^Y&$@A"LJ;\0.P<B^R%E!(_P(2VX]GNC:UGE+OS8$]CJ#CX,.?S"8K1
M$4C.?,'$,][\8]'W_F/O\#J$SH**;"04@-AA!K$?)W$=5;P9>!CL0U9OS#"K
MJ0DD:'K'0N? YV#DDAF$.4GH[<,V&_L<*?6,<UR7"?BFQ&4B\T@^=&]?1A5R
M8A !**NC />_D06*D@P<TE(2_?CV^VYU%$8@?F%A0@W>B1#06DHDOOF9=Y3[
M\@IC.);#;Y3-Y*>'=^$"2M&:3.ML9KP75MCS"]M@Y.?,D+.<.,.K/*"([.U3
MUG.Z5B&VL.-T1EI/=!#W$Y0IYT$R!#IN+1)3NO0N/3%];#^57G1G<IV@RC3K
MP,+09X%!]DGM^TV!5*R$H"*)LC^NJ$5FJ&;!=7X'I17^Z.CW,9*/09^Q#.CP
M2OF(K4QJK&C/O=H4C#)M,^PG4\+']*G"[D^%'JEA+\7W/+[5;/'TY:YB+8D?
MW<JH3/<?2W%4(WZ"D^;K[V7A<]9:\GL<0@'G4BT5^^0!/_N.@1QBN#(E YZA
MG9Y>14S$_YN>H= H\P;PEUL2X3&%P-&XN&;X'K3\]_"8!C-#67)=R.D23N3<
M/>3T2 A28W,2^^(=+$_[DO?!Y"F9O3D@-D45%K7/[,5'74XUK@_R1\-5AZ(&
M/R#9Q5#!_L(Q])$TN5M?DV8!,FI!QCF/Y14-7YG:XJ-_AZ:MHP8#Q #XQ:/W
MOSO#@)W0D>6_J 'T;=D^.Q[,*S(>Q$Q@&12H1M/@0'P.)$C/ !"O72%N"',V
MD#11.*"LR!4E_VVC(DC8.;8FGIQS5RH!2@HLH,3N/J;,Q+*D_5XL<Z9)G?!4
M=OZ!DLA6R&=<WZY:)7% B-XO\8$'.[MWRZ5WU]Z8;7@;G\"JQ"UF*+C*?Y;L
M>/)PIQ7]]QG/.J&=_")8@@$T#>0M)'"SG0=;]OX'2SSW_XG9/OE?CFQ(_S/E
M%;\%4)(<)%W*!/OB]]9IS"$^_OO?5OF0L4AH?.34;\AK" X@-RY!5"EW:YC+
M1T<R?B7R8),V*\,#6[P8!"B;@+DE+L6=E._!7JRNQ4%94)%SYSO.L+$CN15[
M+2.P['/%J&-J[P?%/QJPPM"MWR/K?1?L:11)$!I@+T89\]$)*8CTX\&D@!Y6
M"A#J0U=_A)!:Q8G]B(33ZQ/#<8DM@F^8UQX78\A97_%%D7G][7GJ_94<XV*_
MS:$WE[TK3"("O$MG3W_KC H&[_&E--MX?>\*'@BEY-4ND^95D/1=1&](.3 3
M*=7#$F1.G\TN:,V*WQRP!)DSO\NB/,1//2PM]P$P7F:V#A%)&97F1W,7,Q)_
MJ<.!H!\-7NV2GZ8DQWY+Y/DJM;8J*$J7+-=E63J7#]L#*?]*5/RJ,_(RA:-+
M@>A@4ZKD'WO+N3L9AOR32EO1*_M/.2H/'IH2Q'XSTH#2T84 _@G9?9O_E6.C
M!_FO^2BPWO]T]HA@PG4"P/M,/!#2B5U6W%BRXL%V5F!;S5XL-RTE\6"O:7?Z
MS8+$,(KHR(W?F48>WHAJVPT\O^2'B15[[/]3?N$D(%KVYP:3J:CIW66Y,=:?
MWY@1G=^@QL^^#>K17:9_JL]4??SP::!R]UX-M]8[4_RCU_]C 4"PWXW[KVO]
M7S\B0P[G'>+!\.\0'.UO4$9V_NVBB-,(28C$CCGS8(>Q>,7_YK36_%]H$K)K
M2]$E0\45"Q&Y=[T-<*T"T47\%KIUD[^J[EZ*ND]>S>?>H2$VV!!EMH?#P0O8
M_["C2&X-"&7NQ ,DPPJ'(S*LX,FH.L(]Y'6$,$>.:?J>Z4S%SV?2U85^HF68
MB!0#L\(?,Q@9ILW"Y5>H<Y5D.BJ> K^Y0/C5.'#P29^J@*SIB&7X\\+W]>EB
MXJKK F=@F.\443:V2P,D__0&RS(7-$S079<3RK.\5;W?W#S0<45!TC'L14G_
MS1/)XFHZXR<\7J<F--_<Q#MG7CKQPVM/'-]N29)@7%*LTD"I2K7YUU!_QZ-/
M"Y>LW5I2%%YI82#H^#C*AO+A1VLW#U9F.5$8S8\R0L,A6*IG9?-@U3&08W3(
M;+78%'KOS2#,E>OG+?W:./@J4>6AB*T)[/^UQ=?KS"*1/)CSQK33@VUSWZ>8
M^6L\V$&PQD"<E0[X57&\ 'ZF.S4S_NC;&"\F(:;6$&Z9=O%]WJ?^A4Q3[?-3
MS;7FQV]D!"G3W*>][P0>>7QSOV3^'K3 !&I^F"G\83.BT_QF4U Y6CL)@CDQ
M@W-,_O9Q.(/R*+MK>?IT ZD=$0?N>E_+]$VN'=T5A+8/5T]J$J\"*!:6 5'Z
M*/AU\.AK1GA6;4;L-E2SS=E@LB39@"\O>%@F!R/J"9Y_MGJIHCUY?ZW+1%H:
M[JG<9%Z^Z.BYDYW4UWVMO>E:%H615WS(IKE.<_:Y_.+^90X_@RS$K7/PJJ7;
M!_P_@:<UCGZX\N:OSP%E%)?\&,+#I.)'E2;1;A4GCU=@0ZBV%H.S6OYO/#X]
M_>E1TA_ 7$9^CZ#%H+4!;6H 43#2J&^8NA1?J\X/K+=YB0&/:59Z\ 2,8C,0
M1<7O*29]1YN5NOJ+2P4E7Q[4]'2C?6UWKA_4*@_4[]".6 FH!O+&A^UQ,_ '
M^+>4%% *[8Z5]6\ \673"?2@Q+R#\0M2L:QRFFO-DB2 H/K&A<4/UDJ7Y(-]
M0T-S'S93NMYCCW<U9\Q*O]U>;9'_ :W-1G/.QYP%W NANYNFT)_5DK=A.M8;
M< G@(8Y?H'RGN)P*M\8@E"E 77I8L?2*4=^JGR*V;L5()4P\4^>8T*3UU4[1
M'5\/^. L&!7:3J[O9]=0@!*\XSI'OR#@KO@'W Y_FT!J0'1$U^U-0E>E_9^6
M@M9S]*I\Q@%!^?;0$;32L'6Y_^:O KG#@>X..)/(L/='^W=F*W""?W:O2N#6
MXFI4+_V2$2@6]TH_7_;L[DV$:Z5=3:ZC6\&L?<XO<[:B7;B_$EOON&VQE#]"
M/@XM?[9(^H2CAKH?6LM?(RRX.M;\LE+[#H3/_/7^?*=<I>%DE;9</<U"YY$K
M#CYVCOX.L<2KN*2,!L6$&DD#?0:Q8[BAODL:+A&Y0M);K*_P K+IF>VLH19Y
M?^)WJ=RZ<MG?SR>(^ZZO1":U*:G_2G+M1UA6,XTR\[_[?0E]:5,4FG> ^P"C
MXJ<GWF[E[,Z,2\(RO:E+L<B)YT8R_4TA63Q8XLWC%>(L-^9X?!3;JMM':W#R
MR4>*N)%L-QVQISTX),TK\LFP5P!<F*Q0SH>X4PGQZ-F@ID,3E*01<C)& @BX
M,-P"1Y_FYANX5[AT,HWC[A. ?-9=)@</OXDV?#&G5QRSVMA>!-0[1Q]T\7=V
M.S,0UO,EXGS?T=X@=4*%U5@0 MMZUL"8T=Y.$0&/1C9.?(U7;"/R=;/]9O0$
M6?',LP$$Z<B8#M2;KB0Z2MC_Q"R(&##8730]+MW7%%6 /LT<K''. (\.5QDH
M8 NF[<?=_5E>2DU!NQ(]+)UB7>P+XY,57*WM8MH[AW/O.IQX7&P16L$M4+5[
M:7'RI;E]L5*5ET68VZL1W,Z^#M/""TXJA18.L@A?URM3>]4,C.3%<>D6 S-4
M^KS_M\I$@C*M3._=HX&G1\H&"%97#OVV!=N1XL)44CMVC]>,G,"[ 2.9.<A
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M/*FZG];;DCGLV2_/WI%I['/C5G!GDPZ9RYY96[ KC,V0R);V<EFM?XAH&D\
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M+!0G1&%!VVA:&]"Z3N/!HK&K)E>-1\'OV.FARD@C#FJ) #XB_#S$1#_G,!,
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MZ\A]FC'%D:%T<I+184]_+]D3?J@]389L+>"KS3;._V#O/:.:VM9X[[@5$5!
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M'[2FU4[<6;FS%3R!^TBQM@@YUPM=+H;OD#^"[61VM-+-2Q.:N (RZR?"F/$
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MA3J>]!XJTO8;;R(6T87;0^G$R"_&$CJ^H7S+;K69K*%/G7K[G"F[/!^53GK
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MBH<Z,(/7J,J/QS[G1VL1 LL<)/%R?!#19<6IJ9%H=,U/-*TXL''6_5!.#2G
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M27 ,6/"L$)0I[0@JFJ72.1;RFKE&-5,&8FA!6T/'!WZ2Q;#* *5C;<G0\%%
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M+(U95\;<,F?>;& N_<&<2D,=WZD!X-TO=QSNDKG^[6-^<QEZF='.@QS#*N\
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MBIA5 8$1KZCL#/(6!:\VH*P>P8#DO1^BX#BVOU))V^BD@G].X)SZIZ:?NNK
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M&3RD0=,WS?2Q<&XN)Y@EUHF1YJBPS0-](-QBM B@OFDP!)%C)6P&LPQ7=(F
MF VWB*>!-.SB:>91.\=^%$\7(ZQ9R:G06]HI!;,]J6:RWQ;;]@ZWQ- 0"XY_
M9MI;6A&,>J9!1XQG(O7X($VTC\0[:\>274<S&!6_7[^O8^E0U1>/-NQQ=VKS
MRN]P]<W*]($]3ONKDO7US)\$5><J2[6A[1,IB2?.](QU%!M'.&+5?C%+Y/\,
MS4X<"2YP=<'GFUQE49UK;(Q#_-QU\/M&RKR;U-I&/ )S_>P^.18'4!^UNI\M
MO0K2?:<"V>A%<S_OF[E70MCC?/=V45%6?&M8=QS:>/IA25;/T1G6>/W.P&C7
MJ1OYP68K4 5USC(Z?X07_6N",OKSQ;R4HX7.O_S1/XX .0Y%.5'\:=9<$_2!
M6(VAT_#ZA+(1?JB.T9@5 WE<\OL,Y)Z\7<*U^G<6-V=VW1LUDBIPP"Q94DY3
M>;NW*PHXZ43EY;6,C.B%/.B01$CL.JGOD_NF]@C"[!2Z?U+CY2CZ@"9I1:P,
MR+;#2$VA9-M:@+[IQQM\T!XOI$5DIB%='G7A_I03L_/<N!8ANBQ3XI)LO9UF
MMMUAH1924W(F1 /SPS P-$[C;:3<NU^O>WLY86-8X'*+ZJNFS:XZ>^-.+F4E
M?\[;Z+:/BO *FF34,VZ9$QCAG#BX:92&K Y6G<J[TNF4Y#(\&#;S*$?!2MQ0
MJX/!(VT\MH>[%<<,S-28V$$L9>I$6_QZ61?KY,DVX>DO%QUS3N?D_\AZ(ZCC
M+ N<LMP"GR8Z,]P3GP'!=,W#FW^1&Y+M@1,1PIWL ]<W\YE[)@^P_";F.A5P
M:4TFXH1G\X;9\6]LOEP#, 2[ZOD[8YADB%7UXCD/ W+4/$8$ZCMA]7;2$(AF
M*72A39B$U!;'Z;XT'@2H(5[]BHQCG"89INM/2:,_3RIRBV_KGZU#(;FE/#,D
MB=J\B:7U231;1#\#[D]9PD6NCB'E#P@A:C?Z%)!-/TL98-'?O-@WQT^"PD\;
MM_<AWSQ<7^\ZRL(E/3];.[:RG4+W_6P/G<U"]BDGHN,1)I].V0T@!=')Z=R5
M,AOE%0\35](9L^B5:WP0<KPA+*-,WLDM_XGXD=Z (5>W0VL959^UHI9<TB+5
MU%Z%>-@967VU_O#M5T_!8([:4)>JJC-G"8AG2R#3WT(5>;L"'8A4ND,R1IPG
M$ZC+L1J:[=>+$Y, <UR9PND<APBVZ<&G$TL[W4WEV.2=Z&Y*AL\)]A^V&,+W
MH!U$ FELIYL/LJF_&SDE3;F&2 '+H-6!P6Y!$MKS*J1%M0ZPI1,2.6>G5]S;
M2W1;$7L#!$33)M\WO7<P6&-=  3-X(YX*[M^K;J0E@M:Q&AF?-MQX)'ZMT8E
MKYX:7X2O'AB)Z?"G_8D<(5J#]E_SO;?*+BMBG#]GEIS'!W5<ISEU45X&A_;L
MV:6UKUV1KA4>&I\5O]"R="ZJ+&5SB $S\D_*=*CISW:9/(Y\\BGB0OA(L?68
MZ_'L3;V%*R.Y9RS BVUV&S$T'^4R:I_"QH+3SLAQG<TI=\*##%BFO;^E'NV3
MO'.^]LL:^,$H&-G:=CJ.#_J*Z(+!TY=YQY 2=!R5+7$HH( /2D9$$L$]4T)1
MVDH<J/?Q#YNAS*GE+=+XHK)L?YLZ\K#CZU'2<68K(:7E/-$32+9/L.@GM5A,
MQW&U80D^?%!B\N5%CBU;:B*(TC"Z7,/4TD[-&W%"?S([^(K9TJ:*V-/R$/C0
MQ\U"Z_+>6V,03[OHE<(/7$/,U'L8U!M1WF&PP8N%'1>14VX.!Q=P-YLR6E0S
ME *'?HL8" F-P&YXKG*M8I$L0I(@LJ5^JCB[ (4C)B)K)Q&/>Z^D=ZIJG+=R
M2H^L,I1CJS5JS?R<"T2F]:J>9J@]*BR:[5W>2!:?E<*GYN@$0J^65[D[$CTM
MPSS2C#*/%EVWWP@=4HC\?HUA[>P2,!AU LX( G^M'K5FK2:CO)XB^\R_Z!%W
M\7;7H@5M +:J\+0.9CK0YCH=DEFPBR/*)\F-#0F>]:SNDLV#%05,(,Z>.=N6
MJ@C+;1D9E4<<+..#VLV"(_M *!>FZVJGA,3BUM2A=6A"B3)"TANEA_TX&-F7
M5&+:S&J=Q$4%0]-^S@ZO]QT^/_IM[^.=)'Q=?BBQTF0Q4]T+2\GO]I$!S7F2
M59H._RD>BY[+(A#(VIS3/M("T.HB_6[B,'X$O/AZWJPLH0NZDO'^RA5DE5ZN
M7NO7"%@.PZUXIKQBQ:B+,@FS/QON'*AU[E70J4PK-Z,CJJ]=\WL<G>U;Y7P7
MR?:3GS4'BIX2[8Q4;;^]Q^F5:6>;*?)Z7OJ @*KK+)/Q+GG%K5 4C%O&4YD8
M^PJ(*YWF\<#8?#.% LV]\2'G[\24XSKR>$<&5[3T8X@WE8_='[6_4#%?O^!6
MCWVQWJIBUZ^W=."$Y>!R9*:*30-YL/&3]N7&^U2[P4;VF;*FQOKGSQLO$6_7
MKOR9ZON2W)1F]&>2D]'#@[]E8 1^5_TOS,M@Y!%%NR7<]FQ)&^=.CW&HP!3N
M@EG&9$%R+.!#AFMO2M>UL_9%]=)^KH,9U\7]&_\<SPC^=')Y9D5E]>0VXN;@
MNLZ3.Q*[Y1]V7$D2<@LI'Y***BH[TEOC?#\M\&#+M3*9(:_,@:"U")[882:E
MY^]'X/@B%%%G $2Y.0FYU3,E:2:&C.Z *>Z4/"FSJ@G*QQWF:&EJ0,E1A6\.
M'._Z"3/(,MY0'[?5OP,WH9\T3?Z5]/<SW@7'_9+J63[H!C%89&P<SI!8GCS;
M=_$PX\3^>Y_WAB)5C/LVJ]@V06,&)-IJDLY"<V;K][_0 Y@&XO=WM>^=QL;I
MI.2;)3?/'3]0;Z7P;N[D74*;4/P^B"_-&0<4><QD&3TNV>[[N8L/.MTVE]AB
MV??*='?*AU^UIUU32U.ZN.'A/;0P_6K+IGJ"1:7] [6T*V%XX=XS!O@[>&+^
MW-4(&E0B[(=?XL>UV^B(Q$Z:#F+W/K^OM:?4G,LVTEX]?A_:Z1L$O57M6C"7
ML8'5N.J<.<7$2' .#O)$;[^)8*L$V8 R(EB8S?"^]]]49H%N:JG1D:.21KZP
M@P*K5^:#IBM$^[/99Y9^5]T?QHK>C*:Q,A@\&3[H,JI\;_N>Z?V"=/X.F)D/
MN!,VN[*0[XZ'?(6N]1P->[NP8LT'B20GO0F21W)."[KV>%L5<J[;,=H3+AXP
MI=7#!ZW%L)QW#)DNPR4176($]D_W"<H.:.%.2UXRDRK!.23&$_4@:++5@JX^
MLH;*0OW#8Z[&#[)06;.61DHQ1W;;:P,G'3A2N1=_<O/T2^]>Z.O"?9LIRMTM
MC.CJWO/GKE_3:U-[*:_JZ7R0&'@[PP/\[!,?U&UWAH5)BE6ZUF-V[V]K,\N%
MLY2 /EX2RI />K",X8,,'V,Z&Y@7W_#&Z9\$,#3UJW5D:DU[]-GD#KCS))QI
M#07.+)J4H3^,/8]H^QW'?$GQGYAU=3+P@P->%M^NO+@?J^KWW=XBT%Q@-(\%
M1I/YU)$/VD^I#4WZ'2J-!LWXW5MA!65</S+_NY+ 9.IXZLSVX:,Y@;%AF;>U
MKGR^3'>Y^>IN2F(<Z&R;F.[C;_=<=^6 "\UYA_@@T>@1C8C_A[?W#FOB7?M]
MHZB@(D6DEZBH"(J(@+1 Q ("0J1WHB(@($9*)$(@*M*;4E5*1$JD1J0)(@%"
M^2E"Z" ((0F]2")M@)0=UUEK[[76N\XY[[G..?L/N')-RMSSS%V^GYEY[H<\
MG<&M4KU<.";'<T!S=D0$>WZ$ V(CV%5@IBELSX/*QC,_7(&EDI#QY2>AR7/+
MH8+4-U#@! ?$/.)@Q[MQ9VC7+B/P$?9NX:9V+0"_V!T0[Y?\N(P/,YE*IEOL
M=5?945V4N>BOKXC>IS5)XV&+5?+$,[)>)ONC>':,Y<[3"U%<(\:F,]987=RD
M)2<ZSZITS]$:T[S=P:Q8T@D^@/GWP7R7T8M_AL LERN2,7CWD T.Z"$T_A[7
MI]((])O-)*;:N0_: :0VP2=UDK/Q:)N.KA[ZP\<R4X-_<3^2#J7?C&C'>"2X
MA3_E@,2ADX87L[,"&#?HH*E)N;JO,AR0.X'K=D[@W^(?2:XI;MJ+[+S^,7RP
M>!M;]!O-OD*YSJ"E\^?3ISLY=?/)>@L8JJY?2A"[DU)F0YAR21KC<JN8,DL:
MI;B2[6?$%IO.+,$,$#[.?<:V\T9")S,QM= X]=HAB,:.OK=C>:98)55OG^DG
M]@FTQ%-Q.SHV&@D[@(K]RRB4<:K;D_V=(9!0[-45(&/81Q^M'HQH&T\=VKRP
M_I(;0.<("/I/=M>;^O<WM8%,NIK"BV!\V^$+VNT]6A(G9GFW7['>-!B\]2+S
MXY>K#QE.3&  )PZHZEI3S&#<8W$LF'UR?/3K;\/.FA '2K8?\P+_D^8GFV3
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MZ*7'RW#B'?N1K0=A;5[-&6R7M^O0-1).%KJ]5;LA?51<[-'KT<<[ZGJ7.*
M\&QLP5I(D[8A=-%56UL]@RE_2^>;$(*UB.S"Z I@C$N_*58W_PCM>T >>YU8
M\WR:,##>*$?"R.\XLE)^+2/80L88MR!?#([,=&*]0ZSM+.I&/UC"ER(P]U1B
M:A]EI&L^^FV*"/)\O.=K@"\2<>+%SRM*9B+UUR4;4_'AA,DW!_(VC@+\(-"I
M-.J3MP]!<##J+0@T"=K?)&,WH<'\$9/_ 2BUE33^>KO"OD$GTUB[]***2(25
MU\5W,Q\6'BA6BRL<&;W.KFBBNJKM#6_[I.3?=HN.*K*R]+^)*CTE?G@R?VGJ
M+4/@@)G"R;VG\*>X@NP.<J_5 &8*'-KJR1*8C3&V3_H%CY'PK\#2Y%_4'2^W
M4;Z:M+3#W')V<$Z9?7:K(T5A>U(T)BY\!E3ZR'-:&_3$S-NXYDEVW?EV\_:S
M=2,$9-+)T/U3B>;&73";92AM:$Q:=>I:TMD[T$^$AT(XSTU_7@EJZ?_1A@ZN
MA7;B@)+'=A0Q(UL,=3:4GH\.5EMOEI^#E86"__[N^)]W-QF:?YYX3[K',[?]
MC]N+WZJA#/7!?<?!RB^_Z4H:"V$Z[RIX"_']_DOR[J)C=9I/TK*+%5LOH*:3
M97]\D67, 24EW]P'WYJ.>BC.,WWBV:Z2?W3#@RNQ6YX(CD1M:() O$LE.WH@
M4!,(+4]_ MK5! H47;?Y#VOTW>0=5/]["PEW[R_JOXY!&1I<[W2>5EV%JKJM
MW-!ICXJ<U2AQ<,2;Z;+U"%/*[DE5SS Q'-# ;;"X%O=8S'L$_!<=ZV;!5EMN
MS'N@?YDD($VM_5\S EYQ0+O^]R["!YYELJU!U@_&8)<O2=)D#5&S R)SJ+69
MK Z)Q>%AR>7PK5FY'W-*8NBMK,.@.7.U9G[>R?&DVY;3ON=2^C'8DA]PWY3J
MB6=!-=AD3*9I7O4$*[UD"BP5]B-G#_"8P4L#/V/Z3))C@A^]I(<8 4:8]ZC^
M:_2P IJ+9IL4KATA/,<6HD=%,!4H'!#OV );=:C!%$EU"3'IH_:?#3Q35YZ?
M/'-=7G6T[B+:9N<>4X(NEA=PF[:#B<GA?0..E%,!/B9121%ANGV^^"J5*+A
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MU#_SE57%';+VUA?Z0M^,7QNW_:9G=Y5A^U(ED]#=(+RS#Q W[W]  9[2H'(
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MY+GHO\VYW7O$POKH/\;O/_T5JAYE=$B2^B%A=S$IL#R968();!T>#MMV,>"
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M86/GB!S7*;(VS^:SG,KR,>26LD9)PSR$L XF=SOLR[N%]%X7K^#&M"(GF.Q
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M"2>"[E[F=IQY9_1P:@;O,XW2#S9F9:XAHU""M0HT@]H FF"3_;O(;!@W(Y+
M%OY,=6"<([L^!DFRI33-KC##PV[CRE3;Z)]X*ON-KU< =@(N@&*XVJ::]*\[
M:/1?]XR2*Y]MTE<MRU\G:IXG+1@=P)I;W^+MN3*F^"+:=Z-NY+MEYMQ9Z\.Z
M'Y,U+T]^,ZQ;=*_E_A1 B2:87BZVT<B_0LBWL28I?%7W.#GS1L$HS1K+&W#X
MK$6QO-;T9W!I?=M@WEFJDB95ACEX8.^-+I+WQ\D.\9G)A!8'E!!CFX"0T-R@
MXILF#J*5FC:D!1,<!OQA@@N>N^+&VH?MQQ@*Y5+B/E'W0_>'._8<K1LH8U6%
M[O*H9._H+7,//>2ICH9<J#O8X/K15 )2]/SN<#+B ".A67I_3ZT>A:=<6;%%
M7[VHG:RZAU%X*>LK,_R&O\1">]OACZ=2M=30<G1IAL%D30BO:  JBGTXM?%S
M0E-4,%\0>45TK]]E*O*Q(;=G&QGY=(+77XGP[LSQ^MW4\=P7=:R?52-=S:H2
MZ5ZZ8)2A'LUI.>ZMLWN]QL0'J:Y(0WV&"QE'P$B[9<$AY:=<E&9-KYOT$4!7
MDN'A1:XT;!SS 65% (UL#CW<4ZXN\()F=876OY15:ICN2]*;@+F/>,5>ANTW
MD7OMN= DJ669=R'HHI<H 1:5;UK\<,"B,,K"N2E26=<J?X_IO'<N_J%B5D^Z
M,V%^=G.D'/TU65'SH&3E?@7*B;*"[P2K-[IE=^-SLF0$NRS+%07S13K,$F'#
M5CF+GN-7,<7J8RILC6 4#45,$&%J,$PFD1$;;'Z&>B$:9L2H(2.CL@QHJA&:
M+&,KVL#CZQ2>Q5 )=VDQ*G?L8JZT(-7PXSO&HWEGN;HRU$'T,RQ5UPYMTX(@
M7<.VOPC]@2HSRI\$P^&"3$VJ!*FDF(0;11#&]<+I".H7QAO<>=IN./PJNP,E
MAG"'R,&6%C'=$[_+?7Q?CW]"C"' T,$-,496&L85^Z<8"I2:.JZFSPY,=^H
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M;_(K#,2>*,V7-U=Y,D^:W[YS7GO<XN?[CRHIPKD%)HJ?7BHV=N?FRYM:Z=C
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M< 'A&) +3#_;>4\MZ[5<24B\GI_E=[-D"&^FL68X/?>0I>Q:'+9PNSC(X>O
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M*\TL&&'?0I9,B(1-*4V.L#*BU(CZ0Z-8B:@;."_R^3.1$H02FI<^4=GG'W*
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M2K(7PKL%(DMN4!90P[^7//DSM+%P(U3 <5T6;+E%[F2!/^56+%69!\[1]]L
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M$.;PB&Z-+W64M#3X[/<\QQ]HD28_--Y46,:4ICZ;@AK5O3%7T3TR]W%NL/!
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M3V.FL AFB(^,8<6C=G* ]3MHV[E-?]S4!"'#40 ]*M(G::C="3./[+-=3^(
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M3Z1>",W!S"#C9$^V;%?^GBG2!+[S+.4 3^"-F#5%1A 'V$F',V\D,,XPQ3C
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M*0S^K;824S9WYW7_B<6O"=^1'>#0-%1GB)NBL75W*Q"3\QFOE(@GZ]4-4=C
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M!B;@M8LT #):]NCD3OK??VCXROFWJX?<KZB9!K\+D7%,^)7 $0P8&Z)G-Z+
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MY+<=NUG3H7'V6_YGET:NW)MB5O+'<N(GT'@:8%[<O17:"0Y=?0%@P0^VN;T
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MU _)6K?![SY=3PN$Y'=?'-E[-E=;N%'D1W#YU3?R/.DG?H-RET#,7/ANU.$
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MD#?L_?!=XA0F'+-]% J:1.I%/%?$@Y93DOS"[2V=JJ!3#OJ\TI#!D6 X:.=
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M+<\=OGAXZ.<(Q*CCCTNW_I4[D3]FJF9FIFPC)/^OD>#5LQZNV?=%Z-&#MM_
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M-!]C-&LN,9NKY@<+"CR+$H.<DV>L.OP:KU3'"7$=L.-PMMT>A$:A[$$$N@R
M&"8Y>[.5,+^R7YN/L6:8\WX2?7N05I6TAV&LL91'3L0*\'[<?0XTQ= WC.;]
M876[KO;;]J1D[57FPR_G],-R"C0F!S^_J9T<C#VB>SPH,5GR6K(*TIUD69F$
M=LL$)*0\JLY*JW\J-7M[*;;)*FJNVO[%]2+Z2GHO0C*SOIXB[:EHWEQ?8"CF
M+9EOWEKO(/YRZW3'M<_V>N0'Y^__PX2VGD\"%#D+^XOW'_0F1QD0VCC M>&/
M$5H(O?@/A%Z"PA9)&#M*.!H(.M=B;,%R%B%583>Y<A]2J-[GLXT;N,IPQ^XI
MC#$Q!!G:.17^2T)PU1-2/=A41T&>QB[ACEH8K\+9UQ "N#Z+QBZ;/<BA2\!<
M+W*^DZ,$!K(RLM0XQV?X*HO828(<5C5LAU/-. AV PF#?#A HIA&*RM2.K!9
M-?.KKM]:P@QJP?<[*QOF2F=6)S_Z[.9R_<((;&O$@L_0DC38!J"800,("8PO
M.R9)DRV>"WC2/\';;/J654;H6M%^/KY[D$1%K[DN:7JG?#1>U"=,@=-9YQ5"
M2W<R6EL,<B\:M%7AK\1H "N7]M?B!':B0ZC/SX0I1(5G%/BK[A+XBM_@ARV4
M,*[LB\L;*#HI\RC&9*(I/#R<I\5$I9E#DP( S2Q=S9R%C3D2TZ?4^LN*2]G/
M:P\/C6P,OY/#7/GK962!E+RLPR%M\82^FI=O6DN!'MJY!O,6JIW5&PV/:NF6
M3]OV _W&U9F99[W,_R$]=2;]!_B1,$ /.+QL4&<WF'>F/C&WQ*5$RR-4__Z7
MM^PO)"9\0=:;+<0[&N.X^R8*FO8(,4@^M.\/WC:/-Z+QF1T:R4F PQ!<+.J"
M?" 8QT(JS7_SW"DC:*9%BXE_5X9[3)_H?+(J^^CJG*M#3(3N]AR\!LF^&J=H
M/[L'H5<NLWV?_O(S'W)QA'->@A=KO407+L12B*M!]-:=^\OS&:F??A@($NI6
M93)@?]IQ'+C#X5\4TYS!K&,H4$TF@0&?C^WC[$%D+8Q6O5'K2< 2B_,$O/R0
M&4:B-0R:;^&D7M!BBC8'_%4!S\=M<<@!!7G#5Q3&PD)JZYI7CFF36CL^*N@K
M,I[0)L$[1J9+#"S37%DQ%%(Z_VP;L+P1R,))@'L0EO1@'1V)[Q@L?,A$B'X]
M"Z+L"RD=[G.4&^&,-?CZO@-/ANO%V!BMC-S^5[I&37;C'CK]:!^STJ4;=E4J
M67FJJMK3G/CTTE!194[*2]>63PDN88LJ*EDB7AW2JU_D0INKS:7JM#_4>E =
MI][7T[^LCLH%N]:9>)!T P\=-H^(=W9.S^O^R1?I9)0*4.!L>P/P].MGC%W%
MJVQ^L>9Z(-?JWUESC:S7A%!U1")M,=VV@--,D2S5;5S?4+MPO%%F=ERB0-T9
MU&+#.6[[!9>Z_^1LR+<,0$V#WC%YWN%= B[(8%Z3+I&."\+A'P5MZ&D..@,"
MK)C]-"C,,QYO\S*Z8)""$^_28JQM@E<P-DPTS,I\;8T%E03]C*;3T05\]H#^
M,QPW$%CC /L_$(Z=A!["ZF#']N&LQP#,66$L#^)2E@S &ZP,/S4&82@<ZO6&
M3<K<<A@1]4VQG]7K47JXX\?]X#^J1V)>OQ7OV%CO)2@!*G,?X?I,<$&$1+BX
MA1#/#"0S'7 '>#KL["PZ_O#"&E0,:[ZZT^BMDO3'@M>IROJ//%/#51-+BU.=
M3U'Y/3</Z$J<DI+*Z/LKR+[@6.5@7,S:\;"9YZO:9W:R,.K53K\J)<(TTVJK
M]^U?*:?#WLYX+C/9+^L_(7--^&HEA5X'"9<L;:"F?H1U[T.JUA[DU2BFV0O]
MSM2)T*UHYZ0WP#]) 0(80GV;661V!"J5;XK>@W 2P!B&<B2G=3<3)E6YC'VW
MS=E!;@@QD?+H@BFF=&$23Y2]NL-9<9IZ/HNY4<>R>1/GZ3D1Q:@:B^4TW>R'
M.5T@S5]P //KL,M0V?VM02@SG8'3JZ BN-ND#/)+:?Q0,3Z1_%IV0XRA%\-)
M81.R&[&&: KE->X85A;C"8H""*9^.1TNA"ZV82?U).Q!#O_:@V0W=?GLDBM
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M2K,\=^"R%UMC,RW:;%T_JC/X9'O.C0"QW(\+?:BCG:6$U>5,>&L[[U@[BS
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M*@61 \W&PD$#SG/H$8M3O#^G,+%<!.9/<(2-XP3O)G39L8N90HFDGK.\"VT
M?D#80M6&R+,#HK=[-T3=IV!23))L:-GQ/#_T)L7"@HU,JYB4"<OO'M?5^U3V
M_DU(X+6ZY'XF,:O:ZF;(;$3U>I"+<UX8[.+I]Q%U3B6GZ@>=JLUHUZI8KLN9
M_RS#9B.HS'LO^V9*7O[2&I@N#79.+->]"+NZ.F!OK&T>6O+QI*EU:'2 =KAK
MQ!U^(BP0D.J'2ACYH"3!*5^$1'!AF2J;E!1NK @:R\;OLR:+ZAV3!-.JL7Y=
ML&THWX:7#-VY72CP=*#5Q6](;_KEI0ZWE*'E8SQ)=N>5-D"3"I6ZCG:XU 5
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MQ_QUCKT(#HX;=I %9?O]+P!"&U-LBCN8M)\2:4+>8 L##IY.&4 >#=FI:8@
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M"*;)%)_OC*M8ZF,@Q-&5=G-;")'%CSYB3@_OOFC[@*5$-%FABDT_F52K1WF
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MXM;N\L8P]_0"YB(;-2 +LAC7N^0! :KW4 )&*HYH15KM6$[M\F%0T# $H\%
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M*.ZB;FNXPZ#,@_9CZ# KX-"7XL;_P==[1C71O6&_^%@0$".]@TJ3+KT(B8J
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M@.SA@[GO</UQAE@58@3:6!=/RR/+#E@E+O']#NHV+0/VAQ;_H5F]#/_.2C)
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M9_@'F8W9?V6<K5E_:O5BRPDOG-PQ*3L)-ZUQ]_!P%U'X)-W5V)BZL404H3L
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MQ;,-MRM?.W@S-@!-P7U(Z@]Y4<P&/"</ #%4"@F2C)!C#B.N "N4P'H)V"H
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ME'2YJZ&MH37O9F=#1V?Q!+&?N1S]4.*2!B'(Y-[]5$7'A@'9XL"8U2W*D0F
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M.IN1DN(E\<7<6#?YT I*<G52OZQ'!ZE$Q*+^\5&R1I OW0&0)$'.;$P<LX2
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M/QM/$?Z)D,N_=\_\UR4I)2>BFQKYX/[XY^&?"2M_X<<L<0$!PF-)",TQ+W2
M^F!YP-! OL/OG,OMA_)^6%%J8K)2[5996Q[//?!<O6IZ[96VE)D9#Z65VZ^7
MI$SW9+?J#V\RO(!0FE6?.,<X-R<KWE-S2E.ANO;A#H'35+,E:WU43,!DW&-A
MF'W1U=-*>MU-?MW$ILV/\JWQ8SKU[2A[+[)>,$U NZEO^M/UCM\<IVUK\LMH
M?#2=1T;"&E73;\Q>E2LJTFQ*Y AO%#7(E(MW/]LR$\;:ZU-IQ1+W'9TR"<B
M8Y:@:=+FPQA;>9VQJOL[GW6^&"!K3"UY QWM$L].ITG*3U_97#-[XV,QM(LD
M1VT9^"\7W?[]QY)V+HO>B?@4G%A;/7?B;SFT<I1Z6J9_Y+%WPO<?U*+>K4BU
M[GQ)EKK;>_H7,7.SB<I*?XN= :NLC;O#? >*;WR8?$@3FU@PBO([P"65IRA
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M?R)"62F1\-[1.C=&X0>Z_*.EF^'24S:R-LF54G?U)[H:2[[9FAWWP"2$1H;
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M/2G9O-YUO3WBH.75-!Y&FG_@NG[4D@-"'1Z=,7CCQNCJIR5=2]E=+&"!I1P
M ^,=$.$!3/!!ZV%%B6<,/HC7QP9%Y%05A[;6/9Z-P>X68>FNO+Y(-LHO[<JD
MB%#7J0/V!&58+I,+.CZ.AWPLFPH]BF($&U,V(8-[SB[V@TK?J6GO/FG]45Y?
M?MKD?M>8+[],J<22KT/8W:##=[JF7A-)6C4NG:VBUTE ]P1Z:SG)"FII5B9B
MO1X4N'0*02&598#S'?GIBQA0.D&JAON)L'#II[V6;:KJAL&=DFVKS,J@([O#
M4*!<LH_]BB_]YOMOTI,8C[:T9[R\2G\;Y33NN>^>,40)WE^J]1RDI>XQ'?\K
MR%8P8_@0XKPLF<_"PKD),-$"SQA>(^E3PG) $:6D%_K3K=&V^?CH)0T>OI2(
M4EQR">W1UHA#"17/K(<%%)-TV6TGSQ7A,QYWJYUZN3F^8K:V,80]GM3<WO;:
M*=E$%L:/W8SZO#C@UN0R9\>A3]%9BH^M>15X>,; 'SF&N]W:U1 [-C(K,0J6
MI%QTF*@SK2=Z?X*HC!,\4*U-UI<>@&O^K;3I\_")0_^I(/21)>/1 A!CFT!N
M+P/FS \HCM?&NFXRSM]*#FC<( #<Q7A/(/&X7Y+U9<]$'WG#^-HTQO":OH>2
MF@0W4VBE=HC?Y#O_2W,K0_"OQY"5UR\R&#Z;7-Q[Q!G[X&W&Y[R+*X:/+ZEK
M*/[3]4^77Q<@K=ZU=,9 1*,NDI+E96T!\X_ #;5!(9N#\#H6O[#R!/^.NU6
M3]]A<_MS#.N[XW<X+L+^B_VMQ^A&YY^S[X6)X[;O7IPQ5/!HN&$5FL*%/U32
M1XL:#].#5-'HB0Y>"G-?#J@UUEBH'9'0X77R/S]'W<E1_9AL$HWCU]=S^?2\
M )+X%2D6B8]D!F;+\*4T5^KPY^4MY?%M^G'/<%1\U$758&SGY,[CR29XLM.\
M+"D8A%6LW'@V5+$1)_\OJ\&V0>'?6A_O]R=@G?=+#7*_TV2UOZ/?/UH0X#1
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M=:6X?"LC HG"(WB[W)4,DQ#7OA-.FEC&X))=]QD#"\T(.U77844Z8XC/-2O
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MUU;?D3&U/^^)WQ/PE<MYE&;BE>;T8J '-/!G>CF:ZGF7HM$_<@-@['$50X@
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MQUT8W__F9$6M2Q:;5GV/Q8 VAK>_;UHF#S=GGO)&^43]K%Y2?%VW2KV=3$*
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M"]'37A:3& ZK^;G>O'NW#!@QG_!'><$0-67)I7Y$4\S4'\IQ47J4MTA*F,C
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M*%$S8R5)QRV3&_B?Y$\?(DW>D2G[%<884(ARC3!/DWF-(N)UH7M\/SG0.7X
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MHC^(A69HI,6CS!\=KO,JG4C<9'HG^F&I)N,^/:]F!^M[ID,1@?5;7&O/V\]
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M[I8DPOO@C#X=W"4>^,YF>URFB8J&T3G-XUP-K99A^9PK3P/#G]PJ$/#[KMF
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M=*K7E-^GZ',<Q3^U)_L"IAI0A@7XZ\Y[P8D&<F39XCAEUIM;6-8=$V+0XQD
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M+H;2W,NWB8.)+>UQ2#PS[2,2_&BY_"*M"6"W7J85UOA /&I^>N?-'<7D=6<
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MQ-3O1EN+&=9/25)H[5J)3TDTOO6'4@6>[0P!XZ674>^!A3JM6_1WDSV%$C&
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M-2LZZ?-L*6\_W9SS9<_F,;$H;LG:#'R [$]?X"%$E="]!C@2'V[/[400]M*
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M.GTY2>+C_\;UA3!V37;:&X\ U\2UOO#K!Q2]_*4O<N,5NN/9FH"_-OCC#=6
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MNLR?AZF0;\ZM3X8PGZ48-L3L8'9XISB.%YS4XDJ^IE7LH-W ^16RGDV$T,'
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M7(7,9UXXY,K-E/@K0>14DBWH3SYZDTA)NM6S/A^#EO7B7N.,>8\2N=A_NF(
M/TV@&Y%#IS!8O.AT>33K6?)9RM=X?FB@]%(5GD(=IZ/>#H'//T["G-2L*O\K
M>[0KC]>WOS.?.%G>I6AK:6MI;6E=OKHF46.84H^*XL>:%BJN;(O3KAH <:F_
M&SD+<4S?76)B/_ ?-DL<JSQ87."8H'!>5N<"F[Y7CWF3FU^7QU4?U-QIPXI@
MOF:/%I^,!B.X!NR#6 IV_!]-$DI4&IUW6G]1[BGH192_ /\6MK^L(@27>^H.
M(#BTJM6KG'32/!.%'4IC]"=FB&8C(W.9Y4_5:Z5NPXH2. #_?_0R9<Q*2P3
M'LO[)?,7IJXS7'.U#Q,5@D9*YLJ]O3MMEYC9-^<(V>$U,7A5-G],H]IKQ(@L
M1:<]Y6\F++1_L92]]CPLT6FLTNF:X#\)XJB+\?Y@"_.>-'JPC6+$ZICW0890
M+N?0K^(O-MXU\RON"L]Y_6% 8X$(M0G]! V8(CENPF\!"N17";ZN@,Z%!%"4
MU7.^@/E*_3*$*G',P(Q.;<+@8IX$C8NT1$:E;M2KTXLG %4(#Y@<3AR;,]@M
ML4#6OVQ4.-L8+#&#U\1,"LXQ;N-IEF%&ED;:ICD%[':4?<#2]Q75;!!J]=^.
M6545#N5/B>VA#G54MIGO%M:HO:=!\_.D@$KOL9$Q[;=*@_ST?]IC(!;)^=)3
M?-5-A,SJ[>%KI6CGS;$[UB13>>:XR[%D)0V%])D0BB#\CA^H9T%6Z,F*)? U
M(GJ^TF3E0.O]0'\H8>/HF 38!%[SV;-$>,Q0:YE1:="==E%DGZ!!#439F4@8
M+$J_R]I,Y'7.)"VGM<(8P"24FYZ]XUEN@)[.DY  6E%\,5WH/*3E.%=H<^<B
M28?]FK/G',OF7KE=QV=-+TG7+4P9?^6C$V>G/#\ =ZI<0W8Q_ =T6(+1H*A8
MB'4$*K&/STQE5/%F1N;V[MG@*01H[H$K)FID3'@1VF @0&+2M<1!AGF61]B5
M62.ZYE.F0L-LXU^KYGC;?&6V-+E\U]]G8R#/&0W6>L8ENY%O$<7_1$QY[\%H
M,@B HRZ!,8L9_6D"'J:; 61'&[C3[J5\<6.(P/21,F#;FB1WS*>8<6MR?=>B
MQ-1'@)?2:&;J;P>-6-/PH%Q:K1\!#)!_;CRS=IX>T"DW+B[7*E0YRW%5I-@O
M/J8IKI[F&%$3AG3621U0"-!T*HC7.B<.;54H.*VI7%8:% @7[W#.Y:DTL;_9
MX<I@7<FMT,W)DII(:B"9>*N^2:RG=6T@#GQ)0-2*W2K%1\C2\>JKJ]H( 7#"
M, )O1)S5,D)=J!=8.YRR''D5@:IIH"I\!H[5FFK\FOVI:4:8\?V>6KBU9/]#
MZ>ZP0TT3GK%TMVT6N; +(LAC9+1V9$QC)1:Q<72#B+M7V]2(DSB!%B^9]_MH
M - PH[G+#6QT6A_KFD_IJN-RQM#TS)M\%JZ!BK_:^RT+9_4_Z?2,K%KO9:51
M+;%G23,Q^.29B)W(/'N5&IGH(((]!5X4:6][(JEYLHC_7#)0B91.>6P)&)AR
M2Q[3G6)J,FBDYV).+/3+85<3*O'%,U>/)XC2OU]J0_=Q-AIHQ6'M9#8+XYH"
M&^FI2;U//N _^J^5G4?7ZBO1)B" /,P BX!A<^\$E4Z;^C*);[:@*SW)DK^'
ME0 C]4,O8^6N^Y+)50G:Y\XDB'$JA#](<CRO:;L:"FX8$%LD4:U"\P\U?XBO
M0/OI&];76-H;-1ZNC3&5P$8I9UZ+??W\0,GR@P6?"6>7@8'( "L(RGJ!%>!3
M.^OQY[>H&'[L\.:ASI"5@#<TKG^QA'NV,C8[,>KTRL[/L:^RKU*TN(02O<".
MD?0+A3ZJ%>PWZ-VE]>5JQJ>/'.R;K8T9LG*2$$^@_'[LV%^2:X?+,0>3\'D%
M' :YTMG<U;9^T$> _DK5X[Q5ME84QPIDRB#Q^$Y8SP 0VNEQD^9ZN\E'<?X%
M<#SLH;1^N<E !F9-4;'/W<NUD7K8DE7KU%4Q77;]M)Z]?N?[UTS",^]:V016
M?>U<=Z/Y!M-W9]3RNR4!QMWO]/WK]ML [$IWCZIB5^X3ZOS8B\LGP,LSS0,.
MO<2?N"_%- RP,"*30(T7+[>W:IX #FX&JX,VD6%"/]TV XD\)6Z]+/:]!G[]
M^A4H6W^*_G=]_WX"?';S@[5W=/@L%BW)OCD.=,EI+D=!DN'XB<&J1BTM^9S,
MOYJI!: K2N(8D3_K,>F!<OW8J6>#/N(#M=WL8.?ALT0SF>5Y'W$AR57C 0:Y
ME9B;HE;2U^78<5Q#NB?:@OIMC-J+:O-';MX/^C.2AY)1^+S5/S?(PSQAR54U
MS['-!6G5/9SI%:8NF F4I(QQLEQ+E4 O,W>*'%G3M'&>-<YTIM5S3,P1_B#/
M]:E-&_)8X.HAA7M]W16/TX32<%KYHU1R_3G%?Y$65[\W7RBM;G*];% ZH15+
M (I:P-V<>RG1!L1)OU'G0_,0'RE1"VWRVL1!S6HE2A[=LLX)"#<G3$7W[?W7
MKYJY3KHE1SNJ&7FYYS;LX,VRWOT)#*G ]-F6)KTT#2.!GX01X-[EUOT4]1OQ
MPW';,4\9]_?4N'[J!NRY?A->4\PE6L[-VZ1G.Q]<>S>#OC%Z?N#1<'&MK8:I
M@X*JE=_,HHTWUCK,0Q/:;AB,D[>K2^N#19O6.@L*6\^B:3<ZW;!P7"#HBU&&
M?/1>>\+W:ZZV7EI!&5R&[3:76QL 9B_POGYY/\5#ESD+=Y<6%R@M,,H<=^"4
MU(++'A$*]HI<V1N6;B=&U=1:WTH&\*-Q$BHR5VNG'W:K&KIUMV2,XDX,3IE
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MU&#QL^6>#/?*'$5];(!2"^%%-ZAW6819X#1U!"9K7P7ZFLC&_=,MX2< WQ-
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M2&BHCLL[T--R*Y!NXX'ZAV*@-,CLI9P'OTU2@7!>;34$'9+5B52U.5@Y#K^
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MR9*2AMR"-NC=$R!B*628B=+DJQ0C_Y!%XO7"N<:+%30Y_ I68F@FTC5(ZK_
MQ(:.E(T,$BO;7Q20RM)?KBFH,'-<%/TA^<[S3,V9X1%"SSHAD&TEV-G?=;$;
M0]=IF6/0D&<X#:7^5- C7&T?:%2@ENEA3V-/)# F;A$'^IPYSVE'FRQ!&"JV
M($ 3Q$2KLWPIW0'KZ?$^OKTXKSFRIQU6Y@ <">)'3KI@]DVJ.P3&Q5#<KX).
M6K<1+S?]-B%?V5EDQZD'B=%\+4.\:B?'C\2/X^8,4]:6_6.F:!BB2]6P(_D;
MFUY@SW.PI%I=XV]R?[*O6ZA*^N+S0GY;N)W[YR"#)P#VO[2,2$"WW_ =A7"
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ME^BL*SA0%&YBRG)W'@#@\DX&-WXX&">*IO)M(XSF-AG(S@8).<_>]J5GV8P
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MZ>]>;4J7V?5]-NFOW=5Y([HP=K0NY;R?*FM=K7T[[:_*Q_&DFJ_>"R9P%X.
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M.1VZ_P!#[7%SM4$  ]^3_=^N..XR0,$X%>@>'/@+\8/$^A6WB'3O#5K;V-W
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MNI:-H-S<:9JJ^$8I;>Y73EMTNXKVVBN+AX)!'_?1]G8'[\A'U'4 Y!Y(P2I
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M&WC3$LDLDJ)$@+/(4!%<;:>/])NQ&+;6M/N2QX6WO[:4MN!D4*$G+$M'M=<
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ML]&M>G<0EAN8[<D@\$ _>.#UQU)!XQQGU-1.VT,Y W?*-N>@RJC//XYIDDA
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MGB<%A)X2G#!1=&'U3"5%5G-T*3A&"4*<E/E4SI_M;!L *"0#AB!DG(&..^T
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M$PQ0#3AU96(4!0!G   %9GIGX'V6IPR01XG1R$RS)(K<C" X#' ;)+,H4$D
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M#F3E"UW'H8I\D'@'>HSYA !^7D#<!@9R1TX8] <6DE.X N,C/())*X]\YR6
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M<GHN<=@<Y!K]7?V0[R6__9E^"=S/(TTK?#_0HVD<@L1!;^0BD@#[B1JH!'
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MHX>I*FITJM>K5C)/V<UH1;RAW.Q)8[3O8X7 P3SD\Y/TP,<U(1_M/_WVX/\
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MFXI_6^',[I*>B=+V:R[%2ES/ELITU*C*S5U-IW@W$_).QM@^W(48;@#)&"0
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M3:C<[<M':6TMQ +FXVLEM$[7$YC@CEE3[W1-H!( 8\-@#D ;0.@Z +G &<=
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M&O[_ "<JDH</98GRNWO14G:]_C;246FG>HHHK^:3^^@I&&<#WY_(TM% #-I
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M5H7AETWQAX[N/$WB;3I/-@BN)'L]2@:2[B%W,9+DF:OLA(F;YBZMD*-Q&2P
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M/6TL)ECL=1LX]0OM9U&YTOP]I-AK>A?VOJVF_;K2W'ZES8  (4$Y !!()VG
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M5]7YFQ*%RV"Q!&TD<GID@*-Y(P%[!R0!P<FL@2./M!&'88$1(&&(P") "![
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MV!/:G]_W,5UW_JS?Y)OT3)**9YB<\YQ_AGO[<_2A75NA'KP0>^.WO0%T^O\
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MN*YUO9J\=VEH]E<9JFJ)@LV 8\+QWZX X. ,'CIUR,]?,]6U;!=U;E@1@9R
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M^R_*;TMH]+N=M7JW:^MM>J^?0_,&:[#!%/&=Q!S@\%.^2<?-GTX'6L6XNO\
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MV]+/9I,]RJXK79\R<F.G@B[_!$N# VR/ ,DP1814!7(,C!MFJ2Z=9?;3*X;
M_-MX""U8B0I$(Z6]$)?Q1) <_ @ 8:2F;NP&2QXX5,*3W"9Q))'U@CS/K] @
MO]=SO=&]<9X7A-^JZJ^X?$$'F.DW:TS6ZI)Z75>R%2 :AR<<IK+^A+!_S$/^
M?(H=??/.Q+4B-47'Y:* G"TON,$QXZ"A5&S.>=#4SI*F8$R%=:E/Y;Q;]%/%
MAW(C3!QAZBQ0MFJIW*\D ! H^LI .XFO^Q0BG.E /MR69%[U:F%BZ".T(\
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M*>;Z$%)VRL#<MV^V5"O8U,[4EI]TC,O/N1A)O%PC,_H(0 -NGB%OR_WT!LZ
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MA>,;"_01LGU>98!':#H^BB)@%]]7JD&@>[%_Y]QK99!2HC:!_Y0N"2D=>J-
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MK?A;4?[QAXV+D[BN[>\;[ <$LN)G34@-(R"D-G+7_VCN_P!02P,$%     @
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MEF-V4$5AIKJ@C,[;Z-2KC,WUV9J;78V.+R,;VV3FWT#H/(2MM>K2C%++,)>
M4NOU?YDV1;CF5_83NJ\$WXH%-U$.4]?P?^^Y[)3L4NGV+ R;"\B*3_A?NW'Z
M\([\'A#"=/<RG.U;\=,M,.$'60R*G?%1?&[X(XYO_\W*&Y:%$L]0XONO#R(/
M]EZ3_D-/'=7ZK[D9JIK,_T?T_^.BCOO^)"A&T&3@4\G-P, />)7_/:&^Y<(=
M)H5F$U%5>/5DD#* 9'S4F!+;?Z%H<<I0_E?:?"5RJ(0-W$[_U_+)_RN?_G='
M887'I,!BXFXQ2SUAQ7^P.+[B_F_&)1;2-DSJI:%9+I5X]1,PJ2BZN2MS*[!7
M9)R4YR?F2CLI<9 ?>&5]?H/D;<5Y+<TXB$FTAO2P1QX;7A6VESN^2B@POQMX
M'X7[+GO1P[C$WOVA&_#YD=0+:C]"KBCOUV;^BN.BJZ[$DT&H<G%4CPC%5!/=
MQ\Y&\=WGUGNSLG\G0'9=F*D^8V70V4XGAFHL!N X\K$)'R?BLM5SF)8B'UI*
MDS LSQ 1'*:'O41>-]*H06=\E!.\]*GGW7) MROJ/BS0E6%BI8KAW42JOLGN
M?LB)T.2@71N#G*"OF1$<&4U[VK;AW%EC8>(>)/1GFL>L_09G3VUG:.\> ([_
M*R9_^]4-\<D20QJSF,U"?+'VPJ;EE!(73\76#RB<@2G(KB(.&^=@IM/9IY<;
MFGIPH%KLJS?K1AONZILA^C1FUXMH:R(QL;MA7;#P&O1CK,!P9;7K>+%UI$,"
M3-K#%>W .>7DR\0Z7]"U7==]$4160&:%\^<UW8-RH_&MF,=@01">3.>N^(W
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MYSZ^Z@GG8RWP4=>41TOE--?IJ,V],Z!?@(K<\'J7FRPY&M!71(=.]:!UF.A
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M)7&,&M3%#BIJ9<HZ:9>65K"Q4QS?)?2H@/DQR:(3C:12")<BEJ':E]9?;"3
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M(RAR4S-)^)CJ;B*L:3?ZCA]K,2CIUU0_@)AB=,ZEG T6P7QS]EN\HBQ\#,7
MXX75R![]IL]=<VJ%#QK+9'6%4&W'@57.$I@?E\'WN1W)#Y9W\I"?O+T)RM,9
M6I8U!MI%WN5_;YO3RVQ=5CP1UG*<-2E8O)CN.E41+? L_Q$4E%/6F3+JS?+^
ML,&H?+"V7U@9J6^/GVE8HCSWN+KRT]M*9#=_C/CNK5KOQ]WTM[0__'CG:G(M
M/3WK&/!TJHSS0UKG#[2J)#,RY'SF#<N[EE,R)$KX?X$.^F]HXK#YH63QCHO]
MMN(&,3$J7VQ!5SY-.3JE:.@VC^S+B+P!K1KS) ?];W_GRE1%*+*%U%#'X6&-
MFOT;D;D:2=58__X+8[%$R%FY+%LW= '*](0XJ$!OV=59<^;<^9++IT:G@&P@
MJX6YMIF)M!:]M+IJX715,'UU)*P\;95HJ86K& ZHCG]5"7@43TE"H/".ME=A
M5W" ,DWR#8G7!$\CSX<!?%Z>F9%=(BH8>?BLZJ]!SY=&*^$!R,F><B=9VF:3
M-;=U*0Z2U-K?BWXGJ\9$HI5!7[[Y:9&GHMZB1Z684PD&17]LDDUA2Q(023\<
MD-A8T1(EJB\+AM)/AZT#K+8YYS(97M*+5\]F<,!7%#,?Z7;-_>6LF53=J/ H
M(I@9/6G-0@^KL4?VR1\8[G]Y_V)G4#^)0XG\RPZ5Q]G7&NL&2H^?5?&#NAIZ
M,AG5W<JG"FX@-2-7%IW7*]%EIVRP36OR$2;J4]<_>KGOO&]'-33'\$*(R_>E
ME2:)7\D$F/TZ3#SKDY"9U.#>IMU6(;=5(E"-U<<3)\R'> &6O5>W<%\_Z%I1
MG#-")7TYT;/9.A&LQK*>)C8P2MG!]J>W/4\U*XI^7"?&P+85ZXB<Z?ESR1HK
MCU#._O/==2[)GK/'8JY_,3$L>(5M5]Z+J;D'=>R*@*S5/B-%S[W>_0#"MO,K
M@V@+T-2 +-E,GCDF+.Y& O'XT3IRX5F2]U#@13JBB_K9_\/!7;\UP?U] ,=
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M\3]";L1Q!TYN;P>/["2)XMT^MNI7PA1M8F1TA-&*Y;D%?--'1,\+ZYP+V<%
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MBE6X]W7L6=?/5:<#3_DMD]17?11# \K79 O*RE4_E=N$?XO/IYWV7F6IPC(
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MJ6.$W2I7G[R",=J#A5&R3\B[9%U:\E+,=L"\]*%V[<,X5/KJTQ3GP9KL)^&
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MCUD%="4P.<NV\\R0V.%J1E65*0Z3^X63UG0,6W*?SFE>0--98VO_EB'<?L!
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MVCH;+1LRKC1;G%Z;30OK>3[7VD^C8>9B3IS'P8R,^,Q3J/D<=,9)\&LRES]
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MNPP+G&DAX'@_7'"U)=@U*I@_1PT-G)58HWV ?4>K]*17_R?$ULGF:9EVEL"
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M2I]3CN/#[PWEQ+I\$C2P1:9;VCYM;FX>U?\ ?)=R?98I?.E@4H8:])^%FJ^
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MD%7+8XBA2K<L<%'"U<1E4\%F&:T?KI]?Z A:& D>7F( (% "!=JX"] , 84
M*JX554  >K:/']SD_P"J/;C[HXSCOZ^H_"N"T>SVHB[ 0JJ 3QG!.,_W2,X
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M/>VT%FCR2M,]A=QL+-7?)D>U>(.UJ7.24DADB+DX9-VU?KR_M@2Y&6QD9;
M]AC&/8Y7)SR>W'7]GNS\H& >V>?]K&#GIQA<@GKW<7:2DMTUH]86NKWAHF[;
M.]X]#&MAZ5=)581DHM2@W:,H34HOF4[-J+2<9*UG%R;>A^3?[0BR_ CP#KGB
MYO#LKZ9HNFZA-?2Z;;07SDB%FACME%S$KW-V(WL;!)3;F:_GA@:2*.<N/Y@O
M$J7?[1WC;P1XR\":C<ZG\1M?\26MYX+TS1II8]<\)VL=P-5OKK5YXG2TTQ=/
M@M)+^>2WN91;&U+22M@+7]QOBSPK9>(-/N-.U"TBN[:Y!26WN;>&X@D0AL*\
M5Q%+&^'$<@R&PT:E<$9KXZTO]C[X2>$_$=WXD\,> ?!_AK5KM[@76H:'X7TG
M3;R:*[G:YN8/M-K9K<103SDR30Q3QPSE8TN$FBCC1/W'@;Q@P_!W"V-R6>13
MQ.83>,>&QE.> H86K#$SDH+,5BJBJO#THS;<Z$:DYV="4(^U<H_QMXC_ $1*
M/&_BO1\1,/Q97P=#$X7(\NQF"S#^UZ^8Y9@<JP%3 XI9!*@G@JM/-*2IU:=)
MU:-+!XI5\PBYUZ\Z2W-&7P-X)^"/AGQ1\1/$-WXBU[7] 6YNH(#;:19(L2-%
M/'-9B:6Y6]+Q227\4MZ(;6\DETV.*1K5I9?E#P7^SE\#-<\9:Q\4?"?@3P[:
MZM/J*FW\3KH>G+K]Y;36@DA>YOOL[SPW4<-XUG,;9K66*-?LS'R$A2/[5U3X
M1>%]2ACMKVVGF@BVL]M#>W,-G*Z!5+RVB$6TDDGEJ'E:(RN$4,Y P=[3/".G
MZ-:QV6F6D5G;1](HE 4G<6). .68[R22<Y(& %'\X9*^/,OXEXES;&<8)Y%G
M6'KT<#P[D\,;@*-*5;$SK3K5ZD:U.C63A5=.C0H4YX>CAY5*3J/VO(_[,S7(
M. ,QR;AW!OA&EB,]R+%3K/B#-J>5YEB(1EA:5"$<&ZV$Q&*P;=7"8/$UIRJ8
M?$5\90J5U*+JU)0X[3]*6SM(;2%/+BC58U7H H55X]1U(R",Y'3%;]M88:-0
MI;([CCJWW@,X(';'U'''4QZ00"2H)W9Y'H![#T]OZUM6VEGC]V!\N/I_]C_/
M'O7ORE*5N9WMM\R:-&E0AR4J<*<=/=A%)?.VYD6%CS'\AY<8R#DX(Y;W'8>Y
MX&..\TRQY4[3DMMR0 2#@$G.?7I[<8 -/T_2F.PD8PX)]SE3SZ]\'Z8'2NUL
M--&8S@_>SR ,XY!;I^ ]SZ<2:EO2[0@1@+P)%Z^@V=>>,= #DXSGD$CO=/MR
M N%!&XG/)(.!R1S\PQD#GGL,<9EA9E0OR@@L2=QZ\ ?-Z'C@<]3P,<=;:0E"
MA /W6;@9!.1][&<$XP1G@ =,X !:MHLA@2PPP;E<9(V<=!Z=!S4TB$'.3PF1
ME?O$%CCIU^G.#^-74C"@'<QY#'Y>_!P<#CH..OK2RJ''5@5R1A>IQ[B@#D-3
MM(9(F,J"8>7)D-'D[<.6 XSTR /?C&:_B<_:^M_&'PB_;G_:53QEXR\0^#KG
M5?$.K^(?AC;-J&J0^$;OP?XMU5_$ME/'I<UR8Y%OG>X^T:I'#,L>M6E_:1R1
M#3)K.O[?;V(E1C<W#<%.#PW#<=#T(XX.:^9_C9\!? 7QGT*?0?'WA+P[XQTF
M=?GTSQ/H]EK-JLB.DJ26ZW4$DEI+'/##/'/:O%-'+&C>;CAOT?PSX\I<!9OC
M<;B<#/'X3,<'2PF(A1JT:.(P\L/B?K>&Q=*6)<</7=*JZD%A*DX.K[5\LDY(
M_#/'KP;I^,_"^"R19E@LMQ.68O&XG#RQ^"K8_#8NGF65RRK&81T\(I8O#UY4
ME1JX7'8>$ZF&K0DE"4:TTOY._P!AOXJ?%CXM?'34]*%M<:WX6\#:6=2N/$ML
M\DVZ34+*^TR.WE^US".YDN+VXMUMELHWN(X8KJ4EPBJO]%GA^WOO[,A-Q:7*
M3&($J\$H8L55L#=&G.3C'ZUO_#[]D[X=?"07-AX!\'>'O"&EW6H-JEW9>'](
MM=-M[R]*D>?<^1"AE:)%6*V5RT5C B6M@MK;;HC[;/I @C6-$VA5(55!V#"@
M!>>PVY'/7KUI>)''5'CCB26<87 /!82E@</@L/3G&A3K35.OC<35JUJ>&<J<
M)RJXV4>3FE:---2:D[<W@GX&X;P@X*EPO#,,/6Q&,SC'YWC7EU+%++J5?&T<
M%AH4<+#'^RQ2E&A@XSQ<ZM.G*KBJDI<B45?P<PW&"3!,,<;3$1GIZMGO]>..
ME?#'[=_[,,W[2?PCFT'29HM)\:^'[JVUWPIJ5U;Q/%<W6G7"ZC_8ETLTD<*0
M7]W9V$MO=2R1I:7]I:RM-:Q++,?TXN]););;RIY'KU*ANXSC R>0" <AJP;K
M1%G5DDC#A@>IQUXP#CMCJ<GH,FOE<EXAS#(,SP6<97*%+'9?6=6A*:E.C/GB
MJ=:ABJ<90=?#5J/-3G1]I3:]I*<91GRM?H/$/A]DO%>29AD&>NMBLMS*BH5%
M3C2I5\/7I-5L#F&"K3C6A0S#+L6J./P&)=*JJ.)IQFX3A4FI?R9>+O@7^T*O
MA.XT36?AAH_A6RTU-.\.:KXP\0ZOX4T'2].CN9]%TZRU*XO]2G%QK,>G7#?V
M7&_AO2UMVL!8C1O$&J6OD:?J/ZA?\$_/A18> _AK9:=IVJ)J]S>>(M=N_$-R
MD6I6SP>(+:XCTN]L;FUU9(=5AOK8:;#<7K:E;VU]?WE[<ZG+;00ZA%;Q?IUX
MS^"OAKQIH.M>'=;T];K2M?TZYTS4;?)4RVUTCI*!*B@1L-X=&*.HDCC=U=4V
MFQX,^%&E>%[N>;2],LM.6ZG6ZNQ8VD5JEU<)"ELDLL<$4<+R1VT*0H[J72-<
M(0Q,K_;\8>*V=\99,\HQF'P>!H2QF%Q-2C@X8JK'$1P\).T\7CL37Q%)*M+G
MIT*,51ITXJ"NVYKYKPT\ _#SPTJ5<\R[$\39KQ;?$X/!8_-*^6PRO#Y=C*7^
MV.I@\OPE&57,YPC'#X;&SQ+GAH>VG2I)8[%45V.G:/'Y,:-$&^1!G&[[P YS
MQV[XY ]<#NM(T:%'++%A^!N"8^G&,8QD9)!/!)X!K1T_1F"H N,;>I Z8SGO
MST[9P#T %=MI^FE-H*'((QP",$]R , >@QCCK7Y8?L _2[0Y*[ ,!1RN#]1D
M>OT&!G'<>@Z=;D!3M VXQMY(QD="._;A<\8SP!1L+  !B/F!S@C\!V! X^4<
M9.*Z^QM>GRD8/\/WAQ]!QZ#Y<X'#=P#2MH0 K;FR2@(*X^Z0<]/?/IU_#0V$
MKM&[&1SM.3R6)QCL0!TQSSVJ6.(+M 9CDJ3Q_N]<#C  ..#5Q0%QR3@,/NGG
M<03V]J .>NHMQ(Y(!4_<R"3A2#QC@#./7W%>>^)O#FC:Y:7-GJ^FV5Y9RA6E
MCO+:.5-T$\5W;3[6C=TFM+JWM[NVGBV7$%S;6UQ"\4D*R5ZQ-$ !AF.YN<KT
MYW9X QS@<]C7*:C;>:'X)S@;NC##9^7 R&'4'.5.&VG RFY13E&?)):QGS*'
M(UJI<[NH<MK\[5H_$]$PTZ\UMGRQ4I6>C48N45)M-I1<HJ3=G*-[K^:CXJ_M
M_:!X8\>?&KP%I7@OQH6^%?C/5/!5Y/?V8A6SN+3S9#%%-9WDP-W:6ULMQJ<M
MY9V5I+>/=1Z5=:@;>5UZWX7?M/>"/&'[..N_M+:]X>+VO@_2_$0DUV?PW=2:
MC96EGJ]G!>3;4M9)8'L;FWT]-32VEN0USI[$SQR11)#]??M:?\$S/A5\=?$'
MC?XDZ5INKZ-\1_%&FB6_AT7Q5?>&/#GBWQ#IMI:VVEW'B>&UL[Y4FU"STW3]
M U34[2.-AIGFWIMFU9I[^;T3X6_L@^#?AW\"H/@7JVAZ'J7AB?PI>^%?$>EV
MD.HR:'KR:I'=C7KS&J3W.IF379[RZU.Z:]U"^N;34;J5;?4KN*VM;E_W#.^,
M/#C$\/<+X7+<BJX?,<#FF3O-XQP:I8F64X:E;.*$<3%M8ZEB8JDJ4H2BJT*G
M(U[1-'\<<#>!'B_PSQ?XG\38SQ,KU*'%F6<797DE.7%.9YI/#9OF%:.*R?-*
M7#^-PE7!91E^75Y3IU%A,>Z.!C4P^5RPN;99[>E/\F->_P""EO@)E\(W%MI.
MM65OK]WI0BBU?2-65;M-:F*VUJT,:R"R,D>T_;))/L5@'ADENI'F-HGV9XT^
M.GP6^ \'A6UUJY\.^#;[QY<7UU;Q):V^F7>KWKW5S>7$ZP2HKW\^I:C<ZCJ#
MSSD1PW@N$>2!1'"?!M6_X)/Z'I'Q ^&^H:3X@\<^-?!7A778M7N_#?Q!\7:+
M=:=I<>D:IITFAPV4-CX.M=8U2.*VNM4EBMKO4I%)T>VTMIH(M6:6'Z(_:D_8
MFMOCOX=^']SIOB&;PCX^^&6J:CJ/A?Q,NC0^(;5K76K-;37=)U;0[JZLK/4+
M*_,-C=0S+=FXCNK:'R%^RWUTH]#.<^\*<QXEX5J8? O!<.QPN/I9_:C7P5*=
M>=&G/)Z>8P2]I4=#$4,=[9PC*+HU4G)2<5+P^&/!KZ1'!OA-XAY/'CW-L9Q7
MQ!B\%C^%G4XJIYYF^ AA,=B(9S7P^/QE65'+LQQV#KT\11IYD\12C4IXK,J-
M#+J]/#PEXSX>^./P4_:4\9ZC\+7FBUZ 6EKKC16E_P#9[A[>RU.(BUU"TL65
MDT^_'VB"Y69+=-3LI;VQE@G@<74WU-\4?V?/!'Q=^%6K_"CQ'97,_AO5XM/9
M'M[@_P!HV&I:1-'>Z-K5E?7B7DS:OIE_!'=Q7]QYT\DWG-</*9FD'P_^Q_\
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M?_6K>\/^%[ZU\;_%'4[NR>'3];OO!TFCW3/"RWT6F^$;33[UXXT=I(Q;WBM
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MIV"'(3402EJ2 #2"PAAS#_#V-;+F\_<"IB68/<-&"W*T1>9BPC)$:KJ>T)8
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MTN:_^;)A]$\3XKCKU/W0_=\"W%%M$_AL<-2*B*>FRQF]TNA/ :OY8B,"$K\
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M 2RVW_3 6 +17$N,$<&C$4 P$,H8$S*K-[H14>9'DQYJ/)F_ISZG75F/1B@
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M$$XT#596)/3?""PNK<=>?@ GW,M,I+4>+;0VW([^S$+;MQ<\$\/M7C-M\/[
MTH^6H:BH\5@%]8L[X"9'EF"<QD@5B^5000<4*\->5IUK(Q_':9%_NJ_)YK0D
M)7P#90CY8/3+F'.Z+;]^'\22X[3B4B9V#7.Q1Q0!T4Z8G\4*^E;V9977;1*#
M[XJ["T5&@EJA+=0^#[(+T!K^I@V=#=8>!Y&"S;P4!Q[M!!ES'TI3S(4^PQP
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MX")J'L5PI*O5,530X\.?KM-:- :0^<YI\PA"S>15<N[JM14,M3^Q8XKB IU
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M<ZFL-,K/0PO*E5!?4%OZC&+6 [TZ4V]Q0QH.;<F0[U$=!F=_ ?#%#2#I8:F
M"(CY#]TF;$%;AQ;U,Z3V<>Z!MS_PY5+#4>&%WGD1<A/).F"$H@MY=CU6G0-0
MBR@@>^XB:.@+%2MTD<J@5J+\9;K3;/PH5W^<D+"^"VI(:DZKV4#9-_252';/
MW0K_1BMT08W1Y=E%7&-5UK"I0J_ 5.!X=+Y?#8/RP$C^Q Z0EL=)36KR;E.Y
M@)LJ,P>,IRF[Z:(Q>&$;V5?!UL%/N\8X/;AXVV61US1UX6Q:W]SHL"H-P/][
M - 1T@UL<0! 5=($@=C@Q]0-I(-"Y%:U(8G'9^AU.*,VO9]A:'5]='L6L[M
MSMCZ#J+R+_3:_O%5C?3>,&95FGL@):]?_7-QMR1W"TD9<+APAQUXQN2&2>;,
M,#,XLC^4&<$A?!O*KV0XAM5M]F$_:+>PC;!Z?8 RR?0UO89VR">A+-'I'L/-
MH[?N?G:Z<[;BSBHSJL7)J:*R-> ].@AQY]*+D(KF+8<"IN;UU7^OP3;NQ<!G
M:B+H\E7$J*+\T^A<EJ)VE1H.L(JT\KO*=62X+XY MK*Z(),(GZV66LR3O>6Y
M:8'9BH"TL<+.%K'"T75%4-/!;H7R?$?(YG*4+LDML@]@J0QSCX(TT;R9RFR0
MG+SRGYA8R$*T[-;GF*'P+<:L4WD"K#PGKG,:UP6,O)S)AHXI1ZDIN7A]THK\
M8<\YN2,^_HT+2BMEF5?>@3[(G$6\9LL=370"-DDP1P#6E\Z5E']19AE93+8
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MDKISBO)M(F7T6Y6IXJD]=;-KNU*J#]%6G$B[)^6>;/%_75!F4=/U]E"2#&X
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M!3SS8%_IA1<A'_H*<1:D!WB001-6\[&&FDYO6&VG$J(7V!L3$I@C["+L[T>
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M1>@=<L;6:>Z!*Z+H#<O==9+N.WSFAYEM[Z)_3'BL/L6@H*%^# *8:Y1"UM%
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MC%T<PU/EW :*:2N.KXV3FZ2K"U'%#,+*/@9L8@^W;LH2T3@<.,M*230-#"E
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MQW32F^ZPRSV_%#O@-.PMVX_I^3A4:L'F)$D-R:W;>S**)M%JK",-[<'8'SX
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MYM)T=W8:QGV)=F:+D-V84?I'?EC%[D<8,SN.A$Z0NR$2IB$,,1=R/,NE"Z:
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M'DHAQK;ZJ!\GX(^CN*C?(D;N_( 3CS*[OQCD:+XE,D):5_98:3)I02<75%1
M$]0*=/GC_P%02P,$%     @ JHG56):-2*CLU $ ^-H! !    !F;W)M,3 M
M:U\P,#8N:G!GI+MG5%--%#8:141 >E-:+!25IE0%3%1>142,@-(A(B("0D1
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MBHKV\L+FIL:FIH22UI;6EI?/CAQHCE%U+LX8/EEH&>9][>9QG X3LQO+^!2
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MN!DC8&-X3<XY*+H*ZT"[B%9!QN&T, S"#FSP/T!8] ]0+O9E%;:/TJE7EQJ
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M(O$,SH99Y1#AZK\F-NU'C8O%&=!;=M*^=]'5^- ;(ESA[]'/QS^^6,\!JMY
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M*RL^B>(I>7[PRZ\EK)PMX+@!$^_]MV%/%"GY\CAW.L2QIZ\)S<\<!B02;G4
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M&NH&AIK3V\<4ZDN3N)._EVB(%\-_:G)Q(RGC#V*C&:H5)= JZX\#=,H'K I
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M@S$FC"5KS R51-:,,F8F"<F9LIP8X^?[^^N\SC_GC^>^[^M]7<\YY^$Y>N9
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M3CHP:ZN_V=K'C!(NVI<;CA5^3_M7[D@34K4+^_'&X>LM#@R:"1-YYNL"ZQ!
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M5R"B\DWK0H)KVHMO^J92.*^N(WJN?<<(IFA_QW*5A^7!@:OF./3GG E78LT
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MGJ%D@X(TV.&MA'(<S?]!:[Q.,71PHLS3COZA)]NR?-:+2Z.3!#?3./)L!<^
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M8XZ8,R*:Y?!#QM; 5PC_GK3(P"\*BZ,?2J=7.$\IB+M;*?R=2Q.;&>@HY\[
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MN:UNK>E<81.V<[_;%/GGNA'6$EC_70ZD,A$K^X(9276D'5[6U='Z @;N,:/
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MKT:QZ:JBZ;U>(S@NW;$[E8G<K>46X%+H66Q?7OJIQ*X"Y?XKW\7H=XE=H'Q
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M./,)>?[5E, ++(_ RALQ'II4% 9L65E@Z@-H<)8IM\L%SN!K^3?#@K,<A)P
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ML $;]F.J'$E>8 G4%0+#&"9^0INKW=&+[72_E0&RF7G:P""$61V#+$%QM(Q
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MP\8.'J@="?/F0Z__&\:A#[,>1!E,>!#4)9HC.ES-L&DMV@(;W!9K)E1WM.B
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MD\SB-&3B.C[&F@W?"6EK#S]^M-+@F7CXVY.7KCR=ZZQ FMVA/:Y2/9<2Y36
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M!U=,-3T(?_=M8?6H[,/@#,L0M%IQJ'_^37"A+T94#<T&C,Q)0X[1Y<!SD=D
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MKW?;D-3\^=0D# B@L1Z$A@L%*A6%/TF9J]H1\:0ZD=N%"V AY<;3_J7Q*)<
M+7/CSMLC,LW!Q84,(RVH,AR1;#VOWQEHQ%^B:F%Q*/U'L71M@CC WF?(>C]
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M3#KBN7\3K2LGMY T=9L(<IT'G?)BP@Y:.?.<';X4^4UB,E"<K,XC4.FZE6-
MWG,P+-QF@]E&Z9&8MS?21\3]_%V]I R) H@!F &LF_HX,PI8T.W;1^5;.[*X
M_=EX+9\%&\M7P/:ETD/@'217%@+:BX*"POD&:DZ19;YAEI\[2^IR1P\#5TW;
M[+.M$.6!WC>1G":#KA)WER:!=54ECP!>H%II0=*7Z7=@R1ASG'6L?G_7/XS0
M'*X3YG;GD:T@UF6S^Y-VC_THYUR !>USVPA_XK,@X$'94Y_/(%$X"(9P+W8F
M^&V]G_)?X7J7QC$=F*. )1H0IQ#G$A1X^4UM YW-:K8)E3B=R7";(X$++YXT
M_C%ZN(#I%+HI=2!BC;H#(84C)? Y;/[K4I,)G/L!D.&9V..%H$FH!G>W7$H.
M.]T3" 5F9LCIFU(W.HYVM<4\$5K#/;,]$KG9S %2!MX":,J>T],XAG-Z!<3V
M>!L;R"]*C@HPDMK@I=\A?01VU!7$7DY7>:A9FU;'_+T;X\=9$F71.09:[6NI
MCKBV$9XX6= 6T5#KP#6JZ'P$>.K!4ME5962LYZI]^QC^+7_F@"O0]WUBR&>=
MI"*9D&P'YC/7#8B>IFTIY?P2LUZ&;+3*"$9U)5IKS!BFB0L'[0&$KR"B9'>!
MAT!1#9YD LFT49\TWLC>CPUALD-Z].X<1F\+8T]D'"_C.6]%SRP&,AS2!54T
M@1+CA(G5[///%DH/3!J(+FH+!\DVE60LF;LIM:(ND%Z$[<&BNCO5!:=J>?HH
M>Q8L1/_V<99VCIWSC<5F9;:S>"B5EF7$U#PI]6.5O8L/[87+B*Z^ ./G9HYZ
M$?:&!<J-D-S';XI4>6>?!&[TU0K\SOE1Y; ,V\=KFU(H,,IO&+<]8F]3I^JH
MZ&@D3_^PB0:ZI[ _FWZT(E1RD4O*1M B'I$16/Q/AS$3"V/8%I#(3C4Z;:$A
M8C^&<KU;V4OS"*C A6F T_V3:G6S&A,F#*704N4M#*6FF;8I9Y'!?D?P$6JN
MQ.TG7&"?8H"#\AAR80R[KYRF7=W6R$[%KB"#-%]"9MLL^1G6](1^M+7;Q/=P
M/>]A*^OX&N\P]J[4]80=_6K'?$GI:U :"BK32$@]C63K3U!X"4'1'!FL;1][
M4XKH5XO_2-A)$RMTM_7X?J'60-2P4&Y(#W47,N:WZRA&+KX;H4I#I)5J =;B
M.LDI.M!WC\SQQZ*W8*5''WUUM)$2Y3!6EW.1-O*835#$9G2S-5NV)3_'(4 F
M<@,6VFG5,!S4*O"8["GG9HC#YKM+CXRLJ'#_!U-JI,I\Q%W/Z?KNM^0[F %-
M$VV[_@Q;05G/+ZO AL$.0%3"8G9U_;XX3L>K\ZCL$&$NT)](=^(E>#$M3Y64
M?T4T?*L52&%[.Q5%KCFV6V4=((,'-# V&@//4%%85$_ML]G0?W'N/E3C#Z8\
MSE5&CC"A>>(S>.^9@]6FE+?(1ES1J8IS%<S6S*'_"(O+;ZA&=JJ,T&^8_$,3
M*&?$/D/]AB19>53.JI9^78K37;31$,PGFP0HS_<6JA!I5*6+A&IRDDD"GM^-
M-VD&."KUDG&$?*7 A0*\@T)0LT<$&@4]B)TBXTD<C!!<[DN=PB'Y,[;<]Z7Z
MK2.K)NIB-P.9CV"!8Z>3-\Z]'(OG]Q4B62*'N6G"?JRV[ZC('3O:OMPXT=/J
M]T'8^F\L3!V&7"*#.5%S%*B+@$K$:X)&O,'VN0]A2W.366L9U"QVY[T*K!;N
ML'1.Q:94]WED-7+D*UY' 'L0K>''9&NE5/+0Z?K <UGJ]H$R>U[R'6>H\![X
M;2NHN*/BR4C+YA21$W]!=#8AX2GN-)A]I^Z_TQZ,?2)#;I%S6%\ ^B)@D/PG
MD1EWBLR3S59>C/-L)3>E57P%1#XL'(R/D)Y&X15?_4;W035$V^9F0GR',4LK
MD2+;\FV8V+(%O)I NKT6?EW[KLA/(,]Q>YGH\JK-+.Y_;=![..=0DX9C<3?P
M?[(FF;%>INS>7IK"KXF2C0"1UC@M=_)FL""\+V]7$CV GZT29EIX3.U;SIS!
M'A#2*]$!=F684)7! J9E4S-7O59?O0\O/QGM6=#5>420&9=7DC>4$9W2 7B6
M4$"B8R<<QI3LL9(@TKXOB,E;>0W\7^D7F$PH*^SK[[4?8#TAB:,\!US#/N-T
MJ9VJW.KMY!C+0VKZJSU%%*<>FY,Y/4-4W[#9+2M+%QE(9U?A#%+F?02KZ70S
MJO^&UWTK@L"I%T%K>E*%S7:=6!N"A)9JBJN-*8C7GH$[!?597!(D2Y97T/5!
M94[8005Y7Q9$4'X)JF]3"L(=%Z&X\<FT]/AXV'YLH<%>=6?=R4"%.&GJ!APT
M@@MR9^5?O=J:JB;(U7\!<@J-(!/:]HW,(RF"'&<&^!/%@\@CV1A)7CDVC./
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MM1T;-?#!<L"U*<1)+_[#<7'/6TR0UHQH7WU!E-%B3*RS^:4OK&M^T]1J WH
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M.9&=27+G:#KA2!B;.IK11H#A(SD%<)SY@M-@/7+O/>U-V!/>(<F)U3'Y)]@
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M';L\^[^'.,8Q8@%>%#!U M0+0&N;CU#Y=%]"U%FPBUJ*HUE@X%.Q_?@+%;C
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M=@0.A%BBVP=\=2[Z9WEHD9C!W>-I4E_]*,<_+))@T*GLI:5"WM\#%"G_J,.
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MY1-1VE[F]!-U@MH*\$L?) 66+B1X!SW*WG3QD]8N9\,1@!4L!IS"VP]IKLA
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M[*E8<B1WRU"?V]I0[+LC<.A,C&\1SM$=N ///\CD'<*B8TN8T\T7IL;FPN_
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M[K?@YV^8KE&$QK'^;QJCWXX!L2Y6\^8X8>6MT0H3,<*8-!C>*59B@W GCV!
M,PC)>H3F;/4_;&Y6G'2 <NNM@Z\CW;J33KH3,7RZ1#;2<8(?D(>BNPJ)1KC
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M,WFI^G49<K@/-;N"R5;HWDXO<DL<8<W?VK'=]5O^O.XS6I#+;?FOJPS$3X-
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M9S\I7;USP6DT;Z'[R(MXOG>?2*25L<5FA/1K>U2-'A0G*9":_/[W]2>P<@$
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M*)E_B6KRAY\\-+_%N8M7VK@M7*-F'G< -."S DD5)P'^/[J8^1]02P,$%
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M,PG(T6MH2WMKA]R(__/.=\@P.]OQA:&+'YTA3TV"3N&#I5L\#%G/Z6%#LR*
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MA0X39:(#P9QS@X1P"0SWP)MF49BN"SL<4F;B&N"3/]H:5J8O_UJU;]+IWH1
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MZUI=D?+559[LF8[U&9IY2)-7,R#7OJ[6(2=^\F@E@=>&-Z"W6V!27:767C?
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MD;[6H^QQ5?S*,FUG]D5[0;%;)G_W@A:1[B)YVRP2I@4N&ODGROP#[Z/]OXZ
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M1*VRJ-V3]\$%6EJ6\.C4@XK[P[DQ6?<N+TF=T']58/FJVL=DDHZZ6\??>Y>
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M LZ3G[X@AI7D'CJVE1E4ZUPF$S2Z?U(XD1SD)L[&=GM$=!-"EQP.DT=:?J^
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M\P\;DOKSN6-T!(4Y"+VGQ[NPDR_5V!;=6W#;7?)@7PYEA6VV5N/-M^C ,4_
ME#V<T:2:I?E3D"G8N77V$N"#D5 ;,YU"'Z.>76OZ-KU;57>^ Y:MP8^>WI*H
M>@WSKOE_F'KKJ":\/^!_)E(B2*>*=$F'A(*T=#-"0, Q1L=H/TI)2DN+,&#
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MDC/I>_JTU"^+C:%BO,E[=;E4L,ZLDCR=SRSRP0:TR$<AO*FC:?(-M0;><25
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ML],4HR-%YV7^+N9RAC*X98H:QQA,0)B:5@\E-(#0E3]4#D2W.-P9E)S/Z[>
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MESI-L_ ;BW(UC5%*\;+.,SN>/$4?>U]\[; A4I$ZY,/" NO"!;IF#D>C@,2
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M8B8[WI56XZ+RZ!QT>"V?]17/.H !*9>4LQ3LX/<331JJNKF/:2K[_GFSU]_
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M@E(1R[+A+A"H"IM=%_B3 P\N0<5^ZW1,4FQ$PO"+#MA$+Q%T;GE4Y5*NY9)
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M[P<7(>=8 L"+/3OTS:$(<3B[^[DE"9L# DWG_(CW!<;I*-6^%#OHV!KZ?FY
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MW#G8L9.K#@&R9;?/YOXNS[<Q6">_.@2)ZGE5G'SRIOQ_RP,$P#A1NSB&L*2
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MD1X/Q@),D]3:F5T5L5M<888Y5B,X9.#= $2_AVE8Y6I-H-QMR%HE(X.J@!/
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MN2 *KWYDC*4C("V/GHZG2&5_WG]U9DL5756W8]-$",/D_H78U^YGZL&1=E8
MAL8CX."":,[.*SL85*=TS22SPH^2$N]/"DOSR.I%\:3EID9AJJ:7VR^/X'^"
MI1@..CKR GN63&AB8('9YIZSY/^F^VS-X)<%9UPCNB78@/59R9,HLBFP"FD)
MJ7)A&8ZH^7#"@!9:!)YIVJU1*-S,V(E[^PK&YQ6<VXVEIESRPU&6>MW*T. Z
MAD=4&;FD:4R^70)0L1[!FVG#-/[W4_856GZ$Q5N%HDU2X[KRY$QA/*RKS.R8
M,J#""N"=U5D71LG0I0@IL$Z)JXR!8GI1RK3X48H;+^(!.Y8[H8+MQC=Q(K^F
MX RG/^U"HYLM>\[Z^X[;WOLEBA (0*9-VM_VD22V"=[9+V+9,88?-$RFJ)"&
M@3"Z3$>_*.UQ5%=Z>P7&<S?3:JFVY[R +Z4L^B3E[DZ=H7<9FT)0VY\JA=9*
MQ_DV]"#.\UTB9^=1@CC^?^I=QH=]T7]84XOF6MF;IT%1&:F?#D%G0 OKKM<_
ML[4_8_\B='+6K>CF*<UEF#K:'Y!G+-/38GS0YY@J1-OVRT./^7K=?1=_(R(D
MVK+ Q1\ -X=$];8?6_:,&H]ZUYR7;^M&Y?'BLJ9)[ ?%G](BNFXJ$<\Z"B^G
M64)!167/M+-JUF_POB2"0/\-"G4L&8G]?BC&G46.[';]N^(B*OF"--Y!]PTL
MAG$D=HY5QN%NX=7S9:VPAO>KV*7Q%KG)XY]M^?]\IB[]^]P-S?([99?6Z_^]
MY43>G'"A2 V/TK<-L(2H9 [](_X=U3)6CCVIQ"'%R]+RF7%W@4F@FV';&0!M
M*!$3BB&.K^[O<;FPS@$O#D'_$1*OM+8-^;S]W ZX,=4IWT3]L4#X0D"&\1&C
M]33FV?QP#TAR&H[X85#V/3MWK.AZ:%#M$_I&FA& I,^<]!ISP,4%]LO^-9-8
M&[0DU_PV?AB&J#(>GO]&75V37W\ZQ_L]72OQ@73T1]ZO0AJ9,W^0]$-07.%9
MYMAKBD8*^#(5([0H@0[6FX#(,^93:,XW?DTF&P1<5VN1F[0($93C^A'O9%CS
M]15;\-0_T3U;3(<\FHOIXS34:LIXMMZ).:FXNKI 9D%+[%%F@S%J7Y,_;&MW
M9:>50-V1I<M!\8_K6U,IPSKB+A.K"D_VI+:2AY<($V)<FW'45DJJ8R80\P*7
MXW90"5;02Z!KVSQK=6( @299Z">P2*)-UU!58IG@F:QK%EGL8UF_X.6SF#>%
M4N&<Z)M4C8(G$.X%(8G+5.,G<L*O4/YOR/GUK%>QD.;*A$YWX6ZW>.(<ZKN
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M*\.FF??*CP G)^O4WM[@H]0PM#5OOS.24R6<=5#N7)**)1,=4*]4N#"/A5&
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M/L)X28"=.!Y[$8%W2 "6,P4^5&8F 2K,H2BQF+A2 DR5NIK0W>(5D'4X3?*
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MZMT.B/!^Y8%LX\03]I'*^E>6[K%_$L.6I=Q==C7);"G6.G?7O>_(E<,=Q_<
MG\K.GYN(F?DCK5KR9^ JR(CK,1_)6]!'S*&W5>!"SSZ8S35/BT3"*CTJO>Z?
MNA&\"2[GHE5/#U7 B?JH;[&WMNE_5/+[SM>!'!A1XS&]V,<>@CP>]JHTJB5
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M1+_[/QNP?Z0\3UX19H$GK;=THA^1>UAJ1'_(C2Z@14#VG>)56&4:G6M,AV/
MN,YQF5&2)?$D5)3S72&UW8EKK7Y9?7/AVAL[ZO\$'KXXC_R3N0E$]<5<>CAU
M7*M+[=A=*>;M%\O.NMC!.]EZY!/L3+:F!(@D&\[]#1.@1 Y$"[C\SO2VO00R
M,Q^N[ PPC&"#R802L4Y8UN%]48H1$TDI^I82P)7=BD>T7G%9 FX8YQC/)H.N
M)U:!6SMOD##@:Q,7>"5/38718?F>9$0\,,@#IWK(J<]>_UU(0P[H(:983:)C
MJD7!?,?Y,QGMG;.:X1U*TEEM)>D@JHOE1<(K[S '^)=/HY>(665:B[<Z ,3\
M/:WI \E(2L^6_K0V8OC"!5[@YCS5TS\(!;S<IQPIM:;VDM9"&W,VO<[+<OM^
M11= !_^K,/^WX4R*%8__IK=>K*U%EDGUB/:,6 6,I3.Q^K-TL(T<CD\W,1H@
MQM]#U$#WE*IU4'\Y8O4$<D@Q@]@9&%^[*-4)][,[=:=%MPHM];$F35&P)4Y0
M?YE#649Z]=<_O6,I84'X_+ET#S+,Y[7 .6'9(&9E777GF[@]>$4')M88P4D)
MH@E:ZY^>/KJ;CFJ##TYU4\%;SD<(K--.IW[748.D*W.&?"IJ_ >WFD%)82\E
MATIU;)-#%JX/J[TY"ZKFZ\U#X"S.B##!->^JLD;GC'9.Z]^!\W@W/]"2=1)-
MCMNK[XP%:V%=#=%Z<1]5!QM"^V NK(7#R\E=]A(@ J]&W#[<(4,\!$=( ,6^
MWH7LCF50;PX/A4+\X.M<V!N+K$.G9Q;_)53$WVSSMLK?O=?H4L0YU'OZAQ!A
MX6(E3F JVDMB4%L4LMH5(!M>Z_R/"L0.OL6UR3$!P/-$QT&2J?2X5K4D=!2C
M+ 7$H^\P;ER<1L7$=:^#!@?=CLZVW8TJ$:]"7. J;A0LW9CY'7RTOGC@+[5'
M LC"OSNI+4$+#%JJWJ0J&);:Q+KR-PI929*QKCQ5_#LMCE#$/-;53]:Y\<(,
M?=/63[@#=K@OEBJ^)I9 )#J$7%HL1:0Z0DA<K!#K(#:+MX@J8#6_):,&MND5
M.X/HI)TY?+)^A-AH@UD'.A.G4>FFO'UW]2OEDR_;T[Y0I:1*00)P2JA+R)Q6
M_&-L-^N#7^>D-HAETA2)FQ?K?I+'M1@D+1-;_R$4LM+%1,SPN0#_N>N^A:%)
M7#.?MGK'!L!3X5?8_RPV_R=;&FB9JJSNGWTN?FJH]?O2>S>S390<IPIZ :>?
MO0K?M0==NW,SE4SIEH%_\A9Q <@#:3C5D$;Q1E+)DQBL 15UHE4)_KUD#20$
MBF*X (,7;'2W/?@T$W WX-GLM_$+&P*]VR.<AH"#X7LM)HWM4C%CJ<=27MG2
MC+(B_5*_6?2WS3WV']S\;(YL_Y[[#?T:KDW?4&;87XAMB7GYJ HWOL<VJ\3'
M_7M1&SHU8';09^XDJ<:RX:.Z!V_+U)S/N9O ;9D)N5\_>T@.LWAPW]P_;-9(
M* -3P+,,UT@%8?GB'>)JD,;;G,=3U)\-UFFE>D#>!);753EWG ;!CUEFG/\I
M,4R><U3)]\9?!WX<HET@W FK\",]N*P>F\P;"3:9/[W5' Y#%ZG5IUQL( W0
MA=*@]DR7QL\)8708M3>!&_7,='/QVJ_.!J_*5G1??TX\_)+WZ_;QY[W49T4+
MJQZX?6K;TO,)68C8DG S5YYOJ$^[OZZX?O<LG/YLX_3;V)!? =\9QU?-] 2O
M+SWD&'%A*/E*\6V;W_,#:S6QT!-7A=WRG4Y3Q@KWG'FU/F=>/TYZ%;DM]_:7
M/1XK+A@[_3WYU'A+;X)>.F)436!W_[U'K8?)@8,;!7CWX:97A?2AV!P'_\[<
MH VA)P]KG@B]8'ES[VS=@ZY,LG.<E&:2)_JZZ7+BM>*Q9U5%\S,\:B):6>Q"
MD.K'OG22;L!TV89WI-54&8(1[Q(LTUQOU+</SL>I.*2?K\KV(VQY&9WB>PU@
MHV]R'YZVT9WP/>OO?<O-[W-,9%2_'.]3PZ\A'R]N[A*68\?A;%N[>]7*[QW/
M+JOQ]8VU<WQZW()[GU&\^4#$<'G LJD+G"KMVT78ML5-8:>6QHBZ?A,0U$>C
M>/TYY,=>JUU*]K8:90JR5-%4'BL8JRE#2^PPDP*2%SUD(3EX'7D)X@8WAE<0
MBKP&?ZIY]&RNYU+U9Q.BDGZRE^F*F45]SL(L[ACBQ'&<.G\8S?RM>]RS):]E
M\\&[\#\O?%LLYHKEX=3?7=1E),N <?@9@]&!AC; $>Z@D-XP.P3CCQ3VW#U=
M?(&$?K<>LZC]LG%%WG[+:UV>"AM"%BNOM]$%:P]OK!*]:#@XE._;?GGTU'.S
M5A]\R?:UYU"&O#)__7-%.GL.I>^JUUEN?=CYX3V^TA[,H\7Y8Y;7ON87[M_/
MM]IUN])7G.AV[:G(T6WK>=&S DJ[TG)HPFG*L38Q&[TNNL])G ;1^G#C#F)E
M@<@%T98 J<$CB,6#":('&"8PY5NIV1)HC)8.V_<7ZHTZ*5&\I<-(8&6.%L,A
M>FX<<1;FH5+[4DQE>UPN-'Q]YTA@/8-EA7=,-B]6+1"W5B.AH#9;]2SV)%L-
M.3[HHO>&:QSC#A>$W)L=1VX\)NX:B?T4&7G,Q(@00L"EAJ:BM+MB13-'CU[U
M_%+");6 ];75<HMSS8)57Q1>7?Q<UWS9I&0Z$I\(URI='WKS*-[G2-':6E6W
M7;%AN_:F>*36&FZJ?,TI/%W3O][+7=UWC]=W:KF63O:2P7BE?I6''2@Y3G;!
M[=PIVA'9C-350(WF186S'T.NN)Q),'ENMU",:"W>(7/JV,K$"'[46$P7^C&M
M-\?&;YCH+SJ(V('F%!VB>9WW/;B-2WHR_JV(9UIQ>G(E^"$KZ-W(J3P^Y'\U
M]*;IJJ88RBW*)%I/JN#9CZ7ZS^@T6HVT"CG2,HCX57R8*1);7!EE!'QKKB:@
MO4=>-638Y!)W5!(2IAAE\EX3FH$.628C]KJ]+L?[OZJ26QX7:8]$ZH1_=WKJ
MMNU-[?T?YS]M;HZ[?KWD['BI(T75<4K!SZ+<19-'%A"%V9#VN;SN44)U6O6^
MC54'?+U>[CV -HO4_L8KC+][IT.L?"@U'U/VVOA<=)\;'XB>&!VIN_U9L!PJ
MF)GIXG7(0GV"1=%Z9!V<7(G80![,J"V] :6TU 6?M#2,$X^M]V$Z("Q[\@ X
M644[W;$<[!'0T\HA(]4N\_2&.[G;:\Q.N(L^BQX>R="YNR.'LT'KA6GU.8"C
M_E'8WWL)_/7P29&X?VW_^@GK@PW6K<9#K0?&:M%VE)?V9V@J-X['$!^T^"PV
MFR3LJU7:ONEXR=6J73'9E^_&/^^S<JNN/5+OT.RF?;!ZQ7^R/_2/F?P;8O3O
MGL[]UW[4CU%(KX^JT>XMS6'&8@YF"V]A+"( WLJ-4B!H"5\V@GJ]6VAZQ,VC
M/Q=R!^A7$#ERR\8@E"L6+( )O;9UQ(#CQYZ>JU3U^&F!9XTR/\D*;PUA.=);
M/#*IAY*E$E^5B .3_4&TH% "+,$X<&A*$2XFT.C5IA'0@R'5V$RHY<FW_H8:
M0,?-:IE9Q]*O9K)_Y?_K$R;Q+FFU;B9K__*Q%Q;"25Q<C@0P%ILB,C"9@QT+
M86"7T4/P*#B.S\K&AB[($A-@F!A!HYIL;H-PC#)#Z+BT?FETZ!#B1&J(#OC4
MUR,GZ/M^S?<RBZ=]\6^JYW&B,^2ND 5Z*"ZIPQ2NE0!R UB#7UDTV1G_N X,
MNDD")"$H/MDPO->LQ .ZV,HA&\/!3DTHC2.5UJ\'CGC;W'H:*K,L\^]S.J<"
MW]I2O!E.$RL^%QVPJ6)?<<&07KIL1(,::.9]Z1KD.T.NZ,9"?_X9+'@ F^U\
MELR5LNXKN\A=NWZZDJ>#X2"0W<O'D-_)\KQ8OX3W/TM/OD1<AD)4>/0/$6+E
M#,X-\P(>]D-MK]6?EA3:D9_\Q+N_/K]3F&_6@;NQG&?81\:9(3W.-H)PCAX+
MKTOJP3:]I'1.4]6^>7X638UWA"X^(G,^HS]4<ZA=8T1O4.'0"&DS,71T4RU*
MC:#'3<O"R$ %G'O%?V_7B6(OQP3!:2"_^R16?:U5>\/N.D>->[Z)V,I,JS\W
MI//ZYYWG/GHC6K"Z$F8QZ,T2(-<%(/5+ /UVT_CJX,,37A!IJP>W.K?=KF'M
M]TUD.3@Y>/_)D6L+:MR3FA^7YEU\%,0DL> 8L;*Q2!%^'L,E3U@)CPRC]FGQ
MZ0Q7LBI<1&75W$$]OD];.>B"030@Y60N/1NM@NS&Z8,2@$E>.GL"+3I&>_(W
M!H&"RR,OA5_2N/%VUNCZU->66.+/61GSCGA.W-NU2WYI'W2OK#D4?M AH6KQ
M37-];NGI*)OU#8!*^-'[K^>9JDDM#K/1?2N?[97OV1V)N:3^X7.L0A5)NB=^
MF)4\J@$<)]S1"M)3$&^>?3EI0AJ]F]X<1Z/"G6]4+F;</?6LXUGLIZC#=IL]
MTLJ#DC[E[4_+*7Q\36]Z(8D-^N(^1 D+H2^L;OK8@K .-H?(/+?ZU*K:3P13
M[N_<GW@-0NF%3SI79L<S!@2'/^_/&-O9\&"O57Q22VV>\,B$4?QMA8G6+V_M
MVV0?\-^9E*;_JK/BNC2G$+R_Y5\<_N2-@QV^;]V=YARO'H5SS ZQ./$XYDM)
M-%ZN\!OO:4'3=<')AAM%!\7^8@=Q/]V0)$_N\J"?O&S*9241O7DV8\D\MN P
M5P*,[PXFD+W>-UMC.6QF[T!LJ1:OHZA![J2/+(-DY_S:Q$HNQ?-3^[XJ4[GZ
M!)<TR) OW I724'"'%3HI2>1EY-,X4HA!6[C43*HRILHLH@V1&%>EN7;7&F/
MY;!0IY[I7<FE<ZGJ_=S+LGCPF2U8]P[NP"FX'W0L6W-N'O>S=GGTS@>_UYMX
MGO>SRD]Y.Y1X-W6=,C]UHF_%E-HE*PNSO"E/?5N?MQ-)T8G 1%XVL $P$#%_
M;?KLL?)O;>'#P[<K8]>N/^6^=U?<'MNV@?5A:P-O["U\_IY+G\F'2HR*.=_/
MN,0Q;&L,EUM[I,SN*4UX;\5SH?5<@!MNK&JJJ6(=C+7P*\_(?L]-K]IC7Y*S
MGW6%S"FE*Q!C02NAPF)IAP;BE3;/7H9!@X.O]D"Z^6?]]CJ;U-3VKW^T)K51
MT[LZ-;<!XYQB?U,PD*N30@J4YH3+/]+"1!YNY&#U"+^%68WP@-T0-@*=.[EF
M0*P,3S&#;=[]\X<!S!)>6KH>H\-6 J0$C-K"84?"Q\A<LRO^AX^'[TK=YQ\B
M 3P=-SAI;@ZVKCCJ;GL"Z&,9O-#_$Y/\^^'I+5Z1/8]9FCV&';S:@NMK7]=Y
M6;TP"UOG:":3=SN6?(SS_CP)'W_"OLFIV>OM[7B_L_TS"AL_!H3/EN:[G$S+
M;/=*+3+ *?B+]!SX'6NJ>PX5?PAW]CMP:J1OCV^5_M-==H5/<J-_A[%, BW,
MG=#]-DQ4JF$? Y^+;:4SR.-&??06'&-!D32 UD5\^5@5!HCB'(,?<6BY)K+0
MU!7$_DY?>4_##K"5C\K<:)-NHI?=S[T!COMPJF16$O*_K'Y-HG!LLB2 &CD$
M.[' TRDK!ZG\HEQ$KU+,9#>BI,4 !=/<X6-UB =$3[H#BO-XAYJVJO0Y;TZ*
MLLGXB=:$'^WR##GE^H.XI?5"Z Y4FP0XA877X^:U1$ZD=\7L>1%?L(.WOK&.
M8.X/5J>1[&!1=[!<23 <!N)[3,Q"BSP&,;$-+4]57UFH"C80@MD]45PGA:+S
MJ]2Y6'<B6K25:#XDWHRX+M9@'%S*[\.O^*BD=B5NZ<DY44#0#D9<F1'H//?X
M%*IBQK/+=$OLG^S<0/4@P%*4]/T1QDXG,ZM[M5%0J^-3+PN+F&T_]C?EG[^X
M:^,@?=,?FOG?->B^=2[V\F5'88KE[>MGU2B*SRZ<]D#ARDJX.GON!F'66?H5
M5'?[QM0X/[EU6+2VQ[=I)<(.1RN2;$@LZF./>06(W$=6$*_J*B<Z2R$XD4 3
M9D L!@H%[S@(H7-=-)"5T+U6*,%'%PMO1[8^<X]21BV;5I^^/Z<_DJ719H4_
M@(3#\9"5,&VQEGX:KX%L!-.RFP18O@>BF8)Q D7,LA7@MQKN%YPV/-27\/Z9
MWM6PRW$O3="08879#\+I4 \WHX_'W!>F2^L$ZW56.JZQ[K'+:SR?#5U3/V??
M-?'^$NOS@\W3HZ_,G_2K1R>_YQP-<WGJ<GWD"4FY?W/QWLLVA)A?.,^7&Z:;
M;CRK97_]@=:/67XV!//MW@&W*<TRR]&8Z.SHY;@=6>MFGC1;=#_7[^H?SIGN
MK])9K8/^W!N5KHD$@.:(9B6G+YD>2J:X&$)1\RQ(Q/F_>OG2J":R=MTH*")"
M!&0>(@)"BY 6111"2D5!F\:H-**M$!4'%!%M4**&*@$A3#$JG]"-+5&PI6V4
MM#(Y("&$044$11G%3(X,4B48MZ92.66?<]:]Y[;WGF_=>^[YD;6R=I*==[_#
M\[Q/[:J]76Q5%9 D;\^II2M$&7K2^X6.-9>J;RIIQLL*WZ4IX_:O*/^EULU%
M<E65&IQOO]>ZS@<<_8/K!]I(%)L(XC3+.*_5K2!9 ?4Y*PNR&+OD&BA%K"=H
M:M?G[D/I9&(JKAHFSNXND"/-DTGFR:QUL\PD;'64XS&KY,U.VSB-;]UW$#7K
MIARHM9[^ZZ<=2Q91N#TSN76]DGNJ4PVK]IY.-Z,7SIA>GTYY9VWW.77*7>MV
MQ89R1W[>[L4K2F>\.R_/XU\L5K5Q*D4/A3Z=^RQSD^?ZGC!K4/[VP<M&_4.I
M;7:QP+RKR.F'RTU_JJAQ07?VA*M"FVLW.UOQ?@WWL3WULM%M/7*_I2G62- ;
MKXS/N*3-C$-B/9W5>94H,CR*JL+ *I4@)6H^)FB([_.0^)GPS[^QG5VA$MJ*
M,V0-11,Q:CK71W3W^4(L&W1*/&W?&!LU#R8)!Z&@(J4FI.)F7;7EQ^Y#G^Y4
MRVY83I/L#UJHVI-7<WMZK_.Y7T:V>D[KG^D]3?'PH2$CVK/R)>=M_\VKUJV'
MM\>W3D,H=G TL!?<O_-KC9[]];R0,^)#'@6%'@.(%?W.E7,W"U^L7KONY:LX
MH6&S?5Q8[I\W5YO;%4 CF_/Z;F(^&^=4#8V]OW_."]FU>GQ_:]^<-9='2JV?
MGO'9^(B_*# HV[V\0I7ZE2W&#X/O:3SA^\5XHHYR_8Q"I@UC&\;H=?_^OSG2
MX2OW)GY]SVRB>"8D_T-F5S<?!*_6GA+O'#T&,Y[4F7*7:2O$NV5&N/$-4':Q
MI[Q$R:( QP#S**S[1)7(Q/GD9>4\Q<B$W+T;9LSM.>EAAK"'WI,MSV$-D[L/
M7"@A'D#VR,[V2;MI,V!?H@6J1#((?X HHD3*2*MZ&5K%_?96T$V%V([CO (3
M9;X@V]RCC;Y1#ETOC^ZN#3&M.:#?>\IUWF&YHX?&AGL(Y&A\X4Y9M6AXDV8M
M_,BVO9E*@1\6Z0&V9@F^&(Q@Y4/!G7C<5E3:LO9,=R7D$)O].V-9D1DV-8YM
M<;?LS)0;03O6HC4G""]80J.2/%8!7:>-6"BH_0L[FPJ11I8>W.7+-A4Q$C3?
MT?F$-=?OB5T]81MGMPKUXHDX6?A\=)QSL?;1%=@JW'O!8E?G,]MIR42SK"*I
M6<1'*I&1+,TVH@^I*.>AL:NUOW%=4;%<G KM1!PX:1(=Q>J@'90NFVK^P*^T
M<4SQ"0]#.YYQI.QH;[##\L6L0'KAV;X V7ZR:O45VF.O\@W;R65ZG<U9>I8%
MKD/&Q]YV$RNN+_GX>FB)*2*]"VV)_\R@'V.#G[X\C'EOP=^'?$IU%),1;:KX
MS0-H)X3/^\)(GX0EA$._9A+RZ&?X 0*BOY3Y&+3$1HB^I_;8$0(CN15A+YR*
MO ]-(#\9>4G:(L>^/W2 4ZH^J_VY=I7)V4->P\UB%<M@3VI+V.:1>2T>UJ>.
MN;G,*:B?2S,ZT?EOD^?#K6*PO>[+Y+[L*5\N;*(AT#%H.M<"]6Z1LX?9&G]^
MA%1655 OL 78N)A',^9^&Z: 4\KO<X_66I=$'EJ0VU0AC8K.HG#=WQ>N6L)4
MZ2@\/E$O&^>P*1#Z H3I**>_$?_-ZMTZBO0VLD7T>3ZU5T *$D3*)G8-TD!2
M_+"%CA*T4>.EHRA.?[EF_&" 0L[!.P%+A.,<B$):^)+#TE$$C[_BR*2O+"L8
M]Z]13]512N9J"Q#T'M='1WFU[]@W7_DU5C-R#M,C#-TTAW#;.\ #$ZLO R>M
M(*'L;=$W)-YFUWZ#I34X.F+B=$9$,<_/*I<1(+)ZX(?'U^S>?O(P9\4*CQO)
M(C*60]I4'>5-JW@G"_>&C*%/1:)%X X9H0%MS@<D76PV+IH,-T,5LT#-#RB4
M-5S+](2-N;Z=K>!,Y>+HCO#-G(0ILICW=@>L?UB_S@2]/^%3N\:4ZTSRK LL
MK3/$!.FU#IH@W!"(R\"[L>]O8>T"PH\; G9@'BVVX-%4/O7[I-//3EU8_MN#
M_9/FY;?\_-"&*[K "/L#D>C7QNLHSJN%?Z4+;:V.8HY,PVV8 Y6TL>["/NUQ
ML?QGJ"))*N[1J#DHU"+KZ50?)-O"=D5\1I'M(V*6PR9%DA0Q8]=D;S5^;<1/
MCGL1NG5M-;\Y:.[]->YSUFC3OK;Z\]36@'@UHJ.D[?-YXKP&;1DV-')<VL%=
M=0$D=4/O/4'J,\?D.I[/ZW7$71FZ;_.Z3\_M00Z:I-#6#\(THDMHQEW(J@M3
MKM7_C(T>FP3?1?XU=;S;>TFPG59 IL[.-V2*'"(D[/$=PNNCA T]0XRW=1@H
M/Q-M$!IT9X&Y@@J^*6UAD>ESD.M*TBT-G/GM;=T-_]HU@RWV:/W!>XSN OP
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MXFI(.$;CU]DX3%ZKS9)_8SI?(3.E37>POS+FU6FGO_/9]W&@Y"+<]@7A=\G
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MWYC727X$%[W)*6X[4,U]"VDL(U=@0EGS:XDL%;K8>BK3GH:%CT"WT=P#F%M
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M ISF4)S_T"',;YP"KJH5/X1RP"\Z7 BH6Q1;6V=HWJ/9<I[!#/WIQ#:I!;+
M<A&8E=FU<<QB00GN02[:ZZQS 8KVNHP",JEWEO/UFJ+B\G)-7/<0RTA1C/A>
M",:,9<Z67*2?)[+FN^8T.<E8"-N(@V?;TB%_SA]C/V26. "O"=<S&3]C.V31
MYA;(I":<,%<-Z.\9[:\$(+83,-^7**PX<\\]_0JMD3S38E87QE'[\[_C,_Z@
M/^QQYS>$UX.?ZUX>%Q:E-!:U!\(NF/@_I1/BB3"P@7C, )^/"C]Y@O;85>LP
MRD][;11LGVV<7YI!&TF$-MCCV^TIUTZAH]7>,I_%)N[8:,GV.; ^8!5TWK+T
ME9,8EJ,N@PIWNQ?4#&G):DU.4IQ*JM^'D).8N;[KF3^>,:$[ABS^,#D.7XC;
MA:P[,H6!1>0H]AAW$@P!IE0R31144C7:C!>0HH [K>@")P]S@!6TY##\?8MS
M?(F>DY>L)PN3HN-E&MHW8ME!>8WY$=)SRC%?*K^+ :HJ:\M[]S%NG"0L]-N<
MSB17##L"/LTDI7/%V#9,. 7Q"'X($\Y<I()/CK0),5KWAB !!I-%9X%65APP
MP_WY!WE,WUK&=&2+<XYK3^=X=??V4Z-Z227+[_9*8W.Z%OQ-?BVO3^7;Z:YS
M<<(/@UB*N&<^NIA* [3B?F(VPS^E)*$@:/)O@KW)0'C?7]U]I:;.FO&(=;>G
M@IF'I.S*Y./E^KQ&SE[14(DW-)'Y;>CUH:=?[Y;BO7UC2:FQE&&JD0. 4J;/
M'.^]7*AJ.Z"2R*64/AW., I)U[!1$;>4G%#M>\D#"?! 09FS]ER%UATU3CE7
M MN#/<@I_=ZA,\04W*,6*2?L+0QEPH0@<>2ZMK %30/^P)GEX%P:QH(C-]),
MSC /URT>'(5)+!QEWRA2&8T(E9A>WLW^R:#9C&-/CL*4F>&,^SW\0B0S;3(?
M@?6!<&9HUSSS&FG&G'Y__7PN_A LF-EOPS)/CPQ-G)G(H^#CC#@9[?1V2?8U
M8/$E4*VACQ-'M>B3D[<AXJ7UX;AN9P;\]=5&\L37.="[GX:?>:!+0W^_G/FX
MN9JVN1KSD%:^U."$[)W&X(\F=7YQU;QM(A]9J_]ME%3H4ZM=4#N-(8LD<T?+
M:BY$/<B;*,ZS)6:U_/7R1\N/0G3+A)^JE<8LQ</_F*\VP-Y,^L:HM>VF:S?G
M3X> N[W5NN5"E,]3%^9L[5QSU<ILMUN>]9Y4O"1K4Q]> %/USJ?8QIV ?"G9
M\>/D? 4,%\G B9]41/S\(<R5!6@R]AS@OG?=G8\=_= C0!?T\R04Y_\M,5:3
M>S[H?FZ>C'QP0B%#O<Z?;JS2(X)"E;F[N7\SD:]-H5C6CE4W(SZ@+C$KN3UD
M*3ZA4=@) FI?\'NO&PS.M-]Y4P^06"8_%YI2ZGF@Y/,=RBSK'3)QKBFIP_C3
M=!>87,7V9'[:3DSLD+SD1UIMB05>SRE=[E42_'2;C8CF!(+FH<:ZK9">7CX*
MD%N$&S]-R(DPW\V-HM^W7LUP3S%87I,N56\FJC4<%3V-*L_3+HWG*A@/AJ>9
M".EP/GYY^GEK>4FWLZVBJC@Q6QMMV1B35FZ>*K:P(W1XV?S0<PT3\ 68S?Y2
M@2=?MI4MBPP2 -R)'M\?E9-QYZIV2KT@"=Z*7].-GCZU@F24;%C>H5K]$N8\
MQX@S-UR8SCU0*4"AERO#Q*=A9?C>:ID8LS6 =J8]G;0FP5K:N9U MZ?'Y^'+
MN,-(R8[?@%8D@&,),$@),/]3HZ_>E)C-D--(M]F7*LWE \N[IYYRXKD*;"F
MP$)RCR+_Q@AQ"MG>!/18][P 5]MZ[R$ZLQ<I!$,0@"N]\R(F)S'0/$K+'UYP
MEDSJ[5 VE&7>.7]\L7E\O0/RSX\01OO15E0PA#G0D)&%NJ4'$>:!/+E&3.=$
M[BFT<B]2#.8>;/PSOBV:CC@&0*F-3C_SW# _HP12(J('A-P:8[A]+M#;9<UC
MI%<^*3]& T*""R=1#Y1SQ'NAW=!X+Q% B4GIA MPE:8_!6(/ RBZIT)7AU1-
M^SBI(;4_6.)*74I?[\5JA%T^8V=WL2]);\K@>-W;M=G+9\:]9CK.1%\3#2J)
MH]$4,JO/>B_WZY;7C&LWO-:8URA@16I/8V";\$J?\*@)YH7;=DLE=@E"DJR.
M,2%!!W8%6+C%M>B/+YG]?KE^3RWO]CIF(&Q<WCOIBE$_2(?;R,J[M'F=*;+=
M?G_FRA6Q9XP:S'BM=L^M"Z%K/X5OKSJP0WF@&# ZE(ZC#"7 %;@27<Q"+A@[
MBA3F:J+'K@"KN ?,+$?FK<I*(&2184!5P,?.1,P9MS%W"OT7/96O,K^-ES"_
M9H56>?73V\\C=?1610R<QD(:H#J #&N,/PMC0KD3>.;US,/<L0X0T"]"7I?:
M,T7-UT,ZH4DF!P'K15+R+J+GDT*O_<K]'3[C-XY>6%=V"6ASIV>N*QB#9ZTF
MD#9CU:19AYB=GU<;/;4\W7>506F?ETX]WC(6H%MD6)S:'-YO!D=N+B,-D:G+
MB[I:IWL6?[0T%T D1[NJL&)[[N+"UL)F0E*)M!%B['N_>*H#(3'C7(Z?XFD/
M?;<[73XFU7)JV6>G3,@B].W;AQ%=S8I-AB7Q[R^<;#3\@O[YQ)L01Z7K (HV
MCDDE3_VN]]*)$]1^K>I+;9$:GFI/WM\9DE$+R3C3(<M%\$#!F8?8U@!>@"U-
MZ8F"=R'3SC/9GH NGP[U3<+DZ .^='+24'*D>JMK!SAHA@=*8(Q%M'K:S3NP
MS&/"P@(7K74I/W??,B=+"$''YCZIN;[3'@5(>R>6X=+<"[@N7XP["[+#KY6T
M!C$1;C?D\#;^ P_D.(F18'Q8Q]%1 <C74BFS7FS#=$V?4?:E18X,M4-AM-[*
M?[1Z&RJ^?$X)V?V7 @I^#,BTF(!7?*J.V;>:%KEBA.?3TBFK^LU-\.^TVJ6B
M\#7SL8(IXA5JU3T9,7.QN/[BN!W).]FJ3B5/%[W=)&MJZ4:8E)>^-J&SU^F6
M#FH= 6_&WNM8>O2I26&,YD2^3+<]]+@'/T_,V '2[JDU0L1S_'Y0QDGIQ-[M
M3^:6CFICJ27)BV[3*8+:3TKM-;N-0C0W1[B.(5P%[CCX-,LIIPJ =.$E;@"U
M%?S6T=@A#D03@ R$$("WF80PZC#7$C;<F8<ZWIPOY$>B9Y9S<(7X,N#U1S=T
MV;Q;>^VX\]KQ^/'?W,62(*\S$OEAYTK/U^'7Q,M015!F7B+N)N(@=](-SR>Y
M'W ,3U+WT%'4G ++[&_N21:\ER0<<'Y&( T>4(VBJR3=;L!+H^NLF!^Y)PJK
M8/[%049S[;A Z5+Z-*[B+X4W E]HV#<+/%!6P<^_B32O:(G9*3#^LP,/1+T<
M*77$YUSH)WIML^)-U1N;:11HJ:OWZ7RB-VNXNSN[-D(9H7>WRS['3;O+IX9%
M-;71#QK3RXS[4;S]S!N=7-'<U@3)<R!EOKW[?K1#B5'\N 5=U5)VKCI@(>QX
MY1,SN727$9(])(;:+UQJ62HHA5A$N0&>B_T\T/025W"C!'V WD@L!^ TN SY
MQH8,^]28B1CW/5**NY^MS^I)PQ]K$XIDD*78,H 4XQG,BB&B\GN1B)KZNMNJ
M]7C#<VN;WM[9'FWK0'HK1WYR;'<.Z D.BV9F,7(*"]M[OGR:HF0JSKI]F+FD
M.3#QB<J5FS@9,S<S=_ )*C6Y-#)%]F3ZER?.+HM.]QQ-TO^1X%BO!VN&[*%O
M#P,_^[/Y]!(J'N;G]1LQOH"I3='0,G*9GA6W:[=\G>O^EU];@[_1'9N["9?,
MVBUKVPCN$JZH(W;9'9EQS:)Y@B,TNPP_9P4-K-/K#TUQ)0D$,_@,V_;YYC!!
M<.)!8#=!TIDOF\Z4V"2(B5446HYD_LCSW;N(3F0@V!+^W"/M?!XCUAV:%)60
M:;!>0B]47Y2)O<DDI^L]]#4#PAAB$NSP,8P=QB?_86%B$DR97NU,R7_W>B(R
ME1B!SC.?H":7=RF-R^BO0NK%NOOG_R0W"*QW0;MQ']0V&83N^:.X+O4V_N#K
MQ!U]P22DXNGDE.J30.'+V16PL'S&DQ.M+*F\Q(C #3:"(2;PS>@C]NR4GK&,
M[5C5]^J0[SZM3=S<RS6"!OX"FAM;M&T>:%OU8-:0;"<X<>J7+YELN3V?]/0=
M(\B!F'<9;3F=Q@-)V$-=,TQRY2/#N<K]=;L34--1HOPTVF]5HS0I-N&DB]MH
M?J792V4!/C2IRIWF I?3-29+->XI"%%D+5U?]/V8:6X>IF=(#5X(BE?W,6XP
M]&;IA_L_G^P>=]0>Z?6FRYBUW5JY G  ?A.^3_7G"JHPH/'\L7B6!Q+#JO$K
M\@S&$_7RW=XY[%N('%]]0QYUG ,*_7 5TRJ);4H+$+ 7.F:55F0P7$SN&,Y,
MT0O4/#.)W[.R;F)^RB"5H9]8#7U3IF=2(.E8*.=/'L@O<Q];$QABB'T(9X0\
M8\KL/+ V[U6AA\;!<*^6Q;_-"[,O!I, A!T32ETW"58;_/XU<N_TYIPKI3)0
MYGSZ<0V[7ZRI^1,N_E]7CBBA3ST1(QTX0 K%C/W9"?X[_'LTOK<Y_+L^J5#C
M7 +RBG#-T[4SY]-J)3)NK<# "%A^MHY#[=,']%JU"#_Y!N,JM6Y[@F#0.8+L
MNR@/37J[*+CH7.GM6:GT7+@ZS:\YB:YJ=29=_ZG_%CJF^IK4;5&M"^]EZJAV
M.?*6\6[V:>H.Q '!)]E^3%(7_,/J3@^?T$A8L<Q[Q8"ST.0..'!\D.8<:PMX
MEW/?\T @KH(;2N9^/F:RQ6^K0XMY)AW%0$'6HC_XC(_.##(NA'YNS!AE-E0]
MH:DPG-=[]M38D4#/WGWN#.YXAPR?E6!_FS01! [L7 9X(+XZ[^2J,LM(1+84
MIV0;&B?>]8 A%H<]_3I_T%B==A=1-D#\&.@%'MNXV8JGND5V)-$0S^V,7N5Q
MKMO_'DQ]HATEBAM"3&U1SBQ>HYUY7VM8"COCZ2Z.A&9XOD,<B.NOJ2W>7CNC
M13!1T*!X!SKF!#FHT]5LQBLK7)KLBM1R,.>E2XV!+ J&D/2C0-K:6>GY<+>W
M;N!7[FBC7\9 [1-J&TDI;^1SK[_L1\\H;8H3E5Z[1?3JD':LL4R_+84Q@<K9
MD'X\V+N!N?S/3['U9 IRYN*B06(U?YH.X.7(-Y8Q1Q?4,V>0.^K EST$^C[=
MN8=SGZ$_D->#3'2:%VD[$+: %V<; \M!C4V(,K9]2^UX/2>\>\8S;^?$1(2F
M_Z6.T5^(&?=.N#3<&Q^'>]U$@\?(3Z5UZ :1Z_%KWHPA0 6>Q'9]!0@X >:+
M0NOW>\\WY=/62(Q6_'X@P0HO^:U#?SCB&;[;#0/6;@YV&_L="/T[T"!99+#T
M=#9\*L!I47.U"-%$OG;@UU0\!LEYCI7 W&,ANQ R;,1().38/'>(!Q(/YFI@
MSM> ?YO<6M]/8X@6WCXQW(:H"G"+7&\L9(B84^PKYH'([8 09XMV78N0@P;W
MASTX8"3CM*#$.V;#ZSS$F?Y 'VV@H,'9Y;W)Q:,(H:?FT+\7[1(4)&R:)OUS
M82&:/KZ"&X<4/:]INK'9\\K/T::IU!&&\"T%XYV/I@4^VLUM6F$:NIT^K]F1
MM^\Y:HQ)%L)LU ^YBRDJ:=!O:$,/KUQ/\+6'$M**$R(^P>-YH$#H=!;5+91]
M7+<74@OM[ \@P9SIT ^;W7-2S$]E*?;6>33P&>;IGXEL),/=_9)>;@V-R+:=
MJ+>^*[,7,>SV<05[!K=NZ-N4_X7V=6A=9._W6>P<LM:_DS0MM.#<E9DAC:_/
M:"!BASJD 1(=(L&6!1XM(/E3:A(N1(+!#5+:$(MD&70J9=)+H798\_/PS:9A
M!8OQ4-*K^M:&C)5^Q-3-!N;ZQK;P X$&@\#%K*ZE)W<OWHG>VG6.SV85>K1?
M?J4+JH/=DTC2\;#/\UE*JX[?<9W4%5&36O$-&"UVO"5K;FO;0Q-9OU.7'B5>
MNLXENK6K;/WZF;"E:^Z4<$"OR#[/%[ _T&78(7A!4';9YT*T5J^Y5#PASP?E
M<]9*@U81*A%+3(L(JR%>D3':$-E>N1#5#P"<.BR8?2)QL8DMU;>TB%][P[K/
M$*"2TV4@HFR!/7%@W@* LB1Z9FR*63[0!"]I&2/$GVV(%\M-\B:/&?&36FW*
M#!&S;P^+D,?15RA%:LR<C.**_OL/Z"*A$_S;T,\7$M=C]XR"9@AQZ^0@R,Q8
M+U:*$V>BQ)=0=3Q0[\8'5"\?:*%;(O9T,H4'.@ YQAW&U4'6G?*E-OZ$R8C%
ML4W#RU=-=)J#'^JU(L#+X#,L@V1W6R.3IWK(%9J 0!'[+EKI$9>\.' HZ@;K
MX[W>\&&LU_8:C5HQ[T2A!_DYJHV4YB'VN65OIGF43\:\_?$Q(T?--E?)L9]Y
M+L'57+N'?HYM RY3UK6E7I$YHI:M X>QY?^N1;?Y*?XHE-^N"[B%#AI^JZU-
M]:XP.34 9(E[M=%3<X2GSCGJ1OWR$E#(7V!%W/E@?E[ZE6"IN;E4'-<81W<.
M,FI:/\'*HB?2X$JN& 5.6>0\<':PE)5*QV?@Z#$\4  T#5+OG(:!EP*;E+L8
M%1:TFS2#ZIH[U\2$)IH<\0#NC0=,@H]/ZED;F#%M8@.K!C#,$MS?#T?V#'%=
M)E@I[C!9%KY0%47KG8^+*LQ+A07NF;(C@ =,$D,@-0)RS.W,(SHT>0XTSC:N
M1$_1VQ->:<+@Y9Y>!DDOWV3UN$4V?,P;#723_G3)_>K8R\1=99H7 EMP!T>9
M_.O (,*K$,UYB+-I&,I@*>M1KQ?"I.2?!0<]U3@LY419/ VIM!)([ZMM,"'(
MNP1)!2ZP[-XQ:XA_4GU0UV-R L922@U'J??\.L1N3GM8&[V)C^(+AES??%\P
M1.I/._3;6W+8^X]>L'Z0^(5.?'JCI(BQ9*7;33_+"++,E2ZUX/BDJTTC/\<N
M2*?N765;,&5ZH"EP);@?7 &]Z<979-'\06X(,]]30*LO$#)A.HQ*$9E%,2I)
M.JCC O,^%2J)MKRJ$<&)[CFOBQ%C?DVFA\K- C9K*W,G:]ND=Z76&W;J2N><
M!+K$8I^P[P Y>XZX;A6^O$]H9=(8&^SCR-X[TX'P?3R0+R0%6=>TMEW%'06+
M X^*@:PNL.)PVPF6VF+/,<QEH(LYU*-BF6<!Q!=[N'N]JU[.S9VYE5R&)G2[
MK?W@@9"=D.<JQ NKG>OC.ZN]1G8@BMQM9OBOS]@K&86_K^>OY"4W9+WWNZ),
M\59)<XE"!Z$Q%(CB^<,Y:LW7;BX*BI0/V@V<]=D4C"P1U"<.Z5)M<Q[84>C'
M%S)CM@K.Y;L4J?0REA?\DHGIE4E]KVGI[U&.)9G]RY;H<GTUA^(GC#N&GAX7
M"S'&;@_,CM=K;ZTPPC[.]T.[U@_0?Z:9'.9'4!J_(-,5C/N]&?#;<\?HCI$#
M\6N9,29GF-=JV)%,4B=.,  OW7$"/3%+,0I"A2-7=B;/MS3U*'R ZG%\?G15
MO8IL'-^*[K>&?QF TL>C$KL'H N>&UUBR<=Q77XR7,$#P2QE*EPRBT_E,M;9
MOL&$*ZP@3[.?BW_P0) L2FZ'?.B?E*YHW\:F,5CH2S36?>HU*R?W$2<_F8'"
MK^T)9""4PHMP2!;W@36AEN8A_$1G6I$'VGT# VL3T7EN\9:O"=GC8;MSZ@J7
MQ@?#LJB6KU3.#]3YQ;\/@SA_??\:'UC@7)S2[R\?P8JH:3YD:+ZR?I&*-K"2
M$L1.P0AR_=#.+^BGMF_O.#!K*/2[L.>G<@W.=E?Y:]D6]N::)Y!B!@+[ZIGZ
MK =9\88:U]RXIN3 T _[QWKQ0O"%!K(,B;L/3?8 /KW CL\ICO- _B3I6<"@
M-QS=.]F'D 1$'SI[ I=SG6(8$>/%;]IXH+A43V9.VY++6/W>P4FM[U7U(MJN
M#]59'H%8$!_/M<O@4TR5F C\C#(#1X.DD>M$G[%B%^9[X1_4&>!61NB?<PK,
MH82VBR'D^J:U#WN6 _1?;"7Z_!%@?Z_?A/ZG\YZ!+\<:/D$=8UQ<UY7'Z\66
M[5&8>0-DZU1F4)C<;Y_3[JVAGJ%3TPI.6TG]F7LR<P<+A1*N[/%C85N<_.ZU
M1H6>PDY( ^RTT2\IQ8F1+N?.0?1,G<W+;S!36.C-MI-=EZ]7QKU?3'Q5YR$:
M;'_L1\%IR]=4^H7$9-TW/I(/ZXK=Y>Q%J)&O'=VU*;<D Q?.=H>5"/^AG?.:
M>0=N,OT]^@9.S>TL:1 Q?3GE[-_[_]-#G4GA"L7R0(>N @-\Y=O)E%G;8\S'
MDL6XLFCN!F,^'8:B%]Z;8MPT47\R;]/ G'M4NK+C+&_./LD]R617ANE-9?5$
M0,'?SR?[Z)RZ]FIHZE&7CZZ&G[#H<9TB%0D50=N"11LM2]WG-N$_?;]WVVQ8
M:[::'_9_YGTN[;#*.9I-!/.I)7:RC6[CZ"<;WBWC0 ^TV'3(>#PY]5#LXZXZ
M(,@#)=7#@^=W#2 ?W'F@?5@MW":MA'MRF-.$^_81YQ?*/O3/W\U#X X"YW<&
M;O<@!4?'R@(X((4MP0-=$49R%73P7W'8>F>F%'_2!6!GR5LA\-=-?%WKP0,M
M99JS38OW0GB@D69NWSP@Q KG@8J,(2L"_,7#9Q1X("%F%W\9,@;WS3N5!Z+<
MTF4/;4RF</>3&9IBL_>YZ;0=)SZ51J;BV:QO_VKJ?[ *SE!G(CC".CC@=B_N
M&6=W!-GI_*_;LZ03UUMY(+/%/77< K1GB(O>PI4K(GB@WY^&LJ$4 ;8I]B@/
M5)P Y8%$G@YMPLEN_Q.!RMP^D,P#?9,0X8'B@1O\57SML:7=PP/1Z^2X_C]7
M37'[D/]F -4-TKC!4<A<J^:!_B3+P'\MCG#_#H-S]GN3F61A"$L*4.$FR)+9
MYWWA[[F< -*"^K]M#J1>V?G$ Y6$<7+(3!G&$@\$BX*/BZKP0']?,^#*T&.Y
M)\D'^;&GR/! ">_]?^'GJZ78A_YM\W_-YNXC*@^T=32!!^IF:^.HS@OX75D?
MOMSYP)? NGO;+\A_DO[5@G_-YO4+>.XC[7D F2#V?PZ<2O9"?G(*_EO(F_X)
M^:M/N*YI'JCQ4YO\S?X]0V[?6NC:Z=8[P5A-;WEC9_NQ;BT3Y:5 JX-9!86#
ME N@@X! <I;5RM/@D+P]K,*+5O;A-J>%LN>N"5I]4_Q^^OY6WCW/:/R\Z?]$
M5A#_P6CD_\7)_S=P\G]&V]GFW.<S)DT<"J^$_82L(7<A9YXS$ EL%3I$#F.=
MQ[ +Z@ SC5#B@#\"<0CCS)KZ,X('6OLRU6#L[_CI?AG::7!GZ^.*A%B3Q\=?
M0I+[+V3U#33[7WBGO<5R31?4*Q^O*K_LP-)#64QDJ]BJR$>5]ML@GBU'Y*Z#
MYTQ[/UZD/JUHUB!(>76<S "[5#PFQI(24TKDLY<-52<PU9L3,5_<ZF<_Z&[)
MI_P@IQ?I3G(A& U68FJ;+CA')2FB7RB@WFQ*4VM;1%K$WG&\*B):X9.SS=BV
M$GC/OJ:F>5RYO65,4[\0S%?DG]9\)K9HA:'5 !0PY8%0&[M:R+K[W),$/DBY
M:?FL$XA\P1*B38%'@7-]]EB(VKE[MJ7V?Y0JN;NUGEH;>DE,NEZ^K*:_,G!9
M__1:L8VE3D&I[*?!=B7WN'I+)\OURI</E4TQ?"@?(:\_Y(%,^W?XF:<Z 'A^
M_K/X8YP':OC)D8%^X$=>W)Z!X\??VOEU)N>@-[\>U,CL]XA)OW\@,,26N<(#
M/4>\#" ])]-E."3RMS?8@7D@!<\'[>ZY 'YS0.YT\$ OONP9X!AJ&#YNOKTK
M^6#.C='F@0 I)/>66%4_]Y$.'M!*Y('.XZ^.( UPW= ])&[D+N<YF25EPB_N
MK9LC_XF=_]$BB&L>9[\OG.DIQ@TV>?RB(^3?]^:*XV;VN*EY:WS?DX@L.+^8
MSV3Z07:/\)7N@B/NUU.3.NCNP5[<0@N$/?,_'2-P'WQ+G.])9P4/M*G]\!9R
MZRB_>71%P'_5[YJE_&K]U]W_+;W&V;AORF(\T"-''NCKC=WWY&\2<GQR^@VW
M&;B5+K5Y_U]WAS!3N5/S6Q[D6QML4P2_LCAR>M%G^=W##,(#[:_D@=YW;3_#
M#9_1Y1.[8?YSQY;EU;]N_-OV\'_)Y8XMO\^FP;F'G'F@9[&KY_[INOY<H6(>
M:( PJN<\,/\ON_];+M=*>*!+LCBV((G?5@7^+X[^?X6CD:E%OE'CN($*MLWW
M,![(/,NSJ7->'DBD\>=#/>D84!- H#Y>];K G&P(HW\RV;LZO"W$ QT -JES
M1YX[C6ZE(YQ9A[B9@540T70GS9,;R*DSHSWTFH>^]GOP68)=:8!A17;%V3Z=
M)W%E,^%?O[04JD69N*J7K4^@PBC'"79ZI6;MJC:Z!<95JN7O[._86XR1W :B
MK[9:F"VW&MS*='^1HJ[\4AW@\$"Q+0)LU]#I<AYHP@6HP/WH'Q;XP2#7J''-
MR0MKH4> UEZ( -E7 7X$;4_E:K;5 R4LIY7O8]U<\"3,-!)U&P.A?XL?F.C(
M](O6;W^3,WH"]O:QG*>RL&<,OG1AV0R&R+:T-M7X8T-57Y+\@77Q77,IZ5[#
MIHD!5780HX#O%L]>TI!T\#WRQH)<18](\WDY.W;S&7"%&;ZCSRG$*G-IY+KM
M2=*>/MN*C[]9!G[-=R^:.S9_#!Z,.,HV!9+%$K!"0.:."Y"\=]6-#:\#XA>"
M[?H] #6L/)"' *P6R(E&;%&N ,OQ>^VB-7C/DG6KL/+C@_RJN=_X^;_"5F0B
MTMA0.A2,'>.!CK4I"\1@+WZ#U^'751DD"8PD<RBN373^.,QU[RQZ=8?$I.+K
M\!DP6Q;*FDE+AHE$^]%%H/1;M8M#:??GA>I#CWH!&UUX&;8%&,]<<L[XB$7R
MS1:I@W?OX1YM\KF*QP#3<G!YH]I$V)*L\!FP"'RH51O)4(4&8^4OA!Z<_?2.
M(33[*<HJ*>*/9]NM_>VNT_,?!\)4/ -9![B"ZM[1S%;[&E;3^H ?$2,ZNBTB
MME!6C&) 9N1G]A:^)U=\N](]4Y;.?/5=_26>OI-#!#R=*48)A715O><7YT4K
M NY??U>JYB8V4R2CF[9JF?'P<H':%'7\<V3AK1);AI)T:5)AZ"W&?V'O3:.:
M2-NUT=@.R!@& 0$AK:BH"'$ $8B)BHA(8Q0:$!#2-JT,:8RV(A&*E(H01M.M
MK;38$I59A"B#*$(BA*%M6R.S@I"DTHH,D2J54)I*<LKWVWOM[]U[G_>LL\Y9
MZ_M^?#^R%HM519[GOJ_[NJ_KKB?A5D_9V^Z\=1^U H./OTYX!A5\$ R^3_@5
MAMN/UFQHV+V98JP7<O#2?.4J3?CW9*.U1]_57KP14<*$5E "DW(JM]>5SZOR
M4]*RI?!NWCS,#;6N07L[2/6)(C$MOU%(01\>A(?EY"Y/ZER,TMU ,@"6:NXV
M\%Y\B(8;V\E6^SG/HU<*X<$.Y\!(WW[J"G9Z!]44GN6!L323N"8WK24?FGD]
MVG@3_?4CWU D*Z*:#)R81E<L&WKKL!B)S0;C!$/3JD)TA7HKMK6NGQ*"/%1Q
M^MT$7(8EQY#M(0=Z1X U*$^6N&&RK7$=VML>NGWZ$7\1Q3A9$9MX>715Y)-5
M?W,_U(Y%:!Y.4^9 DG.#A7SEQ5.PH$OKU(0T\J@VT0> I"8T50':2"=#J<N%
M")A'L3[Z RS-!O:E05LV!B+&LUGN+9MF0YL'Z]7VAR?>1>WN&7WC'6V$^"DU
ML+3MLG NF@21AV/ELV=N4WQB(#5Q'FJ]7W,=(,DF25;CA4]Y6?52RW V0UQ@
M>X3+A!)I[;:'KPKV3PZHUD\,I Q<.U@5.=(%QK*.V7O9W*[8'$!I>U95'>'_
M8<W1;V\=='Z>=ZHR)#]LZE9_!KNG\-<57FN.U!^B[H\UBO9?LOOWS9'KRWTF
MZK_K*5]SR3YE\Q1U9=#?50:_%MPKW5FJ'WKN1I#;Y)\%=RH7KI9\])$58.8\
M%0>1G!;%ML3BM-7@U\DBLB6*,,S[O?.(11N_+BS=74<PB?/B8HMNLK(Y1-2N
M9#^[($QST\W%+XS.Y5#1?5 B'9K-/H)M+-Z6+/-N,6([BP>%JYM:[O2^KL?K
M+PV8GZN*'> X8CX#,]7.D.BL=B[GR:@3/'H5KI,_:ZP$J(A>#M6),RJMETX]
MJ(["?FA&6$H]8C;%WR.GAFJV/_ZS)$MH%XG9]6 6LOB/+;'B4<( %E4\<7)T
M%?;'G49-_8F2;D5/M8CILIZRY1@,38O'R[<AMSK<[ 3IR;;58ZV3U\P2@Y:6
M' !6- \F/1%E?!B'1AG<QH@!P3&Y7O>;ONGHU*%#8\K'-R,G-J6X=RG/E PQ
M'?0?H+%5$>,"I*U3&HRR4J&HR,Y&/I$E;S#S399%BFPF/\_FU@".1P7R3UAP
MS21GZ>76F?S(O<T/L@\>#]\]G56Y^19RZ\(UKR/K0CROK6K:0_V[,OKW7R_M
MG"K\-?+79SSEDK.KU:[&G=N:W2/(A>X)E2'7W&YD7:A\JOXS)+B2='C<^<G^
MI[[!8!4?MU RGI18W*<E=]T DOK<:#D]3%)# 8^B!XO:2'6J!WJM1!-L@^8W
M_,*;V6I#5!"0V^'5U27)D2Y^-Y-_<HSQG'(,A^;Z.(<-?;?=ANW#6D<=$4EV
M$F^*;S9)LM&^$-61'O%0)XG2&5:W1M14)ZOWQ]_;Y+!^D.H,+$:BB^4BKG/)
MRW&'38A(3-(;+Y2T3[_L4A2T3UZ-HD-&'%/:DMN =TRJG+8(G?M(N!(])6?8
M^%:R+^Y%0NY=E(\N09*54CE_"3L56F+&Z8L8RZ9X5A^8O(P+D2MO&58 JYA)
MO(4%W$$?0VEV'44D)+"LJIC]L$WHC9:71;#5D-,YS"^V @6[M&O#W:>MXS\+
MJ]T*$L>E]YRZ6,,\E0+1.S.C(^3K"/K4K__D+'FK7=/=[%3V5F2D=9M8?8B4
MCQVZQ?[0$>8A=$0OW0)\T/3;_A5H>NC/.+A$>2S*%GF4U9-OX+&S]0R3N$W^
MY77BH*?Q4%QPQ^&/Z]EZ/F9+_%;B'NAFY1JW\: \S\2H3E?7H[\ZMY4XK=X=
M<D"XJA/ZR>O^VL ?1=QC["4]F_.6P\)AO>R.[7O+LZNCFU]%7K;<7;)F^Z7]
MH3>\CBRZ87O"_/<'-+HH ><UZ51I)788%<OXZ<_9PZH$J@6"PP^.E=W+E:O)
MBX"3Z#&(9:'M^/*XBBM*(-NC.H+J=[0*\8,T@BRM222V&RXX[R;A4A=T WIR
MAOF+N$&.?4&7;4O-C9CDI'BG[ 0^[(?(7,+H<*F@P\6Q"Y>T)/ 'J2' 1,.K
M@##44B'-9,(#@Q!+Z:TVQQ;!48TYI=W"S:7E9VAQ+(-H3K?7%-^&,J?&!V&V
M2?4QR]A2,"X^^@LRV& 8&O.IA.*G!EQ_03:*%0<T]> =CMN(YJ'"-<N=Q -?
MDJQ9><X)+.&J\=&#=8A&$;'\)"\9>I$4F>WB>'[(/V*>65Y+-&L8;+?BK.A-
M&@>9FN-[D&LZ0LX,PR;^\U_\)0T!).L$SI8!P ZBV2=P5M<+-PZCW+U(8Y;0
M'J ,8HRTJJY325#:\4?4A?TS#\A)1'UVRA@]9_\W Y>\O@TS/?AZCUFY3:J_
M.OYIYR(6.3ZT]A;_7D;$>?-J]Y# G4E+;7:;WOITWC^Z =AQ/\#>MC_M86ZI
MOWR\M:_(\0*U\Y+GWOA]E3LO_'[TXPCY\&L#=Z?%??Q)P=0G'6'>,\VOS:?4
MVR:D<V9 :^RG0:H#.U4U@#JI7=E/.J/7H08B ZJ7E#VX#VY4BDK977O0@UL$
M2DN(STT):\V/[=01ZA(SGDJRL&!XK(-D?O!B<&-W6""LJH0_1/<VI\&D=MH+
MCS:.I29_J>8!L (9BT#HK7RS83:MC6_BTAP&L_QAZ_- "**.1+L0L+5H+6H/
ML4S>2FVUR_>CUF&P7JOHW$] ZD #VB"Q'!X9U[K#X+D?ZP5U$T?1'I8SHG=>
M)+OIL!9QX>8UARC(PQ?;M>MZ9L!Y;&X PLA*TA&&K".1E=<$V ;J,E;FT$SF
M@UL'1A).I@R*.Q%>[O"CH=O6ZZ5H8',D=/FYTQWJT@%CN8)EKGTA-:.:ON7/
M;XZ"I8H%#?(T;P7801_RCAI(HG%%EDF@+;8#[4:X.V$6%PM32+.T*P8MOBUH
M;_K;BW;V=K7;523Q8 JOFGUS-NS^@+O]D<C[#:5^&TLC\OUC3R0$7_IF0T>P
MJJ_4>H\!W6+5FKO<:>?[O3F_>BYQ]/3MW7?V2@80&L@PS"YVL.G85VG ?O#=
MK=N;EEENJ8[>+X__]D3"GH\5J_NNAMCO&-G<$!ITM8R3Z:/6QQFNL8/V@J^R
M@_E?YD[LC9VT^NE'])?IBL!9;-'<?0-")_3U8 0JE^'6(8NS6OL'NB418AD#
MEH-:HW$/^C$X1IR2=!KFMWNSEK!WSD;U:9V8O34W9%43IEJQJ-8/-Q;?#_.&
MYNY&DCM6N:S07.)L GY"5]2,,Q:XU$NRA6L?P#QLD8=86JN]DJ3>-=XD4 ;C
M0#%O*+I:$^_E^RMCX0EP3CPNE,C920)K=ID"\LBCVHZK1.8@M9[\Y;3P-L!%
MQC?&W& 1_EZ)(B-L,WSD 4Z'M'0MB9V,JP\WVEPTH/WFN]F]#DMAT;F/E<H3
M9.)DS-Z^&>>9?K=<NP DK6+"^BRK?O25OY.[O$*42)O_8CB>8YRNJH4O%QR2
MX9K7K;:7LIZ%%&_M_5&X!-C>-QR!X(IWTMMXI7-  &,N>S(\>0 X)+=CQSRG
M[*NJ2TAYG3&#;.S3!)/8[\=^O7DCY-OX[Q/\^PL:J[TN_G[KVXIQK_K2G7D5
M/4'BH/S5J;;'5#4EB6\\?ZC\<X,\[\"M/;S:O%&#7T,6KG7WVEN\.#C#,L+M
MF$$U^_L$+W;3^9NJF36IFWO!*CP&,AZ_3M(FR**9459 O.&-G1YX9ZF+;:4-
M;83*E1[%J+=,(B;: MMK^T2'1>:<9[:^J@)X6ISBH5QYK] A&[DPK#K=1,^<
M9=@D$>>S1>)!AZ^\1+G-EN1,(/9@Y=MFU9=#D95X?OGGFD0=AE*[";Z)TUU-
MKM8$BT1/'9-)"2B5S'78A/X2BU^(P3J"LA29*W9P)YF)$@+#(*U H0QKZ_6+
MAYZRY-9B)G].?.%8UFWL%#&38B9_TH FEVF/H^4=4G@OW3XNA99)84&L869G
MM"T\G=Y XZ;H<8&P*@Q$K#)N8M0!2>:S!MD6IUT#3LV]4Q3KVQ[IE"5#C1G5
MB=#S!D<YR?#JL(V$^Y%7NZT,O:A2=S=[UZ TOT%18J!C&W45/)O9O )B&8P7
MEG<](1JS>6T<([B6;=>JM1RLM_._@5. $4IO-?.528Q0CG8@S7$;G+<.C0VH
MN]>]-*=CQ<&ZC(6>QTP<0FY"O_/K]K[><[5"L?!]3<+YC8'?ABR*?QR4RULC
M<%I[9.OKH'7RM6E>&]]<R,D(_U94*UBX/>CJI>+ 9[\6>VTH]MQSM6ISP)"7
MZ2>;78="[6VV3?_R2]%/>I\FG[JD@-AJ8OYO7=AJ7NY]>SW,F;SD._"U 0\-
M(MF!;_. *!QTAQ0\[;ZPWK3ON9IY^W#\?Q1].@9/ZYU_>,_"ACFNE63I"*^=
M?ML7S=<1#'P4+(T9+U>$_MB,^_0_U]#DNX!$'>'F>B09MVX%YVF??/T&5H'/
M?4D8"3=S!883^W6$+Q,-^29''>'7HH.^_V-%HH\[J:XZ@KP6P;7R*MQ.9RQ%
M&K5971U2;%/T9OP-+4G[;^@(VQ:!<!I9>X 4U/5EG+T1K\*[)*SD@\%@GTC1
M)>:K%N"%V5?0'O(*;/L9'=81=L1 TUH[\A+P?4X#66N Q5V0;-N!>B+QH\9K
MV.4A:+SB<-PAEBFST7#)+;<-,2?/LE<NE*W/B2N9^T/.'I:9W] VS??G<>]9
M\%%T42NR]=/+_[L26.FJW"F=0G,?[O[,&;NK^#6L7$?X+V_W7T,:RO^?MQ [
MLQ;\QXCHJAD>./JZFRTT[2)NI_2S(\D:A%^R%7AXOOVON^#=WJLC7,^AH=0"
M'<&56!GS9?)M@[O[%SQMT*D,S@U.YQ!]JKQ2^YC?2&HGYM-JCUQ!RB'25!<\
MW0I:XO <%IS7$>RH2VKNLA"2@MXF.'M2:]*/><J(9O%%I$!:6RZDB>D,]?HS
M/* JH>FB;_%$HFO!HFB\0<(EU$TZ0O=B%*?JS"==).QF=;6W7*!T+!Z/7O'\
M!,@%26[7]#H+D\[_HG A!L",]FKOG4CFQ3*FE<.R7C>!9?S)E .;J,MZ3TA-
MXR.B1>4OF.NBA\*9*4?X59&^5C<.,8]9.W@&=SQ7K>OLS%7=3RGJ*7+IN509
M5N[U\YL;V>7[;OU:''J5Y^%\?(]_157*E1UWPT]NG+3\:0C]+=4HT&EWS=SA
MCC\;#'X=EURTR*@*]$J*\LK9O01Y#5P(2M%V)3#@W=+TE*CI#O#<$*F#9H6J
MNE2@IGXE:HQ(%)& )5P@%F1?/JDC&(&')$,%"DE'2\"CN1!167R=(_ELW6I/
M_@;=6)H?$(Q>5U&]M(.I4NOQHI7:3EC#:Y-F.:Q7IVA;^4:B&-[IY,+02ZE)
M"D&6E[52 S$R]F$1?2ZN@'?U)']!LY_:0ON'CE!//PLX5J'T;Q!&#L7Z4"4[
M-A3MK_$%;[]-]GB?,'0Q^L 0TSPN*/Z>%<-TW&M,.78=+9OL\G(0J _'C7J(
MD%<ZPJ)I[% I V#W8F$@LGW2?^"CG2 [3+NLGIV4*\WR\++.!OQOO&(/O'G/
M,)<4LW.C>][T%8G#^Q+?G1)9CY/N6;>O*FM$M!?5P>SWAGQ3DM4!'T4B34'*
M778?"8??<>5SH6P(F6=[-@#RD9,-T=@VT7#/@GY0;@._.7,]3:!V\NU-=&DN
MW'S@S\6_N^]^.6-P/R6X/*B!'%>\9F;1HMA3.X_FY)5-^&^+N)I>;A,45%:F
MY5GR'D]\A_3=>;4Z]T9N>U"5CV'DB]W?PG<NA?_Y^\U2VXO'\]UWNYY,BG$/
MVG=;L:\#W XVL#!SLFI+GW##"S9-5JHL;Z4MP(VMA[(W%6%%H4PDF('V'J9:
M<[H<S-!8R 9PAIZ(AA@,]* <IQ%&P^6'M]BO_^ZGN%0!/O7HBAO8B@>]U+5$
MJX24M.9[304=6KS'G]T!K$#3V45+T"AUI!0+[7^G(_Q(S@0) BP6[SARP9D9
M&MZGC+0F0"3"/=ULB/]2$=MN[!V.OI1+;-BE% 8D(HEE(ZZ,=#Q?5+MXT+R9
M7 UL09S:HU:.!?4D]7YZ7(+FJC[A-V;3\S[:)ZMZNBG? \<JL#TLJW';@JX6
M6KL$(>]_?@1SKL)VIIWLV9_D3TFM0B.T.']XE>=%OV[VJT!/?O[@T]QWN.==
M>7V:2TP7 ]Y'-'WQN)2=WLEH='A8%H!8#2OF-9VL$W">%UX[Q[>:JCG87(N6
MJ0H*-D8VMJ=Z_^$RO18[BI/&N:*!=Z-V56E[O+,N^+9E$C??V.U6W'XB]O$>
ML[R)/9;+WUP+"TJR]P^IW.>Y9\DOJKL\E\W;.5.E:7?#+_OF"M;N0'VL _LJ
M@T*6[LS?O5=ULMAV7:DMI_.2<W"I>U!TQ^-GMR=\I*\;)VA3,?_XY*T+-)U1
M-*]%4])UWJ12[8,V:O6+;Z.LX!X\+6A %VTAL$+]C?8%HT$R-0[1%XY'< 2*
M2!>]]I.@Y0G)68[>8 QZ41!WX8F<9L2NH9FR::W"5?>[8QJ01CG8P3)!8]I(
M%L*OV6&M*04Y23Q]-JO3X>OGF/<MME0<ZF"")&E_*4L(L[J<3%T*"R]!C,7Q
M0ZYER Z*.H!FP5QG:G7BX5<Q1M$S$,F"(Q6Z]K]&B#F8CYK)+HZ^WT=QKY)4
MH[P05%V3\"%!:(3L?*#@+4CX*<&K9- CL8)-ZQQU0LAYS:O9A]1^F5@XY *V
MIZR][-595QE]X%-C+H?$Z:72D$T/%2P'MI[J#"+*P_95'IB,7OEE_F6/D-M'
M5R$.=U.TA]Y4"]CI$3W328DQP0\OCCT0];F^<SU\Y(=?SJ\?_^Y@3G&6@&%=
M^%Q@@"3NS5S65]&GJNSHS?<7).W;?>G332G9N^RUYQ_(\7CYL<T45SO7/Y#[
M$??C?2F!W]B%W%UT24\_-;P[Z,CQFM?AY;;9QRO6O*J76XC?"NC_7:_]KTPO
M8$PNHKU=QM,22W6$)[S?/U^F_>-)2>#_%S6@UW?WR[/R/+Q]_NBG(ZRFM(EZ
MKVJ-<6K[=8OV,3@SK!@<5_L#!P4?XOZ;58*E=,QN[.8DU0$O8#_.GT/DK!-I
MD5L';KM2O4JUO)KXQJ:=U=]_T'8SK-[)(D<\]IT=4O67U]]O;,J(/;O1I:'=
MVBPS,VY$Y(ELJO:ZLG+^]FK/AL+>Q.TE*WL^EY%#BX,"G8=#+[0TM/ & 5LQ
M%'_,(69-GW,/?<6MXC7UMWH#-:E?3?TN7S324)O<Z//QH@J/P 4[!6NV>;V.
M4,GC5DF='^D(\3K"IZ5"/)BI;;CP^0U-:7DO6@R^ZQ--SC T[ENU/)[Z-4N]
M0 R.3^T*W7*^(;$BH?#-1:,P_6/7 P_.?W5A[?<VD7OO</>>&]ZP^_V&DHUK
M MYTZ9MG+K1?-_;]?9(Q^,<8XJAM<\ 50-_WG7>]]GS^]]-7HC6@K(1#UC1A
M<R#P3)&[)H>R5,#^_$',F:>I<"=:HAYJJ\EVO@FV3;$2]CA7S3$)QW;"[ZY
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M6O$H6/.69"[Z 332ON10T'A<F@#[KLK*3].84H,)DBDE2;$%#-9<;2;] *Q
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M?UP>UF8)5_-Y222K:&QO'Z:'K"3F:A>C+>7E7:S,H)?L<GE!.G!(3LN*MFQ
MRMLEYL"!C$\M3JJEFCLX$9D#SDW=G.7L7'FR.,T#ZNH$'2:E1&"N.A38B]!R
M*!:5[ \*09L@BS,?*;JKF'9@AW=U-?9HK5$&3D8FE! 9/TO%^?HYX!Q3,8)M
MA _Q\X6V@"_">5AV.>KL]$.UY$6ET G=*>T< (W>45>@H<3LE,M<6O;'::X%
M.N;+A1;<D%\-/Y0YV7[90?]B,,-BE,T9BG/*443<ZWG=N_2"ON+">(3-5S/2
MQ#Z8."RXTYY!8]X7F^6=D2S_X0?BODG&0B 6=40*()(R5^T*!,%*P;D3.D*Z
M:![EX&T\CQV.D0B=6Q(8&=*O78BEH+XK2V^BCGO0U:3V2J%S_!U@?T\]T6C2
M5J(DTEHGB=SC;/&^9O04WFL-AK==W/>I3D&:>JQFHX.*@BZ>+=L96IDOIV6.
MKH$Q6S*7XBR?'HI5G<4UU5K0,)YA3_N!8>\O&WZ[B7V)\Q4JZ6)\I5W"Z9/.
M97%< 1+=Q!]^N \=3H187*$#<WC:G%T;].1.U!<0?37X.6=!K*C%US?V)/-Q
M_S[KS.3#WUE:ZQU?;]#RQPW6C)7O+TF&G?G]-LLC'[^T_R$*J6VZ&QINRMT9
MY'/#J$3@_LD.(K]DJ>H1,,M-1'!_<U'.>*GH<%@W2(E1. ?ZJ>I1.>+8P;&
MO\SW95=)-F#,8QTA-C0JM75 N!3]17Z-K*AI^>+"-9(\LO;K\6.!U5'1:'K@
M\Q)$D%[_]'APN7KSES%+ U<LRI/6#>90XA5I,6*^/L<:<T&/R2^A43+>$.[=
M5L.L#)I\$6JFD&9J/=!XB&; +F\+;6)TB(S8(JA,5 S\T-W,=+F7#TTK-U-6
M)]Y*<+"M16UD/")ZIW;*.DTZRJD?=UA;CQ@D_!3GL.K>H&-W4G6P..7)V\]3
M$87QU&7/QZR:!LY4-EQJGSQ8_79V>>1$8<C+'!V!_GO6$:7\9^5MO@$0 $MX
M>MG$,\W@3?0I8 \I0;F.D,MH$ZZN0^9Q;!!IAFL^-Z?91N!?&C7B5\JN$MN>
M]2]GYVYMB4L*M-B7F48+;KC7TEBT4$=8+W34/N8W\'.!-(AE\U9'6(SY%==D
M0Y+\T<VH;TPQIYMD SB6Q(\N13R4JV%'B-@&H@& D_S*C\!Z*-]0#"[$[!"_
MM@*J*<+A0R*]\3OL6]-M9G$IE].AEB/[T?R-J@V::JU%O C. 4P0/6XBME1!
MS 7KD[.PP-@J;3??ZJ./S)@(66.+AF95%3"85V_HV;Q"X82 V4"@VBTAA7\:
M.'C3M4INDP@<>1]G_5G5>)TMZ2C:V&OHVIH\HAF;<A_,=5F;E&\G;AQ=U5B+
MZ&4IDW*GB7%A*7^'#CUK.23O+O?((KLENL;WJ+]M>%ZPOR<R_/[=L^SZCGXW
M10IL.!GC*AI.6O_[J#1?E*I9HWC==>!#YY9)I%"AVJMIEOHAER]=Q_9[K;@]
MNDQ3DD0R><7D-Y Z'PJRHM=W4YTDZBT30]%<!3_'B\0M9WPU85N.+07MJ+88
M#<V&CS_26O=KOV);=(P2T3/7V0Z,W%_8-V?W!8A>]*K$HEZWQ(! ]"XDF3>"
M>N]%\R&\N'4$HE+$% T9ME\F&0IF1$,>JA1D$)?+\]F*3FMZ++EKQ$DL,@2,
MD;(!!1TM+D.[6HLL[J'EJ3!1[)6<3;5X\7+2>D7!=P_?:3^H?HB>B)W'8)CN
MVNL[TK4V9=78A523,MZ]";:3<O"%WCQ-C8+PN\RB2+]5]J'UH^ I::A.=5!3
M3'4& M#7BNESHD4-TP;A3(:>CO"]]"ML%?Q4U$7*&?WJ>;_63MLO74Q=HWWI
M%3*827%V$YK"LUD<3VQNG]826/5<NR*@)$&X0AAI.+UP=#)Z 5P2D?DP258H
MG>+A6UEX'R&W+L0,D3=CK1&QXNETDAG@E(Q7,:D^K)-HBT(T2W:7S$]Y%9=S
MAN'8-C@ROA9S1<OCX5X%J8/TDM$Y:H7,1?>0K:+'P85'W(E9T9M1W(X2@,V7
MW_Y;H76AW,Z(Y'/U^9'M#LY($B_3S7[N[H>#22.L]NBEC=TG\JU][A@,?AZH
MKI@(VS20<O+B]S7YIRJC XVO59S8^-?50>_\Y%O%BU);MAW8N#KTP0,C&WV3
M$HO?;\Q;-U%B>M07E^HZ@LI"4]SPM\-F]-#U"&P56GE*/8_3)ZHS*:A*$#72
ME4N1U Z:B=89V(&03U/"X+'.RXQ%E*3K$L@^V6=@)M^BHV<B(H_QPP!FEI1Z
M RTS-*8?>,KEJKU%+\94'8@>C\+8=!>);*>28%:6T'E3.3)W'SRMS%;[C20P
M[)JM*\#6'9R%  !W-LH3%SC3C<E35<?@5!49#NN0OE1BAG!NY-UZ9$;:H4)/
MI0H8J)Z\,;V95?7OW4M':)SP_%K*^$I_GMV#UGE'M\V#T_SVLC=_G4.55N@(
M$LVT=@$=;S-AF5H)9P'"$],RO!BG,5:-E,W;"TORJ.3]*#.XOSD*HI.8J^%"
M5I[(E*6=^W9H.A^(<9?F-M,AHA%@W(PFR?-3]R,[RVO89\?"N@6T!LP?8OY]
ME='74I;[CR)^S6^<H'W0$5)Q97Y11T"^31/MTQ'X:BEFQ-<1<F[U[3OTPE4M
M:JY3:?RTX#0(;P"U:WC_?$](1,[:A_.ER;.7,V]4G"^8O8X+QK]QN1G6B\V,
MN7DKMR84>2S[#%M 5<MV-?UFH2,L(I[A+=]$=_+T]'22>KL_>\M_OPAIU.2'
M,CZ?1JUR7?^(F$Z>O<88GB%]TA%:=(1'>%=!;_US:$(25M5.>0NGI]=J_FG%
MQ<K//$Q'&,4;$N[$L)#0F__O-EK?V'2U]F:T=.-Z@UN-R49__774<NOR"_X$
M@OYR69B97)*+Y^/7:-+55JEELS6$ I&)4)54_ZF<D15-0I93U]3"*^N8<HE]
M-/MPE'6HD&X:P79J#QN(T,MS/9'9G-[V^;6RZ&*-_\&*J&TLI\38-=M.,;W'
M?O!8MQNU\7:\%'5G\^-'FVW^'GS?#3_4+E2HDS 3N/%L/>,L8['0"G"_ZJ_)
M%:Y&#X<\YZP$?.!G=V7@T)B"CEO/87#(H%=>T$XR0N<W^WX9A[.49O!Q562/
MI78YVV\/W0%;C2(*08YT\<<MMNH(9-.OB?_&XS,;54_I_(_#.D+!4E%/#37(
M*UVRN/59VFIC50EAY6=TP>-Y(Z\(6S<O7_+A[,+-[]8SGG%NX)[Q/:Y["Z)?
MQ ^5_:+>A5:U-CJ8/A=^.7O($^?2AP6J4F33-1CL*)Q5YL*&$*,-Y JWH+F5
MXTTG!>I -O@(K!-E<#S9"6FQBIVYD-)B3PN:&P_S V%5BXQ/9!_O" 7CM:V,
MVBYE/NRD$"GIBNFAXXJQ\\+U<8Q% %WA+)V?.SUDT4XRU=I.6'F5X^8X:W0S
M;-4B)YTN6HG2Y6.:WQOX>MA2Q.D<QW+2P0'FMDM,V5YOI.)[328%-Q.\K#.:
MG:#-_Q:%B;'_9[Q]H;=P-:=81Z#-BE ;FHY@Z?>?[JKVM?I'D3^AL?K ,>VL
MCC#724> *O[YKI"*F_]#H\7^)[BR .\+_C]B?LMKWN\:7=LW2\E[ILR-VFQ4
M9]Y%(&Q@$TS./L@9IRX!N[A9HJD?^VD?K])O/O[1)>6>9@_I/V:;Y'\]VVP$
MWWW4$29G6!J/'6_^8[3I/P9:GB#:L(M;O3*S960SCW,8/1F4S]8ABY(%,<=*
MAH;8Z=\T]]=,O;8-?9!(O5X8V#*M2LRL*DG@./0)GC9PL^M'@L4%7C573K4"
MJV!!CEM<PQ:]=JI'_PS)+,Z6+%;:,0:4.Z^QDS0,.AQ]A95V^]4(F^O?[^Y=
M]>33+Z5-385LWU</:S(N7?Q&-?G1^"C5%G>1$LA/<XZR44>HZ,C__L15_HO"
M HVQ=AD>;Y:^CO"![*=:6:HC^(!9(MBN#<2>#/KZ$HZ+_L]5__]?=6HZR]W%
ML>VH7Q(DR*G&#=:.3&>^:8+#G.[K/^]X7E+FV6#_U9"'V9:.IETA63N++'^T
MV>NQ39-="3Z70F1L 8S#<\/,W]3U*#T926TOVO2<0T99K;:-;9L_;G&BHT<_
M6S4J7&C0_+ZB%=TS2A+TKD#!K[U74#*,)G][IV!'KUMDE-U>46(8_?Y YX/Y
MO]\;.A[X<?[_@C@<'![W@.F+>M"K!YK/;WHUT+A):[??R6[72^<(=LK Z[#E
MFP[>SWA_G344'MGQWPU8TO096[1/=(3W_HXZ0NTE1*$CA'6U-PW06@4Z F.=
M5/W;WY7:3QDZ@F"S2--//??E@PRWG?\"Z&7"<L2P;5W)$WW&/&S[=\\R6O'.
ME2X'%QN=.TKTI,AB+OB5AQ$KP,?^,%^3I2.8BCYJX,[3-CK"PGP)SC+;=(33
M[T%DB"8W>X#WOK<TV(&N]8[VKM .@@O<!-FCWNBAU KVY;EP<? =O(5T2+,M
M4+^H>G0]?+4C12#VIN45QF9P'+&PEOI[<')&4JHHTZN12PE?_CGS9M/*2\0\
M+2GN\QM!*7H1(I\YP3 [,* C_,AX&2QF+'9"YT"D(4>9*ANYW-OJL![E50"4
M?DJJ?)AD.DXU0-,28RK8@U$#U^^+SAM;$8WCO?*\5)7,6Y)84(_K,D,W3[M4
M[V(7UK=VZY9(K9D=_Y,6%^QS<)FAJ ?;'(_CW/H<E%'XV,EFUG9-K>BPQ'*2
M3[P-."+''T63X?(.^KP1MN(1R9KBK& M8*?+I#G*8&CLM'9^/(?TG.,XSEGV
MX'F2P(I=#(G:02.V75NAU2\N6)..D/V.+[X7)!0.%$:]XAO@^P%?%D :B7B:
MR Y3\%H'T2L(2<[G4EWB^ MNHD]@L%UDN12.S0:,Y:RL@<_%Z/%'U"U(?EE#
M63C;I[/(>O!(,UVF#&O7&CSL;ABQ:_>RSI[A&3,C-C54$%+UL&4>M \:/>U<
MO)ET??DLU,XQ+8@+JD>G:*CRV!!=Z:+V9.H(!C54K[<,DE9_DC'/A4RKJ]%N
MB*=9 OJ5P)J&/MH]9;.[RHZ7=3+EXZA9Y@>MN?<PC:BY'!@5JQU^>*_G7IJ0
M?9WC&*JIIQUVWO\MFZGP$[.RFQ[UB6*O1N(V=PV.TS/8*4A)\]548&GPM'RV
ME;=D@NK0#?B[:/BG*5&I2$"K=FDO)=R-698P2NRS9CPGA><P5[$(6XK_=7)Z
M(S4UHD-$8WQKIA0?B#:4JCKUW(UX;G0#G<NP='_*4M#%B<Y^:"RRP#_V#$4?
MF1LL1-9:11LA%R7,XP;LF/;CXTW# 2S*]^W-&^;W(TY*3_4FMA>8?7*4K+G!
MT6.'CLF$E^2!QQ66HFSJ6M30AR^G9BM:CP#&MX& W.!!Y0_PRDN*]<EQP.H*
M]HT3570SPZKC)8'LE;RC>HG_NE#V:U>AXW! JZW3:2Q00<]C&%(<Y:*<E'L9
MU['U7\[P?XT&;.VF.C*+5O6^[F_>>!,EAO0GI080K2=&E_7<N!K\O'Z:^"K!
MNE#(7]18"'A8=3>G7T! 98QZ+4#M^3ARO.O+UTS@2B#?(KP7(-U^^[DK5[L!
M\(('"FZ]Q>,UH,3FW!IORJR#O)T#E!Y=JP]RM$1A0V$DP\+ETG!<[6AN? XA
MA?PO(<0NR*,ELE[F/A+9D50<A-1)YUZFF=?SYJ'ED%.[_1JZ ]L!EXUMT=:U
M</3-PJ[._:Y80.(M#+=#>_B*IP;JUH+1Y3W*$_ARAM)JW@PA2\_K/1BO9PT-
MJD(0>^V-4C15=47#3U+2_5&_0SB00GKK67E2$_< S489M;0LG!F1W/ET^[.N
M]HNOP@''/K=$>F#_;>'R UW6Z4?JGV[_4VM\."#R_HJ?YW;C$O9_CK[?/^V+
M^1?%2<W0/N9LJ1^<(<[E]#'J!/EK*<XX:P6A=5"N5!_[$8V'O.G&F'-W0Q1K
M>[]V)7/6BY8M6-JM)8U'2#,!_^*$Z(U]T5+Q92\!=Z;%:S(H9WJW*%/Z K-6
M@ N 77#9&86$RW&%NW@ $:K>) V'17F8M6 \>C5<GNV6>SUB,.0YQ??&B#3>
MMO/J3]<;6E373AUCKIO7Y3QGJPT(9[W"Y>-'$DK$]9_]?RJ+AI'NK4N<_F6F
MDD_LU=/_UX",&EDTI^V?"XR'[C@"CGTF8GJXR3D_F.Q+.,K_YY74Q&Z%Z]\G
MC'KYMF0M;@[_X?8WQ+.@? [LX6@.;R >0-);EQ,/UOB(&>]M47RY,6D%VNO4
MA=<-_K?=T/\^*REGV_:]Z()20W_>_3URN+@@9(U=VOF"56T7VK_;'/SX;_/-
M-6\>D W!KJY<T50B[AAZHWE;'0ZJ<7OQV!AI5(]:ZPA]7>+^Z4LRL!XW S]+
M[< 6.:CY!MC"N,J #Q"S240AB?,,MQ0E".L\QQ;U;C=6AV#+$7+F4B19N8/V
M SDKHB9#UEO-P,))7W'<#P#)FJMN-'V SLI(%JY^[N+.L,5BX(*SQ3T O6*\
MH KBF4\ZF,/DW$W_-Y9 [7. F"GZ^SB**YB#1",=86)]3+2E[ ^J$[93<YYC
M+$IOCBV-YYLW[X/399=O:RF]%!\%\^E*N^$68IN7(*O9[^8DP_P$W9(]VW['
M/R')3F-+S&Y*''T(M:DNT\R<_-VWG$R8XIBSF9T1![S*\B&)K73"86WW1]Z<
M>.'*@;46NYNX7_XY"*F\5'O]2$,4832J_@)$OO>$5=X"GV,$EH>_&J$;0"?X
MV_8=F%5M*L>UVI&'>$:+%NL(;T[RIA+IVLR19!P:E/4ZPE]*P@FWL"V:_$H=
MX?EP#<ZT3IFT3]>*U7;!.L*-QB@<'G0C\(/W5GMC2PD8DP!^W#0I0O7E/&UL
MG+:S3T=XFS@(PA9B$O;LN9Z/[W'IBR&^QKAI6OL5.T9'N#)$N]M ^VR7),7F
MP5TZPL;Z.<^[_\^B_I<L"IA5XQ[X\7*>]L^P+IZ&03*?'$K\V++=!KK,,&=:
M'RL^DAJO;*;^_->ZG8]M!W?<NQ_RV/BWV.Q:O:>-7Z.-4R(=8?D%FGHUPX$V
M P !U3$8[D1G/ACK" _.[^9/_\;X_"%71Q@)?KM[U<U:K[;[:3[:W?1S.L*4
M'XK+]O+I3/=7_XT.IP8-BF+<^X  =6 D+ZM@2/2(-02-M4<O12?5U$F.;7=L
M>KOV:\1CZD.9]AEU>3>%C+A:-PX 1%C=&;T([DH'Z%"@\0F7U/9<A+BC>="-
M;OMVU!9QR@+L*H!&F8Z KA"**C!]U%-.S^$[-&]+0LX.RLCM/ -MM\/&.SUN
M/(MPP =5(W4*LE@Z5 59=SS]:LOV+G'3EH9\KG*CK++!FS9O<I38SR&QB^4+
M2H_!Q:$P]<J-JYMZ[Q.73(@:+HO4WZ$JXAFOUP-\J%I/:Y O(W.;<";+ 6BX
MB['$W/"N_4,D$5V6G$5=P>:((3X7,X881E'\](O:09(IP$R2;XGY=L"-;D)3
M6MY^&[IS,@0QN5(6'PS,DI1X3.<;:?B<N4_E IMX9AIB* ;OBI0T]6&F@QM:
M*B>;O9#&I_A-O9;3AQC^:+9L9.=@9^$KX?)OP?-#@JDM-8!7/;(_-V20LQ (
M0LMC2A-J>9E[)Q_-_1@DT>H+2DCG24:B^&J&@ISEA$[#'R!).R-/ !GKM7ZV
MYF+$"K08&F+;M=),3USSD/_5V-1YI9@=^2TZ1Z:6G&TZD5S(RZ(P#GID)[%R
M!X4;!ZBN41.C:P: +X=:X)VDLU[64[A*JZ-G<5:R/[1SC/L LIPTGSDT4W9)
M'J77Z1&]!![$S/]4:/7#CYG\4G7-.XSGVY=$S/3*O(NX2O8R _U/@+83@X4_
M;BJ()A5-#(VU8?'J@V"K?[U4GWUSNG74 F%DGTCS4JO.] NM@%">5O^QFAZO
M=40;%)(%F*VF0+L<,$(-(=9+41"R"#356@)DM!@)ANA*3QA2*,;R7#'R]?AH
M0W2NG+\@ 30[P<OF.-]%'RI86P?!.-%PS:Q"+ZM>PY ).NQC'X$&M/B1[Z7R
M-\5RP<LQJ.@WSG+,L0ZF*Y\FIREB+Q#MV=Y^ ^\ #T3O$<D8C.7KHSZ=*?Q,
MBB-"]NO&]-7!8$*K'!QVE%T2M<J(=<V>:H.X4' >Q1?.[:!NO,CHIS#5/H"9
MYB8E35$!H;F""2$%\7@T;8\M1**SXZ%*JB<0C4Y"B7N9120-'[.#9T-/ ;&:
M7V+DF^6U\!BW?K_;9.3A#R/.6OU+LB@[2'!>N&P(V([8/Q7D:-TCL1//;S<\
M%)'8Z1&P1U8#8^BA#%2F(:2V(MLH!I0O;8NR>\0WQ3=E\KRZP9!E!%C"7?DW
M>P[U*OHIR9#-"4.?X^W86DVIZ,>H,)4G^@$A=DF)S6R^%<4=$>U$T^",CZR7
M?.AU>?Z,E.O@>55VVTI+Z].:LI^T1<]!2E\+3KO3LZ.]&Q!Z;CTQX_,;ODQD
MB'GV83[Q\*3J;!_%HC)>NJA9( ]3TG#<KT5BLSC$R>A5:#B5)S>D&VF[[O'-
M ?)Q]7K@^VXR]6MVN@+/HSH2,T.[H0":!;N6;L 4&:^E6F'+T4.PA^)9PPTF
MR:2XGT(ZI'A*"D;>79&#^NR'W]S92]P.2S%S1B#L)$YDROGBZ:&-$#=]JN8=
MX'1]/UNP!['NI*-[9NCI0N,>#B6>LP3=HN!;="!O!A1:,X;A*)8R0$F4)WK+
M\A@$8#DE39[V%:ZJJ(:XO#_G3K=%[3I2FGB8.=_G0??7S^OYYSGN\"4>ESZ%
MW&9[B5L3%9+Y\1Y\4QTA=D1/K#6_@Y;C>&\5635O.54%;$/H9S_.AZT:(/!L
M4_G4[&TIVRO5$#2;<%B-D,\!AA#?$#L$ST*@,D#MVR)M$^5_ /9T R'J1/9&
MU5)T'Y1&ZL"U?Z?T97*;R(3B=4_4@.=I^(.\*[W9$0F(;!IPO]),@P^+@S3\
MVU0OU.J4K;A=:@[&!I(Z/I=G8?[R!Y3CD#019BD=\32L1L\8V=JR8T+@L"SL
M(,0Z'0&>9\U(7]1!JNQ2[1/A<J2K@[&83530Q/2%$Z.NR*9K<M$0LXU$!(CR
M8Y#Q1E4F++QQ"AX5MP\,2"V3C ,ZP(7"]=AF-%;^'?%!$O]%\1YP#N=Q]%S8
M.M]%:]ZE7N,OV^5&-D?G;D.V%.1(Q:-F!:T7F!PC&,QR)V='7*Z^P7:$5A2<
MH\EMD-ETZHIHC F7YV+.E274M=VXA181V6&=MN0_00.\(5XL7' )+NX0?H5(
M<#*MVU.J( _;^<![+LK5]J3V%+)X&J_D07$:4Q6DN<)9S.9$Q6SK*:^M0XEJ
MTEN^,87,+*%$G"5G]W9N\AAU1!*%@@KT*B-=-7Y1A?$@FC+,:6JPBKE)9%*/
MAT1U[.&=6EXKS69&1S!G@N:EJ$B]WT_QA/7R:B@*0E%VXL_DSGVR)R".EK8$
MAA]R_JYQ'BZ[G?K=*MSV)33QBU"%ZH7FKAO/COWAD5?]YUBQ9J-<H&1>YSRV
MG>512&HJ*E',9E.V@8CU'E2)*,3:5;"?F#AG C>AB*OH.J=K5G17D#4M<(NR
M"(4E&=JUP#?H@^.0:"&:WD8RG*9X'ITS+731$<Z&H<S.PH(\EP9!OL/2^S Y
MRVUZZ*MA/[A$2(!#WI27,3A]U!4H34'/_<#F=EHC40D<UQY2NXZ@=[L4WGG&
MO>8B4Z[1Z_"29E)\:?GU3PWE@]C7:IH-'O/?.);H\#%$L@MQZKCV4Z]<VNF-
M%UAGJ-"R ::=<W67&F![-66B0[G3+RTZM5\W(0U__S2*/FQM<A(''N_P*CC7
MK%<5?W+0:G0E8M<E0!O;J2:PZ#1EJ9QXK=E"_0W> (0K)T#C9D\!2FRGZ6-1
MB.$C![WN)+)Q/+^6U!%)-(E/8;737HS.0K%9HO@P5*IH.1Z%1L')N+0B@@EV
M=CI"IA=YJAH)"T&(N13O4O0DPP#8V8T%5F(1:#)";L,\SM 2R.CJ$>%5W$ '
MWH-)V4#@];?2N_<N*J+\VD$KT6'ZD+688<5Q ;[M P_S\ZD;!UQ7/J=XP*1O
M8-)IK1,:H\I!TV1@YE#LEZ_,QQ.>'S'9^AXMFMP+%^13MB$2%3#H=IHHH#J!
MK6NI2X!O!JA?3_9B=*0Q<X9FS[ZJ ,^;3XI#[Z58OOM%0<X%%WTY;)47L?-V
MT[/TI&+T?!Q@J2"^$,M?+;X[\#&-R8#?- CB&?#/<05'XYIJKJD&I^2P7X"F
MB&KV5F3H5OE1W7$'(;7S%B<,%146;=J?)++$0M K"F+.J#MB_$IJ3ET&A",C
MVCJ(;(T.'ABD;*MBET/DG(:TV*@^=_L(Q5[ZO>IKC6_&N,(M8.LVP!.B9]I:
MMU=O&NM(\=14X@+)J7.H7#S]0JW8Q(7H5MA:]!K,5_D.E@^>N#Z(_WD;]D9Y
M5QL]C^1 W8"R(%IV<R*ND!9,IM#$I(R-HV^+UJ!<Q%D6V\$S 2(0WCFP?@Q;
MM-$/YC^R7S K)_'J1TZ2SS#F5[M+SPU)ILK5.YGK)FS!+/#@.,>9K8;&LFCQ
M]$4)0Z,\F2"'9*(CQ&LL0M'5L6H:L+7/791=6,H_]\Z-9?FVL#&'%D?,H)D"
M)G/4GWPYKNA&*%FYKQ)+UES^2.1!GWL[4F*5.4+KYUB4'#PWN@YUETMS: NI
MJ\!6,H>,):/YLK38K0,S]*QCK]@>\MBNIZZ]@?4#!Y%U[YO#X5YYV&G@4/4!
M8%MOTK0IVJO*.6VPZN9_O/ZFN.L(2P59-)7'2W!BKBQG<O)G7 9E"K_6$5Y(
M#^D(%<2SJ^8*;N:L(OS[2_"F7.:$64O"!]QHA E&??DCC?>CH>JN1^0\L)Z8
M#[C ?T[H".V<E0@W/0G,(M7ZX=;_^^HP&8</I47Z]#8$.BO&\$( +0#]07?0
M;K*(! ]DX%+#%+U:/,+F;X7!C)G\(X.?0P4%1\#O:2\F/NRN>_Y.1S@D.1T6
ML8D/QX1KKJVM?\+/<- OZAR6.66YI])-F;0%BGL%.^.XXBB?Z+L- ^7PL> ;
M('-GTKS:@ <KKCRB46?X*,XTCWA&$T?98+NTKE$9>!,M$!>6MQL[*<JX*R_"
M*[6LE\]8&=)Z4JODY9/.9-!TNE["\RADY;E-LBR!5#0*>KJ,<289M":["PAH
M9M2>T3:R:=S0=*:;M)R&&R=T-;&-.!P&)7<RN"1#CAUV\CGNVL\5%N1,U>,B
MG.,)&Q<5P%>A4L$9[5IT4E:>PZ(ZH _]$!/1Z^CX(F\TM;H6C>P*=3! \F<S
MW(E$]%:7>-;*NO!FG%!T4&W(Z?2*S;P-V)5SGI (4\VKR]@Q47 4CULMM$2]
M7%9*VXI6HQ=O #'(IM/WF"59C$"$U"$P8J="AUM8RYHF';R[3T@M$TAQ \IE
M+8QM*$OM@<U!O16D+-"4LPBP0UFPHE-JU1#9D@K%9F.6<GMK<8KH?$.+3V0_
M3D9,AY5-/=4ND:'][G1S-#T*L:H"DX23WPXV5(>%BRXK]O6YUAPBJ&[]$[Z:
M\9B3'%QUA+OW9G'J2MF2U/"8':FE4G [&),XK2W\F$+X0!P"M;M8^:)16*0M
MHSH(GDI0%T;'-0]98^OT2S5D@RH@TKF4+MS!Q?%-)@=3Z.FB>,%96ATW%XN$
M;]%-V+EM#'MWAK$/\C 4'O@%843 1#%Q,3-%Q955.W<4+2G8A:QXEJ%H"4V,
M_0:^+5P\2-OUWSQY%>*-\&P%RI15]TNG%! _#R0(/;'P:T <'T\FNT#&4]ZX
MS?DCHBP?<89BVZ5G"Z?%TW,>XRUS4&D/$Z-1'D1<#.Q!&?"'SE'B?A<LD@E/
MAZ![M)Y-37!:V;53U52)9I2OX53K"&5O?\>]&(#_]-T+EF9+-LT/C)WM+T&)
M<.",FCPUDJ0UPSS2F'MTA(PS%4"X>L'M4>/N\Z5X11H&A_9C/K=PF^HB+R2B
M^VTOBVH2'#:\UQ'DCLW],\[7=@>\G&W&R]J1W\Y3+V3'Z@C[<FW_+_;>/1RJ
MM>\#GU))TC@+,1512=,N4@XSE2U%FDH18G:ID#2U(U/&K.0P#F&79)>8(DEB
MMIQ*S,1@.NQR)I0Y[2*'K%6,E5FSYK<\S_O'V][O\[S/^_Z>/][K^OVZKKFZ
MQKK=ZWM_CY_/NK_N]1&#=W3&7)J<C"RLA@\4"/(8Q%C1.'\ETWBHC)Y(YUJ;
M/=M+M_J1HOKI#/S;"72IZ<HT/O]5H:]E8D)=26K8$:-?NB:)%8I'IS+XU"^;
M$4Q_O[$2@,G%90]W9W#_<W[XGWS^ZP[G_]T&7&SGAV1BDJE.R-&T%5C0$20&
MK\T>$!$6NGC1PRW#6T8&GK[$YC<!GG\3C<NUT67 )TQC$;@+YEZYQM5=XY.P
M=<6FB#%/2OM$#L4OV7C^9+2K6^MGV] Z@UV\SBM>7[Y2VCY7*LX-NC]Z?-,]
MC"3U[;I7D69H:]6<;>D#<OCC6AL?HTO!P=B('H@</PB2DZ@^;1,>'K7.HJ<9
MS%.,9:6V8[6#7F!=?5>$,RF&><KFQNX"YM&*P/-G/M(?PRQP:#C O(V5CLR/
M8,^#4^JY>"@M78E38R4H<96U9A(E+A$*/LNP!PN3PX5CQ"HXLE&H>1@B)Q2
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M(^?@R1(J.QF=TP,<+?&41#;S.3"+3[M/+_>%BT64N%Q;6.?^5LD.$<_##"N
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M,HT83E#0,\P)J$WH<G 76WT-%P_K;(/6PS1I-9_3VR&V2ZT$6!#:QC0 3\5
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MEM$6TK,D SGBT'&</_PS7]".K*II8RP3U[DVHM80]1*Z["*S'@@>IDYH<;&
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MU@5Y.MWYY2/.7OFPV':75GE969/8$A<HX2\R>LE*<98A17R2G#I#,C6NPZU
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M]]2[&W.FB_6.;^!_B Q79Q__F.BS9@5BNO>ZLV!5 B:# R/OQ12MH2YWI:\
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M;*,]N#5G.EBKZ/-7>4H@$@C6Y.=R-W&< @B24H[5H';9JN[QZ@J:_"J+3FW
MN/P$549K7ADM9ZP4C;A9SM&P)LQE#X[T<NQV]?BPDGS%:57A(8<JFZ#JGC%1
MW>?8/!P&!ZD9B'ISE\]"XYJ"E@N;Z"M39:&TQI>!NA\[)T<%%H'QMWSO;N57
M/KYZ'_XZ[LL1G>-J1MJW@ERU^)IDRK;G/3R.=1@73ZBIV:(%ANNPK_IBH+HG
MM5K1:^5?0*AQ<_<9D@5LU^%S!*5/-4W72I9S;5D#UITB$TZD3+DT+CZ(HOS\
M:9L'>ZZ_BK$"?,:<,U+DV!Y?O\T#FG\4Y#<95Q'"Q1YI^HAN"@8/@)O'$K1!
M8<W,Q<;UW!8O_ECE&92M%J?"*U2*^<!/0Q&C^=L-A=7B/EYC75!#KBY9/9$5
MH_?D4-7B1J89"/?9=D9%,\<]T*,1*X+L9T@[>_ =I<I+%_T?$RY@!W1,0>9$
M!H)4#;O/3[TU[<[OHQ'.A+!*$K VEHY^#7C-HA5M<()FAK2T)OE^_PY-KG=8
MNY$R2J&"_ =#M:$'J_7PYDYW1=9)@F."3#+W)F3@UI$Z_WJ,*><MCH"_L%^K
MK'SU'.W9@=UH*(\._14PI)Z('>ZHHJ[ /X7,?':5]8[8(](C,#,*6R,)96;$
M"Y;^DJ0Q0P[?BIYTH09WA,J#&][ST@D89LQ21VHSW;T+#D%K@S!NVD/\3+>/
MOV<3[9(M<R'LJ8WSTU*;F7-P2G6W1P-E5$.3!IT=E!99H<I+\8VWWI5KWL3&
M[>ZJ@+W+P@"K>=HUI^3(>20=4=WHXU\R+@,%*D4:=RO',P)-S/(QT6^,N=>C
MD3<V,&2U7C09NY>M-I'PDOO\90+3T:)YH!<MD!G)G0ED$WP=49:P(V%3HK)]
M/+7*-,BN:B=(5K.S/6T%U#05R6""*<==4++Z1Z;I.JQ'QEO(B8>_[ARK8J=>
M?3/2]O(,YG>P<].XAW<8>6YH;\5+1=8[IG\#+^([E]4.)7'JUVQ\U[D_AFY%
ME"(Q:N/'!I%QKBRNA'_9Z(KR6RKV(CRHDL@E;=EPQ#+LQ",W<+)'EPSN*I<(
M?3&;=5OM?M'0%LH>QX@VU;9[-%@SU'Q;%M<$XZ5-\JSN5:KY%OZEW]BSQY[5
M7)@8.Z,Q8VIJ\^#$1\:?BY9@3I=#9)!%>J$&6HE_)<)HS2]IZKP2+2\S8GU-
MSN>7.3W!X5N9UIR,@^V3T7$?"MD'.E..Q'179G9HD60B80'( G@9ZB^9R*CS
MS_4Q77\5/2>#GB7BSM"*:&1.%74)_E6GR,;XLQ&JPN0I^#RL3.-;>Z7:!A14
MC,:4#GMQG\Z>MWQ.G9]!J 55I\]1KF,XAW=$5/\/\FUA J%%/ Q7A*9W8T([
M\",YLNZ^_!9&.G_>.Q=XSNU1$:W;G= "$915U]2Z^D?1H2=265MPW]D#@83!
M"6IQINU63^-R[#AW9<\J]"*!W^SX\M'#OJ=G2(0+O%95+LB^<4$P;H(* O-5
M]PH%(TJKTD[\R+UA7<3R#N$:S7*A@];Y7N?I/S,871U-$=N*E.JIW/P==5UK
MT41I6 $SP[@NB-:2N#GZ+)<#>Q/,XP]>J/7@FBR8^YJR$1N4C989,LO0":DB
MBVN*Y4N=Z]_XZ]:"$DRIL<W1T'+V<3JT(K&&FDE?#<1QV*CTD'*9XK+/"?1:
MLZ[HXRKZ1M0DS<>A9$"0\NB"KZ=QL9UJG+P;Y!1SDN0#2UM+Z[ /"AF2S+<<
M$\T;"H;/@4BMS/ ,7J#G#-W@6W#7C42XBRJ!&%7Z@[]0L1KW+)K?CJ]"[XVV
M0.;XNN(AKC?&R(()NA9;GFKT?<'XUP6.!<S>2,(X/$O 'OBCSKH(;$H&F<1.
M3Z0<TLJG:W,W<>U$.2?./8CV6I=7>._H:Y;7/7$Y?ZE"77%L7*RVZ1X3_ ,[
M75G2=*S\:$S1#*G4^'J&].S=4\RA2;SHE,@36'(W<&9(G[=Z($N Z;Y.Y>?8
M[N(9TF)FZF/Z*A"UXWF[1_2FTY-LAU%"$(\ET!RCB8\)/TU..(Y0S-H^**Q#
MP=EPLE_7Q".AEU*W3-@%'9\A]9-UL9BRI8(AO:4<OPF-+W@ M!INCBK<H3E7
M[1NI2T.CT<?/1!;HX:X/Y1#PQRE2_I*8"V^?EX^\'ZK1V;.SA8&:H#@/R&8$
MK\6])Z332EF2V)$SJIVT'TP1)NBW&Q7B&L\6?CIA7P)/J-,QWGB(W@MW )YH
M3G/H1#(><UXKL!IEFG$7*!6HB=I?ZANHMM89/;'?1:ZH]-87,R3'=R)'P),5
MF?0T;N7Z$(T<A$0IDHNV@AZTXP!_?T$+84Q%I?K51^$(]C*_\RHFB1/6**[F
MRQES88=GV O\B^[X?IYI4 RJW(L)(WRQ\"L=??YG2ON0DT=&]BO(F6S8;3P1
MJH7&DJ/4U'F<?T[I,@'SA)J6V5.TY2EZK_J\QCOIL%.^6I[EXK,"^^1BK&E:
MWOOFT,1FI?V(%S-%M#%VP*6V=5*<7N1&]-1B\/;]=LR\LG2XELO$4G64!E".
ME1$RV6H-J#-248'TIQG25V;!TB(39([DT<@-T2>&="2V@-$7V#@MS\"_@D/N
M^1$2W/U)?@1JEP-[(NJ@K]XY%(P[M=C3,L?V\I+4%4F-,-'>\W] $W/P<P\X
M&!ZG8BQ[PQ%(H>JE="]4WL*_-,UH(<\=Y2\5QS)R+GC*%):<X$!4IL@3NIA?
MUR@7C7@=G,IPAVQC>^A.*#M3Z*'A6<80O&RT E*G] +)=FHD?,;P@&9<@0>C
M4",_G8 J(IOP":SLDL\Y+):]"'A& $1M1FNF+H7G/ 21DKJ,3#QL]N!.XP;T
M55;9"'TC%G+%G;D$]D*[2I2Q19NZM)@9+MF%YJ<*CVER30>A3#ZZG^"ZC9C=
MN&\99T(7B!ESB[F_*)_=G2'50-+Q(_0-^+K.#_M1WH'6&5+,1;_&6]]<OST<
M:ABS,]*QW=5Z5\Z@Q*LH(^;Q40[2/'7K7O+]EYKQX("??JI/58H^-?Y6Y([5
MMK#G&MN0>4:WLB;:E2)K<$9+39D>5V;2*:'X[/YHXK0(#\PDW2=L7;I8E>43
MHO+=V]-B7(CYIQWKYBX'\@"LL(A_QS-3>**,(VZ.H+=]>!$.!6B,GW EMOP5
M<>)3E[M%FUBM3.-KY(E_,G*,9S'R3Q#I]U,#*BM+T1HJ+O-M5Z<R"G:V5U],
M"B_0/>YR%?AL89=Q$+_*@J;NF&/N6_M^>Q)SB?I%[ R)2B>#)(U),M=JU$A'
M=5<Q;PW].P_%$LZR$13*9+OGASUEWQ\([=\T7!(SG?N6?W_8BU+\Z$59+R?G
M:,=$O._<BX$AU;=^\>6*O8)U'J!'P\]ASA5M@;\TW/&9XW3%2&;NLGVJX2=3
M2<*#J#/1.!9"T]+?!T:\HIK&$6D/5!4E?1$4HM(U/&0Z$(DD ,0'F=UR>(#2
M+1AS9R_#O:I!@-;PL;*E>MKEO^W72#'1$T#XBQE6JQ]8/D/JE$NZ)CCTLLD9
MTI+WO)R!!2)P'=7*(A9W>!0PR+$7WA0^&[[077R7(8B9_J:T;,3V0D5:2W%)
M6.ST@NX'QW0OEG^I^[7_:+MK5'5,9&VGR_J-7E^7?69X>/8,QM!=E)_"YX$K
M>WT5N/L/BIYYPV&RW?&1U)B]RW)#OXL]?>;T)VGNMZJWW1/8U@:%L=Q?;7QU
MX&DP_VG%EU;%NY<<*-D;L,>&]7SWGH/#[N.?5I<$^78$4;>KIOD=^(:F#U 9
M"%$H7S.K0PPV4"]AQ)?:2=G&+"_HB3A6,/TQ4CEA7$[+5!J6Q3=\-T/B3T*H
M%Q^_+:B IA>T(*J'$/[ZXKS4$82!EIAT&OEJ)H0<XW8Q)P_,D**4^&:FI7AZ
M[9"QV?!0//2  $?P#]$:9#*@;2P?GR$1>)[<.4/Z<\Z'LAG2]I\4N(W_#*F
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MT0Z9<C[=DE.NEF?C^Q\"K0PBXP%H?U/=8 H<J U/DIX#DJ-8NE@=Q-A5UYK
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MYH9(C2*9N@B/TI(O%VWMPIUB%E:@(9K!+*X/Q[5_=YYR5_MQ(-8(TBETX/L
MZ*5UW,*XN1P^DSD79F B/NM<>4.S_#[+<O2[N].OKMZ)&!ZXU\=,5QZIQZQ
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MY^46MG(Q5S=DY-"Z;Q;(>P$ZYYG$1NPQ(M&9WY#1% ?-),!<0+ELT@&@UK7
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MF*BM8+;8?^37S 6/$=,0ZZ0%MX:6.P7FB=N_N3GLG=:\1%XLFOU[:F)WG4,
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M+@5YUX<3*Z8XKN]2.G?ILD#^MJ5&):MCE>FQGLL.0FJ)?2,31;HZ4-F:!7'
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MW4EU<Y-L:>QF.SO1@[8N%/0:A=RK__M<6FIK@FO]W$AUA/_U((ND\]MR/])
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M[.J"M;:=M_M4C>Y17#:YUS&SZPQI#5F/YL5)SM5;QE9P>>LPP!>187%DC$J
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M-WV ;CG@3PV<4?61/?G/VABSDG#";#R%:F@MU_O:VZ:$06_!70'03=&)SEV
M85^*A07(SY<C1$ZYF'T0KH%T^ 34):1GA*W#\BF&\C,M0!#C^QGRCA6$.F@=
M]BM(*12F6P>VCB.=?K"J/*+HS93DJ:-A,W3)]RT2'UMI!=BXO] ;9$?)J'8H
M"BB6,'MQ5QEP- ZDI E@\Y@CW_=))EH-]U@< -J:KERL=E.5)6V&3KR)(!-]
M")N__.DI,)[=F2P6Z'A4A<RQ=%^ B!RRV<<,8?M;U\ %SP<QUH?1N&?20LFU
MRH.>E?9= ?FG V(S>9YW3L=::CS/'GI8GEN-%MTCY6_IT\?!,RM=-)(JJ;4H
M%E?;OK?+N+?TW-\!E6YJMJ1.9SMOSZV%)S$F@807(ENWL4Z5(&PZ"!QC<IQ,
MY4;0<6K\6\\C_M(KBAJ*L<JB!O<(3&<W2GZE."MJV/'T#+PI\J_D+B].R=+[
M)BA=1-24V[('3Y8$O:36D[@]+&>5E4Q[%(<ZWYX4$R_!;V.?Q](0>M1SC"F$
MA*?4A4J%=!JB]3.W 2]ZO&JA._K]/G1-NBBYK0'+.7)FM:=#ZU;$>R@-/Y+\
MUE\4P<^2QXKZ0#CM#$CD4K,QAX"1&9MA1V1L%^:B:N GO#@,]77866Q.F3-H
M72!'BMD%&"/52"^&QM20L-Q=?47/R):J:5S: 1!4<-^-I:F<7",I^AA O-'J
M'<U5FD-Q[27TS-;$>+*Y^.W&WC)#_P-W)HDYG;ZFRF[EKA>#G8=4&)17]B-(
MS"5V.LFL2%][\7 T4K@.NS'Y^09Z@Y ^9=H=N1G$<8_XI!]V@Q)K^R73%SU'
MT>DB@194S4%H[0*+7IK-6 *)R@R=CC5&GO/RAN2HIYUV[L@$3O)<[5>>,-+J
M<9/Z>.&A&&AR=*1(QUGB'11B>Z=NM,)#T[9@3X5[ &AK5'#R[&'ZWFV5KI>>
M%E(:<)M*%'[Y:,NG SR_-\_6C(*J\PM#?4+PS"$5TNQDV3K?F0_BN;?ICW(G
M%-74Q&/05X #STK5I_&(.G.#Y+/-X)=JZYS.A+*=]_M2X1GL&.I$M30&L,ZF
M6,Z$<!]WJ](K;_(Z]0>YET1@ MU:]@BW'&?M6M!\]&8A)?UG@3<9J6!3SV+5
M/E!ZJ5M;\3\HAY/(ORL>4,\RME+^4MJP (\<EA&4QOV?' 469<I<9R?[>G#7
M)S]^,)S9,\A"0F&KDG16NW .&3C<B1:\WS_G<C'^:X0'$[X+;)?K?3X*N8G@
MN1W%/4YY+F,6SD!C@\PQDGP N$7&@LPL1A_&4%$N@IH_SE&0S2""IL=#:*%C
MB37R/2.78L*GCOB[#]['L4=_G;$;0@IT! >H/5C(&IM+AB>J8F:K"X]_76E8
MP.T3Z"UU;@ $/ SRY0L0GX,Q(V,55>0HV;X/"27!V4B$-BF(RRNSP^P%J-E(
M!SAWZ^R:3[L$\2/DSV/9T'T&D$V/2*:A#(@''CR'T= 'MS^M;;/T+;01/ZD_
M";Y/-2('8N/-D*%G;'QNS-;F#P?4>.;=F!_.M_:^S;#XK>ENYSN6Z:9P8W_U
MJZ3L\>J,1J#EV8= LOOF^KA.;Z.HI.T+O@VVMGK2T?+LY!V>?CS7%DKQ,%58
M%[D52( TN3.:@Q3LM(K1B^I49I<_Z( .%3L9SX[A=5DV<A=%%L6:?!EJD.11
M<[P?$X)-TEM7\UN)-TR"LR@(TCZ'X!Z**2"X+E<7Y7D3>(;^<6UE5*9R'-M*
M7'P+ABO55QKF!%J8@^^APV(&_1L"'@'UB<XS*N<G&3GRM*I^V3ER*C153GFK
MM&UZ3G# =J<&=R?NEQPH!QT7Q :9HGYMS=XU9I8S0]LZGXR/IHK>HN Y]>LP
M81EFLRH;<U@[X@4J8(U?AZE_((5W6Y@HGEVR8QBI9AC!ZPIR<)'P%^,8.N=9
M.R%-_T%YA)"OG9#*R'3XALVS4 ?-&7DM6ZR:06=_@HE.85+TD_BGTP+*Z5XO
MVV;M^D O1[>H[-?&?0=_OB'\_?+VIU?@.I^,2HP>-+;MT]^W&&1H'/3H^C0Z
MH/:K>(?/LUY1O#MYN-IV.&#.M5(]X'H-YT9,IM2E),G#*.:@O;L>AO-QQ>8L
M9'\9G_7XLX_^T[U5-:+YH(?_RB-.=+N6'A^H7B($5&;GFS35^+TL0 8K#MV6
M#D/8QEE\TW@/?CL)*_Z'VDI;1 )?12D<0683B2(30= &4.\H9 AF+8CQW=,7
M^]X^F618D,Y_=1TB>XD9.J1Q[MKF8N8ZC).>%"7J"N+WL-33NL[^/$OYB3*M
M&J]./1%Q<B\UFJ\M/P<$T]=A!*=)G B^9 JJA4$O:B"#KQZ0YSIL(^4GB"Y)
MN=JY$:CIM%@U^9P[,R7!YWY!3M&SRZQ? $6/6;I =58G"FV-J7RR4 +*GSSJ
M$JP0[>Z(;+BZ!UW_N,7%Z1T27;',K[OGH36+(C_C#+VQ&^_U>_1IA!!84NAY
MY\H%\+_DWHG%';[^-1F5896H"T7[RG2V]M8^?>7W=TQ>@67@IX)];<&T\N(Q
MIDF\%]Q=9WN<^%"3G^(VM* 2G/U0,&@M9O:\31$M=U--R"CHJ(3ZOD_Z'-(6
MP6G;(/KQT4;T8?"E] U8? -C)P^'RM,/W3NGEM6HBHJQ]'U3N*$BTUFYILAI
M2\AD?$?"A-NC.8#R7@#XXJ\*C"L4]?*C@(O(NM<)3O94//_&N%IF DTPY>$@
M]1H1;2=$;"%O:@?T>QA92EU5!):XX>==6"[C% O2Y:\\C!W(SBY)W._37-9W
M%%BI7WN\6L0NN!3D?-#?DCO"&:WTTC..VN'^P' \24<_BE:*:BFR.=SI73=8
MD7V[QGD^J,(SV6SDR(..O9B?P /[X07<,WN-//_7-\(;K;$N%A5ZZO5P*FV7
MU1R"=+W@82P3C<(#-:>88=NC??RE-PD*E;-/9M]D?E.-TK7T)FP3<9'*ET^N
MOH*I?_Z1; ,T7SB$X.Q_IX,I5)ZAKYHJQI3N[.%JI;ITK\R0TC<-RASE&Q04
M?2C<>N$U,P.D*8^%8A4TL5(%!?[8DVM'UF%_?<VF+@;_N0X;O<,?.'*D[>%?
MUNI3QJ\OWGZ]4>T\M=HJ]WS97A/Z\3N4AF/4@UZAV.#_V+B_E/V/%3WCE'\F
M&:"$6:1R1*QHYC]4I4X> CQ'C8Y^+_\5&L Z:<H/KL-T\>,&59TN'?O65K9L
M>,6_<!2+\\6_ALO-S?8"_5*D42]E%YD@>? #V@D0[&H\N+':ES_$^LS%_6?W
M+PXUN@Y;P>?+UU(11= ;M@2?9*VX)L($O?EC'3:B/!SW*%?9AOWSAY>X'\G[
MH K0YVO8$$M/O@>B@_CP[YM%6A'Z"R@X%[$1JNCK&+LGZMK-*5Z35E9!_EZC
M3.=IG7>$^UYI76>D1LX+H8U+%66?7,HL*8YL/VP4G"Y0)\-E+LHI1K. CHT3
MF%'^LG"&5K"+PV(VC=&B=E5NJ)(/D\@IYBN!!:F:9V$%F"\BM)%V3D;Q'47,
M&+%7HG^WWWO<P[B.+&9,;2CTLM<$4]:1WECYZ1/4&:2Y(5@W@XL.)(UPN_W_
MX07Z9IX[9HLD_%VT;7]/8);)G8^1 0!0&/JD4C_F0-<[LU>_[4<+M#/>@'F;
M,A[L1=H&)5\8,?OLIAW49>9,D,1H6:J+YX<++/2;M@4(/\TT7[H-TNEL +<\
MJ:FR)DO>(%<: *A=ZTR3>4)LH2T4)NE-[7O%S*1N11,2"54D9G>9&9A9T$2M
M(%&/CR=';/3*0;MVN D2%K1+>\NKI_.N_!/QB!4#M'<S;I2A@)0;F)T00F38
M@S<A'X%(S2X\.(+D)N+?Z,0)Z1LT";HU']KS.\/+9]MG$,#=MN%0I#$_&ZFY
MP:!L(>TGK[-?<=_>BN&0+7&1!AJ*8Y=2ZD@>XJP,(#@$7%W*D1U1CF$U,'OD
M>,A+AEM8<\ES)L(H;ZC:2D-OX#,/8Z:XVYDH=,HN2<E6ZI-/ &6MXBZ=J=YB
MI2T4*#9&YOLOKEDN?GT/%0QG0;&JTN(.6<8"4YR2ME)P2D3C, NH:NPX^E2_
M.(A91UJ'2:,457(O$9&^1EWZ?KQ0Y/[!SB0A+I.]";-_EJ'S[?Z2%Z=C>OS/
M1HJ9<AA578 5Z1F:G$,YY;>$.VQ;#AVG6&OS.H.US"VS17\7)@7,?6Q9"*C#
MF;K[UX5KJHOK1JNS.&.5&LEU+TY5/7U7]VJ$NM1BOOL%HSJ:9'TU(1K4XR1E
M:ART+;R8^CPU(,DXG<3)-SM9?IWK6^:DZ]XY+WHJ;< VU.(G[XP[;M3UJ;\#
M_US5+R4IRI$X+2J'6"7_$1(\@79/0IXRI9X#5H3@V0G4TS/Z)AE2IS^=:#D.
MG4>L<L_)B?62XT#R^ZZMI(I [,2D6?LJ8_93.'6B7YK;"3&N *[#4@HTEPS6
M>3]%554 YZ=44<,CT/."3'Y[VCQ*;6%23(^)N!(O;W1\:A:C1M$A.58P+D,I
M_X;ZI>%/+&]+FU_A 7\J#:,&?.;RM>.H%A@[$N%7 "??2N]#/#M0^'!6'<1Z
M#Y'WRI(24DJ:!A''GP[_UM;4-*9\74TZFDC9.Q<D\6S*\QD0%_<8X"?.E5"?
MD'!*#6_9;HC.#2K[ 23RV@?1> D5LF0LZLK0)(:$S:/_H!RD[!@B'P:_2N-4
MZ6_7AS!$:TKR&'\J[:%TV2^$R6">]OX>"_-KB&S,!O!<R8&*VK@B:]XP=/]8
MZPM@:34B<J<XP>=QL4Z:9\J3FHZD-P_F*FUDJ%;A'.7?K96>?G4XK=*$YCKW
M@\DQCA03,^-N_=+=COL":CTF.E@S5;X:@9.^UV>CYMT?EYH4SH]5+Q+.!#PY
M5>W>";J<WU8->0'ATE!H >2+[^ UY#N 9C%YLNBF9%F#!!=GU<0#?7VI'QG=
MZF1O\:P<<: =I @\!AT=.]4K(8H">2B9#IW(NOVSYJ.$@0/]>::9] %GZGN\
M9)F'F-(4%R_B !QWFSP::@+88L->IQ]F^LOOX^"SP6/43?*C#;,6.\!T98TX
M7.: X'1L6IQT3IH;@N@A+07IT:$#Y/V)22G,!51@X?*BM%B5(KLA?4F^O]A\
MF8>?7 Z!PB5L316>_JK<J'R_RM97;B;_ +T6E<*ESU0HVRZ]#+AT=[F)+#*$
MG\'(.@E1 W^B!C*N3($$DL-..E I\K4<7Q__=+XD_]V?(GXN-18WY2'\S&%
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M-*-*OZQ.ARB@6%2\9,PDFT)[06XW0E<EY\W'H:E'4%JWRC7U+<'%\.Q(<_;
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M<6=("73CK*.F=FZ^QGMR37 -VLPV^9/9CFY/YQH1J>PVB6RV(US/C&O3L+3
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M=\4+9SHW2;WA'.$?#HQ^J1#Q]=Y/++ L.H96O.(<)8JL<8R-\O6:H)>:@[$
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MNS4U36MJS9IW#7OOY]W/^_N\?[^?]Y_Y3*N9=7_O^[[NZ[J^-;-6^EB!%X6
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M"GKF=9%F]AC"]2'(U;JQEE#B*388DQKE,OJ\=H>OOH]QL1DY+S#2/\75-2@
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M-)O,Z1E6+_%.X0UDZ'H\ 6\EJ!,9$:C7TA8LI2H"FRG0 "-/-4!&8C/8?[0
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MUNCIB'^@WV3?7V,6SM-.6>U'EL(%GS*+;U-VY]N4[3FJ 68>E3=,0O7++VN
MMG)F>WNQ"S[MH/A&'W9()#LW;F5V)EU(128E1PNYZ)@Q=M&Z_D/,E"9W[]L*
MFS$S]*B?E8DEZ;IJ+^8JU@#9A"@01TO!BF^1\0?VEN[7H]:AO2I\795'B,4Z
M:*< G<W#]%9X>7^)EK\8UP#G0CRP>CCQ(UX[G!*FEFH_;,U2/02SC^/R:/3H
M^$0,#2J#BD.0O<L<S5S&MD!+LW7Q-N>=I<5YS6"RQ@.@31J 57\=:;P:V[*"
MAQ(L1)(0'*QZVI%_5KU?U8U-R:4,*YW!ULV0^ (/WJ8+VGS9+>]D4G+KRRUB
M=3"*P72:L&0@1S ^ U_ :<12#HIMT#F#RG@D5,ZLG\L\P;6F,=JE"\?32=:E
MOOM6E]UHE+(R&21Y4,;TVRL'K[8D^@XR"8,A@>JF_%%UI5]BT>Z2NLB2=ST[
MWF%Y[_H]-WB$,+<Q#E_[14>'IZO#CNJW?_3J\OQC&S[*W!-/]B_?\/2'V:YZ
M!WMI10T6_(S[*^^;W;72G>63;>M23%I9ONPN6R\P<G%EV,T;UZ,>Y#SHC?9J
MM1,-T6SJ#Y4FQ[B]N:5O>67/8'!=P-/GA8Z[C1>WEX2D1/K9IBSNB)O#;[(=
MOKC$9^!QV6CWT!QQDO:ST@_[!+PIM*#6501CVJ XOG%X*A)6?[ T]#LJZBT5
MIH4M@+&T</NQ+V=W[%@?7QIE<FDD+(P\J_CV66',RN7>ULQ1O*UI?E"=C_VK
M!:)RBF OK</NI"1]P;RSAZ(YQJ,"VS_,=_P8?T;P,JO?$QRH6YCZR37,;_F4
M;;HN,M*1X\]DNH^7.QZ./?)F"JUI]5D_-X5UH=.Y9HMSA4\^2OQ<!4?*2/LL
M%IE.RTA=7:978;5$:G3=UHCM0RJLOQE8/#<W*O)S#CF(N2Z[QK'%1?J8DBZ0
MQ<Q<N*DZ^\>4A:>VAX6<;0A*B:P^U]!^M3=KH-A4-\*DX^*0#;8_ IN!L\$T
M2TKMI#D]QM+5P_0GSXFD^PG?)R1.X.QC4*9%'>Z)\N@Q.&F$@=AFCN)!SD]K
M&7T6LK-'$L8'FE\Z_J[>!,+9"5Z.[SZ%L7+'T,FD4_+,U8.7]OE,<!(MH^D?
M*"WK1BL5B<\NO>'&4=V.:YE_X!,['.W ]_*=/'@K;\*)G TAOMXX$3[JPB,&
M0W5>N,*\D^'#5Q4"8IM681=%<#91U0L.G]3RHS-+M?_K4YR7'/>7TA_:JLCS
M-$ +3DNS5>>@5R)7W %\#02VX@:B#G<3XB*S/J4S@OMM_?6G\&0HK(_M.'_Q
M<>W!J2)U-2)K GN#LZSZ*OJ@005.)%3]4R[,[A^R>7[@%>N!3=H[*F"7"8>F
MZ:IBQ@2*;VZ3AV8>XZT16O!L[_6$_83+#/%-Z^B]WP3+PJH3K;C>WV0&CWU#
M RCVBRSP597LPA^:N0>TK*UU*1/X*^:B1X0<],<!_!=Q6AW(<D G6:V\R\*!
M/#+BI8M.,G!H-71^==)@?^A%2/R>J@&66N."LP 7AR:MX'S"Q>'F-P^&6^F=
M8^HS7!?6Y,5NG#T&P*\\"4TX4;*)WZ@3UP"<VL"^=V,0MHCYGQA:N4Y;J14<
M'!7)1WG?](8\81%!00RT>D,>#?Q[Y9!VX0+VMX7'0O])E&?A.HA35#4TL@LJ
MIJ _X@S8\B_'/W!291(^"?XC;]N^6CH-\*K2%C_AY6%LTS=_8!$!_14MX)O!
MN3\X.8]^1"E,T2I)_U\KP"6/@;N>904@O(S7QL$,\8TIB=P+UB=+4OK4%GWL
MH(FXOHEO'AT:M7_.@_>O&;O\7Z3_35P>_N7]Z?@JZW=!!%4B6KMFVS_;!\&Y
M%,R7H[C]#0O$%QI CF>S#.Q[C^'V+5V+B;2O<NW_K7K_9RS._Q!+M>Q/PZAU
M.JL0"7[VZOA![69@4&V;EHKW)@>I5&P=4N$#^1UN0UG'"(=,P%=0X2/HGX#
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M]_!1$<AT>7:#MR;_YD?5OGT5E2I4V#U_\^V;=WD<;S9U;8,HQKW.S..BSHG
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MKOK?A$OZ4A.D9IIHWX)MWUST'"?JY"!EH!>O AA34GH@T/%0=#I!',<4II-
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M"?_Z#7/RN?]YP[L?-3) O\;I%QB@'RRV#-!HABFV OX;.^U-MPY>X#MZHL4
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M&+Y4F\\U_B P&*@50CQC*W2/JF=QUL_\O%+#=9'T29%GI*<LWR!,L/>TJPW
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MNS/H>U$]];^UE/K?1L,;WO_-CZ] R?]$>+J!#Q-FCJ-/8;@N4&&OS9*>Z\\
M*3\M?F;PVJ40Z081.79+V,(8M>?;6_C\I-$9LI6WR$ )/&(B?O<6Z7!#]*#/
M*<.*RA[?*"W;'2%3H5WPY<-*'B%AUU/=8R1X=FK;?#0@3#RPMFA=CO[=J?]C
M?<>EAL-G(=&(KPR07J^- 4_A&'5I0P)2037L88!.$NY^A>S]O G@CY#!5(.;
M>D$+F0.DYKC:<5*@FH2ZQ)M@ ;C.&LR_\XG8(]'5I?Z6J3%XU1I\[>[(S+V\
MZ9N!(3$:/;:<,57V+Z2H0O>)\RM5^DZ]+@_B.'K5+%>%,FOL]QJ51'SK)OYL
M[=T^7A>>8T[3Q:*D :M>E.(1Q@A=O)IKT)N_X)W0JH8Y=$=-MGJ ^8STW_JW
MHJHHP\3K*=9';U4+:HT,#FQR:V#A?T,\_"_4NR]NA5ZWW9$7-QRX\SK^FYG&
MI%WAD_OL8'MSMKKUC=K V\E30]6J-1OSZ1RG4ZQ:KIV.GM4CQW,XJ<?"A2_&
MI<MG< C<+_:GAOS;WJR6*AS.Y5P,LNYO%+F3'^2NEE/G*=B>\]C+)>;S^_=O
M8XDDF,Y,@.EU'3'>N(-QC:+,GMN5U3I@GBK'*GLG1_^QV*ISRI8E^[7T$-RQ
M->)W!FA]DN9W0'.D."NO?-Z/0$/II_BN;A<J0BE?\.J=R;J)?G31\ACC?:_'
M^7&<<S&O=[D@;]]=NO!O BGFV(P7)@WYE1JRUWZ$P3,! T04-S!#99LC:16J
M#CLX?L<%4MF)>#5*<V?5JSNCM0TMN$MAU 6G[QMX[GNS.GFKTT>G.@P8H(Q0
MK,2<<8COX_)[X3GA[VTZP-=')+BE$GSGTR]^IW]<B<E*O<]F\4X%6]UH:&AM
M8H-K'%51WPC<J@ZNKCW35M]>UY;DUX!K^/CT5SQY?%74K6;S3'C\O5=WTB8Y
M%,9 %Q0TMR_*+4'5/4#0!",^^XC"'TR2E[Z<"F$N!C%?7N4[+5!88'O:UYCK
MCW*_*>@BO\*5)TS+(E>>]BN"(NI%(;\*=_]L;6 9((5F:@*]0Q)-+XE0C;+R
M5D5-,4!_X&AQ]#K3<36Q:E[TG7W4XC\2W?^D*+URGU/ZL@+.:B^.>@H1.;^4
MH4:&$G!#-Z\V.>J_6J*>^(J/K^)@?Y![]ZU<HI-%JMGP^Q]I&?"L6)\^FR.H
MU,27N08FR:]_N_B8SJLAW:C*US\2FCUT7Q4#0?KJC4)G>>K-\$BAT"F>,S]B
M7;!@Z.N57_LQY;J2C>]4Y$^YTZ<EG'-.8I3:?^;WM)DJ3,<G37D0S+N$862]
M8CDG<GE\U\*M5[?GAS-S^,X7)W^[>+Z\V&OPW*_PND;?<$I%I-B3AG,X51*8
M$W@D/[@'B2E9R>3G.SB\R7&VQ2=;2FM-%@\ZD13 .S;C=.[RY\Q:3KG?\?J_
M1$F73R7V>UTLO,"FM!'Q M:5IA1ZOO.*\/F1MZP-'B]@([&A4_T*V0U1?,R-
M$3^JS11%$K,*9462NLE5_<UJ_C_R=JO&8/CT4C?;\9*V,]B_-FPVE_M&GTYK
M+Q($:>SE-'/*HW+25U/\H-;STF_/WST9T'E>XZZSH6O_=)23?_JG2N"9M.=3
M;'E:H>$G\:_L/G.?8?EXG?JZ=O?G!:;5CU*I(8,2[[I)R^1WSL2)LLHAK(UC
ME7'5]D@FK%<7GN,<V LKESC7,&*1=^LBHII-G3>]<R('+!;3;=]S"][3N%XU
M%&3WH@9USV)*^_1(:D7K,W^["CT"/R"[T,8 "2\W1_ E3Z\S0/Q&? @DE'RH
M_Z@ZRZ-#/G[0_0D/>_T8.6[1;8%9\:-08D=B#^8AJTPL^*W(GXF>(T4'"E^2
M%C:]4*(^9WYY1?0Y5=:B*2T&3A?^F*,G9'\A3@$^([QO+S;UY5;\E,6GI@\\
M!+-[K668ZI6#H)JR6>/(6Y63QNCR&=.S=3-N/WO]FO*,I)Y];[F[;^QE\O"D
MT<\J 6?!;E_$Y_0R3:9/)'>7Q;[YJL@?2&109F!%I)2C+-HGJ?C<0*;(>?U#
MG$D<<3Q=*/$/3NO^I%?$VK?:DWF6$CKA%O95>;Y2'UK+C1VQ*BA'[.<_."_)
M5(_2Z'?%C:;"+G7([W:FPJ!_M1O7I*^!O<Z563PY%KRDAH@/GZ3[L.]D2GCR
MK"=#"58-C?L-DF$_:%G'S/L!W>FL90O(8V,@G(AR9P!,!J>'8TX9H<G>+"L&
MN@FXP&($_[TT$IK+$ZC]ZT 8W:U1=$_^[=O4+)JS=^.F;/\96.IGX:M1<#IG
MW+&\8QXBS)="Z\UI6H]2*,WN@*$P5- HBC)\V'E,-DD[6+'9FZM>)W C)(Q=
MC.?0>NBT8=4E,U4SSN+4'T3MAA0YP>"I.F@_NBEXW9>23^<^0X5V>?.ASOAC
M^+6@D]M[ME3;I$9OP!8BBL@9Z9KZFXY2 7*)F0BX V4QHVKN7MX1#B_S72L_
M.HR[RLKQL8)*?RC%WR!T;PY)[V* W@]VV@**&1V=AU :*X[ZFP%Z.IB&\Z0R
MP^>2('()/2B%%JI8FE]#Z[A7H-><Y=!MG?SUFO'A216Q3VENUS-%5;T*(A!<
M^F$&&L6IZ>&[+\>J= V"3TBQDB)"Q]1LX3R6+F&/R]$1W-E> WG:R@9UN=K0
MRC^]%VPTG*2=%,K5X']:@ZAV$<H*FW\AA+'&4[R*-NUCVH;O AHV=(8WZ?0_
MI"YCF*\O7/OKS)=O-J+G3B=;R/MTF :9N^^K[]T<V:3!HA88H"G9;IUZDTJD
MQYA\3)?.WVM%GK*DW(3R0[&$ZNB,W6#TV5-5'6]]VC+'N7OLEB["H/Y1?@Y4
MT^9H@M\@[\]+A$2\UAJ\?$WW1HA."F7-5/$&%55QSFP./*7Z1B=GM4L+%^NO
MTYGCQ,4 .=PSL(Z/*8-%*#P/4&DH %^O']X9T/+\X/[#]>;TU&0G?]_/Y%DY
MXTR+,TE[VP=0FT/=E7:"YZ#.H/1K5>AD79R:[[G#QA"#G5SEU.K=SOE?4P\B
MG+L?VF:7%'X7!T6 ]']15R.'ATPM-C 79_FA 9?X%,'45+KF<=+U=>ATVAGR
M97I9%^>Q>?LR]].LEB46EJS":/R=]N,DVO6]99#F8YZ:00"+( 41?Z7-MZ7A
M?W+W8IL 7C)T:IO.I5V%&L8T#'9O/<%+ >!#5=2 USD@C,P <=&/LX08A..8
MP0(CB82&VBHR.A$E2 F.A<@!\,Z#K<2B4:3F&_\Z<RQ@WJ,S>Q;W?6=#R&5$
MNUW'(C3RQ4Q>^P:L:3CPL%)5+C=<$=5_K[#)97P<>.T#UF\V+)^4%]XJJ_U:
MHWZX*F%KYI#><IH!<N=^L[H*J;YT;7>7-<I8A$9",AVU0P.M0TP "RIX(3R5
MQC3/ ('O01O ZZ<.)6FWCU(:U1,,S!-POF2H,'T(6L^W/DT-7BCO2;/RC#+%
M!<_/R="@XR@-VE6@LP01?N7]L2R$EZ(&P:Q&=G L +\Q@=6&2B,,TX?1\T68
MIO17\U V!$MW7EG[ CC#6QH7?J@,&X_():JST'OS&* $(_ \9HJE ]T0GA)$
M5Z!_AHK^/GJG O4#IZ#9(8I ^;P6F)=PUPH]%>P$/*"FF 4&\?$CUH@$<6VL
M" +:D9G^-],9IR_5/!5TWGVZH00++QEISPS4RO_M[)*KX5[EQ67C,F&ZB7=>
MG\UI.Q:T(_=]@YRRGTJ(G_[%SV$D$\L?LFQ>8X W/(K!J]!L@.E#380ZF;W7
MT)9OFG8%TPT502I7>P!P)R"XZL>:LS<?1 VQ1/J;@#.IL*"@R2Z]X'@#[U3M
M03Z$]_51R&G K]-;$.?V!K#MJT?D$B-0;Y[!8+# /7D'Y\!@/WB-P\[[HOW,
MJ DG.*3*Z]ORL3@PX:)=.*;!%&!BOH@6-4IC.G2D!5(4.[$QCQB@#YL5Y.!X
M+Z&C$C1L,'&.B0&ZBYTR62C$+@1+K(0 I[PIT"=AP0D'Z#Y5H0Z\]/>&7&":
MLM:#4@**U=Z2YI+!7'-$,%N@?(S'&,[Z$$-'#[K35(_?EH#8'.C -.K&G 4:
MT=0L+\!Z@6_RSV.(.*!,4J0)_SWF*HKMI2M$LCKQ..->H0;WS@DP0%VJX(V;
MARJ(MH7 ]HFNZ:T3_C*GJ3*E58@,(H%=RQNDO?C<UQ>:BO.L7NG;+]V.5'<9
M"CK@-?3>.BY'U3TOV7[?^@$G91S;3L#4,T Q1B:4\OD <#U; A5+]&("QJKI
MW]RMJQ#H+N@)G-L"-![%F>!%48\S.L&61:H1(ZU+!DQYJ))M^99E!"EI9<4+
M,)P5><:%F"-SGJJ ]ST4/!:XI$I6('+^WH3-A%9L1B=*V&D89T?>QY\&,-=9
M3$=>N"*R^IJ/)QU UYT(>"XZX7P<\.>I*OAS^/@%#S0_W#IB*GOPC4,6;NG7
M8?.<=:0<;N-C 30:\L!V^(@Y^5R)J\N =Q.!EC?7"SX$P1B@@^?+C;NJ_Q??
M*11=&" D R1?/B)4Q0#AT9DCR_^G@F;*E)(52A?>70$.7;X<//460(W*2#1>
MM_:C')+&2ZNO#463>8.[__99N_[R5:D@6/)_>[IGT<A2N_QC8OC/$Y_[$0+I
MK];Z+AM?BF#!6.X7SR_PAI/#^Z 2\[B'B&9;"J3@ FMO$_YDPQ^U8<4367?J
M?YJ>X5H*J7@0^T],US=H9&+_A0*EQ?<]HQ8Z1SEV5YK^6<^,L!(PDM?9* K$
M1IP'.Q'1ZS]L5+Z&IG3>_R;+9!:,( ,9X">?5OYL/*X&[Y5DVNR%G?HKG'<0
ME'P.&[I_XQ@1<TYQH,COM+&";@&/Z9FN\0F=D3,YIU(B,V8\C+6,;WZ-=_5<
MR-$HN9;Z:>Z\]I^MKK443"R:7PW%#<\5PO"L6;]#9) @Q8^5GZF4:7CXX_GS
MW#@%/5<F^!X\",S$:A3_['^EK7PM=W5\9:YR1^*2N5%$V)[41!KM#O!8L9N/
M$Q<14%,&-!/_7H#3N<9&7]X=V3V4$+QV5G/CZ*=!?*>OIOZ?8D'3T-7%&>,_
MFAZ0,Y7Z\6Q2 *UQM,KR=6BA+K?]>9^'OQ\5S2KPI[[3/VR@.K[[MF(9< "1
M^7+_Q>_4?DW_UZ_4(B6%X>.9+XI?++X,=WX,09\0_VR7PUQC^2/@81EAZB'R
M$9377C-;1:XB\G2H'K%B\/H%_?G""X_GA?K^@8W]\N: G#6G\G51_,4>I/ )
MKKBXR("I\6FG^3U@7G(CQE:CF3,9KWA<3 +'<$$:S[_<#K!E72VL&^Y^4W\M
MN;+ZBUMTG!/KA]O=(&%F"[T."2.7M_'=0[VWELGO=V7MT\\JA9;5UI9,W7AQ
M$^??9>E8.0*S%'EK$,1E]\ + F5)^4QMP;6!K7[X7'!-?AFQL_^B^"N[F.2+
MWZ)CEMHKCL6)Q+&4^S4)V"OM^C;9[B$O7CB8O-7C*?F5RLS)&O9)^N+<I?-C
M=;#5/'@KK+;= 5Y\B/$+LEW;G-M<%;8SO2!IH[,#>BUUQ$G_APMHWBL \LE?
M_5R_$^Y"8URJ^'J\DT4SOY+5^8D?%P WRB?-GEJ@S>XYQR&D&!VD,+)C>)\Z
M8ZU</V4DUBSI\77=NX&OMUUHWH\X<)PF_467W,9K@S9HT'D,UU1"E%7/K-88
MM_G;99T+?:]<+=34@LL2C9ZYWIRQXGGHP:&Z2(+>!4?GS1%G%#VI?[L'$G>Q
MZ5#1VMM4Q>Z"@.R7L( 5PG6*3I::Q.DA(]5 N4=GN1_!8;7%RMP0C&^97-1+
MQ)545)N[T@.7>-'41M=D!FA[/S1;2M8_3+MA<:5+E4Y5^;6/Y6B[5++[UV%V
M1K^F-+_5NBFW#>T'.% &NS <2$X2(8'.]4''@#TA]%=C\VS57M7AJXO:>S7O
M/E6615DYML*"U17..)7FWH%)7301CCKZ4L5C9HXHOCJ R](HL>N3U,J\MMFM
M=/:L9GVA@+%/A[8NE[X>*$QQ/\M;&34VJSY6@Q0H0UZD((ET(4*:Y#H$]-VH
MJ!?.J[/QA.K5J'&V/E_:T/Q1(SY/P2WPG]$[^,M=7[__F7WXHMS>OD*__W-(
M5MN+DIGI]N$VF/O>B)5'GT12>7272[?--ZWSLUKK&*V"MU<RDY'#87#+ KUW
MY;I?=3D^WZA;9(#\XK+(S=V8).^&H&+AKZ6K]3]IAH"EHO/YP/G@DUYG_0\:
MFS;Z^6AR$63.;":-S@?!U8F+"'4OK4.#EBUFA-4U"C@.:3@_P\;"]IR4)CI@
M^H'GC='S'T3AAQZ?+S/5!M^="PD_KS(RHU6OKZ&5.I-T.NQT%*)45:;5S7^S
M9O8HL[DP1V/@?GW7/RL.-6K(ZS^IXJT9=*_;'S3#UJ#7(BT=SS! -I31K2U]
M.;OK@KW=<<\Y6:-9SI^N./,41#%FE=HY^UK"%A2S<WIGGFZ.+8]P\9RP[0LF
ME*-R#0=?J3% __%)1.*XCA^E.(6C%(X*\2R(D3YW: ^?.%($L" 3D@JE#6 4
M!JC;6Y"F37$F++1S+#?;>RWWF5-1V+>SB)CK]$\?\Q[O#'[PYS_%69X7Z< S
M+*$<^Y\/7 CKD[3C5%%UK"GGD"A@<CYCLGX^HP<[Q4WV'?N=0<R(QIPT@E&M
M^EPB E-6\ZHAHA3%A# ^P37HI/N=AUT'A16JZ?E:DD&OZ[HF)H:GISG?;NL^
MX=Y&"@,F(52=O@7?P:ZM!!>HI-8@GQ5)U7#A1-]3W'G='D,^KI\2J72).B#Z
MP 11-T'</I5$VS@[YYS>:Z)53:FWDM45NW6H@!K(<XDU0E,.KQ^]AC##9IF
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MP5@UCX75EZY,S+!W_!^DO6=84UNT[QVW(BHETGM11*1+[\E6! 0$I#<ATIN
M"$B40%2DEVRZ4E6Z$)".E$0(14!!NH 0DDAO*PBXD!!>]GO/O<\Y]]SW_7(_
MK6]SS3776&/^_L\<X[_,$B<+F\NZMAE0=X"AU J0B02K]=%VE@7FB_W)U/<T
M7:"I#!Y+%Z4I3\Z,*]M@@=]]_,[U)'_7I>G%A@GYD/C #6'RZ+II&R:GAF<Q
M<^U(5Q++/*Q5<;/@,I^*^D1)2HE^Z65D:-*7ZV"<2Z4'**52;EOFT'2Y4.;]
M6#2_185%E9M\@(:<(F>!&)<)Z>'%M)?4P>E!YN4 WY"'=246Q4$<5=FR\AY7
MT_TGDWE["D;*_6::>P</"Z%(Q-W"6Z"/FW863IQZSR(BYW>/B?"87#RI5R+D
ML0QV<6Z-G8%=?]GU625+'VY%TSF:U*$Y;#!ROW8LI(V76;7I'\7+^F_>RABZ
MC@Y*;Z<]6?3*>F)\>^O+%]\(^9NC#95,.JI])O7UM;5-QG[&M_V+4IB0' *7
MDR'^;TV-A;K;V+><^MV*]@7@!WLGB@RO< ++*BN+KV]]:/3UY%TC.GZE!L5.
MULI&KF6JX[P7/BC_)$X 5L4_*.=VAK!AVGI/K IE;&%BO)4W>9]RSHLP&EF$
MK*CF+:I1;;J')*4F%MW)<R1]Z/2WNXF%2O3_0B/_E4V\OC\XABQ/$NFT$_[L
M'OFO\]D2-/AJJZA_#&D2CJT]P7D*7[MGI#[S]4@I4.9TYI5'UK$3=J&,3(>>
MD8.1?$>->$],PC&D;CB9%D$U(Y4]IRM[7P0->N<E0(6:E4A>\+G$2X^)AO5M
M-J0KP9XJ$J.-*'%<*5 =K:IN%Z$PV>\*E$ZT7\*NYV@:^A^]"7#U[S;O.719
MB720.GVHA/SLHC_Q":Q<Z!6YUK7W6*/WR4)2WJ%$CWR\,Q.H (R1>7JA\9H;
M,&XP""C[-"\+IE,9NW]-^S[-@PD 9L]1\')D48_#[LSC1*]R/_Z7FOK1)0CB
MH$>)G?.:K>&I%[V3X64)$A":R-$S^,(L_'L]_7SMX1W0;+_\* ^F&CG-!FX3
MGL(34$H5R,!>.#N,QQ<-I063S'B\FQV<RTB!0MXYT$XTRUK.4"SWFQEX@O*Z
MG4J;:AW5-D9;#2N3#,OF@W_K9#S?BQ1="#E 4IIUVB*Y#C(/!8\AG6[HA3P$
M<%<D_@^^$SU]>C]S#*= ,_W6SE)!,YR@R?L @Q2S*(]:P#2Y&NE'R"EMG2GK
M1L3"V+\M&IMX]<P+U_GQADJJ&(J8&]X?6W[!U!RU^YW]IF"*@39;2VJOTF>^
MO>5F!Q,GY7W?X:\Z_ >5-:_R"XZF%G9A-UJ.TFCP(/(P+_@!K._V"Z7(SZQ_
M0C3VS.5\]T%XU5$EGD5>0%T'Q3T6UNVOQ-U!Z93[B# K'SW:.<I;&UES*#DJ
M5FQ,Z#EW4&]_#'GA LIM?U(MX!QK#R^?]\MA[!EF1/D"*944_-EIL*9KLD :
MR'Z."@7Z0_ZMGS'0I4*?AYIQ(,,M $QW(&>1@\^\*E!:4>J[;#"I?&0SO;LJ
MNXW+!LPV"8<P)(7 /XP9ZW:6!"2Z-IE,6R<"Z-=1'F 0A?@"S1@@(]MN!HT:
MC5 B8WH"H4AXIT/\N,HTI6FDJ''2V<3U]/XF3"M1(B%X]PGX?$&EWO]&NS^)
M[7ZT]38F;C>TW@;-#$_^IM+?L6.%C[J<WK-2>J<YFA*!\C*T:>,N'@TRUB_B
MSFJ5?K2ZX]QT,RWQ:4-.3@'6&4B^78+-S_ U?"(>N1D9AN(_60%/FCHH22WK
M)'*UJZ%)B5AX%Y8$Y1 ZNTYBC,*&3H#9"\/3RT9'K_U#B8S([#NX.F#[! A]
M"TZ-;*A4XD^#2J2CF$8?\J]*%@DR=_Z""=H9D*OX@[:#\5'-8K1]WJ[.7P7"
MXAKDN9%^=LV'SJED$1;?2?ZMZ/<S!W6? D+F$,8MK6/;;S@ZE:\Z.L;?->9,
MS6(N9EE+>X&7/(8\P(#7'M<?*J!\QR*AW^?I7?-_-;:!YJ3M^*9YM:-6>(#/
M,<0MF:.7!7M"I'3N#J"Y2TO:;/J0<I=ZM/W,MK/I:7-WY4$CE!G#-(.Z 0:S
M5.=7]56;A;O]J45@1)KP4<<0[W^[(+X-4@G[C\# 0UOD^V4$>)J$.86Z.0$[
MA5(Y62$D2A\8*O$ ?O42.5%."T<P^MA^^U$)C(EFEW@2R' VE)-<;BE*]5M-
MNV35*DX^8=;BXQ1*UZMT&FEU>@].PL=?I:*?T03(Z[F%YYR'R87G0*_N>B(-
M1KU![7M6XSD5XJ=CZE=X&IQNR#]%<ULX*%CI)V$X^]^LI"%C;_D)N>Q6,K;[
MW0Y/H Y/'_9QPSEP##0!$%.RIC:#RSW1X-$B+#2_,M^GU86D(PF;<9EVRX4C
MD7M-N(F0X?-KFLTO=S>-MJ0G"HXA9@"NI!SYN&MSJ6ZD9COD,#P\7B<E-E2C
M9C'=>&@&T6R:PS<&BBUST@-M<,Y/?X]?>Y? \G_M<\+B:67S6-V:X=5"'D31
M%'*%NJ)T5Z>;X?8OSJTS$'A2:M?I)'9B&%^_A)"O#Z>FX@?F*M6ZU'\&3,^)
MOC@G)IH4/(J//H9$$9OE>S?A^UC0 !J/]D?,.-ZC/D T1WXD(>*)IQO1<3C1
M<6TM/P!'V$^F+L>JB+"N(9B'7F;]04?OXF-G(IZ;#)]1;;6NXG%=_' 55H#(
MM/I2OA3J$O^)1,I<G/BE?;.77$$JB7M[HXN#L/!6RY@CN7RMS!AJG(.]W5LF
M(R*=$2F=I+XLM]!NR^@2S%P6KZ36V^[T;&&#*U*D?VWI^X-"OE<N0:\:<ZDJ
MOJ&28_WJ@>>-&<53AFKE[% J1@TNUC>5EM'?#3Z-'=52$,F1JHOO)MJ1V@HN
MTBQ]&\+L#8?L<3_7%[7,^""HL@M]S-*KV:)B[NYNO'_RT X'O_9]/SA"7PI#
M/^:=?D(^5T,S?W+=12(_J-J7PZDJQDJF+CU@\K-3G*=TVAM AVY@DMSRC#/@
M"NWMS;PMF8=G?P3TBS*[4Q%BJ9859M>ZVHTR!?4OYU%?E9O"AJQJU?]D4O<H
MUZR,S/,U7_69FK_/()=W6AD9&:S1$'%%B/A@)&G-$ONRT^9MQOUE_8>5IJ4"
M8I\6'OD^*M)\E*G94*G=BGVJ6"9YLT3&1*-S0.7RXH*S*!-Y.$68Y=O9*V/M
MI]XY@X.6F+18FW'BH9)>,MT"-N;?&"A;]_=.28M8)M?V,.^U <9[(6M!SV=/
MO]D76N^$G:_9W^Q+B12[<SZ0'WQ/UI%\?1L.I( /A<2,^*2?\?8]7+R[,:#O
M^/LY=7LVN^!I1$00[>LC8-Q9@BGQ:VEAXU PLZFJ+#%'7=QR;?J!K/2 @MV]
MRWER57,&ZA)\8E^^%-96&C-^R1Y_N N,H?J)W$6;M?6C:]ML]M*R'06M1>E4
M^2B:"KE2S(<L>X%@]PPB=NC1VJ]]6EL@O&0Z^ $A2.M-EBJ?].^'TOUPDCUR
ML'/('72D)%:&,V@5 >ADD][&-[%N+U^,T@+'=S_K<CF5IPUT;X7_<YYK]420
MP\1 :5)A;$"[,05]\?L*OPGNIG'(UI1:_9M?# 6OW<Z%SYGN91K+8I.43&J=
M#:P3-(1@!A,--8DBC?.I%=ZMC4WU0/!^,%4U-[S8MXEY:9"<W7T,8?7C'OV^
MQOVH09&-) +US7E03Q#KN4PT\7_4R6/]?%1OJ\]=PU/S7?<D01.YTM-; #]O
M@10,L<&M]Y"$^;%VP8;]%MT#."$S8HCGCXSVA(][=UAN+Y03%6I42XY>401-
MU"M@ML[MTA*QGRR,[5U]K<O,NQ3MGJJ\UY.@X2+'T< ]! ;!B]-$>8+B_Q8D
MSU\ H!OI5/.&PNG$+CA7B*P%B[0CX-Q<!.8<WJ$N;PJ0AN.XOS5NSJ=21^=_
M]2!88)P&5TM8DTGYNF8@(]5H=+^+Q:WO<>OR!I[&X4:_(!)!95R@'4,@Z5W"
MRN !-7??-8I0P$HU2$(QHM\@LTVI4P391RQ^=,["GD(V,('HV)8EP@5.$9R%
M)FEJ5&X3TX'.1I$D.@1\'5%\0RUV:4S.??\0 5X*H[$G#!K5C5X^2L2)./G,
MA'9DYF-3RLCH!/Y&_/0#9A,_AE'?2,U6Q^^4Z[?L R;=,WIQOBV\(B4%4- -
M^/5)<:Y_ 1$[SP1HYQ3I'=5(1-$DWR!=&BU]L_\::;PZHGS(C>/N):/K(XH_
M7WI2[)W)E.[L^%EA%]EVOINSGN9_#PMT*\J@65T!I-%N+5^UR/6B),(RB)JV
M*4L@V.:?(U__OG&AZ\BT0<-W-*U[(OW>M,J=HX=+/IE!9\6D*W-MR4D$]?[Z
MJD06Q_-'N:FN/TMB23,'D3J3;Y-3G,Y;%>DJ92("+3@,1RS*GH#7P,;#N^O7
MX!_P'BT-2'>92VW4L)Y EIO6CR+#DU4'SFV3"-*2F& -!B'[(M%F\F\:MU8G
M$;!&SVB1IEZ<L'%,8=TF'@.#@O,_D=N4@$8@N <-+2J\*WQA8C.@G0% (P(3
MX5PH#NT_^E@R$@L319::0'4[ZMJ; $P,30U6%NI"AG+X9!6.KD"86:.H])"D
MORW,(&X25^Z[N_^\_TRST/?/ROA^@&*2ZT=QOI*Z %DMG=W'ABO;C7O:7_IB
M/7+O!WV,5(*1+X34,\L^$'KZ,4"))<M5S(#-M(2_KFN2L#BQYN+7&NKYUCGC
M8+6_HDLAPQ(]A*&Q-^^;'[U1,9NN[X8SXA>*$.=@\J"J_'.E6:36@DY?CTB\
M\*DIFIA:)^,W^BS)6,L$3CJ&8&CN69KX3N-U ?RY?K6$:MF09-U.FX*S64Q.
M1F3H18' 2K0'*G+T&,*^Z46-K\60##8(85=S 3_"XU;OT=W"^-:)DHVFR4(^
MA$G*.?^ W3DI7JSL[J-^!<<1%^U2IK=5U36[:GW;[.N%(C"QFHUT8-;R8]U(
M47/])-X;S[^*B0&FHA:1);&?;-3NMZ*[#,@MKVW(<T6IW+W>I%;[JJ(IV?0Q
MNCA*U2SVCWP4*@BHT<,8MH%ZI3.K06"X:7(:T0Z,\!/T*??FN"XK2[";O=(\
M^9M'..)+NB%J8^?>#QYMC1K:58NR@M$2C273E^7DE;&D\56 MB[U/2>UZ%RY
ML1#_ -<'W')S#&O6586T$F?;0U/&@;H_ZN*=F=([WWH,3J(MWVWQ9A/\R+W+
MQ1G*:*OT12=3LX[@9>5F(/%5PRVFQ)8/(=5'MBAY7B&V%O<S&>#ZS?8K."DO
MYE0*1+#:[.^()Q65:4!8?$@-SXHF/#[$,:MU3*62M\;?J;9#^^N2G00D7:BG
MH<O8+^Z59(IWOF;%:6QU0JBD==F%!@G^#%_+,IL\TK4AI3(;MLKSO>8!<DK1
MMX=D54OX)*^.W:%4ZN/X&Q_ KF:LN#[<J[S;?;>"YT*&M'FEIK6W55*:;PE_
MQK)I45UBWA7*5DN3I5 81"GEQO#8V+<CGUUK^EFO9?E-S#'DS!J W\RDBI&:
MN]%L]&_H!D17(C&Z@(,:^)*F1B*^7%Y@Z7OICA!8:V4M(2/8Y[^C$""4ZF4N
M+(-O!H:BWB9;FDXHMVR&2)_]4-OPC+C.PX_Q..2@$YQ%CN)%P487$B;Y&")$
ME_].0U #DBD=GF,4&?S9,3-@.:$!SV*'-+@[@1(II0F#.@#&;&Q+V_'="DX0
MP:U:X5>E6O*$]%7^;G.X]'1C?".\]5H-=R&KNU7]P \3LVN#+MWJ25S:;6SY
M!(:;&B4H7$:^$9*_966F'?CP?LXHY,J<NDE_+T]ZZLPOF2Y[E&*%6Q#[H,\4
M,L'NO%DNDU$;6&E13/&VSIT,Y<PK\:BS\> T=Q[IYC37@Z#ZGAQ#)&+?HJ?K
MP;%CB$W9B\K@_0^@1-"A,7VPL &S0?(GJ],$Y#=/ U"*2"<OS4TN;886R9Y-
M;B;4L('<\AR&;ZK?%JNVY CFK*V9%<O5E*B^:>K]YJOJB6@PB/UO@Z\.0.@.
MQY"%!"+@/U]V\D9>'%6B? Y-S Y=OM._*8"$!9%$W/E"!@+ 2B&]S DID* 2
M"2("\O%G<<<0/E1DLY_'"=.O[E**\_G'YX2L \Z6^._KLO3M"7_"R%R[\I?2
MF/I 2C"FXH]P_JT&"]^U^<*H%ATTM/,'[0T@3^,H@#]',\/.?@6"34"S".KZ
MPE2/ M6Q^^ER@O(P!QC<*2+0R-<0F#3/G7N'ZK^%D4A0&69V6E45X=_#<",M
MNZ]["\MKPA-I6B5G1ZY^: UKH)[HS(4L$6Y7T#\,N#Q&QG158J);"Y(K_9Y.
MQ9W<CXP #0/:P\E04*(LY1AR?_T8PK0JS&#BN4W@/Q&.&C3C$IKQR$P@A]],
ML3#?"_1+DW>]K1%EW=+#/W*DTGV:F@-DCR&S3<T_:Q;?*K[TW!;'+HW-_%@M
M U4]O?^8YK]=;>*W27?Q*O5I]4\NS7<I\]G_\/V[G=WW;M&&^MJZYEO-]0U-
MT1;2X79LEV*N6"7_+;@ZHB=']\=W_ BZ5R'7+]\B?1!]] 8GOPIO@O=TN'WB
MQPYO2)SDRH1Y*!A[Z.> K+<%224T(^I$\T;A(5]DS[QZ!W@O%#'CU^G,?51"
M9RXND#PJQ<DB$[N$50%TG(H?)H;. TQURL=IYJSF&/08XUEJ$D(1JVMX-;0/
M=.8T*? Y7;$/D,2[=YCMQU/ENXDL2!Y+L"+XWW.WTPLCW<Z7FD&\VL9O$H:W
MN0?!"7JN]^5,I;2; 4Q]?R2B9+&;H0A6D/480MA_2DQN)#*L.L1@PAX__O7;
MC2YQHF7:W+>FYC-G(HXAK7F+I=\PW4>AA@B3IRN8$KC;-I\#2N\H ^^)CN,6
M@2K7O'PLK'%4@+L X@@DTVC7',]88*BO&\VJK57I@#Q]:\QBV-21A:?KXESU
M\^)I%BT3[M:(Z'9&T]J0\) _FNVS))[N0B:4ZPDR_*8POJB6#]#FH3I^PK&"
MJ22!9-,3!<V'4J&@H7;(=%V_P_/.AE7RCG?&_9/G,H9V''X<?,@25XRX^AXM
MV.J[NUDYYA0RZQ0RGA#VTW9D_> 8XGQ#C],JBVMGZO_2$28!=:"XP(YJ^B1D
M>A9Y#($[@$J].3T_\- 3;2QDHQ7OB>8#3[0C&%@4;[\<O= 4[L1]VS4Z98QS
M\K?:V5L0Z2M??@RFX8/7IJ@^.<XEY0,]ES]\Z.A(?:9A5=^<]>3<)XV9VO0D
M0<HS/918D5U_Q2JB/O"EQUEC#!?XRPG,QOY]W;!YI#I@[YK'JY-MM>'*U9U(
MK\0EAJ0G2T/2FH(*>3N&O:6P)MOTD;R ,IY7KN-2 ZRR,.2WX R-@"GI=!/]
M]5RQM\SHA'L,-QM\K#I_(IVE*=I=^=Y=)9+?^A4S8XKXQQ?Y*LRS+M?(.GNW
MP)"6Z8L5%EPZ%K.=SM=!B<# <&"'"<.!O#HS.A)*C!V6P03?G]R/%YI\2Y)^
M[52LVRJ1OTN^\+GN7!I?=^+5PF]@'QD7^YXF1F7%D_S_OC?GRQU%:)HT^!)K
M43L96I%^1S7[\<_SV, J\L>65CM'YD'_*[5\E^]N;OL+Q.6?\V (:A%41?8Z
M+EU*N7[;PI#@I5Z3!)-':?L'GT0'!VDW:T8MH6$E ">*C"^9;V7]R(UY>/^;
M[%[;N:8;*N.MB4Z.C2O)'FS.#5/,.Z]*K0M<*VSZRYYCG7FUAX6854VR/=E*
M?Y;%]]U4YS?OL2A.CQQBJ[$G2ZJ/EQEA&JJ6>0>*4<QRB-? EFN]=D&,F-IG
M,4>NG&5!F=+WKL"NM</W'S;2,>)Q6-.+&4%*Q6O OA*7 8-#EN1H?ZVZC$/)
MRYX0$6$Z'"5_].(8XK[-0_,#2^3*)*)PS*!4KV.R!,%FLADG31U.4I%NTV$B
M.)\'/*(W)PO+B. 8V2QESU^IB\[?/"Z_^U6V<?/QC(F;Y:AR^7:H@+/:S:,6
M;2@5WXF&[@U/PT9PFKYH;FV^-^ R@6-&IA4=HZWP!HDQ;1I_L(4377L4UQ>[
MIR/S@XDEO&O,6+B^>#TKC"YR$MAUH8GV,I74=#K3$Q*<DSZ:@]YH(P7R1$Z(
MU!]#-C))(N=I>A.7)^B\]&\6A5 ?9V407^,3^'85P?&6.K>=K*WV;DV8#_18
M2!SFFEF=47Y<]^-)X<70B&#+)STU,5N[QY F^$)\8;UIQZ$"C0E\37)2VZ\_
MRL?[H:,BKX'U8>3MF((K1_G8T<._ 5@'VNTRS1HH^9WX@!9*T9&V;QS7-LH)
M3*IJ\ L.C"#AV<#TWN YLR O,HLBT7 [QHFY^N7UO/=Y'WQ3V///&>1(95Y0
M)AG5-,>J\*>^3\^'&3:]F9UK%)%@Z?Z(YU@._7#@S'67-/#:0]#:^5I9?/$O
MAOQV)_2F3):]Z67.6OM(:2;CK!@IG!R7Q(L^2ZRIU9HD2<KZB.%$F2UKK>\3
MV>@:ZWB@,5*\*%XF:Y\==Q:X[[:$K7G9KG'5WQK[<W9Q3>V#\KJB^-?VBTZ7
M.K+77HT%UCC3\Q:8TQXJI:]%9E[CI?73AKS+'P4V#_XY$/&*_D3Z</<A8>SN
M,FKBO=&>-%DJ8,U5@>-1I4/1TU^F-L9S26YGWG&:W[Y]6N(Y7<]P\DPTG\3I
MJ;4@A!)]#"U0$\D!NAD!OU\\2.^&\^&NKHD "30IX)V,I7$P]MZ3H!_(&#J?
ML#+F)C!JQK6Y]Y70XQU0,#"Y1IZ<#$^L#'0!$ZFGNXC,VEQDN#"RS\))B8#C
M&2-:C%=?Y_?Y2U&\(SKCCNWFTY221\#JG] \_Z6Y^1^=@7Q04;%%Q'31)Y@D
M=3M!!3&#IW 73.)4J'//QNB\2*.5\ZZ@"U#;75,RXQCK:3VE;1CX\/>?$K*!
MX%>&C0V;\;6I5I20G;?EW0*Y5C.H87F75I7II<:-E?)*P]$DK,P="F QEJ.8
M9\\>%L#F8S05>&#YN)6^5^/^9[IA9 -17_/I$/X<QX#1*SAJUZ687428D='Q
MPHHM/N(X*B)91734-VS43*JXQLUWZ\%N^4\KA9F>I7[.,#4UA@[RHO$M*[F-
MNI_^S IY@B\&4]>'[P!/^29N/BMZ0R^##W]8"(&P2J:]N!O-=R5%I_[>GI=F
M7=[2P;):V-?ZCFS9QGOOU1)2*K/G&AM"TA+6FMH<B7H1LF'SD[A6K,.!,2$=
MW84!WZ'X'M8YTM3!_(B@B(77(G0=E Z%QVD&$_,Z,^&&3Z62@5PFO]16X&65
M^)(4^I)9I5BF(+/"E:2=JH\B<7U3C(SE%*XE/*?V*0^J0&=K;*S\W*;<TO4?
MWCGOO#8U86T!\YZYY7]3Z53FX.>"O:HV?O;58K8V#PV6Y3<.CR$,[D<YL,LH
M<V![8[5R?5ZN'DP.(V.]2*:I5-9?G3-I* XPEJK6-373%!]$&CY',TH:] @+
MKR:":*L/P'X-NFPUDHW:'">S.-)^F@QE(_HZL. J=L:#D*8BO02I7E< O,?M
ME5"^<]ZUEO,#->MR?;[#P54^LN]8EA@;_TZ!V*GHDDUI;7$CH,S$O&LL&8ZK
MR?)$>66ZJF.D!ZG367[_N*11-.V86:4%-/D"^/-\%EKP?#+B%]9B6!NEK':^
M+ O$/2PS4R"0%%XEU/ZAE<$G<Z2NE1K^+16<VN)A_PBJ&P-)2GE<^"I$1\KA
M3R3=I.SG6+USQ0IM^+F)H:1>:7%&NNEJA?BUALG5TIP(2Q/OKH1K;US^PZ*<
M\;_;4]>\VO[?RO3WB\B%S"N__\AE5H*Q>J.A9NQ./^R0P7?&]XQEX>94AKWB
MJTMKP[JU;3D"6.>U^3F3[F\^U'O&@J(# Q>YW["L235D9WVH;*_O8]<3,);^
M/,M]+=5^WI#O@YC>K<>>C[BL#:^<,O$[O#*-6^+\96\AN\7Q]7'RHA7FL7:?
M=U&:WJT?O>H_'ZKV_I2N7J]QGL3/?<'MS3%,;$;XAX<V;H8'^I76-$XDAEC!
MO6-% R$?SOS%ZW[QW!JC$R'EHZB;ML4!]?&#7;X+W>[)G]SEE!IB>H,;HKZ]
M0*PWSZ'[$=],2MJ,EY<#A\V<U,3?)>WOTAON7J]9_D6_X$^JB4%PP'VV&4 !
MBC%-!@Q[@U1:"(NE7T)"R8'Q>/?AF;']%U2U9)6YP+YC"%L#5 B$FE.S-Z:I
MF 5Z(LF,$2E]>Z1=_/T,31.,"B/7@'8\</9VW7(?_E L)D;[=@YFEQ$QM+Q)
M/32A,03.J-V+ZH$IC$>J(BV[X"S^=%YO] 4<-_V'L^S1/R@]@'$_$< GHR*"
M*(5"8'\(,4[D_(;*()1SI;7P68BT65PK=R/E&!)'9!0A%=057 ##T1Y4QFX>
M6Q/5$@%X^&LC:?W9Y'W3W\2RK(XQC&):?5BBZ=2(D^INI,V$BN=N1\[1=]",
M]36TBQA[=P7SUKBH<T'^K&YQ/PE];A@X@5X+GR PH%/Y *6U(/VQ6@X%?=/O
M\Q.'63A,S(VG*90UXF)E1G7B'^^V L3I]W!NO4,MV@5,7X':6.15<!'&C))!
M\*&,1DI:6T9AEY E*.A;S$4DT?AC^UA#8BX6WJ-9WC8E*U<V&O)QZQ+.?FDL
MY, ]_)K.)\W:3V*P?*7=(:6QO)#M6SC-Q ,/\8A0PX[MQ57<YU>J%.X_O?+;
MMEO'$(3YN*5N!22J<W56FX+'<Z[I1?^?NH41YC$63*?_.?OHU.:4X".#FV=O
M:X>2_SV,L%/;:*3&\E'^'NMDL#>C)3U5\X0L[*MW;IA (F[_Q\G#'=,:^@'=
MV.S-7SG'D*!CR%S@3Y_QJ4,,?3WT9XB.P5/AX9%-_&?8XU^;RSO$GT]$>K_Z
M[Z*C"U1:;&?%)Y-5,R_>#7N20ZC.X$.J7PJP[X4"2G*&7!0Z9'04D9(3F:,K
M@(B&,[9KO+TED)GH0&42_SH&@0[*9,DWN1K_8\4HNI!"I!!8C,T >#1G&LJ<
MRD10M7P7*U#E'Q @M_7CP[V->$HSZUF^E\_*W=FY!L!S^O75*!<JZ4L%V2P^
M)R73!7X*<1NH,O>95-0OEJX*J-NX\+EZ6#!INHN"T3"RB^3Y%(SN6+;;( >E
M-!/<D=;ZV:H80W)0K6&'^+49;N^^J&TY4:J63E!;O[I83(LNDTKH1NT/GUSK
MKPH-"[/-RG5?WCN/GG^?D#>6\S##?O=+U#4"'Z6LYF"[0&$JX> W*4Y8G(KN
M/HE0UBI@SH]IX0A2P<AO&_,N02#>U?7-@W'Y'*T7+RDH7\'SI]_L(N+G)8\A
M+PT^%4A.%84ZYLI>)<FHN?F,U_PU[3-;Q_IW>TM\/L3+>Z2]P7/A8*^TQ 60
M7Y"96:KF8HQJ%PJM(?9)5SU"^&7[B*_YT-V:U?A3FL/.OCZ3=IOG:X%XFM4%
MHR?J#;4_=+-<Y/(%*YD<U;M[_VA^SY;!RYY(?>AAJ'N:Y6*&%]^U>7HBEIG5
M$M,[GGVYBA*==(#=6'&A:$=JOGL:GI?A;9F7NVB6ZG,5TTT$)?LV5@_UZ=/'
MD ;;KD*VR"$\*PI*U34X2MNBA9+D>5<*%*A+V<#>5B@Z@<YPJZT5V&]\#X8[
MCVUO[3IN*DX93>Z^MIDTOL&2O-A>]V0;4PI?2"#6$WL*_[5(A?=5!B8Y<P%]
MSU&&5-O]+C"?&F8"!$;3G,K 47E6,.PN& 2$?;+1C&Q\O^K@G%K:67VBLL#3
M-BT?:^M?($F-+77Y6\)^'\5B=YGVG0']MPO#4:U"RW&7,]N=*+.YVW%TI=8\
MQ3GC&N20W9Z*8WGQM$S88W[[,>7#N *5G:W-@.OE?,_:2$7'D',BO5@TX>6!
M T_WK"YYCNLZMSK-I*P7 &-FU$<>UCP)%-E/PK;)Z+7>9T\@OK/\0FUI3RC5
ME22L?9>Y]2N/2\4H%MX8%!)$+;@TALS))IAR%-VT_B%:,9'AXZ ]".3!S[E/
M\\39>R6,=I+=NK41&=\6M ^%+/E>2_$^>(_SB"/+<14)EB*CLUP\#)2"!H->
MK=PG)5?&]5C8_7 RNM?@L>O!V9,J2'*46$&_YBV;&CH(A?OA_MT.)U</JLLE
MTU0G)'!_"__\ /$:3X/T\^GT2.=7%MY4ZD5^'A;<'S;U(Q%GO,B,"=IHLK_\
MOC&H59X;*(C\;:H9VR/"/4,_@G&C)%+?)MIT?-S)/^-P#(F7W7KW8?1!21;?
MS\:.O].^#U;Y/,UORB@?9+-0MEQ,*M*P*A_[66:4]^3]D(GRQ)M"*;,<BZ D
MRXRTJQ;FB>E3X7)U$9?;FG:-'P>YQ&Y64%^_B/UX] K& #Y[9E6YBN:CR]AY
M/;%E[!_7%B+=+A:P/S,Y\T_K%8'$"'_6UW_$S[GK69PC7-<071#Z<EW_K.+?
M]R!_+3 X1R6#80M09IH\@(BA,2QLRH84LB(=31/OC,GJB@V,E/XNV-FQLN+1
M3'G[:(>XIA9M8]PV6[&<JJMUZH=-YKI4]<4R'C.HGKIY5.-,G46%%GIP(#G8
MI".2L^-[#\<Y^X\ZGE,='MYSTX?-;;Z3#LU8NAZG^;VE:+_&QXD*$J\O:]Y.
MC-9PUQ!Y\D^D &789.V\"J@$M-'/A9*&8X@-:L]QHB(8S=*/ !,)WL/"0QXF
MB+R0!;:$M'J?>E8LH+GLP%\D1%2[+34._&7>1)5_CN-#]AE]VQ/BDXGD!X-[
M-??S20BF%;HL-:NA%EEWV(OHV+5-?_W3'A9L*U.3L_C]7L2]7!'F,:F*N-)%
M;5874[F+/:1%OIZN]R]+F-;R'$UT9'=_:/7F.7;915[J>CC,YOE:F"=1T:%=
MISM$<8U:Q$P1KS&WQF93-%9M Z(-99W$;S98K5^SQ317?K4Y$]30X,%*?,5>
M5OY)1/H#!?(4<O:OG\]]$Z0GV\+;UHCSLS3YP%LU88]17]-FZ:PYTAVSAN)A
ME8;W_O,_D0Y2MNEFT)O'D'HO:B$=:\9@2[*E<0E/+12D4G_M5U##DK9@9\!U
MLES1H2)*"=A*/Y2)G#J&G$59RB>AO;$279-$SG9CTC KNE,![A,8@[^H7)@
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M0?\+@'?+BSA==C;M\6@>=9XU36U>C1LB^C6=YV?5[K^Y&,4@A-DXAA3Y.HN
M\(4XX<FQ8?P8*SYDN_P.OV/RHR>A<)7,D.D89Z9*KX.$EA^GK#U$D8Q]3-,J
M\A=1MBF#P3_N^>!981P^X8_.?:2:-OI5^UY,[GE$]/C0;BN?MW7?G2DZL$4Y
M&:8C9CBVVV+I@7M=-O/=\9GU33T?/X:&2^:&UM9V5M<$_>_VR1AJ\\5*DYG%
M!9S<\R1?6"0%'$-FE#8\[O16Y[8F0E\0RHO)4XTY:2C@YSTE>:_.C_OW\ZS
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MBJR( 7TDS\[').PH>A]K-)X1%1%:('"4= SQ'+X ZI++"$=BI&*O3@1? R>
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MT*.ZV',,I=;< CXS@IPKAO"&X,1R(3'@RTO-,\ULT"A8 GA HB2O4B')!0>
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M[<)0>C,G)!HU-J,!I-.$$J6"]7L3V<)+A%.,BZFZ<HD$S?BK;L)+^K';*+_
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MH=O+L!#P U8UPIB51+?N3N/':R]5E"U>+'EO^7M)_,SM@Q/??R@V%*;SB+2
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MNB@ :]K^2%!>,I:F"JSQ]SOHZ?5IW\+%O(>G':MT?_]=*Z$W$$&')Y>EWF/
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M=&WL?>ERVTBR[G\\!:Y.GW/LN)1,4KOMU@UJ<VM&EC2BW)Z9F @'"!1%M$&
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MCAM<@+Z6)\D0R=*P+!N?9CAWAFU=N6=&SPX-IUC([%9G%C(TS*L@B)AU'OG
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MS\WY-_/$YXR *6A1+PD08IDH_@;CI,WLY6/CJ 38&$J+5</E*!\FO5EP&5^
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MIO&!9D"_.[;[\V-@=EC7@$?I+_1WQ\>GAD^/+K8ZVZON[M9V7@)K2_P<]GM
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M(27KY5T?YK-=5-C"DV3L\?/%+_,C3GV-B5-?-''R-> +VKVLH6B12D!Z-JF
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M?6(;"Y&"&2ILS"A%*'GMK&.S]L4+,R.D[FV[;9O,WT@(S2!E9MQ \:<1=%9
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M=2U>Q=Q>&LSZ._2[Z;+%4OUP;[]V_%Y_AP\7H+P#I<///%8;@.:._C!JD9S
M0U4)&#R,:,O2,1UH^R+> AKQ3B,BZ@9?FCQO1V^"U-:&/J)8VN, @+5]N )
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M7_& ;MV$R=JAUC9,VP&%5VE=I9[1=Z;AP:S/3(9BGAL%&8&#AEA./E0/8_E
MB@OQ@A%T,@8Y?BEU*;284N9Z#'HR<[B-H,6.(@#C+[7:SCYG!F$"[H )\PSV
MF<]#+<&D#$7*GZB[%B1/18LCPQ_P@1_(5?F!'*E(OU1W#O?W=S0<F6/_9([=
M\3Q+2%UAI:7C&Y]AQLD48!"VG[)E1&"D3^$;=-2;;.I$&J"@R9@E(OZ>^7FX
M('L%]G%=]C0($_D2^@8QU]"9[>A7[8(KD34'B""*DW$#M05S1A$.@W%3U-:$
MZ('A61Z=1;,7% HQ0>#6(238T1MQF2RP0T5 HC2V3=LWHR[:@+0#I[$A8P7D
M<RV-RJHAT6B(O)(:TA=&]>Q%#D\YD8A%4L>T)312_+9\&H4>B$FDLE1<%N;N
MROF3-'I*<H!?P2P82I)!XL+V#F+0T67/91[T\.SY/RD!5:@@((^Q+F! 8R#X
M= P8<<OW8%.W;- T&>_6_"1"-R/..>DI:46#TW.# ]H/4.&56P0E09?P&6K[
M"!?'_C,":1[")%L1813]-$!L+0F2;$76(R/O#K<<^CET%[X[X:$.Z$4]QW!=
M^03R#O3$G@(T:T=<47;Q:3L8GRI3#S(A*2B;?+IPY ,J,&,F_2]AK*-EG2VA
M'6)HB;"N/MLG]W;P4\<$',_G8=BUVB<=O\0@4(=2SP%*M_#BRSA7Z<X3SD $
MP@UC/-LI80G]3(!"/@]O!P$MM=X.-QRPY#430LB*J-X@T1<>W"%G3\@W[8!4
M4& G] )JEA>U0*]HH3L+Z6&T:.NENP77\SW]T>,)TL"%/G:!.-D1QN,F;6D%
MF_3(P,6Z"EQ4@8MO+W!Q(W59W+!D5@0EOV0+O+8ISY3'VL7M!=)FD]17A/Y:
M[$&O'7[*9I51U>A RZH\1N(^:K'PF<'.)\XXBI_,?_)T83BA4B&2SV3U,'+A
M8:8=?R$WN& Z0KG1>%SD,&M8O#BQ3?.7[-">E)G88(E<$Y45>8J;W4<MCU'\
MHM9EABN3  MG2KI0$OJ(H9;I@KS%1J[GY\R)@@>C*DG/K6CT5$R(Q-G8H,_
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M:X?41P9;8NMCU-M+-[1N7IS%'>2C@!=8EY6H.\QI)V5S4T.BCG-!JK?>Z*:
M5 \2VT.,J*#.V_>F"_B)2O>R!GZNPF2N9-]#KJZ;X018[MHADHCB?=1#%N4]
M/#)ZI>ZI-MAP=GA_S0FID&E7.ZPW>OH-6K:Y;&:F6)?69+V!AD2B!68@!V2)
M6;\Z'9TW<@XZJKAKJ6<DFL<2T%$@8&NE!/]!U.LY7&I@)4PO"+>3?N*@%;D6
MERC>8,7B1-X ,F2;CBQW835W+(")$DLCJ81#P>*8V"\(6]7ZV%XAVS02.[(@
ML#U1K%-V&A$=I28??#Q]4+$J6M3C-1X!O%S@I=\NAE;<A2;/.30A.3K9Y94W
M?D2NMEUJ#@("S#7[<7NQ7'G\@N[;<:%P V8'NAH*EXDG7='[7@3B0S3.P998
MHE5%T9.TD4_B%57%4';T4]ZG1#3RH)T :[*FNK"F7FV"_&I'CH.%4@UK4"B1
M^,N\64N_&3NB8^N.5RA1@>5X9-12(][MC*2M9WJ%D^TA*0_?8;SG2-)HY#MU
M1O\7S.,,V/ 2N%/_BI.^2IZDFFRLRXQDE>%G1A6$AV@6O-M.%'8\'^XEW'FN
M;%9$3=\0UKQ_.G%W@BE\J <S_LFW\VQ)X$#T>J$NSO#T@&FCI$P12Z29491
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M ^#K1OCB^ZVE!]C0BK,"C:! +1<<$B1;P%#2"(8H)D=*W:C(]G#P2D.4N+=
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M$'Y8.EJ"\%-1T CI[$6J[MHHV5-)&^O%E^1TY6;S][\G0J;RBM"@PR;FDO#
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M&$8FWD! *%%MPP;:_/+8* OP.H5LI;0#\H@X(+=H&^GJN..!_MIQJNPFRWG
M(/%<2=EFG[L;%S\)?HIL\$ U>87A=4'ZU^J6OENO1!<B5L,[+*5WJ):+Z?H-
M&RSS&7AL8#+0E^F;]25&*' M+@K=Y@T@728TK]:O]*7;VC?,C)!G5^_^Z/].
M5-B[3A'FS:ODNXQ;LC[@R;G+LR0_NT0+Y '*[R:CT+YE#+V:WINX0UVI6DG*
MM<'_EX_P^=]P?Z]:'M"@U@@MLBT:JRV1PYQO9!9,CZ]"$)+XON25KSO#B'@
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M-7^>ACW6>8#8!AX^A9<OVVKSBD_@SZ1#LU(Y+7=%AZ1?ZV*\[@4JZ%(EZ27
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MQV</'_+C0TXLOP_,C]]MJOW\&>:?C<_'NX::Y(OEV__K/UYV_]_CQY_\AQ5
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MDNAM7-<0[[B&K->21@,T3]@J[)YH"Z$GSW?D]Y8M5$&#A]&*.<,/!T3$O-P
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MCH<@9![,JG](%VL#AD-W5;;1>LB8MN:&680#F ].\V93:251("B@!_P$"3>
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MW.QR&_(<WV@UB4"N9]!"P;SH!X/@#_3AH,PJ)OK2^LUI>AT&^N^0+F'!CMX
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MOL-?7ID4#ZLBE[8I&,>NN!Y,^44@)2N#;7"O<YFX[/T2!SM[9;.5-C+%1TT
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MRR(<C@)V_.Y+$2+23U'_-RJ2>;/I%.&KA](+6 T3_A'I;MS+A=N3NKS.U3G
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MQ J0W^J,]])N\3-N)&G,*0I@L691VS:'FS+=_]M6&#_T#-N[KWE@2-Z#*Y"
M TT7<)&>-EFA7\BOD0ARR(O0AX>'TXE0TZ*2T-;0AVX7J-5Q.U. @,+5UNY:
M@.W&G05W-GTL]8:'IHF_<@QTEYC+:DTV 3R(0S97-Q6%[MP,IPDOQBA!1;E@
M/Z:',+:K-LAY3 +2!;DT5-"JOJX\'F1R[&IP'TM7&R+>KI1F4.E2E7:/LX@1
MK*(!&<+B)STB_&#7G!ZK>RB1EAR^2G\0(%A^- ZG1%<G8(YKN$X\9,GS87YV
MS%L%'"R1L6-_KP=%*;&WV+"=LCH;3&K\A+(,)L3A!%]I'7E)A)(!]H2L1D*B
MW*93I'51T\SY;6)>&\F8;7JL2Q8%G> L"0BG?Y;BE.CSG;TPP^T*GB.',QMZ
M NEO09]/)T-%;O(E2(<#=PCIYFB&CCFO.]!#R6W',76$-TQJC<*^9I_R[1C"
M&.B0FC5A6IX[9$=2M>QUDR^NO64%(R%Q6Z//^M;5*2M:THIU#7_E8&0C&R"
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M.&;'.&:$-ZKXK=LQZXC!V:M"6S+,B^S@3YEQ%S5CT3._M64-AA T(0LM V?
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M/'04"<4^O -Y[DA7#G<@CR4CDLKJ2ASY?#'N/.O'[JX,6P,G.97)PM]S$A+
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M1TK5LZ ZYTG3YTT?$\G*L3^+/.3-R)ON(B_D&LL\Z2?Z1K*OV?UMNY%%BN3
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ML;I\;G0:H[(\KP5'$E\<JYV2!VOAAXG&PY5CG^(2Q^M5]L7L+/>CN6YWE7*
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MPUG2_((IG0G5,=@B\R0D_%OWK?J4[H_H4/;G7.D<;G1$/0@">LIT,$TW9BB
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M(HV4S[3*BGV1V9D0EN00^*,CL^;IX V-A(J*%\#S']#W50T1]T&7Y38 (@\
M+<*]>WYY,T/9*QD$]>>X#WCA9$+9%"$\H%(94CO:\%60A\5.$#EK>(M->=,.
M7$#:U#3!-Z6+7)(>'^Y<P#AO2E2C[WF:.>433L1&0B!^7H1 BK/(ZK!Q*-T2
M/L176^B^N*[0D::"&DS^0!WFUM0>_9Y=6@Y.JJ$1>XOJFFP!ZMC&^.(:U8ZM
M,*VC%MK1WF[V$8-R+ILT9*1O1ST!Q75@B83I[/<G#CT::0?"B"<)4[<4$SC'
M_6U)RTI*_31HRH Z3M"KS>OFI'- C6#R_%0'%W@,QM(&QX3QN+O)R,G4&RXZ
M7,:LOCLQSCC,OI2(G&"-]O]@N_A.O$:/I/Q>4<^,:W-74@RA3S'$TE7VO366
MQXSTOH+KG;A0=1@PLI5WI5L#0#KQ(H^KGR.*MKNP02CWV?-DAJ5%S!RP:-K
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M<!1(LUCQ PL3")N1L(4R!>X3G\$-[=40XLALUXZ1#H&260*&J?:.AB^?N4-
MU2@VH' 8$ZZ;ZO(@;L')+3?36V(VJ$:7=$X2Q:^?YL+_(<P5=C#YDX2<X&Y3
M5_6#YZ""9S7R<@R! ?1@PP0T=([?T;:TIR'G[*$!3Q9:L[ RR6%*6N1UQ?&&
MH$E#UQ*V[A8)8\+/,"M]!%ID*?8+?[XM"<"Q1TI98*:2DF+9"0=.BM5IGA+R
MM'>4QJKZNBQH6JFKB17;%",3[T_U7X>0-<!.5Z"-1EN)Y<T+3X6B7SI*"6^N
MVYTKS,]ZB)C4+J>B<M(QAG1=L,U8$0X0Q-3\AQ(UVJJG (ZA05WY"HQ )JL-
M4,WF4: :;.^P;,L4J',AT'LG\A^35&'<))QCOFNWEE[<8H_6+I()$Q F?W<H
M([38P4)%#^.^.-DV@X] >DO$)A5L5':.K1!Q:)C0+??&*7)*F-UT@4J])JG/
MSY9SU:>5<')79D13F0[12,0L8N%EI< L _JXI<WO#E$2D[\06972?BTMS+=[
MEO*1$T1%UR4*R8B^?O*LDT==.%*808NU'MI>^2<)'5)VM\61SJ9\@LAT@ SZ
M/V.5S\Z>R5+:**8V;\:M<2[M#'CPVK/]S)[(9:L,[NG /(A6=\J:(/D<DJT*
M<2Z^X?S_Y'M<VC B.=K%4?G$80Q<RB0#]=ZKV_;>?$H*X2-%$>69.#9EG0#\
MW4Z87$DARMY),UCF EO6TD&)*\O4&1SME[7PT)S;)G1JP\2=EC0!Y?;28DGH
MBB0II$^8)Z=EF] NNH?/Z$Z3Z?<8S6@N,5CC18;0Y8#K7VW^HB04::@F!?!D
M1N25.$H_QBYE%8DP21[G7/LT)IBPP$ 12V?OV.@/[HTG UFMP],*>E/7BD$?
MY\-$C8ET5[*;;6W,##2X#!09G$-@9_"]AD0&X7,9P8>KGH10%/[F26*3&53G
MJ-PU9?&TMQ8HN5TN<\+.[?0.-=B1?*G#<W(EQFE#N9;]W&GJ$8.?$=> I\"?
M!-F$TEJ9!+R53U@%$!^!VR+=%TNE F7NGF^6=D)9>I5%7Y<HDW:<DC&"W%Y=
M\]B1H >AE&T( 2K;S2A\Y$R,\"RO(INJ#A[*\%B[/C^CQJ=X%/Z4HQ+N)W1%
MTG%$C24_A.VN[$Y,^B'I'O=R3*<(H6.>X'HSB57DS^&2[75M,(I&XIA.7(8P
M[>VIJ!5$P\<_SDP#;Y=-7T2_R$__2]I9CP9+?+Z")3XM6.)?5[#$<W;*5K#$
M(PEZ'Y0,"+<?>\=0'OX:#H.2$<#7)\?6Y"A[?:J?.Q5]4\4R"B&;N*=6 DN:
M&A0^KU412F)>(R8B8&$C.=-</-."O-0)WG5Q<)>&LJBX^Z#,QK2C+TD^TF<O
MY!_9?&26K.7L'<KU?0( ,'#T%*4I+6T1IJE:J@:(+?JSSP$9YH(0'9,N*4*0
M%,1N"2]EHW!.$$=:JAN9><8J,_CF)%GCC0]M!$*0(L.G> *I6[3-M&F&, *Z
MGKRPL.;^DT633]IE.39"J^O@1 X*1D-$YRT9[_:V;7OA6+PIN!LH3G>F:L,>
M6D =OY%C2IZ8;SX1IW ("D6^WV.MUU5)V&"\BUA-4;>6GB G?61N-,L$9#HA
ME-3@S6C@&;*]Y*'B\I00=5H;=:G*-ORN=F>).+AU5C@H,FGBG>-@G7R3%-?.
MZTTE_KQ+R5" 03-*?6RS)WGI?N(S?Z*H4\;X"&JZD Z7I/)MRO5<0$S:!>MS
M*!I-<-R[]@G?"&-P'8'59$R+-U()(BFZ"T:\=#B\/(W&<J>Q?@$/DIX-+C<8
MB>TS!_0P0:M3'+CRU$P5$AQ#_50&U5L3JHA,KZ\7C8T:U+Z!6K2H79>1@^2F
MNM,G]$T$\3Q/S6;!>0)/I)CL9KGUC@5?Q,;H*)3DF&TJ@0H]XB[R(U$+!T63
M1B[,OH-#X""N]L?Q]4E-)B*7G,4O<":>?\LS/3M-)OC<P@/Z/9.B_GTR1NR"
MNK*6DT/;<()"0'%N^-D0WD9M<#D%&+9=4YYZV2]"OUTYVB/99I3"0VJ8U?3,
MJ#M>J0\@$[S*7EO!?];@)>!!IA$<I2LZ36$LS>;Y0X /5%X*_*)ZSEEF27XQ
M=O2?/:'@W*8ELLT;/E@UCTKS<ZAZ<H*.754HCT4BSI.6$+(TP3]-&4TZH*1(
MKCU29VIWRP0&FY7 X!G%OZ+V@,W$79P,KT)VS A#* (HB2?F0F^GX7@7X%Q^
MJ8/9U-H8)^$ :2VE$-7EKB6_DM;,_!/>'-_?5G6ICM01LC&@&O;J:)1XMQY=
MA_(@%]K;J,48]X/H97&299(1OQD+BL!4)BXE) +'$7/B4BA4R'YH)0<=-X)B
M[D9716[/W/YJ\T54_PKG='++#]ET$:"QT(I@_7]6,3@W#LM;O'8T@B<]XCN'
MM9&. A?GJFK6]-1G&H ?6H#ZZHH;C(>R'Y;<T&G?!$5(0L0TKQ0X#T79$1>8
M"0BX;U;$=?-RJ_:TH5>*XD['R+5V4B?HQ/Y0NX0R-3$\GX0@/JBCFC$_S4E0
M4:+QVB<PQ2HZ7,;@J%(*&=PM0<:A55<=K0^-&I+X@)S4I%(BA2S_&A8@#<%Y
MD%]&K0H2U#@[#)1/_*0GI13.,6V# >]?>?Y/(U2QXI73R*#259F=VE%VK<ZI
M/J@QPB<R;?#OCT.,.QAC*8''?X<A':A).9U0<0N!LUV2KBSB;*C?MYMX?5%O
M\(SSQRDH0=VAGF0\!.+@IMU'W:27"!L^N[S#OU R\4D%??E;'O?<FQX@@IZD
M89F)9 Q$%[N\L_"_D RK9$^BEP3"9C&>888C]+ZT#)C; IL7RZ_!MC>E-;Q3
MU$*.;"S.JB- -DM8?J#0AKDFSSFXN",EO<X0*; $C-0T 4\<NT;Q &2Q@FFC
MNX%)@=JBA&%==SEVCA23^2KZ08*7:HA[RG;!-0>:*=C9YJ1V#LG2FU::Y'XB
MKK SKG;;K9[V4_7T8E9I;*:**-,03A;_%#_@ KL\96>=*/0ZT5S7[3/-?JZ"
M\T]]V9/P:Z:A.]ZJ02$O /6"B6Q-N._<VDJS K)@EE?:?<G:31F):UR ;YH6
M1!G<W?9$61YRQFKX _2#@]GD,3DGMI6'&@[=)G8+<TF"&WW#I8*#W&M!0W4I
MW @T,V<ZT&<3(Y&\0Q+V2!C=5;N1J4VH]\ DGR=_OX902.:$R)"PBZ)<\9.6
M(/;CWV@])KR^]\%)2<>(.<$I2TT@;:]DJPE#.I3!XT/S=-B4*\969UUT/P4-
M9#Z4D:O"0#3$EK,T%;: ] &[$NT\U(Q1=G>5T+Z$Z>C1]H-G8AXY2="Z2,AG
ME9<C,LUPE=($3^N-'>C)(BL+"KX2M5Y*(9 R]QVNLW,YWGE+8GL&F66VDQ&[
M6ES2^9#;W]\&]U!'.TP781A,AJ>C@O/)].&JCEU1+-N1.LKZ8S64DP<T:B7>
MWW-U<_JX>WL6N%Y3T2G8)[=F,ELS3&^_$8'V_9PMBPF!L.;&&&Q>G+3I<93,
M@C3)0#):M''R+'9?\V*,#=&)6$W2Z$]=64LC48WRY?U--I >^,?8C9B:IBPQ
M322+9W( -"-IRMPL+R+UW3Q'P3LEO.3[MGLOO (YIO0XJHI4T:'6>ET.]Q".
M'UEPG9D,)M4)JTS$SG\R(9X5F0,FVMT4GW-#"79E:4W<-YV"'L^X%RD'0ZIS
MZ+UXKP-[O#WUY!8+#Y?S5<I#I9Z\?8K*8G#*NS9XT[,O>:,<9SP3.@H/5*<5
M9E\/0^R)^5BJZX V;6]12W&2S(GV-^<Y)H7\9.+S2!8GG\MB*Q-=K_,D<GC!
MB> ZA5R>;OE>S!K7^!76L)PJ>DF.RZ/!@[]>P8.?%CSX;RMX\#G'HRMX\!'/
M\EK24YEQM*CGP>CVZJ-\H3.N#Z/?'G"=,LY2LE#*>14>SB:?+A:%SR2$F"UR
M(2D$SM1^8 !4-E2>RM1G_RQ+T)1P?<DI3IOATF/.F+Z7^8UX0)ZNP.)1%]/.
M>TBG*D&SN;*<JD[:!+@@\22#,[D-A M/VI_G6$47J$HN!L(F%X!51.93GI_"
MQ/0ZU"!)C<6^_5$<!_'A;7B9-0^F!:.(5I0"6N$8*L(K "4GRA7DF;?'D:6R
M*>.L?*7D7% "_BR238 ([0"9AC(M4L4PA<H3PJNZBWF'4ZZD2X=KT@\9RN)
M]3$>'<BG0IA$R)9P9M\(&8$"#<C-;:/6@KGG&0M:A)]%'L2_2^3I*64*;$O)
M[S2"&7<C$TEQ*$I]C_A;<9QTX(3+=J7_J!1G7KHG]GR.V0DYN:]/J!O/56/M
M-;R4?$+Y87=7]0CO&&@$Y5-&&HT]\Y3%K(LRKJ1FW!)2VOS$A2!0=<AMNQ68
M\,1W!*D;3LU-LE:2I4*=!?RVB:NM8[ B:H5@7L'OY"I N@5?@LO&:?]8VLH
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M>)07UU^%Y-3AL<F7+>V,\Z;!F8E+9*YX#ZI.RJ,BG^1\,S*PES0=[\WM-<R
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MS]Z[-[=M)?NB_^-3X.8FNZ0J2!&IEYUDITJ6[1G-3BP?RYG<_=<MD%R4$),
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M^PH-W0D\[9:0V#YC[L]P&@[R0UL*L4&W^(>D^%0$'VRB^BO%T,7ON?7V.>'
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M]\Q#4-!64<T# AP,@_L]!HYH&VM7NC;4X@6N YWBX*:-Y-I$#+PC77BE%D:
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MG^38<!^,"MK5R+T<(GG8=;$BV(20#B><WV8CQ*ZY18\_[B>&S4"F7(.EPI=
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M2F73P&;Q<WYR/+B-TS+F_E3S6$\B]8%E7"^T6P%4:"1\20&6%-3F[=2PD;#
M4<89-W>VB(FS>Q&J;LYA.)Y"K@'A9%=)\LRB$(Y#/-?.$@9-L?881BD)YKG$
MC ,ZS4K\/="G?'1P9 [8R\+@-(J=WBXB24RQT9XCPEP@'ANIM5V;<48J+4Q<
M681. @??%P%*,BM B$'LGB&(*"S(=OJ[M4-LRB&XX8 %E="FO83U;B")I, 8
M-.4'9.F\65$75.NI#73X(I3>:-?X<8I8'*#D8Z!0@BV<T^LH_?Q#-2#JM?'U
M&LRHAPX2]_L44\P,U;H@<82:QZJ%&E/"28XI#A2 Z&,[]])TG[F[45+79IS+
MZ"$ ;A[<=X'TI$,>52./-(A'H9R])Y>W8);J\9<9NIJ&1L5)$L1O>$WD 6P(
M F M_5GCG?J._)E3U'(G( :1%% 9@%2>G]R;\AI1\W0,J5*!,'="P9Q\;($%
M>51POJ?PF"_.;NZTV<WKS6X^:K.;-Q(P9B-Y=<M7]"=6)5*=)N.)I',TKUF(
M28O<%$W%^2B15GH_A3O)+F>"8MW_(#:AVR&H,G#5(RX=Z55^F]!A,H2QX9Y%
M0#BLD0XT)MP]/<06@O2:$OY#+N$_8>T*%F9@_SC&EI642DC@?0SV1R564^IP
MZJ(8= ^/PYZ&_8,WH-[D#H?Z*FH0K"7R18B-:TG[&!$:UH  Z'*=&356<>IE
M.IG2>F[+3; *$CG4J0M4:]^;4>57# ;G**&&6E@OC_B$WY\>&'!"Z>5E3L0%
M5L OL!1ZG!5ER-V@02<AU5:5#,Z>47HEG1R8.3E*5,K2VDGDF!G'NKJAE.TS
M<& )N5JR9\&LN6C-YB!@^HRK$#B5[8(7>),KM4?DPVHM51?Z'<FT51/&H\(4
M_FM+8CXI8]740(T$]RT>9!.#&"&:HLW2== +B .D%Z_]E!4BJR#%U+.,< C<
M-&S=X)"V"RBCCQLN9?GP?O1KFXIW8'DV]BC;@D&1!7F DDP-^ O!W#CI-DY:
MJ\F\P712ZL4&.CNFZC2M#&GF:XRR_8#R3HUWA!TA8".DFJYMRJYCB!AKJO%;
MXR+Q.GY[EIB?V!R8DQP0>UC?#-=PZ@Y O7EMJRN8V<U$4* 98H'.<<U&7?=
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MM3N+\&(&UZT6$)5 OT-<8H%WN898[Y\;=LY5350Y4$SHR@ >4]QI:Z>[ZYB
M8D#Z4]/Q1D/'[AI;Q7^3M,^SH"I-L:$9=LI#8#FYVKR[HJJK42V^=H7$!6GF
M7)2OO2!\Q6D%I9_D_>D816!?B3LW&08UJ3[(,$2<18U7B?3E8^MUJ.ZTOE5W
MV))K4+J?RB*(IY*Z<(4K/:<V".9)]]5:0RIN6K-C\X6N/MG8)%GX77RU1\D
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MDILJT)NB$V0^4)C8J&!N%9OVG#LHG2)GN$.J_5B<W3 &4CN0DQO4L,!M^NN
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M*UA,['=^6&H^BW<BXIL1"]Y+<H!04%WA?<A%>FS:&:42108VR^3P!!R(DYH
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M3_#ZL/[TC!AG)9__\@OT0@!>]*'N!?=" LN_HB%X\-VO@1,K6'FVPM@__OH
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M$3O 7A1Q4:BRJ,,L<<KHHB<XWY[RC0=[%*' !C8)9I@FW&*KD-Q;C!-<9]F
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M@];.V0!5+.J3^X!NO0U:M]4,KLJX5+C2JA:PTJ&NU[5?MRXLJ+ENP=(VT-J
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MD>2@RXL\Y3UTNE.B2'F7[8'F/(%-*TKQE3']%GH%;C8^3"OO)P7Y"'!&"L0
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M,+O=&^^2U?VLL_=0RUR@N&]:T US?_7Z]9LW=SGW%W<[[:-U\V[%>;J[I?2
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MQ<S?X-8)2J:Z4SN(-N &G$6QG(H-R0=Y5Z=BWTZ^(^/99+MB:_2+N8P6EQ-
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M\#]<_%-[K@3=HO3G"// _U2HLDP,,'.A7V10R@Z#DZ-#TNWZ_O(Z)3#3]J;
M,P&G.,7FZ5]/=9R)?5^81XBTZ3+>8^,SI@]UGC7)IF5G7>!C2 RU_-W:NBGK
M<)+@THN#_8/CIP1 L)-.I:]PXWSW\]_YHA:[XV,Z'Y55 S%R:>Y?YU3:A;5_
M#U557&L? 9.Y"^XT3=C'!ZU.D_>./V+23HH[Z@)Z_ 404[[5[+]_0 O7]$>"
M4'Q'\V446/WA?9NM)'R/3H+#PUMZGNYM0J?[6VT_?_<S0FVD%KC)-Z\9MUG?
M6#[%5PY6\Q\9Z6(+DF7;G!#WYU8ZV#][/)_F[^&7>/H_K[*)2N]YG<?M#H)'
MVO6#_<%V7Z+W64)Z]._(W-J[*'.R+2[G_N]A@89U;VCL^[XG1[VM.JW>%KI=
MM9/OY7MM3;ZWUJ08B_<>$SG:KAOU@&=TAVY=<XK<"HF-5HVC_D8Y1]CY97=[
M&P[V-TTFV&+7-!MQ2 -#YI#PF,X5?:^NZ&>ZL3?SB]MLZ(*AN(.)9#<F!Z]'
M/#KM$(_:Q/+=(1[U.L2C)P LTR$>=8A'6TF8][84[M.%LJ<KY;$^Y[^MT9F?
MQ KO^+!:HMJ-]=U_O?!$>9(CSQ%5%KA<YT?'5D[H3UV,X0!0CNI#UJ%2%X(;
M8=.%LD2X1S<#HO?J\.OBF$X;.#\<PVNT,9#64XK,?MOD5Q#< ]"8T] @RS[K
MBG+WC'7=3[$&#JVU'JBM(YID7*Q(8_4:_0E2*>)IZ:G0,KFOF%O7I6#+2#$N
MO,6. 2EZ"OA%-9WBI$ 2Q<14+Y,6C48JEXJ./J\S3!UV."8:2$<Q_=5$Y&UA
M@DX$R7/!_1@[08AVPX8=[61ZXUNQW$APB!E;./!:5BM)GO^JTCK+,[A-,Y'6
M#5E:KL[CP?4<9E>JNQB/?3&4M^'YWL K)<4MRNCU2 J;5?F,5 GIJZNSZJ3(
M<'F8ZTD\FGA.1I?EI&"K-Y V9Y[926K,O-;J1310RE?-8<Q1^;DWKLJ*_ADA
M$$(?R2#[_M\=<(5@84JZ/:V_ @? H7@S%WMM-8;!2^2@_<"SD7I*R05<T9R8
M+FI(E).FF'Q,YQ[:)E+E=;;'#8_]*7$NZ8^YZAVR<)VEN/A<S*?HV9Y2&CVA
M)I#UHT(P2D:^I):;_,(<#8W])$LO,?>VU:'$5(@ [R<R+&+B7$IR"$U2GY2G
MVE3((JNAW-Z^?^<V1EU(CT03YBH?34* 12!M_3)7EWS48R<3<RDCWJOK#KBM
M4;..>'6#IL#"9=!C<Y_;=-&2 &)!LR'QH[ZH?!074+_K3$G[BQ&Z=M$5\!I9
MEG1"^_YYW7XX:)] XSAB.8XBG/+12+'>ZI\;Q5LW6:WK?^^'6W=IC5M:*WM\
M][E\"]S\9<U8-XM1/F9"XZ83:E^Y([3N>J7?MJQ6?]_P9XLV(!Z/V[YQXQ#C
M=I+^/:2Q:JFR]61^QPO^Y?DL>*>XV9VMVO:WW86\[):7G[/=#NUK$["1>TX_
M^AI<@VXR.S&9>\JY>6BXQ3^40&0O6X#&;,)5^J69W[,.)Z2!='6[\WJQP5%]
MLYG")05]V!+W2WS=8FZ_F)?]_<%@L]5\91KK0RV$CN7T5@MYD/JE0Y3O;%!*
M?C,.T,+ ]U<6=-A>%M0["8Z/#H+3WE*5PC;6-JU:1-#K'=.)'>_P&OJ#X.2H
MWY;,NT.+6).S^2!H28OU+[_4T57K?7S9NT>6][*WW]N@DNQIS^!P_W2#\JM[
MG $)C:^L_]G![-4'=.WN,ICM7;;7[6T]$"T8WZT@1A>8I/]7J2EOU&*;B)[B
M<D__9:3&\2@N?_B?9<5G,Y3OFTEH]^/?]YZ"NF-YKIOGU9]U>?6K8Q%WD5??
M?_9Y]?<.I/1PT%#WDI(N@\717[\+\_][<#"P]_?W\S_.__;Z]]=_?-1"X<+[
M]>W%JW]>7+Q]]X=__L>O]+_SW_[WXNV%_^[-3F?EVRQ[#RGX;S^:]7UX??'/
MWSYB>?Z[]Z\_</+]Q>ZN].EAF/T4+Z1S1W$QJHK"]!(.TS"9%S%'.;(JUVDC
MQ4*6$GZ);Y.8E)X(:@\^&86S&-H1/4-?CA@";4V.)/W&22=#]@[D$V?_K4P/
ME!Y4;HJ@F<HWCN.%LYD*.1],)86ZGBA.6:,?QL@*RXJ9&I55L>^_(C'%'2(E
MK\C-:D,N3LB99>;!E9N;(X%>Y\^[[_,6WA<X4&;NJW@#:9]G.B=JEH3Z6 K!
M34 V$")4.I% \Z/"'^K,9#.P_.PZS*.]A+1CO*?>*@^=^#BR)1AF(T"MH:_/
M7&<(C9%^E0^1^Y9G5W'!Q('7KAX3>W.AP4'[O==F'U]_T?W$SD?E/E()5CU>
MDY23[T5C)C!R]6B%\L?AJ,QR>]B>^3<M>)3'0R1 K3GFYK;S!+&#_8,?/\3%
M9_^-#,8?]7ZDH^3E2%(62*-".[0\SBK:C#CAM"D<F(=Q+EZ_VO??ELBRBJ?(
M>@PYUS$L_7E6Z6O2M@(_XYLS"BMN.HP\LWI3IF'4M@Q.W^*.&43="2E74.GH
M*,,DL=2_YJ1X=P"NQPEI<D':[H3W/E&<))<4&6V&$N+09XP^$0STIS?PE5V
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MUL-D%;@?;#J@$NFSDIAL(=HN*Y]B0OOA)3LD:M&J[6C:9*@<VI86Z8Q/H.#
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M_05FV2;9-KM./;%Y[))>FNOS VO = MA7-5?3ZII1A/Z07J_V0UEC@"UF?>
M'1P,FO*'CD*X;_>O)QF[,6B?9Z&HQYYL5<QY+W#LB'G%Q->X>YPAD"OG'YH(
M%I9;<PT7H*B(O^PQ7?J2NK-7S2S>T$?D"WB6W.0<-9_B54WC/,]TXD82DN;$
M5$:'K]5_LTPB";J\YJ/Z4C/+8-"CTD>HO\1T]#710(N66/:]CYQ;8].&ZOWA
MN135D.A59Q[0*TF'HV./27[(W<]U ^YB(I3X4_SS+^Q-.I=00X& *[[X!QQ(
M="<'BP&! @(FE5CO52BI0&S$T/X0(V=^M"HXU!X1RJK2AD$BXJHQ)]GP&0IG
MTHE4;(QHKQ$;K]YJ"\=X30TK8+XD@K&,P<T^,181>^*2L$IAFI#I=<7YY\L<
MQ95\-;DB_O2+K,B8M\ )TJ*M*$D0B1$IWBMP'<0LJH2$#ROC[HSQ$\6G[3!\
M>&5Q9^ *(Y9N:-"E:5JAMZ&8?$J*SM-30]\)L].=L_U?Z5X%@,A"BV@+KOJ[
MRH'7=6Z:/ ?FDXMJ2)PUA^=6HA"I;O[I)&EHPFQ"MED66.57#.?JF5@<!^_
ME-D+=PV?D,WGF"\C'8IZL0 J=!W"W9&221:M21>Y4+ICUX#6Z8&9W"9SL24S
MB[DI&;F<"Y4L (F:C"BL&LBC85&(]J,!UDSLI]YO47[T3F-)X4@T-&&SH2"
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M$KA&FC;EQ3#E'@!-!"6'E&H-;F']DK<BBIAYF2;'SJ1[M+;S;R'RB9Y,U_F
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MY!<<:O""UMKBN2-==C9"_O1\9K]R?-?;R!'&[G@VUAKN[FP,#'EQK0'SH,5
MV/?9ZM.&7NM/_%R-$S5"< 2..HP8IZ-L*B'OGANDJ;/Q7O0.G70?3*09NF^
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MZC.Q$_3K"<H*(BU/> ?DS8(VL;@T_>0?,CEWA<MT#9\#=PG"/YKTC?KR.O-
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MHQ;7=LET"0'7J34C_?&^]W?2_$GO$4Z=A"RP((;1_YO[C]E1EX0__<'67O]
M-^2!Q^C%P?[)T9',+(D_JR2>9%DDCJ6)G![6;J?%IVB70).(ZSE;WVW.4>P%
M?72DZQ@U"@E><-W8]@!K)O:JF++I$(S6+YJ9MW)EI.LW=;B:PRYM G&[,DXK
M)>8=K1FBE2:3NKNM-7N:7I3Q-= .:+,A].B*+=CWSZUJA9B9L$"C,H[B?%1-
MH96/< %=VN"-J/4$L=!"WC2>XC L8LEQTPS76W\]6:J;P0*6#?"*X94D0*YP
M)=XGX4@<6W824&_@\YFPE:7(YCAOO?AFX"9IL#96MUBEK;?1AX#T&#YOW6W>
M)T,UIU?#RJNB2\7I6^)8G"]0RM)+_<9+2>9Z\+>E9H1&NSVZY2:. $=?EW>[
MW2LBT5/'>B)UE;&&/L2-*6.<I;@S.()E F Z>9.LB(PM%;HB3 _0>&Q8.B!3
M#JE"51+"LQ"RW@+-!XT;.1=4/S(B,P$915Z9TVM87_SXY]_^(%O^3*)78&^F
M,R11*M$6%.E']_9V5+5Z16\Q,+V(A0B1E-#2\AE*B%2(0L2(VC/T0'/4%;MI
M322^)A)P9N06T\])1:FF'!20A&B6:WBF2HT48,Y6D!2!""S)JBATZ@91,A*F
M$U7J9[1\3"'Q;0=2YH6IPA#P?=',0U\2EDD%+XQ;@M6A;,@OI*/X+!R659@K
M6/U(L1Y-8AJYV;\4?C/K'@CD:BQM5 !1(F.I*) Y9J49T&FE"C&$B3[IV[$^
M]_*LR[V\W]S+?I=[N7NL_T'NZE.28;5F!):LBVU89%B%VU&4)#"U",?84)/6
MJT9A="58D,S_:S'H%645Q494-L7@@NB0&/QJ$01=W:I6"*.EF'1$ XI/.;?V
MP J=R]/FA(Z\<YPH-_^R-4T57(=!,XN(MHS65= !QF-Z7]KL_MVH9VJX]LT4
MZ,"J,>T@YUX&'@O.H%ZC3@B ^Q^9D!P >%/E6,4T6YJ,L4CKB9D3A3)2P"HK
MB@QE5BK2Y^B4/B'$6 V3>.2-Q.E')MMH1.P=(<EYG>R0JH9*X"K53C! VTI/
M6ESO."- #J 0=7LV'Y^V>%'@0ICB H%6L[QPDOJ>("J?J^8LJD&W7EU#"UJI
M+2VB\FT^?HORM SO<>OI"K4]Z"&TP&)LZ;3/CDD7OYMYWW,Z-ES?F!N)F\L<
MN68B!T2L&#O/U+ N^"W\]7X+XQBA3PP3:3[XW_]U>C9H;%,+ALVCT?FN$/8N
MSO/^"Q4[8MK">>X>6RQ&I  'FW''33UX+KMDL\-)",ZFPSAEHP Q&^ HT-MX
M)ABI-EDZWKD#Y-[QSHZ8GC'OK/.A%FL6&D;D @MT>%S3;7.SDZ9CBCM QQU3
M[(CI&3)%X+BQ&C>4_,TR(]T2*6W5C+7'AIO7A&V-[SN<U5!3>+":(0UK4SM\
MB4WR1)8=VG@$X=56KW;'6K?_-G2LM2.F9\A:C;ZI3?,RGMJX6%:5IA]]KBZK
M)"R!_)&KJYA&WY1=;LPJ>18=N]P5"N_894=,SY!=VJQ$89H,=&I!4ATNJ=*K
M.,]2"W6B4C*_=1)W7B6=M;T+9-GQN(Z8GB&/:[&V58'TC;B8:.4M3B4Y"673
MZC(>2:+%,)-:CL!/XA%2JJ%)HM"#=4,N!+G4?DN+'67K!+@@U9:YNC_N6.7V
M4W?'*CMB>H:LLF$]"U.SP/4F;6<I8=7-Z*W!^]I35OV;4U892)MG<;<&N5D
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M?9W&Q.#$XKQ>\I":46 5P<RB281Y(6Q=()68EL3!Z37]MF9531Q9P$S"9VT
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M<3G))5<+;:[PC T,-[HD93J3'0GE;?S"NS&$Y#2P0#*YWJ$T-)GR=M1 =_W
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M2SP4L5FI=,E0)L_Y\B@!\HLP,4DJUHM()G/@7\;T-@-J?A7&"6:SQ)B%LW:
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M#OTW $R\N,R*A?;A?+]*[@?"6JB^@%[=P<;> ")D)G<PL:E+5W/=MH+8S+6
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MFE7$!X(S96QO275B7'2*+\"Z#@\IRYT]_*!#II;P<UD/QJ:MPBP,0<U4&LE
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M;M[41QN\GSBU)O9 \%8I@<C$/(P6P3<92#K4Q;-FQ1FJS W9+5N<2)J"'3)
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MMJDA'BPVE&PKW=8A%U9(X\\+=O_4;Y11JM5P,F6>HL\]!QO-&V7D$=, \ Q
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M:)<(&)1@;=(,:AK8-G2]91&4/.QVX39AB5E>7ZNBZ,'7#J0K].KR)6;+R96
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M59(VA*;4RCFGIH-RX>(EE5CT31>54F!E5.YH)]!R>MI/F$P8']KN<\#@%8A
M=[JD++PP[@%5;VXKET2A5&"0,/X!])1O@>CS!&X6;_+&TM*V?TAM)5UYES+%
MEMD*R9C8+)J@?U$-EY-8XXVN72@!:"S9*@VEGMI)!7O9#/VH/1RX!9R#*]F
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M#K3R<+3,>7I//*2Y;DMD-G<(5]#T"H8<A8LH)$1 %T I:$0]W*!6.AD<&I9
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M6BIY^.#!J5;R?FLECT^UDM,)I$^$9LJDTS@WZ2[E"0T0Y(Y5*L?MWL)[G!,
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MT8_!QYO.)C@I," ?)[V.L6F8X-Z*X^)UB6/_C%BF0<?;-D],\N@EUXE=$ZS
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M1;RB5)/6I8L_@'\!RKG0,"<%[(AK5BI*PF5/>J"&:"VHH4]L% A14>H:4"#
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M@G\)#HFCW?Y"V^O"?;*P&>@EMQHQ\655O^?X'&PBDK\B1:Y8QM/$8[E--%1
MW=59A8-B3Y6[&I=K-=8^0]T$1J87ZHUT.W <=FW(]N0VB; '/U7<.XA='?+#
M) 0-=P77^@1?DX/NU4CN;[\=>;/"D"73TM:+2B\#)ETTD!VYUB?4+[344 F3
M^\Z1,[9NU@B4:;5'B0UXP3OPGXK\ S*5:V( S7,XJ)=[F9EU)8:"!],/M)X1
M'0GM453#R"PO_AE[F&Z<?L=OL+>9;'?N^&[M@?JE O&%75'QL26(^JYIL-N(
MA+$M(WW9BV]_2=-YJVV(STW'YA?#>85P8R)XTPPAK9!RU5$V%_PHL(>"+,<-
MC9_4<CMZ8F\P\1M1] ?&35%3,P=]C\WPTK9KAB//CX)>!<3WGC="L<["@YC>
MPT>QP-.I]JR]:]/2,KJ7X'>=U42O_@?8%:2P#J?_[G)AO#P" ;T?WWO]OZ?'
MW\5_'/]VW[:G0\'<U=BQ =2"^X*5GN&J1KRB)]6EJ7]?#+XB;;+TW^#+_?'[
MR<>^Y; [@X-&*YG$;Z8F+=%"]-_2Q"_Y19%]T9MWQT<W?Q$9 -90><3!+]X]
M.2F_@B(V1?QS774+D/%%Q@VR,!1N9Q?]^O;U1Z^A']P_V ]WW34QEL#]N_H#
M]D%AK=M[>_SJ^,4I6<?2WL+F'/P^%ZTSKITJ;()30]W,\>XD5\(I3LVT9KY[
MBH>Y \KF2&,BUHD\333/_%5 .Y\G0TN:V*3":W.19JEO.U@#5;[ GU!+%6^[
M)DR^3<B*XQWC)$?TEV;F1BG#<I/!?RS4_(*W/NKM72Y)9;N'%$TF0R>0-N@R
MX)E&XU$#?>&^OCDZ/KP?WYOMO]]/X06F(2/I%Y=!7;EO]Z^$7K!-'(@6/_TM
MO6-8>@9DR/##KV"SQ,>EJ3$!#\,4-\'),]I^\5)PLC!W<TGAJA([K<$HSO"D
MY*VQ[0B"MC.)A;((:F+=X5P9VD\&>P7%1[4Q[_N'2D$GPX.,KA@D?O)E=9GZ
MX^KM]*4N8*J6,QROXS<KTACLO0;4TEO[,F\=]_'>7CU*T!+$5GQ)'GWK(NFO
M\NS28!_7LK^4BO%X[C >'EB@?UPM7B!2O$!\$[R ^.(Z> <(V/5@\);/B*TJ
MK7Z5RE>;['O\URPJ$2(3O:F9?U,'@TDH#9RF%TU(H_(,'WSF+Y(N"O/U"+DI
ML3,+RT6;[OBIJMOXMZK+X&:ZU)N7[/*!6@\>1Y[F/\ 66 09PFY9>.@YXY1X
M0\,UJJA-E1GLK:*Y+=@'>(AV<V0(C_B"8 +69])HD8>GBCM2Q7?\ZM2JNV:)
M6:G&7Y_:8(=<ZC!SG,+ZO3,EX0ML*UWNC@5/X1UTF#"%$KUL&NS<:U%*;BMM
M$S.[E6_53W:)3((!2);++B[HMG T*\*'1S^(5!J0/)%(GHQ>JZ:T2!\Q>3@S
M9Q6CC9>,0FE+9N1P"&$UL/7T#KZ,7(K"(+<OES!M"V-B\,T)]_C"P,^[=&'H
ML+TV+<;U&M_PH- E==-%"-"9D6[3%-\D-4]-Y5 V-,8F92EQ%X7!03.MRHJ"
M@]0Y2Y+F?N 7#3UJ7>V&&GJ/5X_:VCE@->"C.;5.8D""8MX%D[[>VJDL/JM2
M B?G<T)#8?\P$7G:@RL,ZND R8322/M)75%?,89"4[2X:EJR;4MLB8S*@OTP
MM6\>>=C.!\\U$MFX "L-L.''@UV,3A#W?@@-9-OUH8F]KKF9'^*U*0>,!/C"
MGOHO=A*)3_H[0INDF0&[0_"6G+JQ7^"= $^QW2-E4 >N4K-$.Y$ZHGDMW2K8
MLYS$]G[40X#*Z;R15"5[SM0^CE/,2F^;^4SNNNB\)KG_9$SNWW)R_]LQN3\:
M!W<JN8^&3H]]02V=;Y_?OJ43K45*2K$2#PJ5R8D%0!Z#BLHQV V*^:J:I-4T
M)[H$CYXRC,Q_?N0"ARFEXPSWE$ZS.2A(RAIBH&&:HORCIIL9:5ER!]I\;G0H
M?K86ENY%?I$3@)FK3HX7.>95.?B)4,U\6E<3#-.^R!OL)ME07=/AE)#;OPBH
MU!6NP)R\##:_SUND7@D)04.](-_+H-.V^DZG;4>-,!719R.6MN3$NF24L_>?
M88<4>E5NSVYN ,"'<8]B27 Z8R BRRETLL3JV*7;N(.R4G)F2"[AB"4L@.C!
MUP_OH"L@ \/#2H>=@O*_=!@P?6L:&!.F+_S0O O8KU8KOC+M;_G,<%Q:0R?R
M2PV?[$?!>Q'""M.1#TDD_QE;ZQS5(?B+]7QH9+4=F0(:Y *[UK.(]+7#"=Z(
MJPZ> M@P.?@G690J(/</N'_4.5EO_D\=ED4&U64_=66FZ%R,?3 4)C:2ON:R
MN1E_C^YS:4S&8T,R!C=3&P&BGL:('!)ID[9IL80]PO@UR*'Y@D(Z5-C)'LM)
M8;(S6\7&!2@DHKCK;X7@#\)&9 Z114*YH1; @FQ"O\Z0>&J7ZF_@@!=@-)O>
M'OF%*U>>.]U%"L*GW'(X!1<O1]@V^(<+$&$!0LI#C?.H60G28"],I*YV/*^D
M,3.,E.+[*N5A,O2S#<!Q+V8JBLG9UQ6L-+I8JJG6' P&SC>&\&J57(/(70.+
M,)'*SCBH\_1]81O"?/C,UXAKRWS[%XZ 97[A8]3_A+N&5C^%>JAWN3_2%=74
M0N^^16-X;\MGQ%I)N%<<[XK-.CS\&FI);5[)X.JP>E&S5XCUZL, W^;->UOD
MZVH$X9+^"XWD-#XZ_5G3]"+G^0\.9YEJ*7 =4;X ZSA YN28*[2UP#6^QT.;
M-571M58T>VBZ O09IA<,%:KPFEE<PV-;!Z^E&SR8))AW%-JPZS1NLKH01XA2
M!4_ K@,F/:OYH@H-5YRS*%3!28!HU47 [\"_L?1Y2?=]FC8=?:*W(L;]W"N:
M! 7NPTX='$#BBST!2+H0%"I-X=0N+(SC__OQ.'Z-S62C0_1YIJG=1/B+3<@(
M=H3>_!3?K)#HA\\\!0#?")>YYRJ(<";L,WL&NHAT\"@."IY!-YG$KP]7RD1=
M<;L.I'>625'7A. T")Z5>C8)1H*?Q"'*68Y!W1H#I*0A30E'WBBR2 M-H]-T
MAB[:B?>0_:LF-T^7?$S^2!$,D?B0Y+#*Z.! W<.>5^//Y!,3U;:PG2K.AXK;
M1PSFU\%@'@G8QT0_$^(9;_6(P-P@O?V'B<[3"TPD<XH#KU=76Y"6$:1Z*NF#
M%'45)I@H[77I;O*TJ!H#VI:&SU4K.:H&\(@:S2(A7@Y$!?ZM::OI>U")F6&)
MP(/P&3,LC,J:X%+\P/(@!<L7-!5FX4 (J$\ UQ\->]1'@CL?G,A435N6&#Q8
M^^K(&1>7()C 8#:MY&:PU!16P?40;UA*\A013(!"D<<[M9-U8[ MQV%>6',Q
M-.$1+_Z59!78KV_!$T-CC;4-[#29#F_(WST[;U>:J&S7''=/>KWIZHCWBJ(O
MUB#P(=@2A*AT$_%6]JWNVA2$I0:K@^KM)+>O!6>!?8$D'/,%!7G0!LH;]^A(
M;35\H4@,E%]@::(\HB)[!3E.EEPLCW+,"20$)JW\TH<!!0] ZZ:B<#/():Y,
MIY /RD?+5)*X$21B"BK+B@UK^<$$?$-.\/*<@_7X./<=0AS-V0LA!%('5AJ(
MR50$7AC:C\(73MF/D'PWRT9<2_HR:8G"G$E2W<N&<UT_O]5"MVAG=)%11A,$
M@Q[B=M:;&+$3\5!,PN])6$=1&I_U"==B#8*JJ>B(F1$&-DZ6GX](EC?3CFE@
M0']0) [D/F+84B1FB611@V/5='.X6'"VV?-S^XR/H*_9@RMU1G&Z0'^JSE&S
MP"CR,U9[6#6(:L2O34B\!V)-).(2(CT^<6;:-"^,!3(@NL/4M JX,3HU\DW<
MVHYZZJOI*1100M2A 5[:VU%!;:"""K7';);F8 !BE).ODD2:&6-*-J!44=A=
M9:4@-DD3$ZD4)55)H=0&K>\4Q4T"-QFE32KEGD?XZ_AEPO^(7KYD 2>_?OD2
MB0&GY_QME,T-R.V&JD9*0[8N_ L\?##R$<+4Y!-,C*+PH@+FG$-Q.,RV0MBN
MHX9Q%C0^E:J11;5$EV#U!_," 3S7YTA)A8[0/8?SL4%"G:8B(&<&G";H\.>U
MJT.?P4IC-342J:B*T,"W[X' OA5%=:G:SY8 'SF*RN]YGNO'&@Q6*]HL"C^)
M.31JHQU<IHJ3\N&0*S-H,%61#4\A_N@IJ.(8F$9D#T5_T1U%*Y?08.+1I@!6
M!LS'XI/'&WGCW8"(OPJD+R)&&3>B;N]+ZQI.C1/K?WD@:U[^Y2:Z9J7?L-D]
MAWM]BL<D@GO.Q$?H\7/!U'[\NY64=5=P&)K_E S&#D!Z85H:;4PPG Q%+_ZL
MU*Y-]04"Y;6IT]4LPWZT8DOU!J V*@5&$F11(*0KAC$Q$DX9,O-!"LM@W8A3
MSZ7BUHYE(,X1?4*88Q($5ZY<2*^"C<(?50F*@ .SI!#@]DNL?"AFHDGL?&8=
MKP7X ZK1TO8&JYT('P3SG&45C*^LVIA"1"G[:KB(Q!Y!8:BJ*S(VY1%J'5G0
MLOF R1...OGGX\\N.U/?<)K6]9*$E$1O0)@M4!529E@RMFY-]N/#GN'/FRA'
MC5/:,+YFMB2'0P\-2,/<N]'Q%$XA7!U,"Q/S J)ORO@M; ;<M\.]1YY1</Q!
M,,6'T]:*\-ZV[9//JB=D=731RNCB3Q[=T=[#CQW=;0FNKRZVUPS@I4#\D99C
M8MBTRB@]XQ]#]/.DCI@6ZV:[WUUU=3V)4O9=U&A SI!Y!Y<K$8(.2M7(Q>5G
MV7LJ(#V6 3UN\ZDC01Y.TR)L/L;WT6LB_H#]UG?QO?0^ABQ /";R)1 Z%85E
MY:>$OCZUA0()DY%4]9*>S<.W8A*C!C,C"41BG FGS:/!%>D3"GV/?[LWN8\B
M$]=P-@,Y0 :U8X1?^\!XX(%W[O"_PRR\=^:C&YSY:V3*%6=^#2R Y=T,^7LI
M$%4LH\R@W9N7K*.](^Z=XB$1F@=4W@$2U<XR5:<-HS42@%'-K^&YPERDH"G!
M)-"14.WON9&;9YSBI<KMGJ:K[!CQH%F4%DP/)77!'TB=\>-,",$XM57/#(AZ
M 1U2AU59B@MJU6C6.3VX9HUX(;VU2>))UY+:+O)YSK'5[[Z0_>KJ+/RZBG[=
MQ4>/(2B[6%N>\4VOU=) #<9JGR1Y],'CQ8=K)CC0[^;Z+Z_&,_P8Q;W\_E7M
M=#[AB>3L$;(+#TUP9.#GIH.3JZ<TN$ZA@*>!J)"_0L8OTMR&TVU57A6^AGS?
M:YIBW6BG/G9S/O?GO^JXKSM'G_T@J7 ,]I(@+TXM6S'E6$\\$CL:A"??K:YV
MCV#!%O+>>1_?'SPVGZ6GTR8[XS:M%I'R;=/WU-.&<P&Z1('3 +\CKS:@6_),
M7]W,\$.LZJP6"W0>;6W7D%Z+IN3ED2\/OF]C HTYI.RL]W=CUV_E:7U?<#^B
M@*GD;WSKUEG/KE,'-3_QJ#@2UQS(VB*4<_2\ZU776CUJ9P,1D)#(35Q:;)WK
MY2>+D*\:-2-_9-C<^LO6ZOHB2/K=4+LZ_[Q?4ZKY="S5O.52S>=CJ>8V9[2V
MM"KS-E*D!#4HP/]4. >2)W7-F"/=L!SI'R:B;E&J^Z9VY_Q8L?8M\(,';*4-
M1+X'HJ.]9^:>!J36$?@-&H?[.WR?W6R'8G[RX+_TQ1?<1XQINQ2R 4Z^S=^Z
M8 08K%0$-$%(D=<6B/#RQ'=!UI+S;XC+S1D2U679K X"31!_$/O4U:A&;87A
MLDM#268#FXF)6QPB.^5917ZYHR#$R'E)ADB-$$[,<&#KH921CG-.640VE#:\
MXKXMXBW\J1<#23ATN':;$]UG&3J.4IY+H\,$0'3OX?U>'F<P\Y/$]P[N$V'P
M1^1):" 50LR1N)<78]WS(PP3/KJ_/B1R\V<14H=.SP5QALHQ\C8$C)>YH4-2
M:-?(QOB;(R%;KA!,PDPKIT=L!H6<<U#[7C4 ^5-HQ' 5E_]E\=_Y0E!\B6A#
M7'K+C2CR3,P;W<I1 G\MY4C.G6M=..K$3=.)[PBADG*35R^/&_!D"F)G.-N3
MK)5,4C7U<:)Q/W(8I'FJQ+I4^(J!9_AOXJJ?7:1.QKT!4([QM%V-4G,U#;9(
MP=4\,()8<Q!8N> ^[LP<&VI@S$(_I6()\M>>O&@8O("Q'"P)!(TWFQGNG$5D
M%CA0YB#SP=T,?X9/<?H^9=,F;>BN,/L7TG'W,> ZN*H\JS"Z8B[2HK-!:^^#
M"F(.*MEL2LDK/[,U-3HJOCZV0:R/WZ71V&F,JO%KJ,;\!\)V.+W(:G$K)[-[
M0@I58A]TKYA5O& K ,O+\WY;U*EK[)[TH:.KV$9!QXK*59A/-8N&X/^,JF$C
MN><-S:HZ#)2'-1$%0FW2Z=(+R*[$:KUZ""EAID&<'A_QG[Z>83UJVX^>T:MZ
MGTF9;;ES([BZ_J%RAT1:AFM]$;/E8C<AVG:/XE'(;<AL),X=]PRKUT731<PR
MD[KN-R52Q.3TR*&"'W;?E?B8*7GU!R8OEG>NV!+CB=SH&:%HM>5-*O#ZAY'S
M]"@IYQ7FS"3CA557W]W.8MSVIFT43N3FS[]1OO^CAWOK]V0 $; 1@WS^]-GS
MSS3*6[;IU",!YP2'2*7FKDPO634R1+\H?[MX(7X,DBZY^FZ#L#2,05(H&+]J
M/G#J.4"1$4Q'GP.VCBG/,%-7PKR&7O7]-3"<KW01-O/D;^:HOK3W,AZ4+SRJ
M[9&)KNJ=@%Y!J;JKO%_4U=1P0;:49Q<5!90TEC.>M:T?U2B4-FY+1J%$MA&Z
MU@MMFT%Y7K*0M)/06IL,B6#9OA-GK+$TA.2M$P'(/.?";(K*AQ\;S^K6CVH4
M:ANW):-04^<SS9#I>;K49!RGYHAVP(HUH=<1.XO;"CE6;;#*,C##5OB'KGX8
M23D:A0:MQ@.\]:,:)=W&;<DHZ7"$MKYHV$9#.<AL)VQ\+0I\0RC.FFFUX#(C
M^H@#)XS'<>M'-<JMC=N2NRJWJ@D&ZGVWTTHRI&<J3&K9L)#;2U%=D^5Z%S0S
MS;3.)XX7<O4S4BSGS#/I_D&#L':?-?6L[VI+_KCK4%RG.:*EI9!W7C4M,152
MJ5[XY#U]*D]O^&Y\E@+-CTW-/GN\?_"$L$2WF;B\ID;NV5@CI]^XG1JYAP_&
M&KGMPE/<XOT<(04CI&![38;52+4#&:RS"FQU/$*=U>O1OM-:A5XI7?\L_ 2!
MR&Q1%RC[(EVCP+_Z.=[,@[N9HQJ]H(W;DKLJTA;8F(ECU%4OTX9NQX! DX*H
M%0\) 5 FG;5(;.4\*9^A1$HBD40/&=JK$M0_T25C,Q!L""##F)BTEAYF>0@&
MUQ96U$A$ZF$(6GE)%"?I>W6]_&*1E&N,L5L!PWT'R5CZ;4T\G-9XD;9^5*/$
MW;@MN:L2=Q6#I1%QQJ#6($%!+ Z7%%"4"N-0*TE !],B&GF,;7$K<2%&9QF8
MM\@@()P"_\A_>&4+]=1.I5&]X)8<6NIPZ)4Z_&3'=525S(=+GWEKD(F./O)F
M(12/5"EM>0J\7A\VU#\X-4HBV-59"\"=V[&/]V[K1S4*Z(W;DE% VX3F#>50
MT+Q( O7" H+V:6W.TIJY.VV_J1B,5!"G"ZU;'!#[-(R@JQ^_M6T-MPR9FKH,
MDJ>)!9LDZ]$FJWVFN+R\SNE@!V,4',IX?;9^5*.<W;@M&>6LE;/SD&#"MBYE
M4;N,34J2#G\H03A-/=N1*RP7W01$5>_/3N[:+&IF+DQ1+>COXV'=^E&-4FWC
MMN2N2C5+ZZ2"S0-S*.\A]93$YAVU:9'O3DRZMC9IJ]%7:O4)3CRZPT:[4 Z:
MD'Y?3F>SV>:A+I))62HEAA?[<3S36S^J4?AMW);<5>'''"E^U8-RH2GA%Y+P
M2$(;&\7X\4\0E!^6SNT=#]S6CVJ43!NW)7=5,JU"=[Q4! HAXDCVR^&18M!\
M6'!*I9]M.>ORS!38A)5KL[10JZV$#Y3Y1KB0'H$[3(W-#<DI?6TC>Y3XZ+$K
M8A,M,/_H!Y/=I!W/>,@W?E2C--RX+1FEX0"0<8C.;'I.>6FO'H+2M?@!4]IV
M9(BY(1)W[I#3* 4N]R__BH4'6P; _@J$=LR_[]+Y6BN\CM^.PA.H\2AN"T<B
MH.'LM3<@PS^M)RGHR[TW'PJSM+TJPV]&RM'Y6MI$#_%YCO2(&STC/$U,W9QF
MU0)[SJ7Q98VGIK1B1 -A*RSLME%G>I'F!1VFBIW$2S.!XVE&KN>OP_7L-\P>
M*9\W]N*M[:[BF)]#VN9KB9]1^&)OG5]-=1G_EI?QS]7Y.J[G%1+[R.]Y:]J;
MT#T[7N>/8GBVP:61X7G;9C3(ISLRZ7[T7,:RM\_OL8]E;]<0M'$7:NV%4U&C
MJ_Q"<6\+:8PF?J!2YJ;J63CJ<U]KC"&,K1_5&.O:N"T9I=>J].K;JQZ2#"45
MMXN8+XIJZ=-/KC9_&@_BUH]JE%@;MR6CQ%J56%X+@_BL2@6T[]E=M2G,!=8?
MB,T5B#<18&OZSHR'<^M'-4JQC=N2NRK%>OU7KI [EB+%%V[@-1;:HY*:-5>U
MH5:3PV(/?DQBDY/I1HVW7  )<PW5&35H<94&U+N2/KVF(;;?WB44P3>922!U
M"RPVB"<I9D:)UB#G*EO7,W,D90M)V;X=2=GT&[=$RO9P)&7;KJ#\2,HV1J?'
MZ/3 6.?$^D/#LX"DE'-)/OS(*YW!WA]K%/AJ-(BI^ZL%^T]@7.#S-1J$F<R6
MP5#3M&'.BKQ$,8W/1'+KIA\OUZ_3Z)IN>BX?D['"6G&!>7M>U3!+2_%*DQ@-
M[ZT?U>BA;=R6W%7).1!GLLQJ0Q1I/7!)B80_:8E41 7(5N21Z,K&%%X0/<TN
M\J9:I;$\%3ZBAP^.U+\[_L"@41K+X70L_]G^48VB;N.VY*Z*NC3#4$Z#[ \B
M[L1TZUEK2<\.(P--C#'\-'+\H[!K1\-L4P[A**W&@[)CTNIJ9AR,/_MLCPXG
M.TW9315^1Q^SO8[24<D9\Q*C[WF5Y5-+PPC>+M5DTR@\JD:BZ(UG.5))VF#Z
MZ?'1H/#4,6%)(R,YB942<6/T=RD0UW?%8_WW[HQJ%*D;MR5W5:2&S!1IJ:03
M*G[*-5C43V*N&.NU=V%4H_3:N"VYJ]+KVGKM=75?8]GV%TS1;F#9]MIZP+%Z
M>SQ4?[5Z>_APC47<FSGX?^0_O*ZX^ KT"-[*(UNW]3-Q%A'N;JSMWM1K6=K=
M8\"!W;TSMWO#)=__-+-9#6+[)Y._-W^MXCL:J/C^N(%]?"'X4/EW-)9_[\B,
M!LJ_\V:L_QX1=E_?W1P1=C36'*\^/!.YI@5G)^YH(JU(WG.KOQ!]AX@1^',.
M/[-/23I'&ON-:=,=&=48)=NX+;FK<JI7<40,K%Y%D5B))'@29V TO3^@1 -K
M)[_(,XSMVY(@)HWUJH(NSZFFB)CV\[(#5QD%7#Y5$4>#8%\:?6'7D70\S%L_
MJE'J;=R6C%*/AJC..%I@$TQ*5M/WYU61B;_N663H<9O"V.[(HU6V.Z,:Y=/&
M;<DHGZQ5-NWJFMME_L>0):8Y++:^JOHL+?/_I'XB2W(2:)NUC6^\7>& !N5?
M*.VX#"LM1KZ>[1_5*.$V;DONJH3S 14LXZI 9BU]8 6Q1PQE2&P/$6HH8KL"
MCR=PZT<UBJJ-VY*[*ZI\()FT*.? EFN(BQQB5.$$XFI05)$9YI("]/,$P;4$
M1V/AA^TERU4+3DT_PK#-#6;?>"R#+VKALUDSXFEW8E2C&-RX+1G%((Y0"Y\(
M(?OQ@!:!Q24PLKJ;MEW- E) ,N?Y(@2Z#$%P>1@C#/<6!K\1,-R/A6[])71N
M-(S.C4=T[K6\<\]'WCG]QBWQSAV,O'.C-+T*I;Q#<_D8+/U':8@=AMC_8V(/
M]61;X><PAZ,J,Q%HYQ^[!IL$-_%156:=Z.7C%G:OV>()[I[8^<-$Y^F%\2[J
M%'80[:N)[N#4VT%#.\BUP61AL;6.!I=0K'M,PMHD0F(>V$W"X%C\CM)@]]O/
M1;5I%HC>QUL]"YM24[4R?&4_/K2AE&FU6+IZK^M''4@-A[+W:D!>5-..#,RH
M,5.?.%Z%2_P'XK)!CE&,2,@H8+ =>S\!QZ$;5DVQ\,LTOQ P0MXV/7LVD&$Q
MK.YYVRZ:[_[^][S>;\U%=6;*?1"#?W=2T?OG7J;C_GMF9FE7M/MIL_BPK:)P
MNZN-)C^<.NA)]-I#I>"1?J'78XNEX-=25;<N#$_JO*HCC3XX#3:?R!XFL8<H
M.@61!B+D) 5SI6OB13<!AS-NP+Z!EV9Y!J8-7&,4KE3S0YSN\&P; K&BLH]-
M<DBF*(B$Q#^!_U-=:NGS\ !1C'R<UYVC+ H%KU=D[1"A*)]EZ";K#70%<;46
M8S40!G( T3CE+ZAQ*"#2$GX/D\APX!'%!G"6@U5\/W=Y9@I<%^6?U2A D5[N
MD$"\VI\_>##Z\[?LSS^Z\_[\#I7\\;GXS#J2'Y9G__--VOS?!P\>6Q__^/\_
M/OK]W<M_'4>'KU_$+UZ^/3YZ]^9M?/3FU<GQZ]/#=R_?O/Y2FO7S3WS;C;=C
M94.B2G$UU^*C7C>I4/F/QMSF28_3TW_]FF#5MD[JLSTY?@/&'!@^17R*5E-5
M)VNZ(](1\AQBH=7/:S*XN(-/G,*'BYR,OTM38YXCGT^ZNA$;"SW'JFOWJMG>
M NPKT\)[\"0:HA5$3Y@,)'!W2[&V.'F"#\];\,\C\2TGYCPM9D+LV@0PAD5%
MD 684 O[!Z]0+UI!65Q,A!_-.@,S@IUD;NS2=[BM%=KLQV^0) R<_-89FA$G
M'[D74!K_NZ- 8+'$!D'HFA<%Z,"EN,\88*#EF*?@08-UV9%/39M*IN%-]P"]
M;[<%$?R$GV/[$C;"K?Y^?*C4C'88"W0(XBL< F^,'=&'S[HR:^)ST,2X:PVL
M,GVWK>'41VC%=ABX ,7?#N\;?OCER9OX'OY#Z"S?X9?C0_ZR\%;>AR66@G X
MU6XM>VLN%:LHL7!FD3U<-+\$AA]Z*GC:T)## 1&Q>=G654&T;PNP$=6#T&Y0
MP>.\W:O"4! '8:Q@M5LSL]OP"2><:.CL*8_#4S[P^1YN)R(>]_E<W23X2DY7
M8.A !XL-_VJ,FRS[,RO+NDAI75?:$.(*O\^Q:9<-@T4SE(*NAQ;[;,0R3T>*
M@F:?=OA[ DCER6Q%#$6>&+*GGO*Q)L R#=R!;?6J=B3B?D.#Y1T'$>/MGNPN
M;-B;"ZR6-9=;/(O=RX,0&8L+KZ';+A&D*4I!D)K40"FMP=Y'"=N F@+UA7JE
MI$)KAL!,0)&1H#QX</"(O@__. B5 '5$RAAEBF);(.\@S5=4I&W$U%Y6\;P"
M*^ \/SL'-6\?:+(AL7^O<NIJS2OTP_>)%8G,&*KB1F78#"GKE(*>+\R4X%WQ
MHX<)37(_?D?Z<& 4PL1$7ZOWX[=+&,UIFF8YJZLCZD1EQ5?\AK^7Q+_F=9O#
MFYK4_V3TD\T&V4\J8]-K [_]J:A _<+8SOSGGTYSTOOY5+]&W_JYJ";PG;?_
MG<X7W[^(?S.I5,"G9(+/#)D=L$,Y]ZV,)2$4X3+ P\4T*]/YX XHNWAE/_GZ
M^$VS+[_>I8OS\;')AV-L\I9CDX_O?&QR5'9W!VN4-U'F>CS,TR6YK6E.::3+
MM,[VBJJB.EF_E0,A&$#6V^[$5)\FR )IB4,*#,0"!S42\DNGK?[DTZ+P[R+7
M:E$0 3W%C_[JE$(-T[8C_WKHSZQS+*H 9Y3E,U!)\$]LY$-P[5E=S;4_])I)
M1G[?"5)B;IVVU6G;]O#R*88<ZF44N&?O4!*/[L!&2945=P#N)]BY*#L:WL/
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M*]@0$O]0$J\O5J$BW8<. C'B^''LT+"'*8WXK*XN:1P9?FB6@VRFXR8D,OJ
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M_<P<.^?^OLN!>]&"6H*;6H;%$6?'HC['[U#$<DOSD)@L&K]^ 1M[S34U:)S
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M_6V08WKL7&/KWV+CM]^7!RY(JM?!95J@V!@>DJPZJLHJQKI73Q]<=?'O?S'
M6&D9&YRQ]--\I;@&7#)]Z?A0B-T]AV%,;<[SZA"EZ-W#6GCL&H$/0JP9AB"H
M+SIXUX%B_ ;=1HXB/$MT$1+8KP(_=3@QB'&2*+##;F$<8A; ]#6U^H$H?*H
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MBVDOM#00P#0M)K(PY;L/#X[-W8V5-!0"4B7<A% C/LX?W?>IHG2^4)S+C:P
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MQ$P5K0/E8C$IRR J)GFX9@!$KA]F8K<(<Z:!>\UC8*J.(+. 9XXF+(#U1Q@
MH@.PA@?;GZUH.B4(B/1G]"0HB'^%;7XUEZI8TV9,)Z8DMHG3$-#YAXO?,T_5
MX1PS!L2I.F0'W"TNLV$J^IF\Y@CVT91&\FYR@*@&R?Q8?E/=]7.8*4.]!8?'
M;\ QWWJW AU19XZ@W(D3I8+Y$C!*_!;(G\'!5MDR4KM+*VHO&PU$)0V718H4
M$E3XG"R6A6Z="4_!. )&FDJ[C68@K[@L>+FHQ(Q -+#E8<VMH7[V>S!-*K5!
M]+(#]Q75M+D<C&:ZD%F2Y/@#9TBMQ<8@.+),K1Q56>02CH$[-_C+900:$3XB
M[&@_XXP%;U83 "BSJA.VXS*(PN Z,&P</+3,=#W%) C;08)V(*'LP(W)#3.V
MTY&4@\C8HLI)K#&$1)%R6K(Y>D$E46!]?'S?XJF'O8_[L/>6P]YG3S_LW9LX
M&\1+V\R.&OP23!\M3(?')]YP>.0=#4]=JW5H0U?IAJ#IO<JP'8V-WDVD?(.G
M9(T0X</UC9PE(SINEY)5R2.KP6A<?' T_>8'%![<QV@Z3='>A"]IK&+W'6Z7
MJI/6)+5JCW[NRF+J(=+@2AZQGA.L#'Z0__UF5!7(:^;7\,JF%,IOA?!9_O,R
M_?X'93NJ'U4+ OJ!SX)<Q[4RM\^\.LW!P0".<.-B-T<8=FLYO_N<-:$7W;HD
M%!^YPV& HP6C1R<ZGN+Q2M)_N.G5Y=YH<.2-#D^]T7B\7S\P+<>!_OH/E^@"
M)M_\,/Y.,>>H>3:N<,LS[_*)R6%JN[!M,]WVH@<=Y/H'?LE7_&,>YD']TXFX
M/$8#K/YRJI(^S[)D@L!$D+]OW[ZH#EF>,/JN^<"4KQHVOJ9Y+=0MQY5[9 '/
MO*/34^_T].RN'UH/M-%RS(KE#WO#?5!?\(^VH3ST',<')ZU#:7K)=X]QVK_Y
MH8HB__7EE@_/<.@=GH#]=/>/W_;%1Y4OOJ4!']<_Y%:^7LLIKXOCYA6Y-_1'
MJ.AQW9<F/@NFT&_D_=?:K63\,0[UQPA_J$2Q>U7Q<*KB<T0  M9-RYRM'_]3
M[^CHT#L[.?[2\W_T,.?_9'!P^I@"H/XNJY_+EN=^YAV?G7G#TR_X5@]RS,8/
M](D^]WC]AF5JAF1TRZMQY)T=GWFCLYK>VO2$C1_FA(T.:K; XQZP^].FU*=Q
MFOJ:Z:9JK#Z$IH13?#S:Q-R^JXW]%9[F$JO^MM?A=.B=G R_]*L=/\Q7N[]#
M\_]:8! /[F$W"_-_!<F-^S:,W9^2^;:MI3.PE$:''=>^N_SE/U>CORC@#1EZ
MS7D2;UM^@S8_'M9D8K\+'O[\7Q09QDJ2:91<^6G73W\O_[<H!2I=P[9M"PS
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MC[VCPZZD*9I[+^W2?ODZEN8(U.WHM"N[IG?1NSZ:>S15?P#'._RO/W5_*>+
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MOOLKJOH:'@\ZV3H'&X]V<# :A_%]KO@>:OI&Z^3N@]ORICC/L@(N(+%TU__
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MP@)$1^Y3@^C3$;GQE6J[B;\,\8*,*8A(EMZ$H&^7?NI>H\?C?CLX@'N&V/.
M;_14XA[S6_",/7_?/1TT/;W6Z6[O<M]M',=21P,RC@:<TZ\E^NMA!/C(X^2*
M>X/_,SP^\8;#(_"M3YV6%R9%GN7P5M3G*LN)Q-RF!07=PQU%[JO1?+=$PM.6
M=F O_CNA7?@^@4W!.JL7>D]6Z+WZ- F6.5HJE-"]0=A!&OQ=A"D;3&2:IV[I
M[V0S3>'O8<SIV[*@04,.ID"6$UN-EF0H29.;$ SB99)E08;&6N1<T]:#7\'6
M(_.0NKA$XF3 [2K7I6J?(\E#@^>2XQNRXG(1YCD')7T7GL<H"DL^'2@+#X.;
M))RE=XX>G:,@&=R=)N*G)2 VZ7E::'='OO6GXL%/A=>VJST\+-QGB?9WG.08
M*[>W$F]+/CP^N$M3=)F41Z),D#WM.3NW'+)]CF.S#\9-H:*5=@3)A?+X3.'_
M6W[4GIPP<9$F]#2X)@KA$/$/>/@1D)&&= 8SA^R%9+:/?Q ,B X6P F!WQ(K
MHVTH9+#*C2:)Q=F(KKT;SJKB@GI$^;,9''J\23W(J3X(_;"F%>;[]1(OBQ0-
MN35K?9M HWFKQSCR&/3ZNB,,GL;)?R!CYV6(JBR>9KVE\\1E^@7G\_#,FJ ,
MV3<JF-4>;4*A8$DE_-$6<)/(STA2WB;I')%TK<J#549%78#)$V#-\E3M5?=F
M'L2D9ZC9.YA% 0Q!=!.%Z1(_G8*L]U<TR2 D01W&SL3/YAB311L.[)@<1D)8
MNC;W%9Q&&$^+,PB_YL'"'P+4(6[JQ^R4ZC]1>1LFPQQR@>$Q2\&CRFHCURL*
M:3VY7I#NV-18D+X-P3R:LM'OO PSL$(*]@ (^AKR2?E]V<O9)RYG?U^"!X7A
M^6O8 7%.Z244,>;'R-HJB$ V6P4NO)&=@MAT=/%F:)^!("/[#005)5$D 3 -
M+D5>LR4:A?YE&''R"7Y+HKXLN6\Q0.?^-;[;&J"M"3P4M22]*U9J&;5=92%W
MM#!L$NKX)T[8(.J$+-",<G25H?G7?AB1-$>_&%8-3/)+6C9R3@OQ2654'HAB
MS.NOE*Q/4KQ4&:QQH? ^[</&7\2J+H'6V&B\#LAHP5 \@7/Z0 +Z/=99+)'\
MQ($-](X.S ?2P;U(?N(B^7;35TFY'+/_8IDI0Y=V2H.)*_D-O]U )&.6X'5L
M'BH;SW-L^>65%8(1YRIT05EQ_:@XL60RQ2:7R]0/,SUPSPTH?,/Y912=E0MT
M -,1<YG\=_=UD>)K,7SAE0JG2DMVB^EN#5%.F^U6<+(%@Q5PB<%Y>DX6QG^A
M[)\5L#H<<YG2_?!T-:LD+=G,EYQ?U[-L28JOB?]XXNK 5XF"JR##Q--M?HFU
M+OD\,5#2BG?4FH7B4)7V40A)JI-MI+1)XPA: -8C+^XOT/KX8*/UD,BC00^)
MW#(D\O!)0R([9$_]$VV*'O"R:U-C6_&5I-Q0([Q4*;?>3'SB9B("8%@KAYG8
M:ICC)54/Y@S;@/@ !0]D:.&52J>B;7@=9(+KP[006P=X[RKPP3J@&& 28R%'
M'"B;TL[J7@:8[Z*,+^>7Z55X\X'9B&1 F;>JJ\&8\]UE5,!OPYSL(<P"9>[$
MSW(7C [?700!Y9=MEUT9+G"!H"G=OXLD+19@B*#QDL%:>Y;Q!K]%VZU8%)%/
MYIWDK*OAS=;,M<>7LL^?%5%N3"++B-*MS9SQX+M*C &G-;TE/3Z!/4%_X20Y
MWU_.GNO7Z@+2.%F$<4 X7PQ.X+1H6&!"!EGNF*@!+ZR.5<L'@,=QODTM= ?"
M!+WTWU#ZZQJR'O'X50A\E0(7GSACL=#NOTGIG\0%J< \A[>0R,/_!YEMXP!$
M9YC( 7NE6LUHWX^BM2!EP/(.,Q:/(EF5!ZN"KU8VOLF?)1@$"&9,?Z'3$2Y]
M? SXS^1.^Y%GH LHK4L1#Z<<RB5QQN,VF/<-T!*NH"4\.X@@RL&\A71<0^K0
MD13<1]M;9O61%+FMOBC$D5SCW-A]KGXU4CFRGM4 "W_Q25)$(,*G&)) ^ B#
M+BAI64)EU>ZN!P!J$%5^-H5&_#@/G^7^7T$"+W(#>HGL"8[=ZV(4GG&>\(QJ
MB(]UJV"_D%0DSP45)&R.%>V&*3V.-P;N_N :HU^X/.X$U.X513:(,2>)K/ X
MQN(=T;QIL*"WX2?\Q-A=+JGE4E&LK)@4*4;5(F$R&9< NA?\R<^K=;O=#;JO
MD\-*>C[VX,HP5N.T//ZX'F&%-E(LJ Y:]^0T"3+"LLDQ7I7%\\%7NL!KMV #
MN*@30U/K], #VF@S_LSZQ%DG)ZNHOSI0QI],T@)WZ=0/R>M$\6Y\MTL_HUHX
M^.TL_ 0/2:6X:_P=P7S]&'P>_!?70^#]7.,H WH'FS\$D\)]0UKW/>C]P-TC
M3K59&+,'2XJC7*OXTE@P:_5 6>U@05D!:^M3))52NY,T@!G ],#W'7WG@@Y+
M5^0M&^>N]>&<<,Y*0":[E$W?>*[64&]G5>%VX'RTWU"_$"S%20)&H0(B(6YI
M+6:)+8'6,9/'255]QK8+'$+2NG[VC#,J% N@#ROX]#2X@@^>D@TJ!I_9(4L_
M9!*X<CJ_TC+K\8]MUV2;A??IDG3;:1V+\+D,/(%8T\=4(!FPH<O8%+@03.8#
M]PW+&3)BN4C-OJXL1\C@E>)F1RA<[*OI(9E7EAYA1BE)D!D*@N+CZR<JM2NC
MO0*!E'.,Z'9!N8P*+OM8)T%(D*'L+6(^JO,T*:Y4_$PG26'L 4U,$-])$4M@
M[<;X I<!B!\EB^;^M#1&QT@/BGFV$74N8+U"9(]!/WC&8;J@O-RIV[:LO2AI
M$"4?]&?L)<G]&TAHLY>-)-R<4HNO-CG8 '#>-!]#J^QPQ?5-)NS92DELJQAA
M?:[K.[+FD< I;9]"WBQI6D2+8XL6>.4ZT4+&H9 ^:>F"\9K84Z4H"%I<!,]N
M G1RT"4'"8%Y6AY0$VH.L2?!-'.^'1^ LZ]KQ72X/K^!)5B!O%IE)5FB.<,0
MQ('VG0[L]S*C06:\T."97F;<K\S043..E^*6%,VXWI]8IS3I$!.71ND0.^OM
M Y6"% =!7VR^/5^H>%#(X@]S9HK[]JA\_LCKR&S\$GD]X',X&).<AHQ!=OTI
MKB#SNSS^ENIZI.T^,T]6M*0+.:>G S!^I.S2'X$C:,B<O6S4QUB 9'G?$E I
MX\X3LN;IQ$X3NAUIP6.R&<!ZKSY#00433-8'[)\P;)",#ZD=<*BTJ?%&NEAG
MLZ?!,J E839.5,>4'"AX1(&?(DK?RD>I@BDI$%ZP]X37"D;!G:E.8>AC3$-2
MZO;8%&JR.CX&3,@PD:H]#6R;3"(F[V"$*G>":\=Q%>LYA+'$H,EEP,DJ1K[J
M1!5\HTD",R1N>KM$%L>$-19J I@=473]7:C3XB/:(7%X";Z,52L-G^HC^/39
M3/)FYU$(J\R?ZCY,ECMJ#3G973=.7DA(PM@0>/;JR42A9;/CEHH!FB1$D4[F
M/B*3:W>7&V(TM,/(2OTPG/9.&*W=+= :54TLJ)W&8QH13T>%/0C1E^R_<TQ1
M?U0IZO<E@CA-^O;6O^F&F=(#G#:'M[Y 4 IQ @K>L8>Y?D5V:3OJR<!.U@)@
MV^"<ZL_$AXZ:) 9C$0&JY/*"RA( )?P%28]"L%0]AXN;X F$ M)03(32,AJ%
M7OV,DWI!NB :-U^@HQY#7CZ%"PXB)7'P# Q&WM&EV2B,IH6G_:B&K,%,3@E"
M:NJ9RAB:A4^E2F'."*]IB-UO$<>*(:X2IA:5+&-I:'F2!4P[;+!@SY&@1:%-
M)]7#:5%TBHF=&:0/Q@9N$IYTYNZ-OC_<5P_'^M5GMI5@XY@Z8+WVDGMSR7UN
MX((8M?T]%J@4]VWH1?=7(+H-8E0"][(%UE!D-K%%E>OI)0:@>3[78RPSJYXV
M7I4 H"'*.!.SC 06J&*--+[?_&SJ_TT"&-P4+,!C8*J:@D!LBTQ0_KY[[:=A
MP-!(Q7(=B%,>.#FZF/Y$T*C^!$0D2UF)0@2+992L M7B+G>7$=S \I]PBSJ-
MT[*R^) BQNA*>AU,O37KRXA5@5^"G@BJ*H*I"^#OE$5!U$:>8^Z/$A^7Y-<U
M8RYQ01>!SU8X)H223RNZ%/QMS\7H$&6=81B>LPC2*R2L5C!?I&_KY?V.38WE
M_84Y?\XY;?'G[H5@>'[E(A.&TEIF1Z\%O@(MT&C >^7R]* =HDXUZFUD71ZS
M!G!5E:9]1)0XV-^:7?02)"](N%B)^I+ENX"5H-(H15U(&;!I$:THMTM"-4:O
MP,*DK:U.D[ZEBDQ2/?9R1>202!Z-<608"I<L6/=6'09%=RIR-F(O8^'_25 B
M%78KL8!A-1F^F8@4K3X 7.ZP2*X#QW8;6'7B:^399F*E2<E*($IO@GS16O-:
MK^ >"W91A4$B8TT%A;Q]Q4UI?X^[?FU=K,<M28-/6/2744;>T-SB!58)QQJ"
MR.XHFE[LW*_8$7X0S[&90]OE#VVZ:GU1=6?6)$]%&&2-T@ D@4-5M" *Y!"5
M0+2=V8+W3"B@MER%5N 64HUA3ZJQ95*-HYY4X\%(-5K.P),YY4]R4AR[FEZ3
MO_Y;DB.ZZ8,%%R WW_)A,.NT3#(_8LM/Y2;<W[! GR,-O9?SQ,T-8N-@,UN,
M#*LT6UD"61!0,![]$>HQ>UED88SM% 2;CK:\N!HM9CC%2?*$R1\PKC3!</F4
MJ.1Q6RH8*K+A6P02^9T>37Z0'CY,."(?!O8_&/:4)N%?HE]BW:F:O,FUVIV2
M B]-W'81("0&.45E/$M8!*P*BL".#R8%85L2##Z)RQ!1=0+R:DBN02C,]+()
M(.EL\,^L6/Z0SV'#P?\C7!?N3Q']$X7R!&?M$X:CAD=8!0.P<B&B&''P4ZD+
MP]^7,<$P7V&E7[?.!\[/R0T6?WG*5^%"$)W4JMP.#I7F%W$/!PQ&5ALFM?YV
M+']C%E8NK:B.&YL(,%HZ1<!7QE461($7)M4=LN^I3UKWFB5O)KM$??(,$4T1
MOA*L7,*R6Y^@^2,Z=_P$:CE0Q#9LCDA5LNQ]VM]\M_!['/L]L!I[JUL>-6QX
ME&G>2#@PG^H8&?*Z+"[!)\5%3@K0+0I,QM?I3>74O_\L3&%]%_Z4OD2A:!E8
MWA!8C#R1V4KC;6QX&Z8P55/#)%U(D7^<Z^HC>W?*87;TN:>PMY75P\ &;G5J
MCEUELF6*"1)N7%_/C5[N+-YPU>D1G+9T8J-"A4E71%H'O*8>K[.I2:4Z>V#F
M6KGD\%%Y'W?'1,)?]O;1UNPC29A1>)(CM6FP#/QJ7(2:SO///M@$*5927P>Z
M250U:%B*B5I\-,R#@E<0LU:%,J8>/*WUI5$ZNID=3+&T9(8C3?A1UH\9CP"H
M^RA NK,V3$1U"HTXB8TF8WC8>%K.^FGER55 [#'8O,+%VO5()NEQC:E$VS&
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M>9GI>HISI:8;%(G+)@79,N!W)#<>(^16!-L[<&5?NA:VPY-28;*:"-SG"YT
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MSG4J4L5K"KKHMM$"]%-MB Q(JXR1R2:PK 5>9RT,VM\'[L_)#;;J]BQ4@5!
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M1C!)")+]D(>@W?WQ8A\]32 -_&(V#?Q!3O>W\/M"\VX,66"&JL=O"%;GCF8
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M"^Y[X>(,[DS31@\S\?48F(:A#O"WGC0'3H)@\1U@J,K.!*!A? =/1CS GBT
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M@_0$M>U0(YM"06?B0,4;<[<Q6Z,+/M#\F03RE C(1!<RJ;\OQ<*$T8X5?^#
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M;@ 1HN9T+M9^*VL^+EZWR,E#'L*)9CLT;^,-W,N'5[ [+NTKE>5T)Y80G,
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MP)][\'4*Z?+3AS=X/;>[S#JP'@N/3B;U+#C/ [-0$! XSX.K6F?37Y4*ZR3
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MZL>#N]SW)1/[!%'NV07?V143RSO*.43:*7!-?)G8$20=0,A-=,>K[$<0X10
M%DXRI)9H=M.9[KIT6N#P5;C#E['#5^<.'U?*>:Q&WH3S*KE'N?[6OF@+O[M7
MXF'K3#SNG!V)I]V+MM@Y.^Y>G+9ZG>X9=VSSPX"LU&.HZ;2EC63[VH>A'+V_
MIL,0CY$C(EX&%A:&$H1+5$<@RT2(B?6"E1 Y+\FM:5;=.I*YA2@%9%6X<UI(
M*0ND8.EW- ,\*UJ+$'*48[%@T7K+.ZVOT0Y;>W"'?##<A8SQB5UKW"<(&'/S
MRK[743/*-T^%#E):(B".J\@L%1+54W.R8'PI>\UBN!WS@W Y8Y%&!RS0RV3+
M+7>'CS+7 JPW7%(G#QS2DCFE90"*B1QD=P*JQMXM4YL7@\<J4^(.0R>?&BI4
MJB/CWE>+2XQZ569I<9^#8?O:2"DC4$[%&02,2JR\60P"2G;A(@HL$N _4>@T
M\:>((<D'\9K</V\')O$<;%QA_#SU^07X4((YPT6!BQNNAO+W*!*S&S[%2KHP
MH!V0E ;B_">U;VL.K=1QG9!8> 1?J\$,4[/C8KAU[0&Y<S9=3XJ/BXNJ+=,
M\\W?X8R@HVZ4HEANB1EX.P 9HMYG[<O3T],'6QU\N#4?/W_4OKQQZ[[*K?N,
MK?L&M^YWQ[K?A$5<=BUB9 *W_Q%Z73"&6V>'G=:)>-EK]=JG[;/>Y6=[,H8/
MXO_F9O&K4.Y2'2'-*YS+2#-/P'K],]'H$*Y#TT*:CRBU8S=.Y[.*=HMHGGSW
MR_.PO%_Z? %Q'ZL6WH%P6V$_S#LJ%%=9E!*I7RBXS=)?&QV'C=1(^" AO=V?
MU=NK'Y4\U#OM7QNX::"K C>&J<[5*(^8"2'DUC*1%PH,95I_B]9M_[U4K!2D
M<J,@5:M[J7-'ILWILGB'O(__O?L/4B'%TKLO%V[:H^-+=OA:D,Y)LJ/E92..
M-6OT^:/\17Q_?MCJ'HB=(_$_8JW1V)O':.NS4;:\<[Q?SI!GKN^08['%C"*]
M^W(@ZSAA=GFGJHX-]-]F<E/8C_<K7$3,I3RR,B\#F=RNF\C;&1ZH\BL_2_A*
MF/"'.,2#4].7$$&D.WQH5E8\4H?:0'-VABEJ7##,Y8_J#'] QO\8,OX[PP-U
M+AAF"5][]P4*Z/ LW2B/=6>HWPA2G^V'W&K_>UM@1ZX<K382H-H(QA7@H?.X
M=BR:Z[8U3(*.RB@5/L)61DOBMNFN+ ;BHB49[)V%**OVY<J@1=$8YD-DZD(H
M!,^KB&8][4LXYI!EG&6KXRF1RBM;0REKGG&UHZ+()*@2])5Q0]C@CM6XXA+L
MV<K7]-1FUH$2J;)I;EC;9-HP"TCQ3C-Z%OJH*H[0,^Y8%T<$?VP32[@6DY2"
M)[W[ F(FI.+WK'U;<T.>]6YS3@KN]HX*D]E C.MH[S9+I.!][[XPJ6[,&X\B
M.Z+2+GK)W.\*^UWTW*X#@UV7#;EC+9\SQOTO+A'CHY/W:^>TMT%#'N^7&]P#
MF\L$,_GJPIQ6TRVB>Y/+@:0L,"=Q71!_)QJAL#V,42ER@3"7&^9FL^?YW#O'
M*24N0I(RS9P4]PXRAL1%R%QNV%S>.W-21Y<Z;IWKOJ7Y7@(UBSLD:+ZJ?4+&
M"[9<_H;W7)*E!;PCBWUC84?6\?Y*/5EOMR-KHU4.*Q\AGG6+X>!4-FT][=/S
M]H5PWKIH]:XNQ=;ASZO.90<&$(B'W8OS[D7:PPA>]<"IEA.]-NGFM\SM,,6V
M,K2=EI%(9N5&ALEWM.FJ^*%>U8RL&8U$J3/KGOG/X6&[?7R\55S &ZTR;[3:
M!#^$NZ#2PT.XGXJB1-Y6JM(39-)/M4$!$&Y^2@]%\6U4.T+ZM8N_-D[?2G;T
M3=HMM2.TSZ1;ZK6N?35#MO U2>T(Z=<NT]HX?6MIXF%!3'C;B=P B+'4*GT2
MC_>E^:%CGZ<<\']GO=]W@0#H_/AGG8<Z,PYU2CL=ZEPA"!-@SNV,_@0F1E$G
ME%[>B_9Y]Z(G=(]%B(.=M]%_G?7$B_;7SF6O?=$^$L^O#DXZAV+K\+![==;K
MG'T5CSL7I[L<%ULOCIY]+C)[8'MDEJ/?6L5I[ -3MO JTB/-4@=DJ\0P4T!\
M8^:#C9_OAQ\?/LHB&:<E1HS3$GSCM/92@#$&PG2DPUS.Z7_ICC4#K_0D0V+C
MFUXSA<*?M,GN1==L_3M=1H.7) P&9.\IA,+Z-%IBXV@)8D AG@D",]7>PZ/
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MXJ_H_-LX5/7:5+K6E?OUHW=I7,X<RL1< ;,P;[:D.'XY/'V\[7ZM'+3[K\8
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M)&=>].?)S4O_]%95;OM]^7SPJI7V$69U3@M+YO/@6I(CA?A.&3%?I5 J+V;
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MY#9T@4C>,QEV>M'E(JN@/A*V& $=ZJB9]0#;R+"<QP(.!2_S"-61GP#/: "
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MT;0<05U90[US4#\I&HTW=B&N3FPKFUVM;$FZ,ZNV/&5.*0J]IGD$&P+*%"2
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M3P.ZCR!/H9J"ZBUA,Q%I(J:^I3W"I>.!C2L:G:AN8!FX%PGZ,>NA( _"4CJ
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M%J;V'!1(0DR.)]X."+_#+S!X8 QQJQS5Z2'[XA;KU(FF60JD<R'!0DY:X <
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M@<>BFA7:F&"VR0/V, TEO"2UL9I$<W5/@0\LX0D-7_0>'=DFUM  L"3^$S-
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MR^P_   @J[$<BL'DT+ZVU-'O^0K+8D>K$0KZC:$&5=0B?Z:0-!6PKS Y")?
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MG"@L4VH T;BT#K.,Y7J+!/8, UI!!0F[5$#2.NNO$7LW;^F0"?)X:O<!Q-)
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M7%Y4?!,2YY1Y=R_V9#\/-RXWCR1^K6]"J9@KC3QHM$<7WW[=% \:&U(JML_
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MD+XBG<BC$A;WJ#)I>E2>+T1[5)E$'A5Z 2E2 + :HE7= 2&FXCUZ#43=4&S
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M!O_V2E8/3-GCQ^Q[8R3,_D*7S9"R1C!G,P7;M7=+.KC'AOH*5\!X*'4Q ?=
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M:3H\UPYP5DB3D@3S"4Q]B*&5,V.T?O)GH/L0=D^G@_W#WNJ"PC&Y?@VD-G0
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M:F7CN(D5X>YRE$\B7NM-^A2<"<$43B%F.I!1#;F:!L!89"A?.S[")PAD/-.
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M+>MH_Y%5&1?;@E(&6@KP2\]6,WAG;_IT*".JO$(;W<M4Q9N4X1!(^YR!GL:
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M_4+VXKRP\G'#YF=7Q\Z+JH578W[ZGMO/H2<%3K"RB/)-<)]Q+?",R;/KT\E
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M-UP$!E-^<:F)?N:I&0^E!("P!+X0T=<^*<T$CS\1?9E L]-[:$YW\2W0$/Y
M7N\%+U$U#9B&H\LC@)&#6)8J>7_@^F07NQV:Y"_Q:[Z-E#DL%?^%-&'?8[N^
M.1XC"$$[NM>E;W\HX^O7^JCX<9Y@4'J5,&QT 5DD"2CBW;QK+&._Q$]/#28
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M#?0Y93&=333\$VJ72M@14[09_NCX''_QW)@@9<QS9'HX"63UB=7$T?=A <R
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MMD,NJS*I>Z9M(AFK3<0#W-7J=NSLE4QZ/32=)MA(P*S6JW.57)'G_I,_N"2
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MR(R=$.(080-4E%Y$@N@)PW@HIH9=5$BQ8O _G(?2OF=B*6'GTC6) ;MOYBO
M[[!G$+Q5>!4#K8#G31V>)9Z,-\0[QZX,)K7!,= 2^!*T4LO8=+%\3O%-GN+/
MN!UI;0B]T\30D]49=F,)8/44.UO^3\[5E<]:I9N8:TA'.O9U9-(!_F6"5$_@
M975;GOH@2!,ZQ^K:J,%G*'8M@U=V?VPB8Y])'TW(C'DKE(, ))N2TK5<V%/
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MFJYK0YA%1L=/N6YH9C%@0T?\#7@[.<V2.EO_?NHF?Q3G\J!J@0H'2ZT].H?
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MXB_'+>Z=^K@E:F!C$[>4UND8VK+C7+,$;)4->U/DGW-9@I]BZPZ3>D4#E9R
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MPLZ8-4%6;-*.1_J',V3<"_"]DYN3*B61NP-9YNJBKF@P[&JND!CH!?<)+:Q
MJ!W\9(--@K\"H5&H>)]ZRXY@<DCH(NRN)9&V1P')7 U,5EV5O\3-;2C4%+Q[
ME6BKE@HE]T TET(A^L<J77:W&WBO!?\W8!JZ3VG[/T*"0$[/D'4E1"E9G_[H
MWW2_?ZXK11>0KK,13!=K)[QGR"DYD"VN]O+9AW+Q#V\H$\[)3]#<\1'46Y%X
M\^W3\HOY4+U]+J1*T"J4V?L(RF/NG6@*:>V=D2YX(+&(Y1*_0V+%[%1$2#D[
M#*BSIO1FF$B%2HCXI"-$UPT20M2.KDU73E!PROD)J5KJ-R3J!IR39'[;MJ4"
M-=J-&5(^]PJ.QW)OE3$LX,%GZX9\;^Y_<%WB0.Y_I+D.C_7>]F6["(]4^KOW
M=?8A>U%<N6C#&;RY(WF\W%9X7@J=FY=N/5=)BCS>JM5HY,FO(4\N>Y$-HP]9
M(4V/8;TK&\_G8Z@?MS%X2%-AF.YM'(2JN,>KQL8ULC!DH&%S&P7\U"MVL7C?
M?_I1=$XPA!(SN\-DD^$<B1Z1S.<M]KNANZB\:C*#/<Q,95E=Z5_Q-:T4+E9M
M94L!$A;R,TC^2!G$*^+YQ>/'Z\_W/U5H_OD%&"2\*KZ\6@^S%8,4US"(=XQ=
MJ*'JLI17C&-N2#H=6 .288JTP5]"M.F29=[)>R1YC+^)H!K+79$_$HV),_(>
MFZ,K+1-7+I;MZMH((<F BI06@^&!SC*V*+*FFBK1'\"[R$\V(,3V8-EP5G5%
M-/"!TJ=X.9@2H.9]D]WCJ-:^=J_NQ*SA=%ST1(4USUD$(VUBFW@PW@:W!&)>
MLQD?]\7NR2##;D(*9JEV(N#9%I225>81;FFIM-?.\F$D-X.^BMZYCP;WA%2D
MP]!'N$4E '(P3)T:FPS#+L-X%MQ!R""29QH6)Y!V# VK#@J[DD0WG>.[ST@!
M&28+>B,.UH?__N?\G+N2D2+]PW6QHOH7?YE$IL"=KA3_I640^._<^3D+UDGR
M2_3<*%W#N:G-B,=O_\#Z2HEX[%N53T0KB@@*#(0G:O#Z@L(Y(:D@FAOQU6!<
MG;MI:5'Q7P[NI'^XFBX.Y=&_7!N+'*5T6P.2YK/N;_UM?0U^Y421K!#2?W]C
MV@><@H[$Y_,APN*"GSTCI^BF>RF [IZ(CO-4]UI@D70=+GXYT)A/RK$I2' ?
M44*_WWSL7#?;F<M6A_O8N6VTVM<]KM6N7_B2]JDU=Z6RJW:GW^QE^AVN_[')
M/;1K#XU6O]G@ZIUVKW/;:M3@'U>M=JU=;]5NN5X?_^"NV>[W5C8=:]=!\K])
MN;DJUM)B<K\GEW0E;66EWZTIZM!<8W213A PNEC1CQ8AM;$%=P!IPS<'2^5[
M__O;W=OW!PD=3;4K9DQ?36(I.UC./\W5GYTK^:J("=)&9J:ECK0IXOZ\U0SC
M+PY3@",DL \S+;D\%B6[5[0PF#\\A])?J! ><2J">!\]'X6<#[:^. /.!QJI
M\>THDQC>ZN?P;TGCK 4T)F*[ FY-_)FIIC)T!FUN8N..-$)D7+WY-"*X)F(O
MFAP21Q/W]]FB5FU["B3& &60Y%T F2.?L4?+FR0:A9@PNB;9FYKG>Q"Z)/ "
M<Y.-HE<UD_,]!NB ?'D'F[R2K,QA-5$)#&3!G\T$$MF83^U&93^]L7. '0B*
MCQ9,>6Z%\CPW4^:TF'NFF5BC ]HJ63$VU3,(>XPC$_.3/,:T7?"$YM;'E(7]
M0<Z K ])A%YP'M'@N..1XM1OD;S_%L'KK=D#P;'GJ>*_CJC_0Z^%]==*S76M
M;/LH[#1WGO4'05QF\S^.^9ZI#I9B3]!_9#^W]6'N[,,] L-$660(0+W$.53!
MGBP6 U&7C-.%LZ\#:ZF9VOP)/Q>:3K(4VN.JUKLD@0<XG=X#U]8NR&_/LR6>
M:Z"AR9&$<NY?[C_Y _GWJVQ..&<&%M'SK(R:04C^V9L/L06*Y;10SIX+V;_(
M9YQ2#=+JD/F())(CLIZ/'VE"6(34JC<QDYA.+KOSBG_T<TZ0(NV'5W)%[KR0
M_>L?-UL!A%#=!0_44O$--&?9:;P*SUM$_XLRKA=A%?3A3_B%D/T7*,.H0GZ2
M^_<OGB&<&/)TILACF;7MB-ZEN)&*9-=2\ V";\KYR+YC[.O">4!FJDF GN-<
MA_XG2G >KL=><*Z%<J)B:!Q29'Q[VUU%IDZ"L0MV'3'84;AF164$V7%D7Y'6
M=9QQ;L9U.Z+7/<&'H:^:&W8@2QZ?LZ_AY])W7G!-<I_!A>4;5>[#G)&T&?Y:
MQK,SE5DCY)<$)DJFML $W[]PK/A0\"%#*!;B9)ZPUAB30QW!U>H*<-'5*^0#
M@%B)[_DYWLAOWB:U#XW4UEY(K)5@/JW52?GS;)D'-=1#3R0C?H]FFDY$[<\^
MT0A"!;1!:PJ0,^Q@,6O3CQ$!LK[9<([8+^<9]B9+SFV9@A]R2)U A!8BK/9#
M#?90%]]0^09A((:>ZQ>D#T\TR*0^JPG%>@ +QH*)Y_0DVJ'9B8SL*"P\%(UD
MHG^GXC.F'C"P^ST@JF :DDXRHK)%#LIH\'I7EX[W*$D$80TL27H(V#92)4I#
MMND,227)4]=[+(DGG^.YD2+B<\;FMJR/YE,P=%GK$565F&G(DO '1-5Z"N*F
M<\649RY"LJH'@\'MC64LR#JQZTDF&(J63!$_52.W3LAJO.<FXUW8^@9H,Y:A
MZ([FEUWCL<0QWB*^JD:4)QD02=YJT*3[I]:ZD0&R E;"-H\J^-PK#1E$<5%
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M8?EQG$@=.>HMG/N\A6.5KQ.#O!.#I*M?=D)6*<!M:9MYK-;T1E1IS)"6-J6
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MHE$2M)DRQ&AEN7?QP?BB?OM1UOX-RCV^,>K T -USQ'/8+8(7&;C:4AS^63
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MY\-.]?W8!SD2GUFTY'M]LB'$^X7?@DU0"8?*[ 5!P\ OP5!_U(S0YX'9Q52
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MY&-+?U(=+<K(CWE=K73'KGF[[A$!8>YE;_]UV3?I]"/\NUHQ;CE7?!7,6]D
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MJGF"V>CECBFF-Y+B;DHA6U'RY<IF;VR>I51*1?"Z%O0J=A2PIBNBB6 )D>D
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M@5A.=I_G4>!7@5P(T@A^V0!_!9;4-<%TI.OH<)7.=I"T:*EG$B7PG(Q,C!P
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MD <LY\*+]MF+_O:KTH7)(#YDAD\"/L<*0A$JP3([V+W,.F$#:IN;$6#]J+\
M;:]/LFS;MGBU5^*+F_Q!W,N]828*'.!:9OI2RR$5%>N.,Z0F"L,,\EDDUL*^
M)9)+D="Q0 VA6,FS$4O(T@J2/!SFJ[D,31OED.AUC;E09XDT)G#S#ML8/YC%
M)R<8L(_PT2 '"ML#P"<#=XHL0YX*YUYT1QU2(0\X:Z@U1!8!(X(1=,FPAQMN
M Z;DHVI9V-\I>2G)Z!-8R?Y/GNZ$[X#WZ+N0MMQS->'$V@/3<DXQM2T;JL,3
M_ZQ!-K#+5Q30FU$Y7SU6SF^Z<K[P*U7.'Z;T/!;)_\)%\@>MI -H)($N.H'S
MD1)N#>3R WHYO=!'YH4^?@8OBA3!(<^D:/D0:[^D&E[JWE7]8EJ&>/83K3VY
MA>YOVF+1C63^<IX;MAPYP0L7,^7"YPK9DBI;\*M36.TS5NGRK:F/CQ;"LF@A
MTR"EG7GZ.?CQ9'A=U]([+)H\,EG='%C26'%'N!Z5UQE'GD.)S[_!^=1]-(Z\
M3L![_IJ*9U0$QQS\]O:<V[)@D'Y0#08)1^ SL8$C_$&Y/Z:.F1"[^F.N<1+B
MTZ7(QP4H>EZA^91Q"/JIK]D+-/J&H5-7<8#U$6R( ]@<!P6FG5N-%T[JJ.HU
MVRN4W/")57'4025&]'M)7.E#H5B7=2@9^0HF(.4K!:6ZPL#[[9'X= $;Q??*
M;9BF\U4E5RT?T 2/G<K,)8>]_L(R$S'C2DIIGBEZ>T!>OY;4+&:40JZBY#/Y
M0Q2;J5/BIDC3F1O=[QEI5=!Q^=P\$T47&I)V',BS]:"%I4G/&B61O<(\OZ:+
M56#)/8:_A/XY@<GAQ$,0X D(H$:/3(57%+8_G,4'\7!=:J2@&DJS(\HAF<SB
MP\.H'='2'-<R.#Q_H)31Q^OGB4;>@KA$5]J9'.B8"W=48BTY*C.;+9<@:=F+
M!+6%7S4M%N3UUCV90]7A-:65S!]O% F+W#'6)1-@[DF^^(=\*N=+\"L&[14X
M(4QI"2"ZH?[#U7OX4V "^/9)A;Y8+?YQ;#3?51<<#7X^V/CV:Z@I#PH947%L
M([8E3:T83CC;1+K+1,Z:0=[!TAT$]IQXP,C5#/QQPHJ=L*OC&0N:QZ[5Q0$<
MHN^9D*BQ$@($ N6&)09L)]17]/?I.-5<2Q$@\M!/F/NXA @.K!K?O0ZZ(\/O
MAEW$9%.JDJ^+EF5%-C3G@'GH-<B!T,T$9L[: 7QK;&BUG3/@0)J_PTP+/D\%
MU#C'\=9MD3#"DB34_(BVBY;**4ZNX;8(L/(3U6QB28FE$;HK5E9Z[>Y2L-W]
M3+[3QF [B,8Q##6@/-)$RHCC>E,G14^T782ZY1FZ!(/W9J68"B6:>+""6F#$
MQ('7)!X.(+44=\EG!QT2G/;$PQ4 (#WYGA'$-1)$U,F=(P2PCIC+C$6+ H.O
MZ)-M(_(ALG.Y/U).#RT#%U&S;;/OX""VU=)RT42;V'!Q8Z&YQ%U=XR0UA-26
M]1$ATO+FQL7"E6+Q^=/"-NXJ>986#K30?'F][!ZV? %7X*02TC&?4_^34(^7
M77SY&'/:%P^"-9#;H>I2W]]/ :Q!YP GXC"_G(,MZU;7'2$X-NN=0I"FX R3
MV,,EK]PY,$W F]\!&M ;IN$#Z@B$>G^4D!=(H<(:?P@'H4'CZA!^"NNL"4]'
MM\F;(+3P<W1L)&HUU0D5'-P>9ML&,+BPH"<(_\1W@SX/06Z@/ (KA[6H'F-T
M![!X,/U)FQQ;X_='"'D<1G$'-M+#"$[U0!<%^Z5,CJNCRD.\0X5!TH2&]+"0
M(OZ<*MNY]*&/,]1ZHQOL*&>TP"<ELJ\\XE10T9WFC682R/>!HG\SH;P?G1+*
MT."P4I0[8K[@7?/>'U;(O1D^AX:O+@C)1TZ=W@_@@2KRT 3CEE88^WQD]@$+
MQ-+T0^T9>]I$2XH9]+?84^B!SZPIAGN/JFWBB)*)Q&<6>7//Z RTGPC\;VN\
M58 _FY]D(D0@]K>!OVBRB3EP$!ZFH*7YSFJ' DVF !X@I%Q>FDB#E^CQ8W7"
MI[QP7S2P"W8(7DZ;8LT@GH<T,$XW/!I >"<$"82].I,QQQ)$_0,[[^E#GQQ9
M1T;-II9$UI<? Q^@<DILN1A;.KW0Z+)B33CV#O;U456FI4:*)<FWY2T:0>@&
M;X(>!MSHZVQ$%_EJ#B)!(>6)&5UT"*);D8^Z$:$TT-8X0<,,'))W>-@6Z7T/
MSM\P1WHW.):!QM8$(:"8HE?X7 :&7QE4^(KDM3URFR!N 03H+=HCR8:2T+-[
MX=$1[&20)E$_BSN,<#R>.%7)2OY[? P*%M(@/$C*<= ;U4"(P=?])!28!&&-
MX?0)GV(%E?,0A BV^/) #8=.V$7YQ.I9*X&SP$IB'[!';$U\YACXW+5R4GLF
M 3NS292B9'ML@ER9<(X6Y=:,UMF]B>$R0'"L2(D1?C\PIE#$VJG-$#Z-DP-5
M+^C.):L4G1 3EM&RD-$$NTJ2&9='DIK;U+J87(COX"UIC/Z"HMCHQ=6* 'WC
M&DXB#?>*"')J0U@NDSDVA*5[\>MI""L>&\(.Q 4X]H7]PGUAK\'AA#W<<7!E
M\JXN ^#*=0ZN?-C;._@K"MU/$/R:L%5\S+S$#"#81S;':(H,$!38E2Y.)V9!
MNL@# T:\YX:JAJ3Y]5B('.=:,O@V/=.R>7,<FZV))IQC/M,P#-;))[Y!8P7!
M39$=U?X.^V:>"(%,")2;($"<9F"S'HM!^H,1=4>3:+FT$)L&] 4A0KW4+?AZ
MKHWX,7R1"!,*B^(Q2=W"3;LT?MEV@N=V*]Q"CN.'P=+P\73\4&E@>"IZ>/!F
M]DCA5%,]%WL@3D\78U4YY'_ I033U0OP<L#]($:'/]J/BDOX+$E8KA2,= 0"
M1P2@CE,9/:QW9V"9[N. 3R@0(\]9&+CKVFPX +/2_:DK\"(;IYD/Z9-@D6-]
MC5B,.&O+Q@GKW+?V: "1@QQ>3A.A S;<4A'S8[V]\8^)$=YB6X$I#[Q27Z"_
M<[]54^&40E8Y*^0)Q5#ZWH6$8_/?#8(J84X%O$@3K.,A%1%.) 8)$.RQRS(!
M[ )8,34#N64CW6FD.4V[T'N2\(L#)0:X'N'^>L?([IM#6'JG0:_FU/R*O(S#
M63QB3./L@U.6&T%RA.M4C^.J=KZ'X%5(*,#Y5"@&"<]Y^=%2>0@KH4)8I09P
M/E U&+02S/FDV2RRP9@S^+4(\*K-XIY24I40R\-A2)>$FUBS%S'#^EZF*DGR
M<MX_98)++ &'!.L\K!Q\LP=V0U/73:NOL>F[DO]4)E,FLMD%]88A5@]G#H7\
MA,,L!3**WE-8P)A&C2,+L!4E[2&\)N\H<;I-PH8)@S>PXZ @]??)ZBU9 )Z5
M0P^#N5/Q.2\+ 8?M3[UA5TN_PA,,J\B@/DRBBWB[OS\#16@2423*""QA&!I1
MGYA7!DH3":(GB:ED(PUAD0RYP:<<T+,0&IG%.6_9+'H^7 SAL81Y]3_];6#D
M&&[WLV>0O8/7:4K@!S1?#ZTD;3@Y?0]._*F8QU!G@^U;WC![N6';+M-=81FG
MOSWJG=U(Z(8!A*=);?7GT0O;I^!W4.+J=$?@S/RDAA%1[,"*.(+8YA.A#!)$
M1:UU(;?-,3!\N9!1D,79U<MT]3+R( XIQ-^^D4+@>S9/UY"\%2SOV:&PJK11
M90*?W,N^\#(2_ I6G/.H([.LG_S9,=X@2"F@+[E02YP?1F>4*%7Q5:S5Q\9J
MW-EKCLP=8X)8I)/Z?&);GP^2]-O%4I;&5 6\S7M RFO9K6J&RFIJ<-5B<#N;
MK8:'*8D2E[#'%ER/\-+]TAPP,U!U7O@)Q'FN+I0A]D#I33;:38H29<1:H+0>
M)YNA_ET;Z@/3[(ELMIVX@&":'Y:,Q()NHT\Q'$V=7@JK5:0P)+SN>+!]"G?'
MW#%7HZR.E$[?@YC4T-NALFB19$?#SK3XBB?,=L%,#O/.AH10"QX7.E>,!9 P
M4K?BU56QS#$8#8$F,Q51@\2,43 48$6(*-_S7&<5D[+6(YE%_D'[AM"MF*Y$
M9,'/;)+&E_@2]G*&<\M-$Z_5+'S&<,U]JN(29$2>; !B?VRY/4';?3"%J2L-
MOBV-P2\V1!F[HSU2@40MH0/8J\0*YYP'-+E%9,W8N</JT+Q*/CIO'B 3DP[^
MQ$FZDZ-UL:.IV7 =UZ9MR[=P^ZT!E44?K'Y^;39&EY6LVZ2<NL@Z-+<,/279
M'E#\$0.(("B1I[U?=R8!H:KU3E6L&WW4(@Z,ZV#8B[X9J,]D/BZIB_@R>OK0
M17DS8R'XG.AB;'<DM'-L789+LH<%!Q-7*,56J,CCH<L'O7BBEM9'G3=LVJE"
MA6+&1&%#2] %A-73@NW8Z_R:K/1.7HFBWR"R3OFG6%A<!RGZ#MZ;;.&(HV"B
M%,MBNQZ4WFJ+XM.Q52H^=_13L7_F #.B86'=U'L3%N!\=;E>A9:MCK2CR-[!
MXFL4TIE37WLD&)SUZ#&)[7O]E$D(2@2L$[1T,BX8(;J&[MA)Y"C%NMW3>204
M??GI61%!E$:?F3E'>*D0)H6\B$:4IJ6 +-*Z*@,0QU=PN3'B!7/DN@Q45K44
M9!HN-(Y0C#OJETO![%FMG0U6A@?R_WXK1<N$5F]M"S+AG-! L2<OAPVTK4/+
MK?_0YH$7FN^P#F2W,2#$S9+&2LV3I4PB"FASIF+8 ,)I\E7/@CE5<H6*DL_'
M2&SY5^U@#YE"=M^06N>&@%MG8F\*HL[_;'?\]D1] _H._A :!'+ 4'/92EZI
M%(IKP9D[X&,H@IS*Y&-8B'L(MY<"C-<V'76X(Q"]!>YA)I)>3BGD<TJV/!,P
M=BX@O0,_BB+B9\^FRE\14W!#?D:H:C_4,! O6P]5\<__BN3I8JM-#LVM>70H
M4W-)"F[^Q6TA:"DO\#\_XL>]_.=P-WFH6H^%$6A6.R6,/(0N+]WES9,*QB46
M64_$OI#51TOC0X?#8<W 6E@[H7SB3X*FB*0:01!^L]!"*%H*[Z;J0SO:X[]8
MB0HF@YYXFFZA120]F49<X_ALJD_UJC.GXQX&DD(8VEQX$>'^86I+CLU\.T09
MFIZGF-%WE3WV76VZ[ZIT[+LZD.3;L>_JV'=UT*E>ZKMB&E7B=9>!HLX6AMRP
M.O:P=WCPM]0PI)K[B(@'N4PNP_)K5[76.4W3P"MKW<LWYAG]]C134N1+K>/(
MIUB_1W^BVKZ+@-UH].0F%5\W.?C(2<OM.%3X5RAG3G.9-S+KPJ.:7<)\A+]+
M[[7>(]+%*3Y, '48<AVHQ?'MM.:S(?.J7O^QE6Q1/BUDWOP5I"_,_ 9C;(T
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M,Y>)36,2VY3PB/P94I63@,KYS.#!!X4W=><&:V?4=DGL$EDB&8+USOHB,^R
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MZ8_ZEG0N5FA.;4QDP+_PE?"O"_,F5$5U!$37 DUK_DK=&+G'FNEC*0K$+G:
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M^3[R67(I\J$]^G,2 J<[6,P1A']%$1"+[WZ4Z^9$4*H52QG&?&HS7_VK4HM
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M>@6O#>T1+%*PO%KE^5QD&0OP1B@7'8S-7T4X02 'AT*Z^8(]GAGB2%37',:
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M]!C.R;#A_$(9$>(8Q9)+@1?#;WU9D)(FHA?$ITOTP^&AQ$=/TBB1#2F]49#
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MB#!R8R8DV)B((BQ6Y+"E$_B"JNKQ=8^4M$;* 2["=7'O+M<R1_BI*17+1YA
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MU"9KZ-X\Z:Q[SR-&#OEIBR7$Q;9)8)V\SOX@_@#^4P-D((=%(5&]W8/)QH=
M<>9*-US,6 E=2,$=8?H^$]]EU]T)%["M\FXE$T8J"Q,0(U7!X?RM+QF(:W4U
MQ(=4JJM\4TOBE1NSZ[_Z>5ABC6R^/9T/'8I=!>+37=V7VPIH"6E24X=FLFX1
M1]2#>3WR.M1DTJC359ESLQS;(O%?9)"$X/W[K L'D/%AYC)9_P"RF'^?S!(Y
MM[ M!?JA]ZP+I@ZQSYJ1A>&T\^ETW1?,GBUZQDP?H-+C9ZZ7BD?II=D.,6=;
MD-MR,[5MZ=:ZL*GB0.H"!$:"'34VPLKLOV8I<(*2P0[D8V-9,($6UQIHO'8
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M-6"*?+FID$F)[&9*S?="+SR'"38N+'E*>X&GBT"OZ6^3ZU[0=FJ@CH#AE3=
MH(Z:VY9++=D?(DBMQ_OW!63SRABN6\GY">I.C'MI $')B^D":^QS@ #=%:6O
M4Y3MK&5]1?V#;D>@<)Q?QO+F[;3Y:8GA?*LB<\=E<N8@+\OCJ7D6?[^ 1;3*
MVZBDY9%E=_3C1&XKJ]>8+Z:$3 49NY'+%W6:EPX@T\%=4O.Y0VB<"I7X*$7K
M34!+]^:;MU\.9SN2FI_)!3IR9Z-.FSQ]T$M$RL7=N;&^[Y.5Z996M%H>.!"J
MH]RCM?RE/K(^@Q35$.',5N_!A*=W+X\'.+P=/VYQUC'@\LC3W)BBL7(+$8<O
M 9L>=<^NI^N6>Y2SD< !Q+,NY[MC%E7BE7BDLY:I7Y!-D4J(EF'$4.QW_1Y)
MG\=_U"L=H24.[@SO'<-> L0[\9,SVSY@)'U=69LLBG%>S*8,P+M:;@ Q^3&*
MR&!!U[FU7=N/9D^WJ]39R]'\C?+!S8U9GA6DMVQ/#I,^*6#:(<1QXT@1TH4]
M1Q9J6",,/[5%6WA<A;V\&*CE^("Q#/8M>1X&/5 ]/=0P@1#F#N5^%<%9:K/\
MZQW6Y;+ITCC"=GN2AK!N]G[>.8B^("N]]_LGJ_4Q8,CG5VMOONK[VQA2:_R]
M70( 5:I&BK^@EBHXG*PE^E/X;;BERCYH5B2\*K_1+?]YU;',[E$!(<Z%LA^[
M*PW>?'FWY/(+("+4I$$(. KESOX,!@"9^L1['XU02RJWKY=JEUNDJ0BOVG=<
M*CXWIC3>U:WOB+I1OLN^A5\L17Y[#I_48K?A?1?V Z"PB1]SR(("@B)+9)2V
MP(#NV6/%]LM8YDO54O[&YT#5 NC2"%;G3?=K<L+/(C <X'$!DXL.(/Y],:4>
M >=U-DNK/%W6U +O<;E80HCNZ+B,*'S^(*/^AR Y$S[-3T-0JI,6F)Y;H#->
M&@L_2F2.TJ&L,W]YK4KE%Y=_S<H!DK=]" F484J9?TM\=EDA//5'LK2!O1^>
MRV/-J;.;-?DY2Q)>_H%%WR>2%Y\?0 [A U/]K(#JI)]0$0P/W2Z]Q/R-1JJA
MQ.[-&+1%8U94)6%+9%6J*G.\I+(E+-M9$='6F&T[?C/-D?#R6E/-P^E/)P0'
M:;TL$9OM,Z#54H$ U@J,8FH@F"NI)%C9V6K:0(2&%,MF3'Y41V(I0VG3H=\9
MR']=,IN9YBK>3ZIO>K39E_)744SZ$I0?)7N)F9V$%:'S<E-CEZ"":)P8E>$B
MI_;I"5U <]UJ[-6YM;\[HPV:"T^//XNG*$OR /V+"):0#8W<@4C./PP2#R "
MW$!HU\Z"(,OU-89B/BP[83J\H1$NP.608-]03RVQ+T-$%L]I\P?CT0&J"DV-
M43[B0I6/H#/'(.S?R=X+:;L3&XU[*O@.>^.CF)<.#2,D5^8>(F>!$H'S*>["
M703.EI5AN8#P\>*VC_VG,E"[]1@I_RP5Q^8;#UW5/PYU'+^+:\=W"!F?@,4O
MU*H_I>_-F"6X@,-+^),8MM6M.&$@3$7R#Z9S0J#",X&MVT,8[^^>-1;>0H:7
MM<O%&<?/93.4.?K0$^3>,V/= <1['BQMR;(,2$!/L6#]4K4 )F#&A#2BDWHS
MQ=)I/*R9*&W1-%P=/O$(&7 [F!'M-[[</.;=D#ZHN[[;ROS^WDL<=%]$\&+U
MF$[YVM5\&&E*CF4<R: T4>IVPXBVN](=U0S7A9UL/8'C*@H#8T7]H7>_S5H/
MR*=<X?D>S1&%WLV-H [GJKV?#/?7.&D9A5KD5S(6"=!OJ&QX:B7<S20OG2VM
M!#\86/*?F9M#M4L#1U,C=7+Y5TIG A./!=%"]QSW?%FAH,]B^N3*$K*+?U :
MX[9B FAT+$BCVOG(=1/:K7MP2;2Q"K.]M!#CU4L)G9Y_3AQD!-KMCLO%:*+&
MW'[MQ%&GYU'7A_"HZBF_Q05&,',-$5\@28(;5Q298L(]^5U&JMVM ;TXG0YT
MB)]8(VW.4>Z%VI;<PV67ST0R82P,_4-%K*QXH3-1BHW X-D"[/V<'UO"E+?H
M!7'<!?!I)W7B_&POS9M]<D2Q5:A/9!!=MDYUDQY0*/X<LI^_N.J&2\76UNCN
M,*V?_ W1PR\^\!(<#X-/J?3.GQM36VXD +T]5?>63#0+WWBM>L&8Y+@P5R+_
MO>'R/CXJG:I-S5!6N!Q2@A":DG?@^N:7HC-@L!W&48F@.TBA>_YLC,>* J(;
MQ:.&-I5!Q-'4]'0V'_S!#_>EL.[?&FJ1C[<U,;>_.[2$W/3.FMB)S.@0(-6;
M[BMA>-Y[G0 ]%\G'689,P3A?6L%1$'Z%,,0R>(U:ZT>7KE)1=4J9Q5&*^2@)
MTHYSI.9 9'2DZD1DZ$"H81WY([P!NJ' E-X>9VZ^+&$YCA#5]+IE3\6O:?!A
MS9AY ^UY] ,(M#>L7Y4JRYGDVP657R/%>>L1A6@QO;\L&(:[MW)\][NR"8=^
MV1] >/@]/"XS^[?ON/CEB.)E0&9+MTK/J=*$'[_'/3Q__)K!AJ*":<.%II4=
M_/LG@S',[([:HYJS\UA]YH^;7^ZY66T:ZMQ^7?2D3YZ4GATAGV$C;(=F[DZP
M!;9!]1W[5+_M!+#M[>KYN"N5:F$%QUP]S87E5.U[H\.#RV=^2X_L;[0Y)G+O
MW#L&9:??;$1-6T#ZRE"EX4+-UQ;?^*>^*TT9P76HAB>N,[]&N"_+MU]57KYH
M?OS7'Q6Y$.CGIVS>WCU%]@",\'F!<#MNSP1K-$H*H<,.]S.G5SJGPSF!$NDZ
M;<[4KG8<V1N!4\SA1_*#Z28%UQX:,#0N/V2[-VV=&57,Z-&.]AM+XN@O:S($
M[I,^5;_MW@ZHES*E:9FE?VJ0;J)*)L$T^D(7[L*$NP-AY&QKT^CK6P#B,?%O
M1AQA8L).:D!M_KKZ692H'-^O.6"!S1N]IX]U!=/IL$0</["5SA8,,#XW'AP^
MX$-A2R>8C9/4CE:5#:CUE(6_<IF?F5K3E]>/Z_H^:U-J63&[VE"M_1<J*TOL
ML+12^^/]!/+BRWR^_41#VR6HA#]<M/TWECF5=9,&8K6BH(FC-K7#JC] '8,8
M1T7"Z)TW^9_7O,()(3'E@=97LN96S(@6SYH@K&W.1/V$[YO@2"^.FMS M'"D
MY5-F70W'V;&EJ <0[ZV9Z&T\IU$\%C[ZKF38\/J[24Y(D)G9Y$MLF]#V//%5
MOR3W^^?+@?!TM@C'MZ&FL;>5CTB5/B+*W+ML^.TDDJHQW;A]@BG.\ $4%^%=
M9#',:#=;8JR=:_W>NKYQ'FV2@%(-7U(GT_+P&[M/UYST],1H089Z)V4#*_]\
M'E1TYCR@ J]G<^*X>OR?>#0T5E895 0DB=*>_%VV)?/3:#?E.MM(2LYR:HQ@
M83':375G.Y(Z[&FJ+8"*2 _JW+G2-D;HQ=#;GXQQ 7)L7O.J5?99L'0O!O/4
M*L,JK/H$IIZ6WUABHXHX4K>Z6_VX76]AJD]>\Y"\IA&QZRIP$2HMG,+%A1SN
MQN'9G0<0)B(X 5Z3A+4-YL+,]'CIMH"OYH6DB+W)<L.O;(T7.@J[$NP2[&(M
M:PG2F[< BU<[=;-]ET($<G[_*RJ4V/N5&X)#_T]"OEV08^!@3HTAW@>6CJ]I
M[!Q,7)!@GT#M[J2PKA@KP(0PW22_I07!>0E#. #OR='-"QMX#=9;CZK&ORA"
MZ9Z7%!Y1\HV?"/_FP:=^E4R$$;+?(X_A1LE'2-%,C9[I>&(1&-Q+E0JLVBRC
M357]1M7>RQ/W&B'9%GFYMOTL_EFX7^ Z'/8K2&VE ;/)<(IV&)9\-,R^2.$X
M*1[PIE1W"9FA!SP#?6\]_3CT>M30Z!B15->O6FM^.L/36%D>Y5J424BT_Q)U
MRY_OV5O(-SPH[Y>LDYX :]1@(/;.L2X )<5+^*FGE!J6): 8[T1G+[B-W@F'
M\8,[%%F)(:Q-Z5JMI>BKYO$?@78QBL[9EE?4#!$*#2_+#;6ZB]P&N."+]'3P
MV_X3^/KZ$IF="!HAZQ;J-#:T./2FQF37%K/DAG\:Y$5V'4!\.&JEHM?X7%N"
M(W"[52:IH&[2:*ZM."[K9>&,K?S.>92;9VIQJ\?5( V!+Q\L]0%8(YPE\IVV
MPYB!4GBQD4L%DA@-MF@86R/[:C"?^1N;_:)\3<3QLZ]E0*JJ1H1.(^L,U>*3
MS;T'N.$PQ30LY0LD1@BHZ!0GG\#?KD[V.CSJ$*4#DV8=!U8>J0I38<:K6UB;
M11EG"Z*-OV9[&,-HPULB4N/%Z1M_S^7\L_T6BS=6 DV@<0<0J7:>!;285&27
M 3RQE,Y='5^]^8I U?'DNL%\]X V,Y.GA6C*,.C_/$2$'B.X337\LW'SJ;AD
MOZ9[>Y(+;YK5L(H*#$9+WDZ:Y@U<\ONM5?Y"98!'>7G6N5>UCM>L+EZ[6/UW
M^G0PF[=C3Y,]M'""X^Z3[NNV+>%CV=J 5V%H%28/"U-_^A9T=IO8VBPBC9',
M]1*(+Y6#[NBDVBT[Y^\3 M&VHT'J+[8*KN[%=,^-_\VSTL@25>FZS],[""J+
M;\0R@VGSU;[T&#3%K?2!H0X]<L@O_;HMORL@WO5U*YR??Y4A2Y=X%R9P[(.:
MGTMBMKYCY;N=F>,.1? Q(UP@NQ?/M$F?(F]? GA8BNT22&', 81^_W(DRF=I
M\)3G=%_HJZD L0K46S<PU'PD,&Q?^NK>+>.PZP'B8A.[0PW-377I-VPN+3]$
MC%A#_OE_YK^*G18[)OT XN'<1R8$;QCL*>.H1Z>#T_'<+.6E5*\/5 ,5F&AL
M&8CNH3J=__L;Y6;@4C#?FALLR=DV"57\0KMQ7'X4N^H;00C6O78 <1T1RC R
M^,EV[6!9!A>'T2XT?6PG77 Y[J7"G52,]TOLH*O<K.A<&_E285*L7*Q0E*V5
MDI61DI5PU#?+M[E=N(1+MY]Y*?\H^5S%PX_GG]\)$JM6(7E\]7Y++58VG^OT
M*+\;>3=7NADTHD-!O8IMV?&@Y0(K()(A2I..4A"V+/6'G2#)A:,.'^9[J&SH
MS-'37?=CS>Y>1FWY-E%DZA^>K![%'X4OIB%K>#J2_?-PO*L%HL1G69=\)]BZ
M<WI=+Q/GA90>Z\:6JY$?JF4:KJBK8M4"5YJ2;-)U&(O^Y&N3/^[DG@H!\22X
MG7+7+4$M!ML%KP4NM[$0,D"^;FRG-Z;:J"J!6&RUK//Z8P:Q^)P0Q2FC(=6:
M]'0M?Z7[#^Q9YJ!*-XG"]=Y#);Y[KHDN9AM7OCC3FGG1N[W9)/?IN'6^E+"-
MV<A0&2=LD7),+<DN<75#3=\N"!3(C"^X&2Q:G)F71T*+ME555?+^->/NWE-Q
MZH1)XBG[MV:.OW-[]N"S5RRI2;]BW ,;9OXC;\[\UQTG+WP-24JR3[)/<4CQ
M.?GF38:54E&&E?Q_YBMODI0D[,U/0OZ/Y=#!U/\#4$L#!!0    ( *J)U5C5
M>.=*M1H  #$M 0 1    ='9G;BTR,#(T,#,S,2YX<V3M76USXS:2_GY5]Q]X
MOJJ[;-7)KYE)9I+9+5F29U1KBXHDSR3W98LF(0D[%*D0I%_RZZ\!\ 4D 0J4
MY3%RRWR86$0#Z,8#-!J-!O#SWQXWOG6/(H+#X,/1V?'ID84"-_1PL/IP=#OO
M]>>#\?C(^MM?__W?+/COY__H]:PKC'SOO34,W=XX6(8_61-G@]Y;'U& (B<.
MHY^LSXZ?T"_A%?919 W"S=9',8($7M-[Z\WQ^;EK]7H:Y7Y&@1=&M[-Q7NXZ
MCK?D_<G)P\/#<1#>.P]A])4<N^%&K\!Y[,0)R4L[?3Q-_]/+?H.)FV=^]_9F
M2WYXG.%?5RCX,1DZP0/YXJ#)X&[Z[H\W__LC0E_7]U\NG^Z^;-Y>//VX'7[Z
M>OIF_N,BGCV>?^^M;%[ES\1=HXUC 1@!^7!$Y4O%>[@X#J/5R?GIZ=G)KS?7
M<T9WQ G?/_HX^"HC/WOW[MT)2\U(:Y2/=Y&?%7UQ0I/O'(+RDB$5-]#C@,1.
MX);HO3C/(!*_.>&))5(L)7W+27%&ZJ$*'4'N\2J\/X$$H#__/B-,2&_E.-N<
M>.F0.U9HFE B)E%<)X2/5:)>_+1%1$K*DTH9O#BJ9"BU&B2?T&2:Y[QW>M&[
M.,MR+CY_G.298G0?0D^BG9D5?WI!"9&/-BB(K\)H,T1+)_%!@M\3Q\=+C+PC
M*W:B%8II[R1;QT7-A64]W F"$ 8"C,;T"_VVW6+HZ?D'^$1[QOLH]-$"N+?H
M'S 2I370M)-!",KDR,+>AR/^IU!65IJ'ECC K.9TX)U9/3K,$BHD_,ER_GQ2
M):Z7E!#DV<%?V=_;"!'(SB2ZA@]I_I2D.:_K^&[B[Y6UX*\I9_H]:\=G-/"E
MX].!-U\C%!/>T.5/6@U^#JU,U2#*6SP@H8\]^.)9:7D6+]#Z[C9P$@]#RE\Z
M3'9C,G4B$'F-8@P22  JIVNA=;$?6M9WI;HZ].3HY2U+[*6]I28,5)T.+46:
M%FK?-Z%6%&R%2ZLHNAMMK? :K)U@A<@XF,>A^W4=^AX8F#!%8A?'=00;J;4P
M?:./:5J9A0-+K.Z_K;3"#NEV2#MD?>6'#Y*!621I8?BV!890LL6*[M#:B=80
M$3?"6UHA*,MHY03X#\;X94)P@ @IM%P_\*[Q[PF&]GSB>.Z;60OQ'ZAY":LV
M/R1)A.B/HC:F?H7Z_L?*:A2ULA-X5EYIA[]\M":;C1,]V<LY7@6P,G&=(.Z[
M;I@$,0Y64QAB+D;9\-6CU4+WQRJZ:>$46:%XJRC?RBKHD)0B.::5.?XTN8-F
MLI=+%$&CP;"S85G6<WP_C*F&Y$AJTFHA^:Z*9%JXQ4NWLN+9<&05]+,*.B2E
M2$XC? \3VM1W7#:K?7&B",9".@J5J3IHG9U6T4J+L_+RK*S #ATI.C/D4Z,#
M5FGQTP(:BCBNL/90IFJA<U9%)RW.8N598H$=.@I7UF:#F7*A)@=8B73J0$$Q
MB341:&%T7L5(*)'IN%*9'4QRLV/M1$BZ\I,D:,%R43,HA)+^ZS]_/#_[X:=L
M%=>!(@4E5?S7V+G#/M2;#1G)=RU(OJ]"DA9D"25U4$BAN')PQ#:K;I!#&X]I
M%XZ&/$D+D#=50&A9?%/,$DOK0%&LE>X(^CT!24?W!1ZUKUI0O*VO?[)B+%Y.
M!X(4A(D30X/9RVS!ST&H?=4"H>9BF/07M[.195]9E[?S\60TGW<H*-Q&]\@/
MMU1;]$CLK- ,DZ]2#]%..BVD:NZ"X>CSZ-J>WHPFB]Y\T?\XLF;C^=_G5G\R
MM*['O]R.A^/%;QUXS_#Y%,W=QOLCY-("MN8]F-_>W/1GO]$Q.!]_G(ROQH/^
M9&'U!P/[=K(83SY:4_MZ/!B/NJ&IV-=,52 L2^YPP%A.-S0E"3H8G==\!IER
MM ;VS>48E.;8GG1H2-$8.5$0)C%;C*1S5?F3%@(UO\"H/YO8MPMK_JD_ZT:"
MHNU!.T4)\D:/6Q001&<=.UZCJ+:^T:#30JGF&0"E-;L=#:W1K]/19#[BLY.]
M^#2:P1S5OQQ?CQ>='E,:>F&,R-1Y<N[\= 8J?=%"I.84F-@+@&':_ZU_>3WJ
M&EZQ@1NZ7WLTL-"C,: P)H1)1)6H!4?-(3!?V(._]R[[<Q@D,)?04=)-)CN0
MD<=+[!<:<5[S"#!$/MG7P]%LGGO-1F"$C1<=**WV ZKVLP:=%F0US\%L=-U?
MP ":]F>+WZS%K ^#:$!'43>S*&86%(\#^(6N0T*F*&*66#K%2).T<*D[$T8+
M:SP!M3:ROKNVY_._6%.8^)G%U@&CY6"K+T&5Z5H0U8,.;B_GHU]N1[# ''V&
M?[L1\QR/P3[1(JVB1L[KW@+MJ!'KN^RO+A3L$"#OYQ[:TTUT47-!Z+N).N /
M _R"+KM:C>TTAQ; -0]'FY'-*^K@;6>@BH#NH-&"L.;^4 >O=)#ML?TKXM5$
MH 56S3.BV KND#J<[MQORJSEU<*W[FII,6%VD+?<8!&'ICI9"[B:1T:VV=)!
M]%S/OXB8-K46@#7_C-XN0 ?I7E[IDE7:2*(%7LV)H_)0=W"U=E77H)(F:\%4
M=^2HW=8=4GMX0T6LF@BTT*IY;1H\HQU:+W)>;XAB!_MD0@-P8WR/GG5^KU:8
M3B_XON;">=YY/NN[E TKYZ/K,PI=[*Z1E_C(7LZ0&P8N&#5.AKD')FKTQ(;T
M/+G[)W+C13B%<8YA$,Z0AS8,GQE:^I"$O'$@7HN0(I"J])>N1:N7U?U(*5NT
MBY49XYV.L\9/"U@I<U8<6AE[5L&?E3-(SX>#B5B^QB'OD5T_W-4/!P73]O+2
M(=@%_3+$?@)M6YUN2KU'T>.>79Y6WZHYN,2^);! ?S(FF,9*V;" #XLS I,>
ML *3'HJJ';#K0@<)797.=GOFU>H:]=-'+=S7W41VT"/.<O3WS*N%?LW9IG\$
MND-?&WW5P6<YWMK46@C7O'+J8],=HGL8!/E^QH2:@1Y"&[H*Y"'2BCE?)XL6
MMO6C6,*T+FR+3)@%F%7$)VS2S=C[AL=)1ZTVM1:R-6]>TXYD-VJ??\1>#FJ;
M#%JXUMQ_C4?P.VCU%7+]]+W"EM8@U(*R'M&E/K;? :D-9/W(OAQ'#3H=&-_4
MG'N2H_X=?'L81GU"4,R]KWE#IO$97C_.;2 ;3" WB>@B@WH>5#;3,TO3Z@J-
M'CC.0.K)+7I&QH/EQ*+%Q0RNE!'F4>G,+?V>\TL"XP_';)S1F]"C#1-@'$AC
MAQ0=9K]"M/I)HS=-K-<2*J:.5V6D4M<UVD77*[QD.ZBTP)7XPRK76W2S@?X.
M;>5R"SEP.ZFT@*NYLNI78G3(M=BMW77]A6ICMG4^+71K;BRM:S0ZP)_CT1+F
MJ%V>+ FI%JRZ'BRA_&ZV;(\DL9<5+[(220FI%I+U^#,IDL2REW6'<P?E(3<-
M][S_1EV*5@>0'%'4C]ONU'3KP3U!HO.C[\+T&M$ E!L4K5"D&.9ZF;3PKON_
M!I]&P]MK9G'1.#DQ1+@_@!EY-AI:XXEU,YI]',VZL=\^6%]N<ND0ZB#Z5NNV
MI&ZL:B-8NBY)CETSB19J.VY8ZO#:QW>Y\UR%RDVIG5$+V[JG2="QNJ<S.CVK
M?5N3PC_11*&%8_-M3MT0W2L@F,01IB&M[$0&C+092?HN-%[A8ZB']VKDT0*T
M?DA1&)B@=1>S\8#>;,-.=["!.9O?6O1RF\^B6Z*#>1?,BI-1J8)5X*R720OH
M^C53 M#*(U:I2NYPWN]HG,*_KTFLA6O=\:0\+M<IYV>?UN#VK;VDT2XA?PYO
M3 @82M1 2F+ZN"]] EKS5$;+TK3Z0]U]55+H WLR (.*]P@Z\KEM#7]!7[F!
M;US1C^=S:I$Q0^QV,5_ ']3/T:F!UD<N&U3  8)WWK8[AMEI@ .'3&K?,/@\
MG^3;FH]*?>-@A_*>/DCA:&V#TU%"I8/@#_7KLZI>1GL^%P_A=JI6U\<1Q+CG
MT2->T-7U@-3)HH5J/=)*]&M,%N/><'Q]"XNE48?Q"V,L>3_\&?FUT&_V:FFC
M_R_]WCC]ARZ%9FAI/;(O,9!].")XLZ6WCO-OZP@M/QS%]ZN@=WYZ_OWIQ<79
M/T#LX\>-GY'0&O*N]/#P</QX%_G'8;0Z.3\]O> =JMI2:<59$4[DUDIYN&!E
MG+U[]^Z$44$AX19%U 5ZDC&?%1#CF&:?"M58M!Y00"<'E-QW[MI*#EF0_X(B
M7]/R7T)6Z*!M9:WTZ1>26#QM_ )RP^AJ*W=Y0+Z0V,.\DKK4/Y\XVRT.EF'Z
M!7X'0<C'0?8)! ^CV J<#2);QVT2"@=T!>P"!P04^<:Y#EU65$,6^JN7Y>O1
M3[VS\][%V?$C\0I.VS!1-$,[)K)\>S#!2B/(/5Z%]P J/J&=0EX_49'3/UAG
MTJUTZ9 [)D)">BO'V>I4*LUS@OR89%_V9H$.$_)\'E@QK9@HP>G%T0DM@A9Z
MW@,<+\[4[.S*R7Z3O3H!"W&)GMIT!#%+]F,_-$@4MP(BH^<@P*^]J]VC%]0K
M5W8!Y/,P/&HI+CY_G/QCANY11)6FZVQQ[/CI33@W:'.'HB/&*UWA-Q-AWZ?;
M:Z#.HX3J3N .OP>=BD-OP52_E_#+=(XL/A5 3^$\OO?"C8.#<8PVE!(D3NX(
M:-V$4G^,PF3[X8@7AX&D21#N3QSX#B'.)(SS^UZ*>U3*,NG3.\!1Y+AQ)IX1
MXLZW84#"J"Q3]:,)C%XA>M5.PEQ"_56$6'*9[682$X10G>HOR[&+RLB.=(4C
M$H\>8Q00R#J Q6&,HC[0>!*@]&A-$(M?@<$W&RHHR5),8'E.=TH\32ATB4T0
M;)I$[AK,0L7P5R>;P/R<W'_M$Q*Z&(8VN?;="@[*9".8I\<86>32#@QT",T0
M***AKV=36#VB*$IC0:JR--*8( ;708I91)IFY-PQ  ZK-DCYFY%L7\'*P$L=
MH97&ER89*43I^IGL.K>R,,TD)@A1[NML\Y /V<5#V#0J%)1FB[0&A:HK5(G6
M:+'L0%<HD=((D:)P@V'JCIYHC.@7'*_%G>RJ::]#:Z2BH$>@LPMO5;-_$XF1
M0@W1?-H?E*6H?#.!36ZEZR"@06B"0&P%. U])[I*V)U*]]1S#ES182%9+.XD
M-4$HWOAZ4FG2FB"6J*&N0U##5:>>(MG( ?\EC+[B8#7@#DC&;SK%E*7:36>D
M>'UO@P-,&:.;]?-D2SW%"EVA1VNDF/RDHD(N5:()C"]XF,8EKIBEDN\FL)LN
M@<'BTE@HJZF,$(7[M/O>/:;F%_!\CUUT536E=Y,9(0S:0(V@<ITX(54P9$DF
M,%TZYEAF6IYD M/%P!0"S55C5T9B@A!IIZ[VE.I7$UA=/,#/)_[O59A$4]^I
M;+@U4I@@PCAPX3=,J77>Y4DF,#U%$;NE#!B\I(=K9O/;JC^QB<($$5)=S9DK
M'_*KS5<["8T02#H7$<TYBY@V:;'%#CM&6^E8]>]&L,MW81NW:&N))C ^3&TP
MX0S%("0Q*?P;RO2=[//PL#A+NN,/R( 8Z ['F4P\#69"%#O1TP$ERAXB8.Q.
MPH#>K8DH-V7!U&1[R^="L2\H( L?Z9>>=LGA4J09+<IE@RCU-%-%40V@?09.
M,>Z_Z<@9K)U@A83[3NF!R=S55/9&%S"US&2J\./-%B2@W^QE?T/#^(8)N@+V
M19=5;III$ILJ++UT!-%<]#FI*'H"_<>P$R/1V(?<_=,BP_Y"O_ 0%<[]#A.J
M\Z>,*?ZP!GI@*<0.<J%;T/_99.;JM(70T@RM#1A.05A9A]F.=AVR'@<Q@@+C
M[ X=82M:D6SJN,Q#JU*E@K8AP>R1P#A<1 G)+N'+72'Z],;V4)@B7(0\0M7G
M ."B^YQ>Y#P$](,HQ!@FT"! ;"KEFZ&9YA$V3 ]0E*F=(YMILUF6VD=E\T@2
M3\P[1G6RWJ\(4QMF[OB9,)=<BD4X!A.$Q&&Q[&VF,79T<+ZSI6-9&N&KL?S3
M\Y]V4';UTRF$'S?BTNR@,;7;40U3W(=952C2PPM%O-H^64UM")AG ;LD\!QF
M\2.PC;U,%2_"!R?R"#T6[.(MLXT;^\*!RC*UJ?C2B'!#6KE,HM.W>%5-I8?P
M/<OB3,DABS16D63@EB[QN0JC\OVTMUL:?B@=0$!H+U6K]!<KW=CV+([3-[T6
MFC\6VD]W]G/WV;[9GQ\BD"XB8EK/079@)/POT&-\Z4,?*#9C=E ]PYD;9\4<
M%%;5P2 UDKMS& =>E>4:;DT$QD%6?Z%,#583K7$P29Y>RP6I0:9+;!Q\PDLF
M\H=,U&BVR&H<N +O<RGO-81;Y3 .YE+\B1I2!9EQ\)4O%%</2PTZ0Z :;<":
MA<:!3 _QFM[\Z01/[-&*]-^Z;&UR&"(E?U[P$_)A!2GZMAH%;9O)$%E+F[3Y
MR4>/KERDAIE"^N<78TA[+!"]U0$6 B-0F'%SW]:D-42R^N3?*)P^N2'RP;+;
M8Y?ZP.+R*J&OV$D>XY@D-$*D>-X.D1L<X$VR$=;\SRMESTD'!S%:H>@ [7 +
MXXWLW&;*Y-6F?NT=*>Z89=Z#6WJF\X&>;PY65PA5?+<J$E,=5P+7['V*DBJ5
MB"8E^G-&#,$86R*ZJZ89.B32&RKQU'EB2PU@E6^"\%"& =LME6TTMLE@K,M+
M2VO>$NC"F<<9U R-P84E2BO-JRY#OS]4)Z$M+^9;-0,]#$SHO=D%^_9#@"*R
MQMM6;;&CH#]?@TQ0O'""%?6Q<VMZO^:0%6.HMF#3;'J'^N@1FAT3>EH<X6B&
M5^MTKQAMTMDXM3K*P7S/*^)9G825<H!6*#;$K_$&QT5WILL'6!A/@9T(^@ 1
M@DQ;YGF&C7JXT2",4U@+K7BO3?$1KS$:+T?TV?*G80B(A3%=-/LHEO5YX5#
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MQ75Q&M86CPE4&3L-:Z/'"*JLJ.*I>;WM\L0)7? VQAL:!>)BD?*24D#6;'%
M40>J>)H^35&E_PA439VV*+LH>10-G<:H4BR/H>:EVB<$AW$"LYLZV=W9_7"W
M]J:P]*PHH!Z11C7U55S//#4S_V,$,G=")E]Z;2K8L,AM>(4;766>3T+?3(%.
M.=;+P3=R/*9*K"Q\2\=GZON-8S$V%;TSUGE\U"Y'TA399+H^R'>.(+L<B<;4
MO/;#S4K\->L(MD 9_]^WP+ #NA6\P<$=#I2UI82NJ0*>ZCI70%'_N:XJL5+
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MZ%588.4@&RW;W):.UEYA.%HC0K9J7U1=W\ V6&@X24.G[FC_E!74!JL1ISK
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MP^TME[^$<!"'ADS/ _+2;!VD+!I'O=J%"9]\$)F&S- 92\9(.;JZ?IBS5\W
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MA,:8]Z7 MI(2VTI\(#9 .(RY5%B&*#].<P]1+EGR&SJ54.@*X1%T:C-<4K9
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MM!82F%Q(\F;KRP/'^ A]3?]24<G9=K<?J1)L0 @:>T@A/'RK0WC0O[48<OF
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M&//>;9Z";6.&-@9-Z'%VVKX?L2<Y"4%R*^'4D5LQ'4YF$)P1FEU%67WF8?9
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MG>MFG\>/ASSF@S'^"L-U=N-U=@/6Q,^0C>($D^2!?FB\I&=?M@3&=&Z^<H(
MQT4_Q#X_GP[YR0?K9*-U-L.ET*0#=G<#UL3/A/C/5+^;!(Z;QO0>1M7M<7#U
MTR$'>??.MG]G-T!-%!>3^Q66/4#QU2'%>?=.VK^S/T!-%+.-S<\RH]&90L]
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MLBV.?UG_^LLMQD9VT/!J) SV,5X9QO^D&RO"(<%$P08-S($35NBEG9/$&**
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MDW]ZD^US8'I/KU:Z>HSJ/(PMG8GCGK)#&D&D.]<3BMD[%I:#;$Z!>1GG;-
MX\YXF>38AWM';;&OXX)<,5JD4?P<1X<@D>RQ2^1L;;(K85:[[$(AY^30(>NS
M@\K2:,F[+(^G'QENLY3D_8"[X!%C1%&<!DB<M%<O;FVD, !=CQ@*6>?D, 38
MYPC6 (T*J'3LKC7HW,56O>N7S'3E(=9RM Y1F2!9E8A4_*"1,4[=BJ6E"K"N
M.U9A-7@,K]IZ'C"+-\. 6XV2[^SBD [B%]%VQK!E>@R_6EKNV<69H.=6K>(Y
ML_HXA_"*;,I.S2K\=>(\S]#K;5; SW&QU98]&*!G,:C;W(Q6:+=>R1-VF2/E
MP[PK59(H#X(7K QLUE$8DFXA?8:Y;"-0)F0U\8(08"?[0D?".7N4L+@\#*70
MY*>%A\<\1/'>\/J:4MS>6:$>='-4*)=US@A#@*( A4K#WKGR%5S=S2[EU.C^
M;HT+(ECUQV__Z,?7%B#J?]XK"%;@#LS >.%ORC#]H4. 7LER>/Z@X4"GX0=-
M3&%*0O(G'B%.#X+;9JA80[2[@H_:6$JQK-4@.!7<3A"<2- YHTS0<40BLN=$
M&!#ILS%C*%57$>^R)$#7AS2ZS+ 'A(KX,8'$5];<1-2IV;V(:&9$]QZB6L<Y
MAP8"%=]"I*J Z(*6,EL+69GJAK/+3,_RA#>07R9*?A!L %+)S.>08NUM@)LL
M2!6GXE)1B_7HE&!;E>B$<G[010U.'2A!Y:>FQ.<,?8G3IS(=-'VD*G[24,<:
M24SAUVS1*?A!&T.47/PE4P-E[4*04 :]V(G*G$6[.(WS@J4T6AWV>^R?&:S6
MS/2L,6J(&36K3)3\8-8 I'P6^;8J*'7!"J+G.)P\J&? VNTZB-&O07* %Z_U
M/_\<0X3?]_;U!CY#4<3/4&6;J[MA!K67>V::SJEY%%S.@\<:@*J 6H<5#9_]
MZLO=NMJJ1;H_%#DUZ;WR $.IX82$<NA"YO'B_M%-BE'.L3/ E,X 50/OO1S_
M/L$@/R ZME\C>F4P%.6(':3I:.33F2(9]F1J_I%0B[5/QI8XJ.6]&^E:*/-[
M<NT081?5;,A3JCJAH8$Q0AXJ]/PCHAZL:EBL-3P:$.,T2,,X2!8I=E\/FBRZ
M4FFKC%-#[I!,+.H/KY3X^'W84AHTXKZ,:0^K-:)]X[6Y/ZT<R50*-MFD!]XF
ME%S:&TYI(?9I]; "E09H77[W9X@2N*(?!B\,/OBR,/@P;&'PP3-ZZ3&:+PP^
M^$VRCX-)]M$7DGT<1K*/;X!D'X\DV4=_2-;R'BE&3?"$7-PFO72@V]R2R7I#
M+ U U3*2RGN5C:IO#+U!>H?B4'PD;J[FDEXR(U0TZ^MX2S<)4"WMSMCM8$!5
M_1W/YE\A"N/\" X*-5W24&&*BHD"-6_)*,=JP,=*V7]*[F%8P(@$PPUD)*_H
MEI R0]1\[&MY3$<)5",V,EU 8QZ])2/M*[]F25#$22RY%#90UR4EE>:H6"E4
M]):8*K0&W&0#9*/O+SWOX_S+-8)XT55 _%*+^T 27'E, RZ)JC=,Q5:YMK>4
MU4(VX"UI@YR=05"U D@S_M*WF@2N2%85F$:#Z:MJP(>I7VZ8B0O :WM+7RWD
M(2Y!U<BX[)5$^GV"Z DB@] ^B:"U6#XET#IX3RCEG#9::#P]B*R/=ZDN#GF<
MPCR?A;\=8I;?2;$A*)6V.3II(+>'(HFH<P*9X>NSJ)(&+?%I+U6MX7/V!-.+
M6)%/B9>Q-H;(X-7#1U_ ^8=7H>(RKS$Q@.4L9?U>IG!@WF^IANW,WQKH_=S?
M$G&K_'B&Z#'+X8V,)D90G:0!5U=#GT7/,<E24@:?7ZN29FE5;%=,UX'OUU"7
MR?LQTIB!E-59K]2J:P3@>OK<6"NXVT-T%Z"@."BNP G%+(XY4I"M@8:3\803
M4F#\6$(D02GJ-C'L/2G4+DD&V_K-5@)8#DZ5]+7^P?G'%J'AOG 1%'%>Q&&0
M@/82=LKS9<V'_A2G\>X@/BH1_&[K@PMA51^]\Z,7'UZ$B%N4,AFW_?I3\%7]
MN;N_6_O<(ECUYV[_Z,?G%B#B/C>3<?NY5^$61@>2?'J.E[#D+*/89A%+5T9&
M'OZO$"I*;9[6G"TRC6%TQ;U3VO*"JB,8(,YV1Y3/QJP$>O+>VNPE0)$FQ*XG
M8W,?30BOO7O6$7!.'A4J[CHTD;&0=&@>H#0KHZH4JQ6AF+75B@)DO5H1R#C_
MX!I@_6]>2EJJ4=_LX5UFNUV6:K;+E.(.]DNEH 5;IYRL'\S0 U1MJ#(=W\KC
M_8KGL3A]4LP7'0F;LX4 6GNN:/WLG!YR3'U&E!*^. QTZ+H(<AAA>NYAF@?T
M1(A.>"A(L><DRQ!_5 MVDR .-JV;&M%8W1OZ#<?,IU'$+9S3)L!=\$JW9F8D
M8= 39-YNV<ZHZ>4ML%A6G^6H%OQBL;!NRQ'J;XC%NGHNQBP>L[B+#19+Z\$<
MV89G3!;7B3FJ@;?$9FW]&',^VR@F4Q[6J<[*>A*VCU2E)V2=GYU31(Y)<C[J
MT0WU.XQ/LDTJ%K$YU(C M4>2]N_.6:  Q=5CP?\UYGZC;*?A!0\JK^S_7F,;
MR6,5&PT*:7O[#%K(S3:#5-0Y%<SP<9L,5!24_T-4 "7*Q-/  G^1E.1^5--#
M*&:-%PJ0-2$$,GXP00Z,/X\H)<?]\D<=N%UN8[B9?X7A@0!:;C9Q",55F;32
MMH[+#"!7IV$*4>>D,</'E74G&J!6 :7.Y,7C(-ID:(?]5N8=WZ\>%!ZE2MI>
MH3@MY*8\G%34.4O,\'&N1Z, V$+D'JS @T<>Z3W,"Q23^R_RDQ&-K$T?50FW
M[:P*!9VSR 0=G]"^DK44'<R"2!G!#=AAJF0STMS,@':PN5K#.7$&P13$FM.P
MX'($FHI/)X]%V!_+=I#$.M(-FAOR$/4])Z6&W3*56NC=FI52<>=4,\<HBE)E
M<:G9!C!U4*F=8?8E=![TY P/=P.(W^QVED97)/U7MJ=135_)9J-ZM]A(T_*D
M:&I*;XK4J7E#1G.L@NF3:M(L]BU=4"K[,_S] E.(@@2;V*T28<))0UV;K!QD
M3IN71HK>,',(VCXW2UU*S5YED+'9.>@J6'[$7;#<G\M@/'S-;;#\35P'XU":
MW@?+1[T0=OSV5IV6VFA[2R9M=7M+#;FSO246=4XH,WSB[:TFC_C8VUNGQVRG
M11S%"=U\:W)1S[^&R2&"T37^BN3@^%!0YW.Y(4&G<?J4WT'$CI9?Q0VH(L"G
M?*+5>/+I7UTG.GVZQSGO7/9LY"+G6PJ=9.S>K*[:VQ,/:5SD]ZN'(=N+?1V'
MVXQB^(KMQJZ"-S0U0:G=?J1:X'NR]_W[R8\[4/P<%+"LVZ@ZZ1 +VCOD4 %M
MSC=$4L[9H87&G6HP65 )^^,5M(H!DWKFAA5&M%HVAQY#$]J#CT;%.<&&X>1<
MT5:!9Z(V>>F1'(8_/&7//T8P9IS#_VBHAO_C[W,\^1:OLRC";RB'^3K V'HV
MR\5LD$D'DK!')N.<+AI@W'TR*@IJ6? W*NV8$S=Q"A<%W/57$VI11]S@P$KX
M4<OYR)$^.#U/B :@*K;)<I6%M"@7N?DJL*S[LRU2B$!51&C_YL7'%P#J?_!*
MA-XOMOR!9_C!$:U!F01/ OB]WVU]8B&LZAMW?O3B(XL0<0OA2@80(5>?^0KF
M(8KW9'FOLJ,C9OVC"T!RW[XEXQ<%>&!R)K1D'0WL]_"I/,LA%Y[+8W'%,":1
MMSWT*V'WYP*AL!>D,4$HG2W:2J#6<L2C69H>@N0>[C.DHD]7S#9K1"#[9&G+
M>,41 3 I-9@L8,*.&/&?AP 5$"6O6E)PDK9Y(8':IT9/S"MVB+%)"5*+N^4(
MN=C(TDYK2<*+6E]N2,!R2X^>G%<\D8"3+TEJ>;=,66UADI"SJ2#5#R@B8=ML
MD0/N\X67](HQ4GA2SE -4*KX0YOY,_'.L9MD:&Q+WB5Y.-@J_M3"WE*HC]"0
M150-$#U'3+J#*,XB[&8C'8<X2=OLD4#M\Z8GYA5CQ-BD7&'B@,J[)\D\C8PH
M4LNY(4@/II@>I9"'Y.@BTU%C3H*JW1'C.L[#(&%8KO'?1*<M"EG;!)'"[9.$
M$_2**#)T4K(PA8HS5,4I8?X* V1&EY:D&[)P4,54J<4\)$H?FXXF1-X)22X/
M"'50RV<<N:@MFNC 5CR1R7E!% TX+A2$B7>(XF@&8J?)UW$";P^"T"*QB-WC
M?1Y<]UB_^=T++DA 28[QB1Q@@DZ^?'5*D!8DLY#4G+Z870:(0799T)7QB E"
M8!(V-+(TT9,31ESBD0D%R2*-X->_P%>I79R<74Y(8'9)T1/RB!5B9!):E,*
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M/L,D^4N:O:0K&.19"B.VER(Z*5++VXV8T<#N!LU(A+V@DPE"2>@,43K_0K1
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MPW@Y;:9G;6TRQ(QZ 6*BY)PZ0Y%R_ER"5P]@!I8HPD,9>BUOX8'5X?$?,"Q
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M+H,D$1WA2K^@7M6?C?]C@4L.&$-R8D-4G0\Z#9?*7;#VD:ELB-$I62Z-:V!
MK_2'0L.;P<((IO( &QSV],2C:L=99182H]$R87DH<I)A6G*BJY+W;T0P0BL)
M6V&'#CG[9EFCY\N'8EPS^D9,] U\GAY0U9<YJSX-ZTY3G0619U1.P5>\O(IS
M&*VW,$;W\=.V6&=LNBGCH<HXO>[4VCG0.*4Y>^=(IQO=G#(=WY;SP7XD _HL
M+H,WR6H=^R0DC?HFQ@N=$.L4$(%@!]-(EZ)KLKWY5O@+V:?^'!?;" 4O*?E#
M>\MZD>(I,(7TW)X(-0G@^5W[T]OT9^@:W2)NC",[^R]5@RR,J+/+3[;]P[I5
M*@J04076"6<GMI[_,TRB\F1#'%!D(.[/IQX"EBLDR1+B;K%2<TR3UGHN%X6#
M I:':?KW[0;BYCQVZ@.6#GM$&RB'[;.J('(*7YC 5.>_S9AQ$^_BHME1)@,*
M]DOO,!R$AYD<BH^ A^E;<S*.,:N>4H8H^^%&'(&8KPE4UUA)2!NM4S Z"^!6
M2%!TALCTD(^0XU,6D-"<:3PF\1/;XRW=(!8C6SKSFSG)"OQZE>&NEA7D;G,"
M"]$.L7".G> I]D(<)GM%C5<U^B/\Z"B3V<4%BM7-$Q<<T0=4\=G5TG(#('T(
MB#(RU&<%.8BCSP&!^'#.RD'<I^ K64&0#$0O>&+#TT]&L@IDZ?PK24\D7GL:
M*%GK'\8&U'37:OC!7E.8W)J0Z8& *8*HT02P5'6^'<TYPJ8.L]U-9RE,Y0K$
M.7]TR/J4F7\M,"T(08(=71=&<)_E,2N\AD<TJEL5#G2_:7D7H"5:%0'&1W,H
MJ^ZN&:CYM]08 IJ;BZHJ8&SB.0/[ (%GFK/]>[Q\C,@E==3<=9MJ7OF<H2\D
M(C;8QT607,%-',;"-85$T-K\H01:SQE"*>?]7 N-JZ?,9$'(A'$_I]+.IX,F
MII65M5ND!<0O238KR,5M3@XZT.UA2";KG$*& /M$:L3Q#$$+$<:E@J/IH5>J
M]#) Z)5DZZ?SV:PH4/QX*&BZN0P/J9*]Q,&-6)XZV'X1G@U0H9H^CC>#VT%.
M KPHF8&L,ZF O"G;NJ_*MIKM&[LH)DR2@L-F[<= TLG4[/VI]!T6&=:;I:"V
M7-DW7V@H<&[[O%)@=QU85R@=HG*Q7NZ$T;]-Y [UK&B@LTXIFM>U*M9<)$/P
MS45BM;SS.6\ 2,7&*:93=UA4KJJ_O:GOHX.I;YY&XTY\'VU-?!-^_UM8^FRD
M%/3L.8@39F)K%5D&'=#TNZ*O/[ )_U;,QQK S19U)G;2OU-8@.\36F";>;F.
MOO!G2.)#8#3#;R)X@MW0D%8<FO3[#FK OZ][''QN\5NV @+6C" @[PP\DB;\
M^LQELFRCF,J!3;R93ZTUX*B/7;;JZ',+DZ.+/JI0T+]/IX;9_T#T5SK"EAL(
MY4!KE(7+XE<I.6+R74I1_[],'RB7F" NSXN._#QVKE$='O,XBK%SMD3,W_L$
MBVT6L:TI"%L9/RY>>>%*3)GP>]1'6+U^-<'+Z01QC=B^\_7@A$9Q46"U%EY:
M *8'V%- I7\&JF1%*Q:=OL;6>I//N[&@]3IN-!FZ=4INNH;* #'911H>TE<!
M4T[('NU&36!]^O6U(-^2WO*,(9),WT6UME?MX^J4K%Y?,S*@<W*MU/"&=48P
MA9'IL-%Z&_D0[>YXZ6X.2.%Q$0'&"<RF>M5CY1[TQK$V1MK_%@]#,GU-.0E.
M';YOMZ\4$(T2O"_K0K=U<OM1;PJ.,BU>7RTN%RDM4R\\3-+(VIX$I7#[<Q\G
MZ-64)T/79\XUQ!V>1MK0B+H,._XQ4:.IG,.LW)QB87<NAN;%;A_$B&638X9<
M'2"Y>W8/$Q)T=A>@XI4;I(VT/)LOAV'F EYJ;3(*1 ?(KM,AIDN"[(I7Y\/!
M0XKJZK'KX.L%3.$FYK(E::5M#@D:R.U!02+JS;"@QL=[ HTT*(*OX+&4]Y5%
M['P-_^$.ID%"BF_,TJ@*$R-1%@<N/>TH+7K QB&F&S#6I#G?63W !F/FDVO)
M1*],4LK:HA6W]M5#G'<.&ABPW'P.2 VP8LEN[M<'DG5=&I8PZ.*UE,M+06D%
MNU-;M>K%C?,*.O[>:4UZTUG&L4.^^G@I%:I[Q"0.!>/?!B2I:3<8B4;[LW^>
M'.,_3:^I4F#0@CWUC_7+D":E.JXMYSW$U%QMO] UY'=O,$3/7U%B:F6MIE9?
M<$[N$VLQ*Q?M([5M]<[<F*^C<\]NC(:]Z1QC6J/=KH)ELVS1&C8-T\4LBP8
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M,Q A&%$36!7N@F1T;0IRWY-UL'1CWE3=[CG(,*.Z)R)FNMXP<"!@\;*RXB-
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M2@&H^GYCZS?G X $$%>^A4JPFWY3Y4 I62*K8-S]W5[N$@&L)B])ZT<_/J4
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MZ?_\XNW77Z/PF8LW&:=DG8!X76F-SV^5Q,C97B&A9/T[)-:7_UCR\8>?* R
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MT[X6SOWLY3H.E-N_IB,4&>S;K0$74/ IB2C_(RAYJT*EM3GXI<L)+!04.X+
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M,^]%6#HXE?PW+.,[1V/NBIW39! HJ-;L"@!4XN[DN8FK*83&:%FS.QR+EH/
M=%A>QRXF:V:$+O XOG0.+]7;B;YH8=+U@V)ES:1@C!6,$^B 3>*4@#>ZUL90
M:*S9((RA4=",CL=U'#T3EE(^-2-H=/V@*%DS4!BC!.,$.F"Y3<7D1))V +^V
M.@.1AG9T;$Q@.081:]8,8T1 8)R;A:.(SEUD#_\A?KJ,/XC$#OPK+W,2D/4F
MKU!)TC0L\\BS=7+K4?:3%V9DNBKZRF'O8VRHF%BSBAQYU>Z/O^@KOG)HW,71
MHYAM]?  G9_M':$@NVI/ 7*F\S;!!W^(N:*+N5%(=&[0LXZ^*U0"3F%\Z2(!
M8.Z<M0S<$$:?/9']L,(NB 1H.T+Q/X4YIPO^0,Y@HJ]Y+L_KD(@,*N(!68EI
M]>59V@L*Z"D,0$: @JASY$2NT A2ON&PG,+6<^3+Q2M0OD66')KF*5@X,T0:
M$"YL)/*5>"H[0?$]A<&HFR:EY0CZJEMRQ3UF'GN!O@%+.T#1.H7AJ M:&DZX
MAM2UQ]@+EZ?A6CS$#-.4T8<L%1KZ,IYY:@VFPU!@QW);Z.K@48()9Q8ZS%W\
M,GKPQ+!0T[(GFX/['AF'X6NYO4..56MC*$@6W64,85'0C(Y')5^?!HQF2R@2
MUJPWG;2,-FHM>23GL9W#*0MHQ+=7J=54M&UO"N6P->N(V?5)1:]-%E_!6=QH
M"F6Q-0-$!Q9+Z$7?3.8D]6A$@I''(I&==>C[V3K+<^CPF[4H"RS?7B!]H5A9
MLRT8;SAPCJ"#-PR"/.6>%\X\&HRCZR*-B<(+2-8!"I,U6X,Q3!K:T;%I$F2B
MX,(1L68=Z$&5?05F'YUZ#[+E27I"(7;5I #E3:_P8V;4+>[23R2E?F6G.4BO
M^[Y;>MW!GP[&OJ3;M479)=WN)=WN9YYN]Y)/3II/#B]W[B6?G"OYY J#4V$7
MT>4I:VN+G9,)G)U,3BCZY:DRM2L##*X,,;!F(.J"P95C&*#E5;1F8[CD5>PC
MKZ(U@\.K2JM8>Z'EM[LIRT_'('_%F!&6&X+!C]CR <XE$:,A1UQ#$%(>K)W2
M[@7"\+-#0)G@&EI[E_T9H[[Y<I/VQTX%V14Y#4/0\3O<S,VW2VA_[ R28/S,
M&.(8?L4^,<S2IYC1/_:V5AUNS7[8"20[XB5C@),XC9,D,\5HVP?[IG44/H>$
M.XD-2.'0=L1.%'D42BZJ&Q6O)/.S"M09^[(,ALR %2[!!C^BE)VP+\U=8'+V
M<&K,47<R23M@IZ'L#HMC9Y)A@6P95=UNO^ZA SN+3NRCL",GF:[*X-8XDI3_
M_4;EG[ ?:!"O!ONA\ L!BZK7:[*;G]X90=KAXG]@OEXTW+^X')P$A8O+P<7E
MH->C_>)R\'FY'%@S:CK@<B"+-=E_T)O$Z2ZWS]X<KBQP"N^.;0?30V!&CU/7
M#^N.(/@N!PX[@OQ (GX1"$7*XF!-(RJ4/Y$]I2R4) =$V_%<GJZ!'$!':L[9
MQS__Q"=Z0YY)&.=U=K0X:;J=S6,UB'QTD/($-:(.4C$O9?:0>LNS>7V6$6D>
M"O)]8>.(R*,P42S1 X(F<11O$X@5]^)MP3BM30+0%5N3 P,,9@/Z>KN/&!&E
MW4GP S]^[V)^'D?CZ)DD1>H:.5S:CMAOTW ,8C/"'$%NEUYS&/PG*R8W7?WL
M,>8I<=-TP];4NZ(&XL:Q^ZN%I'7 VFZ=:[I9>[0V!JJ=#&>!N7[RHD<RCBI9
M;"O)46><'31)8O:2IT>579#-QL"^CG6"M!.?',1[O-YP"HI]H\@4=9.16S[]
M.<FS&\P\UAK/+#H#^V*_AG?"UX@OF+CV\(J6$HZ(_D;8:(C]GM[UT)10?-8H
M2GG1X>;AP&-\5VBU;#CCK!,3DA8D">5< >MA,RB4^)::5OK.&*^?B2B;3((A
MUPJ\1S+)A %W6Q2@XC-RY274E^-I. P4;WQS4"?^H-\_);.^H6'&?VO@#F4\
M$!19?#M01QZA8[O-[K5U4=6L3$ES*$[XX0E*>IU#HQ0?.!Z[#E!$\ ,2-#2C
M8[(KD[&UX>L-W(HN4%SP0Q"T=*,CT_T%Z==W<"2L&6'T#%:_)0DBSEYCG!Y>
M7=1Z?FMC*([XH0<*6L\8P8,[S/#9HV&1<+WB,UYFP]/H%L8#09''CV[HR"/T
M'18^;ZVFTF$H\"O_&>&KUVX0@R8*"W\R/IQQ+=GO01C%7^!A%.7@ QH-JL/_
MM[>)D[\/RJ_@1UA4<@QVJ]$ ZGZ)OC@J^V.'G+R76 RKF%QB,<X/CDLLAFT8
MCH_%^,MK#\:P_P@#!>&S3P-I_WW$' K7@@#0LD':-P@"P;DDA52@9#\-B1%*
M;N>&W-%45N^+UYLX$M=%H!;6WLTQ%0"DB;534MF6D9ZC#J>E4\@DS1T#1"5L
M]:>I=H(<4<U FUI+4V<4,P,DI!2C;V*2^DLZ7#3=G(E_,< (Q ETO.IES71
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M!BRUI6^,2UO_,PB8-Z3(D?TPG[%03SEQP91=>V'8(E2:\PS0_WSBXLTXXCZ
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M:.0QM8U*V0/*:6MY2_2<UM)@USAXD% O/[C* I 1,4@GV-X1:AA$W&R@I."
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MYR?J/RTVQ*<K2JKK0WA)T4CPH/G'8E!QTR61WWJ_SWEZVCD Q<Z:ST4GL<.
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M1N[G+HM+1A\?56K0T0-C*TUZ5/NBU!4[UHVH QYO!!5O$C%;D8ZWR C)%<A
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M<$9U#PJ,N2YG04NNY.:9<9;01+@NBE?V<902#D';"28Z OIA7W>@B +).3<
MKY_$ ^ XNO4HRW,+F"+9,@#V=:@72*6,P</VA/OV#0W% =?'SKT;"OM296WO
MKC'KC 7D9R)B*DDPY&O">R2[_ 7UVA6:8]UP&.P$VH:"T8E)^ :5&I$:""7-
ML?-C&T*E)!H=$J4@%0;S8Q;:P0C8";#[7&,MK#GKZSD_9ECN@^6%Y>%2U)])
MBWOF]MC9YWP2-O7]O5(N'D</C)U*VU!J>F*DFQM#J64TCIEA\)\L2075AOL$
M9$#T)-Q][!MPSKT^U4U&N_&9(A\(/<=W/V>+CE/HNT*=3.T=3=H!/<GWD6I<
M;Q>NEAQ::.]>(B?KFT!01I^)R2/86]4CV'"R'+^Y&=_=+\<_C2Y/8E:SPP@$
MMP#NM8K1)S_,N#R(?%[B"38KY&:ZJA,"3AO3SW?<<&@WW GZ9@)^@IDCZ;C3
M)Z+I[PMNB(R=!5</4^N-:?@9;XZDY>JE?0!-(*/-CUX$L1\^XB?W:9T<)))2
MW],-(3G!X@-)3(_QDCVXS0H7"C\MBP[<1S1-YHM[70(G33=L3Q*H+#<<9P',
M0+]\UF9I")4KN4WZ@:A?:&31Q]E#2/UM8EIUW'%K4^SG5E->RRFQRV=&G[V4
MP!C=WA;[4:P3IU5DH^\V%:^,0Q.];M_1=L1^T>BX P$98FF-"*4DSM+"-*I<
M(:TMT0W$71:(@F;TY7&D3EE4(K%V==L.C^SUW;=AI=][V2$&/3]?NVS#GN78
M/9&4^E[8;M!^UX]!>_"G@V]=#-Q'&[B[)Y$!V[:/_H0;M_[.9NVCZ<>W:&M)
MD%$ L&7W,;8;$M+[JC+-M 7@E .FZU>1-<\.PNV9]/!LN9=,>I]])KV+9;A]
M)SA!\KVSLB9W/IQ&OV<T?=DG@TWRQ#/+)R^:YE6[DI\X_2081T7N$0N*A/$,
MD*_!_6EC?2D8'3$TRE%0_D7\SP/_/O_-_P]02P$"% ,4    " "JB=58?78Y
M2JL+  #T?   "P              @ $     97@Q,#<M,2YH=&U02P$"% ,4
M    " "JB=58P#. ".4#   "$0  "@              @ '4"P  97@R,RTQ
M+FAT;5!+ 0(4 Q0    ( *J)U5B_O*Y<AP(  -P,   *              "
M >$/  !E>#(S+3(N:'1M4$L! A0#%     @ JHG56->-<CTE#@  %%D   D
M             ( !D!(  &5X-2TQ+FAT;5!+ 0(4 Q0    ( *J)U5@W9%@M
M3:D! $;2 0 0              "  =P@  !F;W)M,3 M:U\P,#(N:G!G4$L!
M A0#%     @ JHG56)AGT>2S(P$ Y2<! !               ( !5\H! &9O
M<FTQ,"UK7S P,RYJ<&=02P$"% ,4    " "JB=58) QX^?/F   ]Z   $
M            @ $X[@( 9F]R;3$P+6M?,# T+FIP9U!+ 0(4 Q0    ( *J)
MU5CO6B_=_Z8!  B^ 0 0              "  5G5 P!F;W)M,3 M:U\P,#4N
M:G!G4$L! A0#%     @ JHG56):-2*CLU $ ^-H! !               ( !
MAGP% &9O<FTQ,"UK7S P-BYJ<&=02P$"% ,4    " "JB=585IU#(I . 0#W
M%0$ $               @ &@40< 9F]R;3$P+6M?,# W+FIP9U!+ 0(4 Q0
M   ( *J)U5C$ [[I;5L  *]H   0              "  5Y@" !F;W)M,3 M
M:U\P,#@N:G!G4$L! A0#%     @ JHG56#L88'P\HP$ N],! !
M     ( !^;L( &9O<FTQ,"UK7S P.2YJ<&=02P$"% ,4    " "JB=58.YS?
MQ>3+  !,UP  $               @ %C7PH 9F]R;3$P+6M?,#$P+FIP9U!+
M 0(4 Q0    ( *J)U5C!>3+-^@P& #J]-@ +              "  74K"P!F
M;W)M<RTQ+FAT;5!+ 0(4 Q0    ( *J)U5B1[+JA0R8   0H   /
M      "  9@X$0!F;W)M<RTQ7S P,2YJ<&=02P$"% ,4    " "JB=58U7CG
M2K4:   Q+0$ $0              @ $(7Q$ ='9G;BTR,#(T,#,S,2YX<V10
M2P$"% ,4    " "JB=581I]";\L5   @  $ %0              @ 'L>1$
M='9G;BTR,#(T,#,S,5]C86PN>&UL4$L! A0#%     @ JHG56&)8A];28@
M59D& !4              ( !ZH\1 '1V9VXM,C R-# S,S%?9&5F+GAM;%!+
M 0(4 Q0    ( *J)U5C/7>:V,Y0  !KN!P 5              "  >_R$0!T
M=F=N+3(P,C0P,S,Q7VQA8BYX;6Q02P$"% ,4    " "JB=58CS21IJEL   0
M- < %0              @ %5AQ( ='9G;BTR,#(T,#,S,5]P<F4N>&UL4$L%
3!@     4 !0 SP0  #'T$@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>forms-1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:TVGN="http://tevogen.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tvgn-20240331.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:CommonClassaNotSubjectToRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:CommonClassaNotSubjectToRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ReverseRecapitalizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">TVGN:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FeeReductionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="From2023-06-282023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FeeReductionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-302023-01-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="From2023-01-302023-01-30_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="From2023-01-302023-01-30_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-30_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-30</instant>
        </period>
    </context>
    <context id="AsOf2023-01-30_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-30</instant>
        </period>
    </context>
    <context id="AsOf2023-02-03_custom_FirstExtensionCharterAmendmentMember_custom_PublicSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FirstExtensionCharterAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_FirstExtensionCharterAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:FirstExtensionCharterAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-14_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondExtensionCharterAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="From2023-12-142023-12-14_custom_SecondExtensionCharterAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondExtensionCharterAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondExtensionCharterAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_PrivatePlacementMember_custom_SsvkAssociatesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="AsOf2023-12-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="AsOf2023-06-28_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesA1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_CantorMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:CantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="From2023-06-072023-06-07_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-07</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="From2021-04-222021-04-22_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-22</startDate>
            <endDate>2021-04-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-31_custom_FounderSharesMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="AsOf2021-10-01_custom_FounderSharesMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_PrivatePlacementMember_custom_PurchaseAgreementMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_NonRedeemableOrdinaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:NonRedeemableOrdinaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="From2023-06-062023-06-06_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-07</instant>
        </period>
    </context>
    <context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsTransferredTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsTransferredThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicWarrantsTransferredOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-07</instant>
        </period>
    </context>
    <context id="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SsvkAssociatesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:PublicWarrantsTransferredTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-07</instant>
        </period>
    </context>
    <context id="AsOf2021-04-22_custom_PromissoryNoteWithRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-22</instant>
        </period>
    </context>
    <context id="From2021-11-082021-11-08_custom_PromissoryNoteWithRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2023-10-02</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-03</instant>
        </period>
    </context>
    <context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember_custom_DeSPACMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:DeSPACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-20_us-gaap_InvestorMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember_custom_DeSPACMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:DeSPACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SponsorMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:FirstPolarFundConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="From2023-05-032023-05-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-03_custom_FirstPolarFundConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:FirstPolarFundConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-03</instant>
        </period>
    </context>
    <context id="From2023-06-202023-06-20_custom_FirstPolarFundConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:FirstPolarFundConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2023-06-202023-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2023-06-202023-06-20_custom_SecondPolarFundConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:SecondPolarFundConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-20_custom_SecondPolarFundConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">TVGN:SecondPolarFundConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RelatedPartyLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:RelatedPartyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkingCapitalLoansWarrantMember_custom_RelatedPartyLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:RelatedPartyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember69274765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember69274781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AdministrativeSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AdministrativeSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AdministrativeSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-05-032023-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2021-11-052021-11-05_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-05</startDate>
            <endDate>2021-11-05</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-05-032023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecondSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2024-01-312024-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember_custom_TevogenBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="From2024-03-272024-03-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-26_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesA1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="From2024-04-262024-04-26_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MergerAgreementMember_custom_SponsorAdvisoryServiceFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">TVGN:SponsorAdvisoryServiceFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-04-152024-04-16_custom_MergerAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-15</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TevogenBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_SemperParatusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="From2024-02-162024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwentyTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwentyTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-03-262024-03-27_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-27_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_SponsorAdvisoryServicesFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SponsorAdvisoryServicesFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockMember69286687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember69287000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Integer">
        <measure>TVGN:Integer</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-03-31" id="Fact000004">0001860871</dei:EntityCentralIndexKey>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0046"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ClassBOrdinaryShares
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0189"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ImpairmentOfAmountDueFromRelatedParty
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:NoncashInterestExpenses
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ExtensionAmountDepositedIntoTrustAccount
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:SaleOfClassBSharesToInvestor
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:SaleOfWarrants
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:NumberOfWarrantsIssuedPerUnit
      contextRef="From2021-11-082021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember"
      decimals="INF"
      id="xdx2ixbrl0743"
      unitRef="Shares">0.5</TVGN:NumberOfWarrantsIssuedPerUnit>
    <TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember"
      id="xdx2ixbrl0926">P5D</TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing>
    <TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing
      contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember"
      id="xdx2ixbrl0942">P5D</TVGN:MinimumPeriodForReceivingSpacLoanFromDeSpacClosing>
    <TVGN:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="xdx2ixbrl1024"
      unitRef="Integer">3</TVGN:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl1044"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl1046"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl1048"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1052"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl1059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl1061"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1151"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:DeferredTransactionCosts
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl1189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl1198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1236"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:TransactionCosts
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1324"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1326"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1343"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1346"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1348"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1349"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1371"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1427"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1429"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1440"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1442"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1467"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1469"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1480"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1482"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1546"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:CashAcquiredInConnectionWithReverseRecapitalization
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1556"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1561"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1580"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      id="xdx2ixbrl1583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="xdx2ixbrl1667"
      unitRef="Pure">75</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="xdx2ixbrl1669"
      unitRef="Pure">85</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1774"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1776"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1786"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1788"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1790"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1792"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1798"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1800"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1802"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1804"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1832"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1945"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ConvertiblePromissoryNoteInterest
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1954"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ConvertiblePromissoryNoteChangeInFairValue
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1957"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1969"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1972"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl1975"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1992"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_custom_PublicWarrantsMember"
      id="xdx2ixbrl1995"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_custom_PrivateWarrantsMember"
      id="xdx2ixbrl1998"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl2000"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_custom_EarnoutSharesMember"
      id="xdx2ixbrl2004"
      unitRef="Shares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-03-31" id="Fact000011">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-03-31" id="Fact000012">Tevogen Bio Holdings Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-03-31" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-03-31" id="Fact000014">98-1597194</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-03-31" id="Fact000015">15 Independence Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-03-31" id="Fact000016">Suite #410</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-03-31" id="Fact000017">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-03-31" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-03-31" id="Fact000019">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-03-31" id="Fact000020">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-03-31" id="Fact000021">838-6436</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000022">Ryan Saadi</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000023">Tevogen Bio Holdings Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000024">15 Independence Boulevard</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000025">Suite #410</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000026">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000027">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000028">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000029">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2024-01-012024-03-31_dei_BusinessContactMember"
      id="Fact000030">838-6436</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-03-31" id="Fact000031">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-03-31" id="Fact000032">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-03-31" id="Fact000033">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-03-31" id="Fact000034">false</dei:EntityExTransitionPeriod>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000042"
      unitRef="USD">8835</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">129186</us-gaap:Cash>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000045"
      unitRef="USD">344500</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">2501</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">145170</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">355836</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">274356</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">16681497</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">356864000</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">17037333</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">357138356</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">1142405</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">210454</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">1631725</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">230000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">140000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">3004130</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">350454</us-gaap:LiabilitiesCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">29000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">7250</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <TVGN:DeferredOfferingCostsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">14700000</TVGN:DeferredOfferingCostsNoncurrent>
    <TVGN:DeferredOfferingCostsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">14700000</TVGN:DeferredOfferingCostsNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">17733130</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">15057704</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000129"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000131"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">1502180</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">34500000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="2"
      id="Fact000137"
      unitRef="USDPShares">11.10</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="2"
      id="Fact000139"
      unitRef="USDPShares">10.34</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">16681497</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">356864000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000169"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000171"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000175"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">13433333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">13433333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">1450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">1450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">1502180</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">34500000</us-gaap:TemporaryEquitySharesOutstanding>
    <TVGN:ClassAOrdinaryShares
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">1343</TVGN:ClassAOrdinaryShares>
    <TVGN:ClassAOrdinaryShares
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">145</TVGN:ClassAOrdinaryShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000196"
      unitRef="Shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">11983333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">11983333</us-gaap:CommonStockSharesOutstanding>
    <TVGN:ClassBOrdinaryShares
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">1198</TVGN:ClassBOrdinaryShares>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-17378637</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-14784691</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-17377294</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">-14783348</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">17037333</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">357138356</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">2273970</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">953083</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">2273970</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">953083</us-gaap:CostsAndExpenses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">2734426</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">4948194</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">21750</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-413250</us-gaap:FairValueAdjustmentOfWarrants>
    <TVGN:ImpairmentOfAmountDueFromRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">250000</TVGN:ImpairmentOfAmountDueFromRelatedParty>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">256031</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">2206645</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">5361444</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-67325</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">4408361</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">5333742</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">5333742</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">34500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">34500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000264"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000266"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000268"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000270"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">12317077</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">12317077</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">1450000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">1450000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000280"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000282"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000284"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000286"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000288"
      unitRef="Shares">1116256</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">1116256</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">11983333</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000294"
      unitRef="Shares">11983333</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000296"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000298"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000300"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000302"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">1450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">145</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">11983333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000305"
      unitRef="USD">1198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-14784691</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-14783348</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000320"
      unitRef="Shares">11983333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">1198</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">-11983333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-1198</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">275306</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">275306</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-275306</TVGN:AccretionOfCarryingValueToRedemptionValue>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-2526621</TVGN:AccretionOfCarryingValueToRedemptionValue>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-2801927</TVGN:AccretionOfCarryingValueToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-67325</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000340"
      unitRef="USD">-67325</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">13433333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">1343</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">-17378637</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-17377294</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000358"
      unitRef="Shares">1450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">145</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">11983333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">1198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-14229052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-14227709</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">1450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">145</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">11983333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">1198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-14229052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-14227709</us-gaap:StockholdersEquity>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-4964000</TVGN:AccretionOfCarryingValueToRedemptionValue>
    <TVGN:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000376"
      unitRef="USD">-4964000</TVGN:AccretionOfCarryingValueToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">4408361</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000382"
      unitRef="USD">4408361</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">1450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">145</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000392"
      unitRef="Shares">11983333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">1198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">-14784691</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">-14783348</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000400"
      unitRef="Shares">1450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">145</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">11983333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">1198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">-14784691</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">-14783348</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000407"
      unitRef="USD">-67325</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">4408361</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">2734426</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">4948194</us-gaap:UnrealizedGainLossOnInvestments>
    <TVGN:NoncashInterestExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">256031</TVGN:NoncashInterestExpenses>
    <TVGN:ImpairmentOfAmountDueFromRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">250000</TVGN:ImpairmentOfAmountDueFromRelatedParty>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">21750</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">-413250</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">-142669</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-446609</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">267000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToAffiliatesCurrent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">90000</us-gaap:IncreaseDecreaseInDueToAffiliatesCurrent>
    <us-gaap:IncreaseDecreaseInDueToAffiliatesCurrent
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">120000</us-gaap:IncreaseDecreaseInDueToAffiliatesCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000437"
      unitRef="USD">931950</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">171079</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000440"
      unitRef="USD">-1376351</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-215395</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <TVGN:ExtensionAmountDepositedIntoTrustAccount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000446"
      unitRef="USD">67500</TVGN:ExtensionAmountDepositedIntoTrustAccount>
    <TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000449"
      unitRef="USD">342984430</TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000452"
      unitRef="USD">342916930</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">1323500</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">342984430</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000464"
      unitRef="USD">-341660930</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000467"
      unitRef="USD">-120351</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">-215395</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000470"
      unitRef="USD">129186</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">344581</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000473"
      unitRef="USD">8835</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">129186</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <TVGN:ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">2801927</TVGN:ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount>
    <TVGN:ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">4964000</TVGN:ChangeInValueOfClassOrdinarySharesSubjectToRedemptionAmount>
    <TVGN:SaleOfClassBSharesToInvestor
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">3955111</TVGN:SaleOfClassBSharesToInvestor>
    <TVGN:SaleOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">20000</TVGN:SaleOfWarrants>
    <us-gaap:NatureOfOperations contextRef="From2023-01-012023-12-31" id="Fact000488">&lt;p id="xdx_808_eus-gaap--NatureOfOperations_zDJFUh9gK4b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="s_006"&gt;&lt;/span&gt;Note
1 &#x2014; &lt;span id="xdx_82B_zbRh0MYh8YDi"&gt;Description of Organization, Business Operations and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Semper
Paratus Acquisition Corporation (the &#x201c;Company&#x201d;) was incorporated as a Cayman Islands exempted company on April 21, 2021.
The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with &lt;span id="xdx_907_ecustom--ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_dc_uInteger_c20230101__20231231_zMWGIEMfvKxj" title="Condition for future business combination number of businesses minimum"&gt;one&lt;/span&gt; or more businesses (the &#x201c;Business Combination&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company
is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and
emerging growth companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023, relates to the Company&#x2019;s
formation and Initial Public Offering (&#x201c;IPO&#x201d;), which is described below, and the search for a prospective initial Business
Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at
the earliest. The Company will generate non-operating income in the form of interest income earned on investments from the proceeds derived
from the IPO. The registration statement for the Company&#x2019;s IPO was declared effective on November 3, 2021. On November 8, 2021,
the Company consummated the IPO of &lt;span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_pid_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zLHmTymUPMXd" title="Units Issued During Period, Shares, New Issues"&gt;30,000,000&lt;/span&gt; units (&#x201c;Units&#x201d;) with respect to the ordinary shares included in the Units being
offered (the &#x201c;Public Shares&#x201d;) at $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNGHyHlxNe89" title="Purchase price, per unit"&gt;10.00&lt;/span&gt; per Unit generating gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjIs6le75hF" title="Proceeds from Issuance Initial Public Offering"&gt;300,000,000&lt;/span&gt;, which is discussed in Note 3.
The company has selected December 31 as its fiscal year end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the closing of the IPO, the Company consummated the sale of &lt;span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq6Kw3dFp78a" title="Units Issued During Period, Shares, New Issues"&gt;1,360,000&lt;/span&gt; private placement units (&#x201c;Private Placement Units&#x201d;)
at a price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbYk6jXFSDU4" title="Purchase price, per unit"&gt;10.00&lt;/span&gt; per Private Placement Unit in a private placement to the Company&#x2019;s sponsor, Semper Paratus Sponsor LLC (the
&#x201c;Original Sponsor&#x201d;) and underwriter Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) generating gross proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaiAenvmmHFe" title="Proceeds from Issuance Initial Public Offering"&gt;13,600,000&lt;/span&gt;
which is described in Note 4.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the closing of the IPO, the Company consummated the closing of the sale of &lt;span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBqlRFJutaP6" title="Units issued during period, shares new"&gt;4,500,000&lt;/span&gt; additional Units upon receiving notice of the
underwriter&#x2019;s election to fully exercise its overallotment option (&#x201c;Overallotment Units&#x201d;), generating additional gross
proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zyVOD8AzgT2c" title="Proceeds from issuance initial public offering"&gt;45,000,000&lt;/span&gt; and incurring additional offering costs of $&lt;span id="xdx_90A_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zcZlqCYYSBH" title="Deferred offering costs noncurrent"&gt;2,700,000&lt;/span&gt; in underwriting fees all of which are deferred until completion
of the Company&#x2019;s Business Combination. Simultaneously with the exercise of the overallotment, the Company consummated the Private
Placement of an additional &lt;span id="xdx_900_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zDYXZViuAVrl" title="Common equity securities"&gt;90,000&lt;/span&gt; Private Placement Units to the Original Sponsor, generating gross proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--SponsorMember_zSlgdCB6G0e7" title="Proceeds from issuance initial public offering"&gt;900,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs for the IPO amounted to $&lt;span id="xdx_90D_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zM0kMRZ02hRe"&gt;21,266,594&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
consisting of $&lt;span id="xdx_90E_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6hPQ2q0R0Ue"&gt;6,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of paid underwriting fees, $&lt;span id="xdx_90E_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCkiu10bqmKi"&gt;14,700,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of deferred underwriting fees payable (which
are held in the Trust Account (defined below)) and $&lt;span id="xdx_90A_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zoUEDVkE0YGh" title="Other offering costs"&gt;566,594
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of other costs. On June 28, 2023, the Company
and Cantor entered into a fee reduction agreement (the &#x201c;Fee Reduction Agreement&#x201d;), pursuant to which Cantor agreed to forfeit
$&lt;span id="xdx_90F_ecustom--DeferredOfferingCostsNoncurrentForfeited_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zn4kU3FxyPk9" title="Deferred underwriting fees"&gt;9,700,000&lt;/span&gt; of the deferred underwriting fees payable, resulting in a remainder of $&lt;span id="xdx_909_ecustom--DeferredOfferingCostsNoncurrent_iI_c20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zEO3SgCutDUk" title="Deferred offering costs non current"&gt;5,000,000&lt;/span&gt; of deferred underwriting fees payable (the
&#x201c;Reduced Deferred Fee&#x201d;) by the Company to Cantor upon the closing of the Transaction (as defined below) with Tevogen Bio
Inc (&#x201c;Tevogen Bio&#x201d;), such fee payable to Cantor in the form of &lt;span id="xdx_903_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230628__20230628__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember_zzt6gdXHo7od" title="Common equity securities"&gt;500,000&lt;/span&gt; shares of the common equity securities of the entity
surviving the Transaction. The Fee Reduction Agreement only applies to the consummation of the Transaction with Tevogen Bio and no other
potential Business Combinations that may be contemplated or consummated by the Company. In the event that the Company were not to complete
the Transaction with Tevogen Bio, the Original Deferred fee would become due and payable by the Company to Cantor as originally set forth
in the Underwriting Agreement, upon the consummation of a Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the closing of the IPO, $&lt;span id="xdx_908_ecustom--PaymentsForInvestmentOfCashInTrustAccount_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3KspCMAjPDj" title="Payments for investment of cash in trust account"&gt;351,900,000&lt;/span&gt; ($&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMPFV6fwpes3" title="Purchase price, per unit"&gt;10.20&lt;/span&gt; per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement
Units was placed in a trust account (&#x201c;Trust Account&#x201d;) and will be invested in U.S. government securities, within the meaning
set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;), with a maturity
of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting
the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until
the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale
of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating
a Business Combination. As of December 31, 2023, there is no assurance that the Company will be able to complete a Business Combination successfully. The Company
must complete one or more initial Business Combinations having an aggregate fair market value of at least &lt;span id="xdx_909_ecustom--ConditionForFutureBusinessCombinationUseOfProceedsPercentage_iI_dp_uPure_c20231231_z45et9GfPFY7" title="Condition for future business combination use of proceeds percentage"&gt;80&lt;/span&gt;% of the assets held in the
Trust Account excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of
the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction
company owns or acquires &lt;span id="xdx_90C_ecustom--ConditionForFutureBusinessCombinationThresholdPercentageOwnership_iI_pid_dp_c20231231_z76yREbwvLV6" title="Condition for future business combination threshold ownership (as a percent)"&gt;50&lt;/span&gt;% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest
in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will provide the holders of the outstanding Public Shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem
all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting
called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder
approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to
redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZaHgeiI0YXh" title="Purchase price, per unit"&gt;10.20&lt;/span&gt; per Public
Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to
the Company&#x2019;s warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s
liquidation, if there is a shareholder vote or tender offer in connection with the Company&#x2019;s Business Combination and in connection
with certain amendments to the Company&#x2019;s amended and restated memorandum and articles of association (the &#x201c;Memorandum and
Articles of Association&#x201d;). In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 480-10-S99, redemption provisions
not solely within the control of a company require Class A ordinary shares subject to redemption to be classified outside of permanent
equity. Given that the Public Shares were issued with other freestanding instruments (i.e., public warrants), the initial carrying value
of ordinary shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The ordinary shares
are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either
(i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that
the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting
period. The Company has elected to recognize the changes immediately. While redemptions cannot cause the Company&#x2019;s net tangible
assets to fall below $&lt;span id="xdx_901_ecustom--ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_iI_c20231231_zqwayskvZtv6" title="Net tangible assets"&gt;5,000,001&lt;/span&gt;, the Public Shares are redeemable and are classified as such on the balance sheet until such date that
a redemption event takes place.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Redemptions
of the Company&#x2019;s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to
an agreement relating to the Company&#x2019;s Business Combination. If the Company seeks shareholder approval of the Business Combination,
the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination,
or such other vote as required by law or stock exchange rule. If a shareholder vote is not required by applicable law or stock exchange
listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant
to its Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender
offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required
by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other
reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant
to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed
to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business
Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective
of whether they vote for or against the proposed transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 30, 2023, shareholders (the &#x201c;Initial Shareholders&#x201d;) holding all of the issued and outstanding Class B ordinary shares
(the &#x201c;Founder Shares&#x201d;) of the Company elected to convert their Class B ordinary shares into Class A ordinary shares of the
Company on a &lt;span id="xdx_907_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_zeBYVwN7gdDk" title="Conversion ratio"&gt;one&lt;/span&gt;-for-one basis (the &#x201c;Conversion&#x201d;). As a result, &lt;span id="xdx_90D_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z2ZYNNSqJV0e" title="Shares cancelled"&gt;11,983,333&lt;/span&gt; of the Company&#x2019;s Class B ordinary shares
were cancelled and &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqQyyjgoU3Cc" title="Shares issued upon conversion"&gt;11,983,333&lt;/span&gt; Class A ordinary shares were issued to such converting Class B shareholders. The Initial Shareholders agreed
that all of the terms and conditions applicable to the Founder Shares set forth in the Letter Agreement, dated November 3, 2021, by and
among the Company, its officers, its directors and the Initial Shareholders (the &#x201c;Letter Agreement&#x201d;), shall continue to apply
to the Class A ordinary shares that the Founder Shares converted into, including the voting agreement, transfer restrictions and waiver
of any right, title, interest or claim of any kind to the Trust Account (as defined in the Letter Agreement) or any monies or other assets
held therein. Following the Conversion, on January 30, 2023, the Company had &lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zP1gjbscAhqh" title="Common stock, shares outstanding"&gt;47,933,333&lt;/span&gt; Class A ordinary shares issued and outstanding
and &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgySFaZSCsnl" title="Common stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_do_c20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zwX2xLaD0Bne" title="Common stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; Class B ordinary shares issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 3, 2023, the Company&#x2019;s shareholders approved an amendment (the &#x201c;First Extension Charter Amendment&#x201d;) to the
Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial
Business Combination from February 8, 2023 to December 15, 2023. Under Cayman Islands law, the First Extension Charter Amendment took
effect upon approval by the shareholders. In connection with the meeting, shareholders holding approximately &lt;span id="xdx_904_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_z33fQd6UXHD2" title="Minimum period to file charter amendment"&gt;32,116,947&lt;/span&gt; Public Shares
exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $&lt;span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember_zqFSwarHdFjd" title="Cash withdrawn from Trust Account in connection with redemption"&gt;333&lt;/span&gt;
million (approximately $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230203__us-gaap--TypeOfArrangementAxis__custom--FirstExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrnaTqrsici1" title="Price per share"&gt;10.38&lt;/span&gt; per Public Share) was removed from the Trust Account to pay such holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 14, 2023, the Company&#x2019;s shareholders approved an amendment (the &#x201c;Second Extension Charter Amendment&#x201d;) to the
Amended and Restated Memorandum and Articles of Association to extend the date by which the Company is required to consummate an Initial
Business Combination to September 15, 2024. Under Cayman Islands law, the Second Extension Charter Amendment took effect upon approval
by the shareholders. In connection with the meeting, shareholders holding approximately &lt;span id="xdx_90A_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zXYa3o808VCk" title="Minimum period to file charter amendment"&gt;880,873&lt;/span&gt; Public Shares exercised their right to
redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $&lt;span id="xdx_90F_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn4n6_c20231214__20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember_zt1tLSiARXGi" title="Cash withdrawn from trust account in connection with redemption"&gt;9.71&lt;/span&gt; million (approximately
$&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20231214__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zrf2ccm725nh" title="Price per share"&gt;11.03&lt;/span&gt; per Public Share) was removed from the Trust Account to pay such holders. Approximately $&lt;span id="xdx_907_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pn5n6_c20231231_zQKEGPZSGhh3" title="ash and marketable securities held in Trust Account"&gt;16.7&lt;/span&gt; million remained in the Trust Account
as of December 31, 2023 and the Company had &lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--SecondExtensionCharterAmendmentMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zLJ4vIkIdKbh" title="Common stock shares outstanding"&gt;1,502,180&lt;/span&gt; public shares outstanding as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 4, 2023, the Company entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with SSVK Associates, LLC (the &#x201c;Sponsor&#x201d;)
and the Original Sponsor, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zH5jDdhu5VY7" title="Stock issued during period, Shares new issues"&gt;7,988,889&lt;/span&gt; Class A ordinary shares
and (y) &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zlLyy02ze1qi" title="Stock issued during period, Shares new issues"&gt;1,000,000&lt;/span&gt; Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that
is exercisable for one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter
Agreement, dated November 3, 2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement,
dated November 3, 2021, by and between the Company and Cantor, as representative of the several underwriters (the &#x201c;Underwriting
Agreement&#x201d;)), for an aggregate purchase price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230504__dei--LegalEntityAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember_zVaC2L3t6W2e" title="Purchase price, per unit"&gt;1.00&lt;/span&gt; (the &#x201c;Purchase Price&#x201d;) payable at the time of the initial Business
Combination (see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notwithstanding
the foregoing, the Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder
or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section 13 of the Securities
Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more
than an aggregate of &lt;span id="xdx_907_ecustom--RedemptionLimitPercentageWithoutPriorConsent_dp_uPure_c20230101__20231231_ztHl250zlGz5" title="Redemption limit percentage without prior consent"&gt;15&lt;/span&gt;% or more of the ordinary shares sold in the IPO, without the prior consent of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Initial Shareholders have agreed not to propose an amendment to the Memorandum and Articles of Association that would affect the substance
or timing of the Company&#x2019;s obligation to redeem &lt;span id="xdx_905_ecustom--PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_dp_uPure_c20230101__20231231_z7I1R0qtqSv7" title="Obligation to redeem public shares if entity does not complete a business combination (as a percent)"&gt;100&lt;/span&gt;% of its Public Shares if the Company does not complete a Business Combination,
unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such
amendment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company is unable to complete a Business Combination by September 15, 2024 (&#x201c;Combination Period&#x201d;), the Company will (i)
cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days
thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account including interest earned on the funds held in the Trust Account and not previously released to us to pay the Company&#x2019;s
franchise and income taxes (less up to $&lt;span id="xdx_909_ecustom--MaximumAllowedDissolutionExpenses_c20230101__20231231_zVAJkI5epihf" title="Maximum allowed dissolution expenses"&gt;100,000&lt;/span&gt; of interest to pay dissolution expenses), divided by the number of then outstanding Public
Shares, which redemption will completely extinguish Public Shareholders&#x2019; rights as shareholders (including the right to receive
further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the Company&#x2019;s remaining shareholders and the Company&#x2019;s board of directors, dissolve and liquidate,
subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. On December 18, 2023, the Company deposited $&lt;span id="xdx_902_eus-gaap--AssetsHeldInTrust_iI_c20231218_zVShfNGa696i" title="Extension amount deposited into Trust Account"&gt;67,500&lt;/span&gt; into the Trust Account in order to extend the date by which
the Company has to complete the initial business combination by three months from December 14, 2023, to March 15, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete
a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the
IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails
to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to its deferred
underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within
the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be
available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of
the residual assets remaining available for distribution (including Trust Account assets) will be only $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNODw1vph2m4" title="Shares issued, price per share"&gt;10.20&lt;/span&gt; per share held in the Trust
Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the
extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the
Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not
apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any
monies held in the Trust Account or to any claims under the Company&#x2019;s indemnity of the underwriters of the IPO against certain
liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Moreover, in the
event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent
of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify
the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&#x2019;s independent
registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements
waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt; Business Combination&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On June 28, 2023, the Company entered into an Agreement
and Plan of Merger by and among the Company, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company
(&#x201c;Merger Sub&#x201d;), the Sponsor, in its capacity as purchaser representative, Tevogen Bio, and Ryan Saadi, in his capacity as
seller representative (as may be amended and/or restated from time to time, the &#x201c;Merger Agreement&#x201d;), pursuant to which, among
other things, the parties will affect the merger of Merger Sub with and into Tevogen Bio, with Tevogen Bio continuing as the surviving
entity (the &#x201c;Merger&#x201d;), as a result of which all of the issued and outstanding capital stock of Tevogen Bio shall be exchanged
for shares of Class A common stock, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230628__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zDptEao3aUA7" title="Ordinary shares, par value (in dollar per share)"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Class A Common Stock&#x201d;), of the Company (the &#x201c;Share
Exchange&#x201d;) subject to the conditions set forth in the Merger Agreement, with Tevogen Bio surviving the Share Exchange as a wholly
owned subsidiary of the Company (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the &#x201c;Transaction&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On September 14, 2023, the Company filed a registration
statement on Form S-4 with the SEC relating to the Transaction with Tevogen, and on February 14, 2024, the Company consummated the Transaction. See Note 10 for more information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action,
various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further,
the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements
and the specific impact on the Company&#x2019;s financial condition, results of operations, and cash flows is also not determinable as
of the date of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had $&lt;span id="xdx_906_eus-gaap--Cash_iI_c20231231_zODOpYi3K2e6" title="Cash"&gt;8,835&lt;/span&gt; in its operating bank accounts, $&lt;span id="xdx_906_eus-gaap--AssetsHeldInTrustNoncurrent_iI_c20231231_z9lqJZcCJUD4" title="Assets held in trust noncurrent"&gt;16,681,497&lt;/span&gt; in cash held in the
Trust Account to be used for a Business Combination or to repurchase or redeem its ordinary shares in connection therewith and working
capital deficit of $&lt;span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_c20231231_zSxmpiZut0Td" title="Working capital deficit"&gt;2,648,294&lt;/span&gt;. As of December 31, 2023, approximately $&lt;span id="xdx_903_eus-gaap--InvestmentIncomeInterest_c20230101__20231231_zlzvEPktqM16" title="Investment income interest"&gt;2,734,000&lt;/span&gt; of the amount on deposit in the Trust Account represented
interest income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Company management believes that cash on hand following
consummation of the Transaction as well as $&lt;span id="xdx_904_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7QPqAiWlDL"&gt;2,000,000
&lt;/span&gt;to the Company from a Series A Preferred Stock financing in February 2024 and $&lt;span id="xdx_905_eus-gaap--Cash_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zt1yebqOBlpe"&gt;1,200,000&lt;/span&gt; in connection with the Series A-1
Preferred Stock financing thereafter (see Note 10) is not sufficient to sustain planned operations for 12 months from the issuance
date of these financial statements. As a result, the Company has concluded that substantial doubt exists about its ability to continue
as a going concern for one year from the date that these financial statements are issued. The accompanying financial statements have
been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course
of business. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Management is currently evaluating different strategies to obtain the additional
funding for future operations for subsequent years. These strategies may include but are not limited to private placements of equity and/or
debt, licensing and/or marketing arrangements, and public offerings of equity and/or debt securities. The Company may not be able to obtain
financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable
terms, or at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <TVGN:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000490"
      unitRef="Integer">1</TVGN:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-11-082021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000492"
      unitRef="Shares">30000000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000494"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-11-082021-11-08_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">300000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000498"
      unitRef="Shares">1360000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-08_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000500"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">13600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-11-082021-11-08_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000504"
      unitRef="Shares">4500000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-11-082021-11-08_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      id="Fact000506"
      unitRef="USD">45000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <TVGN:DeferredOfferingCostsNoncurrent
      contextRef="AsOf2021-11-08_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      id="Fact000508"
      unitRef="USD">2700000</TVGN:DeferredOfferingCostsNoncurrent>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember_custom_SponsorMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">90000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-11-082021-11-08_us-gaap_PrivatePlacementMember_custom_SponsorMember"
      decimals="0"
      id="Fact000512"
      unitRef="USD">900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <TVGN:TransactionCosts
      contextRef="From2021-11-082021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">21266594</TVGN:TransactionCosts>
    <TVGN:SaleOfStockUnderwritingFees
      contextRef="From2021-11-082021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000514"
      unitRef="USD">6000000</TVGN:SaleOfStockUnderwritingFees>
    <TVGN:DeferredOfferingCostsNoncurrent
      contextRef="AsOf2021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000515"
      unitRef="USD">14700000</TVGN:DeferredOfferingCostsNoncurrent>
    <TVGN:SaleOfStockOtherOfferingCosts
      contextRef="AsOf2021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">566594</TVGN:SaleOfStockOtherOfferingCosts>
    <TVGN:DeferredOfferingCostsNoncurrentForfeited
      contextRef="AsOf2023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">9700000</TVGN:DeferredOfferingCostsNoncurrentForfeited>
    <TVGN:DeferredOfferingCostsNoncurrent
      contextRef="AsOf2023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">5000000</TVGN:DeferredOfferingCostsNoncurrent>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-282023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember"
      decimals="INF"
      id="Fact000523"
      unitRef="Shares">500000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <TVGN:PaymentsForInvestmentOfCashInTrustAccount
      contextRef="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">351900000</TVGN:PaymentsForInvestmentOfCashInTrustAccount>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000527"
      unitRef="USDPShares">10.20</us-gaap:SharesIssuedPricePerShare>
    <TVGN:ConditionForFutureBusinessCombinationUseOfProceedsPercentage
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000529"
      unitRef="Pure">0.80</TVGN:ConditionForFutureBusinessCombinationUseOfProceedsPercentage>
    <TVGN:ConditionForFutureBusinessCombinationThresholdPercentageOwnership
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000531"
      unitRef="Pure">0.50</TVGN:ConditionForFutureBusinessCombinationThresholdPercentageOwnership>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000533"
      unitRef="USDPShares">10.20</us-gaap:SharesIssuedPricePerShare>
    <TVGN:ConditionForFutureBusinessCombinationThresholdNetTangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">5000001</TVGN:ConditionForFutureBusinessCombinationThresholdNetTangibleAssets>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="From2023-01-302023-01-30"
      decimals="INF"
      id="Fact000537"
      unitRef="Pure">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-01-302023-01-30_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000539"
      unitRef="Shares">11983333</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-01-302023-01-30_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000541"
      unitRef="Shares">11983333</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-01-30_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000543"
      unitRef="Shares">47933333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-01-30_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000545"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-01-30_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000547"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares
      contextRef="AsOf2023-02-03_custom_FirstExtensionCharterAmendmentMember_custom_PublicSharesMember"
      decimals="INF"
      id="Fact000549"
      unitRef="USDPShares">32116947</TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares>
    <TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption
      contextRef="From2023-02-022023-02-03_custom_FirstExtensionCharterAmendmentMember"
      decimals="-6"
      id="Fact000551"
      unitRef="USD">333000000</TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-02-03_custom_FirstExtensionCharterAmendmentMember_custom_PublicSharesMember"
      decimals="INF"
      id="Fact000553"
      unitRef="USDPShares">10.38</us-gaap:SharesIssuedPricePerShare>
    <TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares
      contextRef="AsOf2023-12-14_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember"
      decimals="INF"
      id="Fact000555"
      unitRef="USDPShares">880873</TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares>
    <TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption
      contextRef="From2023-12-142023-12-14_custom_SecondExtensionCharterAmendmentMember"
      decimals="-4"
      id="Fact000557"
      unitRef="USD">9710000</TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-14_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember"
      decimals="INF"
      id="Fact000559"
      unitRef="USDPShares">11.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000561"
      unitRef="USD">16700000</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SecondExtensionCharterAmendmentMember_custom_PublicSharesMember"
      decimals="INF"
      id="Fact000563"
      unitRef="Shares">1502180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember"
      decimals="INF"
      id="Fact000565"
      unitRef="Shares">7988889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_PrivatePlacementMember_custom_SsvkAssociatesLlcMember"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember"
      decimals="INF"
      id="Fact000569"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <TVGN:RedemptionLimitPercentageWithoutPriorConsent
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000571"
      unitRef="Pure">0.15</TVGN:RedemptionLimitPercentageWithoutPriorConsent>
    <TVGN:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000573"
      unitRef="Pure">1</TVGN:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <TVGN:MaximumAllowedDissolutionExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">100000</TVGN:MaximumAllowedDissolutionExpenses>
    <us-gaap:AssetsHeldInTrust
      contextRef="AsOf2023-12-18"
      decimals="0"
      id="Fact000577"
      unitRef="USD">67500</us-gaap:AssetsHeldInTrust>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000579"
      unitRef="USDPShares">10.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-28_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000581"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000583"
      unitRef="USD">8835</us-gaap:Cash>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000585"
      unitRef="USD">16681497</us-gaap:AssetsHeldInTrustNoncurrent>
    <TVGN:WorkingCapitalDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">2648294</TVGN:WorkingCapitalDeficit>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">2734000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:Cash
      contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">2000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">1200000</us-gaap:Cash>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-01-012023-12-31" id="Fact000593">&lt;p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zNRCBCcrYlWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2014; &lt;span id="xdx_82A_z09laoPAkQZ3"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zDufdfSqr987"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--EmergingGrowthCompanyPolicyPolicyTextBlock_zPTHX6hDDIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z51bx9GmNCf6"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS
Act&#x201d;), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for
public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
may make comparison of the Company&#x2019;s financial statements with another public company that is neither an emerging growth company
nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zzoVedJkZirl"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zpjGtuKXUP3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zjW2yciTNI63"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did &lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_z8n1KGVCSxn" title="Cash equivalents"&gt;&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zjnpuZTVh3Wb" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--AssetsHeldInTrustAccountPolicyPolicyTextBlock_ztBsSHZlY6w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zoaPRIdCAmoa"&gt;Investments
Held in Trust Account&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, substantially all of the assets held in the Trust Account were held in a demand deposit cash account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;At December
31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company&#x2019;s investments
held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at
the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included
in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values
of investments held in Trust Account are determined using available market information.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_zCwy56mbqjbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zCXACvIfWnUi"&gt;Offering
Costs associated with the Initial Public Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs, including additional underwriting fees associated with the underwriters&#x2019; exercise of the over-allotment option, consist
principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable
to the underwriters&#x2019; exercise of the over-allotment option in full, amounted to $&lt;span id="xdx_909_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDpn1E4hnJBc" title="Offering costs"&gt;21,266,594&lt;/span&gt; consisting of $&lt;span id="xdx_909_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNa6Aky0zUCa" title="Underwriting fees"&gt;6,000,000&lt;/span&gt; of paid underwriting
fees, $&lt;span id="xdx_90B_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyD2joOQN139" title="Deferred underwriting fee payable"&gt;14,700,000&lt;/span&gt; of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $&lt;span id="xdx_907_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTd94FcM7BSj" title="Other offering costs"&gt;566,594&lt;/span&gt; of other costs
and was charged to shareholders&#x2019; equity upon the completion of the IPO. On June 28, 2023, the Company and Cantor entered into the Fee Reduction
Agreement, pursuant to which Cantor agreed to the Reduced Deferred Fee in the form of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRzNADdXwd9i" title="Number of shares issued"&gt;500,000&lt;/span&gt; shares of the common equity securities of
the entity surviving the Transaction. See Note 1 for more information on the Fee Reduction Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zcm94hOGvmZ9"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount"&gt;250,000&lt;/span&gt;. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_znPUUrddfrUi"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the (&#x201c;FASB&#x201d;) ASC 820,
&#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8Ot8VIhkg52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Related
Party Transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for amounts due from related parties at historical cost and evaluates the collectability of these receivables for determination
on if impairment should be recognized. In the same manner, the Company evaluated the $&lt;span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_z3uF8gdQDCwh" title="Impairment of due from related party"&gt;250,000&lt;/span&gt; loan to Srirama Associates, LLC and determined
that the amount was uncollectable and therefore recognized an impairment loss, see Note 5.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zkpWCEwQfXz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zLIWqLIv8yUi"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;Income Taxes.&#x201d; Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. There were &lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20231231_zVaiAAGIGva9" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zF5N2A4rIB24" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits as of December 31, 2023 and 2022.
The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. &lt;span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20231231_zrUaDPZSdxM3" title="Unrecognized tax benefits accrued for interest and penalties"&gt;&lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20221231_zurXvR5vPrF5" title="Unrecognized tax benefits accrued for interest and penalties"&gt;No&lt;/span&gt;&lt;/span&gt; amounts were accrued for the payment of
interest and penalties for the year ended December 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the
Company. Consequently, income taxes are not reflected in the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--TemporaryEquityPolicyPolicyTextBlock_zD0efC8N3eda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zgtCoOZ7zQ9k"&gt;Class
A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#x201c;Distinguishing
Liabilities from Equity.&#x201d; Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument
and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#x2019;s control) is classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders&#x2019;
equity. The Company&#x2019;s Public Shares feature certain redemption rights that are considered to be outside of the Company&#x2019;s
control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023 and 2022, &lt;span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp8ry42IgPWa" title="Temporary equity, shares outstanding"&gt;1,502,180&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJYI75T357lb" title="Temporary equity, shares outstanding"&gt;34,500,000&lt;/span&gt;, respectively,
Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders&#x2019; deficit
section of the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary
share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable
ordinary share are affected by charges against additional paid in capital and accumulated deficit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zMZGt80hTdmi" style="display: none"&gt;Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold; text-align: left"&gt;Class A ordinary share subject to possible redemption, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;351,900,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Accretion of carrying value to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&lt;p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value"&gt;4,964,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Class A ordinary share subject to possible redemption, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&lt;p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption"&gt;356,864,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of carrying value to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value"&gt;2,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Redemption of ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares"&gt;(342,984,430&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary share subject to possible redemption, December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;16,681,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z1HYxxQQhzOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zK1LsoVBPXid"&gt;Net
Income (Loss) per Ordinary Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#x201c;Founder Shares&#x201d;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)"&gt;17,975,000&lt;/span&gt; ordinary shares at $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants"&gt;11.50&lt;/span&gt; per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share"&gt;17,975,000&lt;/span&gt;&lt;/span&gt; Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zyUK767o3DFd" style="display: none"&gt;Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Non &#x2013; Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class B Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(Redeemable)&lt;/b&gt;&lt;/p&gt;
 Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Non &#x2013; Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Class B Ordinary Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Basic and diluted net (loss) income per share:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 6%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Allocation of net (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right"&gt;(19,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income"&gt;(44,186&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income"&gt;(4,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income"&gt;3,172,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income"&gt;133,355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income"&gt;1,102,090&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted"&gt;5,333,742&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted"&gt;12,317,077&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted"&gt;1,116,256&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted"&gt;34,500,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted"&gt;1,450,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted"&gt;11,983,333&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net (loss) income per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--WarrantLiabilitiesPolicyPolicyTextBlock_z7WEXKlufkK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zVTXpxyIBmS5"&gt;Accounting
for Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment
considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#x2019;s own ordinary shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d;
in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments
are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and Private Placement Warrants
qualify for liability accounting treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zE8ozL4HOjF7"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#x2019;s financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000595">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhjH7Oc6pSnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zDufdfSqr987"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <TVGN:EmergingGrowthCompanyPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000597">&lt;p id="xdx_840_ecustom--EmergingGrowthCompanyPolicyPolicyTextBlock_zPTHX6hDDIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z51bx9GmNCf6"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS
Act&#x201d;), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for
public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
may make comparison of the Company&#x2019;s financial statements with another public company that is neither an emerging growth company
nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:EmergingGrowthCompanyPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-012023-12-31" id="Fact000599">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zMJh4SX2JZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zzoVedJkZirl"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current
information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial
statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000601">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zpjGtuKXUP3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zjW2yciTNI63"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company did &lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_z8n1KGVCSxn" title="Cash equivalents"&gt;&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zjnpuZTVh3Wb" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000603"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <TVGN:AssetsHeldInTrustAccountPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000607">&lt;p id="xdx_844_ecustom--AssetsHeldInTrustAccountPolicyPolicyTextBlock_ztBsSHZlY6w1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zoaPRIdCAmoa"&gt;Investments
Held in Trust Account&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, substantially all of the assets held in the Trust Account were held in a demand deposit cash account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;At December
31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company&#x2019;s investments
held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at
the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included
in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values
of investments held in Trust Account are determined using available market information.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:AssetsHeldInTrustAccountPolicyPolicyTextBlock>
    <TVGN:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000609">&lt;p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_zCwy56mbqjbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zCXACvIfWnUi"&gt;Offering
Costs associated with the Initial Public Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs, including additional underwriting fees associated with the underwriters&#x2019; exercise of the over-allotment option, consist
principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable
to the underwriters&#x2019; exercise of the over-allotment option in full, amounted to $&lt;span id="xdx_909_ecustom--TransactionCosts_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDpn1E4hnJBc" title="Offering costs"&gt;21,266,594&lt;/span&gt; consisting of $&lt;span id="xdx_909_ecustom--SaleOfStockUnderwritingFees_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNa6Aky0zUCa" title="Underwriting fees"&gt;6,000,000&lt;/span&gt; of paid underwriting
fees, $&lt;span id="xdx_90B_ecustom--DeferredOfferingCostsNoncurrent_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyD2joOQN139" title="Deferred underwriting fee payable"&gt;14,700,000&lt;/span&gt; of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $&lt;span id="xdx_907_ecustom--SaleOfStockOtherOfferingCosts_iI_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTd94FcM7BSj" title="Other offering costs"&gt;566,594&lt;/span&gt; of other costs
and was charged to shareholders&#x2019; equity upon the completion of the IPO. On June 28, 2023, the Company and Cantor entered into the Fee Reduction
Agreement, pursuant to which Cantor agreed to the Reduced Deferred Fee in the form of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20230628__20230628__us-gaap--TypeOfArrangementAxis__custom--FeeReductionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRzNADdXwd9i" title="Number of shares issued"&gt;500,000&lt;/span&gt; shares of the common equity securities of
the entity surviving the Transaction. See Note 1 for more information on the Fee Reduction Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock>
    <TVGN:TransactionCosts
      contextRef="From2021-11-082021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000611"
      unitRef="USD">21266594</TVGN:TransactionCosts>
    <TVGN:SaleOfStockUnderwritingFees
      contextRef="From2021-11-082021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000613"
      unitRef="USD">6000000</TVGN:SaleOfStockUnderwritingFees>
    <TVGN:DeferredOfferingCostsNoncurrent
      contextRef="AsOf2021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000615"
      unitRef="USD">14700000</TVGN:DeferredOfferingCostsNoncurrent>
    <TVGN:SaleOfStockOtherOfferingCosts
      contextRef="AsOf2021-11-08_us-gaap_IPOMember"
      decimals="0"
      id="Fact000617"
      unitRef="USD">566594</TVGN:SaleOfStockOtherOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-282023-06-28_us-gaap_IPOMember_custom_FeeReductionAgreementMember"
      decimals="INF"
      id="Fact000619"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-012023-12-31" id="Fact000621">&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zoBCKyePhRr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zcm94hOGvmZ9"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zKqLMpwEzbBk" title="Federal depository insurance coverage amount"&gt;250,000&lt;/span&gt;. At December 31, 2023, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000623"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000625">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zVbZ9Ug7eYO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_znPUUrddfrUi"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the (&#x201c;FASB&#x201d;) ASC 820,
&#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet,
primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-012023-12-31" id="Fact000627">&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8Ot8VIhkg52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Related
Party Transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for amounts due from related parties at historical cost and evaluates the collectability of these receivables for determination
on if impairment should be recognized. In the same manner, the Company evaluated the $&lt;span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_z3uF8gdQDCwh" title="Impairment of due from related party"&gt;250,000&lt;/span&gt; loan to Srirama Associates, LLC and determined
that the amount was uncollectable and therefore recognized an impairment loss, see Note 5.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <TVGN:ImpairmentOfAmountDueFromRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000629"
      unitRef="USD">250000</TVGN:ImpairmentOfAmountDueFromRelatedParty>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000631">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zkpWCEwQfXz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zLIWqLIv8yUi"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;Income Taxes.&#x201d; Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. There were &lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20231231_zVaiAAGIGva9" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zF5N2A4rIB24" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits as of December 31, 2023 and 2022.
The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s only major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. &lt;span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20231231_zrUaDPZSdxM3" title="Unrecognized tax benefits accrued for interest and penalties"&gt;&lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_pp0p0_do_c20221231_zurXvR5vPrF5" title="Unrecognized tax benefits accrued for interest and penalties"&gt;No&lt;/span&gt;&lt;/span&gt; amounts were accrued for the payment of
interest and penalties for the year ended December 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under
review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the
Company. Consequently, income taxes are not reflected in the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000633"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000635"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000637"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000639"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <TVGN:TemporaryEquityPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000641">&lt;p id="xdx_844_ecustom--TemporaryEquityPolicyPolicyTextBlock_zD0efC8N3eda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zgtCoOZ7zQ9k"&gt;Class
A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#x201c;Distinguishing
Liabilities from Equity.&#x201d; Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument
and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within
the Company&#x2019;s control) is classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders&#x2019;
equity. The Company&#x2019;s Public Shares feature certain redemption rights that are considered to be outside of the Company&#x2019;s
control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023 and 2022, &lt;span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp8ry42IgPWa" title="Temporary equity, shares outstanding"&gt;1,502,180&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJYI75T357lb" title="Temporary equity, shares outstanding"&gt;34,500,000&lt;/span&gt;, respectively,
Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders&#x2019; deficit
section of the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary
share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable
ordinary share are affected by charges against additional paid in capital and accumulated deficit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zMZGt80hTdmi" style="display: none"&gt;Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold; text-align: left"&gt;Class A ordinary share subject to possible redemption, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;351,900,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Accretion of carrying value to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&lt;p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value"&gt;4,964,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Class A ordinary share subject to possible redemption, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&lt;p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption"&gt;356,864,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of carrying value to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value"&gt;2,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Redemption of ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares"&gt;(342,984,430&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary share subject to possible redemption, December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;16,681,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z1HYxxQQhzOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:TemporaryEquityPolicyPolicyTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">1502180</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">34500000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact000647">&lt;p id="xdx_893_eus-gaap--TemporaryEquityTableTextBlock_zv4no9KboOrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Class A ordinary share subject to possible redemption reflected in the balance sheet is reconciled in
the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zMZGt80hTdmi" style="display: none"&gt;Schedule
of Reconciliation of Ordinary Share Subject to Possible Redemption Reflected in the Balance Sheet&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold; text-align: left"&gt;Class A ordinary share subject to possible redemption, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zYJ8L2KXvo26" style="width: 16%; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;351,900,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: left"&gt;Accretion of carrying value to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&lt;p id="xdx_98D_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_z8Y2rE2OBYUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accretion of carrying value to redemption value"&gt;4,964,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;Class A ordinary share subject to possible redemption, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;&lt;p id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20230101__20231231_zB7AhPQZU0B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Class A ordinary share subject to possible redemption"&gt;356,864,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of carrying value to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zBl2frCiibxa" style="text-align: right" title="Accretion of carrying value to redemption value"&gt;2,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Redemption of ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TemporaryEquityRedemptionAmount_c20230101__20231231_zLWQLgPDS70b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Redemption of ordinary shares"&gt;(342,984,430&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Class A ordinary share subject to possible redemption, December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20230101__20231231_zXdvBsh1PHHk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Class A ordinary share subject to possible redemption"&gt;16,681,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000649"
      unitRef="USD">351900000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000651"
      unitRef="USD">4964000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">356864000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000655"
      unitRef="USD">2801927</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <TVGN:TemporaryEquityRedemptionAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000657"
      unitRef="USD">-342984430</TVGN:TemporaryEquityRedemptionAmount>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000659"
      unitRef="USD">16681497</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000661">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zFrSWlcMWLBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zK1LsoVBPXid"&gt;Net
Income (Loss) per Ordinary Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two classes of shares, which are referred to as Class A ordinary shares and Class B Ordinary shares (the &#x201c;Founder Shares&#x201d;).
Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants
(see Note 4) to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJpXOu7awvuk" title="Number of warrants issued to purchase ordinary shares (in shares)"&gt;17,975,000&lt;/span&gt; ordinary shares at $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211108__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pp2d" title="Exercise price of warrants"&gt;11.50&lt;/span&gt; per share were issued on November 8, 2021. At December 31, 2023 and 2022,
no Public Warrants or Private Placement Warrants have been exercised. The &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPJildYHpJ4h" title="Number of shares excluded from computation of diluted earnings per ordinary share"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zAl08dZCUM31" title="Number of shares excluded from computation of diluted earnings per ordinary share"&gt;17,975,000&lt;/span&gt;&lt;/span&gt; Class A ordinary shares underlying the Public Warrants
and Private Placement Warrants were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently
exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic
net income (loss) per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used
to compute basic and diluted net income (loss) per share for each class of share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zyUK767o3DFd" style="display: none"&gt;Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Non &#x2013; Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class B Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(Redeemable)&lt;/b&gt;&lt;/p&gt;
 Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Non &#x2013; Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Class B Ordinary Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Basic and diluted net (loss) income per share:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 6%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Allocation of net (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right"&gt;(19,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income"&gt;(44,186&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income"&gt;(4,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income"&gt;3,172,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income"&gt;133,355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income"&gt;1,102,090&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted"&gt;5,333,742&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted"&gt;12,317,077&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted"&gt;1,116,256&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted"&gt;34,500,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted"&gt;1,450,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted"&gt;11,983,333&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net (loss) income per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A9_z39IRg7haemi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">17975000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-08_us-gaap_WarrantMember"
      decimals="2"
      id="Fact000665"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">17975000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Shares">17975000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact000671">&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zDiGpFovVyBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zyUK767o3DFd" style="display: none"&gt;Schedule
of Calculation of Basic and Diluted Net Income (Loss) Per Ordinary Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Non &#x2013; Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class B Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(Redeemable)&lt;/b&gt;&lt;/p&gt;
 Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Class A (Non &#x2013; Redeemable) Ordinary Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Class B Ordinary Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Basic and diluted net (loss) income per share:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 6%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Allocation of net (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zOyXOaFu5e7" style="text-align: right"&gt;(19,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z7oJK70SY7kk" title="Allocation of net (loss) income"&gt;(44,186&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRWIq8R81xi2" title="Allocation of net (loss) income"&gt;(4,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQNTfgwjrRC5" title="Allocation of net (loss) income"&gt;3,172,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3HPdcvCENUb" title="Allocation of net (loss) income"&gt;133,355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdWWw6DEbqS5" title="Allocation of net (loss) income"&gt;1,102,090&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zH4O6oZb7hvg" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJf9xNFXwXCg" title="Weighted average shares outstanding, Diluted"&gt;5,333,742&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zTQQndWo9881" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z63dZIby7nW3" title="Weighted average shares outstanding, Diluted"&gt;12,317,077&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztRdVBdSTFgd" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zgf6f1uf9hd5" title="Weighted average shares outstanding, Diluted"&gt;1,116,256&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfNRyE3rDOG3" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHIdYD5i22ra" title="Weighted average shares outstanding, Diluted"&gt;34,500,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zAzTfEERJBjk" title="Weighted average shares outstanding, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_z3KJUKJZ6Adi" title="Weighted average shares outstanding, Diluted"&gt;1,450,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zRA5a2wXLDRi"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pp0d_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4Ro7qXpKoA5" title="Weighted average shares outstanding, Diluted"&gt;11,983,333&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Basic and diluted net (loss) income per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhEcqEE4gpa5" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zZzjU6b4Olbe" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zNE2Jk5V4B3i" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zghHD1z4tAJ7" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSk47UM218za" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCEz0Qlshw27" title="Dilution net income (loss) per share"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2c1RXG9LaFl" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBdHiBBDOeMd" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zWA0Tey8OuZk" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonClassaNotSubjectToRedemptionMember_zmLvfU4D2WRk" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAbWsY3lJwMh" title="Basic net income (loss) per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZuSsyGUMQeg" title="Dilution net income (loss) per share"&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000672"
      unitRef="USD">-19134</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">-44186</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000676"
      unitRef="USD">-4005</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000678"
      unitRef="USD">3172916</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">133355</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000682"
      unitRef="USD">1102090</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000684"
      unitRef="Shares">5333742</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000686"
      unitRef="Shares">5333742</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="0"
      id="Fact000688"
      unitRef="Shares">12317077</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="0"
      id="Fact000690"
      unitRef="Shares">12317077</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000692"
      unitRef="Shares">1116256</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000694"
      unitRef="Shares">1116256</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000696"
      unitRef="Shares">34500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000698"
      unitRef="Shares">34500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="0"
      id="Fact000700"
      unitRef="Shares">1450000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="0"
      id="Fact000702"
      unitRef="Shares">1450000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000703"
      unitRef="Shares">11983333</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000705"
      unitRef="Shares">11983333</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000707"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000709"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000713"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000715"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000717"
      unitRef="USDPShares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000719"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000721"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_custom_CommonClassaNotSubjectToRedemptionMember"
      decimals="INF"
      id="Fact000725"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000729"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareDiluted>
    <TVGN:WarrantLiabilitiesPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000731">&lt;p id="xdx_842_ecustom--WarrantLiabilitiesPolicyPolicyTextBlock_z7WEXKlufkK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zVTXpxyIBmS5"&gt;Accounting
for Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment
considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#x2019;s own ordinary shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d;
in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments
are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and Private Placement Warrants
qualify for liability accounting treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:WarrantLiabilitiesPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000733">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCZf65CAtdEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zE8ozL4HOjF7"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#x2019;s financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <TVGN:InitialPublicOfferingTextBlock contextRef="From2023-01-012023-12-31" id="Fact000735">&lt;p id="xdx_80B_ecustom--InitialPublicOfferingTextBlock_zGP5ttt1Hp11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2014; &lt;span id="xdx_823_zMij8QymoKDa"&gt;Initial Public Offering and Over-Allotment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the IPO, the Company sold &lt;span id="xdx_90A_ecustom--UnitsIssuedDuringPeriodSharesNewIssue_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of units in initial public offering, gross (in shares ) | shares"&gt;34,500,000&lt;/span&gt; units at a price of $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_c20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp2d" title="Shares issued, price per share"&gt;10.00&lt;/span&gt; per Unit. Each Unit consists of &lt;span id="xdx_90A_ecustom--NumberOfSharesIssuedPerUnit_dc_c20211108__20211108__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ5lLQYbWgT" title="Number of shares in a unit"&gt;one&lt;/span&gt; ordinary share (such ordinary
shares included in the Units being offered, the &#x201c;Public Shares&#x201d;), and &lt;span id="xdx_904_ecustom--NumberOfWarrantsIssuedPerUnit_dxL_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAFYDg8NfD6h" title="Number of warrants in a unit::XDX::0.5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;one&lt;/span&gt;&lt;/span&gt;-half of one redeemable warrant (each, a &#x201c;Public
Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaJHoG2KGFM4" title="Number of shares issuable per warrant"&gt;one&lt;/span&gt; ordinary share at a price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVwZvvcFOcrg" title="Exercise price of warrants"&gt;11.50&lt;/span&gt; per share, subject
to adjustment (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:InitialPublicOfferingTextBlock>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssue
      contextRef="From2021-11-082021-11-08_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">34500000</TVGN:UnitsIssuedDuringPeriodSharesNewIssue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-08_us-gaap_IPOMember"
      decimals="2"
      id="Fact000739"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <TVGN:NumberOfSharesIssuedPerUnit
      contextRef="From2021-11-082021-11-08_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000741"
      unitRef="Shares">1</TVGN:NumberOfSharesIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-08_custom_PublicWarrantsMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000747"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <TVGN:PrivatePlacementTextBlock contextRef="From2023-01-012023-12-31" id="Fact000749">&lt;p id="xdx_805_ecustom--PrivatePlacementTextBlock_zYmNEZKmm2sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2014; &lt;span id="xdx_82E_zp3DtiskTul3"&gt;Private Placement Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 8, 2021, simultaneously with the consummation of the IPO and the underwriters&#x2019; exercise of their over-allotment option,
the Company consummated the issuance and sale (&#x201c;Private Placement&#x201d;) of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZcC7XRRaCX3" title="Number of warrants to purchase shares issued"&gt;1,450,000&lt;/span&gt; units (the &#x201c;Private Placement Units&#x201d;)
in a private placement transaction at a price of $&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp2d" title="Price of warrants"&gt;10.00&lt;/span&gt; per Placement Unit, generating gross proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0d_c20211108__20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCGPjvAzbm6h" title="Aggregate purchase price"&gt;14,500,000&lt;/span&gt;. The Private Placement
Units were purchased by Cantor (&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CantorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Number of warrants to purchase shares issued"&gt;150,000&lt;/span&gt; Units) and the Sponsor (&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIT4Fhke8l7h" title="Number of warrants to purchase shares issued"&gt;1,300,000&lt;/span&gt; Units). Each Private Placement Unit consisted of one Placement
Share and one-half of a redeemable warrant (&#x201c;Placement Warrant&#x201d;). Each whole Placement Warrant will be exercisable to purchase
one Class A ordinary share at a price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20211108__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zzT20lahBfK7" title="Exercise price of warrant"&gt;11.50&lt;/span&gt; per share. A portion of the proceeds from the Private Placement Units was added to the
proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination
Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to
the requirements of applicable law), and the Private Placement Units and all underlying securities will be worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify"&gt;On
June 7, 2023, the Original Sponsor transferred &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230607__20230607__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOngJOFWwf9j" title="Sale of stock, number of shares issued in transaction"&gt;1,000,000&lt;/span&gt; Private Placement Units to the Sponsor in connection with the Purchase Agreement
(see Note 6).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000751"
      unitRef="Shares">1450000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <TVGN:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="2"
      id="Fact000753"
      unitRef="USDPShares">10.00</TVGN:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2021-11-082021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000755"
      unitRef="USD">14500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_CantorMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-08_custom_PrivatePlacementWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="2"
      id="Fact000761"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-06-072023-06-07_custom_PrivatePlacementWarrantsMember_custom_SponsorMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact000765">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z8Gca90BJdx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2014; &lt;span id="xdx_824_z3tPgZy1PhK9"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Founder
Shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Sponsor paid $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z37xhhFLck0j" title="Aggregate purchase price"&gt;25,000&lt;/span&gt; to cover certain offering costs of the Company in consideration for &lt;span id="xdx_908_eus-gaap--CommonStockDividendsShares_c20210422__20210422__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLqmjGsoo5l" title="Share dividend"&gt;8,625,000&lt;/span&gt; Founder Shares which were issued on
April 22, 2021. In August 2021, the Company effectuated a dividend of approximately &lt;span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionRatio_iI_pp4d_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z3fkeWJiaBo8" title="Stock dividend ratio"&gt;0.3628&lt;/span&gt; shares for each outstanding Class B ordinary
share resulting in an aggregate of &lt;span id="xdx_901_ecustom--AggregateNumberOfSharesOwned_c20210831__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Aggregate number of shares owned"&gt;11,754,150&lt;/span&gt; Class B ordinary shares outstanding. On October 1, 2021, the Company effectuated a dividend
of approximately &lt;span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionRatio_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pp4d" title="Stock dividend ratio"&gt;0.0195&lt;/span&gt; shares for each outstanding Class B ordinary share resulting in an aggregate of &lt;span id="xdx_90B_ecustom--AggregateNumberOfSharesOwned_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z8thw2vx3Xzf" title="Aggregate number of shares owned"&gt;11,983,333&lt;/span&gt; Class B Founder shares
outstanding (up to &lt;span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20211001__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zbbYrYEYOVZ8" title="Shares subject to forfeiture"&gt;1,530,000&lt;/span&gt; of which are subject to forfeiture if the underwriters&#x2019; over-allotment option is not exercised in
full). The Founder Shares will automatically convert into Class A ordinary shares at the time of the Company&#x2019;s initial Business
Combination and are subject to certain transfer restrictions. The initial shareholders had agreed to forfeit up to &lt;span id="xdx_908_ecustom--NumberOfSharesSubjectToForfeiture_iI_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_za45SZyhmTw5" title="Shares subject to forfeiture"&gt;1,530,000&lt;/span&gt; Founder
Shares to the extent that the over-allotment option is not exercised in full by the underwriters. Since the underwriters&#x2019; exercised
the over-allotment option in full, no Founder Shares are subject to forfeiture.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial shareholders will agree, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the
earliest of (A) &lt;span id="xdx_90A_ecustom--RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zTgzZxac35I7" title="Restrictions on transfer period of time after business combination completion"&gt;one year&lt;/span&gt; after the completion of our initial business combination and (B) subsequent to our initial business combination,
(x) if the closing price of our Class A ordinary shares equals or exceeds $&lt;span id="xdx_90C_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_pp2d_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zaSUTpiQeMA5" title="Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)"&gt;12.00&lt;/span&gt; per share (as adjusted for share subdivisions, share
capitalizations, reorganizations, recapitalizations and the like) for any &lt;span id="xdx_90B_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLT4KgYAvK21" title="Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"&gt;20&lt;/span&gt; trading days within any &lt;span id="xdx_901_ecustom--TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znQYiGVJBmgg" title="Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"&gt;30&lt;/span&gt;-trading day period commencing
at least &lt;span id="xdx_905_ecustom--ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_dtD_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqLhRrOgfY3k" title="Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences"&gt;150&lt;/span&gt; days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange
or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash,
securities or other property.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On January 30, 2023, the initial shareholders holding
all of the Founder Shares elected to convert their Founder Shares into Class A ordinary shares of the Company on a &lt;span id="xdx_90B_eus-gaap--StockholdersEquityNoteStockSplitConversionRatio1_dc_uPure_c20230130__20230130_z6kgaFsCsbi4" title="Conversion ratio"&gt;one&lt;/span&gt;-for-one basis (the
&#x201c;Conversion&#x201d;). As a result, &lt;span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_pdd" title="Shares cancelled"&gt;11,983,333&lt;/span&gt; of the Company&#x2019;s Class B ordinary shares were cancelled and &lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20230130__20230130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjOqRKSqb3bl" title="Shares issued upon conversion"&gt;11,983,333&lt;/span&gt; Class
A ordinary shares were issued to such converting Initial Shareholders. The Initial Shareholders agreed that all of the terms and conditions
applicable to the Founder Shares set forth in the Letter Agreement shall continue to apply to the Class A ordinary shares that the Founder
Shares converted into, including the voting agreement, transfer restrictions and waiver of any right, title, interest or claim of any
kind to the Trust Account or any monies or other assets held therein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On May 4, 2023, the Company entered into the Purchase
Agreement, pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zqWw1dV3wJTh" title="Number of shares issued"&gt;7,988,889&lt;/span&gt; Class A ordinary shares and (y) &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_z0BuF9bT2ri8" title="Number of shares issued"&gt;1,000,000&lt;/span&gt;
Private Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for
one Class A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Underwriting Agreement), for
an aggregate purchase price of $&lt;span id="xdx_909_ecustom--AggregatePurchasePrice_iI_pp2d_c20230504__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zWdV0O8ECMT" title="Aggregate purchase price"&gt;1.00&lt;/span&gt; payable at the time of the initial Business Combination. On June 7, 2023, the Original Sponsor transferred
&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zg81rbK0W3c6" title="Number of shares issued"&gt;7,988,889&lt;/span&gt; Class A ordinary shares to the Sponsor, pursuant to the Purchase Agreement (see Note 6). The Company estimated the aggregate
fair values of the &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableOrdinaryMember_zm8IjkwCuH2i" title="Number of shares issued"&gt;7,988,889&lt;/span&gt; Class A non-redeemable ordinary shares, the &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230606__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2W0MKjKtkB8" title="Number of shares issued"&gt;1,000,000&lt;/span&gt; Private Placement shares, and the &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zamAYC1vlNR6" title="Class of warrants"&gt;500,000&lt;/span&gt; public warrants
transferred to be $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zv9xZ9pyUphf" title="Proceeds"&gt;3,515,111&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredTwoMember_zeZWU5vFe9Ma" title="Number of shares issued"&gt;440,000&lt;/span&gt;, and $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230606__20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsTransferredThreeMember_zwGWLnWeh8If" title="Number of shares issued"&gt;20,000&lt;/span&gt;, respectively or $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredOneMember_z8FSFlPAmFBj" title="Exercise price"&gt;0.44&lt;/span&gt; per share and $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230607__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SsvkAssociatesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsTransferredTwoMember_zpoAKPyTTn49" title="Exercise price"&gt;0.04&lt;/span&gt; per warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z2fvY4XooUQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The fair value of the Class A non-redeemable shares
was based on the following inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"&gt;&lt;span id="xdx_8B6_zR8Qc92B1zJ5"&gt;Schedule
of Fair Value Non Redeemable Shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230503__20230504_zjRvdjmAJfIf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;May 4, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_zvPeAx7Xrov7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Discount for lack of marketability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;6.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockPriceOfMeasurement_pid_z3xkbBKhZqze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price as of measurement date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProbabilityOfTransactionPercentage_pid_dp_uPure_zhofbGhptox2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Probability of transaction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zRyKqWehGf5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Related
Party Loans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 22, 2021, the Sponsor agreed to loan the Company an aggregate of up to $&lt;span id="xdx_90A_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_c20210422__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Maximum borrowing capacity of related party promissory note"&gt;300,000&lt;/span&gt; to cover expenses related to the IPO pursuant to
a promissory note (the &#x201c;Note&#x201d;). This loan was non-interest bearing and payable on the earlier of December 31, 2021 or the
completion of the IPO. The note payable of $&lt;span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20211108__20211108__us-gaap--RelatedPartyTransactionAxis__custom--PromissoryNoteWithRelatedPartyMember_pp0p0" title="Amount of notes payable repaid"&gt;121,158&lt;/span&gt; was repaid on November 8, 2021. As of December 31, 2022, the Company had &lt;span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_do_c20221231_zjdeSA05noib" title="Borrowings amount"&gt;no&lt;/span&gt; borrowings
under the Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 2, 2023, the Company advanced the Sponsor $&lt;span id="xdx_901_ecustom--WorkingCapital_iI_c20231002_zZpXIhQn8Xvf" title="Working capital"&gt;17,000&lt;/span&gt;
for working capital purposes. The advances are non-interest bearing and are due on demand. This related party transaction is included on the accompanying balance sheet as a due from related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;As of December 31, 2023, the remainder of the Second SPAC Loan of $&lt;span id="xdx_901_eus-gaap--PaymentsForAdvanceToAffiliate_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zehGaV6BMI8h" title="Loan from affiliate"&gt;577,500&lt;/span&gt; is due from the Sponsor. This related
party transaction is included on the accompanying balance sheet as a due from related party. As of December 31, 2023, the Company determined that $&lt;span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zF9dggB2C5u9" title="Impairment of due from related party"&gt;250,000&lt;/span&gt; of the $&lt;span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z1OlrjQ6gNef" title="Loan from affiliate"&gt;577,500&lt;/span&gt; was deemed to be uncollectible, therefore
the Company recorded impairment totaling $&lt;span id="xdx_900_ecustom--ImpairmentOfAmountDueFromRelatedParty_c20230101__20231231_zXicAIVb55D7" title="Impairment of due from related party"&gt;250,000&lt;/span&gt; on the amount due from related party in the other income section of the statement of
operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Subscription
Agreement Loans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 3, 2023, the Company and the Original Sponsor entered into a Subscription Agreement with Polar Multi-Strategy Master Fund (the &#x201c;Investor&#x201d;)
where the Investor agreed to make a cash contribution of $&lt;span id="xdx_902_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zrzfpG4AdEFa" title="Initial capital contribution"&gt;151,000&lt;/span&gt; to the Original Sponsor (the &#x201c;Initial Capital Contribution&#x201d;)
on or prior to May 3, 2023. The Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover
working capital expenses (the &#x201c;First SPAC Loan&#x201d;). In consideration for the Initial Capital Contribution, the Company will
issue &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLiyrpFxH8tk" title="Number of shares issued"&gt;151,000&lt;/span&gt; Class A ordinary shares, par value $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zUh01rxjvlU2" title="Ordinary shares, par value (in dollar per share)"&gt;0.0001&lt;/span&gt; per share, of the Company to the Investor at the closing of the initial business
combination (the &#x201c;De-SPAC Closing&#x201d;). The First SPAC Loan shall not accrue interest and shall be repaid by the Company upon
the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares
of the Company at a rate of one Class A ordinary share for each $&lt;span id="xdx_90D_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zJn5mGhF4Lg3" title="Initial capital contribution"&gt;10.00&lt;/span&gt; of Initial Capital Contribution. If the Company liquidates without
consummating the initial business combination, any amounts remaining in the Sponsor or Company&#x2019;s cash accounts, not including the
Company&#x2019;s Trust Account, will be paid to the Investor within five days of the liquidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 20, 2023, the Sponsor and the Company entered into a second subscription agreement (the &#x201c;Second Subscription
Agreement&#x201d;) with the Investor where the Investor agreed to lend to the Sponsor, which would in turn be lent to the Company, an
aggregate of $&lt;span id="xdx_908_ecustom--MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__dei--LegalEntityAxis__custom--SponsorMember_zppqeb1abZF4" title="Maximum borrowing capacity of related party promissory note"&gt;1,500,000&lt;/span&gt;
(the &#x201c;Additional Capital Commitment&#x201d;) to cover working capital expenses (the &#x201c;Second SPAC Loan&#x201d;). One half
of the Additional Capital Commitment was made by the Investor to the Sponsor in cash on or prior to June 21, 2023, and the remaining
$&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_znxv21J0Pl6h" title="Remaining borrowing capacity amount"&gt;750,000&lt;/span&gt;
would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#x2019;s request and the first filing of the S-4 for
the Company&#x2019;s business combination. In consideration for the Second SPAC Loan, the Company will issue one Class A ordinary
share for each dollar of the Additional Capital Commitment funded by the Investor at the De-SPAC Closing. The Second SPAC Loan shall
not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Investor may elect at the De-SPAC Closing to
receive such payments in (a) cash or (b) Class A ordinary shares at a rate of one Class A ordinary share for each $&lt;span id="xdx_904_ecustom--InitialCapitalContributionPerShare_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DeSPACMember_zVE2avjo7wna" title="Initial capital contribution"&gt;10.00&lt;/span&gt;
of Additional Capital Contribution. If the Company liquidates without consummating the initial business combination, any amounts
remaining in the Sponsor or Company&#x2019;s cash accounts, not including the Company&#x2019;s Trust Account, will be paid to the
Investor within five days of the liquidation. Collectively, the First SPAC Loan and the Second SPAC Loan are referred to as the SPAC
Loans. As of December 31, 2023, the Company had $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--SponsorMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zTOfKsdZSv0d" title="Debt instrument, fee amount"&gt;1,651,000&lt;/span&gt;
borrowings under the  SPAC Loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company accounted for the Class A common stock
they could be converted (&#x201c;equity instrument&#x201d;) to as equity-classified instruments based on an assessment of the specific
terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the equity instrument is freestanding
financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the equity instrument
meets all the requirements for equity classification under ASC 815, including whether the equity instrument is indexed to the Company&#x2019;s
own common stock, among other conditions for the equity classification. This assessment, which requires the use of professional judgment,
was conducted at the time of equity instrument issuance. The SPAC Loans and the equity instrument meet the scope exception of ASC 815-10-15-74(a).
The Company applied the guidance in ASC 470-20-25-2 &#x201c;&lt;i&gt;Debt With Conversion and Other Options&lt;/i&gt;&#x201d;, requiring that the loan
proceeds be allocated to the SPAC Loans based on their relative fair values. At May 3, 2023 the Company allocated $&lt;span id="xdx_909_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zH5tFmPsSaLe"&gt;104,861
&lt;/span&gt;of the proceeds to the First SPAC Loan and $&lt;span id="xdx_901_eus-gaap--ProceedsFromOtherEquity_c20230503__20230503_znpJNBOUam8b"&gt;46,139
&lt;/span&gt;for the equity instrument. The Company estimated the aggregate fair value of the &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zQ5uzwnhioCh"&gt;151,000
&lt;/span&gt;shares to be issued to be $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230503__20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zcUJF80uBLxf"&gt;66,440
&lt;/span&gt;or $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230503__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_znJXZYBHVUVg"&gt;0.44
&lt;/span&gt;per share. At June 20, 2023 the Company allocated $&lt;span id="xdx_90C_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--FirstPolarFundConvertibleNoteMember_zqkCQLrLAbp5"&gt;520,833
&lt;/span&gt;of the proceeds to the Second SPAC Loan and $&lt;span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_c20230620__20230620_zA16ZwwVF4P3"&gt;229,167
&lt;/span&gt;for the equity instruments. The Company estimated the aggregate fair value of the &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zGk94zI4YmL8"&gt;750,000
&lt;/span&gt;shares to be issued to be $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230620__20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zVKj7ZCPgeu6"&gt;330,000
&lt;/span&gt;or $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230620__us-gaap--ShortTermDebtTypeAxis__custom--SecondPolarFundConvertibleNoteMember_zBiMxfWHbnw8"&gt;0.44
&lt;/span&gt;per share. At December 31, 2023 the carrying values of the SPAC Loans and the discounts were $&lt;span id="xdx_909_eus-gaap--OtherNotesPayableCurrent_iI_c20231231_zbRrvzroSfhh"&gt;1,631,725
&lt;/span&gt;and $&lt;span id="xdx_902_ecustom--ConvertibleNotesPayableDiscounts_iI_c20231231_zp5qO5A6B4m"&gt;275,306&lt;/span&gt;, respectively. The Company recorded amortization of the discounts on the SPAC Loans of
$&lt;span id="xdx_906_ecustom--NoncashInterestExpenses_c20230101__20231231_zbT0QTObPMne" title="Non cash interest expenses"&gt;256,031&lt;/span&gt;, which is disclosed in the statement of cash flows as non-cash interest expense. As of
December 31, 2023, the unamortized discount on the SPAC Loans was $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231_zcC6nyEXuTt1"&gt;19,274&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the remainder of the Second SPAC Loan of $&lt;span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zvujXd3eujaf" title="Loan from affiliate"&gt;577,500&lt;/span&gt; is due from the Sponsor. This amount is included on the accompanying
balance sheet as a due from related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Working
Capital Loans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor,
or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working
Capital Loans&#x201d;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the
proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside
the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the
Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements
exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without
interest, or, at the lender&#x2019;s discretion, up to $&lt;span id="xdx_90C_ecustom--MaximumLoansConvertibleIntoWarrants_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_zqF4920S6Gxl" title="Loan conversion agreement warrant"&gt;1.5&lt;/span&gt; million of such Working Capital Loans may be convertible into private placement-equivalent
units at a price of $&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightPriceOfWarrantsOrRights_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--WorkingCapitalLoansWarrantMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyLoansMember_z4W4b2kmRjc4" title="Price of warrant"&gt;10.00&lt;/span&gt; per unit. As of December 31, 2023 and 2022, the Company had &lt;span id="xdx_90B_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zbhE3rm7aWq5" title="Working capital loan"&gt;&lt;span id="xdx_903_ecustom--WorkingCapitalLoan_iI_pp0p0_do_c20221231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zVIH4BX8WiRh" title="Working capital loan"&gt;no&lt;/span&gt;&lt;/span&gt; borrowings under the Working Capital Loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Administrative
Support Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
on the date of the final prospectus, the Company will agree to pay the Sponsor a total of $&lt;span id="xdx_902_ecustom--RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zngBZMp1EOv3" title="Expenses per month"&gt;10,000&lt;/span&gt; per month for office space and administrative
and support services. Upon completion of the Initial Business Combination or the Company&#x2019;s liquidation, the Company will cease
paying these monthly fees. At December 31, 2023 and 2022, $&lt;span id="xdx_90C_eus-gaap--OtherLiabilities_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zTeRuZsi8pS3" title="Amount accrued"&gt;230,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherLiabilities_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zrcFWHNGvSWh" title="Amount accrued"&gt;120,000&lt;/span&gt;, respectively, have been accrued under this arrangement
and included in due to affiliate on the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-222021-04-22_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000767"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockDividendsShares
      contextRef="From2021-04-222021-04-22_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">8625000</us-gaap:CommonStockDividendsShares>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="AsOf2021-08-31_custom_FounderSharesMember_us-gaap_CommonClassBMember"
      decimals="4"
      id="Fact000771"
      unitRef="Pure">0.3628</us-gaap:PreferredStockConvertibleConversionRatio>
    <TVGN:AggregateNumberOfSharesOwned
      contextRef="AsOf2021-08-31_custom_FounderSharesMember_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">11754150</TVGN:AggregateNumberOfSharesOwned>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="AsOf2021-10-01_custom_FounderSharesMember_us-gaap_CommonClassBMember"
      decimals="4"
      id="Fact000775"
      unitRef="Pure">0.0195</us-gaap:PreferredStockConvertibleConversionRatio>
    <TVGN:AggregateNumberOfSharesOwned
      contextRef="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">11983333</TVGN:AggregateNumberOfSharesOwned>
    <TVGN:NumberOfSharesSubjectToForfeiture
      contextRef="AsOf2021-10-01_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">1530000</TVGN:NumberOfSharesSubjectToForfeiture>
    <TVGN:NumberOfSharesSubjectToForfeiture
      contextRef="AsOf2023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">1530000</TVGN:NumberOfSharesSubjectToForfeiture>
    <TVGN:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion
      contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      id="Fact000783">P1Y</TVGN:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
    <TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
      contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      decimals="2"
      id="Fact000785"
      unitRef="USDPShares">12.00</TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger>
    <TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
      contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      id="Fact000787">P20D</TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      id="Fact000789">P30D</TVGN:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <TVGN:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="From2023-01-012023-12-31_custom_FounderSharesMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      id="Fact000791">P150D</TVGN:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="From2023-01-302023-01-30"
      decimals="INF"
      id="Fact000793"
      unitRef="Pure">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-01-302023-01-30_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">11983333</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-01-302023-01-30_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">11983333</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">7988889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-042023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_PrivatePlacementMember_custom_PurchaseAgreementMember_custom_SponsorMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <TVGN:AggregatePurchasePrice
      contextRef="AsOf2023-05-04_custom_SsvkAssociatesLlcMember_us-gaap_CommonClassAMember_custom_PurchaseAgreementMember_custom_SponsorMember"
      decimals="2"
      id="Fact000803"
      unitRef="USDPShares">1.00</TVGN:AggregatePurchasePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">7988889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_NonRedeemableOrdinaryMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">7988889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-062023-06-06_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_us-gaap_CommonClassAMember"
      decimals="0"
      id="Fact000813"
      unitRef="USD">3515111</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">440000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-062023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredThreeMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredOneMember"
      decimals="INF"
      id="Fact000819"
      unitRef="USDPShares">0.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-07_custom_SsvkAssociatesLlcMember_custom_PurchaseAgreementMember_custom_SponsorMember_custom_PublicWarrantsTransferredTwoMember"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">0.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-012023-12-31" id="Fact000823">&lt;p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z2fvY4XooUQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The fair value of the Class A non-redeemable shares
was based on the following inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"&gt;&lt;span id="xdx_8B6_zR8Qc92B1zJ5"&gt;Schedule
of Fair Value Non Redeemable Shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230503__20230504_zjRvdjmAJfIf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;May 4, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_zvPeAx7Xrov7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Discount for lack of marketability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;6.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockPriceOfMeasurement_pid_z3xkbBKhZqze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price as of measurement date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProbabilityOfTransactionPercentage_pid_dp_uPure_zhofbGhptox2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Probability of transaction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="From2023-05-032023-05-04"
      decimals="INF"
      id="Fact000825"
      unitRef="Pure">0.0680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <TVGN:StockPriceOfMeasurement
      contextRef="From2023-05-032023-05-04"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">10.77</TVGN:StockPriceOfMeasurement>
    <TVGN:ProbabilityOfTransactionPercentage
      contextRef="From2023-05-032023-05-04"
      decimals="INF"
      id="Fact000829"
      unitRef="Pure">0.0440</TVGN:ProbabilityOfTransactionPercentage>
    <TVGN:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="AsOf2021-04-22_custom_PromissoryNoteWithRelatedPartyMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">300000</TVGN:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-11-082021-11-08_custom_PromissoryNoteWithRelatedPartyMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">121158</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000835"
      unitRef="USD">0</us-gaap:ShortTermBorrowings>
    <TVGN:WorkingCapital
      contextRef="AsOf2023-10-02"
      decimals="0"
      id="Fact000837"
      unitRef="USD">17000</TVGN:WorkingCapital>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2023-01-012023-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">577500</us-gaap:PaymentsForAdvanceToAffiliate>
    <TVGN:ImpairmentOfAmountDueFromRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000841"
      unitRef="USD">250000</TVGN:ImpairmentOfAmountDueFromRelatedParty>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2023-01-012023-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">577500</us-gaap:PaymentsForAdvanceToAffiliate>
    <TVGN:ImpairmentOfAmountDueFromRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000845"
      unitRef="USD">250000</TVGN:ImpairmentOfAmountDueFromRelatedParty>
    <TVGN:InitialCapitalContribution
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember"
      decimals="0"
      id="Fact000847"
      unitRef="USD">151000</TVGN:InitialCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember"
      decimals="0"
      id="Fact000849"
      unitRef="Shares">151000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact000851"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <TVGN:InitialCapitalContributionPerShare
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember_custom_DeSPACMember"
      decimals="0"
      id="Fact000853"
      unitRef="USDPShares">10.00</TVGN:InitialCapitalContributionPerShare>
    <TVGN:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="AsOf2023-06-20_us-gaap_InvestorMember_custom_SponsorMember"
      decimals="0"
      id="Fact000855"
      unitRef="USD">1500000</TVGN:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="AsOf2023-06-20_us-gaap_InvestorMember"
      decimals="0"
      id="Fact000857"
      unitRef="USD">750000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <TVGN:InitialCapitalContributionPerShare
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember_custom_DeSPACMember"
      decimals="0"
      id="Fact000859"
      unitRef="USDPShares">10.00</TVGN:InitialCapitalContributionPerShare>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2023-12-31_custom_SponsorMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">1651000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember"
      decimals="0"
      id="Fact000862"
      unitRef="USD">104861</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-05-032023-05-03"
      decimals="0"
      id="Fact000863"
      unitRef="USD">46139</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">151000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-032023-05-03_custom_FirstPolarFundConvertibleNoteMember"
      decimals="0"
      id="Fact000865"
      unitRef="USD">66440</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-03_custom_FirstPolarFundConvertibleNoteMember"
      decimals="INF"
      id="Fact000866"
      unitRef="USDPShares">0.44</us-gaap:SharePrice>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-06-202023-06-20_custom_FirstPolarFundConvertibleNoteMember"
      decimals="0"
      id="Fact000867"
      unitRef="USD">520833</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-06-202023-06-20"
      decimals="0"
      id="Fact000868"
      unitRef="USD">229167</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-202023-06-20_custom_SecondPolarFundConvertibleNoteMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-06-202023-06-20_custom_SecondPolarFundConvertibleNoteMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">330000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-20_custom_SecondPolarFundConvertibleNoteMember"
      decimals="INF"
      id="Fact000871"
      unitRef="USDPShares">0.44</us-gaap:SharePrice>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000872"
      unitRef="USD">1631725</us-gaap:OtherNotesPayableCurrent>
    <TVGN:ConvertibleNotesPayableDiscounts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000873"
      unitRef="USD">275306</TVGN:ConvertibleNotesPayableDiscounts>
    <TVGN:NoncashInterestExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000875"
      unitRef="USD">256031</TVGN:NoncashInterestExpenses>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000876"
      unitRef="USD">19274</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2023-01-012023-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">577500</us-gaap:PaymentsForAdvanceToAffiliate>
    <TVGN:MaximumLoansConvertibleIntoWarrants
      contextRef="AsOf2023-12-31_custom_RelatedPartyLoansMember"
      decimals="-5"
      id="Fact000880"
      unitRef="USD">1500000</TVGN:MaximumLoansConvertibleIntoWarrants>
    <TVGN:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_WorkingCapitalLoansWarrantMember_custom_RelatedPartyLoansMember"
      decimals="2"
      id="Fact000882"
      unitRef="USDPShares">10.00</TVGN:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <TVGN:WorkingCapitalLoan
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember69274765"
      decimals="0"
      id="Fact000884"
      unitRef="USD">0</TVGN:WorkingCapitalLoan>
    <TVGN:WorkingCapitalLoan
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember69274781"
      decimals="0"
      id="Fact000886"
      unitRef="USD">0</TVGN:WorkingCapitalLoan>
    <TVGN:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth
      contextRef="From2023-01-012023-12-31_custom_AdministrativeSupportAgreementMember"
      decimals="0"
      id="Fact000888"
      unitRef="USD">10000</TVGN:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_AdministrativeSupportAgreementMember"
      decimals="0"
      id="Fact000890"
      unitRef="USD">230000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_AdministrativeSupportAgreementMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">120000</us-gaap:OtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact000894">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zndJCv4P9LIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2014; &lt;span id="xdx_825_zYPPAmLATiS5"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Registration
Rights&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Founder Shares, Private Placement Units (including the underlying securities), and securities that may be issued upon conversion
of Working Capital Loans, if any, will be entitled to registration rights pursuant to a registration rights agreement signed upon consummation
of the IPO. These holders will be entitled to certain demand and &#x201c;piggyback&#x201d; registration rights. However, the registration
rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective
until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Underwriting
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company granted the underwriters a &lt;span id="xdx_90F_ecustom--UnderwritingOptionPeriod_dtD_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zKq3usiUpiPb" title="Underwriting option period"&gt;45&lt;/span&gt;-day option from the final prospectus relating to the IPO to purchase up to &lt;span id="xdx_906_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjEWU0ZKlgy7" title="Sale of units, net of underwriting discounts (in shares)"&gt;4,500,000&lt;/span&gt; additional
Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On November 5, 2021, the underwriters
elected to fully exercise the over-allotment option purchasing &lt;span id="xdx_908_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20211105__20211105__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0D1xMmG4LCe" title="Sale of units, net of underwriting discounts (in shares)"&gt;4,500,000 &lt;/span&gt;Units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
underwriters were paid a cash underwriting discount of $&lt;span id="xdx_903_ecustom--UnderwritingCashDiscountPerUnit_pp2d_c20230101__20231231_zAMMEaSn8KUb" title="Underwriting cash discount per unit"&gt;0.20&lt;/span&gt; per unit, or $&lt;span id="xdx_901_ecustom--PaymentOfUnderwriterDiscount_pp0p0_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zv3FDpkejT3d" title="Payment of underwriter discount"&gt;6,000,000&lt;/span&gt; in the aggregate at the closing of the IPO. The
underwriters have agreed to defer the cash underwriting discount of $&lt;span id="xdx_903_ecustom--UnderwritingCashDiscountPerUnit_pp2d_c20230101__20231231_z3qhrRkyXa4d" title="Underwriting cash discount per unit"&gt;0.20&lt;/span&gt; per share related to the over-allotment to be paid at Business
Combination ($&lt;span id="xdx_909_ecustom--AggregateUnderwriterCashDiscount_c20230101__20231231_z80p0EzYGGpl" title="Aggregate underwriter cash discount"&gt;900,000&lt;/span&gt; in the aggregate). In addition, the underwriters are entitled to a deferred underwriting commissions of $&lt;span id="xdx_90E_ecustom--DeferredFeePerUnit_iI_pp2d_c20231231_z8IhYd0PEnqd" title="Deferred underwriting commission fee (per unit)"&gt;0.40&lt;/span&gt; per
unit, or $&lt;span id="xdx_90F_ecustom--DeferredUnderwritingFeePayable_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXmGoyaNlnMj" title="Deferred underwriting fee payable"&gt;13,800,000&lt;/span&gt; from the closing of the IPO. The total deferred fee is $&lt;span id="xdx_90D_ecustom--AggregateDeferredUnderwritingFeePayable_c20230101__20231231_zjExYO1ZECU6" title="Aggregate deferred underwriting fee payable"&gt;14,700,000&lt;/span&gt; consisting of the $&lt;span id="xdx_90F_ecustom--DeferredUnderwritingFeePayable_c20230101__20231231_zGMVX4ykE115" title="Deferred underwriting fee payable"&gt;13,800,000&lt;/span&gt; deferred portion
and the $&lt;span id="xdx_902_ecustom--UnderwriterCashDiscount_c20230101__20231231_zNPRC1kHaj6c" title="Underwriter cash discount"&gt;900,000&lt;/span&gt; cash discount agreed to be deferred until Business Combination. The deferred fee will become payable to the underwriters
from the amounts held in the Trust Account solely if the Company completes a Business Combination, subject to the terms of the underwriting
agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Subscription
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted in Note 5, on May 3, 2023, the Company entered into a subscription agreement (&#x201c;Subscription Agreement&#x201d;) with the Investor
and the Original Sponsor. Pursuant to the May 4, 2023 Purchase Agreement, the Sponsor assumed the obligations of the Original Sponsor
under the Subscription Agreement. Subject to, and in accordance with the terms and conditions of the Subscription Agreement, the parties
agreed that:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Investor would make a cash contribution of $&lt;span id="xdx_90C_ecustom--InitialCapitalContribution_pp0p0_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmSM6yYtItk8" title="Initial capital contribution"&gt;151,000&lt;/span&gt; to the Original Sponsor (the &#x201c;Initial Capital Contribution&#x201d;) on or
    prior to May 3, 2023, or on such date as the parties may agree in writing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Initial Capital Contribution would in turn be loaned by the Original Sponsor to the Company to cover working capital expenses (the
    &#x201c;First SPAC Loan&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    consideration for the Initial Capital Contribution, the Company will issue &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z4RpHdiUDdq1" title="Number of shares issued"&gt;151,000&lt;/span&gt; Class A ordinary shares, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zwjIHYyyuwVi" title="Ordinary shares, par value (in dollar per share)"&gt;0.0001&lt;/span&gt; per
    share, of the Company to the Investor at the De-SPAC Closing, which shares shall be subject to no transfer restrictions or any other
    lock-up provisions, earn outs, or other contingencies and shall be registered as part of any registration statement to be filed in
    connection with the De-SPAC Closing or, if no such registration statement is filed in connection with the De-SPAC Closing, pursuant
    to the first registration statement to be filed by the Company or the surviving entity following the De-SPAC Closing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    SPAC Loan shall not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Sponsor will pay to the Investor
    all repayments of the SPAC Loan the Sponsor has received within &lt;span id="xdx_906_ecustom--MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_dxL_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z30n1seYNRR2" title="Minimum period for receiving spac loan from de-spac closing::XDX::P5D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;five&lt;/span&gt;&lt;/span&gt; business days of the De-SPAC Closing. The Investor may elect
    at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares at a rate of &lt;span id="xdx_901_ecustom--NumberOfSharesIssuableForEach10InitialCapitalContribution_iI_c20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zqyTVL6zYLD3" title="Number of shares issuable for each $10 initial capital contribution"&gt;one&lt;/span&gt; Class A ordinary share
    for each $&lt;span id="xdx_909_ecustom--AmountOfInitialCapitalConsideredToIssueOneShare_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zFYoqro2Dr5b" title="Amount of initial capital considered to issue one share"&gt;10.00&lt;/span&gt; of the Initial Capital Contribution. If the Company liquidates without consummating the initial business combination,
    any amounts remaining in the Sponsor or Company&#x2019;s cash accounts, not including the Company&#x2019;s Trust Account, will be paid
    to the Investor within &lt;span id="xdx_906_ecustom--MinimumPeriodForPaymentInCaseOfLiquidation_dc_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zAOm15oQBdVf" title="Minimum period for payment in case of liquidation"&gt;five days&lt;/span&gt; of the liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    the De-SPAC Closing, the Sponsor will pay the Investor an amount equal to the reasonable attorney fees incurred by the Investor in
    connection with the Subscription Agreement not to exceed $&lt;span id="xdx_90C_ecustom--MaximumReasonableAttorneyFees_c20230503__20230503__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zKDgwTu0Kmpb" title="Maximum reasonable attorney fees"&gt;5,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 20, 2023, the Company entered into a second subscription agreement (the &#x201c;Second Subscription Agreement&#x201d;) with the Investor
and the Sponsor. Subject to, and in accordance with the terms and conditions of the Second Subscription Agreement, the parties agreed
that:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Investor would make a cash contribution of up to $&lt;span id="xdx_900_ecustom--InitialCapitalContribution_pp0p0_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_ziuucL2LkLZ5" title="Initial capital contribution"&gt;750,000&lt;/span&gt; to the Sponsor (the &#x201c;Additional Capital Contribution&#x201d;) on or
    prior to June 21, 2023, and the remaining $&lt;span id="xdx_90E_ecustom--InitialCapitalContribution_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zAHmT1WTqsqa" title="Initial capital contribution"&gt;750,000&lt;/span&gt; would be made by the Investor to the Sponsor in cash on the later of the Sponsor&#x2019;s
    request and the first filing of the S-4 for the De-SPAC.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Additional Capital Contribution would in turn be loaned by the Sponsor to the Company in cash on the later of the Sponsor&#x2019;s
    request and the first filing of the S-4 for the SPAC&#x2019;s business combination (the &#x201c;Second SPAC Loan&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    consideration for the Additional Capital Commitment, SPAC will issue a further &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zkvSdiWuJlI1" title="Number of shares issued"&gt;one&lt;/span&gt; Class A ordinary share for each dollar of the
    Additional Capital Commitment funded to the Investor at the close of the business combination (&#x201c;Subscription Shares&#x201d;).
    The Subscription Shares shall be subject to no transfer restrictions or any other lock-up provisions, earn outs, or other contingencies.
    The Subscription Shares (i) shall be registered as part of any registration statement issuing shares before or in connection with
    the De- SPAC Closing or (ii) if no such registration statement is filed in connection with the de-SPAC Closing, shall promptly be
    registered pursuant to the first registration statement filed by the SPAC or the surviving entity following the De-SPAC Closing,
    which shall be filed no later than 30 days after the De-SPAC Closing and declared effective no later than 90 days after the De-SPAC
    Closing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Second SPAC Loan shall not accrue interest and shall be repaid by the Company upon the De-SPAC Closing. The Sponsor will pay to the
    Investor all repayments of the Second SPAC Loan the Sponsor has received within &lt;span id="xdx_906_ecustom--MinimumPeriodForReceivingSpacLoanFromDeSpacClosing_dxL_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zgBkLbKUZo3b" title="Minimum period for receiving spac loan from de-spac closing::XDX::P5D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;five&lt;/span&gt;&lt;/span&gt; business days of the De-SPAC Closing. The Investor
    may elect at the De-SPAC Closing to receive such payments in (a) cash or (b) Class A ordinary shares at a rate of &lt;span id="xdx_902_ecustom--NumberOfSharesIssuableForEach10InitialCapitalContribution_iI_c20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zj2uNiqyPKY8" title="Number of shares issuable for each $10 initial capital contribution"&gt;one&lt;/span&gt; Class A ordinary
    share for each $&lt;span id="xdx_901_ecustom--AmountOfInitialCapitalConsideredToIssueOneShare_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zLdYsqU579O8" title="Amount of initial capital considered to issue one share"&gt;10.00&lt;/span&gt; of the Additional Capital Contribution. If the Company liquidates without consummating the initial business
    combination, any amounts remaining in the Sponsor or Company&#x2019;s cash accounts, not including the Company&#x2019;s Trust Account,
    will be paid to the Investor within five days of the liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    the De-SPAC Closing, the Sponsor will pay the Investor an amount equal to the reasonable attorney fees incurred by the Investor in
    connection with the Second Subscription Agreement not to exceed $&lt;span id="xdx_90D_ecustom--MaximumReasonableAttorneyFees_c20230620__20230620__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementMember_zQiqrVEYjNX2" title="Maximum reasonable attorney fees"&gt;5,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Purchase
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 4, 2023, the Company entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with the Sponsor and the Original Sponsor,
pursuant to which the Sponsor agreed to purchase from the Original Sponsor (x) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_zdO0ljFVGdu6" title="Number of shares issued"&gt;7,988,889 &lt;/span&gt;Class A ordinary shares and (y) &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230504__20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_z1Q4DOn6S8g2" title="Number of shares issued"&gt;1,000,000&lt;/span&gt; Private
Placement Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant that is exercisable for one Class
A ordinary share, free and clear of all liens and encumbrances (other than those contained in the Letter Agreement, dated November 3,
2021, by and among the Company, its officers, directors and the Original Sponsor, and the Underwriting Agreement, dated November 3, 2021,
by and between the Company and Cantor, as representative of the several underwriters (the &#x201c;Underwriting Agreement&#x201d;), for
an aggregate purchase price of $&lt;span id="xdx_906_ecustom--AggregatePurchasePrice_iI_c20230504__srt--CounterpartyNameAxis__custom--SsvkAssociatesLlcMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--SponsorMember_zXUAMPheSpI" title="Purchase price"&gt;1.00&lt;/span&gt; (the &#x201c;Purchase Price&#x201d;) payable at the time of the initial business combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the payment of the Purchase Price, the Sponsor also assumed the following obligations: (i) responsibility for all of Company&#x2019;s
public company reporting obligations; (ii) the obligations of the Original Sponsor under the May 3, 2023 Subscription Agreement, (iii)
responsibility for the Company&#x2019;s D&amp;amp;O insurance premium to extend the Company&#x2019;s existing D&amp;amp;O insurance policy and
maintain D&amp;amp;O coverage through the closing of the initial business combination and obtain appropriate tail coverage; (iv) responsibility
for the Company&#x2019;s outstanding legal fees owed by the Company; and (v) all other obligations of the Original Sponsor related to
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Purchase Agreement, the Sponsor had the right to replace the Company&#x2019;s current directors and officers with directors and
officers as the Sponsor may select in its sole discretion. The obligations of the Original Sponsor to consummate the transactions contemplated
by the Purchase Agreement were subject to the satisfaction or written waiver by the Original Sponsor of the following conditions: (a)
the approval of the board of directors the SPAC; (b) the approval of the members of the Original Sponsor; (c) the consent or waiver of
the underwriters under the Underwriting Agreement; (d) the filing of its quarterly report on Form 10-Q by the SPAC for the quarter ended
March 31, 2023. On June 7, 2023, the parties to the Purchase Agreement closed the transactions contemplated thereby. In connection with
the closing, the Sponsor replaced the Company&#x2019;s directors and officers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Purchase Agreement contains customary representations and warranties of the parties, including, among others, with respect to corporate
organization, corporate authority, and compliance with applicable laws. The representations and warranties of each party set forth in
the Purchase Agreement were made solely for the benefit of the other parties to the Purchase Agreement, and investors are not third-party
beneficiaries of the Purchase Agreement. In addition, such representations and warranties (a) are subject to materiality and other qualifications
contained in the Purchase Agreement, which may differ from what may be viewed as material by investors, (b) were made only as of the
date of the Purchase Agreement or such other date as is specified in the Purchase Agreement and (c) may have been included in the Purchase
Agreement for the purpose of allocating risk between the parties rather than establishing matters as facts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <TVGN:UnderwritingOptionPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_OverAllotmentOptionMember"
      id="Fact000896">P45D</TVGN:UnderwritingOptionPeriod>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">4500000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <TVGN:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-11-052021-11-05_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">4500000</TVGN:UnitsIssuedDuringPeriodSharesNewIssues>
    <TVGN:UnderwritingCashDiscountPerUnit
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000902"
      unitRef="USDPShares">0.20</TVGN:UnderwritingCashDiscountPerUnit>
    <TVGN:PaymentOfUnderwriterDiscount
      contextRef="From2023-01-012023-12-31_us-gaap_IPOMember"
      decimals="0"
      id="Fact000904"
      unitRef="USD">6000000</TVGN:PaymentOfUnderwriterDiscount>
    <TVGN:UnderwritingCashDiscountPerUnit
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000906"
      unitRef="USDPShares">0.20</TVGN:UnderwritingCashDiscountPerUnit>
    <TVGN:AggregateUnderwriterCashDiscount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000908"
      unitRef="USD">900000</TVGN:AggregateUnderwriterCashDiscount>
    <TVGN:DeferredFeePerUnit
      contextRef="AsOf2023-12-31"
      decimals="2"
      id="Fact000910"
      unitRef="USDPShares">0.40</TVGN:DeferredFeePerUnit>
    <TVGN:DeferredUnderwritingFeePayable
      contextRef="From2023-01-012023-12-31_us-gaap_IPOMember"
      decimals="0"
      id="Fact000912"
      unitRef="USD">13800000</TVGN:DeferredUnderwritingFeePayable>
    <TVGN:AggregateDeferredUnderwritingFeePayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000914"
      unitRef="USD">14700000</TVGN:AggregateDeferredUnderwritingFeePayable>
    <TVGN:DeferredUnderwritingFeePayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000916"
      unitRef="USD">13800000</TVGN:DeferredUnderwritingFeePayable>
    <TVGN:UnderwriterCashDiscount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">900000</TVGN:UnderwriterCashDiscount>
    <TVGN:InitialCapitalContribution
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">151000</TVGN:InitialCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact000922"
      unitRef="Shares">151000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-03_us-gaap_InvestorMember_us-gaap_CommonClassAMember_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact000924"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <TVGN:AmountOfInitialCapitalConsideredToIssueOneShare
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">10.00</TVGN:AmountOfInitialCapitalConsideredToIssueOneShare>
    <TVGN:MinimumPeriodForPaymentInCaseOfLiquidation
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SubscriptionAgreementMember"
      id="Fact000932">P5D</TVGN:MinimumPeriodForPaymentInCaseOfLiquidation>
    <TVGN:MaximumReasonableAttorneyFees
      contextRef="From2023-05-032023-05-03_us-gaap_InvestorMember_custom_SponsorMember_custom_SubscriptionAgreementMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">5000</TVGN:MaximumReasonableAttorneyFees>
    <TVGN:InitialCapitalContribution
      contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">750000</TVGN:InitialCapitalContribution>
    <TVGN:InitialCapitalContribution
      contextRef="From2023-01-012023-12-31_us-gaap_InvestorMember_custom_SecondSubscriptionAgreementMember"
      decimals="0"
      id="Fact000938"
      unitRef="USD">750000</TVGN:InitialCapitalContribution>
    <TVGN:AmountOfInitialCapitalConsideredToIssueOneShare
      contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">10.00</TVGN:AmountOfInitialCapitalConsideredToIssueOneShare>
    <TVGN:MaximumReasonableAttorneyFees
      contextRef="From2023-06-202023-06-20_us-gaap_InvestorMember_custom_SponsorMember_custom_SecondSubscriptionAgreementMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">5000</TVGN:MaximumReasonableAttorneyFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember"
      decimals="INF"
      id="Fact000950"
      unitRef="Shares">7988889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-042023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_PrivatePlacementMember_custom_SsvkAssociatesLlcMember"
      decimals="INF"
      id="Fact000952"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <TVGN:AggregatePurchasePrice
      contextRef="AsOf2023-05-04_custom_SponsorMember_custom_PurchaseAgreementMember_us-gaap_CommonClassAMember_custom_SsvkAssociatesLlcMember"
      decimals="INF"
      id="Fact000954"
      unitRef="USDPShares">1.00</TVGN:AggregatePurchasePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact000956">&lt;p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zleahcFRElM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2014; &lt;span id="xdx_829_zxRgFLkxaid1"&gt;Shareholders&#x2019; Deficit&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Class
A Ordinary Shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z3SFuwRzr81f" title="Ordinary shares, shares authorized"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zchjqu3Qokf3" title="Ordinary shares, shares authorized"&gt;200,000,000&lt;/span&gt;&lt;/span&gt; Class A ordinary shares with a par value of $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zImyFic4gI33" title="Ordinary shares, par value (In Dollar per share)"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxQiWvMyIGQl" title="Ordinary shares, par value (In Dollar per share)"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. As of December 31, 2023 and
2022, there were &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcMPHebQv53h" title="Ordinary shares, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z6e2WPRTJ7Oh" title="Ordinary shares, shares outstanding"&gt;13,433,333&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z39e0fKBc1he" title="Ordinary shares, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zBC1BOAGBxoc" title="Ordinary shares, shares outstanding"&gt;1,450,000&lt;/span&gt;&lt;/span&gt; Class A ordinary shares issued and outstanding (excluding &lt;span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfPNNf5ZvKT9" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)"&gt;1,502,180&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2oissxe3H04" title="Class A ordinary shares subject to possible redemption, outstanding (in shares)"&gt;34,500,000&lt;/span&gt; Class A
ordinary shares subject to possible redemption), respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Class
B Ordinary Shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4wWYQu9dw32" title="Ordinary shares, shares authorized"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zsIkoeyUHNQg" title="Ordinary shares, shares authorized"&gt;20,000,000&lt;/span&gt;&lt;/span&gt; Class B ordinary shares with a par value of $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zYmYGRMYhN0h" title="Ordinary shares, par value (In Dollar per share)"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z49zdW0LprNc" title="Ordinary shares, par value (In Dollar per share)"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. Holders of Class B ordinary
shares are entitled to &lt;span id="xdx_903_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zA50ZpBPWOZ1" title="Ordinary shares, vote per share"&gt;&lt;span id="xdx_90D_ecustom--CommonStockNumberOfVotesPerShare_iI_dc_uInteger_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z5P97QEnPJi6" title="Ordinary shares, vote per share"&gt;one&lt;/span&gt;&lt;/span&gt; vote for each share of Class B ordinary shares. As of December 31, 2023 and 2022, there were &lt;span title="Ordinary shares, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAcwgpj0sVZc" title="Ordinary shares, shares outstanding"&gt;0&lt;/span&gt;&lt;/span&gt; and &lt;span title="Ordinary shares, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zvD0066NA6Zk" title="Ordinary shares, shares outstanding"&gt;11,983,333&lt;/span&gt;&lt;/span&gt;
Class B ordinary shares outstanding, respectively, none of which are subject to forfeiture since the underwriters&#x2019; over-allotment
option was exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to our initial Business Combination, only holders of our Class B ordinary shares will have the right to vote on the appointment of directors.
Holders of our Class A ordinary shares will not be entitled to vote on the election of directors during such time. In addition, prior
to the completion of an initial Business Combination, holders of a majority of our Class B ordinary shares may remove a member of the
board of directors for any reason. These provisions of our Memorandum and Articles of Association may only be amended by a special resolution
passed by not less than 90% of our ordinary share shareholders who attend and vote at our general meeting. With respect to any other
matter submitted to a vote of our shareholders, including any vote in connection with our initial Business Combination, except as required
by law, holders of our Class B ordinary shares and holders of our Class A ordinary shares will vote together as a single class, with
each share entitling the holder to one vote.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination on a
one-for-one basis, subject to adjustment. In the case that additional Class A ordinary shares, or equity-linked securities, are issued
or deemed issued in excess of the amounts offered in the IPO and related to the closing of the initial Business Combination, the ratio
at which Class B ordinary shares shall convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the
outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the
number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted
basis, &lt;span id="xdx_905_ecustom--ConvertibleStocksConversionRatio_pp2d_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zmV42KXKTiPc" title="Ratio to be applied to the stock in the conversion"&gt;25&lt;/span&gt;% of the sum of the total number of all ordinary shares outstanding upon the completion of the IPO plus all Class A ordinary
shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares
or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent
warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preference
Shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zazauzFLiK9a" title="Preference shares , shares authorized"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zJDNnakKyA9b" title="Preference shares , shares authorized"&gt;1,000,000&lt;/span&gt;&lt;/span&gt; preference shares with such designations, voting and other rights and preferences as may be
determined from time to time by the Company&#x2019;s board of directors. As of December 31, 2023 and 2022, there were &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_ztPeBlPZ5ec5" title="Preference shares, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zq17rCvt7rs7" title="Preference shares, shares outstanding"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_ztfqe4EbgzA6" title="Preference shares, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_z9Zk2qATZUm2" title="Preference shares, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; preferred shares
issued or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Public
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Public Warrants will become exercisable on the later of (i) &lt;span id="xdx_90A_ecustom--WarrantExercisePeriodConditionOne_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztzdgo41Df2" title="Minimum threshold written notice period for redemption of public warrants"&gt;30&lt;/span&gt; days after the completion of a Business Combination and (ii) &lt;span id="xdx_901_ecustom--WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering_dc_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zQOsYxkSzvij" title="Public warrants exercisable term from the closing of the initial public offering"&gt;one year&lt;/span&gt;
from the closing of the IPO. No warrants will be exercisable for cash unless the Company has an effective and current registration statement
covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such Class A ordinary
shares. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon exercise of the
Public Warrants is not effective within a specified period following the consummation of a Business Combination, warrant holders may,
until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain
an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the
Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not
be able to exercise their warrants on a cashless basis. The Public Warrants will expire &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zkzZ5UAsOTCh" title="Public warrants expiration term"&gt;five years&lt;/span&gt; after the completion of a Business
Combination or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Once
the warrants become exercisable, the Company may redeem the Public Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
    whole and not in part;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at
    a price of $&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zekJbq7X1MQl" title="Redemption price per public warrant (in dollars per share)"&gt;0.01&lt;/span&gt; per warrant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon
    not less than &lt;span id="xdx_906_ecustom--RedemptionPeriod_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrBwEljK2dUf" title="Redemption period"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if,
    and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $&lt;span id="xdx_907_ecustom--WarrantRedemptionConditionMinimumSharePrice_pp2d_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9vhPKWd3Ubk" title="Warrant redemption condition minimum share price"&gt;18.00&lt;/span&gt; per share (as adjusted for share
    subdivisions, share dividends, reorganizations and recapitalizations), for any &lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zOEzySEWuLMd" title="Threshold trading days for redemption of public warrants"&gt;20&lt;/span&gt; trading days within a &lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z63PpM15jw8l" title="Threshold consecutive trading days for redemption of public warrants"&gt;30 &lt;/span&gt;trading day period commencing
    at any time after the warrants become exercisable and ending on the &lt;span id="xdx_909_ecustom--ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_dcxL_uInteger_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zocKlIJZEHTc" title="Threshold number of business days before sending notice of redemption to warrant holders::XDX::3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;third&lt;/span&gt;&lt;/span&gt; business day prior to the notice of redemption to warrant
    holders; and if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying
    the warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the
Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Private Warrants are identical to the Public Warrants underlying the Units being sold in the IPO, except that the Private Warrants and
the Class A ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until
after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable
for cash or on a cashless basis, at the holder&#x2019;s option, and be non-redeemable so long as they are held by the initial purchasers
or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees,
the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price and number of Class A ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including
in the event of a share dividend, extra Class A Ordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of Class A ordinary shares at a price below their respective exercise prices. Additionally,
in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination
within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any
of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of
the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, if the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection
with the closing of a Business Combination at an issue price or effective issue price of less than $&lt;span id="xdx_907_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrnWI2UP5Qyl" title="Share price trigger used to measure dilution of warrant"&gt;9.20&lt;/span&gt; per Class A ordinary share (with
such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors, and in the case of
any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by them prior
to such issuance), (y) the aggregate gross proceeds from such issuances represent more than &lt;span id="xdx_909_ecustom--PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_ztRCScGKUfjj" title="Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant"&gt;60&lt;/span&gt;% of the total equity proceeds, and interest
thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions),
and (z) the volume weighted average trading price of the Company&#x2019;s Class A ordinary shares during the &lt;span id="xdx_905_ecustom--TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_dtD_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwsPSdo8y9sc" title="Trading period after business combination used to measure dilution of warrant"&gt;20&lt;/span&gt; trading day period starting
on the trading day prior to the day on which the Company consummates Business Combination (such price, the &#x201c;Market Value&#x201d;)
is below $&lt;span id="xdx_90E_ecustom--SharePriceTriggerUsedToMeasureDilutionOfWarrants_iI_pp2d_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zdONLKLPoV82" title="Share price trigger used to measure dilution of warrant"&gt;9.20&lt;/span&gt; per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to &lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices_pid_dp_uPure_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrrgKbUSjwrd" title="Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)"&gt;115&lt;/span&gt;% of the greater
of (i) the Market Value or (ii) the price at which the Company issues the additional Class A ordinary shares or equity-linked securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000960"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000962"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000964"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">13433333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000968"
      unitRef="Shares">13433333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000970"
      unitRef="Shares">1450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000972"
      unitRef="Shares">1450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Shares">1502180</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Shares">34500000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000982"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000984"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <TVGN:CommonStockNumberOfVotesPerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000986"
      unitRef="Integer">1</TVGN:CommonStockNumberOfVotesPerShare>
    <TVGN:CommonStockNumberOfVotesPerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000988"
      unitRef="Integer">1</TVGN:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000990"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Shares">11983333</us-gaap:CommonStockSharesOutstanding>
    <TVGN:ConvertibleStocksConversionRatio
      contextRef="From2023-01-012023-12-31_us-gaap_CommonClassBMember"
      decimals="2"
      id="Fact000994"
      unitRef="Pure">0.25</TVGN:ConvertibleStocksConversionRatio>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000996"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000998"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001000"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001002"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001004"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <TVGN:WarrantExercisePeriodConditionOne
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      id="Fact001008">P30D</TVGN:WarrantExercisePeriodConditionOne>
    <TVGN:WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      id="Fact001010">P1Y</TVGN:WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_PublicWarrantsMember"
      id="Fact001012">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <TVGN:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      decimals="2"
      id="Fact001014"
      unitRef="USDPShares">0.01</TVGN:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <TVGN:RedemptionPeriod
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      id="Fact001016">P30D</TVGN:RedemptionPeriod>
    <TVGN:WarrantRedemptionConditionMinimumSharePrice
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      decimals="2"
      id="Fact001018"
      unitRef="USDPShares">18.00</TVGN:WarrantRedemptionConditionMinimumSharePrice>
    <TVGN:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      id="Fact001020">P20D</TVGN:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <TVGN:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      id="Fact001022">P30D</TVGN:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <TVGN:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="AsOf2023-12-31_custom_PublicWarrantsMember"
      decimals="2"
      id="Fact001026"
      unitRef="USDPShares">9.20</TVGN:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <TVGN:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001028"
      unitRef="Pure">0.60</TVGN:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <TVGN:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      id="Fact001030">P20D</TVGN:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
    <TVGN:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="AsOf2023-12-31_custom_PublicWarrantsMember"
      decimals="2"
      id="Fact001032"
      unitRef="USDPShares">9.20</TVGN:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <TVGN:ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Pure">1.15</TVGN:ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrices>
    <TVGN:WarrantLiabilitiesDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact001036">&lt;p id="xdx_80A_ecustom--WarrantLiabilitiesDisclosureTextBlock_zlcP5brLQtCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2014; &lt;span id="xdx_82C_zeu0TEWjRXgf"&gt;Warrant Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_z2XLa9qsk8r4" title="Number of warrants to purchase shares issued"&gt;725,000&lt;/span&gt; Private Placement Warrants in accordance with the guidance contained in ASC 815-40 due to the fact the
Private Placement Warrants will be exercisable for cash or on a cashless basis, at the holder&#x2019;s option, and be non-redeemable so
long as they are held by the initial purchasers or their permitted transferee. Such guidance provides that, based on these features,
the private placement warrants do not meet the criteria for equity treatment thereunder, and each such warrant must be recorded as a
liability. Accordingly, the Company will classify each private placement warrant as a liability at its fair value. This liability is
subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value,
with the change in fair value recognized in the Company&#x2019;s statement of operations. The Company has determined the Public Warrants
do not contain such features, and accordingly will be accounted for as equity and are not subject to subsequent remeasurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:WarrantLiabilitiesDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_PrivatePlacementWarrantsMember"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">725000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-012023-12-31" id="Fact001040">&lt;p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zscPJiCAlwRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2014; &lt;span id="xdx_822_zpLtguBL6Bdf"&gt;Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions
    for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities
    and quoted prices for identical assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the assets held in the Trust Account were held in a demand deposit account. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmjRVkh3pYg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring
basis at December 31, 2023 and 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine
such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zUJd3DIqYfuc" style="display: none"&gt;Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;December 31, 2023:&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted &lt;br/&gt;
Prices in&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Active&lt;br/&gt;
 Markets &lt;br/&gt;
(Level 1)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Observable&lt;br/&gt;
 Inputs&lt;br/&gt;
 (Level 2)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unobservable&lt;br/&gt;
 Inputs &lt;br/&gt;
(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;U.S. Treasury Securities(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zL6j0eZA5kQd" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zzQOWVq1njL9" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1046"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zJHJYSgOXqh5" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrant Liability- Private Placement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzF2KHIA6d1h" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8zohv8G7zn4" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zu6DplRasUnk" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F05_zRz5qzPWqC91" style="width: 15pt; text-align: right"&gt;(1)&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F10_zr00BowB9Rdj" style="text-align: justify"&gt;As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;December 31, 2022:&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;br/&gt;
 Prices in&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Active&lt;br/&gt;
 Markets&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;br/&gt;
 Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;br/&gt;
 Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;U.S. Treasury Securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlSzSgdzh8Qj" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;356,864,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQbFfgPIFlQa" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTtiidvpzIVb" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1061"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrant Liability- Private Placement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7MNmEfSplwb" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgz3GX8Bzzn1" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCeQqJgFIhE8" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;7,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zsi8CYImWPEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model to value the warrants at each reporting period, with changes in fair value recognized
in the statement of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in a Monte
Carlo pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield.
The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining
life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity
similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining
contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;DECEMBER
31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aforementioned warrant liabilities are not subject to qualified hedge accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zW6iO4IeZbtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zXnCn4NfJng1" style="display: none"&gt;Schedule
of Quantitative Information    in Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At &lt;br/&gt;
December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At &lt;br/&gt;
December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Share Price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDNiR2mPr5Tf" style="width: 20%; text-align: right" title="Measurement Input"&gt;11.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHJCNf8UNgHk" style="width: 20%; text-align: right" title="Measurement Input"&gt;10.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zToyf7clZ7g2" style="text-align: right" title="Measurement Input"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z6w3yUrmoJ9d" style="text-align: right" title="Measurement Input"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zHVt8y7rXMvd" style="text-align: right" title="Measurement Input"&gt;5.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z52dsppE8ln7" style="text-align: right" title="Measurement Input"&gt;5.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Industry Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBJriKpznZxe" style="text-align: right" title="Measurement Input"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0Jh1aYzxPrb" style="text-align: right" title="Measurement Input"&gt;4.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk Free Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8GUjclHjgli" style="text-align: right" title="Measurement Input"&gt;3.77&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5935i02fu9d" style="text-align: right" title="Measurement Input"&gt;3.91&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgMQm2a5w1M9" style="text-align: right" title="Measurement Input"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7p3iyXq8RK3" style="text-align: right" title="Measurement Input"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z7L6IdXctr51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001042">&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmjRVkh3pYg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring
basis at December 31, 2023 and 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine
such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zUJd3DIqYfuc" style="display: none"&gt;Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;December 31, 2023:&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted &lt;br/&gt;
Prices in&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Active&lt;br/&gt;
 Markets &lt;br/&gt;
(Level 1)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Observable&lt;br/&gt;
 Inputs&lt;br/&gt;
 (Level 2)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unobservable&lt;br/&gt;
 Inputs &lt;br/&gt;
(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;U.S. Treasury Securities(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zL6j0eZA5kQd" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zzQOWVq1njL9" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1046"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_fKDEp_zJHJYSgOXqh5" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrant Liability- Private Placement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzF2KHIA6d1h" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8zohv8G7zn4" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zu6DplRasUnk" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F05_zRz5qzPWqC91" style="width: 15pt; text-align: right"&gt;(1)&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F10_zr00BowB9Rdj" style="text-align: justify"&gt;As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;December 31, 2022:&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;br/&gt;
 Prices in&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;br/&gt;
 Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Active&lt;br/&gt;
 Markets&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;br/&gt;
 Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;br/&gt;
 Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;U.S. Treasury Securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlSzSgdzh8Qj" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;356,864,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQbFfgPIFlQa" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zTtiidvpzIVb" style="width: 12%; text-align: right" title="U.S. Treasury Securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1061"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrant Liability- Private Placement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7MNmEfSplwb" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgz3GX8Bzzn1" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCeQqJgFIhE8" style="text-align: right" title="Warrant Liability- Private Placement Warrants"&gt;7,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">29000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">356864000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001067"
      unitRef="USD">7250</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001069">&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zW6iO4IeZbtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zXnCn4NfJng1" style="display: none"&gt;Schedule
of Quantitative Information    in Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At &lt;br/&gt;
December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At &lt;br/&gt;
December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Share Price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zDNiR2mPr5Tf" style="width: 20%; text-align: right" title="Measurement Input"&gt;11.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHJCNf8UNgHk" style="width: 20%; text-align: right" title="Measurement Input"&gt;10.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zToyf7clZ7g2" style="text-align: right" title="Measurement Input"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp2d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z6w3yUrmoJ9d" style="text-align: right" title="Measurement Input"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zHVt8y7rXMvd" style="text-align: right" title="Measurement Input"&gt;5.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z52dsppE8ln7" style="text-align: right" title="Measurement Input"&gt;5.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Industry Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zBJriKpznZxe" style="text-align: right" title="Measurement Input"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0Jh1aYzxPrb" style="text-align: right" title="Measurement Input"&gt;4.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk Free Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8GUjclHjgli" style="text-align: right" title="Measurement Input"&gt;3.77&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5935i02fu9d" style="text-align: right" title="Measurement Input"&gt;3.91&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgMQm2a5w1M9" style="text-align: right" title="Measurement Input"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pp4d_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7p3iyXq8RK3" style="text-align: right" title="Measurement Input"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact001071"
      unitRef="Pure">11.13</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="2"
      id="Fact001073"
      unitRef="Pure">10.33</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember"
      decimals="2"
      id="Fact001075"
      unitRef="Pure">11.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember"
      decimals="2"
      id="Fact001077"
      unitRef="Pure">11.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001079">P5Y2M15D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001081">P5Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="Fact001083"
      unitRef="Pure">6.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="Fact001085"
      unitRef="Pure">4.40</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact001087"
      unitRef="Pure">3.77</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact001089"
      unitRef="Pure">3.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="4"
      id="Fact001091"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="4"
      id="Fact001093"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-012023-12-31" id="Fact001095">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zwUj1SXx7tRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2014; &lt;span id="xdx_82C_z5LIHdAv0NUc"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date these financial statements
were available to be issued. Based on this review, other than as described below, the Company did not identify any subsequent events
that would have required adjustment or disclosure in these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On January 31, 2024, in connection with an extraordinary
meeting of shareholders called to approve the proposals relating to the entry into and consummation of the Business Combination, shareholders
holding &lt;span id="xdx_90F_ecustom--ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zESopOj6QJL9" title="Minimum period to file charter amendment"&gt;1,432,457&lt;/span&gt; of the Company&#x2019;s Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of
the funds in the Company&#x2019;s trust account. As a result, approximately $&lt;span id="xdx_908_ecustom--ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption_pn5n6_c20240131__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzcFQlaXULFc" title="Cash withdrawn from Trust Account in connection with redemption"&gt;16.0&lt;/span&gt; million (approximately $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3ofPKqs9OJc" title="Price per share"&gt;11.14&lt;/span&gt; per Public Share) were
removed from the Trust Account to pay such holders.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On February 14, 2024, pursuant to the Merger Agreement
by and among the Company, Merger Sub, the Sponsor, Tevogen Bio, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub
merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company. Prior to
the effective time of the Merger (the &#x201c;Effective Time&#x201d;), pursuant to the Merger Agreement, the Company changed its jurisdiction
of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated
under the laws of the State of Delaware (the &#x201c;Domestication&#x201d;). In connection with the Domestication, the Company changed its
name to &#x201c;Tevogen Bio Holdings Inc.&#x201d; Also in connection with the Domestication, the Company&#x2019;s governing documents were
amended and restated as set forth in the Company&#x2019;s definitive proxy statement filed with the Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) on&#160;&lt;span style="text-decoration: underline"&gt;January 10, 2024&lt;/span&gt;&#160;(the &#x201c;Definitive Proxy Statement&#x201d;). At the Effective Time, in
accordance with the terms and subject to the conditions of the Merger Agreement, each share of the common stock of Tevogen Bio issued
and outstanding immediately prior to the Effective Time was converted into the right to receive the number of shares of duly authorized,
validly issued, fully paid, and nonassessable shares of the common stock of the Company, par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zl1vUIz346fc" title="Common stock, par value"&gt;0.0001&lt;/span&gt; (the &#x201c;Common Stock&#x201d;),
equal to the quotient obtained by dividing (x) the quotient obtained by dividing (i) $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_c20240214__20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--TevogenBioMember_zk7sxtZpvkDa" title="Merger agreement share issuable"&gt;1,200,000,000&lt;/span&gt; by (ii) ten dollars ($&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zpEEP9ZGg5K5" title="Merger agreement share issuable, per share"&gt;10.00&lt;/span&gt;) by (y)
the aggregate number of shares of the common stock of Tevogen Bio that were issued and outstanding immediately prior to the Effective
Time.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024, the Company entered into a securities purchase agreement with an investor pursuant to which the investor agreed
to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0BQ6cP3Jxn3" title="Aggregate purchase price amount"&gt;8.0&lt;/span&gt;
million. On March 27, 2024, the Company entered into an agreement pursuant to which that amount was reduced to $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zMjDSNJx8fye" title="Shares purchase amount"&gt;2.0&lt;/span&gt;
million and the investor agreed to purchase shares of the Company&#x2019;s Series A-1 Preferred Stock for an aggregate purchase price
of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zuAiSl9zOlm3" title="Aggregate purchase price amount"&gt;6.0&lt;/span&gt;
million. As of April 26, 2024, the Company has received $&lt;span id="xdx_90A_eus-gaap--Cash_iI_pn5n6_c20240426__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdvhVzlHnwkg" title="Received"&gt;1.2&lt;/span&gt; million of the $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zwoBPcWviCz5" title="Aggregate purchase price amount"&gt;6.0&lt;/span&gt; million aggregate purchase price for the shares of
Series A-1 Preferred Stock. The shares of Series A Preferred Stock are convertible into a total of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQAix7ayD9Kd" title="Conversion of shares"&gt;500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock and the shares of the Series A-1 Preferred Stock will be convertible into a total of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z7CySHCzWF2a" title="Conversion of shares"&gt;600,000&lt;/span&gt;
shares of the Company&#x2019;s common stock, in each case at the election of the holder. Each of the Series A Preferred Stock is and
the Series A-1 Preferred Stock will be subject to a call right providing the Company the right to call the stock if the volume
weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCt9ozyeW1G8" title="Share price, per share"&gt;5.00&lt;/span&gt;
per share and there is an effective resale registration statement on file covering the underlying common stock. &lt;span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zr4CuyIiL8Lh" title="Preferred stock voting rights"&gt;The
Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no
mandatory redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the
Series A-1 Preferred Stock in no event to more than 15% per year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024, in connection with the consummation of the Business Combination, the Company entered into an agreement with the Sponsor,
pursuant to which the Company assigned to the Sponsor and the Sponsor agreed to assume certain liabilities and obligations in the aggregate
initial amount of approximately $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9aSiJHU6C9"&gt;4.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, which amount was later reduced to approximately
$&lt;span id="xdx_902_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn5n6_c20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGBYMFN8WOCf"&gt;3.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million (the &#x201c;Series B Preferred Stock&#x201d;).
&lt;span id="xdx_902_eus-gaap--PreferredStockVotingRights_c20240214__20240214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhzB2z5Zgcbj"&gt;The
Series B Preferred Stock is non-voting, non-convertible, callable by the Company at any time, and pays a 3.5% quarterly dividend beginning
35 days after issuance. Any dividend will be paid by the Company on behalf of the Sponsor to the creditors to which the assumed liabilities
and obligations are owed, pro rata in accordance with those liabilities and obligations unless otherwise agreed by the Company and the
Sponsor. The dividend rate will increase by 0.25% each month that the Series B Preferred Stock remains outstanding after the first 30
days after its issuance, but in no event will increase to more than 7.5% per quarter.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the Merger Agreement, Tevogen Bio agreed
that at the Effective Time, it would pay $&lt;span id="xdx_900_eus-gaap--SponsorFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_ztou06C0annd"&gt;2,000,000
&lt;/span&gt;to the Sponsor for advisory services (the &#x201c;Sponsor Advisory Services Fee&#x201d;). Thereafter, in connection with the closing
of the Business Combination, the Sponsor Advisory Services Fee was reduced to $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SponsorAdvisoryServiceFeeMember_z8XGWrI0odn6"&gt;500,000&lt;/span&gt;.
On April 16, 2024, the Sponsor agreed to further reduce the Sponsor Advisory Services Fee by informing Tevogen Bio that $&lt;span id="xdx_90D_eus-gaap--SponsorFees_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQnU0u6Np1rd"&gt;250,000
&lt;/span&gt;of the $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240415__20240416__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlPTlKsgfGlj"&gt;577,500
&lt;/span&gt;that was due from the Sponsor as of December 31, 2023 would be applied to offset a portion of the $&lt;span id="xdx_90D_ecustom--OffsetValue_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z9wT2SNHvZRl" title="Offset value"&gt;500,000&lt;/span&gt; Sponsor Advisory Services
Fee. Therefore, the total amount due to the Sponsor under the Sponsor Advisory Services Fee is $&lt;span id="xdx_90F_ecustom--ServicesFees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zuxRHWoHWbCe" title="Service fees"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares
      contextRef="AsOf2024-01-31_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001097"
      unitRef="USDPShares">1432457</TVGN:ShareholdersExercisedTheirRightToRedeemSharesNumberOfShares>
    <TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption
      contextRef="From2024-01-312024-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001099"
      unitRef="USD">16000000.0</TVGN:ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-01-31_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001101"
      unitRef="USDPShares">11.14</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember"
      decimals="INF"
      id="Fact001103"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="From2024-02-142024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember_custom_TevogenBioMember"
      decimals="0"
      id="Fact001105"
      unitRef="USD">1200000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_custom_MergerAgreementMember"
      decimals="INF"
      id="Fact001107"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember"
      decimals="-5"
      id="Fact001109"
      unitRef="USD">8000000.0</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-272024-03-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember"
      decimals="-5"
      id="Fact001111"
      unitRef="USD">2000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-03-272024-03-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember"
      decimals="-5"
      id="Fact001113"
      unitRef="USD">6000000.0</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:Cash
      contextRef="AsOf2024-04-26_us-gaap_SubsequentEventMember_custom_SeriesA1PreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001115"
      unitRef="USD">1200000</us-gaap:Cash>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-04-262024-04-26_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember"
      decimals="-5"
      id="Fact001117"
      unitRef="USD">6000000.0</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001119"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact001121"
      unitRef="Shares">600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-02-14_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001123"
      unitRef="USDPShares">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesAPreferredStockMember"
      id="Fact001125">The
Series A Preferred Stock is and the Series A-1 Preferred Stock will be non-voting, has or will have, as the case may be, no
mandatory redemption, and carries or will carry an annual 5% cumulative dividend, increasing by 2% each year, in the case of the
Series A-1 Preferred Stock in no event to more than 15% per year.</us-gaap:PreferredStockVotingRights>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      id="Fact001126"
      unitRef="USD">4200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="AsOf2024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      id="Fact001127"
      unitRef="USD">3600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2024-02-142024-02-14_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember"
      id="Fact001128">The
Series B Preferred Stock is non-voting, non-convertible, callable by the Company at any time, and pays a 3.5% quarterly dividend beginning
35 days after issuance. Any dividend will be paid by the Company on behalf of the Sponsor to the creditors to which the assumed liabilities
and obligations are owed, pro rata in accordance with those liabilities and obligations unless otherwise agreed by the Company and the
Sponsor. The dividend rate will increase by 0.25% each month that the Series B Preferred Stock remains outstanding after the first 30
days after its issuance, but in no event will increase to more than 7.5% per quarter.</us-gaap:PreferredStockVotingRights>
    <us-gaap:SponsorFees
      contextRef="From2023-01-012023-12-31_custom_MergerAgreementMember"
      decimals="0"
      id="Fact001129"
      unitRef="USD">2000000</us-gaap:SponsorFees>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2023-01-012023-12-31_custom_MergerAgreementMember_custom_SponsorAdvisoryServiceFeeMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SponsorFees
      contextRef="From2024-04-152024-04-16_custom_MergerAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001131"
      unitRef="USD">250000</us-gaap:SponsorFees>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-152024-04-16_custom_MergerAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001132"
      unitRef="USD">577500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <TVGN:OffsetValue
      contextRef="AsOf2023-12-31_custom_MergerAgreementMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">500000</TVGN:OffsetValue>
    <TVGN:ServicesFees
      contextRef="From2023-01-012023-12-31_custom_MergerAgreementMember"
      decimals="0"
      id="Fact001136"
      unitRef="USD">250000</TVGN:ServicesFees>
    <us-gaap:Cash
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001144"
      unitRef="USD">1317900</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001145"
      unitRef="USD">1052397</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001147"
      unitRef="USD">923202</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001148"
      unitRef="USD">670582</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-03-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">158819</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001153"
      unitRef="USD">2399921</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001154"
      unitRef="USD">1722979</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001156"
      unitRef="USD">418099</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001157"
      unitRef="USD">458651</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001159"
      unitRef="USD">412111</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001160"
      unitRef="USD">469862</us-gaap:OperatingLeaseRightOfUseAsset>
    <TVGN:DeferredTransactionCosts
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001163"
      unitRef="USD">2582870</TVGN:DeferredTransactionCosts>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001165"
      unitRef="USD">133276</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001166"
      unitRef="USD">271141</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001168"
      unitRef="USD">3363407</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001169"
      unitRef="USD">5505503</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001177"
      unitRef="USD">5211899</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001178"
      unitRef="USD">3418378</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001180"
      unitRef="USD">1564834</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">1096450</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001183"
      unitRef="USD">260583</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001184"
      unitRef="USD">252714</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001186"
      unitRef="USD">1651000</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001190"
      unitRef="USD">80712000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-03-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001192"
      unitRef="USD">250000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001195"
      unitRef="USD">8938316</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001196"
      unitRef="USD">85479542</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001199"
      unitRef="USD">14220000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">166788</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001202"
      unitRef="USD">234858</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001204"
      unitRef="USD">60973</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">9166077</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001208"
      unitRef="USD">99934400</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001216"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001218"
      unitRef="Shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001220"
      unitRef="Shares">500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Shares">500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">2799990</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001227"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">3613</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Shares">3613</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001233"
      unitRef="Shares">3613</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001224"
      unitRef="USD">3613000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001235"
      unitRef="USD">3613000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001243"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001247"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001253"
      unitRef="Shares">119999989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">119999989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001238"
      unitRef="USD">16462</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001239"
      unitRef="USD">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001257"
      unitRef="USD">76160773</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001258"
      unitRef="USD">5216840</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001260"
      unitRef="USD">-88392895</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001261"
      unitRef="USD">-99657737</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001263"
      unitRef="USD">-5802670</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001264"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001266"
      unitRef="USD">3363407</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001267"
      unitRef="USD">5505503</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001272"
      unitRef="USD">20811582</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">1347173</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001275"
      unitRef="USD">8705142</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001276"
      unitRef="USD">977109</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001278"
      unitRef="USD">29516724</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">2324282</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001281"
      unitRef="USD">-29516724</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001282"
      unitRef="USD">-2324282</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001284"
      unitRef="USD">155786</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">288997</us-gaap:InterestExpense>
    <TVGN:TransactionCosts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001287"
      unitRef="USD">7499353</TVGN:TransactionCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001290"
      unitRef="USD">31973</us-gaap:FairValueAdjustmentOfWarrants>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001293"
      unitRef="USD">-48468678</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">28142865</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001296"
      unitRef="USD">11264842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001297"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">10506866</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001300"
      unitRef="USD">-30756144</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">-37049420</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001303"
      unitRef="USD">-30756144</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001305"
      unitRef="USDPShares">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001306"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001308"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001309"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001311"
      unitRef="Shares">137333802</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001312"
      unitRef="Shares">119999989</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001314"
      unitRef="Shares">142387651</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001315"
      unitRef="Shares">119999989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001328"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001319"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001320"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001321"
      unitRef="USD">-99657737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001322"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001330"
      unitRef="USD">2799990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001335"
      unitRef="USD">2799990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001342"
      unitRef="USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001344"
      unitRef="USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <TVGN:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Shares">3613</TVGN:StockIssuedDuringPeriodSharesNewIssuesOne>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">10337419</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">1034</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001358"
      unitRef="USD">46621593</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">46622627</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001373"
      unitRef="Shares">14778056</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">1478</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001367"
      unitRef="USD">-2885459</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001369"
      unitRef="USD">-2883981</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001382"
      unitRef="Shares">19348954</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">1935</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001378"
      unitRef="USD">-1935</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001391"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001387"
      unitRef="USD">676485</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001389"
      unitRef="USD">676500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">26333249</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001398"
      unitRef="USD">26333249</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001404"
      unitRef="USD">11264842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001405"
      unitRef="USD">11264842</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001414"
      unitRef="Shares">500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001407"
      unitRef="USD">2799990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001416"
      unitRef="Shares">3613</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001408"
      unitRef="USD">3613000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Shares">164614418</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">16462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001410"
      unitRef="USD">76160773</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">-88392895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">-5802670</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001422"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001424"
      unitRef="USD">-39180057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001425"
      unitRef="USD">-33951217</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001444"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001436"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">-39180057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001438"
      unitRef="USD">-33951217</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001450"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001458"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001462"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001463"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">-69936201</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">-64707361</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001484"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001476"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001477"
      unitRef="USD">-69936201</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001478"
      unitRef="USD">-64707361</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">11264842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001490"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">40552</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">39735</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001498"
      unitRef="USD">26333249</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001501"
      unitRef="USD">159305</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001502"
      unitRef="USD">289135</us-gaap:PaidInKindInterest>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001504"
      unitRef="USD">7099353</us-gaap:NoncashMergerRelatedCosts>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001507"
      unitRef="USD">-48468678</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">28142865</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001510"
      unitRef="USD">799990</TVGN:LossOnPreferredStockIssuance>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">31973</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001516"
      unitRef="USD">57751</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001517"
      unitRef="USD">51473</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001522"
      unitRef="USD">250119</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001523"
      unitRef="USD">-70552</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">68446</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001526"
      unitRef="USD">-21344</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001528"
      unitRef="USD">1697346</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">497483</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001531"
      unitRef="USD">-800742</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001532"
      unitRef="USD">-480404</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001534"
      unitRef="USD">-60201</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001535"
      unitRef="USD">-53174</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001537"
      unitRef="USD">-2163825</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001538"
      unitRef="USD">-2177135</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001544"
      unitRef="USD">133000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001547"
      unitRef="USD">-133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <TVGN:CashAcquiredInConnectionWithReverseRecapitalization
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001552"
      unitRef="USD">229328</TVGN:CashAcquiredInConnectionWithReverseRecapitalization>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001555"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001558"
      unitRef="USD">200000</TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001562"
      unitRef="USD">2500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001564"
      unitRef="USD">2429328</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001565"
      unitRef="USD">2500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001567"
      unitRef="USD">265503</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001568"
      unitRef="USD">189865</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001570"
      unitRef="USD">1052397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">5484265</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">1317900</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001574"
      unitRef="USD">5674130</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <TVGN:ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001579"
      unitRef="USD">46622627</TVGN:ConversionOfConvertiblePromissoryNotesIntoCommonStockInConnectionWithMerger>
    <TVGN:IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts
      contextRef="From2024-01-012024-03-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001582"
      unitRef="USD">-3113309</TVGN:IssuanceOfCommonStockForNetLiabilitiesUponReverseRecapitalizationNetOfTransactionCosts>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001585">&lt;p id="xdx_803_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zkerNkuEYq8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82A_zvWj43xTF1V7"&gt;NATURE OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tevogen
Bio Holdings Inc. (f/k/a Semper Paratus Acquisition Corporation), a Delaware corporation (the &#x201c;Company&#x201d;), is a clinical-stage
specialty immunotherapy company harnessing the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies
for the treatment of infectious diseases, cancers, and neurological disorders. The Company&#x2019;s precision T cell technology platform,
ExacTcell, is a set of processes and methodologies to develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies
with proactively selected, precisely defined targets. The Company has completed a Phase 1 proof-of-concept trial for the first clinical
product of ExacTcell, TVGN 489, for the treatment of ambulatory, high-risk adult COVID-19 patients, and has other product candidates
in its pipeline.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024 (the &#x201c;Closing Date&#x201d;), pursuant to the agreement and plan of merger dated June 28, 2023 (the &#x201c;Merger
Agreement&#x201d;), by and among Semper Paratus Acquisition Corporation (&#x201c;Semper Paratus&#x201d;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#x201c;Merger Sub&#x201d;) SSVK Associates, LLC, (the &#x201c;Sponsor&#x201d;) Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#x201c;Tevogen Bio&#x201d;), and Dr. Ryan Saadi in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio with Tevogen Bio being the surviving company and a wholly owned subsidiary of the Company (the &#x201c;Merger,&#x201d;
and together with the other transactions contemplated by the Merger Agreement, the &#x201c;Business Combination&#x201d;), and Semper Paratus
was renamed Tevogen Bio Holdings Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the closing of the Business Combination (the &#x201c;Closing&#x201d;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately &lt;span id="xdx_905_ecustom--ExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhl9FPe3OPhl" title="Exchange ratio"&gt;4.85&lt;/span&gt; shares of Company common
stock for each share of Tevogen Bio common stock (the &#x201c;Exchange Ratio&#x201d;). See Note 4 for more information on the Business
Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held &lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240101__20240331__srt--TitleOfIndividualAxis__custom--TevogenBioMember_zEA80jFaGSh5" title="Equity holders percentage"&gt;90.9&lt;/span&gt;% of the outstanding shares
of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held &lt;span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240101__20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zQjT8fq4JfXk" title="Equity holders percentage"&gt;9.1&lt;/span&gt;% of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <TVGN:ExchangeRatio
      contextRef="AsOf2024-02-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001587"
      unitRef="USDPShares">4.85</TVGN:ExchangeRatio>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2024-01-012024-03-31_custom_TevogenBioMember"
      decimals="INF"
      id="Fact001589"
      unitRef="Pure">0.909</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2024-01-012024-03-31_custom_SemperParatusMember"
      decimals="INF"
      id="Fact001591"
      unitRef="Pure">0.091</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <TVGN:DevelopmentStageRisksAndLiquidityTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001593">&lt;p id="xdx_80C_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zbgRuV5EqCd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_82E_zwIsFmav7HG"&gt;DEVELOPMENT-STAGE RISKS AND LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has generally incurred losses and negative cash flows from operations since inception and had an accumulated deficit of
$&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zMy2obJYRxfa" title="Amount of accumulated undistributed earnings"&gt;88,392,895&lt;/span&gt;
as of March 31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant
sales from its product candidates currently in development. Management believes that cash of $&lt;span id="xdx_90A_eus-gaap--Cash_iI_c20240331_znGHeD1saMK9" title="Management cash"&gt;1,317,900&lt;/span&gt;
as of March 31, 2024, and $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zQzirfvaXBK1" title="Sale of preferred stock"&gt;2,000,000&lt;/span&gt;
received for the sale of Series A-1 Preferred Stock subsequent to March 31, 2024, is not sufficient to sustain planned operations
for 12 months from the issuance date of these unaudited consolidated financial statements. As a result, the Company has concluded
that substantial doubt exists about its ability to continue as a going concern for one year from the date that the unaudited
consolidated financial statements are issued. The accompanying unaudited consolidated financial statements have been prepared on a
going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of
recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this
uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years. These strategies
may include but are not limited to private placements of equity and/or debt, licensing and/or marketing arrangements, and public offerings
of equity and/or debt securities. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely
affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and clinical trials, and pursuing the Business Combination. The Company is subject to those
risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be
no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary
regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of
rapid technological change and is largely dependent on the services of its employees and consultants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:DevelopmentStageRisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001595"
      unitRef="USD">-88392895</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001597"
      unitRef="USD">1317900</us-gaap:Cash>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-03-31_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact001599"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001601">&lt;p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweFcfJCPe72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_821_z7Yxg4Jk1c6b"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of significant accounting policies included in the Company&#x2019;s annual financial statements that can be found in Exhibit 99.1
of the Company&#x2019;s Current Report on Form 8-K/A filed with the SEC on April 29, 2024 (the
&#x201c;Form 8-K&#x201d;), have not materially changed, except as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zGbPuBzg5CKl"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#x2019;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z2UVV4YCU6v4"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
areas that require management&#x2019;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zsweBwNQyFF3"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zJZFeTaEcaDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zPtwxjycLoh9"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_ztdxsUcE1y6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#x2019;s initial public
offering (the &#x201c;IPO&#x201d;) in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity&lt;/i&gt;
(&#x201c;ASC 815&#x201d;), and considering ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;). The
assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to
ASC 480 and meet all of the conditions for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own shares of common stock, among other conditions. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of
issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are
recognized as a non-cash loss on the consolidated statements of operations. Under these standards, the Company&#x2019;s private
placement warrants sold at the time of the IPO do not meet the criteria for equity classification and must be recorded as
liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification and must be recorded as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zOp0Gnh2gwmd"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unadjusted
    quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s
convertible promissory notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zLAFUKdBZV45" style="display: none"&gt;Schedule
of Fair Value Measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; font-weight: bold"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance"&gt;94,932,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense"&gt;159,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Derecognition upon conversion of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;(46,622,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance"&gt;39,297,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance"&gt;289,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance"&gt;28,142,865&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"&gt;70,229,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility"&gt;80&lt;/span&gt;%),
discount rate (&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate"&gt;35&lt;/span&gt;%
- &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate"&gt;36&lt;/span&gt;%),
and probability of a future liquidity event (&lt;span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event"&gt;85&lt;/span&gt;%
- &lt;span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event"&gt;95&lt;/span&gt;%).&lt;/span&gt; The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between levels during the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, the Company acquired private warrants the fair value of which increased by $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants"&gt;31,973&lt;/span&gt;
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zTyrtDvrDzJk"&gt;Schedule
of Fair Values Of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; font-weight: bold"&gt;Balance at February 15, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;31,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending"&gt;60,973&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zSBy0zjFPzxa" style="display: none"&gt;Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in Active Markets &lt;br/&gt;
(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant Other Observable Inputs &lt;br/&gt;
(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant
Other Unobservable Inputs &lt;br/&gt;
(Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 38%; text-align: left"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;60,973&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between &lt;span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1667"&gt;75%&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;85%&lt;/span&gt;&lt;/span&gt;, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from &lt;span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years"&gt;0.5&lt;/span&gt; to &lt;span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years"&gt;10.0&lt;/span&gt; years, and a risk-free interest rate between &lt;span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage"&gt;4.3%&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage"&gt;5.3%&lt;/span&gt;. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock"&gt;2,000,000&lt;/span&gt; upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zuKunqOFiF5k"&gt;Net
Income (Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. &lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zaS2rj0QNrb1"&gt;Recently
Issued Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU No. 2020-06, Debt &#x2013; &lt;i&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity &lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/i&gt;(&#x201c;ASU
2023-07&#x201d;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001603">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdfl9mKZ3uKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zGbPuBzg5CKl"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited consolidated financial statements of the Company are presented in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations
of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification
(&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of a normal
recurring nature, (which consist primarily of accruals, estimates, and assumptions that impact the consolidated financial statements)
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The
accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and Management&#x2019;s
Discussion and Analysis of Financial Condition and Results of Operations of Tevogen Bio filed as Exhibits 99.1 and 99.2 to the Form 8-K. The interim results for the period presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2024, or for any future interim periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-03-31" id="Fact001605">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zWHZLGZuOfea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z2UVV4YCU6v4"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts
of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of
revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
areas that require management&#x2019;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and
development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-03-31" id="Fact001607">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zY5YyGsQ40Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zsweBwNQyFF3"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001609">&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zJZFeTaEcaDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zPtwxjycLoh9"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in one segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001611">&lt;p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_ztdxsUcE1y6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#x2019;s initial public
offering (the &#x201c;IPO&#x201d;) in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity&lt;/i&gt;
(&#x201c;ASC 815&#x201d;), and considering ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;). The
assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to
ASC 480 and meet all of the conditions for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own shares of common stock, among other conditions. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of
issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are
recognized as a non-cash loss on the consolidated statements of operations. Under these standards, the Company&#x2019;s private
placement warrants sold at the time of the IPO do not meet the criteria for equity classification and must be recorded as
liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification and must be recorded as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001613">&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zUHErtxseLdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zOp0Gnh2gwmd"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset
or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unadjusted
    quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company
believes that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of
these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the
Company elected the fair value option to reduce accounting complexity and private warrants after the Merger. Such fair value
measurements are Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s
convertible promissory notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zLAFUKdBZV45" style="display: none"&gt;Schedule
of Fair Value Measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; font-weight: bold"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance"&gt;94,932,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense"&gt;159,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Derecognition upon conversion of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;(46,622,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance"&gt;39,297,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance"&gt;289,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance"&gt;28,142,865&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"&gt;70,229,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zEcKnCyF5Io6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible
promissory notes prior to the Merger included volatility (&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_zhB8KUKgYsed" title="Volatility"&gt;80&lt;/span&gt;%),
discount rate (&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_c20240101__20240331__srt--RangeAxis__srt--MinimumMember_zhKXrMAB1Nq" title="Discount rate"&gt;35&lt;/span&gt;%
- &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_pid_dp_uPure_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zszG5xp2YdGa" title="Discount rate"&gt;36&lt;/span&gt;%),
and probability of a future liquidity event (&lt;span id="xdx_906_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MinimumMember_zAgeMVk1TVtd" title="Percentage of probability of liquidity event"&gt;85&lt;/span&gt;%
- &lt;span id="xdx_907_ecustom--PercentageOfProbabilityOfLiquidityEvent_iI_pid_dp_c20240331__srt--RangeAxis__srt--MaximumMember_zjvrQpXvZTc" title="Percentage of probability of liquidity event"&gt;95&lt;/span&gt;%).&lt;/span&gt; The Company used its stock price on the Closing Date to determine the fair value for the conversion derecognition
of the convertible promissory notes on the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between levels during the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, the Company acquired private warrants the fair value of which increased by $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__srt--RangeAxis__srt--MaximumMember_zlSvr0XSpgAe" title="Change in fair value of warrants"&gt;31,973&lt;/span&gt;
between the Closing Date and March 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a
roll-forward of the aggregate fair values of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zTyrtDvrDzJk"&gt;Schedule
of Fair Values Of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; font-weight: bold"&gt;Balance at February 15, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;31,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending"&gt;60,973&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zXzok5cC4Qd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zSBy0zjFPzxa" style="display: none"&gt;Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in Active Markets &lt;br/&gt;
(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant Other Observable Inputs &lt;br/&gt;
(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant
Other Unobservable Inputs &lt;br/&gt;
(Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 38%; text-align: left"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;60,973&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zepT0P8c8RE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s nonrecurring fair value measurements
consist of Series A and Series B Preferred Stock. Such fair value measurements are Level 3 inputs. The Company determined the fair value
of Series A Preferred Stock using a Monte Carlo simulation. Key inputs utilized in the Monte Carlo simulation to estimate fair value of
Series A Preferred Stock included a range of volatility between &lt;span id="xdx_908_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmjTJPZQCl5c" title="Alternative investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1667"&gt;75%&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_901_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJYKzWtU9Lk4" title="Alternative investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;85%&lt;/span&gt;&lt;/span&gt;, a holding period to a deemed liquidation event, as defined
in the Series A Preferred Stock agreement, ranging from &lt;span id="xdx_902_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MinimumMember_zeDNDpelQS4a" title="Range in years"&gt;0.5&lt;/span&gt; to &lt;span id="xdx_90E_ecustom--RangeInYears_iI_dtY_c20240331__srt--RangeAxis__srt--MaximumMember_z4kz2OJvPC18" title="Range in years"&gt;10.0&lt;/span&gt; years, and a risk-free interest rate between &lt;span id="xdx_90D_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgS5PiddRKj5" title="Risk-free interest rate percentage"&gt;4.3%&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3yVHGQRqn47" title="Risk-free interest rate percentage"&gt;5.3%&lt;/span&gt;. The Company
determined the fair value of Series B Preferred Stock based on the stated redemption value. The difference between the cash received of
$&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnAXPFMa0se" title="Sale of preferred stock"&gt;2,000,000&lt;/span&gt; upon issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense
on the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001615">&lt;p id="xdx_894_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zQccBYpZPxi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zLAFUKdBZV45" style="display: none"&gt;Schedule
of Fair Value Measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; font-weight: bold"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPGBRh1dTMH9" style="width: 14%; text-align: right" title="Fair value beginning balance"&gt;94,932,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1d352fc05il" style="text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YDGMXe4Pc" style="text-align: right" title="Accrued interest expense"&gt;159,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMTopcWrpJlf" style="text-align: right" title="Change in fair value"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Derecognition upon conversion of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z75iEpCTxwze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;(46,622,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqZWYTyScFI" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoq7C3SXjSta" style="text-align: right" title="Fair value beginning balance"&gt;39,297,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zholV7FPnlg6" style="text-align: right" title="Initial fair value at issuance"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJ3qMQ9li4m9" style="text-align: right" title="Initial fair value at issuance"&gt;289,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7cV9hm5bUA4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial fair value at issuance"&gt;28,142,865&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvyt48NT2i6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value ending balance"&gt;70,229,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001617"
      unitRef="USD">94932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001621"
      unitRef="USD">159305</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001623"
      unitRef="USD">-48468678</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable
      contextRef="From2024-01-012024-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001625"
      unitRef="USD">-46622627</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001629"
      unitRef="USD">39297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001631"
      unitRef="USD">2500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001633"
      unitRef="USD">289135</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001635"
      unitRef="USD">28142865</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001637"
      unitRef="USD">70229000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001639"
      unitRef="Pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="From2024-01-012024-03-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001641"
      unitRef="Pure">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="From2024-01-012024-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001643"
      unitRef="Pure">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <TVGN:PercentageOfProbabilityOfLiquidityEvent
      contextRef="AsOf2024-03-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001645"
      unitRef="Pure">0.85</TVGN:PercentageOfProbabilityOfLiquidityEvent>
    <TVGN:PercentageOfProbabilityOfLiquidityEvent
      contextRef="AsOf2024-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001647"
      unitRef="Pure">0.95</TVGN:PercentageOfProbabilityOfLiquidityEvent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31_srt_MaximumMember"
      decimals="0"
      id="Fact001649"
      unitRef="USD">31973</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001651">&lt;p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zFiBX3xqpDn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zTyrtDvrDzJk"&gt;Schedule
of Fair Values Of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; font-weight: bold"&gt;Balance at February 15, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240216__20240331_zD47Ai1ydV7i" style="width: 14%; text-align: right" title="Balance, beginning"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20240216__20240331_zXoCrr7VYwvh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value"&gt;31,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240216__20240331_zw8pUVlDY3G2" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending"&gt;60,973&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-02-15"
      decimals="0"
      id="Fact001653"
      unitRef="USD">29000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-162024-03-31"
      decimals="0"
      id="Fact001655"
      unitRef="USD">31973</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001657"
      unitRef="USD">60973</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001659">&lt;p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zu1PS5gkiT1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring
basis at March 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zSBy0zjFPzxa" style="display: none"&gt;Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in Active Markets &lt;br/&gt;
(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant Other Observable Inputs &lt;br/&gt;
(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant
Other Unobservable Inputs &lt;br/&gt;
(Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 38%; text-align: left"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMBzJOMJKhAa" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zuzxPaIe5Yg1" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zO0akqcGt334" style="width: 12%; text-align: right" title="Derivative warrant liabilities"&gt;60,973&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001665"
      unitRef="USD">60973</us-gaap:DerivativeLiabilitiesNoncurrent>
    <TVGN:RangeInYears
      contextRef="AsOf2024-03-31_srt_MinimumMember"
      id="Fact001671">P0Y6M</TVGN:RangeInYears>
    <TVGN:RangeInYears
      contextRef="AsOf2024-03-31_srt_MaximumMember"
      id="Fact001673">P10Y</TVGN:RangeInYears>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001675"
      unitRef="Pure">4.03</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001677"
      unitRef="Pure">5.03</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001679"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001681">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zlZTZxMxZUde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zuKunqOFiF5k"&gt;Net
Income (Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average common stock outstanding
during the period. The Company determined that each outstanding share of preferred stock and restricted common stock would
participate in earnings available to common stockholders but would not participate in losses. The Company computes diluted net income (loss) per share by dividing the net
income (loss) by the sum of the weighted average number of common stock outstanding during the period, plus the potential dilutive
effects, if any, of potentially dilutive securities. &lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001683">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAOkrU2az03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zaS2rj0QNrb1"&gt;Recently
Issued Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU No. 2020-06, Debt &#x2013; &lt;i&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity &lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/i&gt;(&#x201c;ASU
2023-07&#x201d;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information
on the chief operating decision maker and disclosures for entities with a single reportable segment. Additionally, the amendments enhance
interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and
contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-07 to have a material impact
on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001685">&lt;p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_ztQqt7jA75tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_82B_zB9TrLOIyD8d"&gt;BUSINESS COMBINATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors,
including: (i) former Tevogen Bio equityholders and holders of convertible promissory notes owned approximately &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zrf7MrCxxDz9" title="Ownership percentage"&gt;91.0&lt;/span&gt;% of the Company
following the Merger; (ii) Former Tevogen Bio directors constituted the majority (six of seven) of the directors of the Company following
the Merger; and (iii) former Tevogen Bio management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire the net assets of Semper Paratus. As a
result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date fair value in the consolidated financial
statements and the reported operating results prior to the Merger are those of Tevogen Bio. Immediately after the Merger, there were
&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331_zWmMoVzxq46g" title="Common stock, shares outstanding"&gt;164,614,418&lt;/span&gt; shares of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_z0UveVE1Z4Rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the net liabilities acquired in the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zoftPmTp3y0f" style="display: none"&gt;SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240214_zc4CykHVrO3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 14, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_zV26RK6wEI0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;229,328&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z9ExmMKMHUbh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from Sponsor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_z0ckBmta55U1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses and other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zRRY1Onz2Gog" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zmkHDZ64vAS" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,269,126&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_msBCRIAzgn3_zQHvgagApXC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_iNI_di_msBCRIAzgn3_zPIFDH3dmFli" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maTNLAPz196_zg7P9MDwAob7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total net liabilities acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,654,653&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PlusMergerTransactionCostsLimitedToCashAcquired_iI_maTNLAPz196_z5xGmUJppzPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Plus: Merger transaction costs limited to cash acquired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(229,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalNetLiabilitiesAcquiredPlusTransactionCosts_iTI_mtTNLAPz196_zvfeqz28WXeh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net liabilities acquired plus transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,883,981&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z1QziPvFDykb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
transaction costs of $&lt;span id="xdx_900_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_zIOzuNWVhvIl" title="Transaction costs"&gt;7,728,681&lt;/span&gt;
were incurred in relation to the Merger up through the Closing Date, of which $&lt;span id="xdx_900_ecustom--TransactionCosts_c20240214__20240214_zJWnZosVmtHi" title="Transaction costs"&gt;229,328 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were
charged directly to equity to the extent of the cash received from the Merger with the balance of $&lt;span id="xdx_90D_ecustom--TransactionCost_c20240101__20240331_zE1kFlO5byR4" title="Charged expense"&gt;7,499,353&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;charged
to Merger transaction costs for the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_z1u7azhHCoNa" title="Earnout shares"&gt;24,500,000&lt;/span&gt;
shares of common stock (&#x201c;Earnout Shares&#x201d;) if the volume-weighted average price (the &#x201c;VWAP&#x201d;) of the Company&#x2019;s
common stock reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5,
Earnout Shares, for further details of the earnout arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor. The issuance date fair value of the Series B
Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. See Note 9 for additional
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-03-31_custom_TevogenBioMember"
      decimals="INF"
      id="Fact001687"
      unitRef="Pure">0.910</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001689"
      unitRef="Shares">164614418</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001691">&lt;p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_z0UveVE1Z4Rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the net liabilities acquired in the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zoftPmTp3y0f" style="display: none"&gt;SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240214_zc4CykHVrO3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February 14, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_zV26RK6wEI0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;229,328&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z9ExmMKMHUbh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from Sponsor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_z0ckBmta55U1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses and other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zRRY1Onz2Gog" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zmkHDZ64vAS" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,269,126&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_msBCRIAzgn3_zQHvgagApXC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities_iNI_di_msBCRIAzgn3_zPIFDH3dmFli" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maTNLAPz196_zg7P9MDwAob7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total net liabilities acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,654,653&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PlusMergerTransactionCostsLimitedToCashAcquired_iI_maTNLAPz196_z5xGmUJppzPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Plus: Merger transaction costs limited to cash acquired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(229,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalNetLiabilitiesAcquiredPlusTransactionCosts_iTI_mtTNLAPz196_zvfeqz28WXeh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net liabilities acquired plus transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,883,981&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001693"
      unitRef="USD">229328</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001695"
      unitRef="USD">158819</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001697"
      unitRef="USD">2501</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001699"
      unitRef="USD">96175</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001701"
      unitRef="USD">1269126</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001703"
      unitRef="USD">1651000</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001705"
      unitRef="USD">29000</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDerivativeWarrantLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001707"
      unitRef="USD">-2654653</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <TVGN:PlusMergerTransactionCostsLimitedToCashAcquired
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001709"
      unitRef="USD">-229328</TVGN:PlusMergerTransactionCostsLimitedToCashAcquired>
    <TVGN:TotalNetLiabilitiesAcquiredPlusTransactionCosts
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001711"
      unitRef="USD">-2883981</TVGN:TotalNetLiabilitiesAcquiredPlusTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact001713"
      unitRef="USD">7728681</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <TVGN:TransactionCosts
      contextRef="From2024-02-142024-02-14"
      decimals="0"
      id="Fact001715"
      unitRef="USD">229328</TVGN:TransactionCosts>
    <TVGN:TransactionCost
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001717"
      unitRef="USD">7499353</TVGN:TransactionCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001719"
      unitRef="Shares">24500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <TVGN:EarnoutSharesDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001721">&lt;p id="xdx_802_ecustom--EarnoutSharesDisclosureTextBlock_zezZHVWR3rTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_821_ze9t1JFAlNOg"&gt;EARNOUT SHARES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Closing, former holders of Tevogen Bio common stock may receive up to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zF6pEB5Y4MC6" title="Earnout shares"&gt;20,000,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnout
Shares in tranches of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zSyvwVMMBLbc" title="Earnout shares"&gt;6,666,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zIs0VCfutmub" title="Earnout shares"&gt;6,666,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zk6lHxtoD50h" title="Earnout shares"&gt;6,666,666 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the
Company&#x2019;s common stock is greater or equal to
$&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHKG1bgeCYN3" title="Shares issued, price per share"&gt;15.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
$&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOvg7oReEA0a" title="Shares issued, price per share"&gt;17.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPDwtSTZV8bd" title="Shares issued, price per share"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, &lt;span id="xdx_902_ecustom--EarnoutSharesTradingDaysDescription_c20240101__20240331__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zNkPNJJTyhq9" title="Earnout shares trading days description"&gt;over
any twenty trading days within any thirty consecutive day trading period during the three-year period after the
Closing.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#x2019;s three earnout tranches
are for &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zKessTEbQwKa" title="Earnout shares"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zwIsXdW0uRpf" title="Earnout shares"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zLLVCklvlkle" title="Earnout shares"&gt;1,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of common stock, for an aggregate of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__srt--TitleOfIndividualAxis__custom--SponsorsMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zUewsBnPcgGe" title="Earnout shares"&gt;4,500,000&lt;/span&gt; shares across the entire Sponsor earnout.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Earnout Shares are a form of dividend for holders of Tevogen Bio common stock, and the Earnout Shares earnable by the Sponsor are treated
as contingent consideration in a reverse recapitalization. In accordance with ASC 815, the Earnout Shares were considered to be indexed
to the Company&#x2019;s common stock and are classified within permanent equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:EarnoutSharesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001723"
      unitRef="Shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001725"
      unitRef="Shares">6666667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001727"
      unitRef="Shares">6666667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001729"
      unitRef="Shares">6666666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001731"
      unitRef="USDPShares">15.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001733"
      unitRef="USDPShares">17.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001735"
      unitRef="USDPShares">20.00</us-gaap:SharesIssuedPricePerShare>
    <TVGN:EarnoutSharesTradingDaysDescription
      contextRef="From2024-01-012024-03-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember"
      id="Fact001737">over
any twenty trading days within any thirty consecutive day trading period during the three-year period after the
Closing.</TVGN:EarnoutSharesTradingDaysDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001739"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact001741"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="INF"
      id="Fact001743"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_custom_SponsorsMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001745"
      unitRef="Shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001747">&lt;p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zkfxlxCibSS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_821_zlKXu5pkRWzc"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zllsvmfRvbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z1XStT9irsL4" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240331_zCNwgiFUWVxh" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231__srt--RestatementAxis__custom--ReverseRecapitalizationMember_z9vhWj64T8g6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December, 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedProfessionalServiceFeesCurrent_iI_maALCzC3I_zLX4Kx1CaUm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,337,588&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;976,301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_z1JlnIguFiji" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;227,246&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zBj95Ne7Kmxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,564,834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zA14P3pBJgah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001749">&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zllsvmfRvbu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z1XStT9irsL4" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240331_zCNwgiFUWVxh" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231__srt--RestatementAxis__custom--ReverseRecapitalizationMember_z9vhWj64T8g6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December, 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedProfessionalServiceFeesCurrent_iI_maALCzC3I_zLX4Kx1CaUm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,337,588&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;976,301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_z1JlnIguFiji" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;227,246&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zBj95Ne7Kmxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,564,834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <TVGN:AccruedProfessionalServiceFeesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001751"
      unitRef="USD">1337588</TVGN:AccruedProfessionalServiceFeesCurrent>
    <TVGN:AccruedProfessionalServiceFeesCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001752"
      unitRef="USD">976301</TVGN:AccruedProfessionalServiceFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001754"
      unitRef="USD">227246</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001755"
      unitRef="USD">120149</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001757"
      unitRef="USD">1564834</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ReverseRecapitalizationMember"
      decimals="0"
      id="Fact001758"
      unitRef="USD">1096450</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:MortgageNotesPayableDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001760">&lt;p id="xdx_80A_eus-gaap--MortgageNotesPayableDisclosureTextBlock_z6fM0BTC6wjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_82F_zaNShb19JN88"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#x201c;Polar&#x201d;) for which the proceeds were to be used for working capital purposes by Semper Paratus with
an outstanding balance of $&lt;span id="xdx_90D_ecustom--WorkingCapital_iI_c20240331_z2rd1NgbhOi5"&gt;1,651,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
the Closing Date and remain outstanding at March 31, 2024. The notes payable do not accrue interest. The outstanding balance of the notes was required to be repaid in full within five business days of the Merger, and
the Company is therefore in default of its obligations at March 31, 2024. The notes&#x2019; default provisions require the Sponsor to transfer
a certain number of its own shares to Polar on a monthly basis until the default is cured, subject to an aggregate cap, but do not require
the Company to transfer any shares or pay any amounts to Polar. Polar waived the Sponsor&#x2019;s requirement to transfer shares with respect
to the initial month of default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MortgageNotesPayableDisclosureTextBlock>
    <TVGN:WorkingCapital
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001761"
      unitRef="USD">1651000</TVGN:WorkingCapital>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001763">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1Qm76faae74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_82F_zQsBKeqcG9T6"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#x201c;2024 Plan&#x201d;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). Each restricted stock unit (&#x201c;RSU&#x201d;)
award granted under the 2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into
an award under the 2024 Plan with respect to the common stock of the Company. Such converted awards remain subject to the same terms
and conditions as set forth under the applicable award agreement prior to the Closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the 2024 Plan, the Company is authorized to grant awards up to an aggregate &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember_zotpVhPc43Tl" title="Granted awards shares"&gt;40,000,000&lt;/span&gt;
shares of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, restricted stock, restricted
stock units, and other equity-based awards. As of March 31, 2024, awards for &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zYPiJh01P4Zc" title="Granted awards shares"&gt;20,651,046&lt;/span&gt;
shares remained available to be granted under the 2024 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#x201c;Performance-Based RSUs&#x201d;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company issued an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z9bIoNHLNVW4"&gt;19,348,954 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RSUs
under the 2024 Plan to the Company&#x2019;s Chief Executive Officer, Dr. Ryan Saadi (the &#x201c;Special RSU Award&#x201d;). Such RSUs
immediately converted into shares of restricted common stock (&#x201c;Restricted Stock&#x201d;), the restrictions on which lapse in
four equal annual installments beginning on February 14, 2031 (&#x201c;Vesting Period&#x201d;). Pursuant to the terms of the Special
RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged,
hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock in the
event he departs the Company. The fair value per share for the Special RSU Award was determined to be $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeb7T8TzId62"&gt;4.51 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share, equivalent to the Company&#x2019;s stock price on the Closing Date, resulting in a total grant date fair value of $&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zmWTaIEjNy61"&gt;87,263,783&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In accordance with ASC 718, &lt;i&gt;Compensation &#x2013; Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;), the Company will recognize
compensation expense on a straight-line basis from the Closing Date until the completion of the Vesting Period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zdpajvJt0qTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
Stock and RSU activity was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zhJqhOvAGR6l" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Service-Based Restricted Stock&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Performance-Based RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Nonvested as of January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z83uWATEILW1" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zu0LhFu4Aasj" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaujT7apMUpl" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning"&gt;10,900,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zsyxDlVNXEGl" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;2.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z9yU478s4eg8" style="text-align: right" title="Nonvested Shares, Granted"&gt;19,348,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zbAsZYkbhM2f" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;4.51&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1wIbOm1tbYh" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYg3gbr3SUyg" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zyx6Tm6CnHce" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zoIvjh7wYkxd" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zFAIDCc7Y2K" style="text-align: right" title="Nonvested Shares, Vested"&gt;(7,148,506&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zB1hX4HVoBPf" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;2.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z1p6P8RsdBzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zPUaRSuSVK6l" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zGGyRtxUb7B4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z7ISujfViPa9" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested as of March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOi2SXcJII9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending"&gt;19,348,954&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zS1RixakFqQ3" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;4.51&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zN0k23fzW3vj" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending"&gt;3,751,622&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlPecO79tg4" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;3.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zH39E8Sq4aRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYIPCDMfcVok" title="Compensation cost recognized"&gt;25,233,487&lt;/span&gt; was recognized
for the Performance-Based RSUs, which will be issued and outstanding after March 31, 2024. There was $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyBQiB0pbdsd" title="Unrecognized compensation cost"&gt;86,164,020&lt;/span&gt; of unrecognized compensation cost related to Restricted Stock as
of March 31, 2024 which will be expensed over a weighted average period of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyVejtu9QN68" title="Weighted average period"&gt;9.9&lt;/span&gt; years. There was $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znWueLWMrKP2" title="Unrecognized compensation cost"&gt;7,104,643&lt;/span&gt; of unrecognized compensation
cost related to Performance-Based RSUs as of March 31, 2024 which will be expensed over a weighted average period of &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zLJSwvfiUEO7" title="Weighted average period"&gt;1.2&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zC9fXNTzWGk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zXFl7uLL0Hs7" style="display: none"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240331_zoqt4oqEtHwc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
    months ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDfPraaNw6Qe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19,735,896&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKiaDPHxJTql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,597,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z2AeX3C1J044" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26,333,249&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zJW6Jpols79i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_dxL_c20230101__20230331_zSFgaGmTfXI7" title="Compensation cost recognized::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;No&lt;/span&gt;&lt;/span&gt;
stock-based compensation expense was recognized during the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember"
      decimals="INF"
      id="Fact001765"
      unitRef="Shares">40000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_IncentivePlanMember"
      decimals="INF"
      id="Fact001767"
      unitRef="Shares">20651046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001768"
      unitRef="Shares">19348954</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001769"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">87263783</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001772">&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zdpajvJt0qTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
Stock and RSU activity was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zhJqhOvAGR6l" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Service-Based Restricted Stock&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Performance-Based RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Nonvested as of January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z83uWATEILW1" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zu0LhFu4Aasj" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaujT7apMUpl" style="width: 11%; text-align: right" title="Nonvested Shares, Beginning"&gt;10,900,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zsyxDlVNXEGl" style="width: 11%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;2.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z9yU478s4eg8" style="text-align: right" title="Nonvested Shares, Granted"&gt;19,348,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zbAsZYkbhM2f" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;4.51&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1wIbOm1tbYh" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYg3gbr3SUyg" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zyx6Tm6CnHce" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zoIvjh7wYkxd" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zFAIDCc7Y2K" style="text-align: right" title="Nonvested Shares, Vested"&gt;(7,148,506&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zB1hX4HVoBPf" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;2.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z1p6P8RsdBzk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zPUaRSuSVK6l" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zGGyRtxUb7B4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z7ISujfViPa9" style="padding-bottom: 1.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested as of March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOi2SXcJII9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending"&gt;19,348,954&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zS1RixakFqQ3" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;4.51&lt;/td&gt;&lt;td style="border-right: Black 1.5pt solid; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zN0k23fzW3vj" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Ending"&gt;3,751,622&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20240331__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlPecO79tg4" style="padding-bottom: 2.5pt; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;3.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001778"
      unitRef="Shares">10900128</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001780"
      unitRef="USDPShares">2.97</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001782"
      unitRef="Shares">19348954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001784"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001794"
      unitRef="Shares">7148506</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001796"
      unitRef="USDPShares">2.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-03-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001806"
      unitRef="Shares">19348954</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-03-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001808"
      unitRef="USDPShares">4.51</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-03-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001810"
      unitRef="Shares">3751622</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-03-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001812"
      unitRef="USDPShares">3.19</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">25233487</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">86164020</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember"
      id="Fact001818">P9Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-03-31_custom_PerformanceBasedRSUsMember"
      decimals="0"
      id="Fact001820"
      unitRef="USD">7104643</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-03-31_custom_PerformanceBasedRSUsMember"
      id="Fact001822">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001824">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zC9fXNTzWGk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zXFl7uLL0Hs7" style="display: none"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240331_zoqt4oqEtHwc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
    months ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDfPraaNw6Qe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19,735,896&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKiaDPHxJTql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,597,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z2AeX3C1J044" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;26,333,249&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001826"
      unitRef="USD">19735896</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001828"
      unitRef="USD">6597353</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001830"
      unitRef="USD">26333249</us-gaap:ShareBasedCompensation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001834">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztGFWxBTy8kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_826_zBea3ZTkddpg"&gt;STOCKHOLDERS&#x2019; DEFICIT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;As of February 15, 2024, the Company&#x2019;s
common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#x201c;TVGN&#x201d; and &#x201c;TVGNW&#x201d;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;As of March 31, 2024, the Company had &lt;span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240331_zFhYlpmWMJke" title="Common shares, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zcJLFKJFOmM5" title="Common shares, shares outstanding"&gt;164,614,418&lt;/span&gt;&lt;/span&gt;
shares of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested or are not subject
to repurchase are considered issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zY5jL67Rs2Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Below is a reconciliation of shares of common stock issued and outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zZo8Qih3N086"&gt;SCHEDULE
OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total shares of common stock legally issued and outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20240331_zsMZdC6rjITa" title="Common shares, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zjYfmLv5o8Ea" title="Common shares, shares outstanding"&gt;164,614,418&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Plus: Shares to be issued:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares issuable to Polar &lt;span&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--SharesToBeIssuedOnSharesIssuable_iI_c20240331_fKGEp_zMeI2mD6dNV4" style="text-align: right" title="Shares issuable to Polar"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Shares issuable to Polar"&gt;&lt;p id="xdx_983_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20240331_fKGIp_zXBFTzzS3Bq7" style="margin: 0" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"&gt;7,148,506&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: Shares subject to future vesting:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Issuance of restricted common stock subject to forfeiture
    &lt;span&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20240331_fKGMp_z5jRYgf928xj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"&gt;(19,348,954&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total shares issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20240331_zU2AIRwtMn07" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"&gt;153,913,970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F0E_zSFUsb3mIPXf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zVLlsyBIhf2g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F0A_z3CtrESEccf7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;(b)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt; &lt;p id="xdx_F18_zIQMiBkzr678" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0F_zHMvLEAIjjn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zdgGRYz4aBu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zNrP1QjuNk07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#x2019;s
common stockholders received shares of the Company&#x2019;s common stock in an amount determined by application of the Exchange Ratio,
as discussed in Note 1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331_zYPXBdzcNdI9" title="Preferred shares, shares authorized"&gt;20,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331_zESzwfjnzTsa" title="Preferred shares, par value"&gt;0.0001&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
A Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;I&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n
March 2024, the Company authorized and issued &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1TQsskKFFYe" title="Preferred stock, shares authorized"&gt;2,000&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR1sAf5wyTPj" title="Preferred stock, shares issued"&gt;500&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares,
respectively, of Series A Preferred Stock (the &#x201c;Series A&#x201d;) to an investor at a price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUYzddNAGNmk"&gt;4,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share (the &#x201c;Series A Original Issue Price&#x201d;), for gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCJnWajq7eXj" title="Proceeds from issuance of preferred stock"&gt;2.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt; The Company recorded an expense of $&lt;span id="xdx_904_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zn3WtQPCy6hh" title="Loss on preferred stock issuance"&gt;799,990&lt;/span&gt; in its consolidated statements of operations related to issuance of the Series A equal
to the fair value of the Series A when issued of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW0vScNOJjhf" title="Price per share"&gt;5,600&lt;/span&gt; per share less the purchase price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zWezmWpjHre"&gt;4,000&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of &lt;span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuaTZfQiWyF5" title="Dividend rate, percentage"&gt;5&lt;/span&gt;%
per annum per share on &lt;span id="xdx_90B_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWbqiruCDfd" title="Dividend variable rate, description"&gt;the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the
&#x201c;Series A Accruing Dividends&#x201d;)&lt;/span&gt;. These dividends become payable when and if declared by the Company. The Series A
Preferred Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A ranks senior to common stock and Series B Preferred Stock (the &#x201c;Series B&#x201d;) in liquidation priority. In the
event of a liquidation of the Company, or certain deemed liquidation events, the Series A is redeemable for a price
equal to the greater of the Series A Original Issue Price plus all Series A Accruing Dividends that are unpaid through the
redemption date, or such amount that would have been payable had the Series A converted into shares of
common stock immediately before the liquidation or deemed liquidation event.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A does not have any voting rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Redemption&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence
of a deemed liquidation event. The Company is entitled to redeem that Series A at a price equal to the Series A Original
Issue Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the VWAP of the Company&#x2019;s common stock exceeds
$&lt;span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCWwsmAWOVz6" title="Redemption per share"&gt;5.00&lt;/span&gt; per share for &lt;span id="xdx_905_eus-gaap--PreferredStockRedemptionTerms_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7UH72EETIwl" title="Redemption term"&gt;the twenty days immediately prior to the Company&#x2019;s call election&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal
to the Series A Original Issue Price divided by the Series A Conversion Price, which is initially $&lt;span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20240327__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTbEsICcDl5l" title="Conversion price"&gt;4.00&lt;/span&gt; per share and is subject to standard
antidilution adjustments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
A-1 Preferred Stock &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Series A investor covering the
issuance of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zXZHxPobwsVf" title="Stock issuance"&gt;600&lt;/span&gt; shares of Series A-1 Preferred Stock for a gross purchase price of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zvjrGPPmFNRd" title="Stock issuance, value"&gt;6,000,000&lt;/span&gt;. &lt;span id="xdx_901_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zJ5kIXmKRtdc" title="Dividend variable rate, description"&gt;The terms of the Series A-1 Preferred
Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum and the Series
A-1 Issuance Price is defined as $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zfdbaJOfPvO9"&gt;10,000&lt;/span&gt; per share.&lt;/span&gt; As of March 31, 2024, the investor had paid a non-refundable deposit of $&lt;span id="xdx_90A_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zFh4aSmduqa2" title="Non refundable amount"&gt;200,000&lt;/span&gt;
towards the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
B Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the
Sponsor assuming liabilities and obligations (&#x201c;Assumed Liabilities&#x201d;) of Semper Paratus and Tevogen Bio. On March 15,
2024, &lt;span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8YcxbKTk1M9" title="Conversion of certain liabilities into Series B preferred stock, shares"&gt;3,613&lt;/span&gt;
shares of Series B were issued in return for the assumption of $&lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWozjgcIKip6" title="Conversion of certain liabilities into Series B preferred stock"&gt;3,613,000&lt;/span&gt;
of liabilities. As these liabilities were unpaid and the Company was not legally released by the creditors, &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
liabilities were not extinguished and&lt;/span&gt; remain on the Company&#x2019;s balance sheets at March 31, 2024. The issuance date fair
value of the Series B was determined to be $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240315__20240315__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zC4nA0EymVBi" title="Conversion of certain liabilities into Series B preferred stock"&gt;3,613,000&lt;/span&gt;
and was recorded within Merger transaction costs in the consolidated statements of operations. The Series B is classified as
permanent equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of Series B are entitled to receive cumulative dividends at the Series B Dividend Rate, which accrue quarterly on the basis of a
360-day year and accrue whether or not declared by the Company provided that to the extent the Assumed Liabilities are outstanding,
any dividend(s) will be paid by the Company on behalf of the Sponsor to the creditors first. &lt;span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z46y9HrWiFE9" title="Dividend variable rate, description"&gt;The
Series B Dividend Rate is initially 3.25% per quarter, increases by 0.25% on each 30-day anniversary of the Initial Dividend Date
(Defined below), and capped at 7.5% per quarter.&lt;/span&gt; The &#x201c;Initial Dividend Date&#x201d; is defined as 35 days after the
initial issuance date of the Series B. Subsequent dividends are due and payable on the quarterly anniversary of the initial issuance
date, or if that date is not a business day, due and payable on the next succeeding business day. Series B dividends payable are
calculated as the Dividend Rate multiplied by the Series B Issue Price of $&lt;span id="xdx_90F_eus-gaap--DividendsPayableAmountPerShare_iI_c20240331_zqMcpNZytuxa" title="Dividends payable per share"&gt;1,000&lt;/span&gt;
per share. Series B dividends are payable whether or not declared by the Company, and are recorded within accounts payable of the
consolidated balance sheets as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Series B Preferred Stock ranks senior to common stock and junior to Series A in liquidation priority. In the event of
a liquidation of the Company, the Series B is redeemable for a price equal to the aggregate amount of the liabilities
assumed by the Sponsor following the Closing, which was $&lt;span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyQiao17idza" title="Redemption per share"&gt;1,000&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series B does not have any voting rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Redemption&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series B are not entitled to redeem their shares outside of the liquidation of the Company. The Company is
entitled to redeem the Series B at a price equal to the Series B Issue Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series B Preferred Stock do not contain any conversion rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember_zfYPWcrbQ0pe" title="Number of warrants issued"&gt;17,975,000&lt;/span&gt; warrants initially issued by Semper Paratus in November 2021, comprising &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zlwWEOh4MHud" title="Number of warrants issued"&gt;17,250,000&lt;/span&gt; public warrants sold in the
IPO and &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMSTg0CyeeL9" title="Number of warrants issued"&gt;725,000&lt;/span&gt; warrants issued in a concurrent private placement, were assumed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Public
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public warrants have an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z8zqCNTi4dk1" title="Exercise price"&gt;11.50&lt;/span&gt;
per share, became exercisable on &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zH1p7LRjbER7" title="Exercisable date"&gt;March
15, 2024&lt;/span&gt;, and will expire at 5:00 p.m., New York City time, on February 14, 2029, or earlier upon redemption or liquidation.
Warrant holders may, until such time as there is an effective registration statement and during any period when the Company has
failed to maintain an effective registration statement covering the shares of the Company&#x2019;s common stock issuable upon
exercise of the warrants, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section 3(a)(9) of the Securities
Act of 1933, as amended, or another exception. &lt;span id="xdx_90D_ecustom--WarrantsDescription_c20211101__20211130__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zSMe7Blb9Hpf" title="Warrants description"&gt;The
Company may redeem the public warrants if the Company&#x2019;s common stock equals or exceeds $18.00 per share for 20 trading days
within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption
to the holders of public warrants.&lt;/span&gt; As of March 31, 2024, there are &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zNO0OzvNYTYg" title="Number of warrants outstanding"&gt;17,250,000&lt;/span&gt;
public warrants outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Private
Placement Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the Sponsor or its permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders on a cashless
basis. As of March 31, 2024, there are &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfnAt6a825Vj" title="Number of warrants outstanding"&gt;725,000&lt;/span&gt; private placement warrants outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See Note 3 for additional information on the Company&#x2019;s
warrant accounting policy.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001836"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001838"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001840">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zY5jL67Rs2Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Below is a reconciliation of shares of common stock issued and outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zZo8Qih3N086"&gt;SCHEDULE
OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total shares of common stock legally issued and outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20240331_zsMZdC6rjITa" title="Common shares, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20240331_zjYfmLv5o8Ea" title="Common shares, shares outstanding"&gt;164,614,418&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Plus: Shares to be issued:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares issuable to Polar &lt;span&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--SharesToBeIssuedOnSharesIssuable_iI_c20240331_fKGEp_zMeI2mD6dNV4" style="text-align: right" title="Shares issuable to Polar"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Shares issuable to Polar"&gt;&lt;p id="xdx_983_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20240331_fKGIp_zXBFTzzS3Bq7" style="margin: 0" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"&gt;7,148,506&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: Shares subject to future vesting:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Issuance of restricted common stock subject to forfeiture
    &lt;span&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20240331_fKGMp_z5jRYgf928xj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"&gt;(19,348,954&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total shares issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20240331_zU2AIRwtMn07" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"&gt;153,913,970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F0E_zSFUsb3mIPXf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zVLlsyBIhf2g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F0A_z3CtrESEccf7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;(b)&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt; &lt;p id="xdx_F18_zIQMiBkzr678" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0F_zHMvLEAIjjn1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zdgGRYz4aBu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001842"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001844"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesOutstanding>
    <TVGN:SharesToBeIssuedOnSharesIssuable
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001846"
      unitRef="Shares">1500000</TVGN:SharesToBeIssuedOnSharesIssuable>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001848"
      unitRef="Shares">7148506</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001850"
      unitRef="Shares">-19348954</TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture>
    <TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001852"
      unitRef="Shares">153913970</TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001857"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001859"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001861"
      unitRef="Shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001863"
      unitRef="Shares">500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001864"
      unitRef="USDPShares">4000</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="-5"
      id="Fact001866"
      unitRef="USD">2000000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001868"
      unitRef="USD">799990</TVGN:LossOnPreferredStockIssuance>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001870"
      unitRef="USDPShares">5600</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001871"
      unitRef="USDPShares">4000</us-gaap:SharePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-03-262024-03-27_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001873"
      unitRef="Pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-03-262024-03-27_us-gaap_SeriesAPreferredStockMember"
      id="Fact001875">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the
&#x201c;Series A Accruing Dividends&#x201d;)</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-03-27_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001877"
      unitRef="USDPShares">5.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionTerms
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001879">the twenty days immediately prior to the Company&#x2019;s call election</us-gaap:PreferredStockRedemptionTerms>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-03-27_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001881"
      unitRef="USDPShares">4.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact001883"
      unitRef="Shares">600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">6000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember"
      id="Fact001887">The terms of the Series A-1 Preferred
Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum and the Series
A-1 Issuance Price is defined as $10,000 per share.</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact001888"
      unitRef="USDPShares">10000</us-gaap:SharePrice>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember"
      decimals="0"
      id="Fact001890"
      unitRef="USD">200000</TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance>
    <TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities
      contextRef="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001892"
      unitRef="USD">3613</TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities>
    <TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities
      contextRef="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001894"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities>
    <TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities
      contextRef="From2024-03-152024-03-15_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001896"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-01-012024-03-31_us-gaap_SeriesBPreferredStockMember"
      id="Fact001898">The
Series B Dividend Rate is initially 3.25% per quarter, increases by 0.25% on each 30-day anniversary of the Initial Dividend Date
(Defined below), and capped at 7.5% per quarter.</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001900"
      unitRef="USDPShares">1000</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001902"
      unitRef="USDPShares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-30_custom_SemperParatusMember"
      decimals="INF"
      id="Fact001904"
      unitRef="Shares">17975000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001906"
      unitRef="Shares">17250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001908"
      unitRef="Shares">725000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001910"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      id="Fact001912">2024-03-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <TVGN:WarrantsDescription
      contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      id="Fact001914">The
Company may redeem the public warrants if the Company&#x2019;s common stock equals or exceeds $18.00 per share for 20 trading days
within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption
to the holders of public warrants.</TVGN:WarrantsDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001916"
      unitRef="Shares">17250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001918"
      unitRef="Shares">725000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001920">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdq2OcXxCE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_829_zqHcsCJYp0Qc"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;i&gt;Transactions with Sponsor&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Pursuant to the Merger Agreement, the
Company incurred $&lt;span id="xdx_90D_eus-gaap--SponsorFees_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zGSzqMPEi0e7"&gt;2,000,000
&lt;/span&gt;in fees to the Sponsor for advisory services (the &#x201c;Sponsor Advisory Service Fee&#x201d;). In connection with the Merger and
thereafter, the Company and Sponsor agreed that $&lt;span id="xdx_904_eus-gaap--SponsorFees_c20240101__20240331_zDcK1SOKuNva" title="Sponsor advisory services fee"&gt;250,000&lt;/span&gt; of the Sponsor Advisory Service Fee is payable in cash, $&lt;span id="xdx_90B_eus-gaap--OtherLiabilities_iI_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember_zEqpHQEHwr8a" title="Due to Sponsor"&gt;250,000&lt;/span&gt; would be offset
against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with issuance of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zB1MkZ813bog"&gt;150,000
&lt;/span&gt;shares of the Company&#x2019;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented &lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember__us-gaap--DebtInstrumentAxis__custom--PolarNotesMember_z53BiEN4NwJ9"&gt;on
the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated balance sheets under the line item
&#x201c;Due to related party&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2024, the Sponsor owes the Company $&lt;span id="xdx_908_ecustom--WorkingCapitalExpenses_c20240101__20240331_z5jjTLp86GZ9" title="Working capital expenses"&gt;158,819&lt;/span&gt; to cover working capital expenses which is presented on the consolidated balance
sheets under the line item &#x201c;Due from related party&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 9 for additional information on the Series B issued to the Sponsor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TEVOGEN
BIO HOLDINGS INC.&lt;br/&gt;
NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84Gt1zrAZfg" title="Isssued shares to related party"&gt;40,000&lt;/span&gt; Performance-Based RSUs to the wife of the Company&#x2019;s chair and chief executive officer for
advisory services provided to the Company, and &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZuYGnbdjli4" title="Isssued shares to related party"&gt;20,000&lt;/span&gt; Performance-Based RSUs to Mehtaphoric Consulting Inc, a company controlled by
the daughter of the Company&#x2019;s chief financial officer, for information technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation cost of $&lt;span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20240331_zb5osuQACug2" title="Compensation cost recognized"&gt;800,396&lt;/span&gt; has been recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SponsorFees
      contextRef="From2024-01-012024-03-31_custom_SponsorAdvisoryServicesFeeMember"
      decimals="0"
      id="Fact001921"
      unitRef="USD">2000000</us-gaap:SponsorFees>
    <us-gaap:SponsorFees
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001923"
      unitRef="USD">250000</us-gaap:SponsorFees>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-03-31_custom_SponsorMember"
      decimals="0"
      id="Fact001925"
      unitRef="USD">250000</us-gaap:OtherLiabilities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-03-31_custom_SponsorAdvisoryServicesFeeMember"
      decimals="INF"
      id="Fact001926"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <TVGN:WorkingCapitalExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001929"
      unitRef="USD">158819</TVGN:WorkingCapitalExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001931"
      unitRef="Shares">40000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001933"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001935"
      unitRef="USD">800396</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001937">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zKJHQFDWeYV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE 11. &lt;span id="xdx_823_z0unTaUMmM02"&gt;NET INCOME (LOSS) PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUEM9njRKv4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The following table sets forth the computation of
basic and diluted income (loss) per share:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zvAOzgDMPIJa" style="display: none"&gt;SCHEDULE
OF NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240101__20240331_zBIw8xRlZL0l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230101__20230331_z7sjC8XY7KTh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILATz5q6_z2PwMSipxGSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;11,264,842&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Cumulative undeclared Series A dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iN_di_msNILATz5q6_zmkQDyPhYEve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Less: Undistributed earnings allocated to participating securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(756,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1945"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz5q6_zSf2SWBkWWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net income (loss) attributable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,506,866&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_maNILATzP0S_z2Ff6mKtEnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,264,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Cumulative undeclared Series A dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ConvertiblePromissoryNoteInterest_iT_mtNILATzP0S_zROaggmn9VJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Convertible promissory note interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ConvertiblePromissoryNoteChangeInFairValue_iT_mtNILATzP0S_zBXxLczt6Ci9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Convertible promissory note change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1957"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATzP0S_zO8LeU0GiuFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net loss attributable to common stockholders, diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(37,049,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zUtr9hiU9Yf7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Weighted average common stock outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;137,333,802&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,999,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zSoaT7mNY0Na" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net income (loss) per share attributable to common stockholders, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_zk7Qs7Ur6R39" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Weighted average common stock outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;137,333,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1969"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zV9daeYBB5P" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Effect of potentially dilutive convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,053,849&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1972"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_iT_zxSCH2gN79V3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,053,849&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1975"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zLkpyy5nDPWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Weighted average common stock outstanding, diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;142,387,651&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,999,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zTLtB4KeNMN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net loss per share attributable to common stockholders - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_zmXT4wuhRAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt; text-align: left"&gt;Net loss per share attributable to common stockholders -
    diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A7_zVZkqKtyZ87g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;As of March 31, 2024 and 2023, the
Company&#x2019;s potentially dilutive securities included Series A Preferred Stock, outstanding public warrants and convertible
promissory notes on an as-converted basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Series A and Restricted Stock are
participating securities as Series A is entitled to participate in dividends and in earnings (but not losses) of the Company on an
as-converted basis as common shares and the Restricted Stock holder is entitled to participate in any dividends declared on common
stock. Accordingly, undistributed earnings are allocated to common shares and participating securities based on the weighted-average
shares of each class outstanding during the period. See Note 8 and Note 9 for additional rights and privileges of Restricted Stock
and Series A, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Restricted Stock are excluded from
the weighted average common stock outstanding pending the achievement of underlying service conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company excluded the
following potential shares from the computation of diluted net loss per share because including them would have had an anti-dilutive
effect:&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1svLnbgkff9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zX9yJpSE6KId" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240101__20240331_zjzz6uQ0sK1j" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230101__20230331_zp4V5Ik7QbQe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z1yhHirk81E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding restricted stock units &lt;span id="xdx_F4B_zVGWFtbf7tW2"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,751,622&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,355,527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zbB4ALKPBuLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;19,348,954&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1992"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zRl78jxQ6Duh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Public warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivateWarrantsMember_zg3ia8cpuoPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Private warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;725,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zgoXgyIZ6op5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible promissory notes &lt;span id="xdx_F49_zZoNJbq20IK3"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,946,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zStoCMObkkt" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Earnout Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2004"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zUZkOPaurhna" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;65,575,576&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,301,863&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F07_zDLLC4XmVDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zXrMPp7PXma3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of March 31, 2024, there were an additional &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8" title="Stock option vested"&gt;7,148,506&lt;/span&gt;
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F05_z9Nlj73FiGLd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zjwOKjJ29YB8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zHpNNTXLUHT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001939">&lt;p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zUEM9njRKv4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The following table sets forth the computation of
basic and diluted income (loss) per share:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zvAOzgDMPIJa" style="display: none"&gt;SCHEDULE
OF NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240101__20240331_zBIw8xRlZL0l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230101__20230331_z7sjC8XY7KTh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILATz5q6_z2PwMSipxGSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;11,264,842&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Cumulative undeclared Series A dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iN_di_msNILATz5q6_zmkQDyPhYEve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Less: Undistributed earnings allocated to participating securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(756,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1945"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz5q6_zSf2SWBkWWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net income (loss) attributable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,506,866&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_maNILATzP0S_z2Ff6mKtEnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,264,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Cumulative undeclared Series A dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ConvertiblePromissoryNoteInterest_iT_mtNILATzP0S_zROaggmn9VJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Convertible promissory note interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ConvertiblePromissoryNoteChangeInFairValue_iT_mtNILATzP0S_zBXxLczt6Ci9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Less: Convertible promissory note change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1957"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATzP0S_zO8LeU0GiuFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net loss attributable to common stockholders, diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(37,049,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(30,756,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zUtr9hiU9Yf7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Weighted average common stock outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;137,333,802&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,999,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zSoaT7mNY0Na" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net income (loss) per share attributable to common stockholders, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_zk7Qs7Ur6R39" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Weighted average common stock outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;137,333,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1969"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zV9daeYBB5P" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Effect of potentially dilutive convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,053,849&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1972"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_iT_zxSCH2gN79V3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,053,849&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1975"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zLkpyy5nDPWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Weighted average common stock outstanding, diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;142,387,651&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,999,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zTLtB4KeNMN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net loss per share attributable to common stockholders - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_zmXT4wuhRAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt; text-align: left"&gt;Net loss per share attributable to common stockholders -
    diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001941"
      unitRef="USD">11264842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001942"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001944"
      unitRef="USD">756606</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001947"
      unitRef="USD">10506866</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001948"
      unitRef="USD">-30756144</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001950"
      unitRef="USD">11264842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001951"
      unitRef="USD">-30756144</us-gaap:NetIncomeLoss>
    <TVGN:ConvertiblePromissoryNoteInterest
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001953"
      unitRef="USD">155786</TVGN:ConvertiblePromissoryNoteInterest>
    <TVGN:ConvertiblePromissoryNoteChangeInFairValue
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001956"
      unitRef="USD">-48468678</TVGN:ConvertiblePromissoryNoteChangeInFairValue>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact001959"
      unitRef="USD">-37049420</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact001960"
      unitRef="USD">-30756144</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001962"
      unitRef="Shares">137333802</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001963"
      unitRef="Shares">119999989</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001965"
      unitRef="USDPShares">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001966"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001968"
      unitRef="Shares">137333802</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001971"
      unitRef="Shares">5053849</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001974"
      unitRef="Shares">5053849</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001977"
      unitRef="Shares">142387651</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001978"
      unitRef="Shares">119999989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001980"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001981"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact001983"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact001984"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001986">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1svLnbgkff9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zX9yJpSE6KId" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240101__20240331_zjzz6uQ0sK1j" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230101__20230331_zp4V5Ik7QbQe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z1yhHirk81E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding restricted stock units &lt;span id="xdx_F4B_zVGWFtbf7tW2"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,751,622&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,355,527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zbB4ALKPBuLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;19,348,954&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1992"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zRl78jxQ6Duh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Public warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivateWarrantsMember_zg3ia8cpuoPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Private warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;725,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zgoXgyIZ6op5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible promissory notes &lt;span id="xdx_F49_zZoNJbq20IK3"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,946,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zStoCMObkkt" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Earnout Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2004"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zUZkOPaurhna" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;65,575,576&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,301,863&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F07_zDLLC4XmVDf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zXrMPp7PXma3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of March 31, 2024, there were an additional &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8" title="Stock option vested"&gt;7,148,506&lt;/span&gt;
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F05_z9Nlj73FiGLd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zjwOKjJ29YB8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001988"
      unitRef="Shares">3751622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001989"
      unitRef="Shares">10355527</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockMember69286687"
      decimals="INF"
      id="Fact001991"
      unitRef="Shares">19348954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001994"
      unitRef="Shares">17250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_custom_PrivateWarrantsMember"
      decimals="INF"
      id="Fact001997"
      unitRef="Shares">725000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact002001"
      unitRef="Shares">2946336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact002003"
      unitRef="Shares">24500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact002006"
      unitRef="Shares">65575576</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact002007"
      unitRef="Shares">13301863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember69287000"
      decimals="INF"
      id="Fact002010"
      unitRef="Shares">7148506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact002013">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zU884nHpm3Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12. &lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;Note
10 &#x2014; &lt;span id="xdx_82D_zxi6St8bGCMe"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events and transactions
for potential recognition or disclosure from the balance sheet date through May 28, 2024, the issuance date of these the financial statements
and has not identified any additional items requiring disclosure that have not previously been mentioned elsewhere.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl1044"
          xlink:label="xdx2ixbrl1044"
          xlink:type="locator"/>
        <link:footnote id="Footnote001055" xlink:label="Footnote001055" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of December 31, 2023, the entirety of the marketable securities held in the trust account
were deposited into the demand deposit account.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1044"
          xlink:to="Footnote001055"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1046"
          xlink:label="xdx2ixbrl1046"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1046"
          xlink:to="Footnote001055"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1048"
          xlink:label="xdx2ixbrl1048"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1048"
          xlink:to="Footnote001055"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001846"
          xlink:label="Fact001846"
          xlink:type="locator"/>
        <link:footnote id="Footnote001853" xlink:label="Footnote001853" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares issuable to Polar under a subscription agreement as a result of the Merger. See Note 7 for additional information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001846"
          xlink:to="Footnote001853"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001848"
          xlink:label="Fact001848"
          xlink:type="locator"/>
        <link:footnote id="Footnote001854" xlink:label="Footnote001854" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of March 31, 2024, there were Performance-Based RSUs that had
vested when the liquidity condition applicable to such awards was satisfied upon the Closing but had not been legally settled into common
stock. See Note 8 for additional information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001848"
          xlink:to="Footnote001854"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001850"
          xlink:label="Fact001850"
          xlink:type="locator"/>
        <link:footnote id="Footnote001855" xlink:label="Footnote001855" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs the
    Company. See Note 8 for additional information on the Special RSU Award.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001850"
          xlink:to="Footnote001855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001988"
          xlink:label="Fact001988"
          xlink:type="locator"/>
        <link:footnote id="Footnote002008" xlink:label="Footnote002008" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    of March 31, 2024, there were an additional <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW4ncbDXJpc8"
  title="Stock option vested">7,148,506</xhtml:span>
    restricted stock units that had vested but had not been legally settled into common stock and therefore were included in the basic
    net income per share. See Note 8 for additional information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001988"
          xlink:to="Footnote002008"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001989"
          xlink:label="Fact001989"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001989"
          xlink:to="Footnote002008"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2000"
          xlink:label="xdx2ixbrl2000"
          xlink:type="locator"/>
        <link:footnote id="Footnote002011" xlink:label="Footnote002011" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The number of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements, dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2000"
          xlink:to="Footnote002011"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002001"
          xlink:label="Fact002001"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002001"
          xlink:to="Footnote002011"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
